Reactivity	O
of	O
lymphocytes	O
to	O
a	O
progesterone	B
receptor	I
-	I
specific	I
monoclonal	I
antibody	I
.	O
In	O
this	O
study	O
we	O
present	O
evidence	O
for	O
reactivity	O
of	O
pregnancy	O
lymphocytes	O
,	O
but	O
not	O
nonpregnancy	O
lymphocytes	O
,	O
with	O
the	O
progesterone	B
receptor	I
-	I
specific	I
monoclonal	I
antibody	I
mPRI	B
.	O
Using	O
an	O
avidin	B
-biotin	B
peroxidase	I
detection	O
system	O
,	O
we	O
found	O
a	O
nuclear	O
staining	O
in	O
14.6	O
+	O
/-	O
3.7	O
%	O
(	O
mean	O
+	O
/-	O
SEM	O
,	O
N	O
=	O
27	O
)	O
of	O
pregnancy	O
lymphocytes	O
,	O
while	O
only	O
0.47	O
+	O
/-	O
0.33	O
%	O
(	O
mean	O
+	O
/-	O
SEM	O
,	O
N	O
=	O
15	O
)	O
of	O
nonpregnancy	O
lymphocytes	O
reacted	O
with	O
the	O
antibody	O
.	O
To	O
characterize	O
the	O
receptor	O
-	O
bearing	O
subset	O
,	O
CD8	O
+	O
and	O
CD4	O
+	O
cells	O
were	O
depleted	O
by	O
complement	O
-	O
dependent	O
lysis	O
.	O
Depletion	O
of	O
CD8	O
+	O
cells	O
was	O
accompanied	O
by	O
62	O
+	O
/-	O
18	O
%	O
loss	O
of	O
progesterone	O
receptor	O
-	O
bearing	O
cells	O
,	O
while	O
depletion	O
of	O
CD4	O
+	O
cells	O
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
number	O
of	O
positively	O
staining	O
lymphocytes	O
.	O
In	O
nonpregnancy	O
lymphocytes	O
a	O
3-day	O
PHA	B
treatment	O
,	O
as	O
well	O
as	O
allogeneic	O
stimulation	O
,	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
receptor	O
-	O
containing	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
pregnancy	O
,	O
but	O
not	O
nonpregnancy	O
,	O
lymphocytes	O
contain	O
progesterone	B
binding	I
structures	I
,	O
and	O
that	O
these	O
are	O
inducible	O
by	O
mitogenic	O
or	O
alloantigenic	O
stimuli	O
.	O
Two	O
distinct	O
transcription	B
factors	I
that	O
bind	O
the	O
immunoglobulin	O
enhancer	O
microE5	O
/	O
kappa	O
2	O
motif	O
.	O
Activity	O
of	O
the	O
immunoglobulin	O
heavy	O
and	O
kappa	O
light	O
chain	O
gene	O
enhancers	O
depends	O
on	O
a	O
complex	O
interplay	O
of	O
ubiquitous	B
and	I
developmentally	I
regulated	I
proteins	I
.	O
Two	O
complementary	O
DNAs	O
were	O
isolated	O
that	O
encode	O
proteins	O
,	O
denoted	O
ITF-1	B
and	O
ITF-2	B
,	O
that	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
bind	O
the	O
microE5	O
/	O
kappa	O
2	O
motif	O
found	O
in	O
both	O
heavy	O
and	O
kappa	O
light	O
chain	O
enhancers	O
.	O
The	O
complementary	O
DNAs	O
are	O
the	O
products	O
of	O
distinct	O
genes	O
,	O
yet	O
both	O
ITF-1	B
and	O
ITF-2	B
are	O
structurally	O
and	O
functionally	O
similar	O
.	O
The	O
two	O
proteins	O
interact	O
with	O
one	O
another	O
through	O
their	O
putative	O
helix	B
-	I
loop	I
-	I
helix	I
motifs	I
and	O
each	O
possesses	O
a	O
distinct	O
domain	O
that	O
dictates	O
transcription	O
activation	O
.	O
A	O
factor	O
known	O
to	O
bind	O
to	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
only	O
in	O
lymphocytes	O
is	O
a	O
ubiquitously	B
active	I
transcription	I
factor	I
.	O
The	O
transcriptional	O
enhancer	O
located	O
in	O
the	O
first	O
intron	O
of	O
the	O
immunoglobulin	O
heavy	O
chain	O
constant	O
region	O
is	O
a	O
major	O
determinant	O
of	O
B	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
immunoglobulin	O
genes	O
.	O
Like	O
other	O
enhancers	O
,	O
the	O
Ig	O
heavy	O
chain	O
enhancer	O
contains	O
several	O
short	O
sequence	O
motifs	O
that	O
bind	O
specific	B
transcription	I
factors	I
.	O
Each	O
binding	O
site	O
contributes	O
to	O
the	O
overall	O
activity	O
of	O
the	O
enhancer	O
,	O
however	O
no	O
single	O
element	O
seems	O
absolutely	O
required	O
for	O
activity	O
.	O
For	O
a	O
better	O
understanding	O
of	O
the	O
Ig	O
heavy	O
chain	O
enhancer	O
components	O
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
individual	O
sequence	O
elements	O
.	O
We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	O
enhancer	O
motif	O
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	B
transcription	I
factor	I
.	O
It	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
both	O
B	O
cells	O
and	O
non	O
-	O
B	O
cells	O
,	O
where	O
it	O
can	O
mediate	O
transcriptional	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
However	O
,	O
despite	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
a	O
transfected	O
reporter	O
gene	O
,	O
the	O
factor	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
in	O
non	O
-	O
lymphoid	O
cells	O
:	O
In	O
previous	O
experiments	O
by	O
others	O
,	O
the	O
characteristic	O
in	O
vivo	O
footprint	O
of	O
this	O
factor	O
,	O
designated	O
NF	B
-	I
muE3	I
,	O
was	O
detected	O
in	O
B	O
cells	O
but	O
not	O
in	O
non	O
-	O
B	O
cells	O
.	O
From	O
this	O
and	O
other	O
findings	O
the	O
picture	O
emerges	O
that	O
there	O
are	O
at	O
least	O
three	O
categories	O
of	O
factors	O
which	O
mediate	O
cell	O
-	O
type	O
-	O
specific	O
transcription	O
in	O
B	O
lymphocytes	O
:	O
(	O
a	O
)	O
cell	B
-	I
specific	I
factors	I
such	O
as	O
Oct-2A	B
and	O
Oct-2B	B
that	O
are	O
not	O
expressed	O
in	O
most	O
other	O
cell	O
types	O
:	O
(	O
b	O
)	O
ubiquitous	B
factors	I
such	O
as	O
NF	B
-	I
kappa	I
B	I
that	O
are	O
constitutively	O
active	O
in	O
B	O
cells	O
but	O
are	O
sequestered	O
in	O
an	O
inactive	O
form	O
in	O
other	O
cells	O
;	O
(	O
c	O
)	O
ubiquitously	B
active	I
factors	I
,	O
exemplified	O
by	O
the	O
one	O
binding	O
to	O
the	O
E3	O
sequence	O
motif	O
.	O
This	O
factor	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
a	O
variety	O
of	O
cell	O
types	O
but	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
in	O
non	O
-	O
B	O
cells	O
,	O
perhaps	O
due	O
to	O
a	O
non	O
-	O
permissive	O
chromatin	O
structure	O
of	O
the	O
Ig	O
heavy	O
chain	O
locus	O
.	O
Transcriptional	O
and	O
post	O
-	O
transcriptional	O
regulation	O
of	O
c	O
-	O
jun	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
human	O
myeloid	O
leukemic	O
cells	O
.	O
AP-1	B
,	O
the	O
polypeptide	O
product	O
of	O
c	O
-	O
jun	O
,	O
recognizes	O
and	O
binds	O
to	O
specific	O
DNA	O
sequences	O
and	O
stimulates	O
transcription	O
of	O
genes	O
responsive	O
to	O
certain	O
growth	O
factors	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O
We	O
studied	O
the	O
effects	O
of	O
TPA	O
on	O
the	O
regulation	O
of	O
c	O
-	O
jun	O
gene	O
expression	O
in	O
HL-60	O
cells	O
during	O
monocytic	O
differentiation	O
.	O
Low	O
levels	O
of	O
c	O
-	O
jun	O
transcripts	O
were	O
detectable	O
in	O
untreated	O
HL-60	O
leukemic	O
cells	O
,	O
increased	O
significantly	O
by	O
6	O
h	O
,	O
and	O
reached	O
near	O
maximal	O
levels	O
by	O
24	O
h	O
of	O
exposure	O
to	O
32	O
nM	O
TPA	O
.	O
Similar	O
kinetics	O
of	O
c	O
-	O
jun	O
induction	O
by	O
TPA	O
were	O
observed	O
in	O
human	O
U-937	O
and	O
THP-1	O
monocytic	O
leukemia	O
cells	O
.	O
Similar	O
findings	O
were	O
obtained	O
with	O
bryostatin	O
1	O
(	O
10	O
nM	O
)	O
,	O
another	O
activator	O
of	O
protein	B
kinase	I
C	I
and	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O
Furthermore	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
0.5	O
microM	O
)	O
,	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL-60	O
monocytic	O
differentiation	O
,	O
increased	O
c	O
-	O
jun	O
expression	O
.	O
TPA	O
treatment	O
of	O
HL-60	O
cells	O
in	O
the	O
presence	O
of	O
cycloheximide	O
was	O
associated	O
with	O
superinduction	O
of	O
c	O
-	O
jun	O
transcripts	O
.	O
Run	O
-	O
on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c	O
-	O
jun	O
gene	O
transcription	O
in	O
untreated	O
HL-60	O
cells	O
,	O
and	O
that	O
exposure	O
to	O
TPA	O
increases	O
this	O
rate	O
3.3-fold	O
.	O
Treatment	O
of	O
HL-60	O
cells	O
with	O
both	O
TPA	O
and	O
cycloheximide	O
had	O
no	O
effect	O
on	O
the	O
rates	O
of	O
c	O
-	O
jun	O
transcription	O
.	O
The	O
half	O
-	O
life	O
of	O
c	O
-	O
jun	O
RNA	O
as	O
determined	O
by	O
treating	O
HL-60	O
cells	O
with	O
TPA	O
and	O
actinomycin	O
D	O
was	O
30	O
min	O
.	O
In	O
contrast	O
,	O
the	O
half	O
-	O
life	O
of	O
c	O
-	O
jun	O
RNA	O
in	O
TPA	O
-	O
treated	O
HL-60	O
cells	O
exposed	O
to	O
cycloheximide	O
and	O
actinomycin	O
D	O
was	O
greater	O
than	O
2	O
h	O
.	O
These	O
findings	O
suggested	O
that	O
the	O
increase	O
in	O
c	O
-	O
jun	O
RNA	O
observed	O
during	O
TPA	O
-	O
induced	O
monocytic	O
differentiation	O
is	O
mediated	O
by	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
.	O
The	O
ubiquitous	B
octamer	I
-	I
binding	I
protein	I
(	O
s	O
)	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	O
genes	O
.	O
All	O
immunoglobulin	O
genes	O
contain	O
a	O
conserved	O
octanucleotide	O
promoter	O
element	O
,	O
ATGCAAAT	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
their	O
normal	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
.	O
Proteins	O
that	O
bind	O
this	O
octamer	O
have	O
been	O
purified	O
,	O
and	O
cDNAs	O
encoding	O
octamer	B
-	I
binding	I
proteins	I
have	O
been	O
cloned	O
.	O
Some	O
of	O
these	O
proteins	O
(	O
referred	O
to	O
as	O
OTF-2	B
)	O
are	O
lymphoid	O
specific	O
,	O
whereas	O
at	O
least	O
one	O
other	O
,	O
and	O
possibly	O
more	O
(	O
referred	O
to	O
as	O
OTF-1	B
)	O
,	O
is	O
found	O
ubiquitously	O
in	O
all	O
cell	O
types	O
.	O
The	O
exact	O
role	O
of	O
these	O
different	O
proteins	O
in	O
directing	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
immunoglobulin	O
genes	O
is	O
unclear	O
.	O
We	O
have	O
identified	O
two	O
human	O
pre	O
-	O
B	O
-	O
cell	O
lines	O
that	O
contain	O
extremely	O
low	O
levels	O
of	O
OTF-2	B
yet	O
still	O
express	O
high	O
levels	O
of	O
steady	O
-	O
state	O
immunoglobulin	O
heavy	O
-	O
chain	O
mRNA	O
in	O
vivo	O
and	O
efficiently	O
transcribe	O
an	O
immunoglobulin	O
gene	O
in	O
vitro	O
.	O
Addition	O
of	O
a	O
highly	O
enriched	O
preparation	O
of	O
OTF-1	B
made	O
from	O
one	O
of	O
these	O
pre	O
-	O
B	O
cells	O
or	O
from	O
HeLa	O
cells	O
specifically	O
stimulated	O
in	O
vitro	O
transcription	O
of	O
an	O
immunoglobulin	O
gene	O
.	O
Furthermore	O
,	O
OFT-1	O
appeared	O
to	O
have	O
approximately	O
the	O
same	O
transactivation	O
ability	O
as	O
OTF-2	B
when	O
normalized	O
for	O
binding	O
activity	O
.	O
These	O
results	O
suggest	O
that	O
OTF-1	B
,	O
without	O
OTF-2	B
,	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	O
genes	O
and	O
that	O
OTF-2	B
alone	O
is	O
not	O
responsible	O
for	O
the	O
B	O
-	O
cell	O
-	O
specific	O
regulation	O
of	O
immunoglobulin	O
gene	O
expression	O
.	O
Perceived	O
social	O
support	O
and	O
tumor	O
estrogen	B
/	I
progesterone	I
receptor	I
status	O
as	O
predictors	O
of	O
natural	O
killer	O
cell	O
activity	O
in	O
breast	O
cancer	O
patients	O
.	O
This	O
report	O
is	O
concerned	O
with	O
the	O
prediction	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
in	O
61	O
Stage	O
I	O
and	O
II	O
breast	O
cancer	O
patients	O
,	O
between	O
the	O
ages	O
of	O
25	O
and	O
70	O
,	O
who	O
were	O
accrued	O
to	O
this	O
project	O
.	O
All	O
baseline	O
interview	O
and	O
testing	O
data	O
were	O
obtained	O
either	O
just	O
before	O
patients	O
were	O
discharged	O
from	O
the	O
hospital	O
,	O
or	O
at	O
their	O
first	O
outpatient	O
visit	O
,	O
within	O
two	O
weeks	O
of	O
discharge	O
.	O
A	O
major	O
interest	O
of	O
this	O
project	O
is	O
the	O
predictive	O
value	O
of	O
perceived	O
social	O
support	O
,	O
as	O
a	O
potential	O
`	O
`	O
stress	O
''	O
buffer	O
,	O
related	O
to	O
NK	O
activity	O
.	O
In	O
the	O
main	O
model	O
reported	O
here	O
,	O
we	O
found	O
that	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
could	O
be	O
explained	O
by	O
five	O
variables	O
.	O
Higher	O
NK	O
activity	O
could	O
be	O
predicted	O
by	O
the	O
perception	O
of	O
high	O
quality	O
emotional	O
support	O
from	O
a	O
spouse	O
or	O
intimate	O
other	O
,	O
perceived	O
social	O
support	O
from	O
the	O
patient	O
's	O
physician	O
,	O
estrogen	B
receptor	I
-negative	O
tumor	O
status	O
,	O
having	O
an	O
excisional	O
biopsy	O
as	O
surgical	O
treatment	O
,	O
and	O
actively	O
seeking	O
social	O
support	O
as	O
a	O
major	O
coping	O
strategy	O
(	O
R2	O
=	O
0.33	O
,	O
F	O
(	O
5	O
,	O
55	O
)	O
=	O
5.5	O
,	O
p	O
less	O
than	O
0.0004	O
)	O
.	O
Findings	O
are	O
discussed	O
in	O
terms	O
of	O
host	O
interaction	O
with	O
tumor	O
endocrine	O
status	O
,	O
and	O
the	O
role	O
that	O
social	O
support	O
might	O
play	O
in	O
modulating	O
such	O
activity	O
.	O
Constitutive	O
expression	O
of	O
HIV-1	B
tat	I
protein	I
in	O
human	O
Jurkat	O
T	O
cells	O
using	O
a	O
BK	O
virus	O
vector	O
.	O
The	O
production	O
and	O
characterization	O
of	O
Jurkat	O
cell	O
lines	O
that	O
constitutively	O
express	O
functional	O
human	B
immune	I
deficiency	I
virus	I
type	I
1	I
(	I
HIV-1	I
)	I
tat	I
protein	I
,	O
using	O
a	O
BK	O
virus	O
plasmid	O
expression	O
vector	O
and	O
HIV-1	O
tat	O
cDNA	O
,	O
is	O
described	O
.	O
An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat	O
-	O
tat	O
cell	O
lines	O
as	O
compared	O
with	O
control	O
cell	O
lines	O
was	O
observed	O
.	O
Effects	O
of	O
aldosterone	O
on	O
intralymphocytic	O
sodium	O
and	O
potassium	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O
In	O
vitro	O
binding	O
of	O
aldosterone	O
to	O
mineralocorticoid	B
receptors	I
on	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
and	O
its	O
effects	O
on	O
the	O
intracellular	O
sodium	O
and	O
potassium	O
concentrations	O
of	O
HML	O
have	O
already	O
been	O
described	O
.	O
In	O
the	O
present	O
paper	O
this	O
easily	O
accessible	O
human	O
cell	O
model	O
was	O
investigated	O
in	O
13	O
patients	O
with	O
essential	O
hypertension	O
.	O
In	O
only	O
four	O
patients	O
sodium	O
in	O
HML	O
without	O
incubation	O
was	O
elevated	O
compared	O
with	O
the	O
range	O
for	O
normal	O
persons	O
.	O
A	O
decrease	O
of	O
intracellular	O
sodium	O
or	O
potassium	O
occurred	O
during	O
incubation	O
without	O
aldosterone	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
The	O
addition	O
of	O
1.4	O
nM	O
aldosterone	O
did	O
not	O
prevent	O
this	O
loss	O
of	O
electrolytes	O
as	O
observed	O
in	O
normal	O
persons	O
.	O
Plasma	B
renin	I
activity	O
and	O
aldosterone	O
were	O
not	O
correlated	O
with	O
the	O
electrolyte	O
response	O
and	O
were	O
within	O
the	O
normal	O
limits	O
.	O
The	O
number	O
of	O
mineralocorticoid	B
receptors	I
/cell	O
were	O
within	O
or	O
close	O
to	O
the	O
normal	O
range	O
(	O
n	O
=	O
9	O
)	O
.	O
The	O
independence	O
of	O
intracellular	O
electrolytes	O
from	O
aldosterone	O
despite	O
a	O
normal	O
number	O
of	O
mineralocorticoid	B
receptors	I
may	O
reflect	O
an	O
impairment	O
of	O
the	O
mineralocorticoid	O
effector	O
mechanism	O
in	O
the	O
HML	O
of	O
patients	O
with	O
essential	O
hypertension	O
.	O
Quantitative	O
immunohistochemical	O
analysis	O
of	O
mononuclear	O
infiltrates	O
in	O
breast	O
carcinomas	O
--	O
correlation	O
with	O
tumour	O
differentiation	O
.	O
Inflammatory	O
infiltrates	O
were	O
analysed	O
in	O
tissue	O
sections	O
of	O
76	O
breast	O
carcinomas	O
by	O
counting	O
the	O
percentage	O
of	O
macrophages	O
,	O
IgA+	O
and	O
IgG+	O
plasma	O
cells	O
,	O
T	O
cells	O
with	O
their	O
subpopulations	O
,	O
and	O
natural	O
killer	O
cells	O
,	O
and	O
by	O
measuring	O
postcapillary	O
venules	O
(	O
PCVs	O
,	O
found	O
in	O
12	O
cases	O
)	O
within	O
the	O
infiltrates	O
.	O
These	O
parameters	O
were	O
correlated	O
with	O
nuclear	O
grade	O
and	O
biochemically	O
determined	O
hormone	O
receptor	O
status	O
,	O
known	O
markers	O
of	O
tumour	O
differentiation	O
.	O
A	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
extent	O
of	O
inflammation	O
and	O
nuclear	O
grade	O
(	O
P	O
less	O
than	O
0.0001	O
)	O
,	O
and	O
an	O
inverse	O
correlation	O
between	O
inflammation	O
and	O
oestrogen	B
receptor	I
(	O
OR	B
)	O
positivity	O
(	O
P	O
less	O
than	O
0.05	O
)	O
as	O
well	O
as	O
inflammation	O
and	O
progesterone	B
receptor	I
(	O
PR	B
)	O
positivity	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O
The	O
percentage	O
of	O
the	O
OKT8	O
+	O
suppressor	O
/	O
cytotoxic	O
T	O
cells	O
increased	O
when	O
the	O
inflammation	O
expanded	O
from	O
scanty	O
to	O
moderate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
The	O
diameter	O
of	O
the	O
PCVs	O
also	O
increased	O
with	O
increasing	O
inflammatory	O
infiltrate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
In	O
addition	O
,	O
a	O
direct	O
correlation	O
exists	O
between	O
the	O
diameter	O
of	O
the	O
PCVs	O
and	O
both	O
the	O
percentage	O
of	O
the	O
OKT8	O
+	O
T	O
cells	O
(	O
P	O
less	O
than	O
0.04	O
)	O
and	O
the	O
Leu-7	O
+	O
natural	O
killer	O
cells	O
(	O
P	O
less	O
than	O
0.03	O
)	O
.	O
Mapping	O
of	O
B	B
-	I
cell	I
epitopes	I
of	O
the	O
human	B
hepatitis	I
B	I
virus	I
X	I
protein	I
.	O
The	O
immune	O
response	O
to	O
the	O
X	B
protein	I
of	O
human	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
was	O
studied	O
by	O
epitope	O
mapping	O
by	O
using	O
a	O
set	O
of	O
MS2-HBx	B
fusion	I
proteins	I
and	O
synthetic	O
peptides	O
.	O
Antibodies	O
in	O
sera	O
of	O
patients	O
with	O
acute	O
and	O
chronic	O
HBV	O
infection	O
showed	O
a	O
multispecific	O
immune	O
response	O
.	O
Each	O
serum	O
contained	O
antibodies	B
to	O
a	O
different	O
set	O
of	O
epitopes	B
,	O
which	O
taken	O
together	O
cover	O
most	O
of	O
the	O
HBx	B
sequence	I
.	O
Some	O
of	O
the	O
epitopes	O
were	O
detectable	O
only	O
by	O
immunoblotting	O
with	O
fusion	B
proteins	I
;	O
others	O
were	O
detectable	O
only	O
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
synthetic	O
peptides	O
.	O
The	O
carboxy	B
-	I
terminal	I
half	I
of	O
the	O
HBx	B
protein	I
was	O
preferentially	O
recognized	O
by	O
antibodies	B
from	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
contained	O
a	O
short	O
immunodominant	B
antigenic	I
region	I
with	O
at	O
least	O
two	O
major	O
nonoverlapping	B
epitopes	I
.	O
Anti-	O
HBx	B
antibody	O
titers	O
as	O
revealed	O
by	O
peptide	O
ELISAs	O
were	O
highest	O
and	O
most	O
frequent	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
usually	O
low	O
in	O
acutely	O
infected	O
patients	O
and	O
asymptomatic	O
carriers	O
.	O
The	O
data	O
demonstrate	O
a	O
remarkable	O
qualitative	O
and	O
quantitative	O
heterogeneity	O
of	O
the	O
humoral	O
HBx	B
immune	O
response	O
which	O
can	O
be	O
monitored	O
by	O
HBx	B
-specific	O
peptide	O
ELISAs	O
.	O
Such	O
tests	O
may	O
become	O
useful	O
diagnostic	O
tools	O
.	O
The	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
ORI1yt	O
enhancer	O
is	O
not	O
B	O
-	O
cell	O
specific	O
and	O
does	O
not	O
respond	O
synergistically	O
to	O
the	O
EBV	B
transcription	I
factors	I
R	I
and	I
Z	I
.	O
The	O
Epstein	O
-	O
Barr	O
virus	O
DR	O
promoter	O
is	O
located	O
upstream	O
of	O
the	O
PstI	O
repeats	O
,	O
and	O
in	O
addition	O
to	O
the	O
TATA	O
box	O
,	O
it	O
contains	O
an	O
upstream	O
region	O
(	O
positions	O
-69	O
to	O
-220	O
)	O
responsive	O
to	O
EB1	B
(	I
Z	I
)	I
(	O
the	O
BZLF1-encoded	B
transcription	I
factor	I
)	O
and	O
an	O
enhancer	O
with	O
two	O
functionally	O
distinct	O
domains	O
,	O
A	O
and	O
B	O
.	O
Domain	O
B	O
has	O
been	O
described	O
as	O
a	O
B	O
-	O
cell	O
-	O
specific	O
EB1-responsive	O
element	O
(	O
P.M.Lieberman	O
,	O
J.M.Hardwick	O
,	O
and	O
S.D.Hayward	O
,	O
J.Virol.63	O
:	O
3040	O
-	O
3050	O
,	O
1989	O
)	O
activated	O
synergistically	O
by	O
EB1	B
and	O
R	B
,	O
an	O
EBV	B
early	I
product	I
encoded	O
by	O
the	O
open	O
reading	O
frame	O
BRLF1	O
(	O
M.A.	O
Cox	O
,	O
J.Leahy	O
,	O
and	O
J.M.Hardwick	O
,	O
J.Virol.64	O
:	O
313	O
-	O
321	O
,	O
1990	O
)	O
.	O
We	O
show	O
here	O
that	O
domain	O
B	O
is	O
an	O
R	O
-	O
responsive	O
element	O
in	O
HeLa	O
cells	O
and	O
is	O
therefore	O
not	O
an	O
EB1-responsive	O
B	O
-	O
cell	O
-	O
specific	O
element	O
.	O
However	O
,	O
there	O
is	O
an	O
EB1-binding	O
site	O
(	O
ZRE	O
-	O
B	O
)	O
located	O
within	O
the	O
R	O
-	O
responsive	O
enhancer	O
region	O
.	O
ZRE	O
-	O
B	O
can	O
be	O
deleted	O
without	O
affecting	O
the	O
R	O
-	O
dependent	O
enhancer	O
activity	O
.	O
Moreover	O
,	O
there	O
is	O
no	O
cooperation	O
or	O
synergy	O
between	O
R	B
and	O
EB1	B
when	O
activating	O
the	O
B	O
domain	O
(	O
ZRE	O
-	O
B	O
plus	O
the	O
R	O
-	O
responsive	O
element	O
)	O
positioned	O
as	O
an	O
enhancer	O
.	O
ZRE	O
-	O
B	O
is	O
therefore	O
not	O
part	O
of	O
the	O
R-	O
inducible	O
enhancer	O
.	O
We	O
have	O
tested	O
several	O
subregions	O
of	O
the	O
DR	O
enhancer	O
B	O
domain	O
,	O
either	O
alone	O
or	O
in	O
combination	O
,	O
for	O
their	O
capacity	O
to	O
transmit	O
the	O
R	O
-	O
activating	O
signal	O
to	O
the	O
rabbit	O
beta	O
-	O
globin	O
promoter	O
.	O
We	O
found	O
that	O
the	O
R	O
-	O
responsive	O
element	O
is	O
composed	O
of	O
four	O
protoenhancers	O
that	O
span	O
the	O
whole	O
B	O
domain	O
.	O
These	O
protoenhancers	O
alone	O
are	O
weakly	O
or	O
not	O
responsive	O
to	O
R	B
.	O
One	O
of	O
the	O
protoenhancers	O
contains	O
the	O
overlapping	O
palindromes	O
5'-TTGTCCcgtGGACAAaTGTCC-3	O
'	O
.	O
However	O
,	O
one	O
palindrome	O
,	O
either	O
alone	O
or	O
duplicated	O
,	O
or	O
the	O
overlapping	O
palindromes	O
did	O
not	O
respond	O
to	O
R	O
.	O
Effects	O
of	O
mitogenic	O
agents	O
upon	O
glucocorticoid	O
action	O
in	O
human	O
tonsillar	O
T	O
-	O
lymphocytes	O
.	O
The	O
treatment	O
of	O
human	O
tonsillar	O
T	O
-	O
lymphocytes	O
with	O
4-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
resulted	O
in	O
about	O
two	O
fold	O
increase	O
in	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
number	O
,	O
without	O
any	O
significant	O
change	O
in	O
the	O
receptor	O
affinity	O
.	O
This	O
increase	O
disappeared	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O
Alone	O
,	O
PMA	O
and	O
calcium	O
ionophore	O
A23187	O
did	O
not	O
affect	O
,	O
but	O
together	O
stimulated	O
,	O
like	O
phytohaemagglutinin	B
(	O
PHA	B
)	O
,	O
leucine	O
and	O
,	O
in	O
particular	O
,	O
thymidine	O
incorporation	O
.	O
PMA	O
enhanced	O
slightly	O
the	O
stimulatory	O
effect	O
of	O
PHA	B
.	O
Alone	O
,	O
these	O
agents	O
failed	O
to	O
alter	O
the	O
suppressive	O
effect	O
of	O
dexamethasone	O
on	O
thymidine	O
and	O
leucine	O
incorporation	O
;	O
however	O
,	O
PMA	O
-	O
A23187	O
and	O
PMA	O
-PHA	B
combinations	O
appeared	O
to	O
antagonize	O
the	O
suppression	O
by	O
dexamethasone	O
.	O
Involvement	O
of	O
a	O
second	O
lymphoid	O
-	O
specific	O
enhancer	O
element	O
in	O
the	O
regulation	O
of	O
immunoglobulin	O
heavy	O
-	O
chain	O
gene	O
expression	O
.	O
To	O
determine	O
whether	O
enhancer	O
elements	O
in	O
addition	O
to	O
the	O
highly	O
conserved	O
octamer	O
(	O
OCTA	O
)	O
-nucleotide	O
motif	O
are	O
important	O
for	O
lymphoid	O
-	O
specific	O
expression	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
gene	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
mutating	O
the	O
binding	O
site	O
for	O
a	O
putative	B
additional	I
lymphoid	I
-	I
specific	I
transcription	I
factor	I
,	O
designated	O
NF	B
-	I
microB	I
,	O
in	O
the	O
murine	O
IgH	O
enhancer	O
.	O
We	O
demonstrate	O
that	O
the	O
NF	O
-	O
microB	O
-	O
binding	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
IgH	O
enhancer	O
,	O
because	O
mutation	O
of	O
the	O
microB	O
DNA	O
motif	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
IgH	O
enhancer	O
in	O
cells	O
of	O
the	O
B	O
-	O
cell	O
lineage	O
but	O
not	O
in	O
nonlymphoid	O
cells	O
.	O
This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O
OCTA	O
site	O
.	O
Moreover	O
,	O
combined	O
mutation	O
of	O
both	O
microB	O
and	O
OCTA	O
sites	O
further	O
reduced	O
enhancer	O
activity	O
in	O
lymphoid	O
cells	O
.	O
Interestingly	O
,	O
alteration	O
of	O
either	O
the	O
microB	O
or	O
E3	O
site	O
in	O
a	O
70-base	O
-	O
pair	O
fragment	O
of	O
the	O
IgH	O
enhancer	O
that	O
lacks	O
the	O
binding	O
site	O
for	O
OCTA	O
abolished	O
enhancer	O
activity	O
in	O
lymphoid	O
cells	O
completely	O
.	O
Nevertheless	O
,	O
a	O
multimer	O
of	O
the	O
microB	O
motif	O
alone	O
showed	O
no	O
enhancer	O
activity	O
.	O
DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid	B
-	I
specific	I
protein	I
binds	O
to	O
the	O
microB	O
DNA	O
motif	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
microB	O
element	O
is	O
a	O
new	O
crucial	O
element	O
important	O
for	O
lymphoid	O
-	O
specific	O
expression	O
of	O
the	O
IgH	O
gene	O
but	O
that	O
interaction	O
with	O
another	O
enhancer	O
element	O
is	O
essential	O
for	O
its	O
activity	O
.	O
Involvement	O
of	O
cyclic	B
AMP	I
-	I
dependent	I
protein	I
kinases	I
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
interleukin-1	B
.	O
Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	B
AMP	I
-	I
dependent	I
protein	I
kinases	I
in	O
interleukin-1	O
(	O
IL-1	O
)	O
-responsive	O
cells	O
blocked	O
IL-1-induced	O
gene	O
transcription	O
that	O
was	O
driven	O
by	O
the	O
kappa	O
immunoglobulin	O
enhancer	O
or	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O
This	O
inhibitor	O
did	O
not	O
affect	O
protein	B
kinase	I
C	I
-mediated	O
gene	O
transcription	O
,	O
suggesting	O
that	O
cyclic	B
AMP	I
-	I
dependent	I
protein	I
kinases	I
are	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
IL-1	B
in	O
a	O
number	O
of	O
responsive	O
cell	O
types	O
.	O
Increased	O
glucocorticoid	O
responsiveness	O
of	O
CD4	O
+	O
T	O
-	O
cell	O
clonal	O
lines	O
grown	O
in	O
serum	O
-	O
free	O
media	O
.	O
CEM	O
-	O
C7	O
,	O
a	O
human	O
leukemic	O
CD4	O
+	O
T	O
-	O
lymphocyte	O
cell	O
line	O
and	O
three	O
of	O
its	O
subclones	O
,	O
CEM-4R4	O
,	O
CEM-3R43	O
,	O
and	O
ICR-27	O
,	O
previously	O
cultured	O
in	O
a	O
medium	O
supplemented	O
with	O
5	O
to	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
have	O
been	O
adapted	O
to	O
serum	O
-	O
free	O
media	O
.	O
The	O
best	O
medium	O
of	O
those	O
tested	O
was	O
RPMI	O
1640	O
supplemented	O
with	O
5	O
micrograms	O
/	O
ml	O
each	O
transferrin	B
and	O
insulin	B
+	O
5	O
ng	O
/	O
ml	O
sodium	O
selenite	O
+	O
/-	O
0.1	O
%	O
bovine	B
serum	I
albumin	I
.	O
While	O
growing	O
either	O
with	O
or	O
without	O
albumin	O
,	O
the	O
several	O
clonal	O
lines	O
of	O
CEM	O
cells	O
displayed	O
growth	O
similar	O
to	O
serum	O
-	O
supplemented	O
cultures	O
.	O
Cell	O
proliferation	O
of	O
CEM	O
-	O
C7	O
cells	O
cultured	O
in	O
both	O
serum	O
-	O
free	O
media	O
has	O
been	O
sustained	O
for	O
3	O
mo	O
.	O
with	O
culture	O
doubling	O
times	O
of	O
about	O
25	O
h	O
for	O
both	O
serum	O
-	O
supplemented	O
and	O
serum	O
-	O
free	O
cultures	O
(	O
viability	O
greater	O
than	O
or	O
equal	O
to	O
90	O
%	O
)	O
.	O
Cell	O
morphology	O
remained	O
essentially	O
the	O
same	O
in	O
serum	O
-	O
free	O
or	O
serum	O
containing	O
media	O
.	O
The	O
expression	O
of	O
CD4	B
,	O
a	O
marker	O
for	O
T	O
-	O
derived	O
lymphoid	O
cells	O
,	O
was	O
not	O
significantly	O
different	O
in	O
serum	O
-	O
free	O
medium	O
.	O
When	O
grown	O
in	O
serum	O
-	O
free	O
medium	O
,	O
CEM	O
-	O
C7	O
cells	O
exhibited	O
increased	O
steroid	O
responsiveness	O
as	O
evidenced	O
by	O
increased	O
glucocorticoid	B
receptor	I
binding	O
sites	O
,	O
increased	O
induction	O
of	O
glutamine	B
synthetase	I
,	O
and	O
cell	O
lysis	O
at	O
lower	O
concentrations	O
of	O
steroid	O
.	O
Receptor	O
mutant	O
subclones	O
of	O
CEM	O
-	O
C7	O
,	O
which	O
are	O
proven	O
to	O
be	O
completely	O
unresponsive	O
to	O
micromolar	O
concentrations	O
of	O
dexamethasone	O
when	O
grown	O
in	O
serum	O
-	O
supplemented	O
medium	O
,	O
become	O
partially	O
sensitive	O
to	O
the	O
hormone	O
after	O
growth	O
in	O
defined	O
medium	O
.	O
The	O
increased	O
sensitivity	O
of	O
CEM	O
-	O
C7	O
cells	O
and	O
its	O
subclones	O
to	O
dexamethasone	O
in	O
serum	O
-	O
free	O
medium	O
returned	O
to	O
previous	O
levels	O
when	O
these	O
cells	O
were	O
recultured	O
in	O
serum	O
-	O
containing	O
medium	O
.	O
Our	O
results	O
suggest	O
that	O
substances	O
in	O
serum	O
influence	O
steroid	O
effects	O
on	O
these	O
cells	O
and	O
that	O
the	O
molecular	O
details	O
of	O
glucocorticoid	O
hormone	O
action	O
may	O
be	O
pursued	O
more	O
precisely	O
in	O
a	O
clearly	O
defined	O
culture	O
medium	O
.	O
Mononuclear	O
leukocyte	O
glucocorticoid	B
receptor	I
binding	O
characteristics	O
and	O
down	O
-	O
regulation	O
in	O
major	O
depression	O
.	O
Some	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
have	O
elevated	O
plasma	O
cortisol	O
concentrations	O
and	O
show	O
failure	O
to	O
suppress	O
cortisol	O
secretion	O
upon	O
administration	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
yet	O
they	O
do	O
not	O
have	O
Cushingoid	O
features	O
.	O
To	O
study	O
whether	O
this	O
represents	O
glucocorticoid	O
(	O
GC	O
)	O
resistance	O
,	O
[	O
3H	O
]	O
-DEX	O
-	O
binding	O
assays	O
were	O
used	O
to	O
measure	O
,	O
in	O
vitro	O
,	O
the	O
GC	B
receptor	I
affinity	O
(	O
1	O
/	O
Kd	O
)	O
and	O
number	O
(	O
Bmax	O
)	O
in	O
mononuclear	O
leukocytes	O
of	O
11	O
MDD	O
patients	O
and	O
15	O
control	O
subjects	O
.	O
No	O
receptor	O
abnormalities	O
were	O
detected	O
in	O
the	O
MDD	O
group	O
;	O
thus	O
any	O
cellular	O
defect	O
leading	O
to	O
a	O
lack	O
of	O
responsiveness	O
to	O
GC	O
in	O
the	O
MDD	O
patients	O
,	O
if	O
present	O
,	O
probably	O
lies	O
beyond	O
the	O
initial	O
receptor	O
binding	O
.	O
DEX	O
(	O
1.0	O
mg	O
orally	O
)	O
was	O
administered	O
to	O
study	O
in	O
vivo	B
GC	I
receptor	I
down	O
-	O
regulation	O
.	O
Compared	O
to	O
the	O
control	O
group	O
,	O
fewer	O
depressed	O
subjects	O
down	O
-	O
regulated	O
Bmax	O
after	O
DEX	O
.	O
By	O
paired	O
t	O
-	O
test	O
,	O
Bmax	O
decreased	O
significantly	O
in	O
the	O
control	O
group	O
but	O
not	O
in	O
the	O
depressed	O
group	O
.	O
Receptor	O
number	O
on	O
the	O
control	O
day	O
did	O
not	O
correlate	O
significantly	O
with	O
the	O
degree	O
of	O
receptor	O
down	O
-	O
regulation	O
,	O
severity	O
of	O
depression	O
or	O
cortisol	O
concentrations	O
across	O
all	O
the	O
subjects	O
.	O
These	O
results	O
do	O
not	O
lend	O
support	O
to	O
previous	O
reports	O
suggesting	O
that	O
GC	O
resistance	O
in	O
MDD	O
results	O
from	O
a	O
GC	O
receptor	O
-	O
binding	O
abnormality	O
,	O
and	O
they	O
emphasize	O
the	O
importance	O
of	O
considering	O
receptor	O
studies	O
in	O
the	O
context	O
of	O
GC	O
-	O
mediated	O
cell	O
processes	O
in	O
order	O
to	O
identify	O
the	O
exact	O
cellular	O
defect	O
(	O
s	O
)	O
leading	O
to	O
GC	O
resistance	O
.	O
Two	O
distinct	O
forms	O
of	O
active	B
transcription	I
factor	I
CREB	I
(	O
cAMP	B
response	I
element	I
binding	I
protein	I
)	O
.	O
Mammalian	O
cells	O
express	O
two	O
distinct	O
forms	O
of	O
transcription	B
factor	I
CREB	I
(	O
cAMP	B
response	I
element	I
binding	I
protein	I
)	O
that	O
are	O
apparently	O
the	O
products	O
of	O
alternative	O
splicing	O
of	O
the	O
CREB	O
gene	O
transcript	O
.	O
The	O
two	O
proteins	O
differ	O
by	O
a	O
14-amino	B
acid	I
serine	I
-	I
rich	I
insertion	I
present	O
in	O
one	O
of	O
the	O
CREB	B
isoforms	I
.	O
We	O
show	O
that	O
both	O
CREB	B
isoforms	I
are	O
expressed	O
in	O
many	O
cell	O
types	O
and	O
mammalian	O
species	O
.	O
Both	O
encode	O
proteins	O
that	O
bind	O
specifically	O
to	O
a	O
cAMP	O
response	O
element	O
in	O
vitro	O
.	O
As	O
expected	O
for	O
proteins	O
of	O
this	O
class	O
,	O
the	O
CREB	B
proteins	I
bind	O
DNA	O
as	O
dimers	O
.	O
Both	O
proteins	O
impart	O
cAMP	O
-	O
regulated	O
transcriptional	O
activity	O
to	O
a	O
heterologous	O
DNA	O
-	O
binding	O
domain	O
,	O
showing	O
that	O
cAMP	O
directly	O
modulates	O
the	O
transcriptional	O
stimulatory	O
activity	O
of	O
CREB	B
.	O
The	O
presence	O
of	O
multiple	O
CREB	B
isoforms	I
with	O
identical	O
DNA	O
-	O
binding	O
specificities	O
but	O
differences	O
in	O
the	O
presumed	O
regulatory	B
domain	I
raises	O
the	O
possibility	O
that	O
CREB	B
proteins	I
may	O
be	O
able	O
to	O
integrate	O
distinct	O
regulatory	O
signals	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O
[	O
The	O
inhibitory	O
effect	O
of	O
hydrocortisone	O
on	O
the	O
chemotactic	O
migration	O
of	O
human	O
leukocytes	O
]	O
Random	O
migration	O
(	O
RM	O
)	O
and	O
chemotactic	O
migration	O
(	O
ChtM	O
)	O
of	O
human	O
leukocytes	O
to	O
yeast	O
activated	O
serum	O
were	O
studied	O
with	O
the	O
modified	O
Boyden	O
chamber	O
method	O
.	O
Both	O
RM	O
and	O
ChtM	O
showed	O
circadian	O
rhythm	O
.	O
Leukocytes	O
migrated	O
most	O
rapidly	O
at	O
night	O
.	O
The	O
difference	O
between	O
the	O
peak	O
(	O
0	O
:	O
00	O
)	O
and	O
trough	O
values	O
(	O
8	O
:	O
00	O
)	O
of	O
RM	O
and	O
ChtM	O
was	O
significant	O
statistically	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O
ChtM	O
was	O
inhibited	O
by	O
hydrocortisone	O
(	O
F	O
)	O
of	O
physiological	O
concentration	O
(	O
10	O
(	O
-9	O
)	O
-10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
which	O
was	O
dose	O
-	O
dependent	O
and	O
completely	O
antagonized	O
by	O
the	O
competitive	O
antagonist	O
,	O
RU38486	O
.	O
The	O
inhibitory	O
effect	O
was	O
much	O
more	O
evident	O
with	O
higher	O
dose	O
(	O
more	O
than	O
10	O
(	O
-5	O
)	O
mol	O
/	O
L	O
)	O
and	O
it	O
was	O
also	O
reversed	O
by	O
RU38486	O
,	O
but	O
only	O
partially	O
.	O
It	O
is	O
suggested	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
may	O
be	O
a	O
physiological	O
regulator	O
of	O
the	O
activity	O
of	O
leukocytes	O
and	O
its	O
inhibitory	O
action	O
on	O
ChtM	O
may	O
be	O
involved	O
in	O
antiinflammatory	O
mechanisms	O
of	O
GC	O
of	O
pharmacological	O
doses	O
.	O
The	O
action	O
of	O
physiological	O
and	O
pharmacological	O
concentration	O
of	O
GC	O
may	O
be	O
mediated	O
by	O
low	B
affinity	I
specific	I
binding	I
sites	I
of	O
glucocorticoid	B
receptors	I
.	O
Tandem	O
AP-1-binding	O
sites	O
within	O
the	O
human	O
beta	O
-	O
globin	O
dominant	O
control	O
region	O
function	O
as	O
an	O
inducible	O
enhancer	O
in	O
erythroid	O
cells	O
.	O
A	O
powerful	O
enhancer	O
has	O
been	O
mapped	O
to	O
an	O
18-bp	O
DNA	O
segment	O
located	O
11	O
kb	O
5	O
'	O
to	O
the	O
human	O
epsilon	O
-	O
globin	O
gene	O
within	O
the	O
dominant	O
control	O
or	O
locus	O
-	O
activating	O
region	O
.	O
This	O
enhancer	O
is	O
inducible	O
in	O
K562	O
human	O
erythroleukemia	O
cells	O
,	O
increasing	O
linked	O
gamma	O
-	O
globin	O
promoter	O
/luciferase	B
gene	O
expression	O
to	O
170-fold	O
over	O
an	O
enhancerless	O
construct	O
.	O
The	O
enhancer	O
consists	O
of	O
tandem	O
AP-1-binding	O
sites	O
,	O
phased	O
10	O
bp	O
apart	O
,	O
which	O
are	O
both	O
required	O
for	O
full	O
activity	O
.	O
DNA	O
-	O
protein	O
binding	O
assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	B
molecular	I
weight	I
complex	I
on	O
the	O
enhancer	O
.	O
The	O
formation	O
of	O
this	O
complex	O
also	O
requires	O
both	O
AP-1	O
sites	O
and	O
correlates	O
with	O
maximal	O
enhancer	O
activity	O
.	O
Induction	O
of	O
the	O
enhancer	O
may	O
have	O
a	O
role	O
in	O
the	O
increase	O
in	O
globin	O
gene	O
transcription	O
that	O
characterizes	O
erythroid	O
maturation	O
.	O
Enhancer	O
activity	O
appears	O
to	O
be	O
mediated	O
by	O
the	O
binding	O
of	O
a	O
complex	O
of	O
proteins	O
from	O
the	O
jun	O
and	O
fos	O
families	O
to	O
tandem	O
AP-1	O
consensus	O
sequences	O
.	O
Detection	O
in	O
non	O
-	O
erythroid	O
cells	O
of	O
a	O
factor	O
with	O
the	O
binding	O
characteristics	O
of	O
the	O
erythroid	B
cell	I
transcription	I
factor	I
EF1	B
.	O
The	O
erythroid	B
transcription	I
factor	I
erythroid	B
factor-1	I
(	O
EF1	B
)	O
plays	O
a	O
critical	O
role	O
in	O
the	O
transcription	O
of	O
erythroid	O
-	O
specific	O
genes	O
.	O
Here	O
we	O
report	O
the	O
presence	O
of	O
a	O
factor	O
with	O
the	O
mobility	O
and	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
characteristics	O
of	O
EF1	B
at	O
low	O
abundance	O
in	O
a	O
wide	O
variety	O
of	O
non	O
-	O
erythroid	O
cell	O
types	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
an	O
EF1	B
-like	O
activity	O
in	O
non	O
-	O
erythroid	O
cells	O
and	O
indicates	O
that	O
this	O
factor	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	O
expressed	O
in	O
such	O
cells	O
.	O
Interferon	O
affects	O
nuclear	B
proteins	I
in	O
cells	O
of	O
clinically	O
sensitive	O
chronic	O
myelogenous	O
leukemia	O
patients	O
.	O
Cytoplasmic	O
protein	O
extracts	O
from	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
cells	O
contained	O
an	O
activity	O
that	O
altered	O
the	O
electrophoretic	O
mobility	O
of	O
complexes	O
formed	O
between	O
nuclear	B
proteins	I
and	O
the	O
transcriptional	O
enhancers	O
of	O
interferon	O
(	O
IFN	O
)	O
-inducible	O
genes	O
.	O
Exposure	O
of	O
CML	O
cells	O
to	O
IFN	B
-	I
alpha	I
diminished	O
the	O
effect	O
of	O
the	O
CML	B
cytoplasmic	I
proteins	I
on	O
these	O
nuclear	B
protein	I
-	I
DNA	I
complexes	I
.	O
The	O
presence	O
of	O
clinical	O
responsiveness	O
to	O
IFN	B
-	I
alpha	I
correlated	O
with	O
the	O
sensitivity	O
to	O
the	O
IFN	B
-induced	O
change	O
in	O
the	O
electrophoretic	O
mobility	O
of	O
nuclear	B
protein	I
-	I
DNA	I
complexes	I
.	O
These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
IFN	B
-	I
alpha	I
in	O
CML	O
may	O
be	O
linked	O
to	O
a	O
pathway	O
that	O
can	O
result	O
in	O
posttranslational	O
modification	O
of	O
nuclear	B
proteins	I
.	O
Two	O
glucocorticoid	B
binding	I
sites	I
on	O
the	O
human	B
glucocorticoid	I
receptor	I
.	O
Glucocorticoids	O
are	O
known	O
to	O
have	O
a	O
lytic	O
effect	O
in	O
leukemic	O
cells	O
via	O
interactions	O
with	O
the	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
.	O
Cortisol	O
and	O
various	O
synthetic	O
glucocorticoids	O
bind	O
to	O
the	O
GR	B
with	O
one	O
-	O
site	O
kinetics	O
.	O
Cortivazol	O
(	O
CVZ	O
)	O
is	O
a	O
unique	O
,	O
high	O
potency	O
synthetic	O
glucocorticoid	O
,	O
which	O
has	O
a	O
phenylpyrazol	O
fused	O
to	O
the	O
A	O
-	O
ring	O
of	O
the	O
steroid	O
nucleus	O
and	O
displays	O
binding	O
consistent	O
with	O
two	O
or	O
more	O
sites	O
in	O
the	O
cytosol	O
from	O
CEM	O
C7	O
cells	O
(	O
a	O
human	O
acute	O
lymphoblastic	O
T	O
-	O
cell	O
line	O
)	O
.	O
It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
lower	O
affinity	O
class	O
of	O
sites	O
are	O
similar	O
in	O
affinity	O
and	O
site	O
molarity	O
to	O
those	O
recognized	O
by	O
dexamethasone	O
.	O
The	O
higher	O
affinity	O
sites	O
bind	O
CVZ	O
with	O
20-	O
to	O
50-fold	O
greater	O
affinity	O
,	O
consistent	O
with	O
CVZ	O
's	O
enhanced	O
biological	O
effects	O
.	O
In	O
mutant	O
leukemic	O
cells	O
resistant	O
to	O
the	O
lytic	O
effects	O
of	O
dexamethasone	O
,	O
CVZ	O
both	O
lyses	O
the	O
cells	O
and	O
recognizes	O
a	O
single	O
class	O
of	O
sites	O
similar	O
to	O
the	O
high	O
affinity	O
site	O
in	O
CEM	O
C7	O
cells	O
.	O
We	O
have	O
carried	O
out	O
experiments	O
to	O
define	O
the	O
nature	O
of	O
the	O
higher	B
affinity	I
CVZ	I
binding	I
site	I
.	O
We	O
now	O
show	O
that	O
:	O
1	O
)	O
CVZ	O
has	O
more	O
than	O
one	O
binding	O
site	O
in	O
a	O
second	O
,	O
independent	O
,	O
B	O
-	O
cell	O
line	O
,	O
IM-9	O
;	O
2	O
)	O
the	O
antiglucocorticoid	O
RU	O
38486	O
is	O
able	O
to	O
block	O
both	O
CVZ	O
's	O
higher	O
and	O
lower	O
affinity	O
sites	O
;	O
3	O
)	O
all	O
of	O
CVZ	B
's	I
binding	I
sites	I
are	O
on	O
a	O
protein	O
immunologically	O
indistinguishable	O
from	O
the	O
human	O
GR	B
;	O
and	O
4	O
)	O
freshly	O
isolated	O
clones	O
of	O
CVZ	O
-	O
resistant	O
cells	O
have	O
lost	O
all	O
binding	O
sites	O
for	O
CVZ	O
.	O
These	O
data	O
indicate	O
that	O
CVZ	O
is	O
recognizing	O
two	O
glucocorticoid	B
binding	I
sites	I
on	O
the	O
human	O
GR	B
or	O
a	O
protein	O
very	O
similar	O
to	O
it	O
.	O
Astrocytes	O
and	O
glioblastoma	O
cells	O
express	O
novel	O
octamer	B
-	I
DNA	I
binding	I
proteins	I
distinct	O
from	O
the	O
ubiquitous	B
Oct-1	I
and	I
B	I
cell	I
type	I
Oct-2	I
proteins	I
.	O
The	O
'	O
octamer	O
'	O
sequence	O
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O
is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	O
genes	O
in	O
B	O
-	O
lymphocytes	O
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	O
genes	O
in	O
all	O
cell	O
types	O
.	O
In	O
lymphocytes	O
,	O
the	O
octamer	B
-	I
binding	I
protein	I
Oct-2A	B
and	O
variants	O
thereof	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
B	O
-	O
cell	O
specific	O
gene	O
expression	O
,	O
while	O
the	O
ubiquitous	O
protein	O
Oct-1	O
seems	O
to	O
control	O
general	O
octamer	O
site	O
-dependent	O
transcription	O
.	O
Various	O
other	O
genes	O
,	O
for	O
example	O
interleukin-1	O
and	O
MHC	O
class	O
II	O
genes	O
,	O
contain	O
an	O
octamer	O
sequence	O
in	O
the	O
promoter	O
and	O
are	O
expressed	O
in	O
cells	O
of	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O
This	O
prompted	O
us	O
to	O
analyze	O
the	O
octamer	B
-	I
binding	I
proteins	I
in	O
the	O
latter	O
cells	O
.	O
Using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
at	O
least	O
six	O
novel	O
octamer	B
binding	I
proteins	I
were	O
detected	O
in	O
nuclear	O
extracts	O
of	O
cultured	O
mouse	O
astrocytes	O
.	O
These	O
proteins	O
are	O
differentially	O
expressed	O
in	O
human	O
glioblastoma	O
and	O
neuroblastoma	O
cell	O
lines	O
.	O
The	O
nervous	B
system	I
-	I
derived	I
(	I
N	I
-	I
Oct	I
)	I
proteins	I
bound	O
to	O
the	O
octamer	O
DNA	O
sequence	O
in	O
a	O
manner	O
which	O
is	O
indistinguishable	O
from	O
the	O
Oct-1	B
and	O
Oct-2A	B
proteins	I
.	O
The	O
relationship	O
of	O
the	O
N	B
-	I
Oct	I
proteins	I
to	O
Oct-1	B
and	O
Oct-2A	B
was	O
analyzed	O
by	O
proteolytic	O
clipping	O
bandshift	O
assays	O
and	O
by	O
their	O
reactivity	O
towards	O
antisera	O
raised	O
against	O
recombinant	O
Oct-1	B
and	O
Oct-2A	B
proteins	O
.	O
On	O
the	O
basis	O
of	O
these	O
assays	O
,	O
all	O
N	B
-	I
Oct	I
-	I
factors	I
were	O
found	O
to	O
be	O
distinct	O
from	O
the	O
ubiquitous	B
Oct-1	I
and	O
the	O
lymphoid	B
-	I
specific	I
Oct-2A	I
proteins	O
.	O
In	O
melanoma	O
cells	O
that	O
contain	O
the	O
N	B
-	I
Oct-3	I
factor	I
,	O
a	O
transfected	O
lymphocyte	O
-	O
specific	O
promoter	O
was	O
neither	O
activated	O
nor	O
was	O
it	O
repressed	O
upon	O
contransfection	O
with	O
an	O
Oct-2A	O
expression	O
vector	O
.	O
We	O
therefore	O
speculate	O
that	O
N	B
-	I
Oct-3	I
and	O
other	O
N	B
-	I
Oct	I
factors	I
have	O
a	O
specific	O
role	O
in	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
nervous	O
system	O
.	O
Circadian	O
rhythm	O
of	O
glucocorticoid	B
receptors	I
in	O
human	O
peripheral	O
leukocytes	O
and	O
their	O
reactivity	O
to	O
glucocorticoids	O
.	O
1	O
)	O
There	O
exists	O
a	O
CR	O
of	O
GR	B
in	O
human	O
leukocytes	O
,	O
PMN	O
,	O
and	O
monocytes	O
with	O
the	O
peak	O
values	O
from	O
0400	O
to	O
0800	O
hr	O
and	O
the	O
trough	O
values	O
between	O
2300	O
and	O
0000	O
hr	O
.	O
The	O
difference	O
between	O
them	O
was	O
significant	O
statistically	O
.	O
2	O
)	O
The	O
FI	O
of	O
the	O
chemotactic	O
migration	O
rate	O
of	O
PMN	O
by	O
cortisol	O
also	O
showed	O
diurnal	O
changes	O
which	O
were	O
synchronous	O
with	O
that	O
of	O
GR	B
.	O
This	O
indicates	O
that	O
the	O
CR	O
of	O
GR	B
may	O
be	O
of	O
functional	O
significance	O
.	O
3	O
)	O
In	O
Cushing	O
's	O
syndrome	O
,	O
the	O
CR	O
of	O
GR	B
was	O
normal	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
CR	O
of	O
plasma	O
cortisol	O
was	O
disturbed	O
.	O
This	O
indicates	O
the	O
independency	O
of	O
the	O
CR	O
of	O
GR	B
from	O
that	O
of	O
cortisol	O
.	O
4	O
)	O
In	O
apoplexy	O
caused	O
by	O
brain	O
ischemia	O
,	O
the	O
CR	O
of	O
GR	B
was	O
abolished	O
in	O
patients	O
with	O
basal	O
lesions	O
but	O
preserved	O
when	O
the	O
lesions	O
were	O
located	O
in	O
the	O
cerebral	O
cortex	O
.	O
These	O
results	O
strongly	O
suggest	O
that	O
the	O
main	O
`	O
`	O
circadian	O
pacemaker	O
''	O
of	O
GR	B
is	O
located	O
in	O
the	O
basal	O
brain	O
,	O
most	O
probably	O
in	O
the	O
suprachiasmatic	O
nuclei	O
as	O
has	O
been	O
suggested	O
for	O
rodents	O
.	O
Characterization	O
of	O
defensin	B
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	O
virulence	O
regulon	O
of	O
Salmonella	O
typhimurium	O
.	O
The	O
defensin	B
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O
mutations	O
in	O
the	O
phoP	O
/	O
phoQ	O
two	O
-	O
component	O
virulence	O
regulon	O
were	O
tested	O
by	O
using	O
purified	B
defensins	I
NP-1	B
and	O
NP-2	B
.	O
Strains	O
with	O
mutations	O
in	O
either	O
gene	O
of	O
the	O
regulatory	O
pair	O
(	O
phoP	O
[	O
transcriptional	O
activator	O
]	O
or	O
phoQ	O
[	O
membrane	B
sensor	I
kinase	I
]	O
)	O
had	O
increased	O
sensitivities	O
to	O
defensin	B
.	O
The	O
predicted	O
periplasmic	B
domain	I
of	O
the	O
PhoQ	B
protein	I
contained	O
a	O
markedly	O
anionic	O
domain	O
that	O
could	O
interact	O
with	O
cationic	B
proteins	I
and	O
that	O
could	O
be	O
responsible	O
for	O
resistance	O
to	O
defensin	B
.	O
Because	O
insertion	O
mutations	O
in	O
phoP	O
are	O
polar	O
on	O
phoQ	O
,	O
we	O
constructed	O
strains	O
that	O
expressed	O
the	O
PhoQ	B
protein	I
in	O
the	O
absence	O
of	O
PhoP	B
to	O
test	O
whether	O
resistance	O
to	O
defensin	O
requires	O
only	O
the	O
phoQ	B
gene	I
product	I
.	O
We	O
found	O
that	O
resistance	O
to	O
defensin	O
requires	O
the	O
function	O
of	O
both	O
components	O
of	O
this	O
regulatory	O
system	O
,	O
because	O
strains	O
expressing	O
PhoQ	B
without	O
PhoP	B
were	O
still	O
markedly	O
sensitive	O
to	O
defensins	B
.	O
This	O
implied	O
that	O
a	O
pag	B
(	I
phoP	I
-	I
activated	I
gene	I
)	I
product	I
is	O
responsible	O
for	O
defensin	B
resistance	O
.	O
We	O
also	O
tested	O
for	O
the	O
ability	O
of	O
defensins	B
NP-1	B
,	O
NP-5	B
,	O
and	O
HNP-1	B
to	O
activate	O
pag	O
expression	O
and	O
found	O
that	O
these	O
peptides	O
have	O
no	O
effect	O
.	O
Defensin	O
resistance	O
is	O
not	O
the	O
only	O
virulence	O
characteristic	O
controlled	O
by	O
the	O
PhoP	B
-	I
PhoQ	I
regulon	I
because	O
mutations	O
in	O
pagC	O
,	O
as	O
well	O
as	O
ones	O
in	O
the	O
phoP	O
locus	O
that	O
resulted	O
in	O
constitutive	O
pag	O
activation	O
(	O
phenotype	O
PhoPc	B
)	O
,	O
had	O
no	O
effect	O
on	O
defensin	B
resistance	O
,	O
even	O
though	O
they	O
rendered	O
the	O
organism	O
avirulent	O
and	O
deficient	O
in	O
survival	O
within	O
macrophages	O
.	O
The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP	O
-phoQ	O
two	O
-	O
component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	B
proteins	I
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O
S.	O
typhimurium	O
survival	O
within	O
macrophages	O
.	O
Adherence	O
-	O
dependent	O
increase	O
in	O
human	O
monocyte	O
PDGF	O
(	O
B	O
)	O
mRNA	O
is	O
associated	O
with	O
increases	O
in	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
EGR2	O
mRNA	O
.	O
Adherence	O
is	O
an	O
important	O
initial	O
step	O
in	O
the	O
transition	O
of	O
a	O
circulating	O
monocyte	O
to	O
a	O
tissue	O
macrophage	O
.	O
This	O
differentiation	O
is	O
accompanied	O
by	O
an	O
augmented	O
capacity	O
to	O
generate	O
growth	B
factors	I
.	O
We	O
hypothesized	O
that	O
adherence	O
itself	O
might	O
be	O
an	O
important	O
trigger	O
for	O
a	O
sequence	O
of	O
gene	O
activation	O
culminating	O
in	O
cells	O
with	O
increased	O
mRNA	O
encoding	O
profibrotic	O
growth	B
factors	I
such	O
as	O
platelet	B
-	I
derived	I
growth	I
factor	I
B	I
subunit	I
(	O
PDGF	B
[	I
B	I
]	I
)	O
and	O
transforming	B
growth	I
factor	I
-	I
beta	I
(	O
TGF	B
-	I
beta	I
)	O
.	O
After	O
in	O
vitro	O
adherence	O
,	O
human	O
monocytes	O
had	O
a	O
biphasic	O
increase	O
in	O
PDGF	O
(	O
B	O
)	O
mRNA	O
with	O
peaks	O
at	O
6	O
h	O
and	O
13	O
d	O
.	O
No	O
increase	O
in	O
TGF	O
-	O
beta	O
mRNA	O
was	O
observed	O
.	O
The	O
6-h	O
increase	O
in	O
PDGF	O
(	O
B	O
)	O
mRNA	O
was	O
adherence	O
dependent	O
,	O
and	O
in	O
addition	O
,	O
was	O
abrogated	O
when	O
the	O
cytoskeletal	O
integrity	O
was	O
compromised	O
by	O
cytochalasin	O
D	O
.	O
The	O
6-h	O
increase	O
in	O
PDGF	O
(	O
B	O
)	O
mRNA	O
was	O
unaltered	O
by	O
adherence	O
in	O
the	O
presence	O
of	O
the	O
monocyte	O
stimulus	O
lipopolysaccharide	O
.	O
Adherence	O
to	O
either	O
fibronectin	O
or	O
collagen	O
-	O
coated	O
plastic	O
had	O
little	O
consistent	O
effect	O
on	O
PDGF	O
(	O
B	O
)	O
mRNA	O
accumulation	O
.	O
The	O
increased	O
PDGF	O
(	O
B	O
)	O
mRNA	O
observed	O
in	O
adherent	O
monocytes	O
was	O
accompanied	O
by	O
increases	O
in	O
mRNAs	O
of	O
the	O
early	O
growth	O
response	O
genes	O
c	O
-	O
fos	O
(	O
maximal	O
at	O
20	O
min	O
)	O
,	O
c	O
-	O
jun	O
,	O
and	O
EGR2	O
(	O
maximal	O
at	O
6	O
-	O
24	O
h	O
)	O
.	O
The	O
increase	O
in	O
c	O
-	O
jun	O
and	O
EGR2	O
,	O
but	O
not	O
c	O
-	O
fos	O
,	O
mRNA	O
was	O
also	O
abrogated	O
by	O
cytochalasin	O
D	O
.	O
These	O
observations	O
suggest	O
that	O
adherence	O
results	O
in	O
increases	O
of	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
EGR2	O
,	O
and	O
PDGF	O
(	O
B	O
)	O
mRNA	O
.	O
In	O
addition	O
,	O
the	O
increases	O
in	O
c	O
-	O
jun	O
,	O
EGR2	O
,	O
and	O
PDGF	B
(	I
B	I
)	I
may	O
depend	O
on	O
cytoskeletal	O
rearrangement	O
.	O
Modulation	O
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O
a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished	O
.	O
Cloning	O
of	O
a	O
mitogen	O
-	O
inducible	O
gene	O
encoding	O
a	O
kappa	B
B	I
DNA	I
-	I
binding	I
protein	I
with	O
homology	O
to	O
the	O
rel	O
oncogene	O
and	O
to	O
cell	O
-	O
cycle	O
motifs	O
.	O
We	O
have	O
cloned	O
and	O
characterized	O
a	O
mitogen	O
-	O
inducible	O
gene	O
isolated	O
from	O
human	O
T	O
cells	O
that	O
predicts	O
a	O
protein	O
of	O
968	B
amino	I
acids	I
.	O
The	O
amino	B
-	I
terminal	I
domain	I
has	O
regions	O
homologous	O
to	O
the	O
oncogene	O
rel	O
and	O
to	O
the	O
developmentally	O
important	O
gene	O
dorsal	O
of	O
Drosophila	O
.	O
The	O
carboxy	B
-	I
terminal	I
domain	I
contains	O
repeat	O
structures	O
found	O
in	O
a	O
variety	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
cell	O
-	O
cycle	O
control	O
of	O
yeast	O
and	O
in	O
tissue	O
differentiation	O
in	O
Drosophila	O
and	O
Ceanorhabditis	O
elegans	O
,	O
as	O
well	O
as	O
in	O
the	O
putative	O
human	O
oncogene	O
bcl-3	O
and	O
in	O
the	O
ankyrin	B
protein	I
.	O
A	O
truncated	O
form	O
of	O
the	O
product	O
of	O
this	O
gene	O
translated	O
in	O
vitro	O
is	O
a	O
DNA	B
-	I
binding	I
protein	I
which	O
interacts	O
specifically	O
with	O
the	O
kappa	O
B	O
binding	O
site	O
found	O
in	O
many	O
inducible	O
genes	O
,	O
including	O
the	O
enhancer	O
in	O
human	O
immunodeficiency	O
virus	O
.	O
This	O
gene	O
is	O
yet	O
another	O
in	O
a	O
growing	O
list	O
of	O
important	O
regulatory	O
molecules	O
whose	O
expression	O
is	O
transcriptionally	O
induced	O
upon	O
cellular	O
activation	O
.	O
Stimulation	O
of	O
a	O
human	O
T	O
-	O
cell	O
clone	O
with	O
anti	B
-	I
CD3	I
or	O
tumor	B
necrosis	I
factor	I
induces	O
NF	B
-	I
kappa	I
B	I
translocation	O
but	O
not	O
human	O
immunodeficiency	O
virus	O
1	O
enhancer	O
-	O
dependent	O
transcription	O
.	O
The	O
expression	O
of	O
transiently	O
transfected	O
expression	O
vectors	O
under	O
the	O
control	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
or	O
its	O
enhancer	O
sequence	O
and	O
the	O
translocation	O
of	O
the	O
HIV	B
enhancer	I
-	I
binding	I
protein	I
NF	B
-	I
kappa	I
B	I
were	O
analyzed	O
in	O
two	O
human	O
T	O
-	O
cell	O
clones	O
stimulated	O
through	O
their	O
T	B
-	I
cell	I
receptor	I
complex	I
or	O
by	O
tumor	B
necrosis	I
factor	I
or	O
phorbol	O
12-myristate	O
13-acetate	O
.	O
We	O
found	O
a	O
dissociation	O
of	O
NF	B
-	I
kappa	I
B	I
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	O
LTR	O
or	O
the	O
HIV	O
enhancer	O
.	O
Interleukin	B
2	I
induced	O
proliferation	O
but	O
not	O
NF	B
-	I
kappa	I
B	I
translocation	O
or	O
LTR	O
transactivation	O
.	O
Phorbol	O
ester	O
or	O
specific	O
antigen	O
recognition	O
induced	O
HIV	O
LTR	O
transactivation	O
,	O
whereas	O
stimulation	O
with	O
tumor	B
necrosis	I
factor	I
or	O
antibody	O
to	O
CD3	B
did	O
not	O
.	O
The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF	B
-	I
kappa	I
B	I
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band	O
-	O
shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O
Our	O
finding	O
that	O
induction	O
of	O
NF	B
-	I
kappa	I
B	I
by	O
tumor	B
necrosis	I
factor	I
or	O
antibody	B
to	I
CD3	I
is	O
not	O
sufficient	O
to	O
induce	O
HIV	O
enhancer	O
-dependent	O
transcription	O
in	O
cloned	O
T	O
cells	O
contrasts	O
with	O
results	O
obtained	O
in	O
most	O
lymphoblastoid	O
T	O
-	O
cell	O
lines	O
and	O
indicates	O
that	O
normal	O
T	O
lymphocytes	O
differ	O
from	O
tumoral	O
T	O
cells	O
in	O
terms	O
of	O
requirements	O
for	O
HIV	O
LTR	O
activation	O
.	O
Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T	O
-	O
cell	O
activation	O
,	O
in	O
addition	O
to	O
NF	B
-	I
kappa	I
B	I
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
complex	I
with	O
the	O
HIV	O
enhancer	O
.	O
Regulation	O
of	O
gene	O
expression	O
with	O
double	O
-	O
stranded	O
phosphorothioate	O
oligonucleotides	O
.	O
Alteration	O
of	O
gene	O
transcription	O
by	O
inhibition	O
of	O
specific	O
transcriptional	B
regulatory	I
proteins	I
is	O
necessary	O
for	O
determining	O
how	O
these	O
factors	O
participate	O
in	O
cellular	O
differentiation	O
.	O
The	O
functions	O
of	O
these	O
proteins	O
can	O
be	O
antagonized	O
by	O
several	O
methods	O
,	O
each	O
with	O
specific	O
limitations	O
.	O
Inhibition	O
of	O
sequence	B
-	I
specific	I
DNA	I
-	I
binding	I
proteins	I
was	O
achieved	O
with	O
double	O
-	O
stranded	O
(	O
ds	O
)	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
octamer	O
or	O
kappa	O
B	O
consensus	O
sequences	O
.	O
The	O
phosphorothioate	O
oligonucleotides	O
specifically	O
bound	O
either	O
octamer	B
transcription	I
factor	I
or	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
.	O
The	O
modified	O
oligonucleotides	O
accumulated	O
in	O
cells	O
more	O
effectively	O
than	O
standard	O
ds	O
oligonucleotides	O
and	O
modulated	O
gene	O
expression	O
in	O
a	O
specific	O
manner	O
.	O
Octamer	O
-	O
dependent	O
activation	O
of	O
a	O
reporter	O
plasmid	O
or	O
NF	B
-	I
kappa	I
B	I
-dependent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
enhancer	O
was	O
inhibited	O
when	O
the	O
appropriate	O
phosphorothioate	O
oligonucleotide	O
was	O
added	O
to	O
a	O
transiently	O
transfected	O
B	O
cell	O
line	O
.	O
Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
the	O
octamer	O
consensus	O
to	O
Jurkat	O
T	O
leukemia	O
cells	O
inhibited	O
interleukin-2	B
(	O
IL-2	B
)	O
secretion	O
to	O
a	O
degree	O
similar	O
to	O
that	O
observed	O
with	O
a	O
mutated	O
octamer	O
site	O
in	O
the	O
IL-2	O
enhancer	O
.	O
The	O
ds	O
phosphorothioate	O
oligonucleotides	O
probably	O
compete	O
for	O
binding	O
of	O
specific	O
transcription	O
factors	O
and	O
may	O
provide	O
anti	O
-	O
viral	O
,	O
immunosuppressive	O
,	O
or	O
other	O
therapeutic	O
effects	O
.	O
Single	O
cell	O
assay	O
of	O
a	O
transcription	B
factor	I
reveals	O
a	O
threshold	O
in	O
transcription	O
activated	O
by	O
signals	O
emanating	O
from	O
the	O
T	B
-	I
cell	I
antigen	I
receptor	I
.	O
Stimulation	O
of	O
T	O
lymphocytes	O
through	O
their	O
antigen	B
receptor	I
leads	O
to	O
the	O
appearance	O
of	O
several	O
transcription	B
factors	I
,	O
including	O
NF	B
-	I
AT	I
and	O
NF	B
-	I
kappa	I
B	I
,	O
which	O
are	O
involved	O
in	O
regulating	O
genes	O
required	O
for	O
immunologic	O
activation	O
.	O
To	O
investigate	O
the	O
activity	O
of	O
a	O
single	O
transcription	B
factor	I
in	O
individual	O
viable	O
cells	O
,	O
we	O
have	O
applied	O
an	O
assay	O
that	O
uses	O
the	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
to	O
quantitate	O
beta	B
-	I
galactosidase	I
(	O
beta	B
-	I
gal	I
)	O
.	O
We	O
have	O
analyzed	O
the	O
distribution	O
of	O
NF	B
-	I
AT	I
transcriptional	O
activity	O
among	O
T	O
cells	O
undergoing	O
activation	O
by	O
using	O
a	O
construct	O
in	O
which	O
three	O
tandem	O
copies	O
of	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
directs	O
transcription	O
of	O
the	O
lacZ	O
gene	O
.	O
Unexpectedly	O
,	O
stimulation	O
of	O
cloned	O
stably	O
transfected	O
Jurkat	O
T	O
cells	O
leads	O
to	O
a	O
bimodal	O
pattern	O
of	O
beta	O
-	O
gal	O
expression	O
in	O
which	O
some	O
cells	O
express	O
no	O
beta	B
-	I
gal	I
and	O
others	O
express	O
high	O
levels	O
.	O
This	O
expression	O
pattern	O
can	O
not	O
be	O
accounted	O
for	O
by	O
cell	O
-	O
cycle	O
position	O
or	O
heritable	O
variation	O
.	O
Further	O
results	O
,	O
in	O
which	O
beta	B
-	I
gal	I
activity	O
is	O
correlated	O
with	O
NF	B
-	I
AT	I
-binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF	B
-	I
AT	I
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O
This	O
threshold	O
likely	O
reflects	O
the	O
NF	B
-	I
AT	I
concentration	O
-	O
dependent	O
assembly	O
of	O
transcription	B
complexes	I
at	O
the	O
promoter	O
.	O
Similar	O
constructs	O
controlled	O
by	O
NF	B
-	I
kappa	I
B	I
or	O
the	O
entire	O
interleukin-2	O
enhancer	O
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	B
factors	I
may	O
be	O
a	O
common	O
property	O
of	O
inducible	O
genes	O
.	O
Differences	O
in	O
transcriptional	O
enhancers	O
of	O
HIV-1	O
and	O
HIV-2	O
.	O
Response	O
to	O
T	O
cell	O
activation	O
signals	O
.	O
T	O
cell	O
activation	O
results	O
in	O
high	O
levels	O
of	O
HIV	O
replication	O
and	O
is	O
thought	O
to	O
be	O
one	O
mechanism	O
leading	O
to	O
the	O
conversion	O
from	O
latent	O
to	O
active	O
viral	O
infection	O
.	O
In	O
HIV-1	O
,	O
the	O
sequences	O
that	O
respond	O
to	O
these	O
signaling	O
events	O
are	O
found	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
comprise	O
the	O
transcriptional	O
enhancer	O
,	O
which	O
contains	O
two	O
conserved	O
binding	O
sites	O
for	O
the	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
kappa	I
B	I
)	O
.	O
The	O
corresponding	O
region	O
in	O
the	O
second	O
AIDS	O
retrovirus	O
,	O
HIV-2	O
,	O
contains	O
a	O
conserved	O
and	O
a	O
divergent	O
NF	O
kappa	O
B	O
binding	O
site	O
.	O
We	O
demonstrate	O
that	O
the	O
HIV-1	O
LTR	O
responds	O
better	O
than	O
the	O
HIV-2	O
LTR	O
to	O
T	O
cell	O
activation	O
signals	O
.	O
These	O
qualitative	O
differences	O
in	O
the	O
response	O
to	O
T	O
cell	O
activation	O
are	O
reproduced	O
not	O
only	O
when	O
HIV-1	O
or	O
HIV-2	O
enhancers	O
are	O
placed	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
but	O
also	O
when	O
these	O
enhancers	O
are	O
switched	O
between	O
their	O
respective	O
LTR	O
.	O
In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
NF	B
kappa	I
B	I
binds	O
to	O
both	O
conserved	O
sites	O
in	O
the	O
HIV-1	O
transcriptional	O
enhancer	O
and	O
only	O
to	O
the	O
single	O
conserved	O
site	O
in	O
the	O
HIV-2	O
transcriptional	O
enhancer	O
.	O
Instead	O
of	O
NF	B
kappa	I
B	I
,	O
the	O
activator	B
protein	I
3	I
binds	O
to	O
the	O
divergent	O
site	O
in	O
HIV-2	O
.	O
In	O
conclusion	O
,	O
HIV-1	O
and	O
HIV-2	O
are	O
differentially	O
regulated	O
by	O
T	O
cell	O
activation	O
signals	O
,	O
and	O
this	O
difference	O
may	O
account	O
for	O
the	O
longer	O
period	O
of	O
viral	O
latency	O
observed	O
with	O
HIV-2	O
than	O
with	O
HIV-1	O
infection	O
.	O
The	O
actions	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
suggest	O
a	O
novel	O
step	O
in	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O
Cyclosporin	O
A	O
and	O
FK506	O
are	O
immunosuppressive	O
compounds	O
that	O
have	O
similar	O
inhibitory	O
effects	O
on	O
the	O
expression	O
of	O
several	O
lymphokines	B
produced	O
by	O
T	O
lymphocytes	O
.	O
Despite	O
their	O
similar	O
effects	O
the	O
drugs	O
bind	O
to	O
two	O
different	O
cytosolic	B
protein	I
,	O
cyclophilin	B
and	O
FKBP	B
respectively	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
they	O
have	O
different	O
modes	O
of	O
action	O
.	O
Using	O
constructs	O
in	O
which	O
mRNA	O
production	O
controlled	O
by	O
a	O
specific	O
transcription	B
factor	I
could	O
be	O
readily	O
measured	O
we	O
found	O
that	O
both	O
cyclosporin	O
A	O
and	O
FK506	O
completely	O
inhibited	O
transcription	O
activated	O
by	O
NF	B
-	I
AT	I
,	O
NFIL2	B
A	I
,	O
NFIL2	B
B	I
and	O
partially	O
inhibited	O
transcription	O
activated	O
by	O
NF	B
kappa	I
B	I
.	O
Cyclosporin	O
A	O
and	O
FK506	O
inhibited	O
only	O
transcriptional	O
activation	O
that	O
was	O
dependent	O
on	O
Ca2	O
+	O
mobilization	O
.	O
However	O
,	O
cyclosporin	O
A	O
and	O
FK506	O
did	O
not	O
inhibit	O
Ca2	O
+	O
mobilization	O
dependent	O
expression	O
of	O
c	O
-	O
fos	O
mRNA	O
indicating	O
that	O
only	O
a	O
subset	O
of	O
signalling	O
pathways	O
regulated	O
by	O
Ca2	O
+	O
is	O
sensitive	O
to	O
these	O
drugs	O
.	O
Furthermore	O
,	O
we	O
did	O
not	O
observe	O
any	O
qualitative	O
differences	O
between	O
the	O
effect	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
on	O
six	O
different	O
transcription	B
factors	I
which	O
suggests	O
that	O
these	O
drugs	O
may	O
interfere	O
with	O
the	O
activity	O
of	O
a	O
novel	O
Ca2	O
+	O
dependent	O
step	O
that	O
regulates	O
several	O
transcription	B
factors	I
.	O
Lymphoid	O
specific	O
gene	O
expression	O
of	O
the	O
adenovirus	O
early	O
region	O
3	O
promoter	O
is	O
mediated	O
by	O
NF	O
-	O
kappa	O
B	O
binding	O
motifs	O
.	O
A	O
primary	O
site	O
of	O
infection	O
by	O
human	O
adenoviruses	O
is	O
lymphoid	O
cells	O
.	O
However	O
,	O
analysis	O
of	O
the	O
viral	O
control	O
elements	O
and	O
the	O
cellular	B
factors	I
that	O
regulate	O
adenoviral	O
gene	O
expression	O
in	O
lymphocytes	O
has	O
not	O
been	O
reported	O
.	O
The	O
adenovirus	B
early	I
region	I
3	I
(	I
ES	I
)	I
gene	I
products	I
are	O
involved	O
in	O
the	O
maintenance	O
of	O
viral	O
persistence	O
by	O
complexing	O
with	O
the	O
class	B
I	I
MHC	I
antigens	I
,	O
thus	O
preventing	O
their	O
cell	O
surface	O
expression	O
with	O
a	O
resultant	O
decrease	O
in	O
host	O
immunologic	O
destruction	O
.	O
To	O
determine	O
whether	O
different	O
cellular	B
factors	I
were	O
involved	O
in	O
E3	O
regulation	O
in	O
lymphocytes	O
as	O
compared	O
with	O
HeLa	O
cells	O
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	O
promoter	O
in	O
both	O
cell	O
types	O
were	O
performed	O
.	O
These	O
studies	O
detected	O
two	O
novel	O
domains	O
referred	O
to	O
as	O
L1	O
and	O
L2	O
with	O
a	O
variety	O
of	O
lymphoid	O
but	O
not	O
HeLa	O
extracts	O
.	O
Each	O
of	O
these	O
domains	O
possessed	O
strong	O
homology	O
to	O
motifs	O
previously	O
found	O
to	O
bind	O
the	O
cellular	B
factor	I
NF	I
-	I
kappa	I
B	I
.	O
Transfections	O
of	O
E3	O
constructs	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
gene	O
revealed	O
that	O
mutagenesis	O
of	O
the	O
distal	O
NF	O
-	O
kappa	O
B	O
motif	O
(	O
L2	O
)	O
had	O
minimal	O
effects	O
on	O
promoter	O
expression	O
in	O
HeLa	O
cells	O
,	O
but	O
resulted	O
in	O
dramatic	O
decreases	O
in	O
expression	O
by	O
lymphoid	O
cells	O
.	O
In	O
contrast	O
,	O
mutagenesis	O
of	O
proximal	O
NF	O
-	O
kappa	O
B	O
motif	O
(	O
L1	O
)	O
had	O
minimal	O
effects	O
on	O
gene	O
expression	O
in	O
both	O
HeLa	O
cells	O
and	O
lymphoid	O
cells	O
but	O
resulted	O
in	O
a	O
small	O
,	O
but	O
reproducible	O
,	O
increase	O
in	O
gene	O
expression	O
in	O
lymphoid	O
cells	O
when	O
coupled	O
to	O
the	O
L2	O
mutation	O
.	O
Reversing	O
the	O
position	O
and	O
subsequent	O
mutagenesis	O
of	O
the	O
L1	O
and	O
L2	O
domains	O
indicated	O
that	O
the	O
primary	O
sequence	O
of	O
these	O
motifs	O
rather	O
than	O
their	O
position	O
in	O
the	O
E3	O
promoter	O
was	O
critical	O
for	O
regulating	O
gene	O
expression	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Oncogene	O
amplification	O
correlates	O
with	O
dense	O
lymphocyte	O
infiltration	O
in	O
human	O
breast	O
cancers	O
:	O
a	O
role	O
for	O
hematopoietic	B
growth	I
factor	I
release	O
by	O
tumor	O
cells	O
?	O
One	O
hundred	O
six	O
primary	O
breast	O
cancer	O
samples	O
were	O
analysed	O
for	O
c	O
-	O
erbB2	O
,	O
int-2	O
,	O
and	O
c	O
-	O
myc	O
gene	O
amplification	O
.	O
Surgically	O
confirmed	O
nodal	O
involvement	O
was	O
observed	O
in	O
42	O
%	O
.	O
Level	O
of	O
gene	O
amplification	O
was	O
studied	O
by	O
Southern	O
and/or	O
slot	O
blot	O
techniques	O
.	O
Amplified	O
c	O
-	O
erbB2	O
gene	O
sequences	O
were	O
present	O
in	O
21.5	O
%	O
of	O
all	O
samples	O
.	O
Int-2	O
was	O
amplified	O
in	O
13.1	O
%	O
and	O
c	O
-	O
myc	O
was	O
amplified	O
in	O
10.3	O
%	O
.	O
In	O
a	O
non	O
-	O
parametric	O
test	O
(	O
Kruskal	O
-	O
Wallis	O
)	O
a	O
strong	O
negative	O
association	O
was	O
found	O
between	O
high	O
levels	O
of	O
c	O
-	O
erbB2	O
amplification	O
and	O
absence	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
(	O
P	O
=	O
.0009	O
)	O
or	O
progesterone	B
receptor	I
(	O
PR	B
)	O
(	O
P	O
=	O
.011	O
)	O
expression	O
.	O
No	O
correlations	O
were	O
found	O
between	O
all	O
or	O
high	O
levels	O
of	O
amplification	O
of	O
each	O
oncogene	O
separately	O
or	O
combined	O
with	O
T	O
,	O
N	O
,	O
grade	O
,	O
multifocality	O
of	O
tumor	O
,	O
or	O
associated	O
carcinoma	O
in	O
situ	O
.	O
There	O
was	O
a	O
trend	O
approaching	O
statistical	O
significance	O
for	O
patients	O
with	O
c	O
-	O
erbB2	O
amplifications	O
to	O
have	O
positive	O
lymph	O
nodes	O
at	O
surgery	O
(	O
P	O
=	O
0.09	O
)	O
.	O
A	O
somewhat	O
surprising	O
finding	O
however	O
was	O
a	O
very	O
strong	O
association	O
between	O
oncogene	O
amplification	O
and	O
dense	O
lymphocyte	O
infiltration	O
of	O
the	O
tumor	O
(	O
P	O
=	O
.05	O
)	O
.	O
This	O
correlation	O
is	O
even	O
stronger	O
when	O
only	O
high	O
levels	O
of	O
amplification	O
are	O
considered	O
,	O
either	O
for	O
each	O
oncogene	O
separately	O
(	O
P	O
=	O
.0048	O
)	O
or	O
in	O
combination	O
(	O
P	O
=	O
.0007	O
)	O
.	O
We	O
propose	O
that	O
malignant	O
cell	O
cytokine	B
production	O
may	O
help	O
explain	O
this	O
observation	O
.	O
Nuclear	B
factor	I
kappa	I
B	I
activates	O
proenkephalin	O
transcription	O
in	O
T	O
lymphocytes	O
.	O
Upon	O
activation	O
,	O
T	O
lymphocytes	O
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	O
mRNA	O
in	O
the	O
cells	O
.	O
Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O
The	O
proenkephalin	O
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	O
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	O
B	O
sequence	O
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	B
factor	I
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
.	O
Activation	O
of	O
T	O
lymphocytes	O
induces	O
an	O
NF	B
-	I
kappa	I
B	I
-like	O
binding	O
activity	O
to	O
the	O
B2	O
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	O
promoter	O
.	O
Mutations	O
at	O
the	O
B2	O
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O
The	O
purified	O
homodimer	B
(	O
two	O
p50s	B
)	O
of	O
the	O
DNA	B
-	I
binding	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
binds	O
the	O
B2	O
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	B
(	O
two	O
p65s	B
plus	O
two	O
p50s	B
)	O
form	O
of	O
the	O
factor	O
.	O
Thus	O
,	O
it	O
appears	O
that	O
the	O
T	O
-	O
cell	O
-	O
specific	O
activation	O
of	O
the	O
proenkephalin	O
promoter	O
is	O
mediated	O
by	O
NF	B
-	I
kappa	I
B	I
.	O
However	O
,	O
as	O
NF	B
-	I
kappa	I
B	I
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	O
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T	B
-	I
cell	I
-	I
specific	I
factor	I
which	O
synergizes	O
with	O
NF	B
-	I
kappa	I
B	I
should	O
be	O
considered	O
.	O
Thyroid	B
hormone	I
receptors	I
form	O
distinct	O
nuclear	B
protein	I
-	I
dependent	I
and	I
independent	I
complexes	I
with	O
a	O
thyroid	O
hormone	O
response	O
element	O
.	O
We	O
have	O
examined	O
the	O
binding	O
of	O
nuclear	B
proteins	I
and	O
recombinant	B
thyroid	I
hormone	I
receptors	I
(	O
TRs	B
)	O
to	O
the	O
palindromic	O
thyroid	O
hormone	O
responsive	O
element	O
AGGTCATGACCT	O
(	O
TREp	O
)	O
using	O
a	O
gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
Four	O
specific	O
protein	B
-	I
DNA	I
complexes	I
were	O
detected	O
after	O
incubation	O
of	O
nuclear	O
extracts	O
(	O
NE	O
)	O
from	O
T3-responsive	O
pituitary	O
(	O
GH3	O
)	O
cells	O
with	O
a	O
TREp	O
-	O
containing	O
DNA	O
fragment	O
.	O
This	O
was	O
compared	O
with	O
the	O
TREp	O
binding	O
of	O
reticulocyte	B
lysate	I
-	I
synthesized	I
TRs	I
.	O
TR	B
alpha	I
1	I
and	O
TR	B
beta	I
2	I
each	O
formed	O
a	O
single	O
major	O
TR	B
:	I
TREp	I
complex	I
which	O
comigrated	O
with	O
the	O
least	O
retarded	O
complex	O
formed	O
by	O
GH3	O
NE	O
,	O
while	O
TR	B
beta	I
1	I
formed	O
multiple	O
complexes	O
suggesting	O
that	O
it	O
can	O
bind	O
to	O
TREp	O
as	O
an	O
oligomer	B
.	O
Interestingly	O
,	O
coincubation	O
of	O
35S	B
-	I
TR	I
alpha	I
1	I
,	O
GH3	O
NE	O
,	O
and	O
unlabeled	O
TREp	O
resulted	O
in	O
not	O
only	O
the	O
35S	B
-	I
TR	I
:	I
TREp	I
complex	I
,	O
but	O
in	O
two	O
additional	O
more	O
greatly	O
retarded	O
complexes	O
containing	O
35S	B
-	I
TR	I
alpha	I
1	I
and	O
comigrating	O
with	O
those	O
formed	O
by	O
GH3	O
extract	O
alone	O
.	O
Incubation	O
of	O
each	O
of	O
the	O
TRs	B
with	O
NE	O
from	O
COS-7	O
cells	O
,	O
which	O
do	O
not	O
possess	O
sufficient	O
endogenous	O
TRs	B
to	O
mediate	O
T3-responses	O
,	O
resulted	O
in	O
formation	O
of	O
a	O
new	O
,	O
more	O
greatly	B
shifted	I
complex	I
.	O
A	O
similar	O
,	O
heat	O
labile	O
activity	O
which	O
altered	O
mobility	O
of	O
the	O
TR	B
:	I
TRE	I
complex	I
was	O
also	O
present	O
in	O
NE	O
from	O
T3-unresponsive	O
JEG-3	O
cells	O
.	O
At	O
high	O
concentration	O
of	O
NE	O
,	O
all	O
of	O
the	O
TR	B
bound	O
to	O
TREp	O
was	O
more	O
greatly	O
retarded	O
than	O
in	O
the	O
absence	O
of	O
NE	O
.	O
Truncation	O
of	O
TR	B
alpha	I
1	I
at	O
amino	B
acid	I
210	I
prevented	O
additional	O
complex	O
formation	O
in	O
the	O
presence	O
of	O
NE	O
without	O
affecting	O
DNA	O
binding	O
,	O
suggesting	O
that	O
the	O
carboxyl	B
-	I
terminus	I
of	O
the	O
TRs	B
is	O
essential	O
for	O
interaction	O
with	O
nuclear	B
proteins	I
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
A	O
novel	O
HIV-1	O
isolate	O
containing	O
alterations	O
affecting	O
the	O
NF	O
-	O
kappa	O
B	O
element	O
.	O
Three	O
molecular	O
clones	O
of	O
HIV-1	O
,	O
derived	O
from	O
a	O
single	O
isolate	O
(	O
AL1	O
)	O
,	O
exhibited	O
distinct	O
replicative	O
and	O
cytopathic	O
properties	O
during	O
propagation	O
in	O
a	O
human	O
T	O
cell	O
line	O
.	O
The	O
phenotypic	O
differences	O
observed	O
were	O
attributable	O
,	O
in	O
large	O
part	O
,	O
to	O
changes	O
affecting	O
the	O
viral	O
LTR	O
.	O
Nucleotide	O
sequence	O
and	O
PCR	O
analyses	O
demonstrated	O
the	O
presence	O
of	O
novel	O
duplications	O
or	O
deletions	O
involving	O
the	O
NF	O
-	O
kappa	O
B	O
motif	O
.	O
These	O
changes	O
in	O
the	O
enhancer	O
element	O
were	O
identified	O
in	O
the	O
original	O
AL1	O
virus	O
stock	O
.	O
Subcloning	O
of	O
the	O
variant	O
NF	O
-	O
kappa	O
B	O
segments	O
into	O
LTR	O
-	O
driven	O
CAT	O
expression	O
vectors	O
confirmed	O
a	O
correlation	O
between	O
promoter	O
activity	O
and	O
replicative	O
/	O
cytopathic	O
capacity	O
.	O
Glucocorticoid	B
receptors	I
on	O
mononuclear	O
leukocytes	O
in	O
Alzheimer	O
's	O
disease	O
.	O
Several	O
lines	O
of	O
evidence	O
suggest	O
disturbances	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
system	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O
In	O
an	O
exploration	O
of	O
the	O
potential	O
role	O
of	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
in	O
AD	O
,	O
GR	O
density	O
and	O
affinity	O
were	O
assessed	O
on	O
mononuclear	O
leukocytes	O
of	O
12	O
AD	O
patients	O
and	O
12	O
healthy	O
controls	O
.	O
GR	O
binding	O
characteristics	O
did	O
not	O
differ	O
between	O
patients	O
and	O
controls	O
or	O
between	O
patients	O
subdivided	O
according	O
to	O
diagnosis	O
or	O
associated	O
clinical	O
features	O
.	O
These	O
data	O
suggest	O
that	O
the	O
abnormalities	O
of	O
the	O
HPA	O
system	O
in	O
AD	O
are	O
not	O
related	O
to	O
a	O
GR	B
deficiency	O
.	O
The	O
functional	O
domains	O
of	O
the	O
murine	O
Thy-1	O
gene	O
promoter	O
.	O
The	O
Thy-1	O
gene	O
promoter	O
resembles	O
a	O
`	O
`	O
housekeeping	O
''	O
promoter	O
in	O
that	O
it	O
is	O
located	O
within	O
a	O
methylation	O
-	O
free	O
island	O
,	O
lacks	O
a	O
canonical	O
TATA	O
box	O
,	O
and	O
displays	O
heterogeneity	O
in	O
the	O
5'-end	O
termini	O
of	O
the	O
mRNA	O
.	O
Using	O
transgenic	O
mice	O
,	O
we	O
show	O
that	O
this	O
promoter	O
does	O
not	O
confer	O
any	O
tissue	O
specificity	O
and	O
is	O
active	O
only	O
in	O
a	O
position	O
-	O
dependent	O
manner	O
.	O
It	O
can	O
only	O
be	O
activated	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
by	O
elements	O
that	O
lie	O
downstream	O
of	O
the	O
initiation	O
site	O
.	O
We	O
have	O
analyzed	O
the	O
functional	O
domains	O
of	O
the	O
minimal	O
Thy-1	O
promoter	O
and	O
show	O
that	O
the	O
dominant	O
promoter	O
elements	O
consist	O
of	O
multiple	O
binding	O
sites	O
for	O
the	O
transcription	B
factor	I
Sp1	B
,	O
an	O
inverted	O
CCAAT	O
box	O
,	O
and	O
sequences	O
proximal	O
to	O
the	O
transcription	O
start	O
site	O
.	O
DNase	O
I	O
and	O
gel	O
mobility	O
shift	O
assays	O
show	O
the	O
binding	O
of	O
a	O
number	O
of	O
nuclear	B
factors	I
to	O
these	O
elements	O
,	O
including	O
Sp1	B
and	O
CP1	B
.	O
Our	O
results	O
show	O
that	O
the	O
structure	O
of	O
this	O
promoter	O
only	O
permits	O
productive	O
interactions	O
of	O
the	O
two	O
transcription	B
factors	I
Sp1	B
and	O
CP1	B
with	O
the	O
basal	O
transcription	O
machinery	O
in	O
the	O
presence	O
of	O
enhancer	O
sequences	O
.	O
Estrogen	B
receptor	I
concentration	O
and	O
social	O
factors	O
as	O
predictors	O
of	O
natural	O
killer	O
cell	O
activity	O
in	O
early	O
-	O
stage	O
breast	O
cancer	O
patients	O
.	O
Confirmation	O
of	O
a	O
model	O
.	O
Previous	O
work	O
of	O
ours	O
has	O
demonstrated	O
that	O
a	O
significant	O
amount	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
activity	O
variance	O
after	O
surgery	O
in	O
stage	O
I	O
and	O
II	O
breast	O
cancer	O
patients	O
could	O
be	O
accounted	O
for	O
by	O
both	O
the	O
estrogen	B
receptor	I
(	O
ER	B
)	O
status	O
of	O
the	O
tumor	O
and	O
by	O
social	O
factors	O
,	O
namely	O
,	O
perceived	O
social	O
support	O
and	O
seeking	O
social	O
support	O
as	O
a	O
general	O
coping	O
strategy	O
.	O
As	O
considerable	O
evidence	O
has	O
accumulated	O
that	O
social	O
support	O
in	O
both	O
animal	O
and	O
human	O
populations	O
may	O
have	O
survival	O
value	O
,	O
we	O
sought	O
to	O
test	O
the	O
reliability	O
of	O
this	O
regression	O
model	O
,	O
using	O
coping	O
and	O
perceived	O
support	O
factor	O
values	O
obtained	O
at	O
3	O
months	O
after	O
surgery	O
to	O
account	O
for	O
concurrent	O
follow	O
-	O
up	O
NK	O
activity	O
in	O
this	O
serially	O
assessed	O
group	O
of	O
patients	O
.	O
It	O
was	O
found	O
that	O
the	O
most	O
significant	O
variable	O
predicting	O
NK	O
activity	O
at	O
follow	O
-	O
up	O
was	O
tumor	O
ER	B
concentration	O
,	O
with	O
higher	O
NK	O
activity	O
associated	O
with	O
ER	B
-status	O
.	O
In	O
addition	O
,	O
seeking	O
social	O
support	O
as	O
a	O
coping	O
strategy	O
,	O
as	O
well	O
as	O
the	O
perceived	O
quality	O
of	O
support	O
,	O
also	O
entered	O
the	O
model	O
to	O
account	O
for	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
(	O
multivariate	O
F	O
=	O
5.25	O
,	O
p	O
less	O
than	O
0.001	O
)	O
.	O
If	O
,	O
as	O
the	O
literature	O
suggests	O
,	O
NK	O
activity	O
is	O
relevant	O
to	O
breast	O
cancer	O
control	O
,	O
and	O
since	O
ER	B
-tumors	O
have	O
a	O
worse	O
prognosis	O
,	O
we	O
suggest	O
here	O
that	O
perhaps	O
such	O
tumors	O
are	O
resistant	O
to	O
control	O
by	O
NK	O
cells	O
because	O
they	O
lack	O
the	O
ability	O
to	O
attract	O
an	O
accumulation	O
of	O
effector	O
cells	O
to	O
the	O
tumor	O
site	O
,	O
or	O
because	O
blocking	O
factors	O
at	O
the	O
site	O
of	O
the	O
tumor	O
prevent	O
local	O
tumor	O
control	O
at	O
the	O
site	O
of	O
action	O
.	O
The	O
finding	O
related	O
to	O
social	O
support	O
also	O
replicates	O
results	O
from	O
an	O
independent	O
sample	O
of	O
breast	O
cancer	O
patients	O
.	O
This	O
finding	O
,	O
taken	O
together	O
with	O
other	O
evidence	O
that	O
this	O
social	O
variable	O
is	O
associated	O
with	O
longer	O
survival	O
in	O
breast	O
cancer	O
populations	O
,	O
underscores	O
the	O
potential	O
importance	O
of	O
this	O
social	O
support	O
variable	O
.	O
Our	O
findings	O
also	O
suggest	O
one	O
possible	O
immunological	O
variable	O
involved	O
,	O
with	O
potential	O
clinical	O
significance	O
,	O
for	O
this	O
patient	O
population	O
.	O
Comparison	O
of	O
constitutive	O
and	O
inducible	O
transcriptional	O
enhancement	O
mediated	O
by	O
kappa	O
B	O
-	O
related	O
sequences	O
:	O
modulation	O
of	O
activity	O
in	O
B	O
cells	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
tax	O
gene	O
.	O
The	O
kappa	O
B	O
sequence	O
(	O
GGGACTTTCC	O
)	O
binds	O
a	O
factor	O
,	O
NF	B
-	I
kappa	I
B	I
,	O
that	O
is	O
constitutively	O
found	O
in	O
its	O
functional	O
,	O
DNA	O
binding	O
form	O
only	O
in	O
B	O
lymphocytes	O
.	O
A	O
factor	O
with	O
apparently	O
indistinguishable	O
sequence	O
specificity	O
can	O
be	O
induced	O
in	O
many	O
other	O
cell	O
types	O
,	O
where	O
it	O
is	O
used	O
to	O
regulate	O
inducible	O
gene	O
expression	O
.	O
For	O
example	O
,	O
kappa	O
B	O
-	O
related	O
sequences	O
have	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
transcription	O
of	O
a	O
few	O
inducible	O
genes	O
,	O
such	O
as	O
the	O
interleukin	O
2	O
receptor	O
alpha	O
-	O
chain	O
gene	O
and	O
the	O
beta	O
-	O
interferon	O
gene	O
.	O
However	O
,	O
these	O
genes	O
are	O
not	O
constitutively	O
active	O
in	O
B	O
lymphocytes	O
,	O
suggesting	O
that	O
other	O
regulatory	O
mechanisms	O
must	O
play	O
a	O
role	O
in	O
determining	O
the	O
patterns	O
of	O
expression	O
.	O
We	O
have	O
investigated	O
the	O
constitutive	O
and	O
inducible	O
transcriptional	O
activity	O
mediated	O
by	O
five	O
kappa	O
B	O
-	O
related	O
sequence	O
elements	O
in	O
two	O
different	O
cell	O
types	O
.	O
We	O
show	O
that	O
in	O
S194	O
plasma	O
cells	O
the	O
activity	O
of	O
each	O
element	O
correlates	O
well	O
with	O
the	O
relative	O
affinity	O
of	O
B	B
-	I
cell	I
-	I
derived	I
NF	I
-	I
kappa	I
B	I
for	O
that	O
element	O
.	O
This	O
leads	O
to	O
significantly	O
lower	O
transcription	O
enhancement	O
by	O
sites	O
derived	O
from	O
the	O
interleukin	B
2	I
receptor	I
or	O
T	O
-	O
cell	O
receptor	O
genes	O
in	O
S194	O
cells	O
.	O
However	O
,	O
in	O
either	O
EL-4	O
(	O
T	O
)	O
cells	O
or	O
S194	O
cells	O
,	O
both	O
lower	O
-	O
affinity	O
sites	O
can	O
be	O
significantly	O
induced	O
by	O
the	O
tax	B
gene	I
product	I
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
,	O
showing	O
that	O
NF	B
-	I
kappa	I
B	I
activity	O
can	O
be	O
modulated	O
even	O
in	O
a	O
B	O
-	O
cell	O
line	O
that	O
constitutively	O
expresses	O
this	O
factor	O
.	O
Lymphocyte	O
glucocorticoid	B
receptor	I
number	O
in	O
posttraumatic	O
stress	O
disorder	O
.	O
OBJECTIVE	O
:	O
The	O
authors	O
'	O
objective	O
was	O
to	O
investigate	O
the	O
possibility	O
that	O
glucocorticoid	B
receptor	I
changes	O
may	O
be	O
involved	O
in	O
the	O
dysregulation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
in	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
.	O
METHOD	O
:	O
They	O
measured	O
the	O
number	O
of	O
lymphocyte	B
cytosolic	I
glucocorticoid	I
receptors	I
and	O
plasma	O
cortisol	O
concentrations	O
in	O
15	O
consecutively	O
admitted	O
male	O
combat	O
Vietnam	O
veterans	O
with	O
PTSD	O
and	O
in	O
a	O
normal	O
comparison	O
group	O
of	O
11	O
subjects	O
.	O
RESULTS	O
:	O
Both	O
the	O
patients	O
and	O
the	O
normal	O
comparison	O
subjects	O
showed	O
a	O
morning	O
-	O
to	O
-	O
afternoon	O
decline	O
in	O
glucocorticoid	B
receptor	I
concentrations	O
,	O
paralleling	O
the	O
normal	O
diurnal	O
decline	O
in	O
cortisol	O
levels	O
.	O
The	O
number	O
of	O
glucocorticoid	B
receptors	I
was	O
63	O
%	O
greater	O
in	O
the	O
morning	O
and	O
26	O
%	O
greater	O
in	O
the	O
afternoon	O
in	O
the	O
patients	O
with	O
PTSD	O
than	O
in	O
the	O
normal	O
subjects	O
.	O
No	O
group	O
differences	O
in	O
cortisol	O
levels	O
were	O
observed	O
,	O
nor	O
were	O
glucocorticoid	B
receptor	I
number	O
and	O
cortisol	O
levels	O
correlated	O
.	O
The	O
number	O
of	O
morning	B
glucocorticoid	I
receptors	I
was	O
positively	O
correlated	O
with	O
symptoms	O
of	O
PTSD	O
and	O
anxiety	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
provide	O
further	O
evidence	O
for	O
a	O
dysregulation	O
of	O
the	O
HPA	O
axis	O
in	O
PTSD	O
.	O
The	O
finding	O
that	O
patients	O
with	O
PTSD	O
had	O
a	O
substantially	O
greater	O
number	O
of	O
lymphocyte	B
glucocorticoid	I
receptors	I
than	O
normal	O
comparison	O
subjects	O
is	O
consistent	O
with	O
the	O
authors	O
'	O
previous	O
observations	O
of	O
low	O
24-hour	O
urinary	O
cortisol	O
excretion	O
in	O
subjects	O
with	O
PTSD	O
.	O
Furthermore	O
,	O
the	O
receptor	O
changes	O
observed	O
are	O
opposite	O
of	O
those	O
reported	O
in	O
major	O
depressive	O
disorder	O
.	O
The	O
present	O
data	O
,	O
along	O
with	O
other	O
findings	O
of	O
HPA	O
abnormalities	O
in	O
PTSD	O
,	O
support	O
the	O
possibility	O
of	O
a	O
greater	O
negative	O
feedback	O
sensitivity	O
at	O
one	O
or	O
more	O
levels	O
of	O
the	O
HPA	O
axis	O
.	O
Sex	O
and	O
age	O
distribution	O
of	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptors	I
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
normal	O
human	O
subjects	O
.	O
Specific	O
receptors	O
for	O
1	O
,	O
25	O
Dihydroxyvitamin	O
D3	O
have	O
been	O
described	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O
We	O
have	O
tried	O
to	O
find	O
out	O
whether	O
these	O
receptors	O
could	O
show	O
any	O
difference	O
in	O
sex	O
or	O
age	O
distribution	O
.	O
Twenty	O
two	O
healthy	O
men	O
aged	O
21	O
-	O
66	O
yr	O
(	O
mean	O
+	O
/-	O
SD	O
41.0	O
+	O
/-	O
13.6	O
)	O
and	O
nineteen	O
healthy	O
women	O
aged	O
22	O
-	O
60	O
yr	O
(	O
38.9	O
+	O
/-	O
13.9	O
)	O
have	O
been	O
studied	O
.	O
The	O
mean	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
both	O
sexes	O
(	O
1.35	O
+	O
/-	O
0.70	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
males	O
,	O
1.13	O
+	O
/-	O
0.66	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
females	O
)	O
,	O
but	O
the	O
concentration	O
of	O
binding	O
sites	O
(	O
Nmax	O
)	O
was	O
significantly	O
lower	O
in	O
females	O
(	O
2.32	O
+	O
/-	O
0.92	O
fmol	O
/	O
10	O
(	O
7	O
)	O
PBMC	O
vs	O
4.43	O
+	O
/-	O
1.38	O
fmol	O
/	O
10	O
(	O
7	O
)	O
PBMC	O
in	O
males	O
;	O
p	O
=	O
0.0001	O
)	O
.	O
Neither	O
Kd	O
nor	O
Nmax	O
were	O
significantly	O
correlated	O
with	O
age	O
.	O
No	O
difference	O
was	O
found	O
between	O
pre	O
and	O
postmenopausal	O
women	O
.	O
Further	O
studies	O
are	O
needed	O
to	O
elucidate	O
if	O
this	O
sex	O
difference	O
in	O
PBMC	B
receptors	I
for	O
1.25	O
Dihydroxyvitamin	O
D3	O
is	O
of	O
any	O
pathophysiological	O
relevance	O
.	O
Multiple	O
Oct2	B
isoforms	I
are	O
generated	O
by	O
alternative	O
splicing	O
.	O
The	O
interaction	O
of	O
the	O
Oct2	B
transcription	I
factor	I
with	O
the	O
cognate	O
octamer	O
motif	O
ATGCAAAT	O
is	O
a	O
critical	O
determinant	O
of	O
the	O
lymphoid	O
-	O
specific	O
expression	O
of	O
immunoglobulin	O
genes	O
.	O
Ectopic	O
expression	O
of	O
cloned	O
Oct2	O
cDNA	O
was	O
shown	O
to	O
be	O
sufficient	O
to	O
reconstitute	O
at	O
least	O
some	O
aspects	O
of	O
this	O
regulation	O
in	O
non	O
-	O
lymphoid	O
cells	O
.	O
We	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
multiple	O
cDNAs	O
encoding	O
mouse	B
Oct2	I
from	O
a	O
mature	O
B	O
-	O
cell	O
line	O
and	O
we	O
show	O
that	O
a	O
variety	O
of	O
isoforms	O
of	O
this	O
transcription	B
factor	I
is	O
generated	O
from	O
a	O
single	O
gene	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O
All	O
the	O
isoforms	B
retain	O
the	O
previously	O
characterized	O
POU	O
-	O
domain	O
and	O
are	O
therefore	O
able	O
to	O
bind	O
to	O
the	O
octamer	O
motif	O
.	O
Different	O
amounts	O
of	O
the	O
various	O
isoforms	B
are	O
present	O
within	O
the	O
same	O
B	O
-	O
cell	O
regardless	O
of	O
the	O
developmental	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
and	O
at	O
least	O
some	O
of	O
the	O
isoforms	B
are	O
conserved	O
between	O
mouse	O
and	O
humans	O
.	O
In	O
cotransfection	O
experiments	O
we	O
show	O
that	O
all	O
the	O
isoforms	B
are	O
able	O
to	O
activate	O
an	O
octamer	O
containing	O
promoter	O
element	O
in	O
fibroblasts	O
revealing	O
an	O
unexpected	O
functional	O
redundancy	O
.	O
Finally	O
,	O
we	O
show	O
that	O
one	O
of	O
the	O
isoforms	B
encodes	O
the	O
previously	O
described	O
lymphoid	B
-	I
specific	I
Oct2B	I
protein	I
which	O
has	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
function	O
of	O
the	O
octamer	O
motif	O
in	O
the	O
context	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
enhancer	O
.	O
Murine	B
and	I
human	I
T	I
-	I
lymphocyte	I
GATA-3	I
factors	I
mediate	O
transcription	O
through	O
a	O
cis	O
-	O
regulatory	O
element	O
within	O
the	O
human	O
T	O
-	O
cell	O
receptor	O
delta	O
gene	O
enhancer	O
.	O
A	O
family	O
of	O
transcriptional	B
activators	I
has	O
recently	O
been	O
identified	O
in	O
chickens	O
;	O
these	O
transcriptional	B
activators	I
recognize	O
a	O
common	O
consensus	O
motif	O
(	O
WGATAR	O
)	O
through	O
a	O
conserved	O
C4	B
zinc	I
finger	I
DNA	I
-	I
binding	I
domain	I
.	O
One	O
of	O
the	O
members	O
of	O
this	O
multigene	O
family	O
,	O
cGATA-3	B
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
the	O
T	O
-	O
lymphocyte	O
cell	O
lineage	O
.	O
Analysis	O
of	O
human	B
and	I
murine	I
GATA-3	I
factors	I
shows	O
a	O
striking	O
degree	O
of	O
amino	O
acid	O
sequence	O
identity	O
and	O
similar	O
patterns	O
of	O
tissue	O
specificity	O
of	O
expression	O
in	O
these	O
three	O
organisms	O
.	O
The	O
murine	B
and	I
human	I
factors	I
are	O
abundantly	O
expressed	O
in	O
a	O
variety	O
of	O
human	O
and	O
murine	O
T	O
-	O
cell	O
lines	O
and	O
can	O
activate	O
transcription	O
through	O
a	O
tissue	O
-	O
specific	O
GATA	O
-	O
binding	O
site	O
identified	O
within	O
the	O
human	O
T	O
-	O
cell	O
receptor	O
delta	O
gene	O
enhancer	O
.	O
We	O
infer	O
that	O
the	O
murine	B
and	I
human	I
GATA-3	I
proteins	I
play	O
a	O
central	O
and	O
highly	O
conserved	O
role	O
in	O
vertebrate	O
T	O
-	O
cell	O
-	O
specific	O
transcriptional	O
regulation	O
.	O
A	O
novel	O
T	B
-	I
cell	I
trans	I
-	I
activator	I
that	O
recognizes	O
a	O
phorbol	O
ester	O
-	O
inducible	O
element	O
of	O
the	O
interleukin-2	O
promoter	O
.	O
The	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
promoter	O
is	O
recognized	O
by	O
several	O
cell	B
-	I
type	I
-	I
specific	I
and	I
ubiquitous	I
transcriptional	I
regulators	I
that	O
integrate	O
information	O
transmitted	O
by	O
various	O
signaling	O
systems	O
leading	O
to	O
IL-2	B
production	O
and	O
T	O
-	O
cell	O
activation	O
.	O
Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein	O
-	O
DNA	O
binding	O
,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O
the	O
novel	B
T	I
-	I
cell	I
-	I
specific	I
transcriptional	I
activator	I
TCF-1	B
(	O
for	O
T	B
-	I
Cell	I
Factor-1	I
)	O
,	O
which	O
recognizes	O
a	O
T	O
-	O
cell	O
-	O
specific	O
response	O
element	O
(	O
TCE	O
)	O
located	O
within	O
the	O
IL-2	O
promoter	O
.	O
Although	O
the	O
TCE	O
is	O
similar	O
in	O
sequence	O
to	O
a	O
consensus	O
NF	O
kappa	O
B	O
site	O
,	O
several	O
criteria	O
indicate	O
that	O
TCF-1	B
is	O
distinct	O
from	O
NF	B
kappa	I
B	I
.	O
However	O
,	O
like	O
NF	B
kappa	I
B	I
,	O
TCF-1	B
activity	O
is	O
induced	O
by	O
phorbol	O
esters	O
and	O
other	O
T	O
-	O
cell	O
activators	O
.	O
[	O
Estrogen	B
receptor	I
content	O
of	O
peripheral	O
blood	O
lymphocytes	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
]	O
ER	O
content	O
in	O
lymphocytes	O
of	O
peripheral	O
blood	O
from	O
27	O
SLE	O
patients	O
and	O
20	O
healthy	O
controls	O
were	O
determined	O
by	O
dextran	O
-	O
coated	O
charcoal	O
assay	O
.	O
ER	B
content	O
in	O
lymphocytes	O
of	O
each	O
sample	O
was	O
expressed	O
by	O
both	O
fmol	O
/	O
mg	O
of	O
lymphocyte	B
cytosolic	I
protein	I
and	O
fmol	O
/	O
micrograms	O
of	O
lymphocyte	O
DNA	O
.	O
The	O
results	O
showed	O
that	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
ER	B
content	O
of	O
lymphocytes	O
from	O
the	O
controls	O
and	O
that	O
from	O
patients	O
with	O
SLE	O
.	O
But	O
the	O
logarithmic	O
mean	O
of	O
ER	B
content	O
in	O
lymphocytes	O
,	O
expressed	O
by	O
fmol	O
/	O
mg	O
of	O
cytosolic	B
protein	I
,	O
in	O
14	O
patients	O
with	O
active	O
SLE	O
(	O
0.9356	O
+	O
/-	O
0.31	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
13	O
patients	O
with	O
inactive	O
SLE	O
(	O
0.2979	O
+	O
/-	O
0.23	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
0.6204	O
+	O
/-	O
0.52	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O
The	O
normal	O
upper	O
limit	O
of	O
ER	B
content	O
in	O
lymphocytes	O
,	O
expressed	O
by	O
fmol	O
/	O
micrograms	O
of	O
DNA	O
,	O
was	O
0.136	O
.	O
The	O
elevated	O
rate	O
of	O
ER	B
content	O
in	O
lymphocytes	O
in	O
14	O
active	O
SLE	O
(	O
92.9	O
%	O
)	O
was	O
also	O
higher	O
than	O
that	O
in	O
quieiescent	O
patients	O
(	O
23.1	O
%	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
10	O
%	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O
Moreover	O
,	O
the	O
elevated	O
level	O
of	O
ER	B
content	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
positive	O
antidsDNA	B
antibody	I
and	O
hypocomplementemia	O
.	O
Cloning	O
of	O
murine	B
TCF-1	I
,	O
a	O
T	O
cell	O
-	O
specific	O
transcription	B
factor	I
interacting	O
with	O
functional	O
motifs	O
in	O
the	O
CD3-epsilon	O
and	O
T	O
cell	O
receptor	O
alpha	O
enhancers	O
.	O
CD3	B
-epsilon	O
gene	O
expression	O
is	O
confined	O
to	O
the	O
T	O
cell	O
lineage	O
.	O
We	O
have	O
recently	O
identified	O
and	O
cloned	O
a	O
human	B
transcription	I
factor	I
,	O
TCF-1	B
,	O
that	O
binds	O
to	O
a	O
functional	O
element	O
in	O
the	O
T	O
lymphocyte	O
-	O
specific	O
enhancer	O
of	O
CD3-epsilon	O
.	O
In	O
a	O
panel	O
of	O
human	O
cell	O
lines	O
,	O
TCF-1	B
expression	O
was	O
restricted	O
to	O
T	O
lineage	O
cells	O
.	O
TCF-1	B
belonged	O
to	O
a	O
novel	O
family	O
of	O
genes	O
that	O
contain	O
the	O
so	O
-	O
called	O
high	O
mobility	O
group	O
1	O
(	O
HMG	O
)	O
box	O
.	O
Here	O
we	O
report	O
the	O
cloning	O
of	O
murine	B
TCF-1	I
.	O
Two	O
splice	O
alternatives	O
were	O
identified	O
that	O
were	O
not	O
previously	O
observed	O
in	O
human	B
TCF-1	I
.	O
Murine	B
and	I
human	I
TCF-1	I
displayed	O
a	O
95.5	O
%	O
overall	O
amino	O
acid	O
homology	O
.	O
Recombinant	B
murine	I
and	I
human	I
TCF-1	I
recognized	O
the	O
same	O
sequence	O
motif	O
in	O
the	O
CD3-epsilon	O
enhancer	O
as	O
judged	O
by	O
gel	O
retardation	O
and	O
methylation	O
interference	O
assays	O
.	O
With	O
the	O
murine	O
cDNA	O
clones	O
several	O
aspects	O
of	O
TCF-1	B
were	O
analyzed	O
.	O
First	O
,	O
deletion	O
analysis	O
revealed	O
that	O
a	O
region	O
of	O
TCF-1	B
containing	O
the	O
HMG	O
box	O
was	O
sufficient	O
for	O
sequence	O
-	O
specific	O
binding	O
.	O
Second	O
,	O
by	O
high	O
stringency	O
Northern	O
blotting	O
and	O
in	O
situ	O
hybridization	O
,	O
TCF-1	B
expression	O
was	O
shown	O
to	O
be	O
confined	O
to	O
the	O
thymus	O
and	O
to	O
the	O
T	O
cell	O
areas	O
of	O
the	O
spleen	O
.	O
Third	O
,	O
TCF-1	B
bound	O
specifically	O
to	O
a	O
functional	O
T	O
cell	O
-	O
specific	O
element	O
in	O
the	O
T	O
cell	O
receptor	O
alpha	O
(	O
TCR	O
-	O
alpha	O
)	O
enhancer	O
.	O
The	O
T	O
lineage	O
-	O
specific	O
expression	O
and	O
the	O
affinity	O
for	O
functional	O
motifs	O
in	O
the	O
TCR	O
-	O
alpha	O
and	O
CD3-epsilon	O
enhancers	O
imply	O
an	O
important	O
role	O
for	O
TCF-1	B
in	O
the	O
establishment	O
of	O
the	O
mature	O
T	O
cell	O
phenotype	O
.	O
HIV	O
enhancer	O
activity	O
perpetuated	O
by	O
NF	B
-	I
kappa	I
B	I
induction	O
on	O
infection	O
of	O
monocytes	O
[	O
see	O
comments	O
]	O
Permissiveness	O
to	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
differs	O
in	O
T	O
lymphocytes	O
and	O
macrophages	O
.	O
In	O
T	O
cells	O
,	O
HIV	O
transcription	O
is	O
poorly	O
detected	O
in	O
vivo	O
.	O
Cloned	O
,	O
normal	O
T	O
lymphocytes	O
show	O
very	O
little	O
,	O
if	O
any	O
,	O
basal	O
activity	O
of	O
the	O
HIV	O
enhancer	O
and	O
low	O
nuclear	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
a	O
potent	B
transcriptional	I
activator	I
of	O
the	O
HIV	O
enhancer	O
.	O
In	O
contrast	O
,	O
fixed	O
tissue	O
macrophages	O
express	O
detectable	O
HIV	B
proteins	I
,	O
indicating	O
permanent	O
virus	O
transcription	O
.	O
One	O
explanation	O
for	O
the	O
perpetuation	O
of	O
virus	O
infection	O
in	O
macrophages	O
could	O
be	O
sustained	O
nuclear	O
NF	B
-	I
kappa	I
B	I
expression	O
.	O
However	O
,	O
the	O
U937	O
monocytic	O
cell	O
line	O
,	O
which	O
is	O
fully	O
permissive	O
to	O
HIV	O
replication	O
,	O
is	O
known	O
to	O
express	O
only	O
low	O
levels	O
of	O
nuclear	B
NF	I
-	I
kappa	I
B	I
.	O
We	O
show	O
here	O
that	O
chronic	O
HIV	O
infection	O
results	O
in	O
both	O
induction	O
of	O
a	O
nuclear	B
factor	I
with	O
antigenic	O
properties	O
indistinguishable	O
from	O
those	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
permanently	O
increased	O
HIV	O
enhancer	O
activity	O
.	O
This	O
phenomenon	O
,	O
which	O
is	O
independent	O
of	O
tumour	B
necrosis	I
factor	I
,	O
is	O
associated	O
with	O
HIV	O
replication	O
,	O
and	O
is	O
thus	O
likely	O
to	O
explain	O
at	O
least	O
in	O
part	O
the	O
perpetuation	O
of	O
HIV	O
infection	O
in	O
monocytes	O
.	O
Transforming	B
growth	I
factor	I
-	I
beta	I
suppresses	O
human	B
B	I
lymphocyte	I
Ig	I
production	O
by	O
inhibiting	O
synthesis	O
and	O
the	O
switch	O
from	O
the	O
membrane	O
form	O
to	O
the	O
secreted	O
form	O
of	O
Ig	O
mRNA	O
.	O
Transforming	B
growth	I
factor	I
-	I
beta	I
(	O
TGF	B
-	I
beta	I
)	O
inhibits	O
B	O
cell	O
Ig	B
secretion	O
and	O
reduces	O
B	O
cell	O
membrane	O
Ig	B
expression	O
.	O
The	O
addition	O
of	O
TGF	B
-	I
beta	I
to	O
human	O
B	O
lymphocyte	O
cultures	O
stimulated	O
with	O
Staphylococcus	O
aureus	O
Cowan	O
strain	O
I	O
and	O
IL-2	B
completely	O
inhibited	O
B	O
cell	O
Ig	B
secretion	O
(	O
greater	O
than	O
90	O
%	O
)	O
and	O
decreased	O
B	O
cell	O
surface	O
IgM	O
,	O
IgD	O
,	O
kappa	O
L	O
chain	O
,	O
and	O
lambda	O
L	O
chain	O
expression	O
.	O
In	O
contrast	O
,	O
TGF	B
-	I
beta	I
had	O
only	O
minimal	O
effects	O
on	O
two	O
other	O
B	B
cell	I
membrane	I
proteins	I
,	O
HLA	B
-	I
DR	I
and	O
CD20	B
.	O
Internal	O
labeling	O
with	O
[	O
35S	O
]	O
methionine	O
and	O
immunoprecipitation	O
with	O
anti	B
-	I
IgM	I
,	O
anti	B
-	I
kappa	I
,	O
and	O
anti	B
-	I
lambda	I
antibodies	I
revealed	O
a	O
striking	O
reduction	O
in	O
kappa	B
L	I
chain	I
in	O
the	O
presence	O
of	O
TGF	B
-	I
beta	I
.	O
A	O
less	O
pronounced	O
reduction	O
in	O
lambda	B
L	I
chain	I
and	O
microH	B
chain	I
was	O
also	O
noted	O
.	O
Northern	O
blot	O
analysis	O
of	O
RNA	O
purified	O
from	O
B	O
cells	O
treated	O
with	O
TGF	B
-	I
beta	I
for	O
varying	O
time	O
intervals	O
revealed	O
a	O
significant	O
decrease	O
in	O
steady	O
state	O
kappa	O
and	O
lambda	O
L	O
chain	O
mRNA	O
levels	O
.	O
Furthermore	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
switch	O
from	O
the	O
membrane	O
forms	O
of	O
mu	O
and	O
gamma	O
to	O
their	O
respective	O
secreted	O
forms	O
was	O
noted	O
in	O
the	O
presence	O
of	O
TGF	B
-	I
beta	I
.	O
Nuclear	O
run	O
-	O
on	O
experiments	O
demonstrated	O
decreased	O
transcription	O
of	O
kappa	B
L	I
chain	I
.	O
The	O
effects	O
of	O
TGF	B
-	I
beta	I
on	O
two	O
transcriptional	B
regulatory	I
factors	I
,	O
Oct-2	B
and	O
nuclear	B
factor	I
(	I
NF	I
)	I
kappa	I
B	I
,	O
known	O
to	O
be	O
important	O
in	O
Ig	B
gene	O
transcription	O
were	O
examined	O
.	O
Oct-2	O
mRNA	O
levels	O
and	O
both	O
Oct-2	B
and	O
NF	B
-	I
kappa	I
B	I
proteins	I
in	O
nuclear	O
extracts	O
were	O
not	O
altered	O
by	O
treatment	O
with	O
TGF	B
-	I
beta	I
.	O
In	O
contrast	O
,	O
levels	O
of	O
the	O
transcriptional	B
factor	I
AP-1	I
,	O
which	O
is	O
not	O
known	O
to	O
be	O
important	O
in	O
B	O
cell	O
Ig	B
production	O
,	O
were	O
reduced	O
by	O
TGF	B
-	I
beta	I
.	O
These	O
findings	O
demonstrate	O
that	O
TGF	B
-	I
beta	I
decreases	O
B	O
lymphocyte	O
Ig	B
secretion	O
by	O
inhibiting	O
the	O
synthesis	O
of	O
Ig	O
mRNA	O
and	O
inhibiting	O
the	O
switch	O
from	O
the	O
membrane	O
form	O
to	O
the	O
secreted	O
forms	O
of	O
mu	O
and	O
gamma	O
mRNA	O
.	O
The	O
mechanism	O
by	O
which	O
TGF	B
-	I
beta	I
inhibits	O
Ig	O
chain	O
synthesis	O
is	O
unclear	O
although	O
it	O
does	O
not	O
involve	O
inhibition	O
of	O
the	O
binding	O
of	O
NF	B
-	I
kappa	I
B	I
or	O
Oct-2	B
to	O
their	O
respective	O
target	O
sequences	O
.	O
Cortivazol	O
mediated	O
induction	O
of	O
glucocorticoid	O
receptor	O
messenger	O
ribonucleic	O
acid	O
in	O
wild	O
-	O
type	O
and	O
dexamethasone	O
-	O
resistant	O
human	O
leukemic	O
(	O
CEM	O
)	O
cells	O
.	O
Cortivazol	O
is	O
a	O
phenylpyrazolo	O
glucocorticoid	O
of	O
high	O
potency	O
and	O
unusual	O
structure	O
.	O
In	O
both	O
wild	O
-	O
type	O
and	O
highly	O
dexamethasone	O
(	O
dex	O
)	O
-resistant	O
clones	O
of	O
the	O
human	O
leukemic	O
cell	O
line	O
CEM	O
,	O
exposure	O
to	O
cortivazol	O
leads	O
to	O
cell	O
death	O
.	O
It	O
has	O
been	O
shown	O
recently	O
that	O
in	O
wild	O
-	O
type	O
CEM	O
cells	O
but	O
not	O
in	O
a	O
dex	O
-	O
resistant	O
,	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
-defective	O
clone	O
ICR-27	O
TK-3	O
,	O
dex	O
induces	O
GR	O
mRNA	O
.	O
To	O
test	O
the	O
hypothesis	O
that	O
cortivazol	O
acts	O
in	O
dex	O
-	O
resistant	O
cells	O
by	O
making	O
use	O
of	O
the	O
residual	O
GR	B
found	O
there	O
,	O
wild	O
-	O
type	O
and	O
dex	O
-	O
resistant	O
clones	O
were	O
treated	O
with	O
various	O
concentrations	O
of	O
cortivazol	O
and	O
induction	O
of	O
GR	O
mRNA	O
was	O
studied	O
.	O
Cortivazol	O
significantly	O
induced	O
GR	O
mRNA	O
in	O
the	O
normal	O
CEM	O
-	O
C7	O
as	O
well	O
as	O
in	O
two	O
classes	O
of	O
dex	O
-	O
resistant	O
clones	O
,	O
although	O
the	O
dex	O
-	O
resistant	O
clones	O
needed	O
at	O
least	O
10	O
times	O
more	O
cortivazol	O
than	O
the	O
normal	O
cells	O
for	O
significant	O
GR	O
mRNA	O
induction	O
.	O
Increased	O
levels	O
of	O
GR	O
mRNA	O
were	O
noticed	O
as	O
early	O
as	O
3	O
h	O
after	O
treatment	O
.	O
A	O
general	O
correlation	O
between	O
induction	O
of	O
GR	O
mRNA	O
and	O
lysis	O
of	O
the	O
normal	O
and	O
dex	O
-	O
resistant	O
cells	O
was	O
found	O
.	O
Positive	O
induction	O
of	O
GR	O
mRNA	O
might	O
be	O
one	O
of	O
the	O
earliest	O
crucial	O
steps	O
in	O
the	O
lysis	O
of	O
normal	O
and	O
dex	O
-	O
resistant	O
CEM	O
cells	O
,	O
or	O
might	O
serve	O
as	O
a	O
marker	O
for	O
the	O
process	O
.	O
However	O
,	O
the	O
lysis	O
pathway	O
in	O
the	O
dex	O
-	O
resistant	O
cells	O
is	O
defective	O
in	O
that	O
dex	O
-	O
resistant	O
clones	O
needed	O
significantly	O
more	O
cortivazol	O
than	O
the	O
normal	O
cells	O
for	O
lysis	O
of	O
the	O
cells	O
.	O
Regulation	O
of	O
jun	O
and	O
fos	O
gene	O
expression	O
in	O
human	O
monocytes	O
by	O
the	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
.	O
The	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
(	O
M	B
-	I
CSF	I
)	O
is	O
required	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
mononuclear	O
phagocytes	O
.	O
However	O
,	O
the	O
signaling	O
events	O
responsible	O
for	O
these	O
effects	O
remain	O
unclear	O
.	O
The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
M	B
-	I
CSF	I
on	O
potential	O
signaling	O
pathways	O
involving	O
expression	O
of	O
the	O
jun	O
and	O
fos	O
early	O
response	O
genes	O
.	O
Low	O
levels	O
of	O
c	B
-	I
jun	I
transcripts	I
were	O
detectable	O
in	O
resting	O
human	O
peripheral	O
blood	O
monocytes	O
.	O
Treatment	O
of	O
these	O
cells	O
with	O
10	O
(	O
3	O
)	O
units	O
/	O
ml	O
human	B
recombinant	I
M	I
-	I
CSF	I
was	O
associated	O
with	O
rapid	O
and	O
transient	O
increases	O
in	O
c	O
-	O
jun	O
mRNA	O
levels	O
.	O
Nuclear	O
run	O
-	O
on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M	B
-	I
CSF	I
regulates	O
c	O
-	O
jun	O
expression	O
by	O
both	O
an	O
increase	O
in	O
transcription	O
rate	O
and	O
a	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
c	O
-	O
jun	O
transcripts	O
.	O
M	B
-	I
CSF	I
treatment	O
was	O
also	O
associated	O
with	O
a	O
rapid	O
induction	O
of	O
the	O
jun	O
-	O
B	O
gene	O
,	O
although	O
expression	O
of	O
this	O
gene	O
was	O
prolonged	O
compared	O
to	O
that	O
of	O
c	O
-	O
jun	O
.	O
We	O
further	O
demonstrate	O
that	O
M	B
-	I
CSF	I
increases	O
c	O
-	O
fos	O
mRNA	O
levels	O
in	O
human	O
monocytes	O
through	O
control	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O
Maximal	O
induction	O
of	O
the	O
c	O
-	O
fos	O
gene	O
was	O
followed	O
by	O
that	O
for	O
the	O
fos	O
-	O
B	O
gene	O
.	O
Moreover	O
,	O
M	B
-	I
CSF	I
-induced	O
expression	O
of	O
the	O
fos	O
-	O
related	O
gene	O
,	O
fra-1	O
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c	O
-	O
fos	O
and	O
fos	O
-	O
B	O
.	O
Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
M	B
-	I
CSF	I
treatment	O
is	O
associated	O
with	O
differential	O
activation	O
of	O
multiple	O
members	O
of	O
the	O
jun	O
/	O
fos	O
family	O
and	O
that	O
expression	O
of	O
these	O
genes	O
could	O
contribute	O
to	O
nuclear	O
signaling	O
mechanisms	O
that	O
regulate	O
a	O
specific	O
program	O
of	O
monocyte	O
differentiation	O
.	O
Contribution	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
Sp1	O
binding	O
motifs	O
to	O
the	O
replicative	O
capacity	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
:	O
distinct	O
patterns	O
of	O
viral	O
growth	O
are	O
determined	O
by	O
T	O
-	O
cell	O
types	O
.	O
Starting	O
with	O
a	O
replication	O
-	O
incompetent	O
molecular	O
clone	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
lacking	O
all	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	O
binding	O
sites	O
present	O
in	O
the	O
native	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
proviruses	O
containing	O
reconstructed	O
LTRs	O
with	O
individual	O
or	O
combinations	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	O
elements	O
were	O
generated	O
and	O
evaluated	O
for	O
their	O
capacity	O
to	O
produce	O
virus	O
progeny	O
following	O
transfection	O
-	O
cocultivation	O
.	O
Virus	O
stocks	O
obtained	O
from	O
these	O
experiments	O
exhibited	O
a	O
continuum	O
of	O
replicative	O
capacities	O
in	O
different	O
human	O
T	O
-	O
cell	O
types	O
depending	O
on	O
which	O
element	O
(	O
s	O
)	O
was	O
present	O
in	O
the	O
LTR	O
.	O
For	O
example	O
,	O
in	O
experiments	O
involving	O
proviral	O
clones	O
with	O
LTRs	O
containing	O
one	O
or	O
two	O
NF	O
-	O
kappa	O
B	O
elements	O
(	O
and	O
no	O
Sp1	O
binding	O
sites	O
)	O
,	O
a	O
hierarchy	O
of	O
cellular	O
permissivity	O
to	O
virus	O
replication	O
(	O
peripheral	O
blood	O
lymphocytes	O
=	O
MT4	O
greater	O
than	O
H9	O
greater	O
than	O
CEM	O
greater	O
than	O
Jurkat	O
)	O
was	O
observed	O
.	O
Of	O
note	O
was	O
the	O
associated	O
emergence	O
of	O
second	O
-	O
site	O
LTR	O
revertants	O
which	O
involved	O
an	O
alteration	O
of	O
the	O
TATA	O
box	O
.	O
These	O
results	O
suggest	O
that	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
LTR	O
possesses	O
functional	O
redundancy	O
which	O
ensures	O
virus	O
replication	O
in	O
different	O
T	O
-	O
cell	O
types	O
and	O
is	O
capable	O
of	O
changing	O
depending	O
on	O
the	O
particular	O
combination	O
of	O
transcriptional	B
factors	I
present	O
.	O
[	O
Changes	O
in	O
leucocytic	B
estrogen	I
receptor	I
levels	O
in	O
patients	O
with	O
gynecomastia	O
]	O
The	O
number	O
of	O
estrogen	B
receptor	I
(	O
ER	B
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
13	O
men	O
with	O
gynecomastia	O
were	O
measured	O
by	O
radioligand	O
binding	O
method	O
.	O
The	O
results	O
were	O
compared	O
with	O
those	O
of	O
13	O
sex	O
-	O
and	O
age	O
-	O
matched	O
healthy	O
subjects	O
.	O
It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	B
in	O
leucocytes	O
was	O
significantly	O
increased	O
in	O
gynecomastia	O
(	O
Rs	O
of	O
leucocytes	O
were	O
1054	O
+	O
/-	O
254	O
sites	O
/	O
cell	O
)	O
.	O
It	O
suggested	O
that	O
increase	O
of	O
ER	O
levels	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
gynecomastia	O
.	O
Regulation	O
of	O
M	B
-	I
CSF	I
expression	O
by	O
M	B
-	I
CSF	I
:	O
role	O
of	O
protein	B
kinase	I
C	I
and	O
transcription	B
factor	I
NF	I
kappa	I
B	I
.	O
Macrophage	B
-	I
colony	I
-	I
stimulating	I
factor	I
(	O
M	B
-	I
CSF	I
)	O
,	O
also	O
referred	O
to	O
as	O
CSF-1	B
,	O
regulates	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
and	O
functional	O
activity	O
of	O
monocytes	O
by	O
binding	O
to	O
a	O
single	O
class	O
of	O
high	B
-	I
affinity	I
cell	I
surface	I
receptors	I
,	O
known	O
to	O
be	O
the	O
product	O
of	O
the	O
c	O
-	O
fms	O
protooncogene	O
.	O
The	O
detection	O
of	O
both	O
M	O
-	O
CSF	O
and	O
c	O
-	O
fms	O
expression	O
by	O
cells	O
of	O
the	O
monocyte	O
lineage	O
has	O
suggested	O
that	O
M	B
-	I
CSF	I
may	O
act	O
by	O
an	O
autocrine	O
mechanism	O
.	O
Interestingly	O
,	O
it	O
has	O
been	O
shown	O
that	O
M	B
-	I
CSF	I
can	O
induce	O
the	O
expression	O
of	O
its	O
own	O
gene	O
.	O
Although	O
sensitivity	O
to	O
M	B
-	I
CSF	I
can	O
be	O
modulated	O
by	O
regulation	O
of	O
receptor	O
expression	O
and	O
function	O
,	O
M	B
-	I
CSF	I
responsiveness	O
is	O
largely	O
determined	O
at	O
a	O
postreceptor	O
level	O
.	O
To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
intracellular	O
pathway	O
of	O
M	B
-	I
CSF	I
signal	O
transduction	O
.	O
We	O
have	O
therefore	O
investigated	O
the	O
changes	O
in	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
activity	O
upon	O
exposure	O
of	O
monocytes	O
to	O
M	B
-	I
CSF	I
.	O
We	O
show	O
that	O
M	B
-	I
CSF	I
activates	O
and	O
translocates	O
PKC	B
.	O
Inhibition	O
of	O
PKC	B
by	O
the	O
isoquinoline	O
derivative	O
H7	O
abolishes	O
induction	O
of	O
M	B
-	I
CSF	I
by	O
M	B
-	I
CSF	I
.	O
Furthermore	O
,	O
activation	O
of	O
PKC	B
was	O
pertussis	O
-	O
toxin	O
-	O
sensitive	O
and	O
was	O
associated	O
with	O
the	O
detection	O
of	O
an	O
NF	B
kappa	I
B	I
protein	I
in	O
nuclear	O
extracts	O
of	O
M	O
-	O
CSF	O
-	O
induced	O
blood	O
monocytes	O
but	O
not	O
in	O
monocytes	O
exposed	O
to	O
medium	O
treatment	O
only	O
.	O
The	O
results	O
suggest	O
that	O
M	B
-	I
CSF	I
induction	O
of	O
M	B
-	I
CSF	I
involves	O
G	B
proteins	I
,	O
PKC	B
and	O
NF	B
kappa	I
B	I
.	O
Regulation	O
of	O
glucocorticoid	B
receptors	I
in	O
human	O
mononuclear	O
cells	O
:	O
effects	O
of	O
glucocorticoid	O
treatment	O
,	O
Cushing	O
's	O
disease	O
and	O
ketoconazole	O
.	O
Glucocorticoid	B
receptors	I
(	O
GcR	B
)	O
were	O
determined	O
by	O
a	O
whole	O
cell	O
assay	O
in	O
human	O
mononulear	O
leukocytes	O
(	O
hMNL	O
)	O
from	O
control	O
subjects	O
,	O
patients	O
receiving	O
glucocorticoid	O
therapy	O
for	O
systemic	O
diseases	O
and	O
Cushing	O
's	O
disease	O
patients	O
with	O
or	O
without	O
ketoconazole	O
therapy	O
.	O
Prolonged	O
corticosteroid	O
treatment	O
resulted	O
in	O
down	O
-	O
regulation	O
of	O
GcR	B
,	O
while	O
the	O
mean	O
level	O
of	O
GcR	B
in	O
Cushing	O
's	O
disease	O
was	O
normal	O
.	O
In	O
this	O
group	O
,	O
however	O
,	O
receptor	O
levels	O
and	O
morning	O
plasma	O
cortisol	O
values	O
showed	O
a	O
negative	O
correlation	O
,	O
indicating	O
a	O
subtle	O
down	O
-	O
regulatory	O
effect	O
.	O
Furthermore	O
,	O
GcR	B
were	O
unaltered	O
after	O
these	O
patients	O
received	O
ketoconazole	O
,	O
in	O
spite	O
of	O
a	O
marked	O
reduction	O
in	O
morning	O
plasma	O
cortisol	O
and	O
urinary	O
free	O
cortisol	O
.	O
We	O
also	O
observed	O
that	O
ketoconazole	O
was	O
a	O
weak	O
competitor	O
of	O
GcR	B
in	O
intact	O
cells	O
,	O
although	O
it	O
significantly	O
inhibited	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosolic	O
preparations	O
from	O
rat	O
tissues	O
.	O
The	O
results	O
suggested	O
that	O
GcR	B
in	O
hMNL	O
are	O
down	O
-	O
regulated	O
by	O
synthetic	O
steroids	O
given	O
in	O
vivo	O
,	O
but	O
they	O
showed	O
very	O
mild	O
down	O
-	O
regulation	O
in	O
hypercortisolemic	O
patients	O
suffering	O
from	O
Cushing	O
's	O
disease	O
.	O
Finally	O
,	O
we	O
did	O
not	O
observed	O
either	O
up	O
-	O
regulation	O
or	O
antagonism	O
of	O
GcR	B
by	O
ketoconazole	O
treatment	O
,	O
at	O
the	O
time	O
that	O
cortisol	O
levels	O
of	O
patients	O
with	O
Cushing	O
's	O
disease	O
were	O
reduced	O
.	O
This	O
indicates	O
that	O
the	O
beneficial	O
effects	O
of	O
ketoconazole	O
in	O
Cushing	O
's	O
disease	O
are	O
due	O
to	O
adrenal	O
cortisol	O
suppression	O
and	O
not	O
to	O
interaction	O
with	O
GcR	B
of	O
target	O
cells	O
,	O
and	O
that	O
the	O
process	O
of	O
GcR	B
regulation	O
in	O
hMNL	O
is	O
a	O
complex	O
phenomenon	O
awaiting	O
further	O
elucidation	O
.	O
USF	B
-	I
related	I
transcription	I
factor	I
,	O
HIV	B
-	I
TF1	I
,	O
stimulates	O
transcription	O
of	O
human	O
immunodeficiency	O
virus-1	O
.	O
The	O
transcription	B
factor	I
HIV	B
-	I
TF1	I
,	O
which	O
binds	O
to	O
a	O
region	O
about	O
60	O
bp	O
upstream	O
from	O
the	O
enhancer	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
,	O
was	O
purified	O
from	O
human	O
B	O
cells	O
.	O
HIV	B
-	I
TF1	I
had	O
a	O
molecular	O
weight	O
of	O
39	O
,	O
000	O
.	O
Binding	O
of	O
HIV	B
-	I
TF1	I
to	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
activated	O
transcription	O
from	O
the	O
HIV	O
promoter	O
in	O
vitro	O
.	O
The	O
HIV	O
-	O
TF1-binding	O
site	O
in	O
HIV	O
LTR	O
was	O
similar	O
to	O
the	O
site	O
recognized	O
by	O
upstream	B
stimulatory	I
factor	I
(	O
USF	B
)	O
in	O
the	O
adenovirus	O
major	O
late	O
promoter	O
.	O
DNA	O
-	O
binding	O
properties	O
of	O
HIV	B
-	I
TF1	I
suggested	O
that	O
HIV	B
-	I
TF1	I
might	O
be	O
identical	O
or	O
related	O
to	O
USF	B
.	O
Interestingly	O
,	O
treatment	O
of	O
purified	O
HIV	B
-	I
TF1	I
by	O
phosphatase	B
greatly	O
reduced	O
its	O
DNA	O
-	O
binding	O
activity	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
HIV	B
-	I
TF1	I
was	O
essential	O
for	O
DNA	O
binding	O
.	O
The	O
disruption	O
of	O
HIV	O
-	O
TF1-binding	O
site	O
induced	O
a	O
60	O
%	O
decrease	O
in	O
the	O
level	O
of	O
transcription	O
from	O
the	O
HIV	O
promoter	O
in	O
vivo	O
.	O
These	O
results	O
suggest	O
that	O
HIV	B
-	I
TF1	I
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
HIV-1	O
.	O
Induction	O
of	O
NF	B
-	I
kappa	I
B	I
during	O
monocyte	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
HIV	O
-	O
gene	O
expression	O
.	O
Cells	O
of	O
the	O
monocyte	O
-	O
macrophage	O
lineage	O
are	O
important	O
targets	O
of	O
HIV	O
infection	O
.	O
We	O
report	O
here	O
that	O
the	O
phenotypic	O
differentiation	O
of	O
monocyte	O
cell	O
lines	O
induced	O
by	O
phorbol	O
esters	O
or	O
tumour	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
alpha	I
)	O
is	O
associated	O
with	O
expression	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
.	O
In	O
parallel	O
with	O
such	O
differentiation	O
,	O
HIV	O
transcription	O
,	O
monitored	O
using	O
an	O
HIV	O
long	O
terminal	O
repeat	O
reporter	O
gene	O
construct	O
,	O
is	O
activated	O
in	O
such	O
cells	O
under	O
the	O
influence	O
of	O
enhanced	O
NF	B
-	I
kappa	I
B	I
expression	O
.	O
Also	O
,	O
in	O
a	O
promonocyte	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
,	O
NF	B
-	I
kappa	I
B	I
expression	O
and	O
HIV	O
transcription	O
were	O
enhanced	O
on	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
TNF	B
alpha	I
.	O
Thus	O
,	O
stimulation	O
of	O
monocyte	O
cell	O
lines	O
by	O
phorbol	O
esters	O
or	O
TNF	B
alpha	I
induces	O
cell	O
differentiation	O
and	O
activates	O
HIV	O
transcription	O
.	O
Such	O
a	O
process	O
may	O
have	O
fundamental	O
implications	O
in	O
AIDS	O
pathogenesis	O
in	O
vivo	O
and	O
may	O
be	O
important	O
in	O
disease	O
progression	O
induced	O
by	O
opportunistic	O
infections	O
directly	O
or	O
indirectly	O
involving	O
macrophages	O
.	O
Synergism	O
between	O
two	O
distinct	O
elements	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
during	O
activation	O
by	O
the	O
trans	B
-	I
activator	I
of	O
HTLV	O
-	O
I	O
.	O
We	O
have	O
conducted	O
functional	O
studies	O
of	O
the	O
enhancer	O
elements	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
using	O
the	O
human	O
T	O
-	O
cell	O
lines	O
Jurkat	O
and	O
MOLT	O
4	O
,	O
which	O
are	O
negative	O
for	O
HTLV	O
-	O
I	O
,	O
and	O
MT-2	O
and	O
TL	O
-	O
Mor	O
,	O
which	O
carry	O
the	O
proviral	O
genome	O
of	O
HTLV	O
-	O
I	O
.	O
Two	O
distinct	O
elements	O
have	O
been	O
implicated	O
in	O
function	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
.	O
One	O
is	O
the	O
21-base	O
-	O
pair	O
(	O
bp	O
)	O
core	O
element	O
that	O
is	O
responsible	O
for	O
trans	O
-	O
activation	O
by	O
the	O
HTLV	O
-	O
I	O
trans	B
-	I
activator	I
p40tax	B
and	O
that	O
has	O
the	O
ability	O
to	O
bind	O
to	O
cyclic	B
-	I
AMP	I
responsive	I
element	I
binding	I
factor	I
(	I
CREB	I
)	I
-like	I
factor	I
(	O
s	O
)	O
.	O
The	O
other	O
is	O
a	O
region	O
interposed	O
between	O
the	O
21-bp	O
elements	O
.	O
In	O
this	O
study	O
we	O
demonstrate	O
that	O
a	O
subfragment	O
(	O
C26	O
)	O
in	O
the	O
region	O
between	O
the	O
21-bp	O
elements	O
is	O
involved	O
in	O
trans	O
-	O
activation	O
by	O
p40tax	B
,	O
possibly	O
through	O
binding	O
to	O
an	O
NF	B
-	I
kappa	I
B	I
-	I
like	I
nuclear	I
factor	I
or	O
factors	O
.	O
Formation	O
of	O
the	O
protein	B
-	I
DNA	I
complex	I
with	O
the	O
C26	B
subfragment	I
was	O
positively	O
affected	O
by	O
p40tax	B
.	O
The	O
C26	O
element	O
conferred	O
partial	O
responsiveness	O
to	O
p40tax	B
when	O
linked	O
to	O
one	O
copy	O
of	O
the	O
21-bp	O
element	O
that	O
,	O
by	O
itself	O
,	O
showed	O
little	O
activation	O
in	O
response	O
to	O
p40tax	B
.	O
However	O
,	O
the	O
C26	O
element	O
alone	O
,	O
even	O
when	O
repeated	O
,	O
could	O
not	O
be	O
activated	O
by	O
p40tax	B
,	O
unlike	O
other	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
elements	O
.	O
In	O
contrast	O
,	O
the	O
C26	O
element	O
itself	O
was	O
profoundly	O
activated	O
upon	O
stimulation	O
with	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
.	O
These	O
findings	O
therefore	O
suggest	O
that	O
the	O
HTLV	O
-	O
I	O
enhancer	O
contains	O
multiple	O
functional	O
elements	O
,	O
including	O
binding	O
sites	O
for	O
at	O
least	O
CREB-	B
and	I
NF	I
-	I
kappa	I
B	I
-	I
like	I
factors	I
,	O
which	O
synergistically	O
cooperate	O
in	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
in	O
response	O
to	O
p40tax	B
.	O
Our	O
results	O
also	O
demonstrate	O
that	O
TPA	O
-	O
dependent	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
may	O
be	O
mediated	O
through	O
the	O
C26	O
element	O
.	O
Inhibition	O
of	O
phorbol	O
ester	O
-	O
induced	O
monocytic	O
differentiation	O
by	O
dexamethasone	O
is	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
(	O
AP-1	O
)	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
treatment	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
with	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
is	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
early	O
response	O
genes	O
.	O
The	O
present	O
work	O
demonstrates	O
that	O
the	O
glucocorticoid	O
dexamethasone	O
inhibits	O
TPA	O
-	O
induced	O
increases	O
in	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
mRNA	O
levels	O
in	O
U-937	O
leukemia	O
cells	O
.	O
These	O
findings	O
were	O
associated	O
with	O
a	O
block	O
in	O
appearance	O
of	O
the	O
monocytic	O
phenotype	O
,	O
including	O
inhibition	O
of	O
TPA	O
-	O
induced	O
increases	O
in	O
lamin	O
A	O
,	O
lamin	O
C	O
,	O
and	O
vimentin	O
transcripts	O
.	O
Other	O
studies	O
have	O
demonstrated	O
that	O
TPA	O
-	O
induced	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
genes	O
in	O
myeloid	O
leukemia	O
cells	O
are	O
regulated	O
by	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
.	O
The	O
finding	O
that	O
dexamethasone	O
has	O
no	O
effect	O
on	O
TPA	O
-	O
induced	O
activation	O
of	O
PKC	B
suggests	O
that	O
this	O
glucocorticoid	O
inhibits	O
signals	O
downstream	O
or	O
parallel	O
to	O
this	O
enzyme	B
.	O
Nuclear	O
run	O
-	O
on	O
assays	O
demonstrate	O
that	O
:	O
(	O
1	O
)	O
induction	O
of	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
expression	O
by	O
TPA	O
is	O
regulated	O
by	O
transcriptional	O
mechanisms	O
,	O
(	O
2	O
)	O
TPA	O
-	O
induced	O
expression	O
of	O
c	O
-	O
jun	O
and	O
c	B
-	I
fos	I
does	O
not	O
require	O
protein	O
synthesis	O
,	O
and	O
(	O
3	O
)	O
TPA	O
-	O
induced	O
expression	O
of	O
both	O
genes	O
is	O
inhibited	O
at	O
the	O
transcriptional	O
level	O
by	O
dexamethasone	O
.	O
To	O
further	O
define	O
the	O
effects	O
of	O
dexamethasone	O
at	O
the	O
molecular	O
level	O
,	O
we	O
prepared	O
a	O
series	O
of	O
deleted	O
c	O
-	O
jun	O
promoter	O
fragments	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
.	O
Increases	O
in	O
CAT	B
activity	O
during	O
transient	O
expression	O
of	O
these	O
constructs	O
in	O
TPA	O
-	O
treated	O
U-937	O
cells	O
could	O
be	O
assigned	O
to	O
the	O
region	O
(	O
-97	O
to	O
-20	O
)	O
of	O
the	O
promoter	O
that	O
contains	O
the	O
AP-1	O
binding	O
site	O
.	O
This	O
induction	O
of	O
CAT	B
activity	O
was	O
sensitive	O
to	O
dexamethasone	O
.	O
These	O
findings	O
suggest	O
that	O
dexamethasone	O
down	O
-	O
regulates	O
TPA	O
-	O
induced	O
transcription	O
of	O
the	O
c	O
-	O
jun	O
gene	O
during	O
monocytic	O
differentiation	O
by	O
inhibiting	O
activation	O
of	O
the	O
AP-1	O
site	O
.	O
Clone	O
pAT	O
133	O
identifies	O
a	O
gene	O
that	O
encodes	O
another	O
human	O
member	O
of	O
a	O
class	O
of	O
growth	O
factor	O
-	O
induced	O
genes	O
with	O
almost	O
identical	O
zinc	B
-	I
finger	I
domains	I
.	O
We	O
report	O
the	O
structure	O
and	O
regulation	O
of	O
a	O
gene	O
represented	O
by	O
clone	O
pAT	O
133	O
,	O
which	O
is	O
induced	O
upon	O
transition	O
from	O
a	O
resting	O
state	O
(	O
G0	O
)	O
through	O
the	O
early	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
G1	O
)	O
.	O
The	O
pAT	O
133	O
gene	O
is	O
immediately	O
induced	O
,	O
with	O
FOS	B
-like	O
kinetics	O
,	O
in	O
human	O
T	O
cells	O
and	O
in	O
fibroblasts	O
.	O
Primary	O
structure	O
analysis	O
showed	O
that	O
the	O
encoded	O
protein	O
contains	O
three	O
tandem	B
zinc	I
-	I
finger	I
sequences	I
of	O
the	O
type	O
Cys2-Xaa12-His2	B
.	O
This	O
zinc	B
-	I
finger	I
region	I
,	O
which	O
is	O
thought	O
to	O
bind	O
DNA	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
,	O
is	O
similar	O
(	O
greater	O
than	O
80	O
%	O
on	O
the	O
amino	O
acid	O
level	O
)	O
to	O
two	O
previously	O
described	O
transcription	B
factors	I
pAT	B
225	I
/	I
EGR1	I
and	O
pAT	O
591	B
/	I
EGR2	I
.	O
Except	O
for	O
the	O
conserved	O
zinc	B
-	I
finger	I
domains	I
,	O
the	O
amino	B
acid	I
sequences	I
of	O
the	O
three	O
proteins	O
are	O
distinct	O
.	O
This	O
structural	O
similarity	O
suggests	O
that	O
the	O
pAT	O
133	O
gene	O
encodes	O
a	O
transcription	B
factor	I
with	O
a	O
specific	O
biological	O
function	O
.	O
Comparing	O
the	O
regulation	O
of	O
these	O
related	O
zinc	O
-	O
finger	O
-	O
encoding	O
genes	O
showed	O
coordinate	O
induction	O
upon	O
mitogenic	O
stimulation	O
of	O
resting	O
T	O
lymphocytes	O
and	O
of	O
resting	O
fibroblasts	O
.	O
However	O
,	O
upon	O
transition	O
from	O
a	O
proliferating	O
(	O
G1	O
)	O
to	O
a	O
resting	O
state	O
of	O
the	O
cell	O
cycle	O
the	O
three	O
genes	O
were	O
differently	O
regulated	O
.	O
In	O
human	O
histiocytic	O
U937	O
cells	O
mRNA	O
of	O
clone	O
pAT	O
133	O
was	O
constitutively	O
expressed	O
,	O
whereas	O
mRNA	O
of	O
pAT	B
225	I
/	I
EGR1	I
was	O
induced	O
upon	O
induction	O
of	O
terminal	O
differentiation	O
.	O
In	O
contrast	O
mRNA	O
representing	O
pAT	O
591	B
/	I
EGR2	I
was	O
not	O
expressed	O
in	O
these	O
cells	O
.	O
This	O
difference	O
in	O
gene	O
regulation	O
suggests	O
distinct	O
biological	O
roles	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
for	O
the	O
respective	O
proteins	O
.	O
Regulation	O
of	O
interleukin-1	B
beta	I
production	O
by	O
glucocorticoids	O
in	O
human	O
monocytes	O
:	O
the	O
mechanism	O
of	O
action	O
depends	O
on	O
the	O
activation	O
signal	O
.	O
Glucocorticoids	O
are	O
known	O
to	O
downregulate	O
interleukin-1	B
beta	I
production	O
in	O
monocytic	O
cells	O
by	O
two	O
different	O
mechanims	O
:	O
direct	O
inhibition	O
of	O
the	O
gene	O
transcription	O
and	O
destabilization	O
of	O
the	O
preformed	O
interleukin-1	O
beta	O
mRNA	O
.	O
Now	O
we	O
have	O
examined	O
the	O
effect	O
of	O
the	O
nature	O
of	O
the	O
monocyte	O
activating	O
signal	O
on	O
these	O
two	O
inhibitory	O
mechanims	O
.	O
When	O
human	O
monocytes	O
were	O
preincubated	O
with	O
dexamethasone	O
for	O
1	O
hour	O
and	O
then	O
stimulated	O
either	O
with	O
bacterial	O
lipopolysaccharide	O
or	O
phorbol	O
myristate	O
,	O
it	O
was	O
found	O
that	O
dexamethasone	O
inhibited	O
the	O
lipopolysaccharide	O
-	O
induced	O
interleukin-1	B
beta	I
protein	O
production	O
,	O
but	O
the	O
phorbol	O
myristate	O
-	O
induced	O
production	O
was	O
increased	O
3	O
-	O
10	O
fold	O
.	O
This	O
difference	O
was	O
also	O
seen	O
at	O
the	O
mRNA	O
level	O
.	O
When	O
dexamethasone	O
was	O
added	O
to	O
the	O
cultures	O
3	O
hours	O
after	O
the	O
stimulators	O
,	O
it	O
clearly	O
decreased	O
the	O
interleukin-1	O
beta	O
mRNA	O
levels	O
regardless	O
of	O
the	O
stimulator	O
used	O
(	O
although	O
the	O
effect	O
was	O
clearly	O
weaker	O
on	O
the	O
PMA	O
-	O
induced	O
mRNA	O
)	O
.	O
Thus	O
these	O
data	O
suggest	O
that	O
the	O
phorbol	O
myristate	O
-	O
induced	O
signal	O
(	O
prolonged	O
protein	B
kinase	I
C	I
activation	O
?	O
)	O
can	O
not	O
be	O
inhibited	O
by	O
prior	O
incubation	O
with	O
dexamethasone	O
and	O
it	O
also	O
protects	O
the	O
induced	O
mRNA	O
for	O
the	O
degradative	O
action	O
of	O
dexamethasone	O
.	O
Elevated	O
glucocorticoid	B
receptor	I
concentrations	O
before	O
and	O
after	O
glucocorticoid	O
therapy	O
in	O
peripheral	O
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
atopic	O
dermatitis	O
.	O
The	O
number	O
and	O
affinity	O
of	O
glucocorticoid	O
binding	O
sites	O
in	O
peripheral	O
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
atopic	O
dermatitis	O
(	O
AD	O
)	O
and	O
healthy	O
controls	O
were	O
determined	O
under	O
baseline	O
conditions	O
and	O
after	O
a	O
defined	O
oral	O
glucocorticoid	O
treatment	O
.	O
Patients	O
with	O
AD	O
(	O
n	O
=	O
15	O
)	O
exhibited	O
significantly	O
more	O
glucocorticoid	B
receptors	I
(	O
GR	B
)	O
per	O
cell	O
than	O
the	O
control	O
group	O
(	O
n	O
=	O
22	O
)	O
,	O
while	O
the	O
GR	B
affinity	O
did	O
not	O
differ	O
.	O
Methylprednisolone	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
GR	B
sites	O
per	O
cell	O
in	O
the	O
steroid	O
-	O
treated	O
control	O
group	O
(	O
n	O
=	O
10	O
)	O
in	O
contrast	O
to	O
the	O
patients	O
.	O
The	O
dissociation	O
constant	O
was	O
not	O
affected	O
by	O
methylprednisolone	O
treatment	O
in	O
either	O
group	O
.	O
In	O
view	O
of	O
the	O
therapeutic	O
efficiency	O
of	O
glucocorticoids	O
in	O
AD	O
and	O
findings	O
of	O
abnormal	O
cAMP	O
and	O
cAMP	O
-	O
phosphodiesterase	O
activity	O
,	O
the	O
elevated	O
GR	B
concentrations	O
in	O
AD	O
lend	O
support	O
to	O
the	O
hypothesis	O
of	O
a	O
compensatory	O
GR	B
upregulation	O
due	O
to	O
an	O
insufficient	O
action	O
of	O
endogenous	O
cortisol	O
or	O
to	O
altered	O
cAMP	O
-	O
induced	O
GR	B
expression	O
.	O
The	O
role	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
in	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
induced	O
hemopoietic	O
differentiation	O
.	O
Terminal	O
differentiation	O
of	O
the	O
leukemic	O
cell	O
lines	O
U-937	O
and	O
HL-60	O
by	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
is	O
induced	O
with	O
variable	O
kinetics	O
during	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
induced	O
differentiation	O
,	O
with	O
c	O
-	O
jun	O
expression	O
best	O
paralleling	O
differentiation	O
.	O
The	O
generation	O
of	O
AP-1	B
complexes	I
,	O
as	O
measured	O
by	O
DNA	O
binding	O
activity	O
,	O
closely	O
parallels	O
morphological	O
differentiation	O
.	O
Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP-1	O
driven	O
reporter	O
construct	O
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	O
AP-1	O
regulated	O
genes	O
.	O
Differentiation	O
assays	O
using	O
water	O
soluble	O
phorbol	O
esters	O
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP-1	B
appears	O
.	O
This	O
tight	O
correlation	O
between	O
c	O
-	O
jun	O
expression	O
,	O
the	O
generation	O
of	O
AP-1	B
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	B
complex	I
during	O
this	O
process	O
.	O
The	O
29-kDa	B
proteins	I
phosphorylated	O
in	O
thrombin	O
-	O
activated	O
human	O
platelets	O
are	O
forms	O
of	O
the	O
estrogen	B
receptor	I
-	I
related	I
27-kDa	I
heat	I
shock	I
protein	I
.	O
Thrombin	B
plays	O
a	O
critical	O
role	O
in	O
platelet	O
activation	O
,	O
hemostasis	O
,	O
and	O
thrombosis	O
.	O
Cellular	O
activation	O
by	O
thrombin	O
leads	O
to	O
the	O
phosphorylation	O
of	O
multiple	B
proteins	I
,	O
most	O
of	O
which	O
are	O
unidentified	O
.	O
We	O
have	O
characterized	O
several	O
29-kDa	B
proteins	I
that	O
are	O
rapidly	O
phosphorylated	O
following	O
exposure	O
of	O
intact	O
human	O
platelets	O
to	O
thrombin	B
.	O
A	O
murine	B
monoclonal	I
antibody	I
raised	O
to	O
an	O
unidentified	B
estrogen	I
receptor	I
-	I
related	I
29-kDa	I
protein	I
selectively	O
recognized	O
these	O
proteins	O
as	O
well	O
as	O
a	O
more	O
basic	O
,	O
unphosphorylated	B
27-kDa	I
protein	I
.	O
Cellular	O
activation	O
by	O
thrombin	B
led	O
to	O
a	O
marked	O
shift	O
in	O
the	O
proportion	O
of	O
protein	O
from	O
the	O
27-kDa	B
unphosphorylated	I
form	I
to	O
the	O
29-kDa	B
phosphoprotein	I
species	I
.	O
Using	O
this	O
antibody	O
,	O
we	O
isolated	O
and	O
sequenced	O
a	O
human	O
cDNA	O
clone	O
encoding	O
a	O
protein	O
that	O
was	O
identical	O
to	O
the	O
mammalian	B
27-kDa	I
heat	I
shock	I
protein	I
(	O
HSP27	B
)	O
,	O
a	O
protein	O
of	O
uncertain	O
function	O
that	O
is	O
known	O
to	O
be	O
phosphorylated	O
to	O
several	O
forms	O
and	O
to	O
be	O
transcriptionally	O
induced	O
by	O
estrogen	O
.	O
The	O
29-kDa	B
proteins	I
were	O
confirmed	O
to	O
be	O
phosphorylated	O
forms	O
of	O
HSP27	B
by	O
immunoprecipitation	O
studies	O
.	O
Thus	O
,	O
the	O
`	O
`	O
estrogen	O
receptor	O
-	O
related	O
protein	O
''	O
is	O
HSP27	B
,	O
and	O
the	O
three	O
major	O
29-kDa	B
proteins	I
phosphorylated	O
in	O
thrombin	O
-	O
activated	O
platelets	O
are	O
forms	O
of	O
HSP27	B
.	O
These	O
data	O
suggest	O
a	O
role	O
for	O
HSP27	B
in	O
the	O
signal	O
transduction	O
events	O
of	O
platelet	O
activation	O
.	O
Characterization	O
of	O
a	O
cofactor	B
that	O
regulates	O
dimerization	O
of	O
a	O
mammalian	B
homeodomain	I
protein	I
.	O
Dimerization	O
among	O
transcription	B
factors	I
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O
Hepatocyte	B
nuclear	I
factor-1	I
alpha	I
(	O
HNF-1	B
alpha	I
)	O
is	O
a	O
homeodomain	B
-	I
containing	I
protein	I
that	O
functions	O
as	O
a	O
dimer	B
.	O
A	O
dimerization	B
cofactor	I
of	O
HNF-1	B
alpha	I
(	O
DCoH	B
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	O
and	O
did	O
not	O
bind	O
to	O
DNA	O
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	O
HNF-1	B
alpha	I
dimers	I
.	O
The	O
formation	O
of	O
a	O
stable	O
tetrameric	B
DCoH	I
-	I
HNF-1	I
alpha	I
complex	I
,	O
which	O
required	O
the	O
dimerization	B
domain	I
of	O
HNF-1	B
alpha	I
,	O
did	O
not	O
change	O
the	O
DNA	O
binding	O
characteristics	O
of	O
HNF-1	B
alpha	I
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O
However	O
,	O
DCoH	B
did	O
not	O
confer	O
transcriptional	O
activation	O
to	O
the	O
GAL4	B
DNA	I
binding	I
domain	I
.	O
These	O
results	O
indicate	O
that	O
DCoH	B
regulates	O
formation	O
of	O
transcriptionally	O
active	O
tetrameric	B
complexes	I
and	O
may	O
contribute	O
to	O
the	O
developmental	O
specificity	O
of	O
the	O
complex	B
.	O
Cortisol	O
receptor	O
resistance	O
:	O
the	O
variability	O
of	O
its	O
clinical	O
presentation	O
and	O
response	O
to	O
treatment	O
.	O
Primary	O
(	O
partial	O
)	O
cortisol	B
receptor	I
resistance	O
was	O
previously	O
reported	O
in	O
a	O
total	O
of	O
7	O
patients	O
and	O
14	O
asymptomatic	O
family	O
members	O
.	O
Its	O
occurrence	O
is	O
considered	O
to	O
be	O
extremely	O
rare	O
.	O
In	O
the	O
present	O
study	O
we	O
report	O
on	O
6	O
patients	O
(	O
2	O
males	O
and	O
4	O
females	O
)	O
with	O
the	O
syndrome	O
.	O
The	O
first	O
male	O
patient	O
presented	O
with	O
mild	O
hypertension	O
.	O
Hydrochlorothiazide	O
therapy	O
resulted	O
in	O
life	O
-	O
threatening	O
hypokalemia	O
.	O
The	O
second	O
male	O
patient	O
had	O
slight	O
hypertension	O
without	O
hypokalemia	O
.	O
All	O
four	O
female	O
patients	O
presented	O
between	O
the	O
age	O
of	O
20	O
-	O
30	O
yr	O
with	O
acne	O
,	O
hirsutism	O
,	O
and	O
irregular	O
menstruations	O
.	O
Low	O
dose	O
dexamethasone	O
therapy	O
(	O
1	O
-	O
1.5	O
mg	O
/	O
day	O
)	O
was	O
of	O
clinical	O
benefit	O
in	O
these	O
patients	O
.	O
All	O
patients	O
showed	O
insufficient	O
suppression	O
of	O
serum	O
cortisol	O
concentrations	O
in	O
the	O
overnight	O
1-mg	O
dexamethasone	O
test	O
.	O
The	O
diurnal	O
rhythm	O
of	O
ACTH	O
and	O
cortisol	O
was	O
intact	O
,	O
albeit	O
at	O
an	O
elevated	O
level	O
.	O
There	O
was	O
a	O
normal	O
increase	O
in	O
ACTH	O
,	O
cortisol	O
,	O
and	O
GH	O
(	O
except	O
in	O
one	O
obese	O
patient	O
)	O
in	O
response	O
to	O
insulin	O
-	O
induced	O
hypoglycemia	O
,	O
while	O
cortisol	O
production	O
was	O
elevated	O
in	O
three	O
patients	O
.	O
Circulating	O
adrenal	O
androgen	O
levels	O
were	O
increased	O
in	O
all	O
patients	O
.	O
Glucocorticoid	B
receptors	I
were	O
investigated	O
in	O
a	O
whole	O
cell	O
dexamethasone	O
binding	O
assay	O
in	O
mononuclear	O
leukocytes	O
.	O
In	O
the	O
first	O
male	O
patient	O
,	O
the	O
number	O
of	O
receptors	O
was	O
very	O
low	O
,	O
while	O
the	O
affinity	O
was	O
lower	O
than	O
that	O
in	O
controls	O
.	O
A	O
lowered	O
affinity	O
to	O
dexamethasone	O
was	O
found	O
in	O
one	O
female	O
patient	O
,	O
while	O
a	O
lowered	O
number	O
of	O
receptors	O
was	O
found	O
in	O
three	O
patients	O
.	O
In	O
the	O
second	O
male	O
patient	O
,	O
no	O
abnormalities	O
were	O
found	O
.	O
As	O
a	O
bioassay	O
for	O
glucocorticoid	O
action	O
we	O
also	O
measured	O
dexamethasone	O
suppressibility	O
of	O
mitogen	O
-	O
stimulated	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
in	O
mononuclear	O
leukocytes	O
.	O
In	O
the	O
male	O
patient	O
with	O
normal	O
receptor	O
status	O
,	O
dexamethasone	O
suppressibility	O
of	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
with	O
respect	O
to	O
both	O
maximal	O
suppression	O
and	O
IC50	O
.	O
Partial	O
cortisol	O
receptor	O
resistance	O
might	O
be	O
less	O
rare	O
than	O
previously	O
thought	O
.	O
In	O
the	O
six	O
patients	O
presented	O
,	O
at	O
least	O
three	O
different	O
forms	O
can	O
be	O
recognized	O
.	O
Therapy	O
with	O
dexamethasone	O
was	O
successful	O
in	O
female	O
patients	O
with	O
acne	O
and	O
hirsutism	O
,	O
as	O
the	O
secondary	O
increase	O
in	O
the	O
production	O
of	O
adrenal	O
androgens	O
was	O
effectively	O
controlled	O
.	O
Influence	O
of	O
estradiol	O
and	O
tamoxifen	O
on	O
susceptibility	O
of	O
human	O
breast	O
cancer	O
cell	O
lines	O
to	O
lysis	O
by	O
lymphokine	O
-	O
activated	O
killer	O
cells	O
.	O
The	O
design	O
of	O
combination	O
hormonal	O
and	O
immunotherapeutic	O
protocols	O
for	O
breast	O
cancer	O
patients	O
may	O
be	O
facilitated	O
by	O
analysis	O
of	O
preclinical	O
in	O
vitro	O
model	O
systems	O
.	O
Estrogen	O
receptor	O
positive	O
(	O
ER+	O
:	O
MCF-7	O
)	O
and	O
negative	O
(	O
ER-	O
:	O
MDA	O
-	O
MB-231	O
)	O
human	O
breast	O
cancer	O
cell	O
lines	O
were	O
utilized	O
to	O
evaluate	O
the	O
effects	O
of	O
tamoxifen	O
(	O
TAM	O
)	O
and	O
estradiol	O
(	O
E2	O
)	O
on	O
modulation	O
of	O
breast	O
cancer	O
target	O
susceptibility	O
to	O
lysis	O
by	O
lymphokine	O
-	O
activated	O
killer	O
(	O
LAK	O
)	O
cells	O
.	O
E2-stimulated	O
ER+	O
cells	O
were	O
more	O
susceptible	O
to	O
lysis	O
by	O
LAK	O
cells	O
than	O
corresponding	O
TAM	O
-	O
treated	O
or	O
control	O
cells	O
,	O
while	O
treatment	O
of	O
ER-	O
cells	O
with	O
either	O
E2	O
or	O
TAM	O
alone	O
did	O
not	O
alter	O
from	O
control	O
their	O
susceptibility	O
to	O
this	O
immune	O
-	O
mediated	O
lysis	O
.	O
All	O
ER+	O
and	O
ER-	O
cells	O
tested	O
remained	O
sensitive	O
after	O
treatment	O
with	O
TAM	O
to	O
lysis	O
by	O
LAK	O
cells	O
.	O
In	O
addition	O
,	O
an	O
adenocarcinoma	B
reactive	I
human	I
-	I
mouse	I
chimeric	I
monoclonal	I
antibody	I
(	O
ING-1	B
)	O
was	O
able	O
to	O
significantly	O
boost	O
in	O
vivo	O
generated	O
LAK	O
cell	O
-	O
mediated	O
lysis	O
of	O
control	O
,	O
E2-treated	O
,	O
and	O
TAM	O
-	O
treated	O
ER+	O
and	O
ER-	O
cells	O
.	O
These	O
in	O
vitro	O
results	O
provide	O
a	O
preclinical	O
rationale	O
for	O
in	O
vivo	O
testing	O
of	O
TAM	O
,	O
interleukin-2	B
(	O
IL-2	B
)	O
,	O
and	O
breast	O
cancer	O
reactive	O
antibody	O
-	O
dependent	O
cellular	O
cytotoxicity	O
facilitating	O
antibody	O
in	O
patients	O
with	O
refractory	O
or	O
high	O
risk	O
breast	O
cancer	O
.	O
Glucocorticoid	B
receptor	I
and	O
inhibition	O
of	O
3-O	O
-	O
methyl	O
-	O
D	O
-	O
glucose	O
uptake	O
by	O
glucocorticoids	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
normal	O
humans	O
:	O
correlation	O
between	O
receptor	O
level	O
and	O
hormone	O
effect	O
in	O
vitro	O
.	O
We	O
have	O
measured	O
the	O
glucocorticoid	B
receptor	I
concentration	O
in	O
mononuclear	O
and	O
polymorphonuclear	O
leukocytes	O
,	O
both	O
of	O
which	O
were	O
isolated	O
from	O
peripheral	O
blood	O
from	O
ten	O
healthy	O
male	O
volunteers	O
.	O
In	O
parallel	O
,	O
the	O
inhibitory	O
effect	O
of	O
dexamethasone	O
on	O
3-O	O
-	O
methyl	O
-	O
D	O
-	O
glucose	O
uptake	O
was	O
assayed	O
in	O
the	O
corresponding	O
mononuclear	O
leukocytes	O
.	O
The	O
glucocorticoid	B
receptor	I
levels	O
in	O
mononuclear	O
leukocytes	O
correlated	O
with	O
those	O
in	O
polymorphonuclear	O
leukocytes	O
,	O
and	O
there	O
was	O
a	O
linear	O
relationship	O
between	O
the	O
cellular	O
glucocorticoid	B
receptor	I
levels	O
and	O
glucocorticoid	O
-	O
mediated	O
inhibition	O
of	O
the	O
uptake	O
of	O
3-O	O
-	O
methyl	O
-	O
D	O
-	O
glucose	O
in	O
mononuclear	O
leukocytes	O
.	O
When	O
mononuclear	O
leukocytes	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
8-bromo	O
-	O
cAMP	O
,	O
cellular	O
glucocorticoid	B
receptor	I
levels	O
increased	O
and	O
a	O
more	O
pronounced	O
inhibitory	O
effect	O
of	O
dexamethasone	O
was	O
observed	O
on	O
the	O
transport	O
of	O
3-O	O
-	O
methyl	O
-	O
D	O
-	O
glucose	O
.	O
We	O
conclude	O
that	O
the	O
cellular	O
glucocorticoid	B
receptor	I
levels	O
in	O
peripheral	O
blood	O
leukocytes	O
reflect	O
in	O
vitro	O
responsiveness	O
to	O
glucocorticoids	O
in	O
mononuclear	O
leukocytes	O
from	O
healthy	O
males	O
,	O
and	O
that	O
the	O
individual	O
responsiveness	O
may	O
alter	O
upon	O
changes	O
in	O
the	O
cellular	O
levels	O
of	O
glucocorticoid	B
receptor	I
.	O
Stimulation	O
of	O
interferon	O
beta	O
gene	O
transcription	O
in	O
vitro	O
by	O
purified	O
NF	B
-	I
kappa	I
B	I
and	O
a	O
novel	O
TH	B
protein	I
.	O
The	O
human	O
interferon	O
beta	O
(	O
IFN	O
-	O
beta	O
)	O
regulatory	O
element	O
consists	O
of	O
multiple	O
enhanson	O
domains	O
which	O
are	O
targets	O
for	O
transcription	B
factors	I
involved	O
in	O
inducible	O
expression	O
of	O
the	O
promoter	O
.	O
To	O
further	O
characterize	O
the	O
protein	O
-	O
DNA	O
interactions	O
mediating	O
IFN	B
-	I
beta	I
induction	O
,	O
positive	B
regulatory	I
domain	I
(	I
PRD	I
)	I
II	I
binding	I
proteins	I
were	O
purified	O
from	O
phorbol	O
ester	O
induced	O
Jurkat	O
T	O
-	O
cells	O
and	O
from	O
IFN	O
primed	O
,	O
cycloheximide	O
/	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
treated	O
HeLa	O
S3	O
cells	O
.	O
From	O
HeLa	O
cells	O
,	O
two	O
major	O
proteins	O
of	O
52	B
and	I
45	I
kilodaltons	I
(	I
kD	I
)	I
copurified	O
with	O
DNA	O
binding	O
activity	O
,	O
whereas	O
from	O
T	O
-	O
cells	O
,	O
four	O
proteins	O
--	O
a	O
major	B
protein	I
of	O
52	B
kD	I
and	O
three	O
minor	B
proteins	I
of	O
82	B
,	O
67	B
,	O
and	O
43	B
-	I
47	I
kD	I
--	O
were	O
purified	O
.	O
Also	O
,	O
an	O
induction	O
specific	B
DNA	I
binding	I
protein	I
was	O
purified	O
from	O
HeLa	O
cells	O
that	O
interacted	O
with	O
the	O
(	O
AAGTGA	O
)	O
4	O
tetrahexamer	O
sequence	O
and	O
the	O
PRDI	O
domain	O
.	O
This	O
protein	O
is	O
immunologically	O
distinct	O
from	O
IRF-1	B
/	I
ISGF2	I
.	O
Uninduced	O
or	O
Sendai	O
virus	O
induced	O
HeLa	O
extracts	O
were	O
used	O
to	O
examine	O
transcription	O
in	O
vitro	O
using	O
a	O
series	O
of	O
IFN	O
beta	O
promoter	O
deletions	O
.	O
Deletions	O
upstream	O
of	O
the	O
PRDII	O
element	O
increased	O
transcription	O
in	O
the	O
uninduced	O
extract	O
,	O
indicating	O
predominantly	O
negative	O
regulation	O
of	O
the	O
promoter	O
.	O
A	O
2	O
-	O
4-fold	O
increase	O
in	O
IFN	O
-	O
beta	O
promoter	O
transcription	O
was	O
observed	O
in	O
Sendai	O
virus	O
induced	O
extracts	O
,	O
and	O
deletion	O
of	O
PRDI	O
and	O
PRDII	O
elements	O
decreased	O
this	O
induced	O
level	O
of	O
transcription	O
.	O
When	O
purified	O
PRDII	B
and	I
tetrahexamer	I
binding	I
proteins	I
were	O
added	O
to	O
the	O
induced	O
extract	O
,	O
a	O
4-fold	O
increase	O
in	O
transcription	O
was	O
observed	O
.	O
These	O
experiments	O
demonstrate	O
that	O
it	O
is	O
possible	O
to	O
modulate	O
IFN	O
-	O
beta	O
transcription	O
in	O
vitro	O
but	O
indicate	O
that	O
additional	O
proteins	O
may	O
be	O
required	O
to	O
fully	O
activate	O
IFN	B
-	I
beta	I
transcription	O
.	O
Transcriptional	O
regulation	O
during	O
T	O
-	O
cell	O
development	O
:	O
the	O
alpha	O
TCR	O
gene	O
as	O
a	O
molecular	O
model	O
.	O
The	O
regulation	O
of	O
gene	O
expression	O
during	O
lymphocyte	O
differentiation	O
is	O
a	O
complex	O
process	O
involving	O
interactions	O
between	O
multiple	O
positive	O
and	O
negative	O
transcriptional	O
regulatory	O
elements	O
.	O
In	O
this	O
article	O
,	O
transcriptional	O
regulation	O
of	O
the	O
archetypal	O
T	O
-	O
cell	O
-	O
specific	O
gene	O
,	O
alpha	O
TCR	O
,	O
is	O
discussed	O
.	O
Major	O
recent	O
developments	O
,	O
including	O
the	O
identification	O
of	O
novel	O
families	O
of	O
transcription	O
factors	O
that	O
regulate	O
multiple	O
T	O
-	O
cell	O
genes	O
during	O
thymocyte	O
ontogeny	O
and	O
T	O
-	O
cell	O
activation	O
,	O
are	O
described	O
.	O
Cortisol	O
resistance	O
in	O
acquired	O
immunodeficiency	O
syndrome	O
.	O
This	O
study	O
concerns	O
9	O
iv	O
drug	O
abusers	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
who	O
developed	O
hypercortisolism	O
without	O
the	O
clinical	O
signs	O
or	O
metabolic	O
consequences	O
of	O
hypercortisolism	O
.	O
All	O
patients	O
were	O
characterized	O
by	O
an	O
Addisonian	O
picture	O
(	O
weakness	O
,	O
weight	O
loss	O
,	O
hypotension	O
,	O
hyponatremia	O
,	O
and	O
intense	O
mucocutaneous	O
melanosis	O
)	O
.	O
An	O
acquired	O
form	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
was	O
suspected	O
.	O
We	O
,	O
therefore	O
,	O
examined	O
glucocorticoid	B
receptor	I
characteristics	O
on	O
mononuclear	O
leukocytes	O
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
is	O
one	O
of	O
the	O
effects	O
of	O
glucocorticoid	B
receptor	I
activation	O
.	O
Glucocorticoid	B
receptor	I
density	O
was	O
increased	O
in	O
AIDS	O
patients	O
with	O
an	O
Addisonian	O
picture	O
(	O
group	O
1	O
;	O
16.2	O
+	O
/-	O
9.4	O
fmol	O
/	O
million	O
cells	O
)	O
compared	O
to	O
values	O
in	O
12	O
AIDS	O
patients	O
without	O
an	O
Addisonian	O
picture	O
(	O
group	O
2	O
;	O
6.05	O
+	O
/-	O
2.6	O
fmol	O
/	O
million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
and	O
sex-	O
and	O
age	O
-	O
matched	O
controls	O
(	O
3.15	O
+	O
/-	O
2.3	O
fmol	O
/	O
million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O
The	O
affinity	O
of	O
glucocorticoid	B
receptors	I
(	O
Kd	O
)	O
was	O
strikingly	O
decreased	O
(	O
9.36	O
+	O
/-	O
3.44	O
nM	O
in	O
group	O
1	O
;	O
3.2	O
+	O
/-	O
1.5	O
nM	O
in	O
group	O
2	O
;	O
2.0	O
+	O
/-	O
0.8	O
nM	O
in	O
controls	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O
[	O
3H	O
]	O
Thymidine	O
incorporation	O
was	O
decreased	O
dose	O
-	O
dependently	O
by	O
dexamethasone	O
in	O
controls	O
and	O
patients	O
;	O
the	O
effect	O
was	O
significantly	O
blunted	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
group	O
1	O
patients	O
,	O
which	O
suggests	O
that	O
activation	O
of	O
glucocorticoid	B
receptor	I
is	O
impaired	O
as	O
a	O
result	O
of	O
the	O
glucocorticoid	B
receptor	I
abnormality	O
.	O
In	O
conclusion	O
,	O
AIDS	O
patients	O
with	O
hypercortisolism	O
and	O
clinical	O
features	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
are	O
characterized	O
by	O
abnormal	B
glucocorticoid	I
receptors	I
on	O
lymphocytes	O
.	O
Resistance	O
to	O
glucocorticoids	O
implies	O
a	O
complex	O
change	O
in	O
immune	O
-	O
endocrine	O
function	O
,	O
which	O
may	O
be	O
important	O
in	O
the	O
course	O
of	O
immunodeficiency	O
syndrome	O
.	O
Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF	B
-	I
kappa	I
B	I
-like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
.	O
The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF	B
-	I
kappa	I
B	I
DNA	O
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O
PLB-985	O
cells	O
represent	O
a	O
bipotential	O
myelomonoblastic	O
cell	O
population	O
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O
By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	B
on	O
the	O
cell	O
surface	O
,	O
PLB-985	O
cells	O
were	O
chronically	O
infected	O
with	O
HIV-1	O
strain	O
IIIB	O
.	O
PLB	O
-	O
IIIB	O
cells	O
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	O
myeloblasts	O
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid	B
-	I
specific	I
surface	I
markers	I
,	O
and	O
transcription	O
of	O
the	O
c	O
-	O
fms	O
proto	O
-	O
oncogene	O
.	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
was	O
inducible	O
by	O
tumor	B
necrosis	I
factor	I
and	O
phorbol	O
myristate	O
acetate	O
in	O
PLB-985	O
.	O
However	O
,	O
in	O
PLB	O
-	O
IIIB	O
cells	O
,	O
constitutive	O
expression	O
of	O
a	O
novel	O
NF	B
-	I
kappa	I
B	I
complex	I
was	O
detected	O
,	O
composed	O
of	O
proteins	O
ranging	O
between	O
70	O
and	O
110	O
kD	O
.	O
These	O
proteins	O
interacted	O
specifically	O
with	O
the	O
symmetric	O
NF	O
-	O
kappa	O
B	O
site	O
from	O
the	O
interferon	O
beta	O
(	O
IFN	O
-	O
beta	O
)	O
promoter	O
.	O
Mutations	O
affecting	O
the	O
5	O
'	O
guanine	O
residues	O
of	O
the	O
kappa	O
B	O
site	O
were	O
unable	O
to	O
compete	O
for	O
these	O
NF	B
-	I
kappa	I
B	I
-	I
related	I
proteins	I
.	O
Inducibility	O
of	O
endogenous	O
IFN	O
-	O
beta	O
and	O
IFN	O
-	O
alpha	O
RNA	O
was	O
also	O
increased	O
in	O
PLB	O
-	O
IIIB	O
cells	O
.	O
These	O
studies	O
indicate	O
that	O
HIV-1	O
infection	O
of	O
myelomonoblastic	O
cells	O
may	O
select	O
for	O
a	O
more	O
mature	O
monocytic	O
phenotype	O
and	O
that	O
unique	O
subunit	O
associations	O
of	O
NF	B
-	I
kappa	I
B	I
DNA	I
binding	I
proteins	I
may	O
contribute	O
to	O
differential	O
NF	B
-	I
kappa	I
B	I
-mediated	O
gene	O
expression	O
.	O
Mineralocorticoid	O
effector	O
mechanism	O
in	O
preeclampsia	O
.	O
Mineralocorticoid	O
effector	O
mechanisms	O
were	O
evaluated	O
in	O
29	O
patients	O
with	O
preeclampsia	O
and	O
in	O
25	O
uncomplicated	O
pregnancies	O
by	O
measurement	O
of	O
plasma	O
aldosterone	O
,	O
levels	O
of	O
mineralocorticoid	B
receptor	I
(	O
MR	B
)	O
in	O
mononuclear	O
leucocytes	O
,	O
and	O
subtraction	O
potential	O
difference	O
(	O
SPD	O
;	O
rectal	O
minus	O
oral	O
values	O
)	O
.	O
Mean	O
values	O
for	O
plasma	O
aldosterone	O
were	O
not	O
different	O
between	O
the	O
two	O
groups	O
,	O
but	O
significant	O
differences	O
were	O
observed	O
for	O
MR	B
(	O
preeclampsia	O
,	O
81	O
+	O
/-	O
44	O
receptors	O
/	O
cell	O
;	O
controls	O
,	O
306	O
+	O
/-	O
168	O
)	O
and	O
SPD	O
(	O
preeclampsia	O
,	O
65	O
+	O
/-	O
7	O
mV	O
;	O
controls	O
,	O
12	O
+	O
/-	O
5	O
mV	O
)	O
.	O
In	O
six	O
cases	O
we	O
determined	O
MR	B
,	O
plasma	O
aldosterone	O
,	O
and	O
SPD	O
in	O
patients	O
with	O
preeclampsia	O
before	O
and	O
3	O
months	O
after	O
delivery	O
.	O
MR	B
were	O
reduced	O
before	O
delivery	O
(	O
96	O
+	O
/-	O
27	O
receptors	O
/	O
cell	O
)	O
,	O
and	O
SPD	O
increased	O
(	O
64	O
+	O
/-	O
8	O
mV	O
)	O
,	O
with	O
both	O
parameters	O
normalizing	O
after	O
delivery	O
(	O
MR	B
,	O
242	O
+	O
/-	O
79	O
;	O
SPD	O
,	O
14.0	O
+	O
/-	O
4	O
mV	O
)	O
.	O
Aldosterone	O
levels	O
returned	O
to	O
normal	O
nonpregnant	O
values	O
after	O
delivery	O
.	O
These	O
data	O
suggest	O
an	O
important	O
role	O
for	O
abnormalities	O
in	O
mineralocorticoid	O
effector	O
mechanisms	O
in	O
the	O
etiology	O
of	O
preeclampsia	O
and	O
could	O
be	O
an	O
useful	O
marker	O
for	O
diagnosis	O
.	O
An	O
11-base	O
-	O
pair	O
DNA	O
sequence	O
motif	O
apparently	O
unique	O
to	O
the	O
human	O
interleukin	O
4	O
gene	O
confers	O
responsiveness	O
to	O
T	O
-	O
cell	O
activation	O
signals	O
.	O
We	O
have	O
identified	O
a	O
DNA	O
segment	O
that	O
confers	O
responsiveness	O
to	O
antigen	O
stimulation	O
signals	O
on	O
the	O
human	O
interleukin	O
(	O
IL	O
)	O
4	O
gene	O
in	O
Jurkat	O
cells	O
.	O
The	O
human	O
IL-4	O
gene	O
,	O
of	O
10	O
kilobases	O
,	O
is	O
composed	O
of	O
four	O
exons	O
and	O
three	O
introns	O
.	O
A	O
cis	O
-	O
acting	O
element	O
(	O
P	O
sequence	O
)	O
resides	O
in	O
the	O
5	O
'	O
upstream	O
region	O
;	O
no	O
additional	O
DNA	O
segments	O
with	O
enhancer	O
activity	O
were	O
identified	O
in	O
the	O
human	O
IL-4	O
gene	O
.	O
For	O
further	O
mapping	O
purposes	O
,	O
a	O
fusion	O
promoter	O
was	O
constructed	O
with	O
the	O
granulocyte	O
/	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
basic	O
promoter	O
containing	O
60	O
base	O
pairs	O
of	O
sequence	O
upstream	O
from	O
the	O
cap	O
site	O
of	O
the	O
mouse	O
granulocyte	O
/	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
and	O
various	O
lengths	O
of	O
the	O
5	O
'	O
upstream	O
sequence	O
of	O
the	O
IL-4	O
gene	O
.	O
The	O
P	O
sequence	O
was	O
located	O
between	O
positions	O
-79	O
and	O
-69	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
of	O
the	O
human	O
IL-4	O
gene	O
,	O
and	O
this	O
location	O
was	O
confirmed	O
by	O
base	O
-	O
substitution	O
mutations	O
.	O
The	O
plasmids	O
carrying	O
multiple	O
copies	O
of	O
the	O
P	O
sequence	O
showed	O
higher	O
responsiveness	O
to	O
the	O
stimulation	O
.	O
The	O
binding	B
protein	I
(	O
s	O
)	O
that	O
recognize	O
the	O
P	O
sequence	O
of	O
the	O
IL-4	O
gene	O
were	O
identified	O
by	O
DNA	O
-	O
mobility	O
-	O
shift	O
assays	O
.	O
The	O
binding	O
of	O
NF	B
(	I
P	I
)	I
(	O
a	O
DNA	B
binding	I
protein	I
that	O
specifically	O
recognizes	O
the	O
P	O
sequence	O
)	O
to	O
the	O
P	O
sequence	O
was	O
abolished	O
when	O
oligonucleotides	O
carrying	O
base	O
substitutions	O
were	O
used	O
,	O
indicating	O
that	O
the	O
NF	B
(	I
P	I
)	I
interaction	O
is	O
sequence	O
-	O
specific	O
and	O
that	O
binding	O
specificity	O
of	O
the	O
protein	O
paralleled	O
the	O
sequence	O
requirements	O
for	O
IL-4	B
expression	O
in	O
vivo	O
.	O
The	O
P	O
sequence	O
does	O
not	O
share	O
homology	O
with	O
the	O
5	O
'	O
upstream	O
sequence	O
of	O
the	O
IL-2	O
gene	O
,	O
even	O
though	O
surrounding	O
sequences	O
of	O
the	O
IL-4	O
gene	O
share	O
high	O
homology	O
with	O
the	O
IL-2	O
gene	O
.	O
We	O
conclude	O
that	O
a	O
different	O
set	O
of	O
proteins	B
recognize	O
IL-2	O
and	O
IL-4	O
genes	O
.	O
[	O
Hormonal	O
interactions	O
and	O
glucocorticoid	B
receptors	I
in	O
patients	O
with	O
the	O
nephrotic	O
syndrome	O
]	O
As	O
many	O
as	O
27	O
children	O
aged	O
6	O
to	O
15	O
years	O
with	O
morphologically	O
verified	O
nephropathies	O
were	O
examined	O
.	O
Four	O
variants	O
of	O
changes	O
in	O
the	O
thyroid	O
status	O
,	O
characteristic	O
of	O
children	O
with	O
different	O
variants	O
of	O
nephrotic	O
syndrome	O
were	O
distinguished	O
:	O
1	O
)	O
biochemical	O
signs	O
of	O
primary	O
hypothyroidism	O
,	O
2	O
)	O
biochemical	O
signs	O
of	O
secondary	O
hypothyroidism	O
,	O
3	O
)	O
low	O
content	O
of	O
T3	O
,	O
4	O
)	O
dysfunction	O
of	O
the	O
hypophyseal	O
and	O
thyroid	O
system	O
.	O
It	O
is	O
shown	O
that	O
the	O
low	O
level	O
of	O
steroid	B
receptors	I
,	O
thyroid	O
hormones	O
that	O
the	O
low	O
level	O
of	O
steroid	B
receptors	I
,	O
thyroid	O
hormones	O
(	O
T3	O
and	O
T4	O
)	O
and	O
cortisol	O
is	O
typical	O
of	O
children	O
with	O
the	O
signs	O
of	O
renal	O
dysplasia	O
.	O
It	O
is	O
assumed	O
that	O
superaddition	O
under	O
such	O
conditions	O
of	O
immune	O
glomerulopathy	O
(	O
glomerulonephritis	O
and	O
nephrotic	O
syndrome	O
)	O
gives	O
rise	O
to	O
the	O
resistance	O
to	O
the	O
treatment	O
with	O
glucocorticoids	O
.	O
Studies	O
on	O
the	O
biological	O
activity	O
of	O
triiodothyronine	O
sulfate	O
.	O
Hepatic	O
microsomes	O
and	O
isolated	O
hepatocytes	O
in	O
short	O
term	O
culture	O
desulfate	O
T3	O
sulfate	O
(	O
T3SO4	O
)	O
.	O
We	O
,	O
therefore	O
,	O
wished	O
to	O
determine	O
whether	O
T3SO4	O
could	O
mimic	O
the	O
action	O
of	O
thyroid	O
hormone	O
in	O
vitro	O
.	O
T3SO4	O
had	O
no	O
thyromimetic	O
effect	O
on	O
the	O
activity	O
of	O
Ca	B
(	I
2	I
+	I
)	I
-ATPase	I
in	O
human	O
erythrocyte	O
membranes	O
at	O
doses	O
up	O
to	O
10	O
,	O
000	O
times	O
the	O
maximally	O
effective	O
dose	O
of	O
T3	O
(	O
10	O
(	O
-10	O
)	O
mol	O
/	O
L	O
)	O
.	O
In	O
GH4C1	O
pituitary	O
cells	O
,	O
T3SO4	O
failed	O
to	O
displace	O
[	O
125I	O
]	O
T3	O
from	O
nuclear	B
receptors	I
in	O
intact	O
cells	O
or	O
soluble	O
preparations	O
.	O
Thus	O
,	O
T3SO4	O
was	O
not	O
directly	O
thyromimetic	O
in	O
either	O
an	O
isolated	O
human	O
membrane	O
system	O
or	O
a	O
pituitary	O
cell	O
system	O
in	O
which	O
nuclear	O
receptor	O
occupancy	O
correlates	O
with	O
GH	O
synthesis	O
.	O
Thyroid	O
hormones	O
inhibit	O
[	O
3H	O
]	O
glycosaminoglycan	O
synthesis	O
by	O
cultured	O
human	O
dermal	O
fibroblasts	O
,	O
and	O
T3SO4	O
displayed	O
about	O
0.5	O
%	O
the	O
activity	O
of	O
T3	O
at	O
72	O
h	O
.	O
Human	O
fibroblasts	O
contained	O
roughly	O
the	O
same	O
level	O
of	O
microsomal	O
p	B
-	I
nitrophenyl	I
sulfatase	I
activity	O
as	O
that	O
previously	O
observed	O
in	O
hepatic	O
microsomes	O
.	O
Propylthiouracil	O
(	O
50	O
mumol	O
/	O
L	O
)	O
did	O
not	O
affect	O
the	O
action	O
of	O
T3SO4	O
,	O
suggesting	O
that	O
deiodination	O
was	O
not	O
important	O
for	O
this	O
activity	O
of	O
T3SO4	O
.	O
Thus	O
,	O
it	O
appears	O
T3SO4	O
has	O
no	O
intrinsic	O
biological	O
activity	O
,	O
but	O
,	O
under	O
certain	O
circumstances	O
,	O
may	O
be	O
reactivated	O
by	O
desulfation	O
.	O
Nuclear	B
factor	I
of	O
activated	O
T	O
cells	O
contains	O
Fos	B
and	O
Jun	B
.	O
The	O
nuclear	B
factor	I
NF	I
-	I
AT	I
(	O
ref	O
.	O
1	O
)	O
is	O
induced	O
in	O
T	O
cells	O
stimulated	O
through	O
the	O
T	B
-	I
cell	I
receptor	I
/	I
CD3	I
complex	I
,	O
and	O
is	O
required	O
for	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
induction	O
.	O
Although	O
NF	B
-	I
AT	I
has	O
not	O
been	O
cloned	O
or	O
purified	O
,	O
there	O
is	O
evidence	O
that	O
it	O
is	O
a	O
major	O
target	O
for	O
immunosuppression	O
by	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
(	O
refs	O
2	O
-	O
7	O
)	O
.	O
NF	B
-	I
AT	I
induction	O
may	O
require	O
two	O
activation	O
-	O
dependent	O
events	O
:	O
the	O
CsA	O
-	O
sensitive	O
translocation	O
of	O
a	O
pre	O
-	O
existing	O
component	O
and	O
the	O
CsA	O
-	O
resistant	O
synthesis	O
of	O
a	O
nuclear	B
component	I
.	O
Here	O
we	O
report	O
that	O
the	O
newly	O
synthesized	O
nuclear	B
component	I
of	O
NF	B
-	I
AT	I
is	O
the	O
transcription	B
factor	I
AP-1	B
.	O
We	O
show	O
that	O
the	O
inducible	O
nuclear	O
form	O
of	O
NF	B
-	I
AT	I
contains	O
Fos	B
and	O
Jun	B
proteins	O
.	O
Furthermore	O
,	O
we	O
identify	O
a	O
pre	B
-	I
existing	I
NF	I
-	I
AT	I
-	I
binding	I
factor	I
that	O
is	O
present	O
in	O
hypotonic	O
extracts	O
of	O
unstimulated	O
T	O
cells	O
.	O
On	O
the	O
basis	O
of	O
binding	O
,	O
reconstitution	O
and	O
cotransfection	O
experiments	O
,	O
we	O
propose	O
that	O
activation	O
of	O
NF	B
-	I
AT	I
occurs	O
in	O
at	O
least	O
two	O
stages	O
:	O
a	O
CsA	O
-	O
sensitive	O
stage	O
involving	O
modification	O
and/or	O
translocation	O
of	O
the	O
pre	O
-	O
existing	O
NF	B
-	I
AT	I
complex	I
,	O
and	O
a	O
CsA	O
-	O
insensitive	O
stage	O
involving	O
the	O
addition	O
of	O
newly	O
synthesized	O
Fos	B
or	O
Fos	B
/	I
Jun	I
proteins	I
to	O
the	O
pre	B
-	I
existing	I
complex	I
.	O
The	O
mechanism	O
of	O
action	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
.	O
CsA	O
and	O
FK506	O
are	O
powerful	O
suppressors	O
of	O
the	O
immune	O
system	O
,	O
most	O
notably	O
of	O
T	O
cells	O
.	O
They	O
act	O
at	O
a	O
point	O
in	O
activation	O
that	O
lies	O
between	O
receptor	O
ligation	O
and	O
the	O
transcription	O
of	O
early	O
genes	O
.	O
Here	O
,	O
Stuart	O
Schreiber	O
and	O
Gerald	O
Crabtree	O
review	O
recent	O
findings	O
that	O
indicate	O
CsA	O
and	O
FK506	O
operate	O
as	O
prodrugs	O
:	O
they	O
bind	O
endogenous	B
intracellular	I
receptors	I
,	O
the	O
immunophilins	B
,	O
and	O
the	O
resulting	O
complex	O
targets	O
the	O
protein	B
phosphatase	I
,	I
calcineurin	B
,	O
to	O
exert	O
the	O
immunosuppressive	O
effect	O
.	O
Activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
is	O
not	O
dependent	O
on	O
NFAT-1	B
.	O
The	O
function	O
of	O
a	O
putative	O
NFAT-1	O
site	O
in	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
has	O
been	O
analyzed	O
.	O
Activation	O
by	O
the	O
T	B
-	I
cell	I
antigen	I
receptor	I
is	O
minimal	O
in	O
Jurkat	O
cells	O
and	O
is	O
mediated	O
by	O
the	O
kappa	O
B	O
sites	O
.	O
The	O
putative	O
NFAT-1	O
region	O
is	O
not	O
required	O
for	O
the	O
response	O
to	O
anti	B
-	I
CD3	I
or	O
to	O
mitogens	B
in	O
T	O
-	O
cell	O
,	O
B	O
-	O
cell	O
,	O
or	O
monocyte	O
/	O
macrophage	O
leukemia	O
lines	O
,	O
nor	O
is	O
it	O
a	O
cis	O
-	O
acting	O
negative	O
regulatory	O
element	O
.	O
Reduced	O
susceptibility	O
to	O
HIV-1	O
infection	O
of	O
ethyl	O
-	O
methanesulfonate	O
-	O
treated	O
CEM	O
subclones	O
correlates	O
with	O
a	O
blockade	O
in	O
their	O
protein	B
kinase	I
C	I
signaling	O
pathway	O
.	O
We	O
have	O
described	O
the	O
isolation	O
of	O
chemically	O
induced	O
CEM	O
subclones	O
that	O
express	O
CD4	B
receptors	I
and	O
bind	O
soluble	O
gp120	B
,	O
yet	O
show	O
a	O
markedly	O
reduced	O
susceptibility	O
to	O
infection	O
with	O
HIV-1	O
.	O
Two	O
subclones	O
were	O
found	O
to	O
have	O
an	O
abnormal	O
response	O
to	O
the	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
activator	O
PMA	O
.	O
PMA	O
treatment	O
induced	O
CD3	B
and	I
CD25	I
(	I
IL-2R	I
)	I
receptors	I
on	O
the	O
parental	O
line	O
and	O
on	O
other	O
ethyl	O
-	O
methanesulfonate	O
-	O
derived	O
subclones	O
,	O
but	O
not	O
on	O
these	O
two	O
mutants	O
.	O
Direct	O
assays	O
of	O
PKC	B
activity	O
were	O
conducted	O
.	O
Total	O
cellular	O
PKC	B
enzymatic	O
activity	O
was	O
found	O
to	O
be	O
normal	O
in	O
these	O
subclones	O
.	O
PMA	O
-	O
induced	O
CD4	B
down	O
-	O
modulation	O
occurred	O
normally	O
.	O
In	O
addition	O
,	O
activation	O
of	O
c	B
-	I
raf	I
kinase	I
was	O
normal	O
.	O
Since	O
HIV-1	O
long	O
terminal	O
repeat	O
contains	O
two	O
functional	O
nuclear	O
factor	O
kB	O
(	O
NF	O
-	O
kB	O
)	O
regulatory	O
elements	O
,	O
we	O
studied	O
the	O
ability	O
of	O
PMA	O
to	O
induce	O
NF	B
-	I
kB	I
binding	O
activity	O
by	O
different	O
assays	O
.	O
Chloramphenicol	B
acetyl	I
transferase	I
(	O
CAT	B
)	O
assays	O
using	O
the	O
HIV-1	O
(	O
-139	O
)	O
long	O
terminal	O
repeat	O
-	O
CAT	O
construct	O
showed	O
no	O
PMA	O
induction	O
of	O
CAT	B
activity	O
in	O
these	O
subclones	O
(	O
unlike	O
the	O
parental	O
line	O
and	O
other	O
subclones	O
)	O
.	O
Okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	B
1	I
and	I
2A	I
,	O
did	O
not	O
overcome	O
the	O
defect	O
in	O
these	O
subclones	O
.	O
Gel	O
retardation	O
assays	O
,	O
using	O
a	O
32P	O
-	O
probe	O
containing	O
the	O
HIV-1	O
NF	B
-	I
kB	I
probe	O
and	O
nuclear	O
extracts	O
from	O
PMA	O
-	O
treated	O
cells	O
,	O
showed	O
significantly	O
reduced	O
induction	O
of	O
nuclear	B
NF	I
-	I
kB	I
binding	I
proteins	I
in	O
these	O
two	O
subclones	O
compared	O
with	O
wild	B
type	I
CEM	I
and	O
a	O
control	O
subclone	O
.	O
Deoxycholate	O
treatment	O
of	O
cytoplasmic	O
extracts	O
from	O
these	O
subclones	O
released	O
much	O
reduced	O
NF	B
-	I
kB	I
binding	I
proteins	I
from	O
their	O
cytoplasmic	O
pools	O
.	O
Thus	O
,	O
reduced	O
levels	O
of	O
PKC	B
-induced	O
nuclear	O
NF	B
-	I
kB	I
activity	O
in	O
two	O
T	O
cell	O
subclones	O
did	O
not	O
affect	O
their	O
normal	O
cell	O
growth	O
,	O
but	O
correlated	O
with	O
a	O
pronounced	O
reduction	O
in	O
their	O
susceptibility	O
to	O
HIV-1	O
infection	O
.	O
Cell	O
cycle	O
-	O
dependent	O
initiation	O
and	O
lineage	O
-	O
dependent	O
abrogation	O
of	O
GATA-1	B
expression	O
in	O
pure	O
differentiating	O
hematopoietic	O
progenitors	O
.	O
The	O
programmed	O
activation	O
/	O
repression	O
of	O
transcription	B
factors	I
in	O
early	O
hematopoietic	O
differentiation	O
has	O
not	O
yet	O
been	O
explored	O
.	O
The	O
DNA	B
-	I
binding	I
protein	I
GATA-1	B
is	O
required	O
for	O
normal	O
erythroid	O
development	O
and	O
regulates	O
erythroid	O
-	O
expressed	O
genes	O
in	O
maturing	O
erythroblasts	O
.	O
We	O
analyzed	O
GATA-1	B
expression	O
in	O
early	O
human	O
adult	O
hematopoiesis	O
by	O
using	O
an	O
in	O
vitro	O
system	O
in	O
which	O
`	O
`	O
pure	O
''	O
early	O
hematopoietic	O
progenitors	O
are	O
induced	O
to	O
gradual	O
and	O
synchronized	O
differentiation	O
selectively	O
along	O
the	O
erythroid	O
or	O
granulocyte	O
-	O
macrophage	O
pathway	O
by	O
differential	O
treatment	O
with	O
hematopoietic	O
growth	O
factors	O
.	O
The	O
GATA-1	O
gene	O
,	O
though	O
virtually	O
silent	O
in	O
quiescent	O
progenitors	O
,	O
is	O
activated	O
after	O
entrance	O
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
hematopoietic	O
growth	O
factors	O
.	O
Subsequently	O
,	O
increasing	O
expression	O
along	O
the	O
erythroid	O
pathway	O
contrasts	O
with	O
an	O
abrupt	O
downregulation	O
in	O
the	O
granulocyte	O
-	O
macrophage	O
lineage	O
.	O
These	O
results	O
suggest	O
a	O
microenvironment	O
-	O
directed	O
,	O
two	O
-	O
step	O
model	O
for	O
GATA-1	B
expression	O
in	O
differentiating	O
hematopoietic	O
progenitors	O
that	O
involves	O
(	O
i	O
)	O
cycle	O
-	O
dependent	O
initiation	O
and	O
(	O
ii	O
)	O
lineage	O
-	O
dependent	O
maintenance	O
or	O
suppression	O
.	O
Hypothetically	O
,	O
on	O
/	O
off	O
switches	O
of	O
lineage	B
-	I
restricted	I
transactivators	I
may	O
underlie	O
the	O
binary	O
fate	O
decisions	O
of	O
hematopoietic	O
progenitors	O
.	O
[	O
Age	O
-	O
related	O
changes	O
in	O
glucocorticoid	B
and	I
mineralocorticoid	I
receptors	I
in	O
lymphocytes	O
of	O
healthy	O
persons	O
and	O
patients	O
with	O
hypertension	O
]	O
It	O
has	O
been	O
found	O
that	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
in	O
lymphocytes	O
of	O
the	O
peripheral	O
blood	O
of	O
healthy	O
elderly	O
subjects	O
increases	O
,	O
while	O
the	O
number	O
of	O
mineralocorticoid	O
receptors	O
decreases	O
.	O
The	O
mechanisms	O
of	O
hormone	O
-	O
receptor	O
interactions	O
in	O
hypertension	O
are	O
activated	O
:	O
the	O
number	O
of	O
glucocorticoid	B
and	I
mineralocorticoid	I
binding	I
sites	I
grows	O
in	O
hypertensive	O
patients	O
.	O
Still	O
a	O
more	O
essential	O
rise	O
in	O
the	O
number	O
of	O
receptors	O
is	O
observed	O
in	O
mid	O
-	O
age	O
hypertensive	O
patients	O
than	O
in	O
elderly	O
ones	O
.	O
NF	B
-	I
kappa	I
B	I
-dependent	O
induction	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
p50	O
subunit	O
gene	O
promoter	O
underlies	O
self	O
-	O
perpetuation	O
of	O
human	O
immunodeficiency	O
virus	O
transcription	O
in	O
monocytic	O
cells	O
.	O
The	O
molecular	O
mechanisms	O
underlying	O
the	O
sustained	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
observed	O
in	O
U937	O
monocytic	O
cells	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
were	O
studied	O
.	O
The	O
activity	O
of	O
the	O
promoter	O
regulating	O
the	O
synthesis	O
of	O
the	O
p105	B
precursor	I
of	O
the	O
NF	B
-	I
kappa	I
B	I
p50	I
subunit	I
was	O
enhanced	O
in	O
these	O
cells	O
.	O
Deletions	O
in	O
this	O
promoter	O
indicated	O
that	O
this	O
upregulation	O
was	O
mediated	O
through	O
the	O
NF	O
-	O
kappa	O
B-	O
but	O
not	O
the	O
AP-1-binding	O
motif	O
,	O
by	O
bona	O
fide	O
p50	B
/	I
p65	I
heterodimers	I
.	O
Analysis	O
of	O
cytosolic	O
extracts	O
indicated	O
that	O
NF	B
-	I
kappa	I
B	I
levels	O
were	O
increased	O
in	O
HIV	O
-	O
infected	O
cells	O
.	O
In	O
contrast	O
to	O
the	O
transient	O
NF	B
-	I
kappa	I
B	I
activation	O
induced	O
by	O
phorbol	O
ester	O
,	O
the	O
permanent	O
NF	B
-	I
kappa	I
B	I
translocation	O
induced	O
by	O
HIV	O
infection	O
was	O
not	O
dependent	O
on	O
PKC	B
isoenzymes	I
alpha	I
and	I
beta	I
as	O
shown	O
by	O
the	O
use	O
of	O
a	O
specific	O
inhibitor	O
(	O
GF	O
109203X	O
)	O
.	O
These	O
observations	O
indicate	O
that	O
during	O
chronic	O
HIV	O
infection	O
of	O
U937	O
cells	O
,	O
continuous	O
NF	B
-	I
kappa	I
B	I
(	O
p50	B
/	I
p65	I
)	O
translocation	O
results	O
in	O
p105	O
promoter	O
upregulation	O
with	O
subsequent	O
cytosolic	O
NF	B
-	I
kappa	I
B	I
accumulation	O
,	O
ready	O
for	O
further	O
translocation	O
.	O
This	O
HIV	O
-	O
mediated	O
mechanism	O
results	O
in	O
a	O
self	O
-	O
perpetuating	O
loop	O
of	O
NF	B
-	I
kappa	I
B	I
production	O
.	O
Okadaic	O
acid	O
is	O
a	O
potent	O
inducer	O
of	O
AP-1	B
,	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
in	O
human	O
B	O
lymphocytes	O
.	O
Treatment	O
of	O
human	O
B	O
lymphocytes	O
with	O
an	O
optimal	O
concentration	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	B
1	I
and	I
2A	I
,	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	B
factor	I
,	O
AP-1	B
and	O
a	O
marked	O
increase	O
in	O
NF	B
-	I
kappa	I
B	I
levels	O
.	O
In	O
contrast	O
,	O
no	O
effect	O
on	O
the	O
levels	O
of	O
the	O
octamer	B
binding	I
proteins	I
,	O
Oct-1	B
or	O
Oct-2	B
,	O
were	O
found	O
.	O
Since	O
both	O
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
have	O
been	O
reported	O
to	O
be	O
important	O
in	O
the	O
induction	O
of	O
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
gene	O
we	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
on	O
TNF	O
-	O
alpha	O
mRNA	O
levels	O
.	O
Treatment	O
with	O
okadaic	O
acid	O
resulted	O
in	O
a	O
striking	O
increase	O
in	O
TNF	O
-	O
alpha	O
mRNA	O
transcripts	O
within	O
1	O
h	O
of	O
stimulation	O
and	O
large	O
amounts	O
of	O
TNF	B
-	I
alpha	I
were	O
released	O
into	O
the	O
culture	O
media	O
.	O
Although	O
okadaic	O
acid	O
provides	O
a	O
potent	O
inductive	O
signal	O
for	O
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
it	O
did	O
not	O
induce	O
either	O
B	O
cell	O
proliferation	O
or	O
immunoglobulin	B
secretion	O
.	O
Characterization	O
of	O
a	O
new	O
tissue	O
-	O
specific	O
transcription	B
factor	I
binding	O
to	O
the	O
simian	O
virus	O
40	O
enhancer	O
TC	O
-	O
II	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
element	O
.	O
We	O
have	O
biochemically	O
and	O
functionally	O
characterized	O
a	O
new	O
transcription	B
factor	I
,	O
NP	B
-	I
TCII	I
,	O
which	O
is	O
present	O
in	O
nuclei	O
from	O
unstimulated	O
T	O
and	O
B	O
lymphocytes	O
but	O
is	O
not	O
found	O
in	O
nonhematopoietic	O
cells	O
.	O
This	O
factor	O
has	O
a	O
DNA	O
-	O
binding	O
specificity	O
similar	O
to	O
that	O
of	O
NF	B
-	I
kappa	I
B	I
but	O
is	O
unrelated	O
to	O
this	O
or	O
other	O
Rel	B
proteins	I
by	O
functional	O
and	O
biochemical	O
criteria	O
.	O
It	O
can	O
also	O
be	O
distinguished	O
from	O
other	O
previously	O
described	O
lymphocyte	B
-	I
specific	I
DNA	I
-	I
binding	I
proteins	I
.	O
A	O
novel	B
B	I
cell	I
-	I
derived	I
coactivator	I
potentiates	O
the	O
activation	O
of	O
immunoglobulin	O
promoters	O
by	O
octamer	B
-	I
binding	I
transcription	I
factors	I
.	O
A	O
novel	O
B	O
cell	O
-	O
restricted	O
activity	O
,	O
required	O
for	O
high	O
levels	O
of	O
octamer	O
/	O
Oct	O
-dependent	O
transcription	O
from	O
an	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
promoter	O
,	O
was	O
detected	O
in	O
an	O
in	O
vitro	O
system	O
consisting	O
of	O
HeLa	O
cell	O
-derived	O
extracts	O
complemented	O
with	O
fractionated	B
B	I
cell	I
nuclear	I
proteins	I
.	O
The	O
factor	O
responsible	O
for	O
this	O
activity	O
was	O
designated	O
Oct	B
coactivator	I
from	O
B	O
cells	O
(	O
OCA	B
-	I
B	I
)	O
.	O
OCA	B
-	I
B	I
stimulates	O
the	O
transcription	O
from	O
an	O
IgH	O
promoter	O
in	O
conjunction	O
with	O
either	O
Oct-1	B
or	O
Oct-2	B
but	O
shows	O
no	O
significant	O
effect	O
on	O
the	O
octamer	O
/	O
Oct	O
-dependent	O
transcription	O
of	O
the	O
ubiquitously	O
expressed	O
histone	O
H2B	O
promoter	O
and	O
the	O
transcription	O
of	O
USF-	O
and	O
Sp1-regulated	O
promoters	O
.	O
Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
OCA	B
-	I
B	I
is	O
a	O
tissue-	B
,	I
promoter-	I
,	I
and	I
factor	I
-	I
specific	I
coactivator	I
and	O
that	O
OCA	B
-	I
B	I
may	O
be	O
a	O
major	O
determinant	O
for	O
B	O
cell	O
-	O
specific	O
activation	O
of	O
immunoglobulin	O
promoters	O
.	O
In	O
light	O
of	O
the	O
evidence	O
showing	O
physical	O
and	O
functional	O
interactions	O
between	O
Oct	B
factors	I
and	O
OCA	B
-	I
B	I
,	O
we	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
OCA	B
-	I
B	I
and	O
discuss	O
the	O
implications	O
of	O
OCA	B
-	I
B	I
for	O
the	O
transcriptional	O
regulation	O
of	O
other	O
tissue	O
-	O
specific	O
promoters	O
.	O
A	O
mechanism	O
for	O
the	O
antiinflammatory	O
effects	O
of	O
corticosteroids	O
:	O
the	O
glucocorticoid	B
receptor	I
regulates	O
leukocyte	O
adhesion	O
to	O
endothelial	O
cells	O
and	O
expression	O
of	O
endothelial	B
-	I
leukocyte	I
adhesion	I
molecule	I
1	I
and	O
intercellular	B
adhesion	I
molecule	I
1	I
.	O
Corticosteroids	O
are	O
the	O
preeminent	O
antiinflammatory	O
agents	O
although	O
the	O
molecular	O
mechanisms	O
that	O
impart	O
their	O
efficacy	O
have	O
not	O
been	O
defined	O
.	O
The	O
endothelium	O
plays	O
a	O
critical	O
role	O
in	O
inflammation	O
by	O
directing	O
circulating	O
leukocytes	O
into	O
extravascular	O
tissues	O
by	O
expressing	O
adhesive	B
molecules	I
for	O
leukocytes	O
[	O
e.g.	O
,	O
endothelial	B
-	I
leukocyte	I
adhesion	I
molecule	I
1	I
(	O
ELAM-1	B
)	O
and	O
intercellular	B
adhesion	I
molecule	I
1	I
(	O
ICAM-1	B
)	O
]	O
.	O
We	O
therefore	O
determined	O
whether	O
corticosteroids	O
suppress	O
inflammation	O
by	O
inhibiting	O
endothelial	O
expression	O
of	O
adhesion	B
molecules	I
for	O
neutrophils	O
(	O
polymorphonuclear	O
leukocytes	O
)	O
.	O
Preincubation	O
of	O
endothelial	O
cells	O
with	O
endotoxin	O
[	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
1	O
microgram	O
/	O
ml	O
]	O
led	O
to	O
a	O
4-fold	O
increase	O
in	O
subsequent	O
adherence	O
of	O
polymorphonuclear	O
leukocytes	O
(	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
10	O
)	O
to	O
endothelial	O
cells	O
,	O
an	O
increase	O
that	O
was	O
markedly	O
attenuated	O
when	O
endothelial	O
cells	O
were	O
treated	O
with	O
dexamethasone	O
(	O
IC50	O
<	O
1	O
nM	O
,	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
6	O
or	O
7	O
)	O
during	O
preincubation	O
with	O
LPS	O
.	O
Moreover	O
,	O
the	O
steroid	B
receptor	I
agonist	O
cortisol	O
(	O
10	O
microM	O
)	O
,	O
but	O
not	O
its	O
inactive	O
metabolite	O
tetrahydrocortisol	O
(	O
10	O
microM	O
)	O
,	O
diminished	O
LPS	O
-	O
induced	O
endothelial	O
cell	O
adhesiveness	O
.	O
Further	O
evidence	O
that	O
the	O
action	O
of	O
dexamethasone	O
was	O
mediated	O
through	O
ligation	O
of	O
corticosteroid	B
receptors	I
[	O
human	B
glucocorticoid	I
receptors	I
(	O
hGRs	B
)	O
]	O
was	O
provided	O
by	O
experiments	O
utilizing	O
the	O
steroid	O
antagonist	O
RU-486	O
.	O
RU-486	O
(	O
10	O
microM	O
)	O
,	O
which	O
prevents	O
translocation	O
of	O
ligated	O
hGR	B
to	O
the	O
nucleus	O
by	O
inhibiting	O
dissociation	O
of	O
hGR	B
from	O
heat	O
shock	O
protein	O
90	O
,	O
completely	O
aborted	O
the	O
effect	O
of	O
dexamethasone	O
on	O
adhesiveness	O
of	O
endothelial	O
cells	O
(	O
P	O
<	O
0.0005	O
,	O
n	O
=	O
3	O
)	O
.	O
Treatment	O
of	O
endothelial	O
cells	O
with	O
LPS	O
(	O
1	O
microgram	O
/	O
ml	O
)	O
stimulated	O
transcription	O
of	O
ELAM-1	B
,	O
as	O
shown	O
by	O
Northern	O
blot	O
analysis	O
,	O
and	O
expression	O
of	O
membrane	B
-	I
associated	I
ELAM-1	I
and	O
ICAM-1	B
,	O
as	O
shown	O
by	O
quantitative	O
immunofluorescence	O
(	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
9	O
)	O
.	O
Dexamethasone	O
markedly	O
inhibited	O
LPS	O
-	O
stimulated	O
accumulation	O
of	O
mRNA	O
for	O
ELAM-1	B
and	O
expression	O
of	O
ELAM-1	B
and	O
ICAM-1	B
(	O
IC50	O
<	O
10	O
nM	O
,	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
4	O
-	O
9	O
)	O
;	O
inhibition	O
of	O
expression	O
by	O
dexamethasone	O
was	O
reversed	O
by	O
RU-486	O
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
4	O
-	O
6	O
)	O
.	O
As	O
in	O
the	O
adhesion	O
studies	O
,	O
cortisol	O
but	O
not	O
tetrahydrocortisol	O
inhibited	O
expression	O
of	O
ELAM-1	B
and	O
ICAM-1	B
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
3	O
or	O
4	O
)	O
.	O
In	O
contrast	O
,	O
sodium	O
salicylate	O
(	O
1	O
mM	O
)	O
inhibited	O
neither	O
adhesion	O
nor	O
expression	O
of	O
these	O
adhesion	B
molecules	I
.	O
These	O
studies	O
suggest	O
that	O
antagonism	O
by	O
dexamethasone	O
of	O
endotoxin	B
-induced	O
inflammation	O
is	O
a	O
specific	O
instance	O
of	O
the	O
general	O
biological	O
principle	O
that	O
the	O
glucocorticoid	B
receptor	I
is	O
a	O
hormone	O
-	O
dependent	O
regulator	O
of	O
transcription	O
.	O
Membrane	B
receptors	I
for	O
aldosterone	O
:	O
a	O
novel	O
pathway	O
for	O
mineralocorticoid	O
action	O
.	O
Rapid	O
nongenomic	O
in	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
intracellular	O
electrolytes	O
,	O
cell	O
volume	O
,	O
and	O
Na	B
(	I
+	I
)	I
-H+	I
antiport	I
have	O
been	O
found	O
in	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
.	O
Binding	O
of	O
125I	O
-	O
labeled	O
aldosterone	O
to	O
plasma	O
membranes	O
of	O
HML	O
shares	O
important	O
features	O
with	O
these	O
functional	O
data	O
.	O
This	O
includes	O
a	O
very	O
low	O
apparent	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
0.1	O
nM	O
for	O
both	O
aldosterone	O
and	O
the	O
effect	O
on	O
the	O
Na	B
(	I
+	I
)	I
-H	I
(	I
+	I
)	I
-antiport	I
,	O
a	O
high	O
turnover	O
rate	O
,	O
and	O
the	O
almost	O
exclusive	O
binding	O
selectivity	O
for	O
aldosterone	O
.	O
Dexamethasone	O
,	O
RU	O
26988	O
,	O
corticosterone	O
,	O
ouabain	O
,	O
amiloride	O
,	O
and	O
18-hydroxyprogesterone	O
were	O
inactive	O
as	O
ligands	O
.	O
Deoxycorticosterone	O
acetate	O
had	O
an	O
intermediate	O
activity	O
with	O
an	O
apparent	O
Kd	O
of	O
100	O
nM	O
.	O
These	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
of	O
aldosterone	O
being	O
compatible	O
with	O
major	O
aspects	O
of	O
its	O
nongenomic	O
effects	O
.	O
Transcription	O
of	O
the	O
hypersensitive	O
site	O
HS2	O
enhancer	O
in	O
erythroid	O
cells	O
.	O
In	O
the	O
human	O
genome	O
,	O
the	O
erythroid	O
-	O
specific	O
hypersensitive	O
site	O
HS2	O
enhancer	O
regulates	O
the	O
transcription	O
of	O
the	O
downstream	O
beta	O
-	O
like	O
globin	O
genes	O
10	O
-	O
50	O
kilobases	O
away	O
.	O
The	O
mechanism	O
of	O
HS2	O
enhancer	O
function	O
is	O
not	O
known	O
.	O
The	O
present	O
study	O
employs	O
RNA	O
protection	O
assays	O
to	O
analyze	O
the	O
transcriptional	O
status	O
of	O
the	O
HS2	O
enhancer	O
in	O
transfected	O
recombinant	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
plasmids	O
.	O
In	O
erythroid	O
K562	O
cells	O
in	O
which	O
the	O
HS2	O
enhancer	O
is	O
active	O
,	O
the	O
HS2	O
sequence	O
directs	O
the	O
synthesis	O
of	O
long	O
enhancer	O
transcripts	O
that	O
are	O
initiated	O
apparently	O
from	O
within	O
the	O
enhancer	O
and	O
elongated	O
through	O
the	O
intervening	O
DNA	O
into	O
the	O
cis	O
-	O
linked	O
CAT	O
gene	O
.	O
In	O
nonerythroid	O
HL-60	O
cells	O
in	O
which	O
the	O
HS2	O
enhancer	O
is	O
inactive	O
,	O
long	O
enhancer	O
transcripts	O
are	O
not	O
detectable	O
.	O
Splitting	O
the	O
HS2	O
enhancer	O
between	O
two	O
tandem	O
Ap1	O
sites	O
abolishes	O
the	O
synthesis	O
of	O
a	O
group	O
of	O
long	O
enhancer	O
transcripts	O
and	O
results	O
in	O
loss	O
of	O
enhancer	O
function	O
and	O
transcriptional	O
silencing	O
of	O
the	O
cis	O
-	O
linked	O
CAT	O
gene	O
.	O
In	O
directing	O
the	O
synthesis	O
of	O
RNA	O
through	O
the	O
intervening	O
DNA	O
and	O
the	O
gene	O
by	O
a	O
tracking	O
and	O
transcription	O
mechanism	O
,	O
the	O
HS2	O
enhancer	O
may	O
(	O
i	O
)	O
open	O
up	O
the	O
chromatin	O
structure	O
of	O
a	O
gene	O
domain	O
and	O
(	O
ii	O
)	O
deliver	O
enhancer	B
binding	I
proteins	I
to	O
the	O
promoter	O
sequence	O
where	O
they	O
may	O
stimulate	O
the	O
transcription	O
of	O
the	O
gene	O
at	O
the	O
cap	O
site	O
.	O
Ablation	O
of	O
transplanted	O
HTLV	O
-	O
I	O
Tax	O
-	O
transformed	O
tumors	O
in	O
mice	O
by	O
antisense	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1993	O
Mar	O
12	O
;	O
259	O
(	O
5101	O
)	O
:	O
1523	O
]	O
Mice	O
transgenic	O
for	O
the	O
human	O
T	O
cell	O
leukemia	O
virus	O
(	O
HTLV	O
-	O
I	O
)	O
Tax	O
gene	O
develop	O
fibroblastic	O
tumors	O
that	O
express	O
NF	O
-	O
kappa	O
B	O
-	O
inducible	O
early	O
genes	O
.	O
In	O
vitro	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
expression	O
by	O
antisense	O
oligodeoxynucleotides	O
(	O
ODNs	O
)	O
inhibited	O
growth	O
of	O
these	O
culture	O
-	O
adapted	O
Tax	O
-	O
transformed	O
fibroblasts	O
as	O
well	O
as	O
an	O
HTLV	O
-	O
I	O
-	O
transformed	O
human	O
lymphocyte	O
line	O
.	O
In	O
contrast	O
,	O
antisense	O
inhibition	O
of	O
Tax	B
itself	O
had	O
no	O
apparent	O
effect	O
on	O
cell	O
growth	O
.	O
Mice	O
treated	O
with	O
antisense	O
to	O
NF	B
-	I
kappa	I
B	I
ODNs	O
showed	O
rapid	O
regression	O
of	O
transplanted	O
fibrosarcomas	O
.	O
This	O
suggests	O
that	O
NF	B
-	I
kappa	I
B	I
expression	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
the	O
malignant	O
phenotype	O
and	O
provides	O
a	O
therapeutic	O
approach	O
for	O
HTLV	O
-	O
I	O
-	O
associated	O
disease	O
.	O
Targeted	O
degradation	O
of	O
c	B
-	I
Fos	I
,	O
but	O
not	O
v	B
-	I
Fos	I
,	O
by	O
a	O
phosphorylation	B
-	I
dependent	I
signal	I
on	O
c	B
-	I
Jun	I
.	O
The	O
proto	B
-	I
oncogene	I
products	I
c	B
-	I
Fos	I
and	O
c	B
-	I
Jun	I
heterodimerize	O
through	O
their	O
leucine	B
zippers	I
to	O
form	O
the	O
AP-1	B
transcription	I
factor	I
.	O
The	O
transcriptional	O
activity	O
of	O
the	O
heterodimer	O
is	O
regulated	O
by	O
signal	O
-	O
dependent	O
phosphorylation	O
and	O
dephosphorylation	O
events	O
.	O
The	O
stability	O
of	O
c	B
-	I
Fos	I
was	O
found	O
to	O
also	O
be	O
controlled	O
by	O
intracellular	O
signal	O
transduction	O
.	O
In	O
transient	O
expression	O
and	O
in	O
vitro	O
degradation	O
experiments	O
,	O
the	O
stability	O
of	O
c	B
-	I
Fos	I
was	O
decreased	O
when	O
the	O
protein	O
was	O
dimerized	O
with	O
phosphorylated	B
c	I
-	I
Jun	I
.	O
c	B
-	I
Jun	I
protein	O
isolated	O
from	O
phorbol	O
ester	O
-	O
induced	O
cells	O
did	O
not	O
target	O
c	B
-	I
Fos	I
for	O
degradation	O
,	O
which	O
suggests	O
that	O
c	B
-	I
Fos	I
is	O
transiently	O
stabilized	O
after	O
stimulation	O
of	O
cell	O
growth	O
.	O
v	B
-	I
Fos	I
protein	I
,	O
the	O
retroviral	O
counterpart	O
of	O
c	B
-	I
Fos	I
,	O
was	O
not	O
susceptible	O
to	O
degradation	O
targeted	O
by	O
c	B
-	I
Jun	I
.	O
Mutations	O
in	O
the	O
Pit-1	O
gene	O
in	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
.	O
Pit-1	B
is	O
a	O
pituitary	B
-	I
specific	I
transcription	I
factor	I
that	O
binds	O
to	O
and	O
transactivates	O
promoters	O
of	O
growth	O
hormone	O
and	O
prolactin	O
genes	O
.	O
In	O
three	O
unrelated	O
Japanese	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
,	O
we	O
identified	O
three	O
point	O
mutations	O
in	O
the	O
Pit-1	O
gene	O
,	O
Pro24Leu	O
,	O
Arg143Gln	O
,	O
and	O
Arg271Trp	O
,	O
located	O
on	O
the	O
major	O
transactivation	O
region	O
,	O
POU	O
-	O
specific	O
domain	O
,	O
and	O
POU	O
-	O
homeodomain	O
,	O
respectively	O
.	O
Calcitriol	O
:	O
a	O
hematolymphopoietrope	O
?	O
[	O
editorial	O
]	O
A	O
MEDLINE	O
search	O
of	O
the	O
English	O
-	O
language	O
literature	O
was	O
conducted	O
using	O
the	O
indexing	O
terms	O
'	O
immunology	O
,	O
calcitriol	O
and	O
vitamin	O
D	O
'	O
to	O
identify	O
studies	O
indicating	O
a	O
role	O
for	O
calcitriol	O
as	O
a	O
primary	O
immunomodulator	O
.	O
Sixty	O
-	O
six	O
papers	O
published	O
between	O
January	O
1956	O
and	O
June	O
1991	O
were	O
identified	O
.	O
Forty	O
-	O
five	O
of	O
these	O
reports	O
are	O
cited	O
in	O
this	O
review	O
.	O
The	O
data	O
strongly	O
suggest	O
an	O
endocrine	O
,	O
autocrine	O
and/or	O
paracrine	O
role	O
for	O
calcitriol	O
in	O
immune	O
regulation	O
.	O
No	O
unifying	O
hypothesis	O
has	O
yet	O
emerged	O
explaining	O
this	O
collection	O
of	O
data	O
.	O
This	O
paper	O
provides	O
a	O
brief	O
review	O
of	O
immune	O
properties	O
currently	O
attributed	O
to	O
calcitriol	O
.	O
Activation	O
of	O
protein	B
kinase	I
C	I
and	O
elevation	O
of	O
cAMP	O
interact	O
synergistically	O
to	O
raise	O
c	B
-	I
Fos	I
and	O
AP-1	B
activity	O
in	O
Jurkat	O
cells	O
.	O
We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	B
.	O
Here	O
we	O
have	O
therefore	O
examined	O
the	O
effect	O
of	O
the	O
phorbol	O
ester	O
PMA	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
which	O
stimulates	O
PKC	B
and	O
a	O
combination	O
of	O
the	O
adenosine	B
receptor	I
agonist	O
NECA	O
(	O
5'-	O
(	O
N	O
-	O
ethyl	O
)	O
-carboxamido	O
adenosine	O
)	O
and	O
forskolin	O
to	O
raise	O
cAMP	O
,	O
on	O
the	O
levels	O
of	O
c	B
-	I
Fos	I
and	O
Jun	B
and	O
on	O
the	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
transcription	B
factor	I
,	O
activator	B
protein-1	I
(	O
AP-1	B
)	O
.	O
PMA	O
treatment	O
caused	O
a	O
concentration-	O
and	O
time	O
-	O
dependent	O
increase	O
in	O
both	O
c	O
-	O
Fos	O
and	O
Jun	O
immunoreactivity	O
in	O
contrast	O
to	O
cAMP	O
elevation	O
that	O
had	O
only	O
a	O
slight	O
effect	O
.	O
Both	O
PMA	O
and	O
the	O
combination	O
of	O
NECA	O
and	O
forskolin	O
acted	O
together	O
either	O
to	O
increase	O
(	O
c	B
-	I
Fos	I
)	O
or	O
decrease	O
(	O
Jun	B
)	O
protein	O
levels	O
as	O
well	O
as	O
increasing	O
AP-1	B
binding	O
,	O
as	O
judged	O
by	O
gel	O
-	O
shift	O
assay	O
,	O
and	O
AP-1	B
transcriptional	O
activity	O
.	O
Furthermore	O
there	O
was	O
a	O
clear	O
-	O
cut	O
synergy	O
between	O
the	O
PKC	B
stimulator	O
and	O
the	O
cAMP	O
elevating	O
agents	O
.	O
The	O
results	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
PKC	B
and	O
elevation	O
of	O
cAMP	O
leads	O
to	O
an	O
enhanced	O
AP-1	B
transcriptional	O
activity	O
in	O
a	O
T	O
-	O
leukemia	O
cell	O
line	O
,	O
suggesting	O
that	O
the	O
previously	O
observed	O
interaction	O
between	O
the	O
parallel	O
signal	O
transduction	O
pathways	O
may	O
have	O
functional	O
consequences	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O
The	O
use	O
of	O
interferon	O
-	O
gamma	O
-	O
treated	O
U937	O
cells	O
in	O
chemiluminescence	O
assays	O
to	O
detect	O
red	B
cell	I
,	I
platelet	I
and	I
granulocyte	I
antibodies	I
of	O
potential	O
clinical	O
significance	O
.	O
The	O
chemiluminescent	O
(	O
CL	O
)	O
response	O
of	O
interferon	O
-	O
gamma	O
-	O
treated	O
U937	O
(	O
IFN	O
-	O
U937	O
)	O
cells	O
to	O
sensitized	O
target	O
cells	O
has	O
been	O
used	O
to	O
detect	O
red	B
cell	I
,	O
platelet	B
and	O
granulocyte	B
antibodies	I
.	O
A	O
clone	O
of	O
U937	O
cells	O
was	O
selected	O
which	O
expressed	O
Fc	B
receptor	I
I	I
(	O
Fc	B
gamma	I
RI	I
)	O
and	O
which	O
,	O
after	O
incubation	O
with	O
IFN	B
-	I
gamma	I
for	O
72	O
h	O
,	O
was	O
capable	O
of	O
generating	O
high	O
levels	O
of	O
lucigenin	O
-	O
enhanced	O
CL	O
.	O
The	O
CL	O
responses	O
of	O
IFN	O
-	O
U937	O
cells	O
and	O
peripheral	O
blood	O
human	O
monocytes	O
to	O
sensitized	O
red	O
cells	O
,	O
platelets	O
or	O
granulocytes	O
were	O
then	O
compared	O
.	O
Assays	O
using	O
monocytes	O
or	O
IFN	O
-	O
U937	O
cells	O
were	O
of	O
comparable	O
sensitivity	O
for	O
detection	O
of	O
antibodies	B
against	O
all	O
three	O
types	O
of	O
target	O
cell	O
.	O
In	O
addition	O
,	O
the	O
use	O
of	O
IFN	O
-	O
U937	O
cells	O
reduced	O
interassay	O
variation	O
and	O
simplified	O
assay	O
performance	O
.	O
The	O
potential	O
clinical	O
usefulness	O
of	O
these	O
CL	O
assays	O
was	O
suggested	O
by	O
the	O
ability	O
of	O
both	O
monocytes	O
and	O
IFN	O
-	O
U937	O
cells	O
to	O
respond	O
to	O
red	O
cells	O
,	O
platelets	O
or	O
granulocytes	O
sensitized	O
with	O
sera	O
from	O
pregnant	O
women	O
whose	O
babies	O
had	O
either	O
haemolytic	O
disease	O
of	O
the	O
newborn	O
(	O
HDN	O
)	O
,	O
alloimmune	O
thrombocytopenia	O
or	O
alloimmune	O
neutropenia	O
respectively	O
.	O
In	O
addition	O
,	O
monocytes	O
and	O
IFN	O
-	O
U937	O
cells	O
both	O
responded	O
to	O
red	O
cells	O
sensitized	O
with	O
antibodies	B
against	O
a	O
variety	O
of	O
specificities	O
of	O
assumed	O
(	O
although	O
not	O
documented	O
)	O
clinical	O
significance	O
for	O
blood	O
transfusion	O
recipients	O
.	O
In	O
contrast	O
,	O
monocytes	O
and	O
IFN	O
-	O
U937	O
cells	O
responded	O
only	O
weakly	O
to	O
red	O
cells	O
sensitized	O
with	O
either	O
anti	B
-	I
D	I
in	O
sera	O
from	O
mothers	O
of	O
babies	O
unaffected	O
by	O
HDN	O
,	O
or	O
with	O
antisera	O
containing	O
high	B
titre	I
antibodies	I
with	O
specificities	O
not	O
normally	O
associated	O
with	O
significantly	O
reduced	O
red	O
cell	O
survival	O
.	O
Expression	O
of	O
tal-1	B
and	O
GATA	B
-	I
binding	I
proteins	I
during	O
human	O
hematopoiesis	O
.	O
Tal-1	B
rearrangements	O
are	O
associated	O
with	O
nearly	O
30	O
%	O
of	O
human	O
T	O
acute	O
lymphoblastic	O
leukemia	O
.	O
Tal-1	O
gene	O
encodes	O
a	O
putative	O
transcription	B
factor	I
with	O
a	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
domain	I
and	O
is	O
known	O
to	O
be	O
predominantly	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O
We	O
investigated	O
the	O
pattern	O
of	O
tal-1	B
expression	O
in	O
purified	O
human	O
hematopoietic	O
cells	O
by	O
in	O
situ	O
hybridization	O
and	O
reverse	B
transcriptase	I
polymerase	I
chain	O
reaction	O
analysis	O
.	O
Both	O
methods	O
demonstrated	O
that	O
the	O
tal-1	B
gene	O
is	O
expressed	O
in	O
megakaryocytes	O
and	O
erythroblasts	O
as	O
well	O
as	O
in	O
basophilic	O
granulocytes	O
.	O
In	O
addition	O
,	O
our	O
results	O
indicate	O
that	O
the	O
tal-1	O
1A	O
promoter	O
,	O
which	O
contains	O
two	O
consensus	O
GATA	O
-	O
binding	O
sites	O
,	O
is	O
active	O
mainly	O
in	O
these	O
lineages	O
.	O
Because	O
the	O
GATA-1	O
gene	O
is	O
known	O
to	O
transactivate	O
several	O
genes	O
specific	O
for	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
mastocytic	O
/	O
basophilic	O
lineages	O
,	O
we	O
studied	O
GATA-1	B
expression	O
in	O
these	O
purified	O
hematopoietic	O
cells	O
.	O
We	O
found	O
that	O
GATA-1	O
and	O
tal-1	O
genes	O
are	O
coexpressed	O
in	O
these	O
three	O
lineages	O
.	O
Remarkably	O
,	O
the	O
expression	O
of	O
both	O
genes	O
is	O
downmodulated	O
during	O
erythroid	O
and	O
megakaryocytic	O
terminal	O
maturation	O
.	O
In	O
immature	O
hematopoietic	O
cells	O
,	O
tal-1	O
and	O
GATA-1	O
genes	O
are	O
coexpressed	O
in	O
committed	O
progenitors	O
cells	O
(	O
CD34+	O
/	O
CD38	O
(	O
2	O
+	O
)	O
)	O
,	O
whereas	O
they	O
are	O
not	O
detectable	O
in	O
the	O
most	O
primitive	O
cells	O
(	O
CD34	O
(	O
2	O
+	O
)	O
/CD38-	O
)	O
.	O
In	O
contrast	O
,	O
GATA-2	B
is	O
strongly	O
expressed	O
in	O
both	O
most	O
primitive	O
and	O
committed	O
progenitors	O
cells	O
,	O
whereas	O
GATA-3	B
is	O
mostly	O
detected	O
in	O
most	O
primitive	O
ones	O
.	O
Altogether	O
our	O
results	O
strongly	O
suggest	O
that	O
GATA-1	B
modulates	O
the	O
transcription	O
of	O
tal-1	B
during	O
the	O
differentiation	O
of	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
basosophilic	O
lineages	O
.	O
Interleukin-3	B
expression	O
by	O
activated	O
T	O
cells	O
involves	O
an	O
inducible	O
,	O
T	B
-	I
cell	I
-	I
specific	I
factor	I
and	O
an	O
octamer	B
binding	I
protein	I
.	O
Interleukin-3	B
(	O
IL-3	B
)	O
is	O
exclusively	O
expressed	O
by	O
activated	O
T	O
and	O
natural	O
killer	O
cells	O
,	O
a	O
function	O
that	O
is	O
tightly	O
controlled	O
both	O
in	O
a	O
lineage	O
-	O
specific	O
and	O
in	O
a	O
stimulation	O
-	O
dependent	O
manner	O
.	O
We	O
have	O
investigated	O
the	O
protein	O
binding	O
characteristics	O
and	O
functional	O
importance	O
of	O
the	O
ACT-1-activating	O
region	O
of	O
the	O
IL-3	B
promoter	O
.	O
This	O
region	O
binds	O
an	O
inducible	O
,	O
T	B
-	I
cell	I
-	I
specific	I
factor	I
over	O
its	O
5	O
'	O
end	O
,	O
a	O
site	O
that	O
is	O
necessary	O
for	O
the	O
expression	O
of	O
IL-3	B
in	O
the	O
absence	O
of	O
other	O
upstream	O
elements	O
.	O
Over	O
its	O
3	O
'	O
end	O
,	O
it	O
binds	O
a	O
factor	O
that	O
is	O
ubiquitously	O
and	O
constitutively	O
expressed	O
.	O
This	O
factor	O
is	O
Oct-1	B
or	O
an	O
immunologically	B
related	I
octamer	I
-	I
binding	I
protein	I
,	O
and	O
it	O
plays	O
a	O
role	O
in	O
coordinating	O
the	O
activity	O
of	O
several	O
regulatory	O
elements	O
.	O
These	O
characteristics	O
make	O
the	O
ACT-1	O
site	O
analogous	O
to	O
the	O
activating	O
ARRE-1	O
site	O
in	O
the	O
IL-2	O
promoter	O
.	O
Furthermore	O
,	O
and	O
despite	O
a	O
lack	O
of	O
sequence	O
homology	O
,	O
the	O
promoters	O
of	O
IL-3	B
and	O
IL-2	B
share	O
an	O
organizational	O
pattern	O
of	O
regulatory	O
elements	O
that	O
is	O
likely	O
to	O
be	O
important	O
for	O
the	O
T	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
these	O
genes	O
.	O
ras	B
protein	I
activity	O
is	O
essential	O
for	O
T	B
-	I
cell	I
antigen	I
receptor	I
signal	O
transduction	O
.	O
In	O
a	O
Jurkat	O
cell	O
model	O
of	O
T	O
-	O
cell	O
activation	O
an	O
interleukin-2	O
promoter	O
/	O
reporter	O
gene	O
construct	O
was	O
activated	O
by	O
antigen	B
receptor	I
agonism	O
in	O
combination	O
with	O
the	O
lymphokine	B
interleukin-1	B
.	O
Antigen	O
receptor	O
signals	O
could	O
be	O
mimicked	O
by	O
suboptimal	O
activation	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
with	O
phorbol	O
esters	O
in	O
combination	O
with	O
calcium	O
mobilization	O
by	O
an	O
ionophore	O
.	O
In	O
cotransfection	O
experiments	O
,	O
oncogenic	O
rats	O
obviated	O
the	O
need	O
for	O
PKC	B
stimulation	O
but	O
did	O
not	O
replace	O
either	O
the	O
calcium	O
signal	O
or	O
interleukin-1	B
.	O
Activated	O
ras	B
expression	O
also	O
replaced	O
the	O
requirement	O
for	O
PKC	B
stimulation	O
in	O
activation	O
of	O
the	O
T	B
-	I
cell	I
transcription	I
factor	I
NF	B
-	I
AT	I
.	O
A	O
dominant	B
inhibitory	I
ras	I
mutant	I
specifically	O
blocked	O
antigen	O
receptor	O
agonism	O
,	O
indicating	O
that	O
ras	B
activity	O
is	O
required	O
for	O
antigen	B
receptor	I
signaling	O
.	O
In	O
addition	O
,	O
an	O
inhibitor	O
of	O
PKC	B
blocked	O
both	O
activated	O
ras	B
and	O
phorbol	O
ester	O
stimulation	O
,	O
suggesting	O
a	O
role	O
for	O
ras	B
upstream	O
of	O
PKC	B
.	O
Characterization	O
of	O
the	O
nuclear	O
and	O
cytoplasmic	O
components	O
of	O
the	O
lymphoid	B
-	I
specific	I
nuclear	I
factor	I
of	O
activated	O
T	O
cells	O
(	O
NF	B
-	I
AT	I
)	O
complex	O
.	O
The	O
lymphoid	B
-	I
specific	I
transcription	I
complex	I
,	O
NF	B
-	I
AT	I
,	O
is	O
involved	O
in	O
early	O
gene	O
activation	O
in	O
T	O
cells	O
and	O
is	O
assembled	O
from	O
a	O
pre	O
-	O
existing	O
,	O
T	B
cell	I
restricted	I
cytoplasmic	I
factor	I
and	O
an	O
inducible	O
ubiquitous	B
nuclear	B
component	I
within	O
30	O
min	O
after	O
activation	O
through	O
the	O
antigen	B
receptor	I
.	O
Recent	O
studies	O
have	O
implicated	O
the	O
family	O
of	O
AP1	B
factors	I
as	O
components	O
of	O
the	O
murine	B
NF	I
-	I
AT	I
complex	I
.	O
Evidence	O
is	O
provided	O
here	O
that	O
the	O
nuclear	O
component	O
of	O
human	B
NF	I
-	I
AT	I
contains	O
the	O
phorbol	B
ester	I
-	I
inducible	I
transcription	I
factor	I
AP1	I
(	O
Jun	B
/	I
Fos	I
)	O
.	O
We	O
further	O
characterize	O
which	O
AP1	B
family	I
members	I
can	O
assume	O
this	O
role	O
.	O
Antisera	O
to	O
Fos	B
inhibits	O
NF	B
-	I
AT	I
DNA	O
binding	O
as	O
does	O
an	O
oligonucleotide	O
containing	O
a	O
binding	O
site	O
for	O
AP1	O
.	O
Constitutive	O
expression	O
in	O
vivo	O
of	O
Fos	B
,	O
and	O
to	O
a	O
lesser	O
extent	O
Fra-1	B
,	O
eliminates	O
the	O
requirement	O
for	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
stimulation	O
,	O
leaving	O
NF	B
-	I
AT	I
-directed	O
transcription	O
responsive	O
to	O
calcium	O
ionophore	O
alone	O
.	O
Overexpression	O
of	O
cJun	B
or	O
JunD	B
,	O
but	O
not	O
JunB	B
,	O
also	O
eliminates	O
the	O
requirement	O
for	O
PMA	O
,	O
indicating	O
that	O
many	O
but	O
not	O
all	O
Jun-	B
and	I
Fos	I
-	I
related	I
proteins	I
functionally	O
activate	O
NF	B
-	I
AT	I
-dependent	O
transcription	O
in	O
the	O
presence	O
of	O
the	O
cytoplasmic	O
component	O
.	O
NF	B
-	I
AT	I
DNA	O
binding	O
can	O
be	O
reconstituted	O
in	O
vitro	O
using	O
semi	B
-	I
purified	I
AP1	I
proteins	I
mixed	O
with	O
cytosol	O
from	O
T	O
lymphocytes	O
.	O
Fos	O
proteins	O
are	O
not	O
needed	O
for	O
this	O
reconstitution	O
,	O
and	O
although	O
JunB	B
is	O
not	O
functional	O
,	O
it	O
can	O
participate	O
in	O
the	O
NF	B
-	I
AT	I
DNA	I
binding	I
complex	I
.	O
Finally	O
,	O
we	O
have	O
partially	O
purified	O
the	O
cytoplasmic	O
component	O
of	O
NF	O
-	O
AT	O
and	O
show	O
by	O
elution	O
and	O
renaturation	O
from	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
gels	O
that	O
it	O
has	O
a	O
molecular	O
mass	O
between	O
94	O
and	O
116	O
kDa	O
and	O
may	O
have	O
multiple	O
differentially	O
modified	O
forms	O
.	O
Expression	O
of	O
the	O
Tat	B
protein	I
of	O
HIV1	O
in	O
human	O
promonocytic	O
U937	O
cells	O
.	O
Numerous	O
studies	O
have	O
shown	O
that	O
,	O
upon	O
HIV1	O
infection	O
,	O
human	O
promonocytic	O
U937	O
cells	O
were	O
induced	O
to	O
differentiate	O
,	O
as	O
indicated	O
,	O
for	O
example	O
,	O
by	O
increased	O
expression	O
of	O
adhesion	B
molecules	I
.	O
One	O
of	O
the	O
viral	O
proteins	O
involved	O
in	O
this	O
process	O
might	O
be	O
the	O
Tat	B
protein	I
.	O
Indeed	O
,	O
this	O
viral	B
protein	I
,	O
which	O
is	O
essential	O
for	O
productive	O
infection	O
,	O
has	O
also	O
been	O
shown	O
to	O
display	O
growth	O
-	O
stimulating	O
properties	O
and	O
immunomodulatory	O
activities	O
.	O
In	O
order	O
to	O
apprehend	O
the	O
role	O
of	O
the	O
HIV1	O
tat	O
gene	O
in	O
inducing	O
the	O
differentiation	O
of	O
HIV1-infected	O
U937	O
cells	O
,	O
we	O
have	O
successfully	O
introduced	O
this	O
gene	O
into	O
U937	O
cells	O
by	O
infecting	O
them	O
with	O
retroviral	O
particles	O
transducing	O
tat	O
.	O
The	O
effect	O
of	O
the	O
Tat	B
protein	I
constitutively	O
expressed	O
by	O
these	O
cells	O
upon	O
their	O
differentiation	O
was	O
then	O
evaluated	O
by	O
looking	O
for	O
the	O
expression	O
of	O
the	O
c	O
-	O
fos	O
and	O
of	O
the	O
c	O
-	O
fms	O
proto	O
-	O
oncogenes	O
which	O
are	O
linked	O
to	O
the	O
differentiation	O
of	O
myelomonoblastic	O
cells	O
.	O
Northern	O
blot	O
analysis	O
revealed	O
in	O
these	O
cells	O
,	O
an	O
increase	O
in	O
the	O
transcription	O
of	O
these	O
two	O
proto	O
-	O
oncogenes	O
,	O
and	O
this	O
increase	O
was	O
amplified	O
after	O
treatment	O
with	O
phorbol	O
myristate	O
acetate	O
.	O
No	O
such	O
increase	O
was	O
observed	O
in	O
control	O
U937	O
cells	O
.	O
These	O
results	O
indicate	O
that	O
,	O
among	O
HIV1	B
gene	I
products	I
,	O
the	O
Tat	B
protein	I
appears	O
to	O
trigger	O
monocytic	O
differentiation	O
,	O
and	O
suggests	O
that	O
this	O
viral	B
protein	I
directs	O
progenitors	O
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
towards	O
a	O
differentiation	O
stage	O
in	O
which	O
production	O
of	O
viral	B
antigens	I
and	O
virions	O
might	O
be	O
more	O
efficient	O
.	O
Stimulation	O
of	O
interleukin-1	B
alpha	I
and	O
interleukin-1	B
beta	I
production	O
in	O
human	O
monocytes	O
by	O
protein	O
phosphatase	O
1	O
and	O
2A	O
inhibitors	O
.	O
Protein	B
phosphatases	I
1	I
and	I
2A	I
are	O
important	O
in	O
regulating	O
cellular	O
functions	O
by	O
controlling	O
the	O
phosphorylation	O
state	O
of	O
their	O
substrates	O
.	O
In	O
human	O
monocytes	O
,	O
the	O
inhibitors	O
of	O
these	O
phosphatases	B
,	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
,	O
were	O
found	O
to	O
increase	O
the	O
mRNA	O
accumulation	O
and	O
cytokine	O
production	O
of	O
interleukin-1	B
beta	I
and	O
interleukin-1	B
alpha	I
.	O
The	O
increased	O
mRNA	O
accumulation	O
was	O
found	O
to	O
be	O
primarily	O
because	O
of	O
the	O
increase	O
in	O
the	O
transcription	O
rate	O
of	O
the	O
interleukin-1	O
genes	O
.	O
Stimulation	O
of	O
interleukin-1	O
gene	O
transcription	O
may	O
be	O
caused	O
by	O
the	O
stimulation	O
of	O
transcription	B
factor	I
activities	O
,	O
including	O
those	O
of	O
AP-1	B
,	O
by	O
these	O
protein	B
phosphatase	I
inhibitors	O
.	O
Okadaic	O
acid	O
increased	O
the	O
synthesis	O
of	O
the	O
interleukin-1	B
beta	I
precursor	O
and	O
mature	O
forms	O
and	O
their	O
secretion	O
.	O
This	O
increased	O
processing	O
and	O
secretion	O
correlated	O
with	O
the	O
stimulation	O
of	O
IL-1	O
beta	O
convertase	O
mRNA	O
accumulation	O
.	O
The	O
stimulation	O
of	O
interleukin-1	B
alpha	I
production	O
by	O
okadaic	O
acid	O
was	O
more	O
modest	O
than	O
that	O
of	O
interleukin-1	B
beta	I
.	O
However	O
,	O
the	O
phosphorylation	O
of	O
the	O
precursor	B
interleukin-1	I
alpha	I
cytokine	I
was	O
increased	O
.	O
These	O
results	O
show	O
that	O
protein	O
phosphatase	O
1	O
and	O
2A	O
inhibitors	O
exert	O
multiple	O
effects	O
on	O
cytokine	O
production	O
in	O
human	O
monocytes	O
and	O
suggest	O
that	O
these	O
two	O
phosphatases	B
play	O
important	O
roles	O
in	O
regulating	O
interleukin-1	B
production	O
.	O
Transcription	O
factor	O
jun	O
-	O
B	O
is	O
target	O
of	O
autoreactive	O
T	O
-	O
cells	O
in	O
IDDM	O
.	O
Target	O
antigens	O
defined	O
by	O
autoantibodies	B
in	O
IDDM	O
include	O
insulin	O
,	O
a	O
putative	O
glycolipid	O
that	O
reacts	O
with	O
islet	B
cell	I
antibodies	I
,	O
and	O
a	O
64	B
,	I
000-M	I
(	I
r	I
)	I
protein	I
recently	O
identified	O
as	O
glutamic	B
acid	I
decarboxylase	I
.	O
In	O
addition	O
,	O
some	O
IDDM	O
sera	O
that	O
contain	O
antibodies	B
to	O
glutamic	B
acid	I
decarboxylase	I
also	O
coprecipitate	O
a	O
38	B
,	I
000-M	I
(	I
r	I
)	I
protein	I
from	O
islets	O
.	O
This	O
study	O
used	O
a	O
high	O
titer	O
anti-38	O
,	O
000-M	O
(	O
r	O
)	O
serum	O
to	O
screen	O
bacteriophage	O
lambda	O
cDNA	O
expression	O
libraries	O
and	O
identified	O
human	O
islet	O
and	O
placental	O
clones	O
encoding	O
jun	B
-	I
B	I
,	O
the	O
nuclear	B
transcription	I
protein	I
,	O
of	O
predicted	O
38	O
,	O
000	O
M	O
(	O
r	O
)	O
.	O
Peripheral	O
blood	O
T	O
-	O
cells	O
exhibited	O
significant	O
proliferation	O
in	O
response	O
to	O
a	O
recombinant	O
fragment	O
of	O
jun	B
-	I
B	I
(	O
amino	O
acids	O
1	O
-	O
180	O
)	O
in	O
12	O
of	O
17	O
(	O
71	O
%	O
)	O
recent	O
-	O
onset	O
IDDM	O
subjects	O
,	O
8	O
of	O
16	O
(	O
50	O
%	O
)	O
ICA	O
-	O
positive	O
first	O
-	O
degree	O
relatives	O
of	O
IDDM	O
subjects	O
who	O
were	O
at	O
risk	O
,	O
3	O
of	O
12	O
(	O
25	O
%	O
)	O
other	O
autoimmune	O
disease	O
subjects	O
,	O
and	O
0	O
of	O
10	O
healthy	O
control	O
subjects	O
.	O
Proliferation	O
to	O
tetanus	O
toxoid	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
.	O
Responses	O
to	O
jun	B
-	I
B	I
were	O
not	O
related	O
to	O
age	O
,	O
sex	O
,	O
or	O
human	B
leukocyte	I
antigen	I
status	O
.	O
Thus	O
,	O
autoreactive	O
T	O
-	O
cells	O
identify	O
a	O
novel	B
antigen	I
,	O
p38	B
jun	I
-	I
B	I
,	O
in	O
IDDM	O
and	O
appear	O
to	O
indicate	O
subjects	O
at	O
risk	O
for	O
the	O
development	O
of	O
clinical	O
disease	O
.	O
Induced	O
myeloid	O
differentiation	O
of	O
K562	O
cells	O
with	O
downregulation	O
of	O
erythroid	B
and	I
megakaryocytic	I
transcription	I
factors	I
:	O
a	O
novel	O
experimental	O
model	O
for	O
hemopoietic	O
lineage	O
restriction	O
.	O
The	O
human	O
erythroleukemia	O
cell	O
line	O
K562	O
can	O
be	O
induced	O
to	O
differentiate	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O
Here	O
we	O
demonstrate	O
that	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
induced	O
K562	O
cells	O
to	O
differentiate	O
along	O
a	O
third	O
pathway	O
.	O
This	O
was	O
accompanied	O
by	O
downregulation	O
of	O
two	O
transcription	B
factors	I
normally	O
expressed	O
in	O
erythroid	O
,	O
mast	O
and	O
megakaryocyte	O
lineages	O
.	O
Northern	O
analysis	O
demonstrated	O
coordinate	O
downregulation	O
of	O
alpha	B
globin	I
and	O
gamma	B
globin	I
in	O
addition	O
to	O
the	O
two	O
lineage	O
-	O
restricted	O
transcription	B
factors	I
,	O
SCL	B
and	O
GATA-1	B
.	O
Proliferation	O
of	O
the	O
K562	O
cells	O
was	O
also	O
suppressed	O
.	O
Clonal	O
assay	O
showed	O
that	O
the	O
suppression	O
was	O
irreversible	O
and	O
appeared	O
analogous	O
to	O
the	O
commitment	O
of	O
murine	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
to	O
terminal	O
differentiation	O
.	O
In	O
contrast	O
to	O
MEL	O
cells	O
,	O
however	O
,	O
K562	O
cells	O
acquired	O
a	O
macrophage	O
-	O
like	O
morphology	O
and	O
exhibited	O
a	O
complete	O
failure	O
to	O
generate	O
benzidine	O
-	O
positive	O
cells	O
.	O
Electron	O
microscopy	O
revealed	O
a	O
marked	O
increase	O
in	O
granules	O
resembling	O
those	O
specific	O
for	O
eosinophils	O
.	O
Surface	O
marker	O
analysis	O
showed	O
that	O
HMBA	O
-	O
induced	O
cells	O
expressed	O
reduced	O
levels	O
of	O
glycophorin	B
A	I
,	O
CD5	B
,	O
CD7	B
and	O
CD11b	B
.	O
No	O
upregulation	O
of	O
megakaryocyte	B
or	I
lymphoid	I
markers	I
occurred	O
.	O
Thus	O
the	O
response	O
of	O
K562	O
cells	O
to	O
HMBA	O
may	O
provide	O
a	O
useful	O
experimental	O
system	O
for	O
studying	O
the	O
molecular	O
mechanisms	O
responsible	O
for	O
downmodulation	O
of	O
lineage	O
-	O
restricted	O
transcription	B
factors	I
during	O
hemopoietic	O
lineage	O
commitment	O
.	O
A	O
protein	O
of	O
the	O
AP-1	B
family	I
is	O
a	O
component	O
of	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
.	O
Nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
is	O
a	O
transcriptional	B
activator	I
involved	O
in	O
the	O
induction	O
of	O
IL-2	B
gene	O
expression	O
.	O
The	O
response	O
element	O
for	O
NF	B
-	I
AT	I
is	O
a	O
sequence	O
localized	O
between	O
-285	O
/	O
-254	O
in	O
the	O
IL-2	O
regulatory	O
region	O
.	O
The	O
composition	O
of	O
NF	B
-	I
AT	I
protein	O
is	O
still	O
not	O
fully	O
elucidated	O
.	O
We	O
demonstrate	O
that	O
,	O
in	O
normal	O
human	O
T	O
cells	O
,	O
an	O
AP-1	B
protein	I
is	O
a	O
component	O
of	O
the	O
NF	B
-	I
AT	I
protein	I
complex	I
.	O
This	O
was	O
evidenced	O
by	O
the	O
ability	O
of	O
the	O
AP-1	O
site	O
to	O
compete	O
with	O
the	O
NF	B
-	I
AT	I
site	O
for	O
binding	O
to	O
NF	B
-	I
AT	I
and	O
by	O
the	O
capacity	O
of	O
immobilized	B
anti	I
-	I
Jun	I
and	O
anti	B
-	I
Fos	I
antibodies	O
to	O
deplete	O
NF	B
-	I
AT	I
-binding	O
activity	O
from	O
nuclear	O
extracts	O
of	O
activated	O
T	O
cells	O
.	O
There	O
was	O
no	O
detectable	O
binding	O
of	O
in	O
vitro	O
translated	O
Jun	B
/	I
Fos	I
heterodimer	I
(	O
AP-1	B
)	O
to	O
the	O
NF	B
-	I
AT	I
sequence	O
,	O
and	O
the	O
NF	O
-	O
AT	O
sequence	O
was	O
unable	O
to	O
inhibit	O
the	O
binding	O
of	O
Jun	B
/	I
Fos	I
to	O
the	O
AP-1	O
sequence	O
.	O
The	O
presence	O
of	O
an	O
AP-1	B
protein	O
in	O
the	O
NF	B
-	I
AT	I
protein	O
complex	O
may	O
regulate	O
NF	B
-	I
AT	I
-binding	O
activity	O
through	O
protein	O
-	O
protein	O
interaction	O
.	O
Human	O
CD3-CD16	O
+	O
natural	O
killer	O
cells	O
express	O
the	O
hGATA-3	B
T	I
cell	I
transcription	I
factor	I
and	O
an	O
unrearranged	O
2.3-kb	B
TcR	I
delta	I
transcript	I
.	O
In	O
this	O
study	O
we	O
analyzed	O
the	O
T	B
cell	I
receptor	I
(	I
TcR	I
)	I
delta	I
transcripts	I
expressed	O
by	O
CD3-CD16	O
+	O
cells	O
and	O
we	O
investigated	O
whether	O
these	O
cells	O
expressed	O
the	O
hGATA-3	B
T	I
cell	I
transcription	I
factor	I
and	O
the	O
recombination	O
-	O
activating	O
gene	O
(	O
RAG	O
)	O
-1	O
.	O
Multiple	O
TcR	B
delta	I
transcripts	I
deriving	O
from	O
an	O
unrearranged	O
TcR	O
delta	O
gene	O
were	O
detected	O
in	O
both	O
polyclonal	O
and	O
clonal	O
CD3-CD16	O
+	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
lines	O
.	O
Two	O
unrearranged	O
TcR	B
delta	I
transcripts	I
had	O
a	O
size	O
similar	O
to	O
that	O
of	O
the	O
functional	O
TcR	O
delta	O
mRNA	O
(	O
2.3	O
and	O
1.3	O
kb	O
)	O
found	O
in	O
TcR	O
gamma	O
/	O
delta+	O
T	O
lymphocytes	O
.	O
Sequence	O
analysis	O
of	O
nine	O
different	O
2.3-kb	O
cDNA	O
clones	O
obtained	O
from	O
NK	O
-	O
derived	O
polyA+	O
RNA	O
confirmed	O
that	O
they	O
corresponded	O
to	O
an	O
unrearranged	O
TcR	O
delta	O
gene	O
.	O
These	O
cDNA	O
were	O
2343	O
bp	O
long	O
and	O
their	O
transcription	O
initiation	O
site	O
was	O
located	O
814	O
bp	O
upstream	O
from	O
the	O
J	O
delta	O
1	O
segment	O
.	O
The	O
sequence	O
located	O
upstream	O
of	O
the	O
J	O
delta	O
1	O
segment	O
corresponded	O
to	O
the	O
previously	O
reported	O
germ	O
-	O
line	O
sequence	O
.	O
The	O
J	O
delta	O
1	O
segment	O
was	O
correctly	O
spliced	O
to	O
C	O
delta	O
;	O
in	O
addition	O
the	O
four	O
C	O
delta	O
exons	O
were	O
found	O
to	O
be	O
already	O
assembled	O
.	O
Two	O
polyadenylation	O
sites	O
were	O
present	O
in	O
the	O
fourth	O
C	O
delta	O
exon	O
.	O
However	O
,	O
only	O
that	O
located	O
at	O
the	O
3	O
'	O
end	O
appeared	O
to	O
be	O
utilized	O
in	O
the	O
2.3-kb	O
cDNA	O
.	O
The	O
expression	O
of	O
hGATA-3	B
,	O
a	O
T	B
cell	I
-	I
specific	I
factor	I
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
transcription	O
of	O
TcR	O
delta	O
locus	O
,	O
was	O
analyzed	O
by	O
Northern	O
blot	O
,	O
in	O
cultured	O
NK	O
cell	O
population	O
and	O
clones	O
(	O
but	O
not	O
in	O
freshly	O
derived	O
cell	O
populations	O
)	O
.	O
All	O
NK	O
clones	O
and	O
cell	O
lines	O
studied	O
were	O
found	O
to	O
express	O
hGATA-3-specific	O
mRNA	O
,	O
suggesting	O
that	O
hGATA-3	B
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
unrearranged	O
TcR	O
delta	O
gene	O
expression	O
in	O
NK	O
cells	O
.	O
Finally	O
,	O
no	O
transcription	O
of	O
the	O
RAG-1	O
gene	O
could	O
be	O
detected	O
in	O
all	O
NK	O
cell	O
lines	O
or	O
clones	O
analyzed	O
.	O
Hypertension	O
in	O
pregnancy	O
.	O
Pregnancy	O
-	O
induced	O
hypertension	O
(	O
PIH	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
maternal	O
and	O
neonatal	O
morbidity	O
and	O
mortality	O
.	O
In	O
the	O
present	O
study	O
we	O
focused	O
on	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
mainly	O
on	O
the	O
role	O
of	O
mineralocorticoids	O
,	O
reversed	O
blood	O
pressure	O
patterns	O
,	O
and	O
the	O
resulting	O
necessity	O
of	O
continuous	O
monitoring	O
of	O
the	O
preeclamptic	O
mother	O
.	O
Problems	O
of	O
antihypertensive	O
therapy	O
are	O
discussed	O
and	O
the	O
first	O
results	O
of	O
a	O
pilot	O
study	O
with	O
Urapidil	O
are	O
presented	O
.	O
To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18-hydroxy	O
-	O
corticosterone	O
(	O
18-OH	O
-	O
B	O
)	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
in	O
25	O
healthy	O
pregnant	O
women	O
.	O
Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	B
receptor	I
(	O
MR	B
)	O
count	O
in	O
mononuclear	O
leukocytes	O
in	O
the	O
2	O
groups	O
.	O
The	O
MR	O
-	O
count	O
was	O
significantly	O
decreased	O
in	O
the	O
PIH	O
-	O
group	O
.	O
The	O
values	O
of	O
plasma	O
aldosterone	O
and	O
18-OH	O
-	O
B	O
were	O
also	O
low	O
.	O
These	O
results	O
can	O
not	O
be	O
explained	O
by	O
receptor	O
down	O
-	O
regulation	O
due	O
to	O
higher	O
level	O
of	O
mineralocorticoids	O
of	O
the	O
zona	O
glomerulosa	O
.	O
Perhaps	O
deoxycorticosterone	O
or	O
a	O
hitherto	O
unknown	O
mineralocorticoid	O
is	O
responsible	O
for	O
the	O
hypertension	O
and	O
altered	O
MR	B
-status	O
.	O
The	O
first	O
results	O
of	O
continuous	O
blood	O
pressure	O
measurements	O
with	O
a	O
noninvasive	O
,	O
real	O
-	O
time	O
blood	O
pressure	O
monitor	O
(	O
Finapres	O
)	O
are	O
presented	O
.	O
The	O
comparison	O
of	O
the	O
obtained	O
values	O
with	O
intraarterial	O
measurements	O
demonstrates	O
a	O
good	O
correlation	O
between	O
the	O
two	O
methods	O
.	O
We	O
also	O
report	O
on	O
the	O
first	O
experiences	O
with	O
Urapidil	O
in	O
the	O
treatment	O
of	O
hypertension	O
in	O
severe	O
preeclampsia	O
.	O
The	O
data	O
show	O
that	O
hypertension	O
in	O
preeclamptic	O
women	O
can	O
be	O
treated	O
by	O
Urapidil	O
without	O
side	O
effects	O
or	O
reflex	O
-	O
tachycardia	O
.	O
Further	O
studies	O
will	O
have	O
to	O
prove	O
if	O
Urapidil	O
is	O
suited	O
for	O
prepartal	O
treatment	O
of	O
PIH	O
as	O
well	O
.	O
Aldosterone	B
-	I
specific	I
membrane	I
receptors	I
and	O
rapid	O
non	O
-	O
genomic	O
actions	O
of	O
mineralocorticoids	O
.	O
Functional	O
studies	O
in	O
extrarenal	O
,	O
non	O
-	O
epithelial	O
cells	O
such	O
as	O
smooth	O
muscle	O
cells	O
and	O
more	O
recently	O
circulating	O
human	O
lymphocytes	O
have	O
provided	O
increasing	O
evidence	O
that	O
aldosterone	O
produces	O
not	O
only	O
classical	O
genomic	O
effects	O
,	O
but	O
also	O
rapid	O
,	O
non	O
-	O
genomic	O
effects	O
on	O
transmembrane	O
electrolyte	O
movements	O
.	O
These	O
involve	O
activation	O
of	O
the	O
sodium	B
/	I
proton	I
exchanger	I
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1	O
-	O
2	O
min	O
.	O
A	O
second	O
messenger	O
cascade	O
involved	O
is	O
the	O
inositol	O
1	O
,	O
4	O
,	O
5-trisphosphate	O
/	O
calcium	O
pathway	O
which	O
responds	O
over	O
the	O
same	O
rapid	O
time	O
course	O
.	O
Such	O
changes	O
clearly	O
can	O
not	O
be	O
explained	O
by	O
genomic	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
later	O
effects	O
than	O
the	O
membrane	O
related	O
rapid	O
responses	O
.	O
The	O
mechanisms	O
underlying	O
these	O
rapid	O
effects	O
of	O
aldosterone	O
on	O
electrolytes	O
have	O
been	O
extensively	O
studied	O
in	O
human	O
lymphocytes	O
,	O
which	O
thus	O
may	O
represent	O
valuable	O
tools	O
in	O
the	O
delineation	O
of	O
the	O
receptor	O
-	O
effector	O
mechanisms	O
involved	O
.	O
The	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
its	O
rapid	O
time	O
course	O
,	O
10	O
,	O
000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O
Activation	O
of	O
primary	O
human	O
T	O
-	O
lymphocytes	O
through	O
CD2	B
plus	I
CD28	I
adhesion	I
molecules	I
induces	O
long	O
-	O
term	O
nuclear	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
Stimulation	O
of	O
highly	O
purified	O
human	O
T	O
-	O
cells	O
via	O
CD2	B
and	I
CD28	I
adhesion	I
molecules	I
induces	O
and	O
maintains	O
proliferation	O
for	O
more	O
than	O
3	O
weeks	O
.	O
This	O
potent	O
interleukin	B
2	I
(	O
IL-2	B
)	O
-dependent	O
activation	O
does	O
not	O
require	O
monocytes	O
or	O
accessory	O
cells	O
.	O
Long	O
-	O
lasting	O
IL-2	B
receptivity	O
is	O
associated	O
with	O
high	O
-	O
level	O
expression	O
of	O
the	O
inducible	O
IL-2	O
receptor	O
alpha	O
chain	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
that	O
is	O
regulated	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O
Increase	O
of	O
IL-2R	O
alpha	O
gene	O
transcription	O
involves	O
the	O
enhanced	O
binding	O
of	O
the	O
transcription	O
factor	O
NF	B
-	I
kappa	I
B	I
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5'-regulatory	O
region	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
.	O
To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusually	O
persistent	O
transcription	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
,	O
we	O
analyzed	O
nuclear	O
NF	B
-	I
kappa	I
B	I
binding	O
to	O
a	O
radiolabeled	O
IL-2R	B
alpha	I
kappa	O
B	O
-	O
specific	O
oligonucleotide	O
probe	O
during	O
the	O
time	O
course	O
of	O
CD2	B
+	O
CD28	B
activation	O
.	O
Resting	O
T	O
-	O
cell	O
nuclear	O
extracts	O
contained	O
KBF1	B
/	I
p50	I
homodimer	I
.	O
After	O
stimulation	O
,	O
two	O
new	O
kappa	B
B	I
-	I
specific	I
complexes	I
were	O
identified	O
as	O
NF	B
-	I
kappa	I
B	I
p50-p65	B
heterodimer	I
and	O
putative	O
c	B
-	I
Rel	I
homodimer	I
or	O
c	B
-	I
Rel	I
-	I
p65	I
heterodimer	I
.	O
Both	O
inducible	O
complexes	O
persisted	O
for	O
at	O
least	O
3	O
weeks	O
.	O
Their	O
relative	O
levels	O
were	O
very	O
similar	O
for	O
the	O
duration	O
of	O
proliferation	O
.	O
In	O
parallel	O
,	O
CD2	B
+	O
CD28	B
activation	O
triggered	O
a	O
significant	O
intracellular	O
thiol	O
decrease	O
,	O
suggesting	O
that	O
oxygen	O
radicals	O
are	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
adhesion	B
molecules	I
.	O
Finally	O
,	O
micromolar	O
amounts	O
of	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxygen	O
radical	O
scavenger	O
that	O
efficiently	O
blocked	O
the	O
nuclear	O
appearance	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
T	O
-	O
lymphocytes	O
,	O
also	O
inhibited	O
IL-2	B
secretion	O
,	O
IL-2R	B
alpha	I
cell	O
surface	O
expression	O
,	O
and	O
T	O
-	O
cell	O
proliferation	O
.	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
NF	B
-	I
kappa	I
B	I
plays	O
an	O
important	O
role	O
in	O
long	O
-	O
term	O
activation	O
of	O
human	O
primary	O
T	O
-	O
lymphocytes	O
via	O
CD2	B
+	O
CD28	B
.	O
Oxidoreductive	O
regulation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
.	O
Involvement	O
of	O
a	O
cellular	O
reducing	O
catalyst	O
thioredoxin	B
.	O
We	O
have	O
investigated	O
an	O
oxidoreductive	O
regulatory	O
pathway	O
for	O
the	O
DNA	O
binding	O
activity	O
of	O
a	O
pleiotropic	B
cellular	I
transcription	I
factor	I
,	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
kappa	I
B	I
)	O
,	O
has	O
been	O
investigated	O
by	O
using	O
NF	B
kappa	I
B	I
prepared	O
from	O
the	O
nucleus	O
and	O
the	O
cytosol	O
of	O
the	O
primary	O
human	O
T	O
lymphocytes	O
.	O
We	O
show	O
that	O
a	O
cellular	O
reducing	O
catalyst	O
thioredoxin	B
(	O
Trx	B
)	O
plays	O
a	O
major	O
role	O
in	O
activation	O
of	O
the	O
DNA	O
binding	O
of	O
NF	B
kappa	I
B	I
in	O
vitro	O
and	O
stimulation	O
of	O
transcription	O
from	O
the	O
NF	B
kappa	I
B	I
-dependent	O
gene	O
expression	O
.	O
We	O
demonstrate	O
evidence	O
suggesting	O
that	O
redox	O
regulation	O
of	O
NF	B
kappa	I
B	I
by	O
Trx	B
might	O
be	O
exerted	O
at	O
a	O
step	O
after	O
dissociation	O
of	O
the	O
inhibitory	O
molecule	O
I	B
kappa	I
B	I
,	O
a	O
cytosolic	B
-	I
anchoring	I
protein	I
for	O
NF	B
kappa	I
B	I
.	O
To	O
examine	O
the	O
effect	O
of	O
Trx	B
in	O
intact	O
cells	O
,	O
we	O
performed	O
transient	O
assay	O
with	O
a	O
chloramphenicol	O
acetyltransferase	O
-	O
expressing	O
plasmid	O
under	O
the	O
control	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
long	O
terminal	O
repeat	O
and	O
an	O
effector	O
plasmid	O
expressing	O
human	B
Trx	I
.	O
The	O
promoter	O
activity	O
from	O
HIV	O
long	O
terminal	O
repeat	O
was	O
greatly	O
augmented	O
by	O
co	O
-	O
transfecting	O
the	O
Trx	O
-	O
expressing	O
plasmid	O
,	O
whose	O
effect	O
was	O
dependent	O
on	O
the	O
NF	B
kappa	I
B	I
-binding	O
sites	O
.	O
These	O
findings	O
have	O
suggested	O
that	O
cysteine	O
residue	O
(	O
s	O
)	O
of	O
NF	B
kappa	I
B	I
might	O
be	O
involved	O
in	O
the	O
DNA	O
-	O
recognition	O
by	O
NF	B
kappa	I
B	I
and	O
that	O
the	O
redox	O
control	O
mechanism	O
mediated	O
by	O
Trx	B
might	O
have	O
a	O
regulatory	O
role	O
in	O
the	O
NF	B
kappa	I
B	I
-mediated	O
gene	O
expression	O
.	O
These	O
results	O
may	O
also	O
provide	O
a	O
clue	O
to	O
understanding	O
of	O
the	O
molecular	O
process	O
of	O
AIDS	O
pathogenesis	O
and	O
its	O
possible	O
biochemical	O
intervention	O
.	O
Synergism	O
between	O
the	O
CD3	O
antigen-	O
and	O
CD2	O
antigen	O
-	O
derived	O
signals	O
.	O
Exploration	O
at	O
the	O
level	O
of	O
induction	O
of	O
DNA	B
-	I
binding	I
proteins	I
and	O
characterization	O
of	O
the	O
inhibitory	O
activity	O
of	O
cyclosporine	O
.	O
We	O
have	O
demonstrated	O
earlier	O
that	O
the	O
crosslinkage	O
of	O
the	O
CD3	B
/	I
TCR	I
complex	I
with	O
the	O
CD2	B
antigen	I
results	O
in	O
the	O
proliferation	O
of	O
normal	O
human	O
T	O
cells	O
.	O
The	O
effect	O
of	O
this	O
synergism	O
was	O
perceptible	O
at	O
the	O
level	O
of	O
induction	O
of	O
the	O
IL-2	O
gene	O
,	O
a	O
process	O
critical	O
for	O
T	O
cell	O
growth	O
.	O
To	O
further	O
understand	O
the	O
molecular	O
and	O
nuclear	O
basis	O
for	O
this	O
synergism	O
,	O
we	O
have	O
explored	O
the	O
induction	O
of	O
DNA	B
-	I
binding	I
proteins	I
in	O
highly	O
purified	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
the	O
CD3	B
and/or	O
CD2	B
proteins	I
.	O
The	O
effect	O
of	O
transmembrane	O
signaling	O
of	O
T	O
cells	O
with	O
ionomycin	O
,	O
and/or	O
sn-1	O
,	O
2	O
dioctanoyl	O
glycerol	O
,	O
was	O
also	O
determined	O
.	O
The	O
emergence	O
of	O
nuclear	B
binding	I
proteins	I
was	O
investigated	O
using	O
interleukin-2	O
sequence	O
specific	O
oligonucleotide	O
probes	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
Our	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
CD3	B
antigen	O
-	O
derived	O
signals	O
and	O
CD2	B
antigen	I
-derived	O
signals	O
are	O
synergistic	O
in	O
inducing	O
the	O
emergence	O
of	O
transcription	B
factors	I
that	O
bind	O
to	O
the	O
NF	O
-	O
AT1	O
,	O
AP-1	O
,	O
and	O
NF	O
-	O
kB	O
sites	O
located	O
in	O
the	O
promoter	O
/	O
enhancer	O
region	O
of	O
the	O
IL-2	B
gene	O
.	O
Moreover	O
,	O
cyclosporine	O
,	O
at	O
concentrations	O
readily	O
accomplished	O
in	O
clinical	O
practice	O
,	O
was	O
found	O
to	O
inhibit	O
the	O
emergence	O
of	O
these	O
DNA	B
-	I
binding	I
proteins	I
in	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
cell	O
surface	O
proteins	O
implicated	O
in	O
antigen	O
-	O
dependent	O
T	O
cell	O
activation	O
and	O
in	O
T	O
cells	O
stimulated	O
by	O
mobilization	O
of	O
cellular	O
calcium	O
and	O
activation	O
of	O
protein	B
kinase	I
C	I
.	O
A	O
concatenated	O
form	O
of	O
Epstein	O
-	O
Barr	O
viral	O
DNA	O
in	O
lymphoblastoid	O
cell	O
lines	O
induced	O
by	O
transfection	O
with	O
BZLF1	B
.	O
The	O
replicative	O
form	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
DNA	O
was	O
studied	O
using	O
two	O
lymphoblastoid	O
cell	O
lines	O
,	O
X50	O
-	O
7	O
and	O
6F11	O
,	O
which	O
are	O
latently	O
infected	O
by	O
Epstein	O
-	O
Barr	O
virus	O
.	O
The	O
lytic	O
cycle	O
of	O
EBV	O
infection	O
was	O
induced	O
by	O
transfection	O
of	O
the	O
cells	O
with	O
the	O
BRLF1	O
/	O
BZLF1	O
coding	O
region	O
of	O
the	O
P3HR-1	O
defective	O
genome	O
.	O
We	O
combined	O
two	O
techniques	O
to	O
identify	O
the	O
productive	O
replicative	O
form	O
of	O
Epstein	O
-	O
Barr	O
viral	O
DNA	O
in	O
the	O
lytic	O
cycle	O
-	O
induced	O
cells	O
.	O
Restriction	O
enzyme	O
analysis	O
followed	O
by	O
Southern	O
blot	O
hybridization	O
identified	O
a	O
significant	O
increase	O
in	O
the	O
fused	O
fragment	O
encompassing	O
both	O
ends	O
of	O
EBV	O
DNA	O
.	O
This	O
indicates	O
an	O
increase	O
in	O
either	O
episomal	O
DNA	O
or	O
concatameric	O
linear	O
DNA	O
.	O
Southern	O
blot	O
analysis	O
of	O
in	O
situ	O
lysing	O
gels	O
revealed	O
that	O
the	O
cellular	O
content	O
of	O
linear	O
EBV	O
DNA	O
was	O
also	O
increased	O
significantly	O
after	O
the	O
initiation	O
of	O
the	O
viral	O
lytic	O
cycle	O
,	O
while	O
the	O
amount	O
of	O
circular	O
DNA	O
remained	O
approximately	O
constant	O
.	O
We	O
propose	O
from	O
these	O
results	O
that	O
the	O
source	O
of	O
the	O
fused	O
fragment	O
encompassing	O
both	O
ends	O
of	O
EBV	O
DNA	O
is	O
a	O
concatenated	O
linear	O
EBV	O
DNA	O
molecule	O
,	O
and	O
that	O
such	O
a	O
concatenated	O
molecule	O
most	O
likely	O
represents	O
a	O
replicative	O
form	O
of	O
EBV	O
DNA	O
in	O
productively	O
infected	O
cells	O
.	O
Induction	O
of	O
CD8	B
antigen	I
and	O
suppressor	O
activity	O
by	O
glucocorticoids	O
in	O
a	O
CEM	O
human	O
leukemic	O
cell	O
clone	O
.	O
The	O
relationship	O
between	O
glucocorticoid	O
effect	O
and	O
regulation	O
of	O
cell	B
surface	I
antigens	I
was	O
investigated	O
in	O
two	O
models	O
of	O
leukemic	O
cell	O
lines	O
,	O
CEM	O
C7	O
denoted	O
(	O
r+	O
,	O
ly+	O
)	O
and	O
CEM	O
C1	O
(	O
r+	O
,	O
ly-	O
)	O
.	O
The	O
reactivity	O
of	O
murine	B
monoclonal	I
antibodies	I
,	O
anti	B
-	I
CD4-FITC	I
,	O
anti	B
-	I
CD8-FITC	I
,	O
anti	B
-	I
CD2-FITC	I
and	O
anti	B
-	I
calla	I
-	I
FITC	I
,	O
were	O
analyzed	O
using	O
flow	O
cytometry	O
.	O
The	O
suppressor	O
function	O
was	O
determined	O
using	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
into	O
phytohemagglutinin	O
-	O
activated	O
peripheral	O
blood	O
lymphocytes	O
.	O
Dexamethasone	O
treatment	O
of	O
a	O
human	O
leukemic	O
cell	O
clone	O
CEM	O
C7	O
caused	O
an	O
increase	O
in	O
a	O
subset	O
of	O
cells	O
expressing	O
the	O
surface	B
antigen	I
CD8	I
,	O
which	O
is	O
present	O
on	O
suppressor	O
and	O
cytotoxic	O
T	O
-	O
lymphocytes	O
.	O
By	O
comparison	O
,	O
there	O
was	O
no	O
modification	O
of	O
the	O
expression	O
of	O
CD4	B
antigen	I
,	O
which	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
these	O
cells	O
.	O
After	O
two	O
days	O
of	O
treatment	O
with	O
5	O
x	O
10	O
(	O
-8	O
)	O
M	O
dexamethasone	O
,	O
CEM	O
C7	O
cells	O
showed	O
a	O
two	O
-	O
fold	O
increase	O
in	O
suppressor	O
activity	O
compared	O
to	O
untreated	O
cells	O
.	O
In	O
contrast	O
,	O
there	O
was	O
no	O
regulation	O
by	O
glucocorticoids	O
of	O
either	O
the	O
CD8	B
or	O
CD4	B
antigens	I
in	O
the	O
leukemic	O
clone	O
CEM	O
C1	O
.	O
Furthermore	O
,	O
no	O
modification	O
of	O
the	O
suppressor	O
function	O
in	O
CEM	O
C1	O
cells	O
by	O
dexamethasone	O
was	O
observed	O
.	O
In	O
the	O
human	O
leukemic	O
cells	O
studied	O
here	O
,	O
the	O
ability	O
to	O
induce	O
CD8	B
antigen	I
expression	O
in	O
a	O
CD4	O
+	O
cells	O
correlates	O
with	O
the	O
ability	O
to	O
induce	O
cell	O
lysis	O
in	O
a	O
glucocorticoid	O
receptor	O
positive	O
cell	O
population	O
.	O
Molecular	O
basis	O
of	O
a	O
multiple	O
lymphokine	B
deficiency	O
in	O
a	O
patient	O
with	O
severe	O
combined	O
immunodeficiency	O
.	O
We	O
have	O
previously	O
reported	O
that	O
the	O
T	O
lymphocytes	O
of	O
a	O
child	O
with	O
severe	O
combined	O
immunodeficiency	O
are	O
defective	O
in	O
the	O
transcription	O
of	O
several	O
lymphokine	O
genes	O
that	O
include	O
IL2	O
,	O
IL3	O
,	O
IL4	O
,	O
and	O
IL5	O
,	O
which	O
encode	O
interleukins	B
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
(	O
IL-2	B
,	O
-3	B
,	O
-4	B
,	O
and	O
-5	B
)	O
.	O
To	O
determine	O
whether	O
the	O
defect	O
in	O
the	O
patient	O
's	O
T	O
lymphocytes	O
involved	O
a	O
trans	B
-	I
acting	I
factor	I
common	O
to	O
the	O
affected	O
lymphokine	O
genes	O
,	O
we	O
examined	O
the	O
ability	O
of	O
nuclear	B
factors	I
from	O
the	O
patient	O
's	O
T	O
lymphocytes	O
to	O
bind	O
response	O
elements	O
present	O
in	O
the	O
regulatory	O
region	O
of	O
IL2	O
.	O
Nuclear	B
factor	I
NF	I
-	I
kB	I
,	O
activation	B
protein	I
1	I
(	O
AP-1	B
)	O
,	O
OCT-1	B
,	O
and	O
NF	B
-	I
IL-2B	I
binding	O
activity	O
were	O
normal	O
.	O
In	O
contrast	O
,	O
the	O
binding	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
to	O
its	O
response	O
element	O
in	O
the	O
IL2	O
enhancer	O
and	O
to	O
an	O
NF	O
-	O
AT	O
-	O
like	O
response	O
element	O
present	O
in	O
the	O
IL4	O
enhancer	O
was	O
abnormal	O
.	O
To	O
ascertain	O
whether	O
the	O
abnormal	O
NF	B
-	I
AT	I
binding	O
activity	O
was	O
related	O
to	O
an	O
impaired	O
function	O
,	O
we	O
transfected	O
patient	O
and	O
control	O
T	O
lymphocytes	O
with	O
constructs	O
containing	O
the	O
reporter	O
gene	O
encoding	O
chloramphenicol	B
acetyl	I
transferase	I
(	O
CAT	B
)	O
under	O
the	O
control	O
of	O
the	O
entire	O
IL2	O
regulatory	O
region	O
or	O
of	O
multimers	O
of	O
individual	O
enhancer	O
sequences	O
.	O
CAT	O
expression	O
directed	O
by	O
the	O
IL2	O
regulatory	O
region	O
or	O
by	O
a	O
multimer	O
of	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
was	O
markedly	O
lower	O
in	O
the	O
patient	O
relative	O
to	O
controls	O
.	O
In	O
contrast	O
,	O
CAT	O
gene	O
expression	O
directed	O
by	O
a	O
multimer	O
of	O
the	O
OCT-1	O
proximal	O
(	O
OCT-1p	O
)	O
-binding	O
site	O
was	O
equivalent	O
in	O
patient	O
and	O
controls	O
.	O
These	O
results	O
indicate	O
that	O
an	O
abnormality	O
of	O
/	O
or	O
influencing	O
NF	B
-	I
AT	I
may	O
underlie	O
the	O
multiple	O
lymphokine	B
deficiency	O
in	O
this	O
patient	O
.	O
Expression	O
of	O
mRNA	O
for	O
the	O
GATA	B
-	I
binding	I
proteins	I
in	O
human	O
eosinophils	O
and	O
basophils	O
:	O
potential	O
role	O
in	O
gene	O
transcription	O
.	O
The	O
expression	O
of	O
the	O
hematopoietic	B
transcription	I
factors	I
GATA-1	B
,	O
GATA-2	B
,	O
and	O
GATA-3	B
was	O
studied	O
in	O
eosinophils	O
and	O
basophils	O
.	O
Eosinophils	O
express	O
mRNA	O
for	O
GATA-1	B
,	O
GATA-2	B
,	O
and	O
GATA-3	B
.	O
Basophils	O
express	O
GATA-2	B
and	O
GATA-3	B
.	O
Treatment	O
of	O
HL-60	O
eosinophilic	O
sublines	O
with	O
either	O
interleukin-5	B
or	O
butyric	O
acid	O
increased	O
the	O
expression	O
of	O
GATA-1	O
mRNA	O
concomitant	O
with	O
the	O
expression	O
of	O
eosinophil	O
-	O
specific	O
genes	O
,	O
whereas	O
levels	O
of	O
GATA-2	O
mRNA	O
remained	O
relatively	O
constant	O
.	O
The	O
presence	O
of	O
mRNA	O
for	O
these	O
proteins	O
in	O
eosinophils	O
and	O
basophils	O
suggests	O
that	O
gene	O
transcription	O
in	O
these	O
lineages	O
may	O
be	O
regulated	O
by	O
GATA	B
-	I
binding	I
proteins	I
.	O
Defective	O
translocation	O
of	O
protein	B
kinase	I
C	I
in	O
multidrug	O
-	O
resistant	O
HL-60	O
cells	O
confers	O
a	O
reversible	O
loss	O
of	O
phorbol	O
ester	O
-	O
induced	O
monocytic	O
differentiation	O
.	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
human	O
HL-60	O
myeloid	O
leukemia	O
cells	O
differentiate	O
in	O
response	O
to	O
phorbol	O
esters	O
.	O
This	O
event	O
is	O
associated	O
with	O
induction	O
of	O
the	O
c	O
-	O
jun	O
early	O
response	O
gene	O
and	O
appearance	O
of	O
a	O
monocytic	O
phenotype	O
.	O
The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
vincristine	O
-	O
selected	O
,	O
multidrug	O
resistance	O
on	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
-induced	O
HL-60	O
cell	O
differentiation	O
.	O
The	O
results	O
demonstrate	O
that	O
multidrug	O
-	O
resistant	O
HL-60	O
cells	O
,	O
designated	O
HL-60	O
/	O
vinc	O
,	O
fail	O
to	O
respond	O
to	O
TPA	O
with	O
an	O
increase	O
in	O
c	O
-	O
jun	O
transcripts	O
or	O
other	O
phenotypic	O
characteristics	O
of	O
monocytic	O
differentiation	O
.	O
By	O
contrast	O
,	O
treatment	O
of	O
HL-60	O
/	O
vinc	O
cells	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine	B
/	I
threonine	I
protein	I
phosphatases	I
,	O
induces	O
c	O
-	O
jun	O
transcription	O
,	O
growth	O
arrest	O
,	O
and	O
expression	O
of	O
the	O
c	O
-	O
fms	O
gene	O
.	O
Studies	O
were	O
also	O
performed	O
with	O
an	O
HL-60	O
/	O
vinc	O
revertant	O
(	O
HL-60	O
/	O
vinc	O
/	O
R	O
)	O
line	O
that	O
has	O
regained	O
partial	O
sensitivity	O
to	O
vincristine	O
.	O
The	O
finding	O
that	O
HL-60	O
/	O
vinc	O
/	O
R	O
cells	O
respond	O
to	O
TPA	O
with	O
induction	O
of	O
a	O
monocytic	O
phenotype	O
,	O
but	O
not	O
c	O
-	O
jun	O
expression	O
,	O
suggests	O
that	O
c	O
-	O
jun	O
induction	O
is	O
not	O
obligatory	O
for	O
monocytic	O
differentiation	O
.	O
Other	O
studies	O
further	O
demonstrate	O
that	O
the	O
jun	O
-	O
B	O
and	O
fra-1	O
genes	O
are	O
induced	O
by	O
TPA	O
in	O
both	O
HL-60	O
/	O
vinc	O
and	O
HL-60	O
/	O
vinc	O
/	O
R	O
cells	O
,	O
whereas	O
c	O
-	O
fos	O
expression	O
is	O
attenuated	O
in	O
the	O
HL-60	O
/	O
vinc	O
line	O
.	O
Since	O
TPA	O
activates	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
,	O
we	O
examined	O
translocation	O
of	O
PKC	B
from	O
the	O
cytosol	O
to	O
the	O
membrane	O
fraction	O
.	O
Although	O
HL-60	O
and	O
HL-60	O
/	O
vinc	O
/	O
R	O
cells	O
demonstrated	O
translocation	O
of	O
PKC	B
activity	O
,	O
this	O
subcellular	O
redistribution	O
was	O
undetectable	O
in	O
HL-60	O
/	O
vinc	O
cells	O
.	O
Activity	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
family	I
with	O
associated	O
phosphorylation	O
of	O
c	B
-	I
Jun	I
Y	I
-	I
peptide	I
was	O
markedly	O
diminished	O
in	O
TPA	O
-	O
treated	O
HL-60	O
/	O
vinc	O
cells	O
,	O
but	O
not	O
in	O
response	O
to	O
okadaic	O
acid	O
.	O
Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
vincristine	O
resistance	O
confers	O
insensitivity	O
to	O
TPA	O
-	O
induced	O
differentiation	O
and	O
can	O
include	O
defects	O
in	O
PKC	B
-mediated	O
signaling	O
events	O
and	O
induction	O
of	O
jun	O
/	O
fos	O
early	O
response	O
gene	O
expression	O
.	O
Differential	O
contribution	O
of	O
herpes	B
simplex	I
virus	I
type	I
1	I
gene	I
products	I
and	O
cellular	B
factors	I
to	O
the	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
provirus	O
.	O
We	O
have	O
previously	O
reported	O
that	O
infection	O
with	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV-1	O
)	O
activates	O
expression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
provirus	O
in	O
T	O
cells	O
.	O
Activation	O
of	O
the	O
HIV-1	O
provirus	O
correlated	O
with	O
the	O
activation	O
of	O
binding	O
of	O
55-	B
and	I
85-kDa	I
proteins	I
to	O
the	O
kappa	O
B	O
enhancer	O
and	O
binding	O
of	O
the	O
50-kDa	B
HLP-1	I
protein	I
to	O
the	O
LBP-1	O
sequences	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
.	O
Further	O
examination	O
of	O
this	O
system	O
has	O
shown	O
that	O
the	O
inhibition	O
of	O
HSV-1	O
replication	O
by	O
the	O
antiviral	O
drug	O
acyclovir	O
does	O
not	O
inhibit	O
HSV-1-mediated	O
induction	O
of	O
HIV-1	O
provirus	O
.	O
Surprisingly	O
,	O
the	O
NF	B
-	I
kappa	I
B	I
and	O
HLP-1	O
binding	O
activities	O
were	O
substantially	O
inhibited	O
in	O
acyclovir	O
-	O
treated	O
cells	O
.	O
In	O
the	O
transient	O
-	O
transfection	O
assay	O
,	O
ICP0	B
,	O
but	O
not	O
ICP4	B
,	O
activated	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
promoter	O
region	O
and	O
the	O
effect	O
of	O
ICP0	B
was	O
greatly	O
enhanced	O
in	O
the	O
presence	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
binding	I
proteins	I
,	O
suggesting	O
that	O
induction	O
of	O
the	O
HIV-1	O
provirus	O
involves	O
cooperation	O
between	O
the	O
HSV-1-activated	B
cellular	I
factor	I
,	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
the	O
virus	B
-	I
encoded	I
transactivator	I
,	O
ICP0	B
.	O
Transcriptional	O
activation	O
of	O
the	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
by	O
IL-2	B
is	O
associated	O
with	O
secretion	O
of	O
bioactive	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
protein	I
by	O
monocytes	O
and	O
involves	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
.	O
Human	O
peripheral	O
blood	O
monocytes	O
(	O
Mo	O
)	O
constitutively	O
display	O
the	O
beta	O
-	O
chain	O
of	O
the	O
receptor	O
for	O
IL-2	B
,	O
whereas	O
expression	O
of	O
the	O
IL-2R	B
alpha	I
-	I
chain	I
is	O
not	O
constitutive	O
but	O
inducible	O
with	O
IL-2	B
.	O
Here	O
we	O
report	O
that	O
binding	O
of	O
human	B
IL-2	I
to	O
its	O
binding	O
site	O
leads	O
to	O
transcriptional	O
activation	O
of	O
the	O
macrophage	O
CSF	O
(	O
M	O
-	O
CSF	O
)	O
gene	O
in	O
Mo	O
resulting	O
in	O
accumulation	O
of	O
M	O
-	O
CSF	O
mRNA	O
and	O
subsequent	O
release	O
of	O
bioactive	O
M	B
-	I
CSF	I
protein	I
as	O
demonstrated	O
by	O
ELISA	O
and	O
inhibition	O
of	O
IL-2	B
induced	O
release	O
of	O
an	O
activity	O
-	O
stimulating	O
growth	O
of	O
monocyte	O
-	O
type	O
colonies	O
by	O
a	O
neutralizing	O
anti	B
-	I
M	I
-	I
CSF	I
antibody	I
.	O
Transcriptional	O
activation	O
of	O
the	O
M	O
-	O
CSF	O
gene	O
by	O
IL-2	B
is	O
preceded	O
by	O
enhanced	O
binding	O
activity	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
to	O
its	O
recognition	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
M	O
-	O
CSF	O
gene	O
.	O
Moreover	O
,	O
using	O
a	O
heterologous	O
promoter	O
(	O
herpes	O
thymidine	O
kinase	O
)	O
construct	O
containing	O
the	O
NF	O
-	O
kappa	O
B	O
consensus	O
sequence	O
,	O
it	O
is	O
shown	O
that	O
NF	B
-	I
kappa	I
B	I
binding	O
by	O
an	O
IL-2-induced	B
monocyte	I
-	I
derived	I
nuclear	I
protein	I
confers	O
reporter	O
gene	O
(	O
human	O
growth	O
hormone	O
)	O
activity	O
.	O
Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
IL-2	B
induces	O
gene	O
expression	O
of	O
M	B
-	I
CSF	I
in	O
human	O
blood	O
-	O
derived	O
Mo	O
and	O
provide	O
evidence	O
for	O
involvement	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
.	O
Cell	O
cycle	O
analysis	O
of	O
E2F	B
in	O
primary	O
human	O
T	O
cells	O
reveals	O
novel	B
E2F	I
complexes	I
and	O
biochemically	O
distinct	O
forms	O
of	O
free	O
E2F	B
.	O
The	O
transcription	B
factor	I
E2F	B
activates	O
the	O
expression	O
of	O
multiple	O
genes	O
involved	O
in	O
cell	O
proliferation	O
,	O
such	O
as	O
c	O
-	O
myc	O
and	O
the	O
dihydrofolate	O
reductase	O
gene	O
.	O
Regulation	O
of	O
E2F	B
involves	O
its	O
interactions	O
with	O
other	O
cellular	B
proteins	I
,	O
including	O
the	O
retinoblastoma	B
protein	I
(	O
Rb	B
)	O
,	O
the	O
Rb	B
-	I
related	I
protein	I
p107	B
,	O
cyclin	B
A	I
,	O
and	O
cdk2	B
.	O
We	O
undertook	O
a	O
detailed	O
analysis	O
of	O
E2F	B
DNA	O
-	O
binding	O
activities	O
and	O
their	O
cell	O
cycle	O
behavior	O
in	O
primary	O
human	O
T	O
cells	O
.	O
Three	O
E2F	B
DNA	O
-	O
binding	O
activities	O
were	O
identified	O
in	O
resting	O
(	O
G0	O
)	O
T	O
cells	O
with	O
mobilities	O
in	O
gel	O
shift	O
assays	O
distinct	O
from	O
those	O
of	O
previously	O
defined	O
E2F	B
complexes	O
.	O
One	O
of	O
these	O
activities	O
was	O
found	O
to	O
be	O
a	O
novel	O
,	O
less	O
abundant	O
,	O
Rb-	O
E2F	B
complex	O
.	O
The	O
most	O
prominent	O
E2F	B
activity	O
in	O
resting	O
T	O
cells	O
(	O
termed	O
complex	O
X	O
)	O
was	O
abundant	O
in	O
both	O
G0	O
and	O
G1	O
but	O
disappeared	O
as	O
cells	O
entered	O
S	O
phase	O
,	O
suggesting	O
a	O
possible	O
role	O
in	O
negatively	O
regulating	O
E2F	B
function	O
.	O
Complex	B
X	I
could	O
be	O
dissociated	O
by	O
adenovirus	O
E1A	O
with	O
a	O
requirement	O
for	O
an	O
intact	O
E1A	O
conserved	O
region	O
2	O
.	O
However	O
,	O
X	B
failed	O
to	O
react	O
with	O
a	O
variety	O
of	O
antibodies	O
against	O
Rb	B
or	O
p107	B
,	O
implicating	O
the	O
involvement	O
of	O
an	O
E1A	B
-	I
binding	I
protein	I
other	O
than	O
Rb	B
or	O
p107	B
.	O
In	O
addition	O
to	O
these	O
novel	B
E2F	I
complexes	I
,	O
three	O
distinct	O
forms	O
of	O
unbound	O
(	O
free	O
)	O
E2F	B
were	O
resolved	O
in	O
gel	O
shift	O
experiments	O
.	O
These	O
species	O
showed	O
different	O
cell	O
cycle	O
kinetics	O
.	O
UV	O
cross	O
-	O
linking	O
experiments	O
suggested	O
that	O
a	O
distinct	O
E2F	B
DNA	O
-	O
binding	O
protein	O
is	O
uniquely	O
associated	O
with	O
the	O
S	B
-	I
phase	I
p107	I
complex	I
and	O
is	O
not	O
associated	O
with	O
Rb	B
.	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
E2F	B
consists	O
of	O
multiple	O
,	O
biochemically	O
distinct	O
DNA	B
-	I
binding	I
proteins	I
which	O
function	O
at	O
different	O
points	O
in	O
the	O
cell	O
cycle	O
.	O
Antisense	O
oligonucleotides	O
to	O
the	O
p65	B
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
block	O
CD11b	B
expression	O
and	O
alter	O
adhesion	O
properties	O
of	O
differentiated	O
HL-60	O
granulocytes	O
.	O
NF	B
-	I
kappa	I
B	I
is	O
a	O
pleiotropic	B
regulator	I
of	O
a	O
variety	O
of	O
genes	O
implicated	O
in	O
the	O
cellular	O
response	O
to	O
injury	O
.	O
This	O
function	O
has	O
been	O
attributed	O
to	O
the	O
coordinated	O
binding	O
of	O
subunits	O
of	O
NF	B
-	I
kappa	I
B	I
to	O
distinct	O
regions	O
of	O
the	O
promoter	O
elements	O
of	O
numerous	O
genes	O
,	O
including	O
cytokines	B
,	O
growth	B
factor	I
receptors	I
,	O
and	O
adhesion	B
molecules	I
.	O
Antisense	O
phosphorothioate	O
oligonucleotides	O
to	O
the	O
p50	B
and	O
p65	B
subunits	I
of	O
the	O
NF	B
-	I
kappa	I
B	I
complex	I
were	O
used	O
to	O
define	O
the	O
physiologic	O
role	O
of	O
this	O
transcription	B
factor	I
in	O
resting	O
and	O
stimulated	O
granulocytes	O
.	O
A	O
reduction	O
in	O
the	O
expression	O
of	O
p65	B
was	O
produced	O
by	O
treatment	O
with	O
the	O
phosphorothioate	O
antisense	O
oligodeoxynucleotide	O
.	O
This	O
reduction	O
was	O
accompanied	O
by	O
rapid	O
changes	O
in	O
the	O
cellular	O
adhesion	O
of	O
dimethyl	O
sulfoxide	O
-	O
differentiated	O
HL-60	O
leukemia	O
cells	O
stimulated	O
by	O
12-O	O
-	O
tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
.	O
These	O
effects	O
were	O
characterized	O
by	O
a	O
marked	O
reduction	O
in	O
CD11b	B
integrin	B
expression	O
on	O
the	O
surface	O
of	O
treated	O
cells	O
.	O
Furthermore	O
,	O
the	O
p65	B
antisense	O
oligomer	O
effectively	O
abolished	O
an	O
upregulation	O
of	O
CD11b	B
that	O
was	O
produced	O
by	O
formyl	O
-	O
met	O
-	O
leu	O
-	O
phe	O
and	O
TPA	O
.	O
However	O
,	O
the	O
p65	B
antisense	O
phosphorothioate	O
oligodeoxynucleotide	O
had	O
no	O
significant	O
effect	O
on	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
or	O
on	O
phagocytosis	O
by	O
these	O
cells	O
.	O
These	O
findings	O
indicate	O
that	O
antisense	O
oligomers	O
to	O
p65	B
can	O
be	O
used	O
to	O
define	O
the	O
role	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
the	O
activation	O
pathways	O
of	O
neutrophils	O
.	O
Nuclear	B
factor	I
kappa	I
B	I
,	O
a	O
mediator	O
of	O
lipopolysaccharide	O
effects	O
.	O
Exposure	O
of	O
certain	O
cell	O
types	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
leads	O
to	O
activation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
,	O
an	O
inducible	B
transcription	I
factor	I
.	O
One	O
of	O
NF	B
-	I
kappa	I
B	I
's	O
unique	O
properties	O
is	O
its	O
posttranslational	O
activation	O
via	O
release	O
of	O
an	O
inhibitory	B
subunit	I
,	O
called	O
inhibitor	B
of	I
NF	I
-	I
kappa	I
B	I
(	O
I	B
kappa	I
B	I
)	O
,	O
from	O
a	O
sequestered	O
cytoplasmic	O
form	O
.	O
This	O
event	O
is	O
also	O
triggered	O
under	O
various	O
other	O
conditions	O
of	O
biomedical	O
importance	O
.	O
Other	O
bacterial	O
toxins	O
,	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
)	O
,	O
interleukin-1	B
(	O
IL-1	B
)	O
,	O
T	B
cell	I
mitogens	I
,	O
UV	O
light	O
,	O
gamma	O
rays	O
and	O
oxidative	O
stress	O
were	O
reported	O
to	O
induce	O
NF	B
-	I
kappa	I
B	I
.	O
The	O
activated	O
form	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
which	O
is	O
rapidly	O
taken	O
up	O
into	O
nuclei	O
,	O
initiates	O
transcription	O
from	O
immediate	O
early	O
genes	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O
Most	O
of	O
the	O
target	O
genes	O
for	O
NF	B
-	I
kappa	I
B	I
are	O
of	O
relevance	O
for	O
the	O
immune	O
response	O
and	O
can	O
be	O
grouped	O
into	O
those	O
encoding	O
cytokines	B
,	O
cell	B
surface	I
receptors	I
,	O
acute	B
phase	I
proteins	I
and	O
viral	O
genomes	O
,	O
such	O
as	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O
We	O
will	O
discuss	O
recent	O
experimental	O
evidences	O
suggesting	O
that	O
LPS	O
might	O
share	O
a	O
pathway	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
with	O
other	O
inducers	O
of	O
the	O
factor	O
.	O
This	O
common	O
pathway	O
may	O
involve	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
as	O
messenger	O
molecules	O
.	O
Analysis	O
of	O
the	O
preexisting	O
and	O
nuclear	O
forms	O
of	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
.	O
The	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
3	O
is	O
an	O
inducible	O
DNA	B
-	I
binding	I
protein	I
that	O
is	O
essential	O
for	O
transcriptional	O
induction	O
of	O
the	O
IL-2	O
gene	O
during	O
T	O
cell	O
activation	O
.	O
NF	B
-	I
AT	I
is	O
thought	O
to	O
consist	O
of	O
two	O
components	O
:	O
a	O
ubiquitous	B
,	I
inducible	I
nuclear	I
component	I
that	O
we	O
have	O
identified	O
as	O
Fos	B
and	O
Jun	B
proteins	I
,	O
and	O
a	O
preexisting	O
,	O
T	B
cell	I
-	I
specific	I
component	I
(	O
NF	B
-	I
ATp	I
)	O
which	O
is	O
the	O
target	O
for	O
the	O
immunosuppressive	O
agents	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O
We	O
have	O
previously	O
shown	O
that	O
nuclear	O
extracts	O
from	O
activated	O
T	O
cells	O
form	O
two	O
inducible	O
NF	B
-	I
AT	I
complexes	I
with	O
an	O
oligonucleotide	O
corresponding	O
to	O
the	O
distal	O
NF	O
-	O
AT	O
site	O
of	O
the	O
murine	O
IL-2	O
promoter	O
,	O
although	O
hypotonic	O
extracts	O
of	O
unstimulated	O
T	O
cells	O
form	O
a	O
single	O
complex	O
containing	O
NF	B
-	I
ATp	I
.	O
We	O
show	O
that	O
the	O
ability	O
to	O
detect	O
NF	B
-	I
ATp	I
in	O
a	O
gel	O
shift	O
assay	O
,	O
which	O
is	O
essential	O
for	O
purification	O
and	O
biochemical	O
studies	O
of	O
this	O
protein	O
,	O
is	O
strikingly	O
dependent	O
on	O
the	O
precise	O
sequence	O
of	O
the	O
NF	B
-	I
AT	I
oligonucleotide	O
used	O
as	O
the	O
labeled	O
probe	O
.	O
Moreover	O
we	O
present	O
evidence	O
that	O
the	O
component	O
that	O
forms	O
the	O
faster	O
-	O
migrating	O
(	O
`	O
`	O
lower	O
''	O
)	O
nuclear	B
NF	I
-	I
AT	I
complex	I
is	O
derived	O
by	O
a	O
calcium	O
-	O
dependent	O
,	O
cyclosporin	O
-	O
sensitive	O
,	O
posttranslational	O
modification	O
of	O
NF	B
-	I
ATp	I
,	O
and	O
that	O
Fos	B
and	O
Jun	B
proteins	O
stabilize	O
its	O
interaction	O
with	O
DNA	O
.	O
The	O
results	O
are	O
discussed	O
in	O
the	O
context	O
of	O
a	O
model	O
relating	O
the	O
two	O
nuclear	O
NF	B
-	I
AT	I
complexes	I
to	O
NF	B
-	I
ATp	I
.	O
The	O
impaired	O
transcription	B
factor	I
AP-1	I
DNA	O
binding	O
activity	O
in	O
lymphocytes	O
derived	O
from	O
subjects	O
with	O
some	O
symptoms	O
of	O
premature	O
aging	O
.	O
The	O
study	O
of	O
human	O
disorders	O
known	O
as	O
premature	O
aging	O
syndromes	O
may	O
provide	O
insight	O
into	O
the	O
mechanisms	O
of	O
cellular	O
senescence	O
.	O
The	O
main	O
feature	O
of	O
cellular	O
senescence	O
in	O
vitro	O
is	O
cessation	O
of	O
cell	O
proliferation	O
.	O
Down	O
syndrome	O
(	O
DS	O
)	O
and	O
neuronal	O
ceroid	O
-	O
lypofuscinosis	O
(	O
NCL	O
)	O
are	O
clinically	O
characterized	O
by	O
the	O
premature	O
onset	O
of	O
numerous	O
features	O
normally	O
associated	O
with	O
human	O
aging	O
.	O
Phytohemagglutinin	B
stimulated	O
lymphocytes	O
derived	O
from	O
DS	O
subjects	O
showed	O
a	O
statistically	O
significant	O
diminished	O
proliferation	O
capacity	O
in	O
comparison	O
with	O
lymphocytes	O
derived	O
from	O
NCL	O
and	O
healthy	O
individuals	O
.	O
We	O
demonstrated	O
,	O
by	O
applying	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
slightly	O
impaired	O
AP-1	B
DNA	O
binding	O
activity	O
in	O
NCL	O
lymphocytes	O
and	O
strong	O
in	O
DS	O
ones	O
.	O
Our	O
results	O
showed	O
that	O
the	O
same	O
molecular	O
mechanisms	O
of	O
proliferation	O
cessation	O
could	O
exist	O
in	O
fibroblasts	O
characterized	O
by	O
replicative	O
senescence	O
and	O
in	O
lymphocytes	O
derived	O
from	O
individuals	O
with	O
premature	O
aging	O
syndromes	O
(	O
Down	O
Cellular	O
immune	O
and	O
cytokine	O
pathways	O
resulting	O
in	O
tissue	B
factor	I
expression	O
and	O
relevance	O
to	O
septic	O
shock	O
.	O
Cells	O
of	O
monocyte	O
lineage	O
serve	O
as	O
effector	O
cells	O
in	O
the	O
cellular	O
immune	O
response	O
.	O
In	O
addition	O
,	O
they	O
respond	O
to	O
LPS	O
and	O
cytokines	O
with	O
activation	O
and	O
expression	O
of	O
inflammatory	B
effector	I
gene	I
products	I
similar	O
to	O
those	O
elicited	O
by	O
the	O
antigen	O
driven	O
response	O
.	O
The	O
response	O
to	O
antigen	O
proceeds	O
at	O
the	O
T	O
helper	O
cell	O
level	O
through	O
two	O
independent	O
forms	O
of	O
cellular	O
collaboration	O
,	O
contact	O
and	O
lymphokine	B
.	O
We	O
review	O
the	O
control	O
of	O
expression	O
of	O
the	O
Tissue	O
Factor	O
(	O
TF	O
)	O
gene	O
and	O
the	O
function	O
of	O
the	O
TF	B
protein	I
.	O
The	O
enhanced	O
initiation	O
of	O
transcription	O
of	O
the	O
TF	O
gene	O
appears	O
to	O
require	O
engagement	O
of	O
a	O
56	O
bp	O
LPS	O
Response	O
Element	O
,	O
an	O
enhancer	O
that	O
is	O
engaged	O
by	O
both	O
AP-1	B
type	I
heterodimeric	I
complexes	I
as	O
well	O
as	O
NF	B
kappa	I
B	I
like	I
heterodimeric	I
complexes	I
.	O
Dissociation	O
of	O
NF	B
kappa	I
B	I
from	O
Ig	B
kappa	I
B	I
by	O
cytokine	O
and	O
LPS	O
stimulation	O
,	O
and	O
possibly	O
activated	O
T	O
cells	O
,	O
may	O
represent	O
a	O
common	O
pathway	O
to	O
induction	O
of	O
the	O
TF	O
and	O
other	O
inflammatory	O
genes	O
.	O
Enhancement	O
of	O
expression	O
of	O
TF	B
is	O
observed	O
upon	O
adhesion	O
of	O
Mo	O
to	O
endothelial	O
cells	O
and	O
extracellular	O
matrix	O
proteins	O
,	O
as	O
well	O
as	O
upon	O
engagement	O
of	O
leukocyte	B
integrins	I
.	O
The	O
biological	O
effects	O
that	O
follow	O
from	O
expression	O
of	O
TF	B
by	O
vascular	O
cells	O
have	O
been	O
resolved	O
by	O
analysis	O
of	O
function	O
aided	O
by	O
the	O
use	O
of	O
recombinant	B
full	I
length	I
TF	I
and	O
truncated	B
surface	I
domain	I
of	O
TF	B
.	O
The	O
rules	O
of	O
assembly	O
of	O
the	O
cognate	O
ligands	O
of	O
TF	B
,	O
namely	O
the	O
zymogen	B
plasma	I
factors	I
VII	I
and	O
the	O
serine	B
protease	I
factor	I
VIIa	I
,	O
with	O
the	O
soluble	B
surface	I
domain	I
of	O
TF	B
in	O
free	O
solution	O
,	O
in	O
the	O
presence	O
of	O
phospholipid	O
surfaces	O
and	O
cell	O
surface	O
and	O
of	O
the	O
anchored	B
TF	I
molecule	I
have	O
been	O
described	O
.	O
It	O
is	O
evident	O
that	O
assembly	O
of	O
the	O
surface	B
domain	I
of	O
TF	B
with	O
VIIa	B
to	O
form	O
the	O
binary	O
TF.VIIa	B
complex	I
induces	O
a	O
significant	O
increase	O
in	O
the	O
Kcat	O
of	O
the	O
catalytic	B
domain	I
of	O
VIIa	B
for	O
small	O
peptidyl	O
substrates	O
and	O
more	O
profoundly	O
for	O
protein	B
substrate	I
.	O
This	O
provides	O
substantial	O
evidence	O
for	O
an	O
allosteric	O
effect	O
on	O
the	O
catalytic	O
cleft	O
of	O
VIIa	B
that	O
is	O
imparted	O
by	O
binding	O
to	O
TF	B
,	O
its	O
cognate	O
catalytic	O
cofactor	B
.	O
It	O
is	O
also	O
evident	O
that	O
the	O
TF.VIIa	B
complex	I
is	O
proteolytically	O
active	O
and	O
can	O
activate	O
the	O
zymogen	B
plasma	I
factor	I
X	I
to	O
the	O
serine	B
protease	I
Xa	I
in	O
free	O
solution	O
,	O
inferring	O
that	O
extended	O
substrate	O
recognition	O
by	O
induced	O
structural	O
loci	O
of	O
the	O
TF.VIIa	B
complex	I
are	O
created	O
from	O
either	O
or	O
both	O
proteins	O
to	O
constitute	O
a	O
new	B
recognition	I
structure	I
.	O
It	O
is	O
also	O
evident	O
that	O
association	O
of	O
X	B
with	O
charged	O
phospholipid	O
surfaces	O
enhances	O
the	O
proteolytic	O
activation	O
of	O
this	O
zymogen	B
by	O
increasing	O
recognition	O
and	O
susceptibility	O
of	O
the	O
sessile	O
peptide	O
bond	O
deduced	O
from	O
the	O
markedly	O
decreased	O
Km	O
and	O
increased	O
Kcat	O
.	O
The	O
lymphotoxin	O
promoter	O
is	O
stimulated	O
by	O
HTLV	B
-	I
I	I
tax	I
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
human	O
T	O
-	O
cell	O
lines	O
.	O
The	O
HTLV	B
-	I
I	I
transcriptional	I
activator	I
tax	I
was	O
used	O
to	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
lymphotoxin	O
(	O
LT	O
;	O
TNF	O
-	O
beta	O
)	O
gene	O
induction	O
.	O
Tax	O
-	O
expressing	O
cell	O
lines	O
produce	O
LT	B
biologic	O
activity	O
.	O
An	O
LT	O
promoter	O
(	O
LT-293	O
)	O
CAT	O
construct	O
that	O
contained	O
an	O
NF	O
-	O
kappa	O
B	O
site	O
was	O
active	O
in	O
the	O
LT	O
-	O
producing	O
C81	O
-	O
66	O
-	O
45	O
cell	O
line	O
,	O
which	O
contains	O
defective	O
HTLV	O
-	O
I	O
but	O
expresses	O
tax	B
.	O
The	O
observation	O
that	O
a	O
mutated	O
LT	O
-	O
kappa	O
B	O
construct	O
(	O
M1-CAT	O
)	O
was	O
inactive	O
in	O
C81	O
-	O
66	O
-	O
45	O
,	O
confirmed	O
the	O
importance	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
LT	B
gene	O
expression	O
.	O
Tax	B
was	O
transfected	O
into	O
HTLV	O
-	O
I	O
-	O
negative	O
human	O
T	O
-	O
cell	O
lines	O
.	O
Jurkat	O
T	O
cells	O
stably	O
expressing	O
tax	B
contained	O
elevated	O
levels	O
of	O
NF	B
-	I
kappa	I
B	I
that	O
directly	O
bound	O
to	O
the	O
LT	O
-	O
kappa	O
B	O
site	O
.	O
Tax	B
co	O
-	O
transfected	O
with	O
reporter	O
constructs	O
into	O
Jurkat	O
cells	O
maximally	O
activated	O
HTLV	B
-	I
I	I
-	I
LTR	I
-	I
CAT	I
and	O
kappa	B
B	I
-	I
fos	I
-	I
CAT	I
and	O
also	O
activated	O
LT-293	O
to	O
a	O
lesser	O
extent	O
.	O
In	O
JM	O
T	O
cells	O
,	O
tax	B
induced	O
LT-293	O
activity	O
by	O
two-	O
to	O
four	O
-	O
fold	O
,	O
though	O
there	O
was	O
no	O
induction	O
of	O
M1-CAT	B
.	O
The	O
increase	O
in	O
LT-293	O
CAT	B
activity	O
mirrored	O
the	O
increase	O
in	O
LT	B
biologic	O
activity	O
seen	O
under	O
these	O
conditions	O
.	O
These	O
studies	O
,	O
the	O
first	O
to	O
demonstrate	O
induction	O
of	O
LT	O
promoter	O
activity	O
over	O
basal	O
levels	O
,	O
indicate	O
that	O
HTLV	B
-	I
I	I
tax	I
causes	O
low	O
-	O
level	O
activation	O
of	O
both	O
endogenous	O
LT	B
and	O
the	O
LT	O
promoter	O
,	O
at	O
least	O
in	O
part	O
through	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
Transient	O
pseudohypoaldosteronism	O
in	O
obstructive	O
renal	O
disease	O
with	O
transient	O
reduction	O
of	O
lymphocytic	B
aldosterone	I
receptors	I
.	O
Results	O
in	O
two	O
affected	O
infants	O
.	O
We	O
report	O
two	O
patients	O
with	O
transient	O
pseudohypoaldosteronism	O
due	O
to	O
obstructive	O
renal	O
disease	O
.	O
Both	O
patients	O
presented	O
with	O
a	O
salt	O
-	O
losing	O
episode	O
simulating	O
adrenal	O
insufficiency	O
.	O
In	O
one	O
patient	O
,	O
transient	O
reduction	O
of	O
aldosterone	B
receptors	I
could	O
be	O
documented	O
,	O
while	O
in	O
the	O
second	O
patient	O
the	O
clinical	O
and	O
biochemical	O
parameters	O
were	O
consistent	O
with	O
transient	O
pseudohypoaldosteronism	O
.	O
Aldosterone	B
receptors	I
were	O
normal	O
in	O
both	O
patients	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B
associates	O
with	O
and	O
is	O
negatively	O
regulated	O
by	O
the	O
NF	B
-	I
kappa	I
B2	I
p100	I
gene	I
product	I
:	O
implications	O
for	O
viral	O
latency	O
.	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
the	O
adult	O
T	O
-	O
cell	O
leukemia	O
,	O
an	O
aggressive	O
and	O
often	O
fatal	O
malignancy	O
of	O
activated	O
human	O
CD4	O
T	O
cells	O
.	O
HTLV	O
-	O
I	O
encodes	O
an	O
essential	O
40-kDa	B
protein	I
termed	O
Tax	B
that	O
not	O
only	O
transactivates	O
the	O
long	O
terminal	O
repeat	O
of	O
this	O
retrovirus	O
but	O
also	O
induces	O
an	O
array	O
of	O
cellular	O
genes	O
.	O
Tax	B
-mediated	O
transformation	O
of	O
T	O
cells	O
likely	O
involves	O
the	O
deregulated	O
expression	O
of	O
various	O
cellular	O
genes	O
that	O
normally	O
regulate	O
lymphocyte	O
growth	O
produced	O
by	O
altered	O
activity	O
of	O
various	O
endogenous	O
host	O
transcription	B
factors	I
.	O
In	O
particular	O
,	O
Tax	B
is	O
capable	O
of	O
modulating	O
the	O
expression	O
or	O
activity	O
of	O
various	O
host	O
transcription	B
factors	I
,	O
including	O
members	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
and	O
CREB	B
/	I
ATF	I
families	I
,	O
as	O
well	O
as	O
the	O
cellular	B
factors	I
HEB-1	B
and	O
p67SRF	B
.	O
An	O
additional	O
distinguishing	O
characteristic	O
of	O
HTLV	O
-	O
I	O
infection	O
is	O
the	O
profound	O
state	O
of	O
viral	O
latency	O
that	O
is	O
present	O
in	O
circulating	O
primary	O
leukemic	O
T	O
cells	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
HTLV	O
-	O
I	O
Tax	B
can	O
physically	O
associate	O
with	O
p100	B
,	O
the	O
product	O
of	O
the	O
Rel	O
-	O
related	O
NF	O
-	O
kappa	O
B2	O
gene	O
,	O
both	O
in	O
transfected	O
cells	O
and	O
in	O
HTLV	O
-	O
I	O
-	O
infected	O
leukemic	O
T	O
-	O
cell	O
lines	O
.	O
Furthermore	O
,	O
the	O
physical	O
interaction	O
of	O
Tax	B
with	O
p100	B
leads	O
to	O
the	O
inhibition	O
of	O
Tax	B
-induced	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
and	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeats	O
,	O
reflecting	O
p100	B
-mediated	O
cytoplasmic	O
sequestration	O
of	O
the	O
normally	O
nuclearly	O
expressed	O
Tax	B
protein	I
.	O
In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	B
that	O
selectively	O
fails	O
to	O
activate	O
nuclear	O
NF	B
-	I
kappa	I
B	I
expression	O
does	O
not	O
associate	O
with	O
p100	B
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Effects	O
of	O
CD45	B
on	O
NF	B
-	I
kappa	I
B	I
.	O
Implications	O
for	O
replication	O
of	O
HIV-1	O
.	O
Increased	O
levels	O
of	O
replication	O
of	O
the	O
HIV	O
type	O
1	O
are	O
observed	O
after	O
the	O
activation	O
of	O
infected	O
T	O
cells	O
through	O
the	O
TCR	B
.	O
However	O
,	O
anti-	O
CD45	B
antibodies	O
inhibit	O
these	O
effects	O
in	O
cells	O
from	O
infected	O
individuals	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
interrelationships	O
between	O
CD45	B
and	O
HIV-1	O
further	O
.	O
We	O
measured	O
effects	O
on	O
the	O
HIV-1	O
LTR	O
in	O
T	O
cell	O
lines	O
that	O
were	O
stimulated	O
with	O
antibodies	O
against	O
CD45	B
and	O
in	O
those	O
that	O
lacked	O
the	O
expression	O
of	O
CD45	B
on	O
their	O
surfaces	O
.	O
First	O
,	O
anti	B
-	I
CD45	I
antibodies	I
did	O
not	O
affect	O
basal	O
but	O
decreased	O
activated	O
levels	O
of	O
expression	O
from	O
the	O
HIV-1	O
LTR	O
.	O
Second	O
,	O
T	O
cells	O
,	O
which	O
lack	O
CD45	B
and	O
can	O
not	O
signal	O
via	O
the	O
TCR	B
,	O
supported	O
higher	O
levels	O
of	O
viral	O
replication	O
and	O
gene	O
expression	O
.	O
This	O
was	O
due	O
to	O
the	O
presence	O
of	O
active	O
NF	B
-	I
kappa	I
B	I
complexes	I
in	O
the	O
nucleus	O
of	O
CD45	B
-T	O
cells	O
.	O
Additionally	O
,	O
infected	O
T	O
cells	O
displayed	O
lower	O
levels	O
of	O
CD45	B
on	O
their	O
surfaces	O
.	O
Thus	O
,	O
CD45	B
plays	O
an	O
active	O
role	O
in	O
the	O
physiology	O
of	O
T	O
cells	O
and	O
in	O
the	O
replication	O
of	O
HIV-1	O
.	O
Induction	O
of	O
phosphatidylinositol	O
turnover	O
and	O
EGR-1	O
mRNA	O
expression	O
by	O
crosslinking	O
of	O
surface	O
IgM	B
and	O
IgD	B
in	O
the	O
human	O
B	O
cell	O
line	O
B104	O
.	O
We	O
have	O
previously	O
shown	O
that	O
a	O
human	O
B	O
lymphoma	O
cell	O
line	O
,	O
B104	O
,	O
expressed	O
surface	B
IgM	I
(	O
sIgM	B
)	O
and	O
surface	B
IgD	I
(	O
sIgD	B
)	O
,	O
and	O
that	O
crosslinking	O
of	O
sIgM	B
and	O
sIgD	B
by	O
anti	B
-	I
IgM	I
antibody	I
(	I
Ab	I
)	I
and	O
anti	B
-	I
IgD	I
Ab	I
,	O
respectively	O
,	O
induced	O
Ca2	O
+	O
influx	O
to	O
almost	O
the	O
same	O
degree	O
,	O
whereas	O
only	O
sIgM	B
-crosslinking	O
caused	O
B104	O
cell	O
death	O
.	O
Here	O
,	O
we	O
investigated	O
the	O
accumulation	O
of	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
,	O
the	O
hydrolysis	O
of	O
inositol	O
phosphates	O
,	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
activity	O
and	O
the	O
induction	O
of	O
Egr-1	O
and	O
c	O
-	O
fos	O
mRNA	O
expression	O
by	O
sIgM-	O
and	O
sIgD	O
-	O
crosslinking	O
to	O
examine	O
differences	O
in	O
the	O
signals	O
mediated	O
through	O
sIgM	B
and	O
sIgD	B
in	O
B104	O
cells	O
.	O
Both	O
sIgM-	O
and	O
sIgD	O
-	O
crosslinking	O
with	O
antibodies	O
induced	O
elevation	O
of	O
cAMP	O
levels	O
,	O
phosphatidylinositol	O
turnover	O
,	O
PKC	B
activation	O
and	O
expression	O
of	O
Egr-1	O
and	O
c	O
-	O
fos	O
mRNA	O
,	O
although	O
sIgM	B
-crosslinking	O
was	O
more	O
effective	O
than	O
sIgD	B
-crosslinking	O
,	O
presumably	O
due	O
to	O
the	O
higher	O
expression	O
of	O
sIgM	B
than	O
of	O
sIgD	B
.	O
Egr-1	O
mRNA	O
expression	O
induced	O
by	O
sIgM-	O
and	O
sIgD	O
-	O
crosslinking	O
was	O
inhibited	O
by	O
H7	B
,	O
erbstatin	O
and	O
genistein	O
,	O
but	O
not	O
by	O
HA1004	O
.	O
Erbstatin	O
and	O
genistein	O
inhibited	O
the	O
sIg	O
-	O
crosslinking	O
-	O
induced	O
Egr-1	O
mRNA	O
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
parallel	O
to	O
that	O
observed	O
in	O
the	O
inhibition	O
of	O
sIg	O
-	O
crosslinking	O
-	O
induced	O
protein	O
tyrosine	O
phosphorylation	O
.	O
Phorbol	O
myristate	O
acetate	O
induced	O
Egr-1	O
mRNA	O
expression	O
but	O
forskolin	O
and	O
dibutyryl	O
cyclic	O
AMP	O
did	O
not	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
Egr-1	O
mRNA	O
activating	O
signals	O
through	O
sIgM	B
and	O
sIgD	B
are	O
protein	O
tyrosine	O
kinase-	O
and	O
PKC	O
-	O
dependent	O
,	O
but	O
protein	B
kinase	I
A	I
-independent	O
.	O
Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
rescued	O
B104	O
cells	O
from	O
death	O
induced	O
by	O
anti	B
-	I
IgM	I
Ab	I
,	O
but	O
did	O
not	O
affect	O
the	O
expression	O
of	O
Egr-1	B
and	O
c	O
-	O
fos	O
mRNA	O
,	O
showing	O
that	O
CsA	O
and	O
FK506	O
affect	O
signal	O
transducers	O
differently	O
from	O
or	O
downstream	O
to	O
these	O
molecules	O
.	O
The	O
difference	O
in	O
signals	O
transduced	O
through	O
sIgM	B
and	O
sIgD	B
in	O
B104	O
cells	O
is	O
discussed	O
.	O
G	O
(	O
Anh	O
)	O
MTetra	O
,	O
a	O
natural	O
bacterial	O
cell	O
wall	O
breakdown	O
product	O
,	O
induces	O
interleukin-1	B
beta	I
and	O
interleukin-6	B
expression	O
in	O
human	O
monocytes	O
.	O
A	O
study	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
inflammatory	B
cytokine	I
expression	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1994	O
Jun	O
17	O
;	O
269	O
(	O
24	O
)	O
:	O
16983	O
]	O
It	O
is	O
believed	O
that	O
induction	O
of	O
cytokine	B
expression	O
by	O
bacterial	O
cell	O
wall	O
components	O
plays	O
a	O
role	O
in	O
the	O
development	O
and	O
course	O
of	O
sepsis	O
.	O
However	O
,	O
most	O
attention	O
has	O
been	O
focused	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
We	O
studied	O
the	O
ability	O
of	O
N	O
-	O
acetylglucosaminyl-1	O
,	O
6-anhydro	O
-	O
N	O
-	O
acetylmuramyl	O
-	O
L	O
-	O
alanyl	O
-	O
D-	O
isoglutamyl	O
-	O
m	O
-	O
diaminopimelyl	O
-	O
D	O
-	O
alanine	O
(	O
G	O
(	O
Anh	O
)	O
MTetra	O
)	O
,	O
a	O
naturally	O
occurring	O
breakdown	O
product	O
of	O
peptidoglycan	O
that	O
is	O
produced	O
by	O
soluble	O
lytic	B
transglycosylase	I
of	O
Escherichia	O
coli	O
,	O
to	O
induce	O
cytokine	B
expression	O
in	O
human	O
monocytes	O
.	O
G	O
(	O
Anh	O
)	O
MTetra	O
was	O
found	O
to	O
strongly	O
induce	O
interleukin	B
(	I
IL	I
)	I
-1	I
beta	I
and	O
IL-6	O
mRNA	O
expression	O
after	O
2	O
h	O
and	O
IL-1	B
beta	I
and	O
IL-6	B
protein	I
secretion	O
after	O
48	O
h	O
of	O
activation	O
.	O
The	O
increase	O
in	O
mRNA	O
accumulation	O
was	O
at	O
least	O
partly	O
due	O
to	O
an	O
increase	O
in	O
the	O
transcription	O
rates	O
of	O
the	O
respective	O
genes	O
and	O
was	O
accompanied	O
by	O
a	O
strong	O
induction	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
and	O
activator	O
protein-1	O
transcription	O
factor	O
expression	O
.	O
Experiments	O
using	O
inhibitors	O
of	O
protein	B
kinase	I
C	I
,	O
protein	B
kinase	I
A	I
,	O
and	O
tyrosine	O
kinase	O
-	O
dependent	O
pathways	O
revealed	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL-1	B
beta	I
and	O
IL-6	O
mRNA	O
expression	O
involves	O
activation	O
of	O
an	O
H7-inhibitable	O
pathway	O
.	O
By	O
using	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
,	O
it	O
was	O
shown	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL-6	O
mRNA	O
expression	O
depends	O
on	O
the	O
synthesis	O
of	O
new	O
protein	O
,	O
whereas	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL-1	B
beta	I
mRNA	O
accumulation	O
does	O
not	O
.	O
When	O
responses	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
were	O
compared	O
with	O
those	O
to	O
LPS	O
and	O
muramyldipeptide	O
(	O
MDP	O
)	O
,	O
it	O
was	O
found	O
that	O
the	O
optimal	O
response	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
induction	O
was	O
similar	O
to	O
that	O
of	O
LPS	O
but	O
significantly	O
higher	O
than	O
the	O
response	O
to	O
MDP	O
.	O
Furthermore	O
,	O
maximal	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL-1	B
beta	I
and	O
IL-6	O
mRNA	O
expression	O
could	O
be	O
enhanced	O
by	O
co	O
-	O
stimulation	O
with	O
LPS	O
or	O
MDP	O
,	O
suggesting	O
that	O
different	O
receptors	O
and/or	O
transduction	O
pathways	O
were	O
involved	O
.	O
These	O
results	O
indicate	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
induces	O
IL-1	B
beta	I
and	O
IL-6	B
expression	O
in	O
human	O
monocytes	O
suggesting	O
a	O
possible	O
role	O
for	O
G	O
(	O
Anh	O
)	O
MTetra	O
in	O
the	O
release	O
of	O
cytokines	B
during	O
sepsis	O
.	O
Characterization	O
of	O
NF	B
(	I
P	I
)	I
,	O
the	O
nuclear	B
factor	I
that	O
interacts	O
with	O
the	O
regulatory	O
P	O
sequence	O
(	O
5'-CGAAAATTTCC-3	O
'	O
)	O
of	O
the	O
human	O
interleukin-4	O
gene	O
:	O
relationship	O
to	O
NF	B
-	I
kappa	I
B	I
and	O
NF	B
-	I
AT	I
.	O
The	O
P	O
sequence	O
of	O
the	O
human	O
interleukin-4	O
(	O
IL-4	O
)	O
gene	O
,	O
which	O
was	O
defined	O
as	O
a	O
responsive	O
element	O
for	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
Jurkat	O
T	O
cells	O
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
the	O
NF	O
-	O
AT	O
binding	O
sites	O
.	O
We	O
examined	O
whether	O
NF	B
(	I
P	I
)	I
,	O
a	O
nuclear	B
factor	I
specific	O
for	O
the	O
P	O
sequence	O
,	O
is	O
related	O
to	O
NF	B
-	I
kappa	I
B	I
and	O
NF	B
-	I
AT	I
.	O
NF	B
-	I
kappa	I
B	I
(	O
P65	B
or	O
P65	B
/	I
P50	I
heterodimer	I
)	O
bound	O
to	O
the	O
P	O
sequence	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
and	O
activated	O
transcription	O
through	O
the	O
P	O
sequence	O
when	O
expression	O
plasmids	O
were	O
cotransfected	O
with	O
P	O
sequence	O
-	O
driven	O
reporter	O
plasmids	O
in	O
Jurkat	O
T	O
cells	O
.	O
In	O
EMSAs	O
,	O
NF	B
(	I
P	I
)	I
binding	O
was	O
inhibited	O
by	O
the	O
unlabeled	O
NF	O
-	O
AT	O
binding	O
site	O
but	O
not	O
by	O
the	O
unlabeled	O
AP1	O
binding	O
site	O
and	O
purified	B
NF	I
-	I
AT	I
contained	O
an	O
activity	O
that	O
bound	O
to	O
the	O
P	O
sequence	O
.	O
Both	O
mobility	O
shift	O
and	O
sequence	O
specificity	O
of	O
NF	B
-	I
AT	I
were	O
similar	O
to	O
those	O
of	O
NF	B
(	I
P	I
)	I
and	O
only	O
a	O
small	O
amount	O
of	O
P65	B
was	O
detected	O
in	O
NF	B
(	I
P	I
)	I
in	O
crude	O
nuclear	O
extracts	O
.	O
These	O
results	O
indicate	O
that	O
the	O
component	O
(	O
s	O
)	O
of	O
NF	B
-	I
AT	I
has	O
the	O
potential	O
to	O
reconstitute	O
NF	B
(	I
P	I
)	I
whereas	O
NF	B
-	I
kappa	I
B	I
alone	O
can	O
not	O
account	O
for	O
NF	B
(	I
P	I
)	I
in	O
crude	O
extracts	O
.	O
Unlike	O
NF	B
-	I
AT	I
,	O
NF	B
(	I
P	I
)	I
does	O
not	O
contain	O
AP1	B
as	O
its	O
DNA	B
binding	I
component	I
.	O
Hypoxia	O
causes	O
the	O
activation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
through	O
the	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
on	O
tyrosine	O
residues	O
.	O
The	O
response	O
of	O
mammalian	O
cells	O
to	O
stress	O
is	O
controlled	O
by	O
transcriptional	B
regulatory	I
proteins	I
such	O
as	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
to	O
induce	O
a	O
wide	O
variety	O
of	O
early	O
response	O
genes	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
exposure	O
of	O
cells	O
to	O
hypoxia	O
(	O
0.02	O
%	O
O2	O
)	O
results	O
in	O
I	B
kappa	I
B	I
alpha	I
degradation	O
,	O
increased	O
NF	B
-	I
kappa	I
B	I
DNA	O
binding	O
activity	O
,	O
and	O
transactivation	O
of	O
a	O
reporter	O
gene	O
construct	O
containing	O
two	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
sites	O
.	O
Pretreatment	O
of	O
cells	O
with	O
protein	O
tyrosine	B
kinase	I
inhibitors	O
and	O
the	O
dominant	O
negative	O
allele	O
of	O
c	O
-	O
Raf-1	O
(	O
Raf	B
301	I
)	O
inhibited	O
I	B
kappa	I
B	I
alpha	I
degradation	O
,	O
NF	B
-	I
kappa	I
B	I
binding	O
,	O
and	O
transactivation	O
of	O
kappa	O
B	O
reporter	O
constructs	O
by	O
hypoxia	O
.	O
To	O
demonstrate	O
a	O
direct	O
link	O
between	O
changes	O
in	O
the	O
phosphorylation	O
pattern	O
of	O
I	B
kappa	I
B	I
alpha	I
with	O
NF	B
-	I
kappa	I
B	I
activation	O
,	O
we	O
immunoprecipitated	O
I	B
kappa	I
B	I
alpha	I
after	O
varying	O
times	O
of	O
hypoxic	O
exposure	O
and	O
found	O
that	O
its	O
tyrosine	O
phosphorylation	O
status	O
increased	O
during	O
hypoxic	O
exposure	O
.	O
Inhibition	O
of	O
the	O
transfer	O
of	O
tyrosine	O
phosphoryl	O
groups	O
onto	O
I	B
kappa	I
B	I
alpha	I
prevented	O
I	B
kappa	I
B	I
alpha	I
degradation	O
and	O
NF	B
-	I
kappa	I
B	I
binding	O
.	O
In	O
comparison	O
to	O
other	O
activators	O
of	O
NF	B
-	I
kappa	I
B	I
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
tumor	B
necrosis	I
factor	I
,	O
we	O
did	O
not	O
detect	O
changes	O
in	O
the	O
tyrosine	O
phosphorylation	O
status	O
of	O
I	B
kappa	I
B	I
alpha	I
following	O
treatment	O
with	O
either	O
of	O
these	O
agents	O
.	O
These	O
results	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
during	O
hypoxia	O
is	O
an	O
important	O
proximal	O
step	O
which	O
precedes	O
its	O
dissociation	O
and	O
degradation	O
from	O
NF	B
-	I
kappa	I
B	I
.	O
Androgen	B
binding	I
sites	I
in	O
peripheral	O
human	O
mononuclear	O
leukocytes	O
of	O
healthy	O
males	O
and	O
females	O
.	O
Androgen	B
binding	I
sites	I
have	O
been	O
identified	O
in	O
circulating	O
human	O
mononuclear	O
leukocytes	O
of	O
healthy	O
donors	O
of	O
both	O
sexes	O
.	O
Cells	O
were	O
separated	O
from	O
blood	O
samples	O
on	O
a	O
Ficoll	O
gradient	O
and	O
incubated	O
with	O
different	O
concentrations	O
of	O
[	O
3H	O
]	O
testosterone	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
400-fold	O
excess	O
of	O
unlabelled	O
testosterone	O
.	O
Binding	O
data	O
were	O
derived	O
from	O
Scatchard	O
analysis	O
.	O
The	O
binding	B
sites	I
fulfil	O
the	O
required	O
criteria	O
for	O
specific	O
steroid	B
binding	I
sites	I
however	O
differ	O
somewhat	O
from	O
the	O
classic	O
androgen	B
receptors	I
from	O
genital	O
skin	O
fibroblast	O
:	O
in	O
fertile	O
adult	O
males	O
(	O
n	O
=	O
20	O
)	O
the	O
binding	B
sites	I
showed	O
(	O
1	O
)	O
a	O
high	O
affinity	O
for	O
testosterone	O
(	O
1.32	O
+	O
/-	O
0.49	O
nM	O
;	O
mean	O
+	O
/-	O
SD	O
)	O
,	O
(	O
2	O
)	O
a	O
saturable	O
capacity	O
(	O
184	O
+	O
/-	O
52	O
binding	B
sites	I
per	O
cell	O
;	O
mean	O
+	O
/-	O
SD	O
)	O
,	O
and	O
(	O
3	O
)	O
a	O
characteristic	O
competitive	O
binding	O
profile	O
for	O
other	O
steroid	O
hormones	O
(	O
relative	O
binding	O
affinities	O
:	O
testosterone	O
=	O
dihydrotestosterone	O
>	O
17	O
beta	O
-	O
estradiol	O
>	O
progesterone	O
,	O
whereas	O
aldosterone	O
,	O
17-hydroxy	O
-	O
progesterone	O
and	O
cortisol	O
did	O
not	O
compete	O
appreciably	O
)	O
.	O
Furthermore	O
the	O
number	O
of	O
binding	B
sites	I
determined	O
using	O
[	O
3H	O
]	O
dihydrotestosterone	O
,	O
[	O
3H	O
]	O
RU-1881	O
,	O
or	O
[	O
3H	O
]	O
testosterone	O
were	O
comparable	O
.	O
This	O
raises	O
the	O
possibility	O
that	O
androgen	B
receptors	I
in	O
peripheral	O
mononuclear	O
leukocytes	O
differ	O
from	O
those	O
in	O
genital	O
skin	O
fibroblasts	O
.	O
There	O
was	O
no	O
apparent	O
correlation	O
between	O
serum	O
testosterone	O
concentrations	O
and	O
androgen	B
binding	I
sites	I
.	O
In	O
fertile	O
women	O
remarkable	O
changes	O
in	O
androgen	B
binding	I
sites	I
were	O
seen	O
in	O
the	O
course	O
of	O
the	O
menstrual	O
cycle	O
,	O
with	O
a	O
significant	O
increase	O
in	O
the	O
immediate	O
preovulatory	O
period	O
.	O
The	O
presence	O
of	O
androgen	B
receptors	I
in	O
peripheral	O
mononuclear	O
leukocytes	O
provides	O
for	O
the	O
first	O
time	O
the	O
experimental	O
basis	O
for	O
an	O
hypothesis	O
of	O
direct	O
,	O
receptor	O
-	O
mediated	O
effects	O
of	O
androgens	O
on	O
mature	O
immunocompetent	O
cells	O
.	O
The	O
immunological	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
.	O
Comparative	O
mapping	O
of	O
SRY	O
in	O
the	O
great	O
apes	O
.	O
Cytogenetic	O
studies	O
of	O
the	O
primate	O
Y	O
chromosomes	O
have	O
suggested	O
that	O
extensive	O
rearrangements	O
have	O
occurred	O
during	O
evolution	O
of	O
the	O
great	O
apes	O
.	O
We	O
have	O
used	O
in	O
situ	O
hybridization	O
to	O
define	O
these	O
rearrangements	O
at	O
the	O
molecular	O
level	O
.	O
pHU-14	O
,	O
a	O
probe	O
including	O
sequences	O
from	O
the	O
sex	O
determining	O
gene	O
SRY	O
,	O
hybridizes	O
close	O
to	O
the	O
early	O
replicating	O
pseudoautosomal	O
segment	O
in	O
a	O
telomeric	O
or	O
subtelomeric	O
position	O
of	O
the	O
Y	O
chromosomes	O
of	O
all	O
great	O
apes	O
.	O
The	O
low	O
copy	O
repeat	O
detected	O
by	O
the	O
probe	O
Fr35-II	O
is	O
obviously	O
included	O
in	O
Y	O
chromosomal	O
rearrangements	O
during	O
hominid	O
evolution	O
.	O
These	O
results	O
,	O
combined	O
with	O
previous	O
studies	O
,	O
suggest	O
that	O
the	O
Y	O
chromosome	O
in	O
great	O
apes	O
has	O
a	O
conserved	O
region	O
including	O
the	O
pseudoautosomal	O
region	O
and	O
the	O
testis	O
-	O
determining	O
region	O
.	O
The	O
rest	O
of	O
the	O
Y	O
chromosome	O
has	O
undergone	O
several	O
rearrangements	O
in	O
the	O
different	O
great	O
apes	O
.	O
Activation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
in	O
human	O
neuroblastoma	O
cell	O
lines	O
.	O
The	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
is	O
a	O
eukaryotic	O
transcription	B
factor	I
.	O
In	O
B	O
cells	O
and	O
macrophages	O
it	O
is	O
constitutively	O
present	O
in	O
cell	O
nuclei	O
,	O
whereas	O
in	O
many	O
other	O
cell	O
types	O
,	O
NF	B
-	I
kappa	I
B	I
translocates	O
from	O
cytosol	O
to	O
nucleus	O
as	O
a	O
result	O
of	O
transduction	O
by	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
alpha	I
)	O
,	O
phorbol	O
ester	O
,	O
and	O
other	O
polyclonal	O
signals	O
.	O
Using	O
neuroblastoma	O
cell	O
lines	O
as	O
models	O
,	O
we	O
have	O
shown	O
that	O
in	O
neural	O
cells	O
NF	B
-	I
kappa	I
B	I
was	O
present	O
in	O
the	O
cytosol	O
and	O
translocated	O
into	O
nuclei	O
as	O
a	O
result	O
of	O
TNF	B
alpha	I
treatment	O
.	O
The	O
TNF	B
alpha	I
-activated	O
NF	B
-	I
kappa	I
B	I
was	O
transcriptionally	O
functional	O
.	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
TNF	B
alpha	I
was	O
not	O
correlated	O
with	O
cell	O
differentiation	O
or	O
proliferation	O
.	O
However	O
,	O
reagents	O
such	O
as	O
nerve	B
growth	I
factor	I
(	O
NGF	B
)	O
and	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
which	O
induce	O
phenotypical	O
differentiation	O
of	O
the	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cell	O
line	O
,	O
activated	O
NF	B
-	I
kappa	I
B	I
,	O
but	O
only	O
in	O
that	O
particular	O
cell	O
line	O
.	O
In	O
a	O
NGF	O
-	O
responsive	O
rat	O
pheochromocytoma	O
cell	O
line	O
,	O
PC12	O
,	O
PMA	O
activated	O
NF	B
-	I
kappa	I
B	I
,	O
whereas	O
NGF	B
did	O
not	O
.	O
In	O
other	O
neuroblastoma	O
cell	O
lines	O
,	O
such	O
as	O
SK	O
-	O
N	O
-	O
Be	O
(	O
2	O
)	O
,	O
the	O
lack	O
of	O
PMA	O
induction	O
of	O
differentiation	O
was	O
correlated	O
with	O
the	O
lack	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
We	O
found	O
,	O
moreover	O
,	O
that	O
in	O
SK	O
-	O
N	O
-	O
Be	O
(	O
2	O
)	O
cells	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
enzymatic	O
activity	O
was	O
much	O
lower	O
compared	O
with	O
that	O
in	O
a	O
control	O
cell	O
line	O
and	O
that	O
the	O
low	O
PKC	B
enzymatic	O
activity	O
was	O
due	O
to	O
low	O
PKC	B
protein	O
expression	O
.	O
NF	B
-	I
kappa	I
B	I
was	O
not	O
activated	O
by	O
retinoic	O
acid	O
,	O
which	O
induced	O
morphological	O
differentiation	O
of	O
all	O
the	O
neuroblastoma	O
cell	O
lines	O
used	O
in	O
the	O
present	O
study	O
.	O
Thus	O
,	O
NF	B
-	I
kappa	I
B	I
activation	O
was	O
not	O
required	O
for	O
neuroblastoma	O
cell	O
differentiation	O
.	O
Furthermore	O
,	O
the	O
results	O
obtained	O
with	O
TNF	B
alpha	I
proved	O
that	O
NF	B
-	I
kappa	I
B	I
activation	O
was	O
not	O
sufficient	O
for	O
induction	O
of	O
neuroblastoma	O
differentiation	O
.	O
Function	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
binding	O
sites	O
in	O
the	O
major	O
histocompatibility	O
complex	O
class	O
II	O
invariant	O
chain	O
promoter	O
is	O
dependent	O
on	O
cell	O
-	O
specific	O
binding	O
of	O
different	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
subunits	I
.	O
The	O
promoter	O
of	O
the	O
human	O
major	O
histocompatibility	O
complex	O
class	O
II	O
-	O
associated	O
invariant	O
-	O
chain	O
gene	O
(	O
Ii	O
)	O
contains	O
two	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
binding	O
sites	O
located	O
at	O
-109	O
to	O
-118	O
(	O
Ii	O
kappa	O
B-1	O
)	O
and	O
-163	O
to	O
-172	O
(	O
Ii	O
kappa	O
B-2	O
)	O
from	O
the	O
transcription	O
start	O
site	O
.	O
We	O
report	O
here	O
that	O
the	O
differential	O
function	O
of	O
each	O
of	O
these	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
sites	O
in	O
several	O
distinct	O
cell	O
types	O
depends	O
on	O
cell	O
-	O
specific	O
binding	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
transcription	I
factors	I
.	O
Ii	O
kappa	O
B-1	O
is	O
a	O
positive	O
regulatory	O
element	O
in	O
B	O
-	O
cell	O
lines	O
and	O
in	O
the	O
Ii	O
-	O
expressing	O
T	O
-	O
cell	O
line	O
,	O
H9	O
,	O
but	O
acts	O
as	O
a	O
negative	O
regulatory	O
element	O
in	O
myelomonocytic	O
and	O
glia	O
cell	O
lines	O
.	O
In	O
vivo	O
protein	O
-	O
DNA	O
contacts	O
are	O
detectable	O
at	O
Ii	O
kappa	O
B-1	O
in	O
cell	O
lines	O
in	O
which	O
this	O
site	O
is	O
functional	O
as	O
either	O
a	O
positive	O
or	O
negative	O
regulator	O
.	O
Electrophoretic	O
mobility	O
supershift	O
assays	O
determine	O
that	O
members	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
family	I
of	O
transcription	B
factors	I
can	O
bind	O
to	O
this	O
site	O
in	O
vitro	O
and	O
that	O
DNA	B
-	I
binding	I
complexes	I
that	O
contain	O
p50	B
,	O
p52	B
,	O
p65	B
,	O
and	O
cRel	B
correlate	O
with	O
positive	O
regulation	O
whereas	O
the	O
presence	O
of	O
p50	B
correlates	O
with	O
negative	O
regulation	O
.	O
Ii	O
kappa	O
B-2	O
is	O
a	O
site	O
of	O
positive	O
regulation	O
in	O
B	O
-	O
cell	O
lines	O
and	O
a	O
site	O
of	O
negative	O
regulation	O
in	O
H9	O
T	O
cells	O
,	O
myelomonocytic	O
,	O
and	O
glial	O
cell	O
lines	O
.	O
In	O
vivo	O
occupancy	O
of	O
this	O
site	O
is	O
observed	O
only	O
in	O
the	O
H9	O
T	O
-	O
cell	O
line	O
.	O
Again	O
,	O
in	O
vitro	O
supershift	O
studies	O
indicate	O
that	O
the	O
presence	O
of	O
p50	B
,	O
p52	B
,	O
p65	B
,	O
and	O
cRel	B
correlates	O
with	O
positive	O
function	O
whereas	O
the	O
presence	O
of	O
only	O
p50	B
and	O
p52	B
correlates	O
with	O
negative	O
function	O
.	O
This	O
differential	O
binding	O
of	O
specific	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
subunits	I
is	O
likely	O
to	O
mediate	O
the	O
disparate	O
functions	O
of	O
these	O
two	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
binding	O
sites	O
.	O
Positive	O
regulators	O
of	O
the	O
lineage	O
-	O
specific	O
transcription	B
factor	I
GATA-1	B
in	O
differentiating	O
erythroid	O
cells	O
.	O
The	O
zinc	B
finger	I
transcription	I
factor	I
GATA-1	B
is	O
a	O
major	O
regulator	O
of	O
gene	O
expression	O
in	O
erythroid	O
,	O
megakaryocyte	O
,	O
and	O
mast	O
cell	O
lineages	O
.	O
GATA-1	B
binds	O
to	O
WGATAR	O
consensus	O
motifs	O
in	O
the	O
regulatory	O
regions	O
of	O
virtually	O
all	O
erythroid	O
cell	O
-	O
specific	O
genes	O
.	O
Analyses	O
with	O
cultured	O
cells	O
and	O
cell	O
-	O
free	O
systems	O
have	O
provided	O
strong	O
evidence	O
that	O
GATA-1	B
is	O
involved	O
in	O
control	O
of	O
globin	O
gene	O
expression	O
during	O
erythroid	O
differentiation	O
.	O
Targeted	O
mutagenesis	O
of	O
the	O
GATA-1	O
gene	O
in	O
embryonic	O
stem	O
cells	O
has	O
demonstrated	O
its	O
requirement	O
in	O
normal	O
erythroid	O
development	O
.	O
Efficient	O
rescue	O
of	O
the	O
defect	O
requires	O
an	O
intact	O
GATA	O
element	O
in	O
the	O
distal	O
promoter	O
,	O
suggesting	O
autoregulatory	O
control	O
of	O
GATA-1	B
transcription	O
.	O
To	O
examine	O
whether	O
GATA-1	B
expression	O
involves	O
additional	O
regulatory	B
factors	I
or	O
is	O
maintained	O
entirely	O
by	O
an	O
autoregulatory	O
loop	O
,	O
we	O
have	O
used	O
a	O
transient	O
heterokaryon	O
system	O
to	O
test	O
the	O
ability	O
of	O
erythroid	B
factors	I
to	O
activate	O
the	O
GATA-1	O
gene	O
in	O
nonerythroid	O
nuclei	O
.	O
We	O
show	O
here	O
that	O
proerythroblasts	O
and	O
mature	O
erythroid	O
cells	O
contain	O
a	O
diffusible	O
activity	O
(	O
TAG	O
)	O
capable	O
of	O
transcriptional	O
activation	O
of	O
GATA-1	B
and	O
that	O
this	O
activity	O
decreases	O
during	O
the	O
terminal	O
differentiation	O
of	O
erythroid	O
cells	O
.	O
Nuclei	O
from	O
GATA-1	O
-mutant	O
embryonic	O
stem	O
cells	O
can	O
still	O
be	O
reprogrammed	O
to	O
express	O
their	O
globin	O
genes	O
in	O
erythroid	O
heterokaryons	O
,	O
indicating	O
that	O
de	O
novo	O
induction	O
of	O
GATA-1	B
is	O
not	O
required	O
for	O
globin	O
gene	O
activation	O
following	O
cell	O
fusion	O
.	O
Effects	O
of	O
alpha	O
-	O
lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
on	O
expression	O
of	O
proto	O
-	O
oncogene	O
c	O
-	O
fos	O
.	O
The	O
transcription	B
factor	I
AP-1	B
is	O
an	O
important	O
human	O
mediator	O
of	O
the	O
cellular	O
response	O
to	O
serum	O
,	O
growth	B
factors	I
,	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O	O
-	O
tetradecanoyl	O
-	O
phorbol-13	O
acetate	O
(	O
TPA	O
)	O
.	O
The	O
AP-1	B
complex	O
consists	O
of	O
distinct	O
protein	B
heterodimers	I
encoded	O
by	O
the	O
proto	O
-	O
oncogene	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
whose	O
gene	O
expression	O
can	O
be	O
induced	O
by	O
TPA	O
,	O
cyclic	O
AMP	O
and	O
growth	B
factors	I
.	O
Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
in	O
the	O
pathway	O
of	O
TPA	O
and	O
protein	B
kinase	I
C	I
leading	O
to	O
expression	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
.	O
To	O
investigate	O
the	O
role	O
of	O
reactive	O
oxygen	O
species	O
we	O
studied	O
the	O
effects	O
of	O
alpha	O
-	O
lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
(	O
natural	O
thiol	O
antioxidants	O
)	O
on	O
the	O
expression	O
of	O
c	O
-	O
fos	O
mRNA	O
in	O
human	O
Jurkat	O
T	O
cells	O
.	O
When	O
cells	O
were	O
preincubated	O
with	O
dihydrolipoic	O
acid	O
(	O
0.2	O
mM	O
)	O
the	O
expression	O
of	O
c	O
-	O
fos	O
mRNA	O
was	O
suppressed	O
at	O
30	O
min	O
after	O
stimulation	O
of	O
TPA	O
(	O
0.5	O
microM	O
)	O
whereas	O
in	O
the	O
case	O
of	O
preincubation	O
of	O
alpha	O
-	O
lipoic	O
acid	O
(	O
0.2	O
microM	O
)	O
,	O
the	O
expression	O
was	O
enhanced	O
at	O
30	O
min	O
.	O
These	O
studies	O
support	O
the	O
idea	O
that	O
superoxide	O
anion	O
radical	O
plays	O
a	O
role	O
in	O
the	O
expression	O
of	O
c	O
-	O
fos	O
mRNA	O
.	O
Activation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
in	O
human	O
lymphoblastoid	O
cells	O
by	O
low	O
-	O
dose	O
ionizing	O
radiation	O
.	O
Nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
is	O
a	O
pleiotropic	B
transcription	I
factor	I
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
several	O
specific	O
genes	O
.	O
Recent	O
reports	O
demonstrated	O
that	O
ionizing	O
radiation	O
in	O
the	O
dose	O
range	O
of	O
2	O
-	O
50	O
Gy	O
results	O
in	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
human	O
KG-1	O
myeloid	O
leukemia	O
cells	O
and	O
human	O
B	O
-	O
lymphocyte	O
precursor	O
cells	O
;	O
the	O
precise	O
mechanism	O
involved	O
and	O
the	O
significance	O
are	O
not	O
yet	O
known	O
.	O
The	O
present	O
report	O
demonstrates	O
that	O
even	O
lower	O
doses	O
of	O
ionizing	O
radiation	O
,	O
0.25	O
-	O
2.0	O
Gy	O
,	O
are	O
capable	O
of	O
inducing	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
EBV	O
-	O
transformed	O
244B	O
human	O
lymphoblastoid	O
cells	O
.	O
These	O
results	O
are	O
in	O
a	O
dose	O
range	O
where	O
the	O
viability	O
of	O
the	O
cells	O
remains	O
very	O
high	O
.	O
After	O
exposure	O
to	O
137Cs	O
gamma	O
rays	O
at	O
a	O
dose	O
rate	O
of	O
1.17	O
Gy	O
/	O
min	O
,	O
a	O
maximum	O
in	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
was	O
seen	O
at	O
8	O
h	O
after	O
a	O
0.5-Gy	O
exposure	O
.	O
Time	O
-	O
course	O
studies	O
revealed	O
a	O
biphasic	O
time	O
-	O
dependent	O
expression	O
after	O
0.5-	O
,	O
1-	O
and	O
2-Gy	O
exposures	O
.	O
However	O
,	O
for	O
each	O
time	O
examined	O
,	O
the	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
was	O
maximum	O
after	O
the	O
0.5-Gy	O
exposure	O
.	O
The	O
expression	O
of	O
the	O
p50	B
and	I
p65	I
NF	I
-	I
kappa	I
B	I
subunits	I
was	O
also	O
shown	O
to	O
be	O
regulated	O
differentially	O
after	O
exposures	O
to	O
1.0	O
and	O
2.0	O
Gy	O
.	O
Calcineurin	B
potentiates	O
activation	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
in	O
T	O
cells	O
:	O
involvement	O
of	O
the	O
conserved	O
lymphokine	O
element	O
0	O
.	O
Granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
and	O
interleukin-2	B
(	O
IL-2	B
)	O
are	O
produced	O
by	O
stimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
human	O
T	O
cell	O
leukemia	O
Jurkat	O
cells	O
.	O
The	O
expression	O
of	O
GM	B
-	I
CSF	I
and	O
IL-2	B
is	O
inhibited	O
by	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O
Earlier	O
studies	O
on	O
the	O
IL-2	B
gene	O
expression	O
showed	O
that	O
overexpression	O
of	O
calcineurin	B
(	O
CN	B
)	O
,	O
a	O
Ca2+	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
phosphatase	I
,	O
can	O
stimulate	O
transcription	O
from	O
the	O
IL-2	O
promoter	O
through	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
.	O
In	O
this	O
study	O
,	O
we	O
obtained	O
evidence	O
that	O
transfection	O
of	O
the	O
cDNAs	O
for	O
CN	B
A	I
(	I
catalytic	I
)	I
and	I
CN	I
B	I
(	I
regulatory	I
)	I
subunits	I
also	O
augments	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
and	O
recovers	O
the	O
transcription	O
inhibited	O
by	O
CsA	O
.	O
The	O
constitutively	O
active	O
type	O
of	O
the	O
CN	B
A	I
subunit	I
,	O
which	O
lacks	O
the	O
auto	B
-	I
inhibitory	I
and	O
calmodulin	B
-	I
binding	I
domains	I
,	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
activate	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
.	O
We	O
also	O
found	O
that	O
the	O
active	O
CN	B
partially	O
replaces	O
calcium	O
ionophore	O
in	O
synergy	O
with	O
PMA	O
to	O
induce	O
expression	O
of	O
endogenous	O
GM	B
-	I
CSF	I
and	O
IL-2	B
.	O
By	O
multimerizing	O
the	O
regulatory	O
elements	O
of	O
the	O
GM	O
-	O
CSF	O
promoter	O
,	O
we	O
found	O
that	O
one	O
of	O
the	O
target	O
sites	O
for	O
the	O
CN	B
action	O
is	O
the	O
conserved	O
lymphokine	O
element	O
0	O
(	O
CLE0	O
)	O
,	O
located	O
at	O
positions	O
between	O
-54	O
and	O
-40	O
.	O
Mobility	O
shift	O
assays	O
showed	O
that	O
the	O
CLE0	O
sequence	O
has	O
an	O
AP1-binding	O
site	O
and	O
is	O
associated	O
with	O
an	O
NF	B
-	I
AT	I
-	I
like	I
factor	I
,	O
termed	O
NF	B
-	I
CLE0	I
gamma	I
.	O
NF-	O
CLE0	O
gamma	O
binding	O
is	O
induced	O
by	O
PMA	O
/	O
A23187	O
and	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O
These	O
results	O
suggest	O
that	O
CN	B
is	O
involved	O
in	O
the	O
coordinated	O
induction	O
of	O
the	O
GM	O
-	O
CSF	O
and	O
IL-2	O
genes	O
and	O
that	O
the	O
CLE0	O
sequence	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
is	O
a	O
functional	O
analogue	O
of	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
in	O
the	O
IL-2	O
promoter	O
,	O
which	O
mediates	O
signals	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O
Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
extracellular	B
matrix	I
protein	I
tenascin	B
.	O
Tenascin	B
(	O
TN	B
)	O
is	O
an	O
extracellular	B
matrix	I
protein	I
that	O
is	O
expressed	O
widely	O
in	O
the	O
fetus	O
and	O
sparingly	O
in	O
the	O
adult	O
,	O
but	O
reappears	O
at	O
high	O
levels	O
in	O
certain	O
areas	O
of	O
tissue	O
insult	O
such	O
as	O
tumor	O
matrices	O
and	O
sites	O
of	O
wound	O
healing	O
.	O
We	O
show	O
here	O
that	O
soluble	O
TN	B
inhibits	O
proliferation	O
of	O
human	O
T	O
cells	O
in	O
response	O
to	O
alpha	B
CD3	I
Ab	I
co	O
-	O
immobilized	O
with	O
the	O
extracellular	B
matrix	I
protein	I
fibronectin	B
(	O
FN	B
)	O
.	O
TN	B
also	O
inhibits	O
proliferation	O
driven	O
by	O
alpha	B
CD3	I
/	I
IL-2	I
or	O
by	O
phorbol	B
ester	I
/	I
IL-2	I
,	I
and	O
it	O
prevents	O
high	O
level	O
induction	O
of	O
IL-2R	B
.	O
The	O
presence	O
of	O
TN	B
in	O
culture	O
medium	O
does	O
not	O
detectably	O
alter	O
the	O
pattern	O
of	O
tyrosine	O
phosphorylation	O
resulting	O
from	O
T	O
cell	O
triggering	O
with	O
alpha	B
CD3	I
,	O
but	O
at	O
later	O
time	O
points	O
prevents	O
the	O
appearance	O
of	O
functional	O
NF	B
-	I
AT1	I
transcription	I
factor	I
complexes	I
in	O
T	O
cell	O
nuclear	O
extracts	O
.	O
These	O
findings	O
are	O
consistent	O
with	O
the	O
postulated	O
role	O
for	O
TN	B
as	O
a	O
natural	O
antagonist	O
to	O
FN	B
action	O
,	O
and	O
suggest	O
that	O
T	O
cell	O
responses	O
occurring	O
at	O
tissue	O
sites	O
in	O
which	O
TN	B
is	O
expressed	O
could	O
be	O
influenced	O
by	O
its	O
presence	O
.	O
Central	O
nervous	O
system	O
-	O
derived	O
cells	O
express	O
a	O
kappa	O
B	O
-	O
binding	O
activity	O
that	O
enhances	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
vitro	O
and	O
facilitates	O
TAR	O
-independent	O
transactivation	O
by	O
Tat	B
.	O
The	O
Tat	B
protein	I
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
a	O
potent	O
activator	O
of	O
long	O
terminal	O
repeat	O
-directed	O
transcription	O
.	O
While	O
in	O
most	O
cell	O
types	O
,	O
activation	O
requires	O
interaction	O
of	O
Tat	O
with	O
the	O
unusual	O
transcription	O
element	O
TAR	O
,	O
astrocytic	O
glial	O
cells	O
support	O
TAR	O
-independent	O
transactivation	O
of	O
HIV-1	O
transcription	O
by	O
Tat	O
.	O
This	O
alternative	O
pathway	O
of	O
Tat	B
activation	O
is	O
mediated	O
by	O
the	O
viral	O
enhancer	O
,	O
a	O
kappa	O
B	O
domain	O
capable	O
of	O
binding	O
the	O
prototypical	O
form	O
of	O
the	O
transcription	B
factor	I
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	B
-	I
kappa	I
B	I
)	O
present	O
in	O
many	O
cell	O
types	O
,	O
including	O
T	O
lymphocytes	O
.	O
Tat	B
transactivation	O
mediated	O
by	O
the	O
kappa	O
B	O
domain	O
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR	O
-deleted	O
mutant	O
HIV-1	O
in	O
astrocytes	O
.	O
The	O
present	O
study	O
demonstrates	O
the	O
existence	O
of	O
kappa	B
B	I
-	I
specific	I
binding	I
factors	I
present	O
in	O
human	O
glial	O
astrocytes	O
that	O
differ	O
from	O
prototypical	O
NF	B
-	I
kappa	I
B	I
.	O
The	O
novel	O
astrocyte	O
-	O
derived	O
kappa	O
B	O
-	O
binding	O
activity	O
is	O
retained	O
on	O
an	O
HIV-1	O
Tat	B
affinity	O
column	O
,	O
while	O
prototypical	O
NF	B
-	I
kappa	I
B	I
from	O
Jurkat	O
T	O
cells	O
is	O
not	O
.	O
In	O
vitro	O
transcription	O
studies	O
demonstrate	O
that	O
astrocyte	B
-	I
derived	I
kappa	I
B	I
-	I
binding	I
factors	I
activate	O
transcription	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
kappa	O
B	O
domain	O
.	O
Moreover	O
,	O
TAR	O
-independent	O
transactivation	O
of	O
HIV-1	O
transcription	O
is	O
reproduced	O
in	O
vitro	O
in	O
an	O
astrocyte	O
factor	O
-	O
dependent	O
manner	O
which	O
correlates	O
with	O
kappa	O
B	O
-	O
binding	O
activity	O
.	O
The	O
importance	O
of	O
the	O
central	B
nervous	I
system	I
-	I
enriched	I
kappa	I
B	I
transcription	B
factor	I
in	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
is	O
discussed	O
.	O
Human	B
interleukin-13	I
activates	O
the	O
interleukin-4-dependent	B
transcription	I
factor	I
NF	B
-	I
IL4	I
sharing	O
a	O
DNA	B
binding	I
motif	I
with	O
an	O
interferon	B
-	I
gamma	I
-	I
induced	I
nuclear	I
binding	I
factor	I
.	O
The	O
effects	O
of	O
interleukin-13	B
(	O
IL-13	B
)	O
and	O
interleukin-4	B
(	O
IL-4	B
)	O
on	O
cellular	O
functions	O
were	O
shown	O
to	O
be	O
quite	O
similar	O
.	O
We	O
provide	O
evidence	O
that	O
in	O
monocytes	O
as	O
well	O
as	O
in	O
T	O
lymphocytes	O
both	O
IL-4	B
and	O
IL-13	B
activate	O
the	O
same	O
recently	O
identified	O
transcription	B
factor	I
NF	B
-	I
IL4	I
which	O
binds	O
to	O
the	O
specific	O
responsive	O
element	O
IL-4RE	O
.	O
In	O
addition	O
,	O
we	O
show	O
that	O
a	O
nuclear	B
factor	I
activated	O
by	O
interferon	O
-	O
gamma	O
also	O
interacts	O
with	O
the	O
IL-4RE	O
.	O
It	O
differs	O
from	O
NF	B
-	I
IL4	I
in	O
the	O
electrophoretic	O
mobility	O
of	O
the	O
complex	O
with	O
DNA	O
,	O
in	O
its	O
DNA	O
-	O
binding	O
specificity	O
and	O
in	O
the	O
proteins	O
interacting	O
with	O
the	O
DNA	O
sequence	O
.	O
Sensitivity	O
against	O
various	O
enzyme	O
inhibitors	O
suggests	O
that	O
components	O
of	O
the	O
signal	O
transduction	O
pathway	O
are	O
shared	O
by	O
all	O
three	O
cytokines	B
.	O
JNK	B
is	O
involved	O
in	O
signal	O
integration	O
during	O
costimulation	O
of	O
T	O
lymphocytes	O
.	O
T	O
lymphocyte	O
activation	O
and	O
interleukin-2	B
(	O
IL-2	B
)	O
production	O
require	O
at	O
least	O
two	O
signals	O
,	O
generated	O
by	O
phorbol	O
ester	O
(	O
TPA	O
)	O
and	O
Ca2	O
+	O
ionophore	O
or	O
costimulation	O
of	O
the	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
and	O
the	O
CD28	B
auxiliary	I
receptor	I
.	O
We	O
investigated	O
how	O
these	O
stimuli	O
affect	O
mitogen	B
activated	I
protein	I
(	I
MAP	I
)	I
kinases	I
.	O
Full	O
activation	O
of	O
the	O
MAP	B
kinases	I
that	O
phosphorylate	O
the	O
Jun	B
activation	I
domain	I
,	O
JNK1	B
and	O
JNK2	B
,	O
required	O
costimulation	O
of	O
T	O
cells	O
with	O
either	O
TPA	O
and	O
Ca2	O
+	O
ionophore	O
or	O
antibodies	O
to	O
TCR	B
and	O
CD28	B
.	O
Alone	O
,	O
each	O
stimulus	O
resulted	O
in	O
little	O
or	O
no	O
activation	O
.	O
Similar	O
to	O
its	O
effect	O
on	O
IL-2	B
induction	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
inhibited	O
the	O
synergistic	O
activation	O
of	O
JNK	B
,	O
and	O
a	O
competitive	O
inhibitor	O
of	O
Jun	B
phosphorylation	O
by	O
JNK	B
inhibited	O
IL-2	O
promoter	O
activation	O
.	O
By	O
contrast	O
,	O
the	O
MAP	B
kinases	I
ERK1	B
and	O
ERK2	B
were	O
fully	O
activated	O
by	O
TPA	O
or	O
TCR	B
stimulation	O
and	O
were	O
not	O
affected	O
by	O
Ca2	O
+	O
,	O
CD28	O
,	O
or	O
CsA	O
.	O
Hence	O
,	O
integration	O
of	O
signals	O
that	O
lead	O
to	O
T	O
cell	O
activation	O
occurs	O
at	O
the	O
level	O
of	O
JNK	B
activation	O
.	O
Glucocorticoid	O
-	O
mediated	O
inhibition	O
of	O
interleukin-2	O
receptor	O
alpha	O
and	O
-beta	O
subunit	O
expression	O
by	O
human	O
T	O
cells	O
.	O
To	O
determine	O
the	O
mechanism	O
of	O
glucocorticoid	O
(	O
GC	O
)	O
-mediated	O
inhibition	O
of	O
T	O
cell	O
functions	O
,	O
the	O
effect	O
of	O
dexamethasone	O
(	O
DM	O
)	O
on	O
T	O
cell	O
proliferation	O
and	O
interleukin-2	B
receptor	I
(	O
IL-2R	B
)	O
generation	O
were	O
studied	O
.	O
Dexamethasone	O
inhibited	O
IL-2	B
-induced	O
T	O
cell	O
proliferation	O
by	O
30	O
%	O
-88	O
%	O
,	O
relative	O
to	O
its	O
concentration	O
within	O
the	O
cultures	O
.	O
The	O
effect	O
of	O
DM	O
on	O
expression	O
of	O
IL-2R	B
alpha	I
(	O
Tac	B
,	O
p55	B
,	O
CD25	B
)	O
and	O
beta	O
(	O
p75	O
)	O
genes	O
in	O
activated	O
T	O
cells	O
was	O
examined	O
next	O
.	O
In	O
T	O
cells	O
stimulated	O
with	O
purified	O
phytohemagglutinin	B
(	O
PHA	B
-	I
p	I
)	O
and	O
4	O
beta	O
-	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
addition	O
of	O
DM	O
to	O
the	O
cultures	O
resulted	O
in	O
a	O
60	O
%	O
reduction	O
in	O
IL-2R	B
alpha	I
and	O
a	O
30	O
%	O
reduction	O
in	O
IL-2R	B
beta	I
membrane	O
expression	O
compared	O
to	O
T	O
cells	O
cultured	O
in	O
the	O
absence	O
of	O
DM	O
(	O
p	O
<	O
0.01	O
)	O
.	O
Inhibition	O
of	O
membrane	O
IL-2R	B
alpha	I
and	O
IL-2R	B
beta	I
expression	O
by	O
10	O
(	O
-6	O
)	O
M	O
DM	O
was	O
partially	O
reversible	O
by	O
recombinant	B
human	I
IL-2	I
(	O
rhIL-2	B
)	O
.	O
By	O
Northern	O
blot	O
analysis	O
,	O
DM	O
caused	O
a	O
comparable	O
decrease	O
in	O
IL-2R	B
alpha	I
and	O
in	O
IL-2R	B
beta	I
mRNA	O
levels	O
to	O
membrane	O
receptor	O
expression	O
in	O
mitogen	O
-	O
stimulated	O
T	O
cells	O
.	O
By	O
in	O
vitro	O
transcription	O
assays	O
,	O
DM	O
regulated	O
IL-2R	B
alpha	I
gene	O
expression	O
at	O
a	O
transcriptional	O
level	O
while	O
transcription	O
of	O
IL-2R	O
beta	O
gene	O
was	O
unaffected	O
by	O
DM	O
.	O
The	O
mechanism	O
of	O
action	O
of	O
DM	O
on	O
IL-2R	B
alpha	I
transcription	O
was	O
examined	O
by	O
determining	O
the	O
mRNA	O
levels	O
of	O
the	O
p50	O
subunit	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	B
-	I
kappa	I
B	I
)	O
,	O
a	O
transcription	B
factor	I
that	O
stimulates	O
IL-2R	B
alpha	I
gene	O
expression	O
.	O
The	O
data	O
indicate	O
that	O
10	O
(	O
-6	O
)	O
M	O
DM	O
increased	O
T	O
cell	O
p50	O
NF	O
-	O
kappa	O
B	O
mRNA	O
levels	O
by	O
four	O
-	O
fold	O
compared	O
to	O
the	O
levels	O
obtained	O
in	O
the	O
absence	O
of	O
DM	O
.	O
Further	O
,	O
the	O
level	O
of	O
nuclear	B
proteins	I
capable	O
of	O
binding	O
to	O
the	O
NF	O
-	O
kappa	O
B	O
sites	O
in	O
activated	O
T	O
cells	O
increased	O
in	O
response	O
to	O
DM	O
.	O
In	O
sum	O
,	O
DM	O
regulates	O
T	O
cell	O
membrane	O
expression	O
of	O
IL-2R	B
by	O
more	O
than	O
one	O
molecular	O
mechanism	O
.	O
Stimulation	O
of	O
HIV	O
replication	O
in	O
mononuclear	O
phagocytes	O
by	O
leukemia	B
inhibitory	I
factor	I
.	O
This	O
study	O
examined	O
the	O
effects	O
of	O
leukemia	B
inhibitory	I
factor	I
(	O
LIF	B
)	O
on	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
replication	O
in	O
mononuclear	O
phagocytes	O
(	O
MNP	O
)	O
.	O
LIF	B
induced	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
p24	B
antigen	I
production	O
in	O
the	O
chronically	O
infected	O
promonocytic	O
cell	O
line	O
U1	O
.	O
The	O
magnitude	O
and	O
time	O
kinetics	O
of	O
the	O
LIF	B
effects	O
were	O
similar	O
to	O
interleukin	B
1	I
(	O
IL-1	B
)	O
,	O
IL-6	B
,	O
and	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
,	O
other	O
cytokines	O
known	O
to	O
induce	O
HIV	O
replication	O
in	O
this	O
cell	O
line	O
.	O
To	O
characterize	O
mechanisms	O
responsible	O
for	O
these	O
LIF	B
effects	O
,	O
levels	O
of	O
HIV	O
mRNA	O
,	O
activation	O
of	O
the	O
DNA	B
binding	I
protein	I
nuclear	I
factor	I
(	B
NF	I
)	I
-kB	I
,	O
signal	O
transduction	O
pathways	O
,	O
and	O
potential	O
interactions	O
with	O
other	O
cytokines	B
were	O
analyzed	O
.	O
LIF	B
increased	O
steady	O
-	O
state	O
levels	O
of	O
HIV	O
mRNA	O
at	O
2.0	O
,	O
4.3	O
,	O
and	O
9.2	O
kB	O
.	O
This	O
was	O
detectable	O
by	O
24	O
h	O
and	O
persisted	O
until	O
72	O
h	O
.	O
The	O
DNA	B
binding	I
protein	I
NF	I
-	I
kB	I
is	O
a	O
central	O
mediator	O
in	O
cytokine	B
activation	O
of	O
HIV	O
transcription	O
.	O
NF	B
-	I
kB	I
levels	O
were	O
higher	O
in	O
unstimulated	O
U1	O
cells	O
as	O
compared	O
to	O
the	O
parent	O
cell	O
line	O
U937	O
.	O
In	O
both	O
cell	O
lines	O
LIF	B
increased	O
NF	B
-	I
kB	I
activity	O
.	O
Induction	O
of	O
NF	B
-	I
kB	I
and	O
HIV	O
replication	O
by	O
cytokines	B
are	O
at	O
least	O
in	O
part	O
dependent	O
on	O
reactive	O
oxygen	O
intermediates	O
.	O
The	O
oxygen	O
radical	O
scavenger	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
,	O
but	O
not	O
an	O
inhibitor	O
of	O
nitric	B
oxide	I
synthase	I
,	O
inhibited	O
LIF	B
-induced	O
HIV	O
replication	O
.	O
LIF	B
induces	O
the	O
production	O
of	O
other	O
cytokines	B
in	O
monocytes	O
but	O
its	O
effects	O
on	O
HIV	O
replication	O
were	O
not	O
inhibited	O
by	O
antibodies	B
to	O
IL-1	B
,	O
TNF	B
,	O
or	O
IL-6	B
.	O
These	O
results	O
identify	O
LIF	B
as	O
a	O
stimulus	O
of	O
HIV	O
replication	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Human	B
immunodeficiency	I
virus	I
type	I
1	I
Tat	I
upregulates	O
interleukin-2	B
secretion	O
in	O
activated	O
T	O
cells	O
.	O
Dysregulation	O
of	O
cytokines	B
secreted	O
by	O
T	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O
To	O
investigate	O
the	O
effects	O
of	O
human	B
immunodeficiency	I
virus	I
type	I
1	I
(	I
HIV-1	I
)	I
Tat	I
on	O
interleukin-2	B
(	O
IL-2	B
)	O
expression	O
,	O
we	O
used	O
IL-2	O
promoter	O
-	O
chloramphenicol	O
acetyltransferase	O
constructs	O
and	O
IL-2-secreting	O
Jurkat	O
T	O
cells	O
as	O
a	O
model	O
system	O
.	O
Transient	O
expression	O
of	O
HIV-1	B
Tat	I
induced	O
a	O
five-	O
to	O
eightfold	O
increase	O
in	O
IL-2	O
promoter	O
activity	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
phytohemagglutinin	B
and	O
phorbol	O
myristate	O
acetate	O
.	O
IL-2	B
secretion	O
was	O
increased	O
more	O
than	O
twofold	O
in	O
both	O
Jurkat	O
T	O
cells	O
and	O
primary	O
T	O
cells	O
stimulated	O
by	O
extracellular	B
HIV-1	I
Tat	I
protein	I
.	O
Analysis	O
of	O
mRNA	O
suggested	O
that	O
Tat	O
exerts	O
its	O
effect	O
on	O
IL-2	B
primarily	O
at	O
the	O
transcriptional	O
level	O
.	O
The	O
NF	O
-	O
kappa	O
B	O
site	O
at	O
positions	O
-206	O
to	O
-195	O
of	O
the	O
IL-2	O
promoter	O
was	O
required	O
but	O
not	O
sufficient	O
for	O
the	O
Tat	B
effect	O
.	O
The	O
Tat	B
-mediated	O
increase	O
in	O
IL-2	O
promoter	O
activity	O
could	O
selectively	O
be	O
blocked	O
by	O
antisense	O
tat	O
or	O
-	O
unlike	O
the	O
analogous	O
effect	O
of	O
human	B
T	I
-	I
cell	I
lymphotropic	I
virus	I
type	I
1	I
Tax	I
-by	O
cyclosporin	O
A	O
.	O
The	O
observed	O
increase	O
in	O
IL-2	B
levels	O
might	O
facilitate	O
virus	O
spread	O
from	O
or	O
to	O
T	O
cells	O
.	O
Furthermore	O
,	O
it	O
might	O
contribute	O
to	O
the	O
hypergammaglobulinemia	O
or	O
,	O
together	O
with	O
other	O
cytokines	B
found	O
to	O
be	O
dysregulated	O
,	O
the	O
T	O
-	O
helper	O
cell	O
dysfunctions	O
observed	O
in	O
AIDS	O
patients	O
.	O
Gene	O
for	O
a	O
tissue	B
-	I
specific	I
transcriptional	I
activator	I
(	O
EBF	B
or	O
Olf-1	B
)	O
,	O
expressed	O
in	O
early	O
B	O
lymphocytes	O
,	O
adipocytes	O
,	O
and	O
olfactory	O
neurons	O
,	O
is	O
located	O
on	O
human	O
chromosome	O
5	O
,	O
band	O
q34	O
,	O
and	O
proximal	O
mouse	O
chromosome	O
11	O
.	O
Murine	O
B	O
lymphocytes	O
,	O
adipocytes	O
,	O
and	O
olfactory	O
neurons	O
contain	O
a	O
DNA	B
-	I
binding	I
protein	I
that	O
participates	O
in	O
the	O
regulation	O
of	O
genes	O
encoding	O
tissue	O
-	O
specific	O
components	O
of	O
signal	O
transduction	O
.	O
Purification	O
and	O
cloning	O
of	O
this	O
protein	O
,	O
termed	O
early	O
B	B
-	I
cell	I
factor	I
(	O
EBF	B
)	O
,	O
from	O
murine	O
B	O
lymphocytes	O
and	O
independent	O
cloning	O
of	O
a	O
protein	O
,	O
termed	O
Olf-1	B
,	O
from	O
olfactory	O
neuronal	O
cells	O
revealed	O
virtual	O
complete	O
amino	O
acid	O
sequence	O
identity	O
between	O
these	O
proteins	O
.	O
As	O
a	O
first	O
step	O
towards	O
identifying	O
a	O
human	O
genetic	O
disorder	O
or	O
mouse	O
mutation	O
for	O
which	O
EBF	B
could	O
be	O
a	O
candidate	O
gene	O
,	O
we	O
have	O
chromosomally	O
mapped	O
the	O
corresponding	O
locus	O
in	O
both	O
species	O
.	O
By	O
Southern	O
hybridization	O
analyses	O
of	O
somatic	O
cell	O
hybrid	O
panels	O
with	O
murine	O
cDNA	O
probe	O
,	O
fluorescence	O
chromosomal	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
of	O
human	O
genomic	O
clones	O
,	O
and	O
analysis	O
of	O
recombinant	O
inbred	O
mouse	O
strains	O
,	O
we	O
have	O
found	O
single	O
sites	O
for	O
EBF	O
homologous	O
sequences	O
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
5	O
,	O
band	O
q34	O
,	O
and	O
on	O
proximal	O
mouse	O
Chr	O
11	O
,	O
in	O
an	O
evolutionarily	O
conserved	O
region	O
.	O
Effects	O
of	O
prostaglandin	B
E2	I
on	O
Th0-type	O
human	O
T	O
cell	O
clones	O
:	O
modulation	O
of	O
functions	O
of	O
nuclear	B
proteins	I
involved	O
in	O
cytokine	B
production	O
.	O
The	O
effects	O
of	O
prostaglandin	B
E2	I
(	O
PGE2	B
)	O
on	O
cytokine	B
production	O
and	O
proliferation	O
of	O
the	O
CD4	O
+	O
human	O
helper	O
T	O
cell	O
clone	O
SP	O
-	O
B21	O
were	O
investigated	O
.	O
In	O
cells	O
stimulated	O
with	O
anti	B
-	I
CD3	I
mAb	I
,	O
PGE2	B
inhibited	O
cell	O
proliferation	O
and	O
the	O
production	O
of	O
all	O
the	O
cytokines	B
examined	O
.	O
Addition	O
of	O
rIL-2	B
fully	O
restored	O
the	O
proliferative	O
response	O
and	O
partially	O
restored	O
the	O
production	O
of	O
IL-4	B
and	O
IL-5	B
,	O
but	O
not	O
that	O
of	O
other	O
cytokines	B
.	O
In	O
contrast	O
,	O
in	O
cells	O
stimulated	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
/A23187	O
,	O
PGE2	B
enhanced	O
the	O
production	O
of	O
IL-4	B
and	O
IL-5	B
,	O
and	O
only	O
partially	O
inhibited	O
the	O
production	O
of	O
other	O
cytokines	B
.	O
Therefore	O
,	O
the	O
effects	O
of	O
PGE2	B
vary	O
depending	O
on	O
the	O
mode	O
of	O
T	O
cell	O
activation	O
,	O
and	O
the	O
IL-4	B
and	O
IL-5	B
are	O
regulated	O
differently	O
from	O
other	O
cytokines	B
.	O
In	O
a	O
mobility	O
shift	O
assay	O
,	O
only	O
the	O
NF	B
-	I
kappa	I
B	I
(	I
p50	I
/	I
p50	I
)	I
homodimer	I
was	O
observed	O
in	O
a	O
complex	O
formed	O
with	O
the	O
kappa	O
B	O
sequence	O
in	O
unstimulated	O
SP	O
-	O
B21	O
cells	O
.	O
When	O
cells	O
were	O
stimulated	O
with	O
anti	B
-	I
CD3	I
mAb	I
or	O
PMA	O
/	O
A23187	O
,	O
a	O
complex	O
formation	O
of	O
NF	B
-	I
kappa	I
B	I
(	O
p50	B
/p65	B
)	O
heterodimer	O
with	O
the	O
kappa	O
B	O
sequence	O
was	O
induced	O
.	O
Interestingly	O
,	O
PGE2	B
or	O
di	O
-	O
butyryl	O
(	O
Bt2	O
)	O
cAMP	O
abolished	O
the	O
binding	O
of	O
NF	B
-	I
kappa	I
B	I
(	I
p50	I
/	I
p65	I
)	I
heterodimer	I
to	O
the	O
kappa	O
B	O
sequence	O
in	O
cells	O
stimulated	O
with	O
anti	B
-	I
CD3	I
mAb	I
but	O
not	O
with	O
PMA	O
/	O
A23187	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
target	O
of	O
PGE2	B
action	O
is	O
a	O
component	O
in	O
the	O
signal	O
transduction	O
pathway	O
leading	O
to	O
the	O
activation	O
of	O
protein	B
kinase	I
C	I
.	O
However	O
,	O
the	O
inhibition	O
of	O
the	O
T	O
cell	O
activation	O
signals	O
by	O
PGE2	B
is	O
selective	O
.	O
PGE2	B
enhanced	O
the	O
complex	O
formation	O
with	O
NF	O
-	O
AT	O
,	O
AP-1	O
and	O
CLE0	O
sequences	O
when	O
the	O
cells	O
were	O
activated	O
by	O
either	O
anti	B
-	I
CD3	I
mAb	I
or	O
PMA	O
/	O
A23187	O
stimulation	O
.	O
It	O
seems	O
therefore	O
that	O
PGE2	B
,	O
by	O
elevating	O
cAMP	O
levels	O
,	O
interferes	O
with	O
the	O
activation	O
pathway	O
for	O
NF	B
-	I
kappa	I
B	I
but	O
not	O
for	O
NF	B
-	I
AT	I
,	O
AP-1	B
or	O
CLE0	B
binding	I
protein	I
.	O
Positive	O
and	O
negative	O
regulation	O
of	O
IL-2	B
gene	O
expression	O
:	O
role	O
of	O
multiple	O
regulatory	O
sites	O
.	O
Interleukin	O
2	O
(	O
IL-2	B
)	O
is	O
an	O
important	O
lymphokine	B
required	O
in	O
the	O
process	O
of	O
T	O
cell	O
activation	O
,	O
proliferation	O
,	O
clonal	O
expansion	O
and	O
differentiation	O
.	O
The	O
IL-2	O
gene	O
displays	O
both	O
T	O
cell	O
specific	O
and	O
inducible	O
expression	O
:	O
it	O
is	O
only	O
expressed	O
in	O
CD4	O
+	O
T	O
cells	O
after	O
antigenic	O
or	O
mitogenic	O
stimulation	O
.	O
Several	O
cis	O
-	O
acting	O
regulatory	O
sites	O
are	O
required	O
for	O
induction	O
of	O
the	O
IL-2	O
gene	O
after	O
stimulation	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
analysed	O
the	O
function	O
of	O
these	O
cis	O
-	O
acting	O
regulatory	O
sites	O
in	O
the	O
context	O
of	O
the	O
native	O
IL-2	O
enhancer	O
and	O
promoter	O
sequence	O
.	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
NFAT	B
(	O
-276	O
to	O
-261	O
)	O
,	O
the	O
distal	O
octamer	O
(	O
-256	O
to	O
-248	O
)	O
and	O
the	O
proximal	O
octamer	O
(	O
-75	O
to	O
-66	O
)	O
sites	O
not	O
only	O
act	O
as	O
enhancers	O
of	O
IL-2	O
gene	O
transcription	O
in	O
the	O
presence	O
of	O
cellular	O
stimulation	O
,	O
but	O
also	O
have	O
a	O
silencing	O
effect	O
on	O
IL-2	O
gene	O
expression	O
in	O
resting	O
cells	O
.	O
Two	O
other	O
sites	O
display	O
disparate	O
effects	O
on	O
IL-2	O
gene	O
expression	O
in	O
different	O
T	O
leukemia	O
cell	O
lines	O
:	O
the	O
distal	O
purine	O
box	O
(	O
-291	O
to	O
-277	O
)	O
and	O
the	O
proximal	O
purine	O
box	O
sites	O
(	O
-145	O
to	O
-128	O
)	O
.	O
Finally	O
,	O
the	O
AP-1	O
(	O
-186	O
to	O
-176	O
)	O
and	O
the	O
kappa	O
B	O
sites	O
(	O
-206	O
to	O
-195	O
)	O
respond	O
to	O
different	O
cellular	O
activation	O
in	O
EL4	O
cells	O
.	O
The	O
AP-1	O
site	O
mediated	O
the	O
response	O
to	O
PMA	O
stimulation	O
while	O
the	O
kappa	O
B	O
site	O
responded	O
to	O
IL-1	B
stimulation	O
.	O
These	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
IL-2	O
gene	O
expression	O
is	O
a	O
complex	O
process	O
and	O
multiple	O
cis	O
-	O
acting	O
regulatory	O
sites	O
interact	O
to	O
exert	O
different	O
effects	O
in	O
T	O
cells	O
representative	O
of	O
alternative	O
stages	O
of	O
differentiation	O
.	O
Tat	B
-	I
binding	I
protein	I
7	I
is	O
a	O
subunit	O
of	O
the	O
26S	B
protease	I
.	O
Subunit	B
6	I
(	O
S6	B
)	O
,	O
an	O
integral	O
component	O
of	O
the	O
26S	B
protease	I
from	O
human	O
erythrocytes	O
,	O
has	O
been	O
studied	O
by	O
SDS	O
-	O
PAGE	O
,	O
peptide	O
mapping	O
and	O
sequence	O
analysis	O
.	O
S6	B
was	O
cleaved	O
with	O
CNBr	B
and	O
three	O
internal	O
peptides	O
were	O
sequenced	O
.	O
A	O
comparison	O
with	O
known	O
proteins	O
in	O
Genbank	O
revealed	O
that	O
all	O
three	O
S6	B
peptides	O
match	O
the	O
predicted	O
sequence	O
of	O
TBP7	B
,	O
Tat	B
-	I
binding	I
protein	I
7	I
.	O
Based	O
on	O
peptide	O
matches	O
covering	O
more	O
than	O
10	O
%	O
of	O
the	O
TBP7	B
sequence	O
,	O
and	O
the	O
fact	O
that	O
the	O
migration	O
of	O
S6	B
on	O
SDS	O
-	O
PAGE	O
is	O
consistent	O
with	O
the	O
estimated	O
molecular	O
mass	O
for	O
TBP7	B
,	O
we	O
conclude	O
that	O
subunit	B
6	I
of	O
the	O
26S	B
protease	I
is	O
TBP7	B
.	O
The	O
severe	O
phenotype	O
of	O
females	O
with	O
tiny	O
ring	O
X	O
chromosomes	O
is	O
associated	O
with	O
inability	O
of	O
these	O
chromosomes	O
to	O
undergo	O
X	O
inactivation	O
.	O
Mental	O
retardation	O
and	O
a	O
constellation	O
of	O
congenital	O
malformations	O
not	O
usually	O
associated	O
with	O
Turner	O
syndrome	O
are	O
seen	O
in	O
some	O
females	O
with	O
a	O
mosaic	O
45	O
,	O
X	O
/	O
46	O
,	O
X	O
,	O
r	O
(	O
X	O
)	O
karyotype	O
.	O
Studies	O
of	O
these	O
females	O
show	O
that	O
the	O
XIST	O
locus	O
on	O
their	O
tiny	O
ring	O
X	O
chromosomes	O
is	O
either	O
not	O
present	O
or	O
not	O
expressed	O
.	O
As	O
XIST	O
transcription	O
is	O
well	O
correlated	O
with	O
inactivation	O
of	O
the	O
X	O
chromosome	O
in	O
female	O
somatic	O
cells	O
and	O
spermatogonia	O
,	O
nonexpression	O
of	O
the	O
locus	O
even	O
when	O
it	O
is	O
present	O
suggests	O
that	O
these	O
chromosomes	O
are	O
transcriptionally	O
active	O
.	O
We	O
examined	O
the	O
transcriptional	O
activity	O
of	O
ring	O
X	O
chromosomes	O
lacking	O
XIST	O
expression	O
(	O
XISTE-	O
)	O
,	O
from	O
three	O
females	O
with	O
severe	O
phenotypes	O
.	O
The	O
two	O
tiny	O
ring	O
X	O
chromosomes	O
studied	O
with	O
an	O
antibody	B
specific	O
for	O
the	O
acetylated	O
isoforms	O
of	O
histone	B
H4	I
marking	O
transcribed	O
chromatin	O
domains	O
were	O
labeled	O
at	O
a	O
level	O
consistent	O
with	O
their	O
being	O
active	O
.	O
We	O
also	O
examined	O
tow	O
of	O
the	O
XISTE-	O
ring	O
chromosomes	O
to	O
determine	O
whether	O
genes	O
that	O
are	O
normally	O
silent	O
on	O
an	O
inactive	O
X	O
are	O
expressed	O
from	O
these	O
chromosomes	O
.	O
Analyses	O
of	O
hybrid	O
cells	O
show	O
that	O
TIMP	O
,	O
ZXDA	O
,	O
and	O
ZXDB	O
loci	O
on	O
the	O
proximal	O
short	O
arm	O
,	O
and	O
AR	O
and	O
PHKA1	O
loci	O
on	O
the	O
long	O
arm	O
,	O
are	O
well	O
expressed	O
from	O
the	O
tiny	O
ring	O
X	O
chromosome	O
lacking	O
XIST	O
DNA	O
.	O
Studies	O
of	O
the	O
ring	O
chromosome	O
that	O
has	O
XIST	O
DNA	O
but	O
does	O
not	O
transcribe	O
it	O
show	O
that	O
its	O
AR	O
allele	O
is	O
transcribed	O
along	O
with	O
the	O
one	O
on	O
the	O
normal	O
X	O
allele	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
An	O
interleukin-4-induced	B
transcription	I
factor	I
:	O
IL-4	B
Stat	I
.	O
Interleukin-4	B
(	O
IL-4	B
)	O
is	O
an	O
immunomodulatory	O
cytokine	O
secreted	O
by	O
activated	O
T	O
lymphocytes	O
,	O
basophils	O
,	O
and	O
mast	O
cells	O
.	O
It	O
plays	O
an	O
important	O
role	O
in	O
modulating	O
the	O
balance	O
of	O
T	O
helper	O
(	O
Th	O
)	O
cell	O
subsets	O
,	O
favoring	O
expansion	O
of	O
the	O
Th2	O
lineage	O
relative	O
to	O
Th1	O
.	O
Imbalance	O
of	O
these	O
T	O
lymphocyte	O
subsets	O
has	O
been	O
implicated	O
in	O
immunological	O
diseases	O
including	O
allergy	O
,	O
inflammation	O
,	O
and	O
autoimmune	O
disease	O
.	O
IL-4	B
may	O
mediate	O
its	O
biological	O
effects	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
activating	O
a	O
tyrosine	B
-	I
phosphorylated	I
DNA	I
binding	I
protein	I
.	O
This	O
protein	O
has	O
now	O
been	O
purified	O
and	O
its	O
encoding	O
gene	O
cloned	O
.	O
Examination	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
indicates	O
that	O
it	O
is	O
a	O
member	O
of	O
the	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
Stat	I
)	I
family	I
of	O
DNA	B
binding	I
proteins	I
,	O
hereby	O
designated	O
IL-4	B
Stat	I
.	O
Study	O
of	O
the	O
inhibitory	O
activities	O
of	O
phosphotyrosine	O
-	O
containing	O
peptides	O
derived	O
from	O
the	O
intracellular	B
domain	I
of	I
the	I
IL-4	I
receptor	I
provided	O
evidence	O
for	O
direct	O
coupling	O
of	O
receptor	B
and	O
transcription	B
factor	I
during	O
the	O
IL-4	B
Stat	I
activation	O
cycle	O
.	O
Such	O
observations	O
indicate	O
that	O
IL-4	B
Stat	I
has	O
the	O
same	O
functional	B
domain	I
for	O
both	O
receptor	O
coupling	O
and	O
dimerization	O
.	O
Structure	O
and	O
expression	O
of	O
the	O
human	O
GATA3	O
gene	O
.	O
GATA3	B
,	O
a	O
member	O
of	O
the	O
GATA	B
family	I
that	O
is	O
abundantly	O
expressed	O
in	O
the	O
T	O
-	O
lymphocyte	O
lineage	O
,	O
is	O
thought	O
to	O
participate	O
in	O
T	B
-	I
cell	I
receptor	I
gene	O
activation	O
through	O
binding	O
to	O
enhancers	O
.	O
To	O
understand	O
GATA3	O
gene	O
regulation	O
,	O
we	O
cloned	O
the	O
human	O
gene	O
and	O
the	O
5	O
'	O
end	O
of	O
the	O
mouse	O
GATA3	O
gene	O
.	O
We	O
show	O
that	O
the	O
human	O
GATA3	O
gene	O
contains	O
six	O
exons	O
distributed	O
over	O
17	O
kb	O
of	O
DNA	O
.	O
The	O
two	O
human	B
GATA3	I
zinc	I
fingers	I
are	O
encoded	O
by	O
two	O
separate	O
exons	O
highly	O
conserved	O
with	O
those	O
of	O
GATA1	B
,	O
but	O
no	O
other	O
structural	O
homologies	O
between	O
these	O
two	O
genes	O
can	O
be	O
found	O
.	O
The	O
human	O
and	O
mouse	O
GATA3	O
transcription	O
units	O
start	O
at	O
a	O
major	O
initiation	O
site	O
.	O
The	O
promoter	O
sequence	O
analysis	O
of	O
these	O
two	O
genes	O
revealed	O
that	O
they	O
are	O
embedded	O
within	O
a	O
CpG	O
island	O
and	O
share	O
structural	O
features	O
often	O
found	O
in	O
the	O
promoters	O
of	O
housekeeping	O
genes	O
.	O
Finally	O
,	O
we	O
show	O
that	O
a	O
DNA	O
fragment	O
containing	O
the	O
human	O
GATA3	O
transcription	O
unit	O
,	O
3	O
kb	O
upstream	O
from	O
the	O
initiation	O
site	O
and	O
4	O
kb	O
downstream	O
from	O
the	O
polyadenylation	O
site	O
,	O
displays	O
T	O
-	O
cell	O
specificity	O
.	O
T	O
cells	O
from	O
renal	O
cell	O
carcinoma	O
patients	O
exhibit	O
an	O
abnormal	O
pattern	O
of	O
kappa	O
B	O
-	O
specific	O
DNA	O
-	O
binding	O
activity	O
:	O
a	O
preliminary	O
report	O
.	O
Recent	O
data	O
suggest	O
that	O
the	O
poor	O
induction	O
of	O
a	O
T	O
-	O
cell	O
response	O
to	O
human	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
may	O
be	O
related	O
to	O
alterations	O
in	O
signal	O
transduction	O
pathways	O
.	O
We	O
report	O
that	O
T	O
cells	O
from	O
RCC	O
patients	O
have	O
two	O
alterations	O
in	O
kappa	O
B	O
motif	O
-	O
specific	O
DNA	O
-	O
binding	O
activity	O
.	O
The	O
first	O
alteration	O
involves	O
the	O
constitutive	O
expression	O
of	O
substantial	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
which	O
was	O
observed	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
The	O
magnitude	O
of	O
kappa	O
B	O
activity	O
in	O
unstimulated	O
patient	O
T	O
cells	O
was	O
similar	O
to	O
that	O
observed	O
in	O
T	O
cells	O
from	O
normal	O
individuals	O
that	O
had	O
been	O
activated	O
in	O
vitro	O
.	O
On	O
the	O
basis	O
of	O
Western	O
blotting	O
experiments	O
using	O
antibodies	B
to	O
kappa	B
B	I
/	I
Rel	I
family	I
proteins	I
,	O
the	O
kappa	O
B	O
-	O
binding	O
activity	O
constitutively	O
expressed	O
in	O
T	O
cells	O
from	O
RCC	O
patients	O
is	O
composed	O
mostly	O
of	O
the	O
NF	B
-	I
kappa	I
B1	I
(	I
p50	I
)	I
subunit	I
.	O
The	O
second	O
abnormality	O
in	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
from	O
these	O
patients	O
is	O
that	O
RelA	B
,	O
a	O
member	O
of	O
the	O
Rel	B
homology	I
family	I
which	O
is	O
part	O
of	O
the	O
normal	O
NF	B
-	I
kappa	I
B	I
complex	I
,	O
was	O
not	O
induced	O
in	O
the	O
nucleus	O
following	O
activation	O
.	O
Western	O
blotting	O
analysis	O
did	O
not	O
detect	O
any	O
RelA	B
in	O
nuclear	O
extracts	O
either	O
before	O
or	O
after	O
stimulation	O
of	O
T	O
cells	O
.	O
The	O
altered	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
from	O
RCC	O
patients	O
may	O
impair	O
their	O
capacity	O
to	O
respond	O
normally	O
to	O
various	O
stimuli	O
.	O
In	O
vivo	O
modification	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
DRA	O
promoter	O
occupancy	O
mediated	O
by	O
the	O
AIR-1	B
trans	I
-	I
activator	I
.	O
RJ	O
2.2.5	O
is	O
a	O
human	O
B	O
cell	O
mutant	O
derived	O
from	O
the	O
Burkitt	O
lymphoma	O
Raji	O
cell	O
which	O
is	O
defective	O
in	O
the	O
AIR-1	O
locus	O
function	O
.	O
This	O
locus	O
encodes	O
a	O
transcriptional	O
trans	O
-	O
activator	O
required	O
for	O
the	O
constitutive	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
.	O
Here	O
we	O
show	O
,	O
by	O
in	O
vivo	O
DNase	B
I	I
footprinting	O
,	O
that	O
the	O
AIR-1	O
locus	O
defect	O
correlates	O
with	O
changes	O
in	O
the	O
DRA	O
promoter	O
occupancy	O
.	O
Interestingly	O
,	O
reexpression	O
of	O
human	O
MHC	O
class	O
II	O
genes	O
in	O
RJ	O
2.2.5	O
x	O
mouse	O
spleen	O
cell	O
hybrids	O
is	O
associated	O
with	O
partial	O
reversion	O
of	O
DRA	O
promoter	O
occupancy	O
to	O
the	O
Raji	O
pattern	O
.	O
DRA	O
promoter	O
occupancy	O
in	O
other	O
class	O
II	O
-	O
negative	O
B	O
cell	O
lines	O
,	O
derived	O
from	O
patients	O
with	O
bare	O
lymphocyte	O
syndrome	O
,	O
is	O
drastically	O
different	O
from	O
the	O
one	O
observed	O
in	O
RJ	O
2.2.5	O
and	O
Raji	O
cells	O
.	O
Moreover	O
,	O
the	O
use	O
of	O
the	O
DNase	B
I	I
as	O
an	O
in	O
vivo	O
footprinting	O
agent	O
reveals	O
that	O
the	O
patients	O
'	O
cell	O
lines	O
do	O
not	O
display	O
a	O
completely	O
`	O
`	O
bare	O
promoter	O
`	O
`	O
as	O
previously	O
reported	O
using	O
dimethyl	O
sulfate	O
as	O
the	O
footprinting	O
agent	O
.	O
Thus	O
,	O
the	O
use	O
of	O
DNase	B
I	I
allowed	O
us	O
,	O
for	O
the	O
first	O
time	O
,	O
to	O
correlate	O
the	O
AIR-1	O
locus	O
defect	O
with	O
class	O
II	O
promoter	O
occupancy	O
alterations	O
and	O
distinguish	O
these	O
alterations	O
from	O
the	O
ones	O
observed	O
in	O
phenotypically	O
similar	O
but	O
genetically	O
distinct	O
MHC	O
class	O
II	O
-	O
negative	O
cells	O
.	O
Mechanism	O
of	O
antiandrogen	O
action	O
:	O
conformational	O
changes	O
of	O
the	O
receptor	O
.	O
Androgen	O
receptor	O
mRNA	O
was	O
translated	O
in	O
vitro	O
,	O
and	O
androgen-	B
and	I
antiandrogen	I
-	I
bound	I
receptor	I
complexes	I
were	O
studied	O
using	O
limited	O
proteolytic	O
digestion	O
by	O
trypsin	B
.	O
Partial	O
proteolysis	O
of	O
androgen	B
-	I
bound	I
receptor	I
protein	I
resulted	O
in	O
a	O
29-kDa	B
proteolysis	I
-	I
resisting	I
fragment	I
,	O
whereas	O
antiandrogen	O
binding	O
stabilised	O
a	O
35-kDa	B
fragment	I
.	O
Both	O
fragments	O
contain	O
the	O
entire	O
ligand	B
binding	I
domain	I
,	O
and	O
the	O
35-kDa	B
fragment	I
extended	O
into	O
the	O
hinge	B
region	I
of	O
the	O
receptor	O
.	O
Several	O
antiandrogens	O
show	O
agonistic	O
properties	O
for	O
a	O
mutated	B
androgen	I
receptor	I
(	O
LNCaP	O
cell	O
variant	O
)	O
;	O
trypsin	B
digestion	O
of	O
antiandrogen	B
-	I
bound	I
mutated	I
receptor	I
also	O
resulted	O
in	O
a	O
29-kDa	B
fragment	I
.	O
Our	O
results	O
point	O
to	O
an	O
important	O
difference	O
between	O
antiandrogens	O
and	O
antagonists	O
of	O
other	O
steroid	B
hormone	I
receptors	I
.	O
Antiandrogens	O
result	O
in	O
protection	O
of	O
both	O
the	O
hinge	B
region	I
and	O
C	B
-	I
terminus	I
of	O
the	O
androgen	B
receptor	I
agonist	O
proteolytic	O
attack	O
,	O
whereas	O
other	O
studies	O
showed	O
that	O
antiestrogens	O
and	O
antiprogestagens	O
expose	O
the	O
C	B
-	I
terminal	I
end	I
of	O
the	O
ligand	B
binding	I
domain	I
of	O
their	O
respective	O
receptors	O
to	O
protease	B
.	O
Differences	O
in	O
conformation	O
of	O
the	O
hinge	B
region	I
distinguish	O
androgen	B
-	I
bound	I
from	O
antiandrogen	B
-	I
bound	I
receptor	I
complexes	I
,	O
which	O
represents	O
an	O
important	O
feature	O
of	O
antiandrogen	O
action	O
.	O
[	O
An	O
overexpression	O
of	O
retinoic	B
acid	I
receptor	I
alpha	I
blocks	O
myeloid	O
cell	O
differentiation	O
at	O
the	O
promyelocyte	O
stage	O
]	O
Retinoic	O
acid	O
(	O
RA	O
)	O
,	O
a	O
vitamin	O
A	O
derivative	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
effects	O
related	O
to	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
The	O
pleiotropic	O
effects	O
of	O
RA	O
are	O
thought	O
to	O
be	O
mediated	O
through	O
specific	O
nuclear	O
RA	B
receptors	I
(	O
RARs	B
)	O
.	O
RARs	B
are	O
members	O
of	O
the	O
steroid	B
/	I
thyroid	I
hormone	I
receptor	I
superfamily	I
and	O
exhibit	O
a	O
molecular	O
structure	O
that	O
possess	O
discrete	O
DNA	O
-	O
binding	O
and	O
RA	B
(	I
ligand	I
)	I
-binding	I
domains	I
.	O
In	O
hematopoietic	O
system	O
,	O
RA	O
and	O
RARs	B
,	O
predominantly	O
RAR	B
alpha	I
may	O
play	O
key	O
roles	O
for	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	O
progenitors	O
.	O
However	O
,	O
it	O
is	O
currently	O
unknown	O
how	O
RA	O
and	O
RARs	B
are	O
involved	O
in	O
regulating	O
normal	O
hematopoietic	O
differentiation	O
.	O
To	O
make	O
clear	O
the	O
roles	O
of	O
RA	O
and	O
RAR	B
alpha	I
in	O
the	O
normal	O
hematopoiesis	O
,	O
I	O
have	O
introduced	O
the	O
construct	O
of	O
human	B
RAR	I
alpha	I
(	O
hRAR	B
alpha	I
)	O
into	O
murine	O
bone	O
marrow	O
cells	O
with	O
retroviral	O
vector	O
,	O
and	O
selected	O
infected	O
cells	O
with	O
drug	O
resistant	O
marker	O
(	O
Neo	O
(	O
r	O
)	O
)	O
cultured	O
on	O
the	O
stroma	O
cell	O
line	O
(	O
PA6-neo	O
)	O
,	O
and	O
analyzed	O
the	O
behavior	O
of	O
infected	O
cells	O
.	O
All	O
of	O
procedure	O
were	O
done	O
in	O
vitro	O
.	O
Most	O
cells	O
infected	O
with	O
hRAR	B
alpha	I
exhibited	O
promyelocytic	O
morphology	O
and	O
were	O
thought	O
to	O
be	O
blocked	O
at	O
the	O
promyelocytic	O
stage	O
in	O
their	O
myeloid	O
differentiation	O
.	O
Furthermore	O
,	O
these	O
immature	O
cells	O
differentiated	O
terminally	O
into	O
mature	O
granulocytes	O
by	O
adding	O
with	O
RA	O
(	O
10	O
(	O
-6	O
)	O
M	O
)	O
.	O
RAR	B
alpha	I
infected	O
cells	O
were	O
also	O
able	O
to	O
differentiate	O
into	O
mature	O
macrophages	O
in	O
the	O
both	O
of	O
long	O
term	O
culture	O
and	O
IL3	O
colony	O
.	O
These	O
observations	O
suggest	O
that	O
an	O
overexpression	O
of	O
RAR	B
alpha	I
alone	O
is	O
effective	O
to	O
suppress	O
myeloid	O
cell	O
differentiation	O
and	O
RAR	B
alpha	I
plays	O
a	O
crucial	O
role	O
in	O
the	O
terminal	O
differentiation	O
of	O
myeloid	O
precursors	O
.	O
The	O
system	O
described	O
here	O
may	O
serve	O
as	O
a	O
model	O
for	O
studying	O
the	O
the	O
essential	O
genes	O
for	O
differentiation	O
of	O
normal	O
bone	O
marrow	O
cells	O
.	O
Protease	O
inhibitors	O
block	O
lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
by	O
preventing	O
activation	O
of	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
.	O
Tissue	B
factor	I
(	O
TF	B
)	O
is	O
expressed	O
rapidly	O
by	O
human	O
monocytes	O
exposed	O
to	O
bacterial	B
endotoxin	I
(	O
lipopolysaccharide	O
,	O
or	O
LPS	O
)	O
.	O
Transcriptional	O
regulation	O
is	O
mediated	O
by	O
binding	O
of	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
to	O
a	O
kappa	O
B	O
-	O
like	O
site	O
in	O
the	O
TF	O
promoter	O
.	O
Nuclear	O
translocation	O
of	O
cytosolic	B
c	I
-	I
Rel	I
/	I
p65	I
heterodimers	I
and	O
other	O
members	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
family	I
requires	O
dissociation	O
and	O
proteolytic	O
degradation	O
of	O
the	O
inhibitor	B
protein	I
,	O
I	B
kappa	I
B	I
alpha	I
.	O
The	O
protease	O
inhibitors	O
N	O
alpha	O
-	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
and	O
N	O
alpha	O
-	O
tosyl	O
-	O
L	O
-	O
lysine	O
chloromethyl	O
ketone	O
(	O
TLCK	O
)	O
block	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
proteins	I
by	O
preventing	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
.	O
To	O
determine	O
if	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	B
expression	O
,	O
freshly	O
isolated	O
human	O
monocytes	O
and	O
monocytic	O
THP-1	O
cells	O
were	O
pretreated	O
with	O
these	O
inhibitors	O
for	O
30	O
min	O
before	O
LPS	O
stimulation	O
.	O
Both	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	B
protein	I
,	O
TF	O
mRNA	O
and	O
TF	B
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
These	O
inhibitors	O
specifically	O
prevented	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
and	O
nuclear	O
translocation	O
of	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
.	O
In	O
contrast	O
,	O
TPCK	O
and	O
TLCK	O
did	O
not	O
block	O
induction	O
of	O
an	O
immediate	O
-	O
early	O
gene	O
encoding	O
the	O
transcription	B
factor	I
,	O
Egr-1	B
.	O
Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
inhibiting	O
nuclear	O
translocation	O
of	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
prevented	O
LPS	O
induction	O
of	O
TF	B
gene	O
transcription	O
in	O
monocytic	O
cells	O
.	O
C	B
/	I
EBP	I
beta	I
regulation	O
of	O
the	O
tumor	O
necrosis	O
factor	O
alpha	O
gene	O
.	O
Activated	O
macrophages	O
contribute	O
to	O
chronic	O
inflammation	O
by	O
the	O
secretion	O
of	O
cytokines	B
and	O
proteinases	B
.	O
Tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
alpha	I
)	O
is	O
particularly	O
important	O
in	O
this	O
process	O
because	O
of	O
its	O
ability	O
to	O
regulate	O
other	O
inflammatory	O
mediators	O
in	O
an	O
autocrine	O
and	O
paracrine	O
fashion	O
.	O
The	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
the	O
cell	O
type	O
-	O
specific	O
regulation	O
of	O
TNF	B
alpha	I
is	O
not	O
known	O
.	O
We	O
present	O
data	O
to	O
show	O
that	O
the	O
expression	O
of	O
TNF	B
alpha	I
is	O
regulated	O
by	O
the	O
transcription	B
factor	I
C	B
/	I
EBP	I
beta	I
(	O
NF	B
-	I
IL6	I
)	O
.	O
C	B
/	I
EBP	I
beta	I
activated	O
the	O
TNF	O
alpha	O
gene	O
promoter	O
in	O
cotransfection	O
assays	O
and	O
bound	O
to	O
it	O
at	O
a	O
site	O
which	O
failed	O
to	O
bind	O
the	O
closely	O
related	O
protein	O
C	B
/	I
EBP	I
alpha	I
.	O
Finally	O
,	O
a	O
dominant	O
-	O
negative	O
version	O
of	O
C	B
/	I
EBP	I
beta	I
blocked	O
TNF	O
alpha	O
promoter	O
activation	O
in	O
myeloid	O
cells	O
.	O
Our	O
results	O
implicate	O
C	B
/	I
EBP	I
beta	I
as	O
an	O
important	O
regulator	O
of	O
TNF	B
alpha	I
by	O
myelomonocytic	O
cells	O
.	O
Simultaneous	O
activation	O
of	O
Ig	B
and	O
Oct-2	B
synthesis	O
and	O
reduction	O
of	O
surface	O
MHC	B
class	I
II	I
expression	O
by	O
IL-6	B
.	O
Terminal	O
differentiation	O
of	O
B	O
cells	O
to	O
plasma	O
cells	O
in	O
vivo	O
is	O
characterized	O
by	O
secretion	O
of	O
Ig	B
and	O
extinction	O
of	O
MHC	B
class	I
II	I
expression	O
on	O
the	O
cell	O
surface	O
.	O
We	O
show	O
that	O
IL-6	B
signaling	O
leads	O
to	O
marked	O
increases	O
in	O
the	O
synthesis	O
and	O
secretion	O
of	O
Ig	B
in	O
clonal	O
human	O
B	O
cell	O
lines	O
and	O
newly	O
isolated	O
polyclonal	O
B	O
lymphocytes	O
in	O
vitro	O
.	O
The	O
IL-6-induced	O
cells	O
resemble	O
plasma	O
cells	O
in	O
ultrastructure	O
and	O
in	O
reduced	O
expression	O
of	O
surface	B
MHC	I
class	I
II	I
.	O
Enhanced	O
Ig	B
synthesis	O
is	O
a	O
result	O
of	O
coordinated	O
transcriptional	O
activation	O
of	O
Ig	O
genes	O
without	O
promoter	O
or	O
isotype	O
specificity	O
,	O
and	O
differential	O
accumulation	O
of	O
the	O
mRNA	O
encoding	O
the	O
secreted	O
form	O
of	O
Ig	B
heavy	I
chain	I
.	O
It	O
is	O
saturable	O
and	O
subject	O
to	O
negative	O
control	O
when	O
IL-6	B
stimulation	O
is	O
prolonged	O
.	O
Coordinate	O
with	O
temporal	O
changes	O
in	O
Ig	B
synthesis	O
,	O
the	O
DNA	O
-	O
binding	O
activity	O
and	O
the	O
synthesis	O
of	O
the	O
B	B
cell	I
-	I
enriched	I
transcription	I
factor	I
Oct-2	B
are	O
regulated	O
.	O
Thus	O
,	O
differentiation	O
of	O
B	O
cells	O
with	O
IL-6	B
in	O
vitro	O
recapitulates	O
the	O
hallmarks	O
of	O
terminal	O
B	O
differentiation	O
in	O
vivo	O
;	O
Oct-2	B
may	O
have	O
a	O
role	O
in	O
this	O
process	O
.	O
Positive	O
and	O
negative	O
regulation	O
of	O
the	O
composite	O
octamer	O
motif	O
of	O
the	O
interleukin	O
2	O
enhancer	O
by	O
AP-1	B
,	O
Oct-2	B
,	O
and	O
retinoic	B
acid	I
receptor	I
.	O
The	O
differentiating	O
agent	O
retinoic	O
acid	O
(	O
RA	O
)	O
has	O
been	O
previously	O
reported	O
to	O
interfere	O
with	O
12-O	O
-	O
tetradecanoyl	O
-	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
/Ca	O
(	O
2	O
+	O
)	O
-induced	O
signals	O
for	O
the	O
regulation	O
of	O
the	O
-96	O
to	O
-66-bp	O
octamer	O
motif	O
found	O
in	O
the	O
enhancer	O
for	O
the	O
interleukin	O
(	O
IL	O
)	O
-2	O
gene	O
,	O
which	O
encodes	O
a	O
major	O
T	B
lymphocyte	I
growth	I
factor	I
.	O
The	O
IL-2	O
octamer	O
motif	O
is	O
a	O
composite	O
cis	O
-	O
element	O
which	O
binds	O
Oct-1	B
and	O
Oct-2	B
as	O
well	O
as	O
a	O
TPA	B
/	I
Ca	I
(	I
2	I
+	I
)	I
-inducible	I
nuclear	I
factor	I
,	O
previously	O
termed	O
octamer	B
-	I
associated	I
protein	I
(	O
OAP40	B
)	O
.	O
We	O
show	O
here	O
that	O
Oct-2	B
,	O
despite	O
the	O
presence	O
of	O
an	O
active	O
transcriptional	O
activation	O
domain	O
,	O
requires	O
TPA	O
/	O
Ca	O
(	O
2	O
+	O
)	O
-induced	O
signals	O
to	O
strongly	O
transactivate	O
the	O
IL-2	O
octamer	O
motif	O
in	O
Jurkat	O
T	O
cells	O
.	O
This	O
Oct-2	B
-dependent	O
transactivation	O
is	O
inhibited	O
by	O
RA	O
.	O
The	O
presence	O
of	O
an	O
intact	B
COOH	I
-	I
terminal	I
domain	I
of	O
Oct-2	B
contributes	O
to	O
both	O
TPA	O
/	O
Ca	O
(	O
2	O
+	O
)	O
-induced	O
transactivation	O
and	O
the	O
RA	O
-	O
mediated	O
repression	O
.	O
We	O
also	O
show	O
that	O
both	O
Fos	B
and	O
Jun	B
components	O
of	O
the	O
AP-1	B
factors	O
participate	O
in	O
the	O
OAP40	B
complex	I
.	O
Furthermore	O
,	O
transfected	O
c	O
-	O
jun	O
,	O
jun	O
-	O
B	O
,	O
jun	O
-	O
D	O
,	O
c	O
-	O
fos	O
,	O
or	O
Fos	O
-	O
B	O
expression	O
vectors	O
partially	O
substitute	O
for	O
TPA	O
and	O
Ca2	O
+	O
and	O
cooperate	O
with	O
Oct-2	B
for	O
the	O
transactivation	O
of	O
the	O
combined	O
OAP	O
/	O
octamer	O
cis	O
-	O
element	O
.	O
Mutations	O
of	O
the	O
genuine	O
octamer	O
-	O
binding	O
site	O
abrogate	O
both	O
the	O
binding	O
of	O
Oct-1	B
and	O
Oct-2	B
and	O
the	O
TPA	O
/	O
Ca	O
(	O
2	O
+	O
)	O
-induced	O
transactivation	O
of	O
the	O
OAP	O
/	O
octamer	O
motif	O
.	O
OAP	B
confers	O
to	O
Oct-2	B
responsivity	O
to	O
both	O
TPA	O
/	O
Ca2	O
+	O
and	O
RA	O
,	O
since	O
specific	O
mutations	O
of	O
the	O
AP-1	O
/	O
OAP	O
-	O
binding	O
site	O
significantly	O
reduce	O
the	O
transactivation	O
by	O
Oct-2	B
in	O
response	O
to	O
TPA	O
and	O
Ca2	O
+	O
and	O
abolish	O
the	O
inhibition	O
by	O
RA	O
.	O
Furthermore	O
,	O
retinoic	B
acid	I
receptor	I
(	O
RAR	B
)	O
alpha	O
is	O
able	O
to	O
inhibit	O
in	O
vitro	O
the	O
formation	O
of	O
the	O
complex	O
between	O
the	O
nuclear	O
AP-1	B
/OAP	B
and	O
its	O
specific	O
binding	O
site	O
,	O
resulting	O
in	O
the	O
interference	O
with	O
Oct-2	B
-dependent	O
cis	O
-	O
regulatory	O
function	O
of	O
this	O
AP-1	B
element	O
.	O
Therefore	O
,	O
we	O
propose	O
that	O
the	O
TPA	O
/	O
calcium	O
-	O
activated	O
AP-1	B
/OAP	B
element	O
is	O
the	O
main	O
target	O
of	O
positive	O
or	O
negative	O
regulatory	O
signals	O
influencing	O
the	O
IL-2	O
octamer	O
motif	O
,	O
through	O
synergism	O
with	O
Oct-2	B
and	O
antagonism	O
by	O
RAR	B
.	O
Inhibition	O
of	O
rat	O
splenocyte	O
proliferation	O
with	O
methylprednisolone	O
:	O
in	O
vivo	O
effect	O
of	O
liposomal	O
formulation	O
.	O
The	O
effect	O
of	O
a	O
liposomal	O
formulation	O
of	O
methylprednisolone	O
(	O
MPL	O
)	O
on	O
the	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
in	O
spleen	O
cells	O
was	O
investigated	O
following	O
IV	O
dosing	O
in	O
rats	O
.	O
Liposomes	O
do	O
not	O
alter	O
the	O
suppressive	O
action	O
of	O
MPL	O
when	O
placed	O
in	O
lymphocyte	O
culture	O
.	O
Rat	O
splenocytes	O
were	O
found	O
to	O
have	O
greater	O
sensitivity	O
to	O
MPL	O
(	O
EC50	O
=	O
7.9	O
nM	O
)	O
than	O
do	O
human	O
peripheral	O
blood	O
lymphocytes	O
(	O
EC50	O
=	O
28	O
nM	O
)	O
.	O
In	O
vivo	O
studies	O
in	O
rats	O
utilized	O
2	O
mg	O
/	O
kg	O
IV	O
bolus	O
doses	O
of	O
liposomal	O
MPL	O
compared	O
to	O
drug	O
in	O
solution	O
.	O
Animals	O
were	O
sacrificed	O
at	O
various	O
times	O
post	O
-	O
dosing	O
until	O
120	O
h	O
,	O
spleen	O
was	O
excised	O
and	O
,	O
after	O
incubation	O
of	O
lymphocytes	O
with	O
PHA	B
,	O
splenocyte	O
blastogenic	O
responses	O
were	O
assessed	O
by	O
measuring	O
cellular	O
incorporation	O
of	O
3H	O
-	O
thymidine	O
.	O
The	O
suppressive	O
effect	O
of	O
liposomal	O
MPL	O
in	O
comparison	O
with	O
free	O
drug	O
was	O
significantly	O
prolonged	O
(	O
>	O
120	O
h	O
vs	O
<	O
18	O
h	O
)	O
.	O
Inhibition	O
effects	O
versus	O
time	O
were	O
described	O
by	O
a	O
pharmacodynamic	O
model	O
using	O
MPL	O
concentrations	O
in	O
plasma	O
as	O
an	O
input	O
function	O
.	O
A	O
nonlinear	O
relationship	O
was	O
found	O
between	O
suppression	O
of	O
splenocyte	O
proliferation	O
and	O
the	O
concentration	O
of	O
bound	O
glucocorticoid	B
receptors	I
in	O
spleen	O
.	O
Only	O
partial	O
receptor	O
occupancy	O
accompanied	O
complete	O
lymphocyte	O
suppression	O
.	O
The	O
suppression	O
of	O
endogenous	O
corticosterone	O
in	O
plasma	O
for	O
both	O
treatments	O
was	O
similar	O
with	O
values	O
from	O
L	O
-	O
MPL	O
rats	O
returning	O
to	O
baseline	O
after	O
24	O
h	O
.	O
These	O
results	O
demonstrate	O
enhanced	O
efficacy	O
of	O
local	O
immunosuppression	O
by	O
targeting	O
spleen	O
with	O
liposomal	O
MPL	O
.	O
Steel	B
factor	I
affects	O
SCL	B
expression	O
during	O
normal	O
erythroid	O
differentiation	O
.	O
Steel	B
factor	I
is	O
one	O
of	O
the	O
growth	B
factors	I
that	O
controls	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	O
cells	O
and	O
SCL	B
,	O
also	O
known	O
as	O
Tcl-5	B
or	O
Tal-1	B
,	O
is	O
a	O
transcription	B
factor	I
involved	O
in	O
erythropoiesis	O
.	O
In	O
this	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
SCL	O
in	O
the	O
proliferation	O
of	O
human	O
peripheral	O
blood	O
burst	O
-	O
forming	O
unit	O
-	O
erythroid	O
(	O
BFU	O
-	O
E	O
)	O
and	O
the	O
effects	O
of	O
Steel	B
factor	I
on	O
SCL	B
expression	O
in	O
proliferating	O
erythroid	O
cells	O
.	O
BFU	O
-	O
E	O
-	O
derived	O
colonies	O
increase	O
progressively	O
in	O
size	O
,	O
as	O
determined	O
by	O
cell	O
number	O
,	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
with	O
the	O
greatest	O
increase	O
in	O
colony	O
size	O
(	O
10-fold	O
expansion	O
)	O
occurring	O
between	O
day	O
7	O
and	O
day	O
10	O
.	O
SCL	B
protein	I
levels	O
in	O
BFU	O
-	O
E	O
-	O
derived	O
cells	O
were	O
highest	O
in	O
day	O
7	O
cells	O
and	O
decreased	O
progressively	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
suggesting	O
an	O
association	O
of	O
SCL	B
with	O
erythroid	O
proliferation	O
.	O
In	O
contrast	O
,	O
SCL	O
mRNA	O
levels	O
did	O
not	O
decrease	O
significantly	O
between	O
day	O
7	O
and	O
day	O
14	O
cells	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
are	O
largely	O
responsible	O
for	O
the	O
decrease	O
in	O
SCL	B
protein	I
observed	O
.	O
The	O
role	O
of	O
SCL	B
in	O
Steel	B
factor	I
-induced	O
erythroid	O
proliferation	O
was	O
then	O
examined	O
.	O
In	O
BFU	O
-	O
E	O
-	O
derived	O
colonies	O
cultured	O
with	O
Steel	B
factor	I
,	O
colony	O
size	O
was	O
significantly	O
increased	O
compared	O
to	O
control	O
.	O
In	O
day	O
7	O
and	O
day	O
10	O
erythroid	O
precursors	O
cultured	O
with	O
Steel	B
factor	I
,	O
SCL	B
protein	I
was	O
increased	O
significantly	O
compared	O
to	O
control	O
.	O
The	O
increase	O
in	O
SCL	B
protein	O
levels	O
in	O
early	O
erythroid	O
precursors	O
stimulated	O
with	O
Steel	B
factor	I
suggests	O
one	O
mechanism	O
through	O
which	O
Steel	B
factor	I
may	O
enhance	O
normal	O
erythroid	O
proliferation	O
.	O
SCL	O
mRNA	O
levels	O
assessed	O
by	O
Northern	O
blot	O
in	O
day	O
7	O
cells	O
did	O
not	O
increase	O
significantly	O
in	O
response	O
to	O
Steel	B
factor	I
stimulation	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
may	O
also	O
be	O
important	O
in	O
the	O
increase	O
in	O
SCL	B
protein	I
observed	O
in	O
response	O
to	O
Steel	B
.	O
Functions	O
of	O
glutathione	O
and	O
glutathione	O
disulfide	O
in	O
immunology	O
and	O
immunopathology	O
.	O
Even	O
a	O
moderate	O
increase	O
in	O
the	O
cellular	O
cysteine	O
supply	O
elevates	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
levels	O
and	O
potentiates	O
immunological	O
functions	O
of	O
lymphocytes	O
in	O
vitro	O
.	O
At	O
low	O
GSSG	O
levels	O
,	O
T	O
cells	O
can	O
not	O
optimally	O
activate	O
the	O
immunologically	O
important	O
transcription	B
factor	I
NF	B
kappa	I
B	I
,	O
whereas	O
high	O
GSSG	O
levels	O
inhibit	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	B
kappa	I
B	I
.	O
The	O
effects	O
of	O
GSSG	O
are	O
antagonized	O
by	O
reduced	O
thioredoxin	B
(	O
TRX	B
)	O
.	O
As	O
the	O
protein	B
tyrosine	I
kinase	I
activities	O
p56lck	B
and	O
p59fyn	B
are	O
activated	O
in	O
intact	O
cells	O
by	O
hydrogen	O
peroxide	O
,	O
they	O
are	O
likely	O
targets	O
for	O
GSSG	O
action	O
.	O
These	O
redox	B
-	I
regulated	I
enzymes	I
trigger	O
signal	O
cascades	O
for	O
NF	B
kappa	I
B	I
activation	O
and	O
transduce	O
signals	O
from	O
the	O
T	B
cell	I
antigen	I
receptor	I
,	O
from	O
CD4	B
and	O
CD8	B
molecules	I
,	O
and	O
from	O
the	O
IL-2	B
receptor	I
beta	I
-	I
chain	I
.	O
The	O
effector	O
phase	O
of	O
cytotoxic	O
T	O
cell	O
responses	O
and	O
IL-2	B
-dependent	O
functions	O
are	O
inhibited	O
even	O
by	O
a	O
partial	O
depletion	O
of	O
the	O
intracellular	O
GSH	O
pool	O
.	O
As	O
signal	O
transduction	O
is	O
facilitated	O
by	O
prooxidant	O
conditions	O
,	O
we	O
propose	O
that	O
the	O
well	O
-	O
known	O
immunological	O
consequences	O
of	O
GSH	O
depletion	O
ultimately	O
may	O
be	O
results	O
of	O
the	O
accompanying	O
GSSG	O
deficiency	O
.	O
As	O
HIV	O
-	O
infected	O
patients	O
and	O
SIV	O
-	O
infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
significantly	O
decreased	O
plasma	O
cyst	O
(	O
e	O
)	O
ine	O
and	O
intracellular	O
GSH	O
levels	O
,	O
we	O
also	O
hypothesize	O
that	O
AIDS	O
may	O
be	O
the	O
consequence	O
of	O
a	O
GSSG	O
deficiency	O
as	O
well	O
.	O
Cross	O
-	O
linking	O
CD40	B
on	O
B	O
cells	O
rapidly	O
activates	O
nuclear	B
factor	I
-	I
kappa	I
B	I
.	O
The	O
B	B
cell	I
-	I
associated	I
surface	I
molecule	I
CD40	I
functions	O
to	O
regulate	O
B	O
cell	O
responses	O
.	O
Cross	O
-	O
linking	O
CD40	B
on	O
B	O
cells	O
can	O
lead	O
to	O
homotypic	O
cell	O
adhesion	O
,	O
IL-6	B
production	O
,	O
and	O
,	O
in	O
combination	O
with	O
cytokines	B
,	O
to	O
Ig	O
isotype	O
switching	O
.	O
Tyrosine	O
kinase	O
activity	O
is	O
increased	O
shortly	O
after	O
engagement	O
of	O
this	O
receptor	O
.	O
Little	O
is	O
known	O
about	O
how	O
the	O
very	O
early	O
events	O
induced	O
by	O
CD40	B
cross	O
-	O
linking	O
link	O
to	O
cellular	O
responses	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
and	O
NF	B
-	I
kappa	I
B	I
-	I
like	I
transcription	I
factors	I
are	O
activated	O
after	O
cross	O
-	O
linking	O
CD40	B
on	O
resting	O
human	O
tonsillar	O
B	O
cells	O
and	O
on	O
B	O
cell	O
lines	O
.	O
The	O
activation	O
is	O
rapid	O
and	O
is	O
mediated	O
through	O
a	O
tyrosine	O
kinase	O
-	O
dependent	O
pathway	O
.	O
The	O
complexes	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
contain	O
p50	B
,	O
p65	B
(	O
RelA	B
)	O
,	O
c	B
-	I
Rel	I
,	O
and	O
most	O
likely	O
other	O
components	O
.	O
By	O
using	O
transient	O
transfection	O
assays	O
,	O
we	O
found	O
that	O
cross	O
-	O
linking	O
CD40	B
supports	O
NF	B
-	I
kappa	I
B	I
-dependent	O
gene	O
expression	O
.	O
Our	O
results	O
define	O
the	O
NF	B
-	I
kappa	I
B	I
system	O
as	O
an	O
intermediate	O
event	O
in	O
CD40	B
signaling	O
and	O
suggest	O
that	O
the	O
CD40	B
pathway	O
can	O
influence	O
the	O
expression	O
of	O
B	O
cell	O
-	O
associated	O
genes	O
with	O
NF	O
-	O
kappa	O
B	O
consensus	O
sites	O
.	O
One	O
gene	O
,	O
two	O
transcripts	O
:	O
isolation	O
of	O
an	O
alternative	O
transcript	O
encoding	O
for	O
the	O
autoantigen	B
La	I
/	I
SS	I
-	I
B	I
from	O
a	O
cDNA	O
library	O
of	O
a	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O
A	O
cDNA	O
library	O
was	O
prepared	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
an	O
autoimmune	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O
The	O
cDNA	O
library	O
was	O
screened	O
with	O
the	O
patients	O
own	O
autoimmune	O
serum	O
being	O
monospecific	O
for	O
the	O
nuclear	B
autoantigen	I
La	I
/	I
SS	I
-	I
B	I
.	O
Thereby	O
an	O
alternative	O
type	O
of	O
La	O
mRNA	O
was	O
identified	O
that	O
differed	O
from	O
the	O
known	O
La	O
mRNA	O
due	O
to	O
an	O
exchange	O
of	O
the	O
exon	O
1	O
.	O
Sequencing	O
of	O
the	O
genomic	O
region	O
between	O
the	O
exons	O
1	O
and	O
2	O
showed	O
that	O
the	O
alternative	O
5'-end	O
is	O
a	O
part	O
of	O
the	O
intron	O
.	O
In	O
addition	O
,	O
the	O
presence	O
of	O
an	O
alternative	O
promoter	O
site	O
,	O
which	O
exists	O
within	O
the	O
intron	O
downstream	O
of	O
the	O
exon	O
1	O
,	O
became	O
evident	O
.	O
In	O
consequence	O
,	O
the	O
alternative	O
La	O
mRNA	O
is	O
the	O
result	O
of	O
a	O
promoter	O
switching	O
combined	O
with	O
an	O
alternative	O
splicing	O
mechanism	O
.	O
In	O
the	O
intron	O
,	O
further	O
transcription	B
factor	I
binding	O
sites	O
,	O
including	O
a	O
NF	O
-	O
kappa	O
B	O
element	O
,	O
were	O
identified	O
leading	O
to	O
the	O
suggestion	O
that	O
the	O
expression	O
of	O
the	O
gene	O
encoding	O
for	O
the	O
nuclear	B
autoantigen	I
La	I
/	I
SS	I
-	I
B	I
alters	O
in	O
dependence	O
on	O
disease	O
conditions	O
.	O
DNA	O
-	O
binding	O
studies	O
of	O
the	O
Epstein	B
-	I
Barr	I
virus	I
nuclear	I
antigen	I
2	I
(	O
EBNA-2	B
)	O
:	O
evidence	O
for	O
complex	O
formation	O
by	O
latent	B
membrane	I
protein	I
gene	I
promoter	I
-	I
binding	I
proteins	I
in	O
EBNA-2-positive	O
cell	O
lines	O
.	O
The	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
nuclear	I
antigen	I
2	I
(	O
EBNA-2	B
)	O
protein	O
is	O
essential	O
for	O
the	O
immortalization	O
of	O
human	O
primary	O
B	O
cells	O
by	O
EBV	O
.	O
EBNA-2	B
trans	O
-	O
activates	O
cellular	O
and	O
viral	O
genes	O
like	O
CD23	O
,	O
c	O
-	O
fgr	O
,	O
latent	B
membrane	I
protein	I
1	I
(	O
LMP1	B
)	O
and	O
terminal	B
protein	I
1	I
(	O
TP1	B
)	O
.	O
Trans	O
-	O
activation	O
of	O
the	O
TP1	O
promoter	O
and	O
of	O
the	O
BamHI	O
C	O
promoter	O
has	O
already	O
been	O
investigated	O
in	O
detail	O
and	O
appears	O
to	O
be	O
mediated	O
via	O
protein	O
-	O
protein	O
interactions	O
and	O
not	O
by	O
direct	O
binding	O
of	O
EBNA-2	B
type	I
A	I
(	O
of	O
EBV	O
type	O
1	O
)	O
to	O
the	O
DNA	O
.	O
EBNA-2	B
is	O
able	O
to	O
trans	O
-	O
activate	O
the	O
expression	O
of	O
the	O
LMP	O
gene	O
in	O
several	O
cell	O
lines	O
.	O
Various	O
reports	O
have	O
delineated	O
the	O
cis	O
-	O
acting	O
elements	O
of	O
the	O
LMP	O
promoter	O
through	O
which	O
EBNA-2	B
mediates	O
trans	O
-	O
activation	O
.	O
To	O
determine	O
whether	O
EBNA-2	B
also	O
trans	O
-	O
activates	O
the	O
LMP	O
promoter	O
by	O
protein	O
-	O
protein	O
interactions	O
,	O
we	O
performed	O
a	O
series	O
of	O
gel	O
retardation	O
assays	O
and	O
competition	O
experiments	O
with	O
LMP	O
promoter	O
fragments	O
of	O
different	O
sizes	O
.	O
We	O
determined	O
that	O
the	O
protein	O
-	O
binding	O
region	O
on	O
the	O
LMP	O
promoter	O
was	O
within	O
a	O
42	O
bp	O
fragment	O
encompassing	O
nucleotides	O
-135	O
to	O
-176	O
relative	O
to	O
the	O
LMP	O
transcriptional	O
start	O
site	O
.	O
None	O
of	O
the	O
DNA	O
fragments	O
investigated	O
indicated	O
interaction	O
of	O
EBNA-2	B
with	O
the	O
DNA	O
via	O
protein	O
-	O
protein	O
interactions	O
.	O
No	O
significant	O
differences	O
between	O
EBNA-2	B
-positive	O
and	O
EBNA-2	B
-negative	O
nuclear	O
extracts	O
could	O
be	O
seen	O
in	O
the	O
gel	O
retardation	O
assay	O
under	O
conditions	O
that	O
clearly	O
showed	O
binding	O
of	O
EBNA-2A	B
to	O
the	O
TP1	O
promoter	O
.	O
However	O
,	O
analysis	O
of	O
sucrose	O
gradient	O
fractions	O
in	O
the	O
gel	O
retardation	O
assay	O
provided	O
evidence	O
that	O
the	O
LMP	B
promoter	I
-	I
binding	I
proteins	I
form	O
a	O
complex	O
of	O
higher	O
M	O
(	O
r	O
)	O
in	O
EBNA-2-positive	O
cell	O
extracts	O
.	O
These	O
complexes	O
were	O
destroyed	O
by	O
detergent	O
.	O
We	O
deduce	O
from	O
these	O
results	O
that	O
EBNA-2-positive	O
cells	O
might	O
indeed	O
contain	O
specific	B
complexes	I
bound	O
to	O
the	O
LMP	O
promoter	O
which	O
are	O
,	O
however	O
,	O
too	O
labile	O
to	O
be	O
detected	O
in	O
a	O
standard	O
gel	O
retardation	O
assay	O
.	O
Separation	O
of	O
oxidant	O
-	O
initiated	O
and	O
redox	O
-	O
regulated	O
steps	O
in	O
the	O
NF	B
-	I
kappa	I
B	I
signal	O
transduction	O
pathway	O
.	O
Studies	O
presented	O
here	O
show	O
that	O
overall	O
NF	B
-	I
kappa	I
B	I
signal	O
transduction	O
begins	O
with	O
a	O
parallel	O
series	O
of	O
stimuli	O
-	O
specific	O
pathways	O
through	O
which	O
cytokines	B
(	O
tumor	B
necrosis	I
factor	I
alpha	I
)	O
,	O
oxidants	O
(	O
hydrogen	O
peroxide	O
and	O
mitomycin	O
C	O
)	O
,	O
and	O
phorbol	O
ester	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
individually	O
initiate	O
signaling	O
.	O
These	O
initial	O
pathways	O
culminate	O
in	O
a	O
common	O
pathway	O
through	O
which	O
all	O
of	O
the	O
stimulating	O
agents	O
ultimately	O
signal	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
We	O
distinguish	O
the	O
stimuli	O
-	O
specific	O
pathways	O
by	O
showing	O
that	O
the	O
oxidative	O
stimuli	O
trigger	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
only	O
one	O
of	O
two	O
human	O
T	O
-	O
cell	O
lines	O
(	O
Wurzburg	O
but	O
not	O
Jurkat	O
)	O
,	O
whereas	O
tumor	B
necrosis	I
factor	I
alpha	I
and	O
phorbol	O
12-myristate	O
13-acetate	O
readily	O
stimulate	O
in	O
both	O
lines	O
.	O
We	O
propose	O
the	O
common	O
pathway	O
as	O
the	O
simplest	O
way	O
of	O
accounting	O
for	O
the	O
common	O
requirements	O
and	O
properties	O
of	O
the	O
signaling	O
pathway	O
.	O
We	O
include	O
a	O
redox	O
-	O
regulatory	O
mechanism	O
(	O
s	O
)	O
in	O
this	O
common	O
pathway	O
to	O
account	O
for	O
the	O
previously	O
demonstrated	O
redox	O
regulation	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
Jurkat	O
cells	O
(	O
in	O
which	O
oxidants	O
do	O
n't	O
activate	O
NF	B
-	I
kappa	I
B	I
)	O
;	O
we	O
put	O
tyrosine	O
phosphorylation	O
in	O
the	O
common	O
pathway	O
by	O
showing	O
that	O
kinase	O
activity	O
(	O
inhibitable	O
by	O
herbimycin	O
A	O
and	O
tyrphostin	O
47	O
)	O
is	O
required	O
for	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
all	O
stimuli	O
tested	O
in	O
both	O
cell	O
lines	O
.	O
Since	O
internal	O
sites	O
of	O
oxidant	O
production	O
have	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
cytokine	B
-stimulated	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
since	O
tyrosine	O
kinase	O
and	O
phosphatase	O
activities	O
are	O
known	O
to	O
be	O
altered	O
by	O
oxidants	O
,	O
these	O
findings	O
suggest	O
that	O
intracellular	O
redox	O
status	O
controls	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
regulating	O
tyrosine	O
phosphorylation	O
event	O
(	O
s	O
)	O
within	O
the	O
common	O
step	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
signal	O
transduction	O
pathway	O
.	O
Prevalence	O
of	O
aneuploidy	O
,	O
overexpressed	O
ER	B
,	O
and	O
overexpressed	O
EGFR	B
in	O
random	O
breast	O
aspirates	O
of	O
women	O
at	O
high	O
and	O
low	O
risk	O
for	O
breast	O
cancer	O
.	O
Breast	O
tissue	O
biomarkers	O
which	O
accurately	O
predict	O
breast	O
cancer	O
development	O
within	O
a	O
10	O
year	O
period	O
in	O
high	O
risk	O
women	O
are	O
needed	O
but	O
currently	O
not	O
available	O
.	O
We	O
initiated	O
this	O
study	O
to	O
determine	O
1	O
)	O
the	O
prevalence	O
of	O
one	O
or	O
more	O
breast	O
tissue	O
abnormalities	O
in	O
a	O
group	O
of	O
women	O
at	O
high	O
risk	O
for	O
breast	O
cancer	O
,	O
and	O
2	O
)	O
if	O
the	O
prevalence	O
of	O
biomarker	O
abnormalities	O
is	O
greater	O
in	O
high	O
risk	O
than	O
in	O
low	O
risk	O
women	O
.	O
Eligible	O
high	O
risk	O
women	O
were	O
those	O
with	O
a	O
first	O
degree	O
relative	O
with	O
breast	O
cancer	O
,	O
prior	O
breast	O
cancer	O
,	O
or	O
precancerous	O
mastopathy	O
.	O
Low	O
risk	O
women	O
were	O
those	O
without	O
these	O
or	O
other	O
major	O
identifiable	O
risk	O
factors	O
.	O
Ductal	O
cells	O
were	O
obtained	O
via	O
random	O
fine	O
needle	O
aspirations	O
and	O
cytologically	O
classified	O
.	O
Biomarkers	O
included	O
DNA	O
ploidy	O
,	O
estrogen	B
receptor	I
(	O
ER	B
)	O
,	O
and	O
epidermal	B
growth	I
factor	I
receptor	I
(	O
EGFR	B
)	O
.	O
The	O
prevalence	O
of	O
DNA	O
aneuploidy	O
was	O
30	O
%	O
,	O
overexpression	O
of	O
ER	B
10	O
%	O
,	O
and	O
overexpression	O
of	O
EGFR	B
35	O
%	O
,	O
in	O
the	O
206	O
high	O
risk	O
women	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
(	O
projected	O
probability	O
)	O
of	O
developing	O
breast	O
cancer	O
was	O
4.5	O
%	O
.	O
The	O
prevalence	O
of	O
aneuploidy	O
and	O
overexpressed	O
EGFR	B
was	O
significantly	O
higher	O
in	O
the	O
high	O
risk	O
women	O
than	O
in	O
the	O
25	O
low	O
risk	O
controls	O
(	O
p	O
<	O
0.002	O
)	O
,	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
was	O
0.7	O
%	O
.	O
The	O
difference	O
in	O
the	O
prevalence	O
of	O
ER	B
overexpression	O
between	O
high	O
and	O
low	O
risk	O
groups	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.095	O
)	O
.	O
This	O
may	O
be	O
due	O
to	O
the	O
low	O
prevalence	O
of	O
overexpressed	O
ER	B
and	O
the	O
small	O
number	O
of	O
controls	O
.	O
A	O
significant	O
difference	O
was	O
noted	O
in	O
the	O
prevalence	O
of	O
one	O
or	O
more	O
abnormal	O
biomarkers	O
between	O
the	O
high	O
risk	O
and	O
low	O
risk	O
women	O
(	O
p	O
<	O
0.001	O
)	O
.	O
A	O
large	O
prospective	O
trial	O
is	O
needed	O
to	O
determine	O
if	O
one	O
or	O
more	O
of	O
these	O
biomarkers	O
,	O
is	O
predictive	O
of	O
breast	O
cancer	O
development	O
.	O
Influence	O
of	O
age	O
on	O
the	O
production	O
of	O
Fos	B
and	O
Jun	B
by	O
influenza	O
virus	O
-	O
exposed	O
T	O
cells	O
.	O
This	O
study	O
investigated	O
age	O
-	O
related	O
T	O
cell	O
responses	O
after	O
in	O
vitro	O
exposure	O
to	O
influenza	O
A	O
virus	O
.	O
Mononuclear	O
leukocytes	O
from	O
young	O
or	O
elderly	O
persons	O
were	O
sham	O
-	O
exposed	O
or	O
exposed	O
to	O
influenza	O
virus	O
for	O
1	O
,	O
24	O
,	O
and	O
72	O
h	O
.	O
Immunofluorescent	O
staining	O
and	O
flow	O
cytometric	O
analysis	O
were	O
then	O
used	O
to	O
detect	O
T	O
cells	O
producing	O
the	O
transcriptional	B
regulating	I
proteins	I
Fos	B
and	O
Jun	B
.	O
Fewer	O
virus	O
-	O
exposed	O
cells	O
from	O
elderly	O
donors	O
stained	O
for	O
Fos	B
and	O
Jun	B
at	O
each	O
data	O
point	O
compared	O
with	O
cells	O
from	O
young	O
donors	O
.	O
Flow	O
cytometric	O
analysis	O
also	O
showed	O
that	O
at	O
72	O
h	O
of	O
virus	O
exposure	O
fewer	O
T	O
cells	O
from	O
the	O
elderly	O
produced	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
,	O
suggesting	O
a	O
link	O
between	O
the	O
magnitude	O
of	O
the	O
Fos	B
and	O
Jun	B
and	O
IFN	B
-	I
gamma	I
responses	O
.	O
Thus	O
,	O
failure	O
of	O
virus	O
-	O
exposed	O
T	O
cells	O
to	O
produce	O
Fos	B
and	O
Jun	B
could	O
contribute	O
to	O
the	O
increase	O
in	O
illness	O
due	O
to	O
influenza	O
virus	O
in	O
the	O
elderly	O
.	O
[	O
The	O
changes	O
in	O
glucocorticoid	O
receptors	O
in	O
peripheral	O
leukocytes	O
in	O
asthmatic	O
subjects	O
]	O
The	O
number	O
of	O
glucocorticoid	B
receptors	I
(	O
GCR	B
)	O
in	O
peripheral	O
leukocytes	O
was	O
determined	O
by	O
radioligand	O
-	O
binding	O
assay	O
in	O
extrinsic	O
and	O
intrinsic	O
asthmatics	O
.	O
Their	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed	O
.	O
The	O
results	O
showed	O
that	O
the	O
average	O
number	O
of	O
GCR	B
in	O
asthmatics	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
there	O
was	O
a	O
linear	O
correlation	O
between	O
the	O
number	O
of	O
GCR	B
and	O
the	O
course	O
of	O
asthma	O
.	O
Besides	O
,	O
there	O
was	O
also	O
a	O
linear	O
correlation	O
between	O
the	O
number	O
of	O
GCR	B
and	O
the	O
age	O
of	O
the	O
initial	O
attack	O
of	O
asthma	O
.	O
No	O
difference	O
in	O
plasma	O
cortisol	O
level	O
was	O
found	O
between	O
asthmatics	O
and	O
healthy	O
subjects	O
.	O
These	O
findings	O
suggest	O
that	O
there	O
is	O
no	O
primary	O
and	O
general	O
impairment	O
of	O
glucocorticoid	O
metabolism	O
in	O
the	O
asthmatics	O
,	O
but	O
the	O
number	O
of	O
GCR	B
in	O
the	O
asthmatics	O
is	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
.	O
The	O
decrease	O
of	O
the	O
number	O
of	O
GCR	B
in	O
asthmatics	O
,	O
we	O
think	O
,	O
is	O
related	O
to	O
heredity	O
and	O
repeated	O
attacks	O
of	O
asthma	O
.	O
Identification	O
of	O
the	O
promoter	O
region	O
of	O
chicken	O
anemia	O
virus	O
(	O
CAV	O
)	O
containing	O
a	O
novel	O
enhancer	O
-	O
like	O
element	O
.	O
The	O
single	O
promoter	O
region	O
in	O
the	O
cloned	O
genome	O
[	O
Noteborn	O
et	O
al.	O
,	O
J.	O
Virol	O
.	O
65	O
(	O
1991	O
)	O
3131	O
-	O
3139	O
]	O
of	O
chicken	O
anemia	O
virus	O
(	O
CAV	O
)	O
in	O
chicken	O
T	O
-	O
cells	O
was	O
analysed	O
via	O
CAT	B
assays	O
.	O
A	O
unique	O
region	O
containing	O
four	O
or	O
five	O
near	O
-	O
perfect	O
direct	O
repeats	O
(	O
DR	O
)	O
of	O
21	O
bp	O
with	O
one	O
12-bp	O
insert	O
was	O
proven	O
to	O
be	O
the	O
main	O
transcription	O
-	O
activation	O
element	O
,	O
with	O
enhancer	O
-	O
like	O
characteristics	O
.	O
PCR	O
studies	O
revealed	O
that	O
CAV	O
isolates	O
from	O
across	O
the	O
world	O
all	O
contained	O
this	O
promoter	O
sequence	O
.	O
Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
(	O
EMSA	O
)	O
showed	O
that	O
individual	O
DR	O
units	O
,	O
as	O
well	O
as	O
the	O
12-bp	O
insert	O
,	O
can	O
bind	O
to	O
nuclear	B
factors	I
of	O
chicken	O
T	O
-	O
cells	O
.	O
Competition	O
assays	O
revealed	O
that	O
the	O
DR	O
units	O
bound	O
to	O
factors	O
other	O
than	O
the	O
12-bp	O
insert	O
.	O
A	O
synthetic	O
oligodeoxyribonucleotide	O
containing	O
an	O
SP1-box	O
(	O
5'-GGGCGG	O
)	O
could	O
compete	O
with	O
factors	O
binding	O
to	O
the	O
12-bp	O
insert	O
.	O
Purified	O
human	B
SP1	I
was	O
shown	O
to	O
have	O
very	O
strong	O
affinity	O
for	O
the	O
12-bp	O
insert	O
.	O
T	O
-	O
cell	O
functional	O
regions	O
of	O
the	O
human	O
IL-3	O
proximal	O
promoter	O
.	O
The	O
human	O
interleukin-3	O
(	O
IL-3	O
)	O
gene	O
is	O
expressed	O
almost	O
exclusively	O
in	O
activated	O
T	O
cells	O
.	O
Its	O
expression	O
is	O
regulated	O
at	O
both	O
the	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
level	O
.	O
We	O
have	O
previously	O
shown	O
that	O
treatment	O
of	O
Jurkat	O
T	O
cells	O
with	O
phytohemaglutinin	B
(	O
PHA	B
)	O
and	O
the	O
phorbol	O
ester	O
,	O
PMA	O
,	O
activated	O
transcription	O
initiation	O
from	O
the	O
IL-3	O
gene	O
.	O
To	O
define	O
the	O
regions	O
of	O
the	O
gene	O
required	O
for	O
transcription	O
activation	O
,	O
we	O
generated	O
a	O
series	O
of	O
reporter	O
constructs	O
containing	O
different	O
regions	O
of	O
the	O
IL-3	O
gene	O
5	O
'	O
and	O
3	O
'	O
flanking	O
sequences	O
.	O
Both	O
positive	O
and	O
negative	O
regulatory	O
elements	O
were	O
identified	O
in	O
the	O
proximal	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL-3	O
gene	O
.	O
The	O
promoter	O
region	O
between	O
-173	O
and	O
-60	O
contained	O
the	O
strongest	O
activating	O
elements	O
.	O
The	O
transcription	B
factor	I
AP-1	B
could	O
bind	O
to	O
this	O
positive	O
activator	O
region	O
of	O
the	O
promoter	O
.	O
We	O
also	O
examined	O
the	O
function	O
of	O
the	O
IL-3	O
CK-1	O
/	O
CK-2	O
elements	O
that	O
are	O
present	O
in	O
many	O
cytokine	O
genes	O
and	O
found	O
that	O
they	O
acted	O
as	O
a	O
repressor	O
of	O
basal	O
level	O
expression	O
when	O
cloned	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
but	O
were	O
also	O
inducible	O
by	O
PMA	O
/PHA	B
.	O
Alternate	O
immune	O
system	O
targets	O
for	O
TCDD	O
:	O
lymphocyte	O
stem	O
cells	O
and	O
extrathymic	O
T	O
-	O
cell	O
development	O
.	O
We	O
here	O
summarize	O
evidence	O
that	O
thymic	O
atrophy	O
induced	O
by	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
can	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
damage	O
to	O
extrathymic	O
T	O
-	O
cell	O
precursors	O
in	O
bone	O
marrow	O
and	O
fetal	O
liver	O
.	O
This	O
atrophy	O
induction	O
does	O
not	O
involve	O
apoptotic	O
mechanisms	O
in	O
thymocytes	O
affected	O
by	O
the	O
bcl-2	O
proto	O
-	O
oncogene	O
.	O
TCDD	O
mediates	O
atrophy	O
induction	O
through	O
its	O
specific	O
receptor	O
(	O
the	O
AhR	B
)	O
and	O
not	O
through	O
effects	O
on	O
the	O
estrogen	O
receptor	O
.	O
Both	O
TCDD	O
and	O
estradiol	O
induce	O
extrathymic	O
T	O
-	O
cell	O
differentiation	O
in	O
the	O
liver	O
.	O
These	O
extrathymic	O
T	O
-	O
cell	O
populations	O
include	O
cells	O
expressing	O
elevated	O
levels	O
of	O
V	B
beta	I
T	I
-	I
cell	I
receptors	I
that	O
are	O
normally	O
deleted	O
in	O
thymic	O
development	O
.	O
Two	O
distinct	O
signalling	O
pathways	O
are	O
involved	O
in	O
the	O
control	O
of	O
the	O
biphasic	O
junB	O
transcription	O
induced	O
by	O
interleukin-6	B
in	O
the	O
B	O
cell	O
hybridoma	O
7TD1	O
.	O
We	O
have	O
measured	O
the	O
level	O
of	O
junB	O
mRNA	O
in	O
the	O
B	O
hybridoma	O
cell	O
line	O
7TD1	O
,	O
under	O
interleukin-6	B
(	O
IL-6	B
)	O
stimulation	O
.	O
IL-6	B
increases	O
junB	O
mRNA	O
in	O
a	O
biphasic	O
fashion	O
.	O
The	O
first	O
early	O
-	O
induced	O
peak	O
was	O
transient	O
and	O
likely	O
corresponds	O
to	O
the	O
well	O
documented	O
typical	O
junB	O
mRNA	O
,	O
stimulated	O
in	O
response	O
to	O
numerous	O
growth	B
factors	I
,	O
including	O
IL-6	B
.	O
At	O
variance	O
,	O
the	O
second	O
peak	O
which	O
has	O
never	O
been	O
reported	O
previously	O
,	O
lasted	O
several	O
hours	O
.	O
As	O
a	O
consequence	O
of	O
its	O
effect	O
on	O
junB	O
mRNA	O
,	O
IL-6	B
stimulated	O
,	O
in	O
a	O
biphasic	O
fashion	O
,	O
the	O
nuclear	O
accumulation	O
of	O
the	O
JunB	B
protein	I
.	O
In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
IL-6	B
regulation	O
occurred	O
exclusively	O
at	O
the	O
transcriptional	O
level	O
and	O
that	O
the	O
bimodal	O
increase	O
of	O
junB	O
mRNA	O
and	O
JunB	B
protein	I
can	O
be	O
accounted	O
for	O
by	O
a	O
biphasic	O
stimulation	O
of	O
junB	O
transcription	O
.	O
Furthermore	O
,	O
our	O
data	O
point	O
to	O
two	O
major	O
differences	O
between	O
the	O
mechanism	O
of	O
control	O
of	O
the	O
early	O
and	O
the	O
late	O
IL-6	B
-induced	O
junB	O
transcription	O
waves	O
.	O
First	O
,	O
cycloheximide	O
strongly	O
potentiated	O
the	O
transcription	O
of	O
the	O
second	O
wave	O
,	O
whereas	O
it	O
failed	O
to	O
affect	O
the	O
early	O
-	O
induced	O
burst	O
.	O
Second	O
,	O
tyrphostin	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
impaired	O
the	O
expression	O
of	O
the	O
first	O
but	O
not	O
the	O
second	O
junB	O
mRNA	O
peak	O
.	O
Conversely	O
,	O
genistein	O
,	O
another	O
tyrosine	O
kinase	O
inhibitor	O
,	O
totally	O
abolished	O
the	O
expression	O
of	O
the	O
second	O
peak	O
of	O
junB	O
mRNA	O
whereas	O
it	O
did	O
not	O
affect	O
the	O
expression	O
of	O
the	O
first	O
peak	O
.	O
Altogether	O
these	O
data	O
indicate	O
that	O
,	O
in	O
7TD1	O
cells	O
,	O
IL-6	B
controls	O
junB	O
transcription	O
in	O
a	O
biphasic	O
fashion	O
by	O
means	O
of	O
two	O
separate	O
transduction	O
pathways	O
.	O
Association	O
of	O
alterations	O
in	O
NF	B
-	I
kappa	I
B	I
moieties	I
with	O
HIV	O
type	O
1	O
proviral	O
latency	O
in	O
certain	O
monocytic	O
cells	O
.	O
Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virally	B
encoded	I
and	I
cellular	I
proteins	I
.	O
A	O
wide	O
spectrum	O
of	O
levels	O
of	O
HIV-1	O
expression	O
have	O
been	O
demonstrated	O
in	O
various	O
cells	O
,	O
both	O
in	O
cell	O
culture	O
and	O
in	O
vivo	O
.	O
Molecular	O
mechanisms	O
leading	O
to	O
restricted	O
HIV-1	O
replication	O
may	O
differ	O
between	O
certain	O
cell	O
types	O
.	O
It	O
is	O
now	O
demonstrated	O
that	O
HIV-1	O
proviral	O
latency	O
in	O
the	O
monocytic	O
cell	O
line	O
U1	O
,	O
in	O
which	O
only	O
extremely	O
low	O
levels	O
of	O
HIV-1	O
expression	O
are	O
detected	O
in	O
the	O
baseline	O
unstimulated	O
state	O
,	O
is	O
associated	O
with	O
alterations	O
in	O
nuclear	O
factor	B
-	I
kappa	I
B	I
(	I
NF	I
-	I
kappa	I
B	I
)	I
moieties	I
demonstrated	O
in	O
these	O
cells	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
and	O
in	O
situ	O
UV	O
cross	O
-	O
linking	O
studies	O
.	O
A	O
predominance	O
of	O
p50	B
NF	I
-	I
kappa	I
B	I
moieties	I
and	O
possibly	O
p50	B
homodimers	I
or	O
closely	O
related	O
species	O
,	O
rather	O
than	O
the	O
p50-p56	B
heterodimer	I
of	O
NF	B
-	I
kappa	I
B	I
that	O
is	O
the	O
predominant	O
NF	B
-	I
kappa	I
B	I
species	O
in	O
most	O
T	O
lymphocytic	O
and	O
monocytic	O
cells	O
,	O
is	O
demonstrated	O
in	O
the	O
nuclei	O
of	O
U1	O
cells	O
.	O
This	O
pattern	O
of	O
NF	B
-	I
kappa	I
B	I
-	I
related	I
moieties	I
differs	O
from	O
the	O
latently	O
infected	O
T	O
lymphocytic	O
cell	O
line	O
ACH-2	O
,	O
and	O
from	O
the	O
U937	O
monocytic	O
line	O
,	O
the	O
parental	O
cell	O
line	O
of	O
the	O
U1	O
cellular	O
clone	O
.	O
As	O
such	O
,	O
these	O
data	O
suggest	O
that	O
different	O
proximal	O
mechanisms	O
may	O
lead	O
to	O
restricted	O
HIV-1	O
replication	O
in	O
various	O
cell	O
types	O
.	O
Alteration	O
of	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membrane	O
by	O
glucocorticoids	O
and	O
the	O
influence	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486	O
.	O
High	O
-	O
dose	O
pulse	O
glucocorticoid	O
therapy	O
has	O
been	O
used	O
successfully	O
in	O
the	O
clinic	O
in	O
severe	O
pathological	O
conditions	O
for	O
about	O
20	O
years	O
.	O
The	O
mode	O
of	O
glucocorticoid	O
action	O
after	O
administration	O
of	O
such	O
megadoses	O
is	O
inexplicable	O
up	O
to	O
now	O
.	O
It	O
is	O
supposed	O
that	O
some	O
effects	O
may	O
be	O
due	O
to	O
membrane	O
alterations	O
.	O
In	O
the	O
present	O
in	O
-	O
vitro	O
experiments	O
the	O
effect	O
of	O
dexamethasone	O
,	O
of	O
further	O
glucocorticoids	O
,	O
and	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486	O
,	O
on	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membranes	O
was	O
investigated	O
by	O
determining	O
the	O
steady	O
-	O
state	O
fluorescence	O
anisotropy	O
of	O
diphenylhexatriene	O
(	O
DPH	O
)	O
.	O
Dexamethasone	O
was	O
found	O
to	O
induce	O
a	O
significant	O
decrease	O
in	O
membrane	O
structural	O
order	O
at	O
concentrations	O
of	O
about	O
10	O
(	O
-6	O
)	O
M	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O
We	O
found	O
a	O
correlation	O
between	O
the	O
uptake	O
of	O
dexamethasone	O
by	O
the	O
ghost	O
membranes	O
and	O
the	O
decrease	O
in	O
the	O
structural	O
order	O
.	O
The	O
other	O
glucocorticoids	O
tested	O
,	O
methylprednisolone	O
and	O
corticosterone	O
,	O
were	O
also	O
effective	O
at	O
concentrations	O
of	O
10	O
(	O
-5	O
)	O
M	O
or	O
greater	O
.	O
We	O
observed	O
no	O
change	O
in	O
membrane	O
structural	O
order	O
with	O
RU	O
486	O
up	O
to	O
a	O
concentration	O
of	O
10	O
(	O
-4	O
)	O
M	O
.	O
However	O
,	O
simultaneous	O
incubation	O
of	O
RU	O
486	O
with	O
dexamethasone	O
caused	O
a	O
distinct	O
interference	O
of	O
RU	O
486	O
with	O
dexamethasone	O
.	O
Thus	O
,	O
the	O
glucocorticoid	O
-	O
induced	O
membrane	O
perturbation	O
,	O
the	O
possibility	O
to	O
inhibit	O
it	O
by	O
RU	O
486	O
,	O
and	O
the	O
inactivity	O
of	O
the	O
structurally	O
related	O
progesterone	O
,	O
refer	O
to	O
relatively	O
specific	O
binding	O
sites	O
for	O
the	O
glucocorticoids	O
in	O
the	O
membrane	O
of	O
erythrocyte	O
ghosts	O
.	O
Glucocorticoid	O
-	O
induced	O
apoptosis	O
of	O
human	O
leukemic	O
cells	O
is	O
caused	O
by	O
the	O
repressive	O
function	O
of	O
the	O
glucocorticoid	B
receptor	I
.	O
Induction	O
of	O
apoptosis	O
in	O
lymphocytes	O
,	O
which	O
may	O
account	O
for	O
the	O
therapeutic	O
effects	O
of	O
glucocorticoids	O
in	O
various	O
diseases	O
including	O
leukemia	O
,	O
depends	O
on	O
the	O
glucocorticoid	B
receptor	I
.	O
However	O
,	O
the	O
events	O
leading	O
from	O
the	O
activated	O
receptor	O
to	O
cell	O
lysis	O
are	O
not	O
understood	O
.	O
A	O
prevailing	O
hypothesis	O
postulates	O
induction	O
of	O
so	O
-	O
called	O
'	O
lysis	O
genes	O
'	O
by	O
the	O
activated	B
receptor	I
.	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
an	O
activation	B
-	I
deficient	I
glucocorticoid	I
receptor	I
mutant	I
is	O
as	O
effective	O
as	O
the	O
wild	B
-	I
type	I
receptor	I
in	O
repression	O
of	O
AP-1	B
activity	O
,	O
inhibition	O
of	O
interleukin-2	B
production	O
,	O
inhibition	O
of	O
c	O
-	O
myc	O
expression	O
and	O
induction	O
of	O
apoptosis	O
.	O
Furthermore	O
,	O
we	O
show	O
that	O
retinoic	O
acid	O
can	O
also	O
induce	O
apoptosis	O
in	O
these	O
cells	O
through	O
the	O
retinoic	B
acid	I
receptor	I
,	O
whose	O
repressive	O
functions	O
but	O
not	O
target	O
site	O
specificity	O
,	O
are	O
similar	O
to	O
those	O
of	O
the	O
glucocorticoid	B
receptor	I
.	O
Therefore	O
,	O
the	O
primary	O
effect	O
of	O
the	O
receptor	O
in	O
glucocorticoid	O
-	O
mediated	O
apoptosis	O
correlates	O
with	O
transcriptional	O
repression	O
rather	O
than	O
activation	O
and	O
could	O
be	O
mediated	O
by	O
interference	O
with	O
other	O
transcription	B
factors	I
required	O
for	O
cell	O
survival	O
.	O
HIV-1	B
Tat	I
potentiates	O
TNF	B
-induced	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
cytotoxicity	O
by	O
altering	O
the	O
cellular	O
redox	O
state	O
.	O
This	O
study	O
demonstrates	O
that	O
human	B
immunodeficiency	I
virus	I
type	I
1	I
(	I
HIV-1	I
)	I
Tat	I
protein	I
amplifies	O
the	O
activity	O
of	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
,	O
a	O
cytokine	O
that	O
stimulates	O
HIV-1	O
replication	O
through	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
In	O
HeLa	O
cells	O
stably	O
transfected	O
with	O
the	O
HIV-1	O
tat	O
gene	O
(	O
HeLa	O
-	O
tat	O
cells	O
)	O
,	O
expression	O
of	O
the	O
Tat	B
protein	I
enhanced	O
both	O
TNF	B
-induced	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
TNF	B
-mediated	O
cytotoxicity	O
.	O
A	O
similar	O
potentiation	O
of	O
TNF	B
effects	O
was	O
observed	O
in	O
Jurkat	O
T	O
cells	O
and	O
HeLa	O
cells	O
treated	O
with	O
soluble	O
Tat	B
protein	I
.	O
TNF	B
-mediated	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
cytotoxicity	O
involves	O
the	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
.	O
Therefore	O
,	O
Tat	B
-mediated	O
effects	O
on	O
the	O
cellular	O
redox	O
state	O
were	O
analyzed	O
.	O
In	O
both	O
T	O
cells	O
and	O
HeLa	O
cells	O
HIV-1	B
Tat	I
suppressed	O
the	O
expression	O
of	O
Mn	B
-	I
dependent	I
superoxide	I
dismutase	I
(	O
Mn	B
-	I
SOD	I
)	O
,	O
a	O
mitochondrial	B
enzyme	I
that	O
is	O
part	O
of	O
the	O
cellular	O
defense	O
system	O
against	O
oxidative	O
stress	O
.	O
Thus	O
,	O
Mn	B
-	I
SOD	I
RNA	O
protein	O
levels	O
and	O
activity	O
were	O
markedly	O
reduced	O
in	O
the	O
presence	O
of	O
Tat	B
.	O
Decreased	O
Mn	B
-	I
SOD	I
expression	O
was	O
associated	O
with	O
decreased	O
levels	O
of	O
glutathione	O
and	O
a	O
lower	O
ratio	O
of	O
reduced	O
:	O
oxidized	O
glutathione	O
.	O
A	O
truncated	O
Tat	B
protein	I
(	O
Tat1	B
-	I
72	I
)	O
,	O
known	O
to	O
transactivate	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
no	O
longer	O
affected	O
Mn	B
-	I
SOD	I
expression	O
,	O
the	O
cellular	O
redox	O
state	O
or	O
TNF	B
-mediated	O
cytotoxicity	O
.	O
Thus	O
,	O
our	O
experiments	O
demonstrate	O
that	O
the	O
C	B
-	I
terminal	I
region	I
of	O
HIV-1	B
Tat	I
is	O
required	O
to	O
suppress	O
Mn	B
-	I
SOD	I
expression	O
and	O
to	O
induce	O
pro	O
-	O
oxidative	O
conditions	O
reflected	O
by	O
a	O
drop	O
in	O
reduced	O
glutathione	O
(	O
GSH	B
)	O
and	O
the	O
GSH	O
:	O
oxidized	O
GSH	O
(	O
GSSG	O
)	O
ratio	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Expression	O
of	O
the	O
Runt	O
domain	O
-	O
encoding	O
PEBP2	O
alpha	O
genes	O
in	O
T	O
cells	O
during	O
thymic	O
development	O
.	O
The	O
PEBP2	O
alpha	O
A	O
and	O
PEBP2	O
alpha	O
B	O
genes	O
encode	O
the	O
DNA	B
-	I
binding	I
subunit	I
of	O
a	O
murine	B
transcription	I
factor	I
,	O
PEBP2	B
,	O
which	O
is	O
implicated	O
as	O
a	O
T	B
-	I
cell	I
-	I
specific	I
transcriptional	I
regulator	I
.	O
These	O
two	O
related	O
genes	O
share	O
the	O
evolutionarily	O
conserved	O
region	O
encoding	O
the	O
Runt	B
domain	I
.	O
PEBP2	B
alpha	I
B	I
is	O
the	O
murine	B
counterpart	I
of	O
human	B
AML1	I
,	O
which	O
is	O
located	O
at	O
the	O
breakpoints	O
of	O
the	O
8	O
;	O
21	O
and	O
3	O
;	O
21	O
chromosome	O
translocations	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
.	O
Northern	O
(	O
RNA	O
)	O
blots	O
of	O
various	O
adult	O
mouse	O
tissues	O
revealed	O
that	O
the	O
levels	O
of	O
expression	O
of	O
both	O
genes	O
were	O
most	O
prominent	O
in	O
the	O
thymus	O
.	O
Furthermore	O
,	O
transcripts	O
of	O
PEBP2	B
alpha	I
A	I
and	O
mouse	B
AML1	I
/	I
PEBP2	I
alpha	I
B	I
were	O
detected	O
in	O
T	O
lymphocytes	O
in	O
the	O
thymuses	O
from	O
day	O
16	O
embryos	O
and	O
newborns	O
,	O
as	O
well	O
as	O
4-week	O
-	O
old	O
adult	O
mice	O
,	O
by	O
in	O
situ	O
hybridization	O
.	O
The	O
expression	O
of	O
the	O
genes	O
persisted	O
in	O
peripheral	O
lymph	O
nodes	O
of	O
adult	O
mice	O
.	O
The	O
transcripts	O
were	O
detected	O
in	O
all	O
the	O
CD4-	O
CD8-	O
,	O
CD4	O
+	O
CD8	O
+	O
,	O
CD4	O
+	O
CD8-	O
,	O
and	O
CD4-	O
CD8	O
+	O
cell	O
populations	O
.	O
The	O
results	O
indicated	O
that	O
both	O
genes	O
are	O
expressed	O
in	O
T	O
cells	O
throughout	O
their	O
development	O
,	O
supporting	O
the	O
notion	O
that	O
PEBP2	B
is	O
a	O
T	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
.	O
Transcripts	O
of	O
mouse	B
AML1	I
/	I
PEBP2	I
alpha	I
B	I
were	O
also	O
detected	O
in	O
day	O
12	O
fetal	O
hematopoietic	O
liver	O
and	O
in	O
the	O
bone	O
marrow	O
cells	O
of	O
newborn	O
mice	O
.	O
The	O
implication	O
of	O
mouse	O
AML1	B
/	I
PEBP2	I
alpha	I
B	I
expression	O
in	O
hematopoietic	O
cells	O
other	O
than	O
those	O
of	O
T	O
-	O
cell	O
lineage	O
is	O
discussed	O
in	O
relation	O
to	O
myeloid	O
leukemogenesis	O
.	O
Effects	O
of	O
glucocorticoids	O
on	O
transcription	O
factor	O
activation	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
Glucocorticoids	O
have	O
an	O
inhibitory	O
effect	O
on	O
inflammatory	O
and	O
immune	O
responses	O
,	O
and	O
this	O
may	O
be	O
through	O
the	O
modulation	O
of	O
transcription	B
factor	I
binding	O
to	O
DNA	O
.	O
The	O
interaction	O
of	O
the	O
transcription	B
factors	I
,	O
activator	B
protein-1	I
(	O
AP-1	B
)	O
,	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
kappa	I
B	I
)	O
,	O
and	O
cAMP	B
-	I
responsive	I
element	I
binding	I
protein	I
(	O
CREB	B
)	O
with	O
DNA	O
and	O
glucocorticoid	B
receptors	I
(	O
GR	B
)	O
was	O
analyzed	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
gel	O
mobility	O
shift	O
assays	O
.	O
TNF	O
-	O
alpha	O
,	O
IL-1	O
beta	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
treatment	O
increased	O
AP-1	B
and	O
NF	O
kappa	O
B	O
DNA	O
binding	O
by	O
up	O
to	O
200	O
%	O
but	O
decreased	O
CREB	B
binding	O
(	O
38	O
%	O
)	O
over	O
a	O
60-min	O
time	O
course	O
.	O
Dexamethasone	O
produced	O
a	O
rapid	O
and	O
sustained	O
increase	O
in	O
glucocorticoid	O
response	O
element	O
binding	O
and	O
a	O
concomitant	O
40	O
-	O
50	O
%	O
decrease	O
in	O
AP-1	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
CREB	O
DNA	O
binding	O
that	O
was	O
blocked	O
by	O
combined	O
dexamethasone	O
and	O
cytokine	B
or	O
PMA	O
treatment	O
.	O
These	O
latter	O
effects	O
were	O
due	O
to	O
increases	O
in	O
the	O
nuclear	O
localization	O
of	O
GR	B
,	O
not	O
to	O
reduced	O
amounts	O
of	O
the	O
other	O
transcription	B
factors	I
.	O
This	O
suggests	O
that	O
in	O
these	O
cells	O
GR	B
within	O
the	O
nucleus	O
interacts	O
with	O
cytokine	B
-	I
stimulated	I
transcription	I
factors	I
by	O
the	O
process	O
of	O
cross	O
coupling	O
.	O
This	O
may	O
be	O
an	O
important	O
molecular	O
site	O
of	O
steroid	O
action	O
.	O
Control	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
proteolysis	O
by	O
site	O
-	O
specific	O
,	O
signal	O
-	O
induced	O
phosphorylation	O
.	O
I	B
kappa	I
B	I
-	I
alpha	I
inhibits	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
by	O
retaining	O
it	O
in	O
the	O
cytoplasm	O
.	O
Various	O
stimuli	O
,	O
typically	O
those	O
associated	O
with	O
stress	O
or	O
pathogens	O
,	O
rapidly	O
inactivate	O
I	B
kappa	I
B	I
-	I
alpha	I
.	O
This	O
liberates	O
NF	B
-	I
kappa	I
B	I
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
initiate	O
transcription	O
of	O
genes	O
important	O
for	O
the	O
defense	O
of	O
the	O
organism	O
.	O
Activation	O
of	O
NF	B
-	I
kappa	I
B	I
correlates	O
with	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
and	O
requires	O
the	O
proteolysis	O
of	O
this	O
inhibitor	O
.	O
When	O
either	O
serine-32	O
or	O
serine-36	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
was	O
mutated	O
,	O
the	O
protein	O
did	O
not	O
undergo	O
signal	O
-	O
induced	O
phosphorylation	O
or	O
degradation	O
,	O
and	O
NF	B
-	I
kappa	I
B	I
could	O
not	O
be	O
activated	O
.	O
These	O
results	O
suggest	O
that	O
phosphorylation	O
at	O
one	O
or	O
both	O
of	O
these	O
residues	O
is	O
critical	O
for	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
HIV-1	B
Nef	I
leads	O
to	O
inhibition	O
or	O
activation	O
of	O
T	O
cells	O
depending	O
on	O
its	O
intracellular	O
localization	O
.	O
Nef	B
of	O
primate	O
lentiviruses	O
is	O
required	O
for	O
viremia	O
and	O
progression	O
to	O
AIDS	O
in	O
monkeys	O
.	O
Negative	O
,	O
positive	O
,	O
and	O
no	O
effects	O
of	O
Nef	B
have	O
also	O
been	O
reported	O
on	O
viral	O
replication	O
in	O
cells	O
.	O
To	O
reconcile	O
these	O
observations	O
,	O
we	O
expressed	O
a	O
hybrid	B
CD8-Nef	I
protein	I
in	O
Jurkat	O
cells	O
.	O
Two	O
opposite	O
phenotypes	O
were	O
found	O
,	O
which	O
depended	O
on	O
the	O
intracellular	O
localization	O
of	O
Nef	B
.	O
Expressed	O
in	O
the	O
cytoplasm	O
or	O
on	O
the	O
cell	O
surface	O
,	O
the	O
chimera	B
inhibited	O
or	O
activated	O
early	O
signaling	O
events	O
from	O
the	O
T	B
cell	I
antigen	I
receptor	I
.	O
Activated	O
Jurkat	O
cells	O
died	O
by	O
apoptosis	O
,	O
and	O
only	O
cells	O
with	O
mutated	O
nef	O
genes	O
expressing	O
truncated	O
Nefs	B
survived	O
,	O
which	O
rendered	O
Nef	B
nonfunctional	O
.	O
These	O
mutations	O
paralleled	O
those	O
in	O
other	O
viral	O
strains	O
passaged	O
in	O
vitro	O
.	O
Not	O
only	O
do	O
these	O
positional	O
effects	O
of	O
Nef	B
reconcile	O
diverse	O
phenotypes	O
of	O
Nef	B
and	O
suggest	O
a	O
role	O
for	O
its	O
N	O
-	O
terminal	O
myristylation	O
,	O
but	O
they	O
also	O
explain	O
effects	O
of	O
Nef	B
in	O
HIV	O
infection	O
and	O
progression	O
to	O
AIDS	O
.	O
The	O
regulation	O
of	O
HIV	O
by	O
retinoic	O
acid	O
correlates	O
with	O
cellular	O
expression	O
of	O
the	O
retinoic	B
acid	I
receptors	I
.	O
OBJECTIVES	O
:	O
To	O
analyze	O
the	O
effect	O
of	O
retinoic	O
acids	O
(	O
RA	O
)	O
on	O
HIV-1	O
expression	O
and	O
correlate	O
this	O
effect	O
with	O
expression	O
levels	O
of	O
RA	B
receptors	I
(	O
RARs	B
)	O
in	O
T	O
-	O
lymphoid	O
and	O
monocytoid	O
cell	O
lines	O
.	O
DESIGN	O
AND	O
METHODS	O
:	O
The	O
effect	O
of	O
all	O
-	O
trans	O
and	O
9-cis	O
RA	O
on	O
HIV-1	O
production	O
in	O
T	O
-	O
lymphoid	O
(	O
H9	O
,	O
CEM	O
)	O
and	O
monocytoid	O
(	O
U937	O
,	O
THP-1	O
)	O
cell	O
lines	O
was	O
measured	O
during	O
acute	O
and	O
chronic	O
infection	O
.	O
The	O
expression	O
levels	O
of	O
human	B
RAR	I
alpha	I
(	O
hRAR	B
alpha	I
,	I
receptor	I
for	O
all	O
-	O
trans	O
RA	O
)	O
and	O
the	O
human	B
retinoid	I
-	I
X	I
receptor	I
alpha	I
(	O
hRXR	B
alpha	I
receptor	I
for	O
9-cis	O
RA	O
)	O
were	O
determined	O
by	O
Northern	O
blot	O
analysis	O
.	O
RESULTS	O
:	O
Both	O
all	O
-	O
trans	O
and	O
9-cis	O
RA	O
inhibited	O
virus	O
replication	O
in	O
HIV-1	O
IIIB	O
-	O
infected	O
monocytoid	O
cells	O
,	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
co	O
-	O
stimulatory	O
agent	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O
The	O
retinoids	O
had	O
weak	O
or	O
no	O
stimulatory	O
effects	O
on	O
HIV	O
production	O
by	O
T	O
-	O
cell	O
lines	O
.	O
HIV	O
production	O
by	O
PMA	O
-	O
stimulated	O
T	O
-	O
cell	O
lines	O
was	O
inhibited	O
by	O
these	O
retinoids	O
.	O
The	O
9-cis	O
RA	O
was	O
generally	O
more	O
effective	O
than	O
all	O
-	O
trans	O
RA	O
in	O
inhibiting	O
HIV	O
production	O
and	O
in	O
combination	O
generally	O
more	O
effective	O
than	O
the	O
single	O
agents	O
alone	O
.	O
Human	B
RAR	I
alpha	I
was	O
expressed	O
in	O
H9	O
,	O
U937	O
and	O
THP-1	O
cells	O
,	O
but	O
almost	O
undetectable	O
in	O
CEM	O
cells	O
.	O
Human	B
RXR	I
alpha	I
was	O
significantly	O
expressed	O
in	O
U937	O
and	O
THP-1	O
cells	O
,	O
weakly	O
expressed	O
in	O
H9	O
cells	O
and	O
not	O
detectable	O
in	O
CEM	O
cells	O
.	O
After	O
stimulation	O
by	O
PMA	O
,	O
RXR	B
alpha	I
expression	O
increased	O
in	O
H9	O
and	O
U937	O
cells	O
but	O
not	O
in	O
CEM	O
cells	O
.	O
Human	O
RAR	O
alpha	O
expression	O
was	O
unchanged	O
in	O
H9	O
and	O
CEM	O
cells	O
,	O
and	O
elevated	O
in	O
U937	O
cells	O
,	O
after	O
PMA	O
stimulation	O
.	O
CONCLUSION	O
:	O
The	O
effect	O
of	O
RA	O
on	O
HIV-1	O
expression	O
was	O
cell	O
-	O
type	O
-	O
dependent	O
and	O
partially	O
correlated	O
with	O
cellular	O
expression	O
of	O
RARs	B
.	O
Endogenous	O
or	O
exogenously	O
administered	O
RA	O
may	O
have	O
a	O
significant	O
role	O
in	O
HIV	O
regulation	O
.	O
Identification	O
of	O
human	O
TR2	O
orphan	O
receptor	O
response	O
element	O
in	O
the	O
transcriptional	O
initiation	O
site	O
of	O
the	O
simian	O
virus	O
40	O
major	O
late	O
promoter	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Nov	O
3	O
;	O
270	O
(	O
44	O
)	O
:	O
26721	O
]	O
A	O
DNA	O
response	O
element	O
(	O
TR2RE	O
-	O
SV40	O
)	O
for	O
the	O
TR2	B
orphan	I
receptor	I
,	O
a	O
member	O
of	O
the	O
steroid	B
-	I
thyroid	I
hormone	I
receptor	I
superfamily	I
,	O
has	O
been	O
identified	O
in	O
the	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
+	O
55	O
region	O
(	O
nucleotide	O
numbers	O
368	O
-	O
389	O
,	O
5'-GTTAAGGTTCGTAGGTCATGGA-3	O
'	O
)	O
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
,	O
using	O
in	O
vitro	O
translated	O
TR2	B
orphan	I
receptor	I
with	O
a	O
molecular	O
mass	O
of	O
67	B
kilodaltons	I
,	O
showed	O
a	O
specific	O
binding	O
with	O
high	O
affinity	O
(	O
dissociation	O
constant	O
=	O
9	O
nM	O
)	O
for	O
this	O
DNA	O
sequence	O
.	O
DNA	O
-	O
swap	O
experiments	O
using	O
chloramphenicol	B
acetyl	I
-	I
transferase	I
assay	O
demonstrated	O
that	O
androgen	O
can	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
SV40	O
early	O
promoter	O
via	O
the	O
interaction	O
between	O
this	O
TR2RE	O
-	O
SV40	O
and	O
the	O
chimeric	B
receptor	I
AR	I
/	I
TR2	I
/	I
AR	I
with	O
the	O
DNA	B
-	I
binding	I
domain	I
of	O
the	O
TR2	B
orphan	I
receptor	I
flanked	O
by	O
the	O
N	B
-	I
terminal	I
and	I
androgen	I
-	I
binding	I
domains	I
of	O
the	O
androgen	B
receptor	I
.	O
In	O
addition	O
,	O
this	O
TR2RE	O
-	O
SV40	O
can	O
function	O
as	O
a	O
repressor	O
to	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
both	O
SV40	O
early	O
and	O
late	O
promoters	O
.	O
Together	O
,	O
these	O
data	O
suggest	O
the	O
TR2RE	O
-	O
SV40	O
may	O
represent	O
the	O
first	O
identified	O
natural	O
DNA	O
response	O
element	O
for	O
the	O
TR2	B
orphan	I
receptor	I
that	O
may	O
function	O
as	O
a	O
repressor	O
for	O
the	O
SV40	O
gene	O
expression	O
.	O
[	O
Regulation	O
of	O
transcription	O
of	O
the	O
interleukin-2	O
gene	O
in	O
B	O
-	O
lymphocytes	O
]	O
Since	O
most	O
B	O
cell	O
clones	O
immortalized	O
with	O
EBV	O
virus	O
can	O
be	O
induced	O
to	O
produce	O
interleukin-2	B
,	O
a	O
typical	O
T	B
cell	I
cytokine	I
,	O
we	O
studied	O
the	O
role	O
of	O
different	O
elements	O
of	O
the	O
IL-2	O
promoter	O
in	O
such	O
clones	O
by	O
transfection	O
.	O
It	O
was	O
found	O
,	O
in	O
particular	O
,	O
that	O
the	O
element	O
TCEd	O
,	O
which	O
binds	O
the	O
transcription	B
factor	I
NF	B
-	I
kB	I
,	O
is	O
very	O
active	O
in	O
all	O
three	O
B	O
clones	O
tested	O
.	O
This	O
element	O
has	O
no	O
activity	O
in	O
T	O
cells	O
of	O
the	O
Jurkat	O
line	O
.	O
The	O
NFATd	O
element	O
,	O
which	O
binds	O
the	O
transcription	B
factor	I
NFAT-1	B
and	O
is	O
very	O
active	O
in	O
T	O
cells	O
,	O
is	O
only	O
weakly	O
active	O
in	O
one	O
B	O
clone	O
and	O
not	O
at	O
all	O
in	O
another	O
.	O
Different	O
elements	O
thus	O
contribute	O
to	O
IL-2	O
promoter	O
activity	O
in	O
different	O
cells	O
.	O
Changes	O
in	O
triiodothyronine	O
(	O
T3	O
)	O
mononuclear	O
leukocyte	O
receptor	O
kinetics	O
after	O
T3	O
administration	O
and	O
multiple	O
cold	O
-	O
air	O
exposures	O
.	O
Repeated	O
cold	O
-	O
air	O
exposures	O
increase	O
human	O
triiodothyronine	O
(	O
T3	O
)	O
plasma	O
clearance	O
rates	O
.	O
To	O
study	O
the	O
response	O
of	O
the	O
nuclear	B
T3	I
receptor	I
(	O
NT3R	B
)	O
in	O
this	O
condition	O
,	O
binding	O
characteristics	O
were	O
analyzed	O
in	O
human	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
.	O
In	O
addition	O
,	O
we	O
supplemented	O
one	O
group	O
of	O
individuals	O
with	O
a	O
daily	O
oral	O
replacement	O
dose	O
of	O
T3	O
to	O
isolate	O
the	O
influence	O
of	O
serum	O
thyroxine	O
(	O
T4	O
)	O
and	O
thyrotropin	O
(	O
TSH	O
)	O
levels	O
on	O
receptor	O
kinetics	O
.	O
The	O
subjects	O
were	O
exposed	O
to	O
cold	O
air	O
(	O
4	O
degrees	O
C	O
)	O
twice	O
/	O
d	O
,	O
30	O
min	O
/	O
exposure	O
,	O
for	O
a	O
total	O
of	O
80	O
exposures	O
.	O
The	O
T3-subjects	O
received	O
placebo	O
[	O
n	O
=	O
8	O
]	O
and	O
the	O
T3	O
+	O
subjects	O
received	O
T3	O
(	O
30	O
micrograms	O
/	O
d	O
)	O
[	O
n	O
=	O
8	O
]	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
.	O
Mononuclear	O
leukocytes	O
were	O
isolated	O
from	O
peripheral	O
blood	O
before	O
the	O
cold	O
exposure	O
and	O
drug	O
regimen	O
began	O
,	O
and	O
then	O
after	O
every	O
20	O
exposures	O
.	O
The	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
maximum	O
binding	O
capacity	O
(	O
MBC	O
)	O
of	O
the	O
NT3R	B
values	O
were	O
log	O
transformed	O
to	O
minimize	O
between	O
-	O
subject	O
variability	O
.	O
In	O
the	O
T3	O
+	O
group	O
,	O
serum	O
total	O
thyroxine	O
(	O
TT4	O
)	O
,	O
free	O
T4	O
(	O
FT4	O
)	O
,	O
and	O
TSH	O
were	O
approx	O
50	O
%	O
lower	O
than	O
both	O
basal	O
and	O
T3-values	O
.	O
The	O
log10Kd	O
increased	O
0.304	O
+	O
/-	O
0.139	O
(	O
p	O
<	O
0.04	O
)	O
and	O
the	O
log10MBC	O
increased	O
0.49	O
+	O
/-	O
0.10	O
(	O
p	O
<	O
0.001	O
)	O
in	O
the	O
T3	O
+	O
subjects	O
compared	O
to	O
baseline	O
.	O
This	O
change	O
in	O
MBC	O
represents	O
a	O
311	O
%	O
increase	O
in	O
the	O
MBC	O
over	O
baseline	O
and	O
a	O
fivefold	O
increase	O
over	O
placebo	O
-	O
treated	O
subjects	O
.	O
The	O
T3	O
-group	O
showed	O
no	O
change	O
in	O
MBC	O
over	O
the	O
study	O
.	O
These	O
results	O
describe	O
for	O
the	O
first	O
time	O
the	O
rapid	O
modulation	O
of	O
the	O
NT3R	B
in	O
response	O
to	O
the	O
combined	O
influence	O
of	O
cold	O
exposure	O
and	O
reduced	O
circulating	O
T4	O
and	O
TSH	O
.	O
Nitric	O
oxide	O
-	O
stimulated	O
guanine	O
nucleotide	O
exchange	O
on	O
p21ras	B
.	O
The	O
protooncogene	O
p21ras	O
,	O
a	O
monomeric	B
G	I
protein	I
family	I
member	I
,	O
plays	O
a	O
critical	O
role	O
in	O
converting	O
extracellular	O
signals	O
into	O
intracellular	O
biochemical	O
events	O
.	O
Here	O
,	O
we	O
report	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
activates	O
p21ras	O
in	O
human	O
T	O
cells	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
GTP	B
-	I
bound	I
p21ras	I
.	O
In	O
vitro	O
studies	O
using	O
pure	B
recombinant	I
p21ras	I
demonstrate	O
that	O
the	O
activation	O
is	O
direct	O
and	O
reversible	O
.	O
Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	O
in	O
association	O
with	O
GDP	O
/	O
GTP	O
exchange	O
.	O
The	O
mechanism	O
of	O
activation	O
is	O
due	O
to	O
S	O
-	O
nitrosylation	O
of	O
a	O
critical	O
cysteine	O
residue	O
which	O
stimulates	O
guanine	O
nucleotide	O
exchange	O
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
p21ras	B
is	O
essential	O
for	O
NO	O
-	O
induced	O
downstream	O
signaling	O
,	O
such	O
as	O
NF	B
-	I
kappa	I
B	I
activation	O
,	O
and	O
that	O
endogenous	O
NO	O
can	O
activate	O
p21ras	B
in	O
the	O
same	O
cell	O
.	O
These	O
studies	O
identify	O
p21ras	O
as	O
a	O
target	O
of	O
the	O
same	O
cell	O
.	O
These	O
studies	O
identify	O
p21ras	O
as	O
a	O
target	O
of	O
NO	O
in	O
T	O
cells	O
and	O
suggest	O
that	O
NO	O
activates	O
p21ras	O
by	O
an	O
action	O
which	O
mimics	O
that	O
of	O
guanine	B
nucleotide	I
exchange	I
factors	I
.	O
Functional	O
characterization	O
of	O
novel	O
IL-2	B
transcriptional	O
inhibitors	O
.	O
IL-2	B
-mediated	O
T	O
cell	O
proliferation	O
is	O
a	O
critical	O
early	O
event	O
in	O
the	O
inflammatory	O
process	O
.	O
Formation	O
of	O
the	O
NFAT-1	B
transcriptional	I
complex	I
on	O
the	O
IL-2	O
promoter	O
is	O
essential	O
for	O
IL-2	B
transcription	O
.	O
Using	O
a	O
cell	O
line	O
that	O
is	O
stably	O
transfected	O
with	O
a	O
trimer	O
of	O
the	O
NFAT-1	O
regulatory	O
element	O
linked	O
to	O
a	O
lac	O
-	O
Z	O
reporter	O
gene	O
,	O
we	O
screened	O
for	O
inhibitors	O
of	O
NFAT	B
-1-mediated	O
beta	B
-	I
galactosidase	I
activity	O
.	O
WIN	O
61058	O
and	O
WIN	O
53071	O
were	O
identified	O
as	O
microM	O
inhibitors	O
.	O
These	O
compounds	O
also	O
inhibited	O
beta	O
-	O
galactosidase	O
mRNA	O
levels	O
.	O
Similar	O
inhibition	O
of	O
NFAT	B
-1-mediated	O
gene	O
expression	O
was	O
observed	O
in	O
a	O
second	O
cell	O
line	O
,	O
which	O
is	O
stably	O
transfected	O
with	O
NFAT-1	O
regulatory	O
elements	O
linked	O
to	O
the	O
reporter	O
gene	O
for	O
sCD8	O
.	O
At	O
10	O
microM	O
,	O
both	O
compounds	O
inhibited	O
IL-2	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
NFAT-1-linked	O
lac	O
-	O
Z	O
transfectants	O
,	O
and	O
in	O
human	O
lymphocytes	O
.	O
Both	O
compounds	O
inhibited	O
the	O
mixed	O
lymphocyte	O
reaction	O
,	O
and	O
this	O
inhibition	O
was	O
reversed	O
by	O
exogenous	O
IL-2	B
.	O
WIN	O
53071	O
inhibited	O
IL-2	B
production	O
induced	O
in	O
the	O
calcium	O
-	O
dependent	O
PMA	O
and	O
ionomycin	O
pathway	O
.	O
Conversely	O
,	O
calcium	B
-	I
independent	I
anti	I
-	I
CD28	I
Ab	I
and	O
PMA	O
-	O
induced	O
IL-2	B
production	O
was	O
resistant	O
.	O
Both	O
compounds	O
altered	O
the	O
NFAT-1	B
transcriptional	I
complex	I
,	O
causing	O
its	O
retarded	O
mobility	O
on	O
gels	O
.	O
By	O
these	O
functional	O
criteria	O
,	O
we	O
believe	O
we	O
have	O
identified	O
two	O
structurally	O
distinct	O
,	O
novel	O
inhibitors	O
of	O
NFAT	B
-1-mediated	O
transcription	O
.	O
cDNA	O
cloning	O
of	O
a	O
NGFI	B
-	I
B	I
/	I
nur77-related	I
transcription	I
factor	I
from	O
an	O
apoptotic	O
human	O
T	O
cell	O
line	O
.	O
A	O
human	O
T	O
lymphoid	O
cell	O
line	O
,	O
PEER	O
,	O
dies	O
by	O
apoptosis	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
calcium	O
ionophore	O
.	O
A	O
new	O
gene	O
,	O
TINUR	O
,	O
was	O
cloned	O
from	O
apoptotic	O
PEER	O
cells	O
.	O
The	O
expression	O
of	O
the	O
TINUR	O
gene	O
is	O
induced	O
within	O
1	O
h	O
after	O
the	O
cross	O
-	O
linking	O
of	O
the	O
T	B
cell	I
Ag	I
receptor	I
complex	I
.	O
TINUR	O
belongs	O
to	O
the	O
NGFI	B
-	I
B	I
/	I
nur77	I
family	I
of	O
the	O
steroid	B
receptor	I
superfamily	I
and	O
is	O
an	O
orphan	B
receptor	I
.	O
TINUR	O
binds	O
to	O
the	O
same	O
DNA	O
sequence	O
as	O
NGFI	B
-	I
B	I
/	I
nur77	I
.	O
We	O
also	O
propose	O
that	O
the	O
NGFI	B
-	I
B	I
/	I
nur77	I
family	I
can	O
be	O
classified	O
into	O
two	O
subtypes	O
.	O
Platelet	B
-	I
activating	I
factor	I
stimulates	O
transcription	O
of	O
the	O
heparin	B
-	I
binding	I
epidermal	I
growth	I
factor	I
-	I
like	I
growth	I
factor	I
in	O
monocytes	O
.	O
Correlation	O
with	O
an	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O
Human	O
peripheral	O
blood	O
monocytes	O
responded	O
to	O
stimulation	O
of	O
platelet	B
-	I
activating	I
factor	I
(	O
PAF	B
)	O
with	O
up	O
-	O
regulation	O
of	O
the	O
transcript	O
for	O
heparin	B
-	I
binding	I
epidermal	I
growth	I
factor	I
-	I
like	I
growth	I
factor	I
(	O
HB	B
-	I
EGF	I
)	O
,	O
a	O
potent	B
mitogen	I
for	O
vascular	O
smooth	O
muscle	O
cells	O
.	O
This	O
function	O
of	O
PAF	B
was	O
observed	O
at	O
nanomolar	O
concentrations	O
of	O
the	O
ligand	O
,	O
starting	O
at	O
30	O
min	O
after	O
stimulation	O
.	O
The	O
PAF	B
-induced	O
up	O
-	O
regulation	O
of	O
HB	O
-	O
EGF	O
mRNA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
kappa	O
B	O
binding	O
activity	O
.	O
These	O
functions	O
of	O
PAF	B
appeared	O
to	O
be	O
mediated	O
through	O
the	O
cell	B
surface	I
PAF	I
receptors	I
,	O
as	O
two	O
PAF	B
receptor	O
antagonists	O
,	O
WEB	O
2086	O
and	O
L-659	O
,	O
989	O
,	O
blocked	O
both	O
the	O
up	O
-	O
regulation	O
of	O
HB	O
-	O
EGF	O
mRNA	O
and	O
kappa	O
B	O
binding	O
activity	O
induced	O
by	O
PAF	B
.	O
The	O
antagonists	O
,	O
however	O
,	O
had	O
no	O
effect	O
on	O
phorbol	O
ester	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
HB	O
-	O
EGF	O
mRNA	O
and	O
kappa	O
B	O
binding	O
activity	O
.	O
Pretreatment	O
of	O
monocytes	O
with	O
pertussis	O
toxin	O
inhibited	O
these	O
functions	O
of	O
PAF	B
,	O
whereas	O
cholera	O
toxin	O
had	O
no	O
inhibitory	O
effect	O
.	O
Pyrrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
for	O
NF	B
-	I
kappa	I
B	I
activation	O
,	O
markedly	O
reduced	O
PAF	B
-stimulated	O
kappa	O
B	O
binding	O
activity	O
as	O
well	O
as	O
up	O
-	O
regulation	O
of	O
HB	O
-	O
EGF	O
mRNA	O
.	O
These	O
results	O
suggest	O
a	O
potential	O
role	O
of	O
PAF	B
in	O
HB	B
-	I
EGF	I
expression	O
and	O
provide	O
evidence	O
that	O
this	O
stimulation	O
may	O
occur	O
through	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O
Identification	O
and	O
purification	O
of	O
human	B
Stat	I
proteins	I
activated	O
in	O
response	O
to	O
interleukin-2	B
.	O
A	O
key	O
cytokine	B
induced	O
during	O
the	O
immune	O
response	O
is	O
IL-2	B
.	O
Following	O
T	O
cell	O
activation	O
,	O
the	O
genes	O
encoding	O
IL-2	B
and	O
the	O
various	O
chains	O
of	O
its	O
receptor	O
are	O
transcriptionally	O
induced	O
.	O
In	O
turn	O
,	O
secreted	O
IL-2	B
serves	O
to	O
stimulate	O
the	O
proliferation	O
and	O
differentiation	O
of	O
T	O
lymphocytes	O
.	O
Several	O
recent	O
studies	O
have	O
implicated	O
Jak	O
kinases	O
in	O
the	O
signaling	O
pathway	O
induced	O
by	O
IL-2	B
.	O
Following	O
this	O
lead	O
,	O
we	O
set	O
out	O
to	O
identify	O
transcription	B
factors	I
induced	O
in	O
response	O
to	O
IL-2	B
.	O
Human	O
peripheral	O
blood	O
lymphocytes	O
were	O
observed	O
to	O
contain	O
several	O
IL-2	B
-inducible	O
DNA	O
binding	O
activities	O
.	O
Similar	O
activities	O
were	O
also	O
observed	O
in	O
a	O
transformed	O
human	O
lymphocyte	O
line	O
,	O
termed	O
YT	O
.	O
We	O
have	O
purified	O
these	O
activities	O
and	O
found	O
that	O
the	O
principal	O
IL-2-inducible	B
component	I
bears	O
significant	O
relatedness	O
to	O
a	O
prolactin	B
-	I
induced	I
transcription	I
factor	I
first	O
identified	O
in	O
sheep	O
mammary	O
gland	O
tissue	O
.	O
We	O
hypothesize	O
that	O
activation	O
of	O
this	O
protein	O
,	O
designated	O
hStat5	B
,	O
helps	O
govern	O
the	O
biological	O
effects	O
of	O
IL-2	B
during	O
the	O
immune	O
response	O
.	O
Growth	O
regulation	O
and	O
cellular	O
changes	O
during	O
differentiation	O
of	O
human	O
prostatic	O
cancer	O
LNCaP	O
cells	O
as	O
induced	O
by	O
T	O
lymphocyte	O
-	O
conditioned	O
medium	O
.	O
Human	O
prostatic	O
epithelial	O
cells	O
from	O
an	O
androgen	O
-	O
dependent	O
LNCaP	O
cell	O
line	O
were	O
examined	O
in	O
response	O
to	O
conditioned	O
medium	O
(	O
CM	O
)	O
derived	O
from	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-stimulated	O
lymphocytes	O
.	O
Addition	O
of	O
CM	O
caused	O
a	O
greater	O
than	O
70	O
%	O
reduction	O
of	O
cell	O
proliferation	O
by	O
cell	O
counting	O
and	O
cell	O
cycle	O
.	O
These	O
cells	O
showed	O
G1	O
phase	O
arrest	O
and	O
the	O
clonogenicity	O
was	O
reduced	O
.	O
The	O
growth	O
-	O
modulating	O
effect	O
was	O
dose	O
-	O
dependent	O
and	O
not	O
due	O
to	O
cell	O
lysis	O
or	O
apoptosis	O
.	O
The	O
binding	O
of	O
androgen	O
to	O
androgen	B
receptor	I
on	O
these	O
cells	O
showed	O
approximately	O
50	O
%	O
reduction	O
,	O
underlining	O
a	O
proliferation	O
reduction	O
mechanism	O
.	O
The	O
prostate	B
-	I
specific	I
antigen	I
(	O
PSA	B
)	O
was	O
downregulated	O
to	O
approximately	O
75	O
%	O
during	O
the	O
process	O
.	O
Cell	O
morphology	O
showed	O
dendritic	O
processes	O
extending	O
from	O
cytoplasm	O
and	O
other	O
neuroendocrine	O
cell	O
characteristics	O
.	O
The	O
expression	O
of	O
several	O
cytoskeleton	B
and	I
intracellular	I
proteins	I
increased	O
as	O
determined	O
by	O
immunostaining	O
on	O
slides	O
and	O
by	O
ELISA	O
procedures	O
.	O
These	O
included	O
vimentin	B
,	O
correlating	O
to	O
cell	O
shape	O
changes	O
,	O
cytokeratins	B
8	I
and	I
18	I
,	O
associated	O
with	O
differentiated	O
cell	O
types	O
of	O
prostate	O
epithelia	O
,	O
and	O
neuron	B
-	I
specific	I
enolase	I
and	O
serotonin	O
,	O
associated	O
with	O
neuroendocrine	O
cells	O
.	O
From	O
these	O
cellular	O
changes	O
,	O
we	O
can	O
infer	O
that	O
the	O
cell	O
growth	O
was	O
modulated	O
along	O
with	O
induction	O
of	O
terminal	O
differentiation	O
.	O
Activated	O
T	O
cells	O
were	O
demonstrated	O
to	O
be	O
important	O
in	O
providing	O
the	O
modulating	O
activity	O
.	O
This	O
growth	B
modulator	I
was	O
semipurified	O
and	O
had	O
an	O
estimated	O
molecular	O
weight	O
13	O
,	O
000	O
to	O
24	O
,	O
000	O
Da	O
.	O
The	O
activity	O
was	O
determined	O
to	O
be	O
distinct	O
from	O
TGF	B
,	O
TNF	B
,	O
and	O
some	O
commonly	O
known	O
lymphokines	B
.	O
The	O
interaction	O
between	O
lymphoid	O
and	O
prostatic	O
cells	O
in	O
growth	O
and	O
development	O
is	O
described	O
.	O
Mouse	O
interleukin-2	O
receptor	O
alpha	O
gene	O
expression	O
.	O
Interleukin-1	B
and	O
interleukin-2	B
control	O
transcription	O
via	O
distinct	O
cis	O
-	O
acting	O
elements	O
.	O
We	O
have	O
shown	O
that	O
interleukin-1	B
(	O
IL-1	B
)	O
and	O
IL-2	B
control	O
IL-2	O
receptor	O
alpha	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
transcription	O
in	O
CD4-CD8-	O
murine	O
T	O
lymphocyte	O
precursors	O
.	O
Here	O
we	O
map	O
the	O
cis	O
-	O
acting	O
elements	O
that	O
mediate	O
interleukin	O
responsiveness	O
of	O
the	O
mouse	O
IL-2R	O
alpha	O
gene	O
using	O
a	O
thymic	O
lymphoma	O
-	O
derived	O
hybridoma	O
(	O
PC60	O
)	O
.	O
The	O
transcriptional	O
response	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
to	O
stimulation	O
by	O
IL-1	B
+	O
IL-2	B
is	O
biphasic	O
.	O
IL-1	B
induces	O
a	O
rapid	O
,	O
protein	O
synthesis	O
-	O
independent	O
appearance	O
of	O
IL-2R	O
alpha	O
mRNA	O
that	O
is	O
blocked	O
by	O
inhibitors	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
It	O
also	O
primes	O
cells	O
to	O
become	O
IL-2	B
responsive	O
and	O
thereby	O
prepares	O
the	O
second	O
phase	O
,	O
in	O
which	O
IL-2	B
induces	O
a	O
100-fold	O
further	O
increase	O
in	O
IL-2R	O
alpha	O
transcripts	O
.	O
Transient	O
transfection	O
experiments	O
show	O
that	O
several	O
elements	O
in	O
the	O
promoter	O
-	O
proximal	O
region	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
contribute	O
to	O
IL-1	B
responsiveness	O
,	O
most	O
importantly	O
an	O
NF	O
-	O
kappa	O
B	O
site	O
conserved	O
in	O
the	O
human	O
and	O
mouse	O
gene	O
.	O
IL-2	B
responsiveness	O
,	O
on	O
the	O
other	O
hand	O
,	O
depends	O
on	O
a	O
78-nucleotide	O
segment	O
1.3	O
kilobases	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
.	O
This	O
segment	O
functions	O
as	O
an	O
IL-2-inducible	O
enhancer	O
and	O
lies	O
within	O
a	O
region	O
that	O
becomes	O
DNase	B
I	I
hypersensitive	O
in	O
normal	O
T	O
cells	O
in	O
which	O
IL-2R	B
alpha	I
expression	O
has	O
been	O
induced	O
.	O
IL-2	B
responsiveness	O
requires	O
three	O
distinct	O
elements	O
within	O
the	O
enhancer	O
.	O
Two	O
of	O
these	O
are	O
potential	O
binding	O
sites	O
for	O
STAT	B
proteins	I
.	O
Neutrophils	O
and	O
monocytes	O
express	O
high	O
levels	O
of	O
PU.1	B
(	O
Spi-1	B
)	O
but	O
not	O
Spi	B
-	I
B	I
.	O
PU.1	B
(	O
the	O
Spi-1	O
oncogene	O
)	O
and	O
Spi	B
-	I
B	I
are	O
closely	O
related	O
members	O
of	O
the	O
ets	B
transcription	I
factor	I
family	I
,	O
sharing	O
similar	O
DNA	O
binding	O
specificities	O
mediated	O
by	O
similar	O
DNA	B
binding	I
domains	I
.	O
PU.1	B
and	O
Spi	B
-	I
B	I
have	O
been	O
previously	O
described	O
as	O
being	O
predominantly	O
expressed	O
coordinately	O
in	O
macrophages	O
and	O
B	O
cells	O
,	O
but	O
their	O
expression	O
in	O
early	O
hematopoietic	O
stages	O
and	O
during	O
the	O
course	O
of	O
myeloid	O
differentiation	O
to	O
monocytes	O
and	O
macrophages	O
or	O
to	O
neutrophils	O
has	O
not	O
been	O
extensively	O
investigated	O
.	O
Here	O
,	O
we	O
report	O
that	O
PU.1	O
mRNA	O
is	O
upregulated	O
during	O
myeloid	O
differentiation	O
of	O
human	O
purified	O
CD34	O
+	O
cells	O
and	O
murine	O
multipotential	O
FDCP	O
-	O
mix	O
A4	O
cells	O
,	O
suggesting	O
that	O
PU.1	B
is	O
upregulated	O
as	O
an	O
early	O
event	O
during	O
differentiation	O
of	O
multipotential	O
progenitor	O
cells	O
.	O
PU.1	B
expression	O
is	O
maintained	O
at	O
stable	O
levels	O
during	O
differentiation	O
of	O
myeloid	O
cell	O
lines	O
U937	O
and	O
HL-60	O
to	O
monocytic	O
and	O
neutrophilic	O
cells	O
.	O
PU.1	B
is	O
expressed	O
at	O
highest	O
levels	O
in	O
mature	O
human	O
monocytes	O
and	O
human	O
peripheral	O
blood	O
neutrophils	O
.	O
In	O
contrast	O
to	O
PU.1	B
,	O
significant	O
levels	O
of	O
Spi	O
-	O
B	O
mRNA	O
and	O
protein	O
are	O
found	O
only	O
in	O
some	O
B	O
-	O
cell	O
lines	O
and	O
spleen	O
but	O
are	O
not	O
found	O
in	O
myeloid	O
cell	O
lines	O
,	O
neutrophils	O
,	O
or	O
macrophages	O
.	O
In	O
vitro	O
translated	O
Spi	B
-	I
B	I
protein	I
can	O
bind	O
to	O
PU.1	O
binding	O
sites	O
in	O
myeloid	O
promoters	O
and	O
transactivate	O
these	O
promoters	O
in	O
nonmyeloid	O
cells	O
.	O
Therefore	O
,	O
although	O
PU.1	B
and	O
Spi	B
-	I
B	I
may	O
bind	O
to	O
similar	O
DNA	O
control	O
elements	O
and	O
have	O
redundancy	O
of	O
transactivation	O
function	O
in	O
vitro	O
,	O
the	O
lack	O
of	O
significant	O
levels	O
of	O
Spi	B
-	I
B	I
in	O
myeloid	O
cells	O
makes	O
it	O
unlikely	O
that	O
Spi	B
-	I
B	I
plays	O
a	O
significant	O
role	O
in	O
myeloid	O
lineage	O
development	O
and	O
gene	O
expression	O
.	O
In	O
contrast	O
,	O
PU.1	B
is	O
expressed	O
at	O
high	O
levels	O
not	O
only	O
in	O
monocytes	O
and	O
macrophages	O
but	O
also	O
in	O
neutrophils	O
,	O
indicating	O
that	O
PU.1	B
can	O
activate	O
gene	O
expression	O
in	O
both	O
major	O
myeloid	O
lineages	O
.	O
Differential	O
induction	O
of	O
the	O
NF	B
-	I
AT	I
complex	I
during	O
restimulation	O
and	O
the	O
induction	O
of	O
T	O
-	O
cell	O
anergy	O
.	O
Stimulation	O
of	O
human	O
CD4	O
+	O
T	O
-	O
cell	O
clones	O
through	O
the	O
T	B
-	I
cell	I
receptor	I
(	O
TcR	B
)	O
by	O
high	O
doses	O
of	O
specific	O
peptide	O
results	O
in	O
the	O
induction	O
of	O
a	O
long	O
-	O
lived	O
state	O
of	O
nonresponsiveness	O
that	O
has	O
been	O
called	O
anergy	O
.	O
During	O
the	O
induction	O
of	O
anergy	O
,	O
T	O
cells	O
are	O
phenotypically	O
similar	O
to	O
cells	O
responding	O
to	O
an	O
immunogenic	O
stimulus	O
.	O
The	O
amount	O
of	O
TcR	B
at	O
the	O
cell	O
surface	O
is	O
downmodulated	O
,	O
whereas	O
the	O
CD2	B
and	I
CD25	I
receptors	I
are	O
increased	O
.	O
When	O
restimulated	O
,	O
however	O
,	O
anergic	O
T	O
cells	O
fail	O
to	O
up	O
-	O
regulate	O
transcription	O
of	O
the	O
IL-2	O
gene	O
and	O
in	O
consequence	O
do	O
not	O
produce	O
IL-2	B
.	O
In	O
this	O
study	O
,	O
we	O
have	O
compared	O
the	O
ability	O
of	O
various	O
transcription	B
factors	I
to	O
bind	O
to	O
their	O
appropriate	O
site	O
on	O
DNA	O
.	O
Factors	O
were	O
isolated	O
from	O
the	O
nuclei	O
of	O
T	O
cells	O
that	O
were	O
in	O
the	O
induction	O
phase	O
of	O
anergy	O
or	O
were	O
undergoing	O
activation	O
.	O
The	O
pattern	O
of	O
binding	O
activity	O
in	O
restimulated	O
T	O
cells	O
is	O
consistent	O
with	O
the	O
pattern	O
that	O
has	O
previously	O
been	O
shown	O
to	O
regulate	O
T	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
IL-2	B
and	O
the	O
beta	O
chain	O
of	O
the	O
TcR	O
genes	O
.	O
The	O
measured	O
binding	O
to	O
a	O
TCF-1	O
site	O
is	O
the	O
same	O
in	O
the	O
nuclei	O
of	O
resting	O
,	O
activated	O
,	O
and	O
anergized	O
cells	O
.	O
The	O
inducible	B
factors	I
NK	B
-	I
kappa	I
B	I
,	O
beta	B
E2	I
,	O
CD28RC	B
,	O
and	O
AP-1	B
are	O
not	O
expressed	O
in	O
resting	O
cells	O
and	O
are	O
twofold	O
lower	O
in	O
anergized	O
as	O
compared	O
with	O
activated	O
cells	O
.	O
In	O
contrast	O
,	O
anergic	O
T	O
cells	O
express	O
approximately	O
eightfold	O
lower	O
amounts	O
of	O
NF	B
-	I
AT	I
,	O
a	O
member	O
of	O
the	O
class	O
of	O
inducible	B
factors	I
that	O
regulates	O
IL-2	O
gene	O
transcription	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Erythropoietin	B
stimulates	O
transcription	O
of	O
the	O
TAL1	O
/	O
SCL	O
gene	O
and	O
phosphorylation	O
of	O
its	O
protein	B
products	I
.	O
Activation	O
of	O
the	O
TAL1	O
(	O
or	O
SCL	O
)	O
gene	O
,	O
originally	O
identified	O
through	O
its	O
involvement	O
by	O
a	O
recurrent	O
chromosomal	O
translocation	O
,	O
is	O
the	O
most	O
frequent	O
molecular	O
lesion	O
recognized	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
.	O
The	O
protein	B
products	I
of	O
this	O
gene	O
contain	O
the	O
basic	B
-	I
helix	I
-	I
loop	I
-	I
helix	I
motif	I
characteristic	O
of	O
a	O
large	O
family	O
of	O
transcription	B
factors	I
that	O
bind	O
to	O
the	O
canonical	O
DNA	O
sequence	O
CANNTG	O
as	O
protein	B
heterodimers	I
.	O
TAL1	B
expression	O
by	O
erythroid	O
cells	O
in	O
vivo	O
and	O
in	O
chemical	O
-	O
induced	O
erythroleukemia	O
cell	O
lines	O
in	O
vivo	O
suggested	O
the	O
gene	O
might	O
regulate	O
aspects	O
of	O
erythroid	O
differentiation	O
.	O
Since	O
the	O
terminal	O
events	O
of	O
erythropoiesis	O
are	O
controlled	O
by	O
the	O
glycoprotein	B
hormone	I
erythropoietin	I
(	O
Epo	B
)	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
or	O
activity	O
of	O
the	O
TAL1	O
gene	O
and	O
its	O
protein	B
products	I
were	O
affected	O
by	O
Epo	B
in	O
splenic	O
erythroblasts	O
from	O
mice	O
infected	O
with	O
an	O
anemia	O
-	O
inducing	O
strain	O
of	O
Friend	O
virus	O
(	O
FVA	O
cells	O
)	O
.	O
Epo	B
elicited	O
a	O
rapid	O
,	O
dose	O
-	O
related	O
increase	O
in	O
TAL1	O
mRNA	O
by	O
increasing	O
transcription	O
of	O
the	O
gene	O
and	O
stabilizing	O
one	O
of	O
its	O
mRNAs	O
.	O
An	O
Epo	B
-inducible	O
TAL1	B
DNA	O
binding	O
activity	O
was	O
identified	O
in	O
FVA	O
cell	O
nuclear	O
extracts	O
that	O
subsequently	O
decayed	O
despite	O
accumulating	O
mRNA	O
and	O
protein	O
.	O
Induction	O
of	O
DNA	O
binding	O
activity	O
was	O
associated	O
temporally	O
with	O
Epo	B
-induced	O
phosphorylation	O
of	O
nuclear	B
TAL1	I
protein	I
.	O
These	O
results	O
indicate	O
that	O
Epo	B
acts	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
on	O
the	O
TAL1	B
locus	O
in	O
Friend	O
virus	O
-	O
induced	O
erythroblasts	O
and	O
establish	O
a	O
link	O
between	O
Epo	B
signaling	O
mechanisms	O
and	O
a	O
member	O
of	O
a	O
family	O
of	O
transcription	B
factors	I
involved	O
in	O
the	O
differentiation	O
of	O
diverse	O
cell	O
lineages	O
.	O
The	O
retinoblastoma	B
gene	I
product	I
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	B
cytomegalovirus	I
IE2	I
protein	I
.	O
The	O
IE2	B
gene	I
product	I
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	B
regulatory	I
proteins	I
expressed	O
immediately	O
upon	O
infection	O
of	O
the	O
host	O
cell	O
.	O
It	O
is	O
a	O
potent	O
transcriptional	B
activator	I
of	O
many	O
viral	O
and	O
cellular	O
promoters	O
.	O
We	O
found	O
that	O
the	O
retinoblastoma	B
susceptibility	I
gene	I
product	I
(	O
Rb	B
)	O
dramatically	O
suppressed	O
this	O
IE2	B
transactivation	O
of	O
various	O
promoters	O
.	O
However	O
,	O
unlike	O
another	O
tumor	B
suppressor	I
protein	I
,	O
p53	B
,	O
Rb	B
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	B
specifically	O
interacts	O
with	O
IE2	B
rather	O
than	O
other	O
cellular	B
factors	I
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O
We	O
found	O
by	O
protein	O
-	O
affinity	O
chromatography	O
that	O
Rb	B
in	O
nuclear	O
extracts	O
or	O
produced	O
by	O
in	O
vitro	O
translation	O
directly	O
bound	O
to	O
IE2	B
.	O
Our	O
results	O
suggest	O
that	O
Rb	B
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O
Furthermore	O
,	O
these	O
data	O
may	O
provide	O
new	O
insights	O
into	O
the	O
slow	O
rate	O
of	O
HCMV	O
DNA	O
replication	O
in	O
cells	O
and	O
the	O
possible	O
involvement	O
of	O
HCMV	O
in	O
tumorigenesis	O
.	O
Epstein	O
-	O
Barr	O
virus	O
replicative	O
gene	O
transcription	O
during	O
de	O
novo	O
infection	O
of	O
human	O
thymocytes	O
:	O
simultaneous	O
early	O
expression	O
of	O
BZLF-1	B
and	O
its	O
repressor	O
RAZ	B
.	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
known	O
to	O
infect	O
B	O
cells	O
and	O
epithelial	O
cells	O
.	O
We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	O
.	O
Infection	O
of	O
thymocytes	O
was	O
accompanied	O
by	O
the	O
appearance	O
of	O
linear	O
EBV	O
genome	O
within	O
8	O
hr	O
of	O
infection	O
.	O
Circularization	O
of	O
the	O
EBV	O
genome	O
was	O
not	O
detected	O
.	O
This	O
is	O
in	O
contrast	O
to	O
the	O
infection	O
in	O
B	O
cells	O
where	O
the	O
genome	O
can	O
circularize	O
within	O
24	O
hr	O
of	O
infection	O
.	O
The	O
appearance	O
of	O
the	O
BamHI	B
ZLF-1	I
gene	I
product	I
,	O
ZEBRA	B
,	O
by	O
RT	O
-	O
PCR	O
,	O
was	O
observed	O
within	O
8	O
hr	O
of	O
infection	O
.	O
The	O
appearance	O
of	O
a	O
novel	O
fusion	B
transcript	I
(	O
RAZ	B
)	O
,	O
which	O
comprised	O
regions	O
of	O
the	O
BZLF-1	O
locus	O
and	O
the	O
adjacent	O
BRLF-1	O
locus	O
,	O
was	O
detected	O
by	O
RT	O
-	O
PCR	O
.	O
ZEBRA	B
protein	I
was	O
also	O
identified	O
in	O
infected	O
thymocytes	O
by	O
immunoprecipitation	O
.	O
In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
EBNA-1	O
gene	O
in	O
infected	O
thymocytes	O
was	O
transcribed	O
from	O
the	O
Fp	O
promoter	O
,	O
rather	O
than	O
from	O
the	O
Cp	O
/	O
Wp	O
promoter	O
which	O
is	O
used	O
in	O
latently	O
infected	O
B	O
cells	O
.	O
Transcripts	O
encoding	O
gp350	B
/	I
220	I
,	O
the	O
major	B
coat	I
protein	I
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP-2A	O
or	O
EBER-1	O
loci	O
in	O
infected	O
thymocytes	O
.	O
These	O
observations	O
suggest	O
that	O
de	O
novo	O
EBV	O
infection	O
of	O
thymocytes	O
differs	O
from	O
infection	O
of	O
B	O
cells	O
.	O
The	O
main	O
difference	O
is	O
that	O
with	O
thymocytes	O
,	O
no	O
evidence	O
could	O
be	O
found	O
that	O
the	O
virus	O
ever	O
circularizes	O
.	O
Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	O
genes	O
are	O
transcribed	O
.	O
Induction	O
of	O
Sp1	B
phosphorylation	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
independent	O
HIV	O
promoter	O
domain	O
activity	O
in	O
T	O
lymphocytes	O
stimulated	O
by	O
okadaic	O
acid	O
.	O
In	O
contrast	O
to	O
the	O
purely	O
enhancer	O
-	O
dependent	O
effect	O
of	O
cytokines	B
such	O
as	O
TNF	B
on	O
the	O
activity	O
of	O
the	O
HIV	O
regulatory	O
region	O
(	O
LTR	O
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
the	O
promoter	O
domain	O
of	O
the	O
LTR	O
.	O
The	O
inducibility	O
of	O
HIV	O
LTR	O
-	O
driven	O
luciferase	O
expression	O
constructs	O
in	O
lymphoblastoid	O
cells	O
stimulated	O
by	O
OKA	O
depended	O
on	O
both	O
functional	O
Sp1	O
binding	O
elements	O
and	O
the	O
ability	O
of	O
the	O
TATA	O
box	O
to	O
bind	O
the	O
protein	O
TBP	B
.	O
In	O
both	O
transformed	O
and	O
normal	O
lymphocytes	O
,	O
OKA	O
stimulation	O
induced	O
intense	O
phosphorylation	O
of	O
the	O
constitutively	O
expressed	O
Sp1	B
protein	I
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	O
shared	O
by	O
TNF	B
,	O
phorbol	O
ester	O
,	O
or	O
PHA	B
and	O
interleukin	B
2	I
.	O
Responsiveness	O
of	O
LTR	O
constructs	O
deleted	O
of	O
kappa	O
B	O
elements	O
to	O
HIV	B
Tat	I
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	B
stimulation	O
.	O
Our	O
results	O
suggest	O
that	O
SP1	B
phosphorylation	O
induced	O
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine	B
-	I
threonine	I
phosphatase	I
PP2A	B
,	O
facilitates	O
the	O
formation	O
of	O
a	O
transcription	B
complex	I
involving	O
general	O
transcription	B
factors	I
,	O
HIV	B
Tat	I
,	O
and	O
Sp1	B
proteins	I
.	O
The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF	B
-	I
kappa	I
B	I
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	O
LTR	O
observed	O
in	O
normal	O
T	O
lymphocytes	O
.	O
GM	B
-	I
CSF	I
and	O
IL-2	B
share	O
common	O
control	O
mechanisms	O
in	O
response	O
to	O
costimulatory	O
signals	O
in	O
T	O
cells	O
.	O
Antigen	O
complexed	O
with	O
major	B
histocompatibility	I
complex	I
class	I
I	I
or	I
II	I
molecules	I
on	O
the	O
surface	O
of	O
antigen	O
presenting	O
cells	O
interacts	O
with	O
the	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
on	O
the	O
surface	O
of	O
T	O
cells	O
and	O
initiates	O
an	O
activation	O
cascade	O
.	O
So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	B
cytokines	I
produced	O
by	O
antigen	O
presenting	O
cells	O
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O
High	O
levels	O
of	O
cytokine	B
gene	O
expression	O
in	O
T	O
cells	O
also	O
required	O
both	O
TCR	B
and	O
costimulatory	O
signals	O
.	O
The	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
requires	O
sequences	O
in	O
the	O
promoter	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	O
located	O
3	O
kb	O
upstream	O
to	O
respond	O
to	O
TCR	B
-like	O
signals	O
.	O
These	O
promoter	O
and	O
enhancer	O
regions	O
are	O
mainly	O
activated	O
by	O
the	O
transcription	B
factor	I
nuclear	I
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
.	O
The	O
activation	O
of	O
NFAT	B
by	O
TCR	B
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin-2	O
(	O
IL-2	B
)	O
and	O
IL-4	O
gene	O
transcription	O
in	O
T	O
cells	O
.	O
Costimulatory	O
signals	O
,	O
such	O
as	O
activation	O
of	O
the	O
CD28	B
cell	I
surface	I
molecule	I
on	O
T	O
cells	O
,	O
lead	O
to	O
activation	O
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
promoter	O
.	O
This	O
region	O
is	O
termed	O
the	O
CK-1	O
or	O
CD28RE	O
and	O
appears	O
to	O
bind	O
specific	O
members	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
family	I
of	O
transcription	B
factors	I
.	O
Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
infects	O
T	O
cells	O
and	O
can	O
lead	O
to	O
increase	O
GM	B
-	I
CSF	I
expression	O
.	O
We	O
have	O
found	O
that	O
the	O
HTLV-1	B
transactivator	I
protein	I
,	O
tax	B
,	O
acts	O
as	O
a	O
costimulatory	O
signal	O
for	O
GM	O
-	O
CSF	O
and	O
IL-2	O
gene	O
transcription	O
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	B
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O
Tax	O
activates	O
the	O
GM	O
-	O
CSF	O
promoter	O
through	O
the	O
CK-1	O
/CD28RE	O
region	O
and	O
also	O
activates	O
nuclear	B
factor	I
-	I
kappa	I
B	I
binding	O
to	O
this	O
region	O
.	O
However	O
,	O
other	O
transcription	B
factors	I
or	O
coactivators	O
of	O
NF	B
-	I
kappa	I
B	I
are	O
required	O
for	O
tax	B
activation	O
but	O
these	O
remain	O
to	O
be	O
identified	O
.	O
The	O
CK-1	O
/CD28RE	O
of	O
GM	B
-	I
CSF	I
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
the	O
IL-2	B
CD28RE	O
and	O
the	O
IL-3	O
gene	O
also	O
contains	O
a	O
related	O
region	O
.	O
This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM	B
-	I
CSF	I
and	O
IL-2	B
respond	O
to	O
TCR	B
signals	O
via	O
NFAT	B
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	B
gene	O
expression	O
in	O
T	O
cells	O
.	O
A	O
Myc	O
-	O
associated	O
zinc	O
finger	O
protein	O
binding	O
site	O
is	O
one	O
of	O
four	O
important	O
functional	O
regions	O
in	O
the	O
CD4	O
promoter	O
.	O
The	O
CD4	O
promoter	O
plays	O
an	O
important	O
role	O
in	O
the	O
developmental	O
control	O
of	O
CD4	B
transcription	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
minimal	O
CD4	O
promoter	O
has	O
four	O
factor	O
binding	O
sites	O
,	O
each	O
of	O
which	O
is	O
required	O
for	O
full	O
function	O
.	O
Using	O
biochemical	O
and	O
mutagenesis	O
analyses	O
,	O
we	O
determined	O
that	O
multiple	O
nuclear	B
factors	I
bind	O
to	O
these	O
independent	O
sites	O
.	O
We	O
determined	O
that	O
an	O
initiator	O
-	O
like	O
sequence	O
present	O
at	O
the	O
cap	O
site	O
and	O
an	O
Ets	O
consensus	O
sequence	O
are	O
required	O
for	O
full	O
promoter	O
function	O
.	O
We	O
also	O
demonstrate	O
that	O
the	O
Myc	B
-	I
associated	I
zinc	I
finger	I
protein	I
(	O
MAZ	B
)	O
appears	O
to	O
be	O
the	O
predominant	B
factor	I
binding	O
to	O
one	O
of	O
these	O
sites	O
.	O
This	O
last	O
site	O
closely	O
resembles	O
the	O
ME1a1	O
G3AG4AG3	O
motif	O
previously	O
shown	O
to	O
be	O
a	O
critical	O
element	O
in	O
the	O
P2	O
promoter	O
of	O
the	O
c	O
-	O
myc	O
gene	O
.	O
We	O
therefore	O
believe	O
that	O
the	O
MAZ	B
transcription	I
factor	I
is	O
also	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
developmental	O
expression	O
of	O
the	O
CD4	O
gene	O
.	O
Does	O
activation	O
of	O
the	O
TAL1	O
gene	O
occur	O
in	O
a	O
majority	O
of	O
patients	O
with	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
?	O
A	O
pediatric	O
oncology	O
group	O
study	O
.	O
Almost	O
25	O
%	O
of	O
patients	O
with	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
have	O
tumor	O
-	O
specific	O
rearrangements	O
of	O
the	O
TAL1	O
gene	O
.	O
Although	O
TAL1	B
expression	O
has	O
not	O
been	O
observed	O
in	O
normal	O
lymphocytes	O
,	O
TAL1	B
gene	I
products	I
are	O
readily	O
detected	O
in	O
leukemic	O
cells	O
that	O
harbor	O
a	O
rearranged	O
TAL1	O
allele	O
.	O
Hence	O
,	O
it	O
has	O
been	O
proposed	O
that	O
ectopic	O
expression	O
of	O
TAL1	B
promotes	O
the	O
development	O
of	O
T	O
-	O
ALL	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
TAL1	B
is	O
expressed	O
in	O
the	O
leukemic	O
cells	O
of	O
most	O
patients	O
with	O
T	O
-	O
ALL	O
,	O
including	O
many	O
that	O
do	O
not	O
display	O
an	O
apparent	O
TAL1	O
gene	O
alteration	O
.	O
A	O
polymorphic	O
dinucleotide	O
repeat	O
in	O
the	O
transcribed	O
sequences	O
of	O
TAL1	B
was	O
used	O
to	O
determine	O
the	O
allele	O
specificity	O
of	O
TAL1	B
transcription	O
in	O
primary	O
T	O
-	O
ALL	O
cells	O
.	O
Monoallelic	O
expression	O
of	O
TAL1	B
was	O
observed	O
in	O
the	O
leukemic	O
cells	O
of	O
all	O
patients	O
(	O
8	O
of	O
8	O
)	O
bearing	O
a	O
TAL1	O
gene	O
rearrangement	O
.	O
In	O
the	O
leukemic	O
cells	O
of	O
patients	O
without	O
detectable	O
TAL1	B
rearrangements	O
,	O
TAL1	B
transcription	O
occurred	O
in	O
either	O
a	O
monoallelic	O
(	O
3	O
of	O
7	O
patients	O
)	O
or	O
a	O
biallelic	O
(	O
4	O
of	O
7	O
patients	O
)	O
fashion	O
.	O
Thus	O
,	O
TAL1	B
activation	O
in	O
these	O
patients	O
may	O
result	O
from	O
subtle	O
alterations	O
in	O
cis	O
-	O
acting	O
regulatory	O
sequences	O
(	O
affecting	O
expression	O
of	O
a	O
single	O
TAL1	O
allele	O
)	O
or	O
changes	O
in	O
trans	O
-	O
acting	O
factors	O
that	O
control	O
TAL1	B
transcription	O
(	O
affecting	O
expression	O
of	O
both	O
TAL1	O
alleles	O
)	O
.	O
Hematopoietic	O
lineage	O
commitment	O
:	O
role	O
of	O
transcription	B
factors	I
.	O
This	O
review	O
focuses	O
on	O
the	O
roles	O
of	O
transcription	B
factors	I
in	O
hematopoietic	O
lineage	O
commitment	O
.	O
A	O
brief	O
introduction	O
to	O
lineage	O
commitment	O
and	O
asymmetric	O
cell	O
division	O
is	O
followed	O
by	O
a	O
discussion	O
of	O
several	O
methods	O
used	O
to	O
identify	O
transcription	B
factors	I
important	O
in	O
specifying	O
hematopoietic	O
cell	O
types	O
.	O
Next	O
is	O
presented	O
a	O
discussion	O
of	O
the	O
use	O
of	O
embryonic	O
stem	O
cells	O
in	O
the	O
analysis	O
of	O
hematopoietic	O
gene	O
expression	O
and	O
the	O
use	O
of	O
targeted	O
gene	O
disruption	O
to	O
analyze	O
the	O
role	O
of	O
transcription	B
factors	I
in	O
hematopoiesis	O
.	O
Finally	O
,	O
the	O
status	O
of	O
our	O
current	O
knowledge	O
concerning	O
the	O
roles	O
of	O
transcription	B
factors	I
in	O
the	O
commitment	O
to	O
erythroid	O
,	O
myeloid	O
and	O
lymphoid	O
cell	O
types	O
is	O
summarized	O
.	O
E1A	O
gene	O
expression	O
induces	O
susceptibility	O
to	O
killing	O
by	O
NK	O
cells	O
following	O
immortalization	O
but	O
not	O
adenovirus	O
infection	O
of	O
human	O
cells	O
.	O
Adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
E1A	B
transfection	O
were	O
used	O
to	O
model	O
changes	O
in	O
susceptibility	O
to	O
NK	O
cell	O
killing	O
caused	O
by	O
transient	O
vs	O
stable	O
E1A	B
expression	O
in	O
human	O
cells	O
.	O
Only	O
stably	O
transfected	O
target	O
cells	O
exhibited	O
cytolytic	O
susceptibility	O
,	O
despite	O
expression	O
of	O
equivalent	O
levels	O
of	O
E1A	B
proteins	I
in	O
Ad	O
-	O
infected	O
targets	O
.	O
The	O
inability	O
of	O
E1A	O
gene	O
products	O
to	O
induce	O
cytolytic	O
susceptibility	O
during	O
infection	O
was	O
not	O
explained	O
by	O
an	O
inhibitory	O
effect	O
of	O
viral	O
infection	O
on	O
otherwise	O
susceptible	O
target	O
cells	O
or	O
by	O
viral	O
gene	O
effects	O
on	O
class	B
I	I
MHC	I
antigen	I
expression	O
on	O
target	O
cells	O
.	O
This	O
differential	O
effect	O
of	O
E1A	B
expression	O
on	O
the	O
cytolytic	O
phenotypes	O
of	O
infected	O
and	O
stably	O
transfected	O
human	O
cells	O
suggests	O
that	O
human	O
NK	O
cells	O
provide	O
an	O
effective	O
immunologic	O
barrier	O
against	O
the	O
in	O
vivo	O
survival	O
and	O
neoplastic	O
progression	O
of	O
E1A	O
-	O
immortalized	O
cells	O
that	O
may	O
emerge	O
from	O
the	O
reservoir	O
of	O
persistently	O
infected	O
cells	O
in	O
the	O
human	O
host	O
.	O
Distinct	O
signaling	O
properties	O
identify	O
functionally	O
different	O
CD4	B
epitopes	I
.	O
The	O
CD4	B
coreceptor	I
interacts	O
with	O
non	B
-	I
polymorphic	I
regions	I
of	O
major	B
histocompatibility	I
complex	I
class	I
II	I
molecules	I
on	O
antigen	O
-	O
presenting	O
cells	O
and	O
contributes	O
to	O
T	O
cell	O
activation	O
.	O
We	O
have	O
investigated	O
the	O
effect	O
of	O
CD4	B
triggering	O
on	O
T	O
cell	O
activating	O
signals	O
in	O
a	O
lymphoma	O
model	O
using	O
monoclonal	B
antibodies	I
(	O
mAb	B
)	O
which	O
recognize	O
different	O
CD4	B
epitopes	I
.	O
We	O
demonstrate	O
that	O
CD4	B
triggering	O
delivers	O
signals	O
capable	O
of	O
activating	O
the	O
NF	B
-	I
AT	I
transcription	I
factor	I
which	O
is	O
required	O
for	O
interleukin-2	B
gene	O
expression	O
.	O
Whereas	O
different	O
anti	B
-	I
CD4	I
mAb	I
or	O
HIV-1	B
gp120	I
could	O
all	O
trigger	O
activation	O
of	O
the	O
protein	B
tyrosine	I
kinases	I
p56lck	B
and	O
p59fyn	B
and	O
phosphorylation	O
of	O
the	O
Shc	B
adaptor	I
protein	I
,	O
which	O
mediates	O
signals	O
to	O
Ras	B
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF	B
-	I
AT	I
.	O
Lack	O
of	O
full	O
activation	O
of	O
NF	B
-	I
AT	I
could	O
be	O
correlated	O
to	O
a	O
dramatically	O
reduced	O
capacity	O
to	O
induce	O
calcium	O
flux	O
and	O
could	O
be	O
complemented	O
with	O
a	O
calcium	O
ionophore	O
.	O
The	O
results	O
identify	O
functionally	O
distinct	O
epitopes	B
on	O
the	O
CD4	B
coreceptor	I
involved	O
in	O
activation	O
of	O
the	O
Ras	B
/	I
protein	I
kinase	I
C	I
and	O
calcium	O
pathways	O
.	O
A	O
functional	O
T	B
-	I
cell	I
receptor	I
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B
activity	O
.	O
Stimulation	O
of	O
the	O
T	B
-	I
cell	I
antigen	I
receptor	I
(	O
TCR	B
)	O
induces	O
activation	O
of	O
multiple	O
tyrosine	B
kinases	I
,	O
resulting	O
in	O
phosphorylation	O
of	O
numerous	O
intracellular	O
substrates	O
.	O
One	O
substrate	O
is	O
p95vav	B
,	O
which	O
is	O
expressed	O
exclusively	O
in	O
hematopoietic	O
and	O
trophoblast	O
cells	O
.	O
It	O
contains	O
a	O
number	O
of	O
structural	B
motifs	I
,	O
including	O
Src	B
homology	I
2	I
,	I
Src	I
homology	I
3	I
,	I
and	I
pleckstrin	I
homology	I
domains	I
and	O
a	O
putative	B
guanine	I
nucleotide	I
exchange	I
domain	I
.	O
The	O
role	O
of	O
p95vav	B
in	O
TCR	B
-mediated	O
signaling	O
processes	O
is	O
unclear	O
.	O
Here	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
p95vav	B
alone	O
in	O
Jurkat	O
T	O
cells	O
leads	O
to	O
activation	O
of	O
the	O
nuclear	B
factors	I
,	O
including	O
NFAT	B
,	O
involved	O
in	O
interleukin-2	B
expression	O
.	O
Furthermore	O
,	O
p95vav	B
synergizes	O
with	O
TCR	B
stimulation	O
in	O
inducing	O
NFAT-	O
and	O
interleukin-2-dependent	O
transcription	O
.	O
In	O
contrast	O
,	O
NFAT	B
activation	O
by	O
a	O
G	B
-	I
protein	I
-	I
coupled	I
receptor	I
is	O
not	O
modulated	O
by	O
p95vav	B
overexpression	O
,	O
suggesting	O
that	O
the	O
effect	O
is	O
specific	O
to	O
the	O
TCR	B
signaling	O
pathways	O
.	O
Although	O
removal	O
of	O
the	O
first	B
67	I
amino	I
acids	I
of	O
p95vav	B
activates	O
its	O
transforming	O
potential	O
in	O
NIH	O
3T3	O
cells	O
,	O
this	O
region	O
appears	O
to	O
be	O
required	O
for	O
its	O
function	O
in	O
T	O
cells	O
.	O
We	O
further	O
demonstrate	O
that	O
the	O
p95vav	B
-induced	O
NFAT	B
activation	O
is	O
not	O
mimicked	O
by	O
Ras	B
activation	O
,	O
though	O
its	O
function	O
is	O
dependent	O
upon	O
Ras	B
and	O
Raf	B
.	O
Furthermore	O
,	O
the	O
activating	O
function	O
of	O
p95vav	B
is	O
blocked	O
by	O
FK506	O
,	O
suggesting	O
that	O
its	O
activity	O
also	O
depends	O
on	O
calcineurin	B
.	O
To	O
further	O
dissect	O
p95vav	B
involvement	O
in	O
TCR	B
signaling	O
,	O
we	O
analyzed	O
various	O
Jurkat	O
mutants	O
deficient	O
in	O
TCR	B
signaling	O
function	O
or	O
TCR	B
expression	O
and	O
showed	O
that	O
an	O
intact	O
TCR	B
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B
to	O
function	O
.	O
However	O
,	O
overexpression	O
of	O
p95vav	B
does	O
not	O
appear	O
to	O
influence	O
TCR	B
-induced	O
protein	O
tyrosine	O
phosphorylation	O
or	O
increases	O
in	O
cytoplasmic	O
free	O
calcium	O
.	O
Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
p95vav	B
plays	O
an	O
important	O
role	O
at	O
an	O
yet	O
unidentified	O
proximal	O
position	O
in	O
the	O
TCR	B
signaling	O
cascade	O
.	O
Lipopolysaccharide	O
-	O
induced	O
E	B
-	I
selectin	I
expression	O
requires	O
continuous	O
presence	O
of	O
LPS	O
and	O
is	O
inhibited	O
by	O
bactericidal	B
/	I
permeability	I
-	I
increasing	I
protein	I
.	O
Endothelial	O
cells	O
stimulated	O
by	O
LPS	O
express	O
E	B
-	I
selectin	I
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
neutrophil	O
adhesion	O
during	O
inflammation	O
.	O
E	B
-	I
selectin	I
is	O
induced	O
within	O
1	O
-	O
2	O
h	O
,	O
peaks	O
at	O
4	O
-	O
6	O
h	O
,	O
and	O
gradually	O
returns	O
to	O
basal	O
level	O
by	O
24	O
h	O
.	O
rBPI21	B
,	O
a	O
recombinant	B
N	I
-	I
terminal	I
fragment	I
of	O
human	B
bactericidal	I
/	I
permeability	I
-	I
increasing	I
protein	I
(	O
BPI	B
)	O
,	O
inhibited	O
LPS	O
-	O
induced	O
E	B
-	I
selectin	I
expression	O
when	O
added	O
at	O
the	O
same	O
time	O
as	O
,	O
and	O
up	O
to	O
6	O
h	O
after	O
,	O
LPS	O
.	O
Delayed	O
administration	O
of	O
rBPI21	B
also	O
affected	O
LPS	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	B
factor	I
,	O
NF	B
-	I
kappa	I
B	I
.	O
Two	O
to	O
4	O
h	O
following	O
LPS	O
addition	O
to	O
endothelial	O
cells	O
,	O
when	O
NF	B
-	I
kappa	I
B	I
was	O
already	O
activated	O
,	O
addition	O
of	O
rBPI21	B
resulted	O
in	O
marked	O
reduction	O
of	O
NF	B
-	I
kappa	I
B	I
detectable	O
at	O
4	O
or	O
6	O
h	O
.	O
These	O
results	O
indicate	O
that	O
endothelial	O
activation	O
requires	O
continuous	O
presence	O
of	O
LPS	O
,	O
and	O
rBPI21	B
acts	O
to	O
reverse	O
LPS	O
-	O
mediated	O
endothelial	O
activation	O
by	O
interrupting	O
the	O
on	O
-	O
going	O
LPS	O
signal	O
.	O
Activation	O
of	O
NF	B
-	I
kappa	I
B	I
by	O
phosphatase	B
inhibitors	O
involves	O
the	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
at	O
phosphatase	B
2A	I
-	I
sensitive	I
sites	I
.	O
Activation	O
of	O
NF	B
-	I
kappa	I
B	I
by	O
various	O
cellular	O
stimuli	O
involves	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
its	O
inhibitor	O
,	O
I	B
kappa	I
B	I
alpha	I
,	O
although	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
serine	B
/	I
threonine	I
phosphatases	I
in	O
the	O
regulation	O
of	O
I	B
kappa	I
B	I
alpha	I
phosphorylation	O
was	O
investigated	O
.	O
Our	O
studies	O
demonstrate	O
that	O
incubation	O
of	O
human	O
T	O
cells	O
with	O
low	O
concentrations	O
(	O
approximately	O
1	O
-	O
5	O
nM	O
)	O
of	O
calyculin	O
A	O
or	O
okadaic	O
acid	O
,	O
potent	O
inhibitors	O
of	O
protein	B
phosphatase	I
type	I
1	I
(	I
PP-1	I
)	I
and	I
type	I
2A	I
(	O
PP-2A	B
)	O
,	O
induces	O
the	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
even	O
in	O
the	O
absence	O
of	O
any	O
cellular	O
stimulus	O
.	O
This	O
action	O
of	O
the	O
phosphatase	O
inhibitors	O
,	O
which	O
is	O
associated	O
with	O
the	O
activation	O
of	O
the	O
RelA.p50	B
NF	I
-	I
kappa	I
B	I
heterodimer	I
,	O
is	O
not	O
affected	O
by	O
agents	O
that	O
block	O
the	O
induction	O
of	O
I	B
kappa	I
B	I
alpha	I
phosphorylation	O
by	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
.	O
Furthermore	O
,	O
the	O
phosphorylated	B
I	I
kappa	I
B	I
alpha	I
from	O
calyculin	O
A	O
-	O
treated	O
cells	O
,	O
but	O
not	O
that	O
from	O
TNF	O
-	O
alpha	O
-	O
stimulated	O
cells	O
,	O
is	O
sensitive	O
to	O
PP-2A	B
in	O
vitro	O
,	O
suggesting	O
the	O
existence	O
of	O
fundamental	O
differences	O
in	O
the	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
induced	O
by	O
the	O
two	O
different	O
NF	B
-	I
kappa	I
B	I
inducers	O
.	O
However	O
,	O
induction	O
of	O
I	B
kappa	I
B	I
alpha	I
phosphorylation	O
by	O
both	O
TNF	B
-	I
alpha	I
and	O
the	O
phosphatase	O
inhibitors	O
is	O
associated	O
with	O
the	O
subsequent	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
.	O
We	O
further	O
demonstrate	O
that	O
TNF	O
-	O
alpha-	O
and	O
calyculin	O
A	O
-	O
induced	O
I	O
kappa	O
B	O
alpha	O
degradation	O
exhibits	O
similar	O
but	O
not	O
identical	O
sensitivities	O
to	O
a	O
proteasome	O
inhibitor	O
.	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
,	O
mediated	O
through	O
both	O
the	O
TNF	B
-	I
alpha	I
-inducible	O
and	O
the	O
PP-2A	B
-	I
opposing	I
kinases	I
,	O
may	O
serve	O
to	O
target	O
I	B
kappa	I
B	I
alpha	I
for	O
proteasome	B
-mediated	O
degradation	O
.	O
IL-10	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B
and	O
Jak1	B
and	O
the	O
differential	O
assembly	O
of	O
STAT1	B
alpha	I
and	O
STAT3	B
complexes	I
in	O
human	O
T	O
cells	O
and	O
monocytes	O
.	O
IL-10	B
affects	O
monocytes	O
and	O
T	O
cells	O
by	O
driving	O
the	O
progression	O
of	O
immune	O
responsiveness	O
such	O
that	O
Th2	O
lymphocyte	O
-	O
mediated	O
effects	O
predominate	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
monocytes	O
and	O
T	O
cells	O
IL-10	B
stimulates	O
tyrosine	O
phosphorylation	O
of	O
the	O
signal	B
transducers	I
and	O
activators	B
of	I
transcription	I
,	O
STAT1	B
alpha	I
and	O
STAT3	B
,	O
in	O
a	O
differential	O
manner	O
such	O
that	O
the	O
relative	O
formation	O
of	O
homo-	B
and	I
heterodimers	I
varies	O
between	O
the	O
two	O
cell	O
types	O
.	O
Moreover	O
,	O
monocytes	O
express	O
a	O
novel	O
IL-10-stimulated	B
STAT	I
protein	I
with	O
an	O
M	O
(	O
r	O
)	O
of	O
70	B
kDa	I
that	O
is	O
recognized	O
by	O
the	O
anti	B
-	I
STAT3	I
Ab	I
but	O
is	O
not	O
observed	O
in	O
T	O
cells	O
.	O
IL-10	B
treatment	O
of	O
both	O
T	O
cells	O
and	O
monocytes	O
results	O
in	O
the	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B
and	O
Jak1	B
,	O
but	O
not	O
Jak2	B
or	O
Jak3	B
.	O
Selective	O
modulation	O
of	O
immune	O
responsiveness	O
by	O
IL-10	B
in	O
cells	O
such	O
as	O
monocytes	O
and	O
T	O
cells	O
may	O
result	O
in	O
part	O
from	O
the	O
differential	O
activation	O
of	O
STAT	B
protein	I
pairs	I
.	O
Characterization	O
of	O
5	O
'	O
end	O
of	O
human	O
thromboxane	O
receptor	O
gene	O
.	O
Organizational	O
analysis	O
and	O
mapping	O
of	O
protein	O
kinase	O
C	O
--	O
responsive	O
elements	O
regulating	O
expression	O
in	O
platelets	O
.	O
Platelet	B
thromboxane	I
receptors	I
are	O
acutely	O
and	O
reversibly	O
upregulated	O
after	O
acute	O
myocardial	O
infarction	O
.	O
To	O
determine	O
if	O
platelet	O
thromboxane	B
receptors	I
are	O
under	O
transcriptional	O
control	O
,	O
we	O
isolated	O
and	O
characterized	O
human	O
genomic	O
DNA	O
clones	O
containing	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
.	O
The	O
exon	O
-	O
intron	O
structure	O
of	O
the	O
5	O
'	O
portion	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
was	O
determined	O
initially	O
by	O
comparing	O
the	O
nucleotide	O
sequence	O
of	O
the	O
5	O
'	O
flanking	O
genomic	O
clone	O
with	O
that	O
of	O
a	O
novel	O
human	O
uterine	O
thromboxane	O
receptor	O
cDNA	O
that	O
extended	O
the	O
mRNA	O
141	O
bp	O
further	O
upstream	O
than	O
the	O
previously	O
identified	O
human	O
placental	O
cDNA	O
.	O
A	O
major	O
transcription	O
initiation	O
site	O
was	O
located	O
in	O
three	O
human	O
tissues	O
approximately	O
560	O
bp	O
upstream	O
from	O
the	O
translation	O
initiation	O
codon	O
and	O
380	O
bp	O
upstream	O
from	O
any	O
previously	O
identified	O
transcription	O
initiation	O
site	O
.	O
The	O
thromboxane	O
receptor	O
gene	O
has	O
neither	O
a	O
TATA	O
nor	O
a	O
CAAT	O
consensus	O
site	O
.	O
Promoter	O
function	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
was	O
evaluated	O
by	O
transfection	O
of	O
thromboxane	O
receptor	O
gene	O
promoter	O
/	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
chimera	O
plasmids	O
into	O
platelet	O
-	O
like	O
K562	O
cells	O
.	O
Thromboxane	O
receptor	O
promoter	O
activity	O
,	O
as	O
assessed	O
by	O
CAT	B
expression	O
,	O
was	O
relatively	O
weak	O
but	O
was	O
significantly	O
enhanced	O
by	O
phorbol	O
ester	O
treatment	O
.	O
Functional	O
analysis	O
of	O
5	O
'	O
deletion	O
constructs	O
in	O
transfected	O
K562	O
cells	O
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	O
ester	O
-	O
responsive	O
motifs	O
in	O
the	O
thromboxane	O
receptor	O
gene	O
promoter	O
to	O
a	O
cluster	O
of	O
activator	O
protein-2	O
(	O
AP-2	O
)	O
binding	O
consensus	O
sites	O
located	O
approximately	O
1.8	O
kb	O
5	O
'	O
from	O
the	O
transcription	O
initiation	O
site	O
.	O
These	O
studies	O
are	O
the	O
first	O
to	O
determine	O
the	O
structure	O
and	O
organization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
and	O
demonstrate	O
that	O
thromboxane	O
receptor	O
gene	O
expression	O
can	O
be	O
regulated	O
by	O
activation	O
of	O
protein	B
kinase	I
C	I
via	O
induction	O
of	O
an	O
AP-2-like	B
nuclear	I
factor	I
binding	O
to	O
upstream	O
promoter	O
elements	O
.	O
These	O
findings	O
strongly	O
suggest	O
that	O
the	O
mechanism	O
for	O
previously	O
described	O
upregulation	O
of	O
platelet	B
thromboxane	I
receptors	I
after	O
acute	O
myocardial	O
infarction	O
is	O
increased	O
thromboxane	O
receptor	O
gene	O
transcription	O
in	O
platelet	O
-	O
progenitor	O
cells	O
.	O
HIV-1	B
envelope	I
glycoproteins	I
induce	O
activation	O
of	O
activated	O
protein-1	B
in	O
CD4	O
+	O
T	O
cells	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Dec	O
1	O
;	O
270	O
(	O
48	O
)	O
:	O
29038	O
]	O
Activation	O
of	O
CD4	O
positive	O
T	O
cells	O
is	O
a	O
primary	O
requirement	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
entry	O
,	O
efficient	O
HIV	O
replication	O
,	O
and	O
progression	O
to	O
AIDS	O
,	O
Utilizing	O
CD4	O
positive	O
T	O
cell	O
lines	O
and	O
purified	O
T	O
cells	O
from	O
normal	O
individuals	O
,	O
we	O
have	O
demonstrated	O
that	O
native	B
envelope	I
glycoproteins	I
of	O
HIV	O
,	O
gp	B
160	I
,	O
can	O
induce	O
activation	O
of	O
transcription	B
factor	I
,	I
activated	I
protein-1	I
(	O
AP-1	B
)	O
.	O
The	O
stimulatory	O
effects	O
of	O
gp160	B
are	O
mediated	O
through	O
the	O
CD4	B
molecule	I
,	O
since	O
treatment	O
of	O
gp160	B
with	O
soluble	O
CD4-IgG	B
abrogates	O
its	O
activity	O
,	O
and	O
CD4	O
negative	O
T	O
cell	O
lines	O
fail	O
to	O
be	O
stimulated	O
with	O
gp160	B
.	O
Immunoprecipitation	O
of	O
the	O
gp	B
160	I
-induced	O
nuclear	O
extracts	O
with	O
polyclonal	B
antibodies	I
to	O
Fos	B
and	O
Jun	B
proteins	I
indicates	O
that	O
AP-1	B
complex	I
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O
The	O
gp160-induced	B
AP-1	I
complex	I
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
and	O
is	O
protein	O
synthesis	O
-	O
independent	O
.	O
This	O
stimulation	O
can	O
also	O
be	O
abolished	O
by	O
inhibitors	O
of	O
protein	B
kinase	I
C	I
,	O
but	O
it	O
is	O
unaffected	O
by	O
calcium	O
channel	O
blocker	O
or	O
cyclosporine	O
A	O
.	O
This	O
gp160	B
treatment	O
adversely	O
affects	O
the	O
functional	O
capabilities	O
of	O
T	O
cells	O
:	O
pre	O
-	O
treatment	O
of	O
CD4	O
+	O
T	O
cells	O
with	O
gp160	B
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O
inhibited	O
anti	B
-	I
CD3	I
-induced	O
interleukin-2	B
secretion	O
.	O
Effects	O
similar	O
to	O
gp160	B
were	O
seen	O
with	O
anti	B
-	I
CD4	I
mAb	I
.	O
The	O
aberrant	O
activation	O
of	O
AP-1	B
by	O
gp160	B
in	O
CD4	O
positive	O
T	O
cells	O
could	O
result	O
in	O
up	O
-	O
regulation	O
of	O
cytokines	B
containing	O
AP-1	O
sites	O
,	O
e.g	O
.	O
interleukin-3	B
and	O
granulocyte	B
macrophage	I
colony	I
-	I
stimulating	I
factor	I
,	O
and	O
concurrently	O
lead	O
to	O
T	O
cell	O
unresponsiveness	O
by	O
inhibiting	O
interleukin-2	B
secretion	O
.	O
Infection	O
and	O
replication	O
of	O
Tat-	O
human	O
immunodeficiency	O
viruses	O
:	O
genetic	O
analyses	O
of	O
LTR	O
and	O
tat	B
mutations	I
in	O
primary	O
and	O
long	O
-	O
term	O
human	O
lymphoid	O
cells	O
.	O
Tat	B
is	O
an	O
essential	O
regulatory	B
protein	I
for	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O
Mutations	O
in	O
the	O
tat	O
gene	O
have	O
been	O
shown	O
to	O
block	O
HIV	O
replication	O
in	O
human	O
T	O
cells	O
.	O
Several	O
studies	O
have	O
established	O
that	O
Tat	B
releases	O
an	O
elongation	B
block	I
to	O
the	O
transcription	O
of	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
whether	O
this	O
mechanism	O
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
block	O
to	O
HIV	O
replication	O
in	O
human	O
T	O
cells	O
when	O
Tat	B
is	O
absent	O
.	O
It	O
is	O
possible	O
that	O
Tat	B
is	O
also	O
needed	O
for	O
other	O
functions	O
during	O
HIV	O
replication	O
.	O
To	O
test	O
these	O
hypotheses	O
,	O
we	O
studied	O
several	O
tat	B
mutants	I
,	O
including	O
two	O
stop	B
codon	I
mutants	I
and	O
one	O
deletion	B
mutant	I
using	O
replication	O
-	O
competent	O
HIV-1	O
constructs	O
carrying	O
wild	O
-	O
type	O
or	O
mutant	O
LTRs	O
with	O
modifications	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
and/or	O
Sp1	O
binding	O
sites	O
.	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
Tat-	O
HIV-1	O
with	O
wild	O
-	O
type	O
LTRs	O
can	O
replicate	O
in	O
HeLa	O
cells	O
,	O
and	O
the	O
virus	O
produced	O
from	O
HeLa	O
cells	O
can	O
infect	O
primary	O
peripheral	O
blood	O
lymphocytes	O
and	O
macrophages	O
.	O
It	O
was	O
found	O
that	O
the	O
propagation	O
of	O
the	O
Tat	B
mutants	I
containing	O
wild	O
-	O
type	O
LTRs	O
was	O
less	O
efficient	O
than	O
that	O
of	O
the	O
LTR	B
-	I
modified	I
Tat	I
mutants	I
.	O
Large	O
amounts	O
of	O
viral	O
RNA	O
and	O
particles	O
were	O
synthesized	O
in	O
infections	O
established	O
using	O
the	O
tat	B
mutants	I
that	O
contain	O
modified	O
LTRs	O
.	O
However	O
,	O
this	O
efficient	O
propagation	O
of	O
the	O
LTR	B
-	I
modified	I
tat	I
mutants	I
was	O
restricted	O
to	O
some	O
lymphoid	O
cell	O
lines	O
that	O
have	O
been	O
transformed	O
with	O
other	O
viruses	O
.	O
Thus	O
,	O
despite	O
its	O
essential	O
role	O
for	O
releasing	O
an	O
elongation	B
block	I
,	O
Tat	B
is	O
not	O
otherwise	O
absolutely	O
required	O
for	O
synthesis	O
of	O
full	O
-	O
length	O
HIV	O
transcripts	O
and	O
assembly	O
of	O
virus	O
particles	O
.	O
Direct	O
sequencing	O
of	O
the	O
viral	O
genomes	O
and	O
reinfection	O
kinetics	O
showed	O
no	O
evidence	O
of	O
wild	O
-	O
type	O
reversion	O
even	O
after	O
prolonged	O
infection	O
with	O
the	O
Tat	B
-virus	O
.	O
The	O
implications	O
for	O
in	O
vivo	O
HIV-1	O
replication	O
and	O
potential	O
application	O
of	O
this	O
system	O
to	O
the	O
study	O
of	O
alternative	O
Tat	B
function	O
are	O
discussed	O
.	O
Expression	O
of	O
erythroid	O
-	O
specific	O
genes	O
in	O
acute	O
megakaryoblastic	O
leukaemia	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
.	O
Acute	O
megakaryoblastic	O
leukaemia	O
(	O
M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	O
blast	O
cells	O
which	O
express	O
megakaryocytic	B
markers	I
.	O
To	O
clarify	O
properties	O
of	O
the	O
blast	O
cells	O
in	O
M7	O
and	O
TMD	O
cases	O
,	O
we	O
examined	O
erythroid	O
markers	O
expression	O
in	O
blasts	O
from	O
six	O
cases	O
with	O
M7	O
and	O
seven	O
cases	O
with	O
TMD	O
in	O
this	O
study	O
.	O
Erythroid	O
-	O
specific	O
mRNAs	O
encoding	O
gamma	B
-	I
globin	I
and	O
erythroid	B
delta	I
-	I
aminolevulinate	I
synthase	I
were	O
found	O
to	O
be	O
expressed	O
in	O
blasts	O
from	O
most	O
of	O
these	O
cases	O
,	O
indicating	O
that	O
majorities	O
of	O
the	O
blasts	O
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O
We	O
also	O
found	O
that	O
mRNAs	O
encoding	O
GATA-1	B
and	O
GATA-2	B
are	O
expressed	O
in	O
all	O
these	O
cases	O
.	O
These	O
results	O
suggest	O
that	O
M7	O
blasts	O
and	O
TMD	O
blasts	O
correspond	O
to	O
the	O
erythroid	O
/	O
megakaryocytic	O
bipotential	O
progenitor	O
cells	O
.	O
Relationship	O
between	O
Rap1	B
protein	I
phosphorylation	O
and	O
regulation	O
of	O
Ca2	O
+	O
transport	O
in	O
platelets	O
:	O
a	O
new	O
approach	O
.	O
Although	O
the	O
interrelationship	O
between	O
the	O
two	O
messengers	O
Ca2	O
+	O
and	O
cyclic	O
AMP	O
in	O
platelet	O
function	O
is	O
well	O
documented	O
,	O
its	O
mechanism	O
of	O
action	O
still	O
remains	O
to	O
be	O
established	O
.	O
We	O
investigated	O
here	O
the	O
question	O
of	O
the	O
regulation	O
of	O
platelet	B
Ca	I
(	I
2	I
+	I
)	I
-ATPases	I
by	O
cyclic	O
AMP	O
through	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B
protein	I
using	O
a	O
pathological	O
model	O
.	O
We	O
first	O
found	O
experimental	O
conditions	O
where	O
Ca	O
(	O
2	O
+	O
)	O
-transport	O
by	O
platelet	O
membrane	O
vesicles	O
appeared	O
to	O
be	O
dependent	O
on	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B
protein	I
.	O
Then	O
,	O
we	O
studied	O
platelets	O
of	O
patients	O
with	O
congestive	O
heart	O
failure	O
for	O
their	O
expression	O
of	O
the	O
potential	O
97	B
kDa	I
Ca	I
(	I
2	I
+	I
)	I
-ATPase	I
target	I
of	O
regulation	O
through	O
the	O
Rap1	B
protein	I
as	O
well	O
as	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B
protein	I
using	O
the	O
catalytic	B
subunit	I
of	O
the	O
cyclic	B
AMP	I
-	I
dependent	I
protein	I
kinase	I
(	O
C.	B
Sub	I
.	I
)	O
.	O
In	O
the	O
first	O
patients	O
studied	O
,	O
we	O
found	O
no	O
significant	O
modification	O
in	O
the	O
expression	O
of	O
the	O
97	B
kDa	I
Ca	I
(	I
2	I
+	I
)	I
-ATPase	I
by	O
Western	O
blotting	O
using	O
the	O
PL	B
/	I
IM	I
430	I
monoclonal	I
antibody	I
which	O
specifically	O
recognized	O
this	O
isoform	O
.	O
In	O
contrast	O
,	O
the	O
Rap1	B
protein	I
was	O
differentially	O
phosphorylated	O
when	O
using	O
15	O
micrograms	O
/	O
ml	O
of	O
the	O
C.	B
Sub	I
.	I
These	O
results	O
allowed	O
us	O
to	O
use	O
these	O
pathological	O
platelets	O
to	O
study	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
Rap1	B
protein	I
and	O
the	O
regulation	O
of	O
Ca2	O
+	O
transport	O
by	O
selecting	O
a	O
patient	O
with	O
severe	O
heart	O
failure	O
.	O
We	O
could	O
show	O
a	O
decrease	O
in	O
the	O
expression	O
as	O
well	O
as	O
in	O
the	O
phosphorylation	O
of	O
Rap1	B
protein	I
and	O
demonstrate	O
a	O
lower	O
effect	O
of	O
C.	B
Sub	I
.	I
on	O
Ca2	O
+	O
transport	O
.	O
Finally	O
,	O
by	O
studying	O
a	O
further	O
series	O
of	O
patients	O
,	O
we	O
could	O
confirm	O
that	O
the	O
decrease	O
in	O
Rap1	B
protein	I
expression	O
in	O
heart	O
failure	O
,	O
whatever	O
its	O
extent	O
,	O
was	O
variable	O
,	O
and	O
could	O
strictly	O
correlate	O
the	O
expression	O
of	O
Rap1	B
protein	I
with	O
the	O
stimulatory	O
effect	O
of	O
C.	B
Sub	I
.	I
on	O
Ca2	O
+	O
transport	O
.	O
Besides	O
the	O
evidence	O
for	O
regulation	O
of	O
the	O
expression	O
of	O
the	O
Rap1	B
protein	I
in	O
platelets	O
from	O
patients	O
with	O
heart	O
failure	O
,	O
these	O
findings	O
constitute	O
a	O
new	O
approach	O
in	O
favour	O
of	O
the	O
regulation	O
of	O
platelet	O
Ca2	O
+	O
transport	O
through	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B
protein	I
.	O
Constitutive	O
activation	O
of	O
different	O
Jak	B
tyrosine	I
kinases	I
in	O
human	B
T	I
cell	I
leukemia	I
virus	I
type	I
1	I
(	I
HTLV-1	I
)	I
tax	I
protein	I
or	O
virus	O
-	O
transformed	O
cells	O
.	O
HTLV-1	O
infection	O
causes	O
an	O
adult	O
T	O
cell	O
leukemia	O
in	O
humans	O
.	O
The	O
viral	B
encoded	I
protein	I
tax	B
,	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
oncogenesis	O
.	O
Our	O
previous	O
data	O
obtained	O
from	O
a	O
tax	B
transgenic	O
mouse	O
model	O
revealed	O
that	O
tax	B
transforms	O
mouse	O
fibroblasts	O
but	O
not	O
thymocytes	O
,	O
despite	O
comparable	O
levels	O
of	O
tax	B
expression	O
in	O
both	O
tissues	O
.	O
Constitutive	O
tyrosine	O
phosphorylation	O
of	O
a	O
130-kD	B
protein	I
(	O
s	O
)	O
was	O
observed	O
in	O
the	O
tax	B
transformed	O
fibroblast	O
B	O
line	O
and	O
in	O
HTLV-1	O
transformed	O
human	O
lymphoid	O
lines	O
,	O
but	O
not	O
in	O
thymocytes	O
from	O
Thy	O
-	O
tax	O
transgenic	O
mice	O
.	O
Phosphotyrosine	O
immunoprecipitation	O
followed	O
by	O
Western	O
blot	O
analysis	O
with	O
a	O
set	O
of	O
Jak	B
kinase	I
specific	I
antibodies	I
,	O
identified	O
p130	O
as	O
Jak2	B
in	O
the	O
tax	B
transformed	O
mouse	O
fibroblastic	O
cell	O
line	O
and	O
Jak3	B
in	O
HTLV-1	O
transformed	O
human	O
T	O
cell	O
lines	O
.	O
Phosphorylation	O
of	O
Jak2	B
in	O
tax	O
transformed	O
cells	O
resulted	O
from	O
high	O
expression	O
of	O
IL-6	O
.	O
Tyrosine	O
phosphorylation	O
of	O
this	O
protein	O
could	O
also	O
be	O
induced	O
in	O
Balb	O
/	O
c3T3	O
cells	O
using	O
a	O
supernatant	O
from	O
the	O
B	O
line	O
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O
Both	O
phosphorylation	O
and	O
proliferation	O
were	O
inhibited	O
by	O
IL-6	B
neutralizing	I
antibodies	I
.	O
Constitutive	O
phosphorylation	O
of	O
Jak	B
kinases	I
may	O
facilitate	O
tumor	O
growth	O
in	O
both	O
HTLV-1	O
infected	O
human	O
T	O
cells	O
and	O
the	O
transgenic	O
mouse	O
model	O
.	O
Disruption	O
of	O
a	O
GATA	O
motif	O
in	O
the	O
Duffy	O
gene	O
promoter	O
abolishes	O
erythroid	O
gene	O
expression	O
in	O
Duffy	O
-	O
negative	O
individuals	O
.	O
The	O
mRNA	O
for	O
the	O
Duffy	B
blood	I
group	I
antigen	I
,	O
the	O
erythrocyte	B
receptor	I
for	O
the	O
Plasmodium	O
vivax	O
malaria	O
parasite	O
,	O
has	O
recently	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
widely	O
expressed	O
chemokine	B
receptor	I
.	O
Here	O
,	O
we	O
show	O
that	O
the	O
Duffy	O
antigen	O
/	O
chemokine	O
receptor	O
gene	O
(	O
DARC	O
)	O
is	O
composed	O
of	O
a	O
single	O
exon	O
and	O
that	O
most	O
Duffy	O
-	O
negative	O
blacks	O
carry	O
a	O
silent	O
FY*B	O
allele	O
with	O
a	O
single	O
T	O
to	O
C	O
substitution	O
at	O
nucleotide	O
-46	O
.	O
This	O
mutation	O
impairs	O
the	O
promoter	O
activity	O
in	O
erythroid	O
cells	O
by	O
disrupting	O
a	O
binding	O
site	O
for	O
the	O
GATA1	B
erythroid	I
transcription	I
factor	I
.	O
With	O
the	O
recent	O
characterization	O
of	O
the	O
FY*A	O
and	O
FY*B	O
alleles	O
,	O
these	O
findings	O
provide	O
the	O
molecular	O
basis	O
of	O
the	O
Duffy	O
blood	O
group	O
system	O
and	O
an	O
explanation	O
for	O
the	O
erythroid	O
-	O
specific	O
repression	O
of	O
the	O
DARC	O
gene	O
in	O
Duffy	O
-	O
negative	O
individuals	O
.	O
Interleukin-2	O
promoter	O
activity	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
transformed	O
B	O
lymphocytes	O
is	O
controlled	O
by	O
nuclear	B
factor	I
-	I
chi	I
B	I
.	O
The	O
regulation	O
of	O
interleukin	O
(	O
IL	O
)	O
-2	O
gene	O
expression	O
has	O
been	O
investigated	O
mainly	O
in	O
T	O
lymphocytes	O
,	O
the	O
predominant	O
producers	O
of	O
IL-2	B
.	O
However	O
,	O
B	O
cells	O
can	O
also	O
synthesize	O
IL-2	B
.	O
In	O
the	O
present	O
study	O
we	O
analyzed	O
the	O
control	O
of	O
IL-2	O
promoter	O
activity	O
in	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-transformed	O
B	O
cell	O
clones	O
which	O
are	O
capable	O
of	O
secreting	O
IL-2	B
at	O
a	O
low	O
level	O
after	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
the	O
Ca2	O
+	O
ionophore	O
ionomycin	O
.	O
Transient	O
transfections	O
using	O
reporter	O
constructs	O
with	O
multiples	O
of	O
transcription	O
factor	O
binding	O
sites	O
from	O
the	O
IL-2	O
promoter	O
[	O
distal	B
nuclear	I
factor	I
(	I
NF	I
)	I
-AT	I
,	O
proximal	B
NF	I
-	I
AT	I
,	O
AP-1	B
/	I
Octamer	I
(	O
UPS	B
)	O
or	O
NF	B
-	I
chi	I
B	I
(	O
TCEd	B
)	O
sites	O
]	O
were	O
performed	O
.	O
In	O
EBV	O
-	O
transformed	O
B	O
clones	O
,	O
the	O
chi	O
B	O
site	O
exerted	O
the	O
strongest	O
inducible	O
activity	O
;	O
the	O
NF	O
-	O
AT	O
binding	O
sites	O
showed	O
either	O
no	O
or	O
only	O
weak	O
activity	O
compared	O
to	O
Jurkat	O
T	O
cells	O
.	O
An	O
IL-2	O
promoter	O
bearing	O
a	O
defective	O
NF	O
-	O
chi	O
B	O
site	O
was	O
completely	O
inactive	O
in	O
EBV	O
-	O
transformed	O
B	O
cells	O
,	O
while	O
it	O
still	O
had	O
activity	O
in	O
Jurkat	O
T	O
cells	O
.	O
In	O
seven	O
EBV	O
-	O
B	O
cell	O
clones	O
or	O
lines	O
differing	O
in	O
their	O
capacity	O
to	O
secrete	O
IL-2	B
,	O
the	O
activity	O
of	O
the	O
IL-2	O
promoter	O
correlated	O
well	O
with	O
the	O
status	O
of	O
IL-2	B
secretion	O
.	O
Similarly	O
,	O
a	O
human	O
immunodeficiency	O
virus	O
promoter	O
,	O
whose	O
activity	O
is	O
controlled	O
through	O
chi	B
B	I
factors	I
,	O
was	O
found	O
to	O
be	O
active	O
in	O
the	O
IL-2	O
producing	O
EBV	O
-	O
B	O
cells	O
,	O
but	O
inactive	O
in	O
the	O
non	O
-	O
IL-2-producing	O
cells	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
protein	O
extracts	O
from	O
EBV	O
-	O
B	O
cells	O
and	O
the	O
IL-2	B
NF	B
-	I
chi	I
B	I
probe	O
revealed	O
the	O
constitutive	O
generation	O
of	O
chi	B
B	I
complexes	I
in	O
IL-2-secreting	O
cells	O
consisting	O
mainly	O
of	O
heterodimeric	B
p50	I
/	I
p65	I
complexes	I
.	O
A	O
weaker	O
chi	O
B	O
complex	O
formation	O
and	O
faster	O
-	O
migrating	O
complexes	O
were	O
detected	O
in	O
non	O
-	O
IL-2-secreting	O
cells	O
.	O
These	O
results	O
demonstrate	O
that	O
the	O
IL-2	O
NF	O
-	O
chi	O
B	O
site	O
is	O
indispensable	O
for	O
the	O
activity	O
of	O
the	O
IL-2	O
promoter	O
in	O
EBV	O
-	O
transformed	O
B	O
cells	O
,	O
whereas	O
other	O
transcription	B
factors	I
appear	O
to	O
be	O
less	O
important	O
for	O
IL-2	B
expression	O
in	O
these	O
cells	O
.	O
A	O
regulatory	O
element	O
in	O
the	O
human	O
interleukin	O
2	O
gene	O
promoter	O
is	O
a	O
binding	O
site	O
for	O
the	O
zinc	B
finger	I
proteins	I
Sp1	B
and	O
EGR-1	B
.	O
Activation	O
of	O
the	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function	O
.	O
Prior	O
studies	O
have	O
identified	O
several	O
transcription	B
factors	I
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	O
promoter	O
in	O
stimulated	O
T	O
lymphocytes	O
.	O
Here	O
we	O
describe	O
a	O
novel	O
regulatory	O
element	O
within	O
the	O
IL-2	O
promoter	O
located	O
immediately	O
upstream	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NFAT	O
)	O
domain	O
.	O
This	O
region	O
(	O
termed	O
the	O
zinc	O
finger	O
protein	O
binding	O
region	O
(	O
ZIP	O
)	O
)	O
serves	O
as	O
binding	O
site	O
for	O
two	O
differently	O
regulated	O
zinc	B
finger	I
proteins	I
:	O
the	O
constitutively	B
expressed	I
transcription	I
factor	I
Sp1	B
and	O
the	O
inducible	B
early	I
growth	I
response	I
protein	I
EGR-1	B
.	O
In	O
unstimulated	O
cells	O
which	O
do	O
not	O
secrete	O
IL-2	B
,	O
only	O
Sp1	B
binds	O
to	O
this	O
region	O
,	O
while	O
in	O
stimulated	O
IL-2	O
secreting	O
cells	O
the	O
inducible	B
EGR-1	I
protein	I
recognizes	O
this	O
element	O
.	O
In	O
Jurkat	O
T	O
cells	O
,	O
the	O
ZIP	O
site	O
serves	O
as	O
an	O
activator	O
for	O
IL-2	B
gene	O
expression	O
,	O
and	O
a	O
combination	O
of	O
ZIP	O
and	O
NFAT	O
binding	O
sites	O
is	O
required	O
for	O
maximal	O
IL-2	O
promoter	O
activity	O
.	O
These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
the	O
ZIP	O
site	O
for	O
IL-2	O
promoter	O
activity	O
.	O
Direct	O
demonstration	O
of	O
NFATp	B
dephosphorylation	O
and	O
nuclear	O
localization	O
in	O
activated	O
HT-2	O
cells	O
using	O
a	O
specific	O
NFATp	B
polyclonal	I
antibody	I
.	O
Nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	B
genes	I
,	O
and	O
NFAT	B
DNA	O
binding	O
activity	O
is	O
stimulated	O
following	O
T	O
cell	O
activation	O
.	O
Several	O
lines	O
of	O
evidence	O
have	O
suggested	O
that	O
NFAT	B
is	O
a	O
substrate	O
for	O
calcineurin	B
,	O
a	O
serine	B
/	I
threonine	I
phosphatase	I
.	O
Using	O
a	O
polyclonal	O
antibody	O
to	O
murine	B
NFATp	I
,	O
Western	O
blot	O
analysis	O
of	O
various	O
mouse	O
tissues	O
demonstrated	O
that	O
the	O
110	O
-	O
130-kDa	O
NFATp	B
protein	I
was	O
highly	O
expressed	O
in	O
thymus	O
and	O
spleen	O
.	O
Treatment	O
of	O
immunoprecipitated	O
NFATp	B
from	O
untreated	O
HT-2	O
cells	O
with	O
calcineurin	B
resulted	O
in	O
the	O
dephosphorylation	O
of	O
NFATp	B
,	O
demonstrating	O
that	O
NFATp	B
is	O
an	O
in	O
vitro	O
substrate	O
for	O
calcineurin	B
.	O
NFATp	B
immunoprecipitated	O
from	O
32P	O
-	O
labeled	O
HT-2	O
cells	O
migrated	O
as	O
an	O
approximately	O
120-kDa	O
protein	O
that	O
was	O
localized	O
to	O
the	O
cytosol	O
of	O
the	O
cells	O
.	O
Treatment	O
of	O
the	O
cells	O
with	O
ionomycin	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
molecular	O
weight	O
of	O
NFATp	B
and	O
a	O
loss	O
of	O
32P	O
,	O
consistent	O
with	O
NFATp	B
dephosphorylation	O
.	O
The	O
dephosphorylation	O
of	O
NFATp	B
was	O
accompanied	O
by	O
localization	O
of	O
the	O
protein	O
to	O
the	O
nuclear	O
fraction	O
.	O
Both	O
of	O
these	O
events	O
were	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
FK506	O
,	O
a	O
calcineurin	B
inhibitor	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
NFATp	B
is	O
a	O
calcineurin	B
substrate	O
in	O
cells	O
.	O
Temperature	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
the	O
glucocorticoid	B
receptor	I
in	O
peripheral	O
blood	O
mononuclear	O
leucocyte	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O
OBJECTIVE	O
:	O
Activation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
is	O
of	O
vital	O
importance	O
during	O
critical	O
illness	O
.	O
We	O
have	O
studied	O
the	O
adaptive	O
mechanisms	O
which	O
occur	O
at	O
the	O
level	O
of	O
the	O
glucocorticoid	B
receptor	I
in	O
glucocorticoid	O
target	O
tissues	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O
DESIGN	O
:	O
The	O
effects	O
of	O
hypercortisolaemia	O
,	O
hyperthermia	O
and	O
cellular	O
composition	O
on	O
number	O
of	O
glucocorticoid	B
receptors	I
per	O
cell	O
and	O
their	O
affinity	O
were	O
evaluated	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
leucocytes	O
of	O
control	O
subjects	O
and	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O
SUBJECTS	O
:	O
Fifteen	O
patients	O
(	O
age	O
25	O
-	O
79	O
)	O
with	O
sepsis	O
or	O
septic	O
shock	O
who	O
were	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
were	O
studied	O
.	O
The	O
control	O
group	O
consisted	O
of	O
24	O
healthy	O
laboratory	O
employees	O
.	O
MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	B
receptors	I
were	O
measured	O
and	O
compared	O
to	O
clinical	O
data	O
and	O
the	O
plasma	O
cortisol	O
concentrations	O
.	O
RESULTS	O
:	O
Hypercortisolaemia	O
,	O
in	O
vitro	O
,	O
resulted	O
in	O
a	O
decreased	O
affinity	O
and	O
a	O
decreased	O
binding	O
capacity	O
of	O
the	O
glucocorticoid	B
receptor	I
.	O
In	O
vitro	O
,	O
hyperthermia	O
as	O
well	O
as	O
variations	O
in	O
the	O
cellular	O
composition	O
did	O
not	O
influence	O
the	O
glucocorticoid	O
receptor	O
.	O
In	O
vivo	O
,	O
there	O
was	O
no	O
change	O
in	O
the	O
number	O
of	O
receptors	O
per	O
cell	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O
However	O
,	O
a	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B
receptor	I
was	O
observed	O
.	O
There	O
was	O
a	O
weak	O
but	O
significant	O
negative	O
correlation	O
between	O
body	O
temperature	O
and	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
in	O
the	O
patient	O
group	O
.	O
There	O
was	O
no	O
relation	O
between	O
circulating	O
cortisol	O
concentrations	O
and	O
glucocorticoid	B
receptor	I
affinity	O
and	O
number	O
.	O
CONCLUSIONS	O
:	O
There	O
is	O
no	O
obvious	O
regulation	O
of	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
by	O
plasma	O
cortisol	O
concentrations	O
in	O
vivo	O
.	O
The	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B
receptor	I
together	O
with	O
the	O
negative	O
correlation	O
between	O
hyperthermia	O
and	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
suggest	O
that	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
activation	O
during	O
critical	O
illness	O
is	O
accompanied	O
by	O
peripheral	O
adaptation	O
in	O
glucocorticoid	B
receptor	I
number	O
and	O
affinity	O
.	O
N-	B
and	I
C	I
-	I
terminal	I
sequences	I
control	O
degradation	O
of	O
MAD3	B
/	I
I	I
kappa	I
B	I
alpha	I
in	O
response	O
to	O
inducers	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
.	O
The	O
proteolytic	O
degradation	O
of	O
the	O
inhibitory	B
protein	I
MAD3	B
/	I
I	I
kappa	I
B	I
alpha	I
in	O
response	O
to	O
extracellular	O
stimulation	O
is	O
a	O
prerequisite	O
step	O
in	O
the	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
.	O
Analysis	O
of	O
the	O
expression	O
of	O
human	B
I	I
kappa	I
B	I
alpha	I
protein	I
in	O
stable	O
transfectants	O
of	O
mouse	O
70Z	O
/	O
3	O
cells	O
shows	O
that	O
,	O
as	O
for	O
the	O
endogenous	O
murine	O
protein	O
,	O
exogenous	O
I	B
kappa	I
B	I
alpha	I
is	O
degraded	O
in	O
response	O
to	O
inducers	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
,	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
lipopolysaccharide	O
.	O
In	O
addition	O
,	O
pretreatment	O
of	O
the	O
cells	O
with	O
the	O
proteasome	B
inhibitor	O
N	O
-	O
Ac	O
-	O
Leu	O
-	O
Leu	O
-	O
norleucinal	O
inhibits	O
this	O
ligand	O
-	O
induced	O
degradation	O
and	O
,	O
in	O
agreement	O
with	O
previous	O
studies	O
,	O
stabilizes	O
a	O
hyperphosphorylated	O
form	O
of	O
the	O
human	B
I	I
kappa	I
B	I
alpha	I
protein	I
.	O
By	O
expressing	O
mutant	O
forms	O
of	O
the	O
human	O
protein	O
in	O
this	O
cell	O
line	O
,	O
we	O
have	O
been	O
able	O
to	O
delineate	O
the	O
sequences	O
responsible	O
for	O
both	O
the	O
ligand	O
-	O
induced	O
phosphorylation	O
and	O
the	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
.	O
Our	O
results	O
show	O
that	O
deletion	O
of	O
the	O
C	B
terminus	I
of	O
the	O
I	B
kappa	I
B	I
alpha	I
molecule	O
up	O
to	O
amino	B
acid	I
279	I
abolishes	O
constitutive	O
but	O
not	O
ligand	O
-	O
inducible	O
phosphorylation	O
and	O
inhibits	O
ligand	O
-	O
inducible	O
degradation	O
.	O
Further	O
analysis	O
reveals	O
that	O
the	O
inducible	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
maps	O
to	O
two	O
serines	O
in	O
the	O
N	B
terminus	I
of	O
the	O
protein	O
(	O
residues	O
32	O
and	O
36	O
)	O
and	O
that	O
the	O
mutation	O
of	O
either	O
residue	O
is	O
sufficient	O
to	O
abolish	O
ligand	O
-	O
induced	O
degradation	O
,	O
whereas	O
both	O
residues	O
must	O
be	O
mutated	O
to	O
abolish	O
inducible	O
phosphorylation	O
of	O
the	O
protein	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
The	O
human	O
TCF-1	O
gene	O
encodes	O
a	O
nuclear	B
DNA	I
-	I
binding	I
protein	I
uniquely	O
expressed	O
in	O
normal	O
and	O
neoplastic	O
T	O
-	O
lineage	O
lymphocytes	O
.	O
The	O
TCF-1	O
gene	O
encodes	O
a	O
putative	B
transcription	I
factor	I
with	O
affinity	O
for	O
a	O
sequence	O
motif	O
occurring	O
in	O
a	O
number	O
of	O
T	O
-	O
cell	O
enhancers	O
.	O
TCF-1	O
mRNA	O
was	O
originally	O
found	O
to	O
be	O
expressed	O
in	O
a	O
T	O
cell	O
-	O
specific	O
fashion	O
within	O
a	O
set	O
of	O
human	O
and	O
mouse	O
cell	O
lines	O
.	O
In	O
contrast	O
,	O
expression	O
reportedly	O
occurs	O
in	O
multiple	O
nonlymphoid	O
tissues	O
during	O
murine	O
embryogenesis	O
.	O
We	O
have	O
now	O
raised	O
a	O
monoclonal	B
antibody	I
to	O
document	O
expression	O
and	O
biochemistry	O
of	O
the	O
human	B
TCF-1	I
protein	I
.	O
As	O
expected	O
,	O
the	O
TCF-1	B
protein	I
was	O
detectable	O
only	O
in	O
cell	O
lines	O
of	O
T	O
lineage	O
.	O
Its	O
expression	O
was	O
always	O
restricted	O
to	O
the	O
nucleus	O
.	O
Immunohistochemistry	O
on	O
a	O
panel	O
of	O
human	O
tissues	O
revealed	O
that	O
the	O
TCF-1	B
protein	I
was	O
found	O
exclusively	O
in	O
thymocytes	O
and	O
in	O
CD3	O
+	O
T	O
cells	O
in	O
peripheral	O
lymphoid	O
tissues	O
.	O
Western	O
blotting	O
yielded	O
a	O
set	O
of	O
bands	O
ranging	O
from	O
25	O
kD	O
to	O
55	O
kD	O
,	O
resulting	O
from	O
extensive	O
alternative	O
splicing	O
.	O
The	O
TCF-1	B
protein	O
was	O
detectable	O
in	O
all	O
samples	O
of	O
a	O
set	O
of	O
22	O
T	O
-	O
cell	O
malignancies	O
of	O
various	O
stages	O
of	O
maturation	O
,	O
but	O
was	O
absent	O
from	O
a	O
large	O
number	O
of	O
other	O
hematologic	O
neoplasms	O
.	O
These	O
observations	O
imply	O
a	O
T	O
cell	O
-	O
specific	O
function	O
for	O
TCF-1	B
,	O
a	O
notion	O
corroborated	O
by	O
recent	O
observations	O
on	O
Tcf-1	O
knock	O
-	O
out	O
mice	O
.	O
In	O
addition	O
,	O
these	O
results	O
indicate	O
that	O
nuclear	O
TCF-1	B
expression	O
can	O
serve	O
as	O
a	O
pan	O
-	O
T	O
-	O
lineage	O
marker	O
in	O
the	O
diagnosis	O
of	O
lymphoid	O
malignancies	O
.	O
Constitutive	O
overexpression	O
of	O
the	O
L	O
-	O
selectin	O
gene	O
in	O
fresh	O
leukemic	O
cells	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
that	O
can	O
be	O
transactivated	O
by	O
human	B
T	I
-	I
cell	I
lymphotropic	I
virus	I
type	I
1	I
Tax	I
.	O
L	B
-	I
selectin	I
is	O
an	O
adhesion	O
molecule	O
of	O
the	O
selectin	O
family	O
that	O
mediates	O
the	O
initial	O
step	O
of	O
leukocyte	O
adhesion	O
to	O
vascular	O
endothelium	O
.	O
Upon	O
cellular	O
activation	O
,	O
expression	O
of	O
the	O
L	O
-	O
selectin	O
gene	O
is	O
downregulated	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
.	O
To	O
understand	O
the	O
mechanism	O
of	O
leukemic	O
cell	O
infiltration	O
into	O
organs	O
,	O
we	O
studied	O
the	O
expression	O
and	O
regulation	O
of	O
L	O
-	O
selectin	O
mRNA	O
in	O
fresh	O
leukemic	O
cells	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
patients	O
and	O
investigated	O
the	O
response	O
of	O
the	O
L	O
-	O
selectin	O
promoter	O
to	O
human	B
T	I
-	I
cell	I
lymphotropic	I
virus	I
type	I
1	I
(	I
HTLV-1	I
)	I
Tax	I
,	O
which	O
is	O
a	O
viral	B
transcriptional	I
transactivator	I
.	O
Flow	O
cytometry	O
showed	O
that	O
L	B
-	I
selectin	I
was	O
expressed	O
on	O
fresh	O
ATL	O
cells	O
along	O
with	O
other	O
activation	B
antigens	I
.	O
Northern	O
blot	O
analysis	O
showed	O
that	O
ATL	O
cells	O
overexpressed	O
that	O
L	O
-	O
selectin	O
mRNA	O
and	O
that	O
the	O
level	O
was	O
aberrantly	O
upregulated	O
after	O
PMA	O
stimulation	O
.	O
Studies	O
using	O
in	O
situ	O
hybridization	O
showed	O
expression	O
of	O
the	O
L	O
-	O
selectin	O
mRNA	O
in	O
the	O
infiltrating	O
leukemic	O
cells	O
in	O
the	O
liver	O
of	O
two	O
ATL	O
patients	O
.	O
Intravenous	O
injection	O
of	O
a	O
rat	O
T	O
-	O
cell	O
line	O
that	O
overexpresses	O
L	B
-	I
selectin	I
showed	O
increased	O
organ	O
infiltration	O
.	O
The	O
induction	O
of	O
Tax	B
expression	O
in	O
JPX9	O
cells	O
resulted	O
in	O
about	O
a	O
twofold	O
increase	O
in	O
the	O
mRNA	O
expression	O
levels	O
compared	O
with	O
the	O
basal	O
level	O
.	O
Chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
assay	O
after	O
transient	O
cotransfection	O
showed	O
about	O
a	O
fivefold	O
transactivation	O
of	O
the	O
L	O
-	O
selectin	O
promoter	O
by	O
Tax	B
.	O
The	O
serum	O
level	O
of	O
the	O
shed	O
form	O
of	O
L	B
-	I
selectin	I
was	O
significantly	O
increased	O
in	O
ATL	O
patients	O
(	O
mean	O
+	O
/-	O
SD	O
,	O
4	O
,	O
215.4	O
+	O
/-	O
4	O
,	O
111	O
ng	O
/	O
mL	O
)	O
compared	O
with	O
those	O
of	O
asymptomatic	O
carriers	O
and	O
healthy	O
blood	O
donors	O
(	O
mean	O
+	O
/-	O
SD	O
,	O
1	O
,	O
148.0	O
+	O
/-	O
269.0	O
ng	O
/	O
mL	O
and	O
991.9	O
+	O
/-	O
224	O
ng	O
/	O
mL	O
,	O
respectively	O
)	O
.	O
These	O
results	O
indicated	O
that	O
ATL	O
cells	O
constitutively	O
overexpress	O
the	O
L	O
-	O
selectin	O
gene	O
that	O
can	O
be	O
transactivated	O
by	O
HTLV-1	O
Tax	B
.	O
The	O
overexpression	O
of	O
L	B
-	I
selectin	I
,	O
as	O
well	O
as	O
of	O
inflammatory	B
cytokines	I
,	O
by	O
ATL	O
cells	O
may	O
provide	O
a	O
basis	O
for	O
ATL	O
cells	O
to	O
attach	O
the	O
vascular	O
endothelium	O
,	O
leading	O
to	O
transmigration	O
and	O
organ	O
infitration	O
.	O
Tissue	O
-	O
specific	O
regulation	O
of	O
the	O
rabbit	O
15-lipoxygenase	O
gene	O
in	O
erythroid	O
cells	O
by	O
a	O
transcriptional	O
silencer	O
.	O
The	O
15-lipoxygenase	O
(	O
lox	O
)	O
gene	O
is	O
expressed	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	O
cells	O
but	O
also	O
in	O
airway	O
epithelial	O
cells	O
and	O
eosinophils	O
.	O
We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	O
'	O
flanking	O
DNA	O
of	O
the	O
15-lox	O
gene	O
contains	O
sequences	O
which	O
down	O
-	O
regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non	O
-	O
erythroid	O
cell	O
lines	O
but	O
not	O
in	O
two	O
erythroid	O
cell	O
lines	O
.	O
The	O
element	O
has	O
characteristics	O
of	O
a	O
transcriptional	O
'	O
silencer	O
'	O
since	O
it	O
functions	O
in	O
both	O
orientations	O
.	O
The	O
main	O
activity	O
of	O
the	O
silencer	O
has	O
been	O
mapped	O
to	O
the	O
first	O
900	O
bp	O
of	O
5	O
'	O
flanking	O
DNA	O
,	O
which	O
contains	O
nine	O
binding	O
sites	O
for	O
a	O
nuclear	B
factor	I
present	O
in	O
non-	O
erythroid	O
cells	O
but	O
not	O
in	O
erythroid	O
cells	O
.	O
These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	O
sites	O
confer	O
tissue	O
-	O
specific	O
down	O
-	O
regulation	O
when	O
attached	O
to	O
a	O
minimal	O
lox	O
promoter	O
fragment	O
.	O
The	O
5	O
'	O
flanking	O
DNA	O
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	O
sites	O
for	O
the	O
GATA	B
family	I
of	O
transcription	B
factors	I
.	O
Mutually	O
exclusive	O
interaction	O
of	O
a	O
novel	O
matrix	B
attachment	I
region	I
binding	I
protein	I
and	O
the	O
NF	B
-	I
muNR	I
enhancer	I
repressor	I
.	O
Implications	O
for	O
regulation	O
of	O
immunoglobulin	B
heavy	I
chain	I
expression	O
.	O
The	O
immunoglobulin	B
heavy	I
chain	I
(	O
IgH	B
)	O
intronic	O
enhancer	O
stimulates	O
transcription	O
from	O
functional	O
promoters	O
in	O
B	O
lymphocytes	O
but	O
not	O
other	O
cell	O
types	O
.	O
The	O
observation	O
that	O
binding	O
sites	O
for	O
the	O
nuclear	B
factor	I
-	I
mu	I
negative	I
regulator	I
(	I
NF	I
-	I
muNR	I
)	I
enhancer	I
repressor	I
overlap	I
nuclear	I
matrix	I
attachment	I
regions	I
(	O
MARs	B
)	O
in	O
this	O
enhancer	O
has	O
lead	O
to	O
the	O
hypothesis	O
that	O
the	O
cell	O
type	O
specificity	O
of	O
the	O
enhancer	O
might	O
be	O
controlled	O
by	O
regulating	O
nuclear	O
matrix	O
attachment	O
(	O
Scheuermann	O
,	O
R.	O
H.	O
,	O
and	O
Chen	O
,	O
U.	O
(	O
1989	O
)	O
Genes	O
&	O
Dev	O
.	O
3	O
,	O
1255	O
-	O
1266	O
)	O
.	O
To	O
understand	O
the	O
role	O
of	O
MARs	B
in	O
IgH	O
enhancer	O
regulation	O
,	O
we	O
have	O
identified	O
a	O
novel	O
MAR	B
-	I
binding	I
protein	I
,	O
MAR	B
-	I
BP1	I
,	O
from	O
soluble	O
nuclear	O
matrix	O
preparations	O
based	O
on	O
its	O
ability	O
to	O
bind	O
to	O
the	O
MARs	B
associated	O
with	O
the	O
IgH	O
enhancer	O
.	O
Purified	O
MAR	B
-	I
BP1	I
migrates	O
as	O
a	O
33-kDa	B
protein	I
,	O
and	O
it	O
can	O
be	O
found	O
in	O
nuclear	O
matrix	O
preparations	O
from	O
a	O
number	O
of	O
different	O
types	O
of	O
lymphoid	O
cell	O
lines	O
.	O
Although	O
specific	O
binding	O
sites	O
have	O
been	O
difficult	O
to	O
localize	O
by	O
chemical	O
or	O
enzymatic	O
footprinting	O
procedures	O
,	O
NF	B
-	I
muNR	I
binding	O
sites	O
are	O
critical	O
for	O
efficient	O
MAR	B
-	I
BP1	I
binding	O
.	O
Indeed	O
,	O
binding	O
of	O
the	O
IgH	O
enhancer	O
to	O
either	O
intact	O
nuclear	O
matrix	O
preparations	O
or	O
to	O
MAR	B
-	I
BP1	I
is	O
mutually	O
exclusive	O
to	O
NF	B
-	I
muNR	I
binding	O
.	O
These	O
results	O
are	O
consistent	O
with	O
a	O
model	O
for	O
cell	O
-	O
type	O
specific	O
regulation	O
in	O
which	O
binding	O
of	O
the	O
NF	B
-	I
muNR	I
repressor	I
to	O
the	O
IgH	O
enhancer	O
prevents	O
nuclear	O
matrix	O
attachment	O
in	O
inappropriate	O
cells	O
by	O
interfering	O
with	O
MAR	B
-	I
BP1	I
/enhancer	O
interaction	O
.	O
Identification	O
of	O
essential	O
GATA	O
and	O
Ets	O
binding	O
motifs	O
within	O
the	O
promoter	O
of	O
the	O
platelet	O
glycoprotein	O
Ib	O
alpha	O
gene	O
.	O
Platelet	B
glycoprotein	I
(	O
GP	B
)	O
Ib	B
-	I
IX	I
-	I
V	I
is	O
a	O
multisubunit	B
adhesion	I
receptor	I
that	O
supports	O
platelet	O
attachment	O
to	O
thrombogenic	O
surfaces	O
at	O
sites	O
of	O
vascular	O
injury	O
.	O
The	O
congenital	O
absence	O
of	O
the	O
receptor	O
results	O
in	O
a	O
bleeding	O
disorder	O
associated	O
with	O
`	O
`	O
giant	O
''	O
platelets	O
,	O
a	O
condition	O
linking	O
the	O
expression	O
of	O
the	O
complex	O
to	O
platelet	O
morphogenesis	O
.	O
To	O
understand	O
better	O
the	O
expression	O
of	O
the	O
GP	B
Ib	I
-	I
IX	I
-	I
V	I
complex	I
,	O
studies	O
were	O
undertaken	O
to	O
define	O
the	O
essential	O
genetic	O
elements	O
supporting	O
the	O
expression	O
of	O
the	O
alpha	B
-	I
subunit	I
of	O
the	O
complex	O
(	O
GP	B
Ib	I
alpha	I
)	O
.	O
GP	O
Ib	O
alpha	O
promoter	O
activity	O
was	O
evaluated	O
by	O
transfection	O
of	O
human	O
erythroleukemia	O
cells	O
with	O
reporter	O
plasmids	O
coding	O
for	O
the	O
enzyme	B
,	O
luciferase	B
.	O
Studies	O
were	O
initiated	O
with	O
a	O
fragment	O
extending	O
2	O
,	O
738	O
nucleotides	O
5	O
'	O
to	O
the	O
transcription	O
start	O
site	O
and	O
lead	O
to	O
the	O
identification	O
of	O
253	O
nucleotides	O
retaining	O
full	O
promoter	O
activity	O
in	O
human	O
erythroleukemia	O
cells	O
.	O
In	O
cells	O
of	O
nonhematopoietic	O
lineage	O
,	O
human	O
endothelial	O
and	O
HeLa	O
cells	O
,	O
the	O
GP	O
Ib	O
alpha	O
promoter	O
activity	O
was	O
no	O
greater	O
than	O
background	O
levels	O
obtained	O
with	O
promoterless	O
constructs	O
.	O
Gel	O
shift	O
assays	O
and	O
site	O
-	O
directed	O
mutagenesis	O
studies	O
defined	O
essential	O
GATA	O
and	O
Ets	O
binding	O
motifs	O
93	O
and	O
150	O
nucleotides	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
,	O
a	O
finding	O
which	O
further	O
substantiates	O
these	O
elements	O
as	O
important	O
determinants	O
of	O
megakaryocytic	O
gene	O
expression	O
.	O
The	O
results	O
define	O
essential	O
cis	O
-	O
acting	O
elements	O
responsible	O
for	O
the	O
expression	O
of	O
GP	B
Ib	I
alpha	I
and	O
provide	O
insights	O
into	O
molecular	O
events	O
coinciding	O
with	O
the	O
release	O
of	O
normal	O
platelets	O
into	O
the	O
bloodstream	O
.	O
Immunosuppression	O
by	O
glucocorticoids	O
:	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
through	O
induction	O
of	O
I	B
kappa	I
B	I
synthesis	O
[	O
see	O
comments	O
]	O
Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
agents	O
.	O
They	O
inhibit	O
synthesis	O
of	O
almost	O
all	O
known	O
cytokines	B
and	O
of	O
several	O
cell	B
surface	I
molecules	I
required	O
for	O
immune	O
function	O
,	O
but	O
the	O
mechanism	O
underlying	O
this	O
activity	O
has	O
been	O
unclear	O
.	O
Here	O
it	O
is	O
shown	O
that	O
glucocorticoids	O
are	O
potent	O
inhibitors	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
activation	O
in	O
mice	O
and	O
cultured	O
cells	O
.	O
This	O
inhibition	O
is	O
mediated	O
by	O
induction	O
of	O
the	O
I	B
kappa	I
B	I
alpha	O
inhibitory	O
protein	O
,	O
which	O
traps	O
activated	O
NF	B
-	I
kappa	I
B	I
in	O
inactive	B
cytoplasmic	I
complexes	I
.	O
Because	O
NF	B
-	I
kappa	I
B	I
activates	O
many	O
immunoregulatory	O
genes	O
in	O
response	O
to	O
pro	O
-	O
inflammatory	O
stimuli	O
,	O
the	O
inhibition	O
of	O
its	O
activity	O
can	O
be	O
a	O
major	O
component	O
of	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
glucocorticoids	O
.	O
The	O
murine	O
BCL6	O
gene	O
is	O
induced	O
in	O
activated	O
lymphocytes	O
as	O
an	O
immediate	O
early	O
gene	O
.	O
The	O
chromosomal	O
translocation	O
involving	O
3q27	O
is	O
often	O
detected	O
in	O
human	O
B	O
-	O
cell	O
lymphomas	O
,	O
especially	O
diffuse	O
lymphomas	O
with	O
a	O
large	O
-	O
cell	O
component	O
.	O
The	O
BCL6	O
gene	O
has	O
been	O
isolated	O
from	O
the	O
chromosomal	O
breakpoint	O
in	O
these	O
lymphomas	O
.	O
Here	O
we	O
cloned	O
the	O
murine	O
BCL6	O
(	O
mBCL6	O
)	O
cDNA	O
from	O
the	O
muscle	O
cDNA	O
library	O
using	O
the	O
human	O
BCL6	O
(	O
hBCL6	O
)	O
cDNA	O
as	O
a	O
probe	O
.	O
The	O
predicted	O
amino	O
acid	O
sequence	O
was	O
95	O
%	O
identical	O
to	O
that	O
of	O
hBCL6	B
.	O
It	O
contains	O
six	O
repeats	O
of	O
the	O
Kruppel	B
-	I
like	I
zinc	I
-	I
finger	I
motif	I
that	O
are	O
completely	O
identical	O
to	O
those	O
of	O
hBCL6	B
,	O
indicating	O
that	O
the	O
BCL6	O
gene	O
is	O
well	O
conserved	O
between	O
humans	O
and	O
mice	O
.	O
Expression	O
of	O
the	O
mBCL6	O
gene	O
was	O
ubiquitously	O
detected	O
in	O
adult	O
mouse	O
tissues	O
including	O
lymphatic	O
organs	O
.	O
Furthermore	O
,	O
it	O
was	O
induced	O
in	O
lymphocytes	O
activated	O
with	O
phorbol	O
ester	O
and	O
Ca2	O
+	O
ionophore	O
within	O
30	O
min	O
after	O
stimulation	O
.	O
This	O
induction	O
was	O
not	O
inhibited	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
a	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
.	O
These	O
results	O
suggest	O
that	O
BCL6	B
plays	O
a	O
role	O
in	O
activated	O
lymphocytes	O
as	O
an	O
immediate	O
early	O
gene	O
.	O
Vitamin	O
E	O
therapy	O
of	O
acute	O
CCl4-induced	O
hepatic	O
injury	O
in	O
mice	O
is	O
associated	O
with	O
inhibition	O
of	O
nuclear	B
factor	I
kappa	I
B	I
binding	O
.	O
Oxidative	O
stress	O
,	O
with	O
reactive	O
oxygen	O
intermediate	O
formation	O
,	O
may	O
represent	O
a	O
common	O
mechanism	O
by	O
which	O
liver	O
injury	O
is	O
induced	O
by	O
diverse	O
etiologies	O
.	O
Oxidative	O
stress	O
enhances	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
activity	O
,	O
and	O
NF	B
-	I
kappa	I
B	I
activity	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
cytotoxic	B
cytokines	I
.	O
Acute	O
hepatic	O
injury	O
caused	O
by	O
reactive	O
oxygen	O
intermediate	O
production	O
was	O
induced	O
by	O
an	O
intraperitoneal	O
injection	O
of	O
CCl4	O
in	O
mice	O
.	O
This	O
injury	O
was	O
significantly	O
inhibited	O
by	O
intravenous	O
pretreatment	O
of	O
the	O
mice	O
with	O
a	O
water	O
-	O
soluble	O
emulsion	O
of	O
alpha	O
-	O
tocopherol	O
.	O
Alpha	O
-	O
tocopherol	O
treatment	O
of	O
the	O
mice	O
given	O
the	O
CCl4	O
also	O
reduced	O
the	O
NF	B
-	I
kappa	I
B	I
binding	O
to	O
levels	O
approaching	O
those	O
found	O
in	O
normal	O
mice	O
.	O
In	O
vitro	O
treatment	O
of	O
a	O
monocyte	O
/	O
macrophage	O
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF	B
-	I
kappa	I
B	I
binding	O
and	O
an	O
increase	O
in	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
messenger	O
RNA	O
levels	O
.	O
Liver	O
specimens	O
taken	O
from	O
patients	O
with	O
acute	O
fulminant	O
hepatitis	O
had	O
markedly	O
increased	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
in	O
comparison	O
with	O
the	O
binding	O
of	O
normal	O
livers	O
.	O
These	O
data	O
demonstrate	O
that	O
abolishing	O
acute	O
hepatic	O
injury	O
with	O
alpha	O
-	O
tocopherol	O
,	O
a	O
free	O
radical	O
scavenger	O
,	O
also	O
eliminated	O
increased	O
NF	B
-	I
kappa	I
B	I
binding	O
.	O
It	O
is	O
tempting	O
to	O
speculate	O
that	O
enhanced	O
NF	B
-	I
kappa	I
B	I
expression	O
caused	O
by	O
free	O
radical	O
production	O
/	O
oxidative	O
stress	O
may	O
modulate	O
liver	O
injury	O
,	O
perhaps	O
through	O
an	O
effect	O
on	O
cytotoxic	B
cytokine	I
synthesis	O
.	O
Triggering	O
of	O
complement	B
receptors	I
CR1	B
(	O
CD35	B
)	O
and	O
CR3	B
(	O
CD11b	B
/	I
CD18	I
)	O
induces	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
(	O
p50	B
/	I
p65	I
)	O
in	O
human	O
monocytes	O
and	O
enhances	O
viral	O
replication	O
in	O
HIV	O
-	O
infected	O
monocytic	O
cells	O
.	O
Monocyte	O
/	O
macrophages	O
may	O
harbor	O
HIV	O
in	O
a	O
nonproductive	O
fashion	O
for	O
prolonged	O
periods	O
of	O
time	O
.	O
Viral	O
gene	O
expression	O
may	O
be	O
reactivated	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
LPS	O
or	O
cytokines	B
such	O
as	O
TNF	B
-	I
alpha	I
in	O
vitro	O
.	O
The	O
effect	O
of	O
LPS	O
and	O
TNF	B
-	I
alpha	I
is	O
mediated	O
by	O
their	O
ability	O
to	O
induce	O
nuclear	O
translocation	O
of	O
the	O
DNA	B
-	I
binding	I
heterodimer	I
NF	B
-	I
kappa	I
B	I
(	O
p50	B
/	I
p65	I
)	O
,	O
which	O
binds	O
to	O
a	O
specific	O
sequence	O
in	O
the	O
HIV	O
-	O
long	O
terminal	O
repeat	O
.	O
The	O
present	O
study	O
demonstrates	O
that	O
triggering	O
of	O
complement	B
receptors	I
CR1	B
(	O
CD35	B
)	O
and	O
CR3	B
(	O
CD11b	B
/	I
CD18	I
)	O
enhances	O
viral	O
replication	O
in	O
HIV	O
-	O
infected	O
human	O
monocytic	O
cells	O
.	O
Monocytic	O
cell	O
lines	O
and	O
normal	O
peripheral	O
blood	O
monocytes	O
were	O
infected	O
with	O
HIV-1	O
in	O
vitro	O
and	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
F	B
(	I
ab	I
'	I
)	I
2	I
fragments	I
of	O
monoclonal	B
anti	I
-	I
CR1	I
or	O
anti	B
-	I
CR3	I
Abs	I
or	O
with	O
C3	B
fragments	I
.	O
Stimulation	O
of	O
CR1	B
or	O
CR3	B
induces	O
a	O
two-	O
to	O
fourfold	O
increase	O
in	O
the	O
amount	O
of	O
cell	O
-	O
associated	O
and	O
released	O
p24	B
Ag	I
in	O
cell	O
cultures	O
that	O
was	O
equivalent	O
to	O
that	O
observed	O
in	O
control	O
cultures	O
triggered	O
with	O
LPS	O
.	O
We	O
further	O
observed	O
that	O
stimulation	O
of	O
CR1	B
or	O
CR3	B
induces	O
the	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
p50	B
/	I
p65	I
in	O
infected	O
cells	O
.	O
Translocation	O
of	O
NF	B
-	I
kappa	I
B	I
p50	B
/	I
p65	I
was	O
also	O
observed	O
following	O
stimulation	O
of	O
CR1	B
or	O
CR3	B
of	O
uninfected	O
peripheral	O
blood	O
monocytes	O
from	O
HIV	O
-	O
seronegative	O
donors	O
.	O
The	O
amount	O
of	O
protein	O
translocated	O
was	O
similar	O
to	O
that	O
observed	O
when	O
cells	O
were	O
stimulated	O
with	O
rhTNF	B
-	I
alpha	I
.	O
TNF	B
-	I
alpha	I
did	O
not	O
mediate	O
the	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
p50	B
/	I
p65	I
induced	O
by	O
triggering	O
of	O
complement	B
receptors	I
.	O
Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
HIV	O
gene	O
expression	O
may	O
be	O
activated	O
in	O
infected	O
monocytes	O
through	O
interaction	O
of	O
the	O
cells	O
with	O
complement	B
-	I
opsonized	I
particles	I
and	O
that	O
enhanced	O
viral	O
replication	O
is	O
associated	O
with	O
C3	B
receptor	I
-mediated	O
nuclear	O
translocation	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
complex	I
.	O
BCL-6	B
and	O
the	O
molecular	O
pathogenesis	O
of	O
B	O
-	O
cell	O
lymphoma	O
.	O
The	O
results	O
presented	O
identify	O
the	O
first	O
genetic	O
lesion	O
associated	O
with	O
DLCL	O
,	O
the	O
most	O
clinically	O
relevant	O
form	O
of	O
NHL	O
.	O
Although	O
no	O
proof	O
yet	O
exists	O
of	O
a	O
role	O
for	O
these	O
lesions	O
in	O
DLCL	O
pathogenesis	O
,	O
the	O
feature	O
of	O
the	O
BCL-6	B
gene	I
product	I
,	O
its	O
specific	O
pattern	O
of	O
expression	O
in	O
B	O
cells	O
,	O
and	O
the	O
clustering	O
of	O
lesions	O
disrupting	O
its	O
regulatory	O
domain	O
strongly	O
suggest	O
that	O
deregulation	O
of	O
BCL-6	B
expression	O
may	O
contribute	O
to	O
DLCL	O
development	O
.	O
A	O
more	O
precise	O
definition	O
of	O
the	O
role	O
of	O
BCL-6	B
in	O
normal	O
and	O
neoplastic	O
B	O
-	O
cell	O
development	O
is	O
the	O
goal	O
of	O
ongoing	O
study	O
of	O
transgenic	O
mice	O
engineered	O
either	O
to	O
express	O
BCL-6	B
under	O
heterologous	O
promoters	O
or	O
lacking	O
BCL-6	B
function	O
due	O
to	O
targeted	O
deletions	O
.	O
In	O
addition	O
to	O
contributing	O
to	O
the	O
understanding	O
of	O
DLCL	O
pathogenesis	O
,	O
the	O
identification	O
of	O
BCL-6	B
lesions	O
may	O
have	O
relevant	O
clinical	O
implications	O
.	O
DLCL	O
represent	O
a	O
heterogeneous	O
group	O
of	O
neoplasms	O
which	O
are	O
treated	O
homogeneously	O
despite	O
the	O
fact	O
that	O
only	O
50	O
%	O
of	O
patients	O
experience	O
long	O
-	O
term	O
disease	O
-	O
free	O
survival	O
(	O
Schneider	O
et	O
al.	O
1990	O
)	O
.	O
The	O
fact	O
that	O
BCL-6	B
rearrangements	O
identify	O
biologically	O
and	O
clinically	O
distinct	O
subsets	O
of	O
DLCL	O
suggests	O
that	O
these	O
lesions	O
may	O
be	O
useful	O
as	O
markers	O
in	O
selection	O
of	O
differential	O
therapeutic	O
strategies	O
based	O
on	O
different	O
risk	O
groups	O
.	O
Furthermore	O
,	O
the	O
BCL-6	B
rearrangements	O
can	O
be	O
used	O
to	O
identify	O
and	O
monitor	O
the	O
malignant	O
clone	O
with	O
sensitive	O
PCR	O
-	O
based	O
techniques	O
.	O
Since	O
clinical	O
remission	O
has	O
been	O
observed	O
in	O
a	O
significant	O
fraction	O
of	O
DLCL	O
cases	O
,	O
these	O
markers	O
may	O
serve	O
as	O
critical	O
tools	O
for	O
sensitive	O
monitoring	O
of	O
minimal	O
residual	O
disease	O
and	O
early	O
diagnosis	O
of	O
relapse	O
(	O
Gribben	O
et	O
al.	O
1993	O
)	O
.	O
Inhibition	O
of	O
dexamethasone	O
binding	O
to	O
human	B
glucocorticoid	I
receptor	I
by	O
New	O
World	O
primate	O
cell	O
extracts	O
.	O
To	O
determine	O
if	O
New	O
World	O
primates	O
express	O
an	O
inhibitor	O
that	O
influences	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
binding	O
characteristics	O
,	O
we	O
examined	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosol	O
prepared	O
from	O
B95	O
-	O
8	O
lymphoid	O
cells	O
,	O
derived	O
from	O
the	O
cotton	O
top	O
tamarin	O
(	O
Saguinus	O
oedipus	O
)	O
,	O
in	O
combination	O
with	O
cytosol	O
prepared	O
from	O
human	O
or	O
rat	O
tissues	O
.	O
B95	O
-	O
8	O
cytosol	O
inhibited	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
(	O
P	O
<	O
0.01	O
)	O
when	O
mixed	O
with	O
cytosol	O
prepared	O
from	O
either	O
a	O
human	O
lymphoid	O
cell	O
line	O
(	O
HL	O
)	O
or	O
rat	O
thymus	O
.	O
The	O
inhibitory	O
activity	O
was	O
heat	O
labile	O
and	O
trypsin	B
sensitive	O
.	O
Peak	O
inhibitory	O
activity	O
was	O
found	O
in	O
the	O
150	O
-	O
200	O
kd	O
fractions	O
after	O
Sephacryl	O
G-200	O
ultrafiltration	O
.	O
Scatchard	O
analysis	O
of	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
using	O
mixed	O
cytosol	O
showed	O
a	O
diminished	O
GR	B
apparent	O
binding	O
affinity	O
when	O
compared	O
to	O
HL	O
cytosol	O
.	O
Kinetic	O
studies	O
using	O
mixed	O
cytosol	O
indicated	O
that	O
B95	O
-	O
8	O
cytosol	O
did	O
not	O
affect	O
the	O
apparent	O
dissociation	O
rate	O
of	O
[	O
3H	O
]	O
dexamethasone	O
.	O
These	O
data	O
demonstrate	O
that	O
B95	O
-	O
8	O
cells	O
contain	O
a	O
competitive	O
inhibitor	O
that	O
prevents	O
binding	O
of	O
dexamethasone	O
to	O
its	O
cognate	B
receptor	I
.	O
Initiation	B
binding	I
repressor	I
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	O
h5	O
gene	O
,	O
is	O
a	O
glycosylated	B
member	I
of	O
a	O
family	O
of	O
cell	B
growth	I
regulators	I
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:	O
735	O
]	O
Initiation	B
binding	I
repressor	I
[	O
corrected	O
]	O
(	O
IBR	B
)	O
is	O
a	O
chicken	B
erythrocyte	I
factor	I
(	O
apparent	O
molecular	O
mass	O
,	O
70	O
to	O
73	O
kDa	O
)	O
that	O
binds	O
to	O
the	O
sequences	O
spanning	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	O
h5	O
gene	O
,	O
repressing	O
its	O
transcription	O
.	O
A	O
variety	O
of	O
other	O
cells	O
,	O
including	O
transformed	O
erythroid	O
precursors	O
,	O
do	O
not	O
have	O
IBR	B
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	B
(	O
68	O
to	O
70	O
kDa	O
)	O
that	O
recognizes	O
the	O
same	O
IBR	B
sites	O
.	O
We	O
have	O
cloned	O
the	O
IBR	O
cDNA	O
and	O
studied	O
the	O
relationship	O
of	O
IBR	B
and	O
IBF	B
.	O
IBR	B
is	O
a	O
503-amino	B
-	I
acid	I
-	I
long	I
acidic	I
protein	I
which	O
is	O
99.0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	B
NRF-1	I
/	I
alpha	I
-	I
Pal	I
factor	I
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	B
factors	I
P3A2	B
and	O
erected	B
wing	I
gene	I
product	I
(	O
EWG	B
)	O
.	O
We	O
present	O
evidence	O
that	O
IBR	B
and	O
IBF	B
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O
We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR	B
/	I
F	I
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	O
homodimers	B
and	O
that	O
the	O
dimer	B
is	O
the	O
relevant	B
DNA	I
-	I
binding	I
species	I
.	O
The	O
evolutionarily	O
conserved	O
N	B
-	I
terminal	I
half	I
of	O
IBR	B
/	I
F	I
harbors	O
the	O
DNA	B
-	I
binding	I
/	I
dimerization	I
domain	I
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	B
kinase	I
II	I
sites	I
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O
bipartite	B
nuclear	I
localization	I
signal	I
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
nuclear	O
targeting	O
.	O
Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	B
RCGCRYGCGY	I
consensus	I
constitutes	O
high	O
-	O
affinity	O
IBR	O
/	O
F	O
binding	O
sites	O
and	O
that	O
the	O
direct	O
-	O
repeat	O
palindrome	O
TGCGCATGCGCA	O
is	O
the	O
optimal	O
site	O
.	O
A	O
survey	O
of	O
genes	O
potentially	O
regulated	O
by	O
this	O
family	O
of	O
factors	B
primarily	O
revealed	O
genes	O
involved	O
in	O
growth	O
-	O
related	O
metabolism	O
.	O
Correlation	O
of	O
differentiation	O
-	O
inducing	O
activity	O
of	O
retinoids	O
on	O
human	O
leukemia	O
cell	O
lines	O
HL-60	O
and	O
NB4	O
.	O
Retinoids	O
,	O
including	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
,	O
its	O
isomers	O
,	O
and	O
fifty	O
synthetic	O
retinoids	O
(	O
retinobenzoic	O
acids	O
)	O
,	O
were	O
tested	O
for	O
differentiation	O
-	O
inducing	O
activity	O
on	O
human	O
leukemia	O
cell	O
lines	O
HL-60	O
and	O
NB4	O
.	O
A	O
good	O
linear	O
correlation	O
,	O
with	O
an	O
r	O
value	O
of	O
0.91	O
,	O
between	O
the	O
ED50	O
values	O
for	O
the	O
differentiation	O
-	O
inducing	O
activity	O
towards	O
HL-60	O
cells	O
and	O
that	O
towards	O
NB4	O
cells	O
was	O
found	O
.	O
Staphylococcal	B
enterotoxins	I
modulate	O
interleukin	B
2	I
receptor	I
expression	O
and	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B
protein	I
-	I
tyrosine	I
kinase	I
3	I
(	O
Jak3	B
)	O
and	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	O
Stat	B
proteins	I
)	O
.	O
Staphylococcal	B
enterotoxins	I
(	O
SE	B
)	O
stimulate	O
T	O
cells	O
expressing	O
the	O
appropriate	O
variable	B
region	I
beta	I
chain	I
of	I
(	I
V	I
beta	I
)	I
T	I
-	I
cell	I
receptors	I
and	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
diseases	O
.	O
Depending	O
on	O
costimulatory	O
signals	O
,	O
SE	B
induce	O
either	O
proliferation	O
or	O
anergy	O
in	O
T	O
cells	O
.	O
In	O
addition	O
,	O
SE	B
can	O
induce	O
an	O
interleukin-2	B
(	O
IL-2	B
)	O
nonresponsive	O
state	O
and	O
apoptosis	O
.	O
Here	O
,	O
we	O
show	O
that	O
SE	B
induce	O
dynamic	O
changes	O
in	O
the	O
expression	O
of	O
and	O
signal	O
transduction	O
through	O
the	O
IL-2	B
receptor	I
(	I
IL-2R	I
)	I
beta	I
and	I
gamma	I
chains	I
(	O
IL-2R	B
beta	I
and	O
IL-2R	B
gamma	I
)	O
in	O
human	O
antigen	O
-	O
specific	O
CD4	O
+	O
T	O
-	O
cell	O
lines	O
.	O
Thus	O
,	O
after	O
4	O
hr	O
of	O
exposure	O
to	O
SEA	B
and	O
SEB	B
,	O
the	O
expression	O
of	O
IL-2R	B
beta	I
was	O
down	O
-	O
regulated	O
,	O
IL-2R	B
gamma	I
was	O
slightly	O
up	O
-	O
regulated	O
,	O
while	O
IL-2R	B
alpha	I
remained	O
largely	O
unaffected	O
.	O
The	O
changes	O
in	O
the	O
composition	O
of	O
IL-2Rs	B
were	O
accompanied	O
by	O
inhibition	O
of	O
IL-2	B
-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B
protein	I
-	I
tyrosine	I
kinase	I
3	I
(	O
Jak3	B
)	O
and	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
called	O
Stat3	B
and	O
Stat5	B
.	O
In	O
parallel	O
experiments	O
,	O
IL-2	B
-driven	O
proliferation	O
was	O
inhibited	O
significantly	O
.	O
After	O
16	O
hr	O
of	O
exposure	O
to	O
SE	B
,	O
the	O
expression	O
of	O
IL-2R	B
beta	I
remained	O
low	O
,	O
while	O
that	O
of	O
IL2R	B
alpha	I
and	O
IL2R	B
gamma	I
was	O
further	O
up	O
-	O
regulated	O
,	O
and	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B
and	O
Stat	B
proteins	I
was	O
partly	O
normalized	O
.	O
Yet	O
,	O
IL-2	B
-driven	O
proliferation	O
remained	O
profoundly	O
inhibited	O
,	O
suggesting	O
that	O
signaling	O
events	O
other	O
than	O
Jak3	B
/Stat	B
activation	O
had	O
also	O
been	O
changed	O
following	O
SE	B
stimulation	O
.	O
In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
SE	B
can	O
modulate	O
IL-2R	B
expression	O
and	O
signal	O
transduction	O
involving	O
the	O
Jak	B
/	I
Stat	I
pathway	O
in	O
CD4	O
+	O
T	O
-	O
cell	O
lines	O
.	O
IFN	B
-	I
gamma	I
priming	O
of	O
monocytes	O
enhances	O
LPS	O
-	O
induced	O
TNF	B
production	O
by	O
augmenting	O
both	O
transcription	O
and	O
MRNA	O
stability	O
.	O
The	O
induction	O
of	O
cytokine	B
expression	O
in	O
monocytes	O
/	O
macrophages	O
by	O
bacterial	B
endotoxin	I
or	O
lipopolysaccharide	O
is	O
a	O
critical	O
,	O
highly	O
regulated	O
host	O
defence	O
response	O
.	O
The	O
augmentation	O
of	O
LPS	O
responses	O
by	O
interferon	B
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
,	O
referred	O
to	O
as	O
priming	O
,	O
is	O
well	O
established	O
.	O
However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
priming	O
occurs	O
is	O
poorly	O
defined	O
.	O
Using	O
tumour	B
necrosis	I
factor	I
(	O
TNF	B
)	O
induction	O
as	O
a	O
model	O
,	O
experiments	O
were	O
designed	O
to	O
analyse	O
in	O
detail	O
the	O
priming	O
effect	O
on	O
the	O
LPS	O
response	O
in	O
human	O
monocytes	O
.	O
Priming	O
by	O
IFN	B
-	I
gamma	I
was	O
primarily	O
manifested	O
at	O
the	O
level	O
of	O
TNF	O
mRNA	O
accumulation	O
.	O
IFN	B
-	I
gamma	I
pre	O
-	O
treatment	O
affected	O
the	O
magnitude	O
rather	O
than	O
the	O
sensitivity	O
of	O
the	O
LPS	O
response	O
.	O
Priming	O
occurred	O
after	O
several	O
hours	O
of	O
treatment	O
,	O
and	O
the	O
primed	O
state	O
was	O
induced	O
by	O
either	O
IFN	B
-	I
gamma	I
or	O
GM	B
-	I
CSF	I
,	O
but	O
not	O
M	B
-	I
CSF	I
.	O
Primed	O
monocytes	O
transcribed	O
TNF	O
mRNA	O
at	O
a	O
higher	O
rate	O
than	O
freshly	O
isolated	O
monocytes	O
upon	O
activation	O
with	O
LPS	O
.	O
The	O
increased	O
transcriptional	O
rate	O
correlated	O
with	O
a	O
marked	O
increase	O
in	O
nuclear	B
factor	I
-	I
kappa	I
B	I
activity	O
in	O
these	O
cells	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
consensus	O
NF	O
-	O
kappa	O
B	O
oligonucleotide	O
.	O
An	O
additional	O
significant	O
finding	O
was	O
than	O
TNF	O
mRNA	O
induced	O
in	O
primed	O
cells	O
was	O
much	O
more	O
stable	O
than	O
in	O
unprimed	O
cells	O
(	O
T1	O
/	O
2	O
increased	O
6	O
-	O
8-fold	O
)	O
.	O
Consistent	O
with	O
the	O
increased	O
mRNA	O
stability	O
,	O
the	O
duration	O
of	O
mRNA	O
accumulation	O
was	O
longer	O
following	O
LPS	O
stimulation	O
in	O
primed	O
monocytes	O
,	O
in	O
addition	O
to	O
being	O
of	O
greater	O
magnitude	O
.	O
Finally	O
,	O
primed	O
and	O
unprimed	O
cells	O
possessed	O
a	O
differential	O
sensitivity	O
to	O
the	O
kinase	O
inhibitor	O
H-89	O
.	O
H-89	O
substantially	O
suppressed	O
LPS	O
-	O
induced	O
TNF	O
mRNA	O
accumulation	O
in	O
unprimed	O
cells	O
,	O
but	O
had	O
no	O
effect	O
on	O
primed	O
monocytes	O
following	O
LPS	O
stimulation	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Prolactin	B
and	O
interleukin-2	B
receptors	I
in	O
T	O
lymphocytes	O
signal	O
through	O
a	O
MGF	B
-	I
STAT5-like	I
transcription	I
factor	I
.	O
The	O
cell	O
surface	O
receptors	O
for	O
PRL	B
and	O
interleukin-2	B
(	O
IL-2	B
)	O
are	O
structurally	O
distinct	O
,	O
but	O
share	O
regulatory	O
tasks	O
in	O
T	O
lymphocytes	O
.	O
They	O
can	O
stimulate	O
proliferation	O
and	O
activate	O
transcription	O
of	O
over	O
-	O
lapping	O
sets	O
of	O
genes	O
of	O
T	O
cells	O
.	O
PRL	B
and	O
IL-2	B
receptor	O
activation	O
are	O
both	O
linked	O
to	O
the	O
Jak	B
/	I
Stat	I
(	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
)	O
pathway	O
.	O
We	O
investigated	O
the	O
ability	O
of	O
PRL	B
and	O
IL-2	B
to	O
activate	O
Stat	B
proteins	I
in	O
different	O
T	O
cell	O
lines	O
.	O
The	O
DNA	O
binding	O
specificities	O
,	O
the	O
reactivities	O
toward	O
Stat	O
-	O
specific	O
antisera	O
,	O
and	O
the	O
mol	O
wt	O
of	O
IL-2	B
-and	O
PRL	B
-	I
induced	I
DNA	I
-	I
binding	I
proteins	I
in	O
Nb2	O
and	O
C196	O
T	O
cell	O
lines	O
were	O
investigated	O
.	O
A	O
comparison	O
with	O
the	O
Stat	B
proteins	I
induced	O
by	O
interferon	B
-	I
gamma	I
,	O
PRL	B
,	O
and	O
IL-6	B
in	O
T47D	O
mammary	O
tumor	O
cells	O
was	O
made	O
.	O
We	O
found	O
that	O
these	O
parameters	O
were	O
indistinguishable	O
for	O
one	O
of	O
the	O
PRL-	B
and	I
IL-2-induced	I
factors	I
.	O
A	O
transcription	O
factor	O
closely	O
related	O
to	O
mammary	B
gland	I
factor	I
-	I
Stat5	I
is	O
rapidly	O
activated	O
upon	O
interaction	O
of	O
IL-2	B
and	O
PRL	B
with	O
their	O
respective	O
receptors	O
.	O
Activation	O
of	O
a	O
second	O
protein	O
related	O
to	O
Stat1	B
was	O
also	O
observed	O
.	O
Our	O
results	O
emphasize	O
the	O
role	O
of	O
PRL	B
as	O
a	O
regulator	O
of	O
the	O
immune	O
response	O
and	O
indicate	O
that	O
the	O
Stat	B
factors	I
mammary	B
gland	I
factor	I
-	I
Stat5	I
and	O
Stat1	B
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
T	O
cell	O
development	O
.	O
Salicylates	O
inhibit	O
lipopolysaccharide	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O
Binding	O
of	O
plasma	B
Factor	I
VII	I
/	I
VIIa	I
to	O
the	O
tissue	B
factor	I
(	I
TF	I
)	I
receptor	I
initiates	O
the	O
coagulation	B
protease	I
cascades	O
.	O
TF	O
expression	O
by	O
circulating	O
monocytes	O
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O
Transcriptional	O
activation	O
of	O
the	O
human	O
TF	O
gene	O
in	O
monocytic	O
cells	O
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
to	O
a	O
kappa	O
B	O
site	O
in	O
the	O
TF	O
promoter	O
.	O
Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti	O
-	O
inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
activity	O
and	O
TF	O
gene	O
transcription	O
in	O
human	O
monocytes	O
and	O
monocytic	O
THP-1	O
cells	O
at	O
clinically	O
relevant	O
doses	O
.	O
Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS	O
-	O
induced	O
proteolytic	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
.	O
In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	O
gene	O
.	O
These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
gene	O
transcription	O
in	O
monocytic	O
cells	O
by	O
preventing	O
nuclear	O
translocation	O
of	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
.	O
The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O
Synergy	O
between	O
signal	O
transduction	O
pathways	O
is	O
obligatory	O
for	O
expression	O
of	O
c	O
-	O
fos	O
in	O
B	O
and	O
T	O
cell	O
lines	O
:	O
implication	O
for	O
c	O
-	O
fos	O
control	O
via	O
surface	B
immunoglobulin	I
and	O
T	B
cell	I
antigen	I
receptors	I
.	O
Expression	O
of	O
the	O
protooncogene	O
c	O
-	O
fos	O
is	O
controlled	O
by	O
three	O
main	O
regulatory	O
pathways	O
involving	O
kinase	B
C	I
,	O
cAMP	O
,	O
and	O
calcium	O
.	O
Kinase	B
C	I
mediates	O
its	O
effects	O
via	O
phosphorylation	O
of	O
serum	B
response	I
factor	I
(	O
SRF	B
)	O
which	O
interacts	O
with	O
the	O
serum	O
response	O
element	O
(	O
SRE	O
)	O
;	O
cAMP	O
and	O
calcium	O
mediate	O
their	O
effects	O
via	O
phosphorylation	O
of	O
CREB	B
(	O
cAMP	B
regulatory	I
element	I
binding	I
protein	I
)	O
presumably	O
by	O
activation	O
of	O
a	O
protein	B
kinase	I
A	I
or	O
calmodulin	B
-	I
regulated	I
kinase	I
.	O
We	O
have	O
examined	O
the	O
function	O
of	O
these	O
elements	O
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
(	O
Ramos	O
and	O
Daudi	O
)	O
as	O
well	O
as	O
a	O
T	O
lymphocytic	O
cell	O
line	O
(	O
Jurkat	O
)	O
.	O
We	O
have	O
found	O
that	O
stimulation	O
of	O
any	O
one	O
of	O
these	O
pathways	O
alone	O
has	O
little	O
or	O
no	O
effect	O
on	O
c	O
-	O
fos	O
induction	O
.	O
However	O
,	O
kinase	B
C	I
activation	O
(	O
PMA	O
stimulation	O
)	O
combined	O
with	O
either	O
cAMP	O
(	O
forskolin	O
plus	O
MIX	O
)	O
or	O
calcium	O
stimulation	O
(	O
ionophore	O
)	O
leads	O
to	O
greatly	O
enhanced	O
c	O
-	O
fos	O
induction	O
.	O
By	O
contrast	O
,	O
cAMP	O
in	O
the	O
presence	O
of	O
calcium	O
shows	O
no	O
synergy	O
in	O
c	O
-	O
fos	O
induction	O
.	O
Okadaic	O
acid	O
augments	O
PMA-	O
as	O
well	O
as	O
calcium	O
-	O
mediated	O
activation	O
of	O
c	O
-	O
fos	O
,	O
and	O
has	O
little	O
or	O
no	O
effect	O
when	O
combined	O
with	O
cAMP	O
.	O
The	O
main	O
difference	O
between	O
Ramos	O
(	O
B	O
cells	O
)	O
and	O
Jurkat	O
(	O
T	O
cells	O
)	O
in	O
the	O
regulation	O
of	O
c	O
-	O
fos	O
is	O
that	O
cAMP	O
plus	O
calcium	O
is	O
strongly	O
synergistic	O
in	O
Jurkat	O
and	O
is	O
without	O
effect	O
in	O
Ramos	O
.	O
Analysis	O
of	O
AP-1	B
activity	O
using	O
gel	O
mobility	O
shift	O
assays	O
confirms	O
that	O
the	O
requirements	O
for	O
synergy	O
in	O
c	O
-	O
fos	O
mRNA	O
induction	O
are	O
paralleled	O
by	O
requirements	O
for	O
synergy	O
in	O
induction	O
of	O
AP-1	B
activity	O
.	O
Signaling	O
in	O
B	O
cells	O
due	O
to	O
anti	B
-	I
Ig	I
stimulation	O
involves	O
both	O
kinase	B
C	I
activation	O
and	O
release	O
of	O
intracellular	O
calcium	O
,	O
and	O
results	O
in	O
c	O
-	O
fos	O
mRNA	O
induction	O
.	O
Our	O
results	O
indicate	O
that	O
synergy	O
between	O
the	O
kinase	B
C	I
activation	O
and	O
calcium	O
is	O
needed	O
for	O
efficient	O
c	O
-	O
fos	O
induction	O
since	O
neither	O
of	O
these	O
two	O
alone	O
induces	O
c	O
-	O
fos	O
well	O
.	O
That	O
synergy	O
of	O
signaling	O
pathways	O
is	O
relevant	O
for	O
the	O
anti	B
-	I
Ig	I
induction	O
of	O
c	O
-	O
fos	O
is	O
supported	O
by	O
the	O
fact	O
that	O
cAMP	O
-	O
inducing	O
agents	O
and	O
okadaic	O
acid	O
further	O
enhance	O
anti	B
-	I
Ig	I
induction	O
of	O
c	O
-	O
fos	O
.	O
These	O
results	O
suggest	O
that	O
cell	O
-	O
specific	O
patterns	O
of	O
synergy	O
are	O
an	O
essential	O
feature	O
for	O
c	O
-	O
fos	O
induction	O
and	O
may	O
be	O
relevant	O
for	O
c	O
-	O
fos	O
control	O
through	O
B	B
and	I
T	I
cell	I
antigen	I
receptors	I
.	O
Anti	B
-	I
immunoglobulin	I
M	I
activates	O
nuclear	B
calcium	I
/	I
calmodulin	I
-	I
dependent	I
protein	I
kinase	I
II	I
in	O
human	O
B	O
lymphocytes	O
.	O
We	O
and	O
others	O
have	O
previously	O
shown	O
that	O
the	O
nuclear	B
protein	I
,	O
Ets-1	B
,	O
is	O
phosphorylated	O
in	O
a	O
calcium	O
-	O
dependent	O
manner	O
after	O
ligation	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
M	O
on	O
B	O
lymphocytes	O
.	O
As	O
this	O
phosphorylation	O
was	O
independent	O
of	O
protein	B
kinase	I
C	I
activity	O
,	O
we	O
tested	O
whether	O
a	O
calcium	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
kinase	I
(	O
CaM	B
kinase	I
)	O
might	O
phosphorylate	O
the	O
Ets-1	B
protein	I
after	O
elevation	O
of	O
intracellular	O
free	O
calcium	O
concentrations	O
.	O
The	O
dephosphorylated	O
form	O
of	O
Ets-1	B
has	O
been	O
shown	O
to	O
bind	O
to	O
chromatin	O
,	O
suggesting	O
that	O
the	O
operative	B
kinase	I
should	O
be	O
detectable	O
in	O
the	O
nucleus	O
.	O
We	O
prepared	O
nuclear	O
extracts	O
from	O
two	O
human	O
B	O
cell	O
lines	O
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
levels	O
correlated	O
with	O
increased	O
phosphorylation	O
of	O
the	O
Ets-1	B
protein	O
.	O
Activity	O
of	O
the	O
CaM	B
kinases	I
was	O
determined	O
using	O
a	O
synthetic	O
peptide	O
substrate	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
inhibitor	O
specific	O
for	O
the	O
CaM	B
kinase	I
family	I
,	O
KN-62	O
.	O
Stimulation	O
of	O
cells	O
with	O
anti	B
-	I
IgM	I
led	O
to	O
increased	O
activity	O
of	O
a	O
nuclear	B
kinase	I
that	O
could	O
phosphorylate	O
the	O
peptide	O
,	O
and	O
this	O
activity	O
was	O
reduced	O
by	O
10	O
microM	O
KN-62	O
.	O
Kinase	O
activity	O
was	O
reduced	O
in	O
lysates	O
preadsorbed	O
using	O
an	O
antibody	B
specific	O
for	O
CaM	B
kinase	I
II	I
.	O
Two	O
-	O
dimensional	O
phosphopeptide	O
maps	O
of	O
the	O
Ets-1	B
protein	O
from	O
cells	O
incubated	O
with	O
ionomycin	O
or	O
anti	B
-	I
IgM	I
contained	O
two	O
unique	O
phosphopeptides	O
that	O
were	O
absent	O
in	O
untreated	O
cells	O
.	O
Incubation	O
of	O
isolated	B
Ets-1	I
protein	I
with	O
purified	O
CaM	B
kinase	I
II	I
produced	O
phosphorylation	O
of	O
peptides	O
that	O
migrated	O
identically	O
to	O
those	O
found	O
in	O
cells	O
incubated	O
with	O
either	O
anti	B
-	I
IgM	I
or	O
ionomycin	O
.	O
These	O
data	O
suggest	O
a	O
model	O
of	O
signal	O
transduction	O
by	O
the	O
antigen	B
receptor	I
on	O
B	O
lymphocytes	O
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
can	O
rapidly	O
activate	O
nuclear	B
CaM	I
kinase	I
II	I
,	O
potentially	O
resulting	O
in	O
phosphorylation	O
and	O
regulation	O
of	O
DNA	B
-	I
binding	I
proteins	I
.	O
Cross	O
-	O
linking	O
of	O
Fc	B
gamma	I
receptors	I
activates	O
HIV-1	O
long	O
terminal	O
repeat	O
-driven	O
transcription	O
in	O
human	O
monocytes	O
.	O
Elevation	O
of	O
the	O
levels	O
of	O
circulating	B
immune	I
complexes	I
frequently	O
accompanies	O
HIV-1	O
infection	O
and	O
is	O
a	O
prognostic	O
indicator	O
of	O
clinical	O
progression	O
from	O
asymptomatic	O
infection	O
to	O
AIDS	O
.	O
Here	O
we	O
report	O
that	O
cross	O
-	O
linking	O
of	O
Fc	B
gamma	I
RI	I
or	O
Fc	B
gamma	I
RII	I
by	O
adherent	B
human	I
IgG	I
or	O
by	O
specific	O
anti	B
-	I
Fc	I
gamma	I
R	I
mAb	I
activates	O
HIV-1	O
gene	O
expression	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
BF24	O
and	O
increased	O
HIV	O
RNA	O
expression	O
in	O
monocytes	O
from	O
HIV	O
infected	O
patients	O
as	O
assayed	O
by	O
reverse	O
transcription	O
-	O
PCR	O
.	O
In	O
THP-1	O
cells	O
,	O
Fc	B
gamma	I
R	I
cross	O
-	O
linking	O
induced	O
NF	B
-	I
kappa	I
B	I
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
the	O
regulatory	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV-1	O
and	O
to	O
activate	O
HIV-1	O
transcription	O
.	O
Anti	B
-	I
TNF	I
-	I
alpha	I
antibody	I
but	O
not	O
anti	B
-	I
IL-1	I
beta	I
antibody	I
strongly	O
inhibited	O
both	O
the	O
induction	O
of	O
HIV-1-	O
LTR	O
-driven	O
transcription	O
and	O
the	O
induction	O
of	O
NF	B
-	I
kappa	I
B	I
by	O
Fc	B
gamma	I
R	I
cross	O
-	O
linking	O
.	O
These	O
results	O
indicate	O
that	O
Fc	B
gamma	I
R	I
can	O
mediate	O
a	O
TNF	B
-	I
alpha	I
-dependent	O
induction	O
of	O
HIV-1	O
gene	O
transcription	O
and	O
suggest	O
that	O
immune	B
complexes	I
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
HIV-1	O
infection	O
by	O
augmenting	O
viral	O
replication	O
in	O
monocytes	O
.	O
E2F-1	B
blocks	O
terminal	O
differentiation	O
and	O
causes	O
proliferation	O
in	O
transgenic	O
megakaryocytes	O
.	O
The	O
transcription	B
factor	I
E2F-1	B
plays	O
a	O
central	O
role	O
in	O
the	O
cell	O
cycle	O
through	O
its	O
ability	O
to	O
activate	O
genes	O
involved	O
in	O
cell	O
division	O
.	O
E2F-1	B
activity	O
is	O
regulated	O
by	O
a	O
number	O
of	O
proteins	O
,	O
including	O
the	O
retinoblastoma	O
susceptibility	O
gene	O
product	O
,	O
cyclin	B
-	I
dependent	I
kinases	I
,	O
and	O
their	O
inhibitors	O
,	O
proteins	O
that	O
have	O
been	O
implicated	O
in	O
the	O
control	O
of	O
certain	O
developmental	O
processes	O
.	O
To	O
investigate	O
a	O
potential	O
role	O
of	O
E2F-1	B
in	O
differentiation	O
,	O
we	O
assayed	O
the	O
ability	O
of	O
megakaryocytes	O
to	O
form	O
platelets	O
in	O
an	O
in	O
vivo	O
transgenic	O
model	O
.	O
E2F-1	B
expression	O
in	O
megakaryocytes	O
blocked	O
differentiation	O
during	O
maturation	O
,	O
resulting	O
in	O
severe	O
thrombocytopenia	O
.	O
Ultrastructural	O
analysis	O
of	O
megakaryocytes	O
revealed	O
abnormal	O
development	O
characterized	O
by	O
hyperdemarcation	O
of	O
cytoplasmic	O
membranes	O
and	O
reduced	O
numbers	O
of	O
alpha	O
granules	O
.	O
Administration	O
of	O
megakaryocyte	B
growth	I
and	I
development	I
factor	I
or	O
interleukin	B
6	I
could	O
not	O
overcome	O
the	O
differentiation	O
block	O
.	O
Additionally	O
,	O
E2F-1	B
caused	O
massive	O
megakaryocyte	O
accumulation	O
in	O
both	O
normal	O
and	O
ectopic	O
sites	O
,	O
first	O
evident	O
in	O
E15	O
embryonic	O
liver	O
.	O
Furthermore	O
,	O
significant	O
apoptosis	O
was	O
observed	O
in	O
transgenic	O
megakaryocytes	O
.	O
These	O
data	O
indicate	O
that	O
E2F-1	B
can	O
prevent	O
terminal	O
differentiation	O
,	O
probably	O
through	O
its	O
cell	O
cycle	O
-	O
stimulatory	O
activity	O
.	O
Identification	O
of	O
an	O
ionomycin	O
/	O
cyclosporin	O
A	O
-	O
responsive	O
element	O
within	O
the	O
human	O
T	O
cell	O
receptor	O
gamma	O
enhancer	O
.	O
Activation	O
through	O
the	O
Ca2+	O
/	O
calcineurin	B
pathway	O
is	O
essential	O
to	O
the	O
transcription	O
of	O
many	O
cytokine	O
genes	O
.	O
The	O
conserved	O
cis	O
-	O
acting	O
sequence	O
,	O
GGAAAA	O
,	O
and	O
transcription	B
factors	I
binding	O
to	O
this	O
sequence	O
are	O
involved	O
in	O
the	O
response	O
to	O
increased	O
intracellular	O
Ca2	O
+	O
concentrations	O
.	O
Here	O
we	O
report	O
the	O
identification	O
and	O
importance	O
of	O
the	O
same	O
sequence	O
in	O
a	O
non	O
-	O
cytokine	O
gene	O
,	O
the	O
human	O
T	O
cell	O
receptor	O
gamma	O
(	O
TCRG	O
)	O
enhancer	O
.	O
Results	O
from	O
site	O
-	O
directed	O
mutations	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
strongly	O
suggest	O
that	O
this	O
sequence	O
mediates	O
the	O
ionomycin	O
-	O
induced	O
activation	O
of	O
the	O
TCRG	O
enhancer	O
.	O
Our	O
studies	O
provide	O
an	O
explanation	O
for	O
a	O
previous	O
observation	O
that	O
TCRG	O
mRNA	O
levels	O
,	O
but	O
not	O
mRNA	O
levels	O
for	O
T	B
cell	I
receptor	I
alpha	I
and	I
-beta	I
,	O
are	O
increased	O
by	O
ionomycin	O
treatment	O
.	O
Thrombopoietin	B
induces	O
tyrosine	O
phosphorylation	O
of	O
Stat3	B
and	O
Stat5	B
in	O
human	O
blood	O
platelets	O
.	O
Thrombopoietin	B
is	O
known	O
to	O
be	O
essential	O
for	O
megakaryocytopoiesis	O
and	O
thrombopoiesis	O
.	O
Recently	O
,	O
we	O
and	O
others	O
have	O
shown	O
that	O
thrombopoietin	B
induces	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
Jak2	B
and	O
other	O
proteins	O
in	O
human	O
platelets	O
and	O
BaF3	O
cells	O
,	O
genetically	O
engineered	O
to	O
express	O
c	B
-	I
Mpl	I
,	O
a	O
receptor	O
for	O
thrombopoietin	B
.	O
The	O
Jak	O
family	O
of	O
tyrosine	B
kinases	I
are	O
known	O
to	O
mediate	O
some	O
of	O
the	O
effects	O
of	O
cytokines	B
or	O
hematopoietic	B
growth	I
factors	I
by	O
recruitment	O
and	O
tyrosine	O
phosphorylation	O
of	O
a	O
variety	O
of	O
Stat	B
(	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
)	O
proteins	O
.	O
Hence	O
,	O
we	O
have	O
investigated	O
whether	O
Stat	B
proteins	I
are	O
present	O
in	O
platelets	O
and	O
,	O
if	O
so	O
,	O
whether	O
they	O
become	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
thrombopoietin	B
.	O
We	O
immunologically	O
identified	O
Stat1	B
,	O
Stat2	B
,	O
Stat3	B
,	O
and	O
Stat5	B
in	O
human	O
platelet	O
lysates	O
.	O
Thrombopoietin	B
induced	O
tyrosine	O
phosphorylation	O
of	O
Stat3	B
and	O
Stat5	B
in	O
these	O
cells	O
.	O
Thrombopoietin	B
also	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Stat3	B
and	O
Stat5	B
in	O
FDCP-2	O
cells	O
genetically	O
engineered	O
to	O
constitutively	O
express	O
human	B
c	I
-	I
Mpl	I
.	O
Thus	O
,	O
our	O
data	O
indicate	O
that	O
Stat3	B
and	O
Stat5	B
may	O
be	O
involved	O
in	O
signal	O
transduction	O
after	O
ligand	O
binding	O
to	O
c	B
-	I
Mpl	I
and	O
that	O
this	O
event	O
may	O
have	O
a	O
role	O
in	O
megakaryopoiesis	O
/	O
thrombopoiesis	O
or	O
possibly	O
a	O
mature	O
platelet	O
function	O
such	O
as	O
aggregation	O
.	O
Inhibition	O
of	O
lipopolysaccharide	O
-	O
induced	O
monocyte	B
interleukin-1	I
receptor	I
antagonist	O
synthesis	O
by	O
cortisol	O
:	O
involvement	O
of	O
the	O
mineralocorticoid	B
receptor	I
.	O
Glucocorticoids	O
,	O
as	O
a	O
part	O
of	O
their	O
physiological	O
role	O
in	O
the	O
control	O
of	O
inflammatory	O
and	O
immune	O
processes	O
,	O
suppress	O
the	O
expression	O
of	O
interleukin-1	B
(	O
IL-1	B
)	O
and	O
other	O
cytokines	B
.	O
Human	O
monocyte	O
IL-1	O
receptor	O
antagonist	O
(	O
IL-1ra	O
)	O
messenger	O
ribonucleic	O
acid	O
(	O
mRNA	O
)	O
expression	O
and	O
protein	O
secretion	O
are	O
inhibited	O
by	O
dexamethasone	O
.	O
We	O
have	O
now	O
further	O
studied	O
the	O
regulation	O
of	O
IL-1ra	B
by	O
the	O
major	O
physiological	O
human	O
glucocorticoid	O
,	O
cortisol	O
.	O
We	O
found	O
that	O
cortisol	O
incubation	O
induced	O
a	O
decrease	O
in	O
IL-1ra	O
mRNA	O
expression	O
and	O
a	O
significant	O
inhibition	O
of	O
IL-1ra	B
protein	I
secretion	O
in	O
cell	O
cultures	O
of	O
human	O
peripheral	O
monocytes	O
stimulated	O
with	O
the	O
bacterial	O
endotoxin	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
Oral	O
administration	O
of	O
276	O
mumol	O
cortisol	O
to	O
normal	O
subjects	O
also	O
decreased	O
LPS	O
-	O
induced	O
IL-1ra	B
synthesis	O
in	O
cultured	O
monocytes	O
.	O
By	O
coincubating	O
the	O
monocytes	O
with	O
either	O
the	O
mineralocorticoid	O
antagonist	O
spironolactone	O
or	O
the	O
glucocorticoid	B
receptor	I
antagonist	O
RU	O
38486	O
,	O
the	O
in	O
vitro	O
cortisol	O
-	O
induced	O
inhibition	O
of	O
LPS	O
-	O
stimulated	O
IL-1ra	B
secretion	O
was	O
partially	O
reversed	O
.	O
The	O
mineralocorticoid	O
aldosterone	O
exerted	O
a	O
significant	O
decrease	O
in	O
LPS	O
-	O
induced	O
monocyte	O
IL-1ra	B
secretion	O
in	O
vitro	O
,	O
which	O
was	O
blocked	O
by	O
coincubation	O
with	O
spironolactone	O
.	O
In	O
addition	O
,	O
the	O
expression	O
of	O
mineralocorticoid	O
receptor	O
mRNA	O
in	O
human	O
monocytes	O
was	O
observed	O
by	O
PCR	O
of	O
reversed	O
transcribed	O
RNA	O
.	O
Our	O
results	O
further	O
indicate	O
that	O
corticosteroids	O
physiologically	O
control	O
the	O
IL-1	O
/	O
IL-1ra	B
system	O
during	O
inflammatory	O
or	O
immune	O
processes	O
.	O
Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
,	O
in	O
addition	O
to	O
a	O
glucocorticoid	B
receptor	I
-mediated	O
effect	O
,	O
the	O
mineralocorticoid	B
receptor	I
is	O
involved	O
in	O
the	O
inhibition	O
of	O
monocyte	O
IL-1ra	B
secretion	O
by	O
cortisol	O
.	O
HIV	B
glycoprotein	I
120	I
enhances	O
intercellular	B
adhesion	I
molecule-1	I
gene	O
expression	O
in	O
glial	O
cells	O
.	O
Involvement	O
of	O
Janus	B
kinase	I
/signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
and	O
protein	B
kinase	I
C	I
signaling	O
pathways	O
.	O
It	O
is	O
well	O
established	O
that	O
the	O
two	O
major	O
glial	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
astrocytes	O
and	O
microglia	O
,	O
are	O
key	O
participants	O
in	O
mediating	O
the	O
neurologic	O
dysfunction	O
associated	O
with	O
HIV	O
infection	O
of	O
the	O
CNS	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
the	O
major	B
envelope	I
glycoprotein	I
of	O
HIV	O
,	O
glycoprotein	B
120	I
(	O
gp120	B
)	O
,	O
to	O
regulate	O
intercellular	B
adhesion	I
molecule-1	I
(	O
ICAM-1	B
)	O
expression	O
in	O
glial	O
cells	O
,	O
because	O
ICAM-1	B
is	O
important	O
in	O
mediating	O
immune	O
responsiveness	O
in	O
the	O
CNS	O
,	O
facilitating	O
entry	O
of	O
HIV	O
-	O
infected	O
cells	O
into	O
the	O
CNS	O
,	O
and	O
promoting	O
syncytia	O
formation	O
.	O
Our	O
results	O
indicate	O
that	O
gp120	B
enhances	O
ICAM-1	B
gene	O
expression	O
in	O
primary	O
rat	O
astrocytes	O
,	O
primary	O
human	O
astrocytes	O
,	O
a	O
human	O
astroglioma	O
cell	O
line	O
CRT	O
,	O
and	O
primary	O
rat	O
microglia	O
.	O
The	O
signal	O
transduction	O
events	O
involved	O
in	O
gp120	B
-mediated	O
enhancement	O
of	O
ICAM-1	B
appear	O
to	O
involve	O
activation	O
of	O
both	O
protein	B
kinase	I
C	I
and	O
tyrosine	B
kinase	I
,	O
because	O
inhibitors	O
of	O
protein	B
kinase	I
C	I
and	O
tyrosine	B
kinase	I
abrogate	O
gp120	B
-mediated	O
ICAM-1	B
expression	O
in	O
both	O
astrocytes	O
and	O
microglia	O
.	O
Moreover	O
,	O
gp120	B
induces	O
tyrosine	O
phosphorylation	O
of	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	O
STAT-1	B
alpha	I
)	O
as	O
well	O
as	O
the	O
Janus	B
kinase	I
(	O
JAK2	B
)	O
in	O
glial	O
cells	O
.	O
We	O
also	O
demonstrate	O
that	O
gp120	B
-mediated	O
ICAM-1	B
expression	O
has	O
functional	O
significance	O
,	O
as	O
it	O
enhances	O
the	O
ability	O
of	O
monocytic	O
cells	O
to	O
bind	O
to	O
gp120-stimulated	O
human	O
astrocytes	O
in	O
an	O
ICAM-1	B
/beta	O
2	O
integrin	B
-dependent	O
fashion	O
.	O
These	O
results	O
provide	O
new	O
insights	O
into	O
how	O
gp120	B
can	O
influence	O
the	O
involvement	O
of	O
glial	O
cells	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
dementia	O
complex	O
.	O
Aspirin	O
-	O
like	O
drugs	O
can	O
protect	O
human	O
T	O
lymphocytes	O
against	O
benzoquinone	O
cytotoxicity	O
:	O
evidence	O
for	O
a	O
NAD	B
(	I
P	I
)	I
H	I
:	I
quinone	I
reductase	I
-dependent	O
mechanism	O
.	O
Benzene	O
toxicity	O
towards	O
lymphocytes	O
is	O
thought	O
to	O
be	O
mediated	O
by	O
metabolites	O
of	O
benzene	O
including	O
benzoquinone	O
(	O
BQ	O
)	O
.	O
NAD	B
(	I
P	I
)	I
H	I
:	I
quinone	I
reductase	I
(	O
QR	B
)	O
is	O
known	O
to	O
protect	O
against	O
BQ	O
toxicity	O
.	O
The	O
expression	O
of	O
the	O
QR	O
gene	O
is	O
regulated	O
by	O
the	O
transcription	B
factor	I
AP-1	B
.	O
We	O
had	O
previously	O
found	O
that	O
aspirin	O
-	O
like	O
drugs	O
(	O
ALD	O
)	O
induce	O
AP-1	B
in	O
human	O
T	O
lymphocytes	O
.	O
It	O
was	O
therefore	O
hypothesized	O
that	O
ALD	O
would	O
protect	O
lymphocytes	O
against	O
BQ	O
toxicity	O
by	O
inducing	O
QR	B
.	O
Molt-4	O
cells	O
(	O
M4	O
)	O
,	O
a	O
human	O
T	O
lymphocyte	O
cell	O
line	O
,	O
were	O
incubated	O
with	O
different	O
concentrations	O
of	O
two	O
ALD	O
,	O
flurbiprofen	O
and	O
sodium	O
diclofenac	O
,	O
and	O
then	O
exposed	O
to	O
BQ	O
.	O
Toxicity	O
was	O
measured	O
by	O
viability	O
(	O
trypan	O
blue	O
exclusion	O
)	O
.	O
Both	O
drugs	O
protected	O
the	O
cells	O
against	O
BQ	O
cytotoxicity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
e.g.	O
,	O
sodium	O
diclofenac	O
at	O
15	O
microM	O
reduced	O
the	O
fraction	O
of	O
BQ	O
-	O
treated	O
dead	O
cells	O
by	O
70	O
%	O
.	O
ALDs	O
induced	O
QR	B
activity	O
in	O
the	O
M4	O
cells	O
in	O
the	O
same	O
range	O
of	O
concentrations	O
that	O
protected	O
the	O
cells	O
against	O
BQ	O
toxicity	O
.	O
The	O
protective	O
effect	O
of	O
ALD	O
was	O
significantly	O
reduced	O
by	O
dicoumarol	O
,	O
a	O
QR	B
-specific	O
inhibitor	O
.	O
Since	O
human	O
T	O
cells	O
and	O
T	O
cell	O
lines	O
do	O
not	O
metabolize	O
arachidonic	O
acid	O
,	O
our	O
data	O
suggest	O
that	O
ALD	O
can	O
protect	O
human	O
T	O
lymphocytes	O
against	O
a	O
metabolite	O
of	O
benzene	O
by	O
induction	O
of	O
QR	B
activity	O
.	O
Translocation	O
breakpoints	O
in	O
three	O
patients	O
with	O
campomelic	O
dysplasia	O
and	O
autosomal	O
sex	O
reversal	O
map	O
more	O
than	O
130	O
kb	O
from	O
SOX9	O
.	O
Campomelic	O
dysplasia	O
(	O
CMPD1	O
)	O
and	O
autosomal	O
XY	O
sex	O
reversal	O
(	O
SRA1	O
)	O
are	O
caused	O
by	O
mutations	O
in	O
the	O
SRY	O
-	O
related	O
gene	O
SOX9	O
on	O
17q	O
.	O
Unexpectedly	O
,	O
the	O
17q	O
breakpoints	O
in	O
four	O
CMPD1	O
translocation	O
cases	O
previously	O
analyzed	O
by	O
us	O
and	O
others	O
map	O
50	O
kb	O
or	O
more	O
from	O
SOX9	O
.	O
Here	O
,	O
we	O
present	O
clinical	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
data	O
from	O
a	O
new	O
CMPD1	O
/	O
SRA1	O
patient	O
with	O
t	O
(	O
6	O
;	O
17	O
)	O
(	O
q14	O
;	O
q24	O
)	O
.	O
Fluorescence	O
in	O
situ	O
hybridization	O
has	O
shown	O
that	O
the	O
17q	O
breakpoint	O
in	O
this	O
case	O
maps	O
to	O
the	O
same	O
region	O
as	O
the	O
breakpoints	O
in	O
the	O
other	O
translocation	O
cases	O
,	O
at	O
least	O
130	O
kb	O
from	O
SOX9	O
.	O
Likewise	O
,	O
the	O
breakpoints	O
in	O
two	O
of	O
the	O
previously	O
described	O
cases	O
also	O
map	O
more	O
than	O
130	O
kb	O
and	O
,	O
as	O
shown	O
by	O
pulsed	O
field	O
gel	O
electrophoresis	O
analysis	O
,	O
at	O
most	O
400	O
kb	O
or	O
690	O
kb	O
from	O
SOX9	O
.	O
By	O
using	O
a	O
SOX9	O
coding	O
sequence	O
polymorphism	O
,	O
expression	O
of	O
both	O
SOX9	O
alleles	O
has	O
been	O
demonstrated	O
by	O
the	O
reverse	B
transcriptase	I
polymerase	O
chain	O
reaction	O
in	O
lymphoblastoid	O
cells	O
from	O
one	O
of	O
the	O
translocation	O
cases	O
.	O
GATA	B
transcription	I
factors	I
associate	O
with	O
a	O
novel	O
class	O
of	O
nuclear	O
bodies	O
in	O
erythroblasts	O
and	O
megakaryocytes	O
.	O
The	O
nuclear	O
distribution	O
of	O
GATA	B
transcription	I
factors	I
in	O
murine	O
haemopoietic	O
cells	O
was	O
examined	O
by	O
indirect	O
immunofluorescence	O
.	O
Specific	O
bright	O
foci	O
of	O
GATA-1	B
fluorescence	O
were	O
observed	O
in	O
erythroleukaemia	O
cells	O
and	O
primary	O
murine	O
erythroblasts	O
and	O
megakaryocytes	O
,	O
in	O
addition	O
to	O
diffuse	O
nucleoplasmic	O
localization	O
.	O
These	O
foci	O
,	O
which	O
were	O
preferentially	O
found	O
adjacent	O
to	O
nucleoli	O
or	O
at	O
the	O
nuclear	O
periphery	O
,	O
did	O
not	O
represent	O
sites	O
of	O
active	O
transcription	O
or	O
binding	O
of	O
GATA-1	B
to	O
consensus	O
sites	O
in	O
the	O
beta	O
-	O
globin	O
loci	O
.	O
Immunoelectron	O
microscopy	O
demonstrated	O
the	O
presence	O
of	O
intensely	O
labelled	O
structures	O
likely	O
to	O
represent	O
the	O
GATA-1	B
foci	O
seen	O
by	O
immunofluorescence	O
.	O
The	O
GATA-1	B
nuclear	O
bodies	O
differed	O
from	O
previously	O
described	O
nuclear	O
structures	O
and	O
there	O
was	O
no	O
co	O
-	O
localization	O
with	O
nuclear	B
antigens	I
involved	O
in	O
RNA	O
processing	O
or	O
other	O
ubiquitous	B
(	I
Spl	I
,	I
c	I
-	I
Jun	I
and	I
TBP	I
)	I
or	I
haemopoietic	I
(	I
NF	I
-	I
E2	I
)	I
transcription	I
factors	I
.	O
Interestingly	O
,	O
GATA-2	B
and	O
GATA-3	B
proteins	I
also	O
localized	O
to	O
the	O
same	O
nuclear	O
bodies	O
in	O
cell	O
lines	O
co	O
-	O
expressing	O
GATA-1	B
and	I
-2	I
or	I
GATA-1	I
and	I
-3	I
gene	I
products	I
.	O
This	O
pattern	O
of	O
distribution	O
is	O
,	O
thus	O
far	O
,	O
unique	O
to	O
the	O
GATA	B
transcription	I
factors	I
and	O
suggests	O
a	O
protein	O
-	O
protein	O
interaction	O
with	O
other	O
components	O
of	O
the	O
nuclear	O
bodies	O
via	O
the	O
GATA	B
zinc	I
finger	I
domain	I
.	O
Activation	O
of	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
in	O
bacterial	O
lipopolysaccharide	O
-	O
stimulated	O
macrophages	O
.	O
Activation	O
of	O
macrophages	O
by	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
transcription	O
of	O
genes	O
that	O
encode	O
for	O
proinflammatory	B
regulators	I
of	O
the	O
immune	O
response	O
.	O
Previous	O
work	O
has	O
suggested	O
that	O
activation	O
of	O
the	O
transcription	B
factor	I
activator	I
protein	I
1	I
(	O
AP-1	B
)	O
is	O
one	O
LPS	O
-	O
induced	O
event	O
that	O
mediates	O
this	O
response	O
.	O
Consistent	O
with	O
this	O
notion	O
,	O
we	O
found	O
that	O
LPS	O
stimulated	O
AP-1	B
-mediated	O
transcription	O
of	O
a	O
transfected	O
reporter	O
gene	O
in	O
the	O
murine	O
macrophage	O
cell	O
line	O
RAW	O
264.7	O
.	O
As	O
AP-1	B
activity	O
is	O
regulated	O
in	O
part	O
by	O
activation	O
of	O
the	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
,	O
which	O
phosphorylates	O
and	O
subsequently	O
increases	O
the	O
transcriptional	O
activity	O
of	O
c	O
-	O
Jun	O
,	O
we	O
examined	O
whether	O
LPS	O
treatment	O
of	O
macrophages	O
resulted	O
in	O
activation	O
of	O
this	O
kinase	B
.	O
LPS	O
treatment	O
of	O
RAW	O
264.7	O
cells	O
,	O
murine	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
,	O
and	O
the	O
human	O
monocyte	O
cell	O
line	O
THP-1	O
resulted	O
in	O
rapid	O
activation	O
of	O
the	O
p46	B
and	I
p54	I
isoforms	I
of	O
JNK	B
.	O
Treatment	O
with	O
wild	O
-	O
type	O
and	O
rough	O
mutant	O
forms	O
of	O
LPS	O
and	O
synthetic	O
lipid	O
A	O
resulted	O
in	O
JNK	B
activation	O
,	O
while	O
pretreatment	O
with	O
the	O
tyrosine	B
kinase	I
inhibitor	O
herbimycin	O
A	O
inhibited	O
this	O
response	O
.	O
Binding	O
of	O
LPS-	O
LPS	B
binding	I
protein	I
(	I
LBP	I
)	I
complexes	I
to	O
CD14	B
,	O
a	O
surface	B
receptor	I
that	O
mediates	O
many	O
LPS	O
responses	O
,	O
was	O
found	O
to	O
be	O
crucial	O
,	O
as	O
pretreatment	O
of	O
THP-1	O
cells	O
with	O
the	O
monoclonal	B
antibody	I
60b	I
,	O
which	O
blocks	O
this	O
binding	O
,	O
inhibited	O
JNK	B
activation	O
.	O
These	O
results	O
suggest	O
that	O
LPS	O
activation	O
of	O
JNK	B
in	O
monocyte	O
/	O
macrophage	O
cells	O
is	O
a	O
CD14-	O
and	O
protein	O
tyrosine	O
phosphorylation	O
-	O
dependent	O
event	O
that	O
may	O
mediate	O
the	O
early	O
activation	O
of	O
AP-1	B
in	O
regulating	O
LPS	O
-	O
triggered	O
gene	O
induction	O
.	O
IL-13	B
induces	O
phosphorylation	O
and	O
activation	O
of	O
JAK2	B
Janus	I
kinase	I
in	O
human	O
colon	O
carcinoma	O
cell	O
lines	O
:	O
similarities	O
between	O
IL-4	B
and	O
IL-13	B
signaling	O
.	O
We	O
have	O
recently	O
reported	O
that	O
IL-13R	B
may	O
share	O
a	O
component	O
with	O
IL-4R	B
.	O
Here	O
we	O
report	O
that	O
both	O
IL-4	B
and	O
IL-13	B
share	O
signaling	O
events	O
in	O
human	O
colon	O
carcinoma	O
cell	O
lines	O
(	O
HT-29	O
and	O
WiDr	O
)	O
.	O
IL-13	B
caused	O
rapid	O
phosphorylation	O
of	O
the	O
three	O
out	O
of	O
four	O
members	O
of	O
the	O
known	O
Janus	B
family	I
of	I
kinases	I
(	O
JAKs	B
)	O
.	O
We	O
show	O
that	O
JAK2	B
kinase	I
is	O
rapidly	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
IL-13	B
.	O
Within	O
1	O
min	O
of	O
activation	O
,	O
JAK2	B
was	O
phosphorylated	O
,	O
and	O
peaked	O
in	O
10	O
min	O
.	O
In	O
addition	O
,	O
IL-13	B
phosphorylated	O
insulin	B
response	I
substrate-1	I
,	O
IL-4R	B
p140	I
,	O
JAK1	B
,	O
and	O
Tyk2	B
,	O
but	O
not	O
JAK3	B
kinase	I
.	O
IL-4	B
also	O
stimulated	O
all	O
three	O
kinases	B
and	O
substrates	O
,	O
but	O
unlike	O
in	O
immune	O
cells	O
,	O
IL-4	B
did	O
not	O
involve	O
JAK3	B
activation	O
for	O
its	O
signaling	O
in	O
colon	O
cancer	O
cell	O
lines	O
.	O
Furthermore	O
,	O
JAK2	B
associated	O
with	O
the	O
IL-4R	B
p140	I
before	O
and	O
after	O
stimulation	O
with	O
IL-13	B
.	O
Both	O
IL-13	B
and	O
IL-4	B
induced	O
phosphorylation	O
of	O
IL-4	B
STAT	I
(	O
STAT6	B
)	O
but	O
not	O
STAT1	B
,	O
STAT3	B
,	O
or	O
STAT5	B
.	O
125I	B
-	I
IL-13	I
did	O
not	O
bind	O
to	O
colon	O
cancer	O
cell	O
lines	O
,	O
but	O
unlabeled	O
IL-13	B
competed	O
for	O
the	O
binding	O
of	O
125I	B
-	I
IL-4	I
.	O
Our	O
data	O
suggest	O
that	O
IL-13	B
utilizes	O
IL-4R	B
and	O
its	O
signaling	O
pathway	O
,	O
and	O
JAK2	B
may	O
play	O
an	O
important	O
role	O
in	O
the	O
function	O
of	O
IL-4R	B
and	O
IL-13R	B
in	O
colon	O
cancer	O
cells	O
.	O
Efficient	O
transcription	O
and	O
replication	O
of	O
simian	O
immunodeficiency	O
virus	O
in	O
the	O
absence	O
of	O
NF	O
-	O
kappaB	O
and	O
Sp1	O
binding	O
elements	O
.	O
Ten	O
mutants	O
of	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
SIVmac239	O
bearing	O
deletions	O
(	O
delta	O
)	O
or	O
substitutions	O
(	O
subst	O
)	O
in	O
the	O
NF	O
-	O
kappaB	O
and/or	O
Sp1	O
binding	O
elements	O
were	O
created	O
,	O
and	O
the	O
replicative	O
capacities	O
of	O
the	O
mutants	O
were	O
analyzed	O
.	O
All	O
mutants	O
,	O
including	O
one	O
extensively	O
mutagenized	O
strain	O
entirely	O
missing	O
the	O
NF	O
-	O
kappaB	O
and	O
four	O
Spl	O
binding	O
elements	O
,	O
replicated	O
with	O
wild	O
-	O
type	O
kinetics	O
and	O
to	O
a	O
wild	O
-	O
type	O
level	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
cultures	O
in	O
50	O
to	O
100	O
%	O
of	O
the	O
experiments	O
.	O
One	O
group	O
of	O
mutants	O
replicated	O
very	O
similarly	O
to	O
SIVmac239	O
in	O
kinetics	O
and	O
yield	O
in	O
CEMxl74	O
cells	O
(	O
2x	O
NFKappaB	B
>	O
or	O
=	O
SlVmac239	B
approximately	O
deltaNFkappaB	B
approximately	O
deltaSpl234	B
approximately	O
substNFkappaB	B
approximately	O
substSpl2	B
approximately	O
substSp23	B
)	O
,	O
while	O
a	O
second	O
group	O
replicated	O
with	O
delayed	O
or	O
slightly	O
delayed	O
kinetics	O
in	O
CEMxl74	O
cells	O
(	O
SIVmac239	O
>	O
substSp34	B
>	O
deltaNFkappaBdeltaSpl234	B
approximately	O
deltaNFkappaBdeltaSp1	B
>	O
substSpl234	B
)	O
.	O
Reversions	O
or	O
additional	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
U3	O
and	O
R	O
regions	O
of	O
proviral	O
DNA	O
from	O
CEMxl74	O
cells	O
infected	O
with	O
the	O
SIVmac239	O
mutants	O
.	O
Similar	O
results	O
were	O
obtained	O
when	O
mutants	O
of	O
SIVmacMER	O
(	O
a	O
macrophage	O
-	O
competent	O
derivative	O
of	O
SIVmac239	O
)	O
were	O
tested	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
and	O
CEMx174	O
cultures	O
.	O
However	O
,	O
the	O
growth	O
of	O
most	O
mutated	O
viruses	O
was	O
suppressed	O
in	O
primary	O
rhesus	O
monkey	O
alveolar	O
macrophages	O
(	O
SIVmacMER	O
approximately	O
2xNFkappaB	B
approximately	O
substNFkappaB	B
>	O
deltaNFkappaB	B
>	O
deltaNFkappaB	B
deltaSpl234	B
approximately	O
deltaNFkappaBdeltaSpl	B
>	O
deltaSpl234	B
approximately	O
substSpl2	B
>	O
substSp23	B
approximately	O
substSp34	B
approximately	O
substSpl234	B
>	O
or	O
=	O
SIVmac239	O
)	O
.	O
Thus	O
,	O
changes	O
in	O
the	O
Sp1	O
binding	O
sites	O
had	O
the	O
most	O
dramatic	O
effects	O
on	O
SIVmac	O
replication	O
in	O
primary	O
macrophage	O
cultures	O
.	O
Analysis	O
of	O
long	O
terminal	O
repeat	O
-driven	O
secreted	O
alkaline	B
phosphatase	I
activity	O
in	O
transient	O
assays	O
showed	O
that	O
,	O
unlike	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
the	O
SIV	O
long	O
terminal	O
repeat	O
possesses	O
an	O
enhancer	O
region	O
just	O
upstream	O
of	O
the	O
NF	O
-	O
kappaB	O
element	O
which	O
maintains	O
significant	O
levels	O
of	O
basal	O
transcription	O
in	O
the	O
absence	O
of	O
NF	O
-	O
kappaB	O
and	O
Sp1	O
sites	O
.	O
This	O
region	O
is	O
responsive	O
to	O
transactivation	O
by	O
Tat	B
.	O
In	O
addition	O
,	O
the	O
SIV	O
TATA	O
box	O
was	O
shown	O
to	O
be	O
stronger	O
than	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O
Therefore	O
,	O
the	O
surprisingly	O
high	O
replicative	O
capacity	O
of	O
NF	O
-	O
kappaB	O
and	O
Sp1	O
binding	O
site	O
mutants	O
of	O
SIVmac	O
is	O
due	O
to	O
unique	O
features	O
or	O
the	O
enhancer	O
/	O
promoter	O
region	O
.	O
AM580	O
,	O
a	O
stable	O
benzoic	O
derivative	O
of	O
retinoic	O
acid	O
,	O
has	O
powerful	O
and	O
selective	O
cyto	O
-	O
differentiating	O
effects	O
on	O
acute	O
promyelocytic	O
leukemia	O
cells	O
.	O
All	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
successfully	O
used	O
in	O
the	O
cyto	O
-	O
differentiating	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O
Paradoxically	O
,	O
APL	O
cells	O
express	O
PML	B
-	I
RAR	I
,	O
an	O
aberrant	O
form	O
of	O
the	O
retinoic	B
acid	I
receptor	I
type	I
alpha	I
(	O
RAR	B
alpha	I
)	O
derived	O
from	O
the	O
leukemia	O
-	O
specific	O
t	O
(	O
15	O
;	O
17	O
)	O
chromosomal	O
translocation	O
.	O
We	O
show	O
here	O
that	O
AM580	O
,	O
a	O
stable	O
retinobenzoic	O
derivative	O
originally	O
synthesized	O
as	O
a	O
RAR	B
alpha	I
agonist	O
,	O
is	O
a	O
powerful	O
inducer	O
of	O
granulocytic	O
maturation	O
in	O
NB4	O
,	O
an	O
APL	O
-	O
derived	O
cell	O
line	O
,	O
and	O
in	O
freshly	O
isolated	O
APL	O
blasts	O
.	O
After	O
treatment	O
of	O
APL	O
cells	O
with	O
AM580	O
either	O
alone	O
or	O
in	O
combination	O
with	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
(	O
G	B
-	I
CSF	I
)	O
,	O
the	O
compound	O
induces	O
granulocytic	O
maturation	O
,	O
as	O
assessed	O
by	O
determination	O
of	O
the	O
levels	O
of	O
leukocyte	O
alkaline	O
phosphatase	O
,	O
CD11b	O
,	O
CD33	O
,	O
and	O
G	O
-	O
CSF	O
receptor	O
mRNA	O
,	O
at	O
concentrations	O
that	O
are	O
10-	O
to	O
100-fold	O
lower	O
than	O
those	O
of	O
ATRA	O
necessary	O
to	O
produce	O
similar	O
effects	O
.	O
By	O
contrast	O
,	O
AM580	O
is	O
not	O
effective	O
as	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
these	O
differentiation	B
markers	I
in	O
the	O
HL-60	O
cell	O
line	O
and	O
in	O
freshly	O
isolated	O
granulocytes	O
obtained	O
from	O
the	O
peripheral	O
blood	O
of	O
chronic	O
myelogenous	O
leukemia	O
patients	O
during	O
the	O
stable	O
phase	O
of	O
the	O
disease	O
.	O
In	O
NB4	O
cells	O
,	O
two	O
other	O
synthetic	O
nonselective	O
RAR	O
ligands	O
are	O
capable	O
of	O
inducing	O
LAP	B
as	O
much	O
as	O
AM580	O
,	O
whereas	O
RAR	O
beta-	O
or	O
RAR	O
gamma	O
-	O
specific	O
ligands	O
are	O
totally	O
ineffective	O
.	O
These	O
results	O
show	O
that	O
AM580	O
is	O
more	O
powerful	O
than	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
differentiation	O
antigens	O
only	O
in	O
cells	O
in	O
which	O
PML	B
-	I
RAR	I
is	O
present	O
.	O
Binding	O
experiments	O
,	O
using	O
COS-7	O
cells	O
transiently	O
transfected	O
with	O
PML	B
-	I
RAR	I
and	O
the	O
normal	O
RAR	B
alpha	I
,	O
show	O
that	O
AM580	O
has	O
a	O
lower	O
affinity	O
than	O
ATRA	O
for	O
both	O
receptors	O
.	O
However	O
,	O
in	O
the	O
presence	O
of	O
PML	B
-	I
RAR	I
,	O
the	O
synthetic	O
retinoid	O
is	O
a	O
much	O
better	O
transactivator	O
of	O
retinoic	O
acid	O
-	O
responsive	O
element	O
-	O
containing	O
promoters	O
than	O
the	O
natural	O
retinoid	O
,	O
whereas	O
,	O
in	O
the	O
presence	O
of	O
RAR	B
alpha	I
,	O
AM580	O
and	O
ATRA	O
have	O
similar	O
activity	O
.	O
This	O
may	O
explain	O
the	O
strong	O
cyto	O
-	O
differentiating	O
potential	O
of	O
AM580	O
in	O
PML	O
-	O
RAR	O
-	O
containing	O
leukemic	O
cells	O
.	O
An	O
element	O
upstream	O
from	O
the	O
human	O
delta	O
-	O
globin	O
-	O
encoding	O
gene	O
specifically	O
enhances	O
beta	O
-	O
globin	O
reporter	O
gene	O
expression	O
in	O
murine	O
erythroleukemia	O
cells	O
.	O
We	O
have	O
previously	O
shown	O
that	O
a	O
DNA	B
-	I
binding	I
factor	I
specific	O
to	O
adult	O
hematopoietic	O
cells	O
(	O
polypryrimidine	B
-	I
binding	I
factor	I
,	O
PYBF	B
)	O
binds	O
to	O
a	O
pyrimidine	O
-	O
rich	O
region	O
1	O
kb	O
upstream	O
from	O
the	O
human	O
delta	O
-	O
globin	O
-	O
encoding	O
gene	O
(	O
HBD	O
)	O
.	O
The	O
developmental	O
stage	O
-	O
specificity	O
of	O
PYBF	B
and	O
the	O
location	O
of	O
its	O
binding	O
site	O
between	O
the	O
fetal	O
and	O
adult	O
beta	O
-	O
globin	O
(	O
HBB	O
)	O
-like	O
genes	O
suggest	O
that	O
PBYF	B
and	O
its	O
binding	O
site	O
may	O
function	O
in	O
fetal	O
-	O
to	O
-	O
adult	O
globin	O
gene	O
switching	O
.	O
Here	O
,	O
we	O
describe	O
the	O
effect	O
of	O
383-bp	O
(	O
delta383	O
)	O
and	O
99-bp	O
(	O
delta99	O
)	O
sequences	O
containing	O
the	O
PYBF	O
-	O
binding	O
site	O
on	O
transcription	O
from	O
various	O
globin	O
and	O
non	O
-	O
globin	O
promoters	O
,	O
using	O
a	O
transient	O
assay	O
with	O
the	O
cat	O
reporter	O
gene	O
in	O
murine	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
,	O
a	O
cell	O
line	O
with	O
abundant	O
PYBF	B
activity	O
.	O
We	O
show	O
that	O
both	O
delta383	O
and	O
delta99	O
specifically	O
enhance	O
expression	O
of	O
cat	B
for	O
plasmids	O
containing	O
a	O
human	O
adult	O
globin	O
(	O
HBB	O
)	O
promoter	O
,	O
whereas	O
expression	O
of	O
similar	O
constructs	O
using	O
human	O
fetal	O
(	O
A	O
gamma-	O
)	O
globin	O
(	O
HBG1	O
)	O
or	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
promoters	O
is	O
not	O
enhanced	O
.	O
The	O
results	O
suggest	O
that	O
PYBF	B
and	O
the	O
pyrimidine	O
-	O
rich	O
region	O
upstream	O
from	O
HBD	O
can	O
specifically	O
enhance	O
HBB	O
transcription	O
in	O
adult	O
erythroid	O
cells	O
.	O
cAMP	O
inducibility	O
of	O
transcriptional	B
repressor	I
ICER	B
in	O
developing	O
and	O
mature	O
human	O
T	O
lymphocytes	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jul	O
23	O
;	O
93	O
(	O
15	O
)	O
:	O
8154	O
]	O
Stimulation	O
of	O
the	O
cAMP	O
-	O
dependent	O
signaling	O
pathway	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
the	O
proliferation	O
and	O
effector	O
functions	O
of	O
T	O
cells	O
.	O
The	O
ability	O
of	O
T	O
cells	O
to	O
form	O
high	O
intracellular	O
levels	O
of	O
cAMP	O
is	O
acquired	O
during	O
development	O
in	O
the	O
human	O
thymus	O
and	O
is	O
retained	O
by	O
the	O
majority	O
of	O
mature	O
peripheral	O
T	O
lymphocytes	O
.	O
Here	O
we	O
show	O
that	O
elevated	O
cAMP	O
levels	O
in	O
T	O
cells	O
correlate	O
with	O
the	O
expression	O
of	O
the	O
potent	B
transcriptional	I
repressor	I
ICER	B
(	O
inducible	B
cAMP	I
early	I
repressor	I
)	O
previously	O
described	O
in	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
gonadal	O
axis	O
.	O
Further	O
,	O
in	O
transcriptional	O
assays	O
in	O
vivo	O
,	O
ICER	B
inhibits	O
calcineurin	B
-mediated	O
expression	O
of	O
the	O
interleukin	O
2	O
promoter	O
as	O
well	O
as	O
Tax	B
-mediated	O
transactivation	O
of	O
the	O
human	O
T	O
-	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
promoter	O
.	O
Thus	O
,	O
the	O
induction	O
of	O
ICER	B
in	O
T	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
cAMP	O
-	O
induced	O
quiescence	O
and	O
the	O
persistent	O
latency	O
of	O
HTLV	O
-	O
I	O
.	O
Second	O
messenger	O
up	O
-	O
regulation	O
of	O
androgen	O
receptor	O
gene	O
transcription	O
is	O
absent	O
in	O
androgen	O
insensitive	O
human	O
prostatic	O
carcinoma	O
cell	O
lines	O
,	O
PC-3	O
and	O
DU-145	O
.	O
A	O
theoretical	O
pathway	O
of	O
transcriptional	O
regulation	O
of	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
gene	O
is	O
via	O
a	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
present	O
in	O
its	O
promoter	O
region	O
(	O
-508	O
to	O
-501	O
)	O
.	O
After	O
20	O
h	O
of	O
stimulation	O
with	O
8-bromo	O
-	O
cAMP	O
,	O
AR	O
mRNA	O
was	O
upregulated	O
in	O
LNCaP	O
but	O
not	O
in	O
either	O
PC-3	O
or	O
DU-145	O
cell	O
lines	O
.	O
We	O
have	O
demonstrated	O
that	O
the	O
level	O
of	O
CRE	B
binding	I
protein	I
(	O
CREB	B
)	O
was	O
the	O
same	O
in	O
all	O
cell	O
lines	O
and	O
that	O
the	O
putative	O
AR	B
-	I
CRE	I
forms	O
specific	O
and	O
compatible	O
protein	O
interactions	O
with	O
CREB	B
.	O
The	O
ability	O
to	O
regulate	O
AR	O
gene	O
transcription	O
via	O
the	O
second	O
messenger	O
pathway	O
is	O
lost	O
in	O
the	O
PC-3	O
and	O
DU-145	O
cell	O
lines	O
.	O
This	O
may	O
be	O
an	O
important	O
primary	O
mechanism	O
of	O
androgen	O
insensitivity	O
in	O
prostate	O
cancer	O
.	O
Involvement	O
of	O
intracellular	O
Ca2	O
+	O
in	O
oxidant	O
-	O
induced	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
In	O
human	O
Jurkat	O
T	O
cells	O
and	O
its	O
subclone	O
Wurzburg	O
cells	O
oxidant	O
challenge	O
elevated	O
[	O
Ca2	O
+	O
]	O
i	O
by	O
mobilizing	O
Ca2	O
+	O
from	O
intracellular	O
stores	O
.	O
In	O
Jurkat	O
cells	O
this	O
effect	O
was	O
rapid	O
and	O
transient	O
,	O
but	O
in	O
Wurzburg	O
cells	O
the	O
response	O
was	O
slow	O
and	O
sustained	O
.	O
H2O2-induced	O
NF	B
-	I
kappaB	I
activation	O
in	O
Wurzburg	O
cells	O
was	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
extracellular	O
EGTA	O
but	O
was	O
totally	O
inhibited	O
in	O
cells	O
that	O
were	O
loaded	O
with	O
esterified	O
EGTA	O
.	O
In	O
Jurkat	O
cells	O
that	O
are	O
not	O
sensitive	O
to	O
H2O2-induced	O
NF	B
-	I
kappaB	I
activation	O
,	O
H2O2	O
potentiated	O
NF	B
-	I
kappaB	I
activation	O
in	O
the	O
presence	O
of	O
sustained	O
high	O
[	O
Ca2	O
+	O
]	O
i	O
following	O
thapsigargin	O
treatment	O
.	O
NF	B
-	I
kappaB	I
regulatory	O
effect	O
of	O
alpha	O
-	O
lipoate	O
and	O
N	O
-	O
acetylcysteine	O
appeared	O
to	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
their	O
ability	O
to	O
stabilize	O
elevation	O
of	O
[	O
Ca2	O
+	O
]	O
i	O
following	O
oxidant	O
challenge	O
.	O
Results	O
of	O
this	O
study	O
indicate	O
that	O
a	O
sustained	O
elevated	O
[	O
Ca2	O
+	O
]	O
i	O
is	O
a	O
significant	O
factor	O
in	O
oxidant	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
.	O
A	O
new	O
variant	O
translocation	O
in	O
acute	O
promyelocytic	O
leukaemia	O
:	O
molecular	O
characterization	O
and	O
clinical	O
correlation	O
.	O
Translocation	O
t	O
(	O
15	O
;	O
17	O
)	O
(	O
q22	O
;	O
q21	O
)	O
is	O
an	O
acquired	O
clonal	O
cytogenetic	O
change	O
present	O
in	O
almost	O
all	O
cases	O
of	O
acute	O
promelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O
The	O
molecular	O
genetic	O
basis	O
of	O
the	O
translocation	O
supports	O
its	O
integral	O
role	O
in	O
pathogenesis	O
.	O
We	O
describe	O
a	O
patient	O
with	O
APL	O
in	O
whom	O
the	O
leukaemic	O
clone	O
was	O
characterized	O
by	O
a	O
true	O
variant	O
of	O
the	O
classical	O
t	O
(	O
15	O
;	O
17	O
)	O
.	O
The	O
patient	O
whose	O
disease	O
had	O
numerous	O
atypical	O
clinical	O
features	O
,	O
had	O
t	O
(	O
11	O
;	O
17	O
)	O
(	O
q13	O
;	O
121	O
)	O
.	O
The	O
chromosome	O
17	O
breakpoint	O
was	O
localized	O
to	O
intron	O
2	O
of	O
RARA	O
by	O
Southern	O
blotting	O
,	O
and	O
there	O
was	O
no	O
evidence	O
at	O
the	O
molecular	O
level	O
for	O
rearrangement	O
at	O
PML	O
locus	O
.	O
These	O
data	O
,	O
along	O
with	O
previous	O
reports	O
of	O
rare	O
variant	O
translocations	O
in	O
APL	O
,	O
indicate	O
that	O
while	O
dysregulation	O
of	O
RARA	O
by	O
gene	O
fusion	O
may	O
be	O
essential	O
for	O
the	O
APL	O
phenotype	O
,	O
the	O
particular	O
fusion	O
partner	O
may	O
determine	O
clinicopathological	O
aspects	O
,	O
including	O
presentation	O
,	O
response	O
to	O
treatment	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
and	O
prognosis	O
.	O
This	O
heterogeneity	O
suggests	O
that	O
the	O
variant	O
fusion	B
partners	I
of	O
RARA	O
in	O
APL	O
encode	O
factors	B
with	O
properties	O
both	O
common	O
to	O
and	O
distinct	O
from	O
those	O
of	O
PML	O
.	O
Investigation	O
of	O
these	O
factors	O
promises	O
to	O
shed	O
light	O
on	O
the	O
complex	O
development	O
pathways	O
involved	O
in	O
the	O
regulation	O
of	O
haematopoiesis	O
.	O
The	O
role	O
of	O
p16	B
in	O
the	O
E2F	B
-	I
dependent	I
thymidine	I
kinase	I
regulation	O
.	O
The	O
role	O
of	O
alterations	O
of	O
the	O
MTS1	O
tumor	O
suppressor	O
gene	O
on	O
chromosome	O
9p21	O
,	O
which	O
encodes	O
p16	B
,	O
the	O
inhibitor	O
of	O
cyclin	B
-	I
dependent	I
-	I
kinase-4	I
and	I
6	I
,	O
in	O
tumorigenesis	O
is	O
not	O
yet	O
clear	O
.	O
Phosphorylation	O
of	O
the	O
retinoblastoma	B
protein	I
by	O
cyclin	B
-	I
dependent	I
kinases	I
4	I
and	I
6	I
prevents	O
its	O
interaction	O
with	O
the	O
transcription	B
factor	I
E2F	B
,	O
which	O
subsequently	O
promotes	O
the	O
expression	O
of	O
S	O
phase	O
regulated	O
genes	O
,	O
such	O
as	O
thymidine	B
kinase	I
.	O
Although	O
a	O
role	O
of	O
p16	B
in	O
this	O
regulation	O
has	O
been	O
presumed	O
,	O
there	O
is	O
no	O
proof	O
so	O
far	O
that	O
loss	O
of	O
this	O
tumor	O
suppressor	O
gene	O
really	O
affects	O
E2F	B
-mediated	O
regulations	O
.	O
We	O
investigated	O
the	O
regulation	O
of	O
thymidine	B
kinase	I
in	O
phytohemagglutinin	O
-	O
stimulated	O
normal	O
human	O
lymphocytes	O
and	O
in	O
the	O
p16-negative	O
human	O
acute	O
lymphoblastic	O
leukemia	O
cell	O
lines	O
,	O
MOLT-4	O
and	O
CEM	O
.	O
Compared	O
to	O
normal	O
lymphocytes	O
,	O
MOLT-4	O
and	O
CEM	O
cells	O
exhibited	O
an	O
altered	O
cell	O
cycle	O
regulation	O
of	O
thymidine	B
kinase	I
,	O
a	O
much	O
higher	O
intracellular	O
activity	O
of	O
this	O
enzyme	B
,	O
and	O
higher	O
thymidine	O
kinase	O
mRNA	O
expression	O
.	O
Transient	O
expression	O
of	O
p16	B
in	O
normal	O
human	O
lymphocytes	O
caused	O
arrest	O
in	O
G1	O
,	O
but	O
was	O
without	O
effect	O
on	O
the	O
cell	O
growth	O
of	O
MOLT-4	O
and	O
CEM	O
cells	O
,	O
although	O
all	O
of	O
them	O
express	O
functional	O
retinoblastoma	B
protein	I
.	O
Nevertheless	O
,	O
in	O
the	O
two	O
leukemia	O
cell	O
lines	O
transient	O
overexpression	O
of	O
p16	B
reestablished	O
the	O
normal	O
regulation	O
of	O
thymidine	B
kinase	I
,	O
paralleled	O
by	O
an	O
increase	O
of	O
the	O
underphosphorylated	O
form	O
of	O
retinoblastoma	B
protein	I
and	O
decrease	O
of	O
free	O
E2F	B
bound	O
to	O
its	O
motif	O
in	O
the	O
thymidine	O
kinase	O
promoter	O
.	O
We	O
demonstrate	O
that	O
loss	O
of	O
p16	B
causes	O
upregulation	O
of	O
this	O
DNA	O
precursor	O
pathway	O
enzyme	B
via	O
activation	O
of	O
E2F	B
by	O
a	O
mechanism	O
involving	O
retinoblastoma	B
protein	I
.	O
Expression	O
of	O
A	O
-	O
myb	O
,	O
but	O
not	O
c	O
-	O
myb	O
and	O
B	O
-	O
myb	O
,	O
is	O
restricted	O
to	O
Burkitt	O
's	O
lymphoma	O
,	O
sIg+	O
B	O
-	O
acute	O
lymphoblastic	O
leukemia	O
,	O
and	O
a	O
subset	O
of	O
chronic	O
lymphocytic	O
leukemias	O
.	O
The	O
A	O
-	O
myb	O
gene	O
encodes	O
a	O
transcription	B
factor	I
that	O
is	O
related	O
both	O
functionally	O
and	O
structurally	O
to	O
the	O
v	O
-	O
myb	O
oncogene	O
.	O
Following	O
our	O
observations	O
that	O
A	O
-	O
myb	O
is	O
expressed	O
in	O
a	O
restricted	O
subset	O
of	O
normal	O
mature	O
human	O
B	O
lymphocytes	O
,	O
with	O
the	O
phenotype	O
CD38	O
+	O
,	O
CD39-	O
,	O
slgM-	O
,	O
we	O
have	O
now	O
investigated	O
the	O
pattern	O
of	O
A	O
-	O
myb	O
expression	O
in	O
neoplastic	O
B	O
cells	O
representating	O
the	O
whole	O
spectrum	O
of	O
B	O
-	O
cell	O
differentiation	O
and	O
compared	O
it	O
to	O
that	O
of	O
c	O
-	O
myb	O
and	O
B	O
-	O
myb	O
.	O
In	O
a	O
panel	O
of	O
32	O
B	O
-	O
cell	O
lines	O
,	O
A	O
-	O
myb	O
was	O
very	O
strongly	O
expressed	O
in	O
most	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
,	O
but	O
weak	O
or	O
negative	O
in	O
2	O
pre	O
-	O
B	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
4	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
,	O
6	O
Epstein	O
-	O
Barr	O
virus	O
-	O
immortalized	O
lymphoblastoid	O
cell	O
lines	O
,	O
and	O
6	O
myeloma	O
lines	O
.	O
Protein	O
expression	O
paralleled	O
that	O
of	O
the	O
RNA	O
.	O
We	O
have	O
also	O
investigated	O
A	O
-	O
myb	O
expression	O
in	O
49	O
fresh	O
cases	O
of	O
B	O
leukemias	O
.	O
Among	O
24	O
ALL	O
,	O
6	O
were	O
of	O
the	O
null	O
and	O
11	O
of	O
the	O
common	O
type	O
and	O
all	O
these	O
were	O
negative	O
for	O
A	B
-	I
myb	I
expression	O
;	O
on	O
the	O
other	O
hand	O
,	O
all	O
7	O
B	O
-	O
ALL	O
cases	O
(	O
slg+	O
)	O
,	O
as	O
well	O
as	O
one	O
fresh	O
BL	O
case	O
with	O
bone	O
marrow	O
infiltration	O
,	O
expressed	O
A	O
-	O
myb	O
.	O
A	O
-	O
myb	O
was	O
undetectable	O
in	O
4	O
prolymphocytic	O
leukemias	O
(	O
PLL	O
)	O
but	O
was	O
strongly	O
expressed	O
in	O
5	O
/	O
20	O
(	O
25	O
%	O
)	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
samples	O
.	O
In	O
the	O
latter	O
A	O
-	O
myb	O
did	O
not	O
correlate	O
with	O
phenotype	O
or	O
clinical	O
stage	O
.	O
Finally	O
,	O
we	O
have	O
studied	O
the	O
progression	O
of	O
one	O
case	O
of	O
CLL	O
into	O
Richter	O
's	O
syndrome	O
and	O
have	O
found	O
that	O
the	O
Richter	O
's	O
cells	O
expressed	O
about	O
25-fold	O
less	O
A	O
-	O
myb	O
RNA	O
than	O
the	O
CLL	O
cells	O
from	O
the	O
same	O
patient	O
.	O
The	O
pattern	O
of	O
c	O
-	O
myb	O
and	O
B	O
-	O
myb	O
was	O
clearly	O
distinct	O
from	O
that	O
of	O
A	O
-	O
myb	O
.	O
C	O
-	O
myb	O
and	O
B	O
-	O
myb	O
were	O
expressed	O
in	O
all	O
neoplastic	O
groups	O
,	O
except	O
in	O
CLL	O
cells	O
.	O
Thus	O
,	O
A	O
-	O
myb	O
expression	O
,	O
unlike	O
that	O
of	O
c	O
-	O
myb	O
and	O
B	O
-	O
myb	O
,	O
is	O
restricted	O
to	O
a	O
subset	O
of	O
B	O
-	O
cell	O
neoplasias	O
(	O
in	O
particular	O
BL	O
and	O
slg+B	O
-	O
ALL	O
)	O
representative	O
of	O
a	O
specific	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
.	O
This	O
expression	O
may	O
in	O
part	O
reflect	O
expression	O
of	O
A	O
-	O
myb	O
by	O
the	O
normal	O
germinal	O
center	O
B	O
cells	O
that	O
are	O
the	O
normal	O
counterpart	O
of	O
these	O
transformed	O
B	O
cells	O
.	O
The	O
data	O
presented	O
strongly	O
support	O
a	O
role	O
for	O
this	O
transcription	B
factor	I
in	O
B	O
-	O
cell	O
differentiation	O
and	O
perhaps	O
in	O
B	O
-	O
cell	O
transformation	O
in	O
some	O
neoplasias	O
.	O
C	B
-	I
terminal	I
activating	I
and	I
inhibitory	I
domains	I
determine	O
the	O
transactivation	O
potential	O
of	O
BSAP	B
(	O
Pax-5	O
)	O
,	O
Pax-2	O
and	O
Pax-8	O
.	O
Pax-5	O
encodes	O
the	O
transcription	B
factor	I
BSAP	B
which	O
plays	O
an	O
essential	O
role	O
in	O
early	O
B	O
cell	O
development	O
and	O
midbrain	O
patterning	O
.	O
In	O
this	O
study	O
we	O
have	O
analysed	O
the	O
structural	O
requirements	O
for	O
transcriptional	O
activation	O
by	O
BSAP	B
.	O
In	O
vitro	O
mutagenesis	O
and	O
transient	O
transfection	O
experiments	O
indicate	O
that	O
the	O
C	B
-	I
terminal	I
serine	I
/	I
threonine	I
/	I
proline	I
-	I
rich	I
region	I
of	O
BSAP	B
contains	O
a	O
potent	O
transactivation	B
domain	I
of	O
55	O
amino	O
acids	O
which	O
is	O
active	O
from	O
promoter	O
and	O
enhancer	O
positions	O
.	O
This	O
transactivation	B
domain	I
was	O
found	O
to	O
be	O
inactivated	O
by	O
a	O
naturally	O
occurring	O
frameshift	O
mutation	O
in	O
one	O
PAX-5	O
allele	O
of	O
the	O
acute	O
lymphoblastic	O
leukemia	O
cell	O
line	O
REH	O
.	O
The	O
function	O
of	O
the	O
transactivation	B
domain	I
is	O
negatively	O
regulated	O
by	O
adjacent	O
sequences	O
from	O
the	O
extreme	B
C	I
-	I
terminus	I
.	O
The	O
activating	O
and	O
inhibitory	O
domains	O
function	O
together	O
as	O
an	O
independent	O
regulatory	O
module	O
in	O
different	O
cell	O
types	O
as	O
shown	O
by	O
fusion	O
to	O
the	O
GAL4	B
DNA	I
binding	I
domain	I
.	O
The	O
same	O
arrangement	O
of	O
positively	O
and	O
negatively	O
acting	O
sequences	O
has	O
been	O
conserved	O
in	O
the	O
mammalian	O
Pax-2	O
and	O
Pax-8	O
,	O
the	O
zebrafish	O
Pax	O
-	O
b	O
as	O
well	O
as	O
the	O
sea	B
urchin	I
Pax-258	I
proteins	I
.	O
These	O
data	O
demonstrate	O
that	O
the	O
transcriptional	O
competence	O
of	O
a	O
subfamily	O
of	O
Pax	B
proteins	I
is	O
determined	O
by	O
a	O
C	B
-	I
terminal	I
regulatory	I
module	I
composed	O
of	O
activating	O
and	O
inhibitory	O
sequences	O
.	O
Putative	B
steroid	I
binding	I
domain	I
of	O
the	O
human	B
mineralocorticoid	I
receptor	I
,	O
expressed	O
in	O
E.	O
coli	O
in	O
the	O
presence	O
of	O
heat	B
shock	I
proteins	I
shows	O
typical	O
native	O
receptor	O
characteristics	O
.	O
Domain	B
E	I
,	O
considered	O
as	O
the	O
putative	B
hormone	I
binding	I
domain	I
(	O
HBD	B
)	O
of	O
the	O
human	B
mineralocorticoid	I
receptor	I
(	O
hMR	B
)	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
as	O
a	O
fusion	O
protein	O
with	O
either	O
maltose	B
binding	I
protein	I
(	O
MBP	B
)	O
or	O
glutathione	B
S	I
-	I
transferase	I
(	O
GST	B
)	O
.	O
These	O
bacterially	O
-	O
produced	O
MR	O
constructs	O
had	O
no	O
steroid	O
binding	O
activity	O
per	O
se	O
.	O
In	O
fact	O
,	O
heat	B
shock	I
protein	I
association	O
(	O
hsp	B
)	O
is	O
required	O
for	O
high	O
affinity	O
ligand	O
-	O
binding	O
of	O
the	O
MR	B
.	O
After	O
incubation	O
of	O
purified	O
MBP-	B
or	I
GST	I
-	I
HBD	I
with	O
rabbit	O
reticulocyte	O
lysate	O
,	O
known	O
to	O
be	O
rich	O
in	O
heat	B
shock	I
proteins	I
,	O
we	O
obtained	O
saturable	O
binding	O
of	O
[	O
3H	O
]	O
aldosterone	O
.	O
The	O
Kd	O
value	O
for	O
aldosterone	O
was	O
0.3	O
nM	O
and	O
the	O
Bmax	O
=	O
32	O
pmol	O
/	O
mg	O
.	O
Hormone	O
binding	O
specificity	O
was	O
assessed	O
by	O
competition	O
studies	O
with	O
various	O
steroid	O
ligands	O
.	O
Sucrose	O
gradient	O
assays	O
performed	O
with	O
[	B
3H	I
]	I
aldosterone	I
-	I
MBP	I
-	I
HBD	I
revealed	O
complex	O
sedimenting	O
at	O
8.3S	O
and	O
4.9S	O
with	O
[	B
3H	I
]	I
progesterone	I
-	I
MBP	I
-	I
HBD	I
.	O
Western	O
-	O
blot	O
analysis	O
of	O
the	O
sedimentation	O
peak	O
showed	O
the	O
concomitant	O
presence	O
of	O
MBP	B
-	I
HBD	I
by	O
a	O
monoclonal	B
anti	I
-	I
MBP	I
antibody	I
,	O
and	O
hsp90	B
by	O
a	O
monoclonal	B
anti	I
-	I
hsp	I
antibody	I
.	O
Moreover	O
,	O
following	O
incubation	O
with	O
the	O
anti	B
-	I
rabbit	I
hsp90	I
monoclonal	I
antibody	I
the	O
sedimenting	O
gradient	O
showed	O
a	O
10.4S	B
sedimenting	I
complex	I
.	O
These	O
analyses	O
demonstrated	O
that	O
the	O
[	O
3H	O
]	O
aldosterone-	O
MBP	B
-	I
HBD	I
complex	I
is	O
at	O
least	O
associated	O
with	O
hsp90	B
in	O
reticulocyte	O
lysate	O
and	O
that	O
the	O
HBD	B
of	O
hMR	B
is	O
sufficient	O
to	O
bind	O
hsp90	B
.	O
Deletions	O
of	O
a	O
relatively	O
short	O
amino-	B
(	I
729	I
-	I
766	I
)	I
or	I
carboxy-	I
terminal	I
(	I
940	I
-	I
984	I
)	I
region	I
of	O
the	O
HBD	B
fragment	I
eliminated	O
all	O
steroid	O
-	O
binding	O
properties	O
.	O
Overall	O
,	O
these	O
results	O
indicate	O
that	O
the	O
integrity	O
of	O
domain	B
E	I
is	O
necessary	O
and	O
sufficient	O
to	O
bind	O
steroid	O
ligands	O
,	O
agonists	O
or	O
antagonists	O
,	O
with	O
characteristics	O
similar	O
to	O
the	O
entire	O
native	O
MR	B
.	O
CNI-1493	O
inhibits	O
monocyte	B
/	I
macrophage	I
tumor	I
necrosis	I
factor	I
by	O
suppression	O
of	O
translation	O
efficiency	O
.	O
Tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
mediates	O
a	O
wide	O
variety	O
of	O
disease	O
states	O
including	O
septic	O
shock	O
,	O
acute	O
and	O
chronic	O
inflammation	O
,	O
and	O
cachexia	O
.	O
Recently	O
,	O
a	O
multivalent	O
guanylhydrazone	O
(	O
CNI-1493	O
)	O
developed	O
as	O
an	O
inhibitor	O
of	O
macrophage	O
activation	O
was	O
shown	O
to	O
suppress	O
TNF	B
production	O
and	O
protect	O
against	O
tissue	O
inflammation	O
and	O
endotoxin	O
lethality	O
[	O
Bianchi	O
,	O
M.	O
,	O
Ulrich	O
,	O
P.	O
,	O
Bloom	O
,	O
O.	O
,	O
Meistrell	O
,	O
M.	O
,	O
Zimmerman	O
,	O
G.A.	O
,	O
Schmidtmayerova	O
,	O
H.	O
,	O
Bukrinsky	O
,	O
M.	O
,	O
Donnelley	O
,	O
T.	O
,	O
Bucala	O
,	O
R.	O
,	O
Sherry	O
,	O
B.	O
,	O
Manogue	O
,	O
K.R.	O
,	O
Tortolani	O
,	O
A.J.	O
,	O
Cerami	O
,	O
A.	O
&	O
Tracey	O
,	O
K.J.	O
(	O
1995	O
)	O
Mol	O
.	O
Med.1	O
,	O
254	O
-	O
266	O
,	O
and	O
Bianchi	O
,	O
M.	O
,	O
Bloom	O
,	O
O.	O
,	O
Raabe	O
,	O
T.	O
,	O
Cohen	O
,	O
P.	O
S.	O
,	O
Chesney	O
,	O
J.	O
,	O
Sherry	O
,	O
B.	O
,	O
Schmidtmayerova	O
,	O
H.	O
,	O
Zhang	O
,	O
X.	O
,	O
Bukrinsky	O
,	O
M.	O
,	O
Ulrich	O
,	O
P.	O
,	O
Cerami	O
,	O
A.	O
&	O
Tracey	O
,	O
J.	O
(	O
1996	O
)	O
J.Exp	O
.	O
Med	O
.	O
,	O
in	O
press	O
]	O
.	O
We	O
have	O
now	O
elucidated	O
the	O
mechanism	O
by	O
which	O
CNI-1493	O
inhibits	O
macrophage	O
TNF	B
synthesis	O
and	O
show	O
here	O
that	O
it	O
acts	O
through	O
suppression	O
of	O
TNF	B
translation	O
efficiency	O
.	O
CNI-1493	O
blocked	O
neither	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
increases	O
in	O
the	O
expression	O
of	O
TNF	O
mRNA	O
nor	O
the	O
translocation	O
of	O
nuclear	B
factor	I
NF	I
-	I
kappa	I
B	I
to	O
the	O
nucleus	O
in	O
macrophages	O
activated	O
by	O
15	O
min	O
of	O
LPS	O
stimulation	O
,	O
indicating	O
that	O
CNI-1493	O
does	O
not	O
interfere	O
with	O
early	O
NF	B
-	I
kappa	I
B	I
-mediated	O
transcriptional	O
regulation	O
of	O
TNF	B
.	O
However	O
,	O
synthesis	O
of	O
the	O
26-kDa	B
membrane	I
form	I
of	O
TNF	B
was	O
effectively	O
blocked	O
by	O
CNI-1493	O
.	O
Further	O
evidence	O
for	O
the	O
translational	O
suppression	O
of	O
TNF	B
is	O
given	O
by	O
experiments	O
using	O
chloram	O
-	O
phenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
constructs	O
containing	O
elements	O
of	O
the	O
TNF	O
gene	O
that	O
are	O
involved	O
in	O
TNF	B
translational	O
regulation	O
.	O
Both	O
the	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
of	O
the	O
TNF	O
gene	O
were	O
required	O
to	O
elicit	O
maximal	O
translational	O
suppression	O
by	O
CNI-1493	O
.	O
Identification	O
of	O
the	O
molecular	O
target	O
through	O
which	O
CNI-	O
1493	O
inhibits	O
TNF	B
translation	O
should	O
provide	O
insight	O
into	O
the	O
regulation	O
of	O
macrophage	O
activation	O
and	O
mechanisms	O
of	O
inflammation	O
.	O
Epstein	B
-	I
Barr	I
virus	I
nuclear	I
antigen	I
2	I
(	I
EBNA2	I
)	I
-oestrogen	I
receptor	I
fusion	I
proteins	I
complement	O
the	O
EBNA2-deficient	O
Epstein	O
-	O
Barr	O
virus	O
strain	O
P3HR1	O
in	O
transformation	O
of	O
primary	O
B	O
cells	O
but	O
suppress	O
growth	O
of	O
human	O
B	O
cell	O
lymphoma	O
lines	O
.	O
To	O
develop	O
a	O
transformation	O
system	O
with	O
a	O
conditional	O
Epstein	O
-	O
Barr	O
virus	O
nuclear	O
antigen	O
2	O
(	O
EBNA2	O
)	O
gene	O
,	O
we	O
fused	O
the	O
hormone	B
binding	I
domain	I
of	O
the	O
oestrogen	O
receptor	O
to	O
the	O
N	B
or	I
C	I
terminus	I
of	O
EBNA2	B
.	O
In	O
promoter	O
transactivation	O
as	O
well	O
as	O
primary	O
B	O
cell	O
transformation	O
assays	O
these	O
chimeric	O
EBNA2	B
proteins	O
are	O
able	O
to	O
substitute	O
for	O
wild	B
-	I
type	I
EBNA2	I
in	O
the	O
presence	O
of	O
oestrogen	O
.	O
Here	O
we	O
provide	O
evidence	O
that	O
this	O
transformation	O
is	O
the	O
result	O
of	O
double	O
infection	O
of	O
a	O
cell	O
with	O
two	O
virions	O
,	O
the	O
P3HR1	O
virus	O
genome	O
and	O
a	O
mini	O
-	O
EBV	O
plasmid	O
carrying	O
the	O
chimeric	O
EBNA2	O
gene	O
.	O
Unexpectedly	O
,	O
expression	O
of	O
the	O
same	O
EBNA2	B
-oestrogen	O
receptor	O
fusion	O
protein	O
in	O
established	O
human	O
B	O
cell	O
lymphoma	O
lines	O
resulted	O
in	O
growth	O
retardation	O
or	O
growth	O
arrest	O
upon	O
the	O
addition	O
of	O
oestrogen	O
.	O
By	O
titrating	O
the	O
oestrogen	O
concentration	O
in	O
these	O
stably	O
transfected	O
cells	O
,	O
the	O
growth	O
retarding	O
and	O
the	O
transactivating	O
function	O
of	O
the	O
chimeric	B
proteins	I
could	O
not	O
be	O
dissociated	O
.	O
We	O
propose	O
that	O
growth	O
inhibition	O
of	O
established	O
B	O
cell	O
lymphoma	O
lines	O
is	O
a	O
novel	O
function	O
of	O
EBNA2	B
which	O
has	O
not	O
been	O
detected	O
in	O
the	O
absence	O
of	O
an	O
inducible	O
system	O
.	O
It	O
remains	O
open	O
whether	O
the	O
growth	O
retarding	O
property	O
of	O
the	O
EBNA2-oestrogen	B
receptor	I
fusion	I
protein	I
in	O
B	O
cell	O
lymphoma	O
lines	O
is	O
due	O
to	O
unphysiologically	O
high	O
expression	O
of	O
the	O
chimeric	B
protein	I
or	O
to	O
interference	O
with	O
a	O
cellular	O
programme	O
driving	O
proliferation	O
in	O
these	O
cell	O
lines	O
.	O
Lymphoid	O
cell	O
resistance	O
to	O
glucocorticoids	O
in	O
HIV	O
infection	O
.	O
In	O
humans	O
infected	O
with	O
the	O
HIV-1	O
virus	O
there	O
may	O
be	O
a	O
disproportionate	O
severity	O
of	O
signs	O
and	O
symptoms	O
of	O
illness	O
compared	O
to	O
the	O
fraction	O
of	O
CD4	O
+	O
infected	O
T	O
-	O
lymphoid	O
cells	O
.	O
In	O
part	O
,	O
this	O
may	O
be	O
due	O
to	O
altered	O
intercellular	O
signalling	O
systems	O
and	O
intracellular	O
signal	O
transduction	O
.	O
Glucocorticoids	O
are	O
well	O
known	O
for	O
their	O
effects	O
on	O
the	O
vitality	O
and	O
function	O
of	O
lymphoid	O
cells	O
.	O
Patients	O
with	O
HIV	O
infections	O
often	O
show	O
elevated	O
circulating	O
levels	O
of	O
cortisol	O
,	O
suggesting	O
some	O
misfunction	O
in	O
the	O
regulatory	O
systems	O
that	O
maintain	O
the	O
levels	O
of	O
this	O
critical	O
hormone	O
.	O
At	O
the	O
cellular	O
level	O
,	O
it	O
is	O
known	O
that	O
both	O
acute	O
HIV	O
infection	O
and	O
glucocorticoids	O
can	O
cause	O
apoptotic	O
cell	O
death	O
in	O
thymic	O
lymphocytes	O
.	O
However	O
,	O
chronically	O
HIV	O
-	O
infected	O
cells	O
appear	O
to	O
be	O
resistant	O
to	O
glucocorticoid	O
-	O
evoked	O
cell	O
death	O
.	O
Glucocorticoid	B
receptor	I
-ligand	O
binding	O
studies	O
on	O
patients	O
'	O
cells	O
have	O
shown	O
reduced	O
affinity	O
between	O
the	O
receptor	B
binding	I
sites	I
and	O
test	O
steroids	O
.	O
In	O
vitro	O
,	O
chronically	O
HIV	O
-	O
infected	O
cells	O
of	O
the	O
lymphoid	O
CEM	O
line	O
displayed	O
resistance	O
to	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
.	O
These	O
cells	O
showed	O
reduced	O
numbers	O
of	O
binding	B
sites	I
with	O
little	O
alteration	O
in	O
apparent	O
affinity	O
between	O
ligand	O
and	O
receptor	O
.	O
Thus	O
it	O
appears	O
that	O
there	O
may	O
often	O
be	O
malfunction	O
of	O
the	O
normal	O
glucocorticoid	O
response	O
in	O
HIV	O
-	O
infected	O
cells	O
probably	O
due	O
to	O
altered	O
interactions	O
between	O
the	O
glucocorticoid	B
receptor	I
and	O
its	O
hormone	O
.	O
Such	O
alterations	O
may	O
have	O
clinical	O
consequences	O
,	O
including	O
the	O
possibility	O
of	O
a	O
relatively	O
longer	O
life	O
span	O
of	O
infected	O
CD4	O
+	O
T	O
-	O
lymphocytes	O
,	O
as	O
well	O
as	O
systemic	O
effects	O
of	O
chronically	O
elevated	O
cortisol	O
level	O
.	O
A	O
novel	O
interferon	B
regulatory	I
factor	I
family	I
transcription	I
factor	I
,	O
ICSAT	B
/	I
Pip	I
/	I
LSIRF	I
,	O
that	O
negatively	O
regulates	O
the	O
activity	O
of	O
interferon	O
-	O
regulated	O
genes	O
.	O
We	O
have	O
isolated	O
a	O
novel	O
cDNA	O
clone	O
encoding	O
interferon	B
(	I
IFN	I
)	I
consensus	I
sequence	I
-	I
binding	I
protein	I
in	O
adult	O
T	O
-	O
cell	O
leukemia	O
cell	O
line	O
or	O
activated	O
T	O
cells	O
(	O
ICSAT	B
)	O
;	O
this	O
protein	O
is	O
the	O
human	O
homolog	O
of	O
the	O
recently	O
cloned	O
Pip	B
/	I
LSIRF	I
.	O
ICSAT	B
is	O
structurally	O
most	O
closely	O
related	O
to	O
the	O
previously	O
cloned	O
ICSBP	B
,	O
a	O
member	O
of	O
the	O
IFN	B
regulatory	I
factor	I
(	I
IRF	I
)	I
family	I
of	O
proteins	O
that	O
binds	O
to	O
interferon	O
consensus	O
sequences	O
(	O
ICSs	O
)	O
found	O
in	O
many	O
promoters	O
of	O
the	O
IFN	O
-	O
regulated	O
genes	O
.	O
Among	O
T	O
-	O
cell	O
lines	O
investigated	O
,	O
ICSAT	B
was	O
abundantly	O
expressed	O
in	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
-infected	O
T	O
cells	O
.	O
When	O
the	O
HTLV-1	O
tax	O
gene	O
was	O
expressed	O
or	O
phorbol	O
myristake	O
acetate	O
-	O
A23187	O
stimulation	O
was	O
used	O
,	O
ICSAT	B
expression	O
was	O
induced	O
in	O
Jurkat	O
cells	O
which	O
otherwise	O
do	O
not	O
express	O
ICSAT	B
.	O
When	O
the	O
binding	O
of	O
ICSAT	B
to	O
four	O
different	O
ICSs	O
was	O
tested	O
,	O
the	O
relative	O
differences	O
in	O
binding	O
affinities	O
for	O
those	O
ICSs	O
were	O
determined	O
.	O
To	O
study	O
the	O
functional	O
role	O
of	O
ICSAT	B
,	O
we	O
performed	O
cotransfection	O
experiments	O
with	O
the	O
human	O
embryonal	O
carcinoma	O
cell	O
line	O
N	O
-	O
Tera2	O
.	O
ICSAT	B
was	O
demonstrated	O
to	O
possess	O
repressive	O
function	O
over	O
the	O
gene	O
activation	O
induced	O
by	O
IFN	B
stimulation	O
or	O
by	O
IRF-1	B
cotransfection	O
.	O
Such	O
repressive	O
function	O
is	O
similar	O
to	O
that	O
seen	O
in	O
IRF-2	B
or	O
ICSBP	B
.	O
However	O
,	O
we	O
have	O
found	O
that	O
ICSAT	B
has	O
a	O
different	O
repressive	O
effect	O
from	O
that	O
of	O
IRF-2	B
or	O
ICSBP	B
in	O
some	O
IFN	O
-	O
responsive	O
reporter	O
constructs	O
.	O
These	O
results	O
suggest	O
that	O
a	O
novel	O
mechanism	O
of	O
gene	O
regulation	O
by	O
`	O
`	O
differential	O
repression	O
''	O
is	O
used	O
by	O
multiple	O
members	O
of	O
repressor	B
proteins	I
with	O
different	O
repressive	O
effects	O
on	O
the	O
IFN	O
-	O
responsive	O
genes	O
.	O
Mapping	O
of	O
the	O
transcriptional	B
repression	I
domain	I
of	O
the	O
lymphoid	B
-	I
specific	I
transcription	I
factor	I
oct-2A	B
.	O
The	O
lymphoid	B
-	I
specific	I
transcription	I
factor	I
Oct-2a	B
is	O
implicated	O
in	O
B	O
cell	O
-	O
specific	O
transcriptional	O
activity	O
via	O
the	O
octamer	O
motif	O
.	O
Structure	O
/	O
function	O
analysis	O
of	O
various	O
Oct-2a	B
effector	I
regions	I
in	O
the	O
context	O
of	O
the	O
GAL4	B
DNA	I
-	I
binding	I
domain	I
revealed	O
that	O
Oct-2a	B
contains	O
two	O
functionally	O
different	O
activation	B
domains	I
at	O
the	O
N	B
and	I
the	I
C	I
termini	I
.	O
The	O
transcriptional	O
activity	O
of	O
both	O
domains	O
is	O
strongly	O
potentiated	O
by	O
interactions	O
with	O
distinct	O
B	B
cell	I
-	I
specific	I
coactivators	I
.	O
Recently	O
,	O
we	O
have	O
identified	O
a	O
repression	B
domain	I
located	O
within	O
the	O
N	B
terminus	I
of	O
Oct-2a	B
(	O
amino	B
acids	I
2	I
-	I
99	I
)	O
.	O
When	O
this	O
domain	O
was	O
transferred	O
to	O
a	O
potent	O
activator	O
,	O
transcription	O
was	O
strongly	O
inhibited	O
.	O
In	O
this	O
study	O
we	O
present	O
a	O
deletion	O
analysis	O
of	O
the	O
N	B
-	I
terminal	I
region	I
of	O
Oct-2a	B
to	O
determine	O
the	O
minimal	B
repression	I
domain	I
.	O
We	O
identified	O
a	O
stretch	O
of	O
23	O
amino	O
acids	O
,	O
rich	O
in	O
serine	O
and	O
threonine	O
residues	O
,	O
which	O
was	O
responsible	O
for	O
most	O
of	O
the	O
repression	O
activity	O
.	O
We	O
show	O
that	O
repression	O
is	O
strongly	O
dependent	O
on	O
the	O
type	O
of	O
enhancer	O
present	O
in	O
the	O
reporter	O
plasmid	O
as	O
well	O
as	O
on	O
the	O
cell	O
line	O
tested	O
.	O
The	O
possibility	O
that	O
Oct-2a	B
can	O
act	O
as	O
an	O
activator	O
and/or	O
a	O
repressor	O
may	O
have	O
important	O
consequences	O
for	O
the	O
function	O
of	O
Oct-2a	B
in	O
B	O
cell	O
differentiation	O
and	O
other	O
developmental	O
processes	O
.	O
Globin	O
gene	O
switching	O
.	O
In	O
vivo	O
protein	O
-	O
DNA	O
interactions	O
of	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
in	O
erythroid	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
gene	O
program	O
.	O
To	O
characterize	O
the	O
protein	O
-	O
DNA	O
interactions	O
important	O
for	O
the	O
developmental	O
control	O
of	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
,	O
we	O
analyzed	O
by	O
in	O
vivo	O
dimethyl	O
sulfate	O
footprinting	O
erythroid	O
cells	O
expressing	O
either	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
developmental	O
program	O
.	O
In	O
the	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
of	O
the	O
beta	O
-	O
globin	O
locus	O
,	O
in	O
vivo	O
footprints	O
on	O
NF	B
-	I
E2	I
(	O
or	O
AP-1	B
)	O
and	O
GATA-1	O
motifs	O
remained	O
the	O
same	O
regardless	O
of	O
whether	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
genes	O
are	O
expressed	O
.	O
In	O
contrast	O
,	O
in	O
vivo	O
footprints	O
on	O
GT	O
(	O
CACCC	O
)	O
motifs	O
differed	O
between	O
the	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
program	O
.	O
In	O
promoter	O
regions	O
,	O
the	O
actively	O
transcribed	O
genes	O
demonstrated	O
extensive	O
and	O
consistent	O
footprints	O
over	O
the	O
canonical	O
elements	O
,	O
such	O
as	O
CACCC	O
and	O
CCAAT	O
motifs	O
.	O
The	O
adult	O
globin	O
expressing	O
cells	O
displayed	O
more	O
extensive	O
footprints	O
than	O
the	O
fetal	O
globin	O
expressing	O
cells	O
in	O
the	O
3	O
'	O
regulatory	O
sequences	O
of	O
both	O
the	O
Agamma-	O
and	O
the	O
beta	O
-	O
globin	O
genes	O
,	O
suggesting	O
a	O
role	O
of	O
these	O
3	O
'	O
elements	O
in	O
beta	O
-	O
globin	O
gene	O
expression	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
bulk	O
of	O
protein	O
-	O
DNA	O
interactions	O
that	O
underlies	O
the	O
developmental	O
control	O
of	O
globin	O
genes	O
takes	O
place	O
in	O
the	O
gamma-	O
and	O
beta	O
-	O
globin	O
gene	O
promoters	O
,	O
and	O
that	O
GT	O
motifs	O
of	O
the	O
beta	O
-	O
globin	O
locus	O
LCR	O
may	O
play	O
a	O
role	O
in	O
the	O
developmental	O
regulation	O
of	O
human	O
beta	O
-	O
globin	O
gene	O
expression	O
,	O
perhaps	O
by	O
increasing	O
the	O
probability	O
of	O
interaction	O
of	O
the	O
LCR	B
holocomplex	I
with	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
gene	O
.	O
Tissue	O
-	O
specific	O
activity	O
of	O
the	O
gammac	O
chain	O
gene	O
promoter	O
depends	O
upon	O
an	O
Ets	O
binding	O
site	O
and	O
is	O
regulated	O
by	O
GA	B
-	I
binding	I
protein	I
.	O
The	O
gammac	B
chain	I
is	O
a	O
subunit	O
of	O
multiple	O
cytokine	B
receptors	I
(	O
interleukin	B
(	I
IL	I
)	I
-2	I
,	O
IL-4	B
,	O
IL-7	B
,	O
IL-9	B
,	O
and	O
IL-15	B
)	O
,	O
the	O
expression	O
of	O
which	O
is	O
restricted	O
to	O
hematopoietic	O
lineages	O
.	O
A	O
defect	O
in	O
gammac	O
leads	O
to	O
the	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
characterized	O
by	O
a	O
block	O
in	O
T	O
cell	O
differentiation	O
.	O
In	O
order	O
to	O
better	O
characterize	O
the	O
human	O
gammac	O
promoter	O
and	O
define	O
the	O
minimal	O
tissue	O
-	O
specific	O
promoter	O
region	O
,	O
progressive	O
5'-deletion	O
constructs	O
of	O
a	O
segment	O
extending	O
1053	O
base	O
pairs	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
were	O
generated	O
and	O
tested	O
for	O
promoter	O
activity	O
in	O
various	O
hematopoietic	O
and	O
nonhematopoietic	O
cell	O
types	O
.	O
The	O
-1053	O
/	O
+34	O
construct	O
allowed	O
promoter	O
activity	O
only	O
in	O
cells	O
of	O
hematopoietic	O
origin	O
,	O
and	O
tissue	O
specificity	O
was	O
conserved	O
in	O
all	O
other	O
constructs	O
tested	O
.	O
The	O
region	O
downstream	O
of	O
-90	O
appeared	O
critical	O
for	O
basal	O
promoter	O
activity	O
.	O
It	O
contains	O
two	O
potential	O
Ets	O
binding	O
sites	O
conserved	O
in	O
the	O
murine	O
gammac	O
promoter	O
gene	O
,	O
one	O
of	O
which	O
was	O
found	O
essential	O
for	O
functional	O
promoter	O
activity	O
as	O
determined	O
by	O
mutational	O
analysis	O
.	O
The	O
functional	O
Ets	O
binding	O
site	O
was	O
found	O
to	O
bind	O
Ets	B
family	I
proteins	I
,	O
principally	O
GA	B
-	I
binding	I
protein	I
and	O
Elf-1	B
and	O
could	O
be	O
transactivated	O
by	O
GABPalpha	B
and	O
-beta	B
synergistically	O
.	O
These	O
results	O
indicate	O
that	O
,	O
as	O
already	O
reported	O
for	O
the	O
IL2Rbeta	O
promoter	O
,	O
GA	B
-	I
binding	I
protein	I
is	O
an	O
essential	O
component	O
of	O
gammac	O
basal	O
promoter	O
activity	O
.	O
Although	O
GABP	B
expression	O
is	O
not	O
restricted	O
to	O
the	O
hematopoietic	O
lineage	O
,	O
its	O
interaction	O
with	O
other	O
specific	B
factors	I
may	O
contribute	O
to	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
gammac	O
gene	O
.	O
Binding	O
and	O
cooperative	O
interactions	O
between	O
two	O
B	B
cell	I
-	I
specific	I
transcriptional	I
coactivators	I
.	O
The	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
and	O
B	B
cell	I
octamer	I
-	I
binding	I
protein	I
1	I
/	I
octamer	I
-	I
binding	I
factor	I
1	I
/	I
Oct	I
coactivator	I
from	O
B	O
cells	O
(	O
Bob1	B
/	I
OBF-1	I
/	I
OCA	I
-	I
B	I
)	O
represent	O
two	O
B	B
cell	I
-	I
specific	I
transcriptional	I
coactivators	I
.	O
CIITA	B
and	O
Bob1	B
interact	O
with	O
proteins	O
that	O
bind	O
to	O
conserved	O
upstream	O
sequences	O
in	O
promoters	O
of	O
class	O
II	O
major	O
histocompatibility	O
genes	O
and	O
octamer	B
-	I
binding	I
transcription	I
factors	I
Oct-1	B
and	O
Oct-2	B
,	O
respectively	O
.	O
Both	O
CIITA	B
and	O
Bob1	B
increase	O
the	O
expression	O
from	O
the	O
DRA	O
promoter	O
,	O
which	O
is	O
a	O
prototypic	O
class	O
II	O
promoter	O
.	O
Moreover	O
,	O
in	O
the	O
presence	O
of	O
CIITA	B
,	O
interactions	O
between	O
class	O
II	O
promoters	O
and	O
Bob1	B
are	O
independent	O
of	O
the	O
octamer	O
-	O
binding	O
site	O
.	O
Using	O
in	O
vivo	O
and	O
in	O
vitro	O
binding	O
assays	O
,	O
we	O
confirm	O
that	O
Bob1	B
binds	O
to	O
CIITA	B
.	O
Thus	O
,	O
CIITA	B
not	O
only	O
activates	O
the	O
expression	O
of	O
class	O
II	O
genes	O
but	O
recruits	O
another	O
B	O
cell	O
-	O
specific	O
coactivator	O
to	O
increase	O
transcriptional	O
activity	O
of	O
class	O
II	O
promoters	O
in	O
B	O
cells	O
.	O
Signals	O
leading	O
to	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
transcription	I
factor	I
are	O
stronger	O
in	O
neonatal	O
than	O
adult	O
T	O
lymphocytes	O
.	O
The	O
molecular	O
background	O
of	O
the	O
defects	O
in	O
the	O
immune	O
reactivity	O
of	O
human	O
neonates	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O
As	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	I
factor	I
has	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
transcription	O
of	O
several	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
,	O
the	O
authors	O
have	O
analysed	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
human	O
umbilical	O
cord	O
T	O
lymphocytes	O
.	O
The	O
activity	O
was	O
tested	O
by	O
quantitating	O
the	O
nuclear	B
proteins	I
binding	O
to	O
an	O
oligonucleotide	O
containing	O
the	O
consensus	O
kappa	O
B	O
binding	O
sequence	O
(	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
.	O
The	O
data	O
obtained	O
demonstrate	O
that	O
phorbol	O
dibutyrate	O
/	O
calcium	O
ionophore	O
A23187	O
(	O
PDBu	O
/	O
iono	O
)	O
combination	O
induced	O
a	O
clearly	O
higher	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
neonatal	O
than	O
adult	O
T	O
cells	O
.	O
This	O
higher	O
NF	B
-	I
kappa	I
B	I
activity	O
was	O
restricted	O
to	O
the	O
CD4	O
+	O
T	O
-	O
cell	O
subset	O
.	O
Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
antibodies	B
directed	O
against	O
the	O
major	O
components	O
of	O
NF	B
-	I
kappa	I
B	I
the	O
p50	B
and	I
RelA	I
(	I
p65	I
)	I
proteins	I
,	O
indicated	O
that	O
the	O
composition	O
of	O
NF	B
-	I
kappa	I
B	I
was	O
similar	O
in	O
neonatal	O
and	O
adult	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
neonatal	O
T	O
cells	O
are	O
exposed	O
to	O
oxidative	O
stress	O
-	O
inducing	O
signals	O
during	O
delivery	O
and/or	O
are	O
inherently	O
more	O
sensitive	O
to	O
NF	B
-	I
kappa	I
B	I
activating	O
signals	O
than	O
adult	O
T	O
cells	O
.	O
Constitutive	O
expression	O
of	O
specific	O
interferon	B
isotypes	I
in	O
peripheral	O
blood	O
leukocytes	O
from	O
normal	O
individuals	O
and	O
in	O
promonocytic	O
U937	O
cells	O
.	O
Constitutive	O
expression	O
of	O
IFN	B
-	I
alpha5	I
and	O
IFN	B
-	I
beta	I
was	O
detected	O
in	O
different	O
lymphoid	O
cells	O
including	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
normal	O
individuals	O
following	O
amplification	O
of	O
IFN	O
mRNA	O
by	O
reverse	B
transcriptase	I
-polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
of	O
the	O
amplified	O
product	O
.	O
The	O
activated	O
form	O
of	O
the	O
interferon	B
-	I
induced	I
transcription	I
factor	I
complex	I
ISGF3	B
was	O
also	O
detected	O
in	O
nuclear	O
extracts	O
from	O
uninduced	O
cells	O
.	O
Culture	O
supernatants	O
from	O
uninduced	O
U937	O
cells	O
were	O
also	O
found	O
to	O
activate	O
an	O
ISRE	O
cloned	O
upstream	O
of	O
the	O
luciferase	O
reporter	O
gene	O
,	O
indicating	O
the	O
presence	O
of	O
endogenous	B
IFN	I
activity	O
equivalent	O
to	O
approximately	O
0.3	O
to	O
0.5	O
IU	O
/	O
mL	O
.	O
This	O
endogenous	B
IFN	I
was	O
also	O
shown	O
to	O
play	O
a	O
role	O
in	O
maintaining	O
the	O
basal	O
level	O
of	O
expression	O
of	O
the	O
major	O
histocompatibility	O
class	O
I	O
genes	O
in	O
lymphoid	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
IFN	B
-	I
alpha5	I
and	O
IFN	B
-	I
beta	I
are	O
produced	O
at	O
low	O
levels	O
in	O
normal	O
tissues	O
and	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
function	O
and	O
in	O
the	O
maintenance	O
of	O
homeostasis	O
.	O
Activation	B
protein	I
1	I
-dependent	O
transcriptional	O
activation	O
of	O
interleukin	O
2	O
gene	O
by	O
Ca2+	B
/	I
calmodulin	I
kinase	I
type	I
IV	I
/	I
Gr	I
.	O
The	O
Ca2+	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
kinase	I
(	I
CaMK	I
)	I
type	I
IV	I
/	I
Gr	I
is	O
selectively	O
expressed	O
in	O
T	O
lymphocytes	O
and	O
is	O
activated	O
after	O
signaling	O
via	O
the	O
T	B
cell	I
antigen	I
receptor	I
(	O
TCR	B
)	O
,	O
indicating	O
that	O
it	O
mediates	O
some	O
of	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
transcriptional	O
events	O
that	O
follow	O
TCR	B
engagement	O
.	O
Here	O
we	O
show	O
that	O
CaMKIV	B
/	I
Gr	I
induces	O
the	O
transcription	B
factor	I
activation	I
protein	I
1	I
(	O
AP-1	B
)	O
alone	O
or	O
in	O
synergy	O
with	O
T	B
cell	I
mitogens	I
and	O
with	O
the	O
p21ras	B
oncoprotein	I
.	O
CaMKIV	B
/	I
Gr	I
signaling	O
is	O
associated	O
with	O
transcriptional	O
activation	O
of	O
c	O
-	O
fos	O
but	O
is	O
independent	O
of	O
p21ras	O
or	O
calcineurin	B
.	O
AP-1	B
is	O
an	O
integral	O
component	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	I
NFAT	I
)	I
transcriptional	I
complex	I
,	O
which	O
is	O
required	O
for	O
interleukin	O
2	O
gene	O
expression	O
in	O
T	O
cells	O
.	O
We	O
demonstrate	O
that	O
CaMKIV	B
/	I
Gr	I
reconstitutes	O
the	O
capacity	O
of	O
the	O
cytosolic	O
component	O
of	O
NFAT	B
to	O
direct	O
transcription	O
from	O
NFAT	O
sites	O
in	O
non-	O
T	O
cells	O
.	O
These	O
results	O
reveal	O
a	O
central	O
role	O
for	O
CaMKIV	B
/	I
Gr	I
as	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-regulated	O
activator	O
of	O
gene	O
transcription	O
in	O
T	O
lymphocytes	O
.	O
IL-10	B
inhibits	O
nuclear	B
factor	I
-	I
kappa	I
B	I
/	I
Rel	I
nuclear	O
activity	O
in	O
CD3-stimulated	O
human	O
peripheral	O
T	O
lymphocytes	O
.	O
IL-10	B
markedly	O
reduces	O
nuclear	O
factor	O
(	B
NF	I
)	I
-kappa	I
B	I
/	I
Rel	I
nuclear	O
activity	O
induced	O
in	O
PBMC	O
by	O
stimulation	O
with	O
the	O
anti	B
-	I
CD3	I
mAb	I
OKT3	B
.	O
The	O
inhibition	O
is	O
exerted	O
specifically	O
on	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
activation	O
induced	O
by	O
mAb	B
OKT3	I
,	O
and	O
not	O
that	O
produced	O
by	O
PMA	O
.	O
As	O
judged	O
by	O
supershifting	O
the	O
DNA	B
-	I
protein	I
complexes	I
with	O
Abs	B
recognizing	O
specific	O
components	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
protein	I
family	I
,	O
the	O
p50	B
/	I
p65	I
(	O
Rel	B
A	I
)	O
heterodimeric	O
form	O
of	O
NF	B
-	I
kappa	I
B	I
is	O
primarily	O
affected	O
.	O
The	O
maximal	O
effect	O
is	O
observed	O
at	O
the	O
IL-10	B
concentration	O
of	O
20	O
U	O
/	O
ml	O
.	O
IL-10	B
inhibitory	O
activity	O
is	O
exerted	O
on	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
monocytes	O
.	O
Indeed	O
,	O
monocytes	O
pretreated	O
with	O
IL-10	B
are	O
able	O
so	O
inhibit	O
NF	B
-	I
kappa	I
B	I
nuclear	O
activity	O
in	O
purified	O
T	O
lymphocytes	O
stimulated	O
with	O
OKT3	B
.	O
Soluble	O
factors	O
do	O
not	O
appear	O
to	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
inhibition	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
up	O
-	O
regulation	O
of	O
CD80	B
Ag	I
,	O
found	O
on	O
monocytes	O
obtained	O
from	O
PBMC	O
incubated	O
with	O
OKT3	B
,	O
is	O
not	O
detected	O
after	O
addition	O
of	O
IL-10	B
,	O
and	O
the	O
anti	B
-	I
CD28	I
mAb	I
CLB	B
-	I
CD28	I
/	I
1	I
restores	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
nuclear	O
activity	O
in	O
IL-10-inhibited	O
lymphocytes	O
.	O
Therefore	O
,	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
inhibition	O
might	O
be	O
ascribed	O
to	O
a	O
lack	O
of	O
cooperation	O
between	O
accessory	O
cells	O
and	O
T	O
lymphocytes	O
,	O
resulting	O
from	O
down	O
-	O
regulation	O
of	O
a	O
costimulatory	O
molecule	O
,	O
such	O
as	O
CD80	B
,	O
produced	O
by	O
IL-10	B
on	O
activated	O
monocytes	O
.	O
Our	O
results	O
demonstrate	O
that	O
IL-10	B
can	O
inhibit	O
the	O
induction	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
nuclear	O
activity	O
in	O
CD3-stimulated	O
T	O
lymphocytes	O
.	O
Since	O
inappropriate	O
activation	O
of	O
kappa	O
B	O
-	O
driven	O
genes	O
has	O
a	O
physiopathologic	O
role	O
in	O
a	O
number	O
of	O
diseases	O
,	O
such	O
as	O
HIV	O
infection	O
,	O
our	O
findings	O
support	O
the	O
possibility	O
of	O
using	O
this	O
cytokine	O
to	O
suppress	O
an	O
undesirable	O
activation	O
of	O
these	O
transcription	B
factors	I
.	O
Effects	O
of	O
IL-10	B
and	O
IL-4	B
on	O
LPS	O
-	O
induced	O
transcription	B
factors	I
(	O
AP-1	B
,	O
NF	B
-	I
IL6	I
and	O
NF	B
-	I
kappa	I
B	I
)	O
which	O
are	O
involved	O
in	O
IL-6	B
regulation	O
.	O
Interleukin-10	B
(	O
IL-10	B
)	O
,	O
like	O
IL-4	B
,	O
is	O
known	O
to	O
inhibit	O
cytokine	B
expression	O
in	O
activated	O
human	O
monocytes	O
.	O
We	O
showed	O
that	O
both	O
IL-10	B
and	O
IL-4	B
inhibit	O
LPS	O
-	O
induced	O
IL-6	O
mRNA	O
and	O
protein	O
expression	O
by	O
inhibiting	O
the	O
transcription	O
rate	O
of	O
the	O
IL-6	O
gene	O
.	O
The	O
strong	O
inhibition	O
of	O
the	O
IL-6	B
transcription	O
rate	O
prompted	O
us	O
to	O
study	O
the	O
effect	O
of	O
IL-10	B
and	O
IL-4	B
on	O
the	O
expression	O
of	O
transcription	B
factors	I
.	O
We	O
questioned	O
whether	O
or	O
not	O
IL-10	B
and	O
IL-4	B
affected	O
the	O
expression	O
of	O
transcription	B
factors	I
that	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
the	O
IL-6	B
transcription	O
rate	O
,	O
namely	O
activator	O
protein-1	O
(	O
AP-1	B
)	O
,	O
nuclear	B
factor	I
IL-6	B
(	O
NF	B
-	I
IL6	I
)	O
,	O
and	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappaB	I
)	O
.	O
In	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
we	O
showed	O
that	O
IL-10	B
and	O
IL-4	B
inhibited	O
LPS	O
-	O
induced	O
AP-1	B
binding	O
activity	O
.	O
The	O
inhibiting	O
effect	O
of	O
IL-4	B
was	O
slightly	O
more	O
pronounced	O
than	O
that	O
of	O
IL-10	B
.	O
Downregulation	O
of	O
LPS	B
-	I
induced	I
AP-1	I
was	O
accompanied	O
,	O
and	O
thus	O
possibly	O
explained	O
,	O
by	O
a	O
reduced	O
expression	O
at	O
mRNA	O
level	O
of	O
the	O
two	O
major	O
components	O
of	O
the	O
AP-1	B
complex	I
,	O
namely	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
as	O
determined	O
by	O
Northern	O
experiments	O
.	O
Binding	O
activity	O
of	O
NF	B
-	I
IL6	I
was	O
also	O
strongly	O
inhibited	O
by	O
IL-4	B
whereas	O
IL-10	B
showed	O
no	O
effect	O
.	O
NF	O
-	O
IL6	O
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
IL-10	B
or	O
IL-4	B
,	O
suggesting	O
that	O
IL-4	B
affects	O
binding	O
activity	O
of	O
preexisting	O
NF	B
-	I
IL6	I
.	O
Neither	O
IL-10	B
nor	O
IL-4	B
inhibited	O
LPS	O
-	O
induced	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
.	O
In	O
agreement	O
with	O
this	O
finding	O
,	O
Northern	O
experiments	O
where	O
p65	O
and	O
p105	O
mRNA	O
levels	O
were	O
determined	O
,	O
demonstrated	O
that	O
expression	O
of	O
these	O
components	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	O
factor	O
were	O
not	O
affected	O
by	O
IL-10	B
or	O
IL-4	B
.	O
Furthermore	O
,	O
neither	O
IL-10	B
nor	O
IL-4	B
showed	O
any	O
effect	O
on	O
I	O
-	O
kappa	O
B	O
mRNA	O
expression	O
as	O
determined	O
by	O
Northern	O
experiments	O
.	O
Thus	O
,	O
IL-10	B
and	O
IL-4	B
similarly	O
affect	O
IL-6	B
expression	O
.	O
However	O
,	O
for	O
IL-4	B
this	O
was	O
accompanied	O
with	O
a	O
reduction	O
of	O
AP-1	O
and	O
NF	O
-	O
IL6	O
binding	O
activity	O
whereas	O
IL-10	B
only	O
inhibited	O
AP-1	B
binding	O
activity	O
.	O
Inhibition	O
of	O
T	O
lymphocyte	O
activation	O
by	O
cAMP	O
is	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
two	O
parallel	O
mitogen	O
-	O
activated	O
protein	B
kinase	I
pathways	O
,	O
the	O
extracellular	B
signal	I
-	I
related	I
kinase	I
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
.	O
The	O
induction	O
of	O
T	O
cell	O
proliferation	O
requires	O
signals	O
from	O
the	O
TCR	B
and	O
a	O
co	B
-	I
receptor	I
molecule	I
,	O
such	O
as	O
CD28	B
,	O
that	O
activate	O
parallel	O
and	O
partially	O
cross	O
-	O
reactive	O
signaling	O
pathways	O
.	O
These	O
pathways	O
are	O
disrupted	O
by	O
agonists	O
that	O
utilize	O
adenylate	B
cyclase	I
and	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
A	I
(	O
PKA	B
)	O
.	O
We	O
found	O
that	O
the	O
adenylate	B
cyclase	I
activator	O
,	O
forskolin	O
,	O
inhibits	O
anti	B
-	I
CD3	I
-induced	O
shift	O
in	O
Lck	B
electrophoretic	O
mobility	O
,	O
suggesting	O
an	O
intervention	O
at	O
the	O
TCR	B
-coupled	O
phosphoinositide	O
turnover	O
that	O
precedes	O
the	O
activation	O
of	O
PKC	B
.	O
The	O
shift	O
of	O
Lck	B
following	O
direct	O
PKC	B
activation	O
by	O
12-O	O
-	O
tetradecanoyl	O
phorbol	O
13-acetate	O
,	O
which	O
bypasses	O
early	O
receptor	O
-	O
triggered	O
biochemical	O
events	O
,	O
is	O
insensitive	O
to	O
forskolin	O
.	O
Nevertheless	O
,	O
forskolin	O
also	O
inhibits	O
PKC	B
downstream	O
events	O
,	O
such	O
as	O
c	O
-	O
jun	O
expression	O
,	O
which	O
is	O
critical	O
for	O
the	O
activation	O
process	O
of	O
T	O
cells	O
.	O
To	O
further	O
analyze	O
potential	O
cross	O
points	O
between	O
positively	O
and	O
negatively	O
regulating	O
signaling	O
pathways	O
in	O
T	O
cells	O
,	O
we	O
tested	O
the	O
effects	O
of	O
activators	O
of	O
the	O
adenylate	B
cyclase	I
or	O
PKA	B
on	O
two	O
parallel	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signaling	O
pathways	O
mediated	O
by	O
extracellular	B
signal	I
-	I
regulated	I
kinase	I
(	O
ERK	B
)	O
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
.	O
Using	O
a	O
PKC	B
-specific	O
inhibitor	O
,	O
GF109203X	O
,	O
or	O
PKC	O
-	O
depleted	O
T	O
cells	O
,	O
we	O
found	O
that	O
a	O
large	O
part	O
of	O
the	O
anti	B
-	I
CD3	I
-induced	O
ERK	B
activation	O
is	O
PKC	B
dependent	O
.	O
Both	O
PKC-	O
dependent	O
and	O
-independent	O
activation	O
of	O
ERK	B
were	O
sensitive	O
to	O
inhibition	O
by	O
forskolin	O
or	O
a	O
cell	O
-	O
permeable	O
cAMP	O
analogue	O
,	O
dbcAMP	O
.	O
Furthermore	O
,	O
the	O
effect	O
of	O
12-O	O
-	O
tetradecanoyl	O
phorbol	O
13-acetate	O
and	O
ionomycin	O
,	O
which	O
synergized	O
to	O
fully	O
activate	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
,	O
was	O
also	O
sensitive	O
to	O
inhibition	O
by	O
forskolin	O
.	O
Our	O
results	O
suggest	O
that	O
PKA	B
inhibits	O
T	O
cell	O
activation	O
by	O
interfering	O
with	O
multiple	O
events	O
along	O
the	O
two	O
signaling	O
pathways	O
operating	O
downstream	O
of	O
the	O
TCR	B
and	O
the	O
CD28	B
co	I
-	I
receptor	I
molecules	I
.	O
oriP	O
is	O
essential	O
for	O
EBNA	O
gene	O
promoter	O
activity	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
immortalized	O
lymphoblastoid	O
cell	O
lines	O
.	O
During	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
infection	O
of	O
B	O
lymphocytes	O
in	O
vitro	O
,	O
six	O
viral	B
nuclear	I
antigens	I
(	O
EBNAs	B
)	O
are	O
expressed	O
from	O
one	O
of	O
two	O
promoters	O
,	O
Cp	O
or	O
Wp	O
,	O
whose	O
activities	O
are	O
mutually	O
exclusive	O
.	O
Upon	O
infection	O
,	O
Wp	O
is	O
initially	O
active	O
,	O
followed	O
by	O
a	O
switch	O
to	O
Cp	O
for	O
the	O
duration	O
of	O
latency	O
.	O
In	O
this	O
study	O
,	O
the	O
region	O
upstream	O
of	O
Cp	O
was	O
analyzed	O
for	O
the	O
presence	O
of	O
cis	O
elements	O
involved	O
in	O
regulating	O
the	O
activities	O
of	O
the	O
EBNA	O
gene	O
promoters	O
in	O
established	O
in	O
vitro	O
immortalized	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
.	O
It	O
was	O
determined	O
that	O
oriP	O
,	O
the	O
origin	O
for	O
episomal	O
maintenance	O
during	O
latency	O
,	O
is	O
essential	O
for	O
efficient	O
transcription	O
initiation	O
from	O
either	O
Cp	O
or	O
Wp	O
in	O
LCLs	O
,	O
as	O
well	O
as	O
in	O
some	O
Burkitt	O
's	O
lymphoma	O
cell	O
lines	O
.	O
Deletion	O
of	O
the	O
EBNA2-dependent	O
enhancer	O
located	O
upstream	O
of	O
Cp	O
resulted	O
in	O
a	O
ca	O
.	O
two-	O
to	O
fivefold	O
reduction	O
in	O
Cp	O
activity	O
in	O
the	O
LCLs	O
assayed	O
.	O
More	O
extensive	O
deletion	O
of	O
sequences	O
upstream	O
of	O
Cp	O
,	O
including	O
the	O
EBNA2-dependent	O
enhancer	O
,	O
resulted	O
in	O
nearly	O
complete	O
loss	O
of	O
Cp	O
activity	O
.	O
This	O
loss	O
of	O
activity	O
was	O
shown	O
to	O
correlate	O
with	O
deletion	O
of	O
two	O
CCAAT	O
boxes	O
,	O
a	O
proximal	O
CCAAT	O
box	O
located	O
at	O
bp	O
-61	O
to	O
-65	O
and	O
a	O
distal	O
CCAAT	O
box	O
located	O
at	O
bp	O
-253	O
to	O
-257	O
,	O
upstream	O
of	O
Cp	O
.	O
Site	O
-	O
directed	O
mutagenesis	O
of	O
these	O
cis	O
elements	O
demonstrated	O
that	O
Cp	O
activity	O
is	O
highly	O
dependent	O
on	O
the	O
presence	O
of	O
a	O
properly	O
positioned	O
CCAAT	O
box	O
,	O
with	O
the	O
dependence	O
on	O
the	O
distal	O
CCAAT	O
box	O
apparent	O
only	O
when	O
the	O
proximal	O
CCAAT	O
box	O
was	O
deleted	O
or	O
mutated	O
.	O
Deletion	O
of	O
the	O
glucocorticoid	O
response	O
elements	O
located	O
at	O
ca	O
.	O
bp	O
-850	O
upstream	O
of	O
Cp	O
did	O
not	O
result	O
in	O
a	O
significant	O
loss	O
in	O
activity	O
.	O
In	O
general	O
,	O
deletions	O
which	O
diminished	O
Cp	O
activity	O
resulted	O
in	O
induction	O
of	O
Wp	O
activity	O
,	O
consistent	O
with	O
suppression	O
of	O
Wp	O
activity	O
by	O
transcriptional	O
interference	O
from	O
Cp	O
.	O
The	O
identification	O
of	O
oriP	O
and	O
the	O
EBNA2-dependent	O
enhancer	O
as	O
the	O
major	O
positive	O
cis	O
elements	O
involved	O
in	O
regulating	O
Cp	O
activity	O
in	O
LCL	O
suggests	O
that	O
EBNA	O
gene	O
transcription	O
is	O
largely	O
autoregulated	O
by	O
EBNA	B
1	I
and	O
EBNA	B
2	I
.	O
Protein	O
-	O
tyrosine	O
kinase	O
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
interleukin	B
1beta	I
and	O
NFkappaB	B
activation	O
,	O
but	O
not	O
NFkappaB	B
nuclear	O
translocation	O
.	O
In	O
human	O
monocytes	O
,	O
interleukin	B
1beta	I
protein	O
production	O
and	O
steady	O
state	O
mRNA	O
levels	O
are	O
increased	O
in	O
response	O
to	O
lipopolysaccharide	O
,	O
predominantly	O
as	O
a	O
result	O
of	O
increased	O
transcription	O
of	O
the	O
interleukin	B
1beta	I
gene	O
.	O
Expression	O
of	O
interleukin	B
1beta	I
and	O
other	O
cytokines	B
,	O
such	O
as	O
interleukin	B
6	I
and	O
tumor	B
necrosis	I
factor	I
alpha	I
,	O
has	O
been	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
activation	O
of	O
the	O
transcription	B
factor	I
,	O
NFkappaB	B
.	O
Since	O
recent	O
studies	O
have	O
shown	O
that	O
lipopolysaccharide	O
-	O
induced	O
tyrosine	B
kinase	I
activation	O
is	O
not	O
required	O
for	O
NFkappaB	B
nuclear	O
translocation	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
NFkappaB	B
translocated	O
in	O
the	O
absence	O
of	O
tyrosine	B
kinase	I
activity	O
was	O
active	O
in	O
stimulating	O
transcription	O
.	O
We	O
have	O
found	O
that	O
,	O
in	O
the	O
human	O
pro	O
-	O
monocytic	O
cell	O
line	O
,	O
THP-1	O
,	O
the	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
interleukin	B
1beta	I
is	O
dependent	O
on	O
tyrosine	B
kinase	I
activation	O
.	O
Tyrosine	O
kinases	O
are	O
not	O
required	O
for	O
lipopolysaccharide	O
-	O
mediated	O
nuclear	O
translocation	O
of	O
NFkappaB	B
.	O
However	O
,	O
in	O
the	O
absence	O
of	O
tyrosine	B
kinase	I
activity	O
,	O
the	O
ability	O
of	O
NFkappaB	B
to	O
stimulate	O
transcription	O
is	O
impaired	O
.	O
This	O
inhibition	O
of	O
transcription	O
is	O
specific	O
for	O
NFkappaB	B
;	O
in	O
the	O
absence	O
of	O
tyrosine	B
kinase	I
activity	O
,	O
AP-1	B
-dependent	O
transcription	O
is	O
enhanced	O
.	O
These	O
results	O
suggest	O
that	O
,	O
while	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
inflammatory	B
mediators	I
requires	O
tyrosine	B
kinase	I
activity	O
,	O
tyrosine	B
kinase	I
activity	O
is	O
not	O
obligatory	O
for	O
lipopolysaccharide	O
signal	O
transduction	O
.	O
LYSP100	B
-associated	O
nuclear	O
domains	O
(	O
LANDs	O
)	O
:	O
description	O
of	O
a	O
new	O
class	O
of	O
subnuclear	O
structures	O
and	O
their	O
relationship	O
to	O
PML	O
nuclear	O
bodies	O
.	O
The	O
PML	O
gene	O
is	O
fused	O
to	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
gene	O
in	O
t	O
(	O
15	O
;	O
17	O
)	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
,	O
creating	O
a	O
PML	B
-	I
RAR	I
alpha	I
fusion	I
oncoprotein	I
.	O
The	O
PML	B
gene	I
product	I
has	O
been	O
localized	O
to	O
subnuclear	O
dot	O
-	O
like	O
structures	O
variously	O
termed	O
PODs	O
,	O
ND10s	O
,	O
Kr	O
bodies	O
,	O
or	O
PML	O
nuclear	O
bodies	O
(	O
PML	O
NBs	O
)	O
.	O
The	O
present	O
study	O
describes	O
the	O
cloning	O
of	O
a	O
lymphoid	O
-	O
restricted	O
gene	O
,	O
LYSP100	O
,	O
that	O
is	O
homologous	O
to	O
another	O
protein	O
that	O
localizes	O
to	O
PML	O
NBs	O
,	O
SP100	B
.	O
In	O
addition	O
to	O
SP100	O
homology	O
regions	O
,	O
one	O
LYSP100	O
cDNA	O
isoform	O
contains	O
a	O
bromodomain	B
and	O
a	O
PHD	B
/	I
TTC	I
domain	I
,	O
which	O
are	O
present	O
in	O
a	O
variety	O
of	O
transcriptional	B
regulatory	I
proteins	I
.	O
By	O
immunofluorescence	O
,	O
LYSP100	O
was	O
localized	O
to	O
nuclear	O
dots	O
that	O
were	O
surprisingly	O
largely	O
nonoverlapping	O
with	O
PML	O
NBs	O
.	O
However	O
,	O
a	O
minority	O
of	O
LYSP100	O
nuclear	O
dots	O
exactly	O
colocalized	O
with	O
PML	O
and	O
SP100	B
.	O
We	O
term	O
the	O
LYSP100	O
structures	O
`	O
`	O
LANDs	O
,	O
''	O
for	O
LYSP100	O
-associated	O
nuclear	O
domains	O
.	O
Although	O
LYSP100	O
is	O
expressed	O
only	O
in	O
lymphoid	O
cells	O
,	O
LANDs	O
could	O
be	O
visualized	O
in	O
HeLa	O
cells	O
by	O
transfection	O
of	O
a	O
LYSP100	O
cDNA	O
.	O
Immunoelectron	O
microscopy	O
revealed	O
LANDs	O
to	O
be	O
globular	O
,	O
electron	O
-	O
dense	O
structures	O
morphologically	O
distinct	O
from	O
the	O
annular	O
structures	O
characteristic	O
of	O
PML	O
NBs	O
.	O
LANDs	O
were	O
most	O
often	O
found	O
in	O
the	O
nucleoplasm	O
,	O
but	O
were	O
also	O
found	O
at	O
the	O
nuclear	O
membrane	O
and	O
in	O
the	O
cytoplasm	O
,	O
suggesting	O
that	O
these	O
structures	O
may	O
traffic	O
between	O
the	O
cytoplasm	O
and	O
the	O
nucleus	O
.	O
By	O
double	O
-	O
immunogold	O
labeling	O
of	O
PML	O
and	O
LYSP100	O
,	O
some	O
LANDs	O
were	O
shown	O
to	O
contain	O
both	O
PML	O
and	O
LYSP100	O
.	O
Thus	O
,	O
PML	O
is	O
localized	O
to	O
a	O
second	O
subnuclear	O
domain	O
that	O
is	O
morphologically	O
and	O
biochemically	O
distinct	O
from	O
PML	O
NBs	O
.	O
[	O
NGFI	B
-	I
B	I
/	I
nur77	I
family	I
involved	O
in	O
T	O
-	O
cell	O
apoptosis	O
]	O
NGFI	B
-	I
B	I
/	I
nur77	I
is	O
a	O
member	O
of	O
the	O
steroid	B
receptor	I
superfamily	I
.	O
NGFI	B
-	I
B	I
/	I
nur77	I
and	O
its	O
related	O
genes	O
constitute	O
a	O
family	O
and	O
the	O
NGFI	B
-	I
B	I
/	I
nur77	I
family	I
consists	O
of	O
three	O
subtypes	O
,	O
named	O
nur77	B
alpha	I
,	O
nur77	B
beta	I
,	O
nur77	B
gamma	I
.	O
We	O
cloned	O
human	O
nur77	O
beta	O
cDNA	O
,	O
called	O
TINUR	O
.	O
Although	O
NGFI	B
-	I
B	I
/	I
nur77	I
is	O
essential	O
for	O
TCR	O
-	O
mediated	O
apoptosis	O
in	O
T	B
-	I
cell	I
hybridomas	I
,	O
the	O
reports	O
on	O
nur77	O
knock	O
-	O
out	O
mice	O
and	O
nur77	O
dominant	O
negative	O
transgenic	O
mice	O
suggest	O
that	O
there	O
is	O
a	O
functional	O
redundancy	O
among	O
NGFI	B
-	I
B	I
/	I
nur77	I
family	I
.	O
NGFI	B
-	I
B	I
/	I
nur77	I
binds	O
to	O
the	O
response	O
element	O
by	O
monomer	O
or	O
heterodimer	O
with	O
retinoid	B
X	I
receptor	I
(	O
RXR	B
)	O
.	O
Assuming	O
that	O
9-cis	O
-	O
retinoic	O
acid	O
(	O
9-cis	O
-	O
RA	O
)	O
inhibits	O
TCR	O
-	O
mediated	O
apoptosis	O
,	O
nur77	B
may	O
cause	O
apoptosis	O
by	O
monomer	O
in	O
the	O
absence	O
of	O
9-cis	O
-	O
RA	O
and	O
may	O
inhibit	O
apoptosis	O
by	O
heterodimer	O
with	O
RXR	B
in	O
the	O
presence	O
of	O
9-cis	O
-	O
RA	O
.	O
Transcriptional	O
analysis	O
of	O
Epstein	O
-	O
Barr	O
virus	O
gene	O
expression	O
in	O
EBV	O
-	O
positive	O
gastric	O
carcinoma	O
:	O
unique	O
viral	O
latency	O
in	O
the	O
tumour	O
cells	O
.	O
Although	O
case	O
-	O
oriented	O
evidence	O
for	O
an	O
association	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
with	O
gastric	O
carcinoma	O
has	O
been	O
accumulating	O
recently	O
,	O
the	O
interaction	O
(	O
s	O
)	O
between	O
EBV	O
and	O
gastric	O
epithelial	O
cells	O
is	O
/	O
are	O
largely	O
unknown	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
seven	O
EBV	O
-	O
positive	O
gastric	O
carcinoma	O
tissues	O
for	O
viral	O
gene	O
expression	O
at	O
the	O
mRNA	O
level	O
,	O
from	O
which	O
studies	O
on	O
the	O
EBV	O
oncogenicity	O
in	O
human	O
epithelial	O
cells	O
will	O
benefit	O
.	O
Reverse	O
transcription	O
-	O
PCR	O
analysis	O
showed	O
that	O
all	O
seven	O
EBV	O
-	O
positive	O
tumour	O
tissues	O
constitutively	O
expressed	O
EBV	O
nuclear	O
antigen	O
(	O
EBNA	O
)	O
1	O
mRNA	O
,	O
but	O
not	O
EBNA2	O
mRNA	O
.	O
The	O
EBNA	B
transcription	O
was	O
initiated	O
from	O
one	O
of	O
three	O
EBNA	O
promoters	O
,	O
Qp	O
:	O
by	O
contrast	O
,	O
both	O
Cp	O
and	O
Wp	O
were	O
silent	O
,	O
thus	O
resulting	O
in	O
the	O
lack	O
of	O
EBNA2	O
mRNA	O
.	O
Latent	O
membrane	O
protein	O
(	O
LMP	O
)	O
2A	O
mRNA	O
was	O
detected	O
in	O
three	O
of	O
seven	O
cases	O
;	O
however	O
,	O
neither	O
LMP1	O
nor	O
LMP2B	O
mRNA	O
was	O
detected	O
in	O
any	O
of	O
the	O
tumours	O
tested	O
.	O
Transcripts	O
from	O
the	O
BamHI	O
-	O
A	O
region	O
of	O
the	O
viral	O
genome	O
were	O
detectable	O
in	O
all	O
cases	O
.	O
BZLF1	O
mRNA	O
and	O
the	O
product	O
,	O
an	O
immediate	O
-	O
early	O
gene	O
for	O
EBV	O
replication	O
,	O
was	O
not	O
expressed	O
in	O
any	O
of	O
them	O
,	O
thereby	O
suggesting	O
that	O
the	O
tumour	O
cells	O
carried	O
EBV	O
genomes	O
in	O
a	O
tightly	O
latent	O
form	O
.	O
These	O
findings	O
further	O
extended	O
our	O
previous	O
data	O
regarding	O
EBV	O
latency	O
in	O
gastric	O
carcinoma	O
cells	O
at	O
the	O
protein	O
level	O
,	O
and	O
have	O
affirmed	O
that	O
the	O
programme	O
of	O
viral	O
gene	O
expression	O
in	O
the	O
tumour	O
more	O
closely	O
resembles	O
'	O
latency	O
I	O
'	O
represented	O
by	O
Burkitt	O
's	O
lymphoma	O
than	O
'	O
latency	O
II	O
'	O
represented	O
by	O
the	O
majority	O
of	O
nasopharyngeal	O
carcinomas	O
.	O
The	O
role	O
of	O
early	O
growth	O
response	O
gene	O
1	O
(	O
egr-1	O
)	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
.	O
The	O
induction	O
of	O
immediate	O
early	O
genes	O
in	O
cells	O
of	O
the	O
immune	O
system	O
is	O
critical	O
to	O
determining	O
the	O
ultimate	O
outcome	O
of	O
exposure	O
to	O
antigen	O
.	O
The	O
importance	O
of	O
many	O
of	O
these	O
genes	O
relates	O
to	O
the	O
role	O
their	O
transcription	B
factor	I
products	I
play	O
in	O
dictating	O
patterns	O
of	O
expression	O
of	O
downstream	O
,	O
function	O
-	O
related	O
genes	O
.	O
Evidence	O
from	O
several	O
systems	O
indicates	O
that	O
the	O
immediate	O
early	O
gene	O
,	O
egr-1	O
may	O
be	O
of	O
particular	O
importance	O
in	O
the	O
immune	O
system	O
.	O
Recently	O
,	O
the	O
egr-1	O
promoter	O
has	O
been	O
shown	O
to	O
be	O
highly	O
responsive	O
to	O
the	O
diverse	O
biochemical	O
signals	O
generated	O
by	O
antigen	O
and	O
cytokines	B
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O
Furthermore	O
,	O
an	O
important	O
role	O
for	O
egr-1	O
in	O
determining	O
the	O
differentiation	O
pathway	O
of	O
myeloid	O
cell	O
precursors	O
has	O
been	O
recently	O
elaborated	O
.	O
Finally	O
,	O
potential	O
targets	O
of	O
regulation	O
by	O
the	O
zinc	B
-	I
finger	I
transcription	I
factor	I
encoded	O
by	O
egr-1	O
include	O
the	O
interleukin-2	O
,	O
CD44	O
,	O
ICAM-1	O
,	O
and	O
tumor	O
necrosis	O
factor	O
genes	O
.	O
The	O
role	O
of	O
egr-1	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
will	O
be	O
discussed	O
in	O
the	O
context	O
of	O
these	O
recent	O
studies	O
.	O
Absence	O
of	O
T	B
-	I
cell-	I
and	I
B	I
-	I
cell	I
-	I
specific	I
transcription	I
factors	I
TCF-1	B
,	O
GATA-3	B
,	O
and	O
BSAP	B
in	O
Hodgkin	O
's	O
Reed	O
-	O
Sternberg	O
cells	O
.	O
Based	O
on	O
the	O
presence	O
of	O
T	O
cell	O
receptor	O
-	O
beta	O
(	O
TcR	O
-	O
beta	O
)	O
gene	O
rearrangements	O
in	O
L428	O
and	O
HDLM-1	O
cells	O
,	O
the	O
expression	O
of	O
CD2	B
in	O
HDLM-1	O
cells	O
,	O
and	O
the	O
presence	O
of	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
gene	O
rearrangement	O
in	O
KM	O
-	O
H2	O
cells	O
,	O
some	O
researchers	O
have	O
concluded	O
that	O
these	O
long	O
-	O
term	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
Hodgkin	O
's	O
disease	O
are	O
lymphoid	O
in	O
nature	O
.	O
The	O
information	O
obtained	O
from	O
these	O
cell	O
lines	O
has	O
also	O
been	O
used	O
in	O
arguments	O
for	O
a	O
lymphoid	O
origin	O
of	O
H	O
-	O
RS	O
cells	O
in	O
tissue	O
despite	O
the	O
frequent	O
absence	O
of	O
lymphoid	B
markers	I
and	O
Ig	O
/	O
TcR	O
gene	O
rearrangements	O
in	O
these	O
cells	O
.	O
We	O
questioned	O
whether	O
one	O
can	O
use	O
the	O
limited	O
expression	O
of	O
lymphoid	B
markers	I
or	O
the	O
limited	O
gene	O
rearrangement	O
to	O
conclude	O
that	O
H	O
-	O
RS	O
cells	O
have	O
a	O
lymphoid	O
origin	O
,	O
because	O
these	O
markers	O
may	O
be	O
aberrant	O
in	O
tumor	O
cells	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
expression	O
of	O
two	O
T	B
-	I
cell	I
-	I
specific	I
transcription	I
factors	I
(	O
TCF-1	B
and	O
GATA-3	B
)	O
and	O
one	O
B	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
(	O
BSAP	B
)	O
in	O
cultured	O
H	O
-	O
RS	O
cells	O
by	O
using	O
a	O
gel	O
mobility	O
shift	O
assay	O
.	O
The	O
sensitivity	O
and	O
specificity	O
of	O
this	O
assay	O
for	O
determination	O
of	O
cell	O
lineage	O
have	O
been	O
established	O
in	O
a	O
large	O
number	O
of	O
cultured	O
human	O
and	O
murine	O
cell	O
lines	O
.	O
All	O
three	O
types	O
of	O
H	O
-	O
RS	O
cell	O
lines	O
were	O
consistently	O
negative	O
for	O
BSAP	B
,	O
TCF-1	B
,	O
and	O
GATA-3	B
.	O
The	O
absence	O
of	O
GATA-3	B
was	O
confirmed	O
in	O
H	O
-	O
RS	O
cells	O
in	O
tissues	O
by	O
an	O
in	O
situ	O
hybridization	O
technique	O
.	O
Virtually	O
all	O
B	O
-	O
cell	O
lines	O
,	O
with	O
the	O
exception	O
of	O
some	O
myeloma	O
cell	O
lines	O
,	O
are	O
positive	O
for	O
BSAP	B
,	O
which	O
is	O
the	O
transcription	B
factor	I
for	O
promoters	O
for	O
several	O
B	B
-	I
cell	I
markers	I
,	O
including	O
VpreB1	B
,	O
lambda	B
5	I
,	O
CD19	B
,	O
and	O
CD20	B
.	O
All	O
T	O
-	O
cell	O
lines	O
tested	O
were	O
positive	O
for	O
TCF-1	B
and	O
GATA-3	B
,	O
which	O
are	O
the	O
transcription	B
factors	I
for	O
promoters	O
for	O
several	O
T	B
-	I
cell	I
-	I
restricted	I
markers	I
,	O
including	O
CD2	B
,	O
CD3	B
,	O
TcR	B
,	O
and	O
lck	B
.	O
The	O
absence	O
of	O
BSAP	B
,	O
TCF-1	B
,	O
and	O
GATA-3	B
clearly	O
indicates	O
an	O
underlying	O
difference	O
between	O
H	O
-	O
RS	O
cells	O
and	O
lymphoid	O
cells	O
.	O
Translocation	O
(	O
3	O
;	O
14	O
)	O
(	O
q27	O
;	O
q11	O
)	O
:	O
a	O
new	O
variant	O
translocation	O
in	O
a	O
patient	O
with	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
of	O
B	O
-	O
cell	O
type	O
with	O
BCL6	O
rearrangement	O
.	O
We	O
report	O
a	O
65-year	O
-	O
old	O
woman	O
with	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
carrying	O
a	O
t	O
(	O
3	O
;	O
14	O
)	O
(	O
q27	O
;	O
q11	O
)	O
and	O
BCL6	O
rearrangement	O
in	O
the	O
affected	O
cells	O
.	O
She	O
had	O
generalized	O
lymphadenopathy	O
and	O
the	O
bone	O
marrow	O
was	O
infiltrated	O
by	O
lymphoma	O
cells	O
at	O
presentation	O
.	O
Histological	O
diagnosis	O
was	O
`	O
`	O
malignant	O
lymphoma	O
,	O
diffuse	O
,	O
large	O
cell	O
''	O
type	O
according	O
to	O
an	O
International	O
Working	O
Formulation	O
.	O
Chromosome	O
analysis	O
revealed	O
a	O
t	O
(	O
3	O
;	O
14	O
)	O
(	O
q27	O
;	O
q11	O
)	O
,	O
which	O
is	O
a	O
new	O
variant	O
translocation	O
of	O
t	O
(	O
3	O
;	O
14	O
)	O
(	O
q27	O
;	O
q32	O
)	O
.	O
Southern	O
blot	O
analysis	O
showed	O
rearrangement	O
of	O
BCL6	O
,	O
JH	O
,	O
and	O
TCR	O
beta	O
but	O
not	O
of	O
TCR	O
delta	O
.	O
Cosmid	O
probe	O
of	O
BCL6	O
hybridized	O
to	O
14q11	O
and	O
3q27	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O
Although	O
the	O
band	O
14q11	O
is	O
a	O
locus	O
of	O
T	B
-	I
cell	I
receptor	I
alpha-	I
and	I
delta	I
-	I
chains	I
(	O
TCR	B
alpha	I
/	I
delta	I
)	O
,	O
lymphoma	O
cells	O
expressed	O
B	O
-	O
cell	O
,	O
IgGk	O
phenotype	O
.	O
The	O
findings	O
suggest	O
that	O
a	O
novel	O
proto	O
-	O
oncogene	O
in	O
the	O
vicinity	O
of	O
TCR	O
alpha	O
/	O
delta	O
is	O
involved	O
in	O
this	O
translocation	O
.	O
Quantitation	O
of	O
beta	O
1	O
triiodothyronine	O
receptor	O
mRNA	O
in	O
human	O
tissues	O
by	O
competitive	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O
Thyroid	O
hormones	O
act	O
by	O
binding	O
to	O
nuclear	B
receptor	I
proteins	I
,	O
the	O
thyroid	B
hormone	I
receptors	I
(	I
TR	I
)	I
alpha	I
and	I
beta	I
.	O
Data	O
from	O
cell	O
culture	O
and	O
animal	O
studies	O
indicate	O
that	O
TR	B
expression	O
may	O
be	O
regulated	O
to	O
modulate	O
target	O
organ	O
responsiveness	O
to	O
thyroid	O
hormone	O
.	O
To	O
investigate	O
whether	O
such	O
adaptive	O
changes	O
in	O
TR	B
expression	O
occur	O
in	O
humans	O
,	O
we	O
determined	O
the	O
mRNA	O
levels	O
of	O
the	O
hTR	B
beta	I
1	I
in	O
various	O
thyroid	O
states	O
.	O
Patients	O
with	O
overt	O
hypo	O
-or	O
hyperthyroidism	O
were	O
enrolled	O
in	O
the	O
study	O
.	O
Total	O
RNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
determined	O
by	O
quantitative	O
competitive	O
reverse	O
transcription	O
PCR	O
.	O
For	O
comparison	O
,	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
were	O
determined	O
in	O
lymphocytes	O
and	O
normal	O
thyroid	O
tissue	O
of	O
euthyroid	O
patients	O
.	O
Human	O
TR	O
beta	O
1	O
mRNA	O
levels	O
in	O
lymphocytes	O
were	O
1.8	O
+	O
/-	O
0.4	O
,	O
1.9	O
+	O
/-	O
0.5	O
,	O
1.1	O
+	O
/-	O
0.4	O
10	O
(	O
-18	O
)	O
mol	O
/	O
microgram	O
RNA	O
in	O
hypo-	O
,	O
eu	O
-and	O
hyperthyroid	O
patients	O
,	O
respectively	O
,	O
corresponding	O
to	O
an	O
estimated	O
0.5	O
-2	O
molecules	O
per	O
cell	O
.	O
Although	O
the	O
mean	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
were	O
40	O
%	O
lower	O
in	O
hyperthyroid	O
than	O
in	O
euthyroid	O
subjects	O
,	O
this	O
difference	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O
Similar	O
levels	O
of	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
were	O
detected	O
in	O
thyroid	O
gland	O
from	O
euthyroid	O
patients	O
.	O
In	O
summary	O
,	O
we	O
developed	O
an	O
assay	O
for	O
the	O
quantitative	O
determination	O
of	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
in	O
small	O
human	O
tissue	O
samples	O
,	O
containing	O
as	O
little	O
as	O
50	O
ng	O
of	O
total	O
RNA	O
.	O
Absolute	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
are	O
very	O
low	O
with	O
an	O
estimated	O
one	O
molecule	O
of	O
mRNA	O
being	O
present	O
in	O
a	O
mononuclear	O
blood	O
cell	O
or	O
thyrocyte	O
.	O
No	O
up	O
-	O
regulation	O
of	O
hTR	B
beta	I
1	I
was	O
seen	O
in	O
hypothyroid	O
relative	O
to	O
euthyroid	O
patients	O
.	O
However	O
,	O
there	O
is	O
a	O
non	O
-	O
significant	O
trend	O
towards	O
a	O
down	O
-	O
regulation	O
of	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
in	O
hyperthyroid	O
patients	O
.	O
Calcineurin	B
mutants	I
render	O
T	O
lymphocytes	O
resistant	O
to	O
cyclosporin	O
A	O
.	O
The	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
have	O
been	O
widely	O
used	O
to	O
prevent	O
and	O
treat	O
graft	O
rejection	O
after	O
human	O
organ	O
and	O
tissue	O
transplantations	O
.	O
CsA	O
and	O
FK506	O
associate	O
with	O
intracellular	B
binding	I
proteins	I
(	O
i.e.	O
,	O
CsA	O
with	O
cyclophilin	B
A	I
and	O
FK506	O
with	O
FKBP12	B
)	O
to	O
form	O
protein	O
/	O
drug	O
complexes	O
that	O
suppress	O
the	O
immune	O
system	O
by	O
preventing	O
activation	O
of	O
T	O
cells	O
in	O
response	O
to	O
antigen	O
presentation	O
.	O
The	O
common	O
target	O
of	O
CsA	O
and	O
FK506	O
is	O
calcineurin	B
,	O
a	O
Ca2+	B
/	I
calmodulin	I
-	I
regulated	I
,	I
serine	I
/	I
threonine	I
-	I
specific	I
protein	I
phosphatase	I
that	O
regulates	O
the	O
nuclear	O
import	O
of	O
a	O
transcription	B
factor	I
,	O
NF	B
-	I
AT	I
,	O
required	O
for	O
expression	O
of	O
T	O
cell	O
activation	O
genes	O
.	O
In	O
previous	O
studies	O
,	O
we	O
identified	O
calcineurin	B
mutations	O
that	O
block	O
binding	O
by	O
the	O
cyclophilin	B
A	I
/	I
CsA	I
or	I
FKBP12	I
/	I
FK506	I
complexes	I
and	O
thereby	O
render	O
yeast	O
cells	O
resistant	O
to	O
the	O
antifungal	O
effects	O
of	O
CsA	O
or	O
FK506	O
.	O
In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
corresponding	O
mutations	O
in	O
murine	O
calcineurin	B
render	O
the	O
T	B
cell	I
receptor	I
signal	O
transduction	O
cascade	O
CsA	O
resistant	O
in	O
human	O
Jurkat	O
T	O
cells	O
.	O
Our	O
findings	O
support	O
the	O
recently	O
determined	O
calcineurin	B
X	O
-	O
ray	O
crystal	O
structure	O
,	O
provide	O
evidence	O
that	O
calcineurin	B
is	O
the	O
only	O
CsA	B
-	I
sensitive	I
component	I
limiting	O
signaling	O
from	O
the	O
T	B
cell	I
receptor	I
to	O
the	O
nucleus	O
,	O
and	O
suggest	O
a	O
means	O
to	O
render	O
cells	O
and	O
tissues	O
resistant	O
to	O
the	O
toxic	O
side	O
effects	O
of	O
CsA	O
and	O
FK506	O
.	O
Characterization	O
of	O
the	O
human	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
gene	O
promoter	O
.	O
MNDA	B
(	O
myeloid	B
cell	I
nuclear	I
differentiation	I
antigen	I
)	O
is	O
an	O
interferon	B
alpha	I
regulated	I
nuclear	I
protein	I
expressed	O
only	O
in	O
cells	O
of	O
the	O
human	O
myelomonocytic	O
lineage	O
.	O
To	O
identify	O
mechanisms	O
responsible	O
for	O
this	O
lineage	O
-	O
specific	O
and	O
interferon	O
-	O
regulated	O
expression	O
,	O
the	O
5	O
'	O
flanking	O
sequence	O
of	O
the	O
gene	O
has	O
been	O
characterized	O
.	O
Two	O
interferon	O
-	O
stimulated	O
response	O
elements	O
(	O
ISRE	O
)	O
flank	O
a	O
multiple	O
transcription	O
start	O
site	O
region	O
identifying	O
MNDA	B
as	O
a	O
TATA	O
-	O
less	O
interferon	O
-	O
regulated	O
gene	O
.	O
Other	O
DNA	O
elements	O
present	O
include	O
a	O
cluster	O
of	O
Myb	O
sites	O
,	O
several	O
Ets	O
,	O
an	O
Ets	O
related	O
PU.1	O
site	O
and	O
an	O
Sp1	O
site	O
located	O
within	O
600	O
bp	O
of	O
the	O
transcription	O
start	O
sites	O
.	O
In	O
addition	O
,	O
DNA	O
methylation	O
was	O
revealed	O
as	O
one	O
of	O
the	O
possible	O
factors	O
in	O
establishing	O
MNDA	B
expression	O
.	O
The	O
5	O
'	O
flanking	O
sequence	O
has	O
promoter	O
activity	O
which	O
is	O
elevated	O
by	O
interferon	B
alpha	I
.	O
The	O
findings	O
indicate	O
that	O
MNDA	B
expression	O
is	O
regulated	O
by	O
mechanisms	O
similar	O
to	O
other	O
myelomonocytic	O
cell	O
specific	O
genes	O
and	O
genes	O
up	O
-	O
regulated	O
by	O
interferon	B
alpha	I
.	O
Abnormality	O
of	O
Oct-1	B
DNA	O
binding	O
in	O
T	O
cells	O
from	O
Sjogren	O
's	O
syndrome	O
patients	O
.	O
Primary	O
Sjogren	O
's	O
syndrome	O
(	O
SS	O
)	O
is	O
an	O
autoimmune	O
rheumatic	O
disease	O
characterized	O
by	O
T	O
cell	O
hypoactivity	O
.	O
To	O
understand	O
the	O
diminished	O
T	O
cell	O
response	O
to	O
activation	O
signals	O
,	O
we	O
measured	O
nucleoprotein	O
DNA	O
-	O
binding	O
activities	O
regulating	O
gene	O
expression	O
during	O
T	O
cell	O
activation	O
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
Peripheral	O
blood	O
lymphocytes	O
from	O
9	O
/	O
19	O
SS	O
patients	O
were	O
found	O
to	O
be	O
defective	O
in	O
their	O
ability	O
to	O
bind	O
an	O
october	B
sequence	I
(	O
Oct-1	B
)	O
.	O
This	O
Oct-1	B
-binding	O
phenotype	O
remained	O
stable	O
in	O
culture	O
for	O
up	O
to	O
3	O
days	O
prior	O
to	O
activation	O
.	O
This	O
abnormality	O
was	O
not	O
seen	O
in	O
resting	O
T	O
cells	O
nor	O
T	O
cells	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
or	O
SS	O
accompanied	O
by	O
RA	O
.	O
The	O
SS	O
Oct-1	B
DNA	O
-	O
binding	O
abnormality	O
correlated	O
significantly	O
with	O
an	O
inability	O
of	O
cells	O
to	O
exit	O
the	O
Gzero	O
/	O
G1	O
cell	O
cycle	O
phase	O
when	O
stimulated	O
in	O
vitro	O
.	O
Importantly	O
,	O
nucleoprotein	O
extracts	O
showing	O
decreased	O
DNA	O
-	O
binding	O
activity	O
had	O
normal	O
amounts	O
of	O
Oct-1	B
proteins	O
as	O
determined	O
by	O
immunoprecipitation	O
,	O
implying	O
a	O
functional	O
defect	O
in	O
the	O
Oct-1	B
protein	I
.	O
Moreover	O
,	O
defective	O
DNA	O
binding	O
was	O
corrected	O
by	O
treatment	O
with	O
acid	O
phosphatase	O
.	O
Severe	O
combined	O
immunodeficiency	O
due	O
to	O
defective	O
binding	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
in	O
T	O
lymphocytes	O
of	O
two	O
male	O
siblings	O
.	O
Peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
and	O
alloreactive	O
T	O
cell	O
lines	O
of	O
two	O
male	O
infants	O
born	O
to	O
consanguinous	O
parents	O
and	O
presenting	O
with	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
showed	O
a	O
pronounced	O
deficiency	O
in	O
T	O
cell	O
activation	O
.	O
Although	O
phenotypically	O
normal	O
,	O
the	O
proliferative	O
response	O
of	O
the	O
childrens	O
'	O
T	O
cells	O
was	O
strongly	O
reduced	O
but	O
could	O
be	O
improved	O
by	O
the	O
addition	O
of	O
interleukin-2	B
(	O
IL-2	B
)	O
.	O
Furthermore	O
both	O
childrens	O
'	O
T	O
cells	O
were	O
unable	O
to	O
produce	O
the	O
cytokines	B
IL-2	B
,	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
,	O
IL-4	B
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
.	O
This	O
multiple	O
cytokine	B
production	O
deficiency	O
could	O
not	O
be	O
restored	O
by	O
IL-2	B
or	O
co	O
-	O
stimulatory	O
signals	O
provided	O
by	O
antigen	O
-	O
presenting	O
cells	O
(	O
APC	O
)	O
.	O
Moreover	O
,	O
mRNA	O
for	O
IL-2	B
and	O
IFN	B
-	I
gamma	I
could	O
not	O
be	O
detected	O
.	O
In	O
contrast	O
,	O
expression	O
of	O
the	O
activation	B
-	I
dependent	I
cell	I
surface	I
markers	I
CD25	B
and	O
CD69	B
was	O
within	O
normal	O
limits	O
.	O
To	O
determine	O
whether	O
the	O
functional	O
defect	O
of	O
the	O
patients	O
'	O
T	O
cells	O
was	O
due	O
to	O
the	O
absence	O
or	O
abnormal	O
binding	O
of	O
transcription	B
factors	I
involved	O
in	O
cytokine	O
gene	O
expression	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
were	O
used	O
to	O
examine	O
the	O
DNA	O
binding	O
of	O
AP-1	B
,	O
Oct	B
,	O
CREB	B
,	O
SP1	B
,	O
NF	B
-	I
kappa	I
B	I
and	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
to	O
their	O
respective	O
response	O
elements	O
in	O
the	O
promoter	O
of	O
the	O
IL-2	O
gene	O
.	O
Whereas	O
AP-1	B
,	O
NF	O
-	O
kappa	O
B	O
,	O
Oct	B
,	O
CREB	B
and	O
SP1	B
displayed	O
normal	O
binding	O
activities	O
in	O
nuclear	O
extracts	O
,	O
the	O
binding	O
of	O
NF	B
-	I
AT	I
to	O
its	O
IL-2	B
promoter	O
response	O
element	O
was	O
barely	O
detectable	O
both	O
before	O
and	O
after	O
T	O
cell	O
stimulation	O
.	O
Our	O
results	O
strongly	O
suggest	O
that	O
this	O
NF	B
-	I
AT	I
/DNA	O
binding	O
defect	O
is	O
responsible	O
for	O
the	O
multiple	O
cytokine	B
deficiency	O
and	O
the	O
SCID	O
phenotype	O
observed	O
in	O
the	O
two	O
infant	O
brothers	O
.	O
Regulation	O
of	O
sialoadhesin	B
expression	O
on	O
rat	O
macrophages	O
.	O
Induction	O
by	O
glucocorticoids	O
and	O
enhancement	O
by	O
IFN	B
-	I
beta	I
,	O
IFN	B
-	I
gamma	I
,	O
IL-4	B
,	O
and	O
lipopolysaccharide	O
.	O
Sialoadhesin	B
is	O
a	O
macrophage	B
-	I
restricted	I
member	I
of	O
the	O
Ig	B
superfamily	I
that	O
mediates	O
adhesion	O
with	O
lymphoid	O
and	O
myeloid	O
cells	O
.	O
It	O
is	O
expressed	O
on	O
a	O
subpopulation	O
of	O
macrophages	O
in	O
lymphoid	O
tissues	O
and	O
in	O
chronic	O
inflammation	O
(	O
e.g.	O
,	O
during	O
autoimmune	O
diseases	O
)	O
.	O
We	O
have	O
studied	O
the	O
regulation	O
of	O
sialoadhesin	B
expression	O
in	O
vitro	O
and	O
show	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
induce	O
sialoadhesin	B
expression	O
on	O
freshly	O
isolated	O
rat	O
macrophages	O
and	O
the	O
rat	O
macrophage	O
cell	O
line	O
R2	O
.	O
The	O
cytokines	B
IFN	B
-	I
beta	I
,	O
IFN	B
-	I
gamma	I
,	O
IL-4	B
,	O
and	O
LPS	O
,	O
although	O
unable	O
to	O
induce	O
sialoadhesin	B
expression	O
by	O
themselves	O
,	O
were	O
able	O
to	O
enhance	O
GC	O
-	O
mediated	O
induction	O
of	O
sialoadhesin	B
.	O
Sialoadhesin	B
expression	O
was	O
functional	O
as	O
shown	O
by	O
cell	O
adhesion	O
assays	O
with	O
human	O
RBCs	O
.	O
Northern	O
blotting	O
experiments	O
indicated	O
that	O
regulation	O
predominantly	O
occurred	O
at	O
the	O
mRNA	O
level	O
.	O
Comparison	O
of	O
the	O
different	O
combinations	O
of	O
GC	O
and	O
cytokines	B
/LPS	O
revealed	O
differences	O
in	O
the	O
level	O
of	O
GC	O
-	O
dependent	O
enhancement	O
of	O
sialoadhesin	B
expression	O
,	O
with	O
IFN	B
-	I
beta	I
and	O
IL-4	B
being	O
more	O
potent	O
than	O
IFN	B
-	I
gamma	I
and	O
LPS	O
.	O
Moreover	O
,	O
the	O
effects	O
of	O
IFN	B
-	I
gamma	I
and	O
LPS	O
could	O
be	O
reproduced	O
by	O
priming	O
,	O
whereas	O
IFN	B
-	I
beta	I
and	O
IL-4	B
were	O
required	O
simultaneously	O
with	O
GC	O
.	O
The	O
regulation	O
of	O
sialoadhesin	B
expression	O
was	O
mediated	O
by	O
the	O
GC	B
receptor	I
,	O
and	O
not	O
by	O
mineralocorticoid	B
receptor	I
,	O
as	O
shown	O
by	O
inhibition	O
experiments	O
with	O
specific	O
antagonists	O
.	O
Finally	O
,	O
it	O
is	O
demonstrated	O
that	O
macrophages	O
in	O
the	O
adrenal	O
gland	O
,	O
the	O
major	O
site	O
of	O
endogenous	O
GC	O
production	O
,	O
express	O
sialoadhesin	B
.	O
This	O
study	O
demonstrates	O
that	O
GC	O
act	O
as	O
a	O
primary	O
inducer	O
of	O
sialoadhesin	B
expression	O
on	O
rat	O
macrophages	O
,	O
and	O
that	O
the	O
response	O
can	O
be	O
enhanced	O
by	O
IFN	B
-	I
beta	I
,	O
T	B
cell	I
-	I
derived	I
cytokines	I
,	O
or	O
LPS	O
.	O
Cell	O
-	O
type	O
-	O
specific	O
regulation	O
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
gene	O
in	O
B	O
cells	O
and	O
T	O
cells	O
by	O
NFATp	B
and	O
ATF-2	B
/	I
JUN	I
.	O
The	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
gene	O
is	O
one	O
of	O
the	O
earliest	O
genes	O
transcribed	O
after	O
the	O
stimulation	O
of	O
a	O
B	O
cell	O
through	O
its	O
antigen	B
receptor	I
or	O
via	O
the	O
CD-40	O
pathway	O
.	O
In	O
both	O
cases	O
,	O
induction	O
of	O
TNF	O
-	O
alpha	O
gene	O
transcription	O
can	O
be	O
blocked	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
and	O
FK506	O
,	O
which	O
suggested	O
a	O
role	O
for	O
the	O
NFAT	B
family	I
of	O
proteins	O
in	O
the	O
regulation	O
of	O
the	O
gene	O
in	O
B	O
cells	O
.	O
Furthermore	O
,	O
in	O
T	O
cells	O
,	O
two	O
molecules	O
of	O
NFATp	B
bind	O
to	O
the	O
TNF	O
-	O
alpha	O
promoter	O
element	O
kappa	O
3	O
in	O
association	O
with	O
ATF-2	B
and	O
Jun	B
proteins	I
bound	O
to	O
an	O
immediately	O
adjacent	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
site	O
.	O
Here	O
,	O
using	O
the	O
murine	O
B	O
-	O
cell	O
lymphoma	O
cell	O
line	O
A20	O
,	O
we	O
show	O
that	O
the	O
TNF	O
-	O
alpha	O
gene	O
is	O
regulated	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
manner	O
.	O
In	O
A20	O
B	O
cells	O
,	O
the	O
TNF	O
-	O
alpha	O
gene	O
is	O
not	O
regulated	O
by	O
NFATp	B
bound	O
to	O
the	O
kappa	O
3	O
element	O
.	O
Instead	O
,	O
ATF-2	B
and	O
Jun	B
proteins	I
bind	O
to	O
the	O
composite	O
kappa	O
3	O
/	O
CRE	O
site	O
and	O
NFATp	B
binds	O
to	O
a	O
newly	O
identified	O
second	O
NFAT	O
site	O
centered	O
at	O
-76	O
nucleotides	O
relative	O
to	O
the	O
TNF	O
-	O
alpha	O
transcription	O
start	O
site	O
.	O
This	O
new	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
calcium	O
-	O
mediated	O
,	O
cyclosporin	O
A	O
-	O
sensitive	O
induction	O
of	O
TNF	B
-	I
alpha	I
in	O
both	O
A20	O
B	O
cells	O
and	O
Ar-5	O
cells	O
.	O
Consistent	O
with	O
these	O
results	O
,	O
quantitative	O
DNase	B
footprinting	O
of	O
the	O
TNF	O
-	O
alpha	O
promoter	O
using	O
increasing	O
amounts	O
of	O
recombinant	O
NFATp	B
demonstrated	O
that	O
the	O
-76	O
site	O
binds	O
to	O
NFATp	B
with	O
a	O
higher	O
affinity	O
than	O
the	O
kappa	O
3	O
site	O
.	O
Two	O
other	O
previously	O
unrecognized	O
NFATp	O
-	O
binding	O
sites	O
in	O
the	O
proximal	O
TNF	O
-	O
alpha	O
promoter	O
were	O
also	O
identified	O
by	O
this	O
analysis	O
.	O
Thus	O
,	O
through	O
the	O
differential	O
use	O
of	O
the	O
same	O
promoter	O
element	O
,	O
the	O
composite	O
kappa	O
3	O
/	O
CRE	O
site	O
,	O
the	O
TNF	O
-	O
alpha	O
gene	O
is	O
regulated	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
manner	O
in	O
response	O
to	O
the	O
same	O
extracellular	O
signal	O
.	O
Induction	O
of	O
bcl-2	B
expression	O
by	O
phosphorylated	O
CREB	O
proteins	O
during	O
B	O
-	O
cell	O
activation	O
and	O
rescue	O
from	O
apoptosis	O
.	O
Engagement	O
of	O
surface	O
immunoglobulin	O
on	O
mature	O
B	O
cells	O
leads	O
to	O
rescue	O
from	O
apoptosis	O
and	O
to	O
proliferation	O
.	O
Levels	O
of	O
bcl-2	O
mRNA	O
and	O
protein	O
increase	O
with	O
cross	O
-	O
linking	O
of	O
surface	B
immunoglobulin	I
.	O
We	O
have	O
located	O
the	O
major	O
positive	O
regulatory	O
region	O
for	O
control	O
of	O
bcl-2	B
expression	O
in	O
B	O
cells	O
in	O
the	O
5'-flanking	O
region	O
.	O
The	O
positive	O
region	O
can	O
be	O
divided	O
into	O
an	O
upstream	O
and	O
a	O
downstream	O
regulatory	O
region	O
.	O
The	O
downstream	O
regulatory	O
region	O
contains	O
a	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
(	O
CRE	O
)	O
.	O
We	O
show	O
by	O
antibody	O
supershift	O
experiments	O
and	O
UV	O
cross	O
-	O
linking	O
followed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
that	O
both	O
CREB	O
and	O
ATF	O
family	O
members	O
bind	O
to	O
this	O
region	O
in	O
vitro	O
.	O
Mutations	O
of	O
the	O
CRE	O
site	O
that	O
result	O
in	O
loss	O
of	O
CREB	B
binding	O
also	O
lead	O
to	O
loss	O
of	O
functional	O
activity	O
of	O
the	O
bcl-2	O
promoter	O
in	O
transient	O
-	O
transfection	O
assays	O
.	O
The	O
presence	O
of	O
an	O
active	O
CRE	O
site	O
in	O
the	O
bcl-2	O
promoter	O
implies	O
that	O
the	O
regulation	O
of	O
bcl-2	B
expression	O
is	O
linked	O
to	O
a	O
signal	O
transduction	O
pathway	O
in	O
B	O
cells	O
.	O
Treatment	O
of	O
the	O
mature	O
B	O
-	O
cell	O
line	O
BAL-17	O
with	O
either	O
anti	O
-	O
immunoglobulin	O
M	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
leads	O
to	O
an	O
increase	O
in	O
bcl-2	B
expression	O
that	O
is	O
mediated	O
by	O
the	O
CRE	O
site	O
.	O
Treatment	O
of	O
the	O
more	O
immature	O
B	O
-	O
cell	O
line	O
,	O
Ramos	O
,	O
with	O
phorbol	O
esters	O
rescues	O
the	O
cells	O
from	O
calcium	O
-	O
dependent	O
apoptosis	O
.	O
bcl-2	B
expression	O
is	O
increased	O
following	O
phorbol	O
ester	O
treatment	O
,	O
and	O
the	O
increased	O
expression	O
is	O
dependent	O
on	O
the	O
CRE	O
site	O
.	O
These	O
stimuli	O
result	O
in	O
phosphorylation	O
of	O
CREB	B
at	O
serine	O
133	O
.	O
The	O
phosphorylation	O
of	O
CREB	B
that	O
results	O
in	O
activation	O
is	O
mediated	O
by	O
protein	B
kinase	I
C	I
rather	O
than	O
by	O
protein	B
kinase	I
A	I
.	O
Although	O
the	O
CRE	O
site	O
is	O
necessary	O
,	O
optimal	O
induction	O
of	O
bcl-2	B
expression	O
requires	O
participation	O
of	O
the	O
upstream	O
regulatory	O
element	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
CREB	B
alters	O
its	O
interaction	O
with	O
the	O
upstream	O
regulatory	O
element	O
.	O
The	O
CRE	O
site	O
in	O
the	O
bcl-2	O
promoter	O
appears	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
induction	O
of	O
bcl-2	B
expression	O
during	O
the	O
activation	O
of	O
mature	O
B	O
cells	O
and	O
during	O
the	O
rescue	O
of	O
immature	O
B	O
cells	O
from	O
apoptosis	O
.	O
It	O
is	O
possible	O
that	O
the	O
CRE	O
site	O
is	O
responsible	O
for	O
induction	O
of	O
bcl-2	B
expression	O
in	O
other	O
cell	O
types	O
,	O
particularly	O
those	O
in	O
which	O
protein	B
kinase	I
C	I
is	O
involved	O
.	O
Interleukin-6	B
promotes	O
multiple	O
myeloma	O
cell	O
growth	O
via	O
phosphorylation	O
of	O
retinoblastoma	B
protein	I
.	O
Interleukin-6	B
(	O
IL-6	B
)	O
mediates	O
autocrine	O
and	O
paracrine	O
growth	O
of	O
multiple	O
myeloma	O
(	O
MM	O
)	O
cells	O
and	O
inhibits	O
tumor	O
cell	O
apoptosis	O
.	O
Abnormalities	O
of	O
retinoblastoma	B
protein	I
(	O
pRB	B
)	O
and	O
mutations	O
of	O
RB	O
gene	O
have	O
been	O
reported	O
in	O
up	O
to	O
70	O
%	O
of	O
MM	O
patients	O
and	O
80	O
%	O
of	O
MM	O
-	O
derived	O
cell	O
lines	O
.	O
Because	O
dephosphorylated	B
(	I
activated	I
)	I
pRB	I
blocks	O
transition	O
from	O
G1	O
to	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
whereas	O
phosphorylated	B
(	I
inactivated	I
)	I
pRB	I
releases	O
this	O
growth	O
arrest	O
,	O
we	O
characterized	O
the	O
role	O
of	O
pRB	B
in	O
IL-6	B
-mediated	O
MM	O
cell	O
growth	O
.	O
Both	O
phosphorylated	O
and	O
dephosphorylated	O
pRB	B
were	O
expressed	O
in	O
all	O
serum	O
-	O
starved	O
MM	O
patient	O
cells	O
and	O
MM	O
-	O
derived	O
cell	O
lines	O
,	O
but	O
pRB	B
was	O
predominantly	O
in	O
its	O
phosphorylated	O
form	O
.	O
In	O
MM	O
cells	O
that	O
proliferated	O
in	O
response	O
to	O
IL-6	B
,	O
exogenous	O
IL-6	B
downregulated	O
dephosphorylated	B
pRB	I
and	O
decreased	O
dephosphorylated	O
pRB	B
-	I
E2F	I
complexes	I
.	O
Importantly	O
,	O
culture	O
of	O
MM	O
cells	O
with	O
RB	O
antisense	O
,	O
but	O
not	O
RB	O
sense	O
,	O
oligonucleotide	O
(	O
ODN	O
)	O
triggered	O
IL-6	B
secretion	O
and	O
proliferation	O
in	O
MM	O
cells	O
;	O
however	O
,	O
proliferation	O
was	O
only	O
partially	O
inhibited	O
by	O
neutralizing	O
anti	B
-	I
IL-6	I
monoclonal	I
antibody	I
(	O
MoAb	B
)	O
.	O
In	O
contrast	O
to	O
MM	O
cells	O
,	O
normal	O
splenic	O
B	O
cells	O
express	O
dephosphorylated	B
pRB	I
.	O
Although	O
CD40	B
ligand	I
(	O
CD40L	B
)	O
triggers	O
a	O
shift	O
from	O
dephosphorylated	O
to	O
phosphorylated	O
pRB	B
and	O
proliferation	O
of	O
B	O
cells	O
,	O
the	O
addition	O
of	O
exogenous	O
IL-6	B
to	O
CD40L	B
-treated	O
B	O
cells	O
does	O
not	O
alter	O
either	O
pRB	B
or	O
proliferation	O
,	O
as	O
observed	O
in	O
MM	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
phosphorylated	B
pRB	I
is	O
constitutively	O
expressed	O
in	O
MM	O
cells	O
and	O
that	O
IL-6	B
further	O
shifts	O
pRB	B
from	O
its	O
dephosphorylated	O
to	O
its	O
phosphorylated	O
form	O
,	O
thereby	O
promoting	O
MM	O
cell	O
growth	O
via	O
two	O
mechanisms	O
;	O
by	O
decreasing	O
the	O
amount	O
of	O
E2F	O
bound	O
by	O
dephosphorylated	B
pRB	I
due	O
to	O
reduced	O
dephosphorylated	B
pRB	I
,	O
thereby	O
releasing	O
growth	O
arrest	O
;	O
and	O
by	O
upregulating	O
IL-6	B
secretion	O
by	O
MM	O
cells	O
and	O
related	O
IL-6	B
-mediated	O
autocrine	O
tumor	O
cell	O
growth	O
.	O
E3	B
,	O
a	O
hematopoietic	B
-	I
specific	I
transcript	I
directly	O
regulated	O
by	O
the	O
retinoic	B
acid	I
receptor	I
alpha	I
.	O
Retinoic	O
acid	O
(	O
RA	O
)	O
-induced	O
maturation	O
mediated	O
by	O
the	O
retinoic	B
acid	I
receptor	I
alpha	I
(	O
RAR	B
alpha	I
)	O
has	O
been	O
implicated	O
in	O
myeloid	O
development	O
.	O
We	O
have	O
used	O
differential	O
hybridization	O
analysis	O
of	O
a	O
cDNA	O
library	O
constructed	O
from	O
the	O
murine	O
RA	O
-	O
inducible	O
MPRO	O
promyelocyte	O
cell	O
line	O
to	O
identify	O
immediate	O
-	O
early	O
genes	O
induced	O
by	O
RA	O
during	O
granulocytic	O
differentiation	O
.	O
E3	B
,	O
one	O
of	O
nine	O
sequences	O
identified	O
,	O
was	O
upregulated	O
in	O
an	O
immediate	O
-	O
early	O
manner	O
,	O
with	O
transcript	O
levels	O
peaking	O
after	O
60	O
minutes	O
exposure	O
to	O
RA	O
.	O
E3	B
transcripts	I
were	O
RA	O
-	O
inducible	O
in	O
HL60	O
cells	O
,	O
but	O
not	O
in	O
an	O
RA	O
-	O
resistant	O
subclone	O
,	O
HL60R	O
,	O
that	O
harbors	O
a	O
mutated	O
RAR	O
alpha	O
gene	O
.	O
However	O
,	O
when	O
HL60R	O
cells	O
were	O
transduced	O
with	O
a	O
functional	O
copy	O
of	O
the	O
RAR	O
alpha	O
gene	O
,	O
RA	O
induced	O
a	O
10-fold	O
increase	O
in	O
E3	B
mRNA	O
levels	O
.	O
E3	B
transcripts	I
are	O
present	O
in	O
the	O
myeloid	O
,	O
B	O
-	O
lymphoid	O
,	O
and	O
erythroid	O
lineages	O
,	O
absent	O
in	O
nonhematopoietic	O
cells	O
,	O
and	O
encode	O
a	O
highly	O
hydrophobic	O
,	O
potentially	O
phosphorylated	O
polypeptide	O
of	O
unknown	O
function	O
with	O
significant	O
homology	O
to	O
a	O
putative	O
protein	O
expressed	O
in	O
myeloid	O
cells	O
.	O
The	O
murine	O
E3	O
promoter	O
harbors	O
a	O
single	O
bipartite	O
retinoic	O
acid	O
response	O
element	O
which	O
in	O
transient	O
transfection	O
assays	O
conferred	O
RA	O
sensitivity	O
.	O
These	O
results	O
indicate	O
that	O
E3	B
is	O
a	O
hematopoietic	O
-	O
specific	O
gene	O
that	O
is	O
an	O
immediate	O
target	O
for	O
the	O
activated	O
RAR	B
alpha	I
during	O
myelopoiesis	O
.	O
DNA	B
-	I
binding	I
phosphoproteins	I
induced	O
after	O
T	O
cell	O
activation	O
:	O
effects	O
of	O
cyclosporin	O
A	O
.	O
To	O
define	O
novel	B
proteins	I
involved	O
in	O
the	O
early	O
transcriptional	O
response	O
during	O
the	O
activation	O
of	O
human	O
T	O
lymphocytes	O
,	O
we	O
used	O
a	O
high	O
-	O
resolution	O
,	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
system	O
to	O
identify	O
nuclear	B
,	I
deoxyribonucleic	I
acid	I
(	I
DNA	I
)	I
binding	I
proteins	I
exhibiting	O
rapid	O
changes	O
in	O
phosphorylation	O
following	O
cell	O
stimulation	O
.	O
We	O
identified	O
18	O
nuclear	B
proteins	I
whose	O
phosphorylation	O
level	O
changed	O
more	O
than	O
5-fold	O
upon	O
activation	O
.	O
Of	O
these	O
,	O
11	O
were	O
found	O
to	O
possess	O
DNA	O
-	O
binding	O
properties	O
.	O
The	O
11	O
phosphoproteins	B
with	O
DNA	O
-	O
binding	O
activity	O
,	O
along	O
with	O
4	O
others	O
,	O
were	O
analyzed	O
further	O
.	O
Phosphoamino	O
acid	O
analysis	O
revealed	O
several	O
sets	O
of	O
proteins	O
with	O
different	O
phosphorylated	O
residues	O
Kinetic	O
analysis	O
of	O
the	O
phosphorylation	O
of	O
the	O
selected	O
proteins	O
was	O
performed	O
and	O
revealed	O
a	O
complex	O
group	O
of	O
transient	O
and	O
sustained	O
responses	O
to	O
cell	O
activation	O
.	O
Finally	O
,	O
the	O
activation	O
-	O
induced	O
changes	O
in	O
one	O
set	O
of	O
phosphoproteins	B
were	O
dramatically	O
inhibited	O
by	O
cyclosporin	O
A	O
.	O
We	O
suggest	O
that	O
these	O
phosphoproteins	B
may	O
be	O
directly	O
involved	O
in	O
regulating	O
the	O
transcriptional	O
response	O
to	O
cellular	O
activation	O
by	O
external	O
stimuli	O
.	O
Transcriptional	O
control	O
of	O
steroid	O
-	O
regulated	O
apoptosis	O
in	O
murine	O
thymoma	O
cells	O
.	O
Early	O
studies	O
in	O
murine	O
T	O
cell	O
lines	O
indicated	O
that	O
transcriptional	O
transactivation	O
functions	O
encoded	O
in	O
the	O
glucocorticoid	B
receptor	I
(	I
GR	I
)	I
N	I
-	I
terminal	I
domain	I
are	O
required	O
for	O
glucocorticoid	O
-	O
mediated	O
apoptosis	O
.	O
However	O
,	O
more	O
recent	O
studies	O
in	O
human	O
T	O
cell	O
lines	O
have	O
suggested	O
that	O
the	O
N	B
-	I
terminal	I
domain	I
is	O
not	O
necessary	O
for	O
steroid	O
-	O
regulated	O
apoptosis	O
and	O
that	O
GR	B
-mediated	O
transrepression	O
may	O
be	O
the	O
more	O
critical	O
mechanism	O
.	O
To	O
better	O
understand	O
the	O
contribution	O
of	O
the	O
GR	B
N	I
-	I
terminal	I
transactivation	I
domain	I
in	O
mediating	O
murine	O
thymocyte	O
apoptosis	O
,	O
we	O
stably	O
transfected	O
GR	B
,	O
GR	B
variants	I
,	O
and	O
the	O
androgen	B
receptor	I
(	O
AR	B
)	O
into	O
receptor	O
-	O
negative	O
S49	O
murine	O
thymoma	O
cells	O
.	O
GR	B
expression	O
levels	O
were	O
shown	O
to	O
be	O
rate	O
-	O
limiting	O
for	O
initiating	O
the	O
apoptotic	O
pathway	O
,	O
and	O
a	O
positive	O
correlation	O
between	O
steroid	O
sensitivity	O
and	O
GR	B
-mediated	O
induction	O
of	O
an	O
integrated	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
LTR	O
reporter	O
gene	O
was	O
observed	O
.	O
Analysis	O
of	O
GR	B
chimeric	I
receptors	I
containing	O
the	O
potent	O
VP16	O
and	O
E1A	O
viral	O
transactivation	O
domains	O
in	O
place	O
of	O
the	O
GR	B
N	I
terminus	I
revealed	O
that	O
even	O
low	O
level	O
expression	O
of	O
these	O
receptors	O
resulted	O
in	O
both	O
enhanced	O
steroid	O
sensitivity	O
and	O
MMTV	O
induction	O
,	O
thus	O
supporting	O
a	O
role	O
for	O
transactivation	O
in	O
apoptosis	O
.	O
In	O
contrast	O
,	O
we	O
found	O
that	O
AR	B
can	O
initiate	O
apoptosis	O
in	O
S49	O
cells	O
after	O
treatment	O
with	O
5	O
alpha	O
-	O
dihydrotestosterone	O
,	O
despite	O
its	O
relative	O
inability	O
to	O
induce	O
high	O
level	O
expression	O
of	O
MMTV	O
.	O
To	O
investigate	O
this	O
further	O
,	O
we	O
examined	O
the	O
steroid	O
-	O
regulated	O
expression	O
of	O
an	O
endogenous	O
thymocyte	O
-	O
specific	O
gene	O
called	O
GIG18	O
.	O
We	O
found	O
that	O
GIG18	O
was	O
rapidly	O
induced	O
to	O
comparable	O
levels	O
by	O
both	O
AR	B
and	O
GR	B
,	O
demonstrating	O
that	O
AR	B
can	O
indeed	O
function	O
as	O
a	O
transcriptional	O
activator	O
in	O
S49	O
cells	O
and	O
,	O
moreover	O
,	O
that	O
GIG18	O
induction	O
may	O
be	O
a	O
marker	O
of	O
early	O
apoptotic	O
events	O
in	O
steroid	O
-	O
treated	O
cells	O
.	O
Taken	O
together	O
,	O
these	O
results	O
support	O
our	O
conclusion	O
that	O
transcriptional	O
transactivation	O
is	O
a	O
necessary	O
signaling	O
component	O
of	O
S49	O
cell	O
apoptosis	O
,	O
although	O
an	O
additional	O
role	O
for	O
GR	B
-mediated	O
transrepression	O
can	O
not	O
be	O
excluded	O
.	O
Suppression	O
of	O
c	O
-	O
jun	O
by	O
antisense	O
oligonucleotides	O
inhibits	O
cell	O
adhesion	O
but	O
not	O
respiratory	O
burst	O
during	O
phorbol	O
ester	O
-	O
induced	O
differentiation	O
of	O
U937	O
human	O
monoblastic	O
cells	O
.	O
We	O
studied	O
the	O
role	O
of	O
the	O
immediate	O
early	O
gene	O
c	O
-	O
jun	O
in	O
cell	O
proliferation	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-induced	O
differentiation	O
in	O
U937	O
human	O
monoblastic	O
cells	O
,	O
using	O
c	O
-	O
jun	O
-specific	O
antisense	O
(	O
AS	O
)	O
phosphorothioate	O
oligonucleotides	O
.	O
In	O
selecting	O
the	O
most	O
specific	O
and	O
potent	O
oligonucleotide	O
sequence	O
,	O
we	O
performed	O
extensive	O
analyses	O
for	O
the	O
binding	O
specificity	O
between	O
all	O
candidates	O
of	O
c	O
-	O
jun	O
AS	O
oligonucleotides	O
and	O
the	O
whole	O
sequences	O
in	O
GenBank	O
database	O
,	O
using	O
a	O
computer	O
program	O
.	O
Among	O
the	O
20	O
selected	O
oligonucleotides	O
,	O
two	O
potent	O
15-mer	O
AS	O
oligonucleotides	O
(	O
C	O
-	O
JUN	O
AS	O
oligonucleotides	O
)	O
exhibited	O
significant	O
inhibition	O
of	O
cell	O
growth	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
between	O
2	O
and	O
10	O
microM	O
.	O
Reverse	O
transcription	O
-	O
PCR	O
and	O
Western	O
blot	O
analysis	O
demonstrated	O
that	O
10	O
microM	O
of	O
C	O
-	O
JUN	O
AS	O
oligonucleotides	O
reduced	O
c	O
-	O
jun	O
expression	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O
More	O
importantly	O
,	O
C	O
-	O
JUN	O
AS	O
oligonucleotides	O
showed	O
distinct	O
effects	O
on	O
two	O
markers	O
of	O
PMA	O
-	O
induced	O
differentiation	O
;	O
the	O
C	O
-	O
JUN	O
AS	O
oligonucleotides	O
inhibited	O
cell	O
adhesion	O
,	O
whereas	O
they	O
did	O
not	O
affect	O
another	O
marker	O
of	O
differentiation	O
,	O
respiratory	O
burst	O
(	O
measured	O
by	O
nitro	O
blue	O
tetrazolium	O
reduction	O
assay	O
)	O
.	O
These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
c	O
-	O
jun	O
in	O
both	O
cell	O
proliferation	O
and	O
PMA	O
-	O
induced	O
cell	O
adhesion	O
but	O
not	O
in	O
PMA	O
-	O
induced	O
respiratory	O
burst	O
in	O
U937	O
cells	O
.	O
Human	B
TAFII	I
105	I
is	O
a	O
cell	B
type	I
-	I
specific	I
TFIID	I
subunit	I
related	O
to	O
hTAFII130	B
.	O
We	O
previously	O
characterized	O
Drosophila	B
and	I
human	I
TAF	I
subunits	I
that	O
make	O
up	O
the	O
core	O
TFIID	B
complex	I
found	O
in	O
all	O
cells	O
.	O
Here	O
,	O
we	O
report	O
that	O
differentiated	O
B	O
cells	O
contain	O
a	O
novel	O
substoichiometric	O
TAF	B
of	O
105	O
kDa	O
not	O
found	O
associated	O
with	O
TFIID	B
isolated	O
from	O
other	O
cell	O
types	O
.	O
The	O
cDNA	O
encoding	O
hTAFII105	B
reveals	O
a	O
highly	O
conserved	O
C	B
-	I
terminal	I
domain	I
shared	O
by	O
hTAFII130	B
and	O
oTAFII110	B
,	O
while	O
the	O
N	B
-	I
terminal	I
coactivator	I
domain	I
has	O
diverged	O
significantly	O
.	O
All	O
cells	O
tested	O
express	O
TAFII105	O
mRNA	O
,	O
but	O
only	O
B	O
cells	O
contain	O
significant	O
levels	O
of	O
protein	O
associated	O
with	O
TFIID	B
.	O
Transient	O
overexpression	O
of	O
hTAFII105	B
selectively	O
squelches	O
the	O
transcription	O
of	O
some	O
genes	O
in	O
B	O
cells	O
.	O
These	O
properties	O
suggest	O
that	O
TAFII105	B
is	O
a	O
cell	O
type	O
-	O
specific	O
subunit	O
of	O
TFIID	B
that	O
may	O
be	O
responsible	O
for	O
mediating	O
transcription	O
by	O
a	O
subset	O
of	O
activators	O
in	O
B	O
cells	O
.	O
Regulation	O
of	O
interferon	B
-	I
gamma	I
gene	O
expression	O
.	O
Interferon	O
-	O
gamma	O
(	O
IFN	B
-	I
gamma	I
)	O
,	O
also	O
known	O
as	O
type	B
II	I
interferon	I
,	O
is	O
an	O
important	O
immunoregulatory	O
gene	O
that	O
has	O
multiple	O
effects	O
on	O
the	O
development	O
,	O
maturation	O
,	O
and	O
function	O
of	O
the	O
immune	O
system	O
.	O
IFN	O
-	O
gamma	O
mRNA	O
and	O
protein	O
are	O
expressed	O
predominantly	O
by	O
T	O
cells	O
and	O
large	O
granular	O
lymphocytes	O
.	O
The	O
IFN	O
-	O
gamma	O
mRNA	O
is	O
induced	O
/	O
inhibited	O
in	O
these	O
cell	O
types	O
by	O
a	O
wide	O
variety	O
of	O
extracellular	O
signals	O
,	O
thus	O
implicating	O
a	O
number	O
of	O
diverse	O
,	O
yet	O
convergent	O
signal	O
transduction	O
pathways	O
in	O
its	O
transcriptional	O
control	O
.	O
In	O
this	O
review	O
,	O
I	O
describe	O
how	O
DNA	O
methylation	O
and	O
specific	O
DNA	B
binding	I
proteins	I
may	O
regulate	O
transcription	O
of	O
the	O
IFN	O
-	O
gamma	O
gene	O
in	O
response	O
to	O
extracellular	O
signals	O
.	O
Inorganic	O
lead	O
activates	O
NF	B
-	I
kappa	I
B	I
in	O
primary	O
human	O
CD4	O
+	O
T	O
lymphocytes	O
.	O
Inorganic	O
lead	O
(	O
Pb	O
)	O
is	O
a	O
ubiquitous	O
environmental	O
contaminant	O
that	O
produces	O
a	O
variety	O
of	O
effects	O
on	O
humoral	O
and	O
cell	O
mediated	O
immune	O
responses	O
.	O
The	O
underlying	O
molecular	O
mechanism	O
for	O
Pb	O
's	O
complex	O
effects	O
on	O
the	O
immune	O
system	O
remain	O
obscure	O
.	O
Many	O
of	O
Pb	O
's	O
effects	O
on	O
the	O
immune	O
system	O
could	O
be	O
explained	O
through	O
activation	O
of	O
the	O
transcription	B
factor	I
,	O
NF	B
-	I
kappa	I
B	I
.	O
NF	B
-	I
kappa	I
B	I
is	O
critical	O
for	O
T	O
lymphocyte	O
function	O
and	O
is	O
a	O
strong	O
inducer	O
of	O
HIV	O
-	O
LTR	O
activation	O
.	O
We	O
demonstrate	O
that	O
Pb	O
at	O
physiologically	O
relevant	O
concentrations	O
activates	O
NF	B
-	I
kappa	I
B	I
in	O
primary	O
human	O
CD4	O
+	O
T	O
lymphocytes	O
.	O
Pb	O
-	O
induced	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
is	O
blocked	O
by	O
antibodies	B
for	O
p65	B
and	O
p50	B
subunits	O
but	O
not	O
cRel	B
,	O
indicating	O
that	O
the	O
p65	B
:	I
p50	I
heterodimer	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
is	O
involved	O
.	O
Functional	O
activation	O
of	O
gene	O
expression	O
by	O
Pb	O
was	O
confirmed	O
using	O
primary	O
CD4	O
+	O
T	O
cells	O
transfected	O
with	O
an	O
NF	O
-	O
kappa	O
B	O
dependent	O
reporter	O
gene	O
construct	O
.	O
Pb	O
did	O
not	O
activate	O
NF	B
-	I
kappa	I
B	I
in	O
4	O
different	O
T	O
cell	O
lines	O
,	O
suggesting	O
that	O
lymphoid	O
cell	O
lines	O
may	O
not	O
be	O
reliable	O
surrogates	O
for	O
the	O
study	O
of	O
transcriptional	O
activation	O
in	O
human	O
T	O
cells	O
.	O
These	O
data	O
suggest	O
that	O
NF	B
-	I
kappa	I
B	I
may	O
be	O
an	O
important	O
molecular	O
mediator	O
of	O
Pb	O
-	O
induced	O
immunotoxicity	O
.	O
Detection	O
of	O
intracellular	B
signal	I
transduction	I
molecules	I
in	O
PBMC	O
from	O
rhesus	O
macaques	O
and	O
sooty	O
mangabeys	O
.	O
One	O
of	O
the	O
manifestations	O
of	O
human	O
HIV-1	O
and	O
nonhuman	O
primate	O
SIV	O
infection	O
that	O
lead	O
to	O
disease	O
is	O
reasoned	O
to	O
be	O
secondary	O
to	O
generalized	O
T	O
-	O
cell	O
dysfunction	O
.	O
The	O
molecular	O
mechanisms	O
associated	O
with	O
the	O
T	O
-	O
cell	O
dysfunction	O
remain	O
to	O
be	O
elucidated	O
.	O
To	O
address	O
this	O
issue	O
,	O
we	O
sought	O
to	O
utilize	O
the	O
nonhuman	O
primate	O
model	O
to	O
study	O
intracellular	O
signaling	O
events	O
in	O
cells	O
from	O
disease	O
-	O
susceptible	O
rhesus	O
macaques	O
and	O
disease	O
-	O
resistant	O
sooty	O
mangabeys	O
.	O
Because	O
relatively	O
little	O
is	O
known	O
about	O
these	O
events	O
in	O
nonhuman	O
primates	O
,	O
our	O
laboratory	O
defined	O
optimal	O
conditions	O
,	O
reagents	O
,	O
and	O
assays	O
for	O
the	O
study	O
of	O
signal	O
transduction	O
events	O
in	O
cells	O
from	O
nonhuman	O
primates	O
.	O
The	O
protein	O
phosphorylation	O
patterns	O
in	O
the	O
two	O
monkeys	O
exhibited	O
quantitative	O
,	O
qualitative	O
,	O
and	O
kinetic	O
differences	O
.	O
Antibodies	O
to	O
Stat6	B
detected	O
a	O
unique	O
band	O
in	O
macaque	O
cell	O
lysates	O
.	O
This	O
band	O
is	O
markedly	O
decreased	O
human	O
cell	O
lysates	O
and	O
never	O
seen	O
in	O
mangabey	O
cell	O
lysates	O
.	O
Detection	O
of	O
various	O
other	O
intracellular	B
signaling	I
proteins	I
is	O
also	O
described	O
.	O
Isolation	O
and	O
characterization	O
of	O
murine	O
fra-1	O
:	O
induction	O
mediated	O
by	O
CD40	B
and	O
surface	B
Ig	I
is	O
protein	B
kinase	I
C	I
dependent	O
.	O
The	O
murine	O
fra-1	O
gene	O
,	O
encoding	O
Fos	B
-	I
related	I
Ag	I
1	I
,	O
was	O
isolated	O
from	O
a	O
splenic	O
cDNA	O
library	O
and	O
sequenced	O
.	O
Murine	O
fra-1	O
was	O
highly	O
homologous	O
to	O
rat	O
and	O
human	O
fra-1	O
.	O
Oligonucleotide	O
primers	O
based	O
on	O
the	O
murine	O
sequence	O
were	O
used	O
to	O
construct	O
a	O
quantitative	O
reverse	O
transcription	O
-	O
PCR	O
assay	O
for	O
gene	O
expression	O
.	O
B	O
lymphocyte	O
stimulation	O
via	O
both	O
CD40	B
and	O
surface	B
Ig	I
(	I
sIg	I
)	I
receptors	I
substantially	O
induced	O
fra-1	O
expression	O
,	O
and	O
for	O
both	O
receptors	O
,	O
induction	O
was	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
dependent	O
.	O
This	O
contrasts	O
with	O
induction	O
of	O
c	O
-	O
fos	O
by	O
both	O
CD40	B
and	O
sIg	B
,	O
which	O
is	O
PKC	B
independent	O
and	O
indicates	O
that	O
CD40	B
is	O
capable	O
of	O
signaling	O
through	O
PKC	B
or	O
a	O
closely	O
related	O
kinase	B
.	O
Induction	O
of	O
fra-1	O
following	O
engagement	O
of	O
CD40	B
did	O
not	O
require	O
protein	O
synthesis	O
,	O
suggesting	O
that	O
the	O
PKC	B
-dependent	O
linkage	O
between	O
CD40	B
and	O
fra-1	O
is	O
direct	O
.	O
CD40	B
-mediated	O
fra-1	O
induction	O
did	O
require	O
tyrosine	B
kinase	I
activity	O
.	O
These	O
results	O
demonstrate	O
that	O
CD40	B
,	O
like	O
sIg	B
,	O
may	O
employ	O
PKC	B
in	O
producing	O
select	O
outcomes	O
,	O
that	O
individual	O
B	B
cell	I
receptors	I
may	O
signal	O
downstream	O
events	O
via	O
both	O
PKC	O
-	O
dependent	O
and	O
PKC	O
-	O
independent	O
pathways	O
,	O
and	O
that	O
multiple	O
signal	O
transduction	O
pathways	O
may	O
be	O
used	O
to	O
activate	O
the	O
expression	O
of	O
closely	O
related	O
genes	O
.	O
Comparative	O
analysis	O
identifies	O
conserved	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
3	O
binding	O
sites	O
in	O
the	O
human	O
and	O
simian	O
Epstein	O
-	O
Barr	O
virus	O
oncogene	O
LMP1	O
.	O
Nonhuman	O
primates	O
are	O
naturally	O
infected	O
with	O
a	O
B	O
-	O
lymphotropic	O
herpesvirus	O
closely	O
related	O
to	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O
These	O
simian	O
EBV	O
share	O
considerable	O
genetic	O
,	O
biologic	O
,	O
and	O
epidemiologic	O
features	O
with	O
human	O
EBV	O
,	O
including	O
virus	O
-	O
induced	O
tumorigenesis	O
.	O
However	O
,	O
latent	O
,	O
transformation	O
-	O
associated	O
viral	O
genes	O
demonstrate	O
marked	O
sequence	O
divergence	O
among	O
species	O
despite	O
the	O
conserved	O
functions	O
.	O
We	O
have	O
cloned	O
the	O
latent	B
membrane	I
protein	I
1	I
(	I
LMP1	I
)	I
homologs	I
from	O
the	O
simian	O
EBV	O
naturally	O
infecting	O
baboons	O
(	O
cercopithicine	O
herpesvirus	O
12	O
,	O
herpesvirus	O
papio	O
)	O
and	O
rhesus	O
monkeys	O
(	O
cercopithicine	O
herpesvirus	O
15	O
)	O
for	O
a	O
comparative	O
study	O
with	O
the	O
human	O
EBV	O
oncogene	O
.	O
The	O
transmembrane	O
domains	O
are	O
well	O
conserved	O
,	O
but	O
there	O
is	O
striking	O
sequence	O
divergence	O
of	O
the	O
carboxy	B
-	I
terminal	I
cytoplasmic	I
domain	I
essential	O
for	O
B	O
-	O
cell	O
immortalization	O
and	O
interaction	O
with	O
the	O
tumor	B
necrosis	I
factor	I
receptor	I
signaling	O
pathway	O
.	O
Nevertheless	O
,	O
the	O
simian	B
EBV	I
LMP1s	I
retain	O
most	O
functions	O
in	O
common	O
with	O
EBV	O
LMP1	B
,	O
including	O
the	O
ability	O
to	O
induce	O
NF-	B
(	I
kappa	I
)	I
B	I
activity	O
in	O
human	O
cells	O
,	O
to	O
bind	O
the	O
tumor	B
necrosis	I
factor	I
-	I
associated	I
factor	I
3	I
(	O
TRAF3	B
)	O
in	O
vitro	O
,	O
and	O
to	O
induce	O
expression	O
of	O
tumor	O
necrosis	O
factor	O
-	O
responsive	O
genes	O
,	O
such	O
as	O
ICAM1	O
,	O
in	O
human	O
B	O
lymphocytes	O
.	O
Multiple	O
TRAF3	O
binding	O
sites	O
containing	O
a	O
PXQXT	O
/	O
S	O
core	O
sequence	O
can	O
be	O
identified	O
in	O
the	O
simian	B
EBV	I
LMP1s	I
by	O
an	O
in	O
vitro	O
binding	O
assay	O
.	O
A	O
PXQXT	O
/	O
S	O
-	O
containing	O
sequence	O
is	O
also	O
present	O
in	O
the	O
cytoplasmic	B
domain	I
of	O
the	O
Hodgkin	O
's	O
disease	O
marker	O
,	O
CD30	B
,	O
and	O
binds	O
TRAF3	B
in	O
vitro	O
.	O
The	O
last	B
13	I
amino	I
acids	I
containing	O
a	O
PXQXT	O
/	O
S	O
sequence	O
are	O
highly	O
conserved	O
in	O
human	O
and	O
simian	O
EBV	O
LMP1	B
but	O
do	O
not	O
bind	O
TRAF3	B
,	O
suggesting	O
a	O
distinct	O
role	O
for	O
this	O
conserved	O
region	O
of	O
LMP1	B
.	O
The	O
conserved	O
TRAF3	O
binding	O
sites	O
in	O
LMP1	B
and	O
the	O
CD30	B
Hodgkin	I
's	I
disease	I
marker	I
provides	O
further	O
evidence	O
that	O
a	O
TRAF3	B
-mediated	O
signal	O
transduction	O
pathway	O
may	O
be	O
important	O
in	O
malignant	O
transformation	O
.	O
Interferons	B
induce	O
normal	O
and	O
aberrant	O
retinoic	B
-	I
acid	I
receptors	I
type	I
alpha	I
in	O
acute	O
promyelocytic	O
leukemia	O
cells	O
:	O
potentiation	O
of	O
the	O
induction	O
of	O
retinoid	O
-	O
dependent	O
differentiation	B
markers	I
.	O
Treatment	O
of	O
the	O
acute	O
promyelocytic	O
(	O
APL	O
)	O
cell	O
line	O
NB4	O
with	O
interferon	B
alpha	I
(	O
IFN	B
(	I
alpha	I
)	I
)	O
,	O
as	O
well	O
as	O
IFN	B
(	I
beta	I
)	I
and	I
gamma	I
,	O
results	O
in	O
an	O
increased	O
expression	O
of	O
the	O
transcripts	O
coding	O
for	O
retinoic	B
-	I
acid	I
receptor	I
type	I
alpha	I
(	O
RAR	B
(	I
alpha	I
)	I
)	O
and	O
the	O
leukemia	B
-	I
specific	I
retinoic	I
acid	I
receptor	I
PML	B
-	I
RAR	I
.	O
Transcriptional	O
induction	O
of	O
the	O
RAR	O
(	O
alpha	O
)	O
and	O
PML	O
-	O
RAR	O
mRNAs	O
is	O
rapid	O
and	O
it	O
is	O
parallelled	O
by	O
an	O
increase	O
in	O
the	O
corresponding	O
proteins	O
.	O
Up	O
-	O
regulation	O
of	O
RAR	B
(	I
alpha	I
)	I
and	O
PML	B
-	I
RAR	I
gene	O
expression	O
by	O
IFN	B
(	I
alpha	I
)	I
is	O
accompanied	O
by	O
a	O
strong	O
potentiation	O
in	O
the	O
induction	O
of	O
2	O
retinoid	B
-	I
dependent	I
granulocytic	I
markers	I
,	O
i.e.	O
,	O
granulocyte	O
-	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
mRNA	O
and	O
leukocyte	B
alkaline	I
phosphatase	I
.	O
However	O
,	O
IFN	B
(	I
alpha	I
)	I
does	O
not	O
have	O
any	O
effects	O
on	O
the	O
retinoid	O
-	O
dependent	O
regulation	O
of	O
the	O
myeloid	B
surface	I
markers	I
CD11b	B
and	O
CD33	B
.	O
The	O
IFN	B
-dependent	O
increase	O
in	O
RAR	B
(	I
alpha	I
)	I
levels	O
and	O
the	O
enhancing	O
effect	O
of	O
the	O
cytokine	B
on	O
retinoid	B
-	I
dependent	I
granulocytic	I
markers	I
expression	O
may	O
be	O
a	O
characteristic	O
of	O
PML	O
-	O
RAR	O
positive	O
cells	O
,	O
since	O
the	O
phenomena	O
are	O
not	O
observed	O
in	O
HL-60	O
promyelocytes	O
.	O
Interferons	B
as	O
well	O
as	O
retinoids	O
inhibit	O
the	O
growth	O
of	O
NB4	O
cells	O
,	O
although	O
the	O
2	O
classes	O
of	O
compounds	O
do	O
not	O
significantly	O
interact	O
in	O
terms	O
of	O
anti	O
-	O
proliferative	O
activity	O
.	O
These	O
results	O
suggest	O
the	O
possible	O
use	O
of	O
combinations	O
between	O
IFNs	B
and	O
retinoic	O
acid	O
in	O
the	O
cyto	O
-	O
differentiating	O
treatment	O
of	O
APL	O
patients	O
.	O
Silencing	O
of	O
human	O
fetal	O
globin	B
expression	O
is	O
impaired	O
in	O
the	O
absence	O
of	O
the	O
adult	B
beta	I
-	I
globin	I
gene	I
activator	I
protein	I
EKLF	B
.	O
Globin	O
genes	O
are	O
subject	O
to	O
tissue	O
-	O
specific	O
and	O
developmental	O
stage	O
-	O
specific	O
regulation	O
.	O
A	O
switch	O
from	O
human	B
fetal	I
(	I
gamma	I
)	I
-to	O
adult	B
(	I
beta	I
)	I
-globin	I
expression	O
occurs	O
within	O
erythroid	O
precursor	O
cells	O
of	O
the	O
adult	O
lineage	O
.	O
Previously	O
we	O
and	O
others	O
showed	O
by	O
targeted	O
gene	O
disruption	O
that	O
the	O
zinc	O
finger	O
gene	O
,	O
erythroid	B
Kruppel	I
-	I
like	I
factor	I
(	O
EKLF	B
)	O
,	O
is	O
required	O
for	O
expression	O
of	O
the	O
beta	O
-	O
globin	O
gene	O
in	O
mice	O
,	O
presumably	O
through	O
interaction	O
with	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
in	O
the	O
proximal	O
promoter	O
.	O
To	O
examine	O
the	O
role	O
of	O
EKLF	B
in	O
the	O
developmental	O
regulation	O
of	O
the	O
human	O
gamma	O
-	O
globin	O
gene	O
we	O
interbred	O
EKLF	B
heterozygotes	I
(	O
+	O
/-	O
)	O
with	O
mice	O
harboring	O
a	O
human	O
beta	O
-	O
globin	O
yeast	O
artificial	O
chromosome	O
transgene	O
.	O
We	O
find	O
that	O
in	O
the	O
absence	O
of	O
EKLF	B
,	O
while	O
human	B
beta	I
-	I
globin	I
expression	O
is	O
dramatically	O
reduced	O
,	O
gamma	O
-	O
globin	O
transcripts	O
are	O
elevated	O
approximately	O
5-fold	O
.	O
Impaired	O
silencing	O
of	O
gamma	B
-	I
globin	I
expression	O
identifies	O
EKLF	B
as	O
the	O
first	O
transcription	B
factor	I
participating	O
quantitatively	O
in	O
the	O
gamma	B
-	I
globin	I
to	O
beta	B
-	I
globin	I
switch	O
.	O
Our	O
findings	O
are	O
compatible	O
with	O
a	O
competitive	O
model	O
of	O
switching	O
in	O
which	O
EKLF	B
mediates	O
an	O
adult	O
stage	O
-	O
specific	O
interaction	O
between	O
the	O
beta	O
-	O
globin	O
gene	O
promoter	O
and	O
the	O
locus	O
control	O
region	O
that	O
excludes	O
the	O
gamma	O
-	O
globin	O
gene	O
.	O
Modulatory	O
effects	O
of	O
glucocorticoids	O
and	O
catecholamines	O
on	O
human	O
interleukin	B
-12	O
and	O
interleukin	B
-10	O
production	O
:	O
clinical	O
implications	O
.	O
Interleukin-12	B
(	O
IL-12	B
)	O
is	O
a	O
key	O
inducer	O
of	O
differentiation	O
of	O
uncommitted	O
T	O
helper	O
(	O
TH	O
)	O
cells	O
toward	O
the	O
TH1	O
phenotype	O
,	O
which	O
regulates	O
cellular	O
immunity	O
,	O
whereas	O
IL-10	B
inhibits	O
TH1	O
functions	O
and	O
potentiates	O
TH2-regulated	O
responses	O
(	O
i.e.	O
,	O
humoral	O
immunity	O
)	O
.	O
To	O
examine	O
the	O
potential	O
effects	O
of	O
stress	O
on	O
TH1	O
/	O
TH2	O
balance	O
,	O
we	O
studied	O
the	O
ability	O
of	O
three	O
prototype	O
stress	O
hormones	O
-	O
dexamethasone	O
(	O
a	O
synthetic	O
glucocorticoid	O
)	O
and	O
the	O
catecholamines	O
norepinephrine	O
and	O
epinephrine	O
-	O
to	O
alter	O
the	O
production	O
of	O
IL-12	B
(	O
p70	B
)	O
and	O
IL-10	B
induced	O
by	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
in	O
human	O
whole	O
blood	O
.	O
Dexamethasone	O
inhibited	O
LPS	O
-	O
induced	O
bioactive	O
IL-12	B
production	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
and	O
at	O
physiologically	O
relevant	O
concentrations	O
;	O
it	O
had	O
no	O
effect	O
on	O
IL-10	B
secretion	O
.	O
The	O
glucocorticoid	O
-	O
induced	O
reduction	O
of	O
IL-12	B
production	O
was	O
antagonized	O
by	O
RU	O
486	O
,	O
a	O
glucocorticoid	O
-	O
receptor	O
antagonist	O
,	O
suggesting	O
that	O
it	O
was	O
mediated	O
by	O
the	O
glucocorticoid	O
receptor	O
.	O
Norepinephrine	O
and	O
epinephrine	O
also	O
suppressed	O
IL-12	B
production	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
and	O
at	O
physiological	O
concentrations	O
;	O
both	O
catecholamines	O
,	O
however	O
,	O
dose	O
-	O
dependently	O
increased	O
the	O
production	O
of	O
IL-10	B
.	O
The	O
effects	O
of	O
either	O
catecholamine	O
on	O
IL-12	B
or	O
IL-10	B
secretion	O
were	O
blocked	O
completely	O
by	O
propranolol	O
,	O
a	O
beta	O
-	O
adrenoreceptor	O
antagonist	O
,	O
indicating	O
that	O
they	O
were	O
mediated	O
by	O
the	O
beta	B
-	I
adrenergic	I
receptor	I
.	O
These	O
findings	O
suggest	O
that	O
the	O
central	O
nervous	O
system	O
may	O
regulate	O
IL-12	O
and	O
IL-10	O
secretion	O
and	O
,	O
hence	O
,	O
TH1	O
/	O
TH2	O
balance	O
via	O
the	O
peripheral	O
end	O
-	O
effectors	O
of	O
the	O
stress	O
system	O
.	O
Thus	O
,	O
stress	O
may	O
cause	O
a	O
selective	O
suppression	O
of	O
TH1	O
functions	O
and	O
a	O
shift	O
toward	O
a	O
TH2	B
cytokine	I
pattern	O
rather	O
than	O
generalized	O
TH	O
suppression	O
.	O
The	O
TH1-to	O
-	O
TH2	O
shift	O
may	O
be	O
responsible	O
for	O
the	O
stress	O
-	O
induced	O
susceptibility	O
of	O
the	O
organism	O
to	O
certain	O
infections	O
.	O
Through	O
the	O
same	O
or	O
a	O
reciprocal	O
mechanism	O
,	O
states	O
associated	O
with	O
chronic	O
hyperactivity	O
or	O
hypoactivity	O
of	O
the	O
stress	O
system	O
might	O
influence	O
the	O
susceptibility	O
of	O
an	O
individual	O
to	O
certain	O
autoimmune	O
,	O
allergic	O
,	O
infectious	O
,	O
or	O
neoplastic	O
diseases	O
.	O
Characterization	O
of	O
a	O
CD43	B
/	I
leukosialin	I
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	O
T	O
-	O
lymphoblastoid	O
cells	O
.	O
The	O
monoclonal	B
antibody	I
(	O
mAb	B
)	O
J393	B
induces	O
apoptosis	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O
NH2	B
-terminal	O
amino	O
acid	O
sequence	O
analysis	O
identified	O
the	O
140-kDa	B
surface	I
antigen	I
for	O
mAb	B
J393	I
as	O
CD43	B
/	I
leukosialin	I
,	O
the	O
major	O
sialoglycoprotein	B
of	O
leukocytes	O
.	O
While	O
Jurkat	O
cells	O
co	O
-	O
expressed	O
two	O
discrete	O
cell	B
-	I
surface	I
isoforms	I
of	O
CD43	B
,	O
recognized	O
by	O
mAb	B
J393	I
and	O
mAb	B
G10	I
-	I
2	I
,	O
respectively	O
,	O
only	O
J393	B
/	I
CD43	I
signaled	O
apoptosis	O
.	O
J393	B
/	I
CD43	I
was	O
found	O
to	O
be	O
hyposialylated	O
,	O
bearing	O
predominantly	O
O	O
-	O
linked	O
monosaccharide	O
glycans	O
,	O
whereas	O
G10	B
-	I
2	I
/	I
CD43	I
bore	O
complex	O
sialylated	O
tetra-	O
and	O
hexasaccharide	O
chains	O
.	O
Treatment	O
with	O
soluble	O
,	O
bivalent	O
mAb	B
J393	I
killed	O
25	O
-	O
50	O
%	O
of	O
the	O
cell	O
population	O
,	O
while	O
concomitant	O
engagement	O
of	O
either	O
the	O
CD3.TcR	B
complex	I
or	O
the	O
integrins	B
CD18	B
and	O
CD29	B
significantly	O
potentiated	O
this	O
effect	O
.	O
Treatment	O
of	O
Jurkat	O
cells	O
with	O
mAb	B
J393	I
induced	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	B
substrates	I
that	O
underwent	O
hyperphosphorylation	O
upon	O
antigen	B
receptor	I
costimulation	O
.	O
Tyrosine	B
kinase	I
inhibition	O
by	O
herbimycin	O
A	O
diminished	O
J393	B
/	I
CD43	I
-mediated	O
apoptosis	O
,	O
whereas	O
inhibition	O
of	O
phosphotyrosine	B
phosphatase	I
activity	O
by	O
bis	O
(	O
maltolato	O
)	O
oxovanadium	O
-	O
IV	O
enhanced	O
cell	O
death	O
.	O
Signal	O
transduction	O
through	O
tyrosine	O
kinase	O
activation	O
may	O
lead	O
to	O
altered	O
gene	O
expression	O
,	O
as	O
J393	O
/	O
CD43	B
ligation	O
prompted	O
decreases	O
in	O
the	O
nuclear	O
localization	O
of	O
the	O
transcriptional	B
regulatory	I
protein	I
NF	B
-	I
kappaB	I
and	O
proteins	O
binding	O
the	O
interferon	O
-	O
inducible	O
regulatory	O
element	O
.	O
Since	O
peripheral	O
blood	O
T	O
-	O
lymphocytes	O
express	O
cryptic	B
epitopes	I
for	O
mAb	B
J393	I
,	O
these	O
findings	O
demonstrate	O
the	O
existence	O
of	O
a	O
tightly	O
regulated	O
CD43	B
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	O
T	O
-	O
cell	O
lineages	O
.	O
Identification	O
and	O
characterization	O
of	O
a	O
leukocyte	O
-	O
specific	O
component	O
of	O
the	O
nuclear	O
body	O
.	O
The	O
nuclear	O
body	O
(	O
NB	O
)	O
is	O
a	O
cellular	O
organelle	O
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O
The	O
NB	O
is	O
also	O
a	O
target	O
of	O
antibodies	B
in	O
the	O
serum	O
of	O
patients	O
with	O
the	O
autoimmune	O
disease	O
primary	O
biliary	O
cirrhosis	O
.	O
In	O
this	O
study	O
,	O
serum	O
from	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
a	O
novel	O
component	O
of	O
the	O
NB	O
,	O
a	O
140-kDa	B
protein	I
designated	O
Sp140	B
.	O
The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
amino	B
-	I
terminal	I
portion	I
of	O
Sp140	B
was	O
similar	O
to	O
Sp100	B
,	O
a	O
previously	O
identified	O
NB	B
protein	I
.	O
The	O
carboxyl	B
portion	I
of	O
Sp140	B
contained	O
a	O
zinc	B
-	I
finger	I
domain	I
and	O
a	O
bromodomain	B
,	O
motifs	O
that	O
are	O
present	O
in	O
proteins	O
regulating	O
gene	O
transcription	O
.	O
High	O
levels	O
of	O
Sp140	O
mRNA	O
were	O
detected	O
in	O
human	O
spleen	O
and	O
peripheral	O
blood	O
leukocytes	O
,	O
but	O
not	O
other	O
human	O
tissues	O
.	O
The	O
level	O
of	O
SP140	O
mRNA	O
in	O
myeloid	O
precursor	O
cell	O
lines	O
HL60	O
and	O
NB4	O
markedly	O
increased	O
in	O
response	O
to	O
chemically	O
induced	O
cellular	O
differentiation	O
.	O
Immunohistochemical	O
techniques	O
were	O
used	O
to	O
demonstrate	O
that	O
SP140	B
localized	O
to	O
the	O
NB	O
in	O
differentiated	O
HL60	O
and	O
NB4	O
cells	O
.	O
The	O
location	O
of	O
Sp140	B
in	O
the	O
NB	O
,	O
and	O
expression	O
of	O
this	O
gene	O
in	O
cells	O
involved	O
in	O
host	O
defense	O
,	O
suggest	O
that	O
Sp140	B
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O
Interferon	O
augments	O
PML	B
and	O
PML	B
/	I
RAR	I
alpha	I
expression	O
in	O
normal	O
myeloid	O
and	O
acute	O
promyelocytic	O
cells	O
and	O
cooperates	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
to	O
induce	O
maturation	O
of	O
a	O
retinoid	O
-	O
resistant	O
promyelocytic	O
cell	O
line	O
.	O
The	O
PML	O
gene	O
is	O
fused	O
to	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
gene	O
(	O
RAR	O
alpha	O
)	O
in	O
the	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
15	O
;	O
17	O
translocation	O
.	O
PML	B
is	O
expressed	O
in	O
diverse	O
tissues	O
and	O
cell	O
lines	O
and	O
localized	O
in	O
the	O
nucleus	O
with	O
a	O
typical	O
speckled	O
pattern	O
.	O
In	O
the	O
bone	O
marrow	O
,	O
it	O
is	O
preferentially	O
expressed	O
in	O
myeloid	O
cells	O
.	O
PML	B
appears	O
to	O
be	O
transcriptionally	O
regulated	O
by	O
class	B
I	I
and	I
II	I
interferons	I
,	O
which	O
raises	O
the	O
possibility	O
that	O
interferons	O
modulate	O
the	O
function	O
and	O
growth	O
and	O
differentiation	O
potential	O
of	O
normal	O
myeloid	O
cells	O
and	O
precursors	O
by	O
activating	O
PML	B
-dependent	O
pathways	O
.	O
Similarly	O
,	O
interferons	O
could	O
act	O
on	O
APL	O
cells	O
,	O
alone	O
or	O
in	O
combination	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
especially	O
if	O
the	O
PML	O
/	O
RAR	O
alpha	O
fusion	O
transcript	O
that	O
results	O
from	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
is	O
induced	O
by	O
interferon	B
.	O
We	O
report	O
here	O
that	O
PML	B
is	O
expressed	O
at	O
low	O
levels	O
or	O
not	O
expressed	O
in	O
normal	O
circulating	O
human	O
monocytes	O
,	O
lymphocytes	O
,	O
and	O
polymorphonucleate	O
cells	O
,	O
but	O
is	O
markedly	O
induced	O
by	O
interferon	B
;	O
that	O
PML	B
and	O
PML	B
/	I
RAR	I
alpha	I
expression	O
is	O
augmented	O
by	O
interferon	B
in	O
the	O
NB4	O
APL	O
cell	O
line	O
,	O
which	O
carries	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
,	O
and	O
in	O
APL	O
blasts	O
from	O
patients	O
;	O
that	O
interferon	B
inhibits	O
growth	O
and	O
survival	O
of	O
NB4	O
APL	O
cells	O
in	O
cooperation	O
with	O
RA	O
;	O
that	O
interferons	O
alone	O
have	O
minimal	O
maturation	O
effect	O
on	O
NB4	O
cells	O
;	O
and	O
,	O
finally	O
,	O
that	O
interferon	B
gamma	I
,	I
but	I
not	I
alpha	I
or	I
beta	I
,	O
induces	O
maturation	O
and	O
growth	O
suppression	O
of	O
NB4	O
cells	O
with	O
de	O
novo	O
retinoid	O
resistance	O
,	O
and	O
partially	O
restores	O
RA	O
response	O
.	O
T	O
cell	O
response	O
to	O
Epstein	B
-	I
Barr	I
virus	I
transactivators	I
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O
Rheumatoid	O
arthritis	O
is	O
a	O
multistep	O
disorder	O
associated	O
with	O
autoimmune	O
features	O
of	O
yet	O
unknown	O
etiology	O
.	O
Implication	O
of	O
viruses	O
such	O
as	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
in	O
rheumatoid	O
arthritis	O
pathogenesis	O
has	O
been	O
suspected	O
on	O
the	O
basis	O
of	O
several	O
indirect	O
observations	O
,	O
but	O
thus	O
far	O
,	O
a	O
direct	O
link	O
between	O
EBV	O
and	O
rheumatoid	O
arthritis	O
has	O
not	O
been	O
provided	O
.	O
Here	O
we	O
show	O
that	O
a	O
large	O
fraction	O
of	O
T	O
cells	O
infiltrating	O
affected	O
joints	O
from	O
a	O
patient	O
with	O
chronic	O
rheumatoid	O
arthritis	O
recognizes	O
two	O
EBV	B
transactivators	I
(	O
BZLF1	B
and	O
BMLF1	B
)	O
in	O
a	O
major	B
histocompatibility	I
complex	I
-restricted	O
fashion	O
.	O
Responses	O
to	O
these	O
EBV	B
antigens	I
by	O
synovial	O
lymphocytes	O
from	O
several	O
other	O
chronic	O
rheumatoid	O
arthritis	O
patients	O
were	O
readily	O
detectable	O
.	O
Thus	O
these	O
results	O
suggest	O
a	O
direct	O
contribution	O
of	O
EBV	O
to	O
chronic	O
rheumatoid	O
arthritis	O
pathogenesis	O
.	O
They	O
also	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
occurrence	O
of	O
T	O
cell	O
responses	O
against	O
EBV	B
transactivating	I
factors	I
,	O
which	O
might	O
be	O
central	O
in	O
the	O
control	O
of	O
virus	O
reactivation	O
.	O
Differential	O
nuclear	O
localization	O
of	O
p50	B
,	O
p52	B
,	O
and	O
RelB	B
proteins	O
in	O
human	O
accessory	O
cells	O
of	O
the	O
immune	O
response	O
in	O
situ	O
.	O
The	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
proteins	I
,	O
p50	B
,	O
p52	B
,	O
p65	B
,	O
c	B
-	I
Rel	I
,	O
and	O
RelB	B
,	O
constitute	O
a	O
family	O
of	O
transcription	B
factors	I
involved	O
in	O
the	O
positive	O
regulation	O
of	O
a	O
variety	O
of	O
genes	O
during	O
the	O
immune	O
response	O
.	O
Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
RelB	B
knockout	O
mice	O
have	O
no	O
dendritic	O
cells	O
(	O
DC	O
)	O
.	O
An	O
overexpression	O
of	O
p50	B
has	O
been	O
described	O
in	O
follicular	O
dendritic	O
cells	O
(	O
FDC	O
)	O
.	O
A	O
constitutive	O
NF	B
-	I
kappa	I
B	I
activity	O
has	O
been	O
reported	O
in	O
mature	O
macrophages	O
.	O
This	O
led	O
to	O
the	O
hypothesis	O
that	O
some	O
of	O
the	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
proteins	I
were	O
key	O
nuclear	B
factors	I
in	O
functions	O
of	O
accessory	O
cells	O
of	O
the	O
immune	O
response	O
.	O
Therefore	O
,	O
we	O
investigated	O
in	O
situ	O
the	O
nuclear	O
localization	O
of	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
proteins	I
in	O
accessory	O
cells	O
of	O
the	O
immune	O
system	O
by	O
immunohistochemistry	O
and	O
double	O
labeling	O
by	O
immunofluorescence	O
from	O
five	O
normal	O
human	O
tonsils	O
and	O
five	O
lymph	O
nodes	O
with	O
follicular	O
hyperplasia	O
.	O
Nuclear	O
p65	B
and	O
c	B
-	I
Rel	I
proteins	O
were	O
found	O
in	O
all	O
cell	O
types	O
including	O
lymphocytes	O
.	O
In	O
germinal	O
centers	O
GC	O
,	O
p50	B
,	O
p52	B
,	O
and	O
RelB	B
were	O
found	O
in	O
the	O
nuclei	O
of	O
FDC	O
only	O
and	O
were	O
not	O
detected	O
in	O
the	O
nuclei	O
of	O
CD68	O
+	O
cells	O
.	O
In	O
T	O
cell	O
areas	O
,	O
p50	B
,	O
p52	B
,	O
and	O
RelB	B
were	O
found	O
in	O
the	O
nuclei	O
of	O
HLA	O
-	O
DR+	O
cells	O
with	O
an	O
antigen	O
-	O
presenting	O
cell	O
(	O
APC	O
)	O
morphology	O
.	O
p52	B
and	O
RelB	B
were	O
detected	O
in	O
the	O
nuclei	O
in	O
both	O
CD1a+	O
and	O
CD68	O
+	O
cells	O
from	O
the	O
T	O
cell	O
area	O
,	O
whereas	O
p50	B
was	O
found	O
only	O
in	O
CD68-	O
and	O
CD1a-	O
cells	O
.	O
Cells	O
with	O
nuclear	O
p50	B
were	O
negative	O
for	O
the	O
CD38	B
,	O
CD20	B
and	O
CD2	B
markers	I
.	O
These	O
results	O
show	O
that	O
,	O
physiologically	O
,	O
high	O
levels	O
of	O
nuclear	O
of	O
p50	B
,	O
p52	B
and	O
RelB	B
are	O
restricted	O
to	O
accessory	O
cells	O
of	O
the	O
immune	O
system	O
,	O
which	O
include	O
FDC	O
in	O
GC	O
,	O
and	O
DC	O
and	O
macrophages	O
in	O
the	O
T	O
cell	O
zone	O
,	O
that	O
specialized	O
scavenger	O
macrophages	O
from	O
GC	O
do	O
not	O
have	O
detectable	O
levels	O
of	O
p52	B
and	O
RelB	B
,	O
whereas	O
macrophages	O
from	O
the	O
T	O
cell	O
area	O
,	O
known	O
to	O
present	O
the	O
antigen	O
to	O
T	O
cells	O
,	O
do	O
have	O
both	O
nuclear	O
p52	B
and	O
RelB	B
,	O
and	O
that	O
in	O
the	O
T	O
cell	O
zone	O
,	O
p52	B
and	O
RelB	B
are	O
located	O
in	O
nuclei	O
of	O
both	O
CD1a+	O
,	O
CD68	O
+	O
or	O
both	O
,	O
cells	O
APC	O
,	O
whereas	O
p50	B
is	O
restricted	O
to	O
CD1a-	O
and	O
CD68-	O
APC	O
.	O
The	O
different	O
patterns	O
of	O
p50	B
,	O
p52	B
and	O
RelB	B
protein	O
nuclear	O
localization	O
may	O
provide	O
insight	O
into	O
their	O
different	O
roles	O
during	O
the	O
immune	O
response	O
in	O
vivo	O
.	O
Cloning	O
and	O
expression	O
of	O
the	O
Epstein	B
-	I
Barr	I
virus	I
-	I
encoded	I
dUTPase	I
:	O
patients	O
with	O
acute	O
,	O
reactivated	O
or	O
chronic	O
virus	O
infection	O
develop	O
antibodies	B
against	O
the	O
enzyme	B
.	O
The	O
gene	O
encoding	O
the	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
-specific	I
dUTPase	I
was	O
amplified	O
from	O
virus	O
DNA	O
by	O
PCR	O
.	O
The	O
active	O
enzyme	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
in	O
insect	O
cells	O
as	O
a	O
non	B
-	I
fusion	I
protein	I
.	O
The	O
protein	O
from	O
E.	O
coli	O
specifically	O
converted	O
dUTP	O
to	O
dUMP	O
and	O
did	O
not	O
react	O
with	O
other	O
dNTPs	O
or	O
NTPs	O
.	O
Preliminary	O
experiments	O
yielded	O
a	O
Km	O
value	O
of	O
about	O
0.8	O
microM	O
for	O
dUTP	O
.	O
MAbs	O
against	O
the	O
dUTPase	B
reacted	O
with	O
a	O
protein	O
of	O
approximately	O
31	O
kDa	O
in	O
12-O	O
-	O
tetradecanoyl	O
-	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
-stimulated	O
B	O
cells	O
harbouring	O
either	O
type	O
1	O
or	O
type	O
2	O
EBV	O
.	O
The	O
protein	O
was	O
found	O
in	O
untreated	O
cells	O
at	O
low	O
levels	O
,	O
whereas	O
induction	O
of	O
the	O
lytic	O
replication	O
cycle	O
by	O
TPA	O
treatment	O
or	O
by	O
providing	O
the	O
immediate	B
early	I
transactivator	I
BZLF1	B
in	O
trans	O
resulted	O
in	O
increased	O
expression	O
.	O
We	O
demonstrated	O
that	O
the	O
virus	B
dUTPase	I
isolated	O
from	O
EBV	O
-	O
infected	O
cells	O
is	O
a	O
phosphoprotein	B
.	O
The	O
protein	O
expressed	O
in	O
insect	O
cells	O
was	O
used	O
to	O
test	O
for	O
the	O
presence	O
of	O
specific	B
antibodies	I
in	O
sera	O
from	O
normal	O
,	O
healthy	O
carriers	O
and	O
from	O
patients	O
with	O
various	O
diseases	O
.	O
While	O
the	O
sera	O
of	O
EBV	O
-	O
negative	O
individuals	O
(	O
0	O
/	O
3	O
)	O
or	O
healthy	O
carriers	O
(	O
0	O
/	O
33	O
)	O
did	O
not	O
contain	O
detectable	O
levels	O
of	O
antibodies	O
,	O
patients	O
with	O
mononucleosis	O
(	O
5	O
/	O
18	O
)	O
,	O
chronic	O
EBV	O
infection	O
(	O
2	O
/	O
7	O
)	O
,	O
EBV	O
reactivation	O
(	O
7	O
/	O
20	O
)	O
and	O
human	O
immunodeficiency	O
virus	O
infection	O
(	O
5	O
/	O
24	O
)	O
showed	O
elevated	O
antibody	O
titres	O
against	O
the	O
enzyme	O
.	O
This	O
indicated	O
that	O
the	O
dUTPase	O
is	O
expressed	O
during	O
EBV	O
replication	O
and	O
reactivation	O
.	O
The	O
enzyme	O
might	O
therefore	O
be	O
a	O
potential	O
target	O
for	O
drug	O
therapy	O
under	O
conditions	O
of	O
active	O
DNA	O
replication	O
.	O
Prostaglandin	O
E2	O
induction	O
of	O
binding	O
activity	O
to	O
CRE	O
and	O
AP-2	O
elements	O
in	O
human	O
T	O
lymphocytes	O
.	O
Prostaglandins	O
of	O
the	O
E	O
series	O
are	O
immunomodulatory	O
agents	O
which	O
exert	O
inhibitory	O
as	O
well	O
as	O
stimulatory	O
effects	O
on	O
a	O
variety	O
of	O
immune	O
responses	O
.	O
Since	O
it	O
is	O
known	O
that	O
PGE2	O
is	O
able	O
to	O
increase	O
cAMP	O
levels	O
,	O
we	O
investigated	O
whether	O
it	O
can	O
affect	O
gene	O
expression	O
through	O
the	O
activation	O
of	O
the	O
transcription	B
factors	I
which	O
bind	O
enhancer	O
elements	O
in	O
the	O
promoter	O
regions	O
of	O
cAMP	O
-	O
regulated	O
genes	O
.	O
Using	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
we	O
demonstrated	O
that	O
a	O
short	O
treatment	O
of	O
human	O
T	O
lymphocytes	O
with	O
PGE2	O
induces	O
specific	O
binding	O
activity	O
to	O
CRE	O
and	O
AP-2	O
,	O
but	O
not	O
AP-1	O
,	O
DNA	O
elements	O
.	O
Since	O
the	O
okadaic	O
acid	O
,	O
a	O
potent	O
protein	O
phosphatase	O
inhibitor	O
,	O
prolongs	O
the	O
induction	O
of	O
the	O
binding	O
activity	O
,	O
phosphorylation	O
events	O
are	O
likely	O
to	O
occur	O
.	O
This	O
activity	O
seems	O
to	O
be	O
due	O
to	O
increased	O
cAMP	O
levels	O
because	O
forskolin	O
and	O
IBMX	O
mimic	O
the	O
effects	O
of	O
PGE2	O
.	O
More	O
interestingly	O
,	O
transfection	O
experiments	O
with	O
CRE	O
-	O
CAT	O
plasmide	O
show	O
that	O
PGE2	O
activates	O
the	O
transcription	O
of	O
a	O
CRE	O
-	O
containing	O
promoter	O
.	O
These	O
data	O
support	O
the	O
positive	O
role	O
for	O
PGE2	O
on	O
some	O
immune	O
functions	O
.	O
Tissue	O
and	O
cell	O
-	O
type	O
specific	O
expression	O
of	O
the	O
tuberous	O
sclerosis	O
gene	O
,	O
TSC2	O
,	O
in	O
human	O
tissues	O
.	O
TSC2	O
is	O
a	O
gene	O
on	O
chromosome	O
16p13.3	O
associated	O
with	O
the	O
autosomal	O
dominant	O
neurocutaneous	O
disorder	O
,	O
tuberous	O
sclerosis	O
complex	O
(	O
TSC	O
)	O
.	O
By	O
using	O
a	O
partial	O
nucleotide	O
sequence	O
from	O
the	O
cloned	O
TSC2	O
and	O
polymerase	O
chain	O
reaction	O
methodology	O
,	O
we	O
constructed	O
a	O
digoxigenin	O
-	O
labeled	O
complementary	O
DNA	O
probe	O
to	O
examine	O
TSC2	O
gene	O
expression	O
in	O
autopsy-	O
or	O
biopsy	O
-	O
derived	O
human	O
tissues	O
by	O
in	O
situ	O
hybridization	O
.	O
TSC2	O
messenger	O
RNA	O
was	O
widely	O
expressed	O
in	O
various	O
cell	O
types	O
throughout	O
the	O
body	O
,	O
including	O
epithelia	O
,	O
lymphocytes	O
,	O
and	O
cells	O
with	O
endocrine	O
functions	O
,	O
e.g.	O
,	O
adrenal	O
cortex	O
and	O
anterior	O
pituitary	O
.	O
It	O
was	O
prominently	O
and	O
selectively	O
(	O
within	O
the	O
central	O
nervous	O
system	O
)	O
expressed	O
in	O
pyramidal	O
cells	O
of	O
the	O
cerebral	O
cortex	O
and	O
other	O
motor	O
neurons	O
,	O
e.g.	O
,	O
in	O
spinal	O
cord	O
and	O
brainstem	O
nuclei	O
.	O
Visceral	O
TSC2	O
expression	O
was	O
comparable	O
in	O
autopsy	O
tissues	O
from	O
patients	O
with	O
and	O
without	O
TSC	O
;	O
TSC2	O
messenger	O
RNA	O
expression	O
was	O
most	O
prominent	O
in	O
cells	O
with	O
a	O
rapid	O
mitotic	O
rate	O
and	O
turnover	O
,	O
e.g.	O
,	O
epithelia	O
and	O
lymphocytes	O
,	O
with	O
central	O
nervous	O
system	O
pyramidal	O
cells	O
and	O
other	O
neurons	O
being	O
an	O
obvious	O
exception	O
,	O
and/or	O
in	O
cells	O
with	O
important	O
secretory	O
/	O
transport	O
functions	O
.	O
This	O
widespread	O
expression	O
of	O
the	O
TSC2	O
gene	O
supports	O
the	O
view	O
that	O
it	O
encodes	O
a	O
protein	O
vital	O
to	O
cell	O
growth	O
and	O
metabolism	O
or	O
one	O
that	O
functions	O
as	O
a	O
tumor	O
/	O
growth	O
suppressor	O
.	O
Elf-1	B
and	O
Stat5	B
bind	O
to	O
a	O
critical	O
element	O
in	O
a	O
new	O
enhancer	O
of	O
the	O
human	O
interleukin-2	O
receptor	O
alpha	O
gene	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1997	O
Apr	O
;	O
17	O
(	O
4	O
)	O
:	O
2351	O
]	O
The	O
interleukin	O
2	O
receptor	O
alpha	O
-	O
chain	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
is	O
a	O
key	O
regulator	O
of	O
lymphocyte	O
proliferation	O
.	O
IL-2R	B
alpha	I
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O
Interleukin	B
2	I
(	O
IL-2	B
)	O
stimulates	O
IL-2R	B
alpha	I
.	O
transcription	O
,	O
thereby	O
amplifying	O
expression	O
of	O
its	O
own	O
high	B
-	I
affinity	I
receptor	I
.	O
IL-2R	B
alpha	I
transcription	O
is	O
at	O
least	O
in	O
part	O
controlled	O
by	O
two	O
positive	B
regulatory	I
regions	I
,	O
PRRI	O
and	O
PRRII	O
.	O
PRRI	O
is	O
an	O
inducible	O
proximal	O
enhancer	O
,	O
located	O
between	O
nucleotides	O
-276	O
and	O
-244	O
,	O
which	O
contains	O
NF	O
-	O
kappaB	O
and	O
SRE	O
/	O
CArG	O
motifs	O
.	O
PRRII	O
is	O
a	O
T	O
-	O
cell	O
-	O
specific	O
enhancer	O
,	O
located	O
between	O
nucleotides	O
-137	O
and	O
-64	O
,	O
which	O
binds	O
the	O
T	B
-	I
cell	I
-	I
specific	I
Ets	I
protein	I
Elf-1	B
and	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
proteins	I
.	O
However	O
,	O
none	O
of	O
these	O
proximal	O
regions	O
account	O
for	O
the	O
induction	O
of	O
IL-2R	O
alpha	O
transcription	O
by	O
IL-2	B
.	O
To	O
find	O
new	O
regulatory	O
regions	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
,	O
8.5	O
kb	O
of	O
the	O
5	O
'	O
end	O
noncoding	O
sequence	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
have	O
been	O
sequenced	O
.	O
We	O
identified	O
an	O
86-nucleotide	O
fragment	O
that	O
is	O
90	O
%	O
identical	O
to	O
the	O
recently	O
characterized	O
murine	O
IL-2-responsive	O
element	O
(	O
mIL-2rE	O
)	O
.	O
This	O
putative	O
human	O
IL-2rE	O
,	O
designated	O
PRRIII	O
,	O
confers	O
IL-2	B
responsiveness	O
on	O
a	O
heterologous	O
promoter	O
.	O
PRRIII	O
contains	O
a	O
Stat	O
protein	O
binding	O
site	O
that	O
overlaps	O
with	O
an	O
EBS	O
motif	O
(	O
GASd	O
/	O
EBSd	O
)	O
.	O
These	O
are	O
essential	O
for	O
IL-2	B
inducibility	O
of	O
PRRIII	O
/	O
CAT	O
reporter	O
constructs	O
.	O
IL-2	B
induced	O
the	O
binding	O
of	O
Stat5a	B
and	I
b	I
proteins	I
to	O
the	O
human	O
GASd	O
element	O
.	O
To	O
confirm	O
the	O
physiological	O
relevance	O
of	O
these	O
findings	O
,	O
we	O
carried	O
out	O
in	O
vivo	O
footprinting	O
experiments	O
which	O
showed	O
that	O
stimulation	O
of	O
IL-2R	B
alpha	I
expression	O
correlated	O
with	O
occupancy	O
of	O
the	O
GASd	O
element	O
.	O
Our	O
data	O
demonstrate	O
a	O
major	O
role	O
of	O
the	O
GASd	O
/	O
EBSd	O
element	O
in	O
IL-2R	B
alpha	I
regulation	O
and	O
suggest	O
that	O
the	O
T	B
-	I
cell	I
-	I
specific	I
Elf-1	I
factor	I
can	O
serve	O
as	O
a	O
transcriptional	B
repressor	I
.	O
Association	O
of	O
TRAF1	B
,	O
TRAF2	B
,	O
and	O
TRAF3	B
with	O
an	O
Epstein	O
-	O
Barr	O
virus	O
LMP1	O
domain	O
important	O
for	O
B	O
-	O
lymphocyte	O
transformation	O
:	O
role	O
in	O
NF	B
-	I
kappaB	I
activation	O
.	O
The	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
transforming	I
protein	I
LMP1	I
appears	O
to	O
be	O
a	O
constitutively	B
activated	I
tumor	I
necrosis	I
factor	I
receptor	I
(	O
TNFR	B
)	O
on	O
the	O
basis	O
of	O
an	O
intrinsic	O
ability	O
to	O
aggregate	O
in	O
the	O
plasma	O
membrane	O
and	O
an	O
association	O
of	O
its	O
cytoplasmic	B
carboxyl	I
terminus	I
(	O
CT	B
)	O
with	O
TNFR	B
-	I
associated	I
factors	I
(	O
TRAFs	B
)	O
.	O
We	O
now	O
show	O
that	O
in	O
EBV	O
-	O
transformed	O
B	O
lymphocytes	O
most	O
of	O
TRAF1	B
or	O
TRAF3	B
and	O
5	O
%	O
of	O
TRAF2	B
are	O
associated	O
with	O
LMP1	B
and	O
that	O
most	O
of	O
LMP1	B
is	O
associated	O
with	O
TRAF1	B
or	O
TRAF3	B
.	O
TRAF1	B
,	O
TRAF2	B
,	O
and	O
TRAF3	B
bind	O
to	O
a	O
single	O
site	O
in	O
the	O
LMP1	B
CT	I
corresponding	O
to	O
amino	O
acids	O
(	O
aa	O
)	O
199	O
to	O
214	O
,	O
within	O
a	O
domain	O
which	O
is	O
important	O
for	O
B	O
-	O
lymphocyte	O
growth	O
transformation	O
(	O
aa	O
187	O
to	O
231	O
)	O
.	O
Further	O
deletional	O
and	O
alanine	O
mutagenesis	O
analyses	O
and	O
comparison	O
with	O
TRAF	O
binding	O
sequences	O
in	O
CD40	O
,	O
in	O
CD30	O
,	O
and	O
in	O
the	O
LMP1	B
of	O
other	O
lymphycryptoviruses	O
provide	O
the	O
first	O
evidence	O
that	O
PXQXT	O
/	O
S	O
is	O
a	O
core	O
TRAF	O
binding	O
motif	O
.	O
The	O
negative	O
effects	O
of	O
point	O
mutations	O
in	O
the	O
LMP1	O
(	O
1	O
-	O
231	O
)	O
core	O
TRAF	O
binding	O
motif	O
on	O
TRAF	O
binding	O
and	O
NF	B
-	I
kappaB	I
activation	O
genetically	O
link	O
the	O
TRAFs	B
to	O
LMP1	B
(	O
1	O
-	O
231	O
)	O
-mediated	O
NF	B
-	I
kappaB	I
activation	O
.	O
NF	B
-	I
kappaB	I
activation	O
by	O
LMP1	B
(	O
1	O
-	O
231	O
)	O
is	O
likely	O
to	O
be	O
mediated	O
by	O
TRAF1	B
/TRAF2	B
heteroaggregates	O
since	O
TRAF1	B
is	O
unique	O
among	O
the	O
TRAFs	B
in	O
coactivating	O
NF	B
-	I
kappaB	I
with	O
LMP1	B
(	O
1	O
-	O
231	O
)	O
,	O
a	O
TRAF2	B
dominant	O
-	O
negative	O
mutant	O
can	O
block	O
LMP1	B
(	O
1	O
-	O
231	O
)	O
-mediated	O
NF	B
-	I
kappaB	I
activation	O
as	O
well	O
as	O
TRAF1	B
coactivation	O
,	O
and	O
30	O
%	O
of	O
TRAF2	B
is	O
associated	O
with	O
TRAF1	B
in	O
EBV	O
-	O
transformed	O
B	O
cells	O
.	O
TRAF3	B
is	O
a	O
negative	O
modulator	O
of	O
LMP1	B
(	O
1	O
-	O
231	O
)	O
-mediated	O
NF	B
-	I
kappaB	I
activation	O
.	O
Surprisingly	O
,	O
TRAF1	B
,	I
-2	I
,	I
or	I
-3	I
does	O
not	O
interact	O
with	O
the	O
terminal	B
LMP1	I
CT	I
aa	O
333	O
to	O
386	O
which	O
can	O
independently	O
mediate	O
NF	B
-	I
kappaB	I
activation	O
.	O
The	O
constitutive	O
association	O
of	O
TRAFs	B
with	O
LMP1	B
through	O
the	O
aa	B
187	I
to	I
231	I
domain	I
which	O
is	O
important	O
in	O
NF	B
-	I
kappaB	I
activation	O
and	O
primary	O
B	O
-	O
lymphocyte	O
growth	O
transformation	O
implicates	O
TRAF	B
aggregation	O
in	O
LMP1	B
signaling	O
.	O
CD40	B
,	O
but	O
not	O
lipopolysaccharide	O
and	O
anti	B
-	I
IgM	I
stimulation	O
of	O
primary	O
B	O
lymphocytes	O
,	O
leads	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B
.	O
In	O
this	O
study	O
we	O
analyzed	O
the	O
effect	O
of	O
CD40	B
stimulation	O
on	O
the	O
activity	O
and	O
nuclear	O
appearance	O
of	O
Rel	B
/	I
nuclear	I
factor	I
kappaB	I
(	I
NF	I
-	I
kappaB	I
)	I
factors	I
in	O
primary	O
murine	O
B	O
lymphocytes	O
.	O
We	O
show	O
that	O
triggering	O
of	O
CD40	B
signaling	O
pathway	O
(	O
s	O
)	O
by	O
CD40	B
ligands	I
expressed	O
on	O
L	O
cells	O
led	O
to	O
strong	O
activation	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
controlled	O
beta	O
-	O
globin	O
reporter	O
gene	O
in	O
primary	O
B	O
lymphocytes	O
from	O
transgenic	O
mice	O
.	O
Analyses	O
of	O
nuclear	O
translocation	O
of	O
individual	O
members	O
of	O
Rel	B
proteins	I
after	O
CD40	B
induction	O
of	O
primary	O
B	O
cells	O
showed	O
a	O
strong	O
and	O
long	O
-	O
lasting	O
accumulation	O
of	O
RelB	B
and	O
,	O
less	O
pronounced	O
,	O
of	O
c	B
-	I
Rel	I
.	O
LPS	O
stimulation	O
did	O
not	O
give	O
rise	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B
and	O
c	B
-	I
Rel	I
,	O
whereas	O
nuclear	O
c	B
-	I
Rel	I
,	O
but	O
not	O
RelB	B
,	O
accumulated	O
after	O
B	O
cell	O
receptor	O
stimulation	O
.	O
CD40	B
induced	O
not	O
only	O
nuclear	O
translocation	O
but	O
also	O
de	O
novo	O
synthesis	O
of	O
RelB	O
RNA	O
and	O
protein	O
.	O
S107	O
plasmacytoma	O
cells	O
,	O
which	O
express	O
CD40	B
but	O
are	O
defective	O
for	O
the	O
nuclear	O
appearance	O
of	O
p50	B
/	I
p65-NF	I
-	I
kappaB	I
,	O
do	O
not	O
express	O
RelB	B
after	O
CD40	B
stimulation	O
.	O
In	O
S107	O
cells	O
stably	O
transfected	O
with	O
relB	O
genes	O
,	O
stimulation	O
of	O
nuclear	O
RelB	B
translocation	O
by	O
CD40	B
was	O
observed	O
.	O
These	O
results	O
indicate	O
that	O
stimulation	O
of	O
CD40	B
signaling	O
pathways	O
exerts	O
a	O
long	O
-	O
lasting	O
stimulatory	O
effect	O
on	O
both	O
the	O
transcription	O
and	O
nuclear	O
translocation	O
of	O
RelB	B
.	O
Since	O
LPS	O
and	O
anti	B
-	I
IgM	I
were	O
unable	O
to	O
activate	O
RelB	B
,	O
CD40	B
appears	O
to	O
trigger	O
a	O
special	O
program	O
of	O
gene	O
expression	O
involved	O
in	O
the	O
proliferation	O
and/or	O
differentiation	O
of	O
B	O
lymphocytes	O
.	O
[	O
Cortisone	O
-	O
resistant	O
bronchial	O
asthma	O
]	O
There	O
is	O
general	O
agreement	O
on	O
the	O
inflammatory	O
pathogenesis	O
of	O
bronchial	O
asthma	O
:	O
an	O
accumulation	O
of	O
activated	O
eosinophils	O
,	O
degranulated	O
mast	O
cells	O
,	O
T	O
lymphocytes	O
and	O
in	O
very	O
severe	O
forms	O
,	O
granulocytes	O
has	O
constantly	O
been	O
found	O
in	O
the	O
bronchial	O
mucosa	O
.	O
In	O
allergic	O
bronchial	O
asthma	O
,	O
inflammation	O
seems	O
to	O
be	O
orchestrated	O
predominantly	O
by	O
a	O
subset	O
of	O
T	O
lymphocytes	O
,	O
with	O
a	O
phenotype	O
similar	O
to	O
the	O
Th2	O
subset	O
able	O
to	O
produce	O
IL-4	B
and	O
IL-5	B
.	O
Although	O
corticosteroids	O
are	O
the	O
most	O
potent	O
therapeutic	O
agents	O
used	O
for	O
this	O
disease	O
,	O
their	O
anti	O
-	O
inflammatory	O
effect	O
differs	O
from	O
patient	O
to	O
patient	O
.	O
Some	O
criteria	O
which	O
can	O
be	O
used	O
to	O
define	O
steroid	O
-	O
resistant	O
bronchial	O
asthma	O
are	O
listed	O
here	O
.	O
This	O
review	O
analyzes	O
various	O
molecular	O
alterations	O
responsible	O
for	O
the	O
deficient	O
response	O
to	O
corticosteroid	O
treatment	O
observed	O
in	O
steroid	O
-	O
resistant	O
bronchial	O
asthmatic	O
subjects	O
.	O
New	O
knowledge	O
on	O
the	O
mechanism	O
of	O
steroid	O
resistance	O
may	O
have	O
important	O
implications	O
for	O
the	O
treatment	O
of	O
chronic	O
asthma	O
and	O
other	O
diseases	O
.	O
The	O
proximal	O
regulatory	O
element	O
of	O
the	O
interferon	O
-	O
gamma	O
promoter	O
mediates	O
selective	O
expression	O
in	O
T	O
cells	O
.	O
Interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
is	O
produced	O
by	O
natural	O
killer	O
cells	O
and	O
certain	O
subsets	O
of	O
T	O
cells	O
,	O
but	O
the	O
basis	O
for	O
its	O
selective	O
expression	O
is	O
unknown	O
.	O
Within	O
the	O
region	O
between	O
-108	O
and	O
-40	O
base	O
pairs	O
of	O
the	O
IFN	B
-	I
gamma	I
promoter	O
are	O
two	O
conserved	O
and	O
essential	O
regulatory	O
elements	O
,	O
which	O
confer	O
activation	O
-	O
specific	O
expression	O
in	O
T	O
cells	O
.	O
This	O
report	O
describes	O
studies	O
indicating	O
that	O
the	O
most	O
proximal	O
of	O
these	O
two	O
regulatory	O
elements	O
is	O
an	O
important	O
determinant	O
of	O
its	O
restricted	O
expression	O
.	O
The	O
proximal	O
element	O
is	O
a	O
composite	O
site	O
that	O
binds	O
members	O
of	O
the	O
CREB	B
/	I
ATF	I
,	O
AP-1	B
,	O
and	O
octamer	B
families	I
of	O
transcription	B
factors	I
.	O
Jun	B
is	O
essential	O
for	O
activation	O
-	O
induced	O
transcription	O
and	O
binds	O
preferably	O
as	O
a	O
heterodimer	O
with	O
ATF-2	B
.	O
In	O
contrast	O
,	O
CREB	B
appears	O
to	O
dampen	O
transcription	O
from	O
this	O
element	O
.	O
The	O
CpG	O
dinucleotide	O
in	O
this	O
element	O
is	O
selectively	O
methylated	O
in	O
Th2	O
T	O
cells	O
and	O
other	O
cells	O
that	O
do	O
not	O
express	O
IFN	B
-	I
gamma	I
,	O
and	O
methylation	O
markedly	O
reduces	O
transcription	B
factor	I
binding	O
.	O
As	O
a	O
target	O
for	O
DNA	O
methylation	O
and	O
for	O
binding	O
of	O
transcription	B
factors	I
that	O
mediate	O
or	O
impede	O
transcription	O
,	O
this	O
element	O
appears	O
to	O
play	O
a	O
central	O
role	O
in	O
controlling	O
IFN	B
-	I
gamma	I
expression	O
.	O
HIV-1	O
LTR	O
activity	O
in	O
human	O
CD40-activated	O
B	O
lymphocytes	O
is	O
dependent	O
on	O
NF	B
-	I
kappaB	I
.	O
CD40-stimulated	O
human	O
B	O
lymphocytes	O
are	O
highly	O
permissive	O
to	O
a	O
productive	O
infection	O
by	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O
In	O
these	O
cells	O
,	O
nuclear	B
factors	I
involved	O
in	O
activation	O
of	O
the	O
HIV-1	O
LTR	O
,	O
which	O
contains	O
the	O
transcriptional	O
control	O
elements	O
of	O
the	O
virus	O
,	O
are	O
unknown	O
.	O
Transient	O
expression	O
assays	O
with	O
plasmids	O
containing	O
deleted	O
parts	O
of	O
the	O
LTR	O
region	O
linked	O
to	O
a	O
reporter	O
gene	O
showed	O
that	O
the	O
NF	O
-	O
kappaB	O
binding	O
site	O
was	O
essential	O
for	O
HIV-1	O
LTR	O
activity	O
in	O
CD40-stimulated	O
B	O
lymphocytes	O
.	O
In	O
addition	O
,	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
revealed	O
that	O
important	O
NF	B
-	I
kappaB	I
binding	O
activity	O
composed	O
of	O
at	O
least	O
p50	B
,	O
p65	B
,	O
and	O
c	B
-	I
Rel	I
NF	B
-	I
kappaB	I
subunits	I
was	O
present	O
in	O
nuclei	O
of	O
CD40-stimulated	O
B	O
cells	O
.	O
These	O
results	O
confirm	O
at	O
a	O
molecular	O
level	O
the	O
ability	O
of	O
HIV-1	O
to	O
replicate	O
in	O
B	O
cells	O
and	O
that	O
this	O
activity	O
is	O
strongly	O
associated	O
with	O
NF	B
-	I
kappaB	I
.	O
Lymphocytes	O
from	O
CML	O
patients	O
lack	O
a	O
47	B
kDa	I
factor	I
having	O
affinity	O
for	O
a	O
genomic	O
sterol	O
regulatory	O
sequence	O
.	O
Deranged	O
cellular	O
cholesterol	O
homeostasis	O
has	O
been	O
widely	O
recognized	O
in	O
the	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O
Since	O
the	O
human	O
genomic	O
sterol	O
regulatory	O
element	O
(	O
SRE	O
)	O
has	O
been	O
shown	O
to	O
regulate	O
various	O
key	O
genes	O
involved	O
in	O
this	O
phenomenon	O
,	O
the	O
present	O
study	O
revealed	O
the	O
existence	O
of	O
a	O
unique	O
47	B
kDa	I
protein	I
factor	I
having	O
affinity	O
for	O
this	O
SRE	O
sequence	O
in	O
lymphocytes	O
from	O
normal	O
subjects	O
,	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	O
from	O
untreated	O
CML	O
patients	O
.	O
However	O
,	O
this	O
factor	O
appeared	O
when	O
these	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha	B
-	I
interferon	I
therapy	O
.	O
Furthermore	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
the	O
LDL	O
receptor	O
gene	O
expression	O
at	O
the	O
transcriptional	O
level	O
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	B
kDa	I
protein	I
factor	I
to	O
the	O
SRE	O
sequence	O
.	O
Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
this	O
factor	O
may	O
have	O
a	O
role	O
in	O
pathophysiology	O
of	O
chronic	O
myeloid	O
leukaemia	O
.	O
Glucocorticoid	O
-	O
mediated	O
inhibition	O
of	O
RANTES	B
expression	O
in	O
human	O
T	O
lymphocytes	O
.	O
The	O
chemokine	B
RANTES	B
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
inflammatory	O
diseases	O
including	O
asthma	O
and	O
rhinitis	O
which	O
are	O
frequently	O
treated	O
with	O
glucocorticoids	O
.	O
We	O
observed	O
that	O
dexamethasone	O
dramatically	O
inhibited	O
RANTES	O
mRNA	O
expression	O
dose	O
dependently	O
in	O
anti	O
-	O
CD3	O
activated	O
Hut-78	O
T	O
cells	O
and	O
human	O
PBMCs	O
.	O
Inhibition	O
of	O
RANTES	B
expression	O
did	O
not	O
appear	O
to	O
be	O
secondary	O
to	O
IL-2	B
inhibition	O
and	O
required	O
binding	O
to	O
the	O
intracellular	O
glucocorticoid	B
receptor	I
.	O
The	O
down	O
-	O
regulation	O
of	O
RANTES	B
expression	O
by	O
glucocorticoids	O
in	O
T	O
cells	O
may	O
directly	O
contribute	O
to	O
the	O
efficacy	O
of	O
these	O
agents	O
in	O
suppressing	O
cellular	O
infiltration	O
and	O
to	O
their	O
anti	O
-	O
inflammatory	O
properties	O
.	O
A	O
novel	O
SP-1	O
site	O
in	O
the	O
human	O
interleukin-1	O
beta	O
promoter	O
confers	O
preferential	O
transcriptional	O
activity	O
in	O
keratinocytes	O
.	O
To	O
investigate	O
the	O
mechanisms	O
of	O
transcriptional	O
activation	O
of	O
interleukin-1beta	B
(	O
IL-1beta	B
)	O
in	O
non	O
-	O
monocytic	O
cells	O
,	O
we	O
constructed	O
a	O
series	O
of	O
reporter	O
plasmids	O
with	O
the	O
bacterial	O
chloramphenicol	O
acetyltransferase	O
gene	O
linked	O
to	O
various	O
parts	O
of	O
the	O
human	O
IL-1beta	O
promoter	O
and	O
performed	O
transient	O
transfection	O
experiments	O
.	O
We	O
identified	O
a	O
promoter	O
segment	O
that	O
activates	O
transcription	O
most	O
efficiently	O
in	O
keratinocytes	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
with	O
a	O
43-mer	O
oligonucleotide	O
derived	O
from	O
the	O
functionally	O
identified	O
cis	O
-	O
acting	O
element	O
revealed	O
specific	O
complexes	O
.	O
By	O
competition	O
analysis	O
with	O
transcription	O
factor	O
consensus	O
sequence	O
oligonucleotides	O
and	O
by	O
immunosupershift	O
,	O
transcription	B
factor	I
SP-1	I
or	O
a	O
closely	O
related	O
protein	O
was	O
shown	O
to	O
bind	O
to	O
this	O
regulatory	O
element	O
.	O
The	O
closest	O
match	O
to	O
the	O
known	O
SP-1	O
consensus	O
sequence	O
within	O
the	O
respective	O
region	O
is	O
a	O
TCCCCTCCCCT	O
motif	O
.	O
Mutation	O
of	O
this	O
motif	O
almost	O
completely	O
,	O
and	O
specifically	O
,	O
abolished	O
the	O
binding	O
of	O
two	O
low	B
-	I
mobility	I
complexes	I
and	O
led	O
to	O
a	O
95	O
%	O
decrease	O
of	O
constitutive	O
transcriptional	O
activation	O
of	O
a	O
reporter	O
construct	O
IL-1beta	B
(	O
-170	O
/	O
+108	O
)	O
.	O
Likewise	O
,	O
activation	O
of	O
this	O
reporter	O
construct	O
by	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
depended	O
on	O
the	O
SP-1	O
site	O
.	O
These	O
observations	O
suggest	O
that	O
a	O
so	O
-	O
far	O
-	O
unrecognized	O
SP-1	O
site	O
in	O
the	O
human	O
IL-1beta	O
promoter	O
may	O
participate	O
in	O
the	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
in	O
keratinocytes	O
.	O
Glycation	O
-	O
dependent	O
,	O
reactive	O
oxygen	O
species	O
-	O
mediated	O
suppression	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
in	O
HIT	O
cells	O
.	O
Prolonged	O
poor	O
glycemic	O
control	O
in	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
patients	O
often	O
leads	O
to	O
a	O
decline	O
in	O
insulin	O
secretion	O
from	O
pancreatic	O
beta	O
cells	O
,	O
accompanied	O
by	O
a	O
decrease	O
in	O
the	O
insulin	O
content	O
of	O
the	O
cells	O
.	O
As	O
a	O
step	O
toward	O
elucidating	O
the	O
pathophysiological	O
background	O
of	O
the	O
so	O
-	O
called	O
glucose	O
toxicity	O
to	O
pancreatic	O
beta	O
cells	O
,	O
we	O
induced	O
glycation	O
in	O
HIT	O
-	O
T15	O
cells	O
using	O
a	O
sugar	O
with	O
strong	O
deoxidizing	O
activity	O
,	O
D	O
-	O
ribose	O
,	O
and	O
examined	O
the	O
effects	O
on	O
insulin	O
gene	O
transcription	O
.	O
The	O
results	O
of	O
reporter	O
gene	O
analyses	O
revealed	O
that	O
the	O
insulin	O
gene	O
promoter	O
is	O
more	O
sensitive	O
to	O
glycation	O
than	O
the	O
control	O
beta	O
-	O
actin	O
gene	O
promoter	O
;	O
approximately	O
50	O
and	O
80	O
%	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
was	O
lost	O
when	O
the	O
cells	O
were	O
kept	O
for	O
3	O
d	O
in	O
the	O
presence	O
of	O
40	O
and	O
60	O
mM	O
D	O
-	O
ribose	O
,	O
respectively	O
.	O
In	O
agreement	O
with	O
this	O
,	O
decrease	O
in	O
the	O
insulin	O
mRNA	O
and	O
insulin	O
content	O
was	O
observed	O
in	O
the	O
glycation	O
-	O
induced	O
cells	O
.	O
Also	O
,	O
gel	O
mobility	O
shift	O
analyses	O
using	O
specific	O
antiserum	O
revealed	O
decrease	O
in	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
an	O
insulin	B
gene	I
transcription	I
factor	I
,	O
PDX-1	B
/	I
IPF1	I
/	I
STF-1	I
.	O
These	O
effects	O
of	O
D	O
-	O
ribose	O
seemed	O
almost	O
irreversible	O
but	O
could	O
be	O
prevented	O
by	O
addition	O
of	O
1	O
mM	O
aminoguanidine	O
or	O
10	O
mM	O
N	O
-	O
acetylcysteine	O
,	O
thus	O
suggesting	O
that	O
glycation	O
and	O
reactive	O
oxygen	O
species	O
,	O
generated	O
through	O
the	O
glycation	O
reaction	O
,	O
serve	O
as	O
mediators	O
of	O
the	O
phenomena	O
.	O
These	O
observations	O
suggest	O
that	O
protein	O
glycation	O
in	O
pancreatic	O
beta	O
cells	O
,	O
which	O
occurs	O
in	O
vivo	O
under	O
chronic	O
hyperglycemia	O
,	O
suppresses	O
insulin	O
gene	O
transcription	O
and	O
thus	O
can	O
explain	O
part	O
of	O
the	O
beta	O
cell	O
glucose	O
toxicity	O
.	O
Ras	B
-dependent	O
,	O
Ca2	O
+	O
-stimulated	O
activation	O
of	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
by	O
a	O
constitutively	O
active	O
Cbl	B
mutant	I
in	O
T	O
cells	O
.	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
stimulation	O
induces	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
cellular	B
proteins	I
,	O
including	O
Cbl	B
,	O
a	O
protooncogene	B
product	I
whose	O
function	O
remains	O
unclear	O
.	O
As	O
a	O
first	O
step	O
toward	O
elucidating	O
the	O
function	O
of	O
Cbl	B
in	O
TCR	B
-initiated	O
signaling	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
wild	B
-	I
type	I
Cbl	I
or	O
a	O
transforming	O
Cbl	B
mutant	I
(	O
70Z	O
/	O
3	O
)	O
to	O
induce	O
transcriptional	O
activation	O
of	O
a	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
element	O
derived	O
from	O
the	O
interleukin	O
2	O
(	O
IL2	O
)	O
promoter	O
in	O
transiently	O
cotransfected	O
Jurkat	O
-	O
TAg	O
T	O
cells	O
.	O
70Z	B
/	I
3	I
,	O
but	O
not	O
Cbl	B
,	O
caused	O
NFAT	B
activation	O
which	O
was	O
significantly	O
enhanced	O
by	O
stimulation	O
with	O
calcium	O
ionophore	O
,	O
and	O
was	O
drastically	O
reduced	O
by	O
cyclosporin	O
A	O
pretreatment	O
.	O
A	O
point	O
mutation	O
of	O
a	O
potential	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3-K	O
)	O
binding	O
site	O
(	O
Y731EAM	O
to	O
Y731EAC	O
)	O
in	O
70Z	B
/	I
3	I
disrupted	O
the	O
association	O
of	O
PI3-K	B
with	O
70Z	B
/	I
3	I
,	O
but	O
did	O
not	O
reduce	O
the	O
induction	O
of	O
NFAT	B
activity	O
,	O
suggesting	O
that	O
the	O
interaction	O
between	O
Cbl	B
and	O
PI3-K	B
is	O
not	O
required	O
in	O
the	O
70Z	B
/	I
3	I
-mediated	O
induction	O
of	O
NFAT	B
.	O
Additional	O
mapping	O
studies	O
indicated	O
that	O
defined	O
deletions	O
of	O
C	O
-	O
terminal	O
70Z	B
/	I
3	I
sequences	O
affected	O
to	O
a	O
variable	O
degree	O
its	O
ability	O
to	O
stimulate	O
NFAT	B
activity	O
.	O
Strikingly	O
,	O
deletion	O
of	O
346	B
C	I
-	I
terminal	I
residues	I
augmented	O
this	O
activity	O
,	O
whereas	O
removal	O
of	O
20	O
additional	O
residues	O
abolished	O
it	O
.	O
Coexpression	O
of	O
dominant	B
negative	I
Ras	I
abrogated	O
the	O
basal	O
or	O
ionomycin	O
-	O
stimulated	O
,	O
70Z	B
/	I
3	I
-mediated	O
NFAT	B
activation	O
,	O
suggesting	O
a	O
functional	B
Ras	I
is	O
required	O
for	O
this	O
activation	O
.	O
These	O
results	O
implicate	O
Cbl	B
in	O
Ras	B
-dependent	O
signaling	O
pathways	O
which	O
lead	O
to	O
NFAT	B
activation	O
.	O
A	O
novel	O
transcription	B
factor	I
regulates	O
expression	O
of	O
the	O
vacuolar	B
H+-ATPase	I
B2	I
subunit	I
through	O
AP-2	O
sites	O
during	O
monocytic	O
differentiation	O
.	O
During	O
monocyte	O
-	O
to	O
-	O
macrophage	O
differentiation	O
,	O
the	O
cellular	O
content	O
of	O
vacuolar	B
H+-ATPase	I
(	O
V	B
-	I
ATPase	I
)	O
increases	O
more	O
than	O
4-fold	O
.	O
We	O
have	O
shown	O
previously	O
that	O
amplified	O
expression	O
of	O
the	O
B2	B
subunit	I
of	O
the	O
V	B
-	I
ATPase	I
occurs	O
solely	O
by	O
increased	O
transcription	O
,	O
and	O
that	O
the	O
5'-untranslated	O
region	O
of	O
the	O
B2	O
gene	O
,	O
containing	O
multiple	O
consensus	O
binding	O
sites	O
for	O
the	O
transcription	B
factors	I
AP-2	B
and	O
Sp1	B
,	O
is	O
required	O
for	O
this	O
expression	O
.	O
The	O
present	O
study	O
demonstrates	O
that	O
AP-2	O
binding	O
sequences	O
are	O
essential	O
for	O
increased	O
transcription	O
from	O
the	O
B2	O
promoter	O
during	O
monocyte	O
-	O
macrophage	O
differentiation	O
and	O
that	O
AP-2	B
,	O
expressed	O
exogenously	O
in	O
THP-1	O
and	O
other	O
cells	O
,	O
activates	O
transcription	O
from	O
the	O
B2	O
promoter	O
.	O
In	O
mobility	O
shift	O
assays	O
,	O
a	O
nuclear	B
factor	I
from	O
THP-1	O
and	O
U-937	O
cells	O
was	O
identified	O
that	O
binds	O
to	O
several	O
AP-2	O
response	O
elements	O
within	O
the	O
B2	O
promoter	O
,	O
but	O
does	O
not	O
react	O
with	O
AP-2	B
antibodies	I
,	O
and	O
has	O
a	O
DNA	O
sequence	O
binding	O
affinity	O
profile	O
that	O
differs	O
from	O
AP-2	B
.	O
These	O
findings	O
suggest	O
that	O
a	O
novel	O
AP-2-like	B
transcription	I
factor	I
is	O
responsible	O
for	O
V	B
-	I
ATPase	I
B	I
subunit	I
amplification	O
during	O
monocyte	O
differentiation	O
.	O
Elf-2	B
,	O
a	O
rhombotin-2	B
binding	I
ets	I
transcription	I
factor	I
:	O
discovery	O
and	O
potential	O
role	O
in	O
T	O
cell	O
leukemia	O
.	O
Rhombotin-2	O
(	O
RBTN-2	O
)	O
is	O
a	O
proto	O
-	O
oncogene	O
only	O
in	O
the	O
context	O
of	O
T	O
lymphocytes	O
.	O
We	O
postulated	O
that	O
the	O
oncogenic	O
effect	O
of	O
RBTN-2	B
in	O
T	O
cells	O
is	O
likely	O
mediated	O
by	O
binding	B
protein	I
(	O
s	O
)	O
with	O
T	O
cell	O
-	O
specific	O
expression	O
.	O
By	O
screening	O
a	O
T	O
cell	O
cDNA	O
library	O
,	O
we	O
identified	O
a	O
novel	B
ets	I
transcription	I
factor	I
that	O
binds	O
RBTN-2	B
.	O
This	O
protein	O
was	O
named	O
elf-2	B
because	O
its	O
DNA	B
-	I
binding	I
domain	I
is	O
virtually	O
identical	O
to	O
that	O
of	O
ets	B
family	I
member	I
elf-1	B
.	O
Northern	O
analyses	O
showed	O
similar	O
levels	O
of	O
two	O
elf-2	O
transcripts	O
(	O
3.5	O
kb	O
and	O
3.8	O
kb	O
)	O
in	O
all	O
tissues	O
except	O
thymus	O
.	O
Thymocytes	O
expressed	O
four-	O
to	O
10-fold	O
greater	O
amounts	O
of	O
the	O
3.5	O
kb	O
transcript	O
than	O
other	O
tissues	O
.	O
Sequence	O
analyses	O
of	O
cDNA	O
clones	O
indicated	O
that	O
these	O
transcripts	O
encode	O
proteins	O
differing	O
only	O
at	O
their	O
amino	B
termini	I
,	O
and	O
likely	O
represent	O
alternatively	O
spliced	O
isoforms	O
.	O
These	O
isoforms	O
(	O
elf-2a	B
and	O
elf-2b	B
)	O
contain	O
identical	O
RBTN-2	B
binding	I
regions	I
and	O
DNA	B
-	I
binding	I
domains	I
.	O
Elf-2b	B
lacks	O
a	O
putative	B
transactivation	I
domain	I
.	O
The	O
expression	O
patterns	O
suggest	O
that	O
RBTN-2	B
normally	O
interacts	O
equally	O
with	O
elf-2a	B
and	O
elf-2b	B
.	O
In	O
contrast	O
,	O
when	O
RBTN-2	B
is	O
inappropriately	O
expressed	O
in	O
T	O
cells	O
,	O
RBTN-2	B
would	O
interact	O
predominantly	O
with	O
elf-2b	B
;	O
this	O
interaction	O
may	O
lead	O
to	O
T	O
cell	O
proliferation	O
.	O
V3	B
loop	I
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
suppresses	O
interleukin	B
2	I
-induced	O
T	O
cell	O
growth	O
[	O
published	O
erratum	O
appears	O
in	O
AIDS	O
Res	O
Hum	O
Retroviruses	O
1997	O
May	O
1	O
;	O
13	O
(	O
7	O
)	O
:	O
633	O
]	O
We	O
tested	O
the	O
effect	O
of	O
three	O
linear	O
or	O
two	O
loop	O
peptides	O
derived	O
from	O
the	O
V3	B
region	I
of	O
the	O
HTLV	O
-	O
III	O
BH10	O
clone	O
or	O
the	O
SF2	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
on	O
IL-2	B
-driven	O
T	O
cell	O
proliferation	O
.	O
V3-BH10	B
,	O
which	O
consists	O
of	O
42	B
amino	I
acids	I
and	O
has	O
a	O
loop	B
structure	I
,	O
suppressed	O
IL-2	B
-driven	O
proliferation	O
of	O
all	O
IL-2-dependent	O
cells	O
[	O
Kit225	O
,	O
ED-40515	O
(	O
+	O
)	O
,	O
KT-3	O
,	O
7-day	O
PHA	O
-	O
blasts	O
,	O
and	O
fresh	O
peripheral	O
blood	O
mononuclear	O
cells	O
]	O
tested	O
,	O
whereas	O
it	O
did	O
not	O
suppress	O
the	O
cell	O
growth	O
of	O
IL-2-independent	O
cell	O
lines	O
(	O
Hut102	O
,	O
Molt-4	O
,	O
and	O
Jurkat	O
)	O
.	O
This	O
suppressive	O
effect	O
was	O
also	O
seen	O
in	O
IL-2	B
-driven	O
cell	O
growth	O
of	O
CD8-positive	O
lymphocytes	O
purified	O
from	O
7-day	O
PHA	O
-	O
blasts	O
,	O
indicating	O
that	O
CD4	B
molecules	I
were	O
not	O
required	O
for	O
the	O
suppression	O
.	O
The	O
treatment	O
with	O
anti	B
-	I
V3	I
loop	I
monoclonal	I
antibody	I
(	O
902	B
antibody	I
)	O
completely	O
abolished	O
the	O
suppressive	O
effect	O
of	O
V3-BH10	B
.	O
In	O
addition	O
,	O
V3-BH10	B
generated	O
the	O
arrest	O
of	O
Kit225	O
cells	O
and	O
also	O
purified	O
CD8-positive	O
lymphocytes	O
in	O
G1	O
phase	O
in	O
the	O
presence	O
of	O
IL-2	B
.	O
Neither	O
chromatin	O
condensation	O
nor	O
DNA	O
fragmentation	O
was	O
detected	O
in	O
Kit225	O
cells	O
cultured	O
with	O
V3-BH10	B
and	O
IL-2	B
.	O
V3-BH10	B
neither	O
blocked	O
radiolabeled	O
IL-2	B
binding	O
to	O
IL-2	B
receptors	I
nor	O
affected	O
tyrosyl	O
phosphorylation	O
of	O
several	O
cellular	B
proteins	I
(	O
p120	B
,	O
p98	B
,	O
p96	B
,	O
p54	B
,	O
and	O
p38	B
)	O
,	O
which	O
is	O
immediately	O
induced	O
by	O
IL-2	B
stimulation	O
.	O
However	O
,	O
V3-BH10	B
enhanced	O
IL-2	B
-induced	O
mRNA	O
expression	O
of	O
c	O
-	O
fos	O
but	O
not	O
c	O
-	O
myc	O
or	O
junB	O
.	O
Thus	O
,	O
the	O
binding	O
of	O
V3	B
loop	I
of	O
gp120	B
to	O
the	O
cell	O
surface	O
molecule	O
(	O
s	O
)	O
appears	O
to	O
affect	O
intracellular	O
IL-2	B
signaling	O
,	O
which	O
leads	O
to	O
the	O
suppression	O
of	O
IL-2	B
-induced	O
T	O
cell	O
growth	O
Differential	O
interaction	O
of	O
nuclear	O
factors	O
with	O
the	O
PRE	O
-	O
I	O
enhancer	O
element	O
of	O
the	O
human	O
IL-4	O
promoter	O
in	O
different	O
T	O
cell	O
subsets	O
.	O
The	O
immunomodulatory	O
cytokine	B
IL-4	B
affects	O
cells	O
of	O
most	O
hemopoietic	O
lineages	O
.	O
IL-4	B
is	O
secreted	O
by	O
activated	O
Th2	O
but	O
not	O
Th1	O
cells	O
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
immune	O
response	O
by	O
modulating	O
the	O
differentiation	O
of	O
naive	O
Th	O
cells	O
toward	O
the	O
Th2	O
phenotype	O
.	O
We	O
have	O
previously	O
identified	O
an	O
enhancer	O
element	O
,	O
PRE	O
-	O
I	O
,	O
that	O
is	O
essential	O
for	O
the	O
function	O
of	O
the	O
human	O
IL-4	O
promoter	O
.	O
To	O
investigate	O
the	O
mechanisms	O
responsible	O
for	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
IL-4	B
gene	O
,	O
we	O
analyzed	O
nuclear	B
factors	I
binding	O
to	O
the	O
PRE	O
-	O
I	O
site	O
and	O
compared	O
the	O
binding	O
activities	O
of	O
these	O
factors	O
to	O
the	O
IL-4	B
promoter	O
of	O
Th1	O
and	O
Th2	O
cells	O
.	O
We	O
show	O
that	O
PRE	O
-	O
I	O
interacts	O
with	O
PMA	O
-and	O
PMA	O
/	O
ionomycin	O
-	O
inducible	O
,	O
cyclosporin	O
A	O
-	O
sensitive	O
nuclear	B
factors	I
.	O
Using	O
anti	B
-	I
C	I
/	I
EBPbeta	I
(	O
NF	B
-	I
IL6	I
)	O
,	O
anti	B
-	I
C	I
/	I
EBPdelta	I
(	O
NF	B
-	I
IL6beta	I
)	O
,	O
anti	B
-	I
NF	I
-	I
ATc	I
,	O
anti	B
-	I
NF	I
-	I
ATp	I
,	O
anti	B
-	I
Fos	I
,	O
and	O
anti	B
-	I
Jun	I
Abs	I
we	O
demonstrate	O
that	O
the	O
previously	O
identified	O
PRE	B
-	I
I	I
binding	I
factor	I
POS-1	B
is	O
composed	O
of	O
different	O
transcription	B
factors	I
in	O
different	O
Th	O
cell	O
subsets	O
.	O
In	O
the	O
IL-4-producing	O
Th0-like	O
human	O
Jurkat	O
and	O
mouse	O
EL-4	O
cells	O
,	O
POS-1	B
(	O
designated	O
POS-1a	B
)	O
contains	O
NF	B
-	I
IL6beta	I
and	O
Jun	B
.	O
In	O
the	O
mouse	O
Th2	O
D10	O
cells	O
and	O
in	O
the	O
human	O
Th2	O
clones	O
,	O
POS-1	B
(	O
designated	O
POS-1b	B
)	O
contains	O
NF	B
-	I
IL6beta	I
,	O
Jun	B
,	O
and	O
NF	B
-	I
ATc	I
/	I
p	I
.	O
In	O
contrast	O
,	O
POS-1	B
was	O
not	O
found	O
in	O
nuclear	O
extracts	O
of	O
human	O
Th1	O
clones	O
.	O
These	O
findings	O
suggest	O
that	O
PRE	O
-	O
I	O
may	O
play	O
a	O
role	O
in	O
the	O
differential	O
regulation	O
of	O
IL-4	O
gene	O
expression	O
levels	O
.	O
Induction	O
of	O
vascular	B
cell	I
adhesion	I
molecule-1	I
by	O
low	B
-	I
density	I
lipoprotein	I
.	O
Low	B
-	I
density	I
lipoprotein	I
(	O
LDL	B
)	O
is	O
a	O
well	O
-	O
established	O
risk	O
factor	O
for	O
atherosclerosis	O
.	O
When	O
endothelial	O
cells	O
are	O
incubated	O
with	O
this	O
lipoprotein	O
in	O
pathophysiologic	O
amounts	O
,	O
the	O
cells	O
are	O
activated	O
.	O
Among	O
the	O
documented	O
cellular	O
responses	O
to	O
LDL	B
is	O
increased	O
recruitment	O
of	O
monocytes	O
,	O
which	O
are	O
believed	O
to	O
play	O
a	O
major	O
role	O
in	O
promoting	O
intimal	O
plaque	O
formation	O
.	O
The	O
findings	O
presented	O
here	O
link	O
an	O
atheogenic	B
lipoprotein	I
,	O
LDL	B
,	O
with	O
the	O
induction	O
of	O
an	O
adhesion	O
molecule	O
important	O
in	O
atherogenesis	O
Human	O
LDL	B
induces	O
the	O
vascular	B
cell	I
adhesion	I
molecule-1	I
(	O
VCAM-1	B
)	O
transcriptionally	O
with	O
an	O
increase	O
in	O
mRNA	O
levels	O
through	O
activation	O
of	O
the	O
VCAM	O
promoter	O
.	O
This	O
effect	O
is	O
blocked	O
by	O
anti	B
-	I
VCAM	I
antibodies	I
.	O
After	O
a	O
2-day	O
incubation	O
in	O
LDL	B
,	O
the	O
binding	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
which	O
is	O
believed	O
to	O
be	O
a	O
key	O
oxidative	O
-	O
stress	O
sensor	O
for	O
VCAM	B
regulation	O
,	O
remains	O
at	O
basal	O
level	O
.	O
In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
AP-1	B
and	O
GATA	B
,	O
on	O
the	O
other	O
hand	O
,	O
are	O
increased	O
by	O
LDL	B
.	O
Thus	O
,	O
a	O
component	O
of	O
LDL	B
-enhanced	O
endothelial	O
recruitment	O
of	O
monocytes	O
is	O
attributed	O
to	O
VCAM-1	B
expression	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
through	O
AP-1	B
and	O
GATA	B
.	O
These	O
data	O
identify	O
LDL	B
as	O
a	O
VCAM	B
-inducer	O
possibly	O
distinct	O
from	O
cytokines	B
and	O
endotoxin	B
.	O
The	O
NF	B
-	I
kappa	I
B	I
inhibitor	O
,	O
tepoxalin	O
,	O
suppresses	O
surface	O
expression	O
of	O
the	O
cell	B
adhesion	I
molecules	I
CD62E	B
,	O
CD11b	B
/	I
CD18	I
and	O
CD106	B
.	O
Tepoxalin	O
,	O
a	O
dual	O
enzyme	O
inhibitor	O
of	O
cyclooxygenase	B
and	O
5-lipoxygenase	B
has	O
been	O
shown	O
to	O
inhibit	O
T	O
-	O
cell	O
activation	O
.	O
Its	O
immunosuppressive	O
property	O
is	O
distinct	O
from	O
cyclosporin	O
because	O
only	O
tepoxalin	O
,	O
but	O
not	O
cyclosporin	O
,	O
suppresses	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
Here	O
we	O
report	O
that	O
tepoxalin	O
selectively	O
inhibits	O
intercellular	B
adhesion	I
molecule-1	I
(	B
ICAM-1	I
,	I
CD54	I
)	I
/MAC-1	I
(	O
CD11b	B
/	I
CD18	I
)	O
dependent	O
adhesion	O
of	O
polymorphonuclear	O
cells	O
to	O
IL-1	B
activated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O
The	O
mechanism	O
of	O
inhibition	O
is	O
related	O
to	O
the	O
surface	O
expression	O
of	O
several	O
cell	O
adhesion	B
molecules	I
.	O
Flow	O
cytometry	O
analyses	O
on	O
cultured	O
cells	O
that	O
were	O
treated	O
with	O
tepoxalin	O
or	O
antisense	O
oligonucleotides	O
to	O
the	O
P65	B
/	I
p50	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
then	O
stimulated	O
with	O
PMA	O
,	O
revealed	O
a	O
reduced	O
expression	O
of	O
CD11b	B
/	I
CD18	I
on	O
monocytic	O
HL60	O
cells	O
,	O
and	O
endothelial	B
adhesion	I
molecule-1	I
(	O
CD62E	B
)	O
and	O
vascular	B
adhesion	I
molecule-1	I
(	O
CD106	B
)	O
on	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O
Expression	O
of	O
other	O
adhesion	B
molecules	I
such	O
as	O
lymphocyte	B
function	I
associated	I
-	I
antigen-1	I
(	O
CD11a	B
/	I
CD18	I
)	O
and	O
CD54	B
were	O
unaffected	O
.	O
Tepoxalin	O
also	O
inhibited	O
the	O
secretion	O
of	O
a	O
NF	B
-	I
kappa	I
B	I
regulated	I
chemokine	I
,	O
IL-8	B
,	O
a	O
known	O
inducer	O
of	O
CD11b	B
/	I
CD18	I
expression	O
.	O
Thus	O
the	O
suppression	O
of	O
CD11b	B
/	I
CD18	I
expression	O
by	O
tepoxalin	O
may	O
involve	O
IL-8	B
.	O
Our	O
results	O
suggest	O
that	O
by	O
inhibiting	O
NF	B
-	I
kappa	I
B	I
activation	O
,	O
surface	O
expression	O
of	O
several	O
adhesion	B
molecules	I
can	O
be	O
modulated	O
and	O
that	O
tepoxalin	O
may	O
be	O
useful	O
in	O
treating	O
selected	O
adhesion	O
mediated	O
events	O
such	O
as	O
leukocyte	O
migration	O
or	O
atherosclerotic	O
plaque	O
formation	O
.	O
Rapid	O
Ca2	O
+	O
-mediated	O
activation	O
of	O
Rap1	B
in	O
human	O
platelets	O
.	O
Rap1	B
is	O
a	O
small	O
,	O
Ras	B
-	I
like	I
GTPase	I
whose	O
function	O
and	O
regulation	O
are	O
still	O
largely	O
unknown	O
.	O
We	O
have	O
developed	O
a	O
novel	O
assay	O
to	O
monitor	O
the	O
active	O
,	O
GTP	B
-	I
bound	I
form	I
of	O
Rap1	B
based	O
on	O
the	O
differential	O
affinity	O
of	O
Rap1GTP	B
and	O
Rap1GDP	B
for	O
the	O
Rap	B
binding	I
domain	I
of	O
RalGDS	B
(	O
RBD	B
)	O
.	O
Stimulation	O
of	O
blood	O
platelets	O
with	O
alpha	B
-	I
thrombin	I
or	O
other	O
platelet	O
activators	O
caused	O
a	O
rapid	O
and	O
strong	O
induction	O
of	O
Rap1	B
that	O
associated	O
with	O
RBD	B
in	O
vitro	O
.	O
Binding	O
to	O
RBD	B
increased	O
from	O
undetectable	O
levels	O
in	O
resting	O
platelets	O
to	O
>	O
50	O
%	O
of	O
total	O
Rap1	B
within	O
30	O
s	O
after	O
stimulation	O
.	O
An	O
increase	O
in	O
the	O
intracellular	O
Ca2	O
+	O
concentration	O
is	O
both	O
necessary	O
and	O
sufficient	O
for	O
Rap1	B
activation	O
since	O
it	O
was	O
induced	O
by	O
agents	O
that	O
increase	O
intracellular	O
Ca2	O
+	O
and	O
inhibited	O
by	O
a	O
Ca2	O
+	O
-chelating	O
agent	O
.	O
Neither	O
inhibition	O
of	O
translocation	O
of	O
Rap1	B
to	O
the	O
cytoskeleton	O
nor	O
inhibition	O
of	O
platelet	O
aggregation	O
affected	O
thrombin	B
-induced	O
activation	O
of	O
Rap1	B
.	O
In	O
contrast	O
,	O
prostaglandin	O
I2	O
(	O
PGI2	O
)	O
,	O
a	O
strong	O
negative	O
regulator	O
of	O
platelet	O
function	O
,	O
inhibited	O
agonist	O
-	O
induced	O
as	O
well	O
as	O
Ca2	O
+	O
-induced	O
activation	O
of	O
Rap1	B
.	O
From	O
our	O
results	O
,	O
we	O
conclude	O
that	O
Rap1	B
activation	O
in	O
platelets	O
is	O
an	O
important	O
common	O
event	O
in	O
early	O
agonist	O
-	O
induced	O
signalling	O
,	O
and	O
that	O
this	O
activation	O
is	O
mediated	O
by	O
an	O
increased	O
intracellular	O
Ca2	O
+	O
concentration	O
Characterization	O
of	O
a	O
mutant	O
cell	O
line	O
that	O
does	O
not	O
activate	O
NF	B
-	I
kappaB	I
in	O
response	O
to	O
multiple	O
stimuli	O
.	O
Numerous	O
genes	O
required	O
during	O
the	O
immune	O
or	O
inflammation	O
response	O
as	O
well	O
as	O
the	O
adhesion	O
process	O
are	O
regulated	O
by	O
nuclear	B
factor	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
.	O
Associated	O
with	O
its	O
inhibitor	O
,	O
I	B
kappaB	I
,	O
NF	B
-	I
kappaB	I
resides	O
as	O
an	O
inactive	O
form	O
in	O
the	O
cytoplasm	O
.	O
Upon	O
stimulation	O
by	O
various	O
agents	O
,	O
I	B
kappaB	I
is	O
proteolyzed	O
and	O
NF	B
-	I
kappaB	I
translocates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
activates	O
its	O
target	O
genes	O
.	O
The	O
transduction	O
pathways	O
that	O
lead	O
to	O
I	B
kappaB	I
inactivation	O
remain	O
poorly	O
understood	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
a	O
cellular	O
mutant	O
,	O
the	O
70	O
/	O
Z3-derived	O
1.3E2	O
murine	O
pre	O
-	O
B	O
cell	O
line	O
,	O
that	O
does	O
not	O
activate	O
NF	B
-	I
kappaB	I
in	O
response	O
to	O
several	O
stimuli	O
.	O
We	O
demonstrate	O
that	O
upon	O
stimulation	O
by	O
lipopolysaccharide	O
,	O
Taxol	O
,	O
phorbol	O
myristate	O
acetate	O
,	O
interleukin-1	B
,	O
or	O
double	O
-	O
stranded	O
RNA	O
,	O
I	B
kappaB	I
alpha	I
is	O
not	O
degraded	O
,	O
as	O
a	O
result	O
of	O
an	O
absence	O
of	O
induced	O
phosphorylation	O
on	O
serines	O
32	O
and	O
36	O
.	O
Neither	O
a	O
mutation	O
in	O
I	B
kappaB	I
alpha	I
nor	O
a	O
mutation	O
in	O
p50	B
or	O
relA	B
,	O
the	O
two	O
major	O
subunits	O
of	O
NF	B
-	I
kappaB	I
in	O
this	O
cell	O
line	O
,	O
accounts	O
for	O
this	O
phosphorylation	O
defect	O
.	O
As	O
well	O
as	O
culminating	O
in	O
the	O
inducible	O
phosphorylation	O
of	O
I	B
kappaB	I
alpha	O
on	O
serines	O
32	O
and	O
36	O
,	O
all	O
the	O
stimuli	O
that	O
are	O
inactive	O
on	O
1.3E2	O
cells	O
exhibit	O
a	O
sensitivity	O
to	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
.	O
In	O
contrast	O
,	O
stimuli	O
such	O
as	O
hyperosmotic	O
shock	O
or	O
phosphatase	O
inhibitors	O
,	O
which	O
use	O
PDTC	O
-	O
insensitive	O
pathways	O
,	O
induce	O
I	B
kappaB	I
alpha	O
degradation	O
in	O
1.3E2	O
.	O
Analysis	O
of	O
the	O
redox	O
status	O
of	O
1.3E2	O
does	O
not	O
reveal	O
any	O
difference	O
from	O
wild	O
-	O
type	O
70Z	O
/	O
3	O
.	O
We	O
also	O
report	O
that	O
the	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
(	I
HTLV-1	I
)	I
-derived	I
Tax	I
trans	I
-	I
activator	I
induces	O
NF	B
-	I
kappaB	I
activity	O
in	O
1.3E2	O
,	O
suggesting	O
that	O
this	O
viral	O
protein	O
does	O
not	O
operate	O
via	O
the	O
defective	O
pathway	O
.	O
Finally	O
,	O
we	O
show	O
that	O
two	O
other	O
I	B
kappaB	I
molecules	I
,	O
I	B
kappaB	I
beta	I
and	O
the	O
recently	O
identified	O
I	B
kappaB	I
epsilon	I
,	O
are	O
not	O
degraded	O
in	O
the	O
1.3E2	O
cell	O
line	O
following	O
stimulation	O
.	O
Our	O
results	O
demonstrate	O
that	O
1.3E2	O
is	O
a	O
cellular	B
transduction	I
mutant	I
exhibiting	O
a	O
defect	O
in	O
a	O
step	O
that	O
is	O
required	O
by	O
several	O
different	O
stimuli	O
to	O
activate	O
NF	B
-	I
kappaB	I
.	O
In	O
addition	O
,	O
this	O
analysis	O
suggests	O
a	O
common	O
step	O
in	O
the	O
signaling	O
pathways	O
that	O
trigger	O
I	B
kappaB	I
alpha	I
,	O
I	B
kappaB	I
beta	I
,	O
and	O
I	B
kappaB	I
epsilon	I
degradation	O
.	O
Transcription	O
mediated	O
by	O
NFAT	B
is	O
highly	O
inducible	O
in	O
effector	O
CD4	O
+	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
but	O
not	O
in	O
Th1	O
cells	O
.	O
Transcriptional	B
factors	I
of	O
the	O
NFAT	B
family	I
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
several	O
cytokine	O
genes	O
during	O
the	O
immune	O
response	O
,	O
such	O
as	O
the	O
genes	O
for	O
interleukin	B
2	I
(	O
IL-2	B
)	O
and	O
IL-4	B
,	O
among	O
others	O
.	O
Upon	O
antigen	O
stimulation	O
,	O
precursor	O
CD4	O
+	O
T	O
helper	O
(	O
pTh	O
)	O
cells	O
proliferate	O
and	O
differentiate	O
into	O
two	O
populations	O
of	O
effector	O
cells	O
(	O
eTh1	O
and	O
eTh2	O
)	O
,	O
each	O
one	O
expressing	O
a	O
specific	O
pattern	O
of	O
cytokines	B
that	O
distinguishes	O
them	O
from	O
their	O
precursors	O
.	O
eTh2	O
cells	O
are	O
the	O
major	O
source	O
of	O
IL-4	B
,	O
while	O
gamma	B
interferon	I
is	O
produced	O
by	O
eTh1	O
cells	O
.	O
Here	O
we	O
have	O
used	O
reporter	O
transgenic	O
mice	O
to	O
show	O
that	O
DNA	O
binding	O
and	O
transcriptional	O
activities	O
of	O
NFAT	B
are	O
transiently	O
induced	O
during	O
the	O
differentiation	O
of	O
pTh	O
cells	O
into	O
either	O
eTh1	O
or	O
eTh2	O
cells	O
to	O
mediate	O
the	O
expression	O
of	O
IL-2	B
as	O
a	O
common	O
growth	O
factor	O
in	O
both	O
pathways	O
.	O
However	O
,	O
although	O
NFAT	B
DNA	O
binding	O
is	O
similarly	O
induced	O
in	O
both	O
eTh1	O
and	O
eTh2	O
cells	O
upon	O
antigen	O
stimulation	O
,	O
only	O
the	O
NFAT	B
complexes	I
present	O
in	O
eTh2	O
cells	O
are	O
able	O
to	O
mediate	O
high	O
-	O
level	O
transcription	O
,	O
and	O
relatively	O
little	O
NFAT	B
transcriptional	O
activity	O
was	O
induced	O
in	O
eTh1	O
cells	O
.	O
In	O
contrast	O
to	O
activated	O
pTh	O
cells	O
,	O
neither	O
eTh1	O
nor	O
eTh2	O
cells	O
produced	O
significant	O
IL-2	B
upon	O
stimulation	O
,	O
but	O
the	O
high	O
levels	O
of	O
NFAT	B
transcriptional	O
activities	O
directly	O
correlate	O
with	O
the	O
IL-4	B
production	O
induced	O
in	O
response	O
to	O
antigen	O
stimulation	O
in	O
eTh2	O
cells	O
.	O
These	O
data	O
suggest	O
that	O
activated	O
NFAT	B
is	O
involved	O
in	O
the	O
effector	O
function	O
of	O
eTh2	O
cells	O
and	O
that	O
the	O
failure	O
of	O
eTh1	O
cells	O
to	O
produce	O
IL-4	B
in	O
response	O
to	O
an	O
antigen	O
is	O
due	O
,	O
at	O
least	O
partially	O
,	O
to	O
a	O
failure	O
to	O
induce	O
high	O
-	O
level	O
transcription	O
of	O
the	O
IL-4	O
gene	O
by	O
NFAT	B
.	O
Regulation	O
of	O
NFAT	B
could	O
be	O
therefore	O
a	O
critical	O
element	O
in	O
the	O
polarization	O
to	O
eTh1	O
or	O
eTh2	O
.	O
Constitutive	O
expression	O
of	O
p50	B
homodimer	I
in	O
freshly	O
isolated	O
human	O
monocytes	O
decreases	O
with	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
:	O
a	O
possible	O
mechanism	O
influencing	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
monocytes	O
and	O
mature	O
macrophages	O
.	O
Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replicates	O
more	O
efficiently	O
in	O
vitro	O
in	O
differentiated	O
macrophages	O
than	O
in	O
freshly	O
isolated	O
monocytes	O
.	O
We	O
investigated	O
whether	O
this	O
may	O
be	O
partly	O
explained	O
by	O
changes	O
in	O
expression	O
of	O
NF	B
-	I
kappaB	I
with	O
monocyte	O
differentiation	O
.	O
We	O
demonstrated	O
that	O
constitutive	O
expression	O
of	O
NF	B
-	I
kappaB	I
in	O
primary	O
human	O
monocytes	O
changed	O
significantly	O
with	O
differentiation	O
in	O
vitro	O
to	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
and	O
differentiation	O
in	O
vivo	O
to	O
alveolar	O
macrophages	O
(	O
AMs	O
)	O
.	O
Freshly	O
isolated	O
monocytes	O
constitutively	O
expressed	O
high	O
levels	O
of	O
transcriptionally	B
inactive	I
p50	I
homodimer	I
which	O
decreased	O
with	O
time	O
in	O
culture	O
in	O
favor	O
of	O
the	O
transcriptionally	O
active	O
p50	B
/	I
p65	I
and	I
p50	I
/	I
RelB	I
heterodimers	I
.	O
As	O
in	O
MDMs	O
,	O
AMs	O
constitutively	O
expressed	O
p50	B
/	I
p65	I
and	O
p50	B
/	I
RelB	I
although	O
at	O
lower	O
levels	O
.	O
HIV	O
infection	O
of	O
fresh	O
monocytes	O
failed	O
to	O
induce	O
p50	B
/	I
p65	I
as	O
seen	O
in	O
MDMs	O
.	O
The	O
replacement	O
of	O
p50	B
homodimers	I
with	O
transcriptionally	O
active	O
heterodimers	O
following	O
time	O
in	O
culture	O
may	O
partially	O
explain	O
the	O
progressive	O
increase	O
in	O
susceptibility	O
of	O
monocytes	O
to	O
HIV	O
infection	O
during	O
in	O
vitro	O
culture	O
.	O
The	O
change	O
in	O
NF	B
-	I
kappaB	I
components	I
with	O
monocyte	O
differentiation	O
in	O
vivo	O
may	O
also	O
explain	O
the	O
different	O
transcriptional	O
activities	O
of	O
these	O
cell	O
populations	O
in	O
HIV	O
-	O
infected	O
individuals	O
.	O
NF	B
-	I
kappa	I
B	I
-independent	O
suppression	O
of	O
HIV	O
expression	O
by	O
ascorbic	O
acid	O
.	O
Ascorbic	O
acid	O
(	O
ascorbate	O
or	O
vitamin	O
C	O
)	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
induction	O
of	O
HIV	O
in	O
latently	O
infected	O
T	O
lymphocytic	O
cells	O
following	O
stimulation	O
with	O
a	O
tumor	O
promoter	O
(	O
PMA	O
)	O
and	O
inflammatory	B
cytokine	I
(	O
TNF	B
-	I
alpha	I
)	O
.	O
To	O
assess	O
whether	O
this	O
inhibition	O
was	O
mediated	O
via	O
modulation	O
of	O
the	O
cellular	B
transcription	I
factor	I
,	O
NF	B
-	I
kappa	I
B	I
,	O
we	O
carried	O
out	O
gel	O
shift	O
analysis	O
on	O
nuclear	O
extracts	O
prepared	O
under	O
different	O
conditions	O
of	O
cell	O
stimulation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
ascorbate	O
,	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
,	O
or	O
zidovudine	O
(	O
AZT	O
)	O
.	O
Pretreatment	O
of	O
ACH-2	O
T	O
cells	O
by	O
NAC	O
followed	O
by	O
stimulation	O
with	O
PMA	O
,	O
TNF	B
-	I
alpha	I
,	O
or	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
resulted	O
in	O
strong	O
suppression	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
In	O
contrast	O
,	O
neither	O
ascorbate	O
nor	O
AZT	O
affected	O
NF	B
-	I
kappa	I
B	I
activity	O
under	O
all	O
three	O
induction	O
conditions	O
in	O
the	O
ACH-2	O
cell	O
line	O
.	O
Ascorbate	O
and	O
AZT	O
also	O
had	O
no	O
effect	O
on	O
NF	B
-	I
kappa	I
B	I
activation	O
following	O
TNF	O
-	O
alpha-	O
or	O
PMA	O
-	O
induced	O
stimulation	O
of	O
U1	O
promonocytic	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
the	O
molecular	O
mechanism	O
of	O
HIV	O
inhibition	O
by	O
ascorbate	O
is	O
not	O
mediated	O
via	O
NF	B
-	I
kappa	I
B	I
inhibition	O
,	O
unlike	O
that	O
seen	O
with	O
other	O
antioxidants	O
.	O
c	B
-	I
Rel	I
is	O
a	O
target	O
of	O
pentoxifylline	O
-	O
mediated	O
inhibition	O
of	O
T	O
lymphocyte	O
activation	O
.	O
The	O
possible	O
clinical	O
use	O
of	O
the	O
methyl	O
xanthine	O
derivative	O
,	O
pentoxifylline	O
(	O
PF	O
)	O
,	O
for	O
the	O
treatment	O
of	O
T	O
cell	O
-	O
dependent	O
diseases	O
is	O
being	O
noted	O
with	O
increasing	O
interest	O
.	O
In	O
this	O
paper	O
,	O
we	O
studied	O
the	O
molecular	O
consequences	O
of	O
PF	O
treatment	O
during	O
lymphocyte	O
activation	O
.	O
We	O
found	O
that	O
in	O
T	O
cells	O
,	O
anti	O
-	O
CD3-induced	O
c	B
-	I
Rel	I
expression	O
was	O
blocked	O
by	O
PF	O
,	O
whereas	O
the	O
induction	O
of	O
other	O
NF	B
-	I
kappaB	I
family	I
members	I
was	O
not	O
significantly	O
affected	O
.	O
However	O
,	O
induction	O
of	O
NF	B
-	I
AT	I
,	O
which	O
has	O
the	O
same	O
signaling	O
requirements	O
as	O
c	B
-	I
Rel	I
induction	O
,	O
was	O
not	O
inhibited	O
by	O
PF	O
.	O
Among	O
genes	O
that	O
respond	O
to	O
these	O
transcription	B
factors	I
,	O
IL-2	O
mRNA	O
induction	O
was	O
suppressed	O
by	O
PF	O
,	O
whereas	O
IL-2R	O
(	O
alpha	O
)	O
chain	O
mRNA	O
induction	O
was	O
not	O
affected	O
.	O
These	O
observations	O
implicated	O
c	B
-	I
Rel	I
as	O
an	O
IL-2	B
promoter	I
factor	I
,	O
for	O
which	O
experimental	O
support	O
was	O
obtained	O
from	O
transient	O
transfection	O
experiments	O
.	O
In	O
contrast	O
with	O
the	O
observation	O
in	O
T	O
cells	O
,	O
c	B
-	I
Rel	I
induction	O
was	O
not	O
blocked	O
by	O
PF	O
in	O
B	O
cells	O
.	O
The	O
greater	O
selectivity	O
of	O
PF	O
,	O
compared	O
with	O
FK506	O
,	O
at	O
both	O
the	O
molecular	O
and	O
cellular	O
levels	O
may	O
prove	O
advantageous	O
in	O
manipulating	O
T	O
cell	O
responses	O
in	O
vivo	O
.	O
Regulation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O
Role	O
of	O
AP-1	B
,	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
,	O
and	O
Sp1	B
proteins	O
in	O
uninduced	O
and	O
lipopolysaccharide	O
-	O
induced	O
expression	O
.	O
Tissue	B
factor	I
(	O
TF	O
)	O
expression	O
by	O
peripheral	O
blood	O
monocytes	O
during	O
sepsis	O
initiates	O
intravascular	O
thrombosis	O
.	O
Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
rapidly	O
induces	O
TF	O
gene	O
transcription	O
in	O
monocytes	O
.	O
The	O
human	O
TF	O
promoter	O
contains	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
AP-1	B
,	O
c	B
-	I
Rel	I
/	I
p65	I
,	O
Egr-1	B
,	O
and	O
Sp1	B
.	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
proteins	I
have	O
been	O
shown	O
to	O
physically	O
interact	O
with	O
both	O
AP-1	B
and	I
Sp1	I
proteins	I
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
these	O
transcription	B
factors	I
in	O
uninduced	O
and	O
LPS	O
-	O
induced	O
TF	O
gene	O
expression	O
in	O
human	O
monocytic	O
THP-1	O
cells	O
.	O
Deletional	O
analysis	O
indicated	O
that	O
five	O
Sp1	O
sites	O
mediated	O
basal	O
expression	O
in	O
uninduced	O
cells	O
.	O
The	O
two	O
AP-1	O
sites	O
bound	O
c	B
-	I
Fos	I
/	I
c	I
-	I
Jun	I
heterodimers	I
in	O
both	O
unstimulated	O
and	O
LPS	O
-	O
stimulated	O
cells	O
.	O
Maximal	O
LPS	O
induction	O
of	O
the	O
TF	O
promoter	O
required	O
the	O
two	O
AP-1	B
sites	O
and	O
the	O
kappa	O
B	O
site	O
within	O
the	O
LPS	O
response	O
element	O
.	O
Disruption	O
of	O
the	O
conserved	O
spacing	O
between	O
the	O
proximal	O
AP-1	O
site	O
and	O
the	O
kappa	O
B	O
site	O
abolished	O
LPS	O
induction	O
.	O
Replacement	O
of	O
the	O
two	O
AP-1	O
sites	O
with	O
intrinsically	O
bent	O
DNA	O
partially	O
restored	O
LPS	O
induction	O
,	O
suggesting	O
an	O
additional	O
structural	O
role	O
for	O
the	O
AP-1	O
sites	O
.	O
Synergistic	O
transactivation	O
of	O
the	O
LPS	O
response	O
element	O
in	O
Drosophila	O
Schneider	O
cells	O
by	O
coexpression	O
of	O
c	B
-	I
Fos	I
,	O
c	B
-	I
Jun	I
,	O
c	B
-	I
Rel	I
,	O
and	O
p65	B
or	O
c	B
-	I
Jun	I
and	O
p65	B
required	O
the	O
transactivation	B
domains	I
of	O
c	B
-	I
Jun	I
and	O
p65	B
.	O
These	O
data	O
indicated	O
that	O
c	B
-	I
Fos	I
/c	B
-	I
Jun	I
,	O
c	B
-	I
Rel	I
/p65	B
,	O
and	O
Sp1	B
regulate	O
TF	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
.	O
Differentiation	O
of	O
U-937	O
promonocytic	O
cells	O
by	O
etoposide	O
and	O
ICRF-193	O
,	O
two	O
antitumour	O
DNA	B
topoisomerase	I
II	I
inhibitors	O
with	O
different	O
mechanisms	O
of	O
action	O
.	O
We	O
have	O
compared	O
the	O
action	O
on	O
U-937	O
human	O
promonocytic	O
leukemia	O
cells	O
of	O
two	O
DNA	B
topoisomerase	I
II	I
inhibitors	O
,	O
namely	O
the	O
epipodophyllotoxin	O
etoposide	O
and	O
the	O
bisdioxopiperazine	O
ICRF-193	O
.	O
One	O
hour	O
pulse	O
-	O
treatment	O
with	O
3	O
microM	O
etoposide	O
caused	O
topoisomerase	B
associated	O
,	O
primary	O
DNA	O
breakage	O
,	O
which	O
was	O
rapidly	O
followed	O
by	O
apoptosis	O
.	O
By	O
contrast	O
,	O
these	O
effects	O
were	O
not	O
observed	O
upon	O
pulse	O
-	O
treatment	O
with	O
6	O
microM	O
ICRF-193	O
.	O
However	O
,	O
continuous	O
treatments	O
with	O
subcytotoxic	O
concentrations	O
of	O
etoposide	O
(	O
0.15	O
microM	O
)	O
and	O
ICRF-193	O
(	O
0.3	O
microM	O
)	O
produced	O
several	O
similar	O
effects	O
,	O
namely	O
decreased	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
cells	O
at	O
G2	O
,	O
increase	O
in	O
cell	O
mass	O
,	O
and	O
induction	O
of	O
differentiation	O
.	O
Under	O
these	O
conditions	O
,	O
etoposide	O
produced	O
a	O
biphasic	O
activation	O
of	O
protein	B
kinase	I
C	I
,	O
which	O
consisted	O
in	O
an	O
early	O
transient	O
activation	O
(	O
from	O
hours	O
1	O
to	O
6	O
)	O
of	O
the	O
membrane	B
-	I
bound	I
enzyme	I
followed	O
by	O
a	O
later	O
activation	O
(	O
hour	O
48	O
)	O
of	O
the	O
total	O
,	O
membrane	B
-	I
bound	I
and	I
cytosolic	I
enzyme	I
.	O
By	O
contrast	O
,	O
ICRF-193	O
only	O
provoked	O
a	O
late	O
activation	O
(	O
from	O
hours	O
72	O
to	O
96	O
)	O
of	O
the	O
total	O
enzyme	O
.	O
When	O
used	O
at	O
differentiation	O
-	O
inducing	O
concentrations	O
,	O
both	O
topoisomerase	B
inhibitors	O
caused	O
a	O
great	O
stimulation	O
of	O
AP-1	B
binding	O
activity	O
,	O
with	O
maximum	O
value	O
at	O
hour	O
12	O
in	O
etoposide	O
-	O
treated	O
cells	O
and	O
at	O
hour	O
48	O
in	O
ICRF-193-treated	O
cells	O
.	O
By	O
contrast	O
,	O
the	O
binding	O
activity	O
of	O
the	O
NF	B
-	I
kappa	I
(	I
B	I
)	I
and	O
EGR-1	B
transcription	B
factors	I
was	O
little	O
affected	O
.	O
It	O
is	O
concluded	O
that	O
topoisomerase	O
II	O
inhibitors	O
may	O
induce	O
the	O
differentiation	O
of	O
promonocytic	O
cells	O
,	O
independently	O
of	O
their	O
capacity	O
to	O
cause	O
DNA	O
strand	O
breaks	O
.	O
However	O
,	O
there	O
are	O
other	O
effects	O
,	O
such	O
as	O
the	O
early	O
activation	O
of	O
protein	B
kinase	I
C	I
,	O
which	O
are	O
probably	O
derived	O
from	O
the	O
production	O
of	O
primary	O
DNA	O
breakage	O
by	O
some	O
anti-	O
topoisomerase	B
drugs	O
.	O
Selective	O
expression	O
of	O
an	O
interleukin-12	B
receptor	I
component	I
by	O
human	O
T	O
helper	O
1	O
cells	O
.	O
Interleukin-12	B
(	O
IL-12	B
)	O
,	O
a	O
heterodimeric	B
cytokine	I
produced	O
by	O
activated	O
monocytes	O
and	O
dendritic	O
cells	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
interferon	B
(	I
IFN	I
)	I
-gamma	I
production	O
and	O
in	O
the	O
generation	O
of	O
IFN	O
-	O
gamma	O
-	O
producing	O
T	O
helper	O
1	O
(	O
Th1	O
)	O
cells	O
.	O
Here	O
we	O
show	O
that	O
the	O
IL-12	B
receptor	I
(	I
IL-12R	I
)	I
beta	I
2	I
subunit	I
,	O
a	O
recently	O
cloned	O
binding	B
and	I
signal	I
transducing	I
component	I
of	O
the	O
IL-12R	B
,	O
is	O
expressed	O
on	O
human	O
Th1	O
but	O
not	O
Th2	O
clones	O
and	O
is	O
induced	O
during	O
differentiation	O
of	O
human	O
naive	O
cells	O
along	O
the	O
Th1	O
but	O
not	O
the	O
Th2	O
pathway	O
.	O
IL-12	B
and	O
type	B
I	I
but	I
not	I
type	I
II	I
interferons	I
induce	O
expression	O
of	O
the	O
IL-12R	B
beta	I
2	I
chain	I
during	O
in	O
vitro	O
T	O
cell	O
differentiation	O
after	O
antigen	O
receptor	O
triggering	O
.	O
The	O
selective	O
expression	O
and	O
regulation	O
of	O
the	O
IL-12R	B
beta	I
2	I
subunit	I
may	O
help	O
to	O
understand	O
the	O
basis	O
of	O
Th1	O
/	O
Th2	O
differentiation	O
and	O
may	O
provide	O
therapeutic	O
options	O
for	O
altering	O
the	O
Th1	O
/	O
Th2	O
balance	O
in	O
several	O
immuno	O
-	O
pathological	O
conditions	O
such	O
as	O
autoimmune	O
diseases	O
and	O
allergies	O
.	O
Activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
in	O
lipopolysaccharide	O
-	O
stimulated	O
U937	O
cells	O
.	O
During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
interacts	O
with	O
monocyte	B
/	I
macrophage	I
receptors	I
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	B
cytokines	I
.	O
Transcription	B
factor	I
NF	B
-	I
kappaB	I
is	O
crucial	O
in	O
activating	O
the	O
transcription	O
of	O
genes	O
encoding	O
proinflammatory	B
cytokines	I
.	O
In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
activation	O
of	O
NF	B
-	I
kappaB	I
by	O
LPS	O
in	O
a	O
promonocytic	O
cell	O
line	O
(	O
U937	O
)	O
followed	O
a	O
rather	O
slow	O
kinetics	O
,	O
depending	O
on	O
the	O
rate	O
of	O
IkappaB	B
-	I
alpha	I
inhibitor	O
hydrolysis	O
.	O
No	O
degradation	O
of	O
p105	B
and	I
p100	I
inhibitors	I
was	O
observed	O
under	O
these	O
conditions	O
.	O
The	O
transduction	O
pathway	O
leading	O
to	O
NF	B
-	I
kappaB	I
activation	O
in	O
U937	O
cells	O
involved	O
the	O
intracellular	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
as	O
demonstrated	O
by	O
the	O
concomitant	O
inhibitory	O
effects	O
of	O
antioxidants	O
on	O
NF	B
-	I
kappaB	I
activation	O
and	O
the	O
emission	O
of	O
a	O
fluorescent	O
probe	O
reacting	O
intracellularly	O
with	O
hydrogen	O
peroxide	O
.	O
This	O
ROS	O
pathway	O
was	O
also	O
characterized	O
by	O
the	O
use	O
of	O
other	O
inhibitors	O
.	O
This	O
finding	O
indicates	O
that	O
phospholipase	B
A2	I
and	O
5-lipoxygenase	B
are	O
also	O
involved	O
.	O
However	O
,	O
the	O
NF	B
-	I
kappaB	I
activation	O
pathway	O
involving	O
the	O
acidic	B
sphingomyelinase	I
of	O
the	O
endolysosomial	O
membrane	O
did	O
not	O
seem	O
to	O
participate	O
in	O
the	O
LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
in	O
U937	O
cells	O
.	O
Detection	O
of	O
adenovirus	O
DNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
polymerase	O
chain	O
reaction	O
assay	O
.	O
Adenovirus	O
can	O
establish	O
persistent	O
infections	O
which	O
may	O
reactivate	O
and	O
cause	O
disease	O
in	O
immunocompromised	O
hosts	O
.	O
Lymphocytes	O
have	O
been	O
postulated	O
to	O
serve	O
as	O
a	O
site	O
of	O
adenoviral	O
persistence	O
based	O
upon	O
the	O
ability	O
to	O
isolate	O
adenovirus	O
from	O
tonsils	O
and	O
to	O
detect	O
adenovirus	O
DNA	O
by	O
Southern	O
blot	O
hybridization	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O
To	O
test	O
this	O
hypothesis	O
,	O
a	O
more	O
sensitive	O
and	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
was	O
developed	O
to	O
detect	O
adenovirus	O
DNA	O
.	O
Two	O
sets	O
of	O
nested	O
primers	O
were	O
designed	O
to	O
conserved	O
sequences	O
in	O
the	O
adenovirus	O
E1A	O
and	O
hexon	O
genes	O
.	O
The	O
E1A	O
and	O
hexon	O
primers	O
amplified	O
DNA	O
from	O
representative	O
adenoviral	O
serotypes	O
in	O
all	O
six	O
adenoviral	O
groups	O
(	O
A	O
-	O
F	O
)	O
.	O
Both	O
primers	O
detected	O
a	O
single	O
copy	O
of	O
the	O
adenovirus	O
type	O
2	O
genome	O
but	O
were	O
less	O
sensitive	O
for	O
the	O
group	O
B	O
type	O
35	O
.	O
None	O
of	O
33	O
PBMC	O
specimens	O
from	O
healthy	O
adults	O
and	O
only	O
one	O
of	O
40	O
pediatric	O
samples	O
was	O
positive	O
(	O
at	O
a	O
low	O
level	O
)	O
for	O
adenovirus	O
DNA	O
by	O
nested	O
PCR	O
assay	O
.	O
In	O
comparison	O
,	O
PBMC	O
from	O
two	O
children	O
with	O
fatal	O
adenoviral	O
infection	O
were	O
both	O
strongly	O
positive	O
for	O
adenovirus	O
DNA	O
.	O
It	O
is	O
concluded	O
that	O
,	O
in	O
contrast	O
to	O
a	O
previous	O
study	O
,	O
PBMC	O
are	O
not	O
a	O
common	O
site	O
of	O
persistent	O
group	O
C	O
adenoviral	O
infection	O
.	O
In	O
addition	O
,	O
assay	O
of	O
PBMC	O
by	O
the	O
adenovirus	O
-	O
specific	O
PCR	O
may	O
help	O
detect	O
early	O
invasive	O
disease	O
and	O
warrants	O
further	O
evaluation	O
.	O
Activation	O
of	O
the	O
transcription	B
factor	I
MEF2C	B
by	O
the	O
MAP	B
kinase	I
p38	I
in	O
inflammation	O
.	O
For	O
cells	O
of	O
the	O
innate	O
immune	O
system	O
to	O
mount	O
a	O
host	O
defence	O
response	O
to	O
infection	O
,	O
they	O
must	O
recognize	O
products	O
of	O
microbial	O
pathogens	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
the	O
endotoxin	O
secreted	O
by	O
Gram	O
-	O
negative	O
bacteria	O
.	O
These	O
cellular	O
responses	O
require	O
intracellular	O
signalling	O
pathways	O
,	O
such	O
as	O
the	O
four	O
MAP	B
kinase	I
(	O
MAPK	B
)	O
pathways	O
.	O
In	O
mammalian	O
cells	O
the	O
MAPK	B
p38	I
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
responses	O
during	O
infection	O
through	O
its	O
effects	O
on	O
the	O
expression	O
of	O
proinflammatory	B
molecules	I
.	O
One	O
means	O
of	O
understanding	O
the	O
role	O
of	O
p38	B
in	O
these	O
responses	O
is	O
to	O
identify	O
proteins	O
with	O
functions	O
regulated	O
by	O
p38	B
-catalysed	O
phosphorylation	O
.	O
Here	O
we	O
demonstrate	O
a	O
link	O
between	O
the	O
p38	B
pathway	O
and	O
a	O
member	O
of	O
the	O
myocyte	B
-	I
enhancer	I
factor	I
2	I
(	I
MEF2	I
)	I
group	I
of	O
transcription	B
factors	I
.	O
We	O
found	O
that	O
in	O
monocytic	O
cells	O
,	O
LPS	O
increases	O
the	O
transactivation	O
activity	O
of	O
MEF2C	B
through	O
p38	B
-catalysed	O
phosphorylation	O
.	O
One	O
consequence	O
of	O
MEF2C	B
activation	O
is	O
increased	O
c	O
-	O
jun	O
gene	O
transcription	O
.	O
Our	O
results	O
show	O
that	O
p38	B
may	O
influence	O
host	O
defence	O
and	O
inflammation	O
by	O
maintaining	O
the	O
balance	O
of	O
c	B
-	I
Jun	I
protein	I
consumed	O
during	O
infection	O
.	O
Signal	B
transducer	I
and	I
activator	I
of	I
transcription-3	I
(	O
STAT3	B
)	O
is	O
constitutively	O
activated	O
in	O
normal	O
,	O
self	O
-	O
renewing	O
B-1	O
cells	O
but	O
only	O
inducibly	O
expressed	O
in	O
conventional	O
B	O
lymphocytes	O
[	O
see	O
comments	O
]	O
Cytokine	B
and	O
growth	B
factor	I
receptor	I
engagement	O
leads	O
to	O
the	O
rapid	O
phosphorylation	O
and	O
activation	O
of	O
latent	O
,	O
cytosolic	B
signal	I
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
STAT	I
)	I
proteins	I
,	O
which	O
then	O
translocate	O
to	O
the	O
nucleus	O
where	O
they	O
regulate	O
transcriptional	O
events	O
from	O
specific	O
promoter	O
sequences	O
.	O
STAT3	B
expression	O
in	O
particular	O
has	O
been	O
associated	O
with	O
Abl	B
,	O
Src	B
,	O
and	O
HTLV-1	O
transformation	O
of	O
normal	O
cells	O
.	O
B-1	O
lymphocytes	O
are	O
self	O
-	O
renewing	O
,	O
CD5	O
+	O
B	O
cells	O
that	O
display	O
a	O
propensity	O
for	O
malignant	O
transformation	O
and	O
are	O
the	O
normal	O
counterpart	O
to	O
human	O
chronic	O
lymphocytic	O
leukemias	O
.	O
Further	O
,	O
B-1	O
cells	O
are	O
characterized	O
by	O
aberrant	O
intracellular	O
signaling	O
,	O
including	O
hyperresponsiveness	O
to	O
phorbol	O
ester	O
PKC	O
agonists	O
.	O
Here	O
we	O
demonstrate	O
that	O
B-1	O
lymphocytes	O
constitutively	O
express	O
nuclear	B
activated	I
STAT3	I
,	O
which	O
is	O
not	O
expressed	O
by	O
unmanipulated	O
conventional	O
(	O
B-2	O
)	O
lymphocytes	O
.	O
In	O
contrast	O
,	O
STAT3	B
activation	O
is	O
induced	O
in	O
B-2	O
cells	O
after	O
antigen	O
receptor	O
engagement	O
in	O
a	O
delayed	O
fashion	O
(	O
after	O
3	O
h	O
)	O
.	O
Induction	O
of	O
STAT3	B
is	O
inhibited	O
by	O
both	O
the	O
serine	O
/	O
threonine	O
protein	O
kinase	O
inhibitor	O
H-7	O
and	O
the	O
immunosuppressive	O
drug	O
rapamycin	O
and	O
requires	O
de	O
novo	O
protein	O
synthesis	O
,	O
demonstrating	O
novel	O
coupling	O
between	O
sIg	B
and	O
STAT	B
proteins	I
that	O
differs	O
from	O
the	O
classical	O
paradigm	O
for	O
STAT	B
induction	O
by	O
cytokine	B
receptors	I
.	O
The	O
inability	O
of	O
prolonged	O
stimulation	O
of	O
conventional	O
B-2	O
cells	O
with	O
anti	B
-	I
Ig	I
,	O
a	O
treatment	O
sufficient	O
to	O
induce	O
CD5	B
expression	O
,	O
to	O
result	O
in	O
sustained	O
STAT3	B
activation	O
suggests	O
that	O
STAT3	B
is	O
a	O
specific	O
nuclear	O
marker	O
for	O
B-1	O
cells	O
.	O
Thus	O
,	O
STAT3	B
may	O
play	O
a	O
role	O
in	O
B	O
cell	O
antigen	O
-	O
specific	O
signaling	O
responses	O
,	O
and	O
its	O
constitutive	O
activation	O
is	O
associated	O
with	O
a	O
normal	O
cell	O
population	O
exhibiting	O
intrinsic	O
proliferative	O
behavior	O
.	O
Suppression	O
by	O
azelastine	O
hydrochloride	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
involved	O
in	O
generation	O
of	O
cytokines	B
and	O
nitric	O
oxide	O
.	O
The	O
influence	O
of	O
the	O
anti	O
-	O
allergy	O
agent	O
azelastine	O
hydrochloride	O
(	O
Azeptin	O
)	O
on	O
NF	B
-	I
kappa	I
B	I
activation	O
associated	O
with	O
the	O
generation	O
of	O
cytokines	B
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
was	O
investigated	O
in	O
various	O
kinds	O
of	O
human	O
and	O
mouse	O
cells	O
.	O
Azeptin	O
dose	O
-	O
dependently	O
suppressed	O
both	O
DNA	O
and	O
protein	O
synthesis	O
in	O
human	O
gingival	O
fibroblasts	O
(	O
HF	O
)	O
and	O
also	O
suppressed	O
blastogenesis	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O
Generation	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
,	O
interleukin	B
1-beta	I
,	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
and	O
interleukin-6	B
from	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
-	O
treated	O
PBL	O
and	O
human	O
monocytes	O
(	O
HM	O
)	O
was	O
decreased	O
to	O
approximately	O
1	O
/	O
3	O
to	O
2	O
/	O
3	O
of	O
the	O
control	O
levels	O
.	O
In	O
parallel	O
with	O
the	O
decreased	O
cytokine	B
generation	O
,	O
each	O
cytokine	O
mRNA	O
was	O
less	O
expressed	O
in	O
the	O
presence	O
of	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
.	O
In	O
addition	O
,	O
both	O
inducible	O
nitric	B
oxide	I
synthase	I
-mRNA	O
level	O
and	O
NO	O
generation	O
in	O
mouse	O
peritoneal	O
macrophages	O
were	O
suppressed	O
by	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
.	O
Being	O
compatible	O
with	O
those	O
results	O
,	O
Azeptin	O
(	O
10	O
(	O
-5	O
)	O
M	O
)	O
suppressed	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
PBL	O
,	O
HM	O
and	O
HF	O
.	O
These	O
results	O
appear	O
to	O
indicate	O
that	O
suppression	O
of	O
cytokine	B
and	O
NO	O
generation	O
by	O
Azeptin	O
results	O
at	O
least	O
partially	O
from	O
the	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
The	O
T	B
cell	I
activation	I
factor	I
NF	B
-	I
ATc	I
positively	O
regulates	O
HIV-1	O
replication	O
and	O
gene	O
expression	O
in	O
T	O
cells	O
.	O
Clinical	O
deterioration	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
is	O
associated	O
with	O
increased	O
levels	O
of	O
viral	O
replication	O
and	O
burden	O
in	O
the	O
peripheral	O
blood	O
and	O
lymphoid	O
organs	O
.	O
T	O
cell	O
activation	O
and	O
ensuing	O
cellular	O
gene	O
activation	O
can	O
be	O
critical	O
for	O
HIV-1	O
replication	O
.	O
The	O
hypothesis	O
that	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
may	O
influence	O
HIV-1	O
replication	O
is	O
therefore	O
compelling	O
given	O
the	O
tight	O
correlation	O
of	O
HIV-1	O
transcriptional	O
induction	O
to	O
T	O
cell	O
activation	O
.	O
We	O
report	O
that	O
certain	O
NF	B
-	I
AT	I
(	I
Rel	I
)	I
family	I
members	I
productively	O
bind	O
the	O
kappaB	O
regulatory	O
elements	O
,	O
synergize	O
with	O
NF	B
-	I
kappaB	I
and	O
Tat	B
in	O
transcriptional	O
activation	O
of	O
HIV-1	O
,	O
and	O
enhance	O
HIV-1	O
replication	O
in	O
T	O
cells	O
.	O
These	O
results	O
link	O
regulatory	B
factors	I
critical	O
to	O
T	O
cell	O
commitment	O
directly	O
to	O
HIV-1	O
replication	O
.	O
Differentiation	O
of	O
T	O
-	O
helper	O
lymphocytes	O
:	O
selective	O
regulation	O
by	O
members	O
of	O
the	O
STAT	B
family	I
of	O
transcription	B
factors	I
.	O
Interleukin-4	B
(	O
IL-4	B
)	O
and	O
interleukin-12	B
(	O
IL-12	B
)	O
control	O
the	O
differentiation	O
of	O
T	O
-	O
helper	O
cells	O
.	O
Here	O
we	O
summarize	O
studies	O
which	O
investigate	O
the	O
mechanism	O
by	O
which	O
these	O
cytokines	B
selectively	O
reprogramme	O
gene	O
expression	O
in	O
T	O
-	O
lymphocytes	O
.	O
Cytokine	B
stimulation	O
leads	O
to	O
the	O
phosphorylation	O
of	O
specific	O
tyrosine	O
residues	O
within	O
the	O
intracellular	B
domain	I
of	O
the	O
corresponding	O
cytokine	B
receptor	I
.	O
These	O
phosphotyrosines	O
serve	O
as	O
docking	B
sites	I
for	O
latent	O
,	O
cytoplasmic	B
transcription	I
factors	I
known	O
as	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
Stat	I
)	I
proteins	I
.	O
Receptor	O
/	O
Stat	O
interaction	O
is	O
mediated	O
by	O
the	O
src	B
homology	I
2	I
(	I
SH2	I
)	I
domain	I
of	O
the	O
corresponding	O
Stat	B
protein	I
.	O
Although	O
Stat	O
binding	O
to	O
the	O
intracellular	B
domain	I
of	O
the	O
cytokine	B
receptor	I
strongly	O
depends	O
on	O
the	O
phosphotyrosine	O
residue	O
,	O
the	O
recruitment	O
of	O
a	O
specific	O
Stat	B
protein	I
is	O
dictated	O
by	O
amino	O
acid	O
residues	O
C	O
-	O
terminal	O
to	O
the	O
phosphotyrosine	O
.	O
Specific	O
docking	B
sites	I
within	O
individual	O
cytokine	B
receptors	I
have	O
been	O
identified	O
for	O
almost	O
all	O
Stat	B
proteins	I
.	O
The	O
direct	O
coupling	O
between	O
cytokine	B
receptor	I
and	O
transcription	B
factor	I
helps	O
to	O
explain	O
how	O
different	O
cytokines	B
elicit	O
distinct	O
patterns	O
of	O
gene	O
expression	O
.	O
Cytokine	B
signal	I
networks	I
and	O
a	O
new	O
era	O
in	O
biomedical	O
research	O
.	O
Elucidation	O
of	O
the	O
biochemical	O
nature	O
of	O
the	O
signal	O
transduction	O
pathway	O
that	O
regulate	O
transcription	O
and	O
replication	O
is	O
the	O
focus	O
of	O
attention	O
in	O
molecular	O
biology	O
.	O
This	O
research	O
may	O
make	O
feasible	O
manipulation	O
of	O
growth	O
and	O
differentiation	O
of	O
mammalian	O
cells	O
,	O
which	O
in	O
turn	O
would	O
have	O
profound	O
implication	O
in	O
biomedical	O
research	O
on	O
cell	O
and	O
gene	O
therapy	O
,	O
and	O
development	O
of	O
pharmaceutical	O
products	O
.	O
Cytokines	B
control	O
growth	O
,	O
differentiation	O
,	O
death	O
,	O
and	O
function	O
of	O
cells	O
of	O
lymphocytic	O
,	O
hemopoietic	O
systems	O
,	O
and	O
together	O
with	O
nerve	O
cells	O
provide	O
a	O
pertinent	O
model	O
to	O
study	O
intercellular	O
communications	O
and	O
intercellular	O
signal	O
networks	O
.	O
This	O
review	O
outlines	O
general	O
features	O
of	O
signal	O
transduction	O
and	O
several	O
aspects	O
of	O
cytokine	B
networks	I
are	O
discussed	O
with	O
emphasis	O
on	O
:	O
transcriptional	O
regulation	O
of	O
Th1	O
and	O
Th2-specific	O
cytokine	O
genes	O
in	O
T	O
cells	O
,	O
the	O
roles	O
of	O
cytokines	B
and	O
their	O
receptors	O
in	O
growth	O
and	O
differentiation	O
of	O
hemopoietic	O
cells	O
,	O
and	O
the	O
manipulation	O
of	O
cytokine	B
networks	I
.	O
Nuclear	B
factor	I
-	I
kappa	I
B	I
potently	O
up	O
-	O
regulates	O
the	O
promoter	O
activity	O
of	O
RANTES	B
,	O
a	O
chemokine	O
that	O
blocks	O
HIV	O
infection	O
.	O
The	O
complex	O
network	O
of	O
cytokines	B
that	O
are	O
involved	O
in	O
inflammatory	O
and	O
immunoregulatory	O
responses	O
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
infection	O
.	O
RANTES	B
(	O
regulated	B
upon	I
activation	I
,	I
normal	I
T	I
cell	I
expressed	I
and	I
secreted	I
)	O
is	O
a	O
cytokine	B
that	O
belongs	O
to	O
the	O
beta	B
-	I
chemokine	I
family	I
;	O
it	O
is	O
chemoattractant	O
for	O
CD4+	O
/	O
CD45RO	O
T	O
cells	O
,	O
it	O
is	O
produced	O
by	O
various	O
cell	O
types	O
including	O
CD8	O
+	O
and	O
CD4	O
+	O
T	O
cells	O
as	O
well	O
as	O
monocytes	O
/	O
macrophages	O
,	O
and	O
has	O
recently	O
been	O
shown	O
to	O
suppress	O
replication	O
of	O
macrophage	O
-	O
tropic	O
strains	O
of	O
HIV	O
in	O
CD4	O
+	O
T	O
cells	O
.	O
To	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
RANTES	B
expression	O
,	O
the	O
RANTES	O
promoter	O
region	O
was	O
analyzed	O
by	O
transient	O
expression	O
and	O
gel	O
-	O
mobility	O
shift	O
assays	O
.	O
We	O
demonstrate	O
that	O
:	O
1	O
)	O
RANTES	B
promoter	O
activity	O
is	O
up	O
-	O
regulated	O
by	O
PMA	O
plus	O
ionomycin	O
,	O
coexpression	O
of	O
the	O
p65	B
subunit	I
of	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
,	O
the	O
proinflammatory	B
cytokines	I
TNF	B
-	I
alpha	I
and	O
IL-1	B
beta	I
,	O
and	O
the	O
CD28	B
costimulatory	O
pathway	O
;	O
2	O
)	O
the	O
RANTES	O
promoter	O
region	O
contains	O
four	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
at	O
positions	O
-30	O
,	O
-44	O
,	O
-213	O
,	O
and	O
-579	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
;	O
3	O
)	O
one	O
site	O
(	O
-213	O
)	O
is	O
an	O
NF	O
-	O
AT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
binding	O
site	O
that	O
also	O
has	O
weak	O
affinity	O
to	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
the	O
most	O
distal	O
site	O
(	O
-579	O
)	O
also	O
serves	O
as	O
a	O
CD28-responsive	O
element	O
;	O
and	O
4	O
)	O
mutation	O
on	O
any	O
of	O
those	O
NF	O
-	O
kappa	O
B	O
sites	O
or	O
coexpression	O
of	O
I	B
kappa	I
B	I
alpha	I
(	O
cytoplasmic	B
inhibitor	I
of	I
NF	I
-	I
kappa	I
B	I
)	O
markedly	O
reduced	O
the	O
promoter	O
activity	O
.	O
Thus	O
,	O
NF	B
-	I
kappa	I
B	I
,	O
a	O
potent	O
transcriptional	O
activator	O
of	O
HIV	O
expression	O
,	O
is	O
also	O
involved	O
in	O
the	O
expression	O
of	O
RANTES	B
,	O
a	O
chemokine	B
that	O
blocks	O
infection	O
by	O
macrophage	O
-	O
tropic	O
strains	O
of	O
HIV	O
.	O
The	O
Pax-5	O
gene	O
is	O
alternatively	O
spliced	O
during	O
B	O
-	O
cell	O
development	O
.	O
The	O
transcription	B
factor	I
Pax-5	I
is	O
expressed	O
during	O
the	O
early	O
stages	O
of	O
B	O
-	O
cell	O
differentiation	O
and	O
influences	O
the	O
expression	O
of	O
several	O
B	O
-	O
cell	O
-	O
specific	O
genes	O
.	O
In	O
addition	O
to	O
the	O
existing	O
isoform	O
(	O
Pax-5	B
,	O
which	O
we	O
have	O
named	O
Pax-5a	B
)	O
,	O
we	O
have	O
isolated	O
three	O
new	O
isoforms	O
,	O
Pax-5b	B
,	O
Pax-5d	B
,	O
and	O
Pax-5e	B
,	O
from	O
murine	O
spleen	O
and	O
B	O
-	O
lymphoid	O
cell	O
lines	O
using	O
library	O
screenings	O
and	O
polymerase	O
chain	O
reaction	O
amplification	O
.	O
Isoforms	O
Pax-5b	B
and	O
Pax-5e	B
have	O
spliced	O
out	O
their	O
second	O
exon	O
,	O
resulting	O
in	O
proteins	O
with	O
only	O
a	O
partial	O
DNA	B
-	I
binding	I
domain	I
.	O
Isoforms	O
Pax-5d	O
and	O
Pax-5e	B
have	O
deleted	O
the	O
3'-region	B
,	O
which	O
encodes	O
the	O
transactivating	O
domain	O
,	O
and	O
replaced	O
it	O
with	O
a	O
novel	O
sequence	O
.	O
The	O
existence	O
of	O
alternative	O
Pax-5	O
transcripts	O
was	O
confirmed	O
using	O
RNase	B
protection	O
assays	O
.	O
Furthermore	O
,	O
Pax-5a	B
and	O
Pax-5b	B
proteins	I
were	O
detected	O
using	O
Western	O
blot	O
analysis	O
.	O
Pax-5a	B
was	O
detectable	O
in	O
pro-	O
,	O
pre-	O
,	O
and	O
mature	O
B	O
-	O
cell	O
lines	O
,	O
but	O
not	O
in	O
two	O
plasmacytomas	O
;	O
Pax-5b	B
was	O
shown	O
to	O
be	O
present	O
at	O
low	O
levels	O
in	O
mature	O
B	O
-	O
cell	O
lines	O
and	O
,	O
unexpectedly	O
,	O
in	O
one	O
plasma	O
cell	O
line	O
,	O
but	O
not	O
in	O
pro	O
-	O
B	O
-	O
cell	O
or	O
T	O
-	O
cell	O
lines	O
.	O
Mobility	O
shift	O
assays	O
showed	O
that	O
in	O
vitro	O
translated	O
Pax-5a	B
and	O
Pax-5d	B
,	O
but	O
not	O
Pax-5b	B
or	O
Pax-5e	B
,	O
could	O
interact	O
with	O
a	O
B	O
-	O
cell	O
-	O
specific	O
activator	O
protein	O
-	O
binding	O
site	O
on	O
the	O
blk	O
promoter	O
.	O
Using	O
this	O
assay	O
,	O
we	O
also	O
showed	O
that	O
Pax-5d	B
was	O
present	O
in	O
nuclear	O
extracts	O
of	O
some	O
(	O
but	O
not	O
all	O
)	O
B	O
-	O
lymphoid	O
lines	O
and	O
interacts	O
with	O
the	O
B	O
-	O
cell	O
-	O
specific	O
activator	O
protein	O
-	O
binding	O
site	O
.	O
The	O
pattern	O
of	O
differential	O
expression	O
of	O
alternatively	B
spliced	I
Pax-5	I
isoforms	I
suggests	O
that	O
they	O
may	O
be	O
important	O
regulators	B
of	I
transcription	I
during	O
B	O
-	O
cell	O
maturation	O
.	O
Use	O
of	O
new	O
biologic	O
markers	O
in	O
the	O
ovulation	O
induction	O
.	O
Biological	O
markers	O
of	O
ovulation	O
,	O
after	O
a	O
great	O
in	O
the	O
past	O
,	O
have	O
been	O
fallen	O
into	O
disuse	O
for	O
the	O
large	O
diffusion	O
of	O
biochemical	O
and	O
biophysical	O
ones	O
.	O
However	O
,	O
the	O
real	O
effect	O
of	O
hormones	O
involved	O
in	O
ovulation	O
is	O
expressed	O
by	O
biological	O
modifications	O
on	O
target	O
tissues	O
.	O
To	O
explore	O
the	O
modifications	O
of	O
not	O
reproductive	O
target	O
tissues	O
as	O
ovulation	O
markers	O
we	O
studied	O
the	O
behaviour	O
of	O
Albuminemia	O
,	O
Platelet	B
Factor	I
IV	I
(	O
as	O
indicator	O
of	O
Platelet	O
Aggregation	O
)	O
,	O
Type	B
II	I
estrogenic	I
receptors	I
in	O
42	O
ovulation	O
induced	O
women	O
,	O
undergoing	O
our	O
observation	O
.	O
33	O
of	O
them	O
had	O
ovulation	O
and	O
9	O
developed	O
a	O
LUF	O
syndrome	O
,	O
constituting	O
two	O
biological	O
models	O
of	O
an	O
opposite	O
situation	O
for	O
the	O
three	O
markers	O
observed	O
.	O
All	O
the	O
markers	O
considered	O
were	O
sufficiently	O
sensitive	O
,	O
but	O
among	O
them	O
,	O
Platelet	B
Factor	I
IV	I
was	O
the	O
most	O
reliable	O
to	O
the	O
hormonal	O
ovulatory	O
situation	O
.	O
c	O
-	O
Jun	O
and	O
GST	O
-	O
pi	O
expression	O
in	O
human	O
plasma	O
cells	O
.	O
Bone	O
marrow	O
samples	O
from	O
33	O
patients	O
affected	O
by	O
MM	O
and	O
MGUS	O
,	O
and	O
8	O
patients	O
not	O
affected	O
by	O
lymphoproliferative	O
diseases	O
were	O
studied	O
for	O
expression	O
of	O
c	B
-	I
Jun	I
(	O
a	O
component	O
of	O
the	O
transcription	B
factor	I
AP-1	B
)	O
and	O
glutathione	B
-	I
S	I
-	I
transferase	I
pi	I
(	O
GST	B
-	I
pi	I
)	O
using	O
immunocytochemical	O
methods	O
.	O
A	O
high	O
and	O
frequent	O
expression	O
of	O
these	O
two	O
proteins	O
was	O
found	O
both	O
in	O
MM	O
and	O
MGUS	O
patients	O
(	O
31	O
/	O
33	O
patients	O
positive	O
for	O
c	B
-	I
Jun	I
and	O
29	O
/	O
33	O
patients	O
positive	O
for	O
GST	B
-	I
pi	I
)	O
and	O
in	O
controls	O
not	O
affected	O
by	O
monoclonal	O
gammopathy	O
(	O
7	O
/	O
8	O
patients	O
positive	O
for	O
both	O
c	B
-	I
Jun	I
and	O
GST	B
-	I
pi	I
)	O
.	O
No	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
c	O
-	O
Jun-	O
and	O
GST	O
-	O
pi	O
-	O
positive	O
plasma	O
cells	O
.	O
The	O
expression	O
of	O
these	O
two	O
proteins	O
was	O
not	O
related	O
to	O
clinical	O
or	O
laboratory	O
data	O
.	O
Our	O
results	O
seem	O
to	O
confirm	O
a	O
possible	O
role	O
of	O
the	O
transcriptional	B
complex	I
AP-1	B
in	O
activating	O
GST	O
-	O
pi	O
promoter	O
in	O
human	O
plasma	O
cells	O
.	O
High	O
levels	O
of	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
E2F	B
in	O
adult	O
T	O
-	O
cell	O
leukemia	O
and	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
-	O
infected	O
cells	O
:	O
possible	O
enhancement	O
of	O
DNA	O
-	O
binding	O
of	O
E2F	B
by	O
the	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
I	I
transactivating	I
protein	I
,	O
Tax	B
.	O
Transcription	B
factor	I
E2F	B
binds	O
to	O
cellular	O
promoters	O
of	O
certain	O
growth-	O
and	O
cell	O
cycle	O
-	O
controlling	O
genes	O
and	O
forms	O
distinct	O
heteromeric	B
complexes	I
with	O
other	O
nuclear	B
proteins	I
.	O
It	O
has	O
therefore	O
been	O
proposed	O
that	O
E2F	B
is	O
involved	O
in	O
cellular	O
proliferation	O
control	O
.	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O
We	O
show	O
here	O
by	O
mobility	O
-	O
shift	O
assay	O
that	O
E2F	B
-	I
containing	I
DNA	I
-	I
binding	I
complexes	I
were	O
detected	O
in	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
-	O
cell	O
lines	O
and	O
leukemic	O
cells	O
obtained	O
from	O
ATL	O
patients	O
but	O
not	O
in	O
an	O
uninfected	O
T	O
-	O
cell	O
line	O
,	O
Jurkat	O
,	O
and	O
normal	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
The	O
Tax	B
protein	I
,	O
encoded	O
by	O
HTLV	O
-	O
I	O
,	O
is	O
a	O
potent	O
transcription	O
activator	O
of	O
viral	O
and	O
several	O
cellular	O
genes	O
.	O
We	O
demonstrate	O
that	O
expression	O
of	O
Tax	B
can	O
induce	O
the	O
E2F	B
-	I
containing	I
DNA	I
-	I
binding	I
complexes	I
in	O
Jurkat	O
T	O
cells	O
.	O
Thus	O
,	O
Tax	B
,	O
through	O
enhancement	O
of	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
E2F	B
,	O
may	O
be	O
capable	O
of	O
regulating	O
cellular	O
gene	O
expression	O
implicated	O
in	O
the	O
proliferation	O
and	O
transformation	O
of	O
T	O
cells	O
in	O
ATL	O
.	O
This	O
activity	O
may	O
be	O
relevant	O
to	O
the	O
mechanisms	O
whereby	O
HTLV	O
-	O
I	O
which	O
does	O
not	O
contain	O
oncogenes	O
induces	O
neoplasia	O
.	O
Reconstitution	O
of	O
T	O
cell	O
antigen	O
receptor	O
-	O
induced	O
Erk2	B
kinase	I
activation	O
in	O
Lck	O
-	O
negative	O
JCaM1	O
cells	O
by	O
Syk	B
.	O
The	O
two	O
related	O
protein	B
-	I
tyrosine	I
kinases	I
Syk	B
and	O
Zap	B
are	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
and	O
enzymatically	O
activated	O
upon	O
crosslinking	O
of	O
the	O
T	B
cell	I
antigen	I
receptor	I
.	O
We	O
have	O
previously	O
reported	O
that	O
the	O
activation	O
of	O
Syk	B
is	O
less	O
dependent	O
on	O
the	O
Src	B
family	I
kinase	I
Lck	B
than	O
the	O
activation	O
of	O
Zap	B
.	O
Here	O
we	O
report	O
that	O
overexpression	O
of	O
Syk	B
in	O
the	O
Lck	O
-	O
negative	O
JCaM1	O
cells	O
enabled	O
the	O
T	B
cell	I
antigen	I
receptor	I
/	I
CD3	I
complex	I
to	O
induce	O
a	O
normal	O
activation	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
pathway	O
and	O
expression	O
of	O
a	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
reporter	O
construct	O
.	O
In	O
contrast	O
,	O
Zap	B
and	O
other	O
protein	B
-	I
tyrosine	I
kinases	I
were	O
unable	O
to	O
reconstitute	O
these	O
signaling	O
pathways	O
when	O
expressed	O
at	O
the	O
same	O
levels	O
.	O
In	O
parallel	O
,	O
Syk	B
was	O
phosphorylated	O
on	O
tyrosine	O
,	O
while	O
Zap	B
was	O
not	O
.	O
The	O
Syk	B
-mediated	O
T	B
cell	I
antigen	I
receptor	I
-induced	O
MAPK	B
activation	O
was	O
detectable	O
within	O
1	O
min	O
of	O
receptor	O
stimulation	O
and	O
peaked	O
at	O
3	O
-	O
5	O
min	O
.	O
The	O
capacity	O
of	O
Syk	B
to	O
reconstitute	O
the	O
MAPK	B
response	O
required	O
the	O
catalytic	O
activity	O
of	O
Syk	B
,	O
an	O
intact	O
autophosphorylation	B
site	I
(	O
Y518	O
and	O
Y519	O
)	O
,	O
both	O
Src	B
homology	I
2	I
domains	I
and	O
it	O
was	O
blocked	O
by	O
the	O
inhibitory	B
N17-mutated	I
dominant	I
-	I
negative	I
Ras	I
construct	I
.	O
A	O
Y341	O
--	O
>	O
F	B
mutant	I
of	O
Syk	B
,	O
which	O
is	O
deficient	O
in	O
its	O
interaction	O
with	O
phospholipase	B
Cy1	I
and	O
Vav	B
,	O
was	O
less	O
efficient	O
than	O
wild	B
-	I
type	I
Syk	I
.	O
Our	O
results	O
suggest	O
that	O
Syk	B
,	O
in	O
contrast	O
to	O
Zap	B
,	O
can	O
transduce	O
signals	O
from	O
the	O
T	B
cell	I
antigen	I
receptor	I
independently	O
of	O
Lck	B
.	O
Retinoic	O
acid	O
-	O
induced	O
modulation	O
of	O
IL-2	O
mRNA	O
production	O
and	O
IL-2	B
receptor	O
expression	O
on	O
T	O
cells	O
.	O
BACKGROUND	O
:	O
Retinoic	O
acid	O
(	O
RA	O
)	O
has	O
important	O
immune	O
-	O
modulating	O
effects	O
on	O
both	O
T	O
and	O
B	O
cell	O
function	O
.	O
Our	O
laboratory	O
has	O
shown	O
that	O
RA	O
can	O
enhance	O
in	O
vitro	O
polyclonal	O
B	O
cell	O
immunoglobulin	B
(	O
Ig	O
)	O
response	O
.	O
Investigating	O
cytokines	B
known	O
to	O
affect	O
B	O
cell	O
differentiation	O
,	O
we	O
have	O
recently	O
shown	O
that	O
IL-6	B
production	O
is	O
augmented	O
by	O
RA	O
.	O
In	O
the	O
present	O
study	O
we	O
have	O
examined	O
the	O
immune	O
modulating	O
effects	O
of	O
RA	O
on	O
IL-2	O
mRNA	O
,	O
another	O
important	O
cytokine	B
for	O
B	O
cell	O
immunoglobulin	B
production	O
,	O
the	O
expression	O
of	O
IL-2	B
receptors	I
on	O
T	O
cells	O
,	O
and	O
the	O
RA	B
nuclear	I
receptors	I
.	O
METHODS	O
:	O
Purified	O
T	O
cells	O
were	O
obtained	O
from	O
adenoidal	O
tissues	O
,	O
and	O
incubated	O
with	O
RA	O
(	O
10	O
(	O
-7	O
)	O
M	O
)	O
or	O
DMSO	O
solvent	O
/	O
media	O
control	O
for	O
0	O
,	O
6	O
-	O
8	O
,	O
and	O
24	O
h	O
.	O
Total	O
mRNA	O
was	O
extracted	O
from	O
T	O
cells	O
,	O
and	O
using	O
RT	O
-	O
PCR	O
,	O
changes	O
in	O
the	O
production	O
of	O
IL-2	B
and	O
RA	B
receptors	I
(	O
RAR	B
)	O
-	O
alpha	O
,	O
beta	O
,	O
gamma	O
mRNA	O
were	O
determined	O
.	O
The	O
effects	O
of	O
RA	O
on	O
IL-2-alpha	O
receptor	O
expression	O
was	O
determined	O
by	O
flow	O
cytometry	O
on	O
T	O
cells	O
.	O
CONCLUSION	O
:	O
These	O
studies	O
suggest	O
that	O
RA	O
can	O
augment	O
IL-2	O
mRNA	O
production	O
by	O
T	O
cells	O
with	O
a	O
possible	O
paracrine	O
effect	O
on	O
IL-2R	B
-	I
alpha	I
expression	O
.	O
These	O
changes	O
appear	O
to	O
be	O
mediated	O
by	O
RAR	B
-	I
alpha	I
.	O
Thus	O
,	O
IL-2	B
may	O
be	O
another	O
important	O
cytokine	B
modulated	O
by	O
RA	O
in	O
the	O
immune	O
response	O
.	O
The	O
tumour	B
associated	I
cell	I
surface	I
antigen	I
A6H	B
is	O
costimulatory	O
for	O
human	O
CD4	O
+	O
but	O
not	O
CD8	O
+	O
T	O
cells	O
.	O
The	O
A6H	B
monoclonal	I
antibody	I
(	O
mAb	O
)	O
recognizes	O
a	O
120	B
,	I
000	I
-	I
140	I
,	I
000	I
MW	I
antigen	I
that	O
is	O
expressed	O
at	O
similar	O
densities	O
on	O
85	O
-	O
90	O
%	O
of	O
human	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
and	O
on	O
renal	O
cell	O
carcinomas	O
.	O
The	O
binding	O
of	O
the	O
A6H	B
mAb	I
induced	O
a	O
costimulatory	O
signal	O
in	O
anti	O
-	O
CD3	O
activated	O
T	O
cells	O
.	O
In	O
the	O
present	O
report	O
,	O
we	O
show	O
that	O
A6H	B
costimulated	O
cell	O
proliferation	O
and	O
cytokine	B
production	O
in	O
purified	O
CD4	O
+	O
T	O
cells	O
.	O
Unexpectedly	O
,	O
the	O
CD8	O
+	O
T	O
-	O
cell	O
subpopulation	O
failed	O
to	O
respond	O
.	O
CD4	O
+	O
T	O
cells	O
costimulated	O
with	O
the	O
A6H	B
mAb	I
upregulated	O
CD80	B
,	O
CD86	B
,	O
CD71	B
,	O
interleukin-2	B
(	I
IL-2	I
)	I
R	I
alpha	I
,	O
IL-2R	B
beta	I
and	O
IL-2R	B
gamma	I
,	O
while	O
no	O
corresponding	O
up	O
-	O
regulation	O
of	O
these	O
cell	B
surface	I
molecules	I
was	O
seen	O
in	O
CD8	O
+	O
T	O
cells	O
.	O
In	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
the	O
A6H	B
mAb	I
costimulus	O
at	O
the	O
transcriptional	O
level	O
we	O
have	O
examined	O
induction	O
of	O
the	O
transcription	B
factors	I
OCT-1	B
,	O
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
which	O
are	O
known	O
to	O
be	O
transcriptional	B
regulators	I
of	O
several	O
cytokine	B
and	O
cytokine	B
receptor	O
genes	O
,	O
including	O
the	O
IL-2	O
and	O
IL-2R	O
genes	O
.	O
Co	O
-	O
ligation	O
of	O
the	O
A6H	B
antigen	O
and	O
the	O
CD3	B
complex	I
induced	O
expression	O
of	O
the	O
transcription	B
factor	I
AP-1	B
in	O
CD4	O
+	O
T	O
cells	O
,	O
whereas	O
no	O
increase	O
in	O
NF	B
-	I
kappa	I
B	I
and	O
octamer	B
-	I
binding	I
(	I
Oct	I
)	I
proteins	I
was	O
seen	O
compared	O
to	O
T	O
cells	O
stimulated	O
with	O
anti	B
-	I
CD3	I
alone	O
.	O
Furthermore	O
,	O
no	O
induction	O
of	O
AP-1	B
was	O
seen	O
in	O
A6H	B
costimulated	O
CD8	O
+	O
T	O
cells	O
.	O
These	O
results	O
suggests	O
that	O
both	O
proximal	O
steps	O
in	O
CD8	O
+	O
T	O
-	O
cell	O
activation	O
as	O
well	O
as	O
the	O
later	O
phases	O
are	O
unresponsive	O
to	O
A6H	B
ligation	O
.	O
Molecular	O
differences	O
of	O
the	O
A6H	B
molecule	I
or	O
distinct	O
regulation	O
of	O
the	O
A6H	B
transduced	O
AP-1	B
activation	O
pathway	O
may	O
exist	O
in	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cell	O
subpopulations	O
.	O
Inhibitor	O
(	O
IK	O
)	O
of	O
IFN	B
-	I
gamma	I
induced	O
HLA	B
class	I
II	I
antigens	I
expression	O
also	O
inhibits	O
HLA	B
class	I
II	I
constitutive	O
expression	O
in	O
the	O
human	O
Raji	O
B	O
cell	O
line	O
.	O
The	O
expression	O
of	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
II	I
antigens	I
is	O
constitutive	O
in	O
professional	O
antigen	O
presenting	O
cells	O
(	O
APCs	O
)	O
but	O
can	O
also	O
be	O
induced	O
by	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
on	O
the	O
majority	O
of	O
the	O
non	O
professional	O
APCs	O
(	O
e.g	O
.	O
fibroblasts	O
)	O
.	O
We	O
have	O
recently	O
characterised	O
a	O
new	O
factor	O
called	O
IK	B
which	O
is	O
an	O
efficient	O
inhibitor	O
of	O
IFN	B
-	I
gamma	I
induction	O
of	O
MHC	B
class	I
II	I
antigens	I
expression	O
.	O
Here	O
,	O
we	O
demonstrate	O
a	O
novel	O
role	O
for	O
IK	B
in	O
MHC	B
class	I
II	I
expression	O
since	O
over	O
-	O
expression	O
of	O
this	O
protein	O
by	O
stable	O
transfection	O
into	O
human	O
B	O
cells	O
led	O
to	O
a	O
total	O
disappearance	O
of	O
constitutive	O
MHC	O
class	O
II	O
mRNA	O
expression	O
.	O
The	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
is	O
necessary	O
for	O
both	O
constitutive	O
and	O
IFN	B
-	I
gamma	I
induced	O
MHC	B
class	I
II	I
expressions	O
.	O
Examination	O
of	O
CIITA	O
mRNA	O
in	O
IK	B
stably	O
transfected	O
clones	O
revealed	O
a	O
marked	O
reduction	O
of	O
CIITA	O
mRNA	O
transcription	O
.	O
Taken	O
together	O
these	O
results	O
demonstrate	O
that	O
the	O
IK	B
protein	I
plays	O
a	O
key	O
role	O
in	O
the	O
constitutive	O
expression	O
of	O
MHC	B
class	I
II	I
antigens	I
and	O
that	O
inhibition	O
induced	O
by	O
IK	B
is	O
upstream	O
of	O
CIITA	O
in	O
this	O
regulatory	O
pathway	O
.	O
CD40	B
is	O
a	O
functional	O
activation	B
antigen	I
and	O
B7-independent	B
T	I
cell	I
costimulatory	I
molecule	I
on	O
normal	O
human	O
lung	O
fibroblasts	O
.	O
CD40	B
is	O
an	O
important	O
signaling	O
and	O
activation	O
Ag	O
found	O
on	O
certain	O
bone	O
marrow	O
-	O
derived	O
cells	O
.	O
Recently	O
,	O
CD40	B
also	O
has	O
been	O
shown	O
to	O
be	O
expressed	O
by	O
mesenchymal	O
cells	O
,	O
including	O
human	O
fibroblasts	O
.	O
Little	O
is	O
known	O
about	O
the	O
role	O
of	O
CD40	B
in	O
fibroblasts	O
.	O
The	O
current	O
study	O
investigates	O
the	O
hypothesis	O
that	O
CD40	B
expressed	O
on	O
lung	O
fibroblasts	O
is	O
an	O
activation	O
structure	O
and	O
mechanism	O
for	O
interaction	O
with	O
hemopoietic	O
cells	O
.	O
Communication	O
between	O
resident	O
tissue	O
fibroblasts	O
and	O
T	O
cells	O
is	O
necessary	O
for	O
normal	O
wound	O
healing	O
,	O
and	O
can	O
be	O
pathologic	O
,	O
resulting	O
in	O
tissue	O
fibrosis	O
.	O
Signaling	O
through	O
CD40	B
with	O
soluble	O
CD40	B
ligand	O
stimulated	O
fibroblast	O
activation	O
,	O
as	O
evidenced	O
by	O
mobilization	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
by	O
induction	O
of	O
the	O
proinflammatory	O
and	O
chemoattractant	O
cytokines	B
IL-6	B
and	O
IL-8	B
.	O
IFN	O
-	O
gamma	O
-	O
primed	O
lung	O
fibroblasts	O
costimulate	O
T	O
lymphocyte	O
proliferation	O
utilizing	O
CD40	B
,	O
but	O
not	O
the	O
well	O
-	O
studied	O
costimulatory	B
molecules	I
B7	B
-	I
1	I
and	O
B7	B
-	I
2	I
.	O
Data	O
reported	O
herein	O
support	O
the	O
hypothesis	O
that	O
cognate	O
interactions	O
between	O
tissue	O
fibroblasts	O
and	O
infiltrating	O
T	O
lymphocytes	O
,	O
via	O
the	O
CD40	B
/CD40L	B
pathway	O
,	O
augment	O
inflammation	O
and	O
may	O
promote	O
fibrogenesis	O
by	O
activating	O
both	O
cell	O
types	O
.	O
HLA	O
-	O
DMA	O
and	O
HLA	O
-	O
DMB	O
gene	O
expression	O
functions	O
through	O
the	O
conserved	O
S	O
-	O
X	O
-	O
Y	O
region	O
.	O
The	O
MHC	B
class	I
II	I
homologous	I
proteins	I
HLA	B
-	I
DMA	I
and	O
HLA	B
-	I
DMB	I
function	O
in	O
the	O
loading	O
of	O
peptides	O
onto	O
class	B
II	I
molecules	I
.	O
Like	O
the	O
class	O
II	O
genes	O
,	O
the	O
HLA	O
-	O
DM	O
genes	O
contain	O
upstream	O
regulatory	O
sequences	O
similar	O
to	O
the	O
S	O
-	O
X	O
-	O
Y	O
regulatory	O
region	O
as	O
well	O
as	O
additional	O
putative	O
regulatory	O
sites	O
.	O
To	O
determine	O
whether	O
the	O
DM	O
genes	O
are	O
regulated	O
in	O
a	O
similar	O
manner	O
as	O
class	O
II	O
genes	O
,	O
a	O
series	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
analyses	O
was	O
performed	O
.	O
Deletion	O
analysis	O
showed	O
that	O
expression	O
from	O
the	O
DM	O
promoters	O
is	O
dependent	O
on	O
the	O
conserved	O
S	O
-	O
X	O
-	O
Y	O
region	O
.	O
The	O
class	B
II	I
-	I
specific	I
transcription	I
factors	I
RFX	B
and	O
CIITA	B
are	O
also	O
required	O
for	O
expression	O
,	O
as	O
cell	O
lines	O
deficient	O
in	O
these	O
factors	O
failed	O
to	O
allow	O
transcription	O
from	O
the	O
DM	O
promoters	O
.	O
In	O
addition	O
,	O
in	O
vivo	O
footprint	O
analysis	O
showed	O
the	O
putative	O
X	O
and	O
Y	O
boxes	O
to	O
be	O
occupied	O
by	O
transcription	B
factors	I
in	O
wild	O
-	O
type	O
B	O
cells	O
,	O
but	O
not	O
in	O
RFX	O
-	O
deficient	O
B	O
cells	O
.	O
In	O
astrocytes	O
,	O
IFN	B
-	I
gamma	I
treatment	O
induced	O
increased	O
occupancy	O
of	O
these	O
sites	O
.	O
None	O
of	O
the	O
other	O
putative	O
regulatory	O
sites	O
was	O
occupied	O
in	O
vivo	O
,	O
indicating	O
that	O
they	O
may	O
not	O
be	O
functional	O
.	O
Finally	O
,	O
gel	O
shift	O
analysis	O
showed	O
synergistic	O
complex	O
formation	O
between	O
proteins	O
that	O
bind	O
to	O
the	O
putative	O
X	O
boxes	O
of	O
the	O
DM	O
genes	O
,	O
as	O
is	O
found	O
for	O
the	O
DRA	O
gene	O
.	O
Therefore	O
,	O
the	O
DM	O
genes	O
share	O
a	O
common	O
mechanism	O
of	O
regulation	O
with	O
the	O
class	O
II	O
genes	O
.	O
An	O
enhancer	O
-	O
blocking	O
element	O
between	O
alpha	O
and	O
delta	O
gene	O
segments	O
within	O
the	O
human	O
T	O
cell	O
receptor	O
alpha	O
/	O
delta	O
locus	O
.	O
T	B
cell	I
receptor	I
(	I
TCR	I
)	I
alpha	I
and	O
delta	O
gene	O
segments	O
are	O
organized	O
within	O
a	O
single	O
genetic	O
locus	O
but	O
are	O
differentially	O
regulated	O
during	O
T	O
cell	O
development	O
.	O
An	O
enhancer	O
-	O
blocking	O
element	O
(	O
BEAD-1	O
,	O
for	O
blocking	O
element	O
alpha	O
/	O
delta	O
1	O
)	O
was	O
localized	O
to	O
a	O
2.0-kb	O
region	O
3	O
'	O
of	O
TCR	O
delta	O
gene	O
segments	O
and	O
5	O
'	O
of	O
TCR	O
alpha	O
joining	O
gene	O
segments	O
within	O
this	O
locus	O
.	O
BEAD-1	O
blocked	O
the	O
ability	O
of	O
the	O
TCR	O
delta	O
enhancer	O
(	O
Edelta	O
)	O
to	O
activate	O
a	O
promoter	O
when	O
located	O
between	O
the	O
two	O
in	O
a	O
chromatin	O
-	O
integrated	O
construct	O
.	O
We	O
propose	O
that	O
BEAD-1	O
functions	O
as	O
a	O
boundary	O
that	O
separates	O
the	O
TCR	O
alpha	O
/	O
delta	O
locus	O
into	O
distinct	O
regulatory	O
domains	O
controlled	O
by	O
Edelta	O
and	O
the	O
TCR	O
alpha	O
enhancer	O
,	O
and	O
that	O
it	O
prevents	O
Edelta	O
from	O
opening	O
the	O
chromatin	O
of	O
the	O
TCR	O
alpha	O
joining	O
gene	O
segments	O
for	O
VDJ	O
recombination	O
at	O
an	O
early	O
stage	O
of	O
T	O
cell	O
development	O
.	O
Acute	O
leukemia	O
with	O
promyelocytic	O
features	O
in	O
PML	O
/	O
RARalpha	O
transgenic	O
mice	O
.	O
Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
associated	O
with	O
reciprocal	O
chromosomal	O
translocations	O
involving	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RARalpha	O
)	O
locus	O
on	O
chromosome	O
17	O
.	O
In	O
the	O
majority	O
of	O
cases	O
,	O
RARalpha	B
translocates	O
and	O
fuses	O
with	O
the	O
promyelocytic	O
leukemia	O
(	O
PML	O
)	O
gene	O
located	O
on	O
chromosome	O
15	O
.	O
The	O
resulting	O
fusion	O
genes	O
encode	O
the	O
two	O
structurally	O
unique	O
PML	B
/	I
RARalpha	I
and	O
RARalpha	B
/	I
PML	I
fusion	I
proteins	I
as	O
well	O
as	O
aberrant	B
PML	I
gene	I
products	I
,	O
the	O
respective	O
pathogenetic	O
roles	O
of	O
which	O
have	O
not	O
been	O
elucidated	O
.	O
We	O
have	O
generated	O
transgenic	O
mice	O
in	O
which	O
the	O
PML	B
/	I
RARalpha	I
fusion	I
protein	I
is	O
specifically	O
expressed	O
in	O
the	O
myeloid	O
-	O
promyelocytic	O
lineage	O
.	O
During	O
their	O
first	O
year	O
of	O
life	O
,	O
all	O
the	O
PML	O
/	O
RARalpha	B
transgenic	O
mice	O
have	O
an	O
abnormal	O
hematopoiesis	O
that	O
can	O
best	O
be	O
described	O
as	O
a	O
myeloproliferative	O
disorder	O
.	O
Between	O
12	O
and	O
14	O
months	O
of	O
age	O
,	O
10	O
%	O
of	O
them	O
develop	O
a	O
form	O
of	O
acute	O
leukemia	O
with	O
a	O
differentiation	O
block	O
at	O
the	O
promyelocytic	O
stage	O
that	O
closely	O
mimics	O
human	O
APL	O
even	O
in	O
its	O
response	O
to	O
retinoic	O
acid	O
.	O
Our	O
results	O
are	O
conclusive	O
in	O
vivo	O
evidence	O
that	O
PML	B
/	I
RARalpha	I
plays	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
APL	O
.	O
Plasma	O
sialyltransferase	B
levels	O
in	O
psychiatric	O
disorders	O
as	O
a	O
possible	O
indicator	O
of	O
HPA	O
axis	O
function	O
.	O
A	O
dysfunction	O
in	O
the	O
regulation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
,	O
possibly	O
attributed	O
to	O
a	O
change	O
in	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
functionality	O
,	O
has	O
been	O
implicated	O
in	O
depression	O
.	O
We	O
have	O
measured	O
both	O
lymphocyte	B
GR	I
receptor	O
binding	O
parameters	O
and	O
plasma	O
sialyltransferase	B
activity	O
,	O
as	O
a	O
biochemical	O
marker	O
of	O
GR	B
function	O
,	O
in	O
two	O
groups	O
of	O
patients	O
suffering	O
from	O
depression	O
or	O
schizophrenia	O
and	O
in	O
a	O
group	O
of	O
age-	O
and	O
sex	O
-	O
matched	O
controls	O
.	O
While	O
there	O
was	O
a	O
significant	O
increase	O
in	O
plasma	O
cortisol	O
levels	O
in	O
the	O
depressed	O
group	O
,	O
there	O
were	O
no	O
changes	O
in	O
the	O
lymphocyte	O
GR	B
binding	O
parameters	O
(	O
K	O
(	O
m	O
)	O
and	O
Bmax	O
)	O
.	O
There	O
was	O
,	O
however	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	B
sialyltransferase	I
:	I
cortisol	O
ratio	O
in	O
the	O
depressed	O
group	O
suggesting	O
an	O
inability	O
of	O
the	O
raised	O
cortisol	O
levels	O
to	O
induce	O
enzyme	O
expression	O
and	O
this	O
ratio	O
may	O
provide	O
a	O
useful	O
biochemical	O
marker	O
of	O
cortisol	O
receptor	O
function	O
.	O
Although	O
there	O
was	O
an	O
increase	O
in	O
the	O
plasma	O
activity	O
of	O
the	O
alpha	B
2	I
,	I
6	I
sialyltransferase	I
isozyme	I
in	O
the	O
schizophrenic	O
group	O
,	O
no	O
other	O
changes	O
were	O
determined	O
.	O
Therefore	O
,	O
while	O
the	O
total	O
plasma	B
sialyltransferase	I
:	O
cortisol	O
ratio	O
reflects	O
HPA	O
axis	O
function	O
,	O
alterations	O
in	O
specific	O
isozyme	O
activity	O
may	O
also	O
be	O
associated	O
with	O
other	O
CNS	O
disease	O
states	O
.	O
Involvement	O
of	O
the	O
N	B
-	I
terminal	I
region	I
of	O
the	O
human	B
mineralocorticoid	I
receptor	I
hormone	I
-	I
binding	I
domain	I
in	O
agonist	O
and	O
antagonist	O
binding	O
as	O
revealed	O
by	O
a	O
new	B
monoclonal	I
antibody	I
.	O
To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
binding	O
to	O
the	O
human	B
mineralocorticoid	I
receptor	I
(	O
hMR	B
)	O
,	O
we	O
developed	O
a	O
new	O
monoclonal	B
antibody	I
(	O
mAb	B
)	O
raised	O
against	O
the	O
hormone	B
-	I
binding	I
domain	I
(	O
HBD	B
)	O
.	O
For	O
this	O
purpose	O
,	O
mice	O
were	O
immunized	O
with	O
a	O
fusion	B
protein	I
including	O
the	O
sequence	O
Thr729-Lys984	B
of	O
hMR	B
.	O
After	O
ELISA	O
screening	O
,	O
mAb	B
18C7	I
was	O
selected	O
for	O
its	O
specificity	O
towards	O
the	O
HBD	B
.	O
This	O
antibody	O
recognized	O
both	O
the	O
denatured	O
and	O
native	B
MR	I
forms	I
,	O
as	O
well	O
as	O
the	O
hetero	B
-	I
oligomeric	I
MR	I
form	I
and	O
the	O
transformed	B
MR	I
state	I
.	O
By	O
using	O
several	O
HBD	B
subfragments	I
,	O
the	O
mAb	B
18C7	I
epitope	I
was	O
located	O
in	O
the	O
N	B
-	I
terminal	I
region	I
of	O
the	O
HBD	B
from	O
Thr729	B
to	I
Leu765	I
.	O
We	O
then	O
studied	O
the	O
effect	O
of	O
the	O
antibody	O
on	O
aldosterone	O
and	O
progesterone	O
binding	O
to	O
the	O
hMR	B
.	O
When	O
18C7	B
was	O
incubated	O
with	O
liganded	B
MR	I
,	O
it	O
was	O
able	O
to	O
partly	O
displace	O
(	O
20	O
%	O
)	O
the	O
hormone	O
from	O
its	O
binding	O
site	O
.	O
When	O
18C7	B
was	O
incubated	O
with	O
MR	B
before	O
aldosterone	O
or	O
progesterone	O
,	O
the	O
antibody	O
inhibited	O
75	O
-	O
80	O
%	O
of	O
the	O
binding	O
.	O
The	O
effect	O
of	O
18C7	B
on	O
the	O
binding	O
was	O
similar	O
with	O
both	O
hormones	O
.	O
A	O
sucrose	O
gradient	O
analysis	O
indicated	O
the	O
simultaneous	O
presence	O
of	O
two	O
kinds	O
of	O
receptor	O
complexes	O
:	O
the	O
steroid	B
-	I
MR	I
complex	I
and	O
the	O
antibody	B
-	I
MR	I
complex	I
.	O
After	O
its	O
associated	O
proteins	O
,	O
especially	O
the	O
heat	B
-	I
shock	I
protein	I
hsp90	I
,	O
had	O
been	O
cross	O
-	O
linked	O
with	O
the	O
hMR	B
by	O
dimethylpimelimidate	O
,	O
18C7	B
was	O
still	O
able	O
to	O
react	O
with	O
the	O
receptor	O
.	O
Our	O
results	O
indicated	O
that	O
the	O
epitope	B
recognized	O
by	O
18C7	B
was	O
directly	O
implicated	O
in	O
hormone	O
binding	O
.	O
The	O
lack	O
of	O
steroid	O
binding	O
of	O
HBD	B
mutants	O
with	O
the	O
Thr729-Leu765	B
sequence	I
deleted	O
[	O
Jalaguier	O
,	O
Mesnier	O
,	O
Leger	O
and	O
Auzou	O
(	O
1996	O
)	O
J.Steroid	O
Biochem	O
.	O
Mol	O
.	O
Biol.57	O
,	O
43	O
-	O
50	O
]	O
supports	O
this	O
hypothesis	O
.	O
Because	O
of	O
the	O
similar	O
behaviours	O
of	O
aldosterone	O
and	O
progesterone	O
,	O
we	O
conclude	O
that	O
the	O
N	B
-	I
terminal	I
Thr729-Leu765	I
region	I
of	O
the	O
HBD	B
is	O
similarly	O
involved	O
in	O
the	O
binding	O
of	O
both	O
hormones	O
.	O
Triggering	O
of	O
HLA	B
-	I
DR	I
antigens	I
differentially	O
modulates	O
tumor	B
necrosis	I
factor	I
alpha	I
release	O
by	O
B	O
cells	O
at	O
distinct	O
stage	O
of	O
maturation	O
.	O
Triggering	O
of	O
HLA	B
class	I
II	I
antigens	I
by	O
the	O
anti	B
-	I
HLA	I
-	I
DR	I
monoclonal	I
antibody	I
(	I
mAb	I
)	I
L243	I
significantly	O
(	O
P	O
<	O
0.05	O
)	O
and	O
differentially	O
enhanced	O
the	O
release	O
of	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
by	O
the	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
cells	O
Ri	O
-	O
I	O
,	O
Ci	O
-	O
I	O
,	O
and	O
Sc	O
-	O
I	O
,	O
which	O
are	O
at	O
a	O
distinct	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
,	O
and	O
by	O
the	O
more	O
mature	O
Burkitt	O
lymphoma	O
cell	O
Raji	O
;	O
in	O
contrast	O
,	O
it	O
did	O
not	O
induce	O
TNF	B
-	I
alpha	I
release	O
by	O
the	O
pre	O
-	O
B	O
leukemia	O
cells	O
Nalm-6	O
and	O
BV173	O
.	O
TNF	B
-	I
alpha	I
release	O
peaked	O
at	O
24	O
h	O
and	O
decreased	O
thereafter	O
,	O
and	O
it	O
was	O
dose	O
dependent	O
and	O
preceded	O
by	O
an	O
increase	O
of	O
TNF	O
-	O
alpha	O
mRNA	O
detectable	O
after	O
3	O
h	O
of	O
stimulation	O
with	O
mAb	B
L243	I
.	O
Secreted	O
TNF	B
-	I
alpha	I
mediated	O
the	O
enhancement	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
and	O
activator	O
protein-1	O
(	O
AP-1	B
)	O
binding	O
activity	O
;	O
in	O
fact	O
,	O
the	O
triggering	O
of	O
HLA	B
-	I
DR	I
antigens	I
in	O
the	O
presence	O
of	O
antihuman	B
TNF	I
-	I
alpha	I
-	I
neutralizing	I
antibodies	I
did	O
not	O
upregulate	O
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
.	O
In	O
contrast	O
,	O
released	O
TNF	B
-	I
alpha	I
was	O
not	O
responsible	O
for	O
the	O
homotypic	O
aggregation	O
of	O
Ri	O
-	O
I	O
,	O
Ci	O
-	O
I	O
,	O
Sc	O
-	O
I	O
,	O
and	O
Raji	O
cells	O
induced	O
by	O
mAb	B
L243	I
,	O
and	O
it	O
did	O
not	O
affect	O
the	O
proliferation	O
of	O
B	O
cells	O
investigated	O
.	O
Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
:	O
(	O
a	O
)	O
the	O
ability	O
of	O
B	O
cells	O
to	O
release	O
TNF	B
-	I
alpha	I
after	O
triggering	O
of	O
HLA	B
-	I
DR	I
antigens	I
depends	O
on	O
their	O
stage	O
of	O
differentiation	O
;	O
(	O
b	O
)	O
levels	O
of	O
released	O
TNF	B
-	I
alpha	I
seem	O
to	O
correlate	O
with	O
the	O
stage	O
of	O
B	O
-	O
cell	O
maturation	O
but	O
do	O
not	O
correlate	O
with	O
the	O
amounts	O
of	O
cell	B
surface	I
HLA	I
-	I
DR	I
antigens	I
;	O
(	O
c	O
)	O
secreted	O
TNF	B
-	I
alpha	I
regulates	O
the	O
levels	O
of	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
by	O
an	O
autocrine	O
loop	O
;	O
and	O
(	O
d	O
)	O
intracellular	O
signals	O
mediating	O
TNF	B
-	I
alpha	I
release	O
by	O
B	O
cells	O
are	O
distinct	O
from	O
those	O
regulating	O
homotypic	O
aggregation	O
and	O
proliferation	O
.	O
Immediate	O
early	O
and	O
early	B
lytic	I
cycle	I
proteins	I
are	O
frequent	O
targets	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
-	O
induced	O
cytotoxic	O
T	O
cell	O
response	O
.	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
,	O
a	O
human	O
gamma	O
-	O
herpesvirus	O
,	O
can	O
establish	O
both	O
nonproductive	O
(	O
latent	O
)	O
and	O
productive	O
(	O
lytic	O
)	O
infections	O
.	O
Although	O
the	O
CD8	O
+	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
latently	O
infected	O
cells	O
is	O
well	O
characterized	O
,	O
very	O
little	O
is	O
known	O
about	O
T	O
cell	O
controls	O
over	O
lytic	O
infection	O
;	O
this	O
imbalance	O
in	O
our	O
understanding	O
belies	O
the	O
importance	O
of	O
virus	O
-	O
replicative	O
lesions	O
in	O
several	O
aspects	O
of	O
EBV	O
disease	O
pathogenesis	O
.	O
The	O
present	O
work	O
shows	O
that	O
the	O
primary	O
CD8	O
+	O
CTL	O
response	O
to	O
EBV	O
in	O
infectious	O
mononucleosis	O
patients	O
contains	O
multiple	O
lytic	O
antigen	O
-	O
specific	O
reactivities	O
at	O
levels	O
at	O
least	O
as	O
high	O
as	O
those	O
seen	O
against	O
latent	B
antigens	I
;	O
similar	O
reactivities	O
are	O
also	O
detectable	O
in	O
CTL	O
memory	O
.	O
Clonal	O
analysis	O
revealed	O
individual	O
responses	O
to	O
the	O
two	O
immediate	B
early	I
proteins	I
BZLF1	B
and	O
BRLF1	B
,	O
and	O
to	O
three	O
(	O
BMLF1	B
,	O
BMRF1	B
,	O
and	O
BALF2	B
)	O
of	O
the	O
six	O
early	B
proteins	I
tested	O
.	O
In	O
several	O
cases	O
,	O
the	O
peptide	O
epitope	O
and	O
HLA	O
-	O
restricting	O
determinant	O
recognized	O
by	O
these	O
CTLs	O
has	O
been	O
defined	O
,	O
one	O
unusual	O
feature	O
being	O
the	O
number	O
of	O
responses	O
restricted	O
through	O
HLA	O
-	O
C	O
alleles	O
.	O
The	O
work	O
strongly	O
suggests	O
that	O
EBV	O
-	O
replicative	O
lesions	O
are	O
subject	O
to	O
direct	O
CTL	O
control	O
in	O
vivo	O
and	O
that	O
immediate	B
early	I
and	I
early	I
proteins	I
are	O
frequently	O
the	O
immunodominant	O
targets	O
.	O
This	O
contrasts	O
with	O
findings	O
in	O
alpha-	O
and	O
beta-	O
herpesvirus	O
systems	O
(	O
herpes	O
simplex	O
,	O
cytomegalovirus	O
)	O
where	O
viral	O
interference	O
with	O
the	O
antigen	O
-	O
processing	O
pathway	O
during	O
lytic	O
infection	O
renders	O
immediate	B
early	I
and	I
early	I
proteins	I
much	O
less	O
immunogenic	O
.	O
The	O
unique	O
capacity	O
of	O
gamma	O
-	O
herpesvirus	O
to	O
amplify	O
the	O
viral	O
load	O
in	O
vivo	O
through	O
a	O
latent	O
growth	O
-	O
transforming	O
infection	O
may	O
have	O
rendered	O
these	O
agents	O
less	O
dependent	O
upon	O
viral	O
replication	O
as	O
a	O
means	O
of	O
successfully	O
colonizing	O
their	O
hosts	O
.	O
Cellular	O
redox	O
status	O
influences	O
both	O
cytotoxic	O
and	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
natural	O
killer	O
cells	O
.	O
The	O
role	O
of	O
cellular	O
redox	O
status	O
in	O
both	O
cytotoxic	O
activity	O
and	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
was	O
investigated	O
.	O
The	O
results	O
indicate	O
that	O
stimulation	O
of	O
NK	O
cells	O
,	O
either	O
freshly	O
isolated	O
from	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
or	O
long	O
-	O
term	O
cultured	O
NK	O
clones	O
,	O
with	O
specific	O
cell	O
targets	O
results	O
in	O
an	O
increased	O
binding	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
transcription	B
factors	I
measured	O
by	O
gel	O
retardation	O
.	O
Pretreatment	O
of	O
NK	O
cells	O
with	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbarmate	O
(	O
PDTC	O
)	O
leads	O
to	O
the	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
but	O
the	O
AP-1	B
binding	O
to	O
DNA	O
was	O
superinduced	O
.	O
The	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
by	O
PDTC	O
paralleled	O
with	O
an	O
inhibition	O
of	O
spontaneous	O
cytotoxicity	O
mediated	O
by	O
NK	O
cells	O
.	O
Moreover	O
,	O
the	O
inhibitors	O
of	O
serine	B
proteases	I
,	O
N	O
-	O
alpha	O
-	O
tosyl	O
-	O
L	O
-	O
lysine	O
chloromethyl	O
ketone	O
and	O
N	O
-	O
alpha	O
-	O
tosyl	O
-	O
L	O
-	O
phenylalanine	O
chloromethyl	O
ketone	O
,	O
also	O
blocked	O
the	O
cytolytic	O
activity	O
of	O
NK	O
cells	O
against	O
the	O
sensitive	O
target	O
K562	O
.	O
In	O
contrast	O
,	O
NK	O
activity	O
was	O
not	O
affected	O
by	O
pretreatment	O
of	O
the	O
effector	O
cells	O
with	O
the	O
proteasome	B
inhibitor	O
N	O
-	O
acetyl	O
-	O
leu	O
-	O
leu	O
-	O
norleucinal	O
which	O
selectively	O
inhibits	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
Altogether	O
,	O
these	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
activation	O
of	O
NK	O
cells	O
involved	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
events	O
,	O
and	O
that	O
reactive	O
intermediates	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
molecular	O
processes	O
related	O
with	O
the	O
generation	O
of	O
a	O
cytotoxic	O
response	O
by	O
NK	O
cells	O
.	O
Homodimerization	O
of	O
the	O
human	B
interleukin	I
4	I
receptor	I
alpha	I
chain	I
induces	O
Cepsilon	O
germline	O
transcripts	O
in	O
B	O
cells	O
in	O
the	O
absence	O
of	O
the	O
interleukin	B
2	I
receptor	I
gamma	I
chain	I
.	O
The	O
cytokines	B
interleukin	B
(	I
IL	I
)	I
-4	I
and	O
IL-13	B
play	O
a	O
critical	O
role	O
in	O
inducing	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	B
isotype	I
switching	O
in	O
human	O
B	O
cells	O
.	O
The	O
IL-4	B
receptor	I
(	O
IL-4R	B
)	O
in	O
B	O
cells	O
is	O
composed	O
of	O
two	O
chains	O
,	O
the	O
IL-4-binding	B
IL-4Ralpha	I
chain	I
,	O
which	O
is	O
shared	O
with	O
the	O
IL-13R	B
,	O
and	O
the	O
IL-2Rgamma	B
(	I
gammac	I
)	I
chain	I
,	O
which	O
is	O
shared	O
with	O
IL-7R	B
,	O
IL-9R	B
,	O
and	O
IL-15R	B
.	O
IL-4	B
induces	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	B
isotype	I
switching	O
in	O
B	O
cells	O
from	O
patients	O
with	O
gammac	B
chain	I
deficiency	O
.	O
Induction	O
of	O
Cepsilon	O
germline	O
transcripts	O
by	O
IL-4	B
in	O
B	O
cells	O
that	O
lack	O
the	O
gammac	B
chain	I
may	O
involve	O
signaling	O
via	O
the	O
IL-13R	B
.	O
Alternatively	O
,	O
the	O
IL-4Ralpha	B
chain	I
may	O
transduce	O
intracellular	O
signals	O
that	O
lead	O
to	O
Cepsilon	O
gene	O
transcription	O
independently	O
of	O
its	O
association	O
with	O
other	O
chains	O
.	O
We	O
show	O
that	O
ligand	O
-	O
induced	O
homodimerization	O
of	O
chimeric	B
surface	I
receptors	I
consisting	O
of	O
the	O
extracellular	B
and	I
transmembrane	I
domains	I
of	O
the	O
erythropoietin	B
receptor	I
and	O
of	O
the	O
intracellular	B
domain	I
of	O
IL-4Ralpha	B
induces	O
Janus	B
kinase	I
1	I
(	O
Jak1	B
)	O
activation	O
,	O
STAT6	B
activation	O
,	O
and	O
Cepsilon	O
germline	O
transcripts	O
in	O
human	O
B	O
cell	O
line	O
BJAB	O
.	O
Disruption	O
of	O
the	O
Jak1-binding	B
proline	I
-	I
rich	I
Box1	I
region	I
of	O
IL-4Ralpha	B
abolished	O
signaling	O
by	O
this	O
chimeric	B
receptor	I
.	O
Furthermore	O
,	O
B	O
cells	O
transfected	O
with	O
a	O
chimeric	B
CD8alpha	I
/	I
IL-4Ralpha	I
receptor	I
,	O
which	O
is	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
a	O
homodimer	B
,	O
constitutively	O
expressed	O
Cepsilon	O
germline	O
transcripts	O
.	O
These	O
results	O
suggest	O
that	O
homodimerization	O
of	O
the	O
IL-4Ralpha	B
chain	I
is	O
sufficient	O
to	O
transduce	O
Jak1	B
-dependent	O
intracellular	O
signals	O
that	O
lead	O
to	O
IgE	B
isotype	I
switching	O
.	O
Abnormal	O
T	O
lymphocyte	O
development	O
induced	O
by	O
targeted	O
overexpression	O
of	O
IkappaB	B
alpha	I
.	O
A	O
role	O
in	O
thymic	O
maturation	O
for	O
factors	O
of	O
the	O
NF	B
-	I
kappaB	I
family	I
has	O
long	O
been	O
suspected	O
,	O
but	O
not	O
yet	O
proven	O
.	O
Transgenic	O
mice	O
with	O
a	O
lymphocyte	O
-	O
specific	O
defect	O
in	O
NF	B
-	I
kappaB	I
activation	O
were	O
produced	O
by	O
targeted	O
expression	O
of	O
human	O
IkappaB	B
alpha	I
.	O
The	O
thymic	O
cellularity	O
of	O
these	O
mice	O
was	O
significantly	O
decreased	O
.	O
The	O
proportion	O
of	O
mature	O
,	O
TCRhigh	O
thymocytes	O
of	O
the	O
alphabeta	O
lineage	O
was	O
reduced	O
,	O
and	O
the	O
remaining	O
TCRhigh	O
population	O
contained	O
an	O
unusually	O
high	O
proportion	O
of	O
double	O
-	O
positive	O
cells	O
.	O
This	O
defect	O
in	O
maturation	O
resulted	O
in	O
a	O
transgene	O
dose	O
-	O
dependent	O
reduction	O
in	O
peripheral	O
T	O
lymphocytes	O
,	O
with	O
the	O
CD8	O
lineage	O
being	O
more	O
severely	O
affected	O
.	O
These	O
data	O
provide	O
direct	O
evidence	O
for	O
the	O
involvement	O
of	O
NF	B
-	I
kappaB	I
/	I
Rel	I
family	I
proteins	I
in	O
late	O
stages	O
of	O
T	O
lymphocyte	O
development	O
,	O
coincident	O
with	O
positive	O
and	O
negative	O
selection	O
.	O
Sequential	O
development	O
of	O
structural	O
and	O
functional	O
alterations	O
in	O
T	O
cells	O
from	O
tumor	O
-	O
bearing	O
mice	O
.	O
The	O
TCR	B
alpha	I
beta	I
or	I
-gamma	I
delta	I
chains	I
bind	O
the	O
peptide	O
ligand	O
,	O
whereas	O
the	O
associated	O
CD3	B
delta	I
epsilon	I
gamma	I
and	O
TCR	B
zeta	I
subunits	I
couple	O
the	O
TCR	B
to	O
intracellular	O
signal	O
transduction	O
components	O
.	O
Recently	O
,	O
several	O
groups	O
have	O
described	O
marked	O
alterations	O
in	O
signal	O
transduction	O
elements	O
in	O
T	O
cells	O
from	O
cancer	O
patients	O
or	O
in	O
mice	O
bearing	O
tumor	O
for	O
a	O
few	O
weeks	O
(	O
>	O
26	O
days	O
)	O
.	O
The	O
sequence	O
in	O
which	O
these	O
alterations	O
develop	O
is	O
unknown	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
kinetics	O
of	O
the	O
development	O
of	O
alterations	O
in	O
signal	O
transduction	O
molecules	O
(	O
TCR	B
zeta	I
chain	I
,	O
NF	B
kappaB	I
family	I
proteins	I
,	O
and	O
tyrosine	B
kinase	I
p56	I
(	I
lck	I
)	I
)	O
in	O
mice	O
bearing	O
MC38	O
colon	O
adenocarcinoma	O
.	O
The	O
results	O
demonstrate	O
that	O
alterations	O
in	O
NF	B
kappaB	I
family	I
proteins	I
,	O
specifically	O
the	O
failure	O
of	O
p65	B
translocation	O
to	O
the	O
nucleus	O
,	O
occur	O
earlier	O
and	O
more	O
frequently	O
than	O
the	O
decrease	O
in	O
zeta	B
-	I
chain	I
.	O
These	O
defects	O
are	O
paralleled	O
by	O
an	O
impaired	O
ability	O
to	O
produce	O
Th1	B
cytokines	I
(	O
IL-2	B
and	O
IFN	B
-	I
gamma	I
)	O
.	O
These	O
initial	O
changes	O
are	O
followed	O
by	O
the	O
eventual	O
loss	O
of	O
TCR	B
zeta	I
chain	I
and	O
p56	B
(	I
lck	I
)	I
and	O
a	O
marked	O
decrease	O
in	O
cytotoxic	O
function	O
.	O
An	O
increased	O
rate	O
of	O
lysosomal	O
degradation	O
is	O
one	O
of	O
the	O
mechanisms	O
responsible	O
for	O
the	O
loss	O
of	O
zeta	B
-	I
chain	I
.	O
Characterization	O
of	O
interleukin-10	B
receptor	I
expression	O
on	O
B	O
-	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
cells	O
.	O
B	O
-	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
B	O
-	O
CLL	O
)	O
cells	O
accumulate	O
in	O
vivo	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
suggesting	O
that	O
their	O
malignant	O
expansion	O
is	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
delay	O
in	O
cell	O
death	O
.	O
However	O
,	O
the	O
cellular	O
or	O
molecular	B
factors	I
responsible	O
for	O
a	O
delay	O
in	O
B	O
-	O
CLL	O
cell	O
death	O
are	O
unknown	O
.	O
B	O
-	O
CLL	O
cells	O
do	O
express	O
receptors	O
for	O
interferon	B
-	I
alpha	I
(	O
IFN	B
-	I
alpha	I
)	O
and	O
IFN	B
-	I
gamma	I
,	O
and	O
activation	O
of	O
both	O
has	O
been	O
shown	O
to	O
promote	O
B	O
-	O
CLL	O
survival	O
in	O
vitro	O
by	O
preventing	O
apoptosis	O
.	O
The	O
interleukin-10	B
(	I
IL-10	I
)	I
receptor	I
is	O
another	O
member	O
of	O
the	O
IFN	B
receptor	I
family	I
,	O
but	O
its	O
ligand	O
,	O
IL-10	B
,	O
has	O
been	O
reported	O
to	O
induce	O
apoptosis	O
in	O
B	O
-	O
CLL	O
cells	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
undertook	O
a	O
biochemical	O
analysis	O
of	O
IL-10	B
receptor	I
expression	O
on	O
freshly	O
isolated	O
B	O
-	O
CLL	O
cells	O
and	O
characterized	O
the	O
functional	O
responsiveness	O
of	O
IL-10	B
binding	O
to	O
its	O
constitutively	B
expressed	I
receptor	I
.	O
We	O
show	O
that	O
B	O
-	O
CLL	O
cells	O
bind	O
IL-10	B
with	O
significant	O
specificity	O
and	O
express	O
between	O
47	O
and	O
127	O
IL-10	B
receptor	I
sites	O
per	O
cell	O
,	O
with	O
a	O
dissociation	O
constant	O
in	O
the	O
range	O
of	O
168	O
to	O
426	O
x	O
10	O
(	O
-12	O
)	O
mol	O
/	O
L	O
.	O
Ligand	O
binding	O
and	O
activation	O
of	O
the	O
IL-10	B
receptor	I
expressed	O
on	O
B	O
-	O
CLL	O
cells	O
results	O
in	O
the	O
phosphorylation	O
of	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
1	I
(	O
STAT1	B
)	O
and	O
STAT3	B
proteins	O
.	O
This	O
pattern	O
of	O
STAT	B
protein	I
phosphorylation	O
is	O
identical	O
to	O
IL-10	B
receptor	I
activation	O
on	O
normal	O
cells	O
and	O
similar	O
to	O
IFN	B
-	I
alpha	I
(	O
STAT1	B
and	O
STAT3	B
)	O
and	O
IFN	B
-	I
gamma	I
(	O
STAT1	B
)	O
receptor	O
activation	O
in	O
CLL	O
.	O
Further	O
,	O
in	O
consecutive	O
samples	O
of	O
fresh	O
blood	O
obtained	O
from	O
patients	O
with	O
B	O
-	O
CLL	O
cells	O
,	O
the	O
addition	O
of	O
IL-10	B
inhibited	O
B	O
-	O
CLL	O
proliferation	O
,	O
enhanced	O
B	O
-	O
CLL	O
differentiation	O
,	O
but	O
did	O
not	O
induce	O
apoptosis	O
.	O
Indeed	O
,	O
IL-10	B
,	O
like	O
IFN	B
-	I
gamma	I
,	O
was	O
able	O
to	O
significantly	O
reduce	O
the	O
amount	O
of	O
B	O
-	O
CLL	O
cell	O
death	O
caused	O
by	O
hydrocortisone	O
-	O
induced	O
apoptosis	O
.	O
We	O
conclude	O
that	O
cytokines	B
,	O
which	O
signal	O
through	O
the	O
interferon	B
family	I
of	O
receptors	O
,	O
have	O
comparable	O
functional	O
effects	O
on	O
B	O
-	O
CLL	O
cells	O
.	O
Tap	B
:	O
a	O
novel	O
cellular	B
protein	I
that	O
interacts	O
with	O
tip	O
of	O
herpesvirus	O
saimiri	O
and	O
induces	O
lymphocyte	O
aggregation	O
.	O
Tip	O
of	O
herpesvirus	O
saimiri	O
associates	O
with	O
Lck	B
and	O
down	O
-	O
regulates	O
Lck	B
-mediated	O
activation	O
.	O
We	O
identified	O
a	O
novel	O
cellular	O
Tip	B
-	I
associated	I
protein	I
(	O
Tap	B
)	O
by	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
.	O
Tap	B
associated	O
with	O
Tip	B
following	O
transient	O
expression	O
in	O
COS-1	O
cells	O
and	O
stable	O
expression	O
in	O
human	O
Jurkat	O
-	O
T	O
cells	O
.	O
Expression	O
of	O
Tip	B
and	O
Tap	B
in	O
Jurkat	O
-	O
T	O
cells	O
induced	O
dramatic	O
cell	O
aggregation	O
.	O
Aggregation	O
was	O
likely	O
caused	O
by	O
the	O
up	O
-	O
regulated	O
surface	O
expression	O
of	O
adhesion	B
molecules	I
including	O
integrin	B
alpha	I
,	O
L	B
-	I
selectin	I
,	O
ICAM-3	B
,	O
and	O
H	B
-	I
CAM	I
.	O
Furthermore	O
,	O
NF	B
-	I
kappaB	I
transcriptional	I
factor	I
of	O
aggregated	O
cells	O
had	O
approximately	O
40-fold	O
higher	O
activity	O
than	O
that	O
of	O
parental	O
cells	O
.	O
Thus	O
,	O
Tap	B
is	O
likely	O
to	O
be	O
an	O
important	O
cellular	O
mediator	O
of	O
Tip	B
function	O
in	O
T	O
cell	O
transformation	O
by	O
herpesvirus	O
saimiri	O
.	O
CCAAT	B
/	I
enhancer	I
binding	I
protein	I
epsilon	I
is	O
preferentially	O
up	O
-	O
regulated	O
during	O
granulocytic	O
differentiation	O
and	O
its	O
functional	O
versatility	O
is	O
determined	O
by	O
alternative	O
use	O
of	O
promoters	O
and	O
differential	O
splicing	O
.	O
CCAAT	B
/	I
enhancer	I
binding	I
protein	I
(	I
C	I
/	I
EBP	I
)	I
epsilon	I
is	O
a	O
recently	O
cloned	O
member	O
of	O
the	O
C	B
/	I
EBP	I
family	I
of	O
transcription	B
factors	I
and	O
is	O
expressed	O
exclusively	O
in	O
cells	O
of	O
hematopoietic	O
origin	O
.	O
The	O
human	O
C	O
/	O
EBPepsilon	O
gene	O
is	O
transcribed	O
by	O
two	O
alternative	O
promoters	O
,	O
Palpha	O
and	O
Pbeta	O
.	O
A	O
combination	O
of	O
differential	O
splicing	O
and	O
alternative	O
use	O
of	O
promoters	O
generates	O
four	O
mRNA	O
isoforms	O
,	O
of	O
2.6	O
kb	O
and	O
1.3	O
-	O
1.5	O
kb	O
in	O
size	O
.	O
These	O
transcripts	O
can	O
encode	O
three	O
proteins	O
of	O
calculated	O
molecular	O
mass	O
32.2	O
kDa	O
,	O
27.8	O
kDa	O
,	O
and	O
14.3	O
kDa	O
.	O
Accordingly	O
,	O
Western	O
blots	O
with	O
antibodies	B
specific	O
for	O
the	O
DNA	O
-	O
binding	O
domain	O
,	O
that	O
is	O
common	O
to	O
all	O
forms	O
,	O
identify	O
multiple	O
proteins	O
.	O
C	O
/	O
EBPepsilon	O
mRNA	O
was	O
greatly	O
induced	O
during	O
in	O
vitro	O
granulocytic	O
differentiation	O
of	O
human	O
primary	O
CD34	O
(	O
+	O
)	O
cells	O
.	O
Retinoic	O
acid	O
treatment	O
of	O
HL60	O
promyelocytic	O
leukemia	O
cells	O
for	O
24	O
hr	O
induced	O
C	O
/	O
EBPepsilon	O
mRNA	O
levels	O
by	O
4-fold	O
,	O
while	O
prolonged	O
treatment	O
gradually	O
reduced	O
mRNA	O
expression	O
to	O
pretreatment	O
levels	O
.	O
Transient	O
transfection	O
experiments	O
with	O
expression	O
vectors	O
for	O
two	O
of	O
the	O
isoforms	O
demonstrated	O
that	O
the	O
32.2-kDa	B
protein	I
is	O
an	O
activator	O
of	O
transcription	O
of	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
promoter	O
,	O
while	O
the	O
14.3-kDa	B
protein	I
is	O
not	O
.	O
Thus	O
,	O
C	B
/	I
EBPepsilon	I
is	O
regulated	O
in	O
a	O
complex	O
fashion	O
and	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	O
involved	O
in	O
myeloid	O
differentiation	O
.	O
Overexpression	O
of	O
HSF2-beta	B
inhibits	O
hemin	B
-induced	O
heat	O
shock	O
gene	O
expression	O
and	O
erythroid	O
differentiation	O
in	O
K562	O
cells	O
.	O
Acquisition	O
of	O
heat	O
shock	O
factor	O
2	O
(	O
HSF2	O
)	O
DNA	O
binding	O
activity	O
is	O
accompanied	O
by	O
induced	O
transcription	O
of	O
heat	O
shock	O
genes	O
in	O
hemin	O
-	O
treated	O
K562	O
cells	O
undergoing	O
erythroid	O
differentiation	O
.	O
Previous	O
studies	O
revealed	O
that	O
HSF2	B
consists	O
of	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
HSF2-alpha	B
and	O
HSF2-beta	B
,	O
whose	O
relative	O
abundance	O
is	O
developmentally	O
regulated	O
and	O
varies	O
between	O
different	O
tissues	O
.	O
To	O
investigate	O
whether	O
the	O
molar	O
ratio	O
of	O
HSF2-alpha	B
and	O
HSF2-beta	B
isoforms	O
is	O
crucial	O
for	O
the	O
activation	O
of	O
HSF2	B
and	O
whether	O
the	O
HSF2	B
isoforms	O
play	O
functionally	O
distinct	O
roles	O
during	O
the	O
hemin	O
-	O
mediated	O
erythroid	O
differentiation	O
,	O
we	O
generated	O
cell	O
clones	O
expressing	O
different	O
levels	O
of	O
HSF2-alpha	B
and	O
HSF2-beta	B
.	O
We	O
show	O
that	O
in	O
parental	O
K562	O
cells	O
,	O
the	O
HSF2-alpha	B
isoform	I
is	O
predominantly	O
expressed	O
and	O
HSF2	B
can	O
be	O
activated	O
upon	O
hemin	O
treatment	O
.	O
In	O
contrast	O
,	O
when	O
HSF2-beta	B
is	O
expressed	O
at	O
levels	O
exceeding	O
those	O
of	O
endogenous	B
HSF2-alpha	I
,	O
the	O
hemin	O
-	O
induced	O
DNA	O
binding	O
activity	O
and	O
transcription	O
of	O
heat	O
shock	O
genes	O
are	O
repressed	O
,	O
whereas	O
overexpression	O
of	O
HSF2-alpha	B
results	O
in	O
an	O
enhanced	O
hemin	B
response	O
.	O
Furthermore	O
,	O
the	O
hemin	B
-induced	O
accumulation	O
of	O
globin	B
,	O
known	O
as	O
a	O
marker	O
of	O
erythroid	O
differentiation	O
,	O
is	O
decreased	O
in	O
cells	O
overexpressing	O
HSF2-beta	B
.	O
We	O
suggest	O
that	O
HSF2-beta	B
acts	O
as	O
a	O
negative	O
regulator	O
of	O
HSF2	B
activity	O
during	O
hemin	O
-	O
mediated	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
.	O
Glucocorticoid	O
-	O
mediated	O
repression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	O
arteritis	B
-	I
SCID	I
chimeras	I
.	O
Giant	O
cell	O
arteritis	O
(	O
GCA	O
)	O
is	O
a	O
vasculitic	O
syndrome	O
that	O
preferentially	O
affects	O
medium	O
and	O
large	O
-	O
sized	O
arteries	O
.	O
Glucocorticoid	O
therapy	O
resolves	O
clinical	O
symptoms	O
within	O
hours	O
to	O
days	O
,	O
but	O
therapy	O
has	O
to	O
be	O
continued	O
over	O
several	O
years	O
to	O
prevent	O
disease	O
relapses	O
.	O
It	O
is	O
not	O
known	O
whether	O
and	O
how	O
glucocorticoids	O
affect	O
the	O
function	O
of	O
the	O
inflammatory	O
infiltrate	O
or	O
why	O
the	O
disease	O
persists	O
subclinically	O
despite	O
chronic	O
treatment	O
.	O
GCA	O
is	O
self	O
-	O
sustained	O
in	O
temporal	O
arteries	O
engrafted	O
into	O
SCID	O
mice	O
,	O
providing	O
a	O
model	O
in	O
which	O
the	O
mechanisms	O
of	O
action	O
and	O
limitations	O
of	O
glucocorticoid	O
therapy	O
can	O
be	O
examined	O
in	O
vivo	O
.	O
Administration	O
of	O
dexamethasone	O
to	O
temporal	O
artery	O
-	O
SCID	O
chimeras	O
for	O
1	O
wk	O
induced	O
a	O
partial	O
suppression	O
of	O
T	O
cell	O
and	O
macrophage	O
function	O
as	O
indicated	O
by	O
the	O
reduced	O
tissue	O
concentrations	O
of	O
IL-2	O
,	O
IL-1beta	O
,	O
and	O
IL-6	O
mRNA	O
,	O
and	O
by	O
the	O
diminished	O
expression	O
of	O
inducible	O
NO	B
synthase	I
.	O
In	O
contrast	O
,	O
synthesis	O
of	O
IFN	O
-	O
gamma	O
mRNA	O
was	O
only	O
slightly	O
decreased	O
,	O
and	O
expression	O
of	O
TGF	B
-	I
beta1	I
was	O
unaffected	O
.	O
These	O
findings	O
correlated	O
with	O
activation	O
of	O
the	O
IkappaBalpha	O
gene	O
and	O
blockade	O
of	O
the	O
nuclear	O
translocation	O
of	O
NFkappaB	B
in	O
the	O
xenotransplanted	O
tissue	O
.	O
Dose	O
-	O
response	O
experiments	O
suggested	O
that	O
steroid	O
doses	O
currently	O
used	O
in	O
clinical	O
medicine	O
are	O
suboptimal	O
in	O
repressing	O
NFkappaB	B
-mediated	O
cytokine	B
production	O
in	O
the	O
inflammatory	O
lesions	O
.	O
Chronic	O
steroid	O
therapy	O
was	O
able	O
to	O
deplete	O
the	O
T	B
cell	I
products	I
IL-2	B
and	O
IFN	B
-	I
gamma	I
,	O
whereas	O
the	O
activation	O
of	O
tissue	O
-	O
infiltrating	O
macrophages	O
was	O
only	O
partially	O
affected	O
.	O
IL-1beta	B
transcription	O
was	O
abrogated	O
;	O
in	O
contrast	O
,	O
TGF	O
-	O
beta1	O
mRNA	O
synthesis	O
was	O
steroid	O
resistant	O
.	O
The	O
persistence	O
of	O
TGF	O
-	O
beta1-transcribing	O
macrophages	O
,	O
despite	O
paralysis	O
of	O
T	O
cell	O
function	O
,	O
may	O
provide	O
an	O
explanation	O
for	O
the	O
chronicity	O
of	O
the	O
disease	O
,	O
and	O
may	O
identify	O
a	O
novel	O
therapeutic	O
target	O
in	O
this	O
inflammatory	O
vasculopathy	O
.	O
Concomitant	O
downregulation	O
of	O
IgH	O
3	O
'	O
enhancer	O
activity	O
and	O
c	O
-	O
myc	O
expression	O
in	O
a	O
plasmacytoma	O
x	O
fibroblast	O
environment	O
:	O
implications	O
for	O
dysregulation	O
of	O
translocated	O
c	O
-	O
myc	O
.	O
Regulation	O
of	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
gene	O
expression	O
is	O
controlled	O
by	O
a	O
B	O
cell	O
-	O
specific	O
promoter	O
,	O
intronic	O
enhancer	O
and	O
additional	O
B	O
cell	O
-	O
specific	O
enhancer	O
elements	O
identified	O
recently	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
IgH	O
locus	O
.	O
One	O
of	O
the	O
latter	O
elements	O
,	O
the	O
IgH	O
3	O
'	O
enhancer	O
,	O
is	O
of	O
particular	O
interest	O
:	O
(	O
1	O
)	O
it	O
is	O
B	O
cell	O
-	O
specific	O
and	O
active	O
only	O
in	O
late	O
B	O
cell	O
development	O
;	O
(	O
2	O
)	O
in	O
rodent	O
plasmacytomas	O
and	O
in	O
some	O
human	O
Burkitt	O
's	O
lymphomas	O
it	O
is	O
part	O
of	O
a	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
that	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
c	O
-	O
myc	O
oncogene	O
as	O
a	O
result	O
of	O
translocation	O
into	O
the	O
IgH	O
locus	O
;	O
and	O
(	O
3	O
)	O
it	O
has	O
been	O
implicated	O
in	O
the	O
mechanisms	O
that	O
control	O
Ig	O
gene	O
class	O
switch	O
recombination	O
.	O
We	O
have	O
used	O
a	O
somatic	O
cell	O
hybridization	O
approach	O
to	O
genetically	O
analyse	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
IgH	O
3	O
'	O
enhancer	O
.	O
When	O
mouse	O
MPC11	O
plasmacytoma	O
cells	O
,	O
in	O
which	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
active	O
,	O
are	O
fused	O
with	O
fibroblasts	O
,	O
Ig	O
expression	O
is	O
extinguished	O
at	O
the	O
level	O
of	O
transcription	O
.	O
Here	O
we	O
show	O
that	O
in	O
a	O
MPC11	O
plasmacytoma	O
x	O
fibroblast	O
environment	O
,	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
transcriptionally	O
inactive	O
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
binding	O
of	O
several	O
B	B
cell	I
-	I
specific	I
transcription	I
factors	I
,	O
essential	O
for	O
IgH	O
3	O
'	O
enhancer	O
activity	O
,	O
is	O
lacking	O
,	O
which	O
may	O
explain	O
3	O
'	O
enhancer	O
inactivity	O
,	O
although	O
the	O
binding	O
of	O
repressors	O
can	O
not	O
be	O
excluded	O
.	O
Moreover	O
,	O
the	O
high	O
expression	O
level	O
of	O
c	O
-	O
myc	O
,	O
characteristic	O
of	O
the	O
parental	O
MPC11	O
cells	O
carrying	O
the	O
t	O
(	O
12	O
;	O
15	O
)	O
translocation	O
,	O
is	O
down	O
-	O
regulated	O
in	O
the	O
hybrids	O
to	O
that	O
in	O
unfused	O
fibroblasts	O
.	O
Therefore	O
,	O
inactivation	O
of	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
a	O
multifactorial	O
process	O
affecting	O
several	O
transcription	B
factors	I
that	O
control	O
the	O
cell	O
-	O
specific	O
and	O
developmental	O
activity	O
of	O
the	O
enhancer	O
.	O
Construction	O
and	O
biological	O
characterization	O
of	O
an	O
interleukin-12	B
fusion	I
protein	I
(	O
Flexi-12	B
)	O
:	O
delivery	O
to	O
acute	O
myeloid	O
leukemic	O
blasts	O
using	O
adeno	O
-	O
associated	O
virus	O
.	O
Interleukin-12	B
(	O
IL-12	B
)	O
is	O
a	O
cytokine	B
that	O
exhibits	O
pleiotropic	O
effects	O
on	O
lymphocytes	O
and	O
natural	O
killer	O
cells	O
and	O
has	O
been	O
shown	O
to	O
have	O
promise	O
for	O
the	O
immunotherapy	O
of	O
cancer	O
.	O
The	O
combination	O
of	O
the	O
immune	B
costimulatory	I
molecule	I
B7.1	B
and	O
IL-12	B
has	O
been	O
shown	O
to	O
be	O
synergistic	O
for	O
T	O
cell	O
activation	O
.	O
By	O
transfecting	O
tumor	O
cells	O
with	O
both	O
IL-12	O
and	O
B7.1	O
cDNAs	O
,	O
it	O
may	O
be	O
possible	O
to	O
use	O
these	O
modified	O
targets	O
as	O
vaccines	O
.	O
A	O
major	O
obstacle	O
in	O
designing	O
a	O
vector	O
to	O
deliver	O
these	O
genes	O
results	O
from	O
the	O
structure	O
of	O
IL-12	B
.	O
Functional	O
IL-12	B
is	O
a	O
heterodimer	B
composed	O
of	O
two	O
distinct	O
subunits	O
that	O
are	O
encoded	O
by	O
separate	O
genes	O
on	O
different	O
chromosomes	O
.	O
Production	O
of	O
functional	B
IL-12	I
requires	O
the	O
coordinated	O
expression	O
of	O
both	O
genes	O
.	O
This	O
presents	O
several	O
problems	O
in	O
vectors	O
,	O
particularly	O
those	O
in	O
which	O
additional	O
genes	O
,	O
either	O
a	O
co	O
-	O
stimulatory	O
gene	O
or	O
a	O
selectable	O
marker	O
,	O
are	O
inserted	O
.	O
Therefore	O
,	O
we	O
have	O
constructed	O
a	O
single	O
cDNA	O
that	O
encodes	O
a	O
single	B
-	I
chain	I
protein	I
,	O
called	O
Flexi-12	B
,	O
which	O
retains	O
all	O
of	O
the	O
biological	O
characteristics	O
of	O
recombinant	O
IL-12	B
(	O
rIL-12	B
)	O
.	O
The	O
monomeric	O
polypeptide	O
Flexi-12	B
is	O
able	O
to	O
induce	O
the	O
proliferation	O
of	O
phytohemagglutinin	O
(	O
PHA	O
)	O
blasts	O
,	O
induce	O
PHA	O
blasts	O
to	O
secrete	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
and	O
additionally	O
,	O
by	O
preincubation	O
,	O
enhance	O
the	O
killing	O
of	O
K562	O
targets	O
by	O
PBLs	O
.	O
These	O
phenomena	O
are	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
comparable	O
to	O
that	O
seen	O
with	O
rIL-12	B
.	O
We	O
have	O
also	O
shown	O
that	O
tyrosine	O
phosphorylation	O
of	O
the	O
STAT	B
4	I
transcription	I
factor	I
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
unique	O
to	O
the	O
IL-12	B
signaling	O
pathway	O
,	O
occurs	O
with	O
Flexi-12	B
at	O
levels	O
similar	O
to	O
those	O
seen	O
with	O
rIL-12	B
.	O
We	O
have	O
packaged	O
Flexi-12	B
into	O
a	O
recombinant	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
and	O
used	O
this	O
vector	O
to	O
infect	O
acute	O
myeloid	O
leukemic	O
(	O
AML	O
)	O
blasts	O
.	O
Infected	O
AML	O
blasts	O
produced	O
between	O
2	O
and	O
6	O
ng	O
of	O
IL-12	O
/	O
10	O
(	O
6	O
)	O
cells	O
per	O
ml	O
per	O
48	O
hr	O
.	O
These	O
studies	O
also	O
confirm	O
that	O
AAV	O
is	O
an	O
efficient	O
delivery	O
vehicle	O
for	O
cytokines	B
to	O
leukemic	O
cells	O
.	O
Direct	O
analysis	O
of	O
these	O
modified	O
cells	O
acting	O
as	O
tumor	O
vaccines	O
is	O
underway	O
.	O
ETS1	B
,	O
NFkappaB	B
and	O
AP1	B
synergistically	O
transactivate	O
the	O
human	O
GM	O
-	O
CSF	O
promoter	O
.	O
Activation	O
of	O
helper	O
T	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	B
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O
Granulocyte	B
-	I
macrophage	I
colony	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
is	O
one	O
such	O
cytokine	B
,	O
whose	O
increased	O
expression	O
results	O
mostly	O
from	O
increases	O
in	O
transcription	O
.	O
Cis	O
-	O
acting	O
elements	O
with	O
NFkappaB	O
,	O
AP1	O
and	O
ETS	O
-	O
like	O
binding	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
,	O
and	O
are	O
important	O
or	O
essential	O
for	O
transcriptional	O
activity	O
following	O
T	O
cell	O
activation	O
.	O
ETS1	B
is	O
a	O
transcription	B
factor	I
of	O
the	O
ETS	B
family	I
that	O
is	O
expressed	O
in	O
T	O
cells	O
.	O
We	O
have	O
previously	O
shown	O
that	O
ETS1	B
can	O
transactivate	O
GM	B
-	I
CSF	I
in	O
Jurkat	O
T	O
cells	O
,	O
but	O
only	O
after	O
the	O
cells	O
have	O
been	O
stimulated	O
by	O
treatment	O
with	O
PMA	O
and	O
ionomycin	O
,	O
agents	O
that	O
mimic	O
T	O
cell	O
activation	O
.	O
Thus	O
we	O
proposed	O
that	O
ETS1	B
,	O
which	O
is	O
expressed	O
constitutively	O
in	O
Jurkat	O
cells	O
,	O
may	O
act	O
in	O
concert	O
with	O
PMA	B
/	I
ionomycin	I
inducible	I
factors	I
.	O
Here	O
we	O
show	O
that	O
ETS1	B
can	O
transactivate	O
a	O
GM	O
-	O
CSF	O
reporter	O
construct	O
in	O
unstimulated	O
Jurkat	O
cells	O
,	O
providing	O
that	O
either	O
NFkappaB	B
or	O
AP1	B
transcription	B
factors	I
are	O
supplied	O
by	O
co	O
-	O
transfection	O
.	O
We	O
confirm	O
that	O
binding	O
of	O
endogenous	O
NFkappaB	B
and	O
AP1	B
is	O
induced	O
following	O
PMA	O
/	O
ionomycin	O
treatment	O
of	O
T	O
cells	O
.	O
Transactivation	O
by	O
ETS1	B
,	O
NFkappaB	B
and	O
AP1	B
is	O
synergistic	O
,	O
and	O
mutation	O
of	O
the	O
individual	O
binding	O
sites	O
reveals	O
that	O
the	O
transcriptional	O
activities	O
of	O
these	O
factors	O
are	O
interdependent	O
.	O
Our	O
results	O
suggest	O
that	O
constitutive	O
ETS1	B
,	O
and	O
inducible	O
NFkappaB	B
and	O
AP1	B
,	O
cooperate	O
as	O
part	O
of	O
a	O
higher	O
order	O
transcriptional	B
complex	I
in	O
activated	O
T	O
cells	O
.	O
Relief	O
of	O
cyclin	B
A	I
gene	O
transcriptional	O
inhibition	O
during	O
activation	O
of	O
human	O
primary	O
T	O
lymphocytes	O
via	O
CD2	B
and	O
CD28	B
adhesion	B
molecules	I
.	O
Cyclin	B
A	I
transcription	O
is	O
cell	O
cycle	O
regulated	O
and	O
induced	O
by	O
cell	O
proliferative	O
signals	O
.	O
To	O
understand	O
the	O
mechanisms	O
underlined	O
in	O
this	O
regulation	O
in	O
normal	O
human	O
cells	O
,	O
we	O
have	O
analysed	O
in	O
vivo	O
protein	O
-	O
DNA	O
interactions	O
at	O
the	O
Cyclin	B
A	I
locus	O
in	O
primary	O
T	O
lymphocytes	O
.	O
Stimulation	O
of	O
purified	O
T	O
lymphocytes	O
by	O
a	O
combination	O
of	O
monoclonal	B
antibodies	I
directed	O
at	O
CD2	B
and	O
CD28	B
adhesion	B
molecules	I
gives	O
rise	O
to	O
a	O
long	O
lasting	O
proliferation	O
in	O
the	O
absence	O
of	O
accessory	O
cells	O
.	O
Cyclin	B
A	I
was	O
observed	O
after	O
4	O
days	O
of	O
costimulation	O
with	O
anti	B
CD2	I
+	O
CD28	B
whereas	O
stimulation	O
by	O
anti	B
CD2	I
or	O
anti	B
CD28	I
alone	O
was	O
not	O
effective	O
.	O
In	O
vivo	O
genomic	O
DMS	O
footprinting	O
revealed	O
upstream	O
of	O
the	O
major	O
transcription	O
initiation	O
sites	O
,	O
the	O
presence	O
of	O
at	O
least	O
three	O
protein	O
binding	O
sites	O
,	O
two	O
of	O
which	O
were	O
constitutively	O
occupied	O
.	O
They	O
bind	O
in	O
vitro	O
respectively	O
ATF-1	B
and	O
NF	B
-	I
Y	I
proteins	I
.	O
The	O
third	O
site	O
was	O
occupied	O
in	O
quiescent	O
cells	O
or	O
in	O
cells	O
stimulated	O
by	O
anti	B
CD2	I
or	O
anti	B
CD28	I
alone	O
.	O
The	O
mitogenic	O
combination	O
of	O
anti	B
CD2	I
+	O
anti	B
CD28	I
released	O
the	O
footprint	O
as	O
cells	O
were	O
committed	O
to	O
proliferation	O
.	O
Consistent	O
with	O
theses	O
results	O
,	O
nuclear	O
extracts	O
prepared	O
from	O
quiescent	O
cells	O
formed	O
a	O
specific	O
complex	O
with	O
this	O
element	O
,	O
whereas	O
extracts	O
prepared	O
from	O
cells	O
treated	O
with	O
anti	B
CD2	I
+	O
anti	B
CD28	I
failed	O
to	O
do	O
so	O
after	O
cells	O
entered	O
a	O
proliferative	O
state	O
.	O
Thrombin	B
generation	O
by	O
apoptotic	O
vascular	O
smooth	O
muscle	O
cells	O
.	O
Thrombin	B
activation	O
requires	O
assembly	O
of	O
a	O
prothrombinase	B
complex	I
of	O
activated	O
coagulation	B
factors	I
on	O
an	O
anionic	O
phospholipid	O
surface	O
,	O
classically	O
provided	O
by	O
activated	O
platelets	O
.	O
We	O
have	O
previously	O
shown	O
that	O
anionic	O
phosphatidylserine	O
is	O
exposed	O
by	O
rat	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
undergoing	O
apoptosis	O
after	O
serum	O
withdrawal	O
.	O
In	O
this	O
study	O
,	O
using	O
a	O
chromogenic	O
assay	O
,	O
we	O
have	O
shown	O
thrombin	B
generation	O
by	O
apoptotic	O
VSMCs	O
expressing	O
c	B
-	I
myc	I
(	O
VSMC	O
-	O
myc	O
)	O
with	O
an	O
area	O
under	O
the	O
thrombin	B
-generation	O
curve	O
(	O
AUC	O
)	O
of	O
305	O
+	O
/-	O
17	O
nmol	O
x	O
min	O
/	O
L	O
and	O
a	O
peak	O
thrombin	B
(	O
PT	O
)	O
of	O
154	O
+	O
/-	O
9	O
nmol	O
/	O
L	O
.	O
The	O
thrombin	B
-generating	O
potential	O
of	O
the	O
apoptotic	O
VSMC	O
-	O
myc	O
cells	O
was	O
greater	O
than	O
that	O
of	O
unactivated	O
platelets	O
(	O
P	O
=	O
.003	O
for	O
AUC	O
;	O
P	O
=	O
.0002	O
for	O
PT	O
)	O
and	O
similar	O
to	O
calcium	O
-	O
ionophore	O
activated	O
platelets	O
(	O
AUC	O
of	O
332	O
+	O
/-	O
15	O
nmol	O
x	O
min	O
/	O
L	O
,	O
P	O
=	O
.3	O
;	O
PT	O
of	O
172	O
+	O
/-	O
8	O
nmol	O
/	O
L	O
,	O
P	O
=	O
.2	O
)	O
.	O
Thrombin	B
activation	O
was	O
also	O
seen	O
with	O
apoptotic	O
human	O
VSMCs	O
(	O
AUC	O
of	O
211	O
+	O
/-	O
8	O
nmol	O
x	O
min	O
/	O
L	O
;	O
PT	O
of	O
103	O
+	O
/-	O
4	O
nmol	O
/	O
L	O
)	O
and	O
was	O
inhibited	O
by	O
annexin	O
V	O
(	O
P	O
<	O
.0001	O
for	O
AUC	O
and	O
PT	O
)	O
.	O
VSMC	O
-	O
myc	O
cells	O
maintained	O
in	O
serum	O
generated	O
less	O
thrombin	B
than	O
after	O
serum	O
withdrawal	O
(	O
P	O
=	O
.0002	O
for	O
AUC	O
and	O
PT	O
)	O
.	O
VSMCs	O
derived	O
from	O
human	O
coronary	O
atherosclerotic	O
plaques	O
that	O
apoptose	O
even	O
in	O
serum	O
also	O
generated	O
thrombin	B
(	O
AUC	O
of	O
260	O
+	O
/-	O
2	O
nmol	O
x	O
min	O
/	O
L	O
;	O
PT	O
of	O
128	O
+	O
/-	O
4	O
nmol	O
/	O
L	O
)	O
.	O
We	O
conclude	O
that	O
apoptotic	O
VSMCs	O
possess	O
a	O
significant	O
thrombin	B
-generating	O
capacity	O
secondary	O
to	O
phosphatidylserine	O
exposure	O
.	O
Apoptotic	O
cells	O
within	O
atherosclerotic	O
plaques	O
may	O
allow	O
local	O
thrombin	B
activation	O
,	O
thereby	O
contributing	O
to	O
disease	O
progression	O
.	O
Interleukin-10	B
inhibits	O
interferon	O
-	O
gamma	O
-	O
induced	O
intercellular	O
adhesion	O
molecule-1	O
gene	O
transcription	O
in	O
human	O
monocytes	O
.	O
Interleukin-10	B
(	O
IL-10	B
)	O
is	O
a	O
potent	O
monocyte	B
regulatory	I
cytokine	I
that	O
inhibits	O
gene	O
expression	O
of	O
proinflammatory	B
mediators	I
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanism	O
by	O
which	O
IL-10	B
downregulates	O
expression	O
of	O
intercellular	B
adhesion	I
molecule-1	I
(	O
ICAM-1	B
)	O
on	O
the	O
cell	O
surface	O
of	O
normal	O
human	O
monocytes	O
activated	O
with	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
.	O
IL-10	B
inhibition	O
of	O
IFN	B
-	I
gamma	I
-induced	O
ICAM-1	B
expression	O
was	O
apparent	O
as	O
early	O
as	O
3	O
hours	O
and	O
was	O
blocked	O
by	O
an	O
anti	B
-	I
IL-10	I
antibody	I
but	O
not	O
by	O
an	O
isotype	B
-	I
matched	I
control	I
antibody	I
.	O
Northern	O
blot	O
analysis	O
showed	O
that	O
IL-10	B
reduced	O
the	O
accumulation	O
of	O
ICAM-1	O
mRNA	O
in	O
IFN	O
-	O
gamma	O
-	O
stimulated	O
monocytes	O
.	O
IL-10	B
inhibition	O
of	O
ICAM-1	O
steady	O
-	O
state	O
mRNA	O
was	O
detected	O
at	O
3	O
hours	O
and	O
remained	O
at	O
24	O
hours	O
.	O
Nuclear	O
run	O
-	O
on	O
transcription	O
assays	O
showed	O
that	O
IL-10	B
inhibited	O
the	O
rate	O
of	O
IFN	B
-	I
gamma	I
-induced	O
transcription	O
of	O
the	O
ICAM-1	O
gene	O
,	O
and	O
mRNA	O
stability	O
studies	O
showed	O
that	O
IL-10	B
did	O
not	O
alter	O
the	O
half	O
-	O
life	O
of	O
IFN	O
-	O
gamma	O
-	O
induced	O
ICAM-1	O
message	O
.	O
Thus	O
,	O
IL-10	B
inhibits	O
IFN	B
-	I
gamma	I
-induced	O
ICAM-1	B
expression	O
in	O
monocytes	O
primarily	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O
Activation	O
of	O
IFN	O
-	O
gamma	O
-	O
responsive	O
genes	O
requires	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcriptional	O
factor	O
STAT-1alpha	B
(	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription-1alpha	I
)	O
.	O
However	O
,	O
IL-10	B
did	O
not	O
affect	O
IFN	B
-	I
gamma	I
-induced	O
tyrosine	O
phosphorylation	O
of	O
STAT-1alpha	B
or	O
alter	O
STAT-1alpha	B
binding	O
to	O
the	O
IFN	O
-	O
gamma	O
response	O
element	O
(	O
IRE	O
)	O
in	O
the	O
ICAM-1	O
promoter	O
.	O
Instead	O
,	O
IL-10	B
prevented	O
IFN	B
-	I
gamma	I
-induced	O
binding	O
activity	O
at	O
the	O
NF	B
-	I
kappaB	I
site	O
of	O
the	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
-responsive	O
NF	O
-	O
kappaB	O
/	O
C	O
-	O
EBP	O
composite	O
element	O
in	O
the	O
ICAM-1	O
promoter	O
.	O
These	O
data	O
indicate	O
that	O
IL-10	B
inhibits	O
IFN	B
-	I
gamma	I
-induced	O
transcription	O
of	O
the	O
ICAM-1	O
gene	O
by	O
a	O
regulatory	O
mechanism	O
that	O
may	O
involve	O
NF	B
-	I
kappaB	I
.	O
Comparison	O
of	O
the	O
transactivation	B
domains	I
of	O
Stat5	B
and	O
Stat6	B
in	O
lymphoid	O
cells	O
and	O
mammary	O
epithelial	O
cells	O
.	O
Stat	B
(	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
)	O
and	O
Jak	B
(	O
Janus	B
kinases	I
)	O
proteins	O
are	O
central	O
components	O
in	O
the	O
signal	O
transduction	O
events	O
in	O
hematopoietic	O
and	O
epithelial	O
cells	O
.	O
They	O
are	O
rapidly	O
activated	O
by	O
various	O
cytokines	B
,	O
hormones	O
,	O
and	O
growth	O
factors	O
.	O
Upon	O
ligand	O
binding	O
and	O
cytokine	B
receptor	I
dimerization	O
,	O
Stat	B
proteins	I
are	O
phosphorylated	O
on	O
tyrosine	O
residues	O
by	O
Jak	B
kinases	I
.	O
Activated	O
Stat	B
proteins	I
form	O
homo-	O
or	O
heterodimers	O
,	O
translocate	O
to	O
the	O
nucleus	O
,	O
and	O
induce	O
transcription	O
from	O
responsive	O
genes	O
.	O
Stat5	B
and	O
Stat6	B
are	O
transcription	B
factors	I
active	O
in	O
mammary	O
epithelial	O
cells	O
and	O
immune	O
cells	O
.	O
Prolactin	O
activates	O
Stat5	B
,	O
and	O
interleukin-4	B
(	O
IL-4	B
)	O
activates	O
Stat6	B
.	O
Both	O
cytokines	B
are	O
able	O
to	O
stimulate	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
.	O
We	O
investigated	O
the	O
transactivation	O
potential	O
of	O
Stat6	B
and	O
found	O
that	O
it	O
is	O
not	O
restricted	O
to	O
lymphocytes	O
.	O
IL-4	B
-dependent	O
activation	O
of	O
Stat6	B
was	O
also	O
observed	O
in	O
HC11	O
mammary	O
epithelial	O
cells	O
.	O
In	O
these	O
cells	O
,	O
Stat6	B
activation	O
led	O
to	O
the	O
induction	O
of	O
the	O
beta	O
-	O
casein	O
gene	O
promoter	O
.	O
The	O
induction	O
of	O
this	O
promoter	O
was	O
confirmed	O
in	O
COS7	O
cells	O
.	O
The	O
glucocorticoid	B
receptor	I
was	O
able	O
to	O
further	O
enhance	O
IL-4	B
-induced	O
gene	O
transcription	O
through	O
the	O
action	O
of	O
Stat6	B
.	O
Deletion	O
analysis	O
of	O
the	O
carboxyl	B
-	I
terminal	I
region	I
of	O
Stat6	B
and	O
recombination	O
of	O
this	O
region	O
with	O
a	O
heterologous	B
DNA	I
binding	I
domain	I
allowed	O
the	O
delimitation	O
and	O
characterization	O
of	O
the	O
transactivation	O
domain	O
of	O
Stat6	B
.	O
The	O
potencies	O
of	O
the	O
transactivation	B
domains	I
of	O
Stat5	B
,	O
Stat6	B
,	O
and	O
viral	B
protein	I
VP16	I
were	O
compared	O
.	O
Stat6	B
had	O
a	O
transactivation	O
domain	O
which	O
was	O
about	O
10-fold	O
stronger	O
than	O
that	O
of	O
Stat5	B
.	O
In	O
pre	O
-	O
B	O
cells	O
(	O
Ba	O
/	O
F3	O
)	O
,	O
the	O
transactivation	O
domain	O
of	O
Stat6	B
was	O
IL-4	B
regulated	O
,	O
independently	O
from	O
its	O
DNA	O
binding	O
function	O
.	O
Effect	O
of	O
adenovirus	O
2	O
on	O
cellular	O
gene	O
activation	O
in	O
blood	O
-	O
derived	O
monocytes	O
and	O
macrophages	O
.	O
We	O
have	O
investigated	O
the	O
effect	O
of	O
adenovirus	O
2	O
(	O
Ad2	O
)	O
infection	O
on	O
human	O
monocytes	O
and	O
monocyte	O
-	O
derived	O
macrophages	O
with	O
regard	O
to	O
expression	O
of	O
TNF	B
-	I
alpha	I
and	O
IL-1	B
beta	I
.	O
In	O
monocytes	O
,	O
the	O
virus	O
was	O
bound	O
to	O
the	O
surface	O
without	O
being	O
internalized	O
.	O
On	O
the	O
other	O
hand	O
,	O
Ad2	O
was	O
internalized	O
by	O
macrophages	O
.	O
No	O
virus	O
replication	O
and	O
no	O
transcription	O
of	O
the	O
Ad2	O
early	O
genes	O
was	O
observed	O
in	O
either	O
of	O
the	O
cells	O
.	O
Ad2	O
infection	O
induced	O
transient	O
increase	O
in	O
the	O
mRNA	O
levels	O
for	O
TNF	B
-	I
alpha	I
and	O
IL-1	B
beta	I
in	O
both	O
monocytes	O
and	O
in	O
macrophages	O
,	O
although	O
the	O
kinetics	O
of	O
the	O
transcription	O
was	O
slightly	O
different	O
.	O
The	O
production	O
of	O
both	O
cytokines	B
,	O
measured	O
by	O
ELISA	O
tests	O
,	O
was	O
enhanced	O
in	O
monocytes	O
.	O
In	O
macrophages	O
,	O
a	O
slight	O
enhancement	O
of	O
TNF	B
-	I
alpha	I
production	O
was	O
seen	O
,	O
whereas	O
IL-1	B
beta	I
was	O
not	O
detected	O
.	O
The	O
data	O
indicate	O
that	O
cellular	O
genes	O
might	O
be	O
activated	O
by	O
Ad2	O
virus	O
infection	O
in	O
nonpermissive	O
cells	O
where	O
no	O
viral	B
gene	I
products	I
could	O
be	O
detected	O
.	O
Activation	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
by	O
beta	O
-	O
amyloid	O
peptides	O
and	O
interferon	B
-	I
gamma	I
in	O
murine	O
microglia	O
.	O
An	O
increasing	O
body	O
of	O
evidence	O
suggests	O
that	O
amyloid	O
-	O
beta	O
(	O
A	O
beta	O
)	O
peptides	O
and	O
microglia	O
are	O
crucially	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	O
disease	O
.	O
In	O
an	O
effort	O
to	O
further	O
elucidate	O
the	O
biological	O
effects	O
of	O
A	O
beta	O
towards	O
microglia	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
A	O
beta	O
peptides	O
to	O
activate	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
in	O
the	O
N9	O
murine	O
microglial	O
cell	O
line	O
.	O
Co	O
-	O
stimulation	O
of	O
microglia	O
with	O
suboptimal	O
concentrations	O
of	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
and	O
100	O
U	O
/	O
ml	O
IFN	B
gamma	I
resulted	O
in	O
the	O
detection	O
of	O
a	O
specific	O
NF	B
-	I
kappa	I
B	I
DNA	O
-	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
mobility	O
shift	O
assays	O
.	O
This	O
response	O
required	O
at	O
least	O
120	O
min	O
to	O
be	O
evident	O
and	O
supershift	O
experiments	O
revealed	O
that	O
the	O
NF	B
-	I
kappa	I
B	I
complex	I
contains	O
both	O
RelA	B
and	O
p50	B
.	O
Accordingly	O
,	O
immunoblot	O
experiments	O
showed	O
that	O
amongst	O
NF	B
-	I
kappa	I
B	I
/Rel	B
proteins	I
,	O
RelA	B
and	O
p50	B
are	O
mobilized	O
to	O
the	O
nucleus	O
following	O
microglial	O
cell	O
stimulation	O
with	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
plus	O
IFN	B
gamma	I
.	O
Higher	O
concentrations	O
of	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
were	O
effective	O
by	O
themselves	O
in	O
inducing	O
NF	B
-	I
kappa	I
B	I
activation	O
,	O
both	O
in	O
the	O
N9	O
microglial	O
cell	O
line	O
and	O
in	O
rat	O
primary	O
microglia	O
,	O
as	O
well	O
as	O
in	O
human	O
monocytes	O
.	O
For	O
purposes	O
of	O
comparison	O
,	O
microglia	O
were	O
also	O
stimulated	O
with	O
bacterial	O
LPS	O
,	O
a	O
known	O
NF	B
-	I
kappa	I
B	I
inducer	O
.	O
As	O
expected	O
,	O
LPS	O
strongly	O
induced	O
the	O
formation	O
of	O
two	O
NF	B
-	I
kappa	I
B	I
DNA	O
-	O
binding	O
activities	O
,	O
one	O
of	O
which	O
was	O
identified	O
as	O
RelA	B
/	I
p50	I
.	O
The	O
LPS	O
response	O
was	O
also	O
more	O
rapid	O
,	O
as	O
it	O
was	O
already	O
evident	O
by	O
40	O
min	O
and	O
remained	O
sustained	O
for	O
up	O
to	O
3	O
h	O
.	O
Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
NF	B
-	I
kappa	I
B	I
activation	O
might	O
constitute	O
one	O
of	O
the	O
mechanisms	O
underlying	O
the	O
inducible	O
expression	O
of	O
kappa	O
B	O
-	O
dependent	O
genes	O
in	O
microglia	O
stimulated	O
by	O
A	O
beta	O
peptides	O
and	O
IFN	B
gamma	I
,	O
or	O
by	O
LPS	O
.	O
Interferons	B
up	O
-	O
regulate	O
STAT1	B
,	O
STAT2	B
,	O
and	O
IRF	B
family	O
transcription	O
factor	O
gene	O
expression	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
macrophages	O
.	O
IFN	B
signaling	O
is	O
mediated	O
by	O
binding	O
of	O
IFNs	B
to	O
their	O
receptors	O
and	O
subsequent	O
activation	O
of	O
Janus	O
tyrosine	O
kinase	O
(	O
JAK	B
)	O
-	O
STAT	B
signaling	O
pathway	O
.	O
Stimulation	O
of	O
cells	O
with	O
IFN	B
-	I
alpha	I
leads	O
to	O
the	O
assembly	O
of	O
IFN	B
-	I
stimulated	I
gene	I
factor	I
3	I
transcription	I
factor	I
complex	I
formed	O
by	O
STAT1	B
,	O
STAT2	B
,	O
and	O
p48	B
protein	I
.	O
IFN	B
-	I
gamma	I
signaling	O
is	O
mediated	O
by	O
homodimeric	B
STAT1	I
protein	I
.	O
Although	O
these	O
signaling	O
molecules	O
are	O
expressed	O
constitutively	O
,	O
there	O
is	O
also	O
evidence	O
of	O
transcriptional	O
regulation	O
by	O
IFNs	B
.	O
We	O
have	O
characterized	O
the	O
expression	O
of	O
STAT	B
and	I
IFN	I
regulatory	I
factor	I
(	I
IRF	I
)	I
family	I
transcription	I
factors	I
in	O
primary	O
human	O
blood	O
mononuclear	O
cells	O
and	O
macrophages	O
in	O
response	O
to	O
IFN	O
-	O
alpha	O
and	O
IFN	O
-	O
gamma	O
stimulation	O
.	O
We	O
show	O
that	O
IFN	B
-	I
alpha	I
and	O
IFN	B
-	I
gamma	I
rapidly	O
and	O
efficiently	O
enhanced	O
STAT1	B
,	O
STAT2	B
,	O
p48	B
,	O
and	O
IRF-1	O
gene	O
expression	O
.	O
IFN	B
-	I
gamma	I
induced	O
IRF-1	O
gene	O
expression	O
more	O
strongly	O
than	O
IFN	B
-	I
alpha	I
.	O
Stimulation	O
experiments	O
in	O
the	O
presence	O
of	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
,	O
suggested	O
that	O
these	O
genes	O
were	O
activated	O
directly	O
by	O
IFNs	B
.	O
IRF-2	O
gene	O
was	O
apparently	O
only	O
weakly	O
responsive	O
to	O
IFNs	B
in	O
these	O
cells	O
.	O
When	O
macrophages	O
were	O
pretreated	O
with	O
low	O
doses	O
of	O
IFN	B
-	I
gamma	I
and	O
then	O
stimulated	O
with	O
IFN	B
-	I
alpha	I
,	O
clearly	O
enhanced	O
formation	O
of	O
specific	O
transcription	B
factor	I
complexes	O
was	O
detected	O
.	O
This	O
suggests	O
that	O
higher	O
intracellular	O
levels	O
of	O
STAT1	B
,	O
STAT2	B
,	O
and	O
p48	B
protein	I
may	O
result	O
in	O
enhanced	O
signal	O
transduction	O
for	O
cytokines	B
utilizing	O
these	O
transcription	B
factors	I
.	O
Cytokines	B
:	O
shared	O
receptors	B
,	O
distinct	O
functions	O
.	O
That	O
the	O
signal	O
transduction	O
pathways	O
used	O
by	O
the	O
cytokines	B
IL-2	B
and	O
IL-15	B
are	O
identical	O
would	O
suggest	O
that	O
these	O
cytokines	B
have	O
redundant	O
roles	O
in	O
lymphoid	O
development	O
;	O
instead	O
,	O
IL-2	B
is	O
the	O
guardian	O
of	O
thymus	O
-	O
derived	O
T	O
-	O
cell	O
homeostasis	O
,	O
while	O
interleukin-15	B
promotes	O
extrathymic	O
development	O
of	O
T	O
and	O
NK	O
cells	O
.	O
In	O
vivo	O
footprinting	O
and	O
mutational	O
analysis	O
of	O
the	O
proximal	O
CD19	O
promoter	O
reveal	O
important	O
roles	O
for	O
an	O
SP1	O
/	O
Egr-1	O
binding	O
site	O
and	O
a	O
novel	O
site	O
termed	O
the	O
PyG	O
box	O
.	O
CD19	B
expression	O
begins	O
at	O
the	O
pro	O
-	O
B	O
cell	O
stage	O
of	O
B	O
cell	O
development	O
.	O
As	O
such	O
it	O
serves	O
as	O
a	O
good	O
prototype	O
for	O
B	O
cell	O
-	O
specific	O
genes	O
whose	O
expression	O
begins	O
shortly	O
after	O
lineage	O
commitment	O
.	O
To	O
understand	O
the	O
molecular	O
mechanisms	O
controlling	O
CD19	B
gene	O
expression	O
,	O
we	O
isolated	O
and	O
functionally	O
characterized	O
the	O
CD19	O
promoter	O
using	O
in	O
vivo	O
footprinting	O
,	O
gel	O
shift	O
assays	O
,	O
and	O
transfection	O
studies	O
.	O
Reporter	O
constructs	O
spanning	O
portions	O
of	O
the	O
promoter	O
identified	O
a	O
region	O
between	O
-85	O
and	O
-200	O
that	O
produced	O
high	O
levels	O
of	O
reporter	O
gene	O
activity	O
in	O
lymphoid	O
cells	O
.	O
In	O
vivo	O
footprinting	O
identified	O
protected	O
regions	O
over	O
the	O
known	O
high	O
affinity	O
B	O
cell	O
lineage	O
-	O
specific	O
activator	O
protein	O
(	O
BSAP	O
)	O
site	O
,	O
the	O
low	O
affinity	O
BSAP	O
site	O
,	O
a	O
SP1	O
/	O
Egr-1	O
site	O
termed	O
the	O
CD19	O
GC	O
box	O
,	O
and	O
two	O
novel	O
sites	O
named	O
the	O
AT	O
box	O
and	O
PyG	O
box	O
.	O
Phorbol	O
ester	O
treatment	O
of	O
a	O
pre	O
-	O
B	O
cell	O
line	O
up	O
-	O
regulated	O
CD19	B
expression	O
,	O
induced	O
Egr-1	B
,	O
and	O
enhanced	O
the	O
footprint	O
over	O
the	O
GC	O
box	O
.	O
Gel	O
shift	O
assays	O
demonstrated	O
SP1	O
and	O
Egr-1	B
binding	O
to	O
the	O
CD19	O
GC	O
box	O
,	O
while	O
unknown	O
nuclear	O
proteins	O
bound	O
the	O
PyG	O
and	O
AT	O
boxes	O
.	O
Mutations	O
in	O
the	O
AT	O
box	O
or	O
in	O
the	O
BSAP	O
sites	O
did	O
not	O
affect	O
CD19	B
reporter	O
construct	O
activity	O
,	O
while	O
a	O
mutation	O
of	O
the	O
GC	O
box	O
reduced	O
it	O
modestly	O
,	O
and	O
a	O
PyG	O
box	O
mutation	O
reduced	O
it	O
dramatically	O
.	O
BSAP	B
failed	O
to	O
trans	O
-	O
activate	O
CD19	O
promoter	O
constructs	O
in	O
B	O
cells	O
or	O
non	O
-	O
B	O
cells	O
,	O
suggesting	O
that	O
cis	O
elements	O
such	O
as	O
the	O
PyG	O
and	O
GC	O
boxes	O
are	O
also	O
necessary	O
for	O
high	O
level	O
CD19	O
promoter	O
expression	O
.	O
A	O
human	O
homologue	O
of	O
the	O
Drosophila	B
Toll	I
protein	I
signals	O
activation	O
of	O
adaptive	O
immunity	O
[	O
see	O
comments	O
]	O
Induction	O
of	O
the	O
adaptive	O
immune	O
response	O
depends	O
on	O
the	O
expression	O
of	O
co	B
-	I
stimulatory	I
molecules	I
and	O
cytokines	B
by	O
antigen	O
-	O
presenting	O
cells	O
.	O
The	O
mechanisms	O
that	O
control	O
the	O
initial	O
induction	O
of	O
these	O
signals	O
upon	O
infection	O
are	O
poorly	O
understood	O
.	O
It	O
has	O
been	O
proposed	O
that	O
their	O
expression	O
is	O
controlled	O
by	O
the	O
non	O
-	O
clonal	O
,	O
or	O
innate	O
,	O
component	O
of	O
immunity	O
that	O
preceded	O
in	O
evolution	O
the	O
development	O
of	O
an	O
adaptive	O
immune	O
system	O
in	O
vertebrates	O
.	O
We	O
report	O
here	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
human	B
homologue	I
of	O
the	O
Drosophila	B
toll	I
protein	I
(	O
Toll	B
)	O
which	O
has	O
been	O
shown	O
to	O
induce	O
the	O
innate	O
immune	O
response	O
in	O
adult	O
Drosophila	O
.	O
Like	O
Drosophila	O
Toll	B
,	O
human	B
Toll	I
is	O
a	O
type	O
I	O
transmembrane	O
protein	O
with	O
an	O
extracellular	O
domain	O
consisting	O
of	O
a	O
leucine	B
-	I
rich	I
repeat	I
(	I
LRR	I
)	I
domain	I
,	O
and	O
a	O
cytoplasmic	O
domain	O
homologous	O
to	O
the	O
cytoplasmic	B
domain	I
of	O
the	O
human	B
interleukin	I
(	I
IL	I
)	I
-1	I
receptor	I
.	O
Both	O
Drosophila	O
Toll	B
and	O
the	O
IL-1	O
receptor	O
are	O
known	O
to	O
signal	O
through	O
the	O
NF	B
-	I
kappaB	I
pathway	O
.	O
We	O
show	O
that	O
a	O
constitutively	O
active	O
mutant	O
of	O
human	B
Toll	I
transfected	O
into	O
human	O
cell	O
lines	O
can	O
induce	O
the	O
activation	O
of	O
NF	B
-	I
kappaB	I
and	O
the	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
controlled	O
genes	O
for	O
the	O
inflammatory	B
cytokines	I
IL-1	B
,	O
IL-6	B
and	O
IL-8	B
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
the	O
co	B
-	I
stimulatory	I
molecule	I
B7.1	B
,	O
which	O
is	O
required	O
for	O
the	O
activation	O
of	O
naive	O
T	O
cells	O
.	O
Bcl-2	B
protein	I
inhibits	O
bufalin	O
-	O
induced	O
apoptosis	O
through	O
inhibition	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
activation	O
in	O
human	O
leukemia	O
U937	O
cells	O
.	O
In	O
a	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
bufalin	O
,	O
which	O
is	O
an	O
active	O
principle	O
of	O
Chinese	O
medicine	O
,	O
chan'su	O
,	O
caused	O
apoptosis	O
in	O
human	O
leukemia	O
U937	O
cells	O
by	O
anomalous	O
activation	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
via	O
the	O
signaling	O
pathway	O
of	O
Ras	B
,	O
Raf-1	B
,	O
and	O
MAPK	B
kinase-1	I
.	O
Here	O
,	O
we	O
report	O
the	O
effect	O
of	O
overexpression	O
of	O
bcl-2	B
in	O
U937	O
cells	O
on	O
the	O
signaling	O
pathway	O
of	O
apoptosis	O
that	O
is	O
induced	O
by	O
bufalin	O
.	O
The	O
results	O
indicated	O
that	O
the	O
apoptosis	O
induced	O
by	O
bufalin	O
in	O
U937	O
cells	O
was	O
significantly	O
inhibited	O
by	O
overexpression	O
of	O
the	O
Bcl-2	B
protein	I
.	O
No	O
significant	O
difference	O
was	O
detected	O
in	O
the	O
activation	O
of	O
MAPK	B
kinase-1	I
that	O
is	O
induced	O
by	O
bufalin	O
in	O
wild	O
-	O
type	O
or	O
Bcl-2-overexpressed	O
U937	O
cells	O
;	O
however	O
,	O
the	O
activation	O
of	O
MAPK	B
by	O
bufalin	O
was	O
significantly	O
attenuated	O
in	O
the	O
cells	O
overexpressing	O
Bcl-2	B
.	O
Bufalin	O
treatment	O
activated	B
activator	I
protein-1	I
transcriptional	O
activity	O
;	O
however	O
,	O
this	O
activation	O
was	O
decreased	O
to	O
40	O
%	O
in	O
bcl-2	B
-overexpressed	O
U937	O
cells	O
.	O
These	O
results	O
indicate	O
that	O
Bcl-2	B
acts	O
downstream	O
of	O
MAPK	B
kinase-1	I
but	O
upstream	O
of	O
MAPK	B
and	O
suggest	O
that	O
,	O
in	O
the	O
signaling	O
pathway	O
of	O
the	O
apoptotic	O
process	O
induced	O
by	O
bufalin	O
,	O
the	O
transcriptional	O
activity	O
of	O
activator	B
protein-1	I
may	O
be	O
down	O
-	O
regulated	O
through	O
the	O
inhibition	O
of	O
MAPK	B
activity	O
by	O
Bcl-2	B
.	O
A	O
shortened	O
life	O
span	O
of	O
EKLF-	O
/	O
-	O
adult	O
erythrocytes	O
,	O
due	O
to	O
a	O
deficiency	O
of	O
beta	B
-	I
globin	I
chains	I
,	O
is	O
ameliorated	O
by	O
human	B
gamma	I
-	I
globin	I
chains	I
.	O
Using	O
homologous	O
recombination	O
,	O
both	O
EKLF	O
alleles	O
in	O
murine	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
were	O
inactivated	O
.	O
These	O
EKLF-	O
/	O
-	O
ES	O
cells	O
were	O
capable	O
of	O
undergoing	O
in	O
vitro	O
differentiation	O
to	O
form	O
definitive	O
erythroid	O
colonies	O
that	O
were	O
similar	O
in	O
size	O
and	O
number	O
to	O
those	O
formed	O
by	O
wild	O
-	O
type	O
ES	O
cells	O
.	O
However	O
,	O
the	O
EKLF-	O
/	O
-	O
colonies	O
were	O
poorly	O
hemoglobinized	O
and	O
enucleated	O
erythrocytes	O
in	O
these	O
colonies	O
contained	O
numerous	O
Heinz	O
bodies	O
.	O
Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analyses	O
revealed	O
that	O
adult	O
and	O
embryonic	O
globin	O
genes	O
were	O
appropriately	O
regulated	O
,	O
with	O
the	O
exception	O
of	O
beta	B
h1-globin	I
,	O
which	O
continued	O
to	O
be	O
expressed	O
at	O
a	O
very	O
low	O
level	O
.	O
The	O
ratio	O
of	O
adult	O
beta	O
-	O
globin	O
/	O
alpha	O
-	O
globin	O
mRNA	O
in	O
the	O
mutant	O
ES	O
cells	O
was	O
1	O
/	O
15	O
of	O
that	O
in	O
wild	O
-	O
type	O
ES	O
cells	O
.	O
When	O
the	O
EKLF-	O
/	O
-	O
cells	O
were	O
injected	O
into	O
blastocysts	O
,	O
they	O
did	O
not	O
contribute	O
at	O
a	O
detectable	O
level	O
to	O
the	O
mature	O
erythrocyte	O
compartment	O
of	O
the	O
chimeric	O
animals	O
,	O
based	O
on	O
analysis	O
of	O
glucose	B
phosphate	I
isomerase-1	I
(	I
GPI-1	I
)	I
isozymes	I
and	O
hemoglobins	O
that	O
distinguish	O
ES	O
cell	O
-	O
derived	O
erythrocytes	O
from	O
host	O
blastocyst	O
-	O
derived	O
erythrocytes	O
.	O
In	O
contrast	O
,	O
semiquantitative	O
RT	O
-	O
PCR	O
analysis	O
of	O
RNA	O
from	O
reticulocytes	O
of	O
the	O
same	O
chimeric	O
animals	O
suggested	O
that	O
the	O
ES	O
cell	O
-	O
derived	O
reticulocytes	O
were	O
present	O
at	O
a	O
level	O
of	O
6	O
%	O
to	O
8	O
%	O
.	O
This	O
indicated	O
that	O
the	O
EKLF-	O
/	O
-	O
erythrocytes	O
in	O
adult	O
animals	O
must	O
be	O
short	O
-	O
lived	O
,	O
apparently	O
due	O
to	O
the	O
imbalance	O
of	O
beta-	B
versus	I
alpha	I
-	I
globin	I
chains	I
,	O
leading	O
to	O
the	O
precipitation	O
of	O
excess	O
alpha	B
-	I
globin	I
chains	I
to	O
form	O
Heinz	O
bodies	O
.	O
Consistent	O
with	O
this	O
hypothesis	O
,	O
the	O
short	O
life	O
span	O
was	O
ameliorated	O
by	O
introduction	O
into	O
the	O
EKLF-	O
/	O
-	O
ES	O
cells	O
of	O
a	O
human	O
LCR	O
/	O
gamma	O
-	O
globin	O
gene	O
,	O
as	O
evidenced	O
by	O
the	O
presence	O
of	O
ES	O
cell	O
-	O
derived	O
reticulocytes	O
as	O
well	O
as	O
mature	O
erythrocytes	O
in	O
the	O
blood	O
of	O
the	O
chimeric	O
animals	O
.	O
Differential	O
interaction	O
of	O
nuclear	B
factors	I
with	O
the	O
leukocyte	O
-	O
specific	O
pp52	O
promoter	O
in	O
B	O
and	O
T	O
cells	O
.	O
The	O
leukocyte	O
-	O
specific	O
,	O
cytoskeleton	O
-	O
binding	O
pp52	O
(	O
LSP-1	O
,	O
WP-34	O
)	O
protein	O
is	O
widely	O
expressed	O
in	O
multiple	O
leukocyte	O
lineages	O
,	O
including	O
B	O
and	O
T	O
lymphocytes	O
,	O
granulocytes	O
,	O
and	O
macrophages	O
.	O
We	O
previously	O
detected	O
a	O
tissue	O
-	O
specific	O
promoter	O
preceding	O
the	O
exon	O
encoding	O
the	O
N	B
terminus	I
of	O
the	O
pp52	B
leukocyte	I
protein	I
.	O
Here	O
we	O
describe	O
the	O
functional	O
characterization	O
of	O
this	O
promoter	O
and	O
identification	O
of	O
the	O
factors	O
in	O
B	O
and	O
T	O
cells	O
that	O
regulate	O
its	O
activity	O
.	O
The	O
pp52	O
promoter	O
contains	O
an	O
initiator	O
specifying	O
the	O
unique	O
5	O
'	O
terminus	O
of	O
pp52	O
mRNA	O
,	O
tandem	O
pairs	O
of	O
Ets	O
and	O
SP1	O
motifs	O
,	O
and	O
a	O
lone	O
C	O
/	O
EBP	O
motif	O
.	O
All	O
these	O
motifs	O
are	O
essential	O
and	O
collectively	O
control	O
transcriptional	O
activity	O
.	O
DNA	O
binding	O
studies	O
and	O
Ab	O
supershift	O
assays	O
revealed	O
that	O
different	O
combinations	O
of	O
factors	O
interact	O
with	O
these	O
motifs	O
in	O
B	O
cells	O
vs	O
T	O
cells	O
.	O
The	O
Ets	O
motifs	O
are	O
preferentially	O
bound	O
by	O
PU-1	B
in	O
B	O
cell	O
extracts	O
from	O
all	O
stages	O
of	O
development	O
,	O
whereas	O
a	O
different	O
Ets	B
family	I
member	I
reacts	O
with	O
these	O
motifs	O
in	O
T	O
cell	O
extracts	O
.	O
The	O
C	O
/	O
EBP	O
motif	O
is	O
bound	O
by	O
Ig	B
/	I
EBP-1	I
in	O
pre	O
-	O
B	O
cell	O
and	O
T	O
cell	O
extracts	O
,	O
but	O
is	O
replaced	O
by	O
nuclear	B
factor	I
-	I
IL-6beta	I
or	O
a	O
nuclear	B
factor	I
-	I
IL-6beta	I
-	I
Ig	I
/	I
EBP-1	I
heterodimer	I
in	O
plasmacytoma	O
cell	O
extracts	O
.	O
Despite	O
its	O
reported	O
role	O
as	O
a	O
negative	O
regulator	O
of	O
transcription	O
,	O
Ig	B
/	I
EBP-1	I
appears	O
to	O
exert	O
a	O
stimulatory	O
effect	O
on	O
this	O
promoter	O
.	O
These	O
findings	O
reveal	O
the	O
features	O
controlling	O
the	O
pp52	O
promoter	O
in	O
B	O
and	O
T	O
cells	O
and	O
provide	O
the	O
foundation	O
for	O
determining	O
the	O
regulation	O
of	O
this	O
promoter	O
in	O
other	O
leukocyte	O
lineages	O
.	O
Activation	O
of	O
transcription	O
factor	O
NF	B
-	I
kappa	I
B	I
by	O
phagocytic	O
stimuli	O
in	O
human	O
neutrophils	O
.	O
Phagocytosis	O
represents	O
an	O
important	O
physiological	O
trigger	O
for	O
the	O
inducible	O
expression	O
of	O
several	O
genes	O
in	O
human	O
neutrophils	O
.	O
Here	O
,	O
we	O
report	O
that	O
a	O
DNA	O
-	O
binding	O
activity	O
primarily	O
consisting	O
of	O
the	O
classical	O
NF	B
-	I
kappa	I
B	I
heterodimer	I
,	O
p50	B
/	I
RelA	I
,	O
is	O
induced	O
in	O
phagocytosing	O
neutrophils	O
.	O
Under	O
these	O
conditions	O
,	O
NF	B
-	I
kappa	I
B	I
activation	O
was	O
found	O
to	O
be	O
a	O
rapid	O
and	O
transient	O
response	O
,	O
reaching	O
a	O
maximum	O
by	O
10	O
-	O
15	O
min	O
,	O
and	O
returning	O
to	O
near	O
-	O
basal	O
levels	O
by	O
30	O
min	O
.	O
In	O
neutrophils	O
undergoing	O
the	O
phagocytosis	O
of	O
opsonized	O
yeasts	O
,	O
the	O
onset	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
was	O
paralleled	O
by	O
a	O
decline	O
in	O
immunoreactive	O
I	B
kappa	I
B	I
-	I
alpha	I
protein	O
levels	O
,	O
and	O
the	O
cellular	O
I	B
kappa	I
B	I
-alpha	O
pool	O
was	O
replenished	O
by	O
30	O
min	O
,	O
in	O
agreement	O
with	O
our	O
gel	O
shift	O
data	O
.	O
We	O
conclude	O
that	O
NF	B
-	I
kappa	I
B	I
activation	O
could	O
constitute	O
one	O
of	O
the	O
mechanisms	O
whereby	O
the	O
expression	O
of	O
kappa	O
B	O
-	O
responsive	O
genes	O
is	O
enhanced	O
in	O
phagocytosing	O
neutrophils	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
represents	O
the	O
first	O
demonstration	O
that	O
phagocytic	O
stimuli	O
can	O
induce	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
human	O
neutrophils	O
.	O
alpha	O
-	O
Tocopheryl	O
succinate	O
inhibits	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
by	O
suppressing	O
NF	B
-	I
kappa	I
B	I
mobilization	O
.	O
The	O
adherence	O
of	O
monocytes	O
to	O
activated	O
endothelium	O
is	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O
Because	O
antioxidants	O
have	O
been	O
considered	O
to	O
be	O
of	O
antiatherosclerotic	O
potential	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
alpha	O
-	O
tocopherol	O
(	O
TCP	O
)	O
and	O
its	O
acetate	O
and	O
succinate	O
esters	O
on	O
monocyte	O
adhesion	O
to	O
cytokine	O
-	O
stimulated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
.	O
Endothelial	O
cells	O
were	O
treated	O
with	O
TCP	O
,	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
TCP	O
acetate	O
)	O
,	O
or	O
alpha	O
-	O
tocopheryl	O
succinate	O
(	O
TCP	O
succinate	O
)	O
before	O
stimulation	O
with	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
;	O
10	O
U	O
/	O
ml	O
,	O
6	O
h	O
)	O
or	O
interleukin-1	B
beta	I
(	O
IL-1	B
beta	I
;	O
10	O
U	O
/	O
ml	O
,	O
6	O
h	O
)	O
.	O
Cytokine	O
-	O
stimulated	O
cell	O
surface	O
expression	O
of	O
vascular	B
cell	I
adhesion	I
molecule-1	I
(	O
VCAM-1	B
,	O
CD106	B
)	O
and	O
E	B
-	I
selectin	I
(	O
ELAM-1	B
,	O
CD62E	B
)	O
,	O
but	O
not	O
of	O
intercellular	B
adhesion	I
molecule-1	I
(	O
ICAM-1	B
,	O
CD54	B
)	O
,	O
was	O
time-	O
and	O
dose	O
-	O
dependently	O
inhibited	O
by	O
TCP	O
succinate	O
but	O
not	O
by	O
TCP	O
or	O
TCP	O
acetate	O
.	O
TCP	O
succinate	O
(	O
200	O
microM	O
,	O
24	O
h	O
)	O
reduced	O
TNF	B
-	I
induced	I
VCAM-1	I
and	O
E	B
-	I
selectin	I
expression	O
from	O
a	O
specific	O
mean	O
fluorescence	O
intensity	O
of	O
151	O
+	O
/-	O
28	O
to	O
12	O
+	O
/-	O
4	O
channels	O
and	O
from	O
225	O
+	O
/-	O
38	O
to	O
79	O
+	O
/-	O
21	O
channels	O
,	O
respectively	O
.	O
Succinate	O
alone	O
had	O
no	O
effect	O
.	O
Decreased	O
adhesion	B
molecule	I
expression	O
was	O
associated	O
with	O
a	O
reduction	O
of	O
monocytic	O
cell	O
adhesion	O
.	O
TCP	O
succinate	O
(	O
20	O
microM	O
,	O
72	O
h	O
)	O
,	O
but	O
not	O
TCP	O
(	O
200	O
microM	O
,	O
72	O
h	O
)	O
,	O
reduced	O
U-937	O
cell	O
adhesion	O
to	O
TNF	O
-	O
alpha	O
-	O
stimulated	O
(	O
10	O
U	O
/	O
ml	O
,	O
6	O
h	O
)	O
HUVEC	O
by	O
30	O
%	O
(	O
P	O
<	O
0.025	O
)	O
and	O
to	O
IL-1	O
beta	O
-	O
stimulated	O
HUVEC	O
by	O
56	O
%	O
(	O
P	O
<	O
0.010	O
)	O
.	O
Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
of	O
HUVEC	O
nuclear	B
proteins	I
revealed	O
a	O
decrease	O
in	O
TNF	B
-	I
alpha	I
-	I
stimulated	I
nuclear	I
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
activation	O
after	O
pretreatment	O
of	O
HUVEC	O
with	O
TCP	O
succinate	O
but	O
not	O
with	O
TCP	O
,	O
TCP	O
acetate	O
,	O
or	O
succinate	O
alone	O
.	O
In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
the	O
vitamin	O
E	O
derivative	O
TCP	O
succinate	O
prevents	O
monocytic	O
cell	O
adhesion	O
to	O
cytokine	O
-	O
stimulated	O
endothelial	O
cells	O
by	O
inhibiting	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
further	O
emphasizing	O
the	O
antiatherosclerotic	O
potential	O
of	O
lipid	O
soluble	O
antioxidants	O
.	O
Sp3	B
mediates	O
transcriptional	O
activation	O
of	O
the	O
leukocyte	O
integrin	O
genes	O
CD11C	O
and	O
CD11B	O
and	O
cooperates	O
with	O
c	O
-	O
Jun	O
to	O
activate	O
CD11C	O
.	O
The	O
leukocyte	O
integrin	O
genes	O
CD11c	O
and	O
CD11b	O
are	O
expressed	O
predominately	O
in	O
myelomonocytic	O
cells	O
.	O
In	O
previous	O
experiments	O
,	O
the	O
-70	O
to	O
-65	O
and	O
-121	O
to	O
-103	O
regions	O
of	O
the	O
CD11c	O
promoter	O
and	O
the	O
-66	O
to	O
-59	O
region	O
of	O
the	O
CD11b	O
promoter	O
were	O
shown	O
to	O
be	O
essential	O
for	O
Sp1-	B
mediated	O
activation	O
of	O
these	O
genes	O
.	O
In	O
vivo	O
genomic	O
footprinting	O
had	O
also	O
revealed	O
cell	O
-	O
specific	O
binding	O
of	O
protein	O
,	O
presumably	O
Sp1	B
,	O
to	O
these	O
regions	O
.	O
In	O
this	O
study	O
,	O
electrophoretic	O
mobility	O
shift	O
analysis	O
showed	O
that	O
the	O
Sp1-related	B
factor	I
,	O
Sp3	B
,	O
also	O
binds	O
at	O
or	O
near	O
these	O
same	O
regions	O
.	O
Cotransfection	O
of	O
Sp3	B
along	O
with	O
CD11c	O
promoter	O
-	O
luciferase	O
constructs	O
into	O
Sp	O
-	O
deficient	O
Drosophila	O
Schneider	O
2	O
cells	O
showed	O
that	O
Sp3	B
could	O
activate	O
the	O
CD11c	O
promoter	O
.	O
Deletion	O
of	O
both	O
the	O
-70	O
to	O
-65	O
and	O
-121	O
to	O
-103	O
regions	O
of	O
the	O
CD11c	O
promoter	O
resulted	O
in	O
the	O
loss	O
of	O
activation	O
by	O
Sp3	B
.	O
Both	O
sites	O
showed	O
activation	O
by	O
Sp3	B
;	O
however	O
,	O
the	O
-70	O
to	O
-65	O
region	O
was	O
more	O
responsive	O
to	O
Sp3	B
than	O
to	O
Sp1	B
.	O
Similar	O
transfection	O
analysis	O
of	O
the	O
-66	O
to	O
-59	O
region	O
of	O
the	O
CD11b	O
promoter	O
showed	O
Sp3	B
-dependent	O
expression	O
.	O
Further	O
,	O
cotransfection	O
analysis	O
in	O
Drosophila	O
cells	O
showed	O
that	O
Sp3	B
,	O
as	O
was	O
previously	O
shown	O
for	O
Sp1	B
,	O
also	O
synergizes	O
with	O
c	B
-	I
Jun	I
to	O
activate	O
CD11c	O
.	O
Antisense	O
experiments	O
that	O
knocked	O
out	O
endogenous	O
Sp3	B
expression	O
in	O
the	O
myelomocytic	O
cell	O
line	O
,	O
HL60	O
,	O
revealed	O
that	O
Sp3	B
participates	O
in	O
activation	O
of	O
the	O
CD11c	O
and	O
CD11b	O
promoters	O
in	O
vivo	O
.	O
Vitamin	B
D	I
receptor	I
:	O
no	O
evidence	O
for	O
allele	O
-	O
specific	O
mRNA	O
stability	O
in	O
cells	O
which	O
are	O
heterozygous	O
for	O
the	O
Taq	B
I	I
restriction	I
enzyme	I
polymorphism	O
.	O
Allelic	O
variations	O
of	O
the	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
gene	O
have	O
been	O
associated	O
with	O
the	O
risk	O
of	O
developing	O
prostate	O
cancer	O
in	O
men	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
.	O
Three	O
RFLPs	O
(	O
TaqI	O
,	O
ApaI	O
,	O
BsmI	O
)	O
define	O
two	O
common	O
haplotypes	O
:	O
BAt	O
and	O
baT	O
.	O
None	O
of	O
these	O
polymorphisms	O
change	O
the	O
translated	B
protein	I
.	O
Since	O
sequence	O
variations	O
in	O
the	O
3	O
'	O
UTR	O
of	O
VDR	B
have	O
been	O
linked	O
to	O
the	O
different	O
haplotypes	O
,	O
investigators	O
have	O
proposed	O
that	O
the	O
stability	O
of	O
VDR	O
mRNA	O
is	O
influenced	O
by	O
allelic	O
variations	O
.	O
Indirect	O
evidence	O
suggested	O
that	O
allele	O
T	O
is	O
less	O
stable	O
than	O
allele	O
t	O
.	O
In	O
this	O
study	O
,	O
we	O
used	O
a	O
RT	O
-	O
PCR	O
based	O
approach	O
to	O
compare	O
the	O
stability	O
of	O
the	O
big	O
T	O
and	O
small	O
t	O
allele	O
in	O
normal	O
heterozygous	O
lymphocytes	O
and	O
the	O
heterozygous	O
cell	O
lines	O
NB4	O
(	O
myeloid	O
leukemia	O
)	O
and	O
PC-3	O
and	O
DU	O
145	O
(	O
prostate	O
cancers	O
)	O
.	O
In	O
all	O
three	O
cases	O
,	O
we	O
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
stability	O
.	O
Interestingly	O
,	O
we	O
consistently	O
observed	O
30	O
%	O
less	O
RT	O
-	O
PCR	O
product	O
derived	O
from	O
the	O
small	O
t	O
allele	O
mRNA	O
in	O
steady	O
state	O
,	O
a	O
finding	O
which	O
also	O
speaks	O
against	O
a	O
higher	O
stability	O
of	O
the	O
small	O
t	O
allele	O
mRNA	O
.	O
These	O
results	O
indicate	O
a	O
variation	O
in	O
transcriptional	O
regulation	O
rather	O
than	O
mRNA	O
stability	O
between	O
the	O
alleles	O
.	O
We	O
hypothesize	O
that	O
an	O
unknown	O
gene	O
or	O
genes	O
in	O
linkage	O
with	O
the	O
polymorphisms	O
is	O
(	O
are	O
)	O
responsible	O
for	O
the	O
relationship	O
between	O
risk	O
of	O
prostate	O
cancer	O
and	O
VDR	B
polymorphisms	O
.	O
The	O
role	O
of	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
proteins	I
in	O
viral	O
oncogenesis	O
and	O
the	O
regulation	O
of	O
viral	O
transcription	O
.	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
is	O
a	O
ubiquitous	B
transcription	I
factor	I
that	O
consists	O
of	O
multiple	B
polypeptide	I
subunits	I
,	O
and	O
is	O
subject	O
to	O
complex	O
regulatory	O
mechanisms	O
that	O
involve	O
protein	O
-	O
protein	O
interactions	O
,	O
phosphorylation	O
,	O
ubiquitination	O
,	O
proteolytic	O
degradation	O
,	O
and	O
nucleocytoplasmic	O
translocation	O
.	O
The	O
sophisticated	O
control	O
of	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
activity	O
is	O
not	O
surprising	O
since	O
this	O
transcription	B
factor	I
is	O
involved	O
in	O
a	O
wide	O
array	O
of	O
cellular	O
responses	O
to	O
extracellular	O
cues	O
,	O
associated	O
with	O
growth	O
,	O
development	O
,	O
apoptosis	O
,	O
and	O
pathogen	O
invasion	O
.	O
Thus	O
,	O
it	O
is	O
not	O
unexpected	O
that	O
this	O
versatile	O
cellular	O
homeostatic	O
switch	O
would	O
be	O
affected	O
by	O
a	O
variety	O
of	O
viral	O
pathogens	O
,	O
which	O
have	O
evolved	O
mechanisms	O
to	O
utilize	O
various	O
aspects	O
of	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
activity	O
to	O
facilitate	O
their	O
replication	O
,	O
cell	O
survival	O
and	O
possibly	O
evasion	O
of	O
immune	O
responses	O
.	O
This	O
review	O
will	O
cover	O
the	O
molecular	O
mechanisms	O
that	O
are	O
utilized	O
by	O
mammalian	O
oncogenic	O
viruses	O
to	O
affect	O
the	O
activity	O
of	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
transcription	B
factors	I
and	O
the	O
role	O
of	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
in	O
the	O
regulation	O
of	O
viral	O
gene	O
expression	O
and	O
replication	O
.	O
Mutations	O
in	O
the	O
TSC2	O
gene	O
:	O
analysis	O
of	O
the	O
complete	O
coding	O
sequence	O
using	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
.	O
Mutations	O
in	O
the	O
TSC2	O
gene	O
on	O
chromosome	O
16p13.3	O
are	O
responsible	O
for	O
approximately	O
50	O
%	O
of	O
familial	O
tuberous	O
sclerosis	O
(	O
TSC	O
)	O
.	O
The	O
gene	O
has	O
41	O
small	O
exons	O
spanning	O
45	O
kb	O
of	O
genomic	O
DNA	O
and	O
encoding	O
a	O
5.5	O
kb	O
mRNA	O
.	O
Large	O
germline	O
deletions	O
of	O
TSC2	O
occur	O
in	O
<	O
5	O
%	O
of	O
cases	O
,	O
and	O
a	O
number	O
of	O
small	O
intragenic	O
mutations	O
have	O
been	O
described	O
.	O
We	O
analysed	O
mRNA	O
from	O
18	O
unrelated	O
cases	O
of	O
TSC	O
for	O
TSC2	O
mutations	O
using	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
.	O
Three	O
cases	O
were	O
predicted	O
to	O
be	O
TSC2	O
mutations	O
on	O
the	O
basis	O
of	O
linkage	O
analysis	O
or	O
because	O
a	O
hamartoma	O
from	O
the	O
patient	O
showed	O
loss	O
of	O
heterozygosity	O
for	O
16p13.3	O
markers	O
.	O
Three	O
overlapping	O
PCR	O
products	O
,	O
covering	O
the	O
complete	O
coding	O
sequence	O
of	O
mRNA	O
,	O
were	O
generated	O
from	O
lymphoblastoid	O
cell	O
lines	O
,	O
translated	O
into	O
35S	B
-	I
methionine	I
labelled	I
protein	I
,	O
and	O
analysed	O
by	O
SDS	O
-	O
PAGE	O
.	O
PCR	O
products	O
showing	O
PTT	O
shifts	O
were	O
directly	O
sequenced	O
,	O
and	O
mutations	O
confirmed	O
by	O
restriction	O
enzyme	O
digestion	O
where	O
possible	O
.	O
Six	O
PTT	O
shifts	O
were	O
identified	O
.	O
Five	O
of	O
these	O
were	O
caused	O
by	O
mutations	O
predicted	O
to	O
produce	O
a	O
truncated	B
protein	I
:	O
(	O
i	O
)	O
a	O
sporadic	O
case	O
showed	O
a	O
32	O
bp	O
deletion	O
in	O
exon	O
11	O
,	O
and	O
a	O
mutant	O
mRNA	O
without	O
exon	O
11	O
was	O
produced	O
;	O
the	O
normal	O
exon	O
10	O
was	O
also	O
spliced	O
out	O
;	O
(	O
ii	O
)	O
a	O
sporadic	O
case	O
had	O
a	O
1	O
bp	O
deletion	O
in	O
exon	O
12	O
(	O
1634delT	O
)	O
;	O
(	O
iii	O
)	O
a	O
TSC2-linked	O
mother	O
and	O
daughter	O
pair	O
had	O
a	O
G	O
--	O
>	O
T	O
transversion	O
in	O
exon	O
23	O
(	O
G2715	O
T	O
)	O
introducing	O
a	O
cryptic	O
splice	O
site	O
causing	O
a	O
29	O
bp	O
truncation	O
of	O
mRNA	O
from	O
exon	O
23	O
;	O
(	O
iv	O
)	O
a	O
sporadic	O
case	O
showed	O
a	O
2	O
bp	O
deletion	O
in	O
exon	O
36	O
;	O
(	O
v	O
)	O
a	O
sporadic	O
case	O
showed	O
a	O
1	O
bp	O
insertion	O
disrupting	O
the	O
donor	O
splice	O
site	O
of	O
exon	O
37	O
(	O
5007	O
+	O
2insA	O
)	O
,	O
resulting	O
in	O
the	O
use	O
of	O
an	O
upstream	O
exonic	O
cryptic	O
splice	O
site	O
to	O
cause	O
a	O
29	O
bp	O
truncation	O
of	O
mRNA	O
from	O
exon	O
37	O
.	O
In	O
one	O
case	O
,	O
the	O
PTT	O
shift	O
was	O
explained	O
by	O
in	O
-	O
frame	O
splicing	O
out	O
of	O
exon	O
10	O
,	O
in	O
the	O
presence	O
of	O
a	O
normal	O
exon	O
10	O
genomic	O
sequence	O
.	O
Alternative	O
splicing	O
of	O
exon	O
10	O
of	O
the	O
TSC2	O
gene	O
may	O
be	O
a	O
normal	O
variant	O
.	O
Three	O
3rd	O
base	O
substitution	O
polymorphisms	O
were	O
also	O
detected	O
during	O
direct	O
sequencing	O
of	O
PCR	O
products	O
.	O
Confirmed	O
mutations	O
were	O
identified	O
in	O
28	O
%	O
of	O
the	O
families	O
studied	O
and	O
on	O
the	O
assumption	O
that	O
half	O
of	O
the	O
sporadic	O
cases	O
should	O
have	O
TSC2	O
mutations	O
,	O
a	O
crude	O
estimate	O
of	O
the	O
detection	O
rate	O
would	O
be	O
60	O
%	O
.	O
This	O
compares	O
favourably	O
with	O
other	O
screening	O
methods	O
used	O
for	O
TSC2	O
,	O
notably	O
SSCP	O
,	O
and	O
since	O
PTT	O
involves	O
much	O
less	O
work	O
it	O
may	O
be	O
the	O
method	O
of	O
choice	O
.	O
Selection	O
of	O
down	O
-	O
regulated	O
sequences	O
along	O
the	O
monocytic	O
differentiation	O
of	O
leukemic	O
HL60	O
cells	O
.	O
In	O
order	O
to	O
dissect	O
the	O
molecular	O
mechanisms	O
of	O
monocytic	O
differentiation	O
we	O
have	O
developed	O
a	O
subtractive	O
hybridisation	O
method	O
based	O
on	O
a	O
simplified	O
'	O
representational	O
difference	O
analysis	O
'	O
.	O
We	O
have	O
selected	O
16	O
sequences	O
and	O
confirmed	O
their	O
down	O
-	O
regulation	O
along	O
the	O
TPA	O
-	O
induced	O
monocytic	O
differentiation	O
of	O
HL60	O
cells	O
.	O
Among	O
these	O
sequences	O
we	O
have	O
identified	O
the	O
alpha	B
-	I
tubulin	I
,	O
the	O
TaxREB	B
protein	I
and	O
two	O
ribosomal	O
protein	O
sequences	O
which	O
had	O
not	O
been	O
previously	O
described	O
as	O
differentially	O
expressed	O
.	O
These	O
results	O
add	O
to	O
our	O
knowledge	O
about	O
the	O
molecules	O
implicated	O
along	O
the	O
monocytic	O
differentiation	O
and	O
growth	O
arrest	O
of	O
leukemic	O
cells	O
and	O
provide	O
a	O
first	O
step	O
in	O
the	O
study	O
of	O
their	O
respective	O
roles	O
.	O
Activation	O
of	O
a	O
novel	O
gene	O
in	O
3q21	O
and	O
identification	O
of	O
intergenic	O
fusion	O
transcripts	O
with	O
ecotropic	O
viral	O
insertion	O
site	O
I	O
in	O
leukemia	O
.	O
We	O
have	O
identified	O
a	O
novel	O
gene	O
,	O
GR6	O
,	O
located	O
within	O
the	O
leukemia	O
breakpoint	O
region	O
of	O
3q21	O
,	O
that	O
is	O
normally	O
expressed	O
in	O
early	O
fetal	O
development	O
but	O
not	O
in	O
adult	O
peripheral	O
blood	O
.	O
GR6	O
is	O
activated	O
in	O
the	O
UCSD	O
-	O
AML1	O
cell	O
line	O
and	O
in	O
a	O
leukemic	O
sample	O
,	O
both	O
of	O
which	O
carry	O
a	O
t	O
(	O
3	O
;	O
3	O
)	O
(	O
q21	O
;	O
q26	O
)	O
.	O
In	O
UCSD	O
-	O
AML1	O
,	O
we	O
have	O
also	O
identified	O
fusion	O
transcripts	O
between	O
the	O
ecotropic	O
viral	O
insertion	O
site	O
I	O
(	O
EVI1	O
)	O
gene	O
in	O
3q26	O
and	O
GR6	O
and	O
between	O
EVI1	O
and	O
Ribophorin	O
I	O
that	O
maps	O
30	O
kb	O
telomeric	O
to	O
GR6	O
in	O
3q21	O
.	O
All	O
fusions	O
splice	O
the	O
5	O
'	O
ends	O
of	O
the	O
3q21	O
genes	O
into	O
exon	O
2	O
of	O
the	O
EVI1	O
gene	O
,	O
an	O
event	O
that	O
is	O
similar	O
to	O
the	O
normal	O
intergenic	O
splicing	O
of	O
MDS1-EVI1	O
and	O
to	O
those	O
previously	O
documented	O
in	O
leukemias	O
with	O
t	O
(	O
3	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
12	O
)	O
,	O
in	O
which	O
acute	O
myelogenous	O
leukemia	O
1-EVI1	O
fusions	O
and	O
ETV6-EVI1	O
fusions	O
,	O
respectively	O
,	O
occur	O
.	O
The	O
Ribophorin	O
I	O
-	O
EVI1	O
fusion	O
in	O
particular	O
may	O
be	O
a	O
common	O
occurrence	O
in	O
t	O
(	O
3	O
;	O
3	O
)	O
.	O
Four	O
P	O
-	O
like	O
elements	O
are	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
mouse	O
IL-4	O
gene	O
:	O
involvement	O
of	O
a	O
distinct	O
set	O
of	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
and	O
activator	B
protein-1	I
family	I
proteins	I
.	O
We	O
previously	O
identified	O
the	O
P	O
sequence	O
as	O
a	O
critical	O
regulatory	O
element	O
of	O
the	O
human	O
IL-4	O
promoter	O
.	O
In	O
the	O
mouse	O
IL-4	O
promoter	O
,	O
there	O
are	O
five	O
elements	O
homologous	O
to	O
the	O
human	O
P	O
sequence	O
designated	O
conserved	O
lymphokine	O
element	O
0	O
(	O
CLE0	O
)	O
,	O
P	O
,	O
P2	O
,	O
P3	O
and	O
P4	O
.	O
To	O
characterize	O
the	O
role	O
of	O
these	O
P	O
-	O
like	O
elements	O
and	O
their	O
binding	B
factors	I
in	O
the	O
native	O
promoter	O
,	O
we	O
did	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
.	O
Transfection	O
of	O
EL-4	O
cells	O
with	O
the	O
IL-4	O
promoter	O
-	O
reporter	O
constructs	O
carrying	O
mutated	O
P	O
-	O
like	O
elements	O
showed	O
that	O
four	O
P	O
-	O
like	O
elements	O
,	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
,	O
but	O
not	O
P3	O
,	O
were	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL-4	O
promoter	O
.	O
EMSA	O
showed	O
that	O
both	O
constitutive	O
and	O
inducible	O
complexes	O
bound	O
to	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
,	O
whereas	O
only	O
a	O
constitutive	O
complex	O
bound	O
to	O
P3	O
.	O
In	O
competition	O
and	O
antibody	O
supershift	O
assays	O
in	O
EMSA	O
,	O
complexes	O
formed	O
with	O
P	O
or	O
P2	O
proved	O
to	O
contain	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	I
NFAT	I
)	I
family	I
proteins	I
as	O
major	O
components	O
.	O
Activator	B
protein	I
(	I
AP	I
)	I
-1	I
family	I
proteins	I
interacted	O
with	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
.	O
NFAT	B
/	I
AP-1	I
complex	I
formed	O
only	O
with	O
P	O
and	O
P2	O
.	O
Cross	O
-	O
competition	O
assays	O
among	O
the	O
P	O
-	O
like	O
elements	O
revealed	O
element	B
-	I
specific	I
and	I
common	I
complexes	I
.	O
Six	O
tandem	O
repeats	O
of	O
the	O
P	O
element	O
linked	O
to	O
the	O
SV40	O
promoter	O
responded	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
while	O
that	O
of	O
other	O
elements	O
did	O
not	O
.	O
It	O
would	O
thus	O
appear	O
that	O
components	O
of	O
each	O
P	B
-	I
like	I
element	I
-	I
binding	I
complexes	I
are	O
not	O
identical	O
and	O
may	O
coordinately	O
contribute	O
to	O
transcriptional	O
activity	O
.	O
Negative	O
regulation	O
by	O
HLA	B
-	I
DO	I
of	O
MHC	B
class	I
II	I
-restricted	O
antigen	O
processing	O
.	O
HLA	B
-	I
DM	I
is	O
a	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
II	I
-	I
like	I
molecule	I
that	O
facilitates	O
antigen	O
processing	O
by	O
catalyzing	O
the	O
exchange	O
of	O
invariant	O
chain	O
-	O
derived	O
peptides	O
(	O
CLIP	O
)	O
from	O
class	B
II	I
molecules	I
for	O
antigenic	O
peptides	O
.	O
HLA	B
-	I
DO	I
is	O
a	O
second	O
class	B
II	I
-	I
like	I
molecule	I
that	O
physically	O
associates	O
with	O
HLA	B
-	I
DM	I
in	O
B	O
cells	O
.	O
HLA	B
-	I
DO	I
was	O
shown	O
to	O
block	O
HLA	B
-	I
DM	I
function	O
.	O
Purified	O
HLA	B
-	I
DM	I
-	I
DO	I
complexes	I
could	O
not	O
promote	O
peptide	O
exchange	O
in	O
vitro	O
.	O
Expression	O
of	O
HLA	B
-	I
DO	I
in	O
a	O
class	O
II+	O
and	O
DM+	O
,	O
DO-	O
human	O
T	O
cell	O
line	O
caused	O
the	O
accumulation	O
of	O
class	B
II	I
-	I
CLIP	I
complexes	I
,	O
indicating	O
that	O
HLA	B
-	I
DO	I
blocked	O
DM	O
function	O
in	O
vivo	O
and	O
suggesting	O
that	O
HLA	B
-	I
DO	I
is	O
an	O
important	O
modulator	O
of	O
class	O
II	O
-	O
restricted	O
antigen	O
processing	O
.	O
Dual	O
effects	O
of	O
LPS	B
antibodies	I
on	O
cellular	O
uptake	O
of	O
LPS	O
and	O
LPS	O
-	O
induced	O
proinflammatory	O
functions	O
.	O
Human	O
phagocytes	O
recognize	O
bacterial	O
LPS	O
(	O
endotoxin	O
)	O
through	O
membrane	B
CD14	I
(	O
mCD14	B
)	O
,	O
a	O
proinflammatory	B
LPS	I
receptor	I
.	O
This	O
study	O
tested	O
the	O
hypothesis	O
that	O
anti	B
-	I
LPS	I
Abs	I
neutralize	O
endotoxin	O
by	O
blocking	O
cellular	O
uptake	O
through	O
mCD14	B
.	O
Ab	O
-	O
associated	O
changes	O
in	O
the	O
uptake	O
and	O
cellular	O
distribution	O
of	O
FITC	O
-	O
LPS	O
were	O
assessed	O
by	O
flow	O
cytometry	O
and	O
laser	O
scanning	O
confocal	O
microscopy	O
in	O
human	O
CD14-transfected	O
Chinese	O
hamster	O
ovary	O
fibroblasts	O
(	O
CHO	O
-	O
CD14	O
cells	O
)	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
.	O
LPS	O
core-	B
and	I
O	I
-	I
side	I
chain	I
-	I
specific	I
mAbs	I
inhibited	O
mCD14	B
-mediated	O
LPS	O
uptake	O
by	O
both	O
cell	O
types	O
in	O
the	O
presence	O
of	O
serum	O
.	O
O	B
-	I
side	I
chain	I
-	I
specific	I
mAb	I
concurrently	O
enhanced	O
complement	O
-	O
dependent	O
LPS	O
uptake	O
by	O
monocytes	O
through	O
complement	B
receptor-1	I
(	O
CR1	B
)	O
and	O
uptake	O
by	O
CHO	O
-	O
CD14	O
cells	O
involving	O
another	O
heat	B
-	I
labile	I
serum	I
factor	I
(	O
s	O
)	O
and	O
cell	B
-	I
associated	I
recognition	I
molecule	I
(	O
s	O
)	O
.	O
Core	B
-	I
specific	I
mAb	I
inhibited	O
mCD14	B
-mediated	O
uptake	O
of	O
homologous	O
and	O
heterologous	O
LPS	O
,	O
while	O
producing	O
less	O
concurrent	O
enhancement	O
of	O
non-	O
mCD14	B
-mediated	O
LPS	O
uptake	O
.	O
The	O
modulation	O
by	O
anti	B
-	I
LPS	I
mAbs	I
of	O
mCD14	B
-mediated	O
LPS	O
uptake	O
was	O
associated	O
with	O
inhibition	O
of	O
LPS	B
-	I
induced	I
nuclear	I
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
translocation	O
and	O
TNF	B
-	I
alpha	I
secretion	O
in	O
CHO	O
-	O
CD14	O
cells	O
and	O
monocytes	O
,	O
respectively	O
,	O
while	O
mAb	O
enhancement	O
of	O
non-	O
mCD14	B
-mediated	O
LPS	O
uptake	O
stimulated	O
these	O
activities	O
.	O
LPS	B
-	I
specific	I
Abs	I
thus	O
mediate	O
anti	O
-	O
inflammatory	O
and	O
proinflammatory	O
functions	O
,	O
respectively	O
,	O
by	O
preventing	O
target	O
cell	O
uptake	O
of	O
LPS	O
through	O
mCD14	B
and	O
augmenting	O
uptake	O
through	O
CR1	B
or	O
other	O
cell	B
receptors	I
.	O
Human	O
neutrophils	O
express	O
GH	O
-	O
N	O
gene	O
transcripts	O
and	O
the	O
pituitary	B
transcription	I
factor	I
Pit-1b	B
.	O
Since	O
GH	B
stimulates	O
the	O
development	O
and	O
function	O
of	O
granulocytes	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
GH	B
in	O
granulocyte	O
subsets	O
.	O
By	O
immunocytochemistry	O
,	O
25	O
+	O
/-	O
7	O
%	O
of	O
the	O
human	O
neutrophils	O
were	O
shown	O
to	O
express	O
immunoreactive	B
GH	I
,	O
whereas	O
eosinophils	O
were	O
negative	O
.	O
Reversed	O
transcription	O
(	O
RT	O
)	O
-PCR	O
analysis	O
demonstrated	O
GH	O
mRNA	O
in	O
neutrophils	O
.	O
Restriction	O
analysis	O
revealed	O
that	O
neutrophils	O
express	O
the	O
GH	O
-	O
N	O
gene	O
but	O
not	O
the	O
GH	O
-	O
V	O
gene	O
.	O
Furthermore	O
,	O
we	O
demonstrated	O
by	O
western	O
blot	O
analysis	O
that	O
neutrophils	O
express	O
an	O
alternatively	O
spliced	O
variant	O
of	O
the	O
pituitary	B
transcription	I
factor	I
Pit-1	B
,	O
designated	O
Pit-1b	B
.	O
Analysis	O
of	O
myeloid	O
-	O
associated	O
genes	O
in	O
human	O
hematopoietic	O
progenitor	O
cells	O
.	O
The	O
distribution	O
of	O
myeloid	B
lineage	I
-	I
associated	I
cytokine	I
receptors	I
and	O
lysosomal	B
proteins	I
was	O
analyzed	O
in	O
human	O
CD34	O
+	O
cord	O
blood	O
cell	O
(	O
CB	O
)	O
subsets	O
at	O
different	O
stages	O
of	O
myeloid	O
commitment	O
by	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O
The	O
highly	O
specific	O
granulomonocyte	B
-	I
associated	I
lysosomal	I
proteins	I
myeloperoxidase	B
(	O
MPO	B
)	O
and	O
lysozyme	B
(	O
LZ	B
)	O
,	O
as	O
well	O
as	O
the	O
transcription	B
factor	I
PU.1	B
,	O
were	O
already	O
detectable	O
in	O
the	O
most	O
immature	O
CD34+Thy-1	O
+	O
subset	O
.	O
Messenger	O
RNA	O
(	O
mRNA	O
)	O
levels	O
for	O
the	O
granulocyte	B
-	I
colony	I
stimulating	I
factor	I
(	I
G	I
-	I
CSF	I
)	I
receptor	I
,	O
granulocyte	B
-	I
macrophage	I
(	I
GM	I
)	I
-CSF	I
receptor	I
alpha	I
subunit	I
and	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
receptors	I
I	I
(	I
p55	I
)	I
and	I
II	I
(	I
p75	I
)	I
were	O
also	O
detected	O
in	O
this	O
subset	O
in	O
addition	O
to	O
c	B
-	I
kit	I
and	O
flt-3	B
,	O
receptors	O
known	O
to	O
be	O
expressed	O
on	O
progenitor	O
cells	O
.	O
By	O
contrast	O
,	O
the	O
monocyte	B
-	I
macrophage	I
colony	I
stimulating	I
factor	I
(	I
M	I
-	I
CSF	I
)	I
receptor	I
was	O
largely	O
absent	O
at	O
this	O
stage	O
and	O
in	O
the	O
CD34+Thy-1-CD45RA-	O
subsets	O
.	O
The	O
M	B
-	I
CSF	I
receptor	I
was	O
first	O
detectable	O
in	O
the	O
myeloid	O
-	O
committed	O
CD34+Thy	O
-	O
l	O
-	O
CD45RA+	O
subset	O
.	O
All	O
other	O
molecules	O
studied	O
were	O
found	O
to	O
be	O
expressed	O
at	O
this	O
stage	O
of	O
differentiation	O
.	O
Different	O
cocktails	O
of	O
the	O
identified	O
ligands	O
were	O
added	O
to	O
sorted	O
CD34+Thy-1	O
+	O
single	O
cells	O
.	O
Low	O
proliferative	O
capacity	O
was	O
observed	O
after	O
1	O
week	O
in	O
culture	O
in	O
the	O
presence	O
of	O
stem	B
cell	I
factor	I
(	O
SCF	B
)	O
+	O
Flt-3	B
ligand	I
(	O
FL	B
)	O
+	O
G	B
-	I
CSF	I
.	O
Addition	O
of	O
GM	B
-	I
CSF	I
to	O
this	O
basic	O
cocktail	O
consistently	O
increased	O
the	O
clonogenic	O
capacity	O
of	O
single	O
CD34+Thy-1	O
+	O
cells	O
,	O
and	O
this	O
effect	O
was	O
further	O
enhanced	O
(	O
up	O
to	O
72.3	O
+	O
/-	O
4.3	O
%	O
on	O
day	O
7	O
)	O
by	O
the	O
inclusion	O
of	O
TNF	B
-	I
alpha	I
.	O
In	O
conclusion	O
,	O
the	O
presence	O
of	O
myeloid	O
-	O
associated	O
growth	O
factor	O
receptor	O
transcripts	O
in	O
CD34	O
+	O
CB	O
subsets	O
does	O
not	O
discriminate	O
the	O
various	O
stages	O
of	O
differentiation	O
,	O
with	O
the	O
exception	O
of	O
the	O
M	B
-	I
CSF	I
receptor	I
.	O
In	O
addition	O
,	O
we	O
show	O
that	O
TNF	B
-	I
alpha	I
is	O
a	O
potent	O
costimulatory	O
factor	O
of	O
the	O
very	O
immature	O
CD34+Thy-1	O
+	O
CB	O
subset	O
.	O
Dominant	O
cytotoxic	O
T	O
lymphocyte	O
response	O
to	O
the	O
immediate	B
-	I
early	I
trans	I
-	I
activator	I
protein	I
,	O
BZLF1	B
,	O
in	O
persistent	O
type	O
A	O
or	O
B	O
Epstein	O
-	O
Barr	O
virus	O
infection	O
.	O
Five	O
healthy	O
human	O
leukocyte	O
antigen	O
-	O
B8	O
(	O
HLA	O
-	O
B8	O
)	O
-positive	O
virus	O
carriers	O
were	O
studied	O
to	O
investigate	O
the	O
CD8	O
+	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
an	O
HLA	O
-	O
B8-restricted	O
peptide	O
,	O
RAKFKQLLQ	O
,	O
located	O
in	O
the	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
immediate	I
-	I
early	I
trans	I
-	I
activator	I
protein	I
,	O
BZLF1	B
.	O
Of	O
the	O
5	O
virus	O
carriers	O
,	O
4	O
were	O
infected	O
with	O
type	O
A	O
and	O
1	O
with	O
type	O
B	O
EBV	O
.	O
Using	O
limiting	O
-	O
dilution	O
analysis	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
a	O
high	O
RAKFKQLLQ	O
-	O
specific	O
CTL	O
precursor	O
frequency	O
was	O
demonstrated	O
after	O
specific	O
peptide	O
or	O
autologous	O
lymphoblastoid	O
cell	O
line	O
stimulation	O
in	O
both	O
type	O
A	O
and	O
type	O
B	O
EBV	O
carriers	O
.	O
The	O
RAKFKQLLQ	O
-	O
specific	O
CTL	O
precursor	O
frequencies	O
in	O
all	O
5	O
persons	O
were	O
at	O
least	O
as	O
dominant	O
as	O
those	O
observed	O
with	O
two	O
other	O
EBV	B
-	I
associated	I
,	I
HLA	I
-	I
B8-restricted	I
latent	I
epitopes	I
,	O
FLRGRAYGL	O
and	O
QAKWRLQTL	O
.	O
These	O
findings	O
show	O
that	O
healthy	O
virus	O
carriers	O
maintain	O
a	O
high	O
frequency	O
of	O
BZLF1-specific	O
memory	O
T	O
cells	O
,	O
potentially	O
to	O
control	O
virus	O
spread	O
from	O
lytically	O
infected	O
cells	O
.	O
Monochloramine	O
inhibits	O
phorbol	O
ester	O
-	O
inducible	O
neutrophil	O
respiratory	O
burst	O
activation	O
and	O
T	O
cell	O
interleukin-2	B
receptor	O
expression	O
by	O
inhibiting	O
inducible	O
protein	B
kinase	I
C	I
activity	O
.	O
Monochloramine	O
derivatives	O
are	O
long	O
lived	O
physiological	O
oxidants	O
produced	O
by	O
neutrophils	O
during	O
the	O
respiratory	O
burst	O
.	O
The	O
effects	O
of	O
chemically	O
prepared	O
monochloramine	O
(	O
NH2Cl	O
)	O
on	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
and	O
PKC	B
-mediated	O
cellular	O
responses	O
were	O
studied	O
in	O
elicited	O
rat	O
peritoneal	O
neutrophils	O
and	O
human	O
Jurkat	O
T	O
cells	O
.	O
Neutrophils	O
pretreated	O
with	O
NH2Cl	O
(	O
30	O
-	O
50	O
microM	O
)	O
showed	O
a	O
marked	O
decrease	O
in	O
the	O
respiratory	O
burst	O
activity	O
induced	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
which	O
is	O
a	O
potent	O
PKC	B
activator	O
.	O
These	O
cells	O
,	O
however	O
,	O
were	O
viable	O
and	O
showed	O
a	O
complete	O
respiratory	O
burst	O
upon	O
arachidonic	O
acid	O
stimulation	O
,	O
which	O
induces	O
the	O
respiratory	O
burst	O
by	O
a	O
PKC	B
-independent	O
mechanism	O
.	O
The	O
NH2Cl	O
-	O
treated	O
neutrophils	O
showed	O
a	O
decrease	O
in	O
both	O
PKC	B
activity	O
and	O
PMA	O
-	O
induced	O
phosphorylation	O
of	O
a	O
47-kDa	B
protein	I
,	O
which	O
corresponds	O
to	O
the	O
cytosolic	B
factor	I
of	O
NADPH	B
oxidase	I
,	O
p47	B
(	I
phox	I
)	I
.	O
Jurkat	O
T	O
cells	O
pretreated	O
with	O
NH2Cl	O
(	O
20	O
-	O
70	O
microM	O
)	O
showed	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
the	O
interleukin-2	B
receptor	B
alpha	I
chain	I
following	O
PMA	O
stimulation	O
.	O
This	O
was	O
also	O
accompanied	O
by	O
a	O
decrease	O
in	O
both	O
PKC	B
activity	O
and	O
nuclear	O
transcription	O
factor-	O
kappaB	B
activation	O
,	O
also	O
without	O
loss	O
of	O
cell	O
viability	O
.	O
These	O
results	O
show	O
that	O
NH2Cl	O
inhibits	O
PKC	B
-mediated	O
cellular	O
responses	O
through	O
inhibition	O
of	O
the	O
inducible	O
PKC	B
activity	O
.	O
Epstein	O
-	O
Barr	O
virus	O
EBNA3C	B
represses	O
Cp	O
,	O
the	O
major	O
promoter	O
for	O
EBNA	B
expression	O
,	O
but	O
has	O
no	O
effect	O
on	O
the	O
promoter	O
of	O
the	O
cell	O
gene	O
CD21	O
.	O
EBNA3C	B
is	O
a	O
potent	O
repressor	O
of	O
transcription	O
when	O
bound	O
to	O
DNA	O
as	O
a	O
fusion	O
with	O
the	O
DNA	B
binding	I
domain	I
(	O
DBD	B
)	O
of	O
GALA	O
.	O
A	O
survey	O
of	O
promoters	O
has	O
revealed	O
that	O
the	O
wild	B
-	I
type	I
,	I
unfused	I
EBNA3C	I
can	O
specifically	O
repress	O
expression	O
from	O
reporter	O
plasmids	O
containing	O
the	O
Epstein	O
-	O
Barr	O
virus	O
Cp	O
latency	O
-	O
associated	O
promoter	O
.	O
Repression	O
of	O
Cp	O
activity	O
required	O
amino	B
acids	I
207	I
to	I
368	I
,	O
which	O
encompasses	O
a	O
region	O
resembling	O
a	O
basic	B
DBD	I
adjacent	O
to	O
a	O
leucine	B
zipper	I
DNA	I
binding	I
motif	I
and	O
a	O
site	O
which	O
binds	O
to	O
the	O
cellular	B
factor	I
CBF1	I
/	I
RBP	I
-	I
Jkappa	I
.	O
However	O
,	O
amino	O
acids	O
207	O
to	O
368	O
are	O
dispensable	O
when	O
the	O
protein	O
is	O
bound	O
to	O
DNA	O
as	O
a	O
fusion	O
with	O
the	O
GAL4	O
DBD	B
,	O
thus	O
implicating	O
this	O
region	O
in	O
DNA	O
binding	O
.	O
Mutation	O
of	O
the	O
CBF1	B
/	I
RBP	I
-	I
Jkappa	I
binding	I
site	I
in	O
EBNA3C	B
abrogated	O
repression	O
,	O
strongly	O
suggesting	O
that	O
CBF1	B
/	I
RBP	I
-	I
Jkappa	I
is	O
necessary	O
for	O
targeting	O
the	O
viral	O
protein	O
to	O
Cp	O
.	O
Consistent	O
with	O
this	O
result	O
,	O
mutation	O
of	O
the	O
EBNA2	O
response	O
element	O
(	O
a	O
CBF1	O
/	O
RBP	O
-	O
Jkappa	O
binding	O
site	O
)	O
in	O
Cp	O
also	O
prevented	O
significant	O
repression	O
.	O
In	O
addition	O
,	O
amino	B
acids	I
346	I
to	I
543	I
,	O
which	O
were	O
previously	O
defined	O
as	O
important	O
for	O
the	O
repressor	O
activity	O
of	O
the	O
GAL4-EBNA3C	B
fusion	I
proteins	I
,	O
also	O
appear	O
to	O
be	O
necessary	O
for	O
the	O
repression	O
of	O
Cp	O
.	O
Since	O
repression	O
by	O
these	O
fusions	O
was	O
not	O
observed	O
in	O
all	O
cell	O
types	O
,	O
it	O
seems	O
likely	O
that	O
EBNA3C	B
either	O
depends	O
on	O
a	O
corepressor	B
which	O
may	O
interact	O
with	O
amino	B
acids	I
346	I
to	I
543	I
or	O
is	O
modified	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
in	O
order	O
to	O
repress	O
.	O
These	O
data	O
are	O
consistent	O
with	O
EBNA3C	B
contributing	O
to	O
the	O
regulation	O
of	O
EBNA	B
expression	O
in	O
latently	O
infected	O
B	O
cells	O
through	O
CBF1	B
/	I
RBP	I
-	I
Jkappa	I
and	O
another	O
factor	O
,	O
but	O
this	O
need	O
not	O
directly	O
involve	O
EBNA2	B
.	O
Finally	O
,	O
although	O
it	O
has	O
been	O
reported	O
that	O
EBNA3C	B
can	O
upregulate	O
CD21	B
in	O
some	O
B	O
cells	O
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
any	O
effect	O
of	O
EBNA3C	B
on	O
reporter	O
plasmids	O
which	O
contain	O
the	O
CD21	O
promoter	O
.	O
Late	O
gene	O
expression	O
from	O
the	O
Epstein	O
-	O
Barr	O
virus	O
BcLF1	O
and	O
BFRF3	O
promoters	O
does	O
not	O
require	O
DNA	O
replication	O
in	O
cis	O
.	O
Late	O
gene	O
expression	O
follows	O
and	O
is	O
dependent	O
upon	O
lytic	O
replication	O
of	O
the	O
viral	O
genome	O
.	O
Although	O
experimental	O
evidence	O
is	O
lacking	O
,	O
lytic	O
viral	O
DNA	O
replication	O
is	O
believed	O
to	O
remove	O
modifications	O
or	O
binding	B
factors	I
from	O
the	O
genome	O
which	O
serve	O
to	O
repress	O
late	O
gene	O
expression	O
during	O
latency	O
or	O
the	O
early	O
lytic	O
cycle	O
.	O
We	O
have	O
developed	O
a	O
reporter	O
assay	O
to	O
begin	O
characterizing	O
the	O
mechanisms	O
that	O
regulate	O
late	O
gene	O
expression	O
in	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O
In	O
this	O
model	O
system	O
,	O
the	O
activities	O
of	O
late	O
promoter	O
-	O
reporter	O
fusions	O
are	O
measured	O
following	O
transient	O
transfection	O
into	O
tissue	O
culture	O
cells	O
expressing	O
EBV	O
during	O
different	O
stages	O
of	O
the	O
lytic	O
cycle	O
.	O
This	O
system	O
faithfully	O
recapitulates	O
late	O
expression	O
patterns	O
from	O
the	O
endogenous	O
virus	O
,	O
implicating	O
specific	O
cis	O
-	O
active	O
sequences	O
in	O
the	O
control	O
of	O
late	O
gene	O
expression	O
.	O
In	O
addition	O
,	O
these	O
promoters	O
respond	O
only	O
indirectly	O
to	O
the	O
viral	O
immediate	O
-	O
early	O
transactivator	O
,	O
ZEBRA	O
.	O
This	O
indirect	O
response	O
is	O
mediated	O
by	O
other	O
viral	O
or	O
virally	O
induced	O
activities	O
downstream	O
of	O
ZEBRA	O
in	O
the	O
lytic	O
cascade	O
.	O
In	O
this	O
system	O
,	O
late	O
gene	O
expression	O
is	O
sensitive	O
to	O
inhibitors	O
of	O
the	O
viral	B
DNA	I
polymerase	I
such	O
as	O
phosphonoacetic	O
acid	O
,	O
although	O
the	O
reporters	O
lack	O
a	O
eukaryotic	O
origin	O
of	O
replication	O
and	O
are	O
not	O
replicated	O
under	O
the	O
assay	O
conditions	O
.	O
Thus	O
,	O
replication	O
of	O
the	O
transcriptional	O
template	O
is	O
not	O
a	O
prerequisite	O
for	O
expression	O
with	O
late	O
kinetics	O
,	O
a	O
finding	O
inconsistent	O
with	O
the	O
current	O
models	O
which	O
posit	O
a	O
cis	O
-	O
active	O
relationship	O
between	O
lytic	O
EBV	O
DNA	O
replication	O
and	O
late	O
gene	O
expression	O
.	O
Rather	O
,	O
analysis	O
of	O
this	O
system	O
has	O
revealed	O
a	O
trans	O
relationship	O
between	O
late	O
gene	O
expression	O
and	O
viral	O
DNA	O
replication	O
and	O
highlights	O
the	O
indirect	O
and	O
complex	O
link	O
between	O
these	O
two	O
events	O
.	O
Purification	O
and	O
characterization	O
of	O
the	O
human	B
SR	I
31747A	I
-	I
binding	I
protein	I
.	O
A	O
nuclear	B
membrane	I
protein	I
related	O
to	O
yeast	B
sterol	I
isomerase	I
.	O
SR	O
31747A	O
,	O
defined	O
as	O
a	O
sigma	O
ligand	O
,	O
is	O
a	O
novel	O
immunosuppressive	O
agent	O
that	O
blocks	O
proliferation	O
of	O
human	O
and	O
mouse	O
lymphocytes	O
.	O
Using	O
a	O
radiolabeled	O
chemical	O
probe	O
,	O
we	O
here	O
purified	O
a	O
target	O
of	O
SR	O
31747A	O
and	O
called	O
it	O
SR	B
31747A	I
-	I
binding	I
protein	I
(	O
SR	B
-	I
BP	I
)	O
.	O
Purified	B
SR	I
-	I
BP	I
retained	O
its	O
binding	O
properties	O
and	O
migrated	O
on	O
SDS	O
-	O
polyacrylamide	O
gel	O
as	O
a	O
Mr	B
28	I
,	I
000	I
protein	I
.	O
Cloning	O
of	O
the	O
cDNA	O
encoding	O
human	B
SR	I
-	I
BP	I
shows	O
an	O
open	O
reading	O
frame	O
for	O
a	O
223-amino	B
acid	I
protein	I
,	O
which	O
is	O
homologous	O
to	O
the	O
recently	O
cloned	O
sigma	B
1	I
receptor	I
.	O
Interestingly	O
,	O
the	O
deduced	O
amino	O
acid	O
sequence	O
was	O
found	O
to	O
be	O
related	O
to	O
fungal	B
C8-C7	I
sterol	I
isomerase	I
,	O
encoded	O
by	O
the	O
ERG2	O
gene	O
.	O
The	O
ERG2	B
gene	I
product	I
has	O
been	O
identified	O
recently	O
as	O
the	O
molecular	O
target	O
of	O
SR	O
31747A	O
that	O
mediates	O
antiproliferative	O
effects	O
of	O
the	O
drug	O
in	O
yeast	O
.	O
Northern	O
blot	O
analysis	O
of	O
SR	B
-	I
BP	I
gene	O
expression	O
revealed	O
a	O
single	O
transcript	O
of	O
2	O
kilobases	O
which	O
was	O
widely	O
expressed	O
among	O
organs	O
,	O
with	O
the	O
highest	O
abundance	O
in	O
liver	O
and	O
the	O
lowest	O
abundance	O
in	O
brain	O
.	O
Subcellular	O
localization	O
analysis	O
in	O
various	O
cells	O
,	O
using	O
a	O
specific	B
monoclonal	I
antibody	I
raised	O
against	O
SR	B
-	I
BP	I
,	O
demonstrated	O
that	O
this	O
protein	O
was	O
associated	O
with	O
the	O
nuclear	O
envelope	O
.	O
When	O
studying	O
the	O
binding	O
of	O
SR	O
31747A	O
on	O
membranes	O
from	O
yeast	O
expressing	O
SR	B
-	I
BP	I
,	O
we	O
found	O
a	O
pharmacological	O
profile	O
of	O
sigma	B
1	I
receptors	I
;	O
binding	O
was	O
displaced	O
by	O
(	O
+	O
)	O
-pentazocine	O
,	O
haloperidol	O
,	O
and	O
(	O
+	O
)	O
-SKF	O
10	O
,	O
047	O
,	O
with	O
(	O
+	O
)	O
-SKF	O
10	O
,	O
047	O
being	O
a	O
more	O
potent	O
competitor	O
than	O
(	O
-	O
)	O
-SKF	O
10	O
,	O
047	O
.	O
Scatchard	O
plot	O
analysis	O
revealed	O
Kd	O
values	O
of	O
7.1	O
nM	O
and	O
0.15	O
nM	O
for	O
(	O
+	O
)	O
-pentazocine	O
and	O
SR	O
31747A	O
,	O
respectively	O
,	O
indicating	O
an	O
affinity	O
of	O
SR	B
-	I
BP	I
50-fold	O
higher	O
for	O
SR	O
31747A	O
than	O
for	O
pentazocine	O
.	O
Additionally	O
,	O
we	O
showed	O
that	O
pentazocine	O
,	O
a	O
competitive	O
inhibitor	O
of	O
SR	O
31747A	O
binding	O
,	O
also	O
prevents	O
the	O
immunosuppressive	O
effect	O
of	O
SR	O
31747A	O
.	O
Taken	O
together	O
,	O
these	O
findings	O
strongly	O
suggest	O
that	O
SR	B
-	I
BP	I
represents	O
the	O
molecular	O
target	O
for	O
SR	O
31747A	O
in	O
mammalian	O
tissues	O
,	O
which	O
could	O
be	O
critical	O
for	O
T	O
cell	O
proliferation	O
.	O
Involvement	O
of	O
different	O
transduction	O
pathways	O
in	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
several	O
inducers	O
.	O
Double	O
-	O
stimulation	O
was	O
used	O
to	O
demonstrate	O
that	O
,	O
in	O
a	O
T	O
lymphocytic	O
cell	O
line	O
(	O
CEM	O
)	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
rapidly	O
induced	O
NF	B
-	I
kappa	I
B	I
through	O
a	O
signaling	O
pathway	O
which	O
did	O
not	O
involve	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
was	O
different	O
from	O
the	O
activation	O
triggered	O
by	O
either	O
H2O2	O
or	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
.	O
Since	O
these	O
latter	O
compounds	O
were	O
known	O
to	O
activate	O
NF	B
-	I
kappa	I
B	I
translocation	O
in	O
a	O
redox	O
-	O
sensitive	O
way	O
,	O
we	O
have	O
demonstrated	O
that	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
PMA	O
was	O
resistant	O
to	O
antioxidant	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
and	O
sensitive	O
to	O
kinase	O
inhibitors	O
staurosporine	O
and	O
H7	O
while	O
activation	O
by	O
H2O2	O
or	O
TNF	B
-	I
alpha	I
were	O
not	O
.	O
Association	O
of	O
glucocorticoid	O
insensitivity	O
with	O
increased	O
expression	O
of	O
glucocorticoid	B
receptor	I
beta	I
.	O
In	O
many	O
chronic	O
inflammatory	O
disorders	O
,	O
glucocorticoid	O
(	O
GC	O
)	O
insensitivity	O
is	O
a	O
challenging	O
clinical	O
problem	O
associated	O
with	O
life	O
-	O
threatening	O
disease	O
progression	O
.	O
The	O
molecular	O
basis	O
of	O
GC	O
insensitivity	O
,	O
however	O
,	O
is	O
unknown	O
.	O
Alternative	O
splicing	O
of	O
the	O
GC	O
receptor	O
(	O
R	O
)	O
pre	O
-	O
messenger	O
RNA	O
generates	O
a	O
second	O
GCR	B
,	O
termed	O
GCR	B
-	I
beta	I
,	O
which	O
does	O
not	O
bind	O
GCs	O
but	O
antagonizes	O
the	O
transactivating	O
activity	O
of	O
the	O
classic	O
GCR	B
,	O
termed	O
GCR	B
-	I
alpha	I
.	O
In	O
the	O
current	O
study	O
,	O
we	O
demonstrate	O
that	O
GC	O
-	O
insensitive	O
asthma	O
is	O
associated	O
with	O
a	O
significantly	O
higher	O
number	O
of	O
GCR	O
-	O
beta	O
-	O
immunoreactive	O
cells	O
in	O
peripheral	O
blood	O
than	O
GC	O
-	O
sensitive	O
asthmatics	O
or	O
normal	O
controls	O
.	O
Furthermore	O
,	O
we	O
show	O
that	O
patients	O
with	O
GC	O
-	O
insensitive	O
asthma	O
have	O
cytokine	O
-	O
induced	O
abnormalities	O
in	O
the	O
DNA	O
binding	O
capability	O
of	O
the	O
GCR	B
.	O
These	O
abnormalities	O
can	O
be	O
reproduced	O
by	O
transfection	O
of	O
cell	O
lines	O
with	O
the	O
GCR	B
-	I
beta	I
gene	O
resulting	O
in	O
significant	O
reduction	O
of	O
their	O
GCR	B
-	I
alpha	I
DNA	O
binding	O
capacity	O
.	O
We	O
conclude	O
that	O
increased	O
expression	O
of	O
GCR	B
-	I
beta	I
is	O
cytokine	B
inducible	O
and	O
may	O
account	O
for	O
GC	O
insensitivity	O
in	O
this	O
common	O
inflammatory	O
condition	O
.	O
Dysregulation	O
of	O
monocytic	B
nuclear	I
factor	I
-	I
kappa	I
B	I
by	O
oxidized	O
low	B
-	I
density	I
lipoprotein	I
.	O
Nuclear	B
factor	I
-	I
kappa	I
B	I
(	I
NF	I
-	I
kappa	I
B	I
)	I
/Rel	I
transcription	I
factors	I
may	O
be	O
involved	O
in	O
atherosclerosis	O
,	O
as	O
is	O
suggested	O
by	O
the	O
presence	O
of	O
activated	O
NF	B
-	I
kappa	I
B	I
in	O
human	O
atherosclerotic	O
lesions	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
oxidized	B
LDL	I
(	O
oxLDL	B
)	O
on	O
the	O
NF	B
-	I
kappa	I
B	I
system	O
in	O
human	O
THP-1	O
monocytic	O
cells	O
as	O
well	O
as	O
adherent	O
monocytes	O
.	O
Our	O
results	O
demonstrate	O
that	O
short	O
-	O
term	O
incubation	O
of	O
these	O
cells	O
with	O
oxLDL	B
activated	I
p50	I
/	I
p65	I
containing	O
NF	B
-	I
kappa	I
B	I
dimers	I
and	O
induced	O
the	O
expression	O
of	O
the	O
target	O
gene	O
IL-8	O
.	O
This	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
was	O
inhibited	O
by	O
the	O
antioxidant	O
and	O
H2O2	O
scavenger	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
proteasome	B
inhibitor	O
PSI	O
.	O
The	O
oxLDL	B
-induced	O
NF	B
-	I
kappa	I
B	I
activation	O
was	O
accompanied	O
by	O
an	O
initial	O
depletion	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
followed	O
by	O
a	O
slight	O
transient	O
increase	O
in	O
the	O
level	O
of	O
this	O
inhibitor	O
protein	O
.	O
In	O
contrast	O
,	O
long	O
-	O
term	O
treatment	O
with	O
oxLDL	B
prevented	O
the	O
lipopolysaccharide	O
-	O
induced	O
depletion	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
,	O
accompanied	O
by	O
an	O
inhibition	O
of	O
both	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
the	O
expression	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
and	O
interleukin-1	O
beta	O
genes	O
.	O
These	O
observations	O
provide	O
additional	O
evidence	O
that	O
oxLDL	B
is	O
a	O
potent	O
modulator	O
of	O
gene	O
expression	O
and	O
suggest	O
that	O
(	O
dys	O
)	O
regulation	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
atherogenesis	O
.	O
Suppression	O
of	O
MHC	B
class	I
II	I
expression	O
by	O
human	O
class	O
II	O
trans	O
-	O
activator	O
constructs	O
lacking	O
the	O
N	B
-	I
terminal	I
domain	I
.	O
The	O
class	B
II	I
trans	I
-	I
activator	I
(	O
CIITA	B
)	O
is	O
a	O
bi-	B
or	I
multi	I
-	I
functional	I
domain	I
protein	I
which	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O
We	O
report	O
that	O
removal	O
of	O
the	O
N	B
-	I
terminal	I
151	I
amino	I
acids	I
,	O
encompassing	O
all	O
of	O
the	O
acidic	B
domain	I
but	O
leaving	O
intact	O
the	O
proline	B
/	I
serine	I
/	I
threonine	I
-	I
rich	I
domain	I
,	O
results	O
in	O
a	O
mutant	O
protein	O
with	O
potent	O
suppressive	O
properties	O
for	O
MHC	B
class	I
II	I
expression	O
.	O
HeLa	O
cells	O
stably	O
or	O
transiently	O
transfected	O
with	O
mutant	O
CIITA	O
constructs	O
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
MHC	B
class	I
II	I
antigen	O
induction	O
by	O
IFN	B
-	I
gamma	I
and	O
marked	O
suppression	O
of	O
HLA	O
-	O
DRA	O
mRNA	O
expression	O
.	O
Transient	O
transfection	O
of	O
a	O
B	O
lymphoma	O
line	O
resulted	O
in	O
up	O
to	O
89	O
%	O
reduction	O
of	O
constitutive	O
MHC	B
class	I
II	I
expression	O
within	O
5	O
days	O
and	O
suppression	O
of	O
HLA	O
-	O
DRA	O
mRNA	O
synthesis	O
.	O
Inhibition	O
of	O
proliferation	O
and	O
apoptosis	O
of	O
human	O
and	O
rat	O
T	O
lymphocytes	O
by	O
curcumin	O
,	O
a	O
curry	O
pigment	O
.	O
Curcumin	O
(	O
diferuoylmethane	O
)	O
,	O
the	O
yellow	O
pigment	O
in	O
the	O
rhizome	O
of	O
tumeric	O
(	O
Curcuma	O
longa	O
)	O
,	O
an	O
ingredient	O
of	O
curry	O
spice	O
,	O
is	O
known	O
to	O
exhibit	O
a	O
variety	O
of	O
pharmacological	O
effects	O
including	O
antitumor	O
,	O
antiinflammatory	O
,	O
and	O
antiinfectious	O
activities	O
.	O
Although	O
its	O
precise	O
mode	O
of	O
action	O
remains	O
elusive	O
,	O
curcumin	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
activity	O
of	O
the	O
AP-1	B
transcription	B
factor	I
in	O
cells	O
stimulated	O
to	O
proliferate	O
.	O
In	O
this	O
study	O
,	O
we	O
observed	O
that	O
curcumin	O
(	O
50	O
microM	O
)	O
inhibited	O
proliferation	O
of	O
rat	O
thymocytes	O
stimulated	O
with	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
as	O
well	O
as	O
that	O
of	O
human	O
Jurkat	O
lymphoblastoid	O
cells	O
in	O
the	O
logarithmic	O
growth	O
phase	O
.	O
The	O
pigment	O
also	O
inhibited	O
apoptosis	O
in	O
dexamethasone	O
-	O
treated	O
rat	O
thymocytes	O
and	O
in	O
UV	O
-	O
irradiated	O
Jurkat	O
cells	O
as	O
judged	O
by	O
DNA	O
ladder	O
formation	O
,	O
cellular	O
morphological	O
changes	O
,	O
and	O
flow	O
cytometry	O
analysis	O
.	O
The	O
inhibition	O
of	O
apoptosis	O
by	O
curcumin	O
in	O
rat	O
thymocytes	O
was	O
accompanied	O
by	O
partial	O
suppression	O
of	O
AP-1	B
activity	O
.	O
Complete	O
suppression	O
of	O
AP-1	B
activity	O
was	O
observed	O
in	O
Con	O
A	O
-	O
treated	O
,	O
proliferating	O
thymocytes	O
.	O
The	O
capacity	O
of	O
curcumin	O
to	O
inhibit	O
both	O
cell	O
growth	O
and	O
death	O
strongly	O
implies	O
that	O
these	O
two	O
biological	O
processes	O
share	O
a	O
common	O
pathway	O
at	O
some	O
point	O
and	O
that	O
curcumin	O
affects	O
a	O
common	O
step	O
,	O
presumably	O
involving	O
a	O
modulation	O
of	O
the	O
AP-1	B
transcription	B
factor	I
.	O
Regulation	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
and	O
its	O
inhibitor	O
I	B
kappa	I
B	I
-	I
alpha	I
/	I
MAD-3	I
in	O
monocytes	O
by	O
Mycobacterium	O
tuberculosis	O
and	O
during	O
human	O
tuberculosis	O
.	O
Blood	O
monocytes	O
from	O
patients	O
with	O
active	O
tuberculosis	O
are	O
activated	O
in	O
vivo	O
,	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
the	O
stimulated	O
release	O
of	O
proinflammatory	B
cytokines	I
,	O
such	O
as	O
TNF	B
-	I
alpha	I
,	O
and	O
the	O
spontaneous	O
expression	O
of	O
IL-2R	B
.	O
Further	O
,	O
monocytes	O
from	O
patients	O
demonstrate	O
an	O
augmented	O
susceptibility	O
to	O
a	O
productive	O
infection	O
with	O
HIV-1	O
in	O
vitro	O
.	O
Mycobacterium	O
tuberculosis	O
and	O
its	O
components	O
are	O
strong	O
signals	O
to	O
activate	O
monocytes	O
to	O
production	O
of	O
cytokines	B
.	O
In	O
this	O
study	O
we	O
examined	O
the	O
basis	O
of	O
activation	O
of	O
monocytes	O
during	O
active	O
tuberculosis	O
and	O
by	O
M.	O
tuberculosis	O
.	O
We	O
found	O
a	O
constitutive	O
degradation	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
,	O
the	O
major	O
cytoplasmic	B
inhibitor	I
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
,	O
in	O
freshly	O
isolated	O
PBMC	O
and	O
monocytes	O
from	O
patients	O
with	O
tuberculosis	O
.	O
In	O
contrast	O
,	O
I	B
kappa	I
B	I
-	I
alpha	I
levels	O
in	O
PBMC	O
and	O
monocytes	O
from	O
healthy	O
subjects	O
or	O
from	O
patients	O
with	O
nontuberculous	O
pulmonary	O
conditions	O
were	O
intact	O
.	O
Further	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
NF	B
-	I
kappa	I
B	I
was	O
activated	O
in	O
monocytes	O
from	O
tuberculous	O
patients	O
.	O
The	O
expression	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
gene	O
,	O
which	O
is	O
responsive	O
to	O
activation	O
by	O
NF	B
-	I
kappa	I
B	I
,	O
was	O
up	O
-	O
regulated	O
in	O
PBMC	O
and	O
monocytes	O
from	O
patients	O
,	O
but	O
not	O
in	O
mononuclear	O
cells	O
from	O
healthy	O
subjects	O
or	O
those	O
with	O
nontuberculous	O
lung	O
diseases	O
.	O
By	O
contrast	O
,	O
the	O
expression	O
of	O
other	O
adherence	O
-	O
associated	O
early	O
genes	O
,	O
such	O
as	O
IL-8	B
and	O
IL-1	B
beta	I
,	O
was	O
not	O
up	O
-	O
regulated	O
in	O
PBMC	O
of	O
tuberculous	O
patients	O
.	O
Further	O
,	O
M.	O
tuberculosis	O
and	O
its	O
tuberculin	B
,	O
purified	B
protein	I
derivative	I
,	O
induced	O
the	O
degradation	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
and	O
the	O
expression	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
mRNA	O
,	O
and	O
purified	O
protein	O
derivative	O
induced	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
monocytes	O
.	O
Analysis	O
of	O
interactions	O
between	O
huGATA-3	B
transcription	O
factor	O
and	O
three	O
GATA	O
regulatory	O
elements	O
of	O
HIV-1	O
long	O
terminal	O
repeat	O
,	O
by	O
surface	O
plasmon	O
resonance	O
.	O
Relative	O
affinities	O
of	O
transcriptional	O
regulatory	O
elements	O
for	O
their	O
respective	O
factor	O
have	O
been	O
essentially	O
studied	O
by	O
bandshift	O
analysis	O
.	O
Here	O
we	O
report	O
a	O
real	O
-	O
time	O
study	O
of	O
factor	O
/	O
DNA	O
interactions	O
using	O
a	O
surface	O
plasmon	O
resonance	O
approach	O
and	O
further	O
characterization	O
of	O
recovered	B
proteins	I
involved	O
in	O
this	O
interaction	O
.	O
For	O
this	O
purpose	O
,	O
human	B
GATA-3	I
,	O
either	O
recombinant	O
or	O
in	O
nuclear	O
extracts	O
,	O
and	O
three	O
natural	O
GATA	O
elements	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
sites	O
1	O
,	O
2	O
,	O
and	O
3	O
)	O
were	O
chosen	O
,	O
in	O
which	O
only	O
site	O
2	O
is	O
a	O
noncanonical	O
GATA	O
site	O
.	O
Direct	O
analysis	O
of	O
sensorgrams	O
,	O
with	O
recombinant	B
huGATA-3	I
,	O
allowed	O
the	O
comparison	O
of	O
association	O
and	O
dissociation	O
profiles	O
of	O
the	O
three	O
DNA	O
regions	O
and	O
their	O
ranking	O
according	O
to	O
their	O
relative	O
affinities	O
.	O
This	O
result	O
,	O
confirmed	O
by	O
competitions	O
with	O
each	O
GATA	O
site	O
,	O
demonstrated	O
the	O
higher	O
relative	O
affinity	O
(	O
at	O
least	O
sevenfold	O
)	O
of	O
site	O
3	O
.	O
Interactions	O
between	O
the	O
canonical	O
and	O
unique	O
GATA	O
site	O
3	O
and	O
nuclear	O
extracts	O
were	O
also	O
studied	O
in	O
real	O
time	O
and	O
provided	O
information	O
on	O
its	O
association	O
and	O
dissociation	O
rates	O
for	O
native	O
huGATA-3	B
.	O
Finally	O
,	O
recovered	O
protein	O
was	O
identified	O
as	O
genuine	O
huGATA-3	B
by	O
SDS	O
-	O
PAGE	O
,	O
Western	O
blotting	O
,	O
and	O
bandshift	O
assays	O
.	O
Copyright	O
1997	O
Academic	O
Press	O
.	O
TNFalpha	B
cooperates	O
with	O
the	O
protein	B
kinase	I
A	I
pathway	O
to	O
synergistically	O
increase	O
HIV-1	O
LTR	O
transcription	O
via	O
downstream	O
TRE	O
-	O
like	O
cAMP	O
response	O
elements	O
.	O
Activating	B
protein-1	I
(	O
AP-1	B
)	O
binding	O
TPA	O
responsive	O
elements	O
(	O
TRE	O
)	O
are	O
located	O
downstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
the	O
U5	O
region	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O
These	O
downstream	O
sequence	O
elements	O
,	O
termed	O
DSE	O
,	O
can	O
bind	O
both	O
AP-1	B
and	O
CREB	B
/	I
ATF	I
transcription	B
factors	I
.	O
Recently	O
,	O
we	O
demonstrated	O
that	O
the	O
DSE	O
are	O
also	O
cAMP	O
-	O
responsive	O
elements	O
(	O
CRE	O
)	O
,	O
since	O
they	O
mediated	O
activation	O
signals	O
elicited	O
by	O
cholera	B
toxin	I
(	O
Ctx	B
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
cAMP	O
-	O
dependent	O
protein	B
kinase	I
A	I
(	O
PKA	B
)	O
signal	O
transduction	O
pathway	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
HIV-1	O
DSE	O
can	O
mediate	O
the	O
transcriptional	O
synergy	O
elicited	O
by	O
the	O
combination	O
of	O
Ctx	B
and	O
TNFalpha	B
.	O
Ctx	B
combined	O
with	O
TNFalpha	B
or	O
IL-1beta	B
to	O
produce	O
a	O
synergistic	O
increase	O
in	O
p24	B
antigen	I
production	O
in	O
U1	O
promonocytic	O
cells	O
.	O
Transfection	O
studies	O
of	O
LTR	O
reporter	O
constructs	O
indicated	O
that	O
mutation	O
of	O
the	O
DSE	O
sites	O
abrogated	O
the	O
LTR	O
-mediated	O
synergy	O
induced	O
by	O
Ctx	B
and	O
TNFalpha	B
,	O
whereas	O
the	O
synergy	O
induced	O
by	O
Ctx	B
and	O
IL-1beta	B
was	O
unaffected	O
,	O
suggesting	O
TNFalpha	B
and	O
IL-1beta	B
cooperate	O
differently	O
with	O
the	O
cAMP	O
/PKA	B
activation	O
pathway	O
to	O
induce	O
HIV-1	O
expression	O
in	O
U1	O
cells	O
.	O
Because	O
the	O
DSE	O
are	O
also	O
TRE	O
sites	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
the	O
agonist	O
combinations	O
on	O
AP-1	B
-dependent	O
transcription	O
.	O
TNFalpha	B
as	O
well	O
as	O
IL-1beta	B
cooperated	O
with	O
Ctx	B
to	O
produce	O
a	O
synergistic	O
activation	O
of	O
AP-1	B
-mediated	O
transcription	O
.	O
These	O
data	O
indicate	O
that	O
the	O
TRE	O
-	O
like	O
cAMP	O
-	O
responsive	O
DSE	O
sites	O
within	O
the	O
5'-untranslated	O
leader	O
can	O
mediate	O
the	O
transcriptional	O
cooperativity	O
between	O
TNFalpha	B
and	O
the	O
cAMP	O
/PKA	B
pathway	O
.	O
Since	O
the	O
DSE	O
and	O
TRE	O
sites	O
can	O
not	O
bind	O
CREB	B
/	I
ATF	I
homodimers	I
,	O
we	O
propose	O
a	O
mechanism	O
in	O
which	O
the	O
HIV-1	O
DSE	O
bind	O
heterodimers	B
composed	O
of	O
both	O
AP-1	B
and	I
CREB	I
/	I
ATF	I
proteins	I
.	O
Copyright	O
1997	O
Academic	O
Press	O
.	O
Modulation	O
of	O
mRNA	O
expression	O
of	O
a	O
novel	O
human	O
myeloid	O
-	O
selective	O
CCAAT	O
/	O
enhancer	O
binding	O
protein	O
gene	O
(	O
C	O
/	O
EBP	O
epsilon	O
)	O
.	O
Human	O
C	O
/	O
EBP	O
epsilon	O
is	O
a	O
newly	O
cloned	O
gene	O
coding	O
for	O
a	O
CCAAT	B
/	I
enhancer	I
binding	I
protein	I
that	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
myeloid	O
differentiation	O
.	O
Our	O
studies	O
showed	O
that	O
levels	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
were	O
markedly	O
increased	O
in	O
NB4	O
cells	O
(	O
promyelocytic	O
leukemia	O
line	O
)	O
,	O
because	O
they	O
were	O
induced	O
by	O
9-cis	O
retinoic	O
acid	O
(	O
9-cis	O
RA	O
)	O
to	O
differentiate	O
towards	O
granulocytes	O
.	O
Accumulation	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
occurred	O
as	O
early	O
as	O
1	O
hour	O
after	O
exposure	O
of	O
NB4	O
cells	O
to	O
9-cis	O
RA	O
(	O
5	O
x	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
;	O
and	O
at	O
48	O
hours	O
,	O
levels	O
were	O
increased	O
by	O
5.1-fold	O
.	O
Dose	O
-	O
response	O
studies	O
showed	O
that	O
10	O
(	O
-7	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol	O
/	O
L	O
9-cis	O
RA	O
(	O
12	O
hours	O
)	O
resulted	O
in	O
peak	O
levels	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
;	O
but	O
even	O
10	O
(	O
-10	O
)	O
mol	O
/	O
L	O
9-cis	O
RA	O
increased	O
levels	O
of	O
these	O
transcripts	O
.	O
NB4	O
cells	O
pulse	O
-	O
exposed	O
(	O
30	O
minutes	O
)	O
to	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
washed	O
,	O
and	O
cultured	O
(	O
3	O
days	O
)	O
with	O
either	O
dimethylsulfoxide	O
(	O
DMSO	O
)	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
had	O
a	O
prominent	O
increase	O
in	O
levels	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
and	O
an	O
increase	O
in	O
granulocytic	O
differentiation	O
,	O
but	O
exposure	O
to	O
either	O
DMSO	O
or	O
HMBA	O
alone	O
had	O
no	O
effect	O
on	O
base	O
levels	O
of	O
C	O
/	O
EBP	O
epsilon	O
and	O
did	O
not	O
induce	O
differentiation	O
.	O
Macrophage	O
-	O
differentiation	O
of	O
NB4	O
reduced	O
levels	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
.	O
Nuclear	O
run	O
-	O
off	O
assays	O
and	O
half	O
-	O
life	O
studies	O
showed	O
that	O
accumulation	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
by	O
9-cis	O
RA	O
was	O
due	O
to	O
enhanced	O
transcription	O
.	O
Furthermore	O
,	O
this	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
accumulation	O
did	O
not	O
require	O
synthesis	O
of	O
new	O
protein	B
factors	I
because	O
9-cis	O
RA	O
induced	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
accumulation	O
in	O
the	O
absence	O
of	O
new	O
protein	O
synthesis	O
.	O
ATRA	O
also	O
induced	O
expression	O
of	O
C	B
/	I
EBP	I
epsilon	I
protein	I
in	O
NB4	O
cells	O
,	O
as	O
shown	O
by	O
Western	O
blotting	O
.	O
In	O
contrast	O
to	O
the	O
increase	O
of	O
C	O
/	O
EBP	O
epsilon	O
in	O
9-cis	O
RA	O
-	O
mediated	O
granulocytic	O
differentiation	O
,	O
the	O
DMSO	O
-	O
induced	O
differentiation	O
of	O
HL-60	O
cells	O
down	O
the	O
granulocytic	O
pathway	O
was	O
associated	O
with	O
an	O
initial	O
reduction	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
levels	O
.	O
In	O
summary	O
,	O
we	O
have	O
discovered	O
that	O
expression	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
is	O
markedly	O
enhanced	O
as	O
the	O
NB4	O
promyelocytes	O
are	O
induced	O
by	O
retinoids	O
to	O
differentiate	O
towards	O
granulocytes	O
.	O
This	O
induction	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
expression	O
is	O
transcriptionally	O
mediated	O
and	O
occurs	O
in	O
the	O
absence	O
of	O
synthesis	O
of	O
additional	O
protein	B
factors	I
.	O
We	O
suspect	O
that	O
the	O
C	O
/	O
EBP	O
epsilon	O
promoter	O
/	O
enhancer	O
contains	O
a	O
retinoic	O
acid	O
-	O
response	O
element	O
that	O
is	O
directly	O
stimulated	O
by	O
retinoids	O
.	O
Paternal	O
expression	O
of	O
WT1	B
in	O
human	O
fibroblasts	O
and	O
lymphocytes	O
.	O
The	O
Wilms	O
'	O
tumor	O
suppressor	O
gene	O
(	O
WT1	B
)	O
was	O
previously	O
identified	O
as	O
being	O
imprinted	O
,	O
with	O
frequent	O
maternal	O
expression	O
in	O
human	O
placentae	O
and	O
fetal	O
brains	O
.	O
We	O
examined	O
the	O
allele	O
-	O
specific	O
expression	O
of	O
WT1	B
in	O
cultured	O
human	O
fibroblasts	O
from	O
15	O
individuals	O
.	O
Seven	O
of	O
15	O
fibroblast	O
lines	O
were	O
heterozygous	O
for	O
polymorphic	O
alleles	O
,	O
and	O
the	O
expression	O
patterns	O
were	O
variable	O
,	O
i.e.	O
,	O
equal	O
,	O
unequal	O
or	O
monoallelic	O
paternal	O
expression	O
in	O
three	O
,	O
two	O
and	O
two	O
cases	O
,	O
respectively	O
.	O
Exclusive	O
paternal	O
expression	O
of	O
WT1	B
was	O
also	O
shown	O
in	O
non	O
-	O
cultured	O
peripheral	O
lymphocytes	O
from	O
the	O
latter	O
two	O
individuals	O
.	O
The	O
allele	O
-	O
specific	O
expression	O
profiles	O
of	O
other	O
imprinted	O
genes	O
,	O
IGF2	O
and	O
H19	O
,	O
on	O
human	O
chromosome	O
11	O
were	O
constant	O
and	O
consistent	O
with	O
those	O
in	O
other	O
tissues	O
.	O
Our	O
unexpected	O
observations	O
of	O
paternal	O
or	O
biallelic	O
expression	O
of	O
WT1	B
in	O
fibroblasts	O
and	O
lymphocytes	O
,	O
together	O
with	O
the	O
previous	O
findings	O
of	O
maternal	O
or	O
biallelic	O
expression	O
in	O
placentae	O
and	O
brains	O
,	O
suggest	O
that	O
the	O
allele	O
-	O
specific	O
regulatory	O
system	O
of	O
WT1	B
is	O
unique	O
and	O
may	O
be	O
controlled	O
by	O
a	O
putative	O
tissue-	O
and	O
individual	O
-	O
specific	O
modifier	O
.	O
Repression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
through	O
the	O
novel	O
cooperation	O
of	O
human	B
factors	I
YY1	B
and	O
LSF	B
[	O
published	O
erratum	O
appears	O
in	O
J	O
Virol	O
1998	O
Feb	O
;	O
72	O
(	O
2	O
)	O
:	O
1709	O
]	O
A	O
subpopulation	O
of	O
stably	O
infected	O
CD4	O
+	O
cells	O
capable	O
of	O
producing	O
virus	O
upon	O
stimulation	O
has	O
been	O
identified	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-positive	O
individuals	O
(	O
T	O
.-	O
W.Chun	O
,	O
D.Finzi	O
,	O
J.Margolick	O
,	O
K.Chadwick	O
,	O
D.Schwartz	O
,	O
and	O
R.F.Siliciano	O
,	O
Nat	O
.	O
Med.1	O
:	O
1284	O
-	O
1290	O
,	O
1995	O
)	O
.	O
Few	O
host	O
factors	O
that	O
directly	O
limit	O
HIV-1	O
transcription	O
and	O
could	O
support	O
this	O
state	O
of	O
nonproductive	O
HIV-1	O
infection	O
have	O
been	O
described	O
.	O
YY1	B
,	O
a	O
widely	O
distributed	O
human	B
transcription	I
factor	I
,	O
is	O
known	O
to	O
inhibit	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
transcription	O
and	O
virus	O
production	O
.	O
LSF	B
(	O
also	O
known	O
as	O
LBP-1	B
,	O
UBP	B
,	O
and	O
CP-2	B
)	O
has	O
been	O
shown	O
to	O
repress	O
LTR	O
transcription	O
in	O
vitro	O
,	O
but	O
transient	O
expression	O
of	O
LSF	B
has	O
no	O
effect	O
on	O
LTR	O
activity	O
in	O
vivo	O
.	O
We	O
report	O
that	O
both	O
YY1	B
and	O
LSF	B
participate	O
in	O
the	O
formation	O
of	O
a	O
complex	O
that	O
recognizes	O
the	O
initiation	O
region	O
of	O
the	O
HIV-1	O
LTR	O
.	O
Further	O
,	O
we	O
have	O
found	O
that	O
these	O
factors	O
cooperate	O
in	O
the	O
repression	O
of	O
LTR	O
expression	O
and	O
viral	O
replication	O
.	O
This	O
cooperative	O
function	O
may	O
account	O
for	O
the	O
divergent	O
effects	O
of	O
LSF	B
previously	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Thus	O
,	O
the	O
cooperation	O
of	O
two	O
general	O
cellular	O
transcription	O
factors	O
may	O
allow	O
for	O
the	O
selective	O
downregulation	O
of	O
HIV	O
transcription	O
.	O
Through	O
this	O
mechanism	O
of	O
gene	O
regulation	O
,	O
YY1	B
and	O
LSF	B
could	O
contribute	O
to	O
the	O
establishment	O
and	O
maintenance	O
of	O
a	O
population	O
of	O
cells	O
stably	O
but	O
nonproductively	O
infected	O
with	O
HIV-1	O
.	O
Ras	B
-	I
related	I
GTP	I
-	I
binding	I
proteins	I
and	O
leukocyte	O
signal	O
transduction	O
.	O
Many	O
aspects	O
of	O
leukocyte	O
function	O
are	O
regulated	O
by	O
both	O
heterotrimeric	B
and	O
Ras	B
-	I
related	I
GTP	I
-	I
binding	I
proteins	I
,	O
but	O
there	O
is	O
little	O
definite	O
information	O
about	O
their	O
roles	O
in	O
the	O
specialized	O
processes	O
utilized	O
by	O
leukocytes	O
for	O
cell	O
killing	O
.	O
Recent	O
progress	O
in	O
understanding	O
the	O
regulation	O
of	O
the	O
phagocyte	B
NADPH	I
oxidase	I
by	O
the	O
Rac	B
GTP	I
-	I
binding	I
proteins	I
provides	O
a	O
basis	O
for	O
defining	O
the	O
operational	O
characteristics	O
of	O
one	O
such	O
phagocyte	O
system	O
.	O
It	O
is	O
clear	O
from	O
various	O
studies	O
that	O
the	O
activity	O
of	O
the	O
NADPH	B
oxidase	I
can	O
be	O
modulated	O
through	O
the	O
regulation	O
of	O
the	O
GTP	O
-	O
GDP	O
state	O
of	O
Rac	B
.	O
Proteins	O
exist	O
in	O
leukocytes	O
able	O
to	O
modify	O
GTP	B
-	I
binding	I
protein	I
function	O
in	O
this	O
manner	O
,	O
and	O
their	O
activity	O
may	O
be	O
regulated	O
by	O
signals	O
generated	O
on	O
phagocyte	O
stimulation	O
.	O
Proteins	O
of	O
the	O
Ras	B
superfamily	I
are	O
likely	O
to	O
be	O
involved	O
in	O
a	O
variety	O
of	O
normal	O
phagocyte	O
functions	O
through	O
their	O
ability	O
to	O
modulate	O
the	O
assembly	O
of	O
actin	B
filaments	I
,	O
direct	O
vesicle	O
trafficking	O
and	O
fusion	O
,	O
and	O
so	O
forth	O
.	O
Extinction	O
of	O
immunoglobulin	O
gene	O
expression	O
in	O
B	O
cells	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
is	O
preceded	O
by	O
rapid	O
nuclear	O
depletion	O
of	O
essential	B
transcription	I
factors	I
and	O
is	O
accompanied	O
by	O
widespread	O
inactivation	O
of	O
genes	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O
When	O
immunoglobulin	O
(	O
Ig	O
)	O
expressing	O
B	O
cells	O
are	O
fused	O
with	O
non	O
-	O
B	O
cells	O
,	O
Ig	O
expression	O
is	O
rapidly	O
suppressed	O
at	O
the	O
level	O
of	O
transcription	O
,	O
a	O
phenomenon	O
termed	O
extinction	O
.	O
Here	O
we	O
demonstrate	O
that	O
fusion	O
of	O
HeLa	O
cells	O
with	O
either	O
diploid	O
or	O
tetraploid	O
B	O
cells	O
(	O
Daudi	O
)	O
results	O
in	O
widespread	O
extinction	O
of	O
several	O
other	O
B	O
cell	O
-	O
encoded	O
genes	O
that	O
are	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O
In	O
contrast	O
,	O
expression	O
of	O
B	O
cell	O
-	O
expressed	O
genes	O
that	O
are	O
not	O
dependent	O
on	O
cell	O
-	O
specific	O
controls	O
is	O
unaffected	O
.	O
We	O
show	O
that	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
Ig	O
gene	O
extinction	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
lack	O
of	O
transcription	B
factors	I
that	O
are	O
essential	O
for	O
Ig	O
gene	O
transcription	O
.	O
These	O
transcription	B
factors	I
are	O
either	O
not	O
produced	O
due	O
to	O
block	O
of	O
transcription	O
of	O
their	O
respective	O
genes	O
(	O
Oct-2	O
,	O
OBF-1	O
,	O
PU.1	B
)	O
,	O
or	O
are	O
rendered	O
inactive	O
posttranslationally	O
(	O
NF	B
-	I
kappa	I
B	I
,	O
E47	O
)	O
.	O
By	O
isolating	O
Daudi	O
x	O
HeLa	O
heterokaryons	O
a	O
few	O
hours	O
after	O
fusion	O
,	O
we	O
have	O
studied	O
the	O
initial	O
fate	O
of	O
two	O
B	B
cell	I
-	I
specific	I
transcription	I
factors	I
involved	O
in	O
Ig	O
gene	O
transcription	O
,	O
Oct-2	O
and	O
NF	B
-	I
kappa	I
B	I
.	O
This	O
report	O
provides	O
the	O
first	O
demonstration	O
that	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
,	O
the	O
nuclear	O
contents	O
of	O
B	B
cell	I
-	I
expressed	I
transcription	I
factors	I
are	O
depleted	O
within	O
a	O
few	O
hours	O
with	O
kinetics	O
that	O
are	O
as	O
fast	O
or	O
faster	O
than	O
that	O
of	O
Ig	O
gene	O
extinction	O
.	O
Thus	O
,	O
the	O
extinguishing	O
mechanism	O
is	O
effective	O
very	O
early	O
after	O
fusion	O
.	O
We	O
suggest	O
that	O
extinction	O
of	O
Ig	O
genes	O
is	O
part	O
of	O
a	O
global	O
mechanism	O
that	O
suppresses	O
the	O
differentiation	O
program	O
foreign	O
to	O
the	O
HeLa	O
phenotype	O
.	O
Nuclear	O
accumulation	O
of	O
NFAT4	B
opposed	O
by	O
the	O
JNK	B
signal	O
transduction	O
pathway	O
.	O
The	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	I
NFAT	I
)	I
group	I
of	O
transcription	B
factors	I
is	O
retained	O
in	O
the	O
cytoplasm	O
of	O
quiescent	O
cells	O
.	O
NFAT	B
activation	O
is	O
mediated	O
in	O
part	O
by	O
induced	O
nuclear	O
import	O
.	O
This	O
process	O
requires	O
calcium	O
-	O
dependent	O
dephosphorylation	O
of	O
NFAT	B
caused	O
by	O
the	O
phosphatase	B
calcineurin	B
.	O
The	O
c	B
-	I
Jun	I
amino	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
phosphorylates	O
NFAT4	B
on	O
two	O
sites	O
.	O
Mutational	O
removal	O
of	O
the	O
JNK	B
phosphorylation	I
sites	I
caused	O
constitutive	O
nuclear	O
localization	O
of	O
NFAT4	B
.	O
In	O
contrast	O
,	O
JNK	B
activation	O
in	O
calcineurin	O
-	O
stimulated	O
cells	O
caused	O
nuclear	O
exclusion	O
of	O
NFAT4	B
.	O
These	O
findings	O
show	O
that	O
the	O
nuclear	O
accumulation	O
of	O
NFAT4	B
promoted	O
by	O
calcineurin	B
is	O
opposed	O
by	O
the	O
JNK	B
signal	O
transduction	O
pathway	O
.	O
Pathogenesis	O
.	O
There	O
are	O
many	O
hypotheses	O
concerning	O
the	O
pathogenesis	O
of	O
endometriosis	O
,	O
though	O
no	O
single	O
theory	O
can	O
explain	O
all	O
cases	O
.	O
It	O
is	O
likely	O
that	O
several	O
mechanisms	O
are	O
involved	O
.	O
Early	O
studies	O
concentrated	O
on	O
the	O
histogenesis	O
of	O
the	O
endometriotic	O
lesion	O
.	O
Recent	O
evidence	O
has	O
implicated	O
components	O
of	O
the	O
immune	O
system	O
in	O
the	O
pathogenesis	O
of	O
endometriosis	O
.	O
This	O
review	O
considers	O
the	O
evidence	O
for	O
different	O
theories	O
of	O
the	O
histogenesis	O
of	O
endometriosis	O
and	O
discusses	O
possible	O
immune	O
factors	O
that	O
may	O
be	O
involved	O
in	O
the	O
pathophysiology	O
of	O
the	O
disease	O
.	O
Phosphatidylinositol	B
3-kinase	I
couples	O
the	O
interleukin-2	B
receptor	I
to	O
the	O
cell	B
cycle	I
regulator	I
E2F	B
.	O
Cell	O
cycle	O
progression	O
initiated	O
by	O
interleukin-2	B
(	O
IL-2	B
)	O
in	O
T	O
cells	O
is	O
critical	O
for	O
lymphoproliferation	O
and	O
an	O
immune	O
response	O
.	O
Phosphatidyl	B
inositol	I
3-kinase	I
(	O
PI3	B
K	I
)	O
is	O
activated	O
by	O
IL-2	B
.	O
However	O
,	O
nuclear	O
targets	O
for	O
PI3	B
K	I
are	O
not	O
known	O
.	O
Here	O
we	O
identify	O
the	O
cell	B
cycle	I
regulator	I
E2F	B
as	O
an	O
IL-2	B
target	O
in	O
T	O
lymphocytes	O
and	O
PI3	B
K	I
as	O
the	O
critical	O
signaling	O
pathway	O
.	O
We	O
eliminate	O
both	O
Stat5	B
and	O
Raf	B
/MEK	B
pathways	O
from	O
E2F	B
regulation	O
.	O
Protein	B
kinase	I
B	I
(	O
PKB	B
)	O
is	O
activated	O
by	O
IL-2	B
via	O
PI3	B
K	I
.	O
The	O
expression	O
of	O
an	O
active	O
PKB	B
is	O
sufficient	O
to	O
induce	O
E2F	B
activity	O
.	O
Inhibition	O
of	O
PI3	B
K	I
inhibits	O
phosphorylation	O
of	O
Rb	B
,	O
induction	O
of	O
cyclin	B
D3	I
,	O
and	O
degradation	O
of	O
p27kip1	B
.	O
These	O
results	O
establish	O
a	O
crucial	O
PI3	B
K	I
/	O
PKB	B
-mediated	O
link	O
between	O
the	O
IL-2	B
teceptor	I
and	O
the	O
cell	O
cycle	O
machinery	O
.	O
Molecular	O
mechanisms	O
of	O
anoxia	O
/	O
reoxygenation	O
-	O
induced	O
neutrophil	O
adherence	O
to	O
cultured	O
endothelial	O
cells	O
.	O
The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
(	O
1	O
)	O
determine	O
the	O
time	O
course	O
of	O
neutrophil	O
adhesion	O
to	O
monolayers	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
that	O
were	O
exposed	O
to	O
60	O
minutes	O
of	O
anoxia	O
followed	O
by	O
30	O
to	O
600	O
minutes	O
of	O
reoxygenation	O
and	O
(	O
2	O
)	O
define	O
the	O
mechanisms	O
responsible	O
for	O
both	O
the	O
early	O
(	O
minutes	O
)	O
and	O
late	O
(	O
hours	O
)	O
hyperadhesivity	O
of	O
postanoxic	O
HUVECs	O
to	O
human	O
neutrophils	O
.	O
The	O
results	O
clearly	O
demonstrate	O
that	O
anoxia	O
/	O
reoxygenation	O
(	O
A	O
/	O
R	O
)	O
leads	O
to	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	O
,	O
with	O
peak	O
responses	O
occurring	O
at	O
30	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
after	O
reoxygenation	O
.	O
Oxypurinol	O
and	O
catalase	B
inhibited	O
phase-1	O
adhesion	O
,	O
suggesting	O
a	O
role	O
for	O
xanthine	B
oxidase	I
and	O
H2O2	O
.	O
In	O
comparison	O
,	O
platelet	B
activating	I
factor	I
(	O
PAF	B
)	O
contributed	O
to	O
both	O
phases	O
of	O
neutrophil	O
adhesion	O
.	O
Anti	B
-	I
intercellular	I
adhesion	I
molecule-1	I
(	O
ICAM-1	B
)	O
and	O
anti	B
-	I
P	I
-	I
selectin	I
antibodies	I
(	O
monoclonal	B
antibodies	I
[	O
mAbs	B
]	O
)	O
attenuated	O
phase-1	O
neutrophil	O
adhesion	O
,	O
consistent	O
with	O
roles	O
for	O
constitutively	O
expressed	O
ICAM-1	B
and	O
enhanced	O
surface	O
expression	O
of	O
preformed	O
P	B
-	I
selectin	I
.	O
Phase-2	O
neutrophil	O
adhesion	O
was	O
attenuated	O
by	O
an	O
anti	B
-	I
E	I
-	I
selectin	I
mAb	I
,	O
indicating	O
a	O
dominant	O
role	O
of	O
this	O
adhesion	O
molecule	O
in	O
the	O
late	O
phase	O
response	O
.	O
Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds	O
-	O
oligonucleotides	O
containing	O
the	O
nuclear	B
factor	I
-	I
kappa	I
B	I
or	O
activator	B
protein-1	I
cognate	O
DNA	O
sequences	O
significantly	O
attenuated	O
phase-2	O
response	O
,	O
suggesting	O
a	O
role	O
for	O
de	O
novo	O
macromolecule	O
synthesis	O
.	O
Surface	O
expression	O
of	O
ICAM-1	B
,	O
P	B
-	I
selectin	I
,	O
and	O
E	B
-	I
selectin	I
on	O
HUVECs	O
correlated	O
with	O
the	O
phase-1	O
and	O
-2	O
neutrophil	O
adhesion	O
responses	O
.	O
Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A	O
/	O
R	O
elicits	O
a	O
two	O
-	O
phase	O
neutrophil	O
-	O
endothelial	O
cell	O
adhesion	O
response	O
that	O
involves	O
transcription	O
-	O
independent	O
and	O
transcription	O
-	O
dependent	O
surface	O
expression	O
of	O
different	O
endothelial	B
cell	I
adhesion	I
molecules	I
.	O
Epstein	O
-	O
Barr	O
virus	O
latent	B
membrane	I
protein-1	I
triggers	O
AP-1	B
activity	O
via	O
the	O
c	B
-	I
Jun	I
N	O
-	O
terminal	O
kinase	O
cascade	O
.	O
The	O
Epstein	O
-	O
Barr	O
virus	O
latent	B
membrane	I
protein-1	I
(	O
LMP-1	B
)	O
is	O
an	O
integral	B
membrane	I
protein	I
which	O
transforms	O
fibroblasts	O
and	O
is	O
essential	O
for	O
EBV	O
-	O
mediated	O
B	O
-	O
cell	O
immortalization	O
.	O
LMP-1	B
has	O
been	O
shown	O
to	O
trigger	O
cellular	O
NF	B
-	I
kappa	I
B	I
activity	O
which	O
,	O
however	O
,	O
can	O
not	O
fully	O
explain	O
the	O
oncogenic	O
potential	O
of	O
LMP-1	B
.	O
Here	O
we	O
show	O
that	O
LMP-1	B
induces	O
the	O
activity	O
of	O
the	O
AP-1	B
transcription	I
factor	I
,	O
a	O
dimer	O
of	O
Jun	B
/	I
Jun	I
or	I
Jun	I
/	I
Fos	I
proteins	I
.	O
LMP-1	B
effects	O
on	O
AP-1	B
are	O
mediated	O
through	O
activation	O
of	O
the	O
c	B
-	I
Jun	I
N	O
-	O
terminal	O
kinase	O
(	O
JNK	B
)	O
cascade	O
,	O
but	O
not	O
the	O
extracellular	B
signal	I
-	I
regulated	I
kinase	I
(	O
Erk	B
)	O
pathway	O
.	O
Consequently	O
,	O
LMP-1	B
triggers	O
the	O
activity	O
of	O
the	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
transactivation	I
domain	I
which	O
is	O
known	O
to	O
be	O
activated	O
upon	O
JNK	B
-mediated	O
phosphorylation	O
.	O
Deletion	O
analysis	O
indicates	O
that	O
the	O
55	O
C	B
-	I
terminal	I
amino	I
acids	I
of	O
the	O
LMP-1	B
molecule	I
,	O
but	O
not	O
its	O
TRAF	B
interaction	I
domain	I
,	O
are	O
essential	O
for	O
AP-1	B
activation	O
.	O
JNK	B
-mediated	O
transcriptional	O
activation	O
of	O
AP-1	B
is	O
the	O
direct	O
output	O
of	O
LMP	B
-1-triggered	O
signaling	O
,	O
as	O
shown	O
by	O
an	O
inducible	O
LMP-1	B
mutant	I
.	O
Using	O
a	O
tetracycline	O
-	O
regulated	O
LMP-1	O
allele	O
,	O
we	O
demonstrate	O
that	O
JNK	B
is	O
also	O
an	O
effector	O
of	O
non	O
-	O
cytotoxic	O
LMP-1	B
signaling	O
in	O
B	O
cells	O
,	O
the	O
physiological	O
target	O
cells	O
of	O
EBV	O
.	O
In	O
summary	O
,	O
our	O
data	O
reveal	O
a	O
novel	O
effector	O
of	O
LMP-1	B
,	O
the	O
SEK	O
/	O
JNK	B
/	O
c	B
-	I
Jun	I
/	O
AP-1	B
pathway	O
,	O
which	O
contributes	O
to	O
our	O
understanding	O
of	O
the	O
immortalizing	O
and	O
transforming	O
potential	O
of	O
LMP-1	B
.	O
c	B
-	I
Rel	I
and	I
p65	I
subunits	I
bind	O
to	O
an	O
upstream	O
NF	O
-	O
kappaB	O
site	O
in	O
human	O
granulocyte	O
macrophage	O
-	O
colony	O
stimulating	O
factor	O
promoter	O
involved	O
in	O
phorbol	O
ester	O
response	O
in	O
5637	O
cells	O
.	O
To	O
further	O
clarify	O
the	O
complex	O
transcriptional	O
regulation	O
of	O
the	O
human	O
GM	O
-	O
CSF	O
gene	O
,	O
which	O
was	O
extensively	O
investigated	O
in	O
activated	O
T	O
cells	O
,	O
we	O
have	O
studied	O
the	O
role	O
of	O
an	O
upstream	O
NF	O
-	O
kappaB	O
like	O
site	O
in	O
the	O
5637	O
non	O
-	O
lymphoid	O
cell	O
line	O
,	O
which	O
derives	O
from	O
a	O
bladder	O
carcinoma	O
and	O
constitutively	O
produces	O
GM	B
-	I
CSF	I
.	O
This	O
sequence	O
,	O
named	O
the	O
A	O
element	O
,	O
has	O
an	O
active	O
role	O
on	O
GM	B
-	I
CSF	I
transcription	O
and	O
is	O
responsive	O
to	O
the	O
tumor	O
promoter	O
PMA	O
in	O
transient	O
transfection	O
experiments	O
.	O
We	O
describe	O
here	O
a	O
heterodimeric	B
binding	I
complex	I
of	O
NF	B
-	I
kappaB	I
subunits	I
(	O
c	B
-	I
Rel	I
and	O
p65	B
)	O
which	O
is	O
identical	O
to	O
the	O
one	O
obtained	O
using	O
the	O
HIV	O
-	O
LTR	O
-	O
kappaB	O
site	O
as	O
recognition	O
sequence	O
and	O
different	O
from	O
the	O
one	O
(	O
c	B
-	I
Rel	I
and	O
p50	B
)	O
observed	O
with	O
nuclear	O
extracts	O
from	O
Mo	O
T	O
-	O
lymphoid	O
HTLV	O
-	O
II	O
infected	O
cells	O
.	O
Selection	O
of	O
a	O
diverse	O
TCR	B
repertoire	I
in	O
response	O
to	O
an	O
Epstein	B
-	I
Barr	I
virus	I
-	I
encoded	I
transactivator	I
protein	I
BZLF1	B
by	O
CD8	O
+	O
cytotoxic	O
T	O
lymphocytes	O
during	O
primary	O
and	O
persistent	O
infection	O
.	O
We	O
investigated	O
the	O
CD8	B
+	I
cytotoxic	I
T	I
lymphocyte	I
(	I
CTL	I
)	I
repertoire	I
to	O
an	O
HLA	O
B8-restricted	O
peptide	O
,	O
RAKFKQLLQ	O
,	O
located	O
in	O
the	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
immediate	I
-	I
early	I
protein	I
,	O
BZLF1	B
.	O
Repertoire	O
selection	O
was	O
monitored	O
by	O
determining	O
the	O
TCR	B
beta	I
chain	I
sequences	I
of	O
RAKFKQLLQ	O
-	O
specific	O
CTL	O
established	O
from	O
primary	O
infected	O
and	O
healthy	O
virus	O
carriers	O
.	O
PCR	O
analysis	O
of	O
spontaneous	O
EBV	O
-	O
transformed	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCL	O
)	O
from	O
three	O
individuals	O
with	O
primary	O
infection	O
showed	O
that	O
two	O
were	O
infected	O
with	O
type	O
A	O
and	O
one	O
with	O
type	O
B	O
EBV	O
.	O
Polyclonal	O
and	O
clonal	O
CTL	O
that	O
were	O
generated	O
by	O
stimulating	O
peripheral	O
blood	O
mononuclear	O
cells	O
with	O
an	O
HLA	O
B8	O
+	O
homozygous	O
LCL	O
lysed	O
T	O
cell	O
blasts	O
pulsed	O
with	O
the	O
peptide	O
,	O
RAKFKQLLQ	O
;	O
lysis	O
of	O
certain	O
HLA	O
B8	O
+	O
LCL	O
targets	O
was	O
associated	O
with	O
the	O
abundance	O
of	O
BZLF1	O
transcripts	O
.	O
TCR	O
beta	O
analysis	O
showed	O
that	O
while	O
there	O
was	O
loop	O
length	O
restriction	O
in	O
the	O
putative	O
peptide	O
contact	O
site	O
of	O
all	O
responding	O
beta	B
chains	I
,	O
diverse	O
and	O
unique	O
(	O
non	O
-	O
recurrent	O
)	O
TCR	O
beta	O
clonotypes	O
were	O
selected	O
in	O
individuals	O
during	O
primary	O
infection	O
and	O
continued	O
to	O
emerge	O
after	O
long	O
-	O
term	O
virus	O
exposure	O
.	O
TCR	B
-contact	O
site	O
heterogeneity	O
was	O
excluded	O
as	O
the	O
selective	O
force	O
in	O
diversity	O
generation	O
since	O
the	O
epitope	O
-	O
encoded	O
sequences	O
were	O
found	O
to	O
be	O
identical	O
within	O
endogenous	O
virus	O
isolates	O
.	O
In	O
this	O
first	O
study	O
of	O
TCR	B
repertoire	I
selection	O
for	O
an	O
EBV	B
lytic	I
antigen	I
,	O
a	O
BZLF1	B
-reactive	O
component	O
of	O
diverse	O
clonotypes	O
was	O
identified	O
in	O
primary	O
type	O
A	O
or	O
type	O
B	O
EBV	O
infection	O
which	O
was	O
sustained	O
in	O
the	O
EBV	O
-	O
specific	O
memory	O
response	O
throughout	O
life	O
-	O
long	O
infection	O
.	O
This	O
diversity	O
selection	O
is	O
likely	O
to	O
play	O
a	O
critical	O
role	O
in	O
maintaining	O
a	O
balanced	O
viral	O
load	O
throughout	O
EBV	O
persistence	O
.	O
Constitutive	O
expression	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
NF	O
kappa	O
B	O
mRNA	O
is	O
in	O
nucleated	O
fetal	O
blood	O
cells	O
and	O
up	O
-	O
regulation	O
of	O
c	B
-	I
fos	I
and	O
c	B
-	I
jun	I
with	O
anti	B
-	I
CD3	I
stimulation	O
.	O
Fetal	O
and	O
neonatal	O
lymphocytes	O
are	O
relatively	O
resistant	O
to	O
activation	O
and	O
cytokine	B
production	O
when	O
stimulated	O
either	O
via	O
their	O
T	B
-	I
cell	I
antigen	I
receptors	I
or	O
lectins	B
.	O
The	O
molecular	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
this	O
phenomenon	O
have	O
not	O
been	O
clearly	O
elucidated	O
.	O
We	O
have	O
hypothesized	O
that	O
such	O
defects	O
in	O
fetal	O
/	O
neonatal	O
T	O
-	O
cell	O
activation	O
may	O
be	O
due	O
to	O
lack	O
of	O
expression	O
of	O
the	O
transcriptional	B
regulatory	I
elements	I
required	O
for	O
T	O
-	O
cell	O
activation	O
.	O
We	O
used	O
reverse	B
transcriptase	I
-polymerase	O
chain	O
reaction	O
to	O
examine	O
both	O
fetal	O
and	O
term	O
neonatal	O
cord	O
bloods	O
for	O
mRNA	O
expression	O
of	O
three	O
transcription	B
factors	I
implicated	O
in	O
T	O
-	O
cell	O
activation	O
:	O
c	B
-	I
jun	I
,	O
c	B
-	I
fos	I
,	O
and	O
NF	B
kappa	I
B	I
(	O
p50	B
subunit	I
)	O
.	O
We	O
demonstrate	O
that	O
mRNAs	O
for	O
all	O
three	O
of	O
these	O
regulatory	O
factors	O
are	O
expressed	O
in	O
fetal	O
blood	O
cells	O
by	O
the	O
27th	O
week	O
of	O
gestation	O
and	O
in	O
term	O
cord	O
bloods	O
.	O
Activation	O
of	O
term	O
infant	O
cord	O
blood	O
mononuclear	O
cells	O
with	O
anti	B
-	I
CD3	I
monoclonal	I
antibodies	I
resulted	O
in	O
up	O
-	O
regulation	O
of	O
both	O
c	B
-	I
jun	I
and	O
c	O
-	O
fos	O
mRNAs	O
within	O
15	O
min	O
of	O
stimulation	O
.	O
However	O
,	O
secretion	O
of	O
IL-2	B
by	O
anti	O
-	O
CD3-stimulated	O
cord	O
blood	O
mononuclear	O
cells	O
was	O
still	O
blunted	O
compared	O
with	O
control	O
cells	O
from	O
adults	O
.	O
We	O
conclude	O
that	O
fetal	O
nucleated	O
blood	O
cells	O
constitutively	O
express	O
important	O
genes	O
for	O
cytokine	B
regulation	O
and	O
are	O
able	O
to	O
increase	O
intracellular	O
accumulation	O
of	O
the	O
mRNAs	O
for	O
these	O
factors	O
in	O
response	O
to	O
anti	B
-	I
CD3	I
stimulation	O
.	O
Thus	O
,	O
qualitative	O
differences	O
in	O
the	O
capacity	O
to	O
regulate	O
these	O
factors	O
could	O
not	O
be	O
shown	O
in	O
fetal	O
blood	O
cells	O
.	O
Quantitative	O
experiments	O
comparing	O
binding	O
of	O
these	O
transcription	B
factors	I
to	O
the	O
IL-2	O
promoter	O
are	O
currently	O
under	O
investigation	O
.	O
Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IL-5	B
synthesis	O
in	O
atopic	O
diseases	O
:	O
a	O
study	O
with	O
allergen	O
-	O
specific	O
human	O
helper	O
T	O
cells	O
.	O
BACKGROUND	O
:	O
Cytokines	B
produced	O
by	O
helper	O
T	O
cells	O
are	O
intimately	O
involved	O
in	O
chronic	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O
OBJECTIVE	O
:	O
We	O
investigated	O
the	O
production	O
of	O
IL-5	B
,	O
a	O
potent	O
growth	O
factor	O
and	O
chemotactic	O
factor	O
for	O
eosinophils	O
,	O
by	O
CD4	O
+	O
T	O
lymphocytes	O
in	O
patients	O
with	O
asthma	O
.	O
METHODS	O
:	O
Allergen	O
-	O
specific	O
T	O
cell	O
clones	O
and	O
T	O
cell	O
hybridomas	O
were	O
established	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
responses	O
to	O
various	O
stimuli	O
were	O
determined	O
.	O
RESULTS	O
:	O
After	O
nonspecific	O
stimulation	O
,	O
IL-5	B
production	O
by	O
CD4	O
+	O
T	O
cells	O
from	O
both	O
atopic	O
and	O
nonatopic	O
subjects	O
with	O
asthma	O
was	O
significantly	O
enhanced	O
compared	O
with	O
that	O
by	O
cells	O
from	O
healthy	O
controls	O
.	O
Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
atopic	O
asthma	O
patients	O
both	O
proliferated	O
and	O
produced	O
IL-5	B
after	O
incubation	O
with	O
mite	O
allergen	O
,	O
suggesting	O
that	O
mite	O
-	O
specific	O
helper	O
T	O
cells	O
were	O
involved	O
in	O
the	O
eosinophilic	O
inflammation	O
of	O
atopic	O
asthma	O
.	O
A	O
human	O
IL-5	O
promoter	O
/	O
enhancer	O
luciferase	O
gene	O
construct	O
transfected	O
into	O
IL-5-producing	O
T	O
cell	O
clones	O
was	O
clearly	O
transcribed	O
after	O
stimulation	O
,	O
indicating	O
that	O
the	O
515	O
base	O
pair	O
IL-5	O
gene	O
segment	O
upstream	O
of	O
the	O
coding	O
region	O
was	O
sufficient	O
to	O
respond	O
to	O
activating	O
signals	O
in	O
human	O
helper	O
T	O
cells	O
.	O
The	O
same	O
gene	O
segment	O
was	O
not	O
transcribed	O
in	O
IL-5-nonproducing	O
T	O
cell	O
clones	O
,	O
suggesting	O
that	O
human	O
T	O
cell	O
IL-5	B
synthesis	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O
Experiments	O
with	O
T	O
cell	O
hybridomas	O
confirmed	O
these	O
findings	O
and	O
suggested	O
that	O
a	O
unique	B
transcription	I
factor	I
may	O
be	O
essential	O
for	O
human	O
IL-5	B
gene	O
transcription	O
.	O
CONCLUSION	O
:	O
Enhanced	O
IL-5	B
production	O
by	O
helper	O
T	O
cells	O
seems	O
to	O
cause	O
the	O
eosinophilic	O
inflammation	O
of	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
.	O
Elucidation	O
of	O
IL-5	B
-specific	O
regulatory	O
mechanisms	O
may	O
facilitate	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O
Regulation	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
by	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
stability	O
.	O
Transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
must	O
be	O
released	O
from	O
cytoplasmic	B
inhibitory	I
molecules	I
(	O
I	B
kappa	I
Bs	I
)	O
in	O
order	O
to	O
move	O
to	O
the	O
nucleus	O
and	O
to	O
activate	O
its	O
target	O
genes	O
.	O
Little	O
is	O
known	O
about	O
the	O
mechanisms	O
regulating	O
the	O
maintenance	O
of	O
constitutive	B
nuclear	I
NF	I
-	I
kappa	I
B	I
in	O
some	O
cell	O
-	O
types	O
and	O
of	O
sustained	O
nuclear	O
NF	B
-	I
kappa	I
B	I
activity	O
after	O
stimulation	O
.	O
Increased	O
turnover	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
constitutive	O
NF	B
-	I
kappa	I
B	I
activity	O
in	O
mature	O
B	O
cells	O
.	O
We	O
therefore	O
compared	O
the	O
turnover	O
of	O
I	B
kappa	I
B	I
alpha	I
and	O
I	B
kappa	I
B	I
beta	I
in	O
mature	O
B	O
cells	O
and	O
HeLa	O
cells	O
.	O
Both	O
proteins	O
display	O
a	O
high	O
turnover	O
in	O
B	O
cells	O
although	O
I	B
kappa	I
B	I
beta	I
is	O
considerably	O
more	O
stable	O
than	O
I	B
kappa	I
B	I
alpha	I
.	O
The	O
half	O
-	O
life	O
of	O
both	O
inhibitors	O
is	O
increased	O
in	O
HeLa	O
cells	O
.	O
In	O
contrast	O
,	O
all	O
other	O
NF	B
-	I
kappa	I
B	I
/I	O
kappa	O
B	O
molecules	O
tested	O
are	O
relatively	O
stable	O
in	O
both	O
cell	O
-	O
types	O
.	O
The	O
elevated	O
turnover	O
of	O
endogenous	O
I	B
kappa	I
B	I
alpha	I
in	O
Namalwa	O
cells	O
is	O
inhibited	O
by	O
a	O
proteasome	O
inhibitor	O
and	O
thus	O
seems	O
to	O
be	O
driven	O
by	O
the	O
same	O
degradation	O
machinery	O
as	O
the	O
slower	O
turnover	O
in	O
non	O
-	O
B	O
cells	O
.	O
Furthermore	O
,	O
we	O
investigated	O
the	O
processes	O
involved	O
in	O
persistent	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
TNF	O
-	O
alpha	O
signaling	O
leads	O
to	O
a	O
rapid	O
depletion	O
of	O
cellular	O
I	B
kappa	I
B	I
beta	I
pools	O
.	O
I	B
kappa	I
B	I
alpha	I
is	O
efficiently	O
resynthesized	O
whereas	O
I	B
kappa	I
B	I
beta	I
levels	O
stay	O
low	O
for	O
a	O
prolonged	O
time	O
.	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
can	O
be	O
detected	O
for	O
several	O
hours	O
after	O
stimulation	O
.	O
We	O
found	O
that	O
removal	O
of	O
the	O
TNF	B
-	I
alpha	I
containing	O
medium	O
causes	O
a	O
rapid	O
decrease	O
in	O
nuclear	B
NF	I
-	I
kappa	I
B	I
.	O
A	O
phosphoform	O
of	O
newly	O
synthesized	O
I	B
kappa	I
B	I
alpha	I
is	O
visible	O
when	O
degradation	O
by	O
the	O
proteasome	B
is	O
inhibited	O
and	O
new	O
I	B
kappa	I
B	I
alpha	I
displays	O
the	O
same	O
properties	O
regarding	O
phosphorylation	O
and	O
degradation	O
in	O
response	O
to	O
a	O
second	O
inducer	O
.	O
There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
turnover	O
of	O
pre-	O
and	O
post	O
-	O
inductive	O
I	B
kappa	I
B	I
alpha	I
.	O
These	O
observations	O
suggest	O
that	O
resynthesis	O
of	O
I	B
kappa	I
B	I
alpha	I
and	O
removal	O
of	O
the	O
stimulus	O
are	O
obligatory	O
steps	O
for	O
the	O
inactivation	O
of	O
nuclear	B
NF	I
kappa	I
B	I
.	O
Control	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
by	O
the	O
I	B
kappa	I
B	I
beta	I
inhibitor	I
.	O
The	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
is	O
maintained	O
in	O
an	O
inactive	O
cytoplasmic	O
state	O
by	O
I	B
kappa	I
B	I
inhibitors	I
.	O
In	O
mammalian	O
cells	O
,	O
I	B
kappa	I
B	I
alpha	I
and	O
I	B
kappa	I
B	I
beta	I
proteins	I
have	O
been	O
purified	O
and	O
shown	O
to	O
be	O
the	O
inhibitors	O
of	O
NF	B
-	I
kappa	I
B	I
through	O
their	O
association	O
with	O
the	O
p65	B
or	I
c	I
-	I
Rel	I
subunits	I
.	O
In	O
addition	O
,	O
we	O
have	O
isolated	O
a	O
third	O
NF	B
-	I
kappa	I
B	I
inhibitor	I
,	O
I	B
kappa	I
B	I
epsilon	I
(	O
1	O
)	O
.	O
Upon	O
treatment	O
with	O
a	O
large	O
variety	O
of	O
inducers	O
,	O
I	B
kappa	I
B	I
alpha	I
,	O
I	B
kappa	I
B	I
beta	I
are	O
proteolytically	O
degraded	O
,	O
resulting	O
in	O
NF	B
-	I
kappa	I
B	I
translocation	O
into	O
the	O
nucleus	O
.	O
Here	O
we	O
show	O
that	O
in	O
E29.1	O
T	O
cell	O
hybridoma	O
I	B
kappa	I
B	I
alpha	I
and	O
I	B
kappa	I
B	I
beta	I
are	O
equally	O
associated	O
with	O
p65	B
and	O
that	O
I	B
kappa	I
B	I
beta	I
is	O
degraded	O
in	O
response	O
to	O
TNF	B
alpha	I
in	O
contrast	O
to	O
what	O
has	O
been	O
originally	O
published	O
.	O
Our	O
data	O
also	O
suggest	O
that	O
,	O
unlike	O
I	B
kappa	I
B	I
alpha	I
,	O
I	B
kappa	I
B	I
beta	I
is	O
constitutively	O
phosphorylated	O
and	O
resynthesized	O
as	O
a	O
hypophosphorylated	B
form	I
.	O
The	O
absence	O
of	O
slow	O
migrating	O
forms	O
of	O
I	B
kappa	I
B	I
beta	I
following	O
stimulation	O
suggests	O
that	O
the	O
phosphorylation	O
does	O
not	O
necessarily	O
constitute	O
the	O
signal	O
-	O
induced	O
event	O
which	O
targets	O
the	O
molecule	O
for	O
proteolysis	O
.	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
family	I
members	I
regulating	O
the	O
ICAM-1	O
promoter	O
in	O
monocytic	O
THP-1	O
cells	O
.	O
A	O
kappa	O
B	O
-	O
site	O
was	O
identified	O
in	O
the	O
promoter	O
of	O
the	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
gene	O
,	O
which	O
is	O
involved	O
in	O
regulation	O
of	O
ICAM-1	B
expression	O
by	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
and	O
glucocorticoids	O
.	O
We	O
now	O
report	O
on	O
the	O
transcription	B
factors	I
which	O
bind	O
and	O
transactivate	O
this	O
enhancer	O
sequence	O
.	O
In	O
vitro	O
,	O
the	O
ICAM-1	O
kappa	O
B	O
site	O
appeared	O
to	O
bind	O
RelA	B
and	O
c	B
-	I
Rel	I
homodimers	I
as	O
well	O
as	O
heterodimers	O
with	O
NF	B
-	I
kappa	I
B1	I
,	O
but	O
weakly	O
NF	B
-	I
kappa	I
B1	I
homodimers	I
.	O
In	O
addition	O
,	O
both	O
RelA	B
and	O
c	B
-	I
Rel	I
,	O
but	O
not	O
NF	B
-	I
kappa	I
B1	I
,	O
were	O
shown	O
to	O
transactivate	O
an	O
ICAM-1	O
kappa	O
B	O
-	O
reporter	O
construct	O
.	O
In	O
monocytic	O
THP-1	O
cells	O
TNF	B
-	I
alpha	I
induced	O
two	O
nuclear	B
complexes	I
which	O
in	O
vitro	O
bound	O
to	O
the	O
ICAM-1	O
kappa	O
B	O
site	O
.	O
Using	O
antibodies	O
in	O
an	O
electrophoretic	O
mobility	O
supershift	O
assay	O
,	O
one	O
of	O
these	O
complexes	O
was	O
shown	O
to	O
contain	O
NF	B
-	I
kappa	I
B1	I
and	O
RelA	B
,	O
and	O
to	O
bind	O
with	O
higher	O
affinity	O
to	O
the	O
consensus	O
kappa	O
B	O
site	O
in	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O
The	O
second	O
complex	O
contained	O
RelA	B
,	O
and	O
exhibited	O
higher	O
affinity	O
towards	O
the	O
ICAM-1	O
kappa	O
B	O
than	O
to	O
the	O
HIV	O
kappa	O
B	O
site	O
.	O
The	O
glucocorticoid	B
receptor	I
was	O
shown	O
to	O
repress	O
activity	O
of	O
both	O
the	O
RelA	B
homodimer	I
and	O
the	O
NF	B
-	I
kappa	I
B1	I
/	I
RelA	I
heterodimer	I
.	O
We	O
argue	O
that	O
in	O
vivo	O
RelA	B
homodimers	I
are	O
likely	O
to	O
play	O
a	O
dominant	O
role	O
in	O
TNF	B
-	I
alpha	I
-induced	O
ICAM-1	B
transcription	O
in	O
monocytic	O
cells	O
.	O
The	O
winged	B
-	I
helix	I
transcription	I
factor	I
Trident	B
is	O
expressed	O
in	O
actively	O
dividing	O
lymphocytes	O
.	O
We	O
recently	O
identified	O
the	O
winged	B
-	I
helix	I
transcription	I
factor	I
Trident	B
and	O
described	O
its	O
expression	O
pattern	O
in	O
synchronized	O
fibroblasts	O
.	O
We	O
have	O
now	O
studied	O
Trident	B
expression	O
in	O
cell	O
lines	O
,	O
differentiating	O
thymocytes	O
and	O
in	O
lymphocytes	O
derived	O
from	O
peripheral	O
blood	O
.	O
During	O
T	O
cell	O
differentiation	O
,	O
expression	O
peaked	O
in	O
the	O
actively	O
dividing	O
immature	O
single	O
positive	O
cells	O
.	O
In	O
peripheral	O
blood	O
lymphocytes	O
,	O
expression	O
of	O
Trident	O
mRNA	O
was	O
absent	O
,	O
but	O
could	O
be	O
induced	O
upon	O
stimulation	O
with	O
mitogens	O
in	O
vitro	O
.	O
These	O
observations	O
imply	O
a	O
function	O
for	O
Trident	B
in	O
dividing	O
lymphocytes	O
.	O
Glucocorticoid	B
receptors	I
,	O
fibromyalgia	O
and	O
low	O
back	O
pain	O
.	O
Recently	O
,	O
fibromyalgia	O
(	O
FMS	O
)	O
was	O
shown	O
to	O
be	O
a	O
disorder	O
associated	O
with	O
an	O
altered	O
functioning	O
of	O
the	O
stress	O
response	O
system	O
.	O
FMS	O
patients	O
display	O
a	O
hyperreactive	O
pituitary	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
)	O
release	O
in	O
response	O
to	O
corticotropin	O
-	O
releasing	O
hormone	O
(	O
CRH	O
)	O
and	O
to	O
insulin	O
-	O
induced	O
hypoglycemia	O
.	O
We	O
suggested	O
that	O
negative	O
feedback	O
of	O
cortisol	O
could	O
be	O
deranged	O
.	O
Therefore	O
we	O
investigated	O
the	O
properties	O
and	O
function	O
of	O
the	O
glucocorticoid	B
receptors	I
(	O
GR	B
)	O
in	O
FMS	O
patients	O
and	O
compared	O
the	O
results	O
with	O
those	O
of	O
healthy	O
persons	O
and	O
patients	O
with	O
chronic	O
low	O
back	O
pain	O
(	O
LBP	O
a	O
localized	O
pain	O
condition	O
)	O
.	O
Forty	O
primary	O
FMS	O
patients	O
(	O
F	O
:	O
M	O
=	O
36	O
:	O
4	O
)	O
,	O
28	O
LBP	O
patients	O
(	O
25	O
:	O
3	O
)	O
and	O
14	O
(	O
12	O
:	O
2	O
)	O
healthy	O
,	O
sedentary	O
control	O
persons	O
were	O
recruited	O
for	O
the	O
study	O
.	O
Urinary	O
free	O
cortisol	O
excretion	O
in	O
FMS	O
and	O
LBP	O
patients	O
was	O
lower	O
compared	O
to	O
controls	O
.	O
Only	O
FMS	O
patients	O
displayed	O
lower	O
CBG	O
and	O
basal	O
serum	O
cortisol	O
concentrations	O
when	O
compared	O
to	O
controls	O
.	O
However	O
,	O
plasma	O
free	O
cortisol	O
concentrations	O
were	O
similar	O
in	O
the	O
three	O
groups	O
.	O
There	O
was	O
no	O
difference	O
in	O
the	O
number	O
of	O
GR	B
per	O
cell	O
among	O
the	O
three	O
groups	O
(	O
FMS	O
:	O
6498	O
+	O
/-	O
252	O
,	O
LBP	O
:	O
6625	O
+	O
/-	O
284	O
,	O
controls	O
:	O
6576	O
+	O
/-	O
304	O
)	O
,	O
but	O
the	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
the	O
FMS	O
(	O
14.5	O
+	O
/-	O
0.9	O
nmol	O
/	O
l	O
)	O
and	O
LBP	O
(	O
14.7	O
+	O
/-	O
1.3	O
nmol	O
/	O
l	O
)	O
subjects	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
controls	O
(	O
10.9	O
+	O
/-	O
0.8	O
nmol	O
/	O
l	O
)	O
(	O
p	O
<	O
.05	O
)	O
.	O
The	O
maximal	O
stimulation	O
of	O
the	O
lymphocytes	O
,	O
as	O
measured	O
by	O
the	O
maximal	O
thymidine	O
incorporation	O
(	O
in	O
the	O
absence	O
of	O
cortisol	O
)	O
in	O
the	O
FMS	O
group	O
was	O
approximately	O
1.5	O
times	O
higher	O
(	O
p	O
<	O
.05	O
)	O
than	O
in	O
the	O
control	O
or	O
LBP	O
group	O
.	O
The	O
ED50	O
(	O
the	O
cortisol	O
concentration	O
giving	O
50	O
%	O
inhibition	O
of	O
the	O
thymidine	O
incorporation	O
)	O
,	O
however	O
,	O
was	O
identical	O
in	O
all	O
three	O
groups	O
.	O
We	O
conclude	O
that	O
FMS	O
patients	O
have	O
a	O
mild	O
hypocortisolemia	O
,	O
increased	O
cortisol	O
feedback	O
resistance	O
in	O
combination	O
probably	O
with	O
a	O
reduced	O
CRH	O
synthesis	O
or	O
release	O
in	O
the	O
hypothalamus	O
.	O
The	O
role	O
of	O
the	O
GR	B
and	O
mineralocorticoid	B
receptor	I
(	O
MR	B
)	O
in	O
the	O
CRH	O
regulation	O
in	O
the	O
FMS	O
patients	O
remains	O
to	O
be	O
solved	O
.	O
Cytokine	B
rescue	O
from	O
glucocorticoid	O
induced	O
apoptosis	O
in	O
T	O
cells	O
is	O
mediated	O
through	O
inhibition	O
of	O
IkappaBalpha	B
.	O
We	O
previously	O
reported	O
that	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
,	O
causes	O
apoptosis	O
in	O
mature	O
Th	O
cell	O
lines	O
,	O
and	O
that	O
this	O
induction	O
of	O
cell	O
death	O
is	O
prevented	O
by	O
specific	O
cytokines	B
,	O
namely	O
,	O
by	O
IL-2	B
in	O
Th1	O
cells	O
and	O
by	O
IL-4	B
in	O
Th2	O
cells	O
.	O
We	O
now	O
show	O
that	O
this	O
differential	O
rescue	O
by	O
specific	O
cytokines	B
in	O
Th	O
cells	O
correlates	O
with	O
the	O
level	O
of	O
IkappaBalpha	B
that	O
is	O
regulated	O
by	O
DEX	O
and	O
cytokines	B
.	O
In	O
both	O
cell	O
types	O
the	O
cellular	O
levels	O
of	O
IkappaBalpha	O
mRNA	O
and	O
protein	O
were	O
evaluated	O
by	O
DEX	O
treatment	O
.	O
Interestingly	O
,	O
the	O
DEX	O
-	O
mediated	O
IkappaBalpha	B
induction	O
was	O
completely	O
inhibited	O
by	O
IL-2	B
,	O
but	O
not	O
IL-4	B
,	O
in	O
Th1	O
cells	O
,	O
while	O
the	O
reverse	O
profile	O
was	O
seen	O
in	O
Th2	O
cells	O
.	O
In	O
both	O
cell	O
types	O
,	O
the	O
cytokine	B
that	O
inhibits	O
the	O
induction	O
of	O
IkappaBalpha	B
by	O
DEX	O
,	O
also	O
rescues	O
these	O
cells	O
from	O
DEX	O
-	O
induced	O
apoptosis	O
,	O
although	O
the	O
rescue	O
cytokine	O
is	O
different	O
in	O
Th1	O
and	O
Th2	O
cells	O
.	O
Our	O
results	O
imply	O
that	O
T	O
cells	O
need	O
to	O
maintain	O
a	O
certain	O
level	O
of	O
NF	B
-	I
kappaB	I
transcriptional	O
activity	O
in	O
order	O
to	O
survive	O
;	O
up-	O
or	O
down	O
-	O
regulation	O
of	O
nuclear	B
NF	I
kappaB	I
through	O
modulation	O
of	O
IkappaBalpha	B
expression	O
by	O
cytokines	B
or	O
DEX	O
may	O
lead	O
to	O
cell	O
survival	O
or	O
cell	O
death	O
,	O
respectively	O
.	O
Endothelial	O
production	O
of	O
MCP-1	B
:	O
modulation	O
by	O
heparin	O
and	O
consequences	O
for	O
mononuclear	O
cell	O
activation	O
.	O
Heparin	O
is	O
a	O
polyanionic	O
glycosaminoglycan	O
(	O
GAG	O
)	O
that	O
can	O
bind	O
with	O
high	O
affinity	O
to	O
a	O
range	O
of	O
cytokines	B
including	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
and	O
members	O
of	O
the	O
chemokine	B
superfamily	I
.	O
This	O
GAG	O
also	O
possesses	O
immunomodulatory	O
activity	O
in	O
vivo	O
and	O
can	O
antagonize	O
the	O
capacity	O
of	O
IFN	B
-	I
gamma	I
to	O
induce	O
class	B
II	I
MHC	I
antigen	I
expression	O
,	O
and	O
to	O
up	O
-	O
regulate	O
intercellular	B
adhesion	I
molecule-1	I
,	O
by	O
cultured	O
endothelial	O
cells	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
binding	O
to	O
cell	O
-	O
surface	O
heparan	O
sulphate	O
is	O
essential	O
for	O
optimal	O
activity	O
of	O
IFN	B
-	I
gamma	I
and	O
that	O
free	O
heparin	O
competitively	O
inhibits	O
this	O
sequestration	O
process	O
.	O
The	O
present	O
study	O
was	O
performed	O
to	O
increase	O
our	O
understanding	O
of	O
the	O
immunosuppressive	O
activity	O
of	O
heparin	O
by	O
investigation	O
of	O
potential	O
antagonism	O
of	O
the	O
production	O
and	O
function	O
of	O
monocyte	B
chemotactic	I
peptide-1	I
(	O
MCP-1	B
)	O
,	O
a	O
chemokine	B
important	O
for	O
mononuclear	O
leucocyte	O
recruitment	O
across	O
vascular	O
endothelium	O
.	O
It	O
was	O
found	O
that	O
mixture	O
of	O
heparin	O
with	O
IFN	B
-	I
gamma	I
inhibited	O
up	O
-	O
regulation	O
of	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
protein	O
,	O
STAT-1	B
produced	O
normally	O
by	O
treatment	O
of	O
endothelial	O
cells	O
with	O
IFN	B
-	I
gamma	I
.	O
An	O
inhibition	O
of	O
MCP-1	B
production	O
was	O
observed	O
that	O
was	O
specifically	O
caused	O
by	O
mixture	O
of	O
IFN	B
-	I
gamma	I
with	O
heparin	O
-	O
like	O
,	O
and	O
therefore	O
cytokine	O
-	O
binding	O
,	O
GAGs	O
.	O
It	O
was	O
also	O
shown	O
that	O
mixture	O
of	O
heparin	O
-	O
like	O
GAGs	O
with	O
MCP-1	B
inhibited	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
phosphatidylinositol	B
3-kinase	I
which	O
is	O
normally	O
produced	O
by	O
treatment	O
of	O
mononuclear	O
leucocytes	O
with	O
this	O
chemokine	B
.	O
Blockade	O
of	O
this	O
intracellular	O
signalling	O
event	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
normal	O
transendothelial	O
migration	O
response	O
towards	O
MCP-1	B
.	O
Results	O
from	O
this	O
study	O
indicate	O
that	O
soluble	O
,	O
heparin	O
-	O
like	O
GAGs	O
can	O
block	O
IFN	B
-	I
gamma	I
-dependent	O
up	O
-	O
regulation	O
of	O
MCP-1	B
production	O
by	O
cultured	O
endothelial	O
cells	O
,	O
and	O
can	O
also	O
antagonize	O
the	O
leucocyte	O
-	O
activating	O
and	O
migration	O
-	O
promoting	O
properties	O
of	O
pre	O
-	O
existing	O
MCP-1	B
.	O
These	O
activities	O
may	O
contribute	O
to	O
the	O
immunomodulatory	O
properties	O
of	O
heparin	O
.	O
Regulation	O
of	O
the	O
human	O
interleukin-2	O
gene	O
by	O
the	O
alpha	B
and	I
beta	I
isoforms	I
of	O
the	O
glucocorticoid	B
receptor	I
.	O
The	O
immunosuppressive	O
effects	O
of	O
glucocorticoids	O
are	O
largely	O
due	O
to	O
transcriptional	O
inhibition	O
of	O
immunologically	O
relevant	O
genes	O
,	O
such	O
as	O
the	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
.	O
These	O
effects	O
are	O
mediated	O
by	O
the	O
intracellular	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
.	O
In	O
humans	O
,	O
alternative	O
splicing	O
of	O
the	O
GR	O
precursor	O
mRNA	O
gives	O
rise	O
to	O
two	O
receptor	O
isoforms	O
,	O
termed	O
GRalpha	B
and	O
GRbeta	B
.	O
We	O
previously	O
demonstrated	O
that	O
GRbeta	B
could	O
antagonize	O
GRalpha	B
-mediated	O
transactivation	O
of	O
a	O
glucocorticoid	O
-	O
responsive	O
element	O
(	O
GRE	O
)	O
-driven	O
reporter	O
gene	O
in	O
COS-7	O
cells	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
roles	O
of	O
the	O
two	O
GR	B
isoforms	I
on	O
glucocorticoid	O
-	O
mediated	O
transrepression	O
of	O
the	O
IL-2	O
gene	O
.	O
Using	O
a	O
recently	O
developed	O
transfection	O
technique	O
,	O
we	O
demonstrate	O
that	O
in	O
primary	O
human	O
lymphocytes	O
,	O
stimulation	O
of	O
a	O
548	O
bp	O
IL-2	O
promoter	O
-	O
luciferase	O
reporter	O
construct	O
by	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
is	O
reversed	O
by	O
dexamethasone	O
to	O
a	O
similar	O
extent	O
as	O
in	O
Jurkat	O
T	O
lymphoma	O
cells	O
transfected	O
with	O
a	O
GRalpha	B
expression	O
vector	O
.	O
Transfection	O
of	O
a	O
GRbeta	B
expression	O
vector	O
alone	O
did	O
not	O
result	O
in	O
IL-2	O
promoter	O
repression	O
in	O
response	O
to	O
glucocorticoids	O
.	O
Furthermore	O
,	O
GRbeta	B
did	O
not	O
antagonize	O
the	O
repressive	O
effects	O
of	O
GRalpha	B
on	O
IL-2	O
promoter	O
activity	O
.	O
Surprisingly	O
,	O
overexpression	O
of	O
GRbeta	B
in	O
Jurkat	O
cells	O
did	O
not	O
cause	O
significant	O
inhibition	O
of	O
GRalpha	B
-induced	O
transactivation	O
of	O
a	O
GRE	O
-	O
dependent	O
luciferase	O
reporter	O
gene	O
either	O
.	O
We	O
conclude	O
that	O
the	O
transrepressive	O
effect	O
of	O
glucocorticoids	O
on	O
IL-2	O
gene	O
transcription	O
is	O
exclusively	O
mediated	O
by	O
GRalpha	B
.	O
GRbeta	B
can	O
neither	O
antagonize	O
GRalpha	B
-mediated	O
transactivation	O
nor	O
transrepression	O
in	O
Jurkat	O
cells	O
,	O
indicating	O
a	O
cell	O
type	O
-	O
specific	O
pattern	O
of	O
GRbeta	B
-mediated	O
antiglucocorticoid	O
activity	O
.	O
Inhibition	O
of	O
nuclear	B
factor	I
kappaB	I
activation	O
attenuates	O
apoptosis	O
resistance	O
in	O
lymphoid	O
cells	O
.	O
Death	B
-	I
inducing	I
ligands	I
(	O
DILs	B
)	O
such	O
as	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNFalpha	B
)	O
or	O
the	O
cytotoxic	O
drug	O
doxorubicin	O
have	O
been	O
shown	O
to	O
activate	O
a	O
nuclear	B
factor	I
kappaB	I
(	O
NFkappaB	B
)	O
-dependent	O
program	O
that	O
may	O
rescue	O
cells	O
from	O
apoptosis	O
induction	O
.	O
We	O
demonstrate	O
here	O
that	O
TRAIL	B
(	O
TNF	B
-	I
related	I
apoptosis	I
-	I
inducing	I
ligand	I
)	O
,	O
a	O
recently	O
identified	O
DIL	B
,	O
also	O
activates	O
NFkappaB	B
in	O
lymphoid	O
cell	O
lines	O
in	O
a	O
kinetic	O
similar	O
to	O
TNFalpha	B
.	O
NFkappaB	B
activity	O
is	O
independent	O
from	O
FADD	B
,	O
caspases	B
,	O
and	O
apoptosis	O
induction	O
.	O
To	O
study	O
the	O
influence	O
of	O
NFkappaB	B
activity	O
on	O
apoptosis	O
mediated	O
by	O
TRAIL	B
,	O
CD95	O
,	O
TNFalpha	B
,	O
or	O
doxorubicin	O
,	O
NFkappaB	B
activation	O
was	O
inhibited	O
using	O
the	O
proteasome	B
inhibitor	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
leucinyl	O
-	O
L	O
-	O
leucinyl	O
-	O
L	O
-	O
norleucinal	O
or	O
transient	O
overexpression	O
of	O
mutant	B
IkappaBalpha	I
.	O
Sensitivity	O
for	O
induction	O
of	O
apoptosis	O
was	O
markedly	O
increased	O
by	O
these	O
treatments	O
in	O
apoptosis	O
sensitive	O
cell	O
lines	O
.	O
Moreover	O
,	O
both	O
in	O
cell	O
lines	O
and	O
in	O
primary	O
leukemia	O
cells	O
that	O
are	O
resistant	O
towards	O
induction	O
of	O
apoptosis	O
by	O
DILs	B
and	O
doxorubicin	O
,	O
antagonization	O
of	O
NFkappaB	B
activity	O
partially	O
restored	O
apoptosis	O
sensitivity	O
.	O
These	O
data	O
suggest	O
that	O
inhibition	O
of	O
NFkappaB	B
activation	O
may	O
provide	O
a	O
molecular	O
approach	O
to	O
increase	O
apoptosis	O
sensitivity	O
in	O
anticancer	O
treatment	O
.	O
MLL	O
and	O
CALM	O
are	O
fused	O
to	O
AF10	O
in	O
morphologically	O
distinct	O
subsets	O
of	O
acute	O
leukemia	O
with	O
translocation	O
t	O
(	O
10	O
;	O
11	O
)	O
:	O
both	O
rearrangements	O
are	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O
The	O
translocation	O
t	O
(	O
10	O
;	O
11	O
)	O
(	O
p13	O
;	O
q14	O
)	O
has	O
been	O
observed	O
in	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
as	O
well	O
as	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O
A	O
recent	O
study	O
showed	O
a	O
MLL	O
/	O
AF10	O
fusion	O
in	O
all	O
cases	O
of	O
AML	O
with	O
t	O
(	O
10	O
;	O
11	O
)	O
and	O
various	O
breakpoints	O
on	O
chromosome	O
11	O
ranging	O
from	O
q13	O
to	O
q23	O
.	O
We	O
recently	O
cloned	O
CALM	O
(	O
Clathrin	O
Assembly	O
Lymphoid	O
Myeloid	O
leukemia	O
gene	O
)	O
,	O
the	O
fusion	O
partner	O
of	O
AF10	O
at	O
11q14	O
in	O
the	O
monocytic	O
cell	O
line	O
U937	O
.	O
To	O
further	O
define	O
the	O
role	O
of	O
these	O
genes	O
in	O
acute	O
leukemias	O
,	O
10	O
cases	O
(	O
9	O
AML	O
and	O
1	O
ALL	O
)	O
with	O
cytogenetically	O
proven	O
t	O
(	O
10	O
;	O
11	O
)	O
(	O
p12	O
-	O
14	O
;	O
q13	O
-	O
21	O
)	O
and	O
well	O
-	O
characterized	O
morphology	O
,	O
immunophenotype	O
,	O
and	O
clinical	O
course	O
were	O
analyzed	O
.	O
Interphase	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
was	O
performed	O
with	O
2	O
YACs	O
flanking	O
the	O
CALM	O
region	O
,	O
a	O
YAC	O
contig	O
of	O
the	O
MLL	O
region	O
,	O
and	O
a	O
YAC	O
spanning	O
the	O
AF10	O
breakpoint	O
.	O
Rearrangement	O
of	O
at	O
least	O
one	O
of	O
these	O
genes	O
was	O
detected	O
in	O
all	O
cases	O
with	O
balanced	O
t	O
(	O
10	O
;	O
11	O
)	O
.	O
In	O
4	O
cases	O
,	O
including	O
3	O
AML	O
with	O
immature	O
morphology	O
(	O
1	O
AML	O
-	O
M0	O
and	O
2	O
AML	O
-	O
M1	O
)	O
and	O
1	O
ALL	O
,	O
the	O
signals	O
of	O
the	O
CALM	O
YACS	O
were	O
separated	O
in	O
interphase	O
cells	O
,	O
indicating	O
a	O
translocation	O
breakpoint	O
within	O
the	O
CALM	O
region	O
.	O
MLL	O
was	O
rearranged	O
in	O
3	O
AML	O
with	O
myelomonocytic	O
differentiation	O
(	O
2	O
AML	O
-	O
M2	O
and	O
1	O
AML	O
-	O
M5	O
)	O
,	O
including	O
1	O
secondary	O
AML	O
.	O
In	O
all	O
3	O
cases	O
,	O
a	O
characteristic	O
immunophenotype	O
was	O
identified	O
(	O
CD4	B
+	I
,	O
CD13	B
-	O
,	O
CD33	O
+	O
,	O
CD65s+	O
)	O
.	O
AF-10	O
was	O
involved	O
in	O
5	O
of	O
6	O
evaluable	O
cases	O
,	O
including	O
1	O
case	O
without	O
detectable	O
CALM	O
or	O
MLL	O
rearrangement	O
.	O
In	O
2	O
complex	O
translocations	O
,	O
none	O
of	O
the	O
three	O
genes	O
was	O
rearranged	O
.	O
All	O
cases	O
had	O
a	O
remarkably	O
poor	O
prognosis	O
,	O
with	O
a	O
mean	O
survival	O
of	O
9.6	O
+	O
/-	O
6.6	O
months	O
.	O
For	O
the	O
7	O
AML	O
cases	O
that	O
were	O
uniformly	O
treated	O
according	O
to	O
the	O
AMLCG86	O
/	O
92	O
protocols	O
,	O
disease	O
-	O
free	O
and	O
overall	O
survival	O
was	O
significantly	O
worse	O
than	O
for	O
the	O
overall	O
study	O
group	O
(	O
P	O
=	O
.03	O
and	O
P	O
=	O
.01	O
,	O
respectively	O
)	O
.	O
We	O
conclude	O
that	O
the	O
t	O
(	O
10	O
;	O
11	O
)	O
(	O
p13	O
;	O
q14	O
)	O
indicates	O
CALM	O
and	O
MLL	O
rearrangements	O
in	O
morphologically	O
distinct	O
subsets	O
of	O
acute	O
leukemia	O
and	O
may	O
be	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O
Loss-	O
and	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
reveal	O
an	O
important	O
role	O
of	O
BSAP	B
(	O
Pax-5	B
)	O
at	O
the	O
start	O
and	O
end	O
of	O
B	O
cell	O
differentiation	O
.	O
Pax-5	B
codes	O
for	O
the	O
transcription	B
factor	I
BSAP	B
which	O
is	O
expressed	O
throughout	O
B	O
cell	O
development	O
except	O
in	O
terminally	O
differentiated	O
plasma	O
cells	O
.	O
Gene	O
targeting	O
experiments	O
in	O
the	O
mouse	O
revealed	O
a	O
differential	O
dependency	O
of	O
fetal	O
and	O
adult	O
B	O
-	O
lymphopoiesis	O
on	O
this	O
transcription	B
factor	I
.	O
BSAP	B
is	O
required	O
for	O
B	O
-	O
lineage	O
commitment	O
in	O
the	O
fetal	O
liver	O
and	O
for	O
progression	O
beyond	O
an	O
early	O
pro	O
-	O
B	O
cell	O
stage	O
in	O
adult	O
bone	O
marrow	O
.	O
The	O
characterization	O
of	O
Pax-5-deficient	O
pro	O
-	O
B	O
cells	O
demonstrated	O
an	O
important	O
role	O
of	O
BSAP	B
in	O
the	O
regulation	O
of	O
the	O
CD19	B
,	O
mb-1	B
(	O
Ig	B
alpha	I
)	O
and	O
N	O
-	O
myc	O
genes	O
as	O
well	O
as	O
in	O
the	O
developmental	O
pathway	O
controlling	O
VH	O
-	O
to	O
-	O
DHJH	O
recombination	O
at	O
the	O
immunoglobulin	B
heavy	I
-	I
chain	I
(	I
IgH	I
)	I
locus	I
.	O
The	O
human	O
PAX-5	O
gene	O
was	O
recently	O
shown	O
to	O
participate	O
together	O
with	O
the	O
IgH	O
locus	O
in	O
the	O
chromosomal	O
translocation	O
t	O
(	O
9	O
;	O
14	O
)	O
(	O
p13	O
;	O
q32	O
)	O
.	O
This	O
translocation	O
is	O
characteristic	O
of	O
a	O
small	O
subset	O
of	O
non	O
-	O
Hodgkin	O
lymphomas	O
exhibiting	O
plasmacytoid	O
differentiation	O
.	O
The	O
translocated	O
PAX-5	O
gene	O
is	O
deregulated	O
by	O
the	O
insertion	O
of	O
IgH	O
regulatory	O
elements	O
into	O
its	O
5	O
'	O
region	O
,	O
which	O
may	O
contribute	O
to	O
tumorigenesis	O
by	O
interfering	O
with	O
the	O
shut	O
-	O
down	O
of	O
PAX-5	B
transcription	O
and	O
thus	O
with	O
the	O
completion	O
of	O
plasma	O
cell	O
differentiation	O
The	O
role	O
of	O
E	B
-	I
proteins	I
in	O
B-	O
and	O
T	O
-	O
lymphocyte	O
development	O
.	O
Department	O
of	O
lymphocytes	O
from	O
hematopoietic	O
stem	O
cells	O
is	O
controlled	O
,	O
in	O
part	O
,	O
by	O
the	O
activity	O
of	O
transcriptional	B
regulatory	I
proteins	I
.	O
In	O
particular	O
,	O
one	O
class	O
of	O
helix	B
-	I
loop	I
-	I
helix	I
proteins	I
,	O
termed	O
E	B
-	I
proteins	I
,	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
B	O
-	O
cell	O
development	O
.	O
Recent	O
analysis	O
of	O
gene	O
-	O
targeted	O
mice	O
has	O
allowed	O
a	O
direct	O
assessment	O
of	O
the	O
functional	O
roles	O
of	O
several	B
E	I
-	I
protein	I
family	I
members	I
in	O
hematopoiesis	O
.	O
In	O
this	O
review	O
we	O
describe	O
the	O
defects	O
in	O
B-	O
and	O
T-	O
lymphocyte	O
development	O
in	O
mice	O
carrying	O
targeted	O
mutations	O
in	O
the	O
E	O
-	O
protein	O
genes	O
and	O
discuss	O
our	O
current	O
understanding	O
of	O
the	O
role	O
of	O
these	O
proteins	O
in	O
lymphoid	O
development	O
Limited	O
proteolysis	O
for	O
assaying	O
ligand	O
binding	O
affinities	O
of	O
nuclear	B
receptors	I
.	O
The	O
binding	O
of	O
natural	O
or	O
synthetic	O
ligands	O
to	O
nuclear	B
receptors	I
is	O
the	O
triggering	O
event	O
leading	O
to	O
gene	O
transcription	O
activation	O
or	O
repression	O
.	O
Ligand	O
binding	O
to	O
the	O
ligand	B
binding	I
domain	I
of	O
these	O
receptors	B
induces	O
conformational	O
changes	O
that	O
are	O
evidenced	O
by	O
an	O
increased	O
resistance	O
of	O
this	O
domain	O
to	O
proteases	B
.	O
In	B
vitro	I
labeled	I
receptors	I
were	O
incubated	O
with	O
various	O
synthetic	O
or	O
natural	O
agonists	O
or	O
antagonists	O
and	O
submitted	O
to	O
trypsin	B
digestion	O
.	O
Proteolysis	O
products	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
quantified	O
.	O
The	O
amount	O
of	O
trypsin	B
-resistant	O
fragments	O
was	O
proportional	O
to	O
receptor	O
occupancy	O
by	O
the	O
ligand	O
,	O
and	O
allowed	O
the	O
determination	O
of	O
dissociation	O
constants	O
(	O
kDa	O
)	O
.	O
Using	O
the	O
wild	B
-	I
type	I
or	I
mutated	I
human	I
retinoic	I
acid	I
receptor	I
alpha	I
as	O
a	O
model	O
,	O
kDa	O
values	O
determined	O
by	O
classical	O
competition	O
binding	O
assays	O
using	O
tritiated	O
ligands	O
are	O
in	O
agreement	O
with	O
those	O
measured	O
by	O
the	O
proteolytic	O
assay	O
.	O
This	O
method	O
was	O
successfully	O
extended	O
to	O
human	B
retinoic	I
X	I
receptor	I
alpha	I
,	O
glucocorticoid	B
receptor	I
,	O
and	O
progesterone	B
receptor	I
,	O
thus	O
providing	O
a	O
basis	O
for	O
a	O
new	O
,	O
faster	O
assay	O
to	O
determine	O
simultaneously	O
the	O
affinity	O
and	O
conformation	O
of	O
receptors	O
when	O
bound	O
to	O
a	O
given	O
ligand	O
.	O
Minimal	O
residual	O
disease	O
in	O
acute	O
myelogenous	O
leukemia	O
with	O
PML	B
/	I
RAR	I
alpha	I
or	O
AML1	O
/	O
ETO	O
mRNA	O
and	O
phenotypic	O
analysis	O
of	O
possible	O
T	O
and	O
natural	O
killer	O
cells	O
in	O
bone	O
marrow	O
.	O
Here	O
we	O
studied	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
who	O
have	O
PML	B
/	I
RAR	I
alpha	I
or	O
AML1	B
/	I
ETO	I
as	O
well	O
as	O
the	O
phenotypic	O
analysis	O
of	O
lymphocyte	O
subsets	O
involved	O
in	O
antitumor	O
immunity	O
.	O
Eight	O
patients	O
in	O
long	O
-	O
term	O
(	O
LT	O
;	O
3	O
to	O
15	O
years	O
)	O
and	O
15	O
patients	O
in	O
short	O
-	O
term	O
(	O
ST	O
;	O
up	O
to	O
3	O
years	O
)	O
remission	O
were	O
studied	O
.	O
Using	O
the	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
)	O
assay	O
,	O
the	O
limit	O
of	O
detection	O
was	O
10	O
(	O
-5	O
)	O
to	O
10	O
(	O
-6	O
)	O
for	O
PML	O
/	O
RAR	O
alpha	O
transcript	O
and	O
10	O
(	O
-4	O
)	O
to	O
10	O
(	O
-5	O
)	O
for	O
the	O
AML1	O
/	O
ETO	O
transcript	O
.	O
Simultaneously	O
,	O
T	O
lymphocyte	O
subsets	O
and	O
NK	O
cells	O
from	O
the	O
peripheral	O
blood	O
(	O
PB	O
)	O
and	O
bone	O
marrow	O
(	O
BM	O
)	O
were	O
investigated	O
by	O
flow	O
cytometric	O
analysis	O
.	O
Four	O
of	O
the	O
eight	O
patients	O
in	O
LT	O
and	O
7	O
of	O
the	O
15	O
patients	O
in	O
ST	O
remission	O
were	O
MRD	O
-	O
positive	O
.	O
Although	O
all	O
MRD	O
-	O
positive	O
patients	O
in	O
LT	O
remission	O
are	O
still	O
until	O
now	O
event	O
-	O
free	O
,	O
3	O
of	O
the	O
7	O
MRD	O
-	O
positive	O
(	O
MRD+	O
)	O
patients	O
in	O
ST	O
remission	O
soon	O
relapsed	O
.	O
The	O
total	O
populations	O
of	O
CD4	B
+	O
,	O
CD8	B
+	O
and	O
CD56	B
+	O
[	O
possible	O
T	O
-	O
cell	O
and	O
natural	O
killer	O
(	O
T	O
/	O
NK	O
)	O
populations	O
]	O
in	O
the	O
BM	O
of	O
ST	O
patients	O
and	O
MRD+	O
/	O
LT	O
patients	O
were	O
significantly	O
(	O
p	O
<	O
.01	O
)	O
low	O
.	O
The	O
CD8	O
+	O
CD28	O
+	O
population	O
showed	O
the	O
same	O
tendency	O
(	O
p	O
<	O
.01-.02	O
)	O
.	O
The	O
T	O
/	O
NK	O
subsets	O
in	O
the	O
BM	O
of	O
MRD	O
-	O
negative	O
(	O
MRD-	O
)	O
LT	O
(	O
MRD-	O
/	O
LT	O
)	O
patients	O
showed	O
similar	O
numbers	O
of	O
cells	O
as	O
normal	O
volunteers	O
.	O
Basically	O
,	O
the	O
total	O
percentage	O
of	O
the	O
CD4	O
+	O
,	O
CD8	O
+	O
and	O
CD56	O
+	O
cell	O
populations	O
in	O
the	O
BM	O
was	O
increased	O
and	O
in	O
the	O
following	O
order	O
:	O
MRD-	O
/	O
LT	O
patients	O
,	O
normal	O
volunteers	O
,	O
MRD+	O
/	O
LT	O
patients	O
and	O
MRD+	O
or	O
-	O
/	O
ST	O
patients	O
.	O
The	O
percentages	O
of	O
the	O
T	O
/	O
NK	O
-	O
cell	O
subsets	O
in	O
the	O
PB	O
were	O
not	O
significantly	O
different	O
among	O
these	O
groups	O
.	O
Thus	O
,	O
the	O
difference	O
of	O
the	O
possible	O
T	O
/	O
NK	O
-	O
cell	O
phenotype	O
in	O
the	O
BM	O
may	O
strongly	O
influence	O
clinical	O
and	O
molecular	O
remission	O
.	O
These	O
results	O
still	O
remain	O
to	O
be	O
confirmed	O
by	O
further	O
studies	O
of	O
the	O
functional	O
anti	O
-	O
tumor	O
immunity	O
of	O
T	O
/	O
NK	O
cells	O
of	O
AML	O
in	O
remission	O
.	O
Ro	O
09	O
-	O
2210	O
exhibits	O
potent	O
anti	O
-	O
proliferative	O
effects	O
on	O
activated	O
T	O
cells	O
by	O
selectively	O
blocking	O
MKK	B
activity	O
.	O
By	O
using	O
high	O
throughput	O
screening	O
of	O
microbial	O
broths	O
,	O
we	O
have	O
identified	O
a	O
compound	O
,	O
designated	O
Ro	O
09	O
-	O
2210	O
,	O
which	O
is	O
able	O
to	O
block	O
anti	B
-	I
CD3	I
induced	O
peripheral	O
blood	O
T	O
cell	O
activation	O
with	O
an	O
IC50	O
=	O
40	O
nM	O
.	O
Ro	O
09	O
-	O
2210	O
was	O
also	O
able	O
to	O
block	O
antigen	O
-	O
induced	O
IL-2	B
secretion	O
with	O
an	O
IC50	O
=	O
30	O
nM	O
,	O
but	O
was	O
considerably	O
less	O
potent	O
at	O
blocking	O
Ca2	O
+	O
flux	O
stimulated	O
by	O
anti	B
-	I
CD3	I
treatment	O
.	O
To	O
determine	O
the	O
mechanism	O
of	O
action	O
of	O
Ro	O
09	O
-	O
2210	O
,	O
we	O
set	O
up	O
a	O
transient	O
expression	O
system	O
in	O
Jurkat	O
T	O
cells	O
using	O
a	O
variety	O
of	O
reporter	O
gene	O
constructs	O
and	O
showed	O
effective	O
inhibition	O
of	O
phorbol	O
ester	O
/	O
ionomycin	O
-	O
induced	O
NF	B
-	I
AT	I
activation	O
and	O
anti	O
-	O
CD3	O
induced	O
NF	B
-	I
AT	I
with	O
IC50	O
=	O
7.7	O
and	O
10	O
nM	O
,	O
respectively	O
.	O
Ro	O
09	O
-	O
2210	O
was	O
also	O
able	O
to	O
inhibit	O
phorbol	O
ester	O
/	O
ionomycin	O
-	O
induced	O
activation	O
of	O
AP1	B
with	O
IC50	O
=	O
<	O
10	O
nM	O
.	O
We	O
further	O
showed	O
that	O
Ro	O
09	O
-	O
2210	O
was	O
unable	O
to	O
inhibit	O
c	O
-	O
jun	O
induced	O
expression	O
of	O
AP1-dependent	O
reporter	O
constructs	O
(	O
IC50	O
>	O
500	O
nM	O
)	O
,	O
but	O
was	O
able	O
to	O
potently	O
inhibit	O
ras	O
-	O
induced	O
AP1	B
activation	O
(	O
IC50	O
=	O
20	O
nM	O
)	O
.	O
This	O
suggested	O
that	O
Ro	O
09	O
-	O
2210	O
was	O
inhibiting	O
an	O
activator	O
of	O
AP-1	B
which	O
was	O
upstream	O
of	O
c	O
-	O
jun	O
and	O
downstream	O
of	O
ras	B
signaling	O
.	O
To	O
investigate	O
further	O
,	O
we	O
then	O
purified	O
a	O
number	O
of	O
different	O
kinases	O
,	O
including	O
PKC	B
,	O
PhK	B
,	O
ZAP-70	B
,	O
ERK	B
,	O
and	O
MEK	B
1	I
(	O
a	O
MKK	B
)	O
,	O
and	O
showed	O
that	O
Ro	O
09	O
-	O
2210	O
was	O
a	O
selective	O
inhibitor	O
of	O
MEK1	B
in	O
vitro	O
(	O
IC50	O
=	O
59	O
nM	O
)	O
.	O
Role	O
of	O
GATA-1	B
in	O
proliferation	O
and	O
differentiation	O
of	O
definitive	O
erythroid	O
and	O
megakaryocytic	O
cells	O
in	O
vivo	O
.	O
To	O
elucidate	O
the	O
contributions	O
of	O
GATA-1	B
to	O
definitive	O
hematopoiesis	O
in	O
vivo	O
,	O
we	O
have	O
examined	O
adult	O
mice	O
that	O
were	O
rendered	O
genetically	O
defective	O
in	O
GATA-1	B
synthesis	O
(	O
Takahashi	O
et	O
al	O
,	O
J	O
Biol	O
Chem	O
272	O
:	O
12611	O
,	O
1997	O
)	O
.	O
Because	O
the	O
GATA-1	O
gene	O
is	O
located	O
on	O
the	O
X	O
chromosome	O
,	O
which	O
is	O
randomly	O
inactivated	O
in	O
every	O
cell	O
,	O
heterozygous	O
females	O
can	O
bear	O
either	O
an	O
active	O
wild	O
-	O
type	O
or	O
mutant	O
(	O
referred	O
to	O
as	O
GATA-1.05	O
)	O
GATA-1	B
allele	O
,	O
consequently	O
leading	O
to	O
variable	O
anemic	O
severity	O
.	O
These	O
heterozygous	O
mutant	O
mice	O
usually	O
developed	O
normally	O
,	O
but	O
they	O
began	O
to	O
die	O
after	O
5	O
months	O
.	O
These	O
affected	O
animals	O
displayed	O
marked	O
splenomegaly	O
,	O
anemia	O
,	O
and	O
thrombocytopenia	O
.	O
Proerythroblasts	O
and	O
megakaryocytes	O
massively	O
accumulated	O
in	O
the	O
spleens	O
of	O
the	O
heterozygotes	O
,	O
and	O
we	O
showed	O
that	O
the	O
neomycin	O
resistance	O
gene	O
(	O
which	O
is	O
the	O
positive	O
selection	O
marker	O
in	O
ES	O
cells	O
)	O
was	O
expressed	O
profusely	O
in	O
the	O
abnormally	O
abundant	O
cells	O
generated	O
in	O
the	O
GATA-1.05	B
mutant	O
females	O
.	O
We	O
also	O
observed	O
hematopoiesis	O
outside	O
of	O
the	O
bone	O
marrow	O
in	O
the	O
affected	O
mutant	O
mice	O
.	O
These	O
data	O
suggest	O
that	O
a	O
small	O
number	O
of	O
GATA-1.05	O
mutant	O
hematopoietic	O
progenitor	O
cells	O
begin	O
to	O
proliferate	O
vigorously	O
during	O
early	O
adulthood	O
,	O
but	O
because	O
the	O
cells	O
are	O
unable	O
to	O
terminally	O
differentiate	O
,	O
this	O
leads	O
to	O
progenitor	O
proliferation	O
in	O
the	O
spleen	O
and	O
consequently	O
death	O
.	O
Thus	O
,	O
GATA-1	B
plays	O
important	O
in	O
vivo	O
roles	O
for	O
directing	O
definitive	O
hematopoietic	O
progenitors	O
to	O
differentiate	O
along	O
both	O
the	O
erythroid	O
and	O
megakaryocytic	O
pathways	O
.	O
The	O
GATA-1	B
heterozygous	O
mutant	O
mouse	O
shows	O
a	O
phenotype	O
that	O
is	O
analogous	O
to	O
human	O
myelodysplastic	O
syndrome	O
and	O
thus	O
may	O
serve	O
as	O
a	O
useful	O
model	O
for	O
this	O
disorder	O
.	O
A	O
novel	O
function	O
of	O
Stat1	B
and	O
Stat3	B
proteins	O
in	O
erythropoietin	B
-induced	O
erythroid	O
differentiation	O
of	O
a	O
human	O
leukemia	O
cell	O
line	O
.	O
We	O
recently	O
determined	O
that	O
erythropoietin	B
(	O
EPO	B
)	O
activates	O
3	O
members	O
of	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
family	O
,	O
Stat1alpha	B
,	O
Stat3	B
,	O
and	O
Stat5	B
,	O
in	O
the	O
human	O
EPO	O
-	O
dependent	O
cell	O
lines	O
,	O
UT-7	O
and	O
UT-7	O
/	O
EPO	O
(	O
Kirito	O
et	O
al	O
,	O
J	O
Biol	O
Chem	O
272	O
:	O
16507	O
,	O
1997	O
)	O
.	O
In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
Stat1alpha	B
,	O
but	O
not	O
Stat3	B
,	O
is	O
involved	O
in	O
EPO	B
-induced	O
cellular	O
proliferation	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
Stat1alpha	B
and	O
Stat3	B
in	O
EPO	B
-induced	O
erythroid	O
differentiation	O
.	O
UT-7	O
/	O
GM	O
was	O
used	O
as	O
a	O
model	O
system	O
,	O
because	O
this	O
cell	O
line	O
can	O
differentiate	O
into	O
erythroid	O
-	O
lineage	O
cells	O
with	O
EPO	B
treatment	O
(	O
Komatsu	O
et	O
al	O
,	O
Blood	O
89	O
:	O
4021	O
,	O
1997	O
)	O
.	O
We	O
found	O
that	O
EPO	B
did	O
not	O
activate	O
Stat1alpha	B
or	O
Stat3	B
in	O
UT-7	O
/	O
GM	O
cells	O
.	O
Transfection	O
experiments	O
showed	O
that	O
both	O
Stat1alpha	B
and	O
Stat3	B
inhibited	O
the	O
induction	O
by	O
EPO	B
of	O
gamma	O
-	O
globin	O
and	O
erythroid	O
-	O
specific	O
5-aminolevulinate	O
synthetase	O
transcripts	O
,	O
resulting	O
in	O
a	O
reduction	O
of	O
the	O
percentage	O
of	O
hemoglobin	O
-	O
positive	O
cells	O
.	O
Dominant	O
negative	O
forms	O
of	O
Stat1alpha	B
or	O
Stat3	B
promoted	O
the	O
EPO	B
-induced	O
erythroid	O
differentiation	O
of	O
UT-7	O
/	O
GM	O
cells	O
,	O
even	O
in	O
the	O
presence	O
of	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
,	O
although	O
this	O
cytokine	O
never	O
induced	O
erythroid	O
differentiation	O
of	O
the	O
parent	O
UT-7	O
/	O
GM	O
cells	O
with	O
or	O
without	O
EPO	B
.	O
A	O
cell	O
cycle	O
analysis	O
showed	O
that	O
the	O
constitutive	O
activation	O
of	O
Stat1alpha	B
,	O
but	O
not	O
Stat3	B
,	O
shortened	O
the	O
period	O
of	O
G0	O
/	O
G1	O
prolongation	O
caused	O
by	O
EPO	B
stimulation	O
.	O
Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
Stat1alpha	B
and	O
Stat3	B
act	O
as	O
negative	O
regulators	O
in	O
EPO	B
-induced	O
erythroid	O
differentiation	O
.	O
Specifically	O
,	O
Stat1alpha	B
may	O
activate	O
a	O
cell	O
cycle	O
-	O
associated	O
gene	O
(	O
s	O
)	O
,	O
leading	O
to	O
the	O
entry	O
of	O
cells	O
into	O
the	O
cell	O
cycle	O
.	O
DNA	O
damaging	O
agents	O
induce	O
expression	O
of	O
Fas	B
ligand	I
and	O
subsequent	O
apoptosis	O
in	O
T	O
lymphocytes	O
via	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
.	O
Apoptosis	O
induced	O
by	O
DNA	O
damage	O
and	O
other	O
stresses	O
can	O
proceed	O
via	O
expression	O
of	O
Fas	B
ligand	I
(	O
FasL	B
)	O
and	O
ligation	O
of	O
its	O
receptor	O
,	O
Fas	O
(	O
CD95	O
)	O
.	O
We	O
report	O
that	O
activation	O
of	O
the	O
two	O
transcription	B
factors	I
NF	I
-	I
kappa	I
B	I
and	I
AP-1	I
is	O
crucially	O
involved	O
in	O
FasL	B
expression	O
induced	O
by	O
etoposide	O
,	O
teniposide	O
,	O
and	O
UV	O
irradiation	O
.	O
A	O
nondegradable	B
mutant	I
of	O
I	B
kappa	I
B	I
blocked	O
both	O
FasL	B
expression	O
and	O
apoptosis	O
induced	O
by	O
DNA	O
damage	O
but	O
not	O
Fas	O
ligation	O
.	O
These	O
stimuli	O
also	O
induced	O
the	O
stress	O
-	O
activated	O
kinase	O
pathway	O
(	O
SAPK	O
/	O
JNK	O
)	O
,	O
which	O
was	O
required	O
for	O
the	O
maximal	O
induction	O
of	O
apoptosis	O
.	O
A	O
1.2	O
kb	O
FasL	O
promoter	O
responded	O
to	O
DNA	O
damage	O
,	O
as	O
well	O
as	O
coexpression	O
with	O
p65	B
Rel	I
or	O
Fos	B
/	I
Jun	I
.	O
Mutations	O
in	O
the	O
relevant	O
NF	O
-	O
kappa	O
B	O
and	O
AP-1	O
binding	O
sites	O
eliminated	O
these	O
responses	O
.	O
Thus	O
,	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
contributes	O
to	O
stress	O
-	O
induced	O
apoptosis	O
via	O
the	O
expression	O
of	O
FasL	B
.	O
Uncoupling	O
of	O
nonreceptor	O
tyrosine	B
kinases	I
from	O
PLC	B
-	I
gamma1	I
in	O
an	O
SLP-76-deficient	O
T	O
cell	O
.	O
Activation	O
of	O
nonreceptor	B
protein	I
tyrosine	I
kinases	I
(	O
PTKs	B
)	O
is	O
essential	O
for	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
responsiveness	O
;	O
however	O
,	O
the	O
function	O
of	O
individual	O
PTK	B
substrates	I
is	O
often	O
uncertain	O
.	O
A	O
mutant	O
T	O
cell	O
line	O
was	O
isolated	O
that	O
lacked	O
expression	O
of	O
SLP-76	B
(	O
SH2	B
domain	I
-	I
containing	I
leukocyte	I
protein	I
of	O
76	O
kilodaltons	O
)	O
,	O
a	O
hematopoietically	B
expressed	I
adaptor	I
protein	I
and	O
PTK	B
substrate	I
.	O
SLP-76	B
was	O
not	O
required	O
for	O
TCR	B
-induced	O
tyrosine	O
phosphorylation	O
of	O
most	O
proteins	O
,	O
but	O
was	O
required	O
for	O
optimal	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
phospholipase	B
C	I
-	I
gamma1	I
(	O
PLC	B
-	I
gamma1	I
)	O
,	O
as	O
well	O
as	O
Ras	B
pathway	O
activation	O
.	O
TCR	B
-inducible	O
gene	O
expression	O
was	O
dependent	O
on	O
SLP-76	B
.	O
Thus	O
,	O
coupling	O
of	O
TCR	B
-	I
regulated	I
PTKs	I
to	O
downstream	O
signaling	O
pathways	O
requires	O
SLP-76	B
.	O
Fibrinogen	B
activates	O
NF	B
-	I
kappa	I
B	I
transcription	I
factors	I
in	O
mononuclear	O
phagocytes	O
.	O
Adhesion	O
to	O
extracellular	O
matrices	O
is	O
known	O
to	O
modulate	O
leukocyte	O
activation	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O
Mononuclear	O
phagocytes	O
are	O
exposed	O
to	O
fibrinous	O
provisional	O
matrix	O
throughout	O
migration	O
into	O
inflammatory	O
foci	O
,	O
so	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
fibrinogen	O
triggers	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
transcription	I
factors	I
.	O
U937	O
cells	O
differentiated	O
with	O
PMA	O
in	O
nonadherent	O
culture	O
were	O
shown	O
to	O
express	O
two	O
fibrinogen	B
-	I
binding	I
integrins	I
,	O
predominately	O
CD11b	B
/	I
CD18	I
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
CD11c	B
/	I
CD18	I
.	O
Cells	O
stimulated	O
with	O
fibrinogen	B
(	O
10	O
-	O
100	O
microg	O
/	O
ml	O
)	O
/Mn2	O
+	O
(	O
50	O
microM	O
)	O
for	O
2	O
h	O
were	O
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
NF	B
-	I
kappa	I
B	I
activation	O
,	O
minimal	O
in	O
unstimulated	O
cells	O
,	O
was	O
substantially	O
up	O
-	O
regulated	O
by	O
fibrinogen	B
.	O
Fibrinogen	B
also	O
caused	O
activation	O
of	O
AP-1	B
,	O
but	O
not	O
SP1	B
or	O
cAMP	B
response	I
element	I
-	I
binding	I
protein	I
(	I
CREB	I
)	I
factors	I
.	O
Blocking	O
mAbs	B
against	O
CD18	B
and	O
CD11b	B
abrogated	O
fibrinogen	B
-induced	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
To	O
determine	O
the	O
effects	O
on	O
transcriptional	O
regulation	O
,	O
U937	O
cells	O
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
HIV-1	O
enhancer	O
(	O
bearing	O
two	O
NF	O
-	O
kappa	O
B	O
sites	O
)	O
coupled	O
to	O
a	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
.	O
Cells	O
were	O
subsequently	O
stimulated	O
with	O
1	O
)	O
PMA	O
for	O
24	O
h	O
,	O
inducing	O
CAT	O
activity	O
by	O
2.6-fold	O
,	O
2	O
)	O
fibrinogen	B
/Mn2	O
+	O
for	O
2	O
h	O
,	O
inducing	O
CAT	O
activity	O
by	O
3.2-fold	O
,	O
or	O
3	O
)	O
costimulation	O
with	O
fibrinogen	B
and	O
PMA	O
,	O
inducing	O
5.7-fold	O
the	O
CAT	O
activity	O
induced	O
by	O
PMA	O
alone	O
.	O
We	O
conclude	O
that	O
contact	O
with	O
fibrinogen	B
-	I
derived	I
proteins	I
may	O
contribute	O
to	O
mononuclear	O
phagocyte	O
activation	O
by	O
signaling	O
through	O
CD11b	B
/	I
CD18	I
,	O
resulting	O
in	O
selective	O
activation	O
of	O
transcriptional	B
regulatory	I
factors	I
,	O
including	O
NF	B
-	I
kappa	I
B	I
.	O
Recognition	O
of	O
herpes	B
simplex	I
virus	I
type	I
2	I
tegument	I
proteins	I
by	O
CD4	O
T	O
cells	O
infiltrating	O
human	O
genital	O
herpes	O
lesions	O
.	O
The	O
local	O
cellular	O
immune	O
response	O
to	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
is	O
important	O
in	O
the	O
control	O
of	O
recurrent	O
HSV	O
infection	O
.	O
The	O
antiviral	O
functions	O
of	O
infiltrating	O
CD4-bearing	O
T	O
cells	O
may	O
include	O
cytotoxicity	O
,	O
inhibition	O
of	O
viral	O
growth	O
,	O
lymphokine	O
secretion	O
,	O
and	O
support	O
of	O
humoral	O
and	O
CD8	O
responses	O
.	O
The	O
antigens	O
recognized	O
by	O
many	O
HSV	O
-	O
specific	O
CD4	O
T	O
cells	O
localizing	O
to	O
genital	O
HSV-2	O
lesions	O
are	O
unknown	O
.	O
T	O
cells	O
recognizing	O
antigens	O
encoded	O
within	O
map	O
units	O
0.67	O
to	O
0.73	O
of	O
HSV	O
DNA	O
are	O
frequently	O
recovered	O
from	O
herpetic	O
lesions	O
.	O
Expression	O
cloning	O
with	O
this	O
region	O
of	O
DNA	O
now	O
shows	O
that	O
tegument	B
protein	I
VP22	B
and	O
the	O
viral	B
dUTPase	I
,	O
encoded	O
by	O
genes	O
UL49	O
and	O
UL50	O
,	O
respectively	O
,	O
are	O
T	B
-	I
cell	I
antigens	I
.	O
Separate	O
epitopes	B
in	O
VP22	B
were	O
defined	O
for	O
T	O
-	O
cell	O
clones	O
from	O
each	O
of	O
three	O
patients	O
.	O
Reactivity	O
with	O
the	O
tegument	B
protein	I
encoded	O
by	O
UL21	O
was	O
identified	O
for	O
an	O
additional	O
patient	O
.	O
Three	O
new	O
epitopes	O
were	O
identified	O
in	O
VP16	B
,	O
a	O
tegument	B
protein	I
associated	O
with	O
VP22	B
.	O
Some	O
tegument	O
-	O
specific	O
CD4	O
T	O
-	O
cell	O
clones	O
exhibited	O
cytotoxic	O
activity	O
against	O
HSV	O
-	O
infected	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
herpes	B
simplex	I
tegument	I
proteins	I
are	O
processed	O
for	O
antigen	O
presentation	O
in	O
vivo	O
and	O
are	O
possible	O
candidate	O
compounds	O
for	O
herpes	O
simplex	O
vaccines	O
.	O
A	O
CD28	B
-associated	O
signaling	O
pathway	O
leading	O
to	O
cytokine	O
gene	O
transcription	O
and	O
T	O
cell	O
proliferation	O
without	O
TCR	B
engagement	O
.	O
Stimulation	O
of	O
resting	O
human	O
T	O
cells	O
with	O
the	O
CD28-specific	B
mAb	I
BW	I
828	I
induces	O
proliferation	O
and	O
cytokine	B
synthesis	O
without	O
further	O
requirement	O
for	O
TCR	B
coengagement	O
.	O
This	O
observation	O
prompted	O
us	O
to	O
postulate	O
that	O
signal	O
2	O
(	O
costimulatory	O
signal	O
)	O
alone	O
without	O
signal	O
1	O
(	O
TCR	B
signal	O
)	O
can	O
activate	O
T	O
cells	O
.	O
To	O
test	O
whether	O
this	O
putative	O
function	O
of	O
CD28	B
is	O
mediated	O
via	O
a	O
particular	O
signaling	O
pathway	O
,	O
we	O
compared	O
early	O
signaling	O
events	O
initiated	O
in	O
resting	O
T	O
cells	O
by	O
the	O
stimulatory	B
mAb	I
BW	I
828	I
with	O
signals	O
triggered	O
by	O
the	O
nonstimulating	B
CD28	I
mAb	I
9.3	I
.	O
Stimulation	O
of	O
T	O
cells	O
with	O
BW	B
828	I
induced	O
an	O
increase	O
in	O
intracellular	O
Ca2	O
+	O
,	O
but	O
did	O
not	O
lead	O
to	O
detectable	O
activation	O
of	O
the	O
protein	B
kinases	I
p56	B
(	I
lck	I
)	I
and	O
c	B
-	I
Raf-1	I
.	O
This	O
pathway	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	B
factors	I
NF	B
-	I
kappa	I
B	I
,	O
NF	B
-	I
AT	I
,	O
and	O
proteins	O
binding	O
to	O
the	O
CD28	B
response	O
element	O
of	O
the	O
IL-2	O
promoter	O
.	O
On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	O
cells	O
with	O
mAb	B
9.3	I
increased	O
the	O
level	O
of	O
intracellular	O
Ca2	O
+	O
and	O
triggered	O
the	O
activation	O
of	O
p56	B
(	I
lck	I
)	I
and	O
c	B
-	I
Raf-1	I
,	O
but	O
was	O
unable	O
to	O
induce	O
the	O
binding	O
of	O
transcription	B
factors	I
to	O
the	O
IL-2	O
promoter	O
.	O
In	O
contrast	O
to	O
the	O
differential	O
signaling	O
of	O
BW	B
828	I
and	O
9.3	B
in	O
resting	O
T	O
cells	O
,	O
the	O
two	O
mAbs	O
exhibited	O
a	O
similar	O
pattern	O
of	O
early	O
signaling	O
events	O
in	O
activated	O
T	O
cells	O
and	O
Jurkat	O
cells	O
(	O
p56	B
(	I
lck	I
)	I
activation	O
,	O
association	O
of	O
phosphatidylinositol	B
3-kinase	I
with	O
CD28	B
)	O
,	O
indicating	O
that	O
the	O
signaling	O
capacity	O
of	O
CD28	B
changes	O
with	O
activation	O
.	O
These	O
data	O
support	O
the	O
view	O
that	O
stimulation	O
through	O
CD28	B
can	O
induce	O
some	O
effector	O
functions	O
in	O
T	O
cells	O
and	O
suggest	O
that	O
this	O
capacity	O
is	O
associated	O
with	O
a	O
particular	O
pattern	O
of	O
early	O
signaling	O
events	O
Retinoic	O
acid	O
inhibits	O
CD40	B
+	O
interleukin-4	B
-mediated	O
IgE	B
production	O
in	O
vitro	O
.	O
To	O
elucidate	O
the	O
role	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
in	O
anti	B
-	I
CD40	I
+	O
interleukin-4	B
(	O
IL-4	B
)	O
-mediated	O
B	O
-	O
cell	O
activation	O
,	O
the	O
effect	O
of	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol	O
/	O
L	O
RA	O
was	O
studied	O
in	O
anti	B
-	I
CD40	I
(	O
1	O
microgram	O
/	O
mL	O
)	O
+	O
IL-4	B
(	O
5	O
ng	O
/	O
mL	O
)	O
-mediated	O
proliferation	O
and	O
Ig	O
synthesis	O
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
B	O
cells	O
in	O
healthy	O
donors	O
.	O
Anti	B
-	I
CD40	I
+	O
IL-4	B
-mediated	O
proliferation	O
of	O
PBMC	O
and	O
B	O
cells	O
was	O
inhibited	O
by	O
RA	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
maximal	O
inhibition	O
of	O
62	O
%	O
+	O
/-	O
5	O
%	O
in	O
PBMC	O
and	O
55	O
%	O
+	O
/-	O
4.4	O
%	O
in	O
B	O
cells	O
by	O
all	O
-	O
trans	O
RA	O
,	O
and	O
58	O
%	O
+	O
/-	O
6.7	O
%	O
and	O
51	O
%	O
+	O
/-	O
4.7	O
%	O
,	O
respectively	O
by	O
13-cis	O
RA	O
.	O
IgE	B
synthesis	O
was	O
even	O
more	O
markedly	O
inhibited	O
by	O
RA	O
starting	O
at	O
concentrations	O
of	O
>	O
10	O
(	O
-14	O
)	O
mol	O
/	O
L	O
for	O
B	O
cells	O
and	O
>	O
10	O
(	O
-10	O
)	O
mol	O
/	O
L	O
for	O
PBMC	O
.	O
Maximal	O
inhibition	O
of	O
IgE	B
production	O
for	O
B	O
cells	O
was	O
at	O
10	O
(	O
-8	O
)	O
mol	O
/	O
L	O
for	O
all	O
-	O
trans	O
RA	O
(	O
94	O
%	O
+	O
/-	O
1.8	O
%	O
)	O
and	O
96	O
%	O
+	O
/-	O
3.2	O
%	O
for	O
13-cis	O
RA	O
.	O
Low	O
concentrations	O
of	O
RA	O
inhibiting	O
IgE	B
synthesis	O
(	O
10	O
(	O
-10	O
)	O
mol	O
/	O
L	O
)	O
affected	O
neither	O
B	O
-	O
cell	O
proliferation	O
nor	O
the	O
production	O
of	O
IgA	B
,	O
IgG	B
,	O
and	O
IgM	B
.	O
Elucidation	O
of	O
the	O
mechanism	O
involved	O
in	O
this	O
inhibition	O
of	O
IgE	B
production	O
shows	O
that	O
epsilon	O
germline	O
transcription	O
is	O
decreased	O
by	O
RA	O
,	O
whereas	O
production	O
of	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
was	O
not	O
enhanced	O
in	O
the	O
presence	O
of	O
RA	O
.	O
To	O
differentiate	O
whether	O
the	O
RA	O
effect	O
was	O
mediated	O
by	O
RA	B
receptors	I
alpha	I
,	I
beta	I
,	I
and	I
gamma	I
,	O
the	O
expression	O
of	O
the	O
retinoic	B
acid	I
receptors	I
(	O
RAR	B
)	O
was	O
examined	O
by	O
reverse	B
transcriptase	I
-polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O
The	O
data	O
show	O
that	O
unstimulated	O
human	O
peripheral	O
B	O
cells	O
express	O
mRNA	O
of	O
the	O
RA	B
receptor	I
alpha	I
,	I
beta	I
,	I
and	I
gamma	I
.	O
Using	O
retinoids	O
with	O
different	O
receptor	O
binding	O
specificity	O
(	O
CD336	O
,	O
CD437	O
,	O
CD2019	O
,	O
CD367	O
)	O
,	O
dose	O
-	O
dependent	O
inhibition	O
of	O
IgE	B
synthesis	O
was	O
shown	O
by	O
all	O
four	O
derivates	O
,	O
but	O
was	O
most	O
marked	O
by	O
an	O
RA	O
binding	O
the	O
alpha	B
receptor	I
with	O
high	O
specificity	O
.	O
Taken	O
together	O
,	O
this	O
study	O
shows	O
that	O
RA	O
inhibits	O
IgE	B
production	O
of	O
anti	O
-	O
CD40	O
+	O
IL-4-stimulated	O
B	O
cells	O
in	O
vitro	O
.	O
Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
.	O
CIITA	B
B	O
-	O
cell	O
-	O
specific	O
promoter	O
suppression	O
in	O
MHC	O
class	O
II	O
-	O
silenced	O
cell	O
hybrids	O
.	O
In	O
this	O
study	O
,	O
various	O
sets	O
of	O
somatic	O
cell	O
hybrids	O
,	O
generated	O
by	O
the	O
fusion	O
of	O
epithelial	O
cell	O
lines	O
with	O
B	O
-	O
lymphoblastoid	O
cell	O
lines	O
,	O
were	O
analyzed	O
for	O
the	O
expression	O
of	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
II	I
antigens	I
.	O
We	O
first	O
demonstrate	O
,	O
in	O
human	O
and	O
mouse	O
intraspecies	O
hybrids	O
,	O
the	O
coordinate	O
suppression	O
of	O
MHC	B
class	I
II	I
,	O
Ii	B
(	O
invariant	B
chain	I
)	O
and	O
HLA	O
-	O
DM	O
gene	O
transcription	O
,	O
and	O
the	O
release	O
of	O
the	O
silencing	O
by	O
the	O
addition	O
of	O
interferon	B
gamma	I
.	O
Using	O
interspecies	O
hybrids	O
,	O
the	O
segregation	O
of	O
human	O
chromosomes	O
allowed	O
us	O
to	O
establish	O
that	O
MHC	B
class	I
II	I
extinction	O
is	O
linked	O
to	O
the	O
presence	O
in	O
the	O
hybrids	O
of	O
the	O
chromosomes	O
from	O
the	O
epithelial	O
fusion	O
partner	O
.	O
Moreover	O
,	O
our	O
data	O
provide	O
evidence	O
that	O
the	O
expression	O
pattern	O
of	O
MHC	O
class	O
II	O
mRNA	O
is	O
correlated	O
with	O
that	O
of	O
the	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
,	O
suggesting	O
that	O
CIITA	B
is	O
the	O
actual	O
target	O
of	O
the	O
silencing	O
.	O
To	O
gain	O
further	O
insight	O
into	O
the	O
suppression	O
phenomenon	O
we	O
performed	O
luciferase	O
assays	O
which	O
show	O
that	O
silencing	O
affects	O
the	O
activity	O
of	O
the	O
B	O
-	O
cell	O
-	O
specific	O
promoter	O
of	O
CIITA	B
.	O
These	O
results	O
therefore	O
demonstrate	O
that	O
the	O
MHC	B
class	I
II	I
gene	O
silencing	O
in	O
somatic	O
cell	O
hybrids	O
is	O
due	O
to	O
an	O
active	O
suppression	O
of	O
one	O
of	O
the	O
promoters	O
of	O
the	O
CIITA	O
gene	O
,	O
mediated	O
by	O
the	O
epithelial	O
cell	O
fusion	O
partner	O
.	O
Regulation	O
of	O
the	O
vitellogenin	O
gene	O
B1	O
promoter	O
after	O
transfer	O
into	O
hepatocytes	O
in	O
primary	O
cultures	O
.	O
The	O
estrogen	O
-	O
dependent	O
and	O
tissue	O
-	O
specific	O
regulation	O
of	O
the	O
Xenopus	O
laevis	O
vitellogenin	O
gene	O
B1	O
promoter	O
has	O
been	O
studied	O
by	O
lipid	O
-	O
mediated	O
DNA	O
transfer	O
into	O
Xenopus	O
hepatocytes	O
in	O
primary	O
culture	O
.	O
Hepatocytes	O
achieve	O
an	O
efficient	O
hormonal	O
control	O
of	O
this	O
promoter	O
through	O
a	O
functional	O
interaction	O
between	O
the	O
estrogen	O
responsive	O
elements	O
and	O
a	O
promoter	O
proximal	O
region	O
upstream	O
of	O
the	O
TATA	O
box	O
,	O
which	O
is	O
characterized	O
by	O
a	O
high	O
density	O
of	O
binding	O
sites	O
for	O
the	O
transcription	B
factors	I
CTF	B
/	I
NF-1	I
,	O
C	B
/	I
EBP	I
and	O
HNF3	B
.	O
DNA	O
accessibility	O
to	O
restriction	B
enzymes	I
within	O
the	O
chromosomal	O
copy	O
of	O
the	O
vitellogenin	O
gene	O
B1	O
promoter	O
shows	O
that	O
the	O
estrogen	O
responsive	O
unit	O
and	O
the	O
promoter	O
proximal	O
region	O
are	O
sensitive	O
to	O
digestion	O
in	O
uninduced	O
and	O
estrogen	O
-	O
induced	O
hepatocytes	O
but	O
not	O
in	O
erythrocyte	O
nuclei	O
.	O
Together	O
,	O
these	O
findings	O
support	O
the	O
notion	O
that	O
chromatin	O
configuration	O
as	O
well	O
as	O
the	O
interplay	O
of	O
promoter	O
elements	O
mediate	O
proper	O
hormone	O
-	O
dependent	O
and	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
B1	O
vitellogenin	O
gene	O
.	O
Peripheral	O
T	O
lymphocytes	O
from	O
women	O
with	O
breast	O
cancer	O
exhibit	O
abnormal	O
protein	O
expression	O
of	O
several	B
signaling	I
molecules	I
.	O
We	O
examined	O
signaling	O
molecules	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
obtained	O
from	O
women	O
with	O
breast	O
cancer	O
.	O
In	O
6	O
of	O
14	O
patients	O
,	O
T	O
lymphocytes	O
displayed	O
an	O
impaired	O
ability	O
to	O
translocate	O
NFeB	B
p65	I
(	O
Rel	B
-	I
A	I
)	O
following	O
activation	O
by	O
anti	O
-	O
CD3	O
and	O
IL-2	B
.	O
This	O
observation	O
was	O
made	O
despite	O
normal	O
cytoplasmic	O
levels	O
of	O
the	O
Rel	B
-	I
A	I
protein	I
.	O
We	O
also	O
detected	O
abnormally	O
low	O
levels	O
of	O
the	O
signaling	B
molecules	I
T	B
-	I
cell	I
receptor	I
(	I
TCR	I
)	I
-zeta	I
,	O
ZAP-70	B
and	O
p56lck	B
in	O
4	O
of	O
14	O
breast	O
cancer	O
patients	O
,	O
i.e.	O
,	O
defects	O
in	O
T	B
-	I
cell	I
signaling	I
molecules	I
.	O
T	O
lymphocytes	O
from	O
6	O
of	O
the	O
14	O
patients	O
also	O
exhibited	O
an	O
increased	O
expression	O
of	O
the	O
dual	O
specificity	B
phosphatase	I
,	O
map	B
kinase	I
phosphatase-1	I
(	O
MKP-1	B
)	O
.	O
MKP-1	B
inactivates	O
MAP	B
kinase	I
and	O
therefore	O
may	O
interfere	O
with	O
the	O
activation	O
of	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
.	O
Abnormalities	O
of	O
I	O
or	O
more	O
signaling	B
molecules	I
were	O
found	O
in	O
9	O
of	O
14	O
patients	O
;	O
however	O
,	O
only	O
3	O
patients	O
had	O
T	O
cells	O
that	O
exhibited	O
all	O
5	O
defects	O
.	O
Our	O
data	O
have	O
implications	O
for	O
the	O
detection	O
of	O
potentially	O
dysfunctional	O
T	O
cells	O
in	O
patients	O
with	O
cancer	O
.	O
For	O
example	O
,	O
the	O
analysis	O
of	O
only	O
1	O
signaling	B
molecule	I
may	O
allow	O
patients	O
with	O
significant	O
defects	O
in	O
T	O
-	O
cell	O
signaling	O
to	O
go	O
unnoticed	O
.	O
Finally	O
,	O
despite	O
impaired	O
Rel	B
-	I
A	I
translocation	O
,	O
T	O
cells	O
were	O
capable	O
of	O
transcribing	O
IL-2	B
.	O
Impairments	O
in	O
the	O
translocation	O
of	O
Rel	B
-	I
B	I
and	O
c	B
-	I
Rel	I
further	O
suggest	O
that	O
the	O
NFKB	B
family	I
members	I
Rel	B
-	I
A	I
,	O
Rel	B
-	I
B	I
and	O
c	B
-	I
Rel	I
are	O
not	O
required	O
for	O
the	O
transcription	O
of	O
IL-2	B
in	O
the	O
peripheral	O
T	O
lymphocytes	O
of	O
patients	O
with	O
breast	O
cancer	O
.	O
Activation	O
of	O
E2F	B
-mediated	O
transcription	O
by	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
I	I
Tax	I
protein	I
in	O
a	O
p16	O
(	O
INK4A	O
)	O
-negative	O
T	O
-	O
cell	O
line	O
.	O
The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
a	O
causative	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O
Although	O
the	O
exact	O
mechanism	O
by	O
which	O
HTLV	O
-	O
I	O
contributes	O
to	O
leukemogenesis	O
is	O
still	O
unclear	O
,	O
the	O
Tax	B
protein	I
is	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
.	O
This	O
40-kDa	O
polypeptide	O
is	O
able	O
to	O
interact	O
with	O
the	O
tumor	B
suppressor	I
p16	B
(	I
INK4A	I
)	I
.	O
Consequently	O
,	O
Tax	B
can	O
activate	O
the	O
signaling	O
pathway	O
that	O
lead	O
to	O
the	O
release	O
of	O
E2F	B
that	O
in	O
turn	O
induces	O
expression	O
of	O
factors	O
required	O
for	O
cell	O
cycle	O
progression	O
.	O
In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
Tax	B
can	O
also	O
activate	O
E2F	B
-mediated	O
transcription	O
independently	O
of	O
p16	B
(	I
INK4A	I
)	I
.	O
Indeed	O
,	O
when	O
Tax	B
is	O
coexpressed	O
with	O
the	O
E2F-1	B
transcription	B
factor	I
in	O
CEM	O
T	O
-	O
cells	O
,	O
which	O
lack	O
expression	O
of	O
p16	B
(	I
INK4A	I
)	I
,	O
it	O
strongly	O
potentiates	O
the	O
E2F	B
-dependent	O
activation	O
of	O
a	O
reporter	O
construct	O
driven	O
by	O
a	O
promoter	O
containing	O
E2F	O
binding	O
sites	O
.	O
This	O
stimulation	O
is	O
abrogated	O
by	O
mutations	O
affecting	O
the	O
E2F	O
-	O
binding	O
sites	O
.	O
In	O
addition	O
,	O
Tax	B
also	O
stimulates	O
the	O
transcription	O
of	O
the	O
E2F-1	O
gene	O
itself	O
.	O
Using	O
Tax	B
mutants	O
that	O
fail	O
to	O
activate	O
either	O
ATF	B
-or	O
NF	O
-	O
kappaB	O
-	O
dependent	O
promoters	O
and	O
different	O
5	O
'	O
truncation	O
mutants	O
of	O
the	O
E2F-1	O
promoter	O
,	O
we	O
show	O
that	O
the	O
Tax	B
-dependent	O
transcriptional	O
control	O
of	O
the	O
E2F1	O
gene	O
involves	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
ATF	O
binding	O
site	O
located	O
in	O
the	O
E2F-1	O
promoter	O
.	O
Calcineurin	B
and	O
the	O
biological	O
effect	O
of	O
cyclosporine	O
and	O
tacrolimus	O
.	O
The	O
mechanism	O
of	O
the	O
immunosuppressive	O
effect	O
of	O
CyA	O
and	O
FK	O
506	O
can	O
be	O
monitored	O
in	O
vivo	O
in	O
humans	O
.	O
The	O
picture	O
emerging	O
is	O
of	O
a	O
close	O
relationship	O
between	O
drug	O
concentrations	O
and	O
CN	O
inhibition	O
.	O
But	O
many	O
puzzles	O
of	O
the	O
drugs	O
remain	O
.	O
What	O
is	O
the	O
role	O
of	O
CyA	O
in	O
the	O
activation	O
of	O
transforming	B
growth	I
factor	I
-	I
beta	I
(	O
TGF	B
-	I
beta	I
)	O
,	O
particularly	O
in	O
relationship	O
to	O
nephrotoxicity	O
and	O
fibrogenesis	O
?	O
How	O
important	O
are	O
the	O
anti	O
-	O
inflammatory	O
(	O
non	O
T	O
)	O
effects	O
of	O
CyA	O
,	O
and	O
which	O
cells	O
do	O
they	O
operate	O
in	O
?	O
Are	O
there	O
effects	O
of	O
CyA	O
and	O
FK	O
506	O
all	O
attributable	O
to	O
CN	O
inhibition	O
,	O
and	O
how	O
much	O
of	O
them	O
are	O
mediated	O
through	O
the	O
NFATC	B
family	I
of	O
transcription	B
factors	I
?	O
Finally	O
,	O
it	O
would	O
be	O
useful	O
to	O
know	O
what	O
the	O
inhibitory	O
effects	O
of	O
CyA	O
are	O
on	O
tolerance	O
and	O
negative	O
regulatory	O
events	O
.	O
p130	B
,	O
p107	B
,	O
and	O
pRb	B
are	O
differentially	O
regulated	O
in	O
proliferating	O
cells	O
and	O
during	O
cell	O
cycle	O
arrest	O
by	O
alpha	B
-	I
interferon	I
.	O
We	O
have	O
determined	O
how	O
the	O
phosphorylation	O
of	O
the	O
retinoblastoma	B
family	I
(	O
pRb	B
,	O
p107	B
,	O
and	O
p130	B
)	O
is	O
governed	O
in	O
individual	O
cell	O
cycle	O
phases	O
of	O
Daudi	O
B	O
-	O
cells	O
during	O
cell	O
cycle	O
exit	O
triggered	O
by	O
alpha	B
-	I
interferon	I
(	O
alpha	B
-	I
IFN	I
)	O
.	O
alpha	B
-	I
IFN	I
causes	O
dephosphorylation	O
of	O
pRb	B
and	O
loss	O
of	O
p130	B
phosphorylated	I
Form	I
3	I
.	O
However	O
,	O
the	O
change	O
in	O
p130	B
phosphorylation	O
in	O
response	O
to	O
alpha	B
-	I
IFN	I
occurs	O
before	O
dephosphorylation	O
of	O
pRb	B
is	O
complete	O
because	O
loss	O
of	O
p130	B
Form	I
3	I
occurs	O
throughout	O
the	O
cell	O
cycle	O
prior	O
to	O
complete	O
arrest	O
in	O
G1	O
,	O
whereas	O
pRb	B
is	O
dephosphorylated	O
only	O
in	O
G1	O
.	O
In	O
contrast	O
,	O
p107	B
is	O
dephosphorylated	O
and	O
is	O
then	O
depleted	O
from	O
cells	O
as	O
they	O
exit	O
the	O
cell	O
cycle	O
.	O
p130	B
,	O
predominantly	O
in	O
Form	O
1	O
,	O
and	O
hypophosphorylated	B
pRb	I
bind	O
an	O
E2F	O
DNA	O
binding	O
site	O
;	O
p130	B
complexes	O
E2F-4	B
,	O
whereas	O
pRb	B
binds	O
both	O
E2F-4	O
and	O
E2F-1	B
.	O
The	O
phosphorylated	O
forms	O
of	O
E2F-4	B
that	O
bind	O
to	O
the	O
E2F	O
DNA	O
site	O
are	O
different	O
from	O
hyperphosphorylated	O
E2F-4	B
,	O
which	O
predominates	O
in	O
primary	O
hemopoietic	O
cells	O
in	O
G0	O
.	O
We	O
conclude	O
that	O
although	O
cell	O
cycle	O
arrest	O
induced	O
by	O
alpha	B
-	I
IFN	I
may	O
be	O
mediated	O
in	O
part	O
by	O
formation	O
of	O
a	O
complex	O
containing	O
p130	B
and	O
E2F-4	B
,	O
alpha	B
-	I
IFN	I
does	O
not	O
induce	O
hyperphosphorylation	O
of	O
E2F-4	B
,	O
which	O
characterizes	O
primary	O
hemopoietic	O
cells	O
in	O
G0	O
.	O
A	O
p56lck	B
-independent	O
pathway	O
of	O
CD2	B
signaling	O
involves	O
Jun	B
kinase	I
.	O
The	O
p56	B
Src	I
family	I
non	I
-	I
receptor	I
tyrosine	I
kinase	I
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
T	O
lymphocyte	O
differentiation	O
and	O
activation	O
.	O
Hence	O
in	O
the	O
absence	O
of	O
p56	B
,	O
T	B
cell	I
receptor	I
triggered	O
activation	O
does	O
not	O
occur	O
.	O
We	O
now	O
provide	O
evidence	O
for	O
a	O
CD2	B
-based	O
signaling	O
pathway	O
which	O
,	O
in	O
contrast	O
to	O
that	O
of	O
the	O
T	B
cell	I
receptor	I
,	O
is	O
independent	O
of	O
p56	B
.	O
CD2	B
-mediated	O
interleukin-2	B
production	O
occurs	O
via	O
activation	O
of	O
Jun	B
kinase	I
in	O
cell	O
lines	O
lacking	O
p56	B
.	O
Jun	B
kinase	I
then	O
facilitates	O
the	O
binding	O
of	O
c	B
-	I
Jun	I
/	I
c	I
-	I
Fos	I
heterodimers	I
to	O
the	O
AP-1	O
consensus	O
site	O
and	O
the	O
subsequent	O
transcriptional	O
activity	O
of	O
the	O
interleukin-2	O
promoter	O
.	O
These	O
data	O
elucidate	O
differences	O
between	O
TCR	B
and	O
CD2	B
signaling	O
pathways	O
in	O
the	O
same	O
T	O
cells	O
.	O
Establishment	O
and	O
characterization	O
of	O
EBV	O
-	O
positive	O
and	O
EBV	O
-	O
negative	O
primary	O
effusion	O
lymphoma	O
cell	O
lines	O
harbouring	O
human	O
herpesvirus	O
type-8	O
.	O
In	O
this	O
study	O
we	O
report	O
on	O
the	O
establishment	O
and	O
characterization	O
of	O
two	O
novel	O
lymphoma	O
cell	O
lines	O
(	O
CRO	O
-	O
AP	O
/	O
3	O
and	O
CRO	O
-	O
AP	O
/	O
5	O
)	O
which	O
carry	O
infection	O
by	O
human	O
herpesvirus	O
type-8	O
(	O
HHV-8	O
)	O
and	O
have	O
derived	O
from	O
AIDS	O
-	O
related	O
primary	O
effusion	O
lymphoma	O
(	O
PEL	O
)	O
.	O
These	O
two	O
cell	O
lines	O
are	O
representative	O
of	O
different	O
virologic	O
subtypes	O
of	O
PEL	O
,	O
i.e	O
.	O
HHV-8+	O
/	O
EBV-	O
PEL	O
in	O
the	O
case	O
of	O
CRO	O
-	O
AP	O
/	O
3	O
and	O
HHV-8+	O
/	O
EBV+	O
PEL	O
in	O
the	O
case	O
of	O
CRO	O
-	O
AP	O
/	O
5	O
.	O
Consistent	O
with	O
the	O
diagnosis	O
of	O
PEL	O
,	O
both	O
CRO	O
-	O
AP	O
/	O
3	O
and	O
CRO	O
-	O
AP	O
/	O
5	O
expressed	O
indeterminate	O
(	O
i.e.	O
non	O
-	O
B	O
,	O
non	O
-	O
T	O
)	O
phenotypes	O
although	O
immunogenotypic	O
studies	O
documented	O
their	O
B	O
-	O
cell	O
origin	O
.	O
Both	O
cell	O
lines	O
are	O
devoid	O
of	O
genetic	O
lesions	O
of	O
c	B
-	I
MYC	I
,	O
BCL-2	B
and	O
p53	B
as	O
well	O
as	O
gross	O
rearrangements	O
of	O
BCL-6	B
.	O
Detailed	O
histogenetic	O
characterization	O
of	O
these	O
novel	O
PEL	O
cell	O
lines	O
suggests	O
that	O
PEL	O
may	O
derive	O
from	O
a	O
post	O
-	O
germinal	O
centre	O
B	O
cell	O
which	O
has	O
undergone	O
pre	O
-	O
terminal	O
differentiation	O
.	O
The	O
CRO	O
-	O
AP	O
/	O
3	O
and	O
CRO	O
-	O
AP	O
/	O
5	O
cell	O
lines	O
may	O
provide	O
a	O
valuable	O
model	O
for	O
clarifying	O
the	O
pathogenesis	O
of	O
PEL	O
.	O
In	O
particular	O
,	O
these	O
cell	O
lines	O
may	O
help	O
understand	O
the	O
relative	O
contribution	O
of	O
HHV-8	O
and	O
EBV	O
to	O
PEL	O
growth	O
and	O
development	O
and	O
may	O
facilitate	O
the	O
identification	O
of	O
recurrent	O
cytogenetic	O
abnormalities	O
highlighting	O
putative	O
novel	O
cancer	O
related	O
loci	O
relevant	O
to	O
PEL	O
.	O
Phosphatidylinositides	O
bind	O
to	O
plasma	B
membrane	I
CD14	I
and	O
can	O
prevent	O
monocyte	O
activation	O
by	O
bacterial	O
lipopolysaccharide	O
.	O
Although	O
bacterial	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
several	O
other	O
microbial	O
agonists	O
can	O
bind	O
to	O
mCD14	B
(	O
membrane	B
CD14	I
)	O
,	O
a	O
cell	O
-	O
surface	O
receptor	O
found	O
principally	O
on	O
monocytes	O
and	O
neutrophils	O
,	O
host	O
-	O
derived	O
mCD14	B
ligands	O
are	O
poorly	O
defined	O
.	O
We	O
report	O
here	O
that	O
phosphatidylinositol	O
(	O
PtdIns	O
)	O
,	O
phosphatidylinositol-4-phosphate	O
,	O
and	O
other	O
phosphatidylinositides	O
can	O
bind	O
to	O
mCD14	B
.	O
Phosphatidylserine	O
(	O
PS	O
)	O
,	O
another	O
anionic	O
glycerophospholipid	O
,	O
binds	O
to	O
mCD14	B
with	O
lower	O
apparent	O
affinity	O
than	O
does	O
PtdIns	O
.	O
LPS	B
-	I
binding	I
protein	I
,	O
a	O
lipid	O
transfer	O
protein	O
found	O
in	O
serum	O
,	O
facilitates	O
both	O
PS	O
-and	O
PtdIns-	O
mCD14	B
binding	O
.	O
PtdIns	O
binding	O
to	O
mCD14	B
can	O
be	O
blocked	O
by	O
anti	B
-	I
CD14	I
monoclonal	I
antibodies	I
that	O
inhibit	O
LPS	O
-mCD14	B
binding	O
,	O
and	O
PtdIns	O
can	O
inhibit	O
both	O
LPS	O
-mCD14	B
binding	O
and	O
LPS	O
-	O
induced	O
responses	O
in	O
monocytes	O
.	O
Serum	O
-	O
equilibrated	O
PtdIns	O
also	O
binds	O
to	O
mCD14-expressing	O
cells	O
,	O
raising	O
the	O
possibility	O
that	O
endogenous	O
PtdIns	O
may	O
modulate	O
cellular	O
responses	O
to	O
LPS	O
and	O
other	O
mCD14	B
ligands	O
in	O
vivo	O
.	O
Low	O
CD3+CD28-induced	O
interleukin-2	B
production	O
correlates	O
with	O
decreased	O
reactive	O
oxygen	O
intermediate	O
formation	O
in	O
neonatal	O
T	O
cells	O
.	O
The	O
capacity	O
of	O
neonatal	O
T	O
cells	O
to	O
secrete	O
interleukin-2	B
(	O
IL-2	B
)	O
has	O
been	O
reported	O
to	O
be	O
variable	O
.	O
We	O
analysed	O
IL-2	B
production	O
in	O
purified	O
neonatal	O
and	O
adult	O
T	O
cells	O
using	O
polyclonal	O
activator	O
phorbol	O
ester	O
+	O
calcium	O
ionophore	O
(	O
PDBu	O
+	O
iono	O
)	O
or	O
receptor	O
-	O
mediated	O
anti	B
-	I
CD3	I
/anti	O
-	O
CD3	O
+	O
anti	B
-	I
CD28	I
stimulation	O
.	O
PDBu	O
+	O
iono	O
induced	O
equally	O
high	O
IL-2	B
levels	O
in	O
both	O
groups	O
and	O
,	O
when	O
stimulated	O
with	O
plate	O
-	O
bound	O
anti	B
-	I
CD3	I
monoclonal	I
antibody	I
(	O
mAb	B
)	O
,	O
the	O
IL-2	B
secretion	O
by	O
neonatal	O
cells	O
was	O
undetectable	O
and	O
adult	O
cells	O
produced	O
low	O
amounts	O
of	O
IL-2	B
(	O
mean	O
331	O
+	O
/-	O
86	O
pg	O
/	O
ml	O
)	O
.	O
The	O
addition	O
of	O
anti	B
-	I
CD28	I
mAb	I
to	O
anti	O
-	O
CD3-stimulated	O
cells	O
markedly	O
increased	O
IL-2	B
production	O
in	O
both	O
cell	O
types	O
,	O
but	O
levels	O
of	O
IL-2	B
in	O
neonatal	O
T	O
cells	O
remained	O
clearly	O
lower	O
than	O
those	O
of	O
adult	O
T	O
cells	O
(	O
respective	O
mean	O
values	O
:	O
385	O
+	O
/-	O
109	O
pg	O
/	O
ml	O
and	O
4494	O
+	O
/-	O
1199	O
pg	O
/	O
ml	O
)	O
.	O
As	O
NF	B
-	I
kappa	I
B	I
is	O
a	O
critical	O
transcription	B
factor	I
in	O
the	O
control	O
of	O
IL-2	B
expression	O
,	O
we	O
next	O
analysed	O
its	O
nuclear	O
translocation	O
in	O
neonatal	O
and	O
adult	O
T	O
cells	O
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
,	O
because	O
induction	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
is	O
required	O
for	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
we	O
also	O
analysed	O
levels	O
of	O
intracellular	O
ROI	O
in	O
these	O
cells	O
using	O
the	O
ROI	O
-	O
reactive	O
fluorochrome	O
DCFH	O
-	O
DA	O
and	O
flow	O
cytometry	O
.	O
In	O
neonatal	O
T	O
cells	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
ROI	O
formation	O
after	O
anti	B
-	I
CD3	I
stimulation	O
were	O
low	O
compared	O
with	O
adult	O
T	O
cells	O
and	O
,	O
although	O
addition	O
of	O
anti	B
-	I
CD28	I
mAb	I
increased	O
induction	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
ROI	O
formation	O
,	O
levels	O
similar	O
to	O
those	O
of	O
adults	O
were	O
not	O
achieved	O
.	O
After	O
PDBu	O
+	O
iono	O
stimulation	O
,	O
the	O
cells	O
showed	O
similar	O
ROI	O
formation	O
and	O
IL-2	B
secretion	O
.	O
Our	O
results	O
suggest	O
that	O
reduced	O
IL-2	B
production	O
by	O
neonatal	O
T	O
cells	O
is	O
specific	O
for	O
anti	B
-	I
CD3	I
and	O
anti	B
-	I
CD3	I
+	O
anti	B
-	I
CD28	I
-mediated	O
stimulation	O
and	O
that	O
these	O
activators	O
can	O
not	O
effectively	O
activate	O
the	O
ROI	O
-NF	B
-	I
kappa	I
B	I
signalling	O
pathway	O
in	O
neonatal	O
T	O
cells	O
.	O
The	O
AD1	B
and	O
AD2	B
transactivation	O
domains	O
of	O
E2A	B
are	O
essential	O
for	O
the	O
antiapoptotic	O
activity	O
of	O
the	O
chimeric	B
oncoprotein	I
E2A	B
-	I
HLF	I
.	O
The	O
chimeric	B
oncoprotein	I
E2A	B
-	I
HLF	I
,	O
generated	O
by	O
the	O
t	O
(	O
17	O
;	O
19	O
)	O
chromosomal	O
translocation	O
in	O
pro	O
-	O
B	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
,	O
incorporates	O
the	O
transactivation	B
domains	I
of	O
E2A	B
and	O
the	O
basic	B
leucine	I
zipper	I
(	I
bZIP	I
)	I
DNA	I
-	I
binding	I
and	I
protein	I
dimerization	I
domain	I
of	O
HLF	B
(	O
hepatic	B
leukemic	I
factor	I
)	O
.	O
The	O
ability	O
of	O
E2A	B
-	I
HLF	I
to	O
prolong	O
the	O
survival	O
of	O
interleukin-3	O
(	O
IL-3	O
)	O
-dependent	O
murine	O
pro	O
-	O
B	O
cells	O
after	O
IL-3	B
withdrawal	O
suggests	O
that	O
it	O
disrupts	O
signaling	O
pathways	O
normally	O
responsible	O
for	O
cell	O
suicide	O
,	O
allowing	O
the	O
cells	O
to	O
accumulate	O
as	O
transformed	O
lymphoblasts	O
.	O
To	O
determine	O
the	O
structural	O
motifs	O
that	O
contribute	O
to	O
this	O
antiapoptotic	O
effect	O
,	O
we	O
constructed	O
a	O
panel	O
of	O
E2A	B
-	I
HLF	I
mutants	I
and	O
programmed	O
their	O
expression	O
in	O
IL-3-dependent	O
murine	O
pro	O
-	O
B	O
cells	O
(	O
FL5.12	O
line	O
)	O
,	O
using	O
a	O
zinc	O
-	O
inducible	O
vector	O
.	O
Neither	O
the	O
E12	B
nor	O
the	O
E47	B
product	O
of	O
the	O
E2A	O
gene	O
nor	O
the	O
wild	B
-	I
type	I
HLF	I
protein	I
was	O
able	O
to	O
protect	O
the	O
cells	O
from	O
apoptosis	O
induced	O
by	O
IL-3	B
deprivation	O
.	O
Surprisingly	O
,	O
different	O
combinations	O
of	O
disabling	O
mutations	O
within	O
the	O
HLF	B
bZIP	I
domain	I
had	O
little	O
effect	O
on	O
the	O
antiapoptotic	O
property	O
of	O
the	O
chimeric	B
protein	I
,	O
so	O
long	O
as	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
E2A	B
remained	O
intact	O
.	O
In	O
the	O
context	O
of	O
a	O
bZIP	B
domain	I
defective	O
in	O
DNA	O
binding	O
,	O
mutants	O
retaining	O
either	O
of	O
the	O
two	O
transactivation	B
domains	I
of	O
E2A	B
were	O
able	O
to	O
extend	O
cell	O
survival	O
after	O
growth	B
factor	I
deprivation	O
.	O
Thus	O
,	O
the	O
block	O
of	O
apoptosis	O
imposed	O
by	O
E2A	B
-	I
HLF	I
in	O
pro	O
-	O
B	O
lymphocytes	O
depends	O
critically	O
on	O
the	O
transactivating	B
regions	I
of	O
E2A	B
.	O
Since	O
neither	O
DNA	O
binding	O
nor	O
protein	O
dimerization	O
through	O
the	O
bZIP	B
domain	I
of	O
HLF	B
is	O
required	O
for	O
this	O
effect	O
,	O
we	O
propose	O
mechanisms	O
whereby	O
protein	O
-	O
protein	O
interactions	O
with	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
E2A	B
allow	O
the	O
chimera	B
to	O
act	O
as	O
a	O
transcriptional	O
cofactor	O
to	O
alter	O
the	O
expression	O
of	O
genes	O
regulating	O
the	O
apoptotic	O
machinery	O
in	O
pro	O
-	O
B	O
cells	O
.	O
Altered	B
DNA	I
-	I
binding	I
specificity	I
mutants	I
of	O
EKLF	B
and	O
Sp1	O
show	O
that	O
EKLF	B
is	O
an	O
activator	O
of	O
the	O
beta	O
-	O
globin	O
locus	O
control	O
region	O
in	O
vivo	O
.	O
The	O
locus	O
control	O
region	O
of	O
the	O
beta	O
-	O
globin	O
cluster	O
contains	O
five	O
DNase	O
I	O
hypersensitive	O
sites	O
(	O
5'HS1	O
-	O
5	O
)	O
required	O
for	O
locus	O
activation	O
.	O
5'HS3	O
contains	O
six	O
G	O
-	O
rich	O
motifs	O
that	O
are	O
essential	O
for	O
its	O
activity	O
.	O
Members	O
of	O
a	O
protein	O
family	O
,	O
characterized	O
by	O
three	O
zinc	B
fingers	I
highly	O
homologous	O
to	O
those	O
found	O
in	O
transcription	B
factor	I
Sp1	I
,	O
interact	O
with	O
these	O
motifs	O
.	O
Because	O
point	O
mutagenesis	O
can	O
not	O
distinguish	O
between	O
family	O
members	O
,	O
it	O
is	O
not	O
known	O
which	O
protein	O
activates	O
5'HS3	O
.	O
We	O
show	O
that	O
the	O
function	O
of	O
such	O
closely	O
related	O
proteins	O
can	O
be	O
distinguished	O
in	O
vivo	O
by	O
matching	O
point	O
mutations	O
in	O
5'HS3	O
with	O
amino	O
acid	O
changes	O
in	O
the	O
zinc	B
fingers	I
of	O
Sp1	B
and	O
EKLF	B
.	O
Testing	O
their	O
activity	O
in	O
transgenic	O
mice	O
shows	O
that	O
EKLF	B
is	O
a	O
direct	O
activator	O
of	O
5'HS3	O
.	O
A	O
novel	O
mutation	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
FY*B	O
allele	O
of	O
the	O
Duffy	O
chemokine	O
receptor	O
gene	O
is	O
associated	O
with	O
an	O
altered	O
erythrocyte	O
phenotype	O
.	O
The	O
Duffy	O
blood	O
group	O
system	O
is	O
of	O
clinical	O
and	O
biological	O
significance	O
.	O
Antibodies	B
to	O
Duffy	B
antigens	I
are	O
responsible	O
for	O
some	O
cases	O
of	O
transfusion	O
incompatibility	O
and	O
newborn	O
hemolytic	O
disease	O
.	O
The	O
Duffy	B
protein	I
is	O
a	O
receptor	O
for	O
the	O
Plasmodium	B
vivax	I
erythrocyte	I
-	I
binding	I
protein	I
and	O
is	O
also	O
a	O
receptor	O
for	O
various	O
chemokines	B
(	O
thus	O
renamed	O
Duffy	B
Antigen	I
Receptor	I
for	I
Chemokines	I
[	O
DARC	B
]	O
)	O
.	O
The	O
two	O
Duffy	B
polymorphic	I
antigens	I
,	O
Fya	B
and	O
Fyb	B
(	O
coded	O
by	O
the	O
FY*A	O
and	O
FY*B	O
alleles	O
)	O
,	O
are	O
present	O
on	O
erythrocyte	B
membranes	I
.	O
The	O
Fy	O
(	O
a	O
-	O
b-	O
)	O
phenotype	O
is	O
the	O
predominant	O
one	O
in	O
populations	O
of	O
black	O
people	O
and	O
also	O
occurs	O
in	O
other	O
populations	O
,	O
including	O
some	O
non	O
-	O
Ashkenazi	O
Jewish	O
groups	O
.	O
The	O
Fy	O
(	O
a	O
-	O
b-	O
)	O
phenotype	O
has	O
been	O
associated	O
with	O
a	O
mutation	O
in	O
the	O
FY*B	O
promoter	O
at	O
the	O
GATA	O
box	O
that	O
abolishes	O
the	O
expression	O
of	O
erythrocyte	B
Duffy	I
protein	I
.	O
We	O
describe	O
here	O
a	O
novel	O
mutation	O
,	O
present	O
in	O
the	O
FY*B	O
coding	O
sequence	O
(	O
271C	O
--	O
>	O
T	O
)	O
,	O
that	O
is	O
associated	O
with	O
some	O
Fy	O
(	O
b-	O
)	O
phenotypes	O
among	O
non	O
-	O
Ashkenazi	O
Jews	O
and	O
among	O
Brazilian	O
blacks	O
.	O
The	O
mutation	O
is	O
present	O
in	O
Fy	O
(	O
b-	O
)	O
individuals	O
,	O
who	O
have	O
wild	O
-	O
type	O
FY*B	O
GATA	O
and	O
carry	O
the	O
previously	O
described	O
304	O
G	O
--	O
>	O
A	O
substitution	O
.	O
The	O
271C	O
--	O
>	O
T	O
and	O
304	O
G	O
--	O
>	O
A	O
can	O
be	O
identified	O
by	O
restriction	O
enzyme	O
-	O
generated	O
restriction	O
fragment	O
length	O
polymorphisms	O
.	O
The	O
271C	O
--	O
>	O
T	O
substitution	O
represents	O
a	O
considerable	O
change	O
in	O
chemical	O
nature	O
(	O
Arg91	O
--	O
>	O
Cys	O
)	O
,	O
one	O
which	O
may	O
affect	O
the	O
antigenic	O
determinants	O
of	O
DARC	B
,	O
and	O
thus	O
be	O
of	O
clinical	O
significance	O
.	O
The	O
mutation	O
may	O
have	O
implications	O
for	O
some	O
physiological	O
roles	O
of	O
DARC	B
and	O
be	O
of	O
interest	O
in	O
malaria	O
research	O
and	O
in	O
studies	O
of	O
population	O
genetics	O
.	O
BCL-6	B
mutations	O
in	O
normal	O
germinal	O
center	O
B	O
cells	O
:	O
evidence	O
of	O
somatic	O
hypermutation	O
acting	O
outside	O
Ig	O
loci	O
.	O
The	O
molecular	O
mechanism	O
involved	O
in	O
the	O
process	O
of	O
antigen	O
-	O
driven	O
somatic	O
hypermutation	O
of	O
Ig	O
genes	O
is	O
unknown	O
,	O
but	O
it	O
is	O
commonly	O
believed	O
that	O
this	O
mechanism	O
is	O
restricted	O
to	O
the	O
Ig	O
loci	O
.	O
B	O
cell	O
lymphomas	O
commonly	O
display	O
multiple	O
somatic	O
mutations	O
clustering	O
in	O
the	O
5'-regulatory	O
region	O
of	O
BCL-6	B
,	O
a	O
proto	O
-	O
oncogene	O
encoding	O
for	O
a	O
POZ	B
/	I
Zinc	I
finger	I
transcriptional	I
repressor	I
expressed	O
in	O
germinal	O
center	O
(	O
GC	O
)	O
B	O
cells	O
and	O
required	O
for	O
GC	O
formation	O
.	O
To	O
determine	O
whether	O
BCL-6	B
mutations	O
represent	O
a	O
tumor	O
-	O
associated	O
phenomenon	O
or	O
reflect	O
a	O
physiologic	O
mechanism	O
,	O
we	O
screened	O
single	O
human	O
tonsillar	O
GC	O
B	O
cells	O
for	O
mutations	O
occurring	O
in	O
the	O
BCL-6	O
5'-noncoding	O
region	O
and	O
in	O
the	O
Ig	O
variable	O
heavy	O
chain	O
sequences	O
.	O
Thirty	O
percent	O
of	O
GC	O
B	O
cells	O
,	O
but	O
not	O
naive	O
B	O
cells	O
,	O
displayed	O
mutations	O
in	O
the	O
742	O
bp	O
region	O
analyzed	O
within	O
the	O
first	O
intron	O
of	O
BCL-6	B
(	O
overall	O
frequency	O
:	O
5	O
x	O
10	O
(	O
-4	O
)	O
/bp	O
)	O
.	O
Accordingly	O
,	O
an	O
expanded	O
survey	O
in	O
lymphoid	O
malignancies	O
showed	O
that	O
BCL-6	B
mutations	O
are	O
restricted	O
to	O
B	O
cell	O
tumors	O
displaying	O
GC	O
or	O
post	O
-	O
GC	O
phenotype	O
and	O
carrying	O
mutated	O
Ig	O
variable	O
heavy	O
chain	O
sequences	O
.	O
These	O
results	O
indicate	O
that	O
the	O
somatic	O
hypermutation	O
mechanism	O
active	O
in	O
GC	O
B	O
cells	O
physiologically	O
targets	O
non	O
-	O
Ig	O
sequences	O
.	O
Transcription	B
factor	I
activation	O
in	O
lymphokine	O
activated	O
killer	O
cells	O
and	O
lymphocytes	O
from	O
patients	O
receiving	O
IL-2	B
immunotherapy	O
.	O
Administration	O
of	O
the	O
cytokine	B
interleukin-2	I
(	O
IL-2	B
)	O
can	O
result	O
in	O
therapeutic	O
benefits	O
for	O
individuals	O
with	O
renal	O
cell	O
carcinoma	O
and	O
melanoma	O
.	O
Here	O
we	O
report	O
an	O
analysis	O
of	O
the	O
transcription	O
factor	O
families	O
AP-1	O
,	O
Sp1	O
,	O
NF	B
-	I
kappaB	I
,	O
and	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	O
STAT	B
)	O
in	O
cancer	O
patients	O
'	O
lymphocytes	O
before	O
and	O
after	O
IL-2	B
immunotherapy	O
,	O
as	O
assessed	O
by	O
a	O
gel	O
-	O
shift	O
assay	O
.	O
An	O
in	O
vitro	O
surrogate	O
of	O
IL-2	B
immunotherapy	O
is	O
the	O
incubation	O
of	O
fresh	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
from	O
healthy	O
individuals	O
in	O
IL-2	B
for	O
several	O
days	O
,	O
resulting	O
in	O
the	O
production	O
of	O
lymphokine	B
-activated	O
killer	O
(	O
LAK	O
)	O
activity	O
in	O
these	O
cultures	O
.	O
One	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
profile	O
of	O
transcription	O
factor	O
activation	O
in	O
these	O
different	O
populations	O
,	O
and	O
assess	O
whether	O
the	O
patterns	O
observed	O
correlated	O
with	O
functional	O
differences	O
in	O
these	O
cells	O
.	O
Prior	O
to	O
in	O
vivo	O
IL-2	B
administration	O
,	O
the	O
typical	O
binding	O
pattern	O
of	O
transcription	B
factors	I
in	O
PBMC	O
from	O
patients	O
resembled	O
that	O
seen	O
in	O
fresh	O
PBMC	O
from	O
healthy	O
individuals	O
.	O
Over	O
a	O
3-week	O
course	O
of	O
IL-2	B
therapy	O
,	O
in	O
most	O
patients	O
the	O
binding	O
patterns	O
of	O
AP-1	B
,	O
Sp1	B
,	O
and	O
NF	B
-	I
kappaB	I
proteins	O
changed	O
to	O
resemble	O
those	O
seen	O
in	O
PBMC	O
activated	O
by	O
IL-2	B
in	O
vitro	O
.	O
However	O
,	O
the	O
cells	O
obtained	O
from	O
IL-2	B
-treated	O
patients	O
did	O
not	O
have	O
low	O
-	O
level	O
constitutive	O
expression	O
of	O
STAT	B
binding	I
factors	I
as	O
did	O
LAK	B
cells	I
.	O
When	O
these	O
patient	O
cells	O
were	O
further	O
stimulated	O
by	O
IL-2	B
in	O
vitro	O
,	O
additional	O
differences	O
in	O
STAT	B
induction	O
patterns	O
were	O
noted	O
.	O
These	O
data	O
provide	O
further	O
information	O
on	O
the	O
molecular	O
events	O
occurring	O
in	O
immune	O
cells	O
generated	O
through	O
in	O
vivo	O
and	O
in	O
vitro	O
administration	O
of	O
IL-2	B
,	O
and	O
further	O
document	O
that	O
there	O
is	O
not	O
a	O
precise	O
congruence	O
between	O
PBMC	O
activated	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
IL-2	B
.	O
Position	O
effect	O
of	O
translocations	O
involving	O
the	O
inactive	O
X	O
chromosome	O
:	O
physical	O
linkage	O
to	O
XIC	O
/	O
XIST	O
does	O
not	O
lead	O
to	O
long	O
-	O
range	O
de	O
novo	O
inactivation	O
in	O
human	O
differentiated	O
cells	O
.	O
Given	O
the	O
reported	O
long	O
-	O
range	O
cis	O
-	O
inactivating	O
effect	O
of	O
the	O
XIST	O
gene	O
in	O
early	O
embryonic	O
development	O
and	O
the	O
lack	O
of	O
requirement	O
of	O
X	O
-	O
chromosome	O
-	O
specific	O
elements	O
for	O
propagating	O
the	O
inactive	O
state	O
,	O
there	O
exists	O
the	O
possibility	O
of	O
cis	O
inactivation	O
of	O
autosomal	O
material	O
after	O
de	O
novo	O
translocation	O
to	O
an	O
inactive	O
X	O
chromosome	O
(	O
Xi	O
)	O
in	O
differentiated	O
cells	O
.	O
We	O
have	O
analyzed	O
de	O
novo	O
radiation	O
-	O
induced	O
translocations	O
between	O
the	O
Xi	O
and	O
autosomes	O
to	O
study	O
the	O
maintenance	O
and	O
spreading	O
of	O
X	O
-	O
chromosome	O
inactivation	O
(	O
X	O
inactivation	O
)	O
in	O
relation	O
to	O
the	O
position	O
of	O
the	O
X	O
-	O
inactivation	O
center	O
(	O
XIC	O
)	O
/XIST	O
in	O
differentiated	O
cells	O
.	O
Autosome	O
/	O
Xi	O
translocations	O
were	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O
The	O
activation	O
status	O
of	O
the	O
chromosomes	O
involved	O
in	O
the	O
translocation	O
was	O
determined	O
by	O
simultaneous	O
immunocytogenetic	O
studies	O
using	O
antibodies	B
against	O
either	O
BrdU	B
incorporated	O
at	O
late	O
S	O
phase	O
or	O
acetylated	B
histone	I
H4	I
.	O
The	O
position	O
of	O
XIC	O
/	O
XIST	O
in	O
the	O
reciprocal	O
products	O
of	O
the	O
translocation	O
was	O
determined	O
by	O
XIST	O
-	O
specific	O
FISH	O
and	O
computer	O
enhancement	O
.	O
In	O
other	O
experiments	O
,	O
the	O
Xq13	O
region	O
carrying	O
XIC	O
/	O
XIST	O
was	O
localized	O
by	O
computer	O
enhancement	O
of	O
the	O
DAPI	O
banding	O
pattern	O
.	O
Our	O
study	O
in	O
differentiated	O
cells	O
provides	O
a	O
visual	O
demonstration	O
that	O
physical	O
separation	O
from	O
XIC	O
/	O
XIST	O
does	O
not	O
result	O
in	O
reactivation	O
of	O
inactive	O
X	O
-	O
chromosome	O
material	O
and	O
that	O
X	O
inactivation	O
is	O
not	O
spread	O
to	O
the	O
translocated	O
autosomes	O
irrespective	O
of	O
the	O
position	O
of	O
XIC	O
/	O
XIST	O
.	O
This	O
observation	O
suggests	O
that	O
physical	O
linkage	O
to	O
XIC	O
/	O
XIST	O
does	O
not	O
lead	O
to	O
de	O
novo	O
inactivation	O
of	O
autosomal	O
material	O
.	O
The	O
interleukin	O
2	O
receptor	O
alpha	O
chain	O
/	O
CD25	O
promoter	O
is	O
a	O
target	O
for	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
.	O
The	O
expression	O
of	O
the	O
murine	B
interleukin	I
(	I
IL	I
)	I
-2	I
receptor	I
alpha	I
chain	I
/	I
CD25	I
is	O
strongly	O
induced	O
at	O
the	O
transcriptional	O
level	O
after	O
T	O
cell	O
activation	O
.	O
We	O
show	O
here	O
that	O
nuclear	B
factor	I
of	I
activated	I
T	I
cell	I
(	I
NF	I
-	I
AT	I
)	I
factors	I
are	O
involved	O
in	O
the	O
control	O
of	O
CD25	O
promoter	O
induction	O
in	O
T	O
cells	O
.	O
NF	B
-	I
ATp	I
and	O
NF	B
-	I
ATc	I
bind	O
to	O
two	O
sites	O
around	O
positions	O
-585	O
and	O
-650	O
located	O
upstream	O
of	O
the	O
proximal	O
CD25	O
promoter	O
.	O
Immediately	O
3	O
'	O
from	O
these	O
NF	O
-	O
AT	O
motifs	O
,	O
nonconsensus	O
sites	O
are	O
located	O
for	O
the	O
binding	O
of	O
AP-1-like	B
factors	I
.	O
Mutations	O
of	O
sites	O
that	O
suppress	O
NF	B
-	I
AT	I
binding	O
impair	O
the	O
induction	O
and	O
strong	O
NF	B
-	I
ATp	I
-mediated	O
transactivation	O
of	O
the	O
CD25	O
promoter	O
in	O
T	O
cells	O
.	O
In	O
T	O
lymphocytes	O
from	O
NF	B
-	I
ATp	I
-deficient	O
mice	O
,	O
the	O
expression	O
of	O
CD25	B
is	O
severely	O
impaired	O
,	O
leading	O
to	O
a	O
delayed	O
IL-2	B
receptor	I
expression	O
after	O
T	O
cell	O
receptor	O
(	O
TCR	B
)	O
/	O
CD3	B
stimulation	O
.	O
Our	O
data	O
indicate	O
an	O
important	O
role	O
for	O
NF	B
-	I
AT	I
in	O
the	O
faithful	O
expression	O
of	O
high	B
affinity	I
IL-2	I
receptors	I
and	O
a	O
close	O
link	O
between	O
the	O
TCR	B
-mediated	O
induction	O
of	O
IL-2	B
and	O
IL-2	O
receptor	O
alpha	O
chain	O
promoters	O
,	O
both	O
of	O
which	O
are	O
regulated	O
by	O
NF	B
-	I
AT	I
factors	I
.	O
Analysis	O
of	O
cytokine	B
signaling	O
in	O
patients	O
with	O
extrinsic	O
asthma	O
and	O
hyperimmunoglobulin	O
E	O
.	O
BACKGROUND	O
:	O
Recent	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
class	O
switching	O
to	O
IgE	B
by	O
cytokines	B
is	O
mediated	O
by	O
STAT	B
transcription	I
factors	I
.	O
The	O
induction	O
of	O
IgE	B
by	O
IL-4	B
and	O
IL-13	B
occurs	O
through	O
the	O
activation	O
of	O
the	O
intracellular	B
signal	I
-	I
transducing	I
protein	I
Stat6	I
,	O
whereas	O
the	O
inhibition	O
of	O
IgE	B
class	O
switching	O
by	O
interferon	B
-	I
y	I
(	O
IFN	B
-	I
gamma	I
)	O
occurs	O
through	O
the	O
activation	O
of	O
Statl	B
.	O
OBJECTIVE	O
:	O
We	O
hypothesized	O
that	O
in	O
extrinsic	O
asthma	O
or	O
in	O
cases	O
of	O
markedly	O
elevated	O
IgE	B
(	O
ie	O
,	O
hyperimmunoglobulin	O
E	O
[	O
HIE	O
]	O
)	O
increased	O
levels	O
of	O
IgE	B
may	O
be	O
associated	O
with	O
alterations	O
in	O
the	O
cytokine	B
levels	O
or	O
the	O
activation	O
of	O
Stat6	B
.	O
METHODS	O
:	O
PBMCs	O
and	O
sera	O
from	O
8	O
patients	O
with	O
extrinsic	O
asthma	O
(	O
mean	O
IgE	B
,	O
285+	O
/	O
-100	O
IU	O
/	O
mL	O
)	O
,	O
3	O
patients	O
with	O
HIE	O
(	O
mean	O
IgE	B
,	O
7050+	O
/	O
-1122	O
IU	O
/	O
mL	O
)	O
,	O
and	O
14	O
nonatopic	O
control	O
subjects	O
(	O
mean	O
IgE	B
,	O
112+	O
/	O
-28	O
IU	O
/	O
mL	O
)	O
were	O
analyzed	O
.	O
RESULTS	O
:	O
The	O
mean	O
IL-4	B
level	O
detected	O
by	O
ELISA	O
was	O
much	O
greater	O
in	O
patients	O
with	O
HIE	O
than	O
control	O
subjects	O
(	O
88.6+	O
/	O
-11.5	O
pg	O
/	O
mL	O
vs	O
11.5+	O
/	O
-7.1	O
pg	O
/	O
mL	O
,	O
P	O
=	O
.005	O
)	O
,	O
and	O
increased	O
IL-4	B
levels	O
among	O
patients	O
with	O
both	O
asthma	O
and	O
HIE	O
correlated	O
with	O
the	O
increased	O
IgE	B
levels	O
.	O
In	O
contrast	O
,	O
IL-13	B
levels	O
were	O
not	O
elevated	O
.	O
Levels	O
of	O
Stat6	B
protein	O
present	O
in	O
PBMCs	O
did	O
not	O
differ	O
in	O
the	O
patients	O
and	O
control	O
subjects	O
.	O
Examination	O
of	O
Stat6	B
DNA	O
-	O
binding	O
activity	O
demonstrated	O
no	O
activation	O
of	O
IL-4	B
signaling	O
in	O
patients	O
with	O
either	O
HIE	O
or	O
acute	O
asthma	O
.	O
Interestingly	O
,	O
evidence	O
for	O
the	O
presence	O
of	O
B	O
cells	O
that	O
have	O
already	O
switched	O
to	O
IgE	B
was	O
seen	O
in	O
PBMCs	O
of	O
several	O
patients	O
with	O
asthma	O
or	O
HIE	O
.	O
CONCLUSION	O
:	O
These	O
results	O
indicate	O
that	O
(	O
1	O
)	O
IgE	B
production	O
in	O
asthma	O
and	O
HIE	O
usually	O
is	O
associated	O
with	O
elevated	O
levels	O
of	O
IL-4	B
,	O
but	O
not	O
IL-13	B
,	O
in	O
the	O
peripheral	O
blood	O
;	O
(	O
2	O
)	O
the	O
increased	O
sera	O
IL-4	B
levels	O
in	O
asthma	O
and	O
HIE	O
are	O
not	O
sufficient	O
to	O
induce	O
Stat6	B
activation	O
in	O
PBMCs	O
;	O
and	O
(	O
3	O
)	O
evidence	O
of	O
switch	O
recombination	O
to	O
epsilon	O
may	O
be	O
detected	O
in	O
isolated	O
cases	O
of	O
elevated	O
IgE	B
.	O
This	O
implies	O
that	O
high	O
levels	O
of	O
IgE	B
in	O
these	O
patients	O
either	O
results	O
from	O
B	O
cells	O
that	O
have	O
already	O
undergone	O
class	O
switching	O
,	O
from	O
Ig	O
class	O
switching	O
that	O
is	O
localized	O
to	O
target	O
tissues	O
,	O
or	O
both	O
.	O
GATA-3	B
-dependent	O
enhancer	O
activity	O
in	O
IL-4	O
gene	O
regulation	O
.	O
Previously	O
,	O
we	O
analyzed	O
the	O
proximal	O
IL-4	O
promoter	O
in	O
directing	O
Th2-specific	O
activity	O
.	O
An	O
800-base	O
pair	O
proximal	O
promoter	O
conferred	O
some	O
Th2-selective	O
expression	O
in	O
transgenic	O
mice	O
.	O
However	O
,	O
this	O
region	O
directed	O
extremely	O
low	O
reporter	O
mRNA	O
levels	O
relative	O
to	O
endogenous	O
IL-4	O
mRNA	O
,	O
suggesting	O
that	O
full	O
gene	O
activity	O
requires	O
additional	O
enhancer	O
elements	O
.	O
Here	O
,	O
we	O
analyzed	O
large	O
genomic	O
IL-4	O
regions	O
for	O
enhancer	O
activity	O
and	O
interaction	O
with	O
transcription	B
factors	I
.	O
The	O
proximal	O
IL-4	O
promoter	O
is	O
only	O
moderately	O
augmented	O
by	O
GATA-3	B
,	O
but	O
certain	O
genomic	O
regions	O
significantly	O
enhanced	O
GATA-3	O
promoter	O
transactivation	O
.	O
Some	O
enhancing	O
regions	O
contained	O
consensus	O
,	O
GATA	O
sites	O
that	O
bound	O
Th2-specific	B
complexes	I
.	O
However	O
,	O
retroviral	O
transduction	O
of	O
GATA-3	B
into	O
developing	O
T	O
cells	O
induced	O
IL-5	B
to	O
full	O
Th2	B
levels	O
,	O
but	O
only	O
partially	O
restored	O
IL-4	B
production	O
.	O
Thus	O
,	O
we	O
propose	O
that	O
GATA-3	B
is	O
permissive	O
,	O
but	O
not	O
sufficient	O
,	O
for	O
full	O
IL-4	B
enhancement	O
and	O
may	O
act	O
through	O
GATA	O
elements	O
surrounding	O
the	O
IL-13	O
/	O
IL-4	O
gene	O
locus	O
.	O
Downstream	O
activation	O
of	O
a	O
TATA	O
-	O
less	O
promoter	O
by	O
Oct-2	B
,	O
Bob1	O
,	O
and	O
NF	B
-	I
kappaB	I
directs	O
expression	O
of	O
the	O
homing	B
receptor	I
BLR1	I
to	O
mature	O
B	O
cells	O
.	O
The	O
chemokine	B
receptor	I
,	O
BLR1	B
,	O
is	O
a	O
major	O
regulator	O
of	O
the	O
microenvironmental	O
homing	O
of	O
B	O
cells	O
in	O
lymphoid	O
organs	O
.	O
In	O
vitro	O
studies	O
identify	O
three	O
essential	O
elements	O
of	O
the	O
TATA	O
-	O
less	O
blr1	O
core	O
promoter	O
that	O
confer	O
cell	O
type-	O
and	O
differentiation	O
-	O
specific	O
expression	O
in	O
the	O
B	O
cells	O
of	O
both	O
humans	O
and	O
mice	O
,	O
a	O
functional	O
promoter	O
region	O
(	O
-36	O
with	O
respect	O
to	O
the	O
transcription	O
start	O
site	O
)	O
,	O
a	O
NF	O
-	O
kappaB	O
motif	O
(	O
+	O
44	O
)	O
,	O
and	O
a	O
noncanonical	O
octamer	O
motif	O
(	O
+	O
157	O
)	O
.	O
The	O
importance	O
of	O
these	O
sites	O
was	O
confirmed	O
by	O
in	O
vivo	O
studies	O
in	O
gene	O
-	O
targeted	O
mice	O
deficient	O
of	O
either	O
Oct-2	B
,	O
Bob1	B
,	O
or	O
both	O
NF	B
-	I
kappaB	I
subunits	O
p50	O
and	O
p52	O
.	O
In	O
all	O
of	O
these	O
animals	O
,	O
the	O
expression	O
of	O
BLR1	B
was	O
reduced	O
or	O
absent	O
.	O
In	O
mice	O
deficient	O
only	O
of	O
p52	B
/	I
NF	I
-	I
kappaB	I
,	O
BLR1	B
expression	O
was	O
unaffected	O
.	O
Thus	O
our	O
data	O
demonstrate	O
that	O
BLR1	B
is	O
a	O
target	O
gene	O
for	O
Oct-2	B
,	O
Bob1	B
,	O
and	O
members	O
of	O
the	O
NF	B
-	I
kappaB	I
/	I
Rel	I
family	I
and	O
provides	O
a	O
link	O
to	O
the	O
impaired	O
B	O
cell	O
functions	O
in	O
mice	O
deficient	O
for	O
these	O
factors	O
.	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
expression	O
in	O
activated	O
cord	O
and	O
adult	O
lymphocytes	O
:	O
an	O
analysis	O
by	O
Northern	O
hybridization	O
.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
To	O
further	O
analyze	O
the	O
neonatal	O
immune	O
response	O
to	O
an	O
antigenic	O
challenge	O
such	O
as	O
blood	O
transfusion	O
,	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
expression	O
were	O
analyzed	O
in	O
twelve	O
in	O
-	O
vitro	O
-	O
stimulated	O
normal	O
cord	O
blood	O
and	O
ten	O
in	O
-	O
vitro	O
-	O
stimulated	O
normal	O
adult	O
peripheral	O
blood	O
lymphocyte	O
samples	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Lymphocyte	O
samples	O
were	O
stimulated	O
by	O
either	O
the	O
mitogen	B
phytohemagglutinin	I
(	O
PHA	B
)	O
or	O
the	O
monoclonal	O
antibody	O
alphaCD3	B
.	O
Proliferation	O
rate	O
and	O
Northern	O
blot	O
hybridization	O
were	O
employed	O
.	O
RESULTS	O
:	O
Cord	O
lymphocytes	O
revealed	O
a	O
greater	O
proliferation	O
rate	O
with	O
PHA	B
and	O
alphaCD3	B
than	O
adult	O
lymphocytes	O
(	O
p	O
=	O
0.0081	O
and	O
0.0023	O
,	O
respectively	O
)	O
.	O
In	O
addition	O
,	O
Northern	O
blot	O
analysis	O
of	O
cord	O
and	O
adult	O
samples	O
revealed	O
similar	O
maximal	O
increases	O
in	O
c	O
-	O
fos	O
(	O
99+	O
/	O
-15	O
and	O
126+	O
/	O
-11	O
%	O
,	O
p	O
=	O
0.0126	O
)	O
and	O
c	O
-	O
jun	O
(	O
123+	O
/	O
-9	O
and	O
185+	O
/	O
-38	O
%	O
,	O
p	O
=	O
0.0291	O
)	O
mRNA	O
expression	O
,	O
respectively	O
,	O
as	O
early	O
as	O
15	O
min	O
post-	O
alphaCD3	B
stimulation	O
.	O
Adult	O
lymphocytes	O
showed	O
an	O
equivalent	O
increase	O
in	O
mRNA	O
expression	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
(	O
140+	O
/	O
-25	O
and	O
155+	O
/	O
-31	O
%	O
)	O
at	O
30	O
min	O
post-	O
PHA	B
stimulation	O
,	O
while	O
cord	O
lymphocyte	O
maximum	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
expression	O
(	O
82+	O
/	O
-6	O
and	O
142+	O
/	O
-12	O
%	O
)	O
occurred	O
at	O
15	O
min	O
post-	O
PHA	B
stimulation	O
(	O
c	O
-	O
fos	O
,	O
p	O
=	O
0.0354	O
;	O
c	O
-	O
jun	O
,	O
p	O
=	O
0.0112	O
)	O
.	O
CONCLUSION	O
:	O
Although	O
cord	O
lymphocyte	O
proliferation	O
rates	O
were	O
significantly	O
greater	O
than	O
those	O
of	O
adult	O
lymphocytes	O
following	O
stimulation	O
,	O
lymphocyte	O
activation	O
,	O
as	O
analyzed	O
by	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
expression	O
,	O
appears	O
similar	O
in	O
both	O
cord	O
and	O
adult	O
samples	O
.	O
We	O
conclude	O
that	O
cord	O
lymphocyte	O
activation	O
exhibits	O
an	O
adult	O
-	O
type	O
profile	O
.	O
Identification	O
of	O
transcription	B
factors	I
expressed	O
during	O
ATRA	O
-	O
induced	O
neutrophil	O
differentiation	O
of	O
HL60	O
cells	O
.	O
A	O
recent	O
clinical	O
therapeutic	O
initiative	O
has	O
been	O
the	O
use	O
of	O
chemical	O
agents	O
which	O
induce	O
the	O
leukaemic	O
cells	O
to	O
overcome	O
their	O
block	O
in	O
differentiation	O
.	O
In	O
order	O
to	O
understand	O
this	O
block	O
the	O
cascade	O
of	O
molecular	O
events	O
needs	O
to	O
be	O
characterized	O
.	O
Haemopoietic	O
differentiation	O
is	O
ultimately	O
controlled	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
which	O
is	O
mediated	O
by	O
an	O
array	O
of	O
transcription	B
factors	I
.	O
Many	O
transcription	B
factors	I
contain	O
similar	O
structural	B
protein	I
sequences	I
,	O
and	O
we	O
have	O
used	O
an	O
RT	O
-	O
PCR	O
-	O
based	O
approach	O
to	O
isolate	O
sequences	O
,	O
from	O
transcription	B
factor	I
gene	O
families	O
which	O
share	O
similar	O
domains	O
.	O
Degenerate	O
primers	O
corresponding	O
to	O
the	O
TFIIIA	O
zinc	O
-	O
finger	O
consensus	O
amino	O
acid	O
sequences	O
and	O
to	O
the	O
POU	B
-	I
homeodomain	I
and	O
POU	B
-	I
specific	I
domain	I
were	O
used	O
to	O
amplify	O
genes	O
on	O
the	O
basis	O
that	O
they	O
contained	O
similarities	O
in	O
structural	O
motifs	O
shared	O
within	O
these	O
families	O
of	O
transcription	B
factors	I
.	O
A	O
serum	O
-	O
independent	O
HL60	O
cell	O
line	O
was	O
induced	O
towards	O
the	O
neutrophil	O
lineage	O
by	O
treatment	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
for	O
24	O
h	O
.	O
CD38	O
+	O
cells	O
committed	O
towards	O
this	O
lineage	O
were	O
enriched	O
and	O
a	O
population	O
of	O
these	O
cells	O
treated	O
with	O
dihydroxyvitamin	O
D3	O
to	O
induce	O
neutrophil	O
maturation	O
.	O
RNA	O
extracted	O
from	O
uninduced	O
,	O
ATRA	O
-	O
induced	O
CD38	O
+	O
cells	O
,	O
and	O
vitamin	O
D3	O
treated	O
maturing	O
cell	O
cultures	O
were	O
amplified	O
using	O
the	O
degenerate	O
primers	O
.	O
PCR	O
fragments	O
were	O
cloned	O
,	O
sequenced	O
,	O
clustered	O
into	O
homologous	O
groups	O
,	O
and	O
the	O
group	O
sequences	O
searched	O
on	O
the	O
GenBank	O
database	O
.	O
The	O
Oct	O
1	O
transcription	B
factor	I
,	O
and	O
a	O
very	O
close	O
homologue	O
,	O
KIAA0144	O
,	O
was	O
identified	O
using	O
the	O
POU	O
family	O
primers	O
.	O
The	O
zinc	O
-	O
finger	O
primers	O
identified	O
three	O
zinc	O
-	O
finger	O
genes	O
.	O
The	O
pattern	O
of	O
gene	O
expression	O
was	O
suggested	O
from	O
the	O
number	O
of	O
clones	O
in	O
each	O
group	O
at	O
neutrophil	O
commitment	O
and	O
maturation	O
.	O
The	O
differential	O
expression	O
of	O
the	O
genes	O
in	O
the	O
zinc	B
finger	I
and	I
POU	I
families	I
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
cascade	O
of	O
gene	O
expression	O
which	O
occurs	O
following	O
ATRA	O
-	O
induced	O
differentiation	O
.	O
Inhibition	O
of	O
RNA	B
polymerase	I
II	I
transcription	O
in	O
human	O
cells	O
by	O
synthetic	O
DNA	O
-	O
binding	O
ligands	O
[	O
see	O
comments	O
]	O
Sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
small	O
molecules	O
that	O
can	O
permeate	O
human	O
cells	O
potentially	O
could	O
regulate	O
transcription	O
of	O
specific	O
genes	O
.	O
Multiple	O
cellular	B
DNA	I
-	I
binding	I
transcription	I
factors	I
are	O
required	O
by	O
HIV	O
type	O
1	O
for	O
RNA	O
synthesis	O
.	O
Two	O
pyrrole	O
-	O
imidazole	O
polyamides	O
were	O
designed	O
to	O
bind	O
DNA	O
sequences	O
immediately	O
adjacent	O
to	O
binding	O
sites	O
for	O
the	O
transcription	B
factors	I
Ets-1	B
,	O
lymphoid	B
-	I
enhancer	I
binding	I
factor	I
1	I
,	O
and	O
TATA	B
-	I
box	I
binding	I
protein	I
.	O
These	O
synthetic	O
ligands	O
specifically	O
inhibit	O
DNA	O
-	O
binding	O
of	O
each	O
transcription	B
factor	I
and	O
HIV	O
type	O
1	O
transcription	O
in	O
cell	O
-	O
free	O
assays	O
.	O
When	O
used	O
in	O
combination	O
,	O
the	O
polyamides	O
inhibit	O
virus	O
replication	O
by	O
>	O
99	O
%	O
in	O
isolated	O
human	O
peripheral	O
blood	O
lymphocytes	O
,	O
with	O
no	O
detectable	O
cell	O
toxicity	O
.	O
The	O
ability	O
of	O
small	O
molecules	O
to	O
target	O
predetermined	O
DNA	O
sequences	O
located	O
within	O
RNA	O
polymerase	O
II	O
promoters	O
suggests	O
a	O
general	O
approach	O
for	O
regulation	O
of	O
gene	O
expression	O
,	O
as	O
well	O
as	O
a	O
mechanism	O
for	O
the	O
inhibition	O
of	O
viral	O
replication	O
.	O
Signalling	O
into	O
the	O
T	O
-	O
cell	O
nucleus	O
:	O
NFAT	B
regulation	O
.	O
The	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
plays	O
an	O
important	O
role	O
in	O
T	O
-	O
cell	O
biology	O
.	O
Activation	O
of	O
T	O
cells	O
results	O
in	O
the	O
rapid	O
calcineurin	B
-dependent	O
translocation	O
of	O
NFAT	B
transcription	B
factors	I
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
.	O
This	O
translocation	O
process	O
coupled	O
to	O
the	O
subsequent	O
active	O
maintenance	O
of	O
NFAT	B
in	O
the	O
nucleus	O
compartment	O
is	O
critical	O
for	O
the	O
induction	O
of	O
expression	O
of	O
several	O
genes	O
encoding	O
cytokines	B
and	O
membrane	B
proteins	I
that	O
modulate	O
immune	O
responses	O
.	O
The	O
molecular	O
cloning	O
of	O
the	O
NFAT	B
family	I
of	O
transcription	B
factors	I
has	O
facilitated	O
rapid	O
progress	O
in	O
the	O
understanding	O
of	O
the	O
signalling	O
mechanisms	O
that	O
control	O
the	O
activity	O
of	O
NFAT	B
.	O
IL-7	B
reconstitutes	O
multiple	O
aspects	O
of	O
v	B
-	I
Abl	I
-mediated	O
signaling	O
.	O
The	O
mechanism	O
by	O
which	O
early	O
lymphoid	O
cells	O
are	O
selectively	O
transformed	O
by	O
v	B
-	I
Abl	I
is	O
currently	O
unknown	O
.	O
Previous	O
studies	O
have	O
shown	O
constitutive	O
activation	O
of	O
IL-4	B
and	O
IL-7	B
signaling	O
pathways	O
,	O
as	O
measured	O
by	O
activation	O
of	O
Janus	B
protein	I
kinase	I
(	I
JAK	I
)	I
1	I
,	O
JAK3	B
,	O
STAT5	B
,	O
and	O
STAT6	B
,	O
in	O
pre	O
-	O
B	O
cells	O
transformed	O
by	O
v	B
-	I
Abl	I
.	O
To	O
determine	O
whether	O
activation	O
of	O
these	O
cytokine	O
signaling	O
pathways	O
by	O
v	B
-	I
Abl	I
is	O
important	O
in	O
the	O
cellular	O
events	O
induced	O
by	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
,	O
the	O
effects	O
of	O
IL-4	B
and	O
IL-7	B
on	O
pre	O
-	O
B	O
cells	O
transformed	O
with	O
a	O
temperature	B
-	I
sensitive	I
v	I
-	I
Abl	I
mutant	I
were	O
examined	O
.	O
Whereas	O
IL-4	B
had	O
little	O
or	O
no	O
effect	O
,	O
IL-7	B
delayed	O
both	O
the	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
that	O
occur	O
upon	O
v	B
-	I
Abl	I
kinase	O
inactivation	O
.	O
IL-7	B
also	O
delayed	O
the	O
decreases	O
in	O
the	O
levels	O
of	O
c	B
-	I
Myc	I
,	O
Bcl-2	B
,	O
and	O
Bcl	B
-	I
xL	I
that	O
occur	O
upon	O
loss	O
of	O
v	B
-	I
Abl	I
kinase	O
activity	O
.	O
IL-7	B
did	O
not	O
maintain	O
v	B
-	I
Abl	I
-mediated	O
differentiation	O
arrest	O
of	O
the	O
pre	O
-	O
B	O
cells	O
,	O
as	O
activation	O
of	O
NF	B
-	I
kappaB	I
and	O
RAG	O
gene	O
transcription	O
was	O
unaffected	O
by	O
IL-7	B
.	O
These	O
results	O
identify	O
a	O
potential	O
role	O
for	O
IL-7	B
signaling	O
pathways	O
in	O
transformation	O
by	O
v	B
-	I
Abl	I
while	O
demonstrating	O
that	O
a	O
combination	O
of	O
IL-4	B
and	O
IL-7	B
signaling	O
can	O
not	O
substitute	O
for	O
an	O
active	O
v	B
-	I
Abl	I
kinase	O
in	O
transformed	O
pre	O
-	O
B	O
cells	O
.	O
Detection	O
of	O
oestrogen	B
receptor	I
variants	I
in	O
endometrium	O
,	O
myometrium	O
,	O
leiomyoma	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
:	O
comparison	O
to	O
variants	O
present	O
in	O
breast	O
cancer	O
.	O
Oestradiol	O
has	O
mitogenic	O
and	O
regulatory	O
effects	O
on	O
various	O
organs	O
and	O
cells	O
,	O
mediated	O
mainly	O
by	O
its	O
nuclear	B
receptor	I
(	O
ER	B
)	O
.	O
The	O
presence	O
of	O
aberrant	O
ER	B
forms	O
in	O
Oestrogen	O
-	O
dependent	O
tumours	O
has	O
been	O
discussed	O
in	O
correlation	O
with	O
tumour	O
progression	O
.	O
ER	B
variants	O
,	O
generated	O
by	O
alternative	O
splicing	O
,	O
have	O
been	O
detected	O
in	O
human	O
breast	O
cancer	O
,	O
but	O
also	O
in	O
normal	O
mammary	O
glands	O
,	O
therefore	O
their	O
role	O
in	O
tumorigenesis	O
has	O
been	O
questioned	O
.	O
We	O
have	O
investigated	O
,	O
by	O
the	O
use	O
of	O
the	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
amplification	O
technique	O
,	O
the	O
possible	O
existence	O
of	O
ER	B
variants	O
in	O
other	O
normal	O
oestrogen	O
target	O
organs	O
and	O
cells	O
,	O
such	O
as	O
uterus	O
(	O
myometrium	O
and	O
endometrium	O
)	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
in	O
a	O
benign	O
uterus	O
tumour	O
(	O
leiomyoma	O
)	O
.	O
We	O
have	O
detected	O
variant	O
ER	B
in	O
these	O
samples	O
and	O
have	O
compared	O
the	O
variant	O
profile	O
to	O
that	O
observed	O
in	O
breast	O
cancer	O
.	O
All	O
tissues	O
and	O
cells	O
studied	O
expressed	O
both	O
wild	B
-	I
type	I
ER	I
and	O
variant	B
species	I
.	O
Variant	O
forms	O
encompassed	O
ER	B
with	O
deletions	O
of	O
exons	O
2	O
,	O
5	O
and	O
7	O
.	O
Variants	O
with	O
exon	O
5	O
deleted	O
were	O
detected	O
only	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
in	O
breast	O
cancer	O
.	O
Variants	O
with	O
exons	O
2	O
and	O
7	O
deleted	O
were	O
present	O
in	O
all	O
specimens	O
tested	O
.	O
These	O
results	O
corroborate	O
previous	O
findings	O
that	O
the	O
presence	O
of	O
ER	B
variants	O
is	O
not	O
a	O
characteristic	O
of	O
breast	O
cancer	O
.	O
The	O
physiological	O
significance	O
and	O
possible	O
clinical	O
relevance	O
of	O
the	O
variant	O
ER	B
forms	O
remain	O
to	O
be	O
elucidated	O
.	O
Transcription	O
factor	O
NF	B
-	I
kappaB	I
regulation	O
of	O
renal	O
fibrosis	O
during	O
ureteral	O
obstruction	O
.	O
Irrespective	O
of	O
the	O
etiology	O
,	O
many	O
kidney	O
diseases	O
result	O
in	O
inflammation	O
and	O
fibrosis	O
of	O
the	O
tubulointerstitium	O
,	O
with	O
the	O
subsequent	O
loss	O
of	O
renal	O
function	O
.	O
To	O
initiate	O
any	O
disease	O
process	O
or	O
for	O
any	O
disease	O
process	O
to	O
progress	O
,	O
there	O
must	O
be	O
changes	O
in	O
the	O
transcription	O
of	O
genes	O
within	O
the	O
affected	O
tissue	O
.	O
The	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	I
NF	I
-	I
kappaB	I
)	I
family	I
of	O
transcription	B
factors	I
regulates	O
genes	O
involved	O
in	O
inflammation	O
,	O
cell	O
proliferation	O
,	O
and	O
cell	O
differentiation	O
.	O
This	O
review	O
discusses	O
the	O
NF	B
-	I
kappaB	I
transcription	I
factor	I
family	I
in	O
general	O
and	O
the	O
association	O
of	O
NF	B
-	I
kappaB	I
activation	O
with	O
cellular	O
/	O
molecular	O
events	O
of	O
renal	O
inflammation	O
and	O
fibrosis	O
Lack	O
of	O
T	O
-	O
cell	O
-	O
mediated	O
recognition	O
of	O
the	O
fusion	O
region	O
of	O
the	O
pml	B
/	I
RAR	I
-	I
alpha	I
hybrid	I
protein	I
by	O
lymphocytes	O
of	O
acute	O
promyelocytic	O
leukemia	O
patients	O
.	O
In	O
previous	O
studies	O
,	O
it	O
was	O
shown	O
that	O
the	O
fusion	O
region	O
of	O
the	O
pml	B
/	I
RAR	I
-	I
alpha	I
protein	I
,	O
expressed	O
by	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
cells	O
,	O
can	O
be	O
specifically	O
recognized	O
in	O
vitro	O
by	O
donor	O
(	O
D.	O
E.	O
)	O
CD4	O
T	O
cells	O
in	O
a	O
HLA	B
class	I
II	I
DR11-restricted	O
fashion	O
.	O
We	O
present	O
here	O
the	O
results	O
on	O
the	O
recognition	O
of	O
several	O
pml	O
/	O
RAR	O
-	O
alpha	O
peptides	O
by	O
APL	O
patients	O
expressing	O
HLA	B
DR11	I
.	O
The	O
in	O
vitro	O
immunization	O
of	O
peripheral	O
blood	O
lymphocytes	O
from	O
four	O
patients	O
in	O
remission	O
(	O
S.R.	O
,	O
F.R.	O
,	O
M.M.	O
,	O
P.	O
G.	O
)	O
with	O
BCR1	O
/	O
25	O
,	O
a	O
25-mer	O
pml	O
/	O
RAR	B
-	I
alpha	I
,	O
did	O
not	O
elicit	O
either	O
a	O
polyclonal	O
or	O
a	O
clonal	O
immune	O
response	O
specific	O
to	O
the	O
peptide	O
.	O
We	O
then	O
generated	O
new	O
donor	O
anti	O
-	O
pml	O
/	O
RAR	O
-	O
alpha	O
CD4	O
(	O
+	O
)	O
T	O
-	O
cell	O
clones	O
.	O
These	O
clones	O
were	O
tested	O
for	O
their	O
recognition	O
of	O
BCR1	O
/	O
25	O
.	O
One	O
clone	O
(	O
C3	O
/	O
5	O
,	O
CD3	O
(	O
+	O
)	O
,	O
CD4	O
(	O
+	O
)	O
,	O
CD8	O
(	O
-	O
)	O
)	O
was	O
selected	O
for	O
further	O
analysis	O
.	O
Clone	O
C3	O
/	O
5	O
showed	O
specific	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cytokine	O
(	O
tumor	B
necrosis	I
factor	I
alpha	I
,	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
)	O
production	O
when	O
challenged	O
with	O
autologous	O
lymphoblastic	O
cell	O
lines	O
pulsed	O
with	O
peptide	O
BCR1	O
/	O
25	O
.	O
C3	O
/	O
5	O
cells	O
developed	O
specific	O
proliferation	O
and	O
cytotoxicity	O
when	O
challenged	O
with	O
peptide	O
-	O
pulsed	O
lymphoblastic	O
cell	O
lines	O
and	O
peripheral	O
blood	O
lymphocytes	O
from	O
the	O
four	O
DR11	O
(	O
+	O
)	O
APL	O
patients	O
.	O
APL	O
blasts	O
,	O
available	O
only	O
from	O
patients	O
F.R.	O
and	O
P.G.	O
,	O
were	O
not	O
lysed	O
by	O
C3	O
/	O
5	O
and	O
were	O
unable	O
to	O
present	O
peptide	O
BCR1	O
/	O
25	O
.	O
Incubation	O
of	O
APL	O
cells	O
with	O
IFN	B
-	I
gamma	I
failed	O
to	O
induce	O
HLA	B
class	I
II	I
molecules	I
and	O
recognition	O
by	O
the	O
C3	O
/	O
5	O
clone	O
.	O
Since	O
APL	O
cells	O
do	O
not	O
express	O
HLA	B
class	I
II	I
molecules	I
,	O
we	O
tested	O
in	O
two	O
donors	O
(	O
D.E.	O
and	O
C.H.R.	O
)	O
and	O
in	O
patients	O
S.R.and	O
P.G.whether	O
the	O
use	O
of	O
9-mer	O
peptides	O
(	O
BCR1	O
/	O
9	O
)	O
would	O
generate	O
a	O
CD8	B
/HLA	B
class	I
I	I
-restricted	O
response	O
.	O
No	O
peptide	O
-	O
specific	O
T	O
-	O
cell	O
line	O
or	O
clone	O
could	O
be	O
generated	O
from	O
both	O
donors	O
and	O
patients	O
.	O
These	O
findings	O
are	O
discussed	O
in	O
relation	O
to	O
possible	O
therapeutic	O
approaches	O
to	O
the	O
immunotherapy	O
of	O
APL	O
.	O
TAL1	B
and	O
LIM	B
-	I
only	I
proteins	I
synergistically	O
induce	O
retinaldehyde	B
dehydrogenase	I
2	I
expression	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
by	O
acting	O
as	O
cofactors	O
for	O
GATA3	B
.	O
Previously	O
,	O
we	O
have	O
shown	O
that	O
TAL1	B
and	O
the	O
LIM	O
-	O
only	O
protein	O
gene	O
(	O
LMO	O
)	O
are	O
regularly	O
coactivated	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
.	O
This	O
observation	O
is	O
likely	O
to	O
relate	O
to	O
the	O
findings	O
that	O
TAL1	B
and	O
LMO	B
are	O
highly	O
synergistic	O
in	O
T	O
-	O
cell	O
tumorigenesis	O
in	O
double	O
-	O
transgenic	O
mice	O
.	O
To	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
functional	O
synergy	O
between	O
TAL1	B
and	O
LMO	B
in	O
tumorigenesis	O
and	O
transcriptional	O
regulation	O
,	O
we	O
tried	O
to	O
identify	O
downstream	O
target	O
genes	O
regulated	O
by	O
TAL1	B
and	O
LMO	B
by	O
a	O
subtractive	O
PCR	O
method	O
.	O
One	O
of	O
the	O
isolated	O
genes	O
,	O
that	O
for	O
retinaldehyde	B
dehydrogenase	I
2	I
(	O
RALDH2	B
)	O
,	O
was	O
regularly	O
expressed	O
in	O
most	O
of	O
the	O
T	O
-	O
ALL	O
cell	O
lines	O
that	O
coexpressed	O
TAL1	B
and	O
LMO	B
.	O
Exogenously	O
transfected	O
TAL1	B
and	O
LMO	B
,	O
but	O
not	O
either	O
alone	O
,	O
induced	O
RALDH2	B
expression	O
in	O
a	O
T	O
-	O
ALL	O
cell	O
line	O
,	O
HPB	O
-	O
ALL	O
,	O
not	O
expressing	O
endogeneous	O
TAL1	B
or	O
LMO	B
.	O
The	O
RALDH2	O
transcripts	O
in	O
T	O
-	O
ALL	O
were	O
,	O
however	O
,	O
mostly	O
initiated	O
within	O
the	O
second	O
intron	O
.	O
Promoter	O
analysis	O
revealed	O
that	O
a	O
GATA	O
site	O
in	O
a	O
cryptic	O
promoter	O
in	O
the	O
second	O
intron	O
was	O
essential	O
and	O
sufficient	O
for	O
the	O
TAL1-	O
and	O
LMO	O
-	O
dependent	O
transcriptional	O
activation	O
,	O
and	O
GATA3	B
binds	O
to	O
this	O
site	O
.	O
In	O
addition	O
,	O
forced	O
expression	O
of	O
GATA3	B
potentiated	O
the	O
induction	O
of	O
RALDH2	B
by	O
TAL1	B
and	O
LMO	B
,	O
and	O
these	O
three	O
factors	O
formed	O
a	O
complex	O
in	O
vivo	O
.	O
Furthermore	O
,	O
a	O
TAL1	B
mutant	O
not	O
binding	O
to	O
DNA	O
also	O
activated	O
the	O
transcription	O
of	O
RALDH2	B
in	O
the	O
presence	O
of	O
LMO	B
and	O
GATA3	B
.	O
Collectively	O
,	O
we	O
have	O
identified	O
the	O
RALDH2	O
gene	O
as	O
a	O
first	O
example	O
of	O
direct	O
transcriptional	O
target	O
genes	O
regulated	O
by	O
TAL1	B
and	O
LMO	B
in	O
T	O
-	O
ALL	O
.	O
In	O
this	O
case	O
,	O
TAL1	B
and	O
LMO	B
act	O
as	O
cofactors	O
for	O
GATA3	B
to	O
activate	O
the	O
transcription	O
of	O
RALDH2	B
Thrombopoietin	B
and	O
its	O
receptor	O
.	O
Thrombopoietin	B
(	O
TPO	B
)	O
,	O
the	O
primary	O
physiological	O
regulator	O
of	O
platelet	O
production	O
,	O
was	O
initially	O
thought	O
to	O
be	O
a	O
lineage	O
-	O
specific	O
factor	O
acting	O
predominantly	O
on	O
megakaryocytopoiesis	O
.	O
Detailed	O
studies	O
establish	O
that	O
this	O
cytokine	O
mediates	O
biological	O
effects	O
on	O
a	O
broad	O
spectrum	O
of	O
hematopoietic	O
progenitor	O
cells	O
,	O
including	O
stem	O
cells	O
.	O
TPO	B
is	O
a	O
hormone	O
constitutively	O
produced	O
mainly	O
by	O
the	O
liver	O
and	O
kidney	O
.	O
Plasma	O
TPO	B
levels	O
are	O
regulated	O
by	O
the	O
platelet	O
and	O
megakaryocyte	O
mass	O
through	O
Mpl	B
receptor	I
binding	O
,	O
internalization	O
and	O
degradation	O
.	O
The	O
Mpl	B
receptor	I
is	O
a	O
member	O
of	O
the	O
hematopoietin	B
receptor	I
superfamily	I
lacking	O
intrinsic	O
kinase	O
activity	O
.	O
Upon	O
ligand	O
-	O
induced	O
Mpl	O
homodimerization	O
,	O
the	O
major	O
signaling	O
events	O
for	O
proliferation	O
are	O
mediated	O
through	O
the	O
JAK2	B
/STAT5	B
pathway	O
,	O
while	O
differentiation	O
might	O
occur	O
through	O
a	O
prolonged	O
activation	O
of	O
the	O
MAPK	B
pathway	O
.	O
Preclinical	O
and	O
clinical	O
studies	O
demonstrate	O
the	O
potential	O
use	O
of	O
TPO	B
in	O
a	O
variety	O
of	O
contexts	O
,	O
but	O
it	O
is	O
too	O
early	O
to	O
evaluate	O
its	O
benefit	O
in	O
reducing	O
platelet	O
transfusion	O
.	O
Differential	O
activation	O
of	O
functionally	O
distinct	O
STAT5	B
proteins	I
by	O
IL-5	B
and	O
GM	B
-	I
CSF	I
during	O
eosinophil	O
and	O
neutrophil	O
differentiation	O
from	O
human	O
CD34	O
+	O
hematopoietic	O
stem	O
cells	O
.	O
Interleukin-5	B
(	O
IL-5	B
)	O
and	O
granulocyte	B
macrophage	I
-	I
colony	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
are	O
important	O
cytokines	B
for	O
the	O
proliferation	O
,	O
differentiation	O
,	O
and	O
activation	O
of	O
myeloid	O
lineages	O
.	O
The	O
JAK	B
/STAT	B
pathway	O
is	O
one	O
of	O
the	O
signaling	O
pathways	O
implicated	O
in	O
mediating	O
biological	O
responses	O
induced	O
by	O
these	O
cytokines	B
.	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
these	O
cytokines	B
predominantly	O
activate	O
an	O
80	B
kDa	I
STAT5	I
isoform	I
in	O
mature	O
granulocytes	O
.	O
To	O
better	O
understand	O
the	O
role	O
of	O
STAT	O
proteins	O
during	O
growth	O
and	O
differentiation	O
of	O
granulocytes	O
,	O
we	O
evaluated	O
differentiation	O
of	O
human	O
CD34	O
+	O
hematopoietic	O
stem	O
cells	O
ex	O
vivo	O
toward	O
eosinophils	O
and	O
neutrophils	O
.	O
Bandshift	O
experiments	O
showed	O
that	O
in	O
an	O
early	O
stage	O
of	O
both	O
differentiation	O
pathways	O
(	O
14	O
days	O
)	O
,	O
the	O
94	O
kDa	O
STAT5B	B
protein	I
was	O
activated	O
by	O
both	O
IL-5	B
(	O
eosinophil	O
lineage	O
)	O
and	O
GM	B
-	I
CSF	I
(	O
neutrophil	O
lineage	O
)	O
.	O
However	O
,	O
during	O
maturation	O
of	O
both	O
lineages	O
(	O
days	O
21	O
and	O
28	O
)	O
,	O
increased	O
expression	O
of	O
a	O
functionally	O
distinct	O
80	B
kDa	I
STAT5	I
isoform	I
was	O
observed	O
,	O
resulting	O
in	O
heterodimer	B
DNA	I
-	I
binding	I
complexes	I
containing	O
both	O
the	O
94	O
and	O
80	O
kDa	O
STAT5	B
proteins	I
.	O
The	O
finding	O
that	O
functionally	O
distinct	O
isoforms	O
of	O
STAT5	B
are	O
activated	O
during	O
the	O
early	O
and	O
late	O
differentiation	O
stages	O
of	O
granulocytes	O
suggests	O
that	O
they	O
might	O
be	O
involved	O
in	O
regulating	O
different	O
biological	O
functions	O
in	O
these	O
cells	O
.	O
Tpl-2	B
induces	O
IL-2	B
expression	O
in	O
T	O
-	O
cell	O
lines	O
by	O
triggering	O
multiple	O
signaling	O
pathways	O
that	O
activate	O
NFAT	B
and	O
NF	B
-	I
kappaB	I
.	O
The	O
Tpl-2	B
kinase	I
activates	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
and	O
induces	O
IL-2	B
expression	O
in	O
T	O
-	O
cell	O
lines	O
.	O
Here	O
we	O
show	O
that	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
by	O
Tpl-2	B
is	O
inhibited	O
by	O
mutant	B
signaling	I
molecules	I
that	O
inhibit	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
or	O
the	O
calcineurin	B
/NFAT	B
pathways	O
and	O
is	O
promoted	O
by	O
combinations	O
of	O
signaling	B
molecules	I
that	O
activate	O
these	O
pathways	O
.	O
We	O
,	O
therefore	O
,	O
conclude	O
that	O
signals	O
generated	O
by	O
the	O
convergence	O
of	O
the	O
MAPK	B
and	O
the	O
calcineurin	B
/NFAT	B
pathway	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
by	O
Tpl-2	B
.	O
The	O
activation	O
of	O
both	O
the	O
IL-2	O
promoter	O
and	O
an	O
NFAT	O
-	O
driven	O
minimal	O
promoter	O
were	O
shown	O
to	O
depend	O
on	O
signals	O
transduced	O
by	O
Raf1	B
.	O
However	O
,	O
it	O
was	O
only	O
the	O
IL-2	O
promoter	O
whose	O
activation	O
by	O
Tpl-2	B
was	O
fully	O
blocked	O
by	O
the	O
dominant	B
negative	I
mutant	I
MEK1S218	I
/	I
222A	I
and	O
the	O
MEK1	O
/	O
MEK2	O
inhibitor	O
PD098059	O
.	O
Since	O
the	O
activation	O
of	O
NFAT	B
is	O
MAPK	B
-dependent	O
these	O
findings	O
suggested	O
that	O
the	O
activation	O
of	O
MAPK	B
by	O
Tpl-2	B
is	O
either	O
independent	O
or	O
only	O
partially	O
dependent	O
on	O
MEK1	B
and	O
MEK2	B
.	O
In	O
addition	O
,	O
they	O
suggested	O
that	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
is	O
under	O
the	O
control	O
of	O
not	O
only	O
NFAT	B
but	O
also	O
a	O
second	O
factor	O
whose	O
activation	O
is	O
MEK	B
-dependent	O
.	O
Experiments	O
in	O
COS-1	O
and	O
EL-4	O
cells	O
confirmed	O
both	O
hypotheses	O
and	O
revealed	O
that	O
the	O
second	O
factor	O
activated	O
by	O
Tpl-2	B
is	O
NF	B
-	I
kappaB	I
.	O
While	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
and	O
an	O
NFAT	O
-	O
driven	O
minimal	O
promoter	O
by	O
Tpl-2	B
was	O
fully	O
blocked	O
by	O
the	O
dominant	B
negative	I
mutant	I
NFAT	B
delta418	I
,	O
it	O
was	O
only	O
partially	O
blocked	O
by	O
the	O
calcineurin	B
inhibitor	O
cyclosporin	O
A	O
suggesting	O
that	O
the	O
Tpl-2	B
-mediated	O
NFAT	B
activation	O
is	O
under	O
the	O
control	O
of	O
a	O
combination	O
of	O
calcineurin	O
-	O
dependent	O
and	O
independent	O
pathways	O
.	O
Both	O
pathways	O
were	O
fully	O
blocked	O
by	O
Bcl-2	B
or	O
Bcl	B
-	I
X	I
(	I
L	I
)	I
.	O
Conserved	O
elements	O
containing	O
NF	O
-	O
E2	O
and	O
tandem	O
GATA	O
binding	O
sites	O
are	O
required	O
for	O
erythroid	O
-	O
specific	O
chromatin	O
structure	O
reorganization	O
within	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
control	O
region	O
.	O
Proper	O
expression	O
of	O
the	O
genes	O
of	O
the	O
human	O
beta	O
-	O
globin	O
gene	O
locus	O
requires	O
the	O
associated	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
.	O
Structurally	O
,	O
the	O
LCR	O
is	O
defined	O
by	O
the	O
presence	O
of	O
four	O
domains	O
of	O
erythroid	O
-	O
specific	O
chromatin	O
structure	O
.	O
These	O
domains	O
,	O
which	O
have	O
been	O
characterized	O
as	O
DNase	O
I	O
hypersensitive	O
sites	O
(	O
HSs	O
)	O
,	O
comprise	O
the	O
active	O
elements	O
of	O
the	O
LCR	O
.	O
The	O
major	O
focus	O
of	O
this	O
research	O
is	O
to	O
define	O
the	O
cis	O
-acting	O
elements	O
which	O
are	O
required	O
for	O
the	O
formation	O
of	O
these	O
domains	O
of	O
unique	O
chromatin	O
structure	O
.	O
Our	O
previous	O
investigations	O
on	O
the	O
formation	O
of	O
LCR	O
HS4	O
demonstrated	O
that	O
NF	O
-	O
E2	O
and	O
tandem	O
,	O
inverted	O
GATA	O
binding	O
sites	O
are	O
required	O
for	O
the	O
formation	O
of	O
the	O
native	O
HS	O
.	O
Similarly	O
arranged	O
NF	O
-	O
E2	O
and	O
tandem	O
GATA	O
sites	O
are	O
present	O
within	O
the	O
core	O
regions	O
of	O
the	O
other	O
human	O
LCR	O
HSs	O
and	O
are	O
evolutionarily	O
conserved	O
.	O
Using	O
site	O
-	O
directed	O
mutagenesis	O
of	O
human	O
HSs	O
2	O
and	O
3	O
we	O
have	O
tested	O
the	O
hypothesis	O
that	O
these	O
NF	O
-	O
E2	O
and	O
GATA	O
sites	O
are	O
common	O
requirements	O
for	O
the	O
formation	O
of	O
all	O
LCR	O
HSs	O
.	O
We	O
find	O
that	O
mutation	O
of	O
these	O
elements	O
,	O
and	O
particularly	O
the	O
GATA	O
elements	O
,	O
results	O
in	O
a	O
decrease	O
or	O
complete	O
loss	O
of	O
DNase	B
I	I
hypersensitivity	O
.	O
These	O
data	O
imply	O
the	O
presence	O
of	O
common	O
structural	O
elements	O
within	O
the	O
core	O
of	O
each	O
LCR	O
HS	O
which	O
are	O
required	O
for	O
erythroid	O
-	O
specific	O
chromatin	O
structure	O
reorganization	O
.	O
Adaptor	O
function	O
for	O
the	O
Syk	B
kinases	I
-	I
interacting	I
protein	I
3BP2	B
in	O
IL-2	B
gene	O
activation	O
.	O
Syk	B
-	I
family	I
tyrosine	I
kinases	I
are	O
essential	O
for	O
lymphocyte	O
development	O
and	O
activation	O
.	O
Using	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
to	O
identify	O
Syk	B
kinases	I
-	I
interacting	I
proteins	I
(	O
SKIPs	B
)	O
,	O
we	O
isolated	O
3BP2	B
,	O
an	O
Abl	B
SH3-interacting	I
protein	I
of	O
unknown	O
function	O
.	O
3BP2	B
was	O
selectively	O
expressed	O
in	O
hematopoietic	O
/	O
lymphoid	O
tissues	O
and	O
bound	O
via	O
its	O
SH2	B
domain	I
activated	I
Syk	I
-	I
family	I
kinases	I
in	O
mammalian	O
cells	O
,	O
including	O
in	O
antigen	O
receptor	O
-	O
stimulated	O
T	O
cells	O
.	O
In	O
addition	O
to	O
Zap-70	B
,	O
the	O
3BP2	B
SH2	I
domain	I
associated	O
in	O
vitro	O
with	O
LAT	B
,	O
Grb2	B
,	O
PLCgamma1	B
,	O
and	O
Cbl	B
from	O
activated	O
T	O
cell	O
lysates	O
.	O
Transient	O
3BP2	B
overexpression	O
induced	O
transcriptional	O
activation	O
of	O
the	O
IL-2	O
promoter	O
and	O
its	O
NFAT	O
or	O
AP-1	O
elements	O
.	O
This	O
activity	O
was	O
dependent	O
on	O
the	O
SH2	B
and	O
pleckstrin	B
-	I
homology	I
domains	I
of	O
3BP2	B
,	O
and	O
required	O
functional	O
Syk	B
kinases	I
,	O
Ras	B
,	O
and	O
calcineurin	B
.	O
Thus	O
,	O
3BP2	B
is	O
an	O
important	O
adaptor	O
that	O
may	O
couple	O
activated	O
Zap-70	B
/	I
Syk	I
to	O
a	O
LAT	B
-	I
containing	I
signaling	I
complex	I
involved	O
in	O
TCR	O
-	O
mediated	O
gene	O
transcription	O
.	O
Activation	O
of	O
human	O
macrophages	O
by	O
mechanical	O
ventilation	O
in	O
vitro	O
.	O
Positive	O
-	O
pressure	O
mechanical	O
ventilation	O
supports	O
gas	O
exchange	O
in	O
patients	O
with	O
respiratory	O
failure	O
but	O
is	O
also	O
responsible	O
for	O
significant	O
lung	O
injury	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
model	O
in	O
which	O
isolated	O
lung	O
cells	O
can	O
be	O
submitted	O
to	O
a	O
prolonged	O
cyclic	O
pressure	O
-	O
stretching	O
strain	O
resembling	O
that	O
of	O
conventional	O
mechanical	O
ventilation	O
.	O
In	O
this	O
model	O
,	O
cells	O
cultured	O
on	O
a	O
Silastic	O
membrane	O
were	O
elongated	O
up	O
to	O
7	O
%	O
of	O
their	O
initial	O
diameter	O
,	O
corresponding	O
to	O
a	O
12	O
%	O
increase	O
in	O
cell	O
surface	O
.	O
The	O
lung	O
macrophage	O
was	O
identified	O
as	O
the	O
main	O
cellular	O
source	O
for	O
critical	O
inflammatory	B
mediators	I
such	O
as	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
,	O
the	O
chemokines	B
interleukin	B
(	I
IL	I
)	I
-8	I
and	I
-6	I
,	O
and	O
matrix	B
metalloproteinase-9	I
in	O
this	O
model	O
system	O
of	O
mechanical	O
ventilation	O
.	O
These	O
mediators	O
were	O
measured	O
in	O
supernatants	O
from	O
ventilated	O
alveolar	O
macrophages	O
,	O
monocyte	O
-	O
derived	O
macrophages	O
,	O
and	O
promonocytic	O
THP-1	O
cells	O
.	O
Nuclear	B
factor	I
-	I
kappaB	I
was	O
found	O
to	O
be	O
activated	O
in	O
ventilated	O
macrophages	O
.	O
Synergistic	O
proinflammatory	O
effects	O
of	O
mechanical	O
stress	O
and	O
molecules	O
such	O
as	O
bacterial	B
endotoxin	I
were	O
observed	O
,	O
suggesting	O
that	O
mechanical	O
ventilation	O
might	O
be	O
particularly	O
deleterious	O
in	O
preinjured	O
or	O
infected	O
lungs	O
.	O
Dexamethasone	O
prevented	O
IL-8	B
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
secretion	O
in	O
ventilated	O
macrophages	O
.	O
Mechanical	O
ventilation	O
induced	O
low	O
levels	O
of	O
IL-8	B
secretion	O
by	O
alveolar	O
type	O
II	O
-	O
like	O
cells	O
.	O
Other	O
lung	O
cell	O
types	O
such	O
as	O
endothelial	O
cells	O
,	O
bronchial	O
cells	O
,	O
and	O
fibroblasts	O
failed	O
to	O
produce	O
IL-8	B
in	O
response	O
to	O
a	O
prolonged	O
cyclic	O
pressure	O
-	O
stretching	O
load	O
.	O
This	O
model	O
is	O
of	O
particular	O
value	O
for	O
exploring	O
physical	O
stress	O
-	O
induced	O
signaling	O
pathways	O
,	O
as	O
well	O
as	O
for	O
testing	O
the	O
effects	O
of	O
novel	O
ventilatory	O
strategies	O
or	O
adjunctive	O
substances	O
aimed	O
at	O
modulating	O
cell	O
activation	O
induced	O
by	O
mechanical	O
ventilation	O
.	O
Constitutive	O
association	O
of	O
JAK1	B
and	O
STAT5	B
in	O
pro	O
-	O
B	O
cells	O
is	O
dissolved	O
by	O
interleukin-4	B
-induced	O
tyrosine	O
phosphorylation	O
of	O
both	O
proteins	O
.	O
The	O
bipartite	B
human	I
interleukin-4	I
(	I
IL-4	I
)	I
receptor	I
was	O
functionally	O
expressed	O
in	O
murine	O
pro	O
-	O
B	O
cells	O
and	O
activated	O
by	O
human	B
IL-4	I
to	O
evoke	O
intracellular	O
signaling	O
.	O
Mutual	O
association	O
of	O
signal	B
transducing	I
proteins	I
within	O
the	O
receptor	O
complex	O
was	O
then	O
studied	O
in	O
dependence	O
of	O
ligand	O
stimulation	O
.	O
Besides	O
ligand	O
-	O
induced	O
receptor	O
heterodimerization	O
and	O
contacts	O
of	O
the	O
two	O
IL-4	B
receptor	I
subunits	I
alpha	I
and	I
gamma	I
with	O
Janus	B
kinases	I
JAK1	B
and	O
JAK3	B
a	O
prominent	O
constitutive	O
binding	O
between	O
JAK1	B
and	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
STAT5	B
was	O
detected	O
.	O
Since	O
both	O
these	O
proteins	O
become	O
phosphorylated	O
in	O
response	O
to	O
IL-4	B
receptor	I
stimulation	O
,	O
the	O
influence	O
of	O
tyrosine	O
phosphorylation	O
on	O
their	O
mutual	O
contact	O
was	O
analyzed	O
.	O
Association	O
of	O
JAK1	B
and	O
STAT5	B
was	O
found	O
to	O
occur	O
exclusively	O
between	O
unphosphorylated	B
proteins	I
.	O
Interleukin-10	B
and	O
transforming	O
growth	O
factor	O
-	O
beta	O
promoter	O
polymorphisms	O
in	O
allergies	O
and	O
asthma	O
.	O
Interleukin-10	B
(	O
IL-10	B
)	O
and	O
transforming	B
growth	I
factor	I
beta	I
(	O
TGF	B
-	I
beta	I
)	O
are	O
inhibitory	O
for	O
B	O
and	O
T	O
cells	O
,	O
IgE	B
production	O
,	O
and	O
mast	O
cell	O
proliferation	O
,	O
and	O
they	O
induce	O
apoptosis	O
in	O
eosinophils	O
.	O
These	O
cytokines	B
are	O
therefore	O
candidate	O
genes	O
which	O
could	O
contribute	O
to	O
the	O
development	O
of	O
asthma	O
or	O
allergies	O
.	O
We	O
investigated	O
the	O
hypothesis	O
that	O
polymorphic	O
nucleotides	O
within	O
the	O
IL-10	O
and	O
TGF	O
-	O
beta	O
gene	O
promoters	O
would	O
link	O
to	O
the	O
expression	O
of	O
allergies	O
and	O
asthma	O
.	O
DNA	O
taken	O
from	O
families	O
with	O
an	O
asthmatic	O
proband	O
was	O
examined	O
for	O
base	O
exchanges	O
by	O
single	O
-	O
stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
.	O
We	O
demonstrated	O
the	O
presence	O
of	O
a	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
IL-10	O
gene	O
and	O
four	O
in	O
the	O
TGF	O
-	O
beta	O
gene	O
promoters	O
(	O
3	O
in	O
TGF	O
-	O
beta1	O
and	O
1	O
in	O
TGF	O
-	O
beta2	O
)	O
.	O
The	O
IL-10	B
gene	O
polymorphism	O
was	O
a	O
C	O
-	O
to	O
-	O
A	O
exchange	O
571	O
base	O
pairs	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
and	O
was	O
present	O
between	O
consensus	O
binding	O
sequences	O
for	O
Sp1	B
and	O
elevated	O
total	O
serum	O
.	O
This	O
polymorphism	O
was	O
associated	O
with	O
elevated	O
total	B
serum	I
IgE	I
in	O
subjects	O
heterozygotic	O
or	O
homozygotic	O
for	O
this	O
base	O
exchange	O
(	O
p	O
<	O
0.009	O
)	O
.	O
The	O
base	O
exchange	O
at	O
-509	O
(	O
from	O
the	O
transcription	O
initiation	O
site	O
)	O
in	O
the	O
TGF	O
-	O
beta	O
promoter	O
also	O
linked	O
to	O
elevated	O
total	O
IgE	B
(	O
p	O
<	O
0.01	O
)	O
.	O
This	O
polymorphism	O
represented	O
a	O
C	O
-	O
to	O
-	O
T	O
base	O
exchange	O
which	O
induced	O
a	O
YY1	O
consensus	O
sequence	O
and	O
is	O
present	O
in	O
a	O
region	O
of	O
the	O
promoter	O
associated	O
with	O
negative	O
transcription	O
regulation	O
.	O
Isolation	O
and	O
utilization	O
of	O
human	O
dendritic	O
cells	O
from	O
peripheral	O
blood	O
to	O
assay	O
an	O
in	O
vitro	O
primary	O
immune	O
response	O
to	O
varicella	O
-	O
zoster	O
virus	O
peptides	O
.	O
A	O
human	O
dendritic	O
cell	O
-	O
based	O
assay	O
used	O
to	O
monitor	O
a	O
T	O
cell	O
proliferation	O
response	O
to	O
viral	O
peptides	O
in	O
vitro	O
is	O
described	O
.	O
Dendritic	O
cells	O
and	O
autologous	O
CD4	O
+	O
T	O
cells	O
were	O
isolated	O
from	O
peripheral	O
blood	O
by	O
a	O
series	O
of	O
density	O
-	O
gradient	O
centrifugations	O
or	O
magnetic	O
bead	O
separations	O
(	O
or	O
both	O
)	O
.	O
Peptides	O
corresponding	O
to	O
residues	O
of	O
the	O
immediate	B
early	I
protein	I
,	O
IE62	B
,	O
of	O
varicella	O
-	O
zoster	O
virus	O
(	O
VZV	O
)	O
were	O
used	O
as	O
stimulating	B
antigens	I
,	O
and	O
persons	O
with	O
no	O
history	O
of	O
varicella	O
and	O
no	O
humoral	O
or	O
cellular	O
immunity	O
to	O
VZV	O
served	O
as	O
naive	O
donors	O
for	O
the	O
assays	O
.	O
Three	O
VZV	O
-	O
susceptible	O
donors	O
were	O
tested	O
,	O
and	O
all	O
demonstrated	O
an	O
in	O
vitro	O
response	O
to	O
multiple	O
VZV	O
peptides	O
.	O
This	O
assay	O
has	O
potential	O
as	O
a	O
screen	O
to	O
establish	O
the	O
immunogenicity	O
of	O
viral	O
antigens	O
in	O
vitro	O
using	O
T	O
cells	O
from	O
naive	O
donors	O
.	O
The	O
modulation	O
of	O
glucocorticoid	B
receptor	I
content	O
by	O
3-O	O
-	O
methyl	O
-	O
D	O
-	O
glucose	O
transport	O
in	O
human	O
mononuclear	O
leukocyte	O
in	O
obesity	O
.	O
Glucocorticoid	B
receptors	I
(	O
GR	B
)	O
and	O
3-O	O
-	O
methyl	O
-	O
D	O
glucose	O
(	O
3-O	O
-	O
MG	O
)	O
transport	O
were	O
determined	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
from	O
11	O
abdominal	O
obese	O
subjects	O
,	O
10	O
pituitary	O
-	O
dependent	O
Cushing	O
's	O
syndrome	O
(	O
Cushing	O
's	O
disease	O
)	O
and	O
10	O
healthy	O
controls	O
.	O
Using	O
a	O
whole	O
-	O
cell	O
competitive	O
binding	O
assay	O
and	O
3H	O
-	O
dexamethasone	O
as	O
tracer	O
,	O
MNL	O
of	O
abdominal	O
obese	O
subjects	O
were	O
found	O
to	O
have	O
4855	O
+	O
/-	O
1389	O
sites	O
/	O
cell	O
which	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0.05	O
)	O
than	O
controls	O
(	O
6234	O
+	O
/-	O
1568	O
sites	O
/	O
cell	O
)	O
,	O
although	O
no	O
significant	O
difference	O
was	O
found	O
in	O
the	O
mean	O
serum	O
cortisol	O
level	O
.	O
Their	O
mean	O
Kd	O
(	O
affinity	O
)	O
was	O
also	O
significantly	O
lower	O
than	O
that	O
found	O
in	O
the	O
healthy	O
controls	O
(	O
obese	O
Kd	O
:	O
2.92	O
+	O
/-	O
0.84	O
nmol	O
/	O
l	O
,	O
control	O
Kd	O
:	O
4.55	O
+	O
/-	O
0.67	O
nM	O
,	O
p	O
<	O
0.05	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
receptor	O
characteristics	O
in	O
Cushing	O
's	O
disease	O
patients	O
were	O
within	O
the	O
normal	O
range	O
.	O
At	O
the	O
same	O
time	O
,	O
3-O	O
-	O
MG	O
transport	O
was	O
determined	O
in	O
the	O
same	O
subjects	O
.	O
In	O
Cushing	O
's	O
disease	O
,	O
3-O	O
-	O
MG	O
transport	O
was	O
within	O
the	O
normal	O
range	O
,	O
whereas	O
in	O
abdominal	O
obesity	O
this	O
value	O
was	O
significantly	O
lower	O
than	O
the	O
healthy	O
controls	O
(	O
abdominal	O
obese	O
:	O
31.90	O
+	O
/-	O
8.20	O
;	O
control	O
:	O
46.26	O
+	O
/-	O
12.91	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cell	O
,	O
min	O
,	O
p	O
<	O
0.05	O
)	O
.	O
We	O
also	O
found	O
a	O
positive	O
correlation	O
between	O
3-O	O
-	O
MG	O
transport	O
and	O
GR	B
binding	O
capacity	O
in	O
abdominal	O
subjects	O
(	O
r	O
=	O
0.89	O
,	O
p	O
<	O
0.001	O
)	O
,	O
however	O
we	O
did	O
not	O
find	O
such	O
a	O
correlation	O
in	O
Cushing	O
's	O
disease	O
(	O
r	O
=	O
0.60	O
,	O
p	O
>	O
0.05	O
)	O
.	O
These	O
results	O
indicated	O
that	O
,	O
in	O
abdominal	O
obesity	O
,	O
the	O
GR	B
binding	O
capacity	O
in	O
MNL	O
is	O
influenced	O
by	O
the	O
changes	O
in	O
glucose	O
transport	O
.	O
Down	O
-	O
regulation	O
of	O
human	O
granzyme	B
B	I
expression	O
by	O
glucocorticoids	O
.	O
Dexamethasone	O
inhibits	O
binding	O
to	O
the	O
Ikaros	B
and	O
AP-1	O
regulatory	O
elements	O
of	O
the	O
granzyme	O
B	O
promoter	O
.	O
The	O
serine	B
protease	I
granzyme	I
B	I
is	O
an	O
essential	O
component	O
of	O
the	O
granule	O
exocytosis	O
pathway	O
,	O
a	O
major	O
apoptotic	O
mechanism	O
used	O
by	O
cytotoxic	O
T	O
lymphocytes	O
and	O
natural	O
killer	O
cells	O
to	O
induce	O
target	O
cell	O
apoptosis	O
.	O
Granzyme	O
B	O
gene	O
transcription	O
is	O
induced	O
in	O
activated	O
lymphocytes	O
upon	O
antigenic	O
stimulation	O
,	O
and	O
several	O
regulatory	O
regions	O
including	O
CBF	B
,	O
AP-1	B
,	O
and	O
Ikaros	O
binding	O
sites	O
have	O
been	O
shown	O
to	O
be	O
essential	O
in	O
the	O
control	O
of	O
granzyme	O
B	O
promoter	O
activation	O
.	O
Dexamethasone	O
,	O
a	O
glucocorticoid	O
that	O
is	O
widely	O
used	O
as	O
an	O
immunomodulatory	O
and	O
anti	O
-	O
inflammatory	O
agent	O
,	O
inhibits	O
granzyme	O
B	O
mRNA	O
transcript	O
in	O
phytohemagglutinin	O
-	O
activated	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
Transfection	O
of	O
a	O
reporter	O
construct	O
containing	O
the	O
-148	O
to	O
+	O
60	O
region	O
of	O
the	O
human	O
granzyme	O
B	O
promoter	O
demonstrated	O
that	O
this	O
region	O
was	O
the	O
target	O
for	O
dexamethasone	O
repression	O
.	O
Mutation	O
of	O
Ikaros	B
or	O
AP-1	O
binding	O
sites	O
in	O
the	O
context	O
of	O
the	O
granzyme	O
B	O
promoter	O
demonstrated	O
that	O
both	O
sites	O
participate	O
in	O
dexamethasone	O
-	O
mediated	O
inhibition	O
of	O
the	O
granzyme	O
B	O
promoter	O
activity	O
.	O
Electromobility	O
shift	O
assay	O
revealed	O
that	O
dexamethasone	O
abolished	O
the	O
binding	O
of	O
nuclear	B
transcription	I
factors	I
to	O
the	O
Ikaros	O
binding	O
site	O
and	O
reduced	O
AP-1	B
binding	O
activity	O
.	O
These	O
results	O
indicate	O
that	O
dexamethasone	O
is	O
able	O
to	O
abrogate	O
the	O
transcriptional	O
activity	O
of	O
the	O
human	O
granzyme	O
B	O
gene	O
promoter	O
by	O
inhibiting	O
the	O
binding	O
of	O
nuclear	B
factors	I
at	O
the	O
AP-1	O
and	O
Ikaros	O
sites	O
.	O
CD27	B
/CD70	O
interaction	O
augments	O
IgE	B
secretion	O
by	O
promoting	O
the	O
differentiation	O
of	O
memory	O
B	O
cells	O
into	O
plasma	O
cells	O
.	O
The	O
induction	O
of	O
IgE	B
switching	O
in	O
B	O
cells	O
requires	O
several	O
signals	O
given	O
by	O
cytokines	B
and	O
cell	O
contact	O
-	O
delivered	O
signals	O
.	O
Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
CD27	B
/CD70	O
interaction	O
in	O
B	O
cell	O
IgE	B
synthesis	O
.	O
The	O
addition	O
of	O
CD27	O
ligand	O
(	O
CD70	O
)	O
transfectants	O
to	O
B	O
cell	O
cultures	O
increased	O
the	O
IgE	B
synthesis	O
synergistically	O
in	O
the	O
presence	O
of	O
IL-4	B
plus	O
anti	B
-	I
CD40	I
mAb	I
(	O
anti	B
-	I
CD40	I
)	O
.	O
The	O
effect	O
of	O
CD70	O
transfectants	O
was	O
dose	O
dependent	O
and	O
was	O
completely	O
blocked	O
by	O
anti	B
-	I
CD70	I
mAb	I
.	I
CD27	O
+	O
B	O
cells	O
had	O
the	O
ability	O
to	O
produce	O
IgE	B
,	O
which	O
was	O
increased	O
by	O
contact	O
with	O
CD70	O
transfectants	O
,	O
whereas	O
CD27-	O
B	O
cells	O
did	O
not	O
produce	O
IgE	B
.	O
CD27	B
/CD70	O
interaction	O
enhanced	O
B	O
cell	O
proliferation	O
in	O
the	O
presence	O
of	O
IL-4	B
or	O
IL-4	B
plus	O
anti	B
-	I
CD40	I
.	O
The	O
augmentation	O
of	O
B	O
cell	O
proliferation	O
by	O
CD70	O
transfectants	O
was	O
apparent	O
in	O
CD27	O
+	O
B	O
cells	O
,	O
but	O
was	O
mild	O
in	O
CD27-	O
B	O
cells	O
.	O
The	O
helper	O
activity	O
for	O
IgE	B
synthesis	O
by	O
the	O
CD27	B
/CD70	O
interaction	O
did	O
not	O
contribute	O
to	O
the	O
enhancement	O
of	O
germline	O
epsilon	O
transcripts	O
.	O
Flow	O
cytometric	O
and	O
morphological	O
analyses	O
demonstrated	O
that	O
the	O
addition	O
of	O
CD70	O
transfectants	O
to	O
B	O
cell	O
cultures	O
remarkably	O
promoted	O
differentiation	O
into	O
plasma	O
cells	O
in	O
the	O
presence	O
of	O
IL-4	B
and	O
CD40	B
signaling	O
.	O
Finally	O
,	O
CD27	B
cross	O
-	O
linking	O
resulted	O
in	O
the	O
up	O
-	O
regulation	O
of	O
positive	B
regulatory	I
domain	I
I	I
-	I
binding	I
factor-1	I
.	O
Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
signaling	O
via	O
CD27	B
on	O
B	O
cells	O
induces	O
IgE	B
synthesis	O
,	O
in	O
cooperation	O
with	O
IL-4	B
and	O
CD40	B
signaling	O
,	O
by	O
promoting	O
the	O
generation	O
of	O
plasma	O
cells	O
through	O
up	O
-	O
regulation	O
of	O
positive	B
regulatory	I
domain	I
I	I
-	I
binding	I
factor-1	I
.	O
The	O
B29	O
(	O
immunoglobulin	O
beta	O
-	O
chain	O
)	O
gene	O
is	O
a	O
genetic	O
target	O
for	O
early	B
B	I
-	I
cell	I
factor	I
.	O
Early	B
B	I
-	I
cell	I
factor	I
(	O
EBF	B
)	O
is	O
a	O
transcription	B
factor	I
suggested	O
as	O
essential	O
for	O
early	O
B	O
-	O
lymphocyte	O
development	O
by	O
findings	O
in	O
mice	O
where	O
the	O
coding	O
gene	O
has	O
been	O
inactivated	O
by	O
homologous	O
disruption	O
.	O
This	O
makes	O
the	O
identification	O
of	O
genetic	O
targets	O
for	O
this	O
transcription	B
factor	I
pertinent	O
for	O
the	O
understanding	O
of	O
early	O
B	O
-	O
cell	O
development	O
.	O
The	O
lack	O
of	O
B29	O
transcripts	O
,	O
coding	O
for	O
the	O
beta	B
subunit	I
of	O
the	O
B	O
-	O
cell	O
receptor	O
complex	O
,	O
in	O
pro	O
-	O
B	O
cells	O
from	O
EBF	B
-deficient	O
mice	O
suggested	O
that	O
B29	O
might	O
be	O
a	O
genetic	O
target	O
for	O
EBF	B
.	O
We	O
here	O
present	O
data	O
suggesting	O
that	O
EBF	B
interacts	O
with	O
three	O
independent	O
sites	O
within	O
the	O
mouse	O
B29	O
promoter	O
.	O
Furthermore	O
,	O
ectopic	O
expression	O
of	O
EBF	B
in	O
HeLa	O
cells	O
activated	O
a	O
B29	O
promoter	O
-	O
controlled	O
reporter	O
construct	O
13-fold	O
and	O
induced	O
a	O
low	O
level	O
of	O
expression	O
from	O
the	O
endogenous	O
B29	O
gene	O
.	O
Finally	O
,	O
mutations	O
in	O
the	O
EBF	B
binding	O
sites	O
diminished	O
B29	O
promoter	O
activity	O
in	O
pre	O
-	O
B	O
cells	O
while	O
the	O
same	O
mutations	O
did	O
not	O
have	O
as	O
striking	O
an	O
effect	O
on	O
the	O
promoter	O
function	O
in	O
B	O
-	O
cell	O
lines	O
of	O
later	O
differentiation	O
stages	O
.	O
These	O
data	O
suggest	O
that	O
the	O
B29	O
gene	O
is	O
a	O
genetic	O
target	O
for	O
EBF	B
in	O
early	O
B	O
-	O
cell	O
development	O
.	O
Effect	O
of	O
environmental	O
estrogens	O
on	O
IL-1beta	O
promoter	O
activity	O
in	O
a	O
macrophage	O
cell	O
line	O
.	O
Environmental	O
estrogens	O
or	O
estrogen	O
disrupters	O
have	O
recently	O
received	O
a	O
great	O
deal	O
of	O
attention	O
because	O
of	O
their	O
potential	O
health	O
impact	O
on	O
reproductive	O
tissues	O
.	O
Few	O
,	O
if	O
any	O
,	O
studies	O
have	O
been	O
made	O
on	O
the	O
impact	O
of	O
these	O
compounds	O
on	O
the	O
immune	O
system	O
.	O
We	O
sought	O
to	O
determine	O
the	O
activities	O
of	O
various	O
environmental	O
estrogens	O
on	O
the	O
modulation	O
of	O
the	O
interleukin-1beta	O
(	O
IL-1beta	O
)	O
gene	O
in	O
a	O
model	O
monocytic	O
cell	O
line	O
,	O
hER	O
+	O
IL-1beta	O
-	O
CAT+	O
.	O
This	O
cell	O
line	O
stably	O
transfected	O
with	O
the	O
human	B
estrogen	I
receptor	I
,	O
and	O
an	O
IL-1beta	O
promoter	O
construct	O
fused	O
to	O
the	O
CAT	O
reporter	O
gene	O
allows	O
us	O
to	O
monitor	O
the	O
effect	O
of	O
estrogenic	O
compounds	O
on	O
IL-1beta	O
promoter	O
activity	O
.	O
17beta	O
-	O
estradiol	O
(	O
E2	O
)	O
markedly	O
enhanced	O
lipopolysaccharide	O
-	O
(	O
LPS	O
)	O
induced	O
IL-1beta	O
promoter	O
-driven	O
CAT	B
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
The	O
mycotoxins	O
alpha	O
-	O
zearalenol	O
and	O
zearalenone	O
both	O
exhibited	O
full	O
agonist	O
activity	O
,	O
but	O
at	O
lower	O
potencies	O
,	O
with	O
EC50	O
values	O
of	O
1.8	O
and	O
54	O
nM	O
,	O
respectively	O
,	O
compared	O
with	O
E2	O
at	O
0.5	O
nM	O
.	O
In	O
addition	O
,	O
genistein	O
was	O
a	O
very	O
low	O
-	O
potency	O
agonist	O
,	O
having	O
an	O
EC50	O
of	O
1.5	O
microM	O
.	O
Similar	O
to	O
the	O
E2	O
response	O
,	O
the	O
slope	O
factors	O
for	O
alpha	O
-	O
zearalenol	O
,	O
zearalenone	O
,	O
and	O
genistein	O
were	O
close	O
to	O
3.0	O
,	O
suggesting	O
positive	O
cooperativity	O
in	O
the	O
estrogenic	O
response	O
.	O
The	O
activity	O
of	O
the	O
mycotoxins	O
appeared	O
to	O
be	O
mediated	O
through	O
the	O
estrogen	O
receptor	O
,	O
since	O
both	O
the	O
antiestrogens	O
H1285	O
and	O
ICI	O
182	O
,	O
780	O
effectively	O
inhibited	O
their	O
agonist	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
Representative	O
environmental	O
estrogenic	O
compounds	O
both	O
from	O
plant	O
and	O
industrial	O
sources	O
were	O
also	O
tested	O
.	O
Unlike	O
the	O
mycoestrogens	O
,	O
none	O
of	O
the	O
compounds	O
,	O
with	O
the	O
exception	O
of	O
genistein	O
,	O
synergized	O
with	O
LPS	O
to	O
enhance	O
IL-1beta	O
promoter	O
activity	O
.	O
When	O
tested	O
for	O
antiestrogenic	O
activity	O
,	O
the	O
industrial	O
compound	O
4-octylphenol	O
was	O
able	O
to	O
antagonize	O
the	O
response	O
to	O
E2	O
;	O
however	O
,	O
the	O
response	O
was	O
three	O
orders	O
of	O
magnitude	O
less	O
potent	O
than	O
H	O
1285	O
.	O
Naringenin	O
,	O
a	O
plant	O
flavonoid	O
,	O
showed	O
little	O
or	O
no	O
ability	O
to	O
antagonize	O
the	O
response	O
to	O
E2	O
.	O
Overall	O
,	O
the	O
results	O
show	O
that	O
some	O
environmental	O
estrogens	O
that	O
display	O
agonist	O
activity	O
in	O
reproductive	O
tissue	O
also	O
have	O
an	O
effect	O
on	O
IL-1	O
gene	O
expression	O
in	O
hemopoietic	O
-	O
derived	O
tissue	O
.	O
X	O
-	O
rays	O
-	O
induced	O
secretion	O
of	O
cellular	B
factor	I
(	O
s	O
)	O
that	O
enhance	O
(	O
s	O
)	O
HIV-1	O
promoter	O
transcription	O
in	O
various	O
non	O
-	O
irradiated	O
transfected	O
cell	O
lines	O
.	O
Various	O
cellular	O
stress	O
agents	O
like	O
ionizing	O
radiation	O
exposure	O
could	O
activate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-	O
1	O
)	O
replication	O
or	O
reporter	O
gene	O
expression	O
.	O
In	O
addition	O
,	O
extracellular	B
factor	I
(	O
s	O
)	O
released	O
by	O
X	O
-	O
ray	O
-	O
treated	O
human	O
colonic	O
carcinoma	O
cell	O
line	O
(	O
HT29	O
)	O
might	O
activate	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV-1	O
in	O
non	O
-	O
irradiated	O
HT29	O
cells	O
.	O
In	O
the	O
present	O
report	O
we	O
show	O
that	O
in	O
various	O
transiently	O
or	O
stably	O
transfected	O
cell	O
lines	O
,	O
X	O
-	O
ray	O
irradiation	O
up	O
-	O
regulates	O
HIV-1	O
LTR	O
transcription	O
through	O
the	O
kappaB	B
regulatory	I
elements	I
.	O
A	O
factor	O
(	O
s	O
)	O
,	O
which	O
is	O
processed	O
by	O
and	O
acts	O
upon	O
a	O
variety	O
of	O
cell	O
types	O
,	O
was	O
detected	O
by	O
addition	O
to	O
non	O
-	O
irradiated	O
cells	O
of	O
either	O
X	O
-	O
ray	O
-	O
treated	O
cells	O
or	O
a	O
conditioned	O
medium	O
taken	O
from	O
irradiated	O
cultures	O
.	O
The	O
magnitude	O
of	O
responsiveness	O
is	O
cell	O
type	O
dependent	O
.	O
In	O
addition	O
,	O
X	O
-	O
ray	O
activation	O
of	O
HIV-1	O
LTR	O
in	O
transiently	O
or	O
stably	O
transfected	O
cell	O
lines	O
is	O
inhibited	O
by	O
a	O
potent	O
antioxidant	O
drug	O
,	O
pyrrolidine	O
dithiocarbamate	O
and	O
by	O
another	O
drug	O
,	O
known	O
for	O
its	O
role	O
in	O
the	O
trapping	O
of	O
growth	B
factors	I
,	O
suramin	O
.	O
The	O
importance	O
of	O
these	O
observations	O
in	O
the	O
pathophysiology	O
of	O
patients	O
with	O
AIDS	O
-	O
related	O
cancers	O
treated	O
by	O
radiotherapy	O
remains	O
to	O
be	O
established	O
.	O
Transcription	B
factor	I
binding	O
to	O
the	O
core	O
promoter	O
of	O
the	O
human	O
monoamine	O
oxidase	O
B	O
gene	O
in	O
the	O
cerebral	O
cortex	O
and	O
in	O
blood	O
cells	O
.	O
Many	O
studies	O
show	O
that	O
monoamine	B
oxidase	I
B	I
in	O
blood	O
cells	O
is	O
a	O
biological	O
marker	O
for	O
personality	O
characteristics	O
such	O
as	O
sensation	O
seeking	O
.	O
The	O
mechanism	O
underlying	O
this	O
association	O
is	O
so	O
far	O
not	O
explored	O
.	O
In	O
the	O
present	O
study	O
we	O
have	O
performed	O
electrophoretic	O
mobility	O
-	O
shift	O
assays	O
to	O
investigate	O
the	O
pattern	O
of	O
protein	O
binding	O
to	O
a	O
150	O
bp	O
fragment	O
of	O
the	O
proximal	O
5'-flanking	O
region	O
of	O
the	O
human	O
monoamine	O
oxidase	O
B	O
gene	O
.	O
We	O
compared	O
the	O
pattern	O
using	O
nuclear	O
extracts	O
from	O
human	O
brain	O
and	O
lymphocytes	O
.	O
Interestingly	O
,	O
a	O
correlation	O
was	O
observed	O
between	O
monoamine	B
oxidase	I
B	I
enzyme	O
activity	O
in	O
blood	O
cells	O
(	O
platelets	O
)	O
and	O
the	O
binding	O
pattern	O
of	O
two	O
uncharacterized	O
transcription	B
factors	I
.	O
These	O
data	O
are	O
well	O
in	O
line	O
with	O
the	O
long	O
-	O
standing	O
notion	O
that	O
interindividual	O
differences	O
in	O
platelet	B
monoamine	I
oxidase	I
may	O
represent	O
differences	O
in	O
expression	O
of	O
the	O
enzyme	O
rather	O
than	O
genotypic	O
variation	O
.	O
Regulation	O
of	O
fas	O
-	O
ligand	O
expression	O
during	O
activation	O
-	O
induced	O
cell	O
death	O
in	O
T	O
lymphocytes	O
via	O
nuclear	B
factor	I
kappaB	I
.	O
T	O
cell	O
receptor	O
engagement	O
activates	O
transcription	B
factors	I
important	O
for	O
cytokine	O
gene	O
regulation	O
.	O
Additionally	O
,	O
this	O
signaling	O
pathway	O
also	O
leads	O
to	O
activation	O
-	O
induced	O
apoptosis	O
in	O
T	O
lymphocytes	O
that	O
is	O
dependent	O
on	O
FasL	O
transcription	O
and	O
expression	O
.	O
Here	O
we	O
demonstrate	O
that	O
nuclear	B
factor	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
many	O
cytokine	O
genes	O
expressed	O
in	O
activated	O
lymphocytes	O
,	O
also	O
plays	O
a	O
role	O
in	O
T	O
cell	O
activation	O
-	O
induced	O
FasL	B
expression	O
.	O
Inhibition	O
of	O
NF	B
-	I
kappaB	I
activity	O
in	O
a	O
T	O
cell	O
hybridoma	O
leads	O
to	O
decreased	O
FasL	B
expression	O
and	O
apoptosis	O
upon	O
T	B
cell	I
receptor	I
stimulation	O
.	O
We	O
identified	O
the	O
NF	O
-	O
kappaB	O
site	O
in	O
the	O
FasL	O
promoter	O
that	O
contributes	O
to	O
such	O
regulation	O
.	O
Co	O
-	O
expression	O
of	O
p65	B
(	I
Rel	I
A	I
)	I
with	O
the	O
FasL	O
promoter	O
enhanced	O
its	O
activity	O
,	O
and	O
co	O
-	O
expression	O
of	O
IkappaB	B
dramatically	O
inhibited	O
the	O
inducible	O
promoter	O
activity	O
.	O
In	O
contrast	O
,	O
the	O
transcription	B
factor	I
AP-1	I
is	O
not	O
required	O
for	O
activation	O
-	O
induced	O
FasL	B
promoter	O
activity	O
.	O
These	O
results	O
define	O
a	O
role	O
for	O
NF	B
-	I
kappaB	I
in	O
mediating	O
FasL	B
expression	O
during	O
T	O
cell	O
activation	O
.	O
Characterisation	O
of	O
regulatory	O
sequences	O
at	O
the	O
Epstein	O
-	O
Barr	O
virus	O
BamHI	O
W	O
promoter	O
.	O
Epstein	O
-	O
Barr	O
virus	O
,	O
a	O
human	O
gammaherpesvirus	O
,	O
possesses	O
a	O
unique	O
set	O
of	O
latent	O
genes	O
whose	O
constitutive	O
expression	O
in	O
B	O
cells	O
leads	O
to	O
cell	O
growth	O
transformation	O
.	O
The	O
initiation	O
of	O
this	O
growth	O
transforming	O
infection	O
depends	O
on	O
a	O
viral	O
promoter	O
in	O
BamHI	O
W	O
(	O
Wp	O
)	O
whose	O
regulation	O
is	O
poorly	O
understood	O
.	O
Using	O
Wp	O
reporter	O
constructs	O
in	O
in	O
vitro	O
transfection	O
assays	O
,	O
we	O
found	O
that	O
Wp	O
was	O
11-	O
to	O
190-fold	O
more	O
active	O
in	O
B	O
cell	O
than	O
in	O
non	O
-	O
B	O
cell	O
lines	O
and	O
that	O
three	O
regions	O
of	O
the	O
promoter	O
(	O
termed	O
UAS1	O
,	O
UAS2	O
,	O
and	O
UAS3	O
)	O
contributed	O
to	O
transcriptional	O
activation	O
.	O
The	O
upstream	O
regions	O
UAS3	O
(	O
-1168	O
to	O
-440	O
)	O
and	O
UAS2	O
(	O
-352	O
to	O
-264	O
)	O
both	O
functioned	O
in	O
a	O
cell	O
lineage	O
-	O
independent	O
manner	O
and	O
were	O
together	O
responsible	O
for	O
the	O
bulk	O
of	O
Wp	O
activity	O
in	O
non	O
-	O
B	O
cells	O
;	O
mutational	O
analysis	O
indicated	O
the	O
importance	O
of	O
a	O
YY1	O
binding	O
site	O
in	O
UAS2	O
in	O
that	O
context	O
.	O
By	O
contrast	O
,	O
UAS1	O
(	O
-140	O
to	O
-87	O
)	O
was	O
B	O
cell	O
specific	O
and	O
was	O
the	O
key	O
determinant	O
of	O
the	O
promoter	O
's	O
increased	O
activity	O
in	O
B	O
cell	O
lines	O
.	O
Mutational	O
analysis	O
of	O
UAS1	O
sequences	O
combined	O
with	O
in	O
vitro	O
bandshift	O
assays	O
revealed	O
the	O
presence	O
of	O
three	O
binding	O
sites	O
for	O
cellular	B
factors	I
in	O
this	O
region	O
.	O
When	O
mutations	O
that	O
abolished	O
factor	O
binding	O
in	O
bandshift	O
assays	O
were	O
introduced	O
into	O
a	O
Wp	O
reporter	O
construct	O
,	O
the	O
loss	O
of	O
any	O
one	O
of	O
the	O
three	O
UAS1	O
binding	O
sites	O
was	O
sufficient	O
to	O
reduce	O
promoter	O
activity	O
by	O
10-	O
to	O
30-fold	O
in	O
B	O
cells	O
.	O
From	O
sequence	O
analysis	O
,	O
two	O
of	O
these	O
appear	O
to	O
be	O
novel	O
transcription	B
factor	I
binding	O
sites	O
,	O
whereas	O
the	O
third	O
was	O
identified	O
as	O
a	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
.	O
Our	O
data	O
indicate	O
that	O
this	O
CRE	O
interacts	O
with	O
CREB	B
and	I
ATF1	I
proteins	I
present	O
in	O
B	O
cell	O
nuclear	O
extracts	O
and	O
that	O
this	O
interaction	O
is	O
important	O
for	O
Wp	O
activity	O
.	O
Direct	O
suppression	O
of	O
Stat1	B
function	O
during	O
adenoviral	O
infection	O
.	O
The	O
action	O
of	O
adenoviral	B
E1A	I
oncoprotein	I
on	O
host	O
immune	O
-	O
response	O
genes	O
has	O
been	O
attributed	O
to	O
interaction	O
with	O
p300	B
/	I
CBP	I
-	I
type	I
transcriptional	I
coactivators	I
in	O
competition	O
with	O
endogenous	B
transcription	I
factors	I
such	O
as	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
STAT	I
)	I
proteins	I
.	O
However	O
,	O
we	O
show	O
that	O
mutant	O
forms	O
of	O
E1A	B
that	O
no	O
longer	O
bind	O
p300	B
/	I
CBP	I
can	O
still	O
interact	O
directly	O
with	O
Stat1	B
(	O
via	O
E1A	B
N	I
-	I
terminal	I
and	I
Stat1	I
C	I
-	I
terminal	I
residues	I
)	O
and	O
block	O
IFNgamma	O
-	O
driven	O
,	O
Stat1	B
-dependent	O
gene	O
activation	O
and	O
consequent	O
function	O
during	O
early	O
-	O
phase	O
infection	O
in	O
the	O
natural	O
host	O
cell	O
.	O
The	O
results	O
provide	O
a	O
distinct	O
and	O
more	O
specific	O
mechanism	O
for	O
E1A	B
-mediated	O
immune	O
suppression	O
and	O
an	O
alternative	O
model	O
of	O
IFNgamma	B
-driven	O
enhanceosome	O
formation	O
that	O
may	O
allow	O
for	O
other	O
adaptors	O
(	O
in	O
addition	O
to	O
p300	B
/	I
CBP	I
)	O
to	O
link	O
Stat1	B
to	O
the	O
basal	B
transcription	I
complex	I
.	O
Human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
tax	I
protein	I
abrogates	O
interleukin-2	B
dependence	O
in	O
a	O
mouse	O
T	O
-	O
cell	O
line	O
.	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O
Tax	B
,	O
the	O
viral	B
protein	I
,	O
is	O
thought	O
to	O
be	O
crucial	O
in	O
the	O
development	O
of	O
the	O
disease	O
,	O
since	O
it	O
transforms	O
healthy	O
T	O
cells	O
in	O
vitro	O
and	O
induces	O
tumors	O
in	O
transgenic	O
animals	O
.	O
We	O
examined	O
the	O
effect	O
of	O
Tax	B
activity	O
on	O
the	O
growth	O
of	O
the	O
interleukin-2	O
(	O
IL-2	O
)	O
-dependent	O
T	O
-	O
cell	O
line	O
CTLL-2	O
.	O
Stable	O
expression	O
of	O
Tax	B
in	O
CTLL-2	O
transformed	O
cell	O
growth	O
from	O
being	O
IL-2	B
dependent	O
to	O
IL-2	B
independent	O
.	O
Tax	B
stimulated	O
transcription	O
through	O
NF	B
-	I
kappaB	I
and	O
the	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
-	O
like	O
sequence	O
in	O
the	O
HTLV-1	O
promoter	O
.	O
The	O
finding	O
of	O
Tax	B
mutants	O
segregating	O
these	O
two	O
pathways	O
suggested	O
that	O
the	O
NF	B
-	I
kappaB	I
pathway	O
was	O
essential	O
for	O
IL-2	B
-independent	O
growth	O
of	O
CTLL-2	O
cells	O
while	O
the	O
CRE	O
pathway	O
was	O
unnecessary	O
.	O
However	O
,	O
both	O
pathways	O
were	O
necessary	O
for	O
another	O
transformation	O
-	O
related	O
activity	O
(	O
colony	O
formation	O
in	O
soft	O
agar	O
)	O
of	O
CTLL-2	B
/	I
Tax	I
.	O
Our	O
results	O
show	O
that	O
Tax	B
has	O
at	O
least	O
two	O
distinct	O
activities	O
on	O
T	O
cells	O
,	O
and	O
suggest	O
that	O
Tax	B
plays	O
a	O
crucial	O
role	O
in	O
IL-2	B
-independent	O
T	O
-	O
cell	O
transformation	O
induced	O
by	O
HTLV-1	O
,	O
in	O
addition	O
to	O
its	O
well	O
-	O
known	O
IL-2	B
-dependent	O
cell	O
transformation	O
.	O
Mice	O
lacking	O
the	O
transcription	B
factor	I
CIITA	B
--	O
a	O
second	O
look	O
.	O
We	O
have	O
generated	O
a	O
second	O
line	O
of	O
mice	O
lacking	O
a	O
transcription	B
factor	I
thought	O
to	O
be	O
a	O
critical	O
regulator	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
,	O
CIITA	B
(	O
for	O
class	O
II	O
transactivator	B
)	O
.	O
Our	O
and	O
the	O
previously	O
published	O
lines	O
differ	O
in	O
the	O
deletion	O
that	O
was	O
engineered	O
and	O
by	O
the	O
fact	O
that	O
we	O
removed	O
the	O
neomycin	O
-	O
resistance	O
promoter	O
and	O
structural	O
gene	O
via	O
the	O
cre	O
-	O
loxP	O
recombination	O
system	O
.	O
Characterization	O
of	O
our	O
line	O
led	O
to	O
two	O
new	O
findings	O
.	O
First	O
,	O
a	O
substantial	O
number	O
of	O
cells	O
can	O
express	O
class	B
II	I
molecules	I
in	O
the	O
absence	O
of	O
CIITA	B
,	O
albeit	O
at	O
5-fold	O
reduced	O
levels	O
,	O
most	O
notably	O
dendritic	O
cells	O
in	O
s.c	O
.	O
lymph	O
nodes	O
;	O
therefore	O
,	O
the	O
CIITA	O
gene	O
can	O
not	O
be	O
an	O
absolute	O
'	O
master	O
gene	O
'	O
controlling	O
the	O
expression	O
of	O
class	B
II	I
molecules	I
,	O
as	O
had	O
been	O
thought	O
.	O
Second	O
,	O
in	O
contrast	O
to	O
recent	O
results	O
on	O
human	O
cell	O
lines	O
,	O
CIITA	B
is	O
not	O
critically	O
involved	O
in	O
the	O
IFN	B
-	I
gamma	I
-induced	O
up	O
-	O
regulation	O
of	O
MHC	O
class	O
I	O
genes	O
.	O
Differential	O
monocyte	O
adhesion	O
and	O
adhesion	B
molecule	I
expression	O
in	O
venous	O
and	O
arterial	O
endothelial	O
cells	O
.	O
We	O
compared	O
U-937	O
cell	O
adhesion	O
and	O
adhesion	B
molecule	I
expression	O
in	O
human	O
umbilical	O
venous	O
(	O
HUVECs	O
)	O
and	O
arterial	O
(	O
HUAECs	O
)	O
endothelial	O
cells	O
exposed	O
to	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
,	O
interleukin-1	B
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
TNF	B
and	O
LPS	O
stimulated	O
vascular	B
cell	I
adhesion	I
molecule	I
(	O
VCAM	B
)	O
-1	O
surface	O
expression	O
and	O
adhesion	O
of	O
U-937	O
monocyte	O
-	O
like	O
cells	O
to	O
HUVECs	O
but	O
not	O
to	O
HUAECs	O
.	O
Antibody	O
studies	O
demonstrated	O
that	O
in	O
HUVECs	O
at	O
least	O
75	O
%	O
of	O
the	O
adhesion	O
response	O
is	O
VCAM-1	B
mediated	O
.	O
Interleukin-1	B
stimulated	O
U-937	O
cell	O
adhesion	O
to	O
and	O
VCAM-1	B
surface	O
expression	O
in	O
both	O
HUVECs	O
and	O
HUAECs	O
.	O
Pyrrolidinedithiocarbamate	O
and	O
the	O
proteasome	O
inhibitor	O
MG-132	O
blocked	O
TNF	B
-and	O
LPS	O
-	O
stimulated	O
U-937	O
cell	O
adhesion	O
to	O
HUVECs	O
.	O
These	O
agents	O
also	O
significantly	O
decreased	O
TNF	B
-and	O
LPS	O
-	O
stimulated	O
increases	O
in	O
HUVEC	B
surface	I
VCAM-1	I
.	O
TNF	B
increased	O
VCAM-1	B
protein	O
and	O
mRNA	O
in	O
HUVECs	O
that	O
was	O
blocked	O
by	O
pyrrolidinedithiocarbamate	O
.	O
However	O
,	O
neither	O
TNF	B
or	O
LPS	O
stimulated	O
VCAM-1	B
expression	O
in	O
HUAECs	O
.	O
TNF	B
stimulated	O
expression	O
of	O
both	O
intercellular	B
adhesion	I
molecule-1	I
and	O
E	B
-	I
selectin	I
in	O
HUVECs	O
,	O
but	O
in	O
HUAECs	O
,	O
only	O
intercellular	B
adhesion	I
molecule-1	I
was	O
increased	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
no	O
difference	O
in	O
the	O
pattern	O
of	O
TNF	B
-stimulated	O
nuclear	B
factor	I
-	I
kappaB	I
activation	O
between	O
HUVECs	O
and	O
HUAECs	O
.	O
These	O
studies	O
demonstrate	O
a	O
novel	O
and	O
striking	O
insensitivity	O
of	O
arterial	O
endothelium	O
to	O
the	O
effects	O
of	O
TNF	B
and	O
LPS	O
and	O
indicate	O
a	O
dissociation	O
between	O
the	O
ability	O
of	O
HUAECs	O
to	O
upregulate	O
nuclear	B
factor	I
-	I
kappaB	I
and	O
VCAM-1	B
.	O
Tissue	O
factor	O
expression	O
of	O
human	O
monocytes	O
is	O
suppressed	O
by	O
lysophosphatidylcholine	O
.	O
The	O
expression	O
of	O
tissue	B
factor	I
(	O
TF	B
)	O
,	O
the	O
principal	O
initiator	O
of	O
coagulation	O
,	O
is	O
increased	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O
Both	O
conditions	O
are	O
promoted	O
by	O
lysophosphatidylcholine	O
(	O
lysoPC	O
)	O
.	O
We	O
observed	O
in	O
the	O
present	O
study	O
that	O
lysoPC	O
(	O
1	O
to	O
10	O
micromol	O
/	O
L	O
)	O
dose	O
-	O
dependently	O
reduced	O
TF	B
activity	O
in	O
human	O
monocytes	O
,	O
as	O
elicited	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
Lysophosphatidylethanolamine	O
(	O
lysoPE	O
)	O
and	O
other	O
lysophospholipids	O
did	O
not	O
affect	O
LPS	O
-	O
induced	O
TF	O
activity	O
of	O
human	O
monocytes	O
.	O
TF	O
antigen	O
expression	O
as	O
elicited	O
by	O
LPS	O
was	O
also	O
lowered	O
by	O
lysoPC	O
.	O
Phospholipid	O
analyses	O
indicated	O
a	O
selective	O
increase	O
in	O
the	O
lysoPC	O
content	O
of	O
the	O
monocytes	O
after	O
preincubation	O
with	O
the	O
lysophospholipid	O
.	O
LysoPC	O
inhibited	O
the	O
TF	O
activity	O
of	O
Mono	O
Mac-6	O
cells	O
to	O
a	O
similar	O
extent	O
as	O
in	O
the	O
monocytes	O
.	O
LPS	O
binding	O
to	O
plasma	O
membrane	O
receptors	O
and	O
internalization	O
of	O
LPS	O
into	O
monocytes	O
were	O
not	O
affected	O
by	O
lysoPC	O
.	O
In	O
contrast	O
,	O
LPS	O
-	O
mediated	O
nuclear	O
binding	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
/	I
Rel	I
to	O
a	O
TF	O
-	O
specific	O
kappaB	O
site	O
was	O
inhibited	O
by	O
lysoPC	O
.	O
Induction	O
of	O
TF	O
mRNA	O
expression	O
by	O
LPS	O
tended	O
to	O
be	O
partially	O
reduced	O
by	O
the	O
lysophospholipid	O
.	O
Preincubation	O
with	O
lysoPC	O
increased	O
monocytic	O
cAMP	O
levels	O
.	O
Inhibition	O
of	O
adenylyl	B
cyclase	I
by	O
pretreatment	O
with	O
2'-deoxy-3'-adenosine	B
monophosphate	I
partially	O
reversed	O
the	O
inhibition	O
of	O
TF	O
activity	O
promoted	O
by	O
lysoPC	O
.	O
In	O
conclusion	O
,	O
lysoPC	O
markedly	O
decreases	O
LPS	O
-	O
mediated	O
TF	O
expression	O
of	O
human	O
monocytes	O
,	O
the	O
effect	O
probably	O
being	O
mediated	O
by	O
both	O
transcriptional	O
and	O
posttranscriptional	O
mechanisms	O
.	O
LysoPC	O
may	O
thus	O
attenuate	O
activation	O
of	O
coagulation	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O
Intranuclear	O
targeted	O
delivery	O
of	O
functional	O
NF	B
-	I
kappaB	I
by	O
70	B
kDa	I
heat	I
shock	I
protein	I
.	O
The	O
70	B
kDa	I
heat	I
shock	I
protein	I
(	O
Hsp70	B
)	O
is	O
a	O
highly	O
conserved	O
,	O
ubiquitous	B
protein	I
involved	O
in	O
chaperoning	B
proteins	I
to	O
various	O
cellular	O
organelles	O
.	O
Here	O
we	O
show	O
that	O
when	O
added	O
exogenously	O
to	O
cells	O
,	O
Hsp70	B
is	O
readily	O
imported	O
into	O
both	O
cytoplasmic	O
and	O
nuclear	O
compartments	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
fashion	O
.	O
We	O
exploited	O
this	O
ability	O
of	O
Hsp70	B
to	O
deliver	O
NF	B
-	I
kappaB	I
,	O
a	O
key	O
transcriptional	O
regulator	O
of	O
inflammatory	O
responses	O
.	O
We	O
demonstrate	O
that	O
a	O
fusion	O
protein	O
composed	O
of	O
a	O
C	O
-	O
terminal	O
Hsp70	B
peptide	O
and	O
the	O
p50	B
subunit	I
of	O
NF	B
-	I
kappaB	I
was	O
directed	O
into	O
the	O
nucleus	O
of	O
cells	O
,	O
could	O
bind	O
DNA	O
specifically	O
,	O
and	O
activated	O
Igkappa	B
expression	O
and	O
TNFalpha	B
production	O
.	O
We	O
therefore	O
propose	O
that	O
Hsp70	B
can	O
be	O
used	O
as	O
a	O
vehicle	O
for	O
intracytoplasmic	O
and	O
intranuclear	O
delivery	O
of	O
proteins	O
or	O
DNA	O
to	O
modulate	O
gene	O
expression	O
and	O
thereby	O
control	O
immune	O
responses	O
.	O
CD2	B
signalling	O
induces	O
phosphorylation	O
of	O
CREB	B
in	O
primary	O
lymphocytes	O
.	O
Promoter	O
sequences	O
responsive	O
to	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
are	O
found	O
in	O
a	O
number	O
of	O
cellular	O
genes	O
,	O
and	O
bind	O
transcription	B
factors	I
of	O
the	O
cAMP	B
response	I
element	I
binding	I
protein	I
(	O
CREB	B
)	I
/activating	I
transcription	I
factor-1	I
(	I
ATF-1	I
)	I
family	I
.	O
We	O
have	O
used	O
a	O
human	O
T	O
-	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
model	O
of	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
transcription	O
to	O
investigate	O
the	O
influence	O
of	O
lymphocyte	O
activation	O
on	O
transcription	O
from	O
homologous	O
regions	O
in	O
the	O
viral	O
promoter	O
.	O
We	O
previously	O
demonstrated	O
increased	O
HTLV-1	O
transcription	O
following	O
CD2	O
but	O
not	O
CD3	O
receptor	O
cross	O
-	O
linking	O
.	O
We	O
hypothesized	O
that	O
this	O
increased	O
viral	O
transcription	O
was	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
phosphorylation	O
of	O
CREB	B
.	O
Therefore	O
,	O
we	O
investigated	O
CD2	B
and	O
CD3	B
receptor	I
-mediated	O
signalling	O
in	O
primary	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O
CD2	B
,	O
but	O
not	O
CD3	B
,	O
cross	O
-	O
linking	O
increased	O
cAMP	O
detected	O
by	O
competitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
approximately	O
fourfold	O
.	O
CD2	B
cross	O
-	O
linking	O
concurrently	O
increased	O
phosphorylation	O
of	O
CREB	B
detected	O
by	O
immunoblot	O
assay	O
eightfold	O
.	O
Consistent	O
with	O
post	O
-	O
translational	O
regulation	O
,	O
no	O
change	O
in	O
total	O
level	O
of	O
CREB	B
protein	O
was	O
observed	O
.	O
Phosphorylation	O
of	O
CREB	B
occurred	O
through	O
a	O
herbimycin	O
A	O
and	O
Rp	O
-	O
cAMP-	O
sensitive	O
pathway	O
,	O
suggesting	O
phosphorylation	O
required	O
antecedent	O
activation	O
of	O
both	O
protein	B
tyrosine	I
kinases	I
(	O
PTK	B
)	O
and	O
protein	B
kinase	I
A	I
(	O
PKA	B
)	O
.	O
Both	O
CD2	B
and	O
CD3	B
cross	O
-	O
linking	O
increased	O
binding	O
of	O
nuclear	B
proteins	I
to	O
a	O
radiolabelled	O
CRE	O
oligonucleotide	O
probe	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggesting	O
that	O
lymphocyte	O
activation	O
enhances	O
binding	O
independently	O
of	O
phosphorylation	O
of	O
CREB	B
at	O
serine	O
133	O
.	O
These	O
data	O
indicate	O
specific	O
modulation	O
of	O
the	O
CREB	B
/	I
ATF-1	I
family	I
of	O
transcription	B
factors	I
by	O
the	O
CD2	B
signalling	O
pathway	O
and	O
suggest	O
CD2	B
receptor	O
modulation	O
of	O
CRE	O
-mediated	O
transcription	O
following	O
ligand	O
engagement	O
(	O
e.g.	O
cell	O
-	O
to	O
-	O
cell	O
contact	O
)	O
.	O
Protective	O
effects	O
of	O
notch-1	B
on	O
TCR	B
-induced	O
apoptosis	O
.	O
The	O
Notch	B
receptor	I
protein	I
was	O
originally	O
identified	O
in	O
Drosophila	O
and	O
is	O
known	O
to	O
mediate	O
cell	O
to	O
cell	O
communication	O
and	O
influence	O
cell	O
fate	O
decisions	O
.	O
Members	O
of	O
this	O
family	O
have	O
been	O
isolated	O
from	O
invertebrates	O
as	O
well	O
as	O
vertebrates	O
.	O
We	O
isolated	O
mouse	B
Notch-1	I
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
with	O
Nur77	B
,	O
which	O
is	O
a	O
protein	O
that	O
has	O
been	O
shown	O
previously	O
to	O
be	O
required	O
for	O
apoptosis	O
in	O
T	O
cell	O
lines	O
.	O
The	O
data	O
presented	O
below	O
indicate	O
that	O
Notch-1	B
expression	O
provides	O
significant	O
protection	O
to	O
T	O
cell	O
lines	O
from	O
TCR	B
-mediated	O
apoptosis	O
.	O
These	O
data	O
demonstrate	O
a	O
new	O
antiapoptotic	O
role	O
for	O
Notch-1	B
,	O
providing	O
evidence	O
that	O
,	O
in	O
addition	O
to	O
regulating	O
cell	O
fate	O
decisions	O
,	O
Notch-1	B
can	O
play	O
a	O
critical	O
role	O
in	O
controlling	O
levels	O
of	O
cell	O
death	O
in	O
T	O
cells	O
.	O
Requirement	O
of	O
GATA-1	B
and	O
p45	B
NF	I
-	I
E2	I
expression	O
in	O
butyric	O
acid	O
-	O
induced	O
erythroid	O
differentiation	O
.	O
Butyric	O
acid	O
(	O
BA	O
)	O
is	O
known	O
to	O
induce	O
overexpression	O
of	O
fetal	B
hemoglobin	I
and	O
then	O
erythroid	O
differentiation	O
.	O
Therefore	O
,	O
BA	O
is	O
currently	O
under	O
clinical	O
investigation	O
as	O
a	O
potential	O
therapy	O
for	O
the	O
treatment	O
of	O
sickle	O
cell	O
disease	O
and	O
cancer	O
.	O
Nevertheless	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
BA	O
-	O
induced	O
differentiation	O
remain	O
largely	O
unknown	O
.	O
Previous	O
reports	O
have	O
shown	O
that	O
BA	O
-	O
induced	O
overexpression	O
of	O
erythroid	O
genes	O
occurred	O
at	O
the	O
transcriptional	O
level	O
,	O
suggesting	O
the	O
involvement	O
of	O
erythroid	B
transcription	I
factors	I
.	O
Here	O
,	O
we	O
intend	O
to	O
demonstrate	O
the	O
requirement	O
of	O
GATA-1	B
and	O
NF	B
-	I
E2	I
transcription	B
factors	I
in	O
the	O
BA	O
-	O
induced	O
erythroid	O
differentiation	O
of	O
human	O
leukemic	O
K562	O
cells	O
.	O
Time	O
-	O
course	O
experiments	O
showed	O
that	O
nuclear	O
levels	O
of	O
GATA-1	B
and	O
p45	B
NF	I
-	I
E2	I
proteins	O
increased	O
during	O
BA	O
treatment	O
.	O
Moreover	O
,	O
antisense	O
oligodeoxynucleotides	O
targeting	O
either	O
GATA-1	B
or	O
p45	B
NF	I
-	I
E2	I
proteins	O
inhibited	O
both	O
protein	O
expression	O
and	O
BA	O
-	O
induced	O
differentiation	O
.	O
In	O
contrast	O
,	O
BA	O
-	O
induced	O
cell	O
growth	O
inhibition	O
was	O
not	O
affected	O
.	O
These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
for	O
the	O
requirement	O
of	O
GATA-1	B
and	O
NF	B
-	I
E2	I
in	O
BA	O
-	O
induced	O
differentiation	O
process	O
.	O
Comparison	O
of	O
HTLV	O
-	O
I	O
basal	O
transcription	O
and	O
expression	O
of	O
CREB	B
/	I
ATF-1	I
/	I
CREM	I
family	I
members	I
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
Jurkat	O
T	O
cells	O
.	O
HTLV	O
-	O
I	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
/	O
lymphoma	O
and	O
is	O
associated	O
with	O
tropical	O
spastic	O
paraparesis	O
/	O
HTLV	O
-	O
I	O
-	O
associated	O
myelopathy	O
.	O
Following	O
integration	O
into	O
the	O
host	O
cell	O
genome	O
,	O
HTLV	O
-	O
I	O
replication	O
is	O
regulated	O
by	O
both	O
host	O
and	O
viral	O
mechanisms	O
that	O
control	O
transcription	O
.	O
Low	O
levels	O
of	O
viral	O
transcription	O
(	O
basal	O
transcription	O
)	O
occur	O
before	O
expression	O
of	O
the	O
virally	B
encoded	I
Tax	I
protein	I
(	O
Tax	B
-mediated	O
transcription	O
)	O
.	O
Members	O
of	O
the	O
cyclic	B
adenosine	I
monophosphate	I
(	I
cAMP	I
)	I
response	I
element	I
binding	I
(	I
CREB	I
)	I
/activating	I
transcription	I
factor	I
1	I
(	I
ATF-1	I
)	I
family	I
of	O
transcription	B
factors	I
bind	O
three	O
21-bp	O
repeats	O
(	O
Tax	O
-	O
responsive	O
element-1	O
,	O
or	O
TRE-1	O
)	O
within	O
the	O
viral	O
promoter	O
and	O
are	O
important	O
for	O
basal	O
and	O
Tax	O
-	O
mediated	O
transcription	O
.	O
Using	O
mitogen	O
stimulated	O
and	O
quiescent	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
Jurkat	O
cells	O
,	O
we	O
compared	O
differences	O
in	O
basal	O
transcription	O
and	O
amounts	O
and	O
binding	O
of	O
transcription	B
factors	I
with	O
TRE-1	O
.	O
We	O
demonstrate	O
that	O
amounts	O
of	O
transcriptionally	O
active	O
phosphorylated	B
CREB	I
protein	I
(	O
P	B
-	I
CREB	I
)	O
differ	O
between	O
activated	O
PBMC	O
and	O
Jurkat	O
cells	O
.	O
Following	O
stimulation	O
,	O
P	B
-	I
CREB	I
levels	O
remain	O
elevated	O
in	O
PBMC	O
for	O
up	O
to	O
24	O
hours	O
whereas	O
CREB	O
is	O
dephosphorylated	O
in	O
Jurkat	O
cells	O
within	O
4	O
hours	O
following	O
stimulation	O
.	O
The	O
differences	O
in	O
P	B
-	I
CREB	I
levels	O
between	O
PBMC	O
and	O
Jurkat	O
cells	O
were	O
directly	O
correlated	O
with	O
basal	O
transcription	O
of	O
HTLV	O
-	O
I	O
in	O
the	O
two	O
cell	O
types	O
.	O
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
determined	O
that	O
the	O
pattern	O
of	O
band	O
migration	O
differed	O
between	O
the	O
two	O
cell	O
types	O
.	O
These	O
data	O
demonstrate	O
that	O
PBMC	O
differentially	O
regulate	O
basal	O
HTLV	O
-	O
I	O
transcription	O
compared	O
with	O
Jurkat	O
T	O
cells	O
,	O
and	O
this	O
differential	O
regulation	O
is	O
due	O
,	O
in	O
part	O
to	O
differential	O
phosphorylation	O
and	O
binding	O
of	O
CREB	B
/	I
ATF-1	I
to	O
TRE-1	O
in	O
the	O
HTLV	O
-	O
I	O
promoter	O
.	O
We	O
demonstrate	O
the	O
utility	O
of	O
using	O
primary	O
lymphocyte	O
models	O
to	O
study	O
HTLV	O
-	O
I	O
transcription	O
in	O
the	O
context	O
of	O
cell	O
signaling	O
and	O
suggest	O
that	O
activated	O
PBMC	O
maintain	O
elevated	O
levels	O
of	O
P	B
-	I
CREB	I
,	O
which	O
promote	O
basal	O
HTLV	O
-	O
I	O
transcription	O
and	O
enhance	O
viral	O
persistence	O
in	O
vivo	O
.	O
Heterogeneity	O
of	O
clonal	O
development	O
in	O
chronic	O
myeloproliferative	O
disorders	O
.	O
Recent	O
reports	O
have	O
suggested	O
a	O
previously	O
unexpected	O
variability	O
in	O
the	O
expression	O
of	O
the	O
dominant	O
neoplastic	O
clone	O
in	O
myeloproliferative	O
disorders	O
(	O
MPD	O
)	O
.	O
We	O
evaluated	O
49	O
female	O
patients	O
with	O
MPD	O
and	O
informative	O
at	O
the	O
X	O
-	O
linked	O
androgen	O
receptor	O
(	O
AR	O
)	O
locus	O
to	O
establish	O
the	O
X	O
chromosome	O
inactivation	O
pattern	O
of	O
hemopoietic	O
cells	O
.	O
Whereas	O
in	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
the	O
granulocytes	O
(	O
PMN	O
)	O
were	O
uniformly	O
of	O
monoclonal	O
origin	O
,	O
a	O
striking	O
heterogeneity	O
of	O
clonal	O
development	O
was	O
found	O
in	O
PMN	O
from	O
patients	O
with	O
other	O
MPD	O
,	O
with	O
up	O
to	O
50	O
%	O
of	O
them	O
expressing	O
a	O
polyclonal	O
pattern	O
of	O
X	O
inactivation	O
.	O
NF	B
-	I
kappaB	I
activation	O
is	O
a	O
critical	O
regulator	O
of	O
human	O
granulocyte	O
apoptosis	O
in	O
vitro	O
.	O
During	O
beneficial	O
inflammation	O
,	O
potentially	O
tissue	O
-	O
damaging	O
granulocytes	O
undergo	O
apoptosis	O
before	O
being	O
cleared	O
by	O
phagocytes	O
in	O
a	O
non	O
-	O
phlogistic	O
manner	O
.	O
Here	O
we	O
show	O
that	O
the	O
rate	O
of	O
constitutive	O
apoptosis	O
in	O
human	O
neutrophils	O
and	O
eosinophils	O
is	O
greatly	O
accelerated	O
in	O
both	O
a	O
rapid	O
and	O
concentration	O
-	O
dependent	O
manner	O
by	O
the	O
fungal	O
metabolite	O
gliotoxin	O
,	O
but	O
not	O
by	O
its	O
inactive	O
analog	O
methylthiogliotoxin	O
.	O
This	O
induction	O
of	O
apoptosis	O
was	O
abolished	O
by	O
the	O
caspase	O
inhibitor	O
zVAD	O
-	O
fmk	O
,	O
correlated	O
with	O
the	O
inhibition	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappaB	I
)	O
,	O
and	O
was	O
mimicked	O
by	O
a	O
cell	O
permeable	O
inhibitory	O
peptide	O
of	O
NF	B
-	I
kappaB	I
,	O
SN-50	O
;	O
other	O
NF	B
-	I
kappaB	I
inhibitors	O
,	O
curcumin	O
and	O
pyrrolidine	O
dithiocarbamate	O
;	O
and	O
the	O
proteasome	O
inhibitor	O
,	O
MG-132	O
.	O
Gliotoxin	O
also	O
augmented	O
dramatically	O
the	O
early	O
(	O
2	O
-	O
6	O
h	O
)	O
pro	O
-	O
apoptotic	O
effects	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
in	O
neutrophils	O
and	O
unmasked	O
the	O
ability	O
of	O
TNF	B
-	I
alpha	I
to	O
induce	O
eosinophil	O
apoptosis	O
.	O
In	O
neutrophils	O
,	O
TNF	B
-	I
alpha	I
caused	O
a	O
gliotoxin	O
-	O
inhibitable	O
activation	O
of	O
an	O
inducible	O
form	O
of	O
NF	B
-	I
kappaB	I
,	O
a	O
response	O
that	O
may	O
underlie	O
the	O
ability	O
of	O
TNF	B
-	I
alpha	I
to	O
delay	O
apoptosis	O
at	O
later	O
times	O
(	O
12	O
-	O
24	O
h	O
)	O
and	O
limit	O
its	O
early	O
killing	O
effect	O
.	O
Furthermore	O
,	O
cycloheximide	O
displayed	O
a	O
similar	O
capacity	O
to	O
enhance	O
TNF	B
-	I
alpha	I
induced	O
neutrophil	O
apoptosis	O
even	O
at	O
time	O
points	O
when	O
cycloheximide	O
alone	O
had	O
no	O
pro	O
-	O
apoptotic	O
effect	O
,	O
suggesting	O
that	O
NF	B
-	I
kappaB	I
may	O
regulate	O
the	O
production	O
of	O
protein	O
(	O
s	O
)	O
which	O
protect	O
neutrophils	O
from	O
the	O
cytotoxic	O
effects	O
of	O
TNF	B
-	I
alpha	I
.	O
These	O
data	O
shed	O
light	O
on	O
the	O
biochemical	O
and	O
molecular	O
mechanisms	O
regulating	O
human	O
granulocyte	O
apoptosis	O
and	O
,	O
in	O
particular	O
,	O
indicate	O
that	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
the	O
physiological	O
cell	O
death	O
pathway	O
in	O
granulocytes	O
.	O
Tuberculosis	O
and	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
in	O
Africans	O
and	O
variation	O
in	O
the	O
vitamin	O
D	O
receptor	O
gene	O
.	O
The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1	O
,	O
25	O
dihydroxyvitamin	O
D3	O
,	O
is	O
an	O
important	O
immunoregulatory	O
hormone	O
[	O
1	O
]	O
.	O
Its	O
effects	O
are	O
exerted	O
by	O
interaction	O
with	O
the	O
vitamin	B
D	I
receptor	I
,	O
which	O
is	O
present	O
on	O
human	O
monocytes	O
and	O
activated	O
T	O
and	O
B	O
lymphocytes	O
.	O
Variation	O
in	O
the	O
vitamin	O
D	O
receptor	O
gene	O
was	O
typed	O
in	O
2015	O
subjects	O
from	O
large	O
case	O
-	O
control	O
studies	O
of	O
three	O
major	O
infectious	O
diseases	O
:	O
tuberculosis	O
,	O
malaria	O
,	O
and	O
hepatitis	O
B	O
virus	O
.	O
Homozygotes	O
for	O
a	O
polymorphism	O
at	O
codon	O
352	O
(	O
genotype	O
tt	O
)	O
were	O
significantly	O
underrepresented	O
among	O
those	O
with	O
tuberculosis	O
(	O
chi2=6.22	O
,	O
1	O
df	O
,	O
P=.01	O
)	O
and	O
persistent	O
hepatitis	O
B	O
infection	O
(	O
chi2=6.25	O
,	O
1	O
df	O
,	O
P=.01	O
)	O
but	O
not	O
in	O
subjects	O
with	O
clinical	O
malaria	O
compared	O
with	O
the	O
other	O
genotypes	O
.	O
Therefore	O
,	O
this	O
genetic	O
variant	O
,	O
which	O
predisposes	O
to	O
low	O
bone	O
mineral	O
density	O
in	O
many	O
populations	O
,	O
may	O
confer	O
resistance	O
to	O
certain	O
infectious	O
diseases	O
.	O
Cutting	O
edge	O
:	O
dominant	O
effect	O
of	O
Ile50Val	B
variant	I
of	O
the	O
human	B
IL-4	I
receptor	I
alpha	I
-	I
chain	I
in	O
IgE	B
synthesis	O
.	O
Two	O
variants	O
of	O
the	O
IL-4R	O
alpha	O
-	O
chain	O
(	O
IL-4Ralpha	O
)	O
gene	O
have	O
been	O
recently	O
identified	O
in	O
association	O
with	O
different	O
atopic	O
disorders	O
.	O
To	O
clarify	O
the	O
etiological	O
relationship	O
between	O
the	O
two	O
variants	O
,	O
we	O
analyzed	O
responsiveness	O
to	O
IL-4	B
of	O
transfectants	O
with	O
four	O
kinds	O
of	O
IL-4Ralpha	B
carrying	O
either	O
Val	O
or	O
Ile	O
at	O
50	B
and	O
either	O
Gln	O
or	O
Arg	O
at	O
551	B
.	O
The	O
substitution	O
of	O
Ile	O
for	O
Val	O
augmented	O
STAT6	B
activation	O
,	O
proliferation	O
,	O
and	O
transcription	O
activity	O
of	O
the	O
Iepsilon	O
promoter	O
by	O
IL-4	B
,	O
whereas	O
that	O
of	O
Arg	O
for	O
Gln	O
did	O
not	O
change	O
these	O
IL-4	B
signals	O
.	O
Arg551	O
was	O
not	O
associated	O
with	O
atopic	O
asthma	O
in	O
the	O
Japanese	O
population	O
.	O
CD23	B
expression	O
and	O
IgE	B
synthesis	O
by	O
IL-4	B
were	O
augmented	O
in	O
Ile50-bearing	O
PBMC	O
,	O
compared	O
with	O
those	O
bearing	O
Val50	O
.	O
Taken	O
together	O
,	O
substitution	O
of	O
Arg551	O
does	O
not	O
enhance	O
the	O
IL-4	B
signal	O
for	O
generation	O
of	O
germline	O
epsilon	O
transcript	O
,	O
whereas	O
the	O
substitution	O
of	O
Ile50	O
contributes	O
to	O
enhancement	O
of	O
IgE	B
synthesis	O
.	O
Evidence	O
for	O
repression	O
of	O
IL-2	O
gene	O
activation	O
in	O
anergic	O
T	O
cells	O
.	O
The	O
induction	O
of	O
clonal	O
anergy	O
in	O
a	O
T	O
cell	O
inhibits	O
IL-2	B
secretion	O
because	O
of	O
the	O
development	O
of	O
a	O
proximal	O
signal	O
transduction	O
defect	O
.	O
Fusion	O
of	O
anergic	O
murine	O
T	O
cells	O
to	O
human	O
Jurkat	O
T	O
leukemia	O
cells	O
and	O
formation	O
of	O
heterokaryons	O
failed	O
to	O
result	O
in	O
a	O
complementation	O
of	O
this	O
signaling	O
defect	O
and	O
restoration	O
of	O
murine	O
IL-2	O
mRNA	O
inducibility	O
.	O
Instead	O
,	O
signal	O
transduction	O
to	O
the	O
human	O
IL-2	O
gene	O
became	O
disrupted	O
.	O
Heterokaryons	O
formed	O
by	O
the	O
fusion	O
of	O
anergic	O
murine	O
T	O
cells	O
to	O
normal	O
murine	O
T	O
cells	O
also	O
failed	O
to	O
accumulate	O
intracellular	B
IL-2	I
protein	I
in	O
response	O
to	O
stimulation	O
either	O
with	O
the	O
combination	O
of	O
CD3	B
and	O
CD28	B
mAbs	I
or	O
with	O
ionomycin	O
plus	O
a	O
protein	B
kinase	I
C	I
-activating	O
phorbol	O
ester	O
.	O
The	O
results	O
argue	O
against	O
a	O
loss	O
-	O
of	O
-	O
function	O
signaling	O
defect	O
as	O
the	O
sole	O
basis	O
for	O
clonal	O
anergy	O
induction	O
and	O
document	O
the	O
presence	O
of	O
a	O
dominant	B
-	I
acting	I
repressor	I
molecule	I
that	O
inhibits	O
signal	O
transduction	O
to	O
the	O
IL-2	O
gene	O
within	O
viable	O
anergic	O
T	O
cells	O
.	O
Fas	B
ligand	I
induction	O
in	O
human	O
NK	O
cells	O
is	O
regulated	O
by	O
redox	O
through	O
a	O
calcineurin	B
-	I
nuclear	I
factors	I
of	O
activated	O
T	O
cell	O
-	O
dependent	O
pathway	O
.	O
Fas	B
ligand	I
(	O
FasL	B
)	O
on	O
cytotoxic	O
lymphocytes	O
is	O
important	O
for	O
mediating	O
apoptosis	O
of	O
activated	O
lymphocytes	O
and	O
other	O
target	O
cells	O
.	O
We	O
have	O
reported	O
that	O
NK	O
cell	O
functions	O
,	O
such	O
as	O
proliferation	O
,	O
cell	O
death	O
,	O
and	O
killing	O
activity	O
,	O
are	O
subject	O
to	O
regulation	O
by	O
cellular	O
redox	O
status	O
.	O
Here	O
,	O
we	O
report	O
that	O
expression	O
of	O
FasL	B
protein	I
and	O
mRNA	O
in	O
activated	O
NK	O
cells	O
is	O
also	O
regulated	O
by	O
redox	O
.	O
Ligation	O
of	O
CD16	B
on	O
IL-2-preactivated	O
NK	O
cells	O
resulted	O
in	O
reduction	O
of	O
intracellular	O
peroxide	O
level	O
as	O
well	O
as	O
induction	O
of	O
FasL	B
expression	O
.	O
This	O
CD16	B
-induced	O
FasL	B
expression	O
was	O
suppressed	O
by	O
oxidative	O
stress	O
,	O
including	O
thiol	O
deprivation	O
or	O
treatment	O
with	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O
Addition	O
of	O
thiol	O
-	O
reducing	O
compounds	O
,	O
such	O
as	O
L	O
-	O
cystine	O
,	O
2-ME	O
,	O
or	O
N	O
-	O
acetyl	O
cysteine	O
,	O
restored	O
FasL	B
expression	O
.	O
These	O
data	O
suggest	O
that	O
CD16	B
stimulation	O
requires	O
cellular	O
reducing	O
status	O
for	O
FasL	B
induction	O
in	O
NK	O
cells	O
.	O
Because	O
FasL	O
gene	O
activation	O
following	O
CD16	B
cross	O
-	O
linking	O
is	O
regulated	O
by	O
the	O
NF	B
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
,	O
we	O
examined	O
the	O
effect	O
of	O
oxidative	O
stresses	O
on	O
NFAT	B
activation	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
that	O
both	O
thiol	O
insufficiency	O
and	O
H2O2	O
treatment	O
suppressed	O
DNA	O
-	O
binding	O
activity	O
of	O
NFAT	B
and	O
that	O
addition	O
of	O
thiol	O
-	O
reducing	O
compounds	O
reversed	O
or	O
even	O
enhanced	O
it	O
.	O
Furthermore	O
,	O
these	O
oxidative	O
stresses	O
inhibited	O
activity	O
of	O
calcineurin	O
,	O
a	O
serine	O
/	O
threonine	B
phosphatase	I
that	O
regulates	O
NFAT	B
activation	O
.	O
These	O
results	O
suggest	O
that	O
suppression	O
of	O
calcineurin	B
and	O
NFAT	B
activation	O
is	O
a	O
mechanism	O
by	O
which	O
oxidative	O
stress	O
inhibits	O
FasL	B
induction	O
in	O
activated	O
NK	O
cells	O
and	O
further	O
support	O
the	O
hypothesis	O
that	O
thiol	O
-	O
reducing	O
compounds	O
might	O
be	O
required	O
for	O
maintenance	O
of	O
optimal	O
NK	O
functions	O
under	O
physiologic	O
oxidative	O
conditions	O
.	O
Glucocorticoid	O
resistance	O
in	O
the	O
squirrel	O
monkey	O
is	O
associated	O
with	O
overexpression	O
of	O
the	O
immunophilin	B
FKBP51	I
.	O
Squirrel	O
monkeys	O
are	O
neotropical	O
primates	O
that	O
have	O
high	O
circulating	O
cortisol	O
to	O
compensate	O
for	O
expression	O
of	O
glucocorticoid	B
receptors	I
(	O
GRs	B
)	O
with	O
reduced	O
affinity	O
.	O
The	O
low	O
binding	O
affinity	O
of	O
squirrel	O
monkey	O
GR	B
does	O
not	O
result	O
from	O
substitutions	O
in	O
the	O
receptor	O
,	O
because	O
squirrel	B
monkey	I
GR	I
expressed	O
in	O
vitro	O
exhibits	O
high	O
affinity	O
.	O
Rather	O
,	O
squirrel	O
monkeys	O
express	O
a	O
soluble	O
factor	O
that	O
,	O
in	O
mixing	O
studies	O
of	O
cytosol	O
from	O
squirrel	O
monkey	O
lymphocytes	O
(	O
SML	O
)	O
and	O
mouse	O
L929	O
cells	O
,	O
reduced	O
GR	O
binding	O
affinity	O
by	O
11-fold	O
.	O
In	O
an	O
effort	O
to	O
identify	O
this	O
factor	O
,	O
the	O
cellular	O
levels	O
of	O
components	O
of	O
the	O
GR	B
heterocomplex	I
in	O
SML	O
and	O
human	O
lymphocytes	O
(	O
HL	O
)	O
were	O
compared	O
.	O
The	O
immunophilin	B
FKBP51	I
was	O
13-fold	O
higher	O
in	O
SML	O
than	O
in	O
HL	O
cytosol	O
;	O
FKBP52	B
in	O
SML	O
was	O
42	O
%	O
of	O
that	O
in	O
HL	O
cytosol	O
.	O
A	O
role	O
for	O
changes	O
in	O
immunophilins	B
,	O
causing	O
glucocorticoid	O
resistance	O
in	O
neotropical	O
primates	O
,	O
is	O
supported	O
by	O
the	O
following	O
:	O
the	O
changes	O
in	O
FKBP51	B
and	O
FKBP52	B
were	O
observed	O
in	O
cells	O
from	O
other	O
neotropical	O
primates	O
with	O
glucocorticoid	O
resistance	O
;	O
the	O
elevated	O
level	O
of	O
FKBP51	B
was	O
reflected	O
in	O
an	O
abundance	O
of	O
FKBP51	B
in	O
heat	B
shock	I
protein	I
90	I
complexes	I
in	O
SML	O
;	O
when	O
cytosols	O
of	O
SML	O
and	O
L929	O
cells	O
were	O
mixed	O
,	O
the	O
decrease	O
in	O
GR	O
binding	O
was	O
associated	O
with	O
incorporation	O
of	O
FKBP51	B
into	O
GR	B
heterocomplexes	I
;	O
the	O
effect	O
of	O
SML	O
cytosol	O
on	O
GR	O
binding	O
was	O
reproduced	O
with	O
cytosol	O
from	O
COS	O
cells	O
expressing	O
squirrel	O
monkey	O
FKBP51	B
;	O
and	O
both	O
the	O
effect	O
of	O
SML	O
cytosol	O
on	O
GR	O
binding	O
and	O
the	O
incorporation	O
of	O
FKBP51	B
into	O
GR	B
heterocomplexes	I
were	O
blocked	O
by	O
FK506	O
.	O
Regulation	O
of	O
GR	O
binding	O
by	O
FKBP51	B
represents	O
a	O
previously	O
unrecognized	O
mechanism	O
for	O
regulating	O
glucocorticoid	O
sensitivity	O
.	O
Osteoclast	B
markers	I
accumulate	O
on	O
cells	O
developing	O
from	O
human	O
peripheral	O
blood	O
mononuclear	O
precursors	O
.	O
Recent	O
studies	O
show	O
that	O
human	O
osteoclasts	O
develop	O
in	O
vitro	O
from	O
hematopoietic	O
cells	O
;	O
however	O
,	O
special	O
cultures	O
conditions	O
and/or	O
cytokine	O
mobilized	O
peripheral	O
blood	O
are	O
apparently	O
required	O
.	O
Here	O
,	O
we	O
report	O
that	O
cells	O
expressing	O
osteoclast	B
markers	I
differentiate	O
from	O
precursors	O
present	O
in	O
nonmobilized	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
,	O
without	O
the	O
addition	O
of	O
stromal	O
cells	O
,	O
growth	B
factors	I
,	O
cytokines	O
or	O
steroids	O
;	O
and	O
characterize	O
their	O
phenotype	O
.	O
Three	O
days	O
after	O
establishing	O
high	O
-	O
density	O
PBMC	O
cultures	O
(	O
1.5	O
x	O
10	O
(	O
6	O
)	O
cells	O
/	O
cm2	O
)	O
,	O
in	O
serum	O
-	O
containing	O
medium	O
,	O
small	O
adherent	O
colonies	O
of	O
tartrate	O
resistant	O
acid	O
phosphatase	O
positive	O
(	O
TRAP+	O
)	O
cells	O
emerge	O
,	O
amidst	O
massive	O
monocyte	O
cell	O
death	O
.	O
These	O
adherent	O
cells	O
have	O
an	O
eccentrically	O
placed	O
,	O
round	O
nucleus	O
,	O
and	O
express	O
low	O
levels	O
of	O
TRAP	B
and	O
sodium	B
fluoride	I
-	I
resistant-	I
alpha	I
-	I
naphthyl	I
-	I
acetate	I
-	I
esterase	I
(	O
NaF	B
-	I
R	I
-	I
NSE	I
)	O
.	O
Over	O
the	O
next	O
week	O
,	O
this	O
cell	O
population	O
accumulates	O
phenotypic	O
markers	O
of	O
osteoclasts	O
(	O
vitronectin	B
receptor	I
[	O
VR	B
]	O
,	O
calcitonin	B
receptor	I
,	O
TRAP	B
,	O
cathepsin	B
K	I
protein	I
,	O
and	O
mRNA	O
)	O
with	O
increased	O
nuclearity	O
,	O
covering	O
the	O
entire	O
surface	O
by	O
15	O
days	O
.	O
When	O
cultured	O
on	O
bone	O
,	O
VR+	O
,	O
TRAP+	O
cells	O
of	O
low	O
multinuclearity	O
appear	O
and	O
cover	O
up	O
to	O
50	O
%	O
of	O
the	O
surface	O
.	O
Resorption	O
lacunae	O
can	O
be	O
observed	O
by	O
day	O
22	O
.	O
Although	O
these	O
pits	O
are	O
not	O
nearly	O
as	O
numerous	O
as	O
the	O
cells	O
of	O
preosteoclast	O
phenotype	O
,	O
they	O
do	O
represent	O
the	O
activity	O
of	O
a	O
subset	O
of	O
osteoclast	O
-	O
like	O
cells	O
that	O
has	O
achieved	O
osteoclastic	O
maturity	O
under	O
these	O
culture	O
conditions	O
.	O
Transcripts	O
for	O
osteoprotegerin	B
ligand	I
(	O
OPGL	B
)	O
,	O
an	O
osteoclast	B
differentiation	I
factor	I
(	O
also	O
known	O
as	O
RANKL	B
and	O
TRANCE	B
)	O
are	O
expressed	O
,	O
likely	O
by	O
adherent	O
cells	O
.	O
Thus	O
,	O
an	O
adherent	O
population	O
of	O
cells	O
,	O
with	O
preosteoclast	O
/	O
osteoclast	O
phenotypic	O
properties	O
,	O
arises	O
selectively	O
under	O
simple	O
culture	O
conditions	O
from	O
normal	O
PBMC	O
.	O
Further	O
characterization	O
of	O
these	O
cells	O
should	O
identify	O
factors	O
involved	O
in	O
the	O
growth	O
,	O
terminal	O
differentiation	O
and	O
activation	O
of	O
osteoclasts	O
.	O
Interleukin-10	B
inhibits	O
expression	O
of	O
both	O
interferon	O
alpha-	O
and	O
interferon	O
gamma-	O
induced	O
genes	O
by	O
suppressing	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B
.	O
Interleukin-10	B
(	O
IL-10	B
)	O
helps	O
maintain	O
polarized	O
T	O
-	O
helper	O
cells	O
in	O
a	O
T	O
-	O
helper	O
lymphocyte	O
2	O
(	O
Th2	O
)	O
phenotype	O
.	O
Part	O
of	O
this	O
process	O
involves	O
the	O
prevention	O
of	O
the	O
development	O
of	O
Th1	O
cells	O
,	O
which	O
are	O
a	O
primary	O
source	O
of	O
interferon	B
gamma	I
(	O
IFNgamma	B
)	O
,	O
a	O
potent	O
activator	O
of	O
monocytes	O
and	O
an	O
inhibitor	O
of	O
Th2	O
proliferation	O
.	O
Because	O
monocytes	O
and	O
macrophages	O
are	O
important	O
mediators	O
of	O
Th1-type	O
responses	O
,	O
such	O
as	O
delayed	O
-	O
type	O
hypersensitivity	O
,	O
we	O
sought	O
to	O
determine	O
if	O
IL-10	B
could	O
directly	O
mediate	O
inhibition	O
of	O
IFNgamma-	O
and	O
IFNalpha	O
-	O
induced	O
gene	O
expression	O
in	O
these	O
cells	O
.	O
Highly	O
purified	O
monocytes	O
were	O
incubated	O
with	O
IL-10	B
for	O
60	O
to	O
90	O
minutes	O
before	O
the	O
addition	O
of	O
IFNgamma	B
or	O
IFNalpha	B
.	O
IL-10	B
preincubation	O
resulted	O
in	O
the	O
inhibition	O
of	O
gene	O
expression	O
for	O
several	O
IFN	O
-	O
induced	O
genes	O
,	O
such	O
as	O
IP-10	B
,	O
ISG54	B
,	O
and	O
intercellular	B
adhesion	I
molecule-1	I
.	O
The	O
reduction	O
in	O
gene	O
expression	O
resulted	O
from	O
the	O
ability	O
of	O
IL-10	B
to	O
suppress	O
IFN	B
-induced	O
assembly	O
of	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
STAT	I
)	I
factors	I
to	O
specific	O
promoter	O
motifs	O
on	O
IFNalpha-	O
and	O
IFNgamma	O
-	O
inducible	O
genes	O
.	O
This	O
was	O
accomplished	O
by	O
preventing	O
the	O
IFN	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B
,	O
a	O
component	O
of	O
both	O
IFNalpha-	B
and	I
IFNgamma	I
-	I
induced	I
DNA	I
binding	I
complexes	I
.	O
Therefore	O
,	O
IL-10	B
can	O
directly	O
inhibit	O
STAT	O
-	O
dependent	O
early	O
response	O
gene	O
expression	O
induced	O
by	O
both	O
IFNalpha	B
and	O
IFNgamma	B
in	O
monocytes	O
by	O
suppressing	O
the	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B
.	O
This	O
may	O
occur	O
through	O
the	O
ability	O
of	O
IL-10	B
to	O
induce	O
expression	O
of	O
the	O
gene	O
,	O
suppressor	O
of	O
cytokine	B
signaling	I
3	I
(	O
SOCS3	B
)	O
.	O
T	O
-	O
cell	O
expression	O
of	O
the	O
human	O
GATA-3	O
gene	O
is	O
regulated	O
by	O
a	O
non	O
-	O
lineage	O
-	O
specific	O
silencer	O
.	O
The	O
GATA-3	B
transcription	I
factor	I
is	O
required	O
for	O
development	O
of	O
the	O
T	O
-	O
cell	O
lineage	O
and	O
Th2	O
cytokine	O
gene	O
expression	O
in	O
CD4	O
T	O
-	O
cells	O
.	O
We	O
have	O
mapped	O
the	O
DNase	O
-	O
I	O
-	O
hypersensitive	O
(	O
HS	O
)	O
regions	O
of	O
the	O
human	O
GATA-3	O
gene	O
in	O
T	O
-	O
cells	O
and	O
non	O
-	O
T	O
-	O
cells	O
and	O
studied	O
their	O
transcriptional	O
activities	O
.	O
HS	O
I	O
-	O
III	O
,	O
located	O
5	O
'	O
from	O
the	O
transcriptional	O
initiation	O
site	O
,	O
were	O
found	O
in	O
hematopoietic	O
and	O
non	O
-	O
hematopoietic	O
cells	O
,	O
whereas	O
HS	O
IV	O
-	O
VII	O
,	O
located	O
3	O
'	O
from	O
the	O
transcriptional	O
start	O
site	O
,	O
were	O
exclusively	O
observed	O
in	O
T	O
-	O
cells	O
.	O
Among	O
these	O
hypersensitive	O
sites	O
,	O
two	O
transcriptional	O
control	O
elements	O
were	O
found	O
,	O
one	O
in	O
the	O
first	O
intron	O
of	O
the	O
GATA-3	O
gene	O
and	O
the	O
other	O
between	O
8.3	O
and	O
5.9	O
kilobases	O
5	O
'	O
from	O
the	O
GATA-3	O
transcriptional	O
initiation	O
site	O
.	O
The	O
first	O
intron	O
acted	O
as	O
a	O
strong	O
transcriptional	O
activator	O
in	O
a	O
position	O
-	O
dependent	O
manner	O
and	O
with	O
no	O
cell	O
-	O
type	O
specificity	O
.	O
The	O
upstream	O
regulatory	O
element	O
could	O
confer	O
T	O
-	O
cell	O
specificity	O
to	O
the	O
GATA-3	O
promoter	O
activity	O
,	O
and	O
analysis	O
of	O
this	O
region	O
revealed	O
a	O
707-base	O
pair	O
silencer	O
that	O
drastically	O
inhibited	O
GATA-3	O
promoter	O
activity	O
in	O
non	O
-	O
T	O
-	O
cells	O
.	O
Two	O
CAGGTG	O
E	O
-	O
boxes	O
,	O
located	O
at	O
the	O
5'-	O
and	O
3'-ends	O
of	O
the	O
silencer	O
,	O
were	O
necessary	O
for	O
this	O
silencer	O
activity	O
.	O
The	O
3'-CAGGTG	O
E	O
-	O
box	O
could	O
bind	O
USF	B
proteins	I
,	O
the	O
ubiquitous	B
repressor	I
ZEB	B
,	O
or	O
the	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
proteins	I
E2A	B
and	O
HEB	B
,	O
and	O
we	O
showed	O
that	O
a	O
competition	O
between	O
ZEB	B
and	O
E2A	B
/	I
HEB	I
proteins	I
is	O
involved	O
in	O
the	O
silencer	O
activity	O
.	O
Binding	O
of	O
c	B
-	I
Rel	I
to	O
STAT5	O
target	O
sequences	O
in	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
.	O
The	O
type	O
I	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
(	O
HTLV	O
-	O
I	O
)	O
induces	O
abnormal	O
growth	O
and	O
subsequent	O
transformation	O
of	O
T	O
cells	O
,	O
which	O
is	O
associated	O
with	O
the	O
development	O
of	O
an	O
acute	O
T	O
-	O
cell	O
malignancy	O
termed	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O
A	O
characteristic	O
of	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
is	O
the	O
constitutive	O
nuclear	O
expression	O
of	O
NF	B
-	I
kappaB	I
/	I
Rel	I
family	I
of	O
transcription	O
factors	O
,	O
which	O
appears	O
to	O
be	O
essential	O
for	O
the	O
growth	O
of	O
these	O
transformed	O
cells	O
.	O
Although	O
NF	B
-	I
kappaB	I
/	I
Rel	I
factors	I
are	O
known	O
to	O
induce	O
the	O
expression	O
of	O
T	B
-	I
cell	I
growth	I
factor	I
interleukin	I
(	I
IL	I
)	I
-2	I
,	O
it	O
is	O
unclear	O
how	O
they	O
participate	O
in	O
the	O
IL-2	B
-independent	O
growth	O
of	O
HTLV	O
-	O
I	O
-	O
transformed	O
cells	O
.	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
certain	O
NF	B
-	I
kappaB	I
/	I
Rel	I
members	I
,	O
predominantly	O
c	B
-	I
Rel	I
,	O
interact	O
with	O
enhancer	O
sequences	O
for	O
STAT5	B
,	O
a	O
key	O
transcription	O
factor	O
mediating	O
IL-2	B
-induced	O
T	O
-	O
cell	O
proliferation	O
.	O
Reporter	O
gene	O
assays	O
reveal	O
that	O
the	O
binding	O
of	O
c	B
-	I
Rel	I
to	O
the	O
STAT5	B
site	O
present	O
in	O
the	O
Fc	O
gammaR1	O
gene	O
leads	O
to	O
potent	O
transactivation	O
of	O
this	O
enhancer	O
.	O
Binding	O
of	O
c	B
-	I
Rel	I
to	O
the	O
Fc	O
gammaR1	O
STAT	O
site	O
also	O
occurs	O
in	O
human	O
peripheral	O
blood	O
T	O
cells	O
immortalized	O
with	O
HTLV	O
-	O
I	O
in	O
vitro	O
and	O
is	O
correlated	O
with	O
enhanced	O
levels	O
of	O
proliferation	O
of	O
these	O
cells	O
.	O
These	O
results	O
raise	O
the	O
possibility	O
that	O
NF	B
-	I
kappaB	I
/	I
Rel	I
may	O
participate	O
in	O
the	O
growth	O
control	O
of	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
by	O
regulating	O
genes	O
driven	O
by	O
both	O
kappaB	O
and	O
certain	O
STAT	O
enhancers	O
.	O
AML	B
and	I
Ets	I
proteins	I
regulate	O
the	O
I	O
alpha1	O
germ	O
-	O
line	O
promoter	O
.	O
The	O
immunoglobulin	B
heavy	I
chain	I
(	O
IgH	B
)	O
class	O
switch	O
recombination	O
of	O
B	O
lymphocytes	O
preferentially	O
targets	O
unrearranged	O
IgH	O
genes	O
that	O
have	O
already	O
been	O
rendered	O
transcriptionally	O
active	O
.	O
Transcription	O
of	O
the	O
germ	O
-	O
line	O
IgH	O
genes	O
is	O
controlled	O
by	O
intervening	O
(	O
I	O
)	O
regions	O
upstream	O
of	O
their	O
switch	O
regions	O
.	O
The	O
I	O
alpha1	O
promoter	O
activates	O
transcription	O
of	O
the	O
human	O
germ	O
-	O
line	O
C	O
alpha1	O
gene	O
for	O
IgA1	B
and	O
mediates	O
the	O
transforming	B
growth	I
factor	I
(	I
TGF	I
)	I
-beta1	I
responsiveness	O
of	O
this	O
locus	O
.	O
Here	O
we	O
show	O
that	O
the	O
I	O
alpha1	O
promoter	O
contains	O
several	O
binding	O
sites	O
for	O
the	O
AML	B
/	I
PEBP2	I
/	I
CBF	I
family	I
of	I
transcription	I
factors	I
and	O
that	O
AML	B
and	I
Ets	I
proteins	I
are	O
major	O
regulators	O
of	O
the	O
basal	O
and	O
TGF	O
-	O
beta	O
-	O
inducible	O
promoter	O
activity	O
.	O
Our	O
data	O
constitute	O
a	O
starting	O
point	O
for	O
studies	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
by	O
which	O
TGF	B
-	I
beta	I
regulates	O
IgA	B
production	O
.	O
High	O
frequency	O
of	O
germ	O
-	O
line	O
BRCA2	O
mutations	O
among	O
Hungarian	O
male	O
breast	O
cancer	O
patients	O
without	O
family	O
history	O
.	O
To	O
determine	O
the	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
mutations	O
to	O
the	O
pathogenesis	O
of	O
male	O
breast	O
cancer	O
in	O
Hungary	O
,	O
the	O
country	O
with	O
the	O
highest	O
male	O
breast	O
cancer	O
mortality	O
rates	O
in	O
continental	O
Europe	O
,	O
a	O
series	O
of	O
18	O
male	O
breast	O
cancer	O
patients	O
and	O
three	O
patients	O
with	O
gynecomastia	O
was	O
analyzed	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O
Although	O
no	O
germ	O
-	O
line	O
BRCA1	O
mutation	O
was	O
observed	O
,	O
6	O
of	O
the	O
18	O
male	O
breast	O
cancer	O
cases	O
(	O
33	O
%	O
)	O
carried	O
truncating	O
mutations	O
in	O
the	O
BRCA2	O
gene	O
.	O
Unexpectedly	O
,	O
none	O
of	O
them	O
reported	O
a	O
family	O
history	O
for	O
breast	O
/	O
ovarian	O
cancer	O
.	O
Four	O
of	O
six	O
truncating	O
mutations	O
were	O
novel	O
,	O
and	O
two	O
mutations	O
were	O
recurrent	O
.	O
Four	O
patients	O
(	O
22	O
%	O
)	O
had	O
a	O
family	O
history	O
of	O
breast	O
/	O
ovarian	O
cancer	O
in	O
at	O
least	O
one	O
first-	O
or	O
second	O
-	O
degree	O
relative	O
;	O
however	O
,	O
no	O
BRCA2	O
mutation	O
was	O
identified	O
among	O
them	O
.	O
No	O
mutation	O
was	O
identified	O
in	O
either	O
of	O
the	O
genes	O
in	O
the	O
gynecomastias	O
.	O
These	O
results	O
provide	O
evidence	O
for	O
a	O
strong	O
genetic	O
component	O
of	O
male	O
breast	O
cancer	O
in	O
Hungary	O
.	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
inhibits	O
primary	O
human	O
T	O
cell	O
responses	O
at	O
the	O
dendritic	O
cell	O
level	O
:	O
association	O
with	O
NF	B
-	I
kappaB	I
inhibition	O
.	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
is	O
an	O
antioxidant	O
molecule	O
endowed	O
with	O
immunomodulatory	O
properties	O
.	O
To	O
investigate	O
the	O
effect	O
of	O
NAC	O
on	O
the	O
induction	O
phase	O
of	O
T	O
cell	O
responses	O
,	O
we	O
analyzed	O
its	O
action	O
on	O
human	O
dendritic	O
cells	O
(	O
DC	O
)	O
derived	O
from	O
adherent	O
PBMC	O
cultured	O
with	O
IL-4	B
and	O
granulocyte	B
-	I
macrophage	I
CSF	I
.	O
We	O
first	O
found	O
that	O
NAC	O
inhibited	O
the	O
constitutive	O
as	O
well	O
as	O
the	O
LPS	O
-	O
induced	O
activity	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
.	O
In	O
parallel	O
,	O
NAC	O
was	O
shown	O
to	O
down	O
-	O
regulate	O
the	O
production	O
of	O
cytokines	B
by	O
DC	O
as	O
well	O
as	O
their	O
surface	O
expression	O
of	O
HLA	B
-	I
DR	I
,	O
CD86	B
(	O
B7	B
-	I
2	I
)	O
,	O
and	O
CD40	B
molecules	I
both	O
at	O
the	O
basal	O
state	O
and	O
upon	O
LPS	O
activation	O
.	O
NAC	O
also	O
inhibited	O
DC	O
responses	O
induced	O
by	O
CD40	B
engagement	O
.	O
The	O
inhibitory	O
effects	O
of	O
NAC	O
were	O
not	O
due	O
to	O
nonspecific	O
toxicity	O
as	O
neither	O
the	O
viability	O
of	O
DC	O
nor	O
their	O
mannose	O
receptor	O
-	O
mediated	O
endocytosis	O
were	O
modified	O
by	O
NAC	O
.	O
Finally	O
,	O
we	O
found	O
that	O
the	O
addition	O
of	O
NAC	O
to	O
MLR	O
between	O
naive	O
T	O
cells	O
and	O
allogeneic	O
DC	O
resulted	O
in	O
a	O
profound	O
inhibition	O
of	O
alloreactive	O
responses	O
,	O
which	O
could	O
be	O
attributed	O
to	O
a	O
defect	O
of	O
DC	O
as	O
APC	O
-	O
independent	O
T	O
cell	O
responses	O
were	O
not	O
inhibited	O
by	O
NAC	O
.	O
Altogether	O
,	O
our	O
results	O
suggest	O
that	O
NAC	O
might	O
impair	O
the	O
generation	O
of	O
primary	O
immune	O
responses	O
in	O
humans	O
through	O
its	O
inhibitory	O
action	O
on	O
DC	O
.	O
NF	B
-	I
ATc	I
isoforms	I
are	O
differentially	O
expressed	O
and	O
regulated	O
in	O
murine	O
T	O
and	O
mast	O
cells	O
.	O
NF	B
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
denotes	O
a	O
family	O
of	O
transcription	B
factors	I
that	O
regulate	O
the	O
activation	O
-	O
dependent	O
expression	O
of	O
many	O
immunologically	B
important	I
proteins	I
.	O
At	O
least	O
four	O
distinct	O
genes	O
encode	O
the	O
various	O
family	O
members	O
,	O
and	O
several	O
isoforms	O
of	O
these	O
have	O
been	O
identified	O
as	O
well	O
.	O
The	O
overlapping	O
expression	O
patterns	O
and	O
similar	O
in	O
vitro	O
binding	O
and	O
trans	O
-	O
activation	O
activities	O
on	O
various	O
promoter	O
elements	O
of	O
NF	O
-	O
AT	O
-	O
regulated	O
genes	O
suggest	O
some	O
redundancy	O
in	O
the	O
function	O
of	O
these	O
proteins	O
.	O
However	O
,	O
the	O
phenotypic	O
analysis	O
of	O
NF	B
-	I
AT	I
-deficient	O
mice	O
supports	O
the	O
idea	O
that	O
there	O
are	O
tissue-	O
and	O
gene-	O
specific	O
functions	O
as	O
well	O
.	O
In	O
this	O
study	O
we	O
have	O
characterized	O
the	O
expression	O
of	O
NF	O
-	O
AT	O
cDNAs	O
in	O
murine	O
mast	O
cells	O
.	O
The	O
majority	O
of	O
clones	O
identified	O
correspond	O
to	O
two	O
NF	B
-	I
ATc	I
isoforms	I
that	O
differ	O
only	O
in	O
their	O
amino	B
-	I
terminal	I
sequence	I
.	O
Despite	O
minimal	O
discrepancies	O
in	O
the	O
coding	O
region	O
,	O
there	O
are	O
striking	O
tissue-	O
and	O
cell	O
type	O
-	O
specific	O
differences	O
in	O
isoform	O
expression	O
patterns	O
.	O
Detection	O
of	O
NF-ATc.alpha	O
mRNA	O
is	O
strictly	O
dependent	O
on	O
cell	O
activation	O
signals	O
in	O
both	O
T	O
and	O
mast	O
cell	O
lines	O
.	O
In	O
contrast	O
,	O
the	O
beta	B
isoform	I
is	O
expressed	O
at	O
very	O
low	O
constitutive	O
levels	O
in	O
both	O
cell	O
types	O
but	O
is	O
only	O
up	O
-	O
regulated	O
in	O
response	O
to	O
mast	O
cell	O
activation	O
signals	O
delivered	O
through	O
the	O
FcepsilonRI	B
or	O
via	O
calcium	O
ionophores	O
.	O
These	O
results	O
demonstrate	O
another	O
level	O
of	O
regulation	O
within	O
the	O
NF	B
-	I
AT	I
family	I
that	O
can	O
contribute	O
to	O
cell	O
type	O
-	O
specific	O
gene	O
expression	O
.	O
Detection	O
of	O
intracellular	B
phosphorylated	I
STAT-1	I
by	O
flow	O
cytometry	O
.	O
We	O
have	O
applied	O
flow	O
cytometry	O
to	O
the	O
investigation	O
of	O
interferon	B
-	I
gamma	I
activation	O
of	O
human	O
monocytes	O
.	O
This	O
approach	O
uses	O
monoclonal	B
antibodies	I
that	O
distinguish	O
between	O
the	O
native	O
and	O
phosphorylated	O
forms	O
of	O
STAT-1	B
.	O
It	O
enables	O
rapid	O
and	O
quantitative	O
assessment	O
of	O
STAT-1	B
phosphorylation	O
on	O
a	O
discrete	O
cell	O
basis	O
and	O
is	O
both	O
more	O
sensitive	O
and	O
less	O
time	O
consuming	O
than	O
immunoblotting	O
.	O
Furthermore	O
,	O
it	O
allows	O
for	O
discrimination	O
between	O
a	O
mixture	O
of	O
cells	O
that	O
differ	O
in	O
their	O
response	O
to	O
interferon	B
-	I
gamma	I
.	O
This	O
approach	O
should	O
allow	O
for	O
the	O
evaluation	O
of	O
different	O
intracellular	O
signaling	O
pathways	O
using	O
a	O
combination	O
of	O
monoclonal	O
reagents	O
that	O
are	O
specific	O
for	O
native	O
and	O
activation	B
modified	I
proteins	I
.	O
Application	O
of	O
this	O
form	O
of	O
testing	O
should	O
prove	O
valuable	O
in	O
screening	O
for	O
signaling	O
defects	O
in	O
selected	O
patients	O
with	O
recurrent	O
infections	O
.	O
In	O
addition	O
,	O
this	O
technique	O
should	O
permit	O
dissection	O
of	O
a	O
full	O
range	O
of	O
cellular	O
signaling	O
pathways	O
at	O
the	O
protein	O
level	O
.	O
Lineage	O
-	O
specific	O
activation	O
of	O
STAT3	B
by	O
interferon	B
-	I
gamma	I
in	O
human	O
neutrophils	O
.	O
Binding	O
of	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
to	O
its	O
heterodimeric	O
receptor	O
induces	O
activation	O
of	O
the	O
tyrosine	B
kinases	I
JAK1	B
and	O
JAK2	B
followed	O
by	O
tyrosine	O
phosphorylation	O
of	O
STAT1alpha	B
.	O
Selective	O
activation	O
of	O
STAT1alpha	B
at	O
the	O
IFN	B
-	I
gamma	I
receptor	I
is	O
achieved	O
by	O
specific	O
interaction	O
between	O
a	O
cytosolic	B
tyrosine	I
motif	I
including	O
Y440	B
in	O
the	O
IFN	B
-	I
gamma	I
receptor	I
alpha	I
-	I
chain	I
and	O
the	O
SH2	B
domain	I
of	O
STAT1alpha	B
.	O
We	O
demonstrate	O
that	O
,	O
in	O
addition	O
to	O
STAT1alpha	B
,	O
STAT3	B
is	O
also	O
activated	O
by	O
IFN	B
-	I
gamma	I
in	O
human	O
neutrophils	O
.	O
The	O
activation	O
of	O
STAT3	B
was	O
not	O
found	O
in	O
human	O
eosinophils	O
,	O
monocytes	O
,	O
and	O
HL-60	O
cells	O
,	O
although	O
the	O
STAT3	B
protein	I
was	O
expressed	O
in	O
these	O
cells	O
.	O
The	O
cell	O
type	O
-	O
specific	O
activation	O
of	O
STAT3	B
by	O
IFN	B
-	I
gamma	I
was	O
also	O
observed	O
in	O
neutrophils	O
that	O
are	O
differentiated	O
in	O
vitro	O
from	O
human	O
CD34	O
+	O
hematopoietic	O
stem	O
cells	O
.	O
These	O
results	O
indicate	O
that	O
a	O
single	O
cytokine	B
receptor	I
can	O
activate	O
different	O
STAT	B
family	I
members	I
in	O
a	O
cell	O
-	O
specific	O
manner	O
,	O
which	O
might	O
result	O
in	O
cell	O
-	O
specific	O
gene	O
transcription	O
.	O
Molecular	O
mechanisms	O
of	O
neutrophil	O
-	O
endothelial	O
cell	O
adhesion	O
induced	O
by	O
redox	O
imbalance	O
.	O
Previous	O
studies	O
have	O
implicated	O
a	O
role	O
for	O
intracellular	O
thiols	O
in	O
the	O
activation	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
and	O
transcriptional	O
regulation	O
of	O
endothelial	B
cell	I
adhesion	I
molecules	I
.	O
This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
changes	O
in	O
endothelial	O
cell	O
glutathione	O
(	O
GSH	O
)	O
or	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
can	O
alter	O
neutrophil	O
adhesivity	O
and	O
to	O
define	O
the	O
molecular	O
mechanism	O
that	O
underlies	O
this	O
GSSG	O
/	O
GSH	O
-	O
induced	O
adhesion	O
response	O
.	O
Treatment	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
(	O
HUVEC	O
)	O
monolayers	O
for	O
6	O
hours	O
with	O
0.2	O
mmol	O
/	O
L	O
diamide	O
and	O
1	O
mmol	O
/	O
L	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
decreased	O
GSH	O
levels	O
and	O
increased	O
the	O
ratio	O
of	O
GSSG	O
to	O
GSH	O
without	O
cell	O
toxicity	O
.	O
These	O
redox	O
changes	O
are	O
similar	O
to	O
those	O
observed	O
with	O
anoxia	O
/	O
reoxygenation	O
.	O
Diamide	O
plus	O
BSO	O
-	O
induced	O
thiol	O
/	O
disulfide	O
imbalance	O
was	O
associated	O
with	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	O
with	O
peak	O
responses	O
observed	O
at	O
15	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
.	O
N	O
-	O
Acetylcysteine	O
treatment	O
attenuated	O
neutrophil	O
adhesion	O
in	O
both	O
phases	O
,	O
which	O
indicated	O
a	O
role	O
for	O
GSH	O
in	O
the	O
adhesion	O
responses	O
.	O
Interestingly	O
,	O
phase	O
1	O
adhesion	O
was	O
inversely	O
correlated	O
with	O
GSH	O
levels	O
but	O
not	O
with	O
the	O
GSSG	O
/	O
GSH	O
ratio	O
,	O
whereas	O
phase	O
2	O
neutrophil	O
adhesion	O
was	O
positively	O
correlated	O
with	O
GSSG	O
/	O
GSH	O
ratio	O
but	O
not	O
with	O
GSH	O
levels	O
.	O
Intercellular	B
adhesion	I
molecule-1	I
and	O
P	B
-	I
selectin	I
-	I
specific	I
monoclonal	I
antibodies	I
attenuated	O
the	O
increased	O
neutrophil	O
adhesion	O
during	O
both	O
phases	O
,	O
whereas	O
an	O
anti	B
-	I
E	I
-	I
selectin	I
monoclonal	I
antibody	I
also	O
attenuated	O
the	O
phase	O
2	O
response	O
.	O
Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds	O
-	O
oligonucleotides	O
that	O
contained	O
nuclear	B
factor	I
-	I
kappaB	I
or	O
activator	B
protein-1	I
cognate	O
DNA	O
sequences	O
significantly	O
attenuated	O
the	O
phase	O
2	O
response	O
,	O
which	O
implicated	O
a	O
role	O
for	O
de	O
novo	O
protein	O
synthesis	O
.	O
Surface	O
expression	O
of	O
intercellular	B
adhesion	I
molecule-1	I
,	O
P	B
-	I
selectin	I
,	O
and	O
E	B
-	I
selectin	I
on	O
HUVECs	O
correlated	O
with	O
the	O
phase	O
1	O
and	O
2	O
neutrophil	O
adhesion	O
responses	O
.	O
This	O
study	O
demonstrates	O
that	O
changes	O
in	O
endothelial	O
cell	O
GSSG	O
/	O
GSH	O
cause	O
transcription	O
-	O
independent	O
and	O
transcription	O
-	O
dependent	O
surface	O
expression	O
of	O
different	O
endothelial	B
cell	I
adhesion	I
molecules	I
,	O
which	O
leads	O
to	O
a	O
2-phase	O
neutrophil	O
-endothelial	O
adhesion	O
response	O
.	O
T	O
helper	O
differentiation	O
proceeds	O
through	O
Stat1-dependent	O
,	O
Stat4-dependent	O
and	O
Stat4-independent	O
phases	O
.	O
Much	O
of	O
our	O
focus	O
in	O
understanding	O
Th1	O
/	O
Th2	O
development	O
has	O
been	O
on	O
the	O
signals	O
delivered	O
by	O
IL-12	B
and	O
IL-4	B
as	O
final	O
determinants	O
of	O
terminal	O
T	O
cell	O
differentiation	O
.	O
Because	O
extinction	O
of	O
IL-12	B
signaling	O
in	O
early	O
Th2	O
development	O
could	O
potentially	O
be	O
important	O
in	O
imprinting	O
a	O
more	O
permanent	O
Th2	O
phenotype	O
on	O
a	O
population	O
of	O
T	O
cells	O
,	O
we	O
have	O
also	O
examined	O
various	O
parameters	O
regulating	O
the	O
IL-12	B
signaling	O
pathway	O
.	O
Whereas	O
IL-4	B
appears	O
to	O
repress	O
functional	O
IL-12	B
signaling	O
through	O
inhibition	O
of	O
IL-12R	B
beta	I
2	I
expression	O
,	O
IFN	B
-	I
gamma	I
in	O
the	O
mouse	O
,	O
and	O
IFN	B
-	I
alpha	I
in	O
the	O
human	O
appear	O
to	O
induce	O
IL-12R	B
beta	I
2	I
expression	O
and	O
promote	O
IL-12	B
responsiveness	O
.	O
We	O
propose	O
that	O
Th1	O
development	O
can	O
be	O
considered	O
in	O
two	O
stages	O
,	O
capacitance	O
and	O
development	O
.	O
Capacitance	O
would	O
simply	O
involve	O
expression	O
of	O
IL-12R	B
beta	I
1	I
and	I
beta	I
2	I
subunits	I
,	O
regulated	O
by	O
TCR	O
,	O
IL-4	B
and	O
IFNs	B
.	O
The	O
second	O
stage	O
,	O
development	O
,	O
we	O
propose	O
is	O
the	O
true	O
IL-12	B
induced	O
developmental	O
stage	O
,	O
involving	O
expression	O
of	O
Stat4	B
inducible	I
proteins	I
.	O
In	O
the	O
human	O
,	O
this	O
may	O
also	O
occur	O
via	O
IFN	B
-	I
alpha	I
,	O
which	O
is	O
able	O
to	O
activate	O
Stat4	B
.	O
It	O
is	O
perhaps	O
possible	O
that	O
all	O
of	O
Stat4	B
actions	O
on	O
Th1	O
development	O
may	O
be	O
exert	O
directly	O
by	O
Stat4	B
at	O
the	O
IFN	O
-	O
gamma	O
gene	O
,	O
however	O
we	O
suggest	O
that	O
,	O
more	O
likely	O
,	O
Stat4	B
may	O
act	O
to	O
induce	O
Th1	O
development	O
through	O
the	O
induction	O
of	O
other	O
non	O
-	O
cytokine	O
genes	O
,	O
whose	O
stable	O
expression	O
maintains	O
the	O
transcriptional	O
state	O
of	O
a	O
Th1	O
cell	O
.	O
The	O
relationship	O
between	O
Ca2	B
+	I
-ATPase	I
and	O
freely	O
exchangeable	O
Ca2	O
+	O
in	O
the	O
dense	O
tubules	O
:	O
a	O
study	O
in	O
platelets	O
from	O
women	O
.	O
The	O
main	O
aims	O
of	O
this	O
work	O
were	O
to	O
examine	O
in	O
women	O
:	O
the	O
relationship	O
between	O
the	O
freely	O
exchangeable	O
Ca2	O
+	O
(	O
FECa2	O
+	O
)	O
in	O
the	O
dense	O
tubules	O
and	O
the	O
activity	O
of	O
the	O
sarco	B
(	I
endo	I
)	I
plasmic	I
reticulum	I
(	I
SER	I
)	I
Ca2	I
+	I
-ATPase	I
(	I
SERCA	I
)	I
in	O
platelets	O
,	O
and	O
the	O
relationship	O
of	O
these	O
parameters	O
with	O
blood	O
pressure	O
and	O
serum	B
lipoproteins	I
.	O
Platelets	O
from	O
14	O
white	O
and	O
13	O
black	O
women	O
in	O
good	O
health	O
were	O
studied	O
.	O
The	O
FECa2	O
+	O
was	O
measured	O
as	O
the	O
ionomycin	O
-	O
evoked	O
Ca2	O
+	O
release	O
(	O
in	O
the	O
presence	O
of	O
thapsigargin	O
)	O
in	O
Ca2	O
+	O
-free	O
medium	O
.	O
SERCA	B
activity	O
was	O
measured	O
as	O
the	O
thapsigargin	O
sensitive	O
,	O
Ca2	O
+	O
dependent	O
and	O
ouabain	O
resistant	O
,	O
ATP	O
hydrolyses	O
in	O
platelet	O
membranes	O
.	O
Relative	O
expressions	O
of	O
SERCA	B
2	O
and	O
3	O
isoforms	O
and	O
Ras	B
-	I
related	I
protein	I
(	I
Rap	I
)	I
1	I
in	O
platelet	O
membranes	O
were	O
determined	O
by	O
Western	O
immunoblots	O
.	O
Highly	O
significant	O
correlations	O
were	O
observed	O
for	O
FECa2	O
+	O
in	O
the	O
dense	O
tubules	O
with	O
:	O
1	O
)	O
the	O
maximal	O
reaction	O
velocity	O
(	O
Vmax	O
)	O
of	O
the	O
SERCA	B
(	O
r	O
=	O
0.592	O
,	O
P	O
=	O
.0014	O
)	O
,	O
and	O
2	O
)	O
Rapl	B
(	O
r	O
=	O
0.551	O
,	O
P	O
=	O
.0035	O
)	O
.	O
In	O
addition	O
,	O
negative	O
correlations	O
were	O
observed	O
between	O
FECa2	O
+	O
in	O
the	O
dense	O
tubules	O
and	O
age	O
.	O
No	O
correlations	O
were	O
observed	O
for	O
these	O
variables	O
with	O
blood	O
pressure	O
or	O
serum	B
lipoproteins	I
.	O
We	O
conclude	O
the	O
FECa2	O
+	O
and	O
the	O
Vmax	O
of	O
the	O
SERCA	B
are	O
reliable	O
indicators	O
of	O
Ca2	O
+	O
load	O
in	O
platelets	O
from	O
women	O
.	O
However	O
,	O
in	O
women	O
,	O
unlike	O
previous	O
observations	O
in	O
men	O
,	O
these	O
platelet	O
parameters	O
are	O
not	O
correlated	O
with	O
blood	O
pressure	O
and	O
serum	B
lipoproteins	I
.	O
Apoptosis	O
-	O
resistant	O
T	O
cells	O
have	O
a	O
deficiency	O
in	O
NF	B
-	I
kappaB	I
-mediated	O
induction	O
of	O
Fas	B
ligand	I
transcription	O
.	O
Apoptosis	O
induced	O
through	O
the	O
TCR	B
in	O
CD4	O
+	O
T	O
cells	O
is	O
mostly	O
mediated	O
by	O
the	O
inducible	O
expression	O
of	O
Fas	B
ligand	I
(	O
FasL	B
)	O
as	O
a	O
primary	O
event	O
leading	O
to	O
the	O
commitment	O
to	O
death	O
.	O
To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
transcriptional	O
events	O
that	O
regulate	O
this	O
expression	O
,	O
we	O
took	O
advantage	O
of	O
our	O
previously	O
described	O
mutant	O
Jurkat	O
cells	O
.	O
These	O
cells	O
are	O
deficient	O
in	O
FasL	B
expression	O
and	O
apoptosis	O
induced	O
upon	O
TCR	B
triggering	O
,	O
although	O
their	O
cytokine	O
(	O
IL-2	B
and	O
IFN	B
-	I
gamma	I
)	O
production	O
is	O
normal	O
.	O
Here	O
we	O
show	O
that	O
both	O
a	O
FasL-	O
and	O
a	O
consensus	O
NF	O
-	O
kappaB-	O
reporter	O
construct	O
are	O
inefficiently	O
induced	O
in	O
these	O
cells	O
compared	O
to	O
wild	O
-	O
type	O
cells	O
.	O
In	O
addition	O
,	O
we	O
demonstrate	O
that	O
the	O
inducible	O
transcriptional	O
activity	O
of	O
the	O
FasL	O
reporter	O
is	O
abolished	O
by	O
specific	O
inhibitors	O
of	O
NF	B
-	I
kappaB	I
activation	O
.	O
Thus	O
,	O
we	O
could	O
trace	O
the	O
deficit	O
of	O
the	O
mutant	O
cells	O
to	O
an	O
inefficient	O
NF	B
-	I
kappaB	I
activation	O
,	O
evidencing	O
a	O
relevant	O
role	O
for	O
NF	B
-	I
kappaB	I
in	O
the	O
regulation	O
of	O
FasL	B
expression	O
in	O
activated	O
T	O
cells	O
.	O
Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
FasL	B
versus	O
cytokine	O
gene	O
expression	O
is	O
differentially	O
sensitive	O
to	O
NF	B
-	I
kappaB	I
deprivation	O
.	O
NF	B
-	I
kappaB	I
regulates	O
Fas	O
/	O
APO-1	O
/	O
CD95-	O
and	O
TCR-	O
mediated	O
apoptosis	O
of	O
T	O
lymphocytes	O
.	O
The	O
maintenance	O
of	O
lymphocyte	O
homeostasis	O
by	O
apoptosis	O
is	O
a	O
critical	O
regulatory	O
mechanism	O
in	O
the	O
normal	O
immune	O
system	O
.	O
The	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
against	O
death	O
mediated	O
by	O
TNF	B
We	O
show	O
here	O
that	O
NF	B
-	I
kappaB	I
also	O
has	O
a	O
role	O
in	O
regulating	O
Fas	B
/	O
APO-1	B
/	O
CD95	B
-mediated	O
death	O
,	O
a	O
major	O
pathway	O
of	O
peripheral	O
T	O
cell	O
death	O
.	O
Transfection	O
of	O
Jurkat	O
cells	O
with	O
the	O
NF	B
-	I
kappaB	I
subunits	I
p50	B
and	O
p65	B
confers	O
resistance	O
against	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O
Reciprocally	O
,	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
or	O
a	O
dominant	O
form	O
of	O
the	O
NF	B
-	I
kappaB	I
inhibitor	O
,	O
IkappaB	B
,	O
makes	O
the	O
cells	O
more	O
susceptible	O
to	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O
Furthermore	O
,	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
rendered	O
a	O
T	O
cell	O
hybridoma	O
more	O
susceptible	O
to	O
TCR	O
-	O
mediated	O
apoptosis	O
.	O
Correspondingly	O
,	O
transfection	O
of	O
p50	B
and	O
p65	B
provided	O
considerable	O
protection	O
from	O
TCR	O
-	O
mediated	O
apoptosis	O
.	O
These	O
observations	O
were	O
corroborated	O
by	O
studies	O
on	O
Fas	B
-mediated	O
death	O
in	O
primary	O
T	O
cells	O
.	O
Concanavalin	O
A	O
-	O
activated	O
cycling	O
T	O
cell	O
blasts	O
from	O
mice	O
that	O
are	O
transgenic	O
for	O
the	O
dominant	B
IkappaB	I
molecule	I
have	O
increased	O
sensitivity	O
to	O
Fas	O
-	O
mediated	O
apoptosis	O
,	O
associated	O
with	O
a	O
down	O
-	O
regulation	O
of	O
NF	B
-	I
kappaB	I
complexes	I
in	O
the	O
nucleus	O
.	O
In	O
addition	O
,	O
blocking	O
TNF	B
,	O
itself	O
a	O
positive	O
regulator	O
of	O
NF	B
-	I
kappaB	I
,	O
with	O
neutralizing	B
antibodies	I
renders	O
the	O
cells	O
more	O
susceptible	O
to	O
anti	O
-	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O
In	O
summary	O
,	O
our	O
results	O
provide	O
compelling	O
evidence	O
that	O
NF	B
-	I
kappaB	I
protects	O
against	O
Fas	B
-mediated	O
death	O
and	O
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
T	O
cell	O
homeostasis	O
and	O
tolerance	O
.	O
Constitutive	O
activation	O
of	O
NF	B
-	I
kappaB	I
in	O
primary	O
adult	O
T	O
-	O
cell	O
leukemia	O
cells	O
.	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O
The	O
viral	B
protein	I
Tax	B
induces	O
the	O
activation	O
and	O
nuclear	O
translocalization	O
of	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
,	O
which	O
is	O
proposed	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O
However	O
,	O
the	O
HTLV	O
-	O
I	O
genes	O
including	O
Tax	B
are	O
not	O
expressed	O
significantly	O
in	O
primary	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
basis	O
for	O
NF	B
-	I
kappaB	I
activation	O
in	O
freshly	O
isolated	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O
We	O
found	O
that	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
,	O
like	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
-	O
cell	O
lines	O
,	O
display	O
constitutive	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
activity	O
and	O
increased	O
degradation	O
of	O
IkappaBalpha	B
(	O
an	O
inhibitor	O
of	O
NF	B
-	I
kappaB	I
)	O
.	O
Whereas	O
the	O
NF	B
-	I
kappaB	I
binding	O
activity	O
in	O
Tax	O
-	O
expressing	O
T	O
-	O
cell	O
lines	O
consisted	O
mostly	O
of	O
p50	B
/	I
c	I
-	I
Rel	I
,	O
fresh	O
ATL	O
samples	O
contained	O
p50	B
/	I
p50	I
and	I
p50	I
/	I
p65	I
heterodimers	I
.	O
One	O
T	O
-	O
cell	O
line	O
derived	O
from	O
ATL	O
leukemic	O
cells	O
,	O
TL	O
-	O
Om1	O
,	O
displayed	O
constitutive	O
NF	B
-	I
kappaB	I
activity	O
,	O
as	O
well	O
as	O
enhanced	O
degradation	O
of	O
IkappaBalpha	B
,	O
despite	O
the	O
lack	O
of	O
detectable	O
Tax	B
expression	O
.	O
Interestingly	O
,	O
the	O
NF	B
-	I
kappaB	I
in	O
TL	O
-	O
Om1	O
consists	O
of	O
p50	B
/	I
p50	I
and	O
p50	B
/	I
p65	I
like	O
that	O
in	O
fresh	O
primary	O
leukemic	O
cells	O
.	O
Our	O
results	O
suggest	O
that	O
activation	O
of	O
NF	B
-	I
kappaB	I
occurs	O
through	O
a	O
Tax	B
-independent	O
mechanism	O
in	O
leukemic	O
cells	O
of	O
ATL	O
patients	O
,	O
possibly	O
due	O
to	O
differential	O
NF	B
-	I
kappaB	I
subunit	O
activation	O
.	O
Differential	O
regulation	O
of	O
4E	B
-	I
BP1	I
and	O
4E	B
-	I
BP2	I
,	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
.	O
Human	O
myeloid	O
differentiation	O
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
cell	O
proliferation	O
.	O
Because	O
the	O
translation	O
rate	O
is	O
an	O
important	O
determinant	O
of	O
cell	O
proliferation	O
,	O
we	O
have	O
investigated	O
translation	O
initiation	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
using	O
the	O
HL-60	O
promyelocytic	O
leukemia	O
cell	O
line	O
and	O
the	O
U-937	O
monoblastic	O
cell	O
line	O
.	O
A	O
decrease	O
in	O
the	O
translation	O
rate	O
is	O
observed	O
when	O
the	O
cells	O
are	O
induced	O
to	O
differentiate	O
along	O
the	O
monocytic	O
/	O
macrophage	O
pathway	O
or	O
along	O
the	O
granulocytic	O
pathway	O
.	O
The	O
inhibition	O
in	O
protein	O
synthesis	O
correlates	O
with	O
specific	O
regulation	O
of	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
4E	B
-	I
BP1	I
and	O
4E	B
-	I
BP2	I
.	O
Induction	O
of	O
HL-60	O
and	O
U-937	O
cell	O
differentiation	O
into	O
monocytes	O
/	O
macrophages	O
by	O
IFN	B
-	I
gamma	I
or	O
PMA	O
results	O
in	O
a	O
dephosphorylation	O
and	O
consequent	O
activation	O
of	O
4E	B
-	I
BP1	I
.	O
Dephosphorylation	O
of	O
4E	B
-	I
BP1	I
was	O
also	O
observed	O
when	O
U-937	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
monocytes	O
/	O
macrophages	O
following	O
treatment	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
.	O
In	O
contrast	O
,	O
treatment	O
of	O
HL-60	O
cells	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
,	O
which	O
results	O
in	O
a	O
granulocytic	O
differentiation	O
of	O
these	O
cells	O
,	O
decreases	O
4E	B
-	I
BP1	I
amount	O
without	O
affecting	O
its	O
phosphorylation	O
and	O
strongly	O
increases	O
4E	B
-	I
BP2	I
amount	O
.	O
Taken	O
together	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
translational	O
machinery	O
during	O
human	O
myeloid	O
differentiation	O
,	O
specific	O
to	O
the	O
monocytic	O
/	O
macrophage	O
pathway	O
or	O
to	O
the	O
granulocytic	O
pathway	O
.	O
Characterization	O
of	O
expression	O
of	O
the	O
gene	O
for	O
human	B
pterin	I
carbinolamine	I
dehydratase	I
/	I
dimerization	I
cofactor	I
of	O
HNF1	B
.	O
Pterin	B
carbinolamine	I
dehydratase	I
/	I
dimerization	I
cofactor	I
of	O
HNF1	B
(	O
PCD	B
/	I
DCoH	I
)	O
is	O
a	O
dual	B
-	I
function	I
protein	I
.	O
In	O
the	O
cytoplasm	O
it	O
acts	O
as	O
a	O
dehydratase	B
in	O
the	O
regeneration	O
of	O
tetrahydrobiopterin	B
,	O
the	O
cofactor	O
for	O
aromatic	B
amino	I
acid	I
hydroxylases	I
.	O
In	O
the	O
nucleus	O
,	O
it	O
functions	O
as	O
a	O
dimerization	B
cofactor	I
of	O
HNF1	B
and	O
increases	O
the	O
transcriptional	O
activity	O
of	O
HNF1	B
.	O
To	O
deepen	O
our	O
understanding	O
of	O
this	O
protein	O
,	O
we	O
characterized	O
its	O
expression	O
in	O
human	O
tissues	O
and	O
cells	O
.	O
Human	O
PCD	B
/	I
DCoH	I
was	O
present	O
predominantly	O
in	O
liver	O
and	O
kidney	O
,	O
with	O
significant	O
amounts	O
in	O
testis	O
and	O
ovary	O
,	O
trace	O
amounts	O
in	O
lung	O
,	O
and	O
undetectable	O
levels	O
in	O
whole	O
brain	O
,	O
heart	O
,	O
and	O
spleen	O
.	O
It	O
was	O
expressed	O
in	O
all	O
of	O
the	O
cells	O
that	O
were	O
examined	O
.	O
Importantly	O
,	O
it	O
was	O
also	O
present	O
in	O
the	O
nucleus	O
of	O
HeLa	O
cells	O
,	O
which	O
lack	O
HNF1	B
,	O
and	O
in	O
the	O
cytoplasm	O
of	O
fibroblasts	O
that	O
have	O
little	O
or	O
no	O
tetrahydrobiopterin	B
.	O
The	O
expression	O
of	O
human	B
PCD	I
/	I
DCoH	I
in	O
the	O
liver	O
and	O
nonhepatic	O
cells	O
was	O
compared	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O
Although	O
the	O
mRNA	O
level	O
in	O
liver	O
was	O
only	O
fourfold	O
higher	O
than	O
that	O
in	O
keratinocytes	O
and	O
fibroblasts	O
,	O
the	O
hepatic	B
PCD	I
/	I
DCoH	I
protein	I
level	O
was	O
20-fold	O
higher	O
than	O
that	O
in	O
normal	O
human	O
epidermal	O
keratinocytes	O
and	O
dermal	O
fibroblasts	O
.	O
Cloning	O
of	O
the	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
human	B
keratinocyte	I
PCD	I
/	I
DCoH	I
revealed	O
that	O
it	O
has	O
53	O
bp	O
more	O
of	O
GC	O
-	O
rich	O
5	O
'	O
untranslated	O
sequence	O
than	O
the	O
published	O
liver	B
PCD	I
/	I
DCoH	I
.	O
In	O
vitro	O
transcription	O
and	O
translation	O
analysis	O
showed	O
that	O
the	O
longer	O
5	O
'	O
UTR	O
resulted	O
in	O
about	O
a	O
35	O
%	O
decrease	O
in	O
translation	O
efficiency	O
.	O
These	O
data	O
show	O
that	O
human	B
PCD	I
/	I
DCoH	I
is	O
not	O
only	O
present	O
in	O
cells	O
where	O
tetrahydrobiopterin	B
is	O
synthesized	O
or	O
HNF1	B
is	O
present	O
but	O
is	O
a	O
widely	O
distributed	O
protein	O
.	O
Its	O
differential	O
expression	O
in	O
different	O
tissues	O
and	O
cells	O
is	O
regulated	O
not	O
only	O
at	O
the	O
transcriptional	O
level	O
but	O
also	O
at	O
the	O
translational	O
level	O
.	O
Jeg-3	O
human	O
choriocarcinoma	O
-	O
induced	O
immunosuppression	O
:	O
downregulation	O
of	O
interleukin-2	B
,	O
interleukin-2	B
receptor	I
alpha	I
-	I
chain	I
,	O
and	O
its	O
Jak	B
/	I
Stat	I
signaling	O
pathway	O
.	O
PROBLEM	O
:	O
The	O
mechanisms	O
of	O
the	O
immunosuppressive	O
and	O
immunosuppression	O
-	O
inducing	O
capacities	O
of	O
Jeg-3	O
human	O
choriocarcinoma	O
cell	O
line	O
supernatants	O
(	O
HCSs	O
)	O
are	O
not	O
yet	O
completely	O
understood	O
.	O
The	O
influence	O
on	O
interleukin	B
(	I
IL	I
)	I
-2	I
,	O
IL-4	B
and	O
interferon	B
(	I
IFN	I
)	I
-gamma	I
production	O
;	O
IL-2	B
receptor	I
(	I
IL-2R	I
)	I
alpha	I
-	O
,	O
beta	B
-	O
,	O
and	O
gamma	B
-	I
chain	I
;	O
and	O
the	O
signaling	B
pathway	I
molecules	I
Janus	B
kinase	I
(	B
Jak	I
)	I
1	I
,	O
Jak3	B
,	O
signal	O
transducers	O
and	O
activators	B
of	I
transcription	I
(	B
Stat	I
)	I
1	I
,	O
Stat3	B
,	O
and	O
Stat5	B
should	O
be	O
investigated	O
.	O
METHOD	O
OF	O
STUDY	O
:	O
For	O
assessment	O
of	O
IL	O
production	O
,	O
whole	O
peripheral	O
venous	O
blood	O
from	O
healthy	O
donors	O
was	O
stimulated	O
with	O
phorbol	O
-	O
myristate	O
-	O
acetate	O
and	O
ionomycine	O
.	O
Secretion	O
of	O
ILs	B
was	O
blocked	O
with	O
monensine	O
.	O
Intracellular	O
ILs	B
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O
For	O
IL-2R	B
and	O
signaling	O
pathway	O
molecule	O
analysis	O
,	O
peripheral	O
blood	O
lymphocytes	O
were	O
stimulated	O
with	O
phytohemagglutinin	B
(	O
PHA	B
)	O
.	O
IL-2R	O
chains	O
were	O
measured	O
by	O
flow	O
cytometry	O
,	O
and	O
Jaks	B
/	I
Stats	I
by	O
sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
Western	O
blot	O
.	O
RESULTS	O
:	O
Phorbol	O
-	O
myristate	O
-	O
acetate	O
and	O
ionomycine	O
strongly	O
increase	O
the	O
percent	O
-	O
age	O
of	O
IL-2	O
+	O
cells	O
;	O
an	O
additional	O
50	O
%	O
HCSs	O
significantly	O
suppresses	O
the	O
percentage	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	O
cells	O
.	O
IFN	O
-	O
gamma	O
production	O
is	O
strongly	O
decreased	O
by	O
HCSs	O
in	O
some	O
cases	O
,	O
but	O
not	O
in	O
others	O
.	O
PHA	B
stimulates	O
IL-2R	O
alpha-	O
,	O
beta-	O
,	O
and	O
gamma	O
-	O
chain	O
expression	O
and	O
their	O
signaling	B
pathway	I
molecules	I
Jak1	B
,	O
Jak3	B
,	O
Stat1	O
,	O
Stat3	B
,	O
and	O
Stat5	B
.	O
50	O
%	O
HCS	O
downregulates	O
the	O
alpha	B
-	I
chain	I
and	O
slightly	O
upregulates	O
the	O
beta	B
-	I
chain	I
.	O
Jak1	O
,	O
Jak3	O
,	O
Stat1	O
,	O
Stat3	O
,	O
and	O
Stat5	O
expression	O
is	O
suppressed	O
approximately	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	O
cells	O
.	O
CONCLUSIONS	O
:	O
HCS	O
forcefully	O
blocks	O
the	O
production	O
of	O
IL-2	B
;	O
the	O
IL-2R	B
alpha	I
-	I
chain	I
;	O
and	O
Jak1	O
,	O
Jak3	O
,	O
Stat1	O
,	O
Stat3	O
,	O
and	O
Stat5	O
expression	O
.	O
The	O
observed	O
phenomena	O
might	O
be	O
caused	O
by	O
downregulation	O
of	O
an	O
IL-2R	O
regulation	O
gene	O
,	O
and	O
might	O
play	O
a	O
key	O
role	O
in	O
the	O
expansion	O
of	O
choriocarcinoma	O
,	O
and	O
possibly	O
in	O
the	O
survival	O
of	O
the	O
fetal	O
allograft	O
.	O
[	O
Induction	O
of	O
apoptosis	O
in	O
lymphocytes	O
by	O
glucocorticoids	O
:	O
between	O
physiology	O
and	O
pharmacology	O
]	O
Glucocorticoids	O
are	O
physiological	O
molecules	O
that	O
are	O
also	O
extensively	O
used	O
in	O
clinics	O
as	O
anti	O
-	O
inflammatory	O
,	O
immunosuppressive	O
or	O
anti	O
-	O
tumoral	O
agents	O
.	O
Glucocorticoids	O
can	O
induce	O
apoptosis	O
on	O
normal	O
lymphoid	O
cells	O
and	O
play	O
a	O
key	O
role	O
in	O
the	O
physiology	O
of	O
thymic	O
selection	O
.	O
In	O
clinics	O
these	O
molecules	O
are	O
also	O
used	O
for	O
their	O
potencies	O
in	O
inducing	O
apoptosis	O
of	O
malignant	O
lymphoid	O
cells	O
.	O
Glucocorticoids	O
are	O
mediating	O
their	O
effects	O
after	O
binding	O
to	O
an	O
intracellular	B
receptor	I
belonging	O
to	O
the	O
steroid	B
receptor	I
superfamily	I
:	O
the	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
.	O
Once	O
activated	O
,	O
the	O
GR	B
,	O
can	O
mediate	O
his	O
effects	O
through	O
direct	O
binding	O
on	O
the	O
DNA	O
or	O
via	O
protein	O
/	O
protein	O
interactions	O
with	O
transcription	B
factors	I
.	O
Depending	O
on	O
the	O
type	O
of	O
lymphocytes	O
,	O
the	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
glucocorticoids	O
fall	O
roughly	O
in	O
two	O
categories	O
:	O
induction	O
of	O
`	O
`	O
death	O
genes	O
''	O
by	O
the	O
activated	O
GR	B
(	O
I	B
kappa	I
B	I
,	O
c	B
-	I
jun	I
)	O
or	O
repression	O
of	O
survival	B
factors	I
(	O
AP-1	B
,	O
c	B
-	I
Myc	I
)	O
.	O
In	O
the	O
case	O
of	O
thymic	O
selection	O
the	O
mechanism	O
is	O
more	O
subtle	O
depending	O
on	O
the	O
mutual	O
repression	O
of	O
Nur77	B
and	O
GR	B
.	O
A	O
human	O
IFNGR1	O
small	O
deletion	O
hotspot	O
associated	O
with	O
dominant	O
susceptibility	O
to	O
mycobacterial	O
infection	O
[	O
see	O
comments	O
]	O
The	O
immunogenetic	O
basis	O
of	O
severe	O
infections	O
caused	O
by	O
bacille	O
Calmette	O
-	O
Guerin	O
vaccine	O
and	O
environmental	O
mycobacteria	O
in	O
humans	O
remains	O
largely	O
unknown	O
.	O
We	O
describe	O
18	O
patients	O
from	O
several	O
generations	O
of	O
12	O
unrelated	O
families	O
who	O
were	O
heterozygous	O
for	O
1	O
to	O
5	O
overlapping	O
IFNGR1	O
frameshift	O
small	O
deletions	O
and	O
a	O
wild	O
-	O
type	O
IFNGR1	O
allele	O
.	O
There	O
were	O
12	O
independent	O
mutation	O
events	O
at	O
a	O
single	O
mutation	O
site	O
,	O
defining	O
a	O
small	O
deletion	O
hotspot	O
.	O
Neighbouring	O
sequence	O
analysis	O
favours	O
a	O
small	O
deletion	O
model	O
of	O
slipped	O
mispairing	O
events	O
during	O
replication	O
.	O
The	O
mutant	O
alleles	O
encode	O
cell	B
-	I
surface	I
IFNgamma	I
receptors	I
that	O
lack	O
the	O
intra	B
-	I
cytoplasmic	I
domain	I
,	O
which	O
,	O
through	O
a	O
combination	O
of	O
impaired	O
recycling	O
,	O
abrogated	O
signalling	O
and	O
normal	O
binding	O
to	O
IFNgamma	B
exert	O
a	O
dominant	O
-	O
negative	O
effect	O
.	O
We	O
thus	O
report	O
a	O
hotspot	O
for	O
human	O
IFNGR1	O
small	O
deletions	O
that	O
confer	O
dominant	O
susceptibility	O
to	O
infections	O
caused	O
by	O
poorly	O
virulent	O
mycobacteria	O
.	O
Erythroid	O
gene	O
expression	O
is	O
differentially	O
regulated	O
by	O
erythropoietin	B
,	O
haemin	O
and	O
delta	O
-	O
aminolaevulinic	O
acid	O
in	O
UT-7	O
cells	O
.	O
Erythropoietin	O
(	O
Epo	O
)	O
is	O
essential	O
for	O
the	O
later	O
stages	O
of	O
erythropoiesis	O
,	O
acting	O
to	O
promote	O
cell	O
survival	O
and	O
proliferation	O
,	O
but	O
its	O
role	O
in	O
differentiation	O
remains	O
to	O
be	O
defined	O
.	O
The	O
UT-7	O
cell	O
line	O
exhibits	O
both	O
erythroid	O
and	O
megakaryocytic	O
characteristics	O
and	O
can	O
be	O
induced	O
to	O
differentiate	O
along	O
the	O
erythroid	O
pathway	O
by	O
Epo	B
or	O
the	O
megakaryocytic	O
pathway	O
by	O
phorbol	O
myristic	O
acetate	O
.	O
We	O
have	O
compared	O
the	O
effects	O
of	O
Epo	B
and	O
the	O
chemical	O
inducers	O
,	O
delta	O
-	O
aminolaevulinic	O
acid	O
(	O
delta	O
-	O
ALA	O
)	O
and	O
haemin	O
on	O
the	O
differentiation	O
capacity	O
of	O
UT-7	O
cells	O
.	O
Epo	B
alone	O
promoted	O
relatively	O
early	O
events	O
in	O
erythroid	O
maturation	O
,	O
without	O
significant	O
changes	O
in	O
haemoglobin	O
production	O
or	O
morphology	O
.	O
GATA-2	B
and	O
c	B
-	I
myb	I
were	O
down	O
-	O
regulated	O
by	O
Epo	B
,	O
and	O
GATA-2	B
was	O
further	O
down	O
-	O
modulated	O
by	O
the	O
inducers	O
.	O
Conversely	O
,	O
SCL	B
expression	O
was	O
up	O
-	O
regulated	O
by	O
Epo	B
and	O
further	O
increased	O
by	O
haemin	O
and	O
delta	O
-	O
ALA	O
.	O
Epo	B
caused	O
an	O
increase	O
in	O
the	O
proportion	O
of	O
cells	O
expressing	O
cell	O
surface	O
glycophorin	B
A	I
(	O
GPA	B
)	O
and	O
up	O
-	O
regulated	O
beta-	B
and	I
gamma	I
-	I
globin	I
by	O
several	O
fold	O
.	O
Both	O
haemin	O
and	O
delta	O
-	O
ALA	O
caused	O
a	O
de	O
novo	O
increase	O
in	O
alpha	B
-	I
globin	I
expression	O
as	O
well	O
as	O
enhancing	O
Epo	B
-induced	O
beta	B
-	I
globin	I
expression	O
,	O
leading	O
to	O
a	O
marked	O
increase	O
in	O
haemoglobin	O
production	O
.	O
These	O
results	O
suggest	O
that	O
haemoglobin	O
production	O
in	O
UT-7	O
cells	O
is	O
limited	O
by	O
a	O
deficiency	O
of	O
erythroid	B
-	I
specific	I
aminolaevulinic	I
acid	I
synthase	I
(	O
ALAS	B
-	I
E	I
)	O
activity	O
or	O
globin	O
synthesis	O
as	O
a	O
consequence	O
of	O
their	O
immaturity	O
as	O
a	O
multipotential	O
cell	O
line	O
.	O
Studies	O
into	O
the	O
effect	O
of	O
tyrosine	B
phosphatase	I
inhibitor	O
phenylarsine	O
oxide	O
on	O
NFkappaB	B
activation	O
in	O
T	O
lymphocytes	O
during	O
aging	O
:	O
evidence	O
for	O
altered	O
IkappaB	B
-	I
alpha	I
phosphorylation	O
and	O
degradation	O
.	O
Nuclear	B
Factor	I
kappa	I
B	I
(	O
NFkappaB	B
)	O
is	O
a	O
critical	O
regulator	O
of	O
several	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O
Treatment	O
of	O
T	O
cells	O
with	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
TNF	B
-	I
alpha	I
,	O
leads	O
to	O
the	O
translocation	O
of	O
the	O
active	O
p65	B
-	I
50	I
heterodimer	I
to	O
the	O
nucleus	O
,	O
albeit	O
at	O
a	O
lower	O
level	O
in	O
T	O
cells	O
from	O
the	O
elderly	O
.	O
We	O
demonstrate	O
here	O
that	O
pretreatment	O
with	O
PAO	O
results	O
in	O
the	O
inhibition	O
of	O
NFkappaB	B
induction	O
in	O
TNF	B
-	I
alpha	I
treated	O
T	O
cells	O
,	O
suggesting	O
a	O
role	O
for	O
PAO	B
-	I
sensitive	I
phosphatase	I
in	O
the	O
activation	O
of	O
the	O
NFkappaB	B
via	O
this	O
pathway	O
in	O
human	O
T	O
cells	O
.	O
Furthermore	O
,	O
it	O
demonstrates	O
that	O
aging	O
does	O
not	O
influence	O
the	O
sensitivity	O
of	O
this	O
phosphatase	B
.	O
Treatment	O
with	O
DMP	O
prior	O
to	O
treatment	O
with	O
PAO	O
and	O
TNF	B
abolishes	O
the	O
inhibition	O
induced	O
by	O
PAO	O
,	O
in	O
T	O
cells	O
from	O
both	O
young	O
and	O
old	O
donors	O
,	O
alike	O
.	O
Finally	O
,	O
we	O
demonstrate	O
that	O
a	O
failure	O
to	O
degrade	O
IkappaB	B
-	I
alpha	I
in	O
cytosols	O
of	O
TNF	O
-	O
treated	O
T	O
cells	O
pretreated	O
with	O
PAO	O
is	O
due	O
to	O
its	O
interference	O
with	O
the	O
phosphorylation	O
of	O
IkappaB	B
-	I
alpha	I
and	O
not	O
due	O
to	O
its	O
inhibitory	O
effect	O
on	O
proteasomal	O
degradation	O
.	O
These	O
data	O
collectively	O
suggest	O
that	O
PAO	O
interferes	O
with	O
the	O
phosphorylation	O
and	O
the	O
regulated	O
degradation	O
of	O
IkappaB	B
-	I
alpha	I
,	O
induced	O
by	O
TNF	B
,	O
without	O
affecting	O
the	O
chymotryptic	O
activity	O
of	O
the	O
proteasome	B
,	O
independent	O
of	O
age	O
.	O
Role	O
of	O
cellular	B
tumor	I
necrosis	I
factor	I
receptor	I
-	I
associated	I
factors	I
in	O
NF	B
-	I
kappaB	I
activation	O
and	O
lymphocyte	O
transformation	O
by	O
herpesvirus	O
Saimiri	O
STP	B
.	O
The	O
STP	B
oncoproteins	I
of	O
the	O
herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
subgroup	O
A	O
strain	O
11	O
and	O
subgroup	O
C	O
strain	O
488	O
are	O
now	O
found	O
to	O
be	O
stably	O
associated	O
with	O
tumor	B
necrosis	I
factor	I
receptor	I
-	I
associated	I
factor	I
(	I
TRAF	I
)	I
1	I
,	I
2	I
,	I
or	I
3	I
.	O
Mutational	O
analyses	O
identified	O
residues	O
of	O
PXQXT	B
/	I
S	I
in	O
STP	B
-	I
A11	I
as	O
critical	O
for	O
TRAF	B
association	O
.	O
In	O
addition	O
,	O
a	O
somewhat	O
divergent	O
region	O
of	O
STP	B
-	I
C488	I
is	O
critical	O
for	O
TRAF	B
association	O
.	O
Mutational	O
analysis	O
also	O
revealed	O
that	O
STP	B
-	I
C488	I
induced	O
NF	B
-	I
kappaB	I
activation	O
that	O
was	O
correlated	O
with	O
its	O
ability	O
to	O
associate	O
with	O
TRAFs	B
.	O
The	O
HVS	O
STP	B
-	I
C488	I
P10	O
--	O
>	O
R	O
mutant	O
was	O
deficient	O
in	O
human	O
T	O
-	O
lymphocyte	O
transformation	O
to	O
interleukin-2-independent	O
growth	O
but	O
showed	O
wild	O
-	O
type	O
phenotype	O
for	O
marmoset	O
T	O
-	O
lymphocyte	O
transformation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
The	O
STP	B
-	I
C488	I
P10	I
--	I
>	I
R	I
mutant	I
was	O
also	O
defective	O
in	O
Rat-1	O
fibroblast	O
transformation	O
,	O
and	O
fibroblast	O
cell	O
transformation	O
was	O
blocked	O
by	O
a	O
TRAF2	B
dominant	O
-	O
negative	O
mutant	O
.	O
These	O
data	O
implicate	O
TRAFs	B
in	O
STP	B
-	I
C488	I
-mediated	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O
Other	O
factors	O
are	O
implicated	O
in	O
immortalization	O
of	O
common	O
marmoset	O
T	O
lymphocytes	O
and	O
may	O
also	O
be	O
critical	O
in	O
the	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O
Engagement	O
of	O
natural	O
cytotoxicity	O
programs	O
regulates	O
AP-1	B
expression	O
in	O
the	O
NKL	O
human	O
NK	O
cell	O
line	O
.	O
NK	O
cell	O
cytotoxicity	O
is	O
a	O
fast	O
and	O
efficient	O
mechanism	O
of	O
target	O
cell	O
lysis	O
.	O
Using	O
transcription	O
analysis	O
,	O
such	O
as	O
multiplex	O
messenger	O
assays	O
,	O
we	O
show	O
here	O
that	O
natural	O
cytotoxicity	O
exerted	O
by	O
the	O
human	O
NKL	O
cell	O
line	O
correlates	O
with	O
mRNA	O
accumulation	O
of	O
very	B
early	I
activator	I
protein	I
(	I
AP	I
)	I
-1	I
transcription	O
factor	O
genes	O
such	O
as	O
JunB	O
,	O
FosB	O
and	O
c	O
-	O
Fos	O
.	O
In	O
addition	O
,	O
DNA	O
-	O
binding	O
activities	O
of	O
Jun	B
-	I
Fos	I
heterodimers	I
were	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
during	O
the	O
course	O
of	O
natural	O
cytotoxicity	O
.	O
Interaction	O
between	O
immunoglobulin	B
-	I
like	I
transcript-2	I
/	I
leukocyte	I
Ig	I
-	I
like	I
receptor	I
1	I
on	O
NKL	O
cells	O
and	O
HLA	B
-	I
B27	I
on	O
target	O
cells	O
leads	O
to	O
an	O
impairment	O
of	O
NKL	O
natural	O
cytotoxicity	O
,	O
which	O
correlates	O
with	O
an	O
absence	O
of	O
JunB	O
,	O
FosB	O
,	O
and	O
c	O
-	O
Fos	O
transcription	O
,	O
as	O
well	O
as	O
an	O
absence	O
of	O
their	O
DNA	O
-	O
binding	O
activity	O
.	O
Our	O
studies	O
thus	O
indicate	O
that	O
,	O
despite	O
the	O
rapidity	O
of	O
NK	O
cell	O
-	O
mediated	O
lysis	O
,	O
AP-1	B
transcription	I
factor	I
is	O
activated	O
during	O
the	O
early	O
stage	O
of	O
NK	O
cell	O
cytolytic	O
programs	O
and	O
that	O
engagement	O
of	O
NK	B
cell	I
inhibitory	I
receptors	I
for	O
MHC	B
class	I
I	I
molecules	I
impairs	O
the	O
very	O
early	O
activation	O
of	O
AP-1	B
.	O
Human	O
cytomegalovirus	O
binding	O
to	O
human	O
monocytes	O
induces	O
immunoregulatory	O
gene	O
expression	O
.	O
To	O
continue	O
our	O
investigation	O
of	O
the	O
cellular	O
events	O
that	O
occur	O
following	O
human	O
CMV	O
(	O
HCMV	O
)	O
infection	O
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
cellular	O
activation	O
following	O
viral	O
binding	O
to	O
human	O
monocytes	O
.	O
First	O
,	O
we	O
showed	O
that	O
viral	O
binding	O
induced	O
a	O
number	O
of	O
immunoregulatory	O
genes	O
(	O
IL-1beta	B
,	O
A20	B
,	O
NF	B
-	I
kappaB	I
-	I
p105	I
/	I
p50	I
,	O
and	O
IkappaBalpha	B
)	O
in	O
unactivated	O
monocytes	O
and	O
that	O
neutralizing	B
Abs	I
to	O
the	O
major	O
HCMV	B
glycoproteins	I
,	O
gB	B
(	O
UL55	B
)	O
and	O
gH	B
(	O
UL75	B
)	O
,	O
inhibited	O
the	O
induction	O
of	O
these	O
genes	O
.	O
Next	O
,	O
we	O
demonstrated	O
that	O
these	O
viral	O
ligands	O
directly	O
up	O
-	O
regulated	O
monocyte	O
gene	O
expression	O
upon	O
their	O
binding	O
to	O
their	O
appropriate	O
cellular	O
receptors	O
.	O
We	O
then	O
investigated	O
if	O
HCMV	O
binding	O
also	O
resulted	O
in	O
the	O
translation	O
and	O
secretion	O
of	O
cytokines	B
.	O
Our	O
results	O
showed	O
that	O
HCMV	O
binding	O
to	O
monocytes	O
resulted	O
in	O
the	O
production	O
and	O
release	O
of	O
IL-1beta	B
protein	I
.	O
Because	O
these	O
induced	O
gene	O
products	O
have	O
NF	O
-	O
kappaB	O
sites	O
in	O
their	O
promoter	O
regions	O
,	O
we	O
next	O
examined	O
whether	O
there	O
was	O
an	O
up	O
-	O
regulation	O
of	O
nuclear	O
NF	B
-	I
kappaB	I
levels	O
.	O
These	O
experiments	O
showed	O
that	O
,	O
in	O
fact	O
,	O
NF	B
-	I
kappaB	I
was	O
translocated	O
to	O
the	O
nucleus	O
following	O
viral	O
binding	O
or	O
purified	O
viral	O
ligand	O
binding	O
.	O
Changes	O
in	O
IkappaBalpha	B
levels	O
correlated	O
with	O
the	O
changes	O
in	O
NF	B
-	I
kappaB	I
translocation	O
.	O
Lastly	O
,	O
we	O
demonstrated	O
that	O
p38	B
kinase	O
activity	O
played	O
a	O
central	O
role	O
in	O
IL-1beta	B
production	O
and	O
that	O
it	O
was	O
rapidly	O
up	O
-	O
regulated	O
following	O
infection	O
.	O
These	O
results	O
support	O
our	O
hypothesis	O
that	O
HCMV	O
initiates	O
a	O
signal	O
transduction	O
pathway	O
that	O
leads	O
to	O
monocyte	O
activation	O
and	O
pinpoints	O
a	O
potential	O
mechanism	O
whereby	O
HCMV	O
infection	O
of	O
monocytes	O
can	O
result	O
in	O
profound	O
pathogenesis	O
,	O
especially	O
in	O
chronic	O
inflammatory	O
-	O
type	O
conditions	O
.	O
Extracellular	B
-	I
regulated	I
kinase	I
1	I
/	I
2	I
,	O
Jun	B
N	I
-	I
terminal	I
kinase	I
,	O
and	O
c	B
-	I
Jun	I
are	O
involved	O
in	O
NF	B
-	I
kappa	I
B	I
-dependent	O
IL-6	B
expression	O
in	O
human	O
monocytes	O
.	O
In	O
the	O
present	O
study	O
we	O
investigated	O
the	O
possible	O
involvement	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
family	I
members	O
extracellular	B
-	I
regulated	I
kinase	I
1	I
/	I
2	I
(	O
ERK1	B
/	I
2	I
)	O
and	O
c-	O
Jun	B
N	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
in	O
mediating	O
IL-6	B
gene	O
expression	O
in	O
human	O
monocytes	O
,	O
in	O
particular	O
their	O
role	O
in	O
enhancing	O
NF	B
-	I
kappa	I
B	I
activity	O
.	O
Freshly	O
isolated	O
monocytes	O
treated	O
with	O
the	O
protein	O
phosphatase	O
inhibitor	O
okadaic	O
acid	O
secreted	O
high	O
levels	O
of	O
IL-6	B
protein	I
,	O
which	O
coincided	O
with	O
enhanced	O
binding	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
as	O
well	O
as	O
with	O
phosphorylation	O
and	O
activation	O
of	O
the	O
ERK1	B
/	I
2	I
and	I
JNK	I
proteins	I
.	O
The	O
ERK	O
pathway	O
-	O
specific	O
inhibitor	O
PD98059	O
inhibited	O
IL-6	B
secretion	O
from	O
monocytes	O
.	O
Transient	O
overexpression	O
of	O
inactive	O
mutants	O
of	O
either	O
Raf-1	B
or	O
JNK1	B
showed	O
that	O
both	O
pathways	O
were	O
involved	O
in	O
kappa	O
B	O
-	O
dependent	O
IL-6	B
promoter	O
activity	O
.	O
By	O
using	O
PD98059	O
,	O
we	O
demonstrated	O
that	O
the	O
Raf1	O
/	O
MEK1	O
/	O
ERK1	B
/	I
2	I
pathway	O
did	O
not	O
affect	O
the	O
DNA	O
binding	O
of	O
NF	B
-	I
kappa	I
B	I
but	O
,	O
rather	O
,	O
acted	O
at	O
the	O
level	O
of	O
transcriptional	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
Interestingly	O
,	O
it	O
was	O
shown	O
that	O
NF	B
-	I
kappa	I
B	I
-mediated	O
gene	O
transcription	O
,	O
both	O
in	O
the	O
context	O
of	O
the	O
IL-6	O
promoter	O
as	O
well	O
as	O
on	O
its	O
own	O
,	O
was	O
dependent	O
on	O
both	O
serine	O
kinase	O
activity	O
and	O
interaction	O
with	O
c	B
-	I
Jun	I
protein	I
.	O
We	O
conclude	O
that	O
okadaic	O
acid	O
-	O
induced	O
IL-6	B
gene	O
expression	O
is	O
at	O
least	O
partly	O
mediated	O
through	O
the	O
ERK1	B
/	I
2	I
and	O
JNK	B
pathway	O
-	O
dependent	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
transcriptional	O
capacity	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
JNK	B
pathway	O
may	O
regulate	O
NF	B
-	I
kappa	I
B	I
-mediated	O
gene	O
transcription	O
through	O
its	O
phosphorylation	O
and	O
activation	O
of	O
c	B
-	I
Jun	I
.	O
Suppressive	O
effects	O
of	O
anti	O
-	O
inflammatory	O
agents	O
on	O
human	O
endothelial	O
cell	O
activation	O
and	O
induction	O
of	O
heat	B
shock	I
proteins	I
.	O
BACKGROUND	O
:	O
Studies	O
from	O
our	O
laboratory	O
have	O
shown	O
that	O
the	O
earliest	O
stages	O
of	O
atherosclerosis	O
may	O
be	O
mediated	O
by	O
an	O
autoimmune	O
reaction	O
against	O
heat	B
shock	I
protein	I
60	I
(	O
Hsp60	B
)	O
.	O
The	O
interactions	O
of	O
Hsp60-specific	O
T	O
cells	O
with	O
arterial	O
endothelial	O
cells	O
(	O
EC	O
)	O
require	O
expression	O
of	O
both	O
Hsp60	B
and	O
certain	O
adhesion	B
molecules	I
shown	O
to	O
be	O
induced	O
simultaneously	O
in	O
EC	O
by	O
mechanical	O
and	O
other	O
types	O
of	O
stress	O
.	O
Recently	O
,	O
it	O
was	O
shown	O
that	O
suppression	O
of	O
T	O
cell	O
-	O
mediated	O
immune	O
responses	O
by	O
cyclosporin	O
A	O
(	O
CyA	O
)	O
enhanced	O
atherosclerotic	O
lesion	O
formation	O
in	O
mice	O
.	O
In	O
contrast	O
,	O
aspirin	O
was	O
found	O
to	O
lower	O
the	O
risk	O
of	O
myocardial	O
infarction	O
in	O
men	O
.	O
These	O
conflicting	O
observations	O
may	O
be	O
due	O
to	O
different	O
effects	O
of	O
anti	O
-	O
inflammatory	O
agents	O
on	O
adhesion	O
molecule	O
and	O
Hsp	O
expression	O
in	O
EC	O
,	O
respectively	O
.	O
MATERIAL	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
CyA	O
,	O
aspirin	O
,	O
and	O
indomethacin	O
on	O
T	O
cell	O
proliferation	O
using	O
a	O
proliferation	O
assay	O
.	O
To	O
explore	O
the	O
expression	O
of	O
adhesion	B
molecules	I
,	O
monocyte	B
chemoattractant	I
protein-1	I
(	O
MCP-1	B
)	O
,	O
and	O
Hsp60	B
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
Northern	O
blot	O
analyses	O
were	O
used	O
.	O
To	O
examine	O
the	O
activation	O
status	O
of	O
the	O
transcription	B
factors	I
nuclear	B
factor	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
and	O
heat	B
shock	I
factor-1	I
(	O
HSF-1	B
)	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
were	O
performed	O
.	O
RESULTS	O
:	O
With	O
the	O
exception	O
of	O
indomethacin	O
,	O
the	O
used	O
immunosuppressive	O
and	O
anti	O
-	O
inflammatory	O
agents	O
significantly	O
inhibited	O
T	O
cell	O
proliferation	O
in	O
response	O
to	O
influenza	B
virus	I
antigen	I
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
Interestingly	O
,	O
CyA	O
and	O
indomethacin	O
did	O
not	O
suppress	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
-induced	O
adhesion	O
molecule	O
expression	O
on	O
HUVECs	O
,	O
whereas	O
aspirin	O
had	O
an	O
inhibitory	O
effect	O
.	O
These	O
observations	O
correlated	O
with	O
the	O
modulation	O
of	O
NF	B
-	I
kappaB	I
activity	O
in	O
EC	O
.	O
All	O
agents	O
tested	O
induced	O
expression	O
of	O
Hsp60	B
6	O
hr	O
after	O
application	O
.	O
In	O
addition	O
,	O
aspirin	O
and	O
indomethacin	O
,	O
but	O
not	O
CyA	O
,	O
induced	O
Hsp70	B
expression	O
in	O
HUVECs	O
that	O
correlated	O
with	O
induction	O
of	O
HSF-1	B
activity	O
.	O
CONCLUSION	O
:	O
Our	O
results	O
show	O
that	O
the	O
tested	O
agents	O
(	O
except	O
indomethacin	O
)	O
are	O
inhibitors	O
of	O
the	O
T	O
cell	O
-	O
mediated	O
immune	O
response	O
,	O
as	O
expected	O
,	O
that	O
aspirin	O
is	O
an	O
effective	O
suppressor	O
of	O
adhesion	B
molecule	I
expression	O
,	O
and	O
that	O
all	O
three	O
agents	O
can	O
induce	O
Hsp60	B
in	O
HUVECs	O
.	O
These	O
data	O
provide	O
the	O
molecular	O
basis	O
for	O
the	O
notion	O
that	O
(	O
1	O
)	O
part	O
of	O
the	O
anti	O
-	O
atherogenic	O
effect	O
of	O
aspirin	O
may	O
be	O
due	O
to	O
the	O
prevention	O
of	O
the	O
adhesion	O
of	O
sensitized	O
T	O
cells	O
to	O
stressed	O
EC	O
;	O
(	O
2	O
)	O
that	O
part	O
of	O
the	O
atherosclerosis	O
-	O
promoting	O
effect	O
of	O
CyA	O
may	O
be	O
due	O
to	O
its	O
potential	O
as	O
an	O
inducer	O
of	O
Hsp60	B
expression	O
and	O
its	O
inability	O
to	O
down	O
-	O
regulate	O
adhesion	B
molecule	I
expression	O
on	O
EC	O
;	O
and	O
(	O
3	O
)	O
that	O
down	O
-	O
regulation	O
of	O
MCP-1	B
expression	O
by	O
aspirin	O
may	O
result	O
in	O
decreased	O
recruitment	O
of	O
monocytes	O
into	O
the	O
arterial	O
intima	O
beneath	O
stressed	O
EC	O
.	O
Retinoid	B
X	I
receptor	I
(	O
RXR	B
)	O
agonist	O
-	O
induced	O
activation	O
of	O
dominant	O
-	O
negative	O
RXR	B
-retinoic	O
acid	O
receptor	O
alpha403	O
heterodimers	O
is	O
developmentally	O
regulated	O
during	O
myeloid	O
differentiation	O
.	O
The	O
multiple	O
biologic	O
activities	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
mediated	O
through	O
RAR	B
and	O
retinoid	B
X	I
receptor	I
(	I
RXR	I
)	I
nuclear	I
receptors	I
that	O
interact	O
with	O
specific	O
DNA	O
target	O
sequences	O
as	O
heterodimers	B
(	O
RXR	B
-	I
RAR	I
)	O
or	O
homodimers	B
(	O
RXR	B
-	I
RXR	I
)	O
.	O
RA	O
receptor	O
activation	O
appears	O
critical	O
to	O
regulating	O
important	O
aspects	O
of	O
hematopoiesis	O
,	O
since	O
transducing	O
a	O
COOH	B
-	I
terminally	I
truncated	I
RARalpha	I
exhibiting	O
dominant	O
-	O
negative	O
activity	O
(	O
RARalpha403	B
)	O
into	O
normal	O
mouse	O
bone	O
marrow	O
generates	O
hematopoietic	O
growth	O
factor	O
-	O
dependent	O
cell	O
lines	O
frozen	O
at	O
the	O
multipotent	O
progenitor	O
(	O
EML	O
)	O
or	O
committed	O
promyelocyte	O
(	O
MPRO	O
)	O
stages	O
.	O
Nevertheless	O
,	O
relatively	O
high	O
,	O
pharmacological	O
concentrations	O
of	O
RA	O
(	O
1	O
to	O
10	O
&	O
mgr	O
;	O
M	O
)	O
overcome	O
these	O
differentiation	O
blocks	O
and	O
induce	O
terminal	O
granulocytic	O
differentiation	O
of	O
the	O
MPRO	O
promyelocytes	O
while	O
potentiating	O
interleukin-3	B
(	O
IL-3	B
)	O
-induced	O
commitment	O
of	O
EML	O
cells	O
to	O
the	O
granulocyte	O
/	O
monocyte	O
lineage	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
utilized	O
RXR	B
-and	O
RAR	B
-specific	O
agonists	O
and	O
antagonists	O
to	O
determine	O
how	O
RA	O
overcomes	O
the	O
dominant	O
-	O
negative	O
activity	O
of	O
the	O
truncated	B
RARalpha	I
in	O
these	O
different	O
myeloid	O
developmental	O
stages	O
.	O
Unexpectedly	O
,	O
we	O
observed	O
that	O
an	O
RXR	B
-specific	O
,	O
rather	O
than	O
an	O
RAR	B
-specific	O
,	O
agonist	O
induces	O
terminal	O
granulocytic	O
differentiation	O
of	O
MPRO	O
promyelocytes	O
,	O
and	O
this	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
DNA	O
response	O
elements	O
corresponding	O
to	O
RAR	B
-	I
RXR	I
heterodimers	I
rather	O
than	O
RXR	B
-	I
RXR	I
homodimers	I
.	O
This	O
RXR	B
agonist	O
activity	O
is	O
blocked	O
by	O
RAR	B
-specific	O
antagonists	O
,	O
suggesting	O
extensive	O
cross	O
-	O
talk	O
between	O
the	O
partners	O
of	O
the	O
RXR	B
-RARalpha403	I
heterodimer	I
.	O
In	O
contrast	O
,	O
in	O
the	O
more	O
immature	O
,	O
multipotent	O
EML	O
cells	O
we	O
observed	O
that	O
this	O
RXR	B
-specific	O
agonist	O
is	O
inactive	O
either	O
in	O
potentiating	O
IL-3	B
-mediated	O
commitment	O
of	O
EML	O
cells	O
to	O
the	O
granulocyte	O
lineage	O
or	O
in	O
transactivating	O
RAR	O
-	O
RXR	O
response	O
elements	O
.	O
RA	O
-triggered	O
GALdbd-	O
RARalpha	B
hybrid	O
activity	O
in	O
these	O
cells	O
indicates	O
that	O
the	O
multipotent	O
EML	O
cells	O
harbor	O
substantial	O
nuclear	O
hormone	O
receptor	O
coactivator	B
activity	O
.	O
However	O
,	O
the	O
histone	B
deacetylase	I
(	I
HDAC	I
)	I
inhibitor	I
trichostatin	O
A	O
readily	O
activates	O
an	O
RXR	O
-	O
RAR	O
reporter	O
construct	O
in	O
the	O
multipotent	O
EML	O
cells	O
but	O
not	O
in	O
the	O
committed	O
MPRO	O
promyelocytes	O
,	O
indicating	O
that	O
differences	O
in	O
HDAC	B
-	I
containing	I
repressor	I
complexes	I
in	O
these	O
two	O
closely	O
related	O
but	O
distinct	O
hematopoietic	O
lineages	O
might	O
account	O
for	O
the	O
differential	O
activation	O
of	O
the	O
RXR	B
-	I
RARalpha403	I
heterodimers	I
that	O
we	O
observed	O
at	O
these	O
different	O
stages	O
of	O
myeloid	O
development	O
.	O
Retinoic	O
acid	O
induces	O
apoptosis	O
of	O
human	O
CD34	O
+	O
hematopoietic	O
progenitor	O
cells	O
:	O
involvement	O
of	O
retinoic	B
acid	I
receptors	I
and	O
retinoid	B
X	I
receptors	I
depends	O
on	O
lineage	O
commitment	O
of	O
the	O
hematopoietic	O
progenitor	O
cells	O
.	O
Retinoids	O
are	O
bifunctional	O
regulators	O
of	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	O
cells	O
.	O
In	O
this	O
study	O
we	O
explored	O
the	O
effects	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
on	O
apoptosis	O
of	O
human	O
CD34	O
+	O
hematopoietic	O
progenitor	O
cells	O
isolated	O
from	O
normal	O
bone	O
marrow	O
.	O
RA	O
(	O
100	O
nM	O
)	O
induced	O
an	O
increase	O
in	O
the	O
percentage	O
of	O
dead	O
cells	O
from	O
24	O
%	O
to	O
44	O
%	O
at	O
day	O
6	O
(	O
p	O
<	O
0.05	O
,	O
n	O
=	O
6	O
)	O
as	O
compared	O
to	O
control	O
cells	O
cultured	O
in	O
medium	O
alone	O
.	O
The	O
effect	O
was	O
dose	O
dependent	O
and	O
appeared	O
relatively	O
late	O
.	O
Significant	O
differences	O
were	O
observed	O
from	O
day	O
4	O
onward	O
.	O
Apoptosis	O
,	O
or	O
programmed	O
cell	O
death	O
,	O
was	O
demonstrated	O
as	O
the	O
mode	O
of	O
cell	O
death	O
by	O
using	O
the	O
TUNEL	O
assay	O
,	O
which	O
detects	O
single	O
strand	O
nicks	O
in	O
DNA	O
,	O
or	O
by	O
the	O
Nicoletti	O
technique	O
demonstrating	O
a	O
subdiploid	O
population	O
by	O
DNA	O
staining	O
.	O
RA	O
previously	O
was	O
found	O
to	O
inhibit	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
--	O
and	O
not	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
--	O
stimulated	O
proliferation	O
of	O
CD34	O
+	O
cells	O
.	O
However	O
,	O
we	O
found	O
that	O
RA	O
opposed	O
anti	O
-	O
apoptotic	O
effects	O
of	O
G	B
-	I
CSF	I
and	O
GM	B
-	I
CSF	I
on	O
CD34	O
+	O
cells	O
(	O
G	B
-	I
CSF	I
:	O
8	O
%	O
dead	O
cells	O
at	O
day	O
6	O
;	O
G	B
-	I
CSF	I
+	O
RA	O
:	O
20	O
%	O
;	O
GM	B
-	I
CSF	I
:	O
12	O
%	O
;	O
GM	B
-	I
CSF	I
+	O
RA	O
:	O
27	O
%	O
)	O
.	O
Moreover	O
,	O
RA	O
induced	O
apoptosis	O
of	O
CD34	O
+	O
cells	O
and	O
CD34+CD71	O
+	O
cells	O
stimulated	O
with	O
erythropoietin	B
.	O
To	O
explore	O
the	O
receptor	O
signaling	O
pathways	O
involved	O
in	O
RA	O
-	O
induced	O
apoptosis	O
,	O
we	O
used	O
selective	O
ligands	O
for	O
retinoic	B
acid	I
receptors	I
(	O
RARs	O
;	O
RO13	O
-	O
7410	O
)	O
and	O
retinoid	B
X	I
receptors	I
(	O
RXRs	B
;	O
RO	O
25	O
-	O
6603	O
)	O
.	O
We	O
found	O
that	O
RARs	B
were	O
involved	O
in	O
RA	O
-	O
mediated	O
apoptosis	O
of	O
myeloid	O
progenitor	O
cells	O
,	O
whereas	O
RARs	B
as	O
well	O
as	O
RXRs	B
were	O
involved	O
in	O
RA	O
-	O
mediated	O
apoptosis	O
of	O
erythroid	O
progenitor	O
cells	O
.	O
Dicarba	O
-	O
closo	O
-	O
dodecaboranes	O
as	O
a	O
pharmacophore	O
.	O
Retinoidal	O
antagonists	O
and	O
potential	O
agonists	O
.	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
the	O
first	O
dicarba	O
-	O
closo	O
-	O
dodecaborane	O
(	O
carborane	O
)	O
derivatives	O
of	O
retinoids	O
are	O
described	O
.	O
Their	O
retinoidal	O
activity	O
were	O
examined	O
in	O
terms	O
of	O
the	O
differentiation	O
-	O
inducing	O
ability	O
toward	O
human	O
promyelocytic	O
leukemia	O
HL-60	O
cells	O
.	O
High	O
retinoidal	O
activity	O
(	O
agonist	O
or	O
antagonist	O
for	O
retinoic	B
acid	I
receptor	I
(	O
RAR	B
)	O
requires	O
a	O
carboxylic	O
acid	O
moiety	O
and	O
an	O
appropriate	O
hydrophobic	O
group	O
located	O
at	O
a	O
suitable	O
position	O
on	O
the	O
molecule	O
.	O
The	O
4-carboranyl	O
-	O
substituted	O
compounds	O
(	O
7	O
,	O
11	O
)	O
showed	O
antagonistic	O
activity	O
but	O
no	O
agonistic	O
activity	O
even	O
in	O
the	O
presence	O
of	O
the	O
potent	O
synergist	O
HX630	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
3-carboranyl	O
-	O
substituted	O
compounds	O
(	O
8	O
,	O
12	O
)	O
showed	O
potential	O
agonistic	O
activity	O
,	O
but	O
no	O
antagonistic	O
activity	O
.	O
The	O
results	O
indicates	O
that	O
carboranes	O
are	O
applicable	O
as	O
the	O
hydrophobic	O
moiety	O
of	O
biologically	O
active	O
molecules	O
.	O
Expression	O
of	O
E2A	B
-	I
HLF	I
chimeric	I
protein	I
induced	O
T	O
-	O
cell	O
apoptosis	O
,	O
B	O
-	O
cell	O
maturation	O
arrest	O
,	O
and	O
development	O
of	O
acute	O
lymphoblastic	O
leukemia	O
.	O
The	O
E2A	O
-	O
HLF	O
fusion	O
gene	O
,	O
generated	O
by	O
t	O
(	O
17	O
;	O
19	O
)	O
(	O
q22	O
;	O
p13	O
)	O
in	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
encodes	O
a	O
chimeric	B
transcription	I
factor	I
in	O
which	O
the	O
trans	B
-	I
activating	I
domains	I
of	O
E2A	B
are	O
fused	O
to	O
the	O
DNA-	B
binding	I
and	I
dimerization	I
domains	I
of	O
hepatic	B
leukemic	I
factor	I
(	O
HLF	B
)	O
.	O
To	O
investigate	O
its	O
biological	O
role	O
,	O
we	O
generated	O
transgenic	O
mice	O
expressing	O
E2A	B
-	I
HLF	I
using	O
Ig	O
enhancer	O
and	O
promoter	O
,	O
which	O
direct	O
transgene	O
expression	O
in	O
cells	O
committed	O
to	O
the	O
lymphoid	O
lineage	O
.	O
The	O
transgenic	O
mice	O
exhibited	O
abnormal	O
development	O
in	O
the	O
thymus	O
and	O
spleen	O
and	O
were	O
susceptible	O
to	O
infection	O
.	O
The	O
thymus	O
contained	O
small	O
numbers	O
of	O
thymocytes	O
,	O
and	O
TUNEL	O
staining	O
showed	O
that	O
higher	O
population	O
of	O
thymocytes	O
were	O
undergoing	O
apoptosis	O
.	O
The	O
spleen	O
exhibited	O
a	O
marked	O
reduction	O
in	O
splenic	O
lymphocytes	O
and	O
the	O
flow	O
cytometric	O
analyses	O
and	O
the	O
in	O
vitro	O
colony	O
formation	O
assays	O
showed	O
that	O
the	O
B	O
-	O
cell	O
maturation	O
was	O
blocked	O
at	O
a	O
very	O
early	O
developmental	O
stage	O
.	O
These	O
findings	O
indicated	O
that	O
the	O
expression	O
of	O
E2A	B
-	I
HLF	I
induced	O
T	O
-	O
cell	O
apoptosis	O
and	O
B	O
-	O
cell	O
maturation	O
arrest	O
in	O
vivo	O
and	O
that	O
the	O
susceptibility	O
of	O
the	O
transgenic	O
mice	O
to	O
infection	O
was	O
due	O
to	O
immunodeficiency	O
.	O
Moreover	O
,	O
several	O
transgenic	O
mice	O
developed	O
acute	O
leukemia	O
,	O
classified	O
as	O
T	O
-	O
ALL	O
based	O
on	O
the	O
surface	O
marker	O
analysis	O
and	O
DNA	O
rearrangements	O
,	O
suggesting	O
that	O
an	O
additional	O
event	O
is	O
required	O
for	O
malignant	O
transformation	O
of	O
lymphoid	O
cells	O
expressing	O
E2A	B
-	I
HLF	I
.	O
Our	O
findings	O
provide	O
insight	O
into	O
the	O
biological	O
function	O
of	O
E2A	B
-	I
HLF	I
in	O
lymphoid	O
development	O
and	O
also	O
its	O
role	O
in	O
leukemogenesis	O
.	O
Leukocyte	O
populations	O
,	O
hormone	B
receptors	I
and	O
apoptosis	O
in	O
eutopic	O
and	O
ectopic	O
first	O
trimester	O
human	O
pregnancies	O
.	O
The	O
implantation	O
of	O
trophoblast	O
cells	O
at	O
extrauterine	O
sites	O
still	O
results	O
in	O
decidualization	O
.	O
The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
decidualization	O
at	O
eutopic	O
and	O
ectopic	O
implantation	O
sites	O
.	O
Tissues	O
from	O
women	O
undergoing	O
elective	O
termination	O
of	O
uterine	O
pregnancy	O
and	O
from	O
women	O
with	O
ectopic	O
pregnancy	O
were	O
used	O
to	O
detect	O
the	O
presence	O
of	O
cells	O
important	O
for	O
the	O
maintenance	O
of	O
pregnancy	O
,	O
such	O
as	O
BCL-2	O
+	O
,	O
CD56	O
+	O
,	O
CD3	O
+	O
,	O
CD8	O
+	O
and	O
CD68	O
+	O
cells	O
,	O
and	O
the	O
presence	O
of	O
oestrogen	B
(	I
ER	I
)	I
and	I
progesterone	I
receptors	I
(	O
PR	B
)	O
by	O
immunohistochemistry	O
.	O
In	O
-	O
situ	O
detection	O
of	O
fragmented	O
DNA	O
was	O
performed	O
to	O
identify	O
apoptotic	O
cells	O
.	O
The	O
percentage	O
of	O
CD3	O
+	O
cells	O
among	O
all	O
immunocompetent	O
cells	O
in	O
the	O
tubal	O
epithelium	O
was	O
46.6	O
%	O
(	O
39.9	O
%	O
of	O
CD3	O
+	O
were	O
also	O
CD8	O
+	O
)	O
;	O
the	O
other	O
53.4	O
%	O
were	O
CD68	O
+	O
cells	O
.	O
CD56	O
+	O
cells	O
were	O
undetectable	O
in	O
ectopic	O
decidua	O
at	O
the	O
feto	O
-	O
maternal	O
interface	O
in	O
ectopic	O
tissue	O
.	O
In	O
uterine	O
decidua	O
,	O
we	O
found	O
29.9	O
%	O
CD3	O
+	O
cells	O
(	O
2.2	O
%	O
of	O
CD3	O
+	O
were	O
CD8	O
+	O
)	O
,	O
51.6	O
%	O
CD56	O
+	O
cells	O
and	O
18.5	O
%	O
CD68	O
+	O
cells	O
.	O
The	O
ratio	O
of	O
BCL2	O
+	O
to	O
CD3	O
+	O
cells	O
in	O
ectopic	O
pregnancy	O
was	O
0.41	O
.	O
In	O
uterine	O
pregnancy	O
,	O
the	O
ratio	O
of	O
BCL-2	B
to	O
CD3	O
was	O
0.44	O
and	O
0.39	O
for	O
CD56	O
.	O
Tissues	O
from	O
both	O
ectopic	O
and	O
uterine	O
pregnancies	O
were	O
positive	O
for	O
PR	B
.	O
Fewer	O
apoptotic	O
cell	O
bodies	O
were	O
present	O
in	O
ectopic	O
pregnancy	O
.	O
The	O
use	O
of	O
tissue	O
obtained	O
from	O
ectopic	O
pregnancy	O
may	O
become	O
an	O
excellent	O
model	O
to	O
identify	O
the	O
mechanism	O
of	O
trophoblast	O
invasion	O
in	O
eutopic	O
pregnancies	O
.	O
Differential	O
inhibition	O
of	O
Smad6	B
and	O
Smad7	B
on	O
bone	O
morphogenetic	O
protein-	O
and	O
activin	O
-	O
mediated	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
B	O
cells	O
.	O
Smad6	B
and	O
Smad7	B
prevent	O
ligand	O
-	O
induced	O
activation	O
of	O
signal	B
-	I
transducing	I
Smad	I
proteins	I
in	O
the	O
transforming	B
growth	I
factor	I
-	I
beta	I
family	I
.	O
Here	O
we	O
demonstrate	O
that	O
both	O
Smad6	B
and	O
Smad7	B
are	O
human	B
bone	I
morphogenetic	I
protein-2	I
(	O
hBMP-2	B
)	O
-inducible	O
antagonists	O
of	O
hBMP-2	B
-induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
mouse	O
B	O
cell	O
hybridoma	O
HS-72	O
cells	O
.	O
Moreover	O
,	O
we	O
confirmed	O
that	O
the	O
ectopic	O
expressions	O
of	O
Smad6	B
and	O
Smad7	B
inhibited	O
the	O
hBMP-2	B
-induced	O
Smad1	B
/	I
Smad5	I
phosphorylation	O
.	O
We	O
previously	O
reported	O
that	O
Smad7	B
is	O
an	O
activin	O
A	O
-	O
inducible	O
antagonist	O
of	O
activin	O
A	O
-	O
induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
HS-72	O
cells	O
.	O
Interestingly	O
,	O
although	O
mRNA	O
expression	O
of	O
Smad6	B
was	O
induced	O
by	O
activin	O
A	O
in	O
HS-72	O
cells	O
,	O
Smad6	B
showed	O
no	O
antagonistic	O
effect	O
on	O
activin	O
A	O
-	O
induced	O
growth	O
arrest	O
and	O
apoptosis	O
.	O
Moreover	O
,	O
we	O
found	O
that	O
the	O
ectopic	O
expression	O
of	O
Smad7	B
,	O
but	O
not	O
Smad6	B
,	O
inhibited	O
the	O
activin	O
A	O
-	O
induced	O
Smad2	O
phosphorylation	O
in	O
HS-72	O
cells	O
.	O
Thus	O
,	O
Smad6	B
and	O
Smad7	B
exhibit	O
differential	O
inhibitory	O
effects	O
in	O
bone	O
morphogenetic	O
protein-2-	O
and	O
activin	O
A	O
-	O
mediated	O
signaling	O
in	O
B	O
lineage	O
cells	O
.	O
Regulation	O
of	O
Fas	B
ligand	I
expression	O
and	O
cell	O
death	O
by	O
apoptosis	O
-	O
linked	O
gene	O
4	O
.	O
Programmed	O
cell	O
death	O
is	O
a	O
process	O
required	O
for	O
the	O
normal	O
development	O
of	O
an	O
organism	O
.	O
One	O
of	O
the	O
best	O
understood	O
apoptotic	O
pathways	O
occurs	O
in	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
Fas	B
/Fas	B
ligand	I
(	O
FasL	B
)	O
interaction	O
.	O
During	O
studies	O
of	O
apoptosis	O
induced	O
by	O
T	O
cell	O
-	O
receptor	O
engagement	O
,	O
we	O
identified	O
ALG-4F	B
,	O
a	O
truncated	B
transcript	I
that	O
prevents	O
T	O
cell	O
-	O
receptor	O
-	O
induced	O
FasL	B
upregulation	O
and	O
cell	O
death	O
.	O
Overexpression	O
of	O
full	B
-	I
length	I
ALG-4	I
induced	O
transcription	O
of	O
FasL	B
and	O
,	O
consequently	O
,	O
apoptosis	O
.	O
These	O
results	O
indicate	O
that	O
ALG-4	B
is	O
necessary	O
and	O
sufficient	O
for	O
FasL	B
expression	O
.	O
Fas	O
/	O
FasL	B
interaction	O
initiates	O
cell	O
death	O
in	O
many	O
other	O
systems	O
,	O
and	O
its	O
dysregulation	O
is	O
a	O
mechanism	O
by	O
which	O
several	O
pathologic	O
conditions	O
arise	O
.	O
Understanding	O
the	O
molecular	O
mechanisms	O
of	O
FasL	B
regulation	O
could	O
be	O
very	O
useful	O
in	O
elucidating	O
how	O
these	O
diseases	O
develop	O
and	O
in	O
identifying	O
potential	O
therapeutic	O
targets	O
.	O
Transcriptional	O
targeting	O
of	O
retroviral	O
vectors	O
to	O
the	O
erythroblastic	O
progeny	O
of	O
transduced	O
hematopoietic	O
stem	O
cells	O
.	O
Targeted	O
expression	O
to	O
specific	O
tissues	O
or	O
cell	O
lineages	O
is	O
a	O
necessary	O
feature	O
of	O
a	O
gene	O
therapy	O
vector	O
for	O
many	O
clinical	O
applications	O
,	O
such	O
as	O
correction	O
of	O
hemoglobinopathies	O
or	O
thalassemias	O
by	O
transplantation	O
of	O
genetically	O
modified	O
hematopoietic	O
stem	O
cells	O
.	O
We	O
developed	O
retroviral	O
vectors	O
in	O
which	O
the	O
constitutive	O
viral	O
enhancer	O
in	O
the	O
U3	O
region	O
of	O
the	O
3	O
'	O
LTR	O
is	O
replaced	O
by	O
an	O
autoregulatory	O
enhancer	O
of	O
the	O
erythroid	O
-	O
specific	O
GATA-1	O
transcription	O
factor	O
gene	O
.	O
The	O
replaced	O
enhancer	O
is	O
propagated	O
to	O
the	O
5	O
'	O
LTR	O
upon	O
integration	O
into	O
the	O
target	O
cell	O
genome	O
.	O
The	O
modified	O
vectors	O
were	O
used	O
to	O
transduce	O
human	O
hematopoietic	O
cell	O
lines	O
,	O
cord	O
blood	O
-	O
derived	O
CD34	O
(	O
+	O
)	O
stem	O
/	O
progenitor	O
cells	O
,	O
and	O
murine	O
bone	O
marrow	O
repopulating	O
stem	O
cells	O
.	O
The	O
expression	O
of	O
appropriate	O
reporter	O
genes	O
(	O
triangle	O
upLNGFR	O
,	O
EGFP	O
)	O
was	O
analyzed	O
in	O
the	O
differentiated	O
progeny	O
of	O
transduced	O
stem	O
cells	O
in	O
vitro	O
,	O
in	O
liquid	O
culture	O
as	O
well	O
as	O
in	O
clonogenic	O
assay	O
,	O
and	O
in	O
vivo	O
,	O
after	O
bone	O
marrow	O
transplantation	O
in	O
lethally	O
irradiated	O
mice	O
.	O
The	O
GATA-1	O
autoregulatory	O
enhancer	O
effectively	O
restricts	O
the	O
expression	O
of	O
the	O
LTR	O
-	O
driven	O
proviral	O
transcription	O
unit	O
to	O
the	O
erythroblastic	O
progeny	O
of	O
both	O
human	O
progenitors	O
and	O
mouse	O
-	O
repopulating	O
stem	O
cells	O
.	O
Packaging	O
of	O
viral	O
particles	O
,	O
integration	O
into	O
the	O
target	O
genome	O
,	O
and	O
stability	O
of	O
the	O
integrated	O
provirus	O
are	O
not	O
affected	O
by	O
the	O
LTR	O
modification	O
.	O
Enhancer	O
replacement	O
is	O
therefore	O
an	O
effective	O
strategy	O
to	O
target	O
expression	O
of	O
a	O
retroviral	O
transgene	O
to	O
a	O
specific	O
progeny	O
of	O
transduced	O
hematopoietic	O
stem	O
cells	O
.	O
An	O
essential	O
role	O
for	O
NF	B
-	I
kappaB	I
in	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cell	O
survival	O
.	O
The	O
transcription	B
factor	I
,	O
NF	B
-	I
kappaB	I
,	O
is	O
important	O
for	O
T	O
-	O
cell	O
activation	O
,	O
B	O
-	O
cell	O
maturation	O
,	O
and	O
human	O
immunodeficiency	O
virus	O
transcription	O
and	O
plays	O
a	O
role	O
in	O
alternatively	O
mediating	O
and	O
protecting	O
against	O
apoptosis	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O
However	O
,	O
a	O
role	O
for	O
NF	B
-	I
kappaB	I
in	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cells	O
has	O
not	O
been	O
described	O
.	O
We	O
provide	O
evidence	O
here	O
that	O
virtually	O
all	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cells	O
express	O
NF	B
-	I
kappaB	I
that	O
can	O
be	O
activated	O
by	O
exposure	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
a	O
variety	O
of	O
cytokines	B
,	O
eg	O
,	O
tumor	B
necrosis	I
factor	I
alpha	I
,	O
interleukin-3	B
,	O
and	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
.	O
In	O
addition	O
,	O
we	O
demonstrate	O
that	O
NF	B
-	I
kappaB	I
may	O
be	O
required	O
for	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cell	O
clonogenic	O
function	O
and	O
survival	O
.	O
These	O
results	O
offer	O
insight	O
into	O
a	O
new	O
role	O
for	O
NF	B
-	I
kappaB	I
in	O
maintaining	O
survival	O
and	O
function	O
in	O
hematopoietic	O
stem	O
and	O
progenitor	O
cells	O
and	O
suggest	O
that	O
proposed	O
strategies	O
involving	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
activation	O
as	O
an	O
adjunct	O
to	O
cancer	O
chemotherapy	O
should	O
be	O
approached	O
with	O
caution	O
.	O
Unicellular	O
-	O
unilineage	O
erythropoietic	O
cultures	O
:	O
molecular	O
analysis	O
of	O
regulatory	O
gene	O
expression	O
at	O
sibling	O
cell	O
level	O
.	O
In	O
vitro	O
studies	O
on	O
hematopoietic	O
control	O
mechanisms	O
have	O
been	O
hampered	O
by	O
the	O
heterogeneity	O
of	O
the	O
analyzed	O
cell	O
populations	O
,	O
ie	O
,	O
lack	O
of	O
lineage	O
specificity	O
and	O
developmental	O
stage	O
homogeneity	O
of	O
progenitor	O
/	O
precursor	O
cells	O
growing	O
in	O
culture	O
.	O
We	O
developed	O
unicellular	O
culture	O
systems	O
for	O
unilineage	O
differentiation	O
of	O
purified	O
hematopoietic	O
progenitor	O
cells	O
followed	O
by	O
daughter	O
cell	O
analysis	O
at	O
cellular	O
and	O
molecular	O
level	O
.	O
In	O
the	O
culture	O
system	O
reported	O
here	O
,	O
(	O
1	O
)	O
the	O
growth	B
factor	I
(	O
GF	B
)	O
stimulus	O
induces	O
cord	O
blood	O
(	O
CB	O
)	O
progenitor	O
cells	O
to	O
proliferate	O
and	O
differentiate	O
/	O
mature	O
exclusively	O
along	O
the	O
erythroid	O
lineage	O
;	O
(	O
2	O
)	O
this	O
erythropoietic	O
wave	O
is	O
characterized	O
by	O
less	O
than	O
4	O
%	O
apoptotic	O
cells	O
;	O
(	O
3	O
)	O
asymmetric	O
divisions	O
are	O
virtually	O
absent	O
,	O
ie	O
,	O
nonresponsive	O
hematopoietic	O
progenitors	O
with	O
no	O
erythropoietic	O
potential	O
are	O
forced	O
into	O
apoptosis	O
;	O
(	O
4	O
)	O
the	O
system	O
is	O
cell	O
division	O
controlled	O
(	O
cdc	O
)	O
,	O
ie	O
,	O
the	O
number	O
of	O
divisions	O
performed	O
by	O
each	O
cell	O
is	O
monitored	O
.	O
Single	O
-	O
cell	O
reverse	B
transcriptase	I
-polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
was	O
applied	O
to	O
this	O
culture	O
system	O
to	O
investigate	O
gene	O
expression	O
of	O
diverse	O
receptors	B
,	O
markers	B
of	I
differentiation	I
,	O
and	O
transcription	B
factors	I
(	O
EKLF	B
,	O
GATA-1	B
,	O
GATA-2	B
,	O
p45	B
NF	I
-	I
E2	I
,	O
PU.1	B
,	O
and	O
SCL	B
/	I
Tal1	I
)	O
at	O
discrete	O
stages	O
of	O
erythropoietic	O
development	O
.	O
Freshly	O
isolated	O
CD34	O
(	O
+	O
)	O
cells	O
expressed	O
CD34	B
,	O
c	B
-	I
kit	I
,	O
PU.1	B
,	O
and	O
GATA-2	B
but	O
did	O
not	O
express	O
CD36	B
,	O
erythropoietin	B
receptor	I
(	O
EpoR	B
)	O
,	O
SCL	B
/	I
Tal1	I
,	O
EKLF	B
,	O
NF	O
-	O
E2	O
,	O
GATA-1	B
,	O
or	O
glyocophorin	B
A	I
(	O
GPA	B
)	O
.	O
In	O
early	O
to	O
intermediate	O
stages	O
of	O
erythroid	O
differentiation	O
we	O
monitored	O
the	O
induction	O
of	O
CD36	B
,	O
Tal1	B
,	O
EKLF	B
,	O
NF	B
-	I
E2	I
,	O
and	O
GATA-1	B
that	O
preceeded	O
expression	O
of	O
EpoR	B
.	O
In	O
late	O
stages	O
of	O
erythroid	O
maturation	O
,	O
GPA	B
was	O
upregulated	O
,	O
whereas	O
CD34	B
,	O
c	B
-	I
kit	I
,	O
PU.1	B
,	O
and	O
GATA-2	B
were	O
barely	O
or	O
not	O
detected	O
.	O
In	O
addition	O
,	O
competitive	O
single	O
-	O
cell	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
assay	O
CD34	O
mRNA	O
transcripts	O
in	O
sibling	O
CD34	O
(	O
+	O
)	O
CD38	O
(	O
-	O
)	O
cells	O
differentiating	O
in	O
unilineage	O
erythroid	O
cultures	O
:	O
this	O
analysis	O
allowed	O
us	O
to	O
semiquantitate	O
the	O
gradual	O
downmodulation	O
of	O
CD34	O
mRNA	O
from	O
progenitor	O
cells	O
through	O
their	O
differentiating	O
erythroid	O
progeny	O
.	O
It	O
is	O
concluded	O
that	O
this	O
novel	O
culture	O
system	O
,	O
coupled	O
with	O
single	O
-	O
cell	O
RT	O
-	O
PCR	O
analysis	O
,	O
may	O
eliminate	O
the	O
ambiguities	O
intrinsic	O
to	O
molecular	O
studies	O
on	O
heterogeneous	O
populations	O
of	O
hematopoietic	O
progenitors	O
/	O
precursors	O
growing	O
in	O
culture	O
,	O
particularly	O
in	O
the	O
initial	O
stages	O
of	O
development	O
.	O
Bacterial	O
peptidoglycan	O
induces	O
CD14	B
-dependent	O
activation	O
of	O
transcription	B
factors	I
CREB	B
/	I
ATF	I
and	O
AP-1	B
.	O
Peptidoglycan	O
(	O
PGN	O
)	O
,	O
the	O
major	O
cell	O
wall	O
component	O
of	O
Gram	O
-	O
positive	O
bacteria	O
,	O
induces	O
secretion	O
of	O
cytokines	B
in	O
macrophages	O
through	O
CD14	B
,	O
the	O
pattern	O
recognition	O
receptor	O
that	O
binds	O
lipopolysaccharide	O
and	O
other	O
microbial	O
products	O
.	O
To	O
begin	O
to	O
elucidate	O
the	O
mechanisms	O
that	O
regulate	O
the	O
transcription	O
of	O
cytokine	O
genes	O
,	O
we	O
wanted	O
to	O
determine	O
which	O
transcription	B
factors	I
are	O
activated	O
by	O
PGN	O
in	O
mouse	O
RAW264.7	O
and	O
human	O
THP-1	O
macrophage	O
cells	O
.	O
Our	O
results	O
demonstrated	O
that	O
:	O
(	O
i	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
the	O
transcription	B
factors	I
ATF-1	B
and	O
CREB	B
;	O
(	O
ii	O
)	O
ATF-1	B
and	O
CREB	B
bound	O
DNA	O
as	O
a	O
dimer	O
and	O
induced	O
transcriptional	O
activation	O
of	O
a	O
CRE	O
reporter	O
plasmid	O
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
CREB	B
and	O
ATF-1	B
;	O
(	O
iii	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
c	B
-	I
Jun	I
,	O
protein	O
synthesis	O
of	O
JunB	B
and	O
c	B
-	I
Fos	I
,	O
and	O
transcriptional	O
activation	O
of	O
the	O
AP-1	O
reporter	O
plasmid	O
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
c	B
-	I
Fos	I
;	O
and	O
(	O
iv	O
)	O
PGN	O
-	O
induced	O
activation	O
of	O
CREB	B
/	I
ATF	I
and	O
AP-1	B
was	O
mediated	O
through	O
CD14	B
.	O
This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
activation	O
of	O
CREB	B
/	I
ATF	I
and	O
AP-1	B
transcription	I
factors	I
by	O
PGN	O
or	O
by	O
any	O
other	O
component	O
of	O
Gram	O
-	O
positive	O
bacteria	O
.	O
c	B
-	I
Myc	I
and	O
E1A	B
induced	O
cellular	O
sensitivity	O
to	O
activated	O
NK	O
cells	O
involves	O
cytotoxic	O
granules	O
as	O
death	O
effectors	O
.	O
The	O
contact	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
with	O
foreign	O
cells	O
and	O
with	O
certain	O
virus	O
-	O
infected	O
or	O
tumor	O
cells	O
triggers	O
the	O
cytolytic	O
machinery	O
of	O
NK	O
cells	O
.	O
This	O
triggering	O
leads	O
to	O
exocytosis	O
of	O
the	O
cytotoxic	O
NK	O
cell	O
granules	O
.	O
The	O
oncoproteins	B
c	B
-	I
Myc	I
and	O
E1A	B
render	O
cells	O
vulnerable	O
to	O
NK	O
cell	O
mediated	O
cytolysis	O
yet	O
the	O
mechanisms	O
of	O
sensitization	O
are	O
not	O
well	O
understood	O
.	O
In	O
a	O
model	O
where	O
foreign	O
cells	O
(	O
rat	O
fibroblasts	O
)	O
were	O
cocultured	O
with	O
human	O
IL-2	O
activated	O
NK	O
cells	O
,	O
we	O
observed	O
that	O
NK	O
cells	O
were	O
capable	O
of	O
efficiently	O
killing	O
their	O
targets	O
only	O
if	O
the	O
cells	O
overexpressed	O
the	O
oncogene	O
c	B
-	I
Myc	I
or	O
E1A	B
.	O
Both	O
the	O
parental	O
and	O
the	O
oncogene	O
expressing	O
fibroblasts	O
similarly	O
triggered	O
phosphoinositide	O
hydrolysis	O
in	O
the	O
bound	O
NK	O
cells	O
,	O
demonstrating	O
that	O
NK	O
cells	O
were	O
cytolytically	O
activated	O
in	O
contact	O
with	O
both	O
resistant	O
parental	O
and	O
oncogene	O
expressing	O
sensitive	O
target	O
fibroblasts	O
.	O
The	O
cell	O
death	O
was	O
independent	O
of	O
wild	B
-	I
type	I
p53	I
and	O
was	O
not	O
inhibited	O
by	O
an	O
anti	B
-	I
apoptotic	I
protein	I
EIB19	I
K	I
.	O
These	O
results	O
provided	O
evidence	O
that	O
c	B
-	I
Myc	I
and	O
E1A	B
activated	O
the	O
NK	O
cell	O
induced	O
cytolysis	O
at	O
a	O
post	O
-	O
triggering	O
stage	O
of	O
NK	O
cell	O
-	O
target	O
cell	O
interaction	O
.	O
In	O
consistence	O
,	O
the	O
c	B
-	I
Myc	I
and	O
E1A	B
overexpressing	O
fibroblasts	O
were	O
more	O
sensitive	O
to	O
the	O
cytolytic	O
effects	O
of	O
isolated	O
NK	O
cell	O
-	O
derived	O
granules	O
than	O
parental	O
cells	O
.	O
The	O
data	O
indicate	O
that	O
oncogenes	O
activate	O
the	O
cytotoxicity	O
of	O
NK	O
cell	O
granules	O
.	O
This	O
mechanism	O
can	O
have	O
a	O
role	O
in	O
directing	O
the	O
cytolytic	O
action	O
of	O
NK	O
cells	O
towards	O
the	O
virus	O
-	O
infected	O
and	O
cancer	O
cells	O
.	O
Paradoxical	O
priming	O
effects	O
of	O
IL-10	B
on	O
cytokine	B
production	O
.	O
IL-10	B
is	O
a	O
well	O
-	O
known	O
immunosuppressive	B
and/or	I
anti	I
-	I
inflammatory	I
cytokine	I
.	O
However	O
,	O
we	O
report	O
in	O
vitro	O
experimental	O
studies	O
in	O
which	O
IL-10	O
primed	O
leukocytes	O
and	O
led	O
to	O
an	O
enhanced	O
production	O
of	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
upon	O
further	O
stimulation	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
Monocytes	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
prepared	O
from	O
whole	O
blood	O
maintained	O
for	O
20	O
h	O
at	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
recombinant	B
human	I
IL-10	I
had	O
an	O
enhanced	O
capacity	O
to	O
produce	O
TNF	B
in	O
response	O
to	O
LPS	O
.	O
In	O
addition	O
to	O
TNF	B
,	O
LPS	O
-	O
induced	O
IL-6	O
and	O
spontaneous	O
IL-1ra	O
production	O
were	O
also	O
enhanced	O
.	O
When	O
isolated	O
PBMC	O
were	O
first	O
cultured	O
for	O
20	O
h	O
in	O
the	O
presence	O
of	O
IL-10	B
on	O
Teflon	O
to	O
prevent	O
adherence	O
,	O
washed	O
to	O
remove	O
IL-10	B
and	O
then	O
further	O
cultured	O
in	O
plastic	O
dishes	O
for	O
an	O
additional	O
20	O
h	O
in	O
the	O
presence	O
of	O
LPS	O
or	O
IL-1beta	B
,	O
an	O
enhanced	O
release	O
of	O
TNF	B
was	O
observed	O
.	O
This	O
was	O
not	O
the	O
case	O
when	O
PBMC	O
were	O
pre	O
-	O
cultured	O
in	O
plastic	O
multidishes	O
in	O
the	O
presence	O
of	O
IL-10	B
.	O
TNF	O
mRNA	O
expression	O
induced	O
by	O
LPS	O
was	O
decreased	O
when	O
the	O
pre	O
-	O
treatment	O
of	O
PBMC	O
with	O
IL-10	B
was	O
performed	O
on	O
plastic	O
,	O
whereas	O
this	O
was	O
not	O
the	O
case	O
when	O
cells	O
were	O
pre	O
-	O
cultured	O
with	O
IL-10	B
on	O
Teflon	O
.	O
Furthermore	O
,	O
NFkappaB	O
translocation	O
following	O
LPS	O
activation	O
was	O
higher	O
after	O
IL-10	B
pre	O
-	O
treatment	O
on	O
Teflon	O
than	O
on	O
plastic	O
.	O
Interestingly	O
,	O
an	O
enhanced	O
frequency	O
of	O
CD16	B
and	O
CD68	O
(	O
+	O
)	O
cells	O
among	O
the	O
CD14	O
(	O
+	O
)	O
cells	O
was	O
observed	O
in	O
the	O
presence	O
of	O
IL-10	B
,	O
independently	O
of	O
the	O
pre	O
-	O
culture	O
conditions	O
of	O
the	O
PBMC	O
.	O
Altogether	O
,	O
these	O
results	O
indicate	O
that	O
the	O
IL-10	B
-induced	O
up	O
-	O
regulation	O
of	O
cytokine	B
production	O
depends	O
on	O
the	O
prevention	O
of	O
monocyte	O
adherence	O
by	O
red	O
cells	O
in	O
the	O
whole	O
blood	O
assays	O
or	O
by	O
cultures	O
of	O
PBMC	O
on	O
Teflon	O
.	O
In	O
contrast	O
,	O
the	O
adherence	O
parameter	O
has	O
no	O
effect	O
on	O
the	O
IL-10	B
-induced	O
modulation	O
of	O
some	O
monocyte	B
surface	I
markers	I
.	O
Different	O
sequence	O
requirements	O
for	O
expression	O
in	O
erythroid	O
and	O
megakaryocytic	O
cells	O
within	O
a	O
regulatory	O
element	O
upstream	O
of	O
the	O
GATA-1	O
gene	O
.	O
The	O
lineage	B
-	I
restricted	I
transcription	I
factor	I
GATA-1	B
is	O
required	O
for	O
differentiation	O
of	O
erythroid	O
and	O
megakaryocytic	O
cells	O
.	O
We	O
have	O
localized	O
a	O
317	O
base	O
pair	O
cis	O
-	O
acting	O
regulatory	O
element	O
,	O
HS	O
I	O
,	O
associated	O
with	O
a	O
hematopoietic	O
-	O
specific	O
DNase	O
I	O
hypersensitive	O
site	O
,	O
which	O
lies	O
approx	O
.	O
3.7	O
kilobases	O
upstream	O
of	O
the	O
murine	O
hematopoietic	O
-	O
specific	O
GATA-1	O
IE	O
promoter	O
.	O
HS	O
I	O
directs	O
high	O
-	O
level	O
expression	O
of	O
reporter	O
GATA-1	O
/	O
lacZ	O
genes	O
to	O
primitive	O
and	O
definitive	O
erythroid	O
cells	O
and	O
megakaryocytes	O
in	O
transgenic	O
mice	O
.	O
Comparative	O
sequence	O
analysis	O
of	O
HS	O
I	O
between	O
human	O
and	O
mouse	O
shows	O
approx	O
.	O
63	O
%	O
nucleotide	O
identity	O
with	O
a	O
more	O
conserved	O
core	O
of	O
169	O
base	O
pairs	O
(	O
86	O
%	O
identity	O
)	O
.	O
This	O
core	O
contains	O
a	O
GATA	O
site	O
separated	O
by	O
10	O
base	O
pairs	O
from	O
an	O
E	O
-	O
box	O
motif	O
.	O
The	O
composite	O
motif	O
binds	O
a	O
multi	B
-	I
protein	I
hematopoietic	I
-	I
specific	I
transcription	I
factor	I
complex	I
which	O
includes	O
GATA-1	B
,	O
SCL	B
/	I
tal-1	I
,	I
E2A	B
,	O
Lmo2	B
and	O
Ldb-1	B
.	O
Point	O
mutations	O
of	O
the	O
GATA	O
site	O
abolishes	O
HS	O
I	O
function	O
,	O
whereas	O
mutation	O
of	O
the	O
E	O
-	O
box	O
motif	O
still	O
allows	O
reporter	O
gene	O
expression	O
in	O
both	O
lineages	O
.	O
Strict	O
dependence	O
of	O
HS	O
I	O
activity	O
on	O
a	O
GATA	O
site	O
implies	O
that	O
assembly	O
of	O
a	O
protein	O
complex	O
containing	O
a	O
GATA	B
-	I
factor	I
,	O
presumably	O
GATA-1	B
or	O
GATA-2	B
,	O
is	O
critical	O
to	O
activating	O
or	O
maintaining	O
its	O
function	O
.	O
Further	O
dissection	O
of	O
the	O
317	O
base	O
pair	O
region	O
demonstrates	O
that	O
,	O
whereas	O
all	O
317	O
base	O
pairs	O
are	O
required	O
for	O
expression	O
in	O
megakaryocytes	O
,	O
only	O
the	O
5	O
'	O
62	O
base	O
pairs	O
are	O
needed	O
for	O
erythroid	O
-	O
specific	O
reporter	O
expression	O
.	O
These	O
findings	O
demonstrate	O
differential	O
lineage	O
requirements	O
for	O
expression	O
within	O
the	O
HS	O
I	O
element	O
.	O
SLP-76	B
and	O
Vav	B
function	O
in	O
separate	O
,	O
but	O
overlapping	O
pathways	O
to	O
augment	O
interleukin-2	O
promoter	O
activity	O
.	O
SLP-76	B
and	O
Vav	B
,	O
two	O
hematopoietic	B
cell	I
specific	I
molecules	I
,	O
are	O
critical	O
for	O
T	O
cell	O
development	O
and	O
activation	O
.	O
Following	O
T	B
cell	I
antigen	I
receptor	I
stimulation	O
,	O
SLP-76	B
and	O
Vav	B
both	O
undergo	O
tyrosine	O
phosphorylation	O
and	O
associate	O
with	O
each	O
other	O
via	O
the	O
SH2	O
domain	O
of	O
Vav	B
and	O
phosphorylated	O
tyrosines	O
of	O
SLP-76	B
.	O
Furthermore	O
,	O
SLP-76	B
and	O
Vav	B
have	O
a	O
synergistic	O
effect	O
on	O
interleukin	O
(	O
IL	O
)	O
-2	O
promoter	O
activity	O
in	O
T	O
cells	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
two	O
tyrosines	O
,	O
Tyr-113	O
and	O
Tyr-128	O
,	O
of	O
SLP-76	B
are	O
required	O
for	O
its	O
binding	O
to	O
Vav	B
,	O
both	O
in	O
vitro	O
and	O
in	O
intact	O
cells	O
.	O
Surprisingly	O
,	O
we	O
find	O
also	O
that	O
the	O
interaction	O
between	O
SLP-76	B
and	O
Vav	B
is	O
not	O
required	O
for	O
their	O
cooperation	O
in	O
augmenting	O
IL-2	O
promoter	O
activity	O
,	O
as	O
the	O
two	O
molecules	O
appear	O
to	O
function	O
in	O
different	O
signaling	O
pathways	O
upstream	O
of	O
IL-2	O
gene	O
expression	O
.	O
Overexpression	O
of	O
SLP-76	B
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
potentiates	O
the	O
activities	O
of	O
both	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
and	O
AP-1	B
transcription	I
factors	I
.	O
In	O
contrast	O
,	O
overexpression	O
of	O
Vav	B
leads	O
to	O
enhanced	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
activity	O
without	O
affecting	O
AP-1	B
.	O
Additionally	O
,	O
overexpression	O
of	O
Vav	B
,	O
but	O
not	O
SLP-76	B
,	O
augments	O
CD28-induced	O
IL-2	O
promoter	O
activity	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
synergy	O
between	O
SLP-76	B
and	O
Vav	B
in	O
regulating	O
IL-2	O
gene	O
expression	O
reflects	O
the	O
cooperation	O
between	O
different	O
signaling	O
pathways	O
.	O
CD28	B
costimulation	O
augments	O
IL-2	B
secretion	O
of	O
activated	O
lamina	O
propria	O
T	O
cells	O
by	O
increasing	O
mRNA	O
stability	O
without	O
enhancing	O
IL-2	B
gene	O
transactivation	O
.	O
The	O
pathways	O
leading	O
to	O
activation	O
in	O
lamina	O
propria	O
(	O
LP	O
)	O
T	O
cells	O
are	O
different	O
from	O
peripheral	O
T	O
cells	O
.	O
LP	O
T	O
cells	O
exhibit	O
enhanced	O
IL-2	B
secretion	O
when	O
activated	O
through	O
the	O
CD2	B
pathway	O
.	O
Coligation	O
of	O
CD28	B
leads	O
to	O
synergistic	O
enhancement	O
of	O
IL-2	B
secretion	O
.	O
Previous	O
studies	O
have	O
characterized	O
the	O
CD28	B
augmentation	O
of	O
TCR	B
-mediated	O
signaling	O
in	O
peripheral	O
blood	O
T	O
cells	O
through	O
transcriptional	O
activation	O
of	O
an	O
IL-2	B
promoter	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
,	O
along	O
with	O
enhanced	O
mRNA	O
stability	O
.	O
This	O
study	O
characterized	O
molecular	O
events	O
involved	O
in	O
CD28	B
costimulation	O
of	O
IL-2	B
production	O
in	O
LP	O
mononuclear	O
cells	O
(	O
LPMC	O
)	O
.	O
LPMC	O
exhibited	O
increased	O
IL-2	B
production	O
in	O
response	O
to	O
CD28	B
costimulation	O
,	O
compared	O
with	O
cells	O
activated	O
through	O
CD2	B
alone	O
.	O
IL-2	B
secretion	O
was	O
paralleled	O
by	O
increased	O
expression	O
of	O
IL-2	O
mRNA	O
,	O
resulting	O
from	O
enhanced	O
IL-2	O
mRNA	O
stability	O
.	O
In	O
contrast	O
to	O
transcriptional	O
activation	O
in	O
PBMC	O
,	O
EMSA	O
revealed	O
that	O
CD28	B
coligation	O
of	O
CD2-activated	O
LPMC	O
does	O
not	O
result	O
in	O
increased	O
binding	O
of	O
trans	O
-	O
factors	O
to	O
the	O
CD28RE	O
,	O
nor	O
did	O
Western	O
blots	O
detect	O
changes	O
in	O
I	B
-	I
kappaBalpha	I
or	O
I	B
-	I
kappaBbeta	I
levels	O
following	O
CD28	B
coligation	O
.	O
Furthermore	O
,	O
CD28	B
coligation	O
fails	O
to	O
enhance	O
IL-2	O
promoter	O
-	O
reporter	O
or	O
RE	B
/	I
AP	I
construct	O
expression	O
in	O
CD2-activated	O
LPMC	O
.	O
The	O
results	O
reported	O
herein	O
indicate	O
that	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
CD28	B
cosignaling	O
and	O
regulation	O
of	O
IL-2	B
secretion	O
in	O
LP	O
T	O
cells	O
are	O
unique	O
to	O
that	O
compartment	O
and	O
differ	O
from	O
those	O
seen	O
in	O
peripheral	O
blood	O
T	O
cells	O
.	O
These	O
observations	O
suggest	O
a	O
biological	O
significance	O
for	O
different	O
mechanisms	O
of	O
IL-2	B
activation	O
in	O
initiation	O
and	O
maintenance	O
of	O
the	O
cytokine	B
repertoire	I
found	O
in	O
the	O
mucosa	O
.	O
Repression	O
by	O
Ikaros	B
and	O
Aiolos	B
is	O
mediated	O
through	O
histone	B
deacetylase	I
complexes	I
.	O
Here	O
we	O
show	O
that	O
the	O
lymphoid	B
lineage	I
-	I
determining	I
factors	I
Ikaros	B
and	O
Aiolos	B
can	O
function	O
as	O
strong	B
transcriptional	I
repressors	I
.	O
This	O
function	O
is	O
mediated	O
through	O
two	O
repression	B
domains	I
and	O
is	O
dependent	O
upon	O
the	O
promoter	O
context	O
and	O
cell	O
type	O
.	O
Repression	O
by	O
Ikaros	B
proteins	I
correlates	O
with	O
hypo	O
-	O
acetylation	O
of	O
core	B
histones	I
at	O
promoter	O
sites	O
and	O
is	O
relieved	O
by	O
histone	B
deacetylase	I
inhibitors	O
.	O
Consistent	O
with	O
these	O
findings	O
,	O
Ikaros	B
and	O
its	O
repression	B
domains	I
can	O
interact	O
in	O
vivo	O
and	O
in	O
vitro	O
with	O
the	O
mSin3	B
family	I
of	O
co	O
-	O
repressors	O
which	O
bind	O
to	O
histone	B
deacetylases	I
.	O
Based	O
on	O
these	O
and	O
our	O
recent	O
findings	O
of	O
associations	O
between	O
Ikaros	B
and	O
Mi-2-HDAC	B
,	O
we	O
propose	O
that	O
Ikaros	B
family	I
members	I
modulate	O
gene	O
expression	O
during	O
lymphocyte	O
development	O
by	O
recruiting	O
distinct	O
histone	B
deacetylase	I
complexes	I
to	O
specific	O
promoters	O
.	O
Development	O
and	O
maturation	O
of	O
secondary	O
lymphoid	O
tissues	O
.	O
The	O
secondary	O
lymphoid	O
tissues	O
are	O
located	O
at	O
strategic	O
sites	O
where	O
foreign	B
antigens	I
can	O
be	O
efficiently	O
brought	O
together	O
with	O
immune	O
system	O
regulatory	O
and	O
effector	O
cells	O
.	O
The	O
organized	O
structure	O
of	O
the	O
secondary	O
lymphoid	O
tissues	O
is	O
thought	O
to	O
enhance	O
the	O
sensitivity	O
of	O
antigen	O
recognition	O
and	O
to	O
support	O
proper	O
regulation	O
of	O
the	O
activation	O
and	O
maturation	O
of	O
the	O
antigen	O
-	O
responsive	O
lymphoid	O
cells	O
.	O
Although	O
a	O
substantial	O
amount	O
is	O
known	O
about	O
the	O
cellular	O
elements	O
that	O
compose	O
the	O
lymphoid	O
and	O
nonlymphoid	O
components	O
of	O
the	O
secondary	O
lymphoid	O
tissues	O
,	O
information	O
concerning	O
the	O
signals	O
that	O
control	O
the	O
development	O
of	O
the	O
tissues	O
and	O
that	O
maintain	O
the	O
organized	O
tissue	O
microenvironment	O
remain	O
undefined	O
.	O
Studies	O
over	O
the	O
past	O
few	O
years	O
have	O
identified	O
lymphotoxin	O
as	O
a	O
critical	O
signaling	O
molecule	O
not	O
only	O
for	O
the	O
organogenesis	O
of	O
secondary	O
lymphoid	O
tissues	O
but	O
for	O
the	O
maintenance	O
of	O
aspects	O
of	O
their	O
microarchitecture	O
as	O
well	O
.	O
Additional	O
signaling	O
molecules	O
that	O
contribute	O
to	O
the	O
formation	O
of	O
normal	O
lymphoid	O
tissue	O
structure	O
are	O
being	O
identified	O
at	O
an	O
accelerating	O
pace	O
.	O
Analyses	O
of	O
mouse	O
strains	O
with	O
congenital	O
defects	O
in	O
different	O
aspects	O
of	O
secondary	O
lymphoid	O
tissue	O
development	O
are	O
beginning	O
to	O
clarify	O
the	O
role	O
of	O
these	O
tissues	O
in	O
immune	O
responses	O
and	O
host	O
defense	O
.	O
This	O
review	O
focuses	O
on	O
studies	O
defining	O
recently	O
identified	O
crucial	O
signals	O
for	O
the	O
biogenesis	O
of	O
secondary	O
lymphoid	O
organs	O
and	O
for	O
the	O
maintenance	O
of	O
their	O
proper	O
microarchitecture	O
.	O
It	O
also	O
discusses	O
new	O
insights	O
into	O
how	O
the	O
structure	O
of	O
these	O
tissues	O
supports	O
effective	O
immune	O
responses	O
.	O
Selection	O
of	O
the	O
T	O
cell	O
repertoire	O
.	O
Advances	O
in	O
gene	O
technology	O
have	O
allowed	O
the	O
manipulation	O
of	O
molecular	O
interactions	O
that	O
shape	O
the	O
T	O
cell	O
repertoire	O
.	O
Although	O
recognized	O
as	O
fundamental	O
aspects	O
of	O
T	O
lymphocyte	O
development	O
,	O
only	O
recently	O
have	O
the	O
mechanisms	O
governing	O
positive	O
and	O
negative	O
selection	O
been	O
examined	O
at	O
a	O
molecular	O
level	O
.	O
Positive	O
selection	O
refers	O
to	O
the	O
active	O
process	O
of	O
rescuing	O
MHC	O
-	O
restricted	O
thymocytes	O
from	O
programmed	O
cell	O
death	O
.	O
Negative	O
selection	O
refers	O
to	O
the	O
deletion	O
or	O
inactivation	O
of	O
potentially	O
autoreactive	O
thymocytes	O
.	O
This	O
review	O
focuses	O
on	O
interactions	O
during	O
thymocyte	O
maturation	O
that	O
define	O
the	O
T	O
cell	O
repertoire	O
,	O
with	O
an	O
emphasis	O
placed	O
on	O
current	O
literature	O
within	O
this	O
field	O
.	O
Multiple	O
NF	B
-	I
ATc	I
isoforms	I
with	O
individual	O
transcriptional	O
properties	O
are	O
synthesized	O
in	O
T	O
lymphocytes	O
.	O
The	O
transcription	B
factor	I
NF	B
-	I
ATc	I
that	O
controls	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
and	O
embryonic	O
cardiac	O
cells	O
is	O
expressed	O
in	O
three	O
prominent	O
isoforms	O
.	O
This	O
is	O
due	O
to	O
alternative	O
splice	O
/	O
polyadenylation	O
events	O
that	O
lead	O
to	O
the	O
predominant	O
synthesis	O
of	O
two	O
long	O
isoforms	O
in	O
naive	O
T	O
cells	O
and	O
a	O
shorter	O
NF	B
-	I
ATc	I
isoform	I
in	O
effector	O
T	O
cells	O
.	O
Whereas	O
the	O
previously	O
described	O
isoform	B
NF	I
-	I
ATc	I
/	I
A	I
contains	O
a	O
relatively	O
short	O
C	B
terminus	I
,	O
the	O
longer	O
isoforms	O
,	O
B	B
and	O
C	B
,	O
span	O
extra	O
C	O
-	O
terminal	O
peptides	O
of	O
128	O
and	O
246	O
aa	O
,	O
respectively	O
.	O
We	O
show	O
here	O
that	O
in	O
addition	O
to	O
the	O
strong	B
N	I
-	I
terminal	I
trans	I
-	I
activation	I
domain	I
,	O
TAD	B
-	I
A	I
,	O
which	O
is	O
common	O
to	O
all	O
three	O
NF	B
-	I
ATc	I
isoforms	I
,	O
NF	B
-	I
ATc	I
/	I
C	I
contains	O
a	O
second	O
trans	B
-	I
activation	I
domain	I
,	O
TAD	B
-	I
B	I
,	O
in	O
its	O
C	O
-	O
terminal	O
peptide	O
.	O
Various	O
stimuli	O
of	O
T	O
cells	O
that	O
induce	O
the	O
activity	O
of	O
TAD	B
-	I
A	I
also	O
enhance	O
the	O
activity	O
of	O
TAD	B
-	I
B	I
,	O
but	O
,	O
unlike	O
TAD	B
-	I
A	I
,	O
TAD	B
-	I
B	I
remains	O
unphosphorylated	O
by	O
protein	O
from	O
12-O	O
-	O
tetradecanoyl	O
12-phorbol	O
13-acetate	O
-	O
stimulated	O
T	O
cells	O
.	O
The	O
shorter	O
C	O
-	O
terminal	O
peptide	O
of	O
isoform	O
NF	B
-	I
ATc	I
/	I
B	I
exerts	O
a	O
suppressive	O
transcriptional	O
effect	O
.	O
These	O
properties	O
of	O
NF	B
-	I
ATc	I
/	I
B	I
and	I
-C	I
might	O
be	O
of	O
importance	O
for	O
gene	O
regulation	O
in	O
naive	O
T	O
lymphocytes	O
in	O
which	O
NF	B
-	I
ATc	I
/	I
B	I
and	I
-C	I
are	O
predominantly	O
synthesized	O
.	O
Effects	O
of	O
diesel	O
organic	O
extracts	O
on	O
chemokine	B
production	O
by	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
BACKGROUND	O
:	O
Polyaromatic	O
hydrocarbons	O
(	O
PAHs	O
)	O
associated	O
with	O
diesel	O
exhaust	O
particles	O
(	O
DEPs	O
)	O
are	O
found	O
in	O
the	O
atmospheric	O
urban	O
pollution	O
.	O
Such	O
compounds	O
have	O
been	O
shown	O
to	O
favor	O
IgE	B
production	O
,	O
bronchial	O
hyperresponsiveness	O
,	O
and	O
airway	O
inflammation	O
.	O
Chemokines	O
are	O
a	O
group	O
of	O
chemotactic	B
cytokines	I
involved	O
in	O
the	O
recruitment	O
of	O
inflammatory	O
cells	O
.	O
OBJECTIVE	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
DEP	O
-	O
PAHs	O
on	O
the	O
release	O
and	O
mRNA	O
expression	O
of	O
IL-8	B
,	O
MCP-1	B
,	O
and	O
RANTES	B
by	O
PBMCs	O
obtained	O
from	O
healthy	O
subjects	O
.	O
METHODS	O
:	O
Protein	O
production	O
in	O
supernatants	O
was	O
assessed	O
by	O
ELISA	O
,	O
and	O
mRNA	O
expression	O
was	O
evaluated	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
.	O
RESULTS	O
:	O
Secretion	O
of	O
IL-8	B
and	O
RANTES	B
increased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
increasing	O
concentrations	O
of	O
DEP	O
-	O
PAHs	O
(	O
range	O
,	O
0.5	O
ng	O
to	O
50	O
ng	O
/	O
mL	O
)	O
.	O
On	O
the	O
contrary	O
,	O
the	O
release	O
of	O
MCP-1	B
was	O
significantly	O
inhibited	O
,	O
also	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
Messenger	O
RNA	O
production	O
coding	O
for	O
IL-8	B
,	O
RANTES	B
,	O
and	O
MCP-1	B
showed	O
parallel	O
variations	O
to	O
the	O
production	O
of	O
the	O
correspondent	B
proteins	I
.	O
Effects	O
of	O
DEP	O
-	O
PAHs	O
became	O
significant	O
at	O
7	O
hours	O
and	O
up	O
to	O
48	O
hours	O
time	O
culture	O
for	O
MCP-1	B
,	O
and	O
up	O
to	O
24	O
hours	O
time	O
culture	O
for	O
IL-8	B
and	O
RANTES	B
.	O
Moreover	O
,	O
supernatants	O
from	O
DEP	O
-	O
PAH	O
-	O
activated	O
cells	O
,	O
compared	O
with	O
those	O
of	O
controls	O
,	O
exhibited	O
a	O
significantly	O
enhanced	O
chemotactic	O
activity	O
for	O
neutrophils	O
and	O
eosinophils	O
,	O
which	O
was	O
significantly	O
inhibited	O
by	O
pretreatment	O
with	O
anti	B
-	I
IL-8	I
and	O
anti	B
-	I
RANTES	I
neutralizing	O
antibodies	O
,	O
respectively	O
.	O
CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
chemokine	B
pathways	O
are	O
modulated	O
by	O
DEP	O
-	O
PAHs	O
at	O
the	O
transcriptional	O
level	O
,	O
reinforcing	O
the	O
idea	O
that	O
the	O
development	O
of	O
inflammatory	O
reactions	O
might	O
be	O
affected	O
by	O
diesel	O
exhaust	O
emission	O
.	O
Binding	O
of	O
YY1	B
and	O
Oct1	B
to	O
a	O
novel	O
element	O
that	O
downregulates	O
expression	O
of	O
IL-5	B
in	O
human	O
T	O
cells	O
.	O
BACKGROUND	O
:	O
IL-5	B
controls	O
development	O
of	O
eosinophilia	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
diseases	O
.	O
In	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
,	O
elevated	O
IL-5	B
has	O
been	O
detected	O
in	O
peripheral	O
blood	O
and	O
the	O
airways	O
.	O
IL-5	B
is	O
produced	O
mainly	O
by	O
activated	O
T	O
cells	O
,	O
and	O
its	O
expression	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O
OBJECTIVE	O
:	O
This	O
study	O
focuses	O
on	O
the	O
functional	O
analysis	O
of	O
the	O
human	O
IL-5	O
(	O
hIL-5	O
)	O
promoter	O
and	O
characterization	O
of	O
cis	O
-regulatory	O
elements	O
and	O
transcription	O
factors	O
involved	O
in	O
the	O
suppression	O
of	O
IL-5	B
transcription	O
in	O
T	O
cells	O
.	O
METHODS	O
:	O
Methods	O
used	O
in	O
this	O
study	O
include	O
DNase	B
I	I
footprint	O
assays	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
functional	O
analysis	O
by	O
mammalian	O
cell	O
transfection	O
involving	O
deletion	O
analysis	O
and	O
site	O
-	O
directed	O
mutagenesis	O
.	O
RESULTS	O
:	O
We	O
identified	O
5	O
protein	O
binding	O
regions	O
(	O
BRs	O
)	O
located	O
within	O
the	O
proximal	O
hIL-5	O
promoter	O
.	O
Functional	O
analysis	O
indicates	O
that	O
the	O
BRs	O
are	O
involved	O
in	O
control	O
of	O
hIL-5	O
promoter	O
activity	O
.	O
Two	O
of	O
these	O
regions	O
,	O
BR3	O
and	O
BR4	O
located	O
at	O
positions	O
-102	O
to	O
-73	O
,	O
have	O
not	O
previously	O
been	O
described	O
as	O
regulators	O
of	O
IL-5	B
expression	O
in	O
T	O
cells	O
.	O
We	O
show	O
that	O
the	O
BR3	O
sequence	O
contains	O
a	O
novel	O
negative	O
regulatory	O
element	O
located	O
at	O
positions	O
-90	O
to	O
-79	O
of	O
the	O
hIL-5	O
promoter	O
,	O
which	O
binds	O
Oct1	B
,	O
octamer	B
-	I
like	I
,	O
and	O
YY1	B
nuclear	I
factors	I
.	O
Substitution	O
mutations	O
,	O
which	O
abolished	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
BR3	O
sequence	O
,	O
significantly	O
increased	O
hIL-5	O
promoter	O
activity	O
in	O
activated	O
T	O
cells	O
.	O
CONCLUSION	O
:	O
We	O
suggest	O
that	O
Oct1	B
,	O
YY1	B
,	O
and	O
octamer	B
-	I
like	I
factors	I
binding	O
to	O
the	O
-90	O
/	O
-79	O
sequence	O
within	O
the	O
proximal	O
IL-5	O
promoter	O
are	O
involved	O
in	O
suppression	O
of	O
IL-5	B
transcription	O
in	O
T	O
cells	O
.	O
Potent	O
and	O
stable	O
attenuation	O
of	O
live	O
-	O
HIV-1	O
by	O
gain	O
of	O
a	O
proteolysis	B
-	I
resistant	I
inhibitor	I
of	O
NF	B
-	I
kappaB	I
(	O
IkappaB	B
-	I
alphaS32	I
/	I
36A	I
)	O
and	O
the	O
implications	O
for	O
vaccine	O
development	O
.	O
Live	O
-	O
attenuated	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
are	O
candidates	O
for	O
Acquired	O
Immunodeficiency	O
Syndrome	O
(	O
AIDS	O
)	O
vaccine	O
.	O
Based	O
on	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
model	O
for	O
AIDS	O
,	O
loss	O
-	O
of	O
-	O
function	O
(	O
e.g.	O
deletion	O
of	O
accessory	O
genes	O
such	O
as	O
nef	O
)	O
has	O
been	O
forwarded	O
as	O
a	O
primary	O
approach	O
for	O
creating	O
enfeebled	O
,	O
but	O
replication	O
-	O
competent	O
,	O
HIV-1	O
/	O
SIV	O
.	O
Regrettably	O
,	O
recent	O
evidence	O
suggests	O
that	O
loss	O
-	O
of	O
-	O
function	O
alone	O
is	O
not	O
always	O
sufficient	O
to	O
prevent	O
the	O
emergence	O
of	O
virulent	O
mutants	O
.	O
New	O
strategies	O
that	O
attenuate	O
via	O
mechanisms	O
distinct	O
from	O
loss	O
-	O
of	O
-	O
function	O
are	O
needed	O
for	O
enhancing	O
the	O
safety	O
phenotype	O
of	O
viral	O
genome	O
.	O
Here	O
,	O
we	O
propose	O
gain	O
-	O
of	O
-	O
function	O
to	O
be	O
used	O
simultaneously	O
with	O
loss	O
-	O
of	O
-	O
function	O
as	O
a	O
novel	O
approach	O
for	O
attenuating	O
HIV-1	O
.	O
We	O
have	O
constructed	O
an	O
HIV-1	O
genome	O
carrying	O
the	O
cDNA	O
of	O
a	O
proteolysis	B
-	I
resistant	I
nuclear	I
factor	I
-	I
kappaB	I
inhibitor	I
(	O
IkappaB	B
-	I
alphaS32	I
/	I
36A	I
)	O
in	O
the	O
nef	O
region	O
.	O
HIV-1	O
expressing	O
IkappaB	B
-	I
alphaS32	I
/	I
36A	I
down	O
-	O
regulates	O
viral	O
expression	O
and	O
is	O
highly	O
attenuated	O
in	O
both	O
Jurkat	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
We	O
provide	O
formal	O
proof	O
that	O
the	O
phenotypic	O
and	O
attenuating	O
characteristics	O
of	O
IkappaB	B
-	I
alphaS32	I
/	I
36A	I
permit	O
its	O
stable	O
maintenance	O
in	O
a	O
live	O
,	O
replicating	O
HIV-1	O
despite	O
180	O
days	O
of	O
forced	O
ex	O
vivo	O
passaging	O
in	O
tissue	O
culture	O
.	O
As	O
compared	O
with	O
other	O
open	O
-	O
reading	O
frames	O
embedded	O
into	O
HIV	O
/	O
SIV	O
genome	O
,	O
this	O
degree	O
of	O
stability	O
is	O
unprecedented	O
.	O
Thus	O
,	O
IkappaB	B
-	I
alphaS32	I
/	I
36A	I
offers	O
proof	O
-	O
of	O
-	O
principle	O
that	O
artifactually	O
gained	O
functions	O
,	O
when	O
used	O
to	O
attenuate	O
the	O
replication	O
of	O
live	O
HIV-1	O
,	O
can	O
be	O
stable	O
.	O
These	O
findings	O
illustrate	O
gain	O
-	O
of	O
-	O
function	O
as	O
a	O
feasible	O
strategy	O
for	O
developing	O
safer	O
live	O
-	O
attenuated	O
HIVs	O
to	O
be	O
tested	O
as	O
candidates	O
for	O
AIDS	O
vaccine	O
.	O
CBP	B
/	I
p300	I
integrates	O
Raf	B
/	O
Rac	B
-signaling	O
pathways	O
in	O
the	O
transcriptional	O
induction	O
of	O
NF	B
-	I
ATc	I
during	O
T	O
cell	O
activation	O
.	O
NF	B
-	I
ATc	I
,	O
an	O
inducibly	O
expressed	O
transcription	B
factor	I
,	O
controls	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
and	O
cardiomyocytes	O
.	O
We	O
show	O
here	O
that	O
the	O
transcriptional	B
co	I
-	I
activators	I
CBP	B
/	I
p300	I
bind	O
to	O
and	O
control	O
the	O
activity	O
of	O
the	O
inducible	B
N	I
-	I
terminal	I
transactivation	I
domain	I
of	O
NF	B
-	I
ATc	I
,	O
TAD	B
-	I
A	I
.	O
Similar	O
to	O
the	O
N	B
terminal	I
transactivation	I
domain	I
of	O
c	B
-	I
Jun	I
,	O
TAD	B
-	I
A	I
is	O
inducibly	O
phosphorylated	O
,	O
but	O
this	O
phosphorylation	O
is	O
dispensable	O
for	O
the	O
interaction	O
with	O
CBP	B
/	I
p300	I
.	O
Constitutive	O
active	O
versions	O
of	O
c	B
-	I
Raf	I
and	O
Rac	B
synergistically	O
enhance	O
the	O
CBP	B
/	I
p300	I
-mediated	O
increase	O
of	O
TAD	B
-	I
A	I
activity	O
,	O
indicating	O
the	O
important	O
role	O
CBP	B
/	I
p300	I
plays	O
in	O
the	O
integration	O
of	O
T	O
cell	O
activation	O
signals	O
.	O
Since	O
a	O
mutation	O
of	O
CBP	B
abolishing	O
HAT	O
activity	O
is	O
almost	O
as	O
active	O
as	O
wild	B
-	I
type	I
CBP	I
in	O
T	O
cells	O
,	O
functions	O
of	O
CBP	B
/	I
p300	I
other	O
than	O
histone	O
acetylation	O
appear	O
to	O
control	O
the	O
NF	B
-	I
AT	I
-dependent	O
transcription	O
in	O
T	O
cells	O
.	O
Expression	O
and	O
role	O
of	O
PML	O
gene	O
in	O
normal	O
adult	O
hematopoiesis	O
:	O
functional	O
interaction	O
between	O
PML	B
and	I
Rb	I
proteins	I
in	O
erythropoiesis	O
.	O
The	O
expression	O
of	O
the	O
PML	O
gene	O
was	O
investigated	O
in	O
purified	O
early	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPCs	O
)	O
induced	O
to	O
unilineage	O
erythroid	O
or	O
granulocytic	O
differentiation	O
.	O
PML	O
mRNA	O
and	O
protein	B
,	O
while	O
barely	O
detectable	O
in	O
quiescent	O
HPCs	O
,	O
are	O
consistently	O
induced	O
by	O
growth	B
factor	I
stimulation	O
through	O
the	O
erythroid	O
or	O
granulocytic	O
lineage	O
.	O
Thereafter	O
,	O
PML	B
is	O
downmodulated	O
in	O
late	O
granulocytic	O
maturation	O
,	O
whereas	O
it	O
is	O
sustainably	O
expressed	O
through	O
the	O
erythroid	O
pathway	O
.	O
In	O
functional	O
studies	O
,	O
PML	B
expression	O
was	O
inhibited	O
by	O
addition	O
of	O
antisense	O
oligomers	O
targeting	O
PML	O
mRNA	O
(	O
alpha	B
-	I
PML	I
)	O
.	O
Interestingly	O
,	O
early	O
treatment	O
(	O
day	O
0	O
HPCs	O
)	O
with	O
alpha	B
-	I
PML	I
reduced	O
the	O
number	O
of	O
both	O
erythroid	O
and	O
granulocytic	O
colonies	O
,	O
whereas	O
late	O
treatment	O
(	O
day	O
5	O
culture	O
)	O
reduced	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
,	O
clonogenesis	O
.	O
These	O
findings	O
suggest	O
that	O
PML	B
is	O
required	O
for	O
early	O
hematopoiesis	O
and	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
maturation	O
.	O
The	O
pattern	O
of	O
PML	B
expression	O
in	O
normal	O
hematopoiesis	O
mimics	O
that	O
of	O
retinoblastoma	O
pRb	B
105	I
.	O
Combined	O
treatment	O
of	O
HPCs	O
with	O
alpha	B
-	I
PML	I
and	O
alpha	O
-	O
Rb	O
oligomers	O
inhibited	O
both	O
PML	O
and	O
Rb	O
protein	O
expression	O
and	O
completely	O
blocked	O
erythroid	O
colony	O
development	O
.	O
Furthermore	O
,	O
PML	B
and	O
pRb	B
105	I
were	O
co	O
-	O
immunoprecipitated	O
in	O
cellular	O
lysates	O
derived	O
from	O
erythroid	O
precursors	O
indicating	O
that	O
this	O
functional	O
interaction	O
may	O
have	O
a	O
biochemical	O
basis	O
.	O
These	O
results	O
suggest	O
a	O
key	O
functional	O
role	O
of	O
PML	B
in	O
early	O
hematopoiesis	O
and	O
late	O
erythropoiesis	O
:	O
the	O
latter	O
phenomenon	O
may	O
be	O
related	O
to	O
the	O
molecular	O
and	O
functional	O
interaction	O
of	O
PML	B
with	O
pRb	B
105	I
.	O
p70	B
(	I
s6k	I
)	I
integrates	O
phosphatidylinositol	B
3-kinase	I
and	O
rapamycin	O
-	O
regulated	O
signals	O
for	O
E2F	B
regulation	O
in	O
T	O
lymphocytes	O
.	O
In	O
T	O
lymphocytes	O
,	O
the	O
hematopoietic	B
cytokine	I
interleukin-2	B
(	O
IL-2	B
)	O
uses	O
phosphatidylinositol	B
3-kinase	I
(	O
PI	B
3-kinase	I
)	O
-induced	O
signaling	O
pathways	O
to	O
regulate	O
E2F	B
transcriptional	O
activity	O
,	O
a	O
critical	O
cell	O
cycle	O
checkpoint	O
.	O
PI	B
3-kinase	I
also	O
regulates	O
the	O
activity	O
of	O
p70	B
(	I
s6k	I
)	I
,	O
the	O
40S	B
ribosomal	I
protein	I
S6	I
kinase	I
,	O
a	O
response	O
that	O
is	O
abrogated	O
by	O
the	O
macrolide	O
rapamycin	O
.	O
This	O
immunosuppressive	O
drug	O
is	O
known	O
to	O
prevent	O
T	O
-	O
cell	O
proliferation	O
,	O
but	O
the	O
precise	O
point	O
at	O
which	O
rapamycin	O
regulates	O
T	O
-	O
cell	O
cycle	O
progression	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O
Moreover	O
,	O
the	O
effects	O
of	O
rapamycin	O
on	O
,	O
and	O
the	O
role	O
of	O
p70	B
(	I
s6k	I
)	I
in	O
,	O
IL-2	B
and	O
PI	B
3-kinase	I
activation	O
of	O
E2Fs	B
have	O
not	O
been	O
characterized	O
.	O
Our	O
present	O
results	O
show	O
that	O
IL-2	B
-and	O
PI	B
3-kinase	I
-induced	O
pathways	O
for	O
the	O
regulation	O
of	O
E2F	B
transcriptional	O
activity	O
include	O
both	O
rapamycin	O
-	O
resistant	O
and	O
rapamycin	O
-	O
sensitive	O
components	O
.	O
Expression	O
of	O
a	O
rapamycin	B
-	I
resistant	I
mutant	I
of	O
p70	B
(	I
s6k	I
)	I
in	O
T	O
cells	O
could	O
restore	O
rapamycin	O
-	O
suppressed	O
E2F	B
responses	O
.	O
Thus	O
,	O
the	O
rapamycin	O
-	O
controlled	O
processes	O
involved	O
in	O
E2F	B
regulation	O
appear	O
to	O
be	O
mediated	O
by	O
p70	B
(	I
s6k	I
)	I
.	O
However	O
,	O
the	O
rapamycin	B
-	I
resistant	I
p70	I
(	I
s6k	I
)	I
could	O
not	O
rescue	O
rapamycin	O
inhibition	O
of	O
T	O
-	O
cell	O
cycle	O
entry	O
,	O
consistent	O
with	O
the	O
involvement	O
of	O
additional	O
,	O
rapamycin	O
-	O
sensitive	O
pathways	O
in	O
the	O
control	O
of	O
T	O
-	O
cell	O
cycle	O
progression	O
.	O
The	O
present	O
results	O
thus	O
show	O
that	O
p70	B
(	I
s6k	I
)	I
is	O
able	O
to	O
regulate	O
E2F	B
transcriptional	O
activity	O
and	O
provide	O
direct	O
evidence	O
for	O
the	O
first	O
time	O
for	O
a	O
link	O
between	O
IL-2	B
receptors	O
,	O
PI	B
3-kinase	I
,	O
and	O
p70	B
(	I
s6k	I
)	I
that	O
regulates	O
a	O
crucial	O
G1	O
checkpoint	O
in	O
T	O
lymphocytes	O
.	O
Signal	O
transduction	O
pathways	O
in	O
normal	O
human	O
monocytes	O
stimulated	O
by	O
cytokines	B
and	O
mediators	O
:	O
comparative	O
study	O
with	O
normal	O
human	O
neutrophils	O
or	O
transformed	O
cells	O
and	O
the	O
putative	O
roles	O
in	O
functionality	O
and	O
cell	O
biology	O
.	O
Granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
and	O
interleukin	B
(	I
IL	I
)	I
-3	I
induced	O
tyrosine	O
phosphorylation	O
of	O
92-kDa	B
protein	I
in	O
normal	O
human	O
monocytes	O
.	O
We	O
identified	O
this	O
92-kDa	B
protein	I
as	O
STAT5	B
,	O
but	O
not	O
as	O
STATs1	B
,	I
3	I
,	I
and	I
6	I
nor	O
c	B
-	I
fes	I
and	O
vav	B
protooncogene	I
products	I
,	O
and	O
demonstrated	O
its	O
translocation	O
to	O
the	O
nucleus	O
,	O
enhancement	O
of	O
specific	O
DNA	O
binding	O
capacity	O
,	O
and	O
potentiation	O
of	O
trancriptional	O
activity	O
by	O
GM	B
-	I
CSF	I
.	O
N	O
-	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
(	O
FMLP	O
)	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
induced	O
tyrosine	O
phosphorylation	O
of	O
42-	B
and	I
44-kDa	I
proteins	I
,	O
which	O
were	O
identified	O
as	O
extracellular	B
signal	I
-	I
regulated	I
kinase	I
(	O
ERK	B
)	O
,	O
in	O
human	O
monocytes	O
.	O
In	O
marked	O
contrast	O
to	O
neutrophils	O
and	O
MO7e	O
cells	O
,	O
GM	B
-	I
CSF	I
did	O
not	O
induce	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
ERK	B
in	O
monocytes	O
.	O
Among	O
upstream	B
signaling	I
molecules	I
of	O
ERK	B
,	O
Shc	B
was	O
constitutively	O
associated	O
with	O
Grb2	O
and	O
was	O
not	O
tyrosine	O
-	O
phosphorylated	O
by	O
GM	B
-	I
CSF	I
and	O
FMLP	O
,	O
and	O
Sos1	B
and	O
c	B
-	I
Raf-1	I
were	O
not	O
phosphorylated	O
by	O
GM	B
-	I
CSF	I
,	O
IL-3	O
,	O
TNF	O
,	O
and	O
FMLP	O
in	O
monocytes	O
,	O
whereas	O
all	O
these	O
signaling	O
molecules	O
were	O
affected	O
and/or	O
utilized	O
by	O
GM	B
-	I
CSF	I
in	O
MO7e	O
cells	O
.	O
In	O
contrast	O
to	O
neutrophils	O
,	O
p38	B
was	O
constitutively	O
phosphorylated	O
and	O
agonist	O
-	O
dependent	O
phosphorylation	O
and	O
activation	O
was	O
not	O
detected	O
in	O
human	O
monocytes	O
.	O
Superoxide	O
release	O
stimulated	O
by	O
FMLP	O
was	O
inhibited	O
partially	O
by	O
PD98059	O
or	O
SB203580	O
,	O
a	O
specific	O
inhibitor	O
of	O
ERK	O
or	O
p38	O
pathway	O
,	O
and	O
was	O
almost	O
completely	O
inhibited	O
by	O
the	O
combination	O
of	O
both	O
inhibitors	O
,	O
whereas	O
PMA	O
-	O
induced	O
superoxide	O
release	O
was	O
resistant	O
to	O
these	O
two	O
inhibitors	O
in	O
monocytes	O
.	O
PD98059	O
inhibited	O
GM	B
-	I
CSF	I
-dependent	O
proliferation	O
of	O
MO7e	O
cells	O
.	O
Present	O
results	O
indicate	O
trancriptional	O
roles	O
of	O
STAT5	B
and	O
functional	O
roles	O
of	O
ERK	B
and/or	O
p38	B
in	O
normal	O
human	O
monocytes	O
stimulated	O
by	O
physiological	O
receptor	O
-	O
mediated	O
agonists	O
GM	B
-	I
CSF	I
and	O
FMLP	O
.	O
Possible	O
roles	O
of	O
ERK	B
in	O
proliferation	O
of	O
transformed	O
cells	O
were	O
also	O
suggested	O
.	O
PPARalpha	O
activators	O
inhibit	O
cytokine	O
-	O
induced	O
vascular	B
cell	I
adhesion	I
molecule-1	I
expression	O
in	O
human	O
endothelial	O
cells	O
.	O
BACKGROUND	O
:	O
Adhesion	O
molecule	O
expression	O
on	O
the	O
endothelial	O
cell	O
(	O
EC	O
)	O
surface	O
is	O
critical	O
for	O
leukocyte	O
recruitment	O
to	O
atherosclerotic	O
lesions	O
.	O
Better	O
understanding	O
of	O
transcriptional	O
regulation	O
of	O
adhesion	B
molecules	I
in	O
ECs	O
may	O
provide	O
important	O
insight	O
into	O
plaque	O
formation	O
.	O
Peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
-	I
alpha	I
(	O
PPARalpha	B
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	B
receptor	I
family	I
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
certain	O
fatty	O
acids	O
and	O
fibric	O
acid	O
derivatives	O
.	O
The	O
present	O
study	O
investigated	O
PPARalpha	B
expression	O
in	O
human	O
ECs	O
and	O
their	O
regulation	O
of	O
vascular	B
cell	I
adhesion	I
molecule-1	I
(	O
VCAM-1	B
)	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
Immunohistochemistry	O
revealed	O
that	O
human	O
carotid	O
artery	O
ECs	O
express	O
PPARalpha	B
.	O
Pretreatment	O
of	O
cultured	O
human	O
ECs	O
with	O
the	O
PPARalpha	B
activators	O
fenofibrate	O
or	O
WY14643	O
inhibited	O
TNF	B
-	I
alpha	I
-	I
induced	I
VCAM-1	I
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
manner	O
,	O
an	O
effect	O
not	O
seen	O
with	O
PPARgamma	B
activators	O
.	O
Both	O
PPARalpha	B
activators	O
decreased	O
cytokine	O
-	O
induced	O
VCAM-1	B
mRNA	O
expression	O
without	O
altering	O
its	O
mRNA	O
half	O
-	O
life	O
.	O
Transient	O
transfection	O
of	O
deletional	O
VCAM-1	O
promoter	O
constructs	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
fenofibrate	O
inhibits	O
VCAM-1	B
transcription	O
in	O
part	O
by	O
inhibiting	O
NF	B
-	I
kappaB	I
.	O
Finally	O
,	O
PPARalpha	B
activators	O
significantly	O
reduced	O
adhesion	O
of	O
U937	O
cells	O
to	O
cultured	O
human	O
ECs	O
.	O
CONCLUSIONS	O
:	O
Human	O
ECs	O
express	O
PPARalpha	B
,	O
a	O
potentially	O
important	O
regulator	O
of	O
atherogenesis	O
through	O
its	O
transcriptional	O
control	O
of	O
VCAM-1	B
gene	O
expression	O
.	O
Such	O
findings	O
also	O
have	O
implications	O
regarding	O
the	O
clinical	O
use	O
of	O
lipid	O
-	O
lowering	O
agents	O
,	O
like	O
fibric	O
acids	O
,	O
which	O
can	O
activate	O
PPARalpha	B
.	O
Genetic	O
evidence	O
for	O
an	O
additional	O
factor	O
required	O
for	O
erythropoietin	B
-induced	O
signal	O
transduction	O
.	O
Erythropoietin	B
(	O
EPO	B
)	O
and	O
its	O
receptor	O
(	O
EPOR	B
)	O
are	O
required	O
for	O
the	O
development	O
of	O
mature	O
erythrocytes	O
.	O
After	O
binding	O
of	O
ligand	O
,	O
the	O
EPOR	B
activates	O
a	O
variety	O
of	O
signaling	O
pathways	O
that	O
ultimately	O
control	O
cellular	O
proliferation	O
,	O
survival	O
,	O
and	O
specific	O
gene	O
expression	O
.	O
Although	O
erythroid	O
progenitors	O
appear	O
to	O
be	O
the	O
principal	O
EPO	O
-	O
responsive	O
cell	O
type	O
in	O
vivo	O
due	O
to	O
the	O
restricted	O
expression	O
of	O
the	O
EPOR	B
,	O
many	O
growth	O
factor	O
-	O
dependent	O
cell	O
lines	O
expressing	O
the	O
EPOR	B
can	O
respond	O
to	O
EPO	B
by	O
activating	O
many	O
or	O
all	O
of	O
these	O
pathways	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
have	O
identified	O
a	O
cellular	O
context	O
(	O
the	O
interleukin-2	O
[	O
IL-2	O
]	O
-dependent	O
HT-2	O
line	O
)	O
in	O
which	O
the	O
EPO	B
stimulation	O
of	O
the	O
EPOR	B
fails	O
to	O
support	O
cellular	O
proliferation	O
,	O
STAT-5	B
induction	O
,	O
or	O
MAPK	B
activation	O
,	O
despite	O
efficient	O
phosphorylation	O
of	O
the	O
EPOR	B
and	O
JAK2	B
and	O
inhibition	O
of	O
apoptosis	O
after	O
withdrawal	O
of	O
IL-2	B
.	O
Interestingly	O
,	O
when	O
we	O
fused	O
HT-2	O
cells	O
expressing	O
the	O
EPOR	B
with	O
Ba	O
/	O
F3	O
cells	O
in	O
a	O
complementation	O
assay	O
,	O
the	O
resulting	O
hybridomas	O
proliferated	O
and	O
potently	O
activated	O
STAT-5	B
and	O
MAPK	B
in	O
response	O
to	O
EPO	B
.	O
These	O
data	O
indicate	O
that	O
an	O
unidentified	B
cellular	I
factor	I
is	O
needed	O
to	O
mediate	O
signaling	O
by	O
the	O
EPOR	B
.	O
Moreover	O
,	O
Ba	O
/	O
F3	O
cells	O
apparently	O
express	O
this	O
factor	O
(	O
s	O
)	O
and	O
somatic	O
fusions	O
can	O
,	O
therefore	O
,	O
confer	O
EPO	B
-responsiveness	O
to	O
HT-2	O
cells	O
that	O
lack	O
this	O
factor	O
.	O
NF	B
-	I
kappaB	I
functions	O
as	O
both	O
a	O
proapoptotic	B
and	I
antiapoptotic	I
regulatory	I
factor	I
within	O
a	O
single	O
cell	O
type	O
.	O
Recently	O
NF	B
-	I
kappaB	I
has	O
been	O
shown	O
to	O
have	O
both	O
proapoptotic	O
and	O
antiapoptotic	O
functions	O
.	O
In	O
T	O
cell	O
hybridomas	O
,	O
both	O
T	O
cell	O
activators	O
and	O
glucocorticoids	O
induce	O
apoptosis	O
.	O
Here	O
we	O
show	O
that	O
blockade	O
of	O
NF	B
-	I
kappaB	I
activity	O
,	O
using	O
a	O
dominant	B
negative	I
IkappaBalpha	I
,	O
has	O
opposite	O
effects	O
on	O
these	O
two	O
apoptotic	O
signals	O
.	O
Treatment	O
with	O
PMA	O
plus	O
ionomycin	O
(	O
P	O
/	O
I	O
)	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	B
Ligand	I
(	O
FasL	B
)	O
and	O
induction	O
of	O
apoptosis	O
.	O
Inhibition	O
of	O
NF	B
-	I
kappaB	I
activity	O
inhibits	O
the	O
P	O
/	O
I	O
mediated	O
induction	O
of	O
FasL	O
mRNA	O
and	O
decreases	O
the	O
level	O
of	O
apoptosis	O
in	O
these	O
cultures	O
,	O
thus	O
establishing	O
NF	B
-	I
kappaB	I
as	O
a	O
proapoptotic	B
factor	I
in	O
this	O
context	O
.	O
Conversely	O
,	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
confers	O
a	O
tenfold	O
increase	O
in	O
glucocorticoid	O
mediated	O
apoptosis	O
,	O
establishing	O
that	O
NF	B
-	I
kappaB	I
also	O
functions	O
as	O
an	O
antiapoptotic	O
factor	O
.	O
We	O
conclude	O
that	O
NF	B
-	I
kappaB	I
is	O
a	O
context	O
-	O
dependent	O
apoptosis	O
regulator	O
.	O
Our	O
data	O
suggests	O
that	O
NF	B
-	I
kappaB	I
may	O
function	O
as	O
an	O
antiapoptotic	O
factor	O
in	O
thymocytes	O
while	O
functioning	O
as	O
a	O
proapoptotic	O
factor	O
in	O
mature	O
peripheral	O
T	O
cells	O
.	O
Functional	O
B	O
-	O
cell	O
response	O
in	O
intrahepatic	O
lymphoid	O
follicles	O
in	O
chronic	O
hepatitis	O
C	O
.	O
Intrahepatic	O
lymphoid	O
follicle	O
(	O
ILF	O
)	O
formation	O
is	O
one	O
of	O
the	O
most	O
characteristic	O
and	O
commonly	O
observed	O
histological	O
features	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
.	O
However	O
,	O
little	O
is	O
known	O
regarding	O
whether	O
follicles	O
in	O
the	O
liver	O
belong	O
to	O
functional	O
lymphoid	O
tissues	O
,	O
where	O
B	O
cells	O
are	O
activated	O
,	O
differentiated	O
,	O
and	O
proliferated	O
,	O
or	O
if	O
the	O
lymphocytes	O
are	O
merely	O
infiltrated	O
after	O
recruitment	O
from	O
the	O
secondary	O
lymphoid	O
organs	O
.	O
To	O
ascertain	O
this	O
possibility	O
,	O
we	O
examined	O
the	O
expression	O
of	O
markers	O
for	O
B	O
-	O
cell	O
activation	O
,	O
differentiation	O
,	O
and	O
proliferation	O
in	O
ILFs	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
using	O
surgically	O
resected	O
specimens	O
,	O
and	O
compared	O
them	O
with	O
specimens	O
of	O
perihepatic	O
lymph	O
nodes	O
by	O
an	O
immunohistochemical	O
technique	O
.	O
Germinal	O
center	O
(	O
GC	O
)	O
formation	O
in	O
the	O
ILFs	O
was	O
frequently	O
found	O
in	O
HCV	O
-	O
positive	O
cases	O
.	O
The	O
distribution	O
of	O
immunoglobulin	O
M	O
(	O
IgM	O
)	O
-	O
,	O
IgD-	O
,	O
and	O
IgG	O
-	O
positive	O
cells	O
and	O
the	O
expression	O
patterns	O
of	O
Ki-67	O
,	O
CD23	O
,	O
or	O
bcl-2	O
and	O
bcl-6	O
gene	O
products	O
in	O
the	O
follicles	O
with	O
GC	O
formation	O
in	O
the	O
liver	O
of	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
were	O
similar	O
to	O
those	O
of	O
lymph	O
nodes	O
,	O
indicating	O
that	O
B	O
cells	O
are	O
activated	O
,	O
proliferated	O
,	O
and	O
differentiated	O
in	O
the	O
ILFs	O
with	O
GC	O
formation	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
.	O
Oligoclonal	O
expansion	O
of	O
B	O
cells	O
in	O
the	O
livers	O
with	O
ILFs	O
was	O
confirmed	O
by	O
an	O
analysis	O
of	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
gene	O
rearrangement	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
These	O
data	O
strongly	O
suggest	O
that	O
ILFs	O
with	O
GC	O
formation	O
,	O
which	O
are	O
frequently	O
found	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
may	O
functionally	O
be	O
the	O
same	O
as	O
those	O
found	O
in	O
lymph	O
nodes	O
with	O
respect	O
to	O
B	O
-	O
cell	O
expansion	O
and	O
maturation	O
.	O
Cutting	O
edge	O
:	O
expression	O
of	O
the	O
NF	B
of	I
activated	I
T	I
cells	I
in	O
eosinophils	O
:	O
regulation	O
by	O
IL-4	B
and	O
IL-5	B
.	O
We	O
report	O
that	O
NF	B
-	I
AT1	I
and	O
NF	B
-	I
AT4	I
are	O
expressed	O
cytoplasmically	O
in	O
resting	O
eosinophils	O
,	O
whereas	O
NF	B
-	I
AT2	I
and	O
NF	B
-	I
AT3	I
have	O
not	O
been	O
seen	O
.	O
Likewise	O
,	O
NF	O
-	O
AT1	O
mRNA	O
and	O
NF	O
-	O
AT4	O
mRNA	O
have	O
been	O
detected	O
in	O
resting	O
eosinophils	O
,	O
and	O
their	O
levels	O
can	O
be	O
significantly	O
up	O
-	O
regulated	O
by	O
the	O
Th2-associated	B
cytokines	I
IL-4	B
and	O
IL-5	B
.	O
There	O
is	O
no	O
detectable	O
NF	B
-	I
AT	I
protein	O
expression	O
in	O
the	O
nuclei	O
of	O
resting	O
eosinophils	O
.	O
However	O
NF	B
-	I
ATs	I
appear	O
in	O
the	O
nuclei	O
of	O
IL-4-	O
,	O
IL-5-	O
,	O
or	O
ionomycin	O
-	O
stimulated	O
eosinophils	O
.	O
Only	O
NF	B
-	I
AT1	I
and	O
NF	B
-	I
AT4	I
,	O
but	O
not	O
NF	B
-	I
AT2	I
and	O
NF	B
-	I
AT3	I
,	O
have	O
translocated	O
into	O
the	O
nuclei	O
in	O
IL-4-	O
or	O
IL-5-stimulated	O
eosinophils	O
.	O
These	O
findings	O
delineate	O
a	O
novel	O
pathway	O
in	O
the	O
cytokine	O
network	O
in	O
which	O
Th2	O
lymphocytes	O
`	O
`	O
control	O
''	O
eosinophils	O
via	O
the	O
release	O
of	O
IL-4	B
and	O
IL-5	B
,	O
and	O
activation	O
of	O
NF	B
-	I
AT	I
in	O
eosinophils	O
.	O
The	O
findings	O
also	O
suggest	O
that	O
a	O
later	O
feedback	O
`	O
`	O
talking	O
''	O
may	O
exist	O
between	O
eosinophils	O
and	O
Th2	O
lymphocytes	O
.	O
Inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
in	O
human	O
T	O
lymphocytes	O
induces	O
caspase	O
-	O
dependent	O
apoptosis	O
without	O
detectable	O
activation	O
of	O
caspase-1	B
and	I
-3	I
.	O
NF	B
-	I
kappa	I
B	I
is	O
involved	O
in	O
the	O
transcriptional	O
control	O
of	O
various	O
genes	O
that	O
act	O
as	O
extrinsic	O
and	O
intrinsic	O
survival	O
factors	O
for	O
T	O
cells	O
.	O
Our	O
findings	O
show	O
that	O
suppression	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
with	O
cell	O
-	O
permeable	O
SN50	O
peptide	O
,	O
which	O
masks	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF	B
-	I
kappa	I
B1	I
dimers	I
and	O
prevents	O
their	O
nuclear	O
localization	O
,	O
induces	O
apoptosis	O
in	O
resting	O
normal	O
human	O
PBL	O
.	O
Inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
resulted	O
in	O
the	O
externalization	O
of	O
phosphatidylserine	O
,	O
induction	O
of	O
DNA	O
breaks	O
,	O
and	O
morphological	O
changes	O
consistent	O
with	O
apoptosis	O
.	O
DNA	O
fragmentation	O
was	O
efficiently	O
blocked	O
by	O
the	O
caspase	B
inhibitor	I
Z	B
-	I
VAD	I
-	I
fmk	I
and	O
partially	O
blocked	O
by	O
Ac	B
-	I
DEVD	I
-	I
fmk	I
,	O
suggesting	O
that	O
SN50-mediated	O
apoptosis	O
is	O
caspase	B
-dependent	O
.	O
Interestingly	O
,	O
apoptosis	O
induced	O
by	O
NF	B
-	I
kappa	I
B	I
suppression	O
,	O
in	O
contrast	O
to	O
that	O
induced	O
by	O
TPEN	O
(	O
N	O
,	O
N	O
,	O
N	O
'	O
,	O
N'-tetrakis	O
[	O
2-pyridylmethyl	O
]	O
ethylenediamine	O
)	O
or	O
soluble	B
Fas	I
ligand	I
(	O
CD95	B
)	O
,	O
was	O
observed	O
in	O
the	O
absence	O
of	O
active	B
death	I
effector	I
proteases	I
caspase-1	B
-like	O
(	O
IL-1	B
converting	I
enzyme	I
)	O
,	O
caspase-3	B
-like	O
(	O
CPP32	B
/	I
Yama	I
/	I
apopain	I
)	O
,	O
and	O
caspase-6	B
-like	O
and	O
without	O
cleavage	O
of	O
caspase-3	B
substrates	I
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	I
and	O
DNA	B
fragmentation	I
factor-45	I
.	O
These	O
findings	O
suggest	O
either	O
low	O
level	O
of	O
activation	O
is	O
required	O
or	O
that	O
different	O
caspases	B
are	O
involved	O
.	O
Preactivation	O
of	O
T	O
cells	O
resulting	O
in	O
NF	B
-	I
kappa	I
B	I
nuclear	O
translocation	O
protected	O
cells	O
from	O
SN50-induced	O
apoptosis	O
.	O
Our	O
findings	O
demonstrate	O
an	O
essential	O
role	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
survival	O
of	O
naive	O
PBL	O
.	O
Clonality	O
analysis	O
using	O
X	O
-	O
chromosome	O
inactivation	O
at	O
the	O
human	O
androgen	O
receptor	O
gene	O
(	O
Humara	O
)	O
.	O
Evaluation	O
of	O
large	O
cohorts	O
of	O
patients	O
with	O
chronic	O
myeloproliferative	O
diseases	O
,	O
secondary	O
neutrophilia	O
,	O
and	O
reactive	O
thrombocytosis	O
.	O
Chronic	O
myeloproliferative	O
diseases	O
(	O
MPDs	O
)	O
are	O
not	O
associated	O
with	O
consistent	O
cytogenetic	O
or	O
molecular	O
abnormalities	O
.	O
Demonstration	O
of	O
clonal	O
cell	O
growth	O
by	O
analysis	O
of	O
X	O
-	O
chromosome	O
inactivation	O
(	O
XCI	O
)	O
patterns	O
in	O
females	O
provides	O
a	O
promising	O
tool	O
for	O
diagnosis	O
.	O
However	O
,	O
this	O
technique	O
can	O
be	O
complicated	O
by	O
excessive	O
lyonization	O
of	O
normal	O
cells	O
mimicking	O
clonal	O
cell	O
growth	O
:	O
We	O
analyzed	O
XCI	O
patterns	O
at	O
the	O
human	O
androgen	O
receptor	O
(	O
HUMARA	O
)	O
locus	O
in	O
146	O
healthy	O
females	O
,	O
65	O
women	O
with	O
secondary	O
neutrophilia	O
,	O
31	O
women	O
with	O
reactive	O
thrombocytosis	O
,	O
and	O
86	O
women	O
with	O
chronic	O
MPDs	O
.	O
A	O
skewed	O
XCI	O
pattern	O
with	O
greater	O
than	O
75	O
%	O
amplification	O
of	O
1	O
allele	O
(	O
allele	O
ratio	O
>	O
3	O
:	O
1	O
)	O
was	O
found	O
in	O
22	O
(	O
9.1	O
%	O
)	O
of	O
242	O
control	O
subjects	O
.	O
The	O
incidence	O
of	O
skewing	O
was	O
statistically	O
significantly	O
lower	O
in	O
women	O
younger	O
than	O
30	O
years	O
(	O
2	O
/	O
73	O
)	O
compared	O
with	O
women	O
older	O
than	O
60	O
years	O
(	O
10	O
/	O
53	O
)	O
.	O
Of	O
86	O
patients	O
with	O
a	O
chronic	O
MPD	O
,	O
71	O
(	O
82	O
%	O
)	O
exhibited	O
an	O
allele	O
ratio	O
greater	O
than	O
3	O
:	O
1	O
,	O
whereas	O
only	O
10	O
(	O
12	O
%	O
)	O
of	O
86	O
age	O
-	O
matched	O
control	O
subjects	O
showed	O
a	O
skewed	O
XCI	O
pattern	O
.	O
Although	O
statistical	O
evaluation	O
of	O
the	O
data	O
showed	O
a	O
significant	O
difference	O
between	O
patients	O
with	O
a	O
chronic	O
MPD	O
and	O
control	O
subjects	O
,	O
proof	O
of	O
clonality	O
in	O
individual	O
,	O
especially	O
elderly	O
,	O
patients	O
is	O
difficult	O
.	O
The	O
glucocorticoid	B
receptor	I
cooperates	O
with	O
the	O
erythropoietin	B
receptor	I
and	O
c	B
-	I
Kit	I
to	O
enhance	O
and	O
sustain	O
proliferation	O
of	O
erythroid	O
progenitors	O
in	O
vitro	O
.	O
Although	O
erythropoietin	B
(	O
Epo	B
)	O
is	O
essential	O
for	O
the	O
production	O
of	O
mature	O
red	O
blood	O
cells	O
,	O
the	O
cooperation	O
with	O
other	O
factors	O
is	O
required	O
for	O
a	O
proper	O
balance	O
between	O
progenitor	O
proliferation	O
and	O
differentiation	O
.	O
In	O
avian	O
erythroid	O
progenitors	O
,	O
steroid	O
hormones	O
cooperate	O
with	O
tyrosine	B
kinase	I
receptors	I
to	O
induce	O
renewal	O
of	O
erythroid	O
progenitors	O
.	O
We	O
examined	O
the	O
role	O
of	O
corticosteroids	O
in	O
the	O
in	O
vitro	O
expansion	O
of	O
primary	O
human	O
erythroid	O
cells	O
in	O
liquid	O
cultures	O
and	O
colony	O
assays	O
.	O
Dexamethasone	O
(	O
Dex	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
hormone	O
,	O
cooperated	O
with	O
Epo	B
and	O
stem	B
cell	I
factor	I
to	O
induce	O
erythroid	O
progenitors	O
to	O
undergo	O
15	O
to	O
22	O
cell	O
divisions	O
,	O
corresponding	O
to	O
a	O
10	O
(	O
5	O
)	O
-	O
to	O
10	O
(	O
6	O
)	O
-fold	O
amplification	O
of	O
erythroid	O
cells	O
.	O
Dex	O
acted	O
directly	O
on	O
erythroid	O
progenitors	O
and	O
maintained	O
the	O
colony	O
-	O
forming	O
capacity	O
of	O
the	O
progenitor	O
cells	O
expanded	O
in	O
liquid	O
cultures	O
.	O
The	O
hormone	O
delayed	O
terminal	O
differentiation	O
into	O
erythrocytes	O
,	O
which	O
was	O
assayed	O
by	O
morphology	O
,	O
hemoglobin	B
accumulation	O
,	O
and	O
the	O
expression	O
of	O
genes	O
characteristic	O
for	O
immature	O
cells	O
.	O
Sustained	O
proliferation	O
of	O
erythroid	O
progenitors	O
could	O
be	O
induced	O
equally	O
well	O
from	O
purified	O
erythroid	O
burst	O
-	O
forming	O
units	O
(	O
BFU	O
-	O
E	O
)	O
,	O
from	O
CD34	O
(	O
+	O
)	O
blast	O
cells	O
,	O
and	O
from	O
bone	O
marrow	O
depleted	O
from	O
CD34	O
(	O
+	O
)	O
cells	O
.	O
Monoclonal	B
anti	I
-	I
endothelial	I
cell	I
antibodies	I
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
activate	O
endothelial	O
cells	O
from	O
large	O
vessels	O
.	O
OBJECTIVE	O
:	O
To	O
create	O
monoclonal	B
anti	I
-	I
endothelial	I
cell	I
antibodies	I
(	O
mAECA	B
)	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
to	O
evaluate	O
their	O
ability	O
to	O
activate	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
and	O
to	O
characterize	O
the	O
mechanism	O
of	O
EC	O
activation	O
.	O
METHODS	O
:	O
A	O
panel	O
of	O
mAECA	B
was	O
generated	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
,	O
using	O
Epstein	O
-	O
Barr	O
virus	O
transformation	O
.	O
Activity	O
against	O
macrovascular	O
EC	O
(	O
HUVEC	O
)	O
and	O
microvascular	O
EC	O
(	O
human	O
bone	O
marrow	O
EC	O
immortalized	O
by	O
SV40	O
)	O
antigens	O
was	O
detected	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O
Inhibition	O
studies	O
were	O
used	O
to	O
select	O
the	O
monoclonal	B
antibodies	I
(	O
mAECA	B
)	O
which	O
share	O
the	O
same	O
EC	O
epitope	O
binding	O
specificity	O
as	O
the	O
total	B
IgG	I
-	I
AECA	I
from	O
the	O
Takayasu	O
arteritis	O
patient	O
.	O
The	O
binding	O
of	O
the	O
mAECA	B
to	O
human	O
aortic	O
EC	O
was	O
studied	O
by	O
immunohistochemistry	O
.	O
The	O
secretion	O
levels	O
of	O
interleukin-6	B
(	O
IL-6	B
)	O
and	O
von	O
Willebrand	O
factor	O
(	O
vWF	O
)	O
were	O
determined	O
,	O
to	O
serve	O
as	O
markers	O
for	O
EC	O
activation	O
.	O
The	O
activated	O
EC	O
were	O
examined	O
for	O
the	O
adherence	O
of	O
a	O
monocytic	O
cell	O
line	O
(	O
U937	O
)	O
,	O
as	O
well	O
as	O
for	O
expression	O
of	O
vascular	B
cell	I
adhesion	I
molecule	I
1	I
,	O
intercellular	O
adhesion	O
molecule	O
1	O
,	O
and	O
E	B
-	I
selectin	I
.	O
In	O
addition	O
,	O
nuclear	O
extracts	O
of	O
the	O
mAECA	O
-	O
treated	O
EC	O
were	O
analyzed	O
for	O
the	O
induction	O
of	O
translocation	O
of	O
nuclear	B
factor	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
,	O
using	O
a	O
specific	O
NF	B
-	I
kappaB	I
oligoprobe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
RESULTS	O
:	O
Six	O
mAECA	B
were	O
selected	O
,	O
the	O
mixture	O
of	O
which	O
produced	O
100	O
%	O
inhibition	O
of	O
binding	O
of	O
the	O
original	O
IgG	B
(	O
from	O
the	O
patient	O
with	O
Takayasu	O
arteritis	O
)	O
to	O
HUVEC	O
.	O
All	O
mAECA	B
possessed	O
high	O
activity	O
against	O
macrovascular	O
EC	O
,	O
but	O
none	O
had	O
significant	O
antimicrovascular	O
EC	O
activity	O
.	O
The	O
mAECA	B
,	O
but	O
not	O
normal	B
human	I
IgG	I
,	O
had	O
anti	O
-	O
human	O
aortic	O
EC	O
activity	O
.	O
Four	O
of	O
the	O
6	O
mAECA	B
activated	O
EC	O
,	O
manifested	O
by	O
increased	O
IL-6	B
and	O
vWF	O
secretion	O
.	O
The	O
4	O
mAECA	B
induced	O
EC	O
expression	O
of	O
adhesion	B
molecules	I
and	O
increased	O
adhesion	O
of	O
U937	O
monocytic	O
cells	O
to	O
EC	O
.	O
In	O
addition	O
,	O
these	O
mAECA	B
stimulated	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF	B
-	I
kappaB	I
transcription	I
factor	I
.	O
CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
AECA	B
may	O
directly	O
stimulate	O
EC	O
in	O
Takayasu	O
arteritis	O
through	O
elevation	O
of	O
adhesion	B
molecule	I
expression	O
associated	O
with	O
NF	B
-	I
kappaB	I
activation	O
and	O
adhesion	O
of	O
monocytes	O
,	O
and	O
may	O
therefore	O
play	O
a	O
pathogenic	O
role	O
in	O
the	O
development	O
of	O
the	O
vasculopathy	O
in	O
Takayasu	O
arteritis	O
.	O
Clonality	O
analysis	O
of	O
granulocytes	O
and	O
T	O
lymphocytes	O
in	O
healthy	O
females	O
by	O
the	O
PCR	O
-	O
based	O
HUMARA	O
method	O
.	O
Clonality	O
analysis	O
utilizing	O
X	O
-	O
chromosome	O
inactivation	O
has	O
been	O
used	O
in	O
the	O
study	O
of	O
various	O
diseases	O
,	O
including	O
hematological	O
malignancies	O
.	O
The	O
human	O
androgen	O
receptor	O
gene	O
(	O
HUMARA	O
)	O
assay	O
is	O
the	O
newest	O
of	O
such	O
methods	O
,	O
and	O
the	O
majority	O
of	O
the	O
female	O
population	O
can	O
be	O
assessed	O
by	O
this	O
relatively	O
simple	O
procedure	O
.	O
One	O
problem	O
in	O
using	O
these	O
clonality	O
analysis	O
methods	O
,	O
however	O
,	O
is	O
that	O
there	O
may	O
be	O
significant	O
variation	O
in	O
Lyonization	O
in	O
blood	O
cells	O
in	O
normal	O
individuals	O
.	O
To	O
determine	O
the	O
diversity	O
in	O
X	O
-	O
chromosome	O
methylation	O
patterns	O
,	O
which	O
reflect	O
Lyonization	O
,	O
assessed	O
by	O
the	O
HUMARA	O
assay	O
in	O
the	O
supposedly	O
normal	O
population	O
,	O
we	O
analyzed	O
granulocytes	O
and	O
T	O
cells	O
from	O
97	O
relatively	O
young	O
(	O
18-	O
to	O
35-year	O
-	O
old	O
)	O
healthy	O
female	O
volunteers	O
.	O
We	O
found	O
that	O
the	O
methylation	O
patterns	O
in	O
the	O
two	O
HUMARA	O
alleles	O
were	O
distributed	O
even	O
more	O
widely	O
,	O
both	O
in	O
granuloctyes	O
and	O
in	O
T	O
cells	O
,	O
than	O
previously	O
reported	O
with	O
other	O
methods	O
.	O
We	O
also	O
found	O
that	O
the	O
deviation	O
of	O
methylation	O
in	O
granulocytes	O
and	O
T	O
cells	O
was	O
well	O
correlated	O
.	O
Thus	O
,	O
we	O
conclude	O
that	O
appropriate	O
controls	O
from	O
the	O
same	O
individuals	O
,	O
such	O
as	O
T	O
cells	O
in	O
the	O
case	O
of	O
stem	O
cell	O
disorders	O
,	O
should	O
always	O
be	O
employed	O
to	O
conclusively	O
determine	O
whether	O
certain	O
cells	O
of	O
hematopoietic	O
origin	O
are	O
clonal	O
.	O
Regulatory	O
effects	O
of	O
interleukin-11	B
during	O
acute	O
lung	O
inflammatory	O
injury	O
.	O
The	O
role	O
of	O
interleukin-11	B
(	O
IL-11	B
)	O
was	O
evaluated	O
in	O
the	O
IgG	B
immune	I
complex	I
model	O
of	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O
IL-11	O
mRNA	O
and	O
protein	O
were	O
both	O
up	O
-	O
regulated	O
during	O
the	O
course	O
of	O
this	O
inflammatory	O
response	O
.	O
Exogenously	O
administered	O
IL-11	B
substantially	O
reduced	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
the	O
intrapulmonary	O
accumulation	O
of	O
neutrophils	O
and	O
the	O
lung	O
vascular	O
leak	O
of	O
albumin	B
.	O
These	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
effects	O
of	O
IL-11	B
were	O
associated	O
with	O
reduced	O
NF	B
-	I
kappaB	I
activation	O
in	O
lung	O
,	O
reduced	O
levels	O
of	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
and	O
diminished	O
up	O
-	O
regulation	O
of	O
lung	B
vascular	I
ICAM-1	I
.	O
It	O
is	O
interesting	O
that	O
IL-11	B
did	O
not	O
affect	O
BAL	O
fluid	O
content	O
of	O
the	O
CXC	B
chemokines	I
,	O
macrophage	B
inflammatory	I
protein-2	I
(	O
MIP-2	B
)	O
and	O
cytokine	B
-	I
inducible	I
neutrophil	I
chemoattractant	I
(	O
CINC	B
)	O
;	O
the	O
presence	O
of	O
IL-11	B
did	O
not	O
affect	O
these	O
chemokines	B
.	O
However	O
,	O
BAL	O
content	O
of	O
C5a	O
was	O
reduced	O
by	O
IL-11	B
.	O
These	O
data	O
indicate	O
that	O
IL-11	B
is	O
a	O
regulatory	B
cytokine	I
in	O
the	O
lung	O
and	O
that	O
,	O
like	O
other	O
members	O
of	O
this	O
family	O
,	O
its	O
anti	O
-	O
inflammatory	O
properties	O
appear	O
to	O
be	O
linked	O
to	O
its	O
suppression	O
of	O
NF	B
-	I
kappaB	I
activation	O
,	O
diminished	O
production	O
of	O
TNF	B
-	I
alpha	I
,	O
and	O
reduced	O
up	O
-	O
regulation	O
of	O
lung	B
vascular	I
ICAM-1	I
.	O
The	O
Epstein	B
-	I
Barr	I
virus	I
oncoprotein	I
latent	I
membrane	I
protein	I
1	I
engages	O
the	O
tumor	B
necrosis	I
factor	I
receptor	I
-	I
associated	I
proteins	I
TRADD	B
and	O
receptor	B
-	I
interacting	I
protein	I
(	O
RIP	B
)	O
but	O
does	O
not	O
induce	O
apoptosis	O
or	O
require	O
RIP	B
for	O
NF	B
-	I
kappaB	I
activation	O
.	O
A	O
site	O
in	O
the	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
transforming	I
protein	I
LMP1	B
that	O
constitutively	O
associates	O
with	O
the	O
tumor	B
necrosis	I
factor	I
receptor	I
1	I
(	I
TNFR1	I
)	I
-associated	I
death	I
domain	I
protein	I
TRADD	B
to	O
mediate	O
NF	B
-	I
kappaB	I
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
activation	O
is	O
critical	O
for	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
proliferation	O
.	O
We	O
now	O
find	O
that	O
LMP1	B
signaling	O
through	O
TRADD	B
differs	O
from	O
TNFR1	B
signaling	O
through	O
TRADD	B
.	O
LMP1	B
needs	O
only	O
11	O
amino	O
acids	O
to	O
activate	O
NF	B
-	I
kappaB	I
or	O
synergize	O
with	O
TRADD	B
in	O
NF	B
-	I
kappaB	I
activation	O
,	O
while	O
TNFR1	B
requires	O
approximately	O
70	O
residues	O
.	O
Further	O
,	O
LMP1	B
does	O
not	O
require	O
TRADD	B
residues	O
294	O
to	O
312	O
for	O
NF	B
-	I
kappaB	I
activation	O
,	O
while	O
TNFR1	B
requires	O
TRADD	B
residues	O
296	O
to	O
302	O
.	O
LMP1	B
is	O
partially	O
blocked	O
for	O
NF	B
-	I
kappaB	I
activation	O
by	O
a	O
TRADD	B
mutant	O
consisting	O
of	O
residues	B
122	I
to	I
293	I
.	O
Unlike	O
TNFR1	B
,	O
LMP1	B
can	O
interact	O
directly	O
with	O
receptor	B
-	I
interacting	I
protein	I
(	O
RIP	B
)	O
and	O
stably	O
associates	O
with	O
RIP	B
in	O
EBV	O
-	O
transformed	O
lymphoblastoid	O
cell	O
lines	O
.	O
Surprisingly	O
,	O
LMP1	B
does	O
not	O
require	O
RIP	B
for	O
NF	B
-	I
kappaB	I
activation	O
.	O
Despite	O
constitutive	O
association	O
with	O
TRADD	B
or	O
RIP	B
,	O
LMP1	B
does	O
not	O
induce	O
apoptosis	O
in	O
EBV	O
-	O
negative	O
Burkitt	O
lymphoma	O
or	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O
These	O
results	O
add	O
a	O
different	O
perspective	O
to	O
the	O
molecular	O
interactions	O
through	O
which	O
LMP1	B
,	O
TRADD	B
,	O
and	O
RIP	B
participate	O
in	O
B	O
-	O
lymphocyte	O
activation	O
and	O
growth	O
.	O
Possible	O
differences	O
in	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
different	O
glucocorticoid	O
hormone	O
compounds	O
.	O
Different	O
glucocorticoid	O
hormones	O
(	O
GCH	O
)	O
show	O
differences	O
in	O
the	O
intensity	O
and	O
in	O
the	O
kinetics	O
of	O
their	O
immunomodulating	O
activity	O
.	O
The	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
GCH	O
is	O
under	O
investigation	O
,	O
but	O
is	O
has	O
been	O
noted	O
that	O
they	O
exert	O
immune	O
activity	O
via	O
the	O
genomic	O
pathway	O
.	O
We	O
have	O
studied	O
the	O
effects	O
of	O
prednisone	O
(	O
PDN	O
)	O
,	O
deflazacort	O
(	O
DFC	O
)	O
,	O
and	O
dexamethasone	O
(	O
DXM	O
)	O
on	O
the	O
production	O
of	O
cytokines	B
(	O
IL-2	B
,	O
IL-6	B
,	O
TNF	B
-	I
alpha	I
,	O
IL-10	B
)	O
by	O
peripheral	O
T	O
lymphocytes	O
,	O
and	O
the	O
effects	O
on	O
the	O
inhibition	O
of	O
NF	B
-	I
kB	I
DNA	O
binding	O
activity	O
by	O
activated	O
Jurkat	O
cell	O
line	O
.	O
The	O
data	O
obtained	O
show	O
that	O
the	O
three	O
GCH	O
molecules	O
exert	O
an	O
immunosuppression	O
on	O
cytokine	B
production	O
by	O
T	O
lymphocytes	O
and	O
a	O
strong	O
decrease	O
in	O
the	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kB	I
in	O
Jurkat	O
cells	O
;	O
moreover	O
,	O
(	O
a	O
)	O
not	O
all	O
the	O
cytokines	B
investigated	O
were	O
affected	O
,	O
and	O
not	O
with	O
the	O
same	O
intensity	O
,	O
by	O
the	O
three	O
GCH	O
and	O
(	O
b	O
)	O
DXM	O
inhibited	O
the	O
binding	O
activity	O
of	O
NF	B
-	I
kB	I
less	O
than	O
that	O
of	O
DFC	O
and	O
PDN	O
.	O
These	O
data	O
are	O
in	O
agreement	O
with	O
the	O
concept	O
that	O
different	O
GCH	O
compounds	O
might	O
differ	O
in	O
their	O
binding	O
and	O
affinity	O
properties	O
,	O
tissue	O
-	O
specific	O
metabolism	O
,	O
and	O
interaction	O
with	O
transcription	B
factor	I
.	O
Extracellular	O
signal	O
-	O
regulated	O
protein	O
kinase	O
(	O
ERK	O
)	O
-dependent	O
and	O
ERK	O
-	O
independent	O
pathways	O
target	O
STAT3	B
on	O
serine-727	O
in	O
human	O
neutrophils	O
stimulated	O
by	O
chemotactic	B
factors	I
and	O
cytokines	B
.	O
STAT3	B
(	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
3	I
)	O
is	O
a	O
latent	O
transcription	O
factor	O
that	O
is	O
activated	O
by	O
tyrosine	O
phosphorylation	O
(	O
Tyr-705	O
)	O
in	O
cells	O
stimulated	O
with	O
cytokines	B
or	O
growth	B
factors	I
.	O
Recent	O
studies	O
suggest	O
that	O
one	O
or	O
more	O
cytoplasmic	B
serine	I
kinases	I
also	O
phosphorylate	O
STAT3	B
and	O
are	O
necessary	O
for	O
maximal	O
gene	O
activation	O
.	O
Here	O
we	O
demonstrate	O
,	O
with	O
a	O
site	O
-	O
specific	O
antibody	O
,	O
that	O
STAT3	B
is	O
phosphorylated	O
on	O
Ser-727	O
in	O
human	O
neutrophils	O
stimulated	O
with	O
chemotactic	B
factors	I
(	O
N	O
-	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
and	O
complement	O
C5a	O
)	O
,	O
cytokines	B
[	O
granulocyte	B
/	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
and	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
(	O
G	B
-	I
CSF	I
)	O
]	O
,	O
or	O
a	O
protein	B
kinase	I
C	I
activator	O
(	O
PMA	O
)	O
.	O
(	O
2-Amino-3'-methoxyphenyl	O
)	O
oxanaphthalen-4-one	O
(	O
PD	O
98059	O
)	O
,	O
an	O
inhibitor	O
of	O
extracellular	O
signal	B
-	I
regulated	I
protein	I
kinase	I
(	O
ERK	B
)	O
activation	O
,	O
blocked	O
the	O
serine	O
phosphorylation	O
of	O
STAT3	B
induced	O
by	O
chemotactic	B
factors	I
or	O
PMA	O
.	O
The	O
drug	O
was	O
less	O
effective	O
on	O
cytokines	B
:	O
it	O
virtually	O
abolished	O
the	O
response	O
to	O
GM	B
-	I
CSF	I
that	O
occurred	O
5	O
min	O
after	O
stimulation	O
but	O
only	O
partly	O
decreased	O
those	O
at	O
15	O
-	O
30	O
min	O
and	O
did	O
not	O
appreciably	O
alter	O
responses	O
to	O
G	B
-	I
CSF	I
regardless	O
of	O
incubation	O
time	O
.	O
1-	O
(	O
5-Isoquinolinylsulphonyl	O
)	O
-2-methylpiperazine	O
dihydrochloride	O
(	O
H7	O
)	O
,	O
an	O
inhibitor	O
of	O
a	O
putative	O
STAT3	B
serine	I
kinase	I
,	O
and	O
4-	O
(	O
4-fluorophenyl	O
)	O
-2-	O
(	O
4-methylsulphinylphenyl	O
)	O
-5-	O
(	O
4-pyridyl	O
)	O
1H	O
-	O
imidazole	O
(	O
SB	O
203580	O
)	O
,	O
an	O
inhibitor	O
of	O
p38	B
mitogen	I
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinase	I
,	O
did	O
not	O
dampen	O
any	O
of	O
these	O
serine	O
phosphorylation	O
responses	O
.	O
We	O
propose	O
that	O
neutrophils	O
use	O
both	O
ERK	O
-	O
dependent	O
and	O
ERK	O
-	O
independent	O
pathways	O
to	O
phosphorylate	O
Ser-727	O
on	O
STAT3	B
.	O
The	O
former	O
pathway	O
is	O
recruited	O
by	O
all	O
ERK	B
-activating	O
stimuli	O
,	O
whereas	O
the	O
latter	O
pathway	O
uses	O
an	O
undefined	O
serine	B
kinase	I
and	O
is	O
recruited	O
selectively	O
by	O
cytokines	B
.	O
Activation	O
of	O
STAT5	B
by	O
IL-4	B
relies	O
on	O
Janus	B
kinase	I
function	O
but	O
not	O
on	O
receptor	O
tyrosine	O
phosphorylation	O
,	O
and	O
can	O
contribute	O
to	O
both	O
cell	O
proliferation	O
and	O
gene	O
regulation	O
.	O
We	O
have	O
investigated	O
mechanisms	O
and	O
consequences	O
of	O
STAT5	B
activation	O
through	O
the	O
human	B
IL-4	I
receptor	I
(	O
IL-4R	B
)	O
.	O
By	O
functionally	O
expressing	O
receptor	B
mutants	I
in	O
the	O
murine	O
pro	O
-	O
B	O
cell	O
line	O
Ba	O
/	O
F3	O
,	O
we	O
could	O
show	O
that	O
phosphorylated	O
tyrosine	O
residues	O
within	O
the	O
IL-4R	B
alpha	I
chain	I
are	O
dispensable	O
for	O
IL-4	B
-induced	O
STAT5	B
activity	O
.	O
However	O
,	O
disruption	O
of	O
a	O
membrane	B
-	I
proximal	I
proline	I
-	I
rich	I
sequence	I
motif	I
(	O
'	O
box1	B
'	O
)	O
in	O
either	O
subunit	O
of	O
the	O
bipartite	B
IL-4R	I
abolished	O
not	O
only	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Janus	B
kinases	I
JAK1	B
and	O
JAK3	B
,	O
but	O
also	O
IL-4	B
-triggered	O
activation	O
of	O
STAT5	B
and	O
concomitant	O
cell	O
proliferation	O
.	O
A	O
dominant	B
-	I
negative	I
version	I
of	O
STAT5b	B
,	O
but	O
not	O
of	O
STAT5a	B
,	O
interfered	O
with	O
IL-4	B
-induced	O
DNA	O
synthesis	O
in	O
Ba	O
/	O
F3	O
cells	O
,	O
suggesting	O
an	O
involvement	O
of	O
STAT5b	B
in	O
the	O
control	O
of	O
cell	O
proliferation	O
through	O
IL-4R	B
.	O
Reporter	O
gene	O
experiments	O
finally	O
showed	O
that	O
transcription	O
from	O
promoters	O
of	O
STAT5	B
target	O
genes	O
can	O
be	O
specifically	O
induced	O
by	O
challenging	O
cells	O
with	O
IL-4	B
,	O
and	O
that	O
both	O
STAT5a	B
and	O
STAT5b	B
can	O
contribute	O
to	O
IL-4	B
-triggered	O
transcriptional	O
control	O
.	O
MHC	O
-	O
peptide	O
ligand	O
interactions	O
establish	O
a	O
functional	O
threshold	O
for	O
antigen	O
-	O
specific	O
T	O
cell	O
recognition	O
.	O
Antigen	O
-	O
specific	O
T	O
cell	O
recognition	O
is	O
dependent	O
on	O
the	O
functional	O
density	O
of	O
the	O
TCR	B
-ligand	O
,	O
which	O
consists	O
of	O
specific	O
MHC	B
molecules	I
and	O
a	O
specifically	O
bound	O
peptide	O
.	O
We	O
have	O
examined	O
the	O
influence	O
of	O
the	O
affinity	O
and	O
concentration	O
of	O
exogenous	O
peptide	O
and	O
the	O
density	O
of	O
specific	O
MHC	B
molecules	I
on	O
the	O
proliferation	O
of	O
a	O
CD4	O
+	O
,	O
DQA1	O
*	O
0501	O
/	O
DQB1	O
*	O
0201	O
(	O
DQ2.1	O
)	O
-restricted	O
,	O
HSV-2-specific	O
T	O
cell	O
clone	O
.	O
Using	O
antigen	O
peptide	O
analogs	O
with	O
different	O
mutations	O
of	O
known	O
DQ2-anchor	O
residues	O
,	O
T	O
cell	O
response	O
was	O
reduced	O
in	O
an	O
peptide	O
-	O
affinity	O
and	O
-	O
concentration	O
specific	O
manner	O
.	O
The	O
decrease	O
using	O
weaker	O
binding	O
peptides	O
was	O
gradual	O
as	O
stimulation	O
with	O
a	O
peptide	O
with	O
intermediate	O
affinity	O
yielded	O
intermediate	O
T	O
cell	O
proliferation	O
and	O
the	O
poorest	O
binding	O
peptide	O
induced	O
an	O
even	O
weaker	O
T	O
cell	O
response	O
.	O
MHC	B
class	I
II	I
density	O
on	O
the	O
APC	O
was	O
modified	O
using	O
DQ2	O
homo	O
-and	O
heterozygous	O
B	O
-	O
LCLs	O
as	O
APCs	O
,	O
however	O
this	O
variation	O
of	O
MHC	O
concentration	O
had	O
no	O
effect	O
on	O
T	O
cell	O
proliferation	O
.	O
We	O
interpret	O
this	O
as	O
a	O
reflection	O
of	O
a	O
low	O
threshold	O
for	O
activation	O
of	O
the	O
T	O
cell	O
clone	O
,	O
in	O
which	O
peptide-	O
MHC	B
avidity	O
is	O
the	O
over	O
-	O
riding	O
determinant	O
of	O
the	O
strength	O
of	O
ligand	O
signal	O
.	O
PPARgamma	B
activation	O
induces	O
the	O
expression	O
of	O
the	O
adipocyte	O
fatty	O
acid	O
binding	O
protein	O
gene	O
in	O
human	O
monocytes	O
.	O
The	O
peroxisome	B
-	I
proliferator	I
activated	I
receptor	I
gamma	I
(	O
PPARgamma	B
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	B
receptor	I
superfamily	I
of	O
ligand	B
activated	I
transcription	I
factors	I
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
anti	O
-	O
diabetic	O
actions	O
of	O
the	O
thiazolidinediones	O
(	O
TZDs	O
)	O
.	O
PPARgamma	B
induces	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
lipid	O
anabolism	O
,	O
including	O
the	O
adipocyte	B
fatty	I
acid	I
binding	I
protein	I
(	O
aP2	B
)	O
,	O
and	O
is	O
a	O
key	O
regulator	O
of	O
adipocyte	O
differentiation	O
.	O
PPARgamma	B
is	O
also	O
expressed	O
in	O
hematopoietic	O
cells	O
and	O
is	O
up	O
-	O
regulated	O
in	O
activated	O
monocytes	O
/	O
macrophages	O
.	O
Activation	O
of	O
PPARgamma	B
may	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
differentiation	O
of	O
macrophages	O
to	O
foam	O
cells	O
that	O
are	O
associated	O
with	O
atherosclerotic	O
lesions	O
.	O
We	O
report	O
that	O
both	O
natural	O
and	O
synthetic	O
PPARgamma	O
agonists	O
induce	O
time-	O
and	O
dose	O
-	O
dependent	O
increases	O
in	O
aP2	O
mRNA	O
in	O
both	O
primary	O
human	O
monocytes	O
and	O
the	O
monocytic	O
cell	O
line	O
,	O
THP-1	O
.	O
These	O
data	O
suggest	O
that	O
PPARgamma	B
activation	O
may	O
play	O
a	O
role	O
in	O
monocyte	O
differentiation	O
and	O
function	O
analogous	O
to	O
its	O
well	O
-	O
characterized	O
role	O
in	O
adipocytes	O
.	O
Host	O
defense	O
mechanisms	O
triggered	O
by	O
microbial	B
lipoproteins	I
through	O
toll	B
-	I
like	I
receptors	I
.	O
The	O
generation	O
of	O
cell	O
-	O
mediated	O
immunity	O
against	O
many	O
infectious	O
pathogens	O
involves	O
the	O
production	O
of	O
interleukin-12	B
(	O
IL-12	B
)	O
,	O
a	O
key	O
signal	O
of	O
the	O
innate	O
immune	O
system	O
.	O
Yet	O
,	O
for	O
many	O
pathogens	O
,	O
the	O
molecules	O
that	O
induce	O
IL-12	B
production	O
by	O
macrophages	O
and	O
the	O
mechanisms	O
by	O
which	O
they	O
do	O
so	O
remain	O
undefined	O
.	O
Here	O
it	O
is	O
shown	O
that	O
microbial	B
lipoproteins	I
are	O
potent	O
stimulators	O
of	O
IL-12	B
production	O
by	O
human	O
macrophages	O
,	O
and	O
that	O
induction	O
is	O
mediated	O
by	O
Toll	B
-	I
like	I
receptors	I
(	O
TLRs	B
)	O
.	O
Several	O
lipoproteins	O
stimulated	O
TLR	O
-	O
dependent	O
transcription	O
of	O
inducible	O
nitric	B
oxide	I
synthase	I
and	O
the	O
production	O
of	O
nitric	O
oxide	O
,	O
a	O
powerful	O
microbicidal	O
pathway	O
.	O
Activation	O
of	O
TLRs	B
by	O
microbial	B
lipoproteins	I
may	O
initiate	O
innate	O
defense	O
mechanisms	O
against	O
infectious	O
pathogens	O
.	O
Distinctive	O
gene	O
expression	O
patterns	O
in	O
human	O
mammary	O
epithelial	O
cells	O
and	O
breast	O
cancers	O
.	O
cDNA	O
microarrays	O
and	O
a	O
clustering	O
algorithm	O
were	O
used	O
to	O
identify	O
patterns	O
of	O
gene	O
expression	O
in	O
human	O
mammary	O
epithelial	O
cells	O
growing	O
in	O
culture	O
and	O
in	O
primary	O
human	O
breast	O
tumors	O
.	O
Clusters	O
of	O
coexpressed	O
genes	O
identified	O
through	O
manipulations	O
of	O
mammary	O
epithelial	O
cells	O
in	O
vitro	O
also	O
showed	O
consistent	O
patterns	O
of	O
variation	O
in	O
expression	O
among	O
breast	O
tumor	O
samples	O
.	O
By	O
using	O
immunohistochemistry	O
with	O
antibodies	O
against	O
proteins	O
encoded	O
by	O
a	O
particular	O
gene	O
in	O
a	O
cluster	O
,	O
the	O
identity	O
of	O
the	O
cell	O
type	O
within	O
the	O
tumor	O
specimen	O
that	O
contributed	O
the	O
observed	O
gene	O
expression	O
pattern	O
could	O
be	O
determined	O
.	O
Clusters	O
of	O
genes	O
with	O
coherent	O
expression	O
patterns	O
in	O
cultured	O
cells	O
and	O
in	O
the	O
breast	O
tumors	O
samples	O
could	O
be	O
related	O
to	O
specific	O
features	O
of	O
biological	O
variation	O
among	O
the	O
samples	O
.	O
Two	O
such	O
clusters	O
were	O
found	O
to	O
have	O
patterns	O
that	O
correlated	O
with	O
variation	O
in	O
cell	O
proliferation	O
rates	O
and	O
with	O
activation	O
of	O
the	O
IFN	B
-regulated	O
signal	O
transduction	O
pathway	O
,	O
respectively	O
.	O
Clusters	O
of	O
genes	O
expressed	O
by	O
stromal	O
cells	O
and	O
lymphocytes	O
in	O
the	O
breast	O
tumors	O
also	O
were	O
identified	O
in	O
this	O
analysis	O
.	O
These	O
results	O
support	O
the	O
feasibility	O
and	O
usefulness	O
of	O
this	O
systematic	O
approach	O
to	O
studying	O
variation	O
in	O
gene	O
expression	O
patterns	O
in	O
human	O
cancers	O
as	O
a	O
means	O
to	O
dissect	O
and	O
classify	O
solid	O
tumors	O
.	O
Cutting	O
edge	O
:	O
TCR	B
stimulation	O
by	O
antibody	O
and	O
bacterial	O
superantigen	O
induces	O
Stat3	B
activation	O
in	O
human	O
T	O
cells	O
.	O
Recent	O
data	O
show	O
that	O
TCR	B
/	I
CD3	I
stimulation	O
induces	O
activation	O
of	O
Stat5	B
in	O
murine	O
T	O
cells	O
.	O
Here	O
,	O
we	O
show	O
that	O
CD3	O
ligation	O
by	O
mAb	O
and	O
Staphylococcal	O
enterotoxin	O
(	O
SE	O
)	O
induce	O
a	O
rapid	O
,	O
gradually	O
accumulating	O
,	O
long	O
-	O
lasting	O
tyrosine	O
,	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B
(	O
but	O
not	O
Stat5	B
)	O
in	O
allogen	O
-	O
specific	O
human	O
CD4	O
+	O
T	O
cell	O
lines	O
.	O
In	O
contrast	O
,	O
IL-2	B
induces	O
a	O
rapid	O
and	O
transient	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B
.	O
Compared	O
with	O
IL-2	B
,	O
CD3	B
ligation	O
induces	O
a	O
delayed	O
Stat3	B
binding	O
to	O
oligonucleotide	O
probes	O
from	O
the	O
ICAM-1	B
and	O
IL-2R	O
alpha	O
promoter	O
.	O
CD3	B
-mediated	O
activation	O
of	O
Stat3	B
is	O
almost	O
completely	O
inhibited	O
by	O
a	O
Src	B
kinase	I
inhibitor	I
(	O
PP1	B
)	O
,	O
whereas	O
IL-2	B
-induced	O
Stat3	B
activation	O
is	O
unaffected	O
.	O
In	O
conclusion	O
,	O
we	O
show	O
that	O
CD3	B
ligation	O
by	O
mAb	B
and	O
SE	O
triggers	O
a	O
rapid	O
,	O
PP1	B
-sensitive	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B
in	O
human	O
CD4	O
+	O
T	O
cells	O
.	O
Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
TCR	B
/	I
CD3	I
and	O
IL-2	B
induce	O
Stat3	B
activation	O
via	O
distinct	O
signaling	O
pathways	O
.	O
[	O
Hormonal	O
metabolic	O
status	O
in	O
breast	O
cancer	O
patients	O
after	O
conservative	O
surgery	O
:	O
comparison	O
with	O
known	O
prognostic	O
criteria	O
]	O
Body	O
weight	O
,	O
body	O
mass	O
index	O
,	O
body	O
fat	O
,	O
lean	O
body	O
mass	O
,	O
blood	O
-	O
glucose	O
,	O
cholesterol	O
,	O
HDL	B
-	I
cholesterol	I
,	O
triglyceride	O
,	O
beta	B
-	I
lipoproteins	I
,	O
insulin	O
,	O
gonadotropin	O
,	O
estradiol	O
,	O
testosterone	O
,	O
SHBG	B
,	O
T3	B
,	O
T4	B
and	O
TSH	O
levels	O
as	O
well	O
as	O
estradiol	O
and	O
progesterone	O
receptor	O
levels	O
in	O
excised	O
tumor	O
were	O
studied	O
in	O
40	O
patients	O
with	O
breast	O
cancer	O
prior	O
to	O
conservative	O
treatment	O
.	O
Said	O
anthropometric	O
,	O
metabolic	O
and	O
hormonal	O
parameters	O
were	O
compared	O
with	O
the	O
index	O
of	O
lymphocytic	O
infiltration	O
of	O
tumor	O
selected	O
as	O
a	O
prognostic	O
factor	O
.	O
A	O
significant	O
correlation	O
between	O
high	O
lymphocytic	O
infiltration	O
(	O
2.5	O
points	O
)	O
,	O
low	O
body	O
mass	O
and	O
fat	O
was	O
identified	O
.	O
Also	O
,	O
smoking	O
contributed	O
to	O
loss	O
of	O
body	O
mass	O
and	O
fat	O
;	O
however	O
,	O
it	O
caused	O
lymphocytic	O
infiltration	O
to	O
rise	O
.	O
Moderate	O
body	O
mass	O
,	O
relatively	O
low	O
fat	O
level	O
and	O
positive	O
receptor	O
status	O
are	O
among	O
factors	O
of	O
good	O
prognosis	O
in	O
breast	O
cancer	O
of	O
early	O
stages	O
.	O
Myb	O
-	O
transformed	O
hematopoietic	O
cells	O
as	O
a	O
model	O
for	O
monocyte	O
differentiation	O
into	O
dendritic	O
cells	O
and	O
macrophages	O
.	O
Immune	O
induction	O
is	O
effected	O
through	O
the	O
interaction	O
of	O
antigen	O
-	O
presenting	O
cells	O
with	O
specific	O
receptors	B
on	O
the	O
surface	O
of	O
thymus	O
-	O
derived	O
lymphocytes	O
.	O
Cells	O
most	O
able	O
to	O
ingest	O
,	O
process	O
,	O
and	O
present	O
antigen	O
appear	O
to	O
be	O
related	O
to	O
the	O
mononuclear	O
phagocyte	O
/	O
neutrophil	O
series	O
.	O
For	O
example	O
dendritic	O
cells	O
(	O
DC	O
)	O
can	O
be	O
found	O
in	O
colonies	O
of	O
GM	O
-	O
CSF	O
-	O
responsive	O
bone	O
marrow	O
cells	O
,	O
and	O
under	O
experimental	O
conditions	O
are	O
routinely	O
expanded	O
as	O
a	O
population	O
in	O
vitro	O
from	O
GM	O
-	O
CSF	O
-	O
responsive	O
progenitor	O
cells	O
.	O
To	O
address	O
the	O
question	O
of	O
DC	O
lineage	O
and	O
to	O
determine	O
what	O
genes	O
are	O
involved	O
in	O
lineage	O
commitment	O
,	O
we	O
have	O
generated	O
a	O
series	O
of	O
GM	O
-	O
CSF	O
-	O
responsive	O
cell	O
lines	O
that	O
can	O
be	O
induced	O
to	O
differentiate	O
in	O
a	O
homogeneous	O
manner	O
in	O
vitro	O
.	O
The	O
cloned	O
cell	O
lines	O
are	O
derived	O
from	O
12-day	O
fetal	O
liver	O
and	O
are	O
transformed	O
with	O
a	O
truncated	O
form	O
of	O
c	O
-	O
myb	O
,	O
which	O
lacks	O
the	O
normal	O
autoregulatory	O
sequences	O
.	O
As	O
far	O
as	O
we	O
know	O
,	O
these	O
myb	O
-	O
transformed	O
hemopoi	O
-	O
etic	O
cells	O
(	O
MTHC	O
)	O
differ	O
from	O
normal	O
only	O
in	O
the	O
unregulated	O
expression	O
of	O
myb	O
,	O
a	O
gene	O
whose	O
expression	O
is	O
obligatory	O
for	O
proliferation	O
of	O
hemopoietic	O
cells	O
.	O
MTHC	O
in	O
the	O
presence	O
of	O
TNF	B
-	I
alpha	I
and	O
IL-4	B
will	O
differentiate	O
into	O
cells	O
that	O
have	O
many	O
of	O
the	O
properties	O
of	O
macrophages	O
.	O
When	O
the	O
same	O
MTHC	O
lines	O
are	O
exposed	O
to	O
TNF	B
-	I
alpha	I
in	O
combination	O
with	O
IFN	B
-	I
gamma	I
,	O
the	O
cells	O
instead	O
become	O
DC	O
.	O
The	O
differentiated	O
DC	O
are	O
potent	O
presenters	O
of	O
antigen	O
in	O
mixed	O
lymphocyte	O
reactions	O
and	O
of	O
soluble	O
antigen	O
to	O
specific	O
T	O
cell	O
lines	O
.	O
Thus	O
,	O
cells	O
with	O
the	O
properties	O
of	O
both	O
macrophages	O
and	O
DC	O
can	O
be	O
derived	O
from	O
a	O
single	O
type	O
of	O
GM	O
-	O
CSF	O
-	O
responsive	O
progenitor	O
cell	O
.	O
We	O
have	O
used	O
this	O
MTHC	O
system	O
to	O
analyze	O
differences	O
in	O
gene	O
expression	O
as	O
the	O
cells	O
mature	O
along	O
the	O
DC	O
and	O
macrophage	O
pathways	O
.	O
A	O
distinctive	O
pattern	O
of	O
differentially	O
expressed	O
cDNAs	O
is	O
evident	O
where	O
macrophage	O
-	O
specific	O
cDNAs	O
are	O
homologous	O
to	O
genes	O
encoding	O
cytoskeletal	B
and	I
cell	I
-	I
surface	I
proteins	I
,	O
whereas	O
the	O
DC	O
-specific	O
cDNAs	O
are	O
homologous	O
to	O
signaling	O
,	O
chemokine	O
,	O
and	O
IFN	O
-	O
gamma	O
-	O
inducible	O
genes	O
.	O
We	O
discuss	O
the	O
utility	O
of	O
MTHC	O
in	O
analyzing	O
the	O
relationships	O
between	O
DC	O
and	O
macrophages	O
,	O
and	O
suggest	O
that	O
DC	O
and	O
macrophages	O
represent	O
extreme	O
phenotypes	O
in	O
a	O
spectrum	O
of	O
antigen	O
handling	O
cells	O
that	O
are	O
somewhat	O
interchangeable	O
,	O
depending	O
on	O
their	O
immediate	O
environment	O
.	O
Differential	O
effects	O
of	O
lipopolysaccharide	O
and	O
tumor	B
necrosis	I
factor	I
on	O
monocytic	B
IkappaB	I
kinase	I
signalsome	O
activation	O
and	O
IkappaB	B
proteolysis	O
.	O
The	O
inflammatory	O
mediators	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
are	O
potent	O
activators	O
of	O
NF	B
-	I
kappaB	I
.	O
This	O
study	O
compared	O
the	O
effect	O
of	O
these	O
stimuli	O
on	O
endogenous	O
IkappaB	B
kinase	I
(	O
IKK	B
)	O
signalsome	O
activation	O
and	O
IkappaB	B
phosphorylation	O
/	O
proteolysis	O
in	O
human	O
monocytic	O
cells	O
and	O
investigated	O
the	O
role	O
of	O
the	O
signalsome	B
proteins	I
IKK	B
-	I
alpha	I
,	O
IKK	B
-	I
beta	I
,	O
NF	B
-	I
kappaB	I
-	I
inducing	I
kinase	I
(	O
NIK	B
)	O
,	O
IKK	B
-	I
gamma	I
(	O
NF	B
-	I
kappaB	I
essential	O
modulator	O
)	O
,	O
and	O
IKK	B
complex	I
-	I
associated	I
protein	I
.	O
Kinase	O
assays	O
showed	O
that	O
TNF	B
elicited	O
a	O
rapid	O
but	O
short	O
-	O
lived	O
induction	O
of	O
IKK	B
activity	O
with	O
a	O
3-fold	O
greater	O
effect	O
on	O
IKK	B
-	I
alpha	I
than	O
on	O
IKK	B
-	I
beta	I
,	O
peaking	O
at	O
5	O
min	O
.	O
In	O
contrast	O
,	O
LPS	O
predominantly	O
stimulated	O
IKK	B
-	I
beta	I
activity	O
,	O
which	O
slowly	O
increased	O
,	O
peaking	O
at	O
30	O
min	O
.	O
A	O
second	O
peak	O
was	O
observed	O
at	O
a	O
later	O
time	O
point	O
following	O
LPS	O
stimulation	O
,	O
which	O
consisted	O
of	O
both	O
IKK	O
-	O
alpha	O
and	O
-beta	O
activity	O
.	O
The	O
endogenous	O
levels	O
of	O
the	O
signalsome	O
components	O
were	O
unaffected	O
by	O
stimulation	O
.	O
Furthermore	O
,	O
our	O
studies	O
showed	O
association	O
of	O
the	O
IKK	B
-	I
alpha	I
/	I
beta	I
heterodimer	I
with	O
NIK	B
,	O
IkappaB	B
-	I
alpha	I
and	O
-epsilon	B
in	O
unstimulated	O
cells	O
.	O
Exposure	O
to	O
LPS	O
or	O
TNF	B
led	O
to	O
differential	O
patterns	O
of	O
IkappaB	B
-	I
alpha	I
and	O
IkappaB	B
-	I
epsilon	I
disappearance	O
from	O
and	O
reassembly	O
with	O
the	O
signalsome	O
,	O
whereas	O
IKK	B
-	I
alpha	I
,	O
IKK	B
-	I
beta	I
,	O
and	O
NIK	B
remained	O
complex	O
-	O
associated	O
.	O
NIK	B
can	O
not	O
phosphorylate	O
IkappaB	B
-	I
alpha	I
directly	O
,	O
but	O
it	O
appears	O
to	O
be	O
a	O
functionally	O
important	O
subunit	O
,	O
because	O
mutated	O
NIK	B
inhibited	O
stimulus	O
-	O
induced	O
kappaB	B
-dependent	O
transcription	O
more	O
effectively	O
than	O
mutated	O
IKK	B
-	I
alpha	I
or	O
-beta	B
.	O
Overexpression	O
of	O
IKK	B
complex	I
-	I
associated	I
protein	I
inhibited	O
stimulus	O
-	O
mediated	O
transcription	O
,	O
whereas	O
NF	B
-	I
kappaB	I
essential	O
modulator	O
enhanced	O
it	O
.	O
The	O
understanding	O
of	O
LPS-	O
and	O
TNF	O
-	O
induced	O
signaling	O
may	O
allow	O
the	O
development	O
of	O
specific	O
strategies	O
to	O
treat	O
sepsis	O
-	O
associated	O
disease	O
.	O
Classification	O
of	O
IVS1	O
-	O
10	O
T	O
--	O
>	O
C	O
as	O
a	O
polymorphism	O
of	O
BRCA1	O
.	O
Mutations	O
inactivating	O
the	O
tumor	O
suppressor	O
gene	O
BRCA1	O
may	O
be	O
responsible	O
for	O
disease	O
for	O
up	O
to	O
80	O
%	O
of	O
familial	O
ovarian	O
cancer	O
cases	O
.	O
In	O
this	O
syndrome	O
,	O
tumorigenesis	O
classically	O
initiates	O
from	O
an	O
inherited	O
mutation	O
in	O
one	O
allele	O
followed	O
by	O
somatic	O
deletion	O
of	O
the	O
normal	O
allele	O
.	O
Sequencing	O
of	O
BRCA1	O
amplified	O
from	O
genomic	O
DNA	O
of	O
lymphocytes	O
and	O
microdissected	O
ovarian	O
tumor	O
cells	O
of	O
a	O
familial	O
ovarian	O
cancer	O
patient	O
revealed	O
three	O
,	O
rare	O
heterozygous	O
DNA	O
variations	O
(	O
2418delA	O
,	O
233	O
G	O
--	O
>	O
A	O
,	O
and	O
IVS1	O
-	O
10	O
T	O
--	O
>	O
C	O
)	O
in	O
both	O
tumor	O
and	O
constitutional	O
(	O
lymphocyte	O
)	O
DNA	O
.	O
Thus	O
,	O
both	O
copies	O
of	O
BRCA1	O
were	O
retained	O
in	O
tumor	O
.	O
Haplotype	O
analysis	O
of	O
the	O
patient	O
and	O
four	O
siblings	O
assigned	O
2418delA	O
to	O
one	O
copy	O
of	O
BRCA1	O
and	O
233	O
G	O
--	O
>	O
A	O
and	O
IVS1	O
-	O
10	O
T	O
--	O
>	O
C	O
to	O
the	O
other	O
.	O
The	O
DNA	O
change	O
,	O
2418delA	O
,	O
is	O
considered	O
a	O
mutation	O
that	O
inactivated	O
one	O
BRCA1	O
allele	O
because	O
it	O
caused	O
a	O
frameshift	O
and	O
generation	O
of	O
a	O
premature	O
stop	O
codon	O
,	O
resulting	O
in	O
synthesis	O
of	O
a	O
truncated	O
peptide	O
as	O
evidenced	O
by	O
an	O
in	O
vitro	O
protein	O
truncation	O
test	O
.	O
The	O
DNA	O
variation	O
,	O
233	O
G	O
--	O
>	O
A	O
,	O
does	O
not	O
result	O
in	O
an	O
amino	O
acid	O
change	O
,	O
and	O
is	O
considered	O
a	O
benign	O
polymorphism	O
.	O
IVS1	O
-	O
10	O
T	O
--	O
>	O
C	O
is	O
a	O
unique	O
BRCA1	O
change	O
that	O
occurs	O
in	O
the	O
last	O
nucleotide	O
of	O
a	O
consensus	O
sequence	O
for	O
a	O
branch	O
site	O
critical	O
for	O
RNA	O
splicing	O
.	O
Therefore	O
,	O
we	O
investigated	O
whether	O
IVS1	O
-	O
10	O
T	O
--	O
>	O
C	O
deleteriously	O
affected	O
BRCA1	O
splicing	O
or	O
expression	O
,	O
and	O
thereby	O
inactivated	O
the	O
other	O
BRCA1	O
allele	O
.	O
Using	O
the	O
technique	O
of	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
RNA	O
isolated	O
from	O
lymphoid	O
cell	O
lines	O
of	O
the	O
patient	O
and	O
of	O
controls	O
,	O
no	O
evidence	O
was	O
found	O
that	O
IVS1	O
-	O
10TC	O
abnormally	O
disrupted	O
mRNA	O
splicing	O
or	O
caused	O
the	O
absence	O
of	O
BRCA1	O
mRNA	O
.	O
Thus	O
,	O
IVS1	O
-	O
10	O
T	O
--	O
>	O
C	O
is	O
not	O
harmful	O
to	O
BRCA1	O
function	O
,	O
and	O
is	O
classified	O
a	O
benign	O
polymorphism	O
.	O
Retention	O
of	O
the	O
normal	O
BRCA1	O
allele	O
in	O
the	O
tumor	O
with	O
the	O
heterozygous	O
germline	O
BRCA1	O
mutation	O
,	O
2418delA	O
,	O
indicated	O
that	O
mutational	O
inactivation	O
of	O
both	O
BRCA1	O
alleles	O
was	O
not	O
required	O
for	O
tumorigenesis	O
.	O
It	O
is	O
possible	O
that	O
the	O
normal	O
allele	O
may	O
be	O
functionally	O
inactivated	O
by	O
a	O
nonmutational	O
mechanism	O
.	O
The	O
beta	O
-	O
globin	O
promoter	O
is	O
important	O
for	O
recruitment	O
of	O
erythroid	B
Kruppel	I
-	I
like	I
factor	I
to	O
the	O
locus	O
control	O
region	O
in	O
erythroid	O
cells	O
.	O
Erythroid	B
Kruppel	I
-	I
like	I
factor	I
(	O
EKLF	B
)	O
,	O
which	O
binds	O
to	O
the	O
CACCC	O
box	O
in	O
the	O
beta	O
-	O
globin	O
promoter	O
,	O
is	O
required	O
for	O
the	O
expression	O
of	O
the	O
beta	O
-	O
globin	O
gene	O
in	O
adult	O
erythroid	O
cells	O
.	O
It	O
was	O
recently	O
demonstrated	O
that	O
EKLF	B
is	O
also	O
required	O
for	O
the	O
activity	O
of	O
the	O
beta	O
-	O
globin	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
5'HS3	O
.	O
Some	O
evidence	O
suggests	O
that	O
the	O
LCR	O
and	O
the	O
beta	O
-	O
globin	O
promoter	O
interact	O
in	O
adult	O
erythroid	O
cells	O
,	O
and	O
the	O
network	O
of	O
protein	O
-	O
protein	O
interactions	O
that	O
exists	O
between	O
these	O
two	O
elements	O
may	O
regulate	O
how	O
EKLF	B
is	O
recruited	O
to	O
the	O
LCR	O
.	O
In	O
this	O
report	O
,	O
we	O
use	O
the	O
PIN*POINT	O
assay	O
to	O
study	O
the	O
role	O
of	O
the	O
promoter	O
on	O
the	O
recruitment	O
of	O
EKLF	B
to	O
5'HS2	O
and	O
5'HS3	O
of	O
the	O
LCR	O
.	O
We	O
find	O
that	O
recruitment	O
of	O
EKLF	B
to	O
5'HS2	O
requires	O
the	O
TATA	O
box	O
,	O
but	O
recruitment	O
to	O
5'HS3	O
depends	O
on	O
the	O
CACCC	O
and	O
TATA	O
boxes	O
of	O
the	O
beta	O
-	O
globin	O
promoter	O
.	O
Furthermore	O
,	O
recruitment	O
of	O
EKLF	B
to	O
5'HS3	O
only	O
occurred	O
in	O
beta	O
-	O
globin	O
-	O
expressing	O
murine	O
erythroid	O
leukemia	O
cells	O
,	O
whereas	O
recruitment	O
of	O
EKLF	B
to	O
5'HS2	O
occurred	O
in	O
both	O
gamma	O
-	O
globin	O
-	O
expressing	O
K562	O
cells	O
and	O
murine	O
erythroid	O
leukemia	O
cells	O
.	O
Unlike	O
EKLF	B
,	O
Sp1	B
,	O
which	O
also	O
binds	O
to	O
CACCC	O
boxes	O
,	O
is	O
not	O
recruited	O
to	O
5'HS3	O
.	O
We	O
have	O
also	O
examined	O
how	O
one	O
5'HS	O
affects	O
the	O
recruitment	O
of	O
EKLF	B
to	O
another	O
5'HS	O
.	O
We	O
have	O
found	O
that	O
the	O
recruitment	O
of	O
EKLF	B
to	O
5'HS3	O
depends	O
on	O
the	O
presence	O
of	O
5'HS2	O
in	O
cis	O
,	O
but	O
the	O
recruitment	O
to	O
5'HS2	O
does	O
not	O
depend	O
on	O
5'HS3	O
.	O
Based	O
on	O
these	O
results	O
,	O
we	O
present	O
a	O
model	O
that	O
illustrates	O
how	O
EKLF	B
may	O
be	O
recruited	O
to	O
the	O
beta	O
-	O
globin	O
locus	O
.	O
Interferons	O
inhibit	O
activation	O
of	O
STAT6	B
by	O
interleukin	B
4	I
in	O
human	O
monocytes	O
by	O
inducing	O
SOCS-1	O
gene	O
expression	O
.	O
Interferons	B
(	O
IFNs	B
)	O
inhibit	O
induction	O
by	O
IL-4	B
of	O
multiple	O
genes	O
in	O
human	O
monocytes	O
.	O
However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	B
mediate	O
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O
IL-4	B
activates	O
gene	O
expression	O
by	O
inducing	O
tyrosine	O
phosphorylation	O
,	O
homodimerization	O
,	O
and	O
nuclear	O
translocation	O
of	O
the	O
latent	B
transcription	I
factor	I
,	O
STAT6	B
(	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription-6	I
)	O
.	O
STAT6	B
-responsive	O
elements	O
are	O
characteristically	O
present	O
in	O
the	O
promoters	O
of	O
IL-4-inducible	O
genes	O
.	O
Because	O
STAT6	B
activation	O
is	O
essential	O
for	O
IL-4	B
-induced	O
gene	O
expression	O
,	O
we	O
examined	O
the	O
ability	O
of	O
type	O
I	O
and	O
type	O
II	O
IFNs	B
to	O
regulate	O
activation	O
of	O
STAT6	B
by	O
IL-4	B
in	O
primary	O
human	O
monocytes	O
.	O
Pretreatment	O
of	O
monocytes	O
with	O
IFN	B
-	I
beta	I
or	O
IFN	B
-	I
gamma	I
,	O
but	O
not	O
IL-1	B
,	O
IL-2	B
,	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
,	O
granulocyte	B
/	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
,	O
IL-6	B
,	O
or	O
transforming	O
growth	O
factor	O
beta	O
suppressed	O
activation	O
of	O
STAT6	B
by	O
IL-4	B
.	O
This	O
inhibition	O
was	O
associated	O
with	O
decreased	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	B
and	O
was	O
not	O
evident	O
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	B
for	O
at	O
least	O
1	O
hr	O
before	O
IL-4	B
stimulation	O
.	O
Furthermore	O
,	O
inhibition	O
by	O
IFN	B
could	O
be	O
blocked	O
by	O
cotreatment	O
with	O
actinomycin	O
D	O
and	O
correlated	O
temporally	O
with	O
induction	O
of	O
the	O
JAK	O
/	O
STAT	O
inhibitory	O
gene	O
,	O
SOCS-1	O
.	O
Forced	O
expression	O
of	O
SOCS-1	O
in	O
a	O
macrophage	O
cell	O
line	O
,	O
RAW264	O
,	O
markedly	O
suppressed	O
trans	O
-	O
activation	O
of	O
an	O
IL-4-inducible	O
reporter	O
as	O
well	O
as	O
IL-6-	O
and	O
IFN	O
-	O
gamma	O
-	O
induced	O
reporter	O
gene	O
activity	O
.	O
These	O
findings	O
demonstrate	O
that	O
IFNs	B
inhibit	O
IL-4	B
-induced	O
activation	O
of	O
STAT6	B
and	O
STAT6	B
-dependent	O
gene	O
expression	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
inducing	O
expression	O
of	O
SOCS-1	O
.	O
Vitamin	O
D	O
analogs	O
,	O
20-Epi-22-oxa-24a	O
,	O
26a	O
,	O
27a	O
,	O
-trihomo-1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-vitamin	O
D3	O
,	O
1	O
,	O
24	O
(	O
OH	O
)	O
2	O
-	O
22-ene-24-cyclopropyl	O
-	O
vitamin	O
D3	O
and	O
1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-lumisterol3	O
prime	O
NB4	O
leukemia	O
cells	O
for	O
monocytic	O
differentiation	O
via	O
nongenomic	O
signaling	O
pathways	O
,	O
involving	O
calcium	O
and	O
calpain	O
.	O
Side	O
-	O
chain	O
modified	O
vitamin	O
D	O
analogs	O
including	O
20-Epi-22-oxa-24a	O
,	O
26a	O
,	O
27a	O
-	O
trihomo-1alpha	O
,	O
2	O
5-dihydroxyvitamin	O
D3	O
(	O
KH1060	O
)	O
,	O
and	O
1	O
,	O
24-dihydroxy-22-ene-24-cyclopropyl	O
-	O
vitamin	O
D3	O
(	O
MC903	O
)	O
were	O
originally	O
designed	O
to	O
aid	O
in	O
the	O
treatment	O
of	O
hyperproliferative	O
disorders	O
including	O
psoriasis	O
and	O
cancer	O
.	O
Here	O
we	O
demonstrate	O
that	O
these	O
analogs	O
,	O
as	O
well	O
as	O
the	O
6-cis	O
-	O
locked	O
conformer	O
,	O
1alpha	O
,	O
25-dihydroxy	O
-	O
lumisterol3	O
(	O
JN	O
)	O
prime	O
NB4	O
cells	O
for	O
monocytic	O
differentiation	O
.	O
Previously	O
,	O
the	O
action	O
of	O
MC903	O
and	O
KH1060	O
was	O
presumed	O
to	O
be	O
mediated	O
by	O
the	O
nuclear	B
vitamin	I
D	I
receptor	I
(	O
VDRnuc	B
)	O
.	O
Differentiation	O
in	O
response	O
to	O
all	O
analogs	O
was	O
shown	O
to	O
be	O
inhibited	O
by	O
1beta	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
HL	O
)	O
,	O
the	O
antagonist	O
to	O
the	O
nongenomic	O
activities	O
of	O
1	O
,	O
25D3	O
.	O
These	O
data	O
suggest	O
that	O
although	O
MC903	O
and	O
KH1060	O
may	O
bind	O
the	O
VDRnuc	B
,	O
that	O
the	O
differentiative	O
activities	O
of	O
these	O
agents	O
requires	O
nongenomic	O
signaling	O
pathways	O
.	O
Here	O
we	O
show	O
that	O
1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-d5-previtamin	O
D3	O
(	O
HF	O
)	O
,	O
JN	O
,	O
KH1060	O
,	O
and	O
MC903	O
induce	O
expression	O
of	O
PKC	B
alpha	I
and	O
PKC	B
delta	I
and	O
translocation	O
of	O
both	O
isoforms	O
to	O
the	O
particulate	O
fraction	O
,	O
and	O
PKC	B
alpha	I
to	O
the	O
nuclear	O
fraction	O
.	O
The	O
full	O
differentiation	O
response	O
with	O
combinations	O
of	O
analogs	O
and	O
TPA	O
was	O
inhibited	O
50	O
%	O
by	O
the	O
membrane	O
permeable	O
Ca2	O
+	O
chelator	O
,	O
1	O
,	O
2-bis	O
(	O
o	O
-	O
aminophenoxy	O
)	O
-ethane	O
-	O
N	O
,	O
N	O
,	O
N	O
'	O
,	O
N'-tetraacetic	O
acid	O
(	O
BAPTA	O
-	O
AM	O
)	O
or	O
calpain	B
inhibitor	O
I	O
.	O
These	O
data	O
demonstrate	O
that	O
intracellular	O
free	O
calcium	O
and	O
the	O
calcium	B
-	I
dependent	I
protease	I
,	O
calpain	B
play	O
critical	O
roles	O
in	O
monocytic	O
differentiation	O
.	O
Intracellular	O
calcium	O
appears	O
to	O
be	O
most	O
critical	O
in	O
the	O
1	O
,	O
25D3-priming	O
stage	O
of	O
differentiation	O
,	O
while	O
calpain	B
is	O
essential	O
in	O
the	O
TPA	O
maturation	O
response	O
.	O
